<SEC-DOCUMENT>0001437749-25-030544.txt : 20251006
<SEC-HEADER>0001437749-25-030544.hdr.sgml : 20251006
<ACCEPTANCE-DATETIME>20251006170136
ACCESSION NUMBER:		0001437749-25-030544
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		89
FILED AS OF DATE:		20251006
DATE AS OF CHANGE:		20251006

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Autonomix Medical, Inc.
		CENTRAL INDEX KEY:			0001617867
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		EIN:				471607810
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-290472
		FILM NUMBER:		251377486

	BUSINESS ADDRESS:	
		STREET 1:		21 WATERWAY AVENUE, SUITE 300
		CITY:			THE WOODLANDS
		STATE:			TX
		ZIP:			77380
		BUSINESS PHONE:		832-277-7816

	MAIL ADDRESS:	
		STREET 1:		21 WATERWAY AVENUE, SUITE 300
		CITY:			THE WOODLANDS
		STATE:			TX
		ZIP:			77380
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>amix20251001c_424b3.htm
<DESCRIPTION>FORM 424B3
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:naics="http://xbrl.sec.gov/naics/2025" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-roles="http://fasb.org/us-roles/2017-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2025" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:thunderdome="http://www.RDGFilings.com" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:amix="http://autonomix.com/20250630" xmlns:rr="http://xbrl.sec.gov/rr/2023" xmlns:currency="http://xbrl.sec.gov/currency/2025" xmlns:sic="http://xbrl.sec.gov/sic/2025" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:exch="http://xbrl.sec.gov/exch/2025" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21">
 <head>
  <title>amix20251001c_424b3.htm</title>
  <!-- Generated by ThunderDome Portal - 10/2/2025 4:23:19 PM -->
  <meta http-equiv="Content-Type" content="text/html"/></head>
 <body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;"><div style="display: none;"><ix:header><ix:hidden>
<ix:nonNumeric contextRef="d_2025-04-01_2025-06-30" name="dei:EntityCentralIndexKey" id="thunderdome-EntityCentralIndexKey">0001617867</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2025-04-01_2025-06-30" name="dei:EntityRegistrantName" id="thunderdome-EntityRegistrantName">Autonomix Medical, Inc.</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2025-04-01_2025-06-30" name="dei:AmendmentFlag" format="ixt:fixed-false" id="ixv-16476">false</ix:nonNumeric>
<ix:nonNumeric name="dei:DocumentType" contextRef="d_2025-04-01_2025-06-30" id="val1759590397299768">424B3</ix:nonNumeric>
<ix:nonFraction id="c134565227" contextRef="i_2025-03-31" unitRef="USD" name="us-gaap:CommitmentsAndContingencies" scale="0" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction id="c134565228" contextRef="i_2024-03-31" unitRef="USD" name="us-gaap:CommitmentsAndContingencies" scale="0" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction id="c134565133" contextRef="i_2025-03-31" unitRef="USDPerShare" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.001</ix:nonFraction>
<ix:nonFraction id="c134565134" contextRef="i_2024-03-31" unitRef="USDPerShare" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.001</ix:nonFraction>
<ix:nonFraction id="c134565135" contextRef="i_2025-03-31" unitRef="Share" name="us-gaap:PreferredStockSharesAuthorized" scale="0" format="ixt:num-dot-decimal" decimals="INF">10,000,000</ix:nonFraction>
<ix:nonFraction id="c134565136" contextRef="i_2024-03-31" unitRef="Share" name="us-gaap:PreferredStockSharesAuthorized" scale="0" format="ixt:num-dot-decimal" decimals="INF">10,000,000</ix:nonFraction>
<ix:nonFraction id="c134565137" contextRef="i_2025-03-31" unitRef="Share" name="us-gaap:PreferredStockSharesIssued" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c134565139" contextRef="i_2025-03-31" unitRef="Share" name="us-gaap:PreferredStockSharesOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c134565138" contextRef="i_2024-03-31" unitRef="Share" name="us-gaap:PreferredStockSharesIssued" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c134565140" contextRef="i_2024-03-31" unitRef="Share" name="us-gaap:PreferredStockSharesOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c134565141" contextRef="i_2025-03-31" unitRef="USDPerShare" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.001</ix:nonFraction>
<ix:nonFraction id="c134565142" contextRef="i_2024-03-31" unitRef="USDPerShare" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.001</ix:nonFraction>
<ix:nonFraction id="c134565143" contextRef="i_2025-03-31" unitRef="Share" name="us-gaap:CommonStockSharesAuthorized" scale="0" format="ixt:num-dot-decimal" decimals="INF">500,000,000</ix:nonFraction>
<ix:nonFraction id="c134565144" contextRef="i_2024-03-31" unitRef="Share" name="us-gaap:CommonStockSharesAuthorized" scale="0" format="ixt:num-dot-decimal" decimals="INF">500,000,000</ix:nonFraction>
<ix:nonFraction id="c134565145" contextRef="i_2025-03-31" unitRef="Share" name="us-gaap:CommonStockSharesIssued" scale="0" format="ixt:num-dot-decimal" decimals="INF">2,497,033</ix:nonFraction>
<ix:nonFraction id="c134565147" contextRef="i_2025-03-31" unitRef="Share" name="us-gaap:CommonStockSharesOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">2,497,033</ix:nonFraction>
<ix:nonFraction id="c134565146" contextRef="i_2024-03-31" unitRef="Share" name="us-gaap:CommonStockSharesIssued" scale="0" format="ixt:num-dot-decimal" decimals="INF">942,575</ix:nonFraction>
<ix:nonFraction id="c134565148" contextRef="i_2024-03-31" unitRef="Share" name="us-gaap:CommonStockSharesOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">942,575</ix:nonFraction>
<ix:nonFraction id="c134564311" contextRef="d_2024-10-24_2024-10-24_NonmonetaryTransactionTypeAxis-ReverseStockSplitMember" unitRef="Pure" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" format="ixt:num-dot-decimal" decimals="INF">20</ix:nonFraction>
<ix:nonFraction id="c134564315" contextRef="d_2024-10-24_2024-10-24_NonmonetaryTransactionTypeAxis-ReverseStockSplitMember" unitRef="Pure" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" format="ixt:num-dot-decimal" decimals="INF">20</ix:nonFraction>
<ix:nonFraction id="c134565165" contextRef="d_2023-04-01_2024-03-31" unitRef="USD" name="us-gaap:Revenues" scale="6" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c134564342" contextRef="i_2024-11-25_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember" unitRef="Share" name="amix:NumberOfSharesPerCommonUnit" scale="0" format="ixt:num-dot-decimal" decimals="INF">1</ix:nonFraction>
<ix:nonFraction id="c134564343" contextRef="i_2024-11-25_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember" unitRef="Share" name="amix:NumberOfWarrantsPerCommonUnit" scale="0" format="ixt:num-dot-decimal" decimals="INF">1</ix:nonFraction>
<ix:nonFraction id="c134564344" contextRef="i_2024-11-25_ClassOfWarrantOrRightAxis-SeriesAWarrantsMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" format="ixt:num-dot-decimal" decimals="INF">1</ix:nonFraction>
<ix:nonFraction id="c134564346" contextRef="i_2024-11-25_ClassOfWarrantOrRightAxis-PrefundedWarrantsMember" unitRef="Share" name="amix:NumberOfWarrantsPerPrefundedUnit" scale="0" format="ixt:num-dot-decimal" decimals="INF">1</ix:nonFraction>
<ix:nonFraction id="c134564347" contextRef="i_2024-11-25_ClassOfWarrantOrRightAxis-PrefundedWarrantsMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" format="ixt:num-dot-decimal" decimals="INF">1</ix:nonFraction>
<ix:nonFraction id="c134564348" contextRef="i_2024-11-25_ClassOfWarrantOrRightAxis-SeriesAWarrantsMember" unitRef="Share" name="amix:NumberOfWarrantsPerPrefundedUnit" scale="0" format="ixt:num-dot-decimal" decimals="INF">1</ix:nonFraction>
<ix:nonNumeric contextRef="i_2024-11-25_ClassOfWarrantOrRightAxis-SeriesAWarrantsMember" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="c134564356" format="ixt-sec:duryear">5</ix:nonNumeric>
<ix:nonNumeric contextRef="i_2025-03-31" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="c134564384" format="ixt-sec:duryear">3</ix:nonNumeric>
<ix:nonFraction id="c134565166" contextRef="i_2024-03-31" unitRef="USD" name="us-gaap:LiabilityForUncertainTaxPositionsCurrent" scale="6" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c134564434" contextRef="d_2024-04-01_2025-03-31" unitRef="Pure" name="us-gaap:NumberOfReportableSegments" scale="0" format="ixt:num-dot-decimal" decimals="INF">1</ix:nonFraction>
<ix:nonFraction id="c134564463" contextRef="d_2024-04-01_2025-03-31" unitRef="Pure" name="us-gaap:NumberOfOperatingSegments" scale="0" format="ixt:num-dot-decimal" decimals="INF">1</ix:nonFraction>
<ix:nonFraction id="c134565294" contextRef="i_2023-07-07_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_MeasurementInputTypeAxis-MeasurementInputDiscountRateMember" unitRef="Pure" name="us-gaap:PercentageOfFIFOInventory" scale="-2" format="ixt:num-dot-decimal" decimals="1">20.00</ix:nonFraction>
<ix:nonFraction id="c134565295" contextRef="i_2023-07-07_MeasurementInputTypeAxis-MeasurementInputProbabilityRateMember_StatementScenarioAxis-QualifiedOfferingOccurringOneMember_ValuationTechniqueAxis-ValuationProbabilityweightedExpectedReturnMethodPWERMMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" format="ixt:num-dot-decimal" decimals="1">70</ix:nonFraction>
<ix:nonFraction id="c134565296" contextRef="i_2023-07-07_MeasurementInputTypeAxis-MeasurementInputProbabilityRateMember_StatementScenarioAxis-QualifiedOfferingOccurringTwoMember_ValuationTechniqueAxis-ValuationProbabilityweightedExpectedReturnMethodPWERMMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" format="ixt:num-dot-decimal" decimals="1">10</ix:nonFraction>
<ix:nonFraction id="c134565297" contextRef="i_2023-07-07_MeasurementInputTypeAxis-MeasurementInputProbabilityRateMember_StatementScenarioAxis-NoQualifiedOfferingOccurringMember_ValuationTechniqueAxis-ValuationProbabilityweightedExpectedReturnMethodPWERMMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" format="ixt:num-dot-decimal" decimals="1">20</ix:nonFraction>
<ix:nonFraction id="c134565299" contextRef="i_2023-07-07_MeasurementInputTypeAxis-MeasurementInputFixedPriceMember_RangeAxis-MinimumMember_ValuationTechniqueAxis-ValuationProbabilityweightedExpectedReturnMethodPWERMMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c134565300" contextRef="i_2023-07-07_MeasurementInputTypeAxis-MeasurementInputFixedPriceMember_RangeAxis-MaximumMember_ValuationTechniqueAxis-ValuationProbabilityweightedExpectedReturnMethodPWERMMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" format="ixt:num-dot-decimal" decimals="INF">8,000,000</ix:nonFraction>
<ix:nonFraction id="c134565302" contextRef="i_2023-07-07_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember_RangeAxis-MinimumMember_ValuationTechniqueAxis-ValuationProbabilityweightedExpectedReturnMethodPWERMMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.48</ix:nonFraction>
<ix:nonFraction id="c134565303" contextRef="i_2023-07-07_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember_RangeAxis-MaximumMember_ValuationTechniqueAxis-ValuationProbabilityweightedExpectedReturnMethodPWERMMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.98</ix:nonFraction>
<ix:nonFraction id="c134564500" contextRef="i_2023-12-31_MeasurementInputTypeAxis-MeasurementInputProbabilityRateMember_StatementScenarioAxis-QualifiedOfferingOccurringTwoMember_ValuationTechniqueAxis-ValuationProbabilityweightedExpectedReturnMethodPWERMMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" format="ixt:num-dot-decimal" decimals="1">10</ix:nonFraction>
<ix:nonFraction id="c134564502" contextRef="i_2023-12-31_MeasurementInputTypeAxis-MeasurementInputProbabilityRateMember_StatementScenarioAxis-NoQualifiedOfferingOccurringMember_ValuationTechniqueAxis-ValuationProbabilityweightedExpectedReturnMethodPWERMMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" format="ixt:num-dot-decimal" decimals="1">20</ix:nonFraction>
<ix:nonNumeric contextRef="i_2023-09-09_ClassOfWarrantOrRightAxis-BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="c134564513" format="ixt-sec:duryear">5</ix:nonNumeric>
<ix:nonFraction id="c134564542" contextRef="i_2023-11-29" unitRef="USDPerShare" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.001</ix:nonFraction>
<ix:nonFraction id="c134564544" contextRef="i_2023-11-29" unitRef="USDPerShare" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.001</ix:nonFraction>
<ix:nonFraction id="c134564555" contextRef="d_2023-04-01_2024-03-31_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="USD" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonNumeric contextRef="d_2024-04-01_2025-03-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2023StockPlanMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="c134564574" format="ixt-sec:duryear">10</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2024-04-01_2025-03-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2023StockPlanMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="c134564575" format="ixt-sec:duryear">4</ix:nonNumeric>
<ix:nonFraction id="c134564614" contextRef="i_2024-11-25_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember" unitRef="Share" name="amix:NumberOfSharesPerCommonUnit" scale="0" format="ixt:num-dot-decimal" decimals="INF">1</ix:nonFraction>
<ix:nonFraction id="c134564616" contextRef="i_2024-11-25_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember" unitRef="Share" name="amix:NumberOfWarrantsPerCommonUnit" scale="0" format="ixt:num-dot-decimal" decimals="INF">1</ix:nonFraction>
<ix:nonFraction id="c134564617" contextRef="i_2024-11-25_ClassOfWarrantOrRightAxis-SeriesAWarrantsMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" format="ixt:num-dot-decimal" decimals="INF">1</ix:nonFraction>
<ix:nonFraction id="c134564619" contextRef="i_2024-11-25_ClassOfWarrantOrRightAxis-PrefundedWarrantsMember" unitRef="Share" name="amix:NumberOfWarrantsPerPrefundedUnit" scale="0" format="ixt:num-dot-decimal" decimals="INF">1</ix:nonFraction>
<ix:nonFraction id="c134564620" contextRef="i_2024-11-25_ClassOfWarrantOrRightAxis-PrefundedWarrantsMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" format="ixt:num-dot-decimal" decimals="INF">1</ix:nonFraction>
<ix:nonFraction id="c134564621" contextRef="i_2024-11-25_ClassOfWarrantOrRightAxis-SeriesAWarrantsMember" unitRef="Share" name="amix:NumberOfWarrantsPerPrefundedUnit" scale="0" format="ixt:num-dot-decimal" decimals="INF">1</ix:nonFraction>
<ix:nonNumeric contextRef="i_2024-11-25_ClassOfWarrantOrRightAxis-SeriesAWarrantsMember" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="c134564635" format="ixt-sec:duryear">5</ix:nonNumeric>
<ix:nonNumeric contextRef="i_2024-01-26_ClassOfWarrantOrRightAxis-EquitybasedWarrantsMember" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="c134564655" format="ixt-sec:duryear">5</ix:nonNumeric>
<ix:nonFraction id="c134564667" contextRef="d_2024-04-01_2025-03-31_ClassOfWarrantOrRightAxis-EquitybasedWarrantsMember" unitRef="Share" name="amix:ClassOfWarrantOrRightExercisedInPeriodCashless" scale="0" format="ixt:num-dot-decimal" decimals="INF">197,098</ix:nonFraction>
<ix:nonFraction id="c134564671" contextRef="i_2024-03-31_AwardTypeAxis-WarrantMember" unitRef="USD" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.1</ix:nonFraction>
<ix:nonFraction id="c134564674" contextRef="i_2025-03-31_LitigationStatusAxis-PendingLitigationMember" unitRef="Pure" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonNumeric contextRef="d_2024-06-17_2024-06-17_TitleOfIndividualAxis-ChiefExecutiveOfficerMember_TypeOfArrangementAxis-EmploymentContractsMember" name="amix:EmploymentAgreementTermOfContract" id="c134564678" format="ixt-sec:duryear">3</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2024-06-17_2024-06-17_AwardTypeAxis-InducementOptionsMember_TitleOfIndividualAxis-ChiefExecutiveOfficerMember_TypeOfArrangementAxis-EmploymentContractsMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="c134564681" format="ixt-sec:duryear">10</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2024-06-17_2024-06-17_TitleOfIndividualAxis-ExecutiveViceChairAndStrategicAdvisorToTheChiefExecutiveOfficerMember_TypeOfArrangementAxis-EmploymentContractsMember" name="amix:EmploymentAgreementTermOfContract" id="c134564696" format="ixt-sec:duryear">2</ix:nonNumeric>
<ix:nonNumeric contextRef="i_2023-07-07_ClassOfWarrantOrRightAxis-TheWarrantMember_RelatedPartyTransactionAxis-TerminationAgreementMember" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="c134564722" format="ixt-sec:duryear">5</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2023-07-07_2023-07-07_ClassOfWarrantOrRightAxis-TheWarrantMember_RelatedPartyTransactionAxis-TerminationAgreementMember_UnderlyingAssetClassAxis-CommonStock6MonthsLockupPeriodMember" name="amix:ClassOfWarrantOrRightLockupAgreementTermOfUnderlyingShares" id="c134564724" format="ixt-sec:durmonth">6</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2023-07-07_2023-07-07_ClassOfWarrantOrRightAxis-TheWarrantMember_RelatedPartyTransactionAxis-TerminationAgreementMember_UnderlyingAssetClassAxis-CommonStock12MonthsLockupPeriodMember" name="amix:ClassOfWarrantOrRightLockupAgreementTermOfUnderlyingShares" id="c134564726" format="ixt-sec:durmonth">12</ix:nonNumeric>
<ix:nonFraction id="c134564749" contextRef="i_2025-03-31" unitRef="USD" name="amix:ReserveForUncertainTaxPositions" scale="6" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonNumeric contextRef="d_2025-04-17_2025-04-17_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_SubsequentEventTypeAxis-SubsequentEventMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="c134564760" format="ixt-sec:duryear">10</ix:nonNumeric>
<ix:nonFraction id="c134565269" contextRef="i_2025-06-30" unitRef="USD" name="us-gaap:CommitmentsAndContingencies" scale="0" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction id="c134565270" contextRef="i_2025-03-31" unitRef="USD" name="us-gaap:CommitmentsAndContingencies" scale="0" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction id="c134565149" contextRef="i_2025-06-30" unitRef="USDPerShare" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.001</ix:nonFraction>
<ix:nonFraction id="c134565150" contextRef="i_2025-03-31" unitRef="USDPerShare" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.001</ix:nonFraction>
<ix:nonFraction id="c134565151" contextRef="i_2025-06-30" unitRef="Share" name="us-gaap:PreferredStockSharesAuthorized" scale="0" format="ixt:num-dot-decimal" decimals="INF">10,000,000</ix:nonFraction>
<ix:nonFraction id="c134565152" contextRef="i_2025-03-31" unitRef="Share" name="us-gaap:PreferredStockSharesAuthorized" scale="0" format="ixt:num-dot-decimal" decimals="INF">10,000,000</ix:nonFraction>
<ix:nonFraction id="c134565153" contextRef="i_2025-06-30" unitRef="Share" name="us-gaap:PreferredStockSharesIssued" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c134565155" contextRef="i_2025-06-30" unitRef="Share" name="us-gaap:PreferredStockSharesOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c134565154" contextRef="i_2025-03-31" unitRef="Share" name="us-gaap:PreferredStockSharesIssued" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c134565156" contextRef="i_2025-03-31" unitRef="Share" name="us-gaap:PreferredStockSharesOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c134565157" contextRef="i_2025-06-30" unitRef="USDPerShare" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.001</ix:nonFraction>
<ix:nonFraction id="c134565158" contextRef="i_2025-03-31" unitRef="USDPerShare" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.001</ix:nonFraction>
<ix:nonFraction id="c134565159" contextRef="i_2025-06-30" unitRef="Share" name="us-gaap:CommonStockSharesAuthorized" scale="0" format="ixt:num-dot-decimal" decimals="INF">500,000,000</ix:nonFraction>
<ix:nonFraction id="c134565160" contextRef="i_2025-03-31" unitRef="Share" name="us-gaap:CommonStockSharesAuthorized" scale="0" format="ixt:num-dot-decimal" decimals="INF">500,000,000</ix:nonFraction>
<ix:nonFraction id="c134565161" contextRef="i_2025-06-30" unitRef="Share" name="us-gaap:CommonStockSharesIssued" scale="0" format="ixt:num-dot-decimal" decimals="INF">4,022,625</ix:nonFraction>
<ix:nonFraction id="c134565163" contextRef="i_2025-06-30" unitRef="Share" name="us-gaap:CommonStockSharesOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">4,022,625</ix:nonFraction>
<ix:nonFraction id="c134565162" contextRef="i_2025-03-31" unitRef="Share" name="us-gaap:CommonStockSharesIssued" scale="0" format="ixt:num-dot-decimal" decimals="INF">2,497,033</ix:nonFraction>
<ix:nonFraction id="c134565164" contextRef="i_2025-03-31" unitRef="Share" name="us-gaap:CommonStockSharesOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">2,497,033</ix:nonFraction>
<ix:nonFraction id="c134564773" contextRef="d_2024-10-24_2024-10-24_NonmonetaryTransactionTypeAxis-ReverseStockSplitMember" unitRef="Pure" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" format="ixt:num-dot-decimal" decimals="INF">20</ix:nonFraction>
<ix:nonFraction id="c134564777" contextRef="d_2024-10-24_2024-10-24_NonmonetaryTransactionTypeAxis-ReverseStockSplitMember" unitRef="Pure" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" format="ixt:num-dot-decimal" decimals="INF">20</ix:nonFraction>
<ix:nonFraction id="c134564791" contextRef="i_2024-11-25_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember" unitRef="Share" name="amix:NumberOfSharesPerCommonUnit" scale="0" format="ixt:num-dot-decimal" decimals="INF">1</ix:nonFraction>
<ix:nonFraction id="c134564792" contextRef="i_2024-11-25_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember" unitRef="Share" name="amix:NumberOfWarrantsPerCommonUnit" scale="0" format="ixt:num-dot-decimal" decimals="INF">1</ix:nonFraction>
<ix:nonFraction id="c134564793" contextRef="i_2024-11-25_ClassOfWarrantOrRightAxis-SeriesAWarrantsMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" format="ixt:num-dot-decimal" decimals="INF">1</ix:nonFraction>
<ix:nonFraction id="c134564795" contextRef="i_2024-11-25_ClassOfWarrantOrRightAxis-PrefundedWarrantsMember" unitRef="Share" name="amix:NumberOfWarrantsPerPrefundedUnit" scale="0" format="ixt:num-dot-decimal" decimals="INF">1</ix:nonFraction>
<ix:nonFraction id="c134564796" contextRef="i_2024-11-25_ClassOfWarrantOrRightAxis-PrefundedWarrantsMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" format="ixt:num-dot-decimal" decimals="INF">1</ix:nonFraction>
<ix:nonFraction id="c134564797" contextRef="i_2024-11-25_ClassOfWarrantOrRightAxis-SeriesAWarrantsMember" unitRef="Share" name="amix:NumberOfWarrantsPerPrefundedUnit" scale="0" format="ixt:num-dot-decimal" decimals="INF">1</ix:nonFraction>
<ix:nonNumeric contextRef="i_2024-11-25_ClassOfWarrantOrRightAxis-SeriesAWarrantsMember" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="c134564805" format="ixt-sec:duryear">5</ix:nonNumeric>
<ix:nonFraction id="c134565170" contextRef="d_2024-04-01_2024-06-30" unitRef="USD" name="us-gaap:Revenues" scale="6" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonNumeric contextRef="i_2025-06-30" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="c134564843" format="ixt-sec:duryear">3</ix:nonNumeric>
<ix:nonFraction id="c134565171" contextRef="i_2025-03-31" unitRef="USD" name="us-gaap:LiabilityForUncertainTaxPositionsCurrent" scale="6" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c134564899" contextRef="d_2025-04-01_2025-06-30" unitRef="Pure" name="us-gaap:NumberOfReportableSegments" scale="0" format="ixt:num-dot-decimal" decimals="INF">1</ix:nonFraction>
<ix:nonNumeric contextRef="i_2023-09-09_ClassOfWarrantOrRightAxis-BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="c134564938" format="ixt-sec:duryear">5</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2025-04-01_2025-06-30_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2023StockPlanMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="c134564987" format="ixt-sec:duryear">4</ix:nonNumeric>
<ix:nonFraction id="c134565018" contextRef="i_2024-11-25_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember" unitRef="Share" name="amix:NumberOfSharesPerCommonUnit" scale="0" format="ixt:num-dot-decimal" decimals="INF">1</ix:nonFraction>
<ix:nonFraction id="c134565019" contextRef="i_2024-11-25_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember" unitRef="Share" name="amix:NumberOfWarrantsPerCommonUnit" scale="0" format="ixt:num-dot-decimal" decimals="INF">1</ix:nonFraction>
<ix:nonFraction id="c134565020" contextRef="i_2024-11-25_ClassOfWarrantOrRightAxis-SeriesAWarrantsMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" format="ixt:num-dot-decimal" decimals="INF">1</ix:nonFraction>
<ix:nonFraction id="c134565022" contextRef="i_2024-11-25_ClassOfWarrantOrRightAxis-PrefundedWarrantsMember" unitRef="Share" name="amix:NumberOfWarrantsPerPrefundedUnit" scale="0" format="ixt:num-dot-decimal" decimals="INF">1</ix:nonFraction>
<ix:nonFraction id="c134565023" contextRef="i_2024-11-25_ClassOfWarrantOrRightAxis-PrefundedWarrantsMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" format="ixt:num-dot-decimal" decimals="INF">1</ix:nonFraction>
<ix:nonFraction id="c134565024" contextRef="i_2024-11-25_ClassOfWarrantOrRightAxis-SeriesAWarrantsMember" unitRef="Share" name="amix:NumberOfWarrantsPerPrefundedUnit" scale="0" format="ixt:num-dot-decimal" decimals="INF">1</ix:nonFraction>
<ix:nonNumeric contextRef="i_2024-11-25_ClassOfWarrantOrRightAxis-SeriesAWarrantsMember" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="c134565038" format="ixt-sec:duryear">5</ix:nonNumeric>
<ix:nonFraction id="c134564291" contextRef="i_2025-03-31" unitRef="USDPerShare" name="amix:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">5.89</ix:nonFraction>
<ix:nonFraction id="c134565070" contextRef="i_2025-06-30_LitigationStatusAxis-PendingLitigationMember" unitRef="Pure" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonNumeric contextRef="i_2023-07-07_ClassOfWarrantOrRightAxis-TheWarrantMember_RelatedPartyTransactionAxis-TerminationAgreementMember" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="c134565085" format="ixt-sec:duryear">5</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2023-07-07_2023-07-07_ClassOfWarrantOrRightAxis-TheWarrantMember_RelatedPartyTransactionAxis-TerminationAgreementMember_UnderlyingAssetClassAxis-CommonStock6MonthsLockupPeriodMember" name="amix:ClassOfWarrantOrRightLockupAgreementTermOfUnderlyingShares" id="c134565087" format="ixt-sec:durmonth">6</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2023-07-07_2023-07-07_ClassOfWarrantOrRightAxis-TheWarrantMember_RelatedPartyTransactionAxis-TerminationAgreementMember_UnderlyingAssetClassAxis-CommonStock12MonthsLockupPeriodMember" name="amix:ClassOfWarrantOrRightLockupAgreementTermOfUnderlyingShares" id="c134565089" format="ixt-sec:durmonth">12</ix:nonNumeric>
<ix:nonFraction id="c134565119" contextRef="d_2025-08-11_2025-08-11_SubsequentEventTypeAxis-SubsequentEventMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" format="ixt:num-dot-decimal" decimals="INF">177,652</ix:nonFraction>
<ix:nonFraction id="c134565120" contextRef="d_2025-08-11_2025-08-11_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-BoardOfDirectorsChairmanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" format="ixt:num-dot-decimal" decimals="INF">8,773</ix:nonFraction>
<ix:nonFraction id="c134565121" contextRef="d_2025-08-11_2025-08-11_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-ExecutiveChairOfTheBoardMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" format="ixt:num-dot-decimal" decimals="INF">65,542</ix:nonFraction>
<ix:nonFraction id="c134565122" contextRef="d_2025-08-11_2025-08-11_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-DirectorMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" format="ixt:num-dot-decimal" decimals="INF">3,750</ix:nonFraction>
<ix:nonFraction id="c134565123" contextRef="d_2025-08-11_2025-08-11_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-ChiefExecutiveOfficerMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" format="ixt:num-dot-decimal" decimals="INF">45,000</ix:nonFraction>
<ix:nonFraction id="c134565124" contextRef="d_2025-08-11_2025-08-11_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-ChiefTechnologyOfficerMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" format="ixt:num-dot-decimal" decimals="INF">8,773</ix:nonFraction>
<ix:nonFraction id="c134565125" contextRef="d_2025-08-11_2025-08-11_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-ChiefMedicalOfficerMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" format="ixt:num-dot-decimal" decimals="INF">13,159</ix:nonFraction>
<ix:nonFraction id="c134565126" contextRef="d_2025-08-11_2025-08-11_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-ChiefFinancialOfficerMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" format="ixt:num-dot-decimal" decimals="INF">32,655</ix:nonFraction>
<ix:footnote xml:lang="en-us" id="f2101127c-6f04-408f-a0d3-ad12ee1ffc63">Amount includes 87,531 common warrants; 91,985 Representative's Warrants and 1,533,096 Series A Warrants.</ix:footnote>
<ix:footnote xml:lang="en-us" id="fd967692e-d595-4e25-9ffc-c4169328cef1">197,098 exercised shares utilized the &#8220;cashless exercise&#8221; option and 695,334 exercised shares were paid in cash.</ix:footnote>
<ix:footnote xml:lang="en-us" id="f51af5ba4-7538-4bb9-928c-0265d9c40dbd">Shares for the convertible note proceeds received

</ix:footnote>
<ix:footnote xml:lang="en-us" id="fa49c6ab1-4932-47d6-9f7c-6d5dd8f7d72e">The initial discount rate was chosen based on private equity rates of return as described in the AICPA Practice Aid on Valuation of Privately-Held-Company Equity securities issued as compensation. For the recurring fair value measurement, the Company updated the discount rate based upon yield curves estimated to be similar in credit quality to the Company;</ix:footnote>
<ix:footnote xml:lang="en-us" id="f0ea65d84-d12a-4647-986e-2fe346aff60b">Aggregate Intrinsic Value = Excess of market value over the exercise price of all in-the-money stock.</ix:footnote>
<ix:footnote xml:lang="en-us" id="f72ee9f5c-8d9f-48fc-99e0-bf910aeb8f9b">Aggregate Intrinsic Value = Excess of market value over the exercise price of all in-the-money warrants. No outstanding or exercisable warrants were in-the-money as of March 31, 2024.</ix:footnote>
<ix:footnote xml:lang="en-us" id="fc7d7f5f5-efe3-420b-8ea0-4b5582e112b7">Scenario probability as of issuance was based on timing expectations of management that a qualified offering occurring as of December 31, 2023 was estimated at 70%, respectively; a qualified offering occurring as of June 30, 2024 was estimated at 10%; and no qualified offering occurring was estimated at 20%;</ix:footnote>
<ix:footnote xml:lang="en-us" id="f6d625244-82fa-42e1-9733-da3f33829574">The warrant has a $0.02 strike price, however, the strike price is low relative to the stock price, making the warrant value close to the value of a stock unit. The agreement has a fixed payment value of $8.0 million, see Note 6 &#8211; Related Party Transactions.</ix:footnote></ix:hidden>
<ix:references>
<link:schemaRef xlink:href="amix-20250630.xsd" xlink:type="simple"/></ix:references>
<ix:resources>
<xbrli:context id="d_2025-04-01_2025-06-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:unit id="NonApplicable"><xbrli:measure>thunderdome:item</xbrli:measure></xbrli:unit>
<xbrli:unit id="USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit>
<xbrli:context id="i_2025-03-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-03-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:unit id="USDPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit>
<xbrli:unit id="Share"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit>
<xbrli:context id="d_2024-04-01_2025-03-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-04-01_2024-03-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-03-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-03-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-04-01_2024-03-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-04-01_2024-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-04-01_2024-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-03-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-04-01_2025-03-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-04-01_2025-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-04-01_2025-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-03-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-04-01_2025-03-31_SubsidiarySaleOfStockAxis-ATMAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">amix:ATMAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-04-01_2024-03-31_SubsidiarySaleOfStockAxis-ATMAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">amix:ATMAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-04-01_2025-03-31_SubsidiarySaleOfStockAxis-PrivatePlacementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-04-01_2024-03-31_SubsidiarySaleOfStockAxis-PrivatePlacementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-04-01_2025-03-31_DebtConversionByUniqueDescriptionAxis-IssuanceOfCommonStockForExtinguishmentOfConvertibleDebtMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">amix:IssuanceOfCommonStockForExtinguishmentOfConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-04-01_2024-03-31_DebtConversionByUniqueDescriptionAxis-IssuanceOfCommonStockForExtinguishmentOfConvertibleDebtMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">amix:IssuanceOfCommonStockForExtinguishmentOfConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:unit id="Pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit>
<xbrli:context id="d_2024-10-17_2024-10-17_NonmonetaryTransactionTypeAxis-ReverseStockSplitMember_RangeAxis-MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:NonmonetaryTransactionTypeAxis">amix:ReverseStockSplitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-17</xbrli:startDate><xbrli:endDate>2024-10-17</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-10-17_2024-10-17_NonmonetaryTransactionTypeAxis-ReverseStockSplitMember_RangeAxis-MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:NonmonetaryTransactionTypeAxis">amix:ReverseStockSplitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-17</xbrli:startDate><xbrli:endDate>2024-10-17</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-10-24_2024-10-24_NonmonetaryTransactionTypeAxis-ReverseStockSplitMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:NonmonetaryTransactionTypeAxis">amix:ReverseStockSplitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-24</xbrli:startDate><xbrli:endDate>2024-10-24</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-10-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-10-24</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-10-24_2024-10-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-24</xbrli:startDate><xbrli:endDate>2024-10-24</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-26_2024-01-26_SubsidiarySaleOfStockAxis-IPOMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-26</xbrli:startDate><xbrli:endDate>2024-01-26</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-01-26_SubsidiarySaleOfStockAxis-IPOMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-26</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-11-22_2024-11-25_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">amix:UnderwrittenPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-22</xbrli:startDate><xbrli:endDate>2024-11-25</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-11-25_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">amix:UnderwrittenPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-11-25</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-11-25_ClassOfWarrantOrRightAxis-SeriesAWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amix:SeriesAWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-11-25</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-11-25_ClassOfWarrantOrRightAxis-PrefundedWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amix:PrefundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-11-25</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:unit id="Day"><xbrli:measure>utr:D</xbrli:measure></xbrli:unit>
<xbrli:context id="d_2024-11-22_2024-11-22_CounterpartyNameAxis-UnderwritersMember_SubsidiarySaleOfStockAxis-OverAllotmentOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">amix:UnderwritersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-22</xbrli:startDate><xbrli:endDate>2024-11-22</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-11-22_CounterpartyNameAxis-UnderwritersMember_SubsidiarySaleOfStockAxis-OverAllotmentOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">amix:UnderwritersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-11-22</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-11-22_ClassOfWarrantOrRightAxis-SeriesAWarrantsMember_CounterpartyNameAxis-UnderwritersMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amix:SeriesAWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">amix:UnderwritersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-11-22</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:unit id="Year"><xbrli:measure>utr:Y</xbrli:measure></xbrli:unit>
<xbrli:context id="i_2024-11-25_ClassOfWarrantOrRightAxis-PrefundedAndSeriesAWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amix:PrefundedAndSeriesAWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-11-25</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-11-22_2024-11-22_ClassOfWarrantOrRightAxis-SeriesAWarrantsMember_CounterpartyNameAxis-UnderwritersMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amix:SeriesAWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">amix:UnderwritersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-22</xbrli:startDate><xbrli:endDate>2024-11-22</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-11-22_2024-11-25_NatureOfExpenseAxis-NoncashExpensesMember_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">amix:NoncashExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">amix:UnderwrittenPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-22</xbrli:startDate><xbrli:endDate>2024-11-25</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-02-28_SubsidiarySaleOfStockAxis-ATMAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">amix:ATMAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-02-28</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-02-28_CounterpartyNameAxis-SellingAgentMember_SubsidiarySaleOfStockAxis-ATMAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">amix:SellingAgentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">amix:ATMAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-02-28</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-03-01_2025-03-31_SubsidiarySaleOfStockAxis-ATMAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">amix:ATMAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-03-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-04-01_2025-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-04-01_2024-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-04-01_2025-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-ConvertibleDebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-04-01_2024-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-ConvertibleDebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-04-01_2025-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-ConvertibleNotesToWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">amix:ConvertibleNotesToWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-04-01_2024-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-ConvertibleNotesToWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">amix:ConvertibleNotesToWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-04-01_2025-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-04-01_2024-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-04-01_2025-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-SeriesAWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">amix:SeriesAWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-04-01_2024-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-SeriesAWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">amix:SeriesAWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-04-01_2025-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-RepresentativesWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">amix:RepresentativesWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-04-01_2024-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-RepresentativesWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">amix:RepresentativesWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_ClassOfWarrantOrRightAxis-EquitybasedWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amix:EquitybasedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-04-01_2024-03-31_RestatementAxis-ScenarioPreviouslyReportedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-04-01_2024-03-31_RestatementAxis-ReverseStockSplitAdjustmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">amix:ReverseStockSplitAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-04-01_2024-03-31_RestatementAxis-RevisionOfPriorPeriodErrorCorrectionAdjustmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-04-01_2024-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember_RestatementAxis-ScenarioPreviouslyReportedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-04-01_2024-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember_RestatementAxis-ReverseStockSplitAdjustmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RestatementAxis">amix:ReverseStockSplitAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-04-01_2024-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember_RestatementAxis-RevisionOfPriorPeriodErrorCorrectionAdjustmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-04-01_2024-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-ConvertibleDebtSecuritiesMember_RestatementAxis-ScenarioPreviouslyReportedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-04-01_2024-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-ConvertibleDebtSecuritiesMember_RestatementAxis-ReverseStockSplitAdjustmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RestatementAxis">amix:ReverseStockSplitAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-04-01_2024-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-ConvertibleDebtSecuritiesMember_RestatementAxis-RevisionOfPriorPeriodErrorCorrectionAdjustmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-04-01_2024-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-ConvertibleNotesToWarrantsMember_RestatementAxis-ScenarioPreviouslyReportedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">amix:ConvertibleNotesToWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-04-01_2024-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-ConvertibleNotesToWarrantsMember_RestatementAxis-ReverseStockSplitAdjustmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">amix:ConvertibleNotesToWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RestatementAxis">amix:ReverseStockSplitAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-04-01_2024-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-ConvertibleNotesToWarrantsMember_RestatementAxis-RevisionOfPriorPeriodErrorCorrectionAdjustmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">amix:ConvertibleNotesToWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-04-01_2024-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember_RestatementAxis-ScenarioPreviouslyReportedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-04-01_2024-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember_RestatementAxis-ReverseStockSplitAdjustmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RestatementAxis">amix:ReverseStockSplitAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-04-01_2024-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember_RestatementAxis-RevisionOfPriorPeriodErrorCorrectionAdjustmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-03-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-03-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByLiabilityClassAxis-WarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-04-01_2024-03-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByLiabilityClassAxis-WarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-03-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByLiabilityClassAxis-WarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-07-07_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_MeasurementInputTypeAxis-MeasurementInputDiscountRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-07-07</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-07-07_MeasurementInputTypeAxis-MeasurementInputProbabilityRateMember_StatementScenarioAxis-QualifiedOfferingOccurringOneMember_ValuationTechniqueAxis-ValuationProbabilityweightedExpectedReturnMethodPWERMMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">amix:MeasurementInputProbabilityRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">amix:QualifiedOfferingOccurringOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">amix:ValuationProbabilityweightedExpectedReturnMethodPWERMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-07-07</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-07-07_MeasurementInputTypeAxis-MeasurementInputProbabilityRateMember_StatementScenarioAxis-QualifiedOfferingOccurringTwoMember_ValuationTechniqueAxis-ValuationProbabilityweightedExpectedReturnMethodPWERMMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">amix:MeasurementInputProbabilityRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">amix:QualifiedOfferingOccurringTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">amix:ValuationProbabilityweightedExpectedReturnMethodPWERMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-07-07</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-07-07_MeasurementInputTypeAxis-MeasurementInputProbabilityRateMember_StatementScenarioAxis-NoQualifiedOfferingOccurringMember_ValuationTechniqueAxis-ValuationProbabilityweightedExpectedReturnMethodPWERMMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">amix:MeasurementInputProbabilityRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">amix:NoQualifiedOfferingOccurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">amix:ValuationProbabilityweightedExpectedReturnMethodPWERMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-07-07</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-07-07_MeasurementInputTypeAxis-MeasurementInputFixedPriceMember_RangeAxis-MinimumMember_ValuationTechniqueAxis-ValuationProbabilityweightedExpectedReturnMethodPWERMMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">amix:MeasurementInputFixedPriceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">amix:ValuationProbabilityweightedExpectedReturnMethodPWERMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-07-07</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-07-07_MeasurementInputTypeAxis-MeasurementInputFixedPriceMember_RangeAxis-MaximumMember_ValuationTechniqueAxis-ValuationProbabilityweightedExpectedReturnMethodPWERMMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">amix:MeasurementInputFixedPriceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">amix:ValuationProbabilityweightedExpectedReturnMethodPWERMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-07-07</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-07-07_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember_RangeAxis-MinimumMember_ValuationTechniqueAxis-ValuationProbabilityweightedExpectedReturnMethodPWERMMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">amix:ValuationProbabilityweightedExpectedReturnMethodPWERMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-07-07</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-07-07_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember_RangeAxis-MaximumMember_ValuationTechniqueAxis-ValuationProbabilityweightedExpectedReturnMethodPWERMMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">amix:ValuationProbabilityweightedExpectedReturnMethodPWERMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-07-07</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_MeasurementInputTypeAxis-MeasurementInputProbabilityRateMember_StatementScenarioAxis-QualifiedOfferingOccurringOneMember_ValuationTechniqueAxis-ValuationProbabilityweightedExpectedReturnMethodPWERMMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">amix:MeasurementInputProbabilityRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">amix:QualifiedOfferingOccurringOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">amix:ValuationProbabilityweightedExpectedReturnMethodPWERMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_MeasurementInputTypeAxis-MeasurementInputProbabilityRateMember_StatementScenarioAxis-QualifiedOfferingOccurringTwoMember_ValuationTechniqueAxis-ValuationProbabilityweightedExpectedReturnMethodPWERMMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">amix:MeasurementInputProbabilityRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">amix:QualifiedOfferingOccurringTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">amix:ValuationProbabilityweightedExpectedReturnMethodPWERMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_MeasurementInputTypeAxis-MeasurementInputProbabilityRateMember_StatementScenarioAxis-NoQualifiedOfferingOccurringMember_ValuationTechniqueAxis-ValuationProbabilityweightedExpectedReturnMethodPWERMMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">amix:MeasurementInputProbabilityRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">amix:NoQualifiedOfferingOccurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">amix:ValuationProbabilityweightedExpectedReturnMethodPWERMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-07-07_2023-07-07_ClassOfWarrantOrRightAxis-TheWarrantMember_RelatedPartyTransactionAxis-TerminationAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amix:TheWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">amix:TerminationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-07</xbrli:startDate><xbrli:endDate>2023-07-07</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-01-29_ClassOfWarrantOrRightAxis-TheWarrantMember_RelatedPartyTransactionAxis-TerminationAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amix:TheWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">amix:TerminationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-29</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-09-09_DebtInstrumentAxis-TheNotesMember_RangeAxis-MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amix:TheNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-09</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-09-09_DebtInstrumentAxis-TheNotesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amix:TheNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-09</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-09-09_ClassOfWarrantOrRightAxis-BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amix:BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-09</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-09-09_2023-09-09_ClassOfWarrantOrRightAxis-BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amix:BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-09</xbrli:startDate><xbrli:endDate>2023-09-09</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-09-10_2024-03-31_DebtInstrumentAxis-TheNotesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amix:TheNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-10</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-01-26_DebtInstrumentAxis-TheNotesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amix:TheNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-26</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-03-31_DebtInstrumentAxis-ConvertibleDebtWith499PercentBeneficialOwnershipLimitationMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amix:ConvertibleDebtWith499PercentBeneficialOwnershipLimitationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-04-01_2025-03-31_DebtInstrumentAxis-ConvertibleDebtWith499PercentBeneficialOwnershipLimitationMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amix:ConvertibleDebtWith499PercentBeneficialOwnershipLimitationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-04-01_2025-03-31_DebtConversionByUniqueDescriptionAxis-ConversionOfConvertibleNotesToCommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">amix:ConversionOfConvertibleNotesToCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-03-31_DebtInstrumentAxis-TheNotesMember_LongtermDebtTypeAxis-ConvertibleDebtMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amix:TheNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-04-01_2025-03-31_DebtInstrumentAxis-TheNotesMember_LongtermDebtTypeAxis-ConvertibleDebtMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amix:TheNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-03-31_DebtInstrumentAxis-TheNotesMember_LongtermDebtTypeAxis-ConvertibleDebtMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amix:TheNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-03-31_ClassOfWarrantOrRightAxis-BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amix:BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-03-31_ClassOfWarrantOrRightAxis-BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amix:BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-03-31_ClassOfWarrantOrRightAxis-BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amix:BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-03-31_ClassOfWarrantOrRightAxis-BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amix:BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-03-31_ClassOfWarrantOrRightAxis-BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember_MeasurementInputTypeAxis-MeasurementInputDiscountRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amix:BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_ClassOfWarrantOrRightAxis-BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember_MeasurementInputTypeAxis-MeasurementInputDiscountForLackOfMarketabilityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amix:BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountForLackOfMarketabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-04-01_2025-03-31_DebtInstrumentAxis-TheNotesMember_RangeAxis-MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amix:TheNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-11-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-11-29</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-02-15_2024-02-15_AwardTypeAxis-RestrictedStockMember_TitleOfIndividualAxis-MarketingConsultantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">amix:MarketingConsultantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-15</xbrli:startDate><xbrli:endDate>2024-02-15</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-02-15_AwardTypeAxis-RestrictedStockMember_TitleOfIndividualAxis-MarketingConsultantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">amix:MarketingConsultantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-15</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:unit id="Month"><xbrli:measure>utr:M</xbrli:measure></xbrli:unit>
<xbrli:context id="d_2024-04-01_2025-03-31_AwardTypeAxis-RestrictedStockMember_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-04-01_2024-03-31_AwardTypeAxis-RestrictedStockMember_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-04-01_2025-03-31_AwardTypeAxis-RestrictedStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-04-01_2024-03-31_AwardTypeAxis-RestrictedStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-03-31_AwardTypeAxis-RestrictedStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-03-31_AwardTypeAxis-RestrictedStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-04-06_SubsidiarySaleOfStockAxis-PrivatePlacementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-06</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-02-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-02-28</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-06-30_PlanNameAxis-The2023StockPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">amix:The2023StockPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-03-31_PlanNameAxis-The2023StockPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">amix:The2023StockPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-08-01_2023-08-31_PlanNameAxis-The2023StockPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">amix:The2023StockPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-01</xbrli:startDate><xbrli:endDate>2023-08-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-04-01_2024-04-01_PlanNameAxis-The2023StockPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">amix:The2023StockPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-04-01</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-04-01_2025-04-01_PlanNameAxis-The2023StockPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">amix:The2023StockPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-04-01</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-04-01"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-04-01</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-04-01_2025-03-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2023StockPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">amix:The2023StockPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-03-31_AwardTypeAxis-EmployeeStockOptionMember_ValuationTechniqueAxis-BlackscholesModelMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">amix:BlackscholesModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-03-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MinimumMember_ValuationTechniqueAxis-BlackscholesModelMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">amix:BlackscholesModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-03-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MaximumMember_ValuationTechniqueAxis-BlackscholesModelMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">amix:BlackscholesModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-04-01_2025-03-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MinimumMember_ValuationTechniqueAxis-BlackscholesModelMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">amix:BlackscholesModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-04-01_2025-03-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MaximumMember_ValuationTechniqueAxis-BlackscholesModelMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">amix:BlackscholesModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-04-01_2025-03-31_AwardTypeAxis-EmployeeStockOptionMember_ValuationTechniqueAxis-BlackscholesModelMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">amix:BlackscholesModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-03-31_AwardTypeAxis-EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-04-01_2025-03-31_AwardTypeAxis-EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-04-01_2025-03-31_AwardTypeAxis-EmployeeStockOptionMember_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-04-01_2025-03-31_AwardTypeAxis-EmployeeStockOptionMember_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-03-31_AwardTypeAxis-EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-04-01_2024-03-31_AwardTypeAxis-EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-04-01_2024-03-31_AwardTypeAxis-EmployeeStockOptionMember_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-04-01_2024-03-31_AwardTypeAxis-EmployeeStockOptionMember_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-07-10_2024-07-10_CounterpartyNameAxis-RfInnovationsIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">amix:RfInnovationsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-10</xbrli:startDate><xbrli:endDate>2024-07-10</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-07-10_CounterpartyNameAxis-RfInnovationsIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">amix:RfInnovationsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-07-10</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-10-01_2024-12-31_CounterpartyNameAxis-RfInnovationsIncMember_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">amix:RfInnovationsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-11-22_2024-11-25_ClassOfWarrantOrRightAxis-RepresentativesWarrantsMember_CounterpartyNameAxis-UnderwritersMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amix:RepresentativesWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">amix:UnderwritersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-22</xbrli:startDate><xbrli:endDate>2024-11-25</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-11-22_2024-11-25_ClassOfWarrantOrRightAxis-RepresentativesWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amix:RepresentativesWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-22</xbrli:startDate><xbrli:endDate>2024-11-25</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-11-25_ClassOfWarrantOrRightAxis-RepresentativesWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amix:RepresentativesWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-11-25</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-11-25_ClassOfWarrantOrRightAxis-SeriesAWarrantsAndTheRepresentativesWarrantsMember_MeasurementInputTypeAxis-ValuationTechniqueDiscountedCashFlowMember_ValuationTechniqueAxis-BlackscholesModelMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amix:SeriesAWarrantsAndTheRepresentativesWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">amix:BlackscholesModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-11-25</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-11-25_ClassOfWarrantOrRightAxis-SeriesAWarrantsAndTheRepresentativesWarrantsMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember_ValuationTechniqueAxis-BlackscholesModelMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amix:SeriesAWarrantsAndTheRepresentativesWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">amix:BlackscholesModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-11-25</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-01-26_ClassOfWarrantOrRightAxis-EquitybasedWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amix:EquitybasedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-26</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-01-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-01-26</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-01-26_ClassOfWarrantOrRightAxis-EquitybasedWarrantsMember_MeasurementInputTypeAxis-MeasurementInputDiscountRateMember_ValuationTechniqueAxis-BlackscholesModelMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amix:EquitybasedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">amix:BlackscholesModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-26</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-01-26_ClassOfWarrantOrRightAxis-EquitybasedWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember_ValuationTechniqueAxis-BlackscholesModelMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amix:EquitybasedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">amix:BlackscholesModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-26</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-01-26_ClassOfWarrantOrRightAxis-EquitybasedWarrantsMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember_ValuationTechniqueAxis-BlackscholesModelMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amix:EquitybasedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">amix:BlackscholesModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-26</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-04-01_2025-03-31_ClassOfWarrantOrRightAxis-EquitybasedWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amix:EquitybasedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-03-31_AwardTypeAxis-WarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-04-01_2025-03-31_AwardTypeAxis-WarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-03-31_AwardTypeAxis-WarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-04-01_2024-03-31_AwardTypeAxis-WarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-03-31_AwardTypeAxis-WarrantMember_RangeAxis-MinimumMember_ValuationTechniqueAxis-BlackscholesModelMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">amix:BlackscholesModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-03-31_AwardTypeAxis-WarrantMember_RangeAxis-MaximumMember_ValuationTechniqueAxis-BlackscholesModelMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">amix:BlackscholesModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-04-01_2024-03-31_AwardTypeAxis-WarrantMember_RangeAxis-MinimumMember_ValuationTechniqueAxis-BlackscholesModelMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">amix:BlackscholesModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-04-01_2024-03-31_AwardTypeAxis-WarrantMember_RangeAxis-MaximumMember_ValuationTechniqueAxis-BlackscholesModelMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">amix:BlackscholesModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-03-31_LitigationStatusAxis-PendingLitigationMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-04-01_2025-03-31_RangeAxis-MinimumMember_TypeOfArrangementAxis-EmploymentContractsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:EmploymentContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-04-01_2025-03-31_RangeAxis-MaximumMember_TypeOfArrangementAxis-EmploymentContractsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:EmploymentContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-06-17_2024-06-17_TitleOfIndividualAxis-ChiefExecutiveOfficerMember_TypeOfArrangementAxis-EmploymentContractsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:EmploymentContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-17</xbrli:startDate><xbrli:endDate>2024-06-17</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-06-17_2024-06-17_AwardTypeAxis-InducementOptionsMember_TitleOfIndividualAxis-ChiefExecutiveOfficerMember_TypeOfArrangementAxis-EmploymentContractsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amix:InducementOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:EmploymentContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-17</xbrli:startDate><xbrli:endDate>2024-06-17</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-06-17_2024-06-17_AwardTypeAxis-InducementOptionsMember_TitleOfIndividualAxis-ChiefExecutiveOfficerMember_TypeOfArrangementAxis-EmploymentContractsMember_VestingAxis-ShareBasedCompensationAwardTrancheOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amix:InducementOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:EmploymentContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-17</xbrli:startDate><xbrli:endDate>2024-06-17</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-06-17_2024-06-17_StatementScenarioAxis-ScenarioContractTerminationMember_TitleOfIndividualAxis-ChiefExecutiveOfficerMember_TypeOfArrangementAxis-EmploymentContractsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">amix:ScenarioContractTerminationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:EmploymentContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-17</xbrli:startDate><xbrli:endDate>2024-06-17</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-06-17_2024-06-17_StatementScenarioAxis-ScenarioContractTerminationWithoutCauseMember_TitleOfIndividualAxis-ChiefExecutiveOfficerMember_TypeOfArrangementAxis-EmploymentContractsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">amix:ScenarioContractTerminationWithoutCauseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:EmploymentContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-17</xbrli:startDate><xbrli:endDate>2024-06-17</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-06-17_2024-06-17_TitleOfIndividualAxis-ExecutiveViceChairAndStrategicAdvisorToTheChiefExecutiveOfficerMember_TypeOfArrangementAxis-EmploymentContractsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">amix:ExecutiveViceChairAndStrategicAdvisorToTheChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:EmploymentContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-17</xbrli:startDate><xbrli:endDate>2024-06-17</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-11-01"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-11-01</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-04-01_2025-03-31_RangeAxis-MaximumMember_RelatedPartyTransactionAxis-AccountingAndFinancialReportingServicesMember_RelatedPartyTransactionsByRelatedPartyAxis-ConsultingFirmOwnedByFormerCFOMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">amix:AccountingAndFinancialReportingServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">amix:ConsultingFirmOwnedByFormerCFOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-03-31_RelatedPartyTransactionAxis-AccountingAndFinancialReportingServicesMember_RelatedPartyTransactionsByRelatedPartyAxis-ConsultingFirmOwnedByFormerCFOMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">amix:AccountingAndFinancialReportingServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">amix:ConsultingFirmOwnedByFormerCFOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-03-31_RelatedPartyTransactionAxis-AccountingAndFinancialReportingServicesMember_RelatedPartyTransactionsByRelatedPartyAxis-ConsultingFirmOwnedByFormerCFOMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">amix:AccountingAndFinancialReportingServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">amix:ConsultingFirmOwnedByFormerCFOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-04-01_2025-03-31_DebtInstrumentAxis-TheBridgeOfferingMember_RelatedPartyTransactionsByRelatedPartyAxis-ManagementBoardOfDirectorFamilyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amix:TheBridgeOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">amix:ManagementBoardOfDirectorFamilyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-04-01_2025-03-31_DebtInstrumentAxis-TheBridgeOfferingMember_RelatedPartyTransactionsByRelatedPartyAxis-ManagementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amix:TheBridgeOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ManagementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-04-01_2025-03-31_DebtInstrumentAxis-TheBridgeOfferingMember_RelatedPartyTransactionsByRelatedPartyAxis-RelatedPartyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amix:TheBridgeOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-07-07_ClassOfWarrantOrRightAxis-TheWarrantMember_RelatedPartyTransactionAxis-TerminationAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amix:TheWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">amix:TerminationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-07-07</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-07-07_2023-07-07_ClassOfWarrantOrRightAxis-TheWarrantMember_RelatedPartyTransactionAxis-TerminationAgreementMember_UnderlyingAssetClassAxis-CommonStock6MonthsLockupPeriodMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amix:TheWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">amix:TerminationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:UnderlyingAssetClassAxis">amix:CommonStock6MonthsLockupPeriodMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-07</xbrli:startDate><xbrli:endDate>2023-07-07</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-07-07_2023-07-07_ClassOfWarrantOrRightAxis-TheWarrantMember_RelatedPartyTransactionAxis-TerminationAgreementMember_UnderlyingAssetClassAxis-CommonStock12MonthsLockupPeriodMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amix:TheWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">amix:TerminationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:UnderlyingAssetClassAxis">amix:CommonStock12MonthsLockupPeriodMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-07</xbrli:startDate><xbrli:endDate>2023-07-07</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-03-31_TaxPeriodAxis-ExpirationCommencingTaxYear20342037Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">amix:ExpirationCommencingTaxYear20342037Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-03-31_TaxPeriodAxis-NolGeneratedDuring20172024Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">amix:NolGeneratedDuring20172024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-04-01_2025-05-28_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-ATMAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">amix:ATMAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-05-28</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-04-17_2025-04-17_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_SubsequentEventTypeAxis-SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-17</xbrli:startDate><xbrli:endDate>2025-04-17</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-04-17_2025-04-17_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_SubsequentEventTypeAxis-SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-17</xbrli:startDate><xbrli:endDate>2025-04-17</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-04-17_2025-04-17_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_SubsequentEventTypeAxis-SubsequentEventMember_VestingAxis-ShareBasedCompensationAwardTrancheOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-17</xbrli:startDate><xbrli:endDate>2025-04-17</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-06-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-04-01_2024-06-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-06-30_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-06-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-06-30_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-04-01_2025-06-30_SubsidiarySaleOfStockAxis-PrivatePlacementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-04-01_2024-06-30_SubsidiarySaleOfStockAxis-PrivatePlacementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-04-01_2025-06-30_SubsidiarySaleOfStockAxis-ATMAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">amix:ATMAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-04-01_2025-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-04-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-04-01_2025-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-ConvertibleDebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-04-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-ConvertibleDebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-04-01_2025-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-ConvertibleNotesToWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">amix:ConvertibleNotesToWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-04-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-ConvertibleNotesToWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">amix:ConvertibleNotesToWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-04-01_2025-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-04-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-04-01_2025-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-SeriesAWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">amix:SeriesAWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-04-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-SeriesAWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">amix:SeriesAWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-04-01_2025-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-RepresentativesWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">amix:RepresentativesWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-04-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-RepresentativesWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">amix:RepresentativesWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-04-01_2024-06-30_RestatementAxis-ScenarioPreviouslyReportedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-04-01_2024-06-30_RestatementAxis-ReverseStockSplitAdjustmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">amix:ReverseStockSplitAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-04-01_2024-06-30_RestatementAxis-RevisionOfPriorPeriodErrorCorrectionAdjustmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-04-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember_RestatementAxis-ScenarioPreviouslyReportedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-04-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember_RestatementAxis-ReverseStockSplitAdjustmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RestatementAxis">amix:ReverseStockSplitAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-04-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember_RestatementAxis-RevisionOfPriorPeriodErrorCorrectionAdjustmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-04-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-ConvertibleDebtSecuritiesMember_RestatementAxis-ScenarioPreviouslyReportedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-04-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-ConvertibleDebtSecuritiesMember_RestatementAxis-ReverseStockSplitAdjustmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RestatementAxis">amix:ReverseStockSplitAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-04-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-ConvertibleDebtSecuritiesMember_RestatementAxis-RevisionOfPriorPeriodErrorCorrectionAdjustmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-04-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-ConvertibleNotesToWarrantsMember_RestatementAxis-ScenarioPreviouslyReportedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">amix:ConvertibleNotesToWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-04-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-ConvertibleNotesToWarrantsMember_RestatementAxis-ReverseStockSplitAdjustmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">amix:ConvertibleNotesToWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RestatementAxis">amix:ReverseStockSplitAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-04-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-ConvertibleNotesToWarrantsMember_RestatementAxis-RevisionOfPriorPeriodErrorCorrectionAdjustmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">amix:ConvertibleNotesToWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-04-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember_RestatementAxis-ScenarioPreviouslyReportedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-04-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember_RestatementAxis-ReverseStockSplitAdjustmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RestatementAxis">amix:ReverseStockSplitAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-04-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember_RestatementAxis-RevisionOfPriorPeriodErrorCorrectionAdjustmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-09-09_2024-03-31_DebtInstrumentAxis-TheNotesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amix:TheNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-09</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-06-30_DebtInstrumentAxis-ConvertibleDebtWith499PercentBeneficialOwnershipLimitationMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amix:ConvertibleDebtWith499PercentBeneficialOwnershipLimitationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-26_2024-01-26_DebtConversionByUniqueDescriptionAxis-ConversionOfConvertibleNotesToCommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">amix:ConversionOfConvertibleNotesToCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-26</xbrli:startDate><xbrli:endDate>2024-01-26</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-03-28_2025-03-28_DebtInstrumentAxis-ConvertibleDebtWith499PercentBeneficialOwnershipLimitationMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amix:ConvertibleDebtWith499PercentBeneficialOwnershipLimitationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-03-28</xbrli:startDate><xbrli:endDate>2025-03-28</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-04-01_2025-06-30_DebtInstrumentAxis-TheNotesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amix:TheNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-04-01_2024-06-30_DebtInstrumentAxis-TheNotesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amix:TheNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-04-01_2025-06-30_AwardTypeAxis-RestrictedStockMember_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-04-01_2024-06-30_AwardTypeAxis-RestrictedStockMember_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-04-01_2025-06-30_AwardTypeAxis-RestrictedStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-04-01_2024-06-30_AwardTypeAxis-RestrictedStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-06-30_AwardTypeAxis-RestrictedStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-04-01_2025-06-30_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2023StockPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">amix:The2023StockPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-06-30_AwardTypeAxis-EmployeeStockOptionMember_ValuationTechniqueAxis-BlackscholesModelMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">amix:BlackscholesModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-04-01_2025-06-30_AwardTypeAxis-EmployeeStockOptionMember_ValuationTechniqueAxis-BlackscholesModelMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">amix:BlackscholesModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-06-30_AwardTypeAxis-EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-04-01_2025-06-30_AwardTypeAxis-EmployeeStockOptionMember_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-04-01_2025-06-30_AwardTypeAxis-EmployeeStockOptionMember_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-04-01_2024-06-30_AwardTypeAxis-EmployeeStockOptionMember_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-04-01_2024-06-30_AwardTypeAxis-EmployeeStockOptionMember_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-06-30_ClassOfWarrantOrRightAxis-SeriesAWarrantsAndTheRepresentativesWarrantsMember_MeasurementInputTypeAxis-MeasurementInputDiscountRateMember_ValuationTechniqueAxis-BlackscholesModelMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amix:SeriesAWarrantsAndTheRepresentativesWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">amix:BlackscholesModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-06-30_ClassOfWarrantOrRightAxis-SeriesAWarrantsAndTheRepresentativesWarrantsMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember_ValuationTechniqueAxis-BlackscholesModelMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amix:SeriesAWarrantsAndTheRepresentativesWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">amix:BlackscholesModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-06-30_ClassOfWarrantOrRightAxis-CommonWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amix:CommonWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-06-30_ClassOfWarrantOrRightAxis-RepresentativesWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amix:RepresentativesWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-06-30_ClassOfWarrantOrRightAxis-SeriesAWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amix:SeriesAWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-06-30_AwardTypeAxis-WarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-04-01_2025-06-30_AwardTypeAxis-WarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-04-01_2024-06-30_AwardTypeAxis-WarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-06-30_LitigationStatusAxis-PendingLitigationMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-04-01_2025-06-30_RangeAxis-MinimumMember_TypeOfArrangementAxis-EmploymentContractsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:EmploymentContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-04-01_2025-06-30_RangeAxis-MaximumMember_TypeOfArrangementAxis-EmploymentContractsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:EmploymentContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-07-21_ClassOfWarrantOrRightAxis-ExistingWarrantsMember_SubsequentEventTypeAxis-SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amix:ExistingWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-07-21</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-07-21_ClassOfWarrantOrRightAxis-ExistingWarrantsAt1723ExercisePriceMember_SubsequentEventTypeAxis-SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amix:ExistingWarrantsAt1723ExercisePriceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-07-21</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-07-21_2025-07-21_ClassOfWarrantOrRightAxis-ExistingWarrantsAt1723ExercisePriceMember_SubsequentEventTypeAxis-SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amix:ExistingWarrantsAt1723ExercisePriceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-21</xbrli:startDate><xbrli:endDate>2025-07-21</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-07-21_ClassOfWarrantOrRightAxis-ExistingWarrantsAt1722ExercisePriceMember_SubsequentEventTypeAxis-SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amix:ExistingWarrantsAt1722ExercisePriceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-07-21</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-07-21_SubsequentEventTypeAxis-SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-07-21</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-07-21_ClassOfWarrantOrRightAxis-SeriesBWarrantsMember_SubsequentEventTypeAxis-SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amix:SeriesBWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-07-21</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-07-21_ClassOfWarrantOrRightAxis-RepresentativesWarrantsMember_SubsequentEventTypeAxis-SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amix:RepresentativesWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-07-21</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-07-21_2025-07-21_ClassOfWarrantOrRightAxis-ExistingWarrantsMember_SubsequentEventTypeAxis-SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amix:ExistingWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-21</xbrli:startDate><xbrli:endDate>2025-07-21</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-07-01_ClassOfWarrantOrRightAxis-SeriesAWarrantsMember_SubsequentEventTypeAxis-SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amix:SeriesAWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-07-01</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-07-01_2025-07-31_ClassOfWarrantOrRightAxis-SeriesAWarrantsMember_SubsequentEventTypeAxis-SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amix:SeriesAWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-07-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-07-31_ClassOfWarrantOrRightAxis-SeriesAWarrantsMember_SubsequentEventTypeAxis-SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amix:SeriesAWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-07-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-08-05_2025-08-05_ClassOfWarrantOrRightAxis-PreipoWarrantsMember_SubsequentEventTypeAxis-SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amix:PreipoWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-08-05</xbrli:startDate><xbrli:endDate>2025-08-05</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-07-01_2025-07-31_SubsequentEventTypeAxis-SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-07-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-08-11_2025-08-11_SubsequentEventTypeAxis-SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-08-11</xbrli:startDate><xbrli:endDate>2025-08-11</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-08-11_2025-08-11_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-BoardOfDirectorsChairmanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-08-11</xbrli:startDate><xbrli:endDate>2025-08-11</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-08-11_2025-08-11_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-ExecutiveChairOfTheBoardMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">amix:ExecutiveChairOfTheBoardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-08-11</xbrli:startDate><xbrli:endDate>2025-08-11</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-08-11_2025-08-11_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-DirectorMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-08-11</xbrli:startDate><xbrli:endDate>2025-08-11</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-08-11_2025-08-11_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-ChiefExecutiveOfficerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-08-11</xbrli:startDate><xbrli:endDate>2025-08-11</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-08-11_2025-08-11_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-ChiefTechnologyOfficerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">amix:ChiefTechnologyOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-08-11</xbrli:startDate><xbrli:endDate>2025-08-11</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-08-11_2025-08-11_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-ChiefMedicalOfficerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">amix:ChiefMedicalOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-08-11</xbrli:startDate><xbrli:endDate>2025-08-11</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-08-11_2025-08-11_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-ChiefFinancialOfficerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-08-11</xbrli:startDate><xbrli:endDate>2025-08-11</xbrli:endDate></xbrli:period></xbrli:context>
<ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="f2101127c-6f04-408f-a0d3-ad12ee1ffc63" fromRefs="c134564300 c134564301"/>
<ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="fd967692e-d595-4e25-9ffc-c4169328cef1" fromRefs="c134564126 c134564127"/>
<ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="f51af5ba4-7538-4bb9-928c-0265d9c40dbd" fromRefs="c134563969 c134563970 c134564214 c134564215"/>
<ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="fa49c6ab1-4932-47d6-9f7c-6d5dd8f7d72e" fromRefs="c134565294"/>
<ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="f0ea65d84-d12a-4647-986e-2fe346aff60b" fromRefs="c134564114 c134564115 c134564121 c134564141 c134564145 c134564288 c134564289"/>
<ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="f72ee9f5c-8d9f-48fc-99e0-bf910aeb8f9b" fromRefs="c134564053 c134564073 c134564077"/>
<ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="fc7d7f5f5-efe3-420b-8ea0-4b5582e112b7" fromRefs="c134565295 c134565296 c134565297"/>
<ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="f6d625244-82fa-42e1-9733-da3f33829574" fromRefs="c134565299 c134565300"/>
<xbrli:context id="d_2024-04-01_2025-06-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001617867</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context></ix:resources>
</ix:header></div>
  <div>
   &#160;
  </div>
  <p>&#160; </p>
  <div><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><a href="#toc" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt">Table of Contents</a></p>
<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align: top; width: 33%;">&#160;</td><td style="vertical-align: top; width: 34%;">&#160;</td><td style="vertical-align: top; width: 33%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b>Filed Pursuant to Rule</b>&#160;<b><span style="-sec-ix-hidden:val1759590397299768">424(b)(3)</span></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b>Registration No. 333-290472</b></p> </td></tr>
</tbody></table>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<div style="text-align: center;">
 <img alt="logolrg.jpg" src="logolrg.jpg"/>
</div>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>2,500,000 Shares of Common Stock </b></p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">This prospectus relates to the offer and resale of up to 2,500,000 shares of our common stock by Lincoln Park Capital Fund, LLC, which we refer to in this prospectus as &#8220;Lincoln Park&#8221; or the &#8220;selling stockholder.&#8221;</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The shares of common stock being offered by the selling stockholder consist of:</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#9679; &#160; &#160; &#160; &#160; &#160;up to 2,238,068 shares of common stock that we may elect to issue and sell to Lincoln Park, in our sole discretion from time to time after the date of this prospectus (the &#8220;Purchase Shares&#8221;), pursuant to a purchase agreement, dated as of August 25, 2025, that we entered into with Lincoln Park, which we refer to in this prospectus as the &#8220;Purchase Agreement&#8221;, providing for up to $15.0 million of committed equity financing; and</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#9679; &#160; &#160; &#160; &#160; &#160;261,932 shares of our common stock that we issued to Lincoln Park on August 25, 2025 as consideration for its irrevocable commitment to purchase our common stock pursuant to the Purchase Agreement (the &#8220;Commitment Shares&#8221;).</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">See &#8220;The Lincoln Park Transaction&#8221; for descriptions of the Purchase Agreement and &#8220;Selling Stockholder&#8221; for additional information regarding Lincoln Park.</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We are not selling any securities under this prospectus and will not receive any of the proceeds from the resale by the selling stockholder of shares of common stock under this prospectus. However, we may receive proceeds of up to $15.0 million from our sale of Purchase Shares, if any, to Lincoln Park under the Purchase Agreement, from time to time in our discretion after the date the registration statement of which this prospectus is a part is declared effective and the other conditions in the Purchase Agreement have been satisfied.</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Lincoln Park may sell the shares of our common stock described in this prospectus in a number of different ways and at varying prices. The price that Lincoln Park will pay for the shares to be resold pursuant to this prospectus will depend upon the timing of sales and will fluctuate based on the trading price of our common stock. Lincoln Park is an &#8220;underwriter&#8221; within the meaning of Section 2(a)(11) of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;).</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The purchase price for the Purchase Shares will be based upon formulas set forth in the Purchase Agreement and described in this prospectus depending on the type of purchase notice we submit to Lincoln Park from time to time. We will pay the expenses incurred in registering the shares of our common stock, including legal and accounting fees. See &#8220;Plan of Distribution&#8221; beginning on page 75&#160;for more information about how Lincoln Park may sell the shares of common stock being registered pursuant to this prospectus..</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Our common stock is listed on Nasdaq under the symbol &#8220;AMIX.&#8221; On September 19, 2025, the last reported sale price of our common stock on the Nasdaq Capital Market was $1.06 per share.</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We are an &#8220;emerging growth company&#8221; as defined in Section 2(a) of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;) and we have elected to comply with certain reduced public company reporting requirements.</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><b>Investing in our securities involves a high degree of risk. See the section entitled </b>&#8220;<b>Risk Factors</b>&#8221;<b> beginning on page </b>5<b> of this prospectus for a discussion of risks that should be considered in connection with an investment in our securities.</b></p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><b>Neither the Securities and Exchange Commission nor any other regulatory body has approved or disapproved of these securities or passed upon the accuracy or adequacy of this prospectus. Any representation to the contrary is a criminal offense. </b></p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">The date of this prospectus is September 30, 2025</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
 <div class="PGFTR" style="text-align: center; width: 100%">
  <div class="hf-row">
   <div class="hf-cell PGNUM">
    &#160;
   </div>
  </div>
 </div>
 <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
 <div class="PGHDR" style="text-align: left; width: 100%">
  <div class="hf-row">
   <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
    <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
   </div>
   <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
    &#160;
   </div>
  </div>
 </div>
</div>
<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</p></div>
  <p></p>
  <div>
   &#160;
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <div>
   &#160;
  </div>
  <div>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="toc" href="#"></a>TABLE OF CONTENTS </b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <table cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 100%; margin-left: 0pt; margin-right: 0pt;">
    <tbody>
     <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
      <td style="vertical-align: bottom; width: 95%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 2px; padding-bottom: 2px;">&#160;</td>
      <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 2px; padding-bottom: 2px;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Page</b></p> </td>
     </tr>

     <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
      <td style="vertical-align: bottom; width: 95%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 2px; padding-bottom: 2px;">&#160;</td>
      <td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 2px; padding-bottom: 2px;">&#160;</td>
     </tr>

     <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
      <td style="border-width: 1px; border-style: solid; border-color: black black rgb(0, 0, 0); vertical-align: bottom; width: 95%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 2px; padding-bottom: 2px;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="#about" style="-sec-extract:exhibit;">ABOUT THIS PROSPECTUS</a></p> </td>
      <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 5%; border-top: 1px solid black; border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 2px; padding-bottom: 2px;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><a class="tocPGNUM" href="#about">i</a></p> </td>
     </tr>

     <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
      <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 95%; border-left: 1px solid black; border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 2px; padding-bottom: 2px;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="#pro_sum" style="-sec-extract:exhibit;">PROSPECTUS SUMMARY</a></p> </td>
      <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 5%; border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 2px; padding-bottom: 2px;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><a class="tocPGNUM" href="#pro_sum">1</a></p> </td>
     </tr>

     <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
      <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 95%; border-left: 1px solid black; border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 2px; padding-bottom: 2px;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="#risk" style="-sec-extract:exhibit;">RISK FACTORS</a></p> </td>
      <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 5%; border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 2px; padding-bottom: 2px;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><a class="tocPGNUM" href="#risk">6</a></p> </td>
     </tr>

     <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
      <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 95%; border-left: 1px solid black; border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 2px; padding-bottom: 2px;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="#caution" style="-sec-extract:exhibit;">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</a></p> </td>
      <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 5%; border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 2px; padding-bottom: 2px;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><a class="tocPGNUM" href="#caution">24</a></p> </td>
     </tr>

     <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
      <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 95%; border-left: 1px solid black; border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 2px; padding-bottom: 2px;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="#lincoln" style="-sec-extract:exhibit;">THE LINCOLN PARK TRANSACTION</a></p> </td>
      <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 5%; border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 2px; padding-bottom: 2px;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><a class="tocPGNUM" href="#lincoln">25</a></p> </td>
     </tr>

     <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
      <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 95%; border-left: 1px solid black; border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 2px; padding-bottom: 2px;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="#proceeds" style="-sec-extract:exhibit;">USE OF PROCEEDS</a></p> </td>
      <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 5%; border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 2px; padding-bottom: 2px;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><a class="tocPGNUM" href="#proceeds">30</a></p> </td>
     </tr>

     <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
      <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 95%; border-left: 1px solid black; border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 2px; padding-bottom: 2px;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="#dividend_policy" style="-sec-extract:exhibit;">DIVIDEND POLICY</a></p> </td>
      <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 5%; border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 2px; padding-bottom: 2px;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><a class="tocPGNUM" href="#dividend_policy">30</a></p> </td>
     </tr>

     <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
      <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 95%; border-left: 1px solid black; border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 2px; padding-bottom: 2px;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="#dilution" style="-sec-extract:exhibit;">DILUTION</a></p> </td>
      <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 5%; border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 2px; padding-bottom: 2px;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><a class="tocPGNUM" href="#dilution">31</a></p> </td>
     </tr>

     <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
      <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 95%; border-left: 1px solid black; border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 2px; padding-bottom: 2px;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="#mda" style="-sec-extract:exhibit;">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</a></p> </td>
      <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 5%; border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 2px; padding-bottom: 2px;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><a class="tocPGNUM" href="#mda">32</a></p> </td>
     </tr>

     <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
      <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 95%; border-left: 1px solid black; border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 2px; padding-bottom: 2px;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="#business" style="-sec-extract:exhibit;">BUSINESS</a></p> </td>
      <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 5%; border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 2px; padding-bottom: 2px;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><a class="tocPGNUM" href="#business">40</a></p> </td>
     </tr>

     <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
      <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 95%; border-left: 1px solid black; border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 2px; padding-bottom: 2px;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="#management" style="-sec-extract:exhibit;">MANAGEMENT</a></p> </td>
      <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 5%; border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 2px; padding-bottom: 2px;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><a class="tocPGNUM" href="#management">59</a></p> </td>
     </tr>

     <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
      <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 95%; border-left: 1px solid black; border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 2px; padding-bottom: 2px;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="#exe_comp" style="-sec-extract:exhibit;">EXECUTIVE AND DIRECTOR COMPENSATION</a></p> </td>
      <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 5%; border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 2px; padding-bottom: 2px;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><a class="tocPGNUM" href="#exe_comp">61</a></p> </td>
     </tr>

     <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
      <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 95%; border-left: 1px solid black; border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 2px; padding-bottom: 2px;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="#certain" style="-sec-extract:exhibit;">CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS AND DIRECTOR INDEPENDENCE</a></p> </td>
      <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 5%; border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 2px; padding-bottom: 2px;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><a class="tocPGNUM" href="#certain">67</a></p> </td>
     </tr>

     <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
      <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 95%; border-left: 1px solid black; border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 2px; padding-bottom: 2px;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="#security_ownership" style="-sec-extract:exhibit;">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</a></p> </td>
      <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 5%; border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 2px; padding-bottom: 2px;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><a class="tocPGNUM" href="#security_ownership">68</a></p> </td>
     </tr>

     <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
      <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 95%; border-left: 1px solid black; border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 2px; padding-bottom: 2px;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="#cap_stock" style="-sec-extract:exhibit;">DESCRIPTION OF CAPITAL STOCK</a></p> </td>
      <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 5%; border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 2px; padding-bottom: 2px;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><a class="tocPGNUM" href="#cap_stock">69</a></p> </td>
     </tr>

     <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
      <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 95%; border-left: 1px solid black; border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 2px; padding-bottom: 2px;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="#selling" style="-sec-extract:exhibit;">SELLING STOCKHOLDER</a></p> </td>
      <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 5%; border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 2px; padding-bottom: 2px;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><a class="tocPGNUM" href="#selling">75</a></p> </td>
     </tr>

     <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
      <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 95%; border-left: 1px solid black; border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 2px; padding-bottom: 2px;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="#plan_distribution" style="-sec-extract:exhibit;">PLAN OF DISTRIBUTION</a></p> </td>
      <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 5%; border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 2px; padding-bottom: 2px;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><a class="tocPGNUM" href="#plan_distribution">76</a></p> </td>
     </tr>

     <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
      <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 95%; border-left: 1px solid black; border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 2px; padding-bottom: 2px;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="#legal" style="-sec-extract:exhibit;">LEGAL MATTERS</a></p> </td>
      <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 5%; border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 2px; padding-bottom: 2px;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><a class="tocPGNUM" href="#legal">78</a></p> </td>
     </tr>

     <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
      <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 95%; border-left: 1px solid black; border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 2px; padding-bottom: 2px;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="#expert" style="-sec-extract:exhibit;">EXPERTS</a></p> </td>
      <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 5%; border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 2px; padding-bottom: 2px;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><a class="tocPGNUM" href="#expert">78</a></p> </td>
     </tr>

     <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
      <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 95%; border-left: 1px solid black; border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 2px; padding-bottom: 2px;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="#where" style="-sec-extract:exhibit;">WHERE YOU CAN FIND MORE INFORMATION</a></p> </td>
      <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 5%; border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 2px; padding-bottom: 2px;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><a class="tocPGNUM" href="#where">78</a></p> </td>
     </tr>

     <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
      <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 95%; border-left: 1px solid black; border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 2px; padding-bottom: 2px;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="#financials" style="-sec-extract:exhibit;">INDEX TO FINANCIAL STATEMENTS</a></p> </td>
      <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 5%; border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-top: 2px; padding-bottom: 2px;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><a class="tocPGNUM" href="#financials">79</a></p> </td>
     </tr>

    </tbody>
   </table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM">
       &#160;
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </div>
   <div>
    &#160;
   </div>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  </div>
  <div>
   &#160;
  </div>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="about" href="#"></a>ABOUT THIS PROSPECTUS</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">This prospectus relates to the resale by the selling stockholder identified in this prospectus under the caption &#8220;Selling Stockholder,&#8221; from time to time, of up to an aggregate of 2,500,000 shares of our common stock.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">You should carefully read this prospectus before deciding to invest in our securities. We have not authorized anyone to provide any information or to make any representations other than those contained in this prospectus or in any free writing prospectuses prepared by or on behalf of us or to which we have referred you. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to sell only the securities offered hereby, and only under circumstances and in jurisdictions where it is lawful to do so. The information contained in this prospectus or in any applicable free writing prospectus is current only as of its date, regardless of its time of delivery or any sale of our securities. Our business, financial condition, results of operations and prospects may have changed since that date.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">For investors outside the United States: We have not done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the securities and the distribution of this prospectus outside the United States.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">This prospectus may contain references to trademarks belonging to other entities. Solely for convenience, trademarks and trade names referred to in this prospectus, including logos, artwork, and other visual displays, may appear without the &#174; or TM symbols. We do not intend our use or display of other companies&#8217; trade names or trademarks to imply a relationship with, or endorsement or sponsorship of us by, any other company.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">No dealer, salesperson or other person is authorized to give any information or to represent anything not contained in this prospectus. You must not rely on any unauthorized information or representations. This prospectus is an offer to sell only the securities offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. The information contained in this prospectus is current only as of its date.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">This prospectus contains estimates and other statistical data made by independent parties and by us relating to market size and growth and other data about our industry. We obtained the industry and market data in this prospectus from our own research as well as from industry and general publications, surveys and studies conducted by third parties. This data involves a number of assumptions and limitations and contains projections and estimates of the future performance of the industries in which we operate that are subject to a high degree of uncertainty. We caution you not to give undue weight to such projections, assumptions and estimates.&#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      i
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;&#160;</p>
  <div>
   &#160;
  </div>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="pro_sum" href="#"></a>PROSPECTUS SUMMARY</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><i>This summary highlights information contained elsewhere in this prospectus. This summary does not contain all of the information that you should consider before deciding to invest in our securities. You should read this entire prospectus carefully, including the </i>&#8220;<i>Risk Factors</i>&#8221;<i> section in this prospectus. References in this prospectus to </i>&#8220;<i>we</i>&#8221;<i>, </i>&#8220;<i>us</i>&#8221;<i>, </i>&#8220;<i>its</i>&#8221;<i>, </i>&#8220;<i>our</i>&#8221;<i> or the </i>&#8220;<i>Company</i>&#8221;<i> are to Autonomix Medical, Inc., as appropriate to the context.</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Overview</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We are a development-stage medical device company pioneering a first-in-class technology platform designed to sense and treat disorders of the nervous system. Our lead system in development is a catheter-based solution that combines diagnostic sensing and therapeutic radiofrequency ("RF") ablation. Initially developed to target intractable pain associated with pancreatic cancer, our platform is intended to provide minimally invasive access to deep neural structures and has the potential to address a wide range of clinical indications, including chronic pain, hypertension, cardiovascular disease, and other nerve-related disorders.&#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">A key differentiator of our technology is its ability to detect neural signals with greater sensitivity than commercially available systems. This performance advantage stems from two core innovations. First, our proprietary antenna array is engineered to capture extremely low-amplitude neural signals that may not be detected by conventional devices. Second, and equally important, our system processes these signals at the point of detection using a proprietary microchip embedded within the catheter. This local signal processing minimizes degradation and noise that typically occur during transmission to external consoles, allowing for high-fidelity, real-time signal capture and interpretation. Together, these capabilities enable more precise identification and targeting of nerve activity and represent a fundamental advancement in transvascular neuromodulation.&#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Our product development strategy is centered around two integrated functions: diagnostic sensing to identify pathological nerve signals, and therapeutic RF ablation to treat the identified targets. In preclinical animal models, our system has demonstrated the ability to detect signals from specific nerve bundles before ablation and confirm signal termination after ablation. We are now refining the catheter design to meet regulatory and manufacturing standards for human use.&#160;&#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In parallel, we have advanced our clinical strategy. In the second quarter of 2025, we completed our initial first-in-human proof-of-concept study ("PoC 1") evaluating the safety and feasibility of transvascular RF ablation in patients with pancreatic cancer pain. Based on the positive clinical outcomes, we have initiated a follow-on study ("PoC 2") that expands the protocol to include patients with pain associated with additional visceral cancers such as gallbladder, liver, and bile duct, as well as earlier-stage pancreatic cancer patients experiencing moderate to severe pain. This expansion reflects our goal of broadening the platform&#8217;s utility across oncology, gastroenterology, and other applicable sectors.&#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">As a development-stage company, our technology remains investigational, and there is no guarantee that our clinical trials will produce favorable outcomes or that our products will ultimately receive regulatory approval. One of the most challenging aspects of our commercialization plan will be scaling from our current prototype, which is built using hand-assembled and 3D-printed components, to a fully integrated commercial-grade device. While we have not yet assembled or tested the final commercial version, ongoing development efforts are focused on improving design robustness and manufacturability to support future clinical and commercial deployment.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <div>
   &#160;
  </div>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Company Information </b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Our principal executive offices are located at 21 Waterway Avenue, Suite 300, The Woodlands, Texas 77380 and our telephone number is (713) 588-6150. Our website address is www.autonomix.com. The information on or accessible through our website is not part of this prospectus.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      1
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Risk Factors Summary</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Our business is subject to a number of risks of which you should be aware before making an investment decision. You should carefully consider all of the information set forth in this prospectus and, in particular, should evaluate the specific factors set forth in the section titled &#8220;Risk Factors&#8221; before deciding whether to invest in our common stock. Among these important risks are the following:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Risks Related to this Offering</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">It is not possible to predict the actual number of shares of common stock we may sell to Lincoln Park under the Purchase Agreement, or the actual gross proceeds resulting from those sales.</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">The terms of the Purchase Agreement limit the amount of shares of common stock we may issue to Lincoln Park, which may limit our ability to utilize the arrangement to enhance our cash resources.</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Investors who buy shares at different times will likely pay different prices.</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">The sale or issuance of our common stock to Lincoln Park may cause dilution and the sale of the shares of common stock by Lincoln Park that it acquires pursuant to the Purchase Agreement, or the perception that such sales may occur, could cause the price of our common stock to decrease.</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Our management will have broad discretion over the use of the net proceeds from our sale of shares of common stock to Lincoln Park, you may not agree with how we use the proceeds and the proceeds may not be invested successfully.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Risks Related to Our Overall Business</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Factors raise substantial doubt about our ability to continue as a going concern;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">We have no approved products, and we cannot assure you that we will generate revenue or become profitable in the future;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">We will need additional financing over the longer term to execute our business plan and fund operations, which additional financing may not be available on reasonable terms or at all;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">We intend to utilize a single manufacturer for the manufacture of our lead product candidate and expect to continue to do so for commercial products. Risks associated with the manufacturing of our products could reduce our gross margins and negatively affect our operating results;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">We are a developmental stage Company and have not yet had a history of generating revenue;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Our business may be adversely affected by the state of the global economy, uncertainties in global financial markets, and possible trade tariffs and trade restrictions;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">We have limited experience in assembling and testing our products and may encounter problems or delays in the assembly of our products or fail to meet certain regulatory requirements which could result in an adverse effect on our business and financial results;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Rapidly changing technology in life sciences could make the products we are developing obsolete;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Adverse developments affecting the financial services industry, such as actual events or concerns involving liquidity, defaults, or non-performance by financial institutions or transactional counterparties, could adversely affect our current and projected business operations and our financial condition and results of operations;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">We may incur substantial costs as a result of litigation or other proceedings relating to patent and other intellectual property rights;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Catastrophic events and disaster recovery may disrupt business continuity;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">We may fail to meet the Sarbanes-Oxley regulations and may lack the financial controls and safeguards required of public companies;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">While our Company&#8217;s management is working to improve our internal controls and procedures, at present management has determined that our internal controls were deemed to contain material weaknesses, which could cause our financial reporting to be unreliable and lead to misinformation being disseminated to the public;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Because of the specialized nature of our business, the termination of relationships with our key employees, consultants and advisors may prevent us from successfully operating our business, including developing our products, conducting clinical studies, commercializing our products and obtaining any necessary financing; and</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Our Certificate of Incorporation and Bylaws, each as amended to date, provide for indemnification of officers and directors at the expense of the Company and limit their liability that may result in a major cost to us and hurt the interests of our stockholders because corporate resources may be expended for the benefit of officers and/or directors.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Risks Related to Government Regulation and Product Approvals</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Changes to United States federal and state regulatory agencies may cause disruptions and delays in approval of the government approval processes and regulation relating to our products;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">There is no guarantee that the FDA will grant 510(k) or de novo clearance or a premarket approval application (&#8220;PMA&#8221;) of our future products and failure to obtain necessary clearances or approvals for our future products would adversely affect our ability to grow our business;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Our product development for our sensing and ablation technologies may not meet the necessary validation requirements to achieve regulatory approvals, or our internal specifications for commercial viability;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Modifications to our future products may require new regulatory clearances or approvals or may require us to recall or cease marketing our products until clearances or approvals are obtained;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">The results of our future clinical trials may not support our product candidate claims or may result in the discovery of adverse side effects;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">We are conducting our initial Proof of Concept trial outside the United States using commercially available RF ablation equipment in a new anatomical region to assess clinical response. We plan to present the relevant data from this trial to the FDA to support the clinical requirements for clearance in the United States. However, there is no assurance that the FDA will accept this data;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Our clinical studies could be delayed or otherwise adversely affected by many factors, including difficulties in enrolling patients;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">We may have limitations in generating statistically significant long-term clinical data and gaining extended-duration indications from clinical studies involving terminal patients;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      2
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Even if our products are cleared or approved by the FDA, if we or our suppliers fail to comply with ongoing FDA requirements, or if we experience unanticipated problems with our products, these products could be subject to restrictions or withdrawal from the market;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Our products may in the future be subject to product recalls that could harm our reputation, business, and financial results;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">If our products cause or contribute to a death or a serious injury, or malfunction in certain ways, we will be subject to medical device reporting regulations, which can result in voluntary corrective actions or agency enforcement actions;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Certain parts used in the manufacturing of our equipment may experience shortages in global supply which could impact our ability to manufacture our device for customers or maintain research and development timelines;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">U.S. legislative or FDA regulatory reforms may make it more difficult and costly for us to obtain regulatory approval of our product candidates and to manufacture, market and distribute our products after approval is obtained;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Failure to secure and maintain adequate coverage and reimbursement from third-party payers could adversely affect acceptance of our products, if approved, and reduce our revenues;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">We may not be successful in securing and maintaining reimbursement codes necessary to facilitate accurate and timely billing for our products or physician services attendant to our products;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">If we are unable to establish good relationships with physicians, our business could be negatively affected; and</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">There is no assurance that Medicare or the Medicare Administrative Contractors will provide coverage or adequate payment rates for our products.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Risks Related to Intellectual Property</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">If third parties claim that our products infringe their intellectual property rights, we may be forced to expend significant financial resources and management time defending against such actions and our financial condition and our results of operations could suffer;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">If we are unable to protect the intellectual property used in our products, others may be able to copy our innovations which may impair our ability to compete effectively in our markets;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">We may be subject to claims that our employees have wrongfully used or disclosed alleged trade secrets of their former employers;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">If we are unable to protect the confidentiality of our proprietary information and know-how, the value of our technology and products could be adversely affected; and</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">We may not be able to protect our intellectual property rights throughout the world.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Risks Related to Information Technology</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Our business and operations would suffer in the event of third-party computer system failures, cyberattacks on third-party systems or deficiency in our cybersecurity;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Artificial intelligence presents risks and challenges that can impact our business, including by posing security risks to our confidential information, proprietary information and personal data; and</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Cybersecurity risks and cyber incidents could adversely affect our business and disrupt operations.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Risks Related to our Common Stock</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Concentration of ownership of our common stock among our existing executive officers and directors may prevent new investors from influencing significant corporate decisions;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">We do not intend to pay cash dividends on our common stock in the foreseeable future;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">If our stock price fluctuates, you could lose a significant part of your investment;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Techniques employed by short sellers may in the future drive down the market price of our common stock;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">If securities or industry analysts do not publish research or reports about us, or if they adversely change their recommendations regarding our common stock, then our stock price and trading volume could decline;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">The market price of our stock may be highly volatile, and you could lose all or part of your investment;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Your ownership may be diluted if additional capital stock is issued to raise capital, to finance acquisitions or in connection with strategic transactions;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">We may be required to issue up to 271,846 shares of common stock in connection with the reverse stock split we completed on October 24, 2024, and we may be subject to potential liability if it is determined that we are required to issue such shares and fail to issue such shares on a timely basis; and</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">If we are unable to maintain compliance with the listing requirements of The Nasdaq Capital Market, our common stock may be delisted from The Nasdaq Capital Market which could have a material adverse effect on our financial condition and could make it more difficult for you to sell your shares.</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Provisions of the Series B Warrants we issued could discourage an acquisition of us by a third party.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      3
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>The Offering</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table cellpadding="2" cellspacing="0" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 100%; margin-left: 0pt; margin-right: 0pt;">
   <tbody>
    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: bottom; width: 45%; border-top: 1px solid black; border-left: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-right: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Shares of common stock offered by the selling shareholders:</b></p> </td>
     <td colspan="3" style="vertical-align: top; width: 4%; border-top: 1px solid black; border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Up to 2,500,000 shares of our common stock consisting of:</p> </td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: bottom; width: 45%; border-left: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-right: 1px solid black;">&#160;</td>
     <td colspan="3" style="vertical-align: top; width: 4%; border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: bottom; width: 45%; border-left: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-right: 1px solid black;">&#160;</td>
     <td style="vertical-align: top; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#9679;</p> </td>
     <td style="vertical-align: top; width: 51%; border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">up to 2,238,068 shares of common stock that we may elect to issue and sell to Lincoln Park as Purchase Shares, in our sole discretion from time to time after the date of this prospectus, pursuant to the Purchase Agreement; and</p> </td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: bottom; width: 45%; border-left: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-right: 1px solid black;">&#160;</td>
     <td style="vertical-align: top; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 51%; border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: bottom; width: 45%; border-left: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-right: 1px solid black;">&#160;</td>
     <td style="vertical-align: top; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#9679;</p> </td>
     <td style="vertical-align: top; width: 51%; border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">261,932 Commitment Shares we issued to Lincoln Park on August 25, 2025 as consideration for its irrevocable commitment to purchase our common stock under the Purchase Agreement, for which we will not receive any cash consideration.</p> </td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 45%; border-left: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-right: 1px solid black;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 51%; border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 45%; border-left: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-right: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Common stock outstanding immediately before this offering:</b></p> </td>
     <td colspan="3" style="vertical-align: top; width: 4%; border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">6,194,147 shares, which includes the Commitment Shares</p> </td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 45%; border-left: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-right: 1px solid black;">&#160;</td>
     <td colspan="3" style="vertical-align: top; width: 4%; border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 45%; border-top: 1px solid black; border-left: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-right: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Common stock outstanding immediately after this offering:</b></p> </td>
     <td colspan="3" style="vertical-align: top; width: 4%; border-top: 1px solid black; border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">8,704,061&#160;shares of common stock, assuming the sale of 2,238,068 Purchase Shares to Lincoln Park under the Purchase Agreement and the issuance of 271,846&#160;shares potentially issuable in connection with the rounding of fractional shares in connection with the reverse stock split completed October 24, 2024 to the holders of our shares held in "street name". The actual number of shares of common stock that we may issue and sell to Lincoln Park will vary depending on the actual prices for the shares of common stock that we may elect to issue and sell to Lincoln Park after the date of this prospectus, but under applicable Nasdaq rules, will not be greater than, 1,075,767 shares in the aggregate (including the Commitment Shares that were issued on August 25, 2025), representing 19.99% of the shares of our common stock outstanding on the date of the Purchase Agreement, unless (i) we first obtain stockholder approval to issue shares in excess of such aggregate share issuance limitation under the Purchase Agreement, or (ii) the average price of all applicable sales of the common stock to Lincoln Park under the Purchase Agreement equals or exceeds $1.3351 per share (the "Base Price"), so that such aggregate share issuance limitation would not apply under applicable Nasdaq rules to issuances and sales of our common stock to Lincoln Park under the Purchase Agreement.</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">At the 2025 annual meeting of our stockholders, to be held on October 30, 2025, among other things, we are seeking the requisite stockholder authorization in accordance with applicable Nasdaq listing rules to issue and sell more than the 1,075,767 aggregate share issuance limitation referred to above, if we so choose, to Lincoln Park under the Purchase Agreement. Accordingly, if such requisite stockholder approval is obtained, we would be able to issue and sell to Lincoln Park, in addition to the 261,932 Commitment Shares we have already issued to Lincoln Park on August 25, 2025, all of the 2,238,068 shares of common stock as Purchase Shares under the Purchase Agreement that are being registered under the Securities Act for resale by Lincoln Park under the registration statement that includes this prospectus, at purchase prices averaging less than the Base Price, without any further aggregate share issuance limitations under Nasdaq rules.</p> </td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 45%; border-left: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-right: 1px solid black;">&#160;</td>
     <td colspan="3" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 4%; border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 45%; border-left: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-right: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Use of proceeds:</b></p> </td>
     <td colspan="3" style="vertical-align: top; width: 4%; border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">We will receive no proceeds from the sale of shares of our common stock by Lincoln Park pursuant to this prospectus. We may receive up to $15.0 million aggregate gross proceeds under the Purchase Agreement from any sales of shares of our common stock we make to Lincoln Park pursuant to the Purchase Agreement after the date of this prospectus, assuming that we sell the full amount of our common stock available to us that we have the right, but not the obligation to sell to Lincoln Park under the Purchase Agreement. Any proceeds that we receive from sales of shares of our common stock to Lincoln Park under the Purchase Agreement will be used for working capital and general corporate purposes, including investing further in research and development efforts. See &#8220;Use of Proceeds.&#8221;</p> </td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 45%; border-left: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-right: 1px solid black;">&#160;</td>
     <td colspan="3" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 4%; border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 45%; border-left: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-right: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Risk Factors:</b></p> </td>
     <td colspan="3" style="vertical-align: top; width: 4%; border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">An investment in our securities involves a high degree of risk. See &#8220;Risk Factors&#8221;&#160;beginning on page 5 of this prospectus for a discussion of the risk factors you should carefully consider before deciding to invest in our securities.</p> </td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 45%; border-left: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-right: 1px solid black;">&#160;</td>
     <td colspan="3" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 4%; border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 45%; border-left: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-right: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Nasdaq listing symbol:</b></p> </td>
     <td colspan="3" style="vertical-align: top; width: 4%; border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Our common stock is listed on The Nasdaq Capital Market under the symbol &#8220;AMIX.&#8221;&#160;</p> </td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 45%; border-left: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-right: 1px solid black;">&#160;</td>
     <td colspan="3" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 4%; border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      4
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The number of shares of common stock to be outstanding <span style="text-decoration: underline; ">after</span> this offering is based on 8,704,061 shares outstanding, which consists of (i) 6,194,147 shares outstanding as of September 19, 2025; (ii) 2,238,068 shares of common stock issuable in this offering; and (iii) 271,846&#160;shares potentially issuable after the date of this prospectus in connection with the rounding of fractional shares in connection with the reverse stock split completed October 24, 2024 to the holders of our shares held in "street name", and excludes:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">58,134 shares of common stock underlying outstanding warrants at a weighted average exercise price of $15.975 per share;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">13,500 shares of common stock underlying outstanding options with a weighted average exercise price of $4.754 per share;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">370,968&#160;shares available for future issuance under the Autonomix Medical, Inc. 2023 Stock Plan; and</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">55,500 shares of common stock underlying outstanding Series A warrants in connection with the November 2024 public offering at a weighted average exercise price of $6.540 per share;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">1,477,596 shares of common stock underlying outstanding Series B warrants in connection with the July 2025 Warrant Inducement offering at a weighted average exercise price of $1.723 per share;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">91,985 shares of common stock underlying the Representative Warrants issuable to the underwriters in connection with the November 2024 public offering at a weighted average exercise price of $10.137; and</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">88,656 shares of common stock underlying the Representative Warrants issuable to the underwriters in connection with the July 2025 Warrant Inducement offering at a weighted average exercise price of $2.671.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Except as otherwise indicated, the information in this prospectus assumes no exercise of options or warrants.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      5
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="risk" href="#"></a>RISK FACTORS</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><i>Investing in our securities involves a high degree of risk. Before investing in our securities, you should consider carefully the risks and uncertainties discussed hereunder </i>&#8220;<i>Risk Factors</i>&#8221;<i>. You should carefully consider each of the following risks, together with all other information set forth in this prospectus, including the financial statements and the related notes, before making a decision to buy our securities. If any of the following risks actually occurs, our business could be harmed. In that case, the trading price of our common stock could decline, and you may lose all or part of your investment. </i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Risks Related to this Offering</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>It is not possible to predict the actual number of shares of common stock we may sell to Lincoln Park under the Purchase Agreement, or the actual gross proceeds resulting from those sales.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Because the purchase price per share to be paid by Lincoln Park for the shares of common stock that we may elect to sell to Lincoln Park under the Purchase Agreement, if any, will fluctuate based on the market prices of our common stock at the time we elect to sell shares to Lincoln Park pursuant to the Purchase Agreement, if any, it is not possible for us to predict, as of the date of this prospectus and prior to any such sales, the number of shares of common stock that we will sell to Lincoln Park under the Purchase Agreement, the purchase price per share that Lincoln Park will pay for shares purchased from us under the Purchase Agreement, or the aggregate gross proceeds that we will receive from those purchases by Lincoln Park under the Purchase Agreement.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Lincoln Park may sell the shares of our common stock described in this prospectus in a number of different ways and at varying prices. The number of shares of our common stock ultimately offered for sale by Lincoln Park is dependent upon the number of shares of common stock, if any, we ultimately sell to Lincoln Park under the Purchase Agreement.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>The terms of the Purchase Agreement limit the amount of shares of common stock we may issue to Lincoln Park, which may limit our ability to utilize the arrangement to enhance our cash resources.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Purchase Agreement includes restrictions on our ability to sell shares of common stock to Lincoln Park, including, subject to specified limitations, if a sale would cause Lincoln Park and its affiliates to beneficially own shares of our common stock in an amount exceeding 4.99% of the outstanding shares of common stock. In addition, under applicable rules of Nasdaq, in no event may we issue or sell to Lincoln Park under the Purchase Agreement shares of our common stock, including the Commitment Shares, in excess of 1,075,767 shares in the aggregate, representing 19.99% of the shares of our common stock outstanding on the date of the Purchase Agreement, unless (i) we first obtain stockholder approval to issue shares in excess of such aggregate share issuance limitation under the Purchase Agreement, or (ii) the average price of all applicable sales of the shares of common stock to Lincoln Park under the Purchase Agreement equals or exceeds $1.3351 per share Base Price, so that such aggregate share issuance limitation would not apply under applicable Nasdaq rules to issuances and sales of our common stock to Lincoln Park under the Purchase Agreement.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">A&#65279;t the 2025 annual meeting of our stockholders to be held on October 30, 2025, among other things, we are seeking the requisite stockholder authorization in accordance with applicable Nasdaq listing rules to issue and sell more than the 1,075,767 aggregate share issuance limitation referred to above, if we so choose, to Lincoln Park under the Purchase Agreement. Accordingly, if such requisite stockholder approval is obtained, we would be able to issue and sell to Lincoln Park, in addition to the 261,932 Commitment Shares we have already issued to Lincoln Park on August 25, 2025, all of the 2,238,068 shares of common stock as Purchase Shares under the Purchase Agreement that are being registered under the Securities Act for resale by Lincoln Park under the registration statement that includes this prospectus, at purchase prices averaging less than the Base Price, without any further aggregate share issuance limitations under Nasdaq rules.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">However, we cannot guarantee that we will obtain such requisite stockholder approval at the 2025 annual meeting of our stockholders to be held on October 30, 2025, and therefore, there can be no assurance that we will be able to issue and sell to Lincoln Park, in addition to the 261,932 Commitment Shares we have already issued to Lincoln Park on August 25, 2025, all of the 2,238,068 shares of common stock as Purchase Shares under the Purchase Agreement that are being registered under the Securities Act for resale by Lincoln Park under the registration statement that includes this prospectus. If we cannot sell to Lincoln Park the full amount of the&#160;Purchase Shares that Lincoln Park has committed to purchase&#160;under the Purchase Agreement because of the beneficial ownership limitation or the applicability of the Nasdaq aggregate share issuance limitation to issuances and sales of our common stock under the Purchase Agreement, we may be required to utilize more costly and time-consuming means of accessing the capital markets, which could materially adversely affect our&#160; liquidity and cash position. If we choose to sell more shares of common stock than are offered under this prospectus, we must first register for resale under the Securities Act such additional shares of common stock.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Investors who buy shares at different times will likely pay different prices.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Pursuant to the Purchase Agreement, we will have discretion, subject to market demand, to vary the timing, prices, and numbers of shares sold to Lincoln Park. If and when we do elect to sell shares of our common stock to Lincoln Park pursuant to the Purchase Agreement, after Lincoln Park has acquired such shares, Lincoln Park may resell all, some or none of such shares at any time or from time to time in its discretion and at different prices. As a result, investors who purchase shares from Lincoln Park in this offering at different times will likely pay different prices for those shares, and so may experience different levels of dilution and in some cases substantial dilution and different outcomes in their investment results. Investors may experience a decline in the value of the shares they purchase from Lincoln Park in this offering as a result of future sales made by us to Lincoln Park at prices lower than the prices such investors paid for their shares in this offering.&#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      6
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>The sale or issuance of our common stock to Lincoln Park may cause dilution and the sale of the shares of common stock by Lincoln Park that it acquires pursuant to the Purchase Agreement, or the perception that such sales may occur, could cause the price of our common stock to decrease.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Pursuant to the Purchase Agreement, Lincoln Park has committed to purchase up to $15.0 million of our common stock. Upon the execution of the Purchase Agreement, we issued 261,932 Commitment Shares to Lincoln Park as a fee for its commitment to purchase shares of our common stock under the Purchase Agreement, for which we will not receive any cash consideration. The shares of our common stock that may be issued under the Purchase Agreement may be sold by us to Lincoln Park at our sole discretion from time to time over a 24-month period commencing after the satisfaction of certain conditions set forth in the Purchase Agreement. The purchase price for the shares that we may sell to Lincoln Park under the Purchase Agreement will fluctuate based on the trading price of our common stock. Depending on market liquidity at the time, sales of such shares may cause the trading price of our common stock to decrease. We generally have the right to control the timing and amount of any future sales of our shares to Lincoln Park. Additional sales of our common stock, if any, to Lincoln Park will depend upon market conditions and other factors to be determined by us. We may ultimately decide to sell to Lincoln Park all, some or none of the additional shares of our common stock that may be available for us to sell pursuant to the Purchase Agreement. If and when we do sell shares to Lincoln Park, after Lincoln Park has acquired the shares, Lincoln Park may resell all, some or none of those shares at any time or from time to time in its discretion. Therefore, sales to Lincoln Park by us could result in substantial dilution to the interests of other holders of our common stock. Additionally, the sale of a substantial number of shares of our common stock to Lincoln Park, or the anticipation of such sales, could make it more difficult for us to sell equity or equity-related securities in the future at a time and at a price that we might otherwise wish to effect sales.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Our management will have broad discretion over the use of the net proceeds from our sale of shares of common stock to Lincoln Park, you may not agree with how we use the proceeds and the proceeds may not be invested successfully.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Our management will have broad discretion as to the use of the net proceeds from our sale of shares of common stock to Lincoln Park, and we could use them for purposes other than those contemplated at the time of commencement of this offering. Accordingly, you will be relying on the judgment of our management with regard to the use of those net proceeds, and you will not have the opportunity, as part of your investment decision, to assess whether the proceeds are being used appropriately. It is possible that, pending their use, we may invest those net proceeds in a way that does not yield a favorable, or any, return for us. The failure of our management to use such funds effectively could have a material adverse effect on our business, financial condition, operating results and cash flows.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Risks Related to Our Overall Business</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Factors raise substantial doubt about our ability to continue as a going concern.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">As of June 30, 2025, we had an accumulated deficit of $53.7 million and working capital of $7.0 million, which raises substantial doubt about our ability to continue as a going concern. Further, we have incurred, and expect to continue to incur, significant costs in pursuit of our business plans. We cannot assure you that our plans to raise sufficient capital to fund our business will be successful. These factors, among others, raise substantial doubt about our ability to continue as a going concern. The financial statements contained elsewhere in this prospectus do not include any adjustments that might result from our inability to raise additional capital or our inability to continue as a going concern.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;text-indent:-8pt;"><b><i>We have no approved products, and we cannot assure you that we will generate revenue or become profitable in the future.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Our products may never be cleared by the United States Food &amp; Drug Administration (&#8220;FDA&#8221;) or become commercially viable or accepted for use. We have incurred significant losses since our inception and expect to continue to experience operating losses and negative cash flow for the foreseeable future. We expect to expend significant resources on hiring of personnel, continued scientific and product research and development, product testing and preclinical and clinical investigation, intellectual property development and prosecution, marketing and promotion, capital expenditures, working capital, general and administrative expenses, and fees and expenses associated with our capital raising efforts. We expect to incur costs and expenses related to consulting costs, hiring of scientists, engineers, science and other operational personnel, and the continued development of relationships with strategic partners.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>We will need additional financing over the longer term to execute our business plan and fund operations, which additional financing may not be available on reasonable terms or at all.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We believe our existing capital resources, will be sufficient to fund our operations into the first calendar quarter of 2026 without additional capital infusion.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We will require significant capital to complete clinical trials, seek approval of our products, mount a major sales and marketing effort and execute our business plan. We cannot give any assurance that we will be able to obtain all the necessary funding that we may need. We may pursue additional funding through various financing sources, including additional equity offerings, the issuance of debt securities, fees associated with licensing some or all of our technology, joint ventures with capital partners and project type financing. There can be no assurance that funds will be available on commercially reasonable terms, if at all. If financing is not available on satisfactory terms, we may be unable to further pursue our business plan and we may be unable to continue operations, in which case you may lose some or all of your investment. In addition, we may seek additional capital due to favorable market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operation plans.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Alternatively, we may consider changes in our business plan that might enable us to achieve aspects of our business objectives and lead to some commercial success with a smaller amount of capital, but we cannot assure that changes in our business plan will result in revenues or maintain any value in your investment.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>We intend to utilize a single manufacturer for the manufacture of our lead product candidate and expect to continue to do so for commercial products. Risks associated with the manufacturing of our products could reduce our gross margins and negatively affect our operating results.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We do not have any manufacturing facilities or direct manufacturing personnel. We currently rely, and expect to continue to rely, on a single manufacturer for the manufacture of our lead product candidate for commercial manufacture. As such, we are subject to numerous risks relating to our reliance on a single manufacturer. If they encounter problems in manufacturing our product candidate, then our business could be significantly impacted. These problems include:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">inability to secure product components in a timely manner, insufficient quantities or on commercially reasonable terms;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">failure to increase production to meet demand;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">inability to modify production lines to enable us to efficiently produce future products or implement changes in current products in response to regulatory requirements;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      7
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">difficulty identifying and qualifying alternative manufacturers in a timely manner;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">inability to establish agreements with future third-party manufacturers or to do so on acceptable terms; or</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">potential damage to or destruction of our manufacturers' equipment or facilities.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">If demand for our future products increases, our manufacturer will need to invest additional resources to purchase components, hire and train employees, and enhance their manufacturing processes. If they fail to increase production capacity efficiently, our sales may not increase in line with our expectations and our operating margins could fluctuate or decline. We do not have a long-term agreement with our manufacturer and there is no assurance that they will continue to provide us with manufacturing services in the future.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>We are a developmental stage company and have not yet had a history of generating revenue.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">As a development-stage entity, we have not generated any revenues. Investors are subject to all the risks incident to the creation and development of a new business and each investor should be prepared to withstand a complete loss of investment. We have not emerged from the development stage and may be unable to raise further equity. These factors raise substantial doubt about our ability to continue as a going concern.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Our business may be adversely affected by the state of the global economy, uncertainties in global financial markets, and possible trade tariffs and trade restrictions.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Our operations and performance will depend significantly on worldwide economic and geopolitical conditions. Uncertainty about global economic conditions could result in potential customers postponing purchases of our future products in response to tighter credit, unemployment, negative financial news and/or declines in income or asset values and other macroeconomic factors, which could have a material negative effect on demand for our future products and, accordingly, on our business, results of operations or financial condition. For example, current global financial markets continue to reflect uncertainty, which has been heightened by the COVID-19 pandemic and the ongoing military conflict&#160;between Russia and Ukraine and the ongoing conflict in Israel. Given these uncertainties, there could be further disruptions to the global economy, financial markets and consumer confidence. If economic conditions deteriorate unexpectedly, our business and results of operations could be materially and adversely affected. For example, our future customers, including our distributors and their customers, may have trouble obtaining the working capital and other financing necessary to support historical or projected purchasing patterns, which could negatively affect our results of operations.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Recent global economic slowdowns could continue and potentially result in certain economies dipping into economic recessions, including in the United States. A weak or declining economy may in the future strain our manufacturers or suppliers, possibly result in supply disruptions. General trade tensions between the United States and the world have recently been escalated by the current U.S. administration, which has recently proposed or enacted significant tariffs and substantial changes to trade policies, which could adversely affect our business. For example, the U.S. administration has imposed significant tariff increases on foreign products, including most recently from Canada, Mexico and China, that in the past have resulted in, and may result in, future retaliatory tariffs on U.S. goods and products or potential currency devaluations. We cannot predict whether these policies will continue, or if new policies will be enacted, or the impact, if any, that any policy changes could have on our business. Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the economic climate and financial market conditions could adversely affect our business.&#160;Additionally, increased inflation around the world, including in the United States, applies pressure to our costs. Continued economic slowdowns or recessions and inflationary pressures could have a negative impact on our business, including decreased demand, increased costs, and other challenges. Government actions to address economic slowdowns and increased inflation, including increased interest rates, also could result in negative impacts to our growth.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Additionally, Russia&#8217;s invasion of Ukraine in early 2022 triggered significant sanctions from U.S. and European countries. Resulting changes in U.S. trade policy could trigger retaliatory actions by Russia, its allies and other affected countries, including China, resulting in a potential trade war. Furthermore, if the conflict between Russia and Ukraine continues for a prolonged period of time, or if other countries, including the U.S., become involved in the conflict, we could face significant adverse effects to our business and financial condition. For example, if our supply or customer arrangements are disrupted due to expanded sanctions or involvement of countries where we have operations or relationships in the future, our business could be materially disrupted. Further, the use of cyberattacks could expand as part of the conflict, which could adversely affect our ability to maintain or enhance our cybersecurity and data protection measures.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The current U.S. administration took several executive actions, including the issuance of a number of executive orders, that imposed significant burdens on, or otherwise materially delayed, the FDA&#8217;s ability to engage in routine oversight activities, such as implementing statutes through rulemaking, issuance of guidance, and review and approval of marketing applications. It is difficult to predict whether or how these orders will be rescinded and replaced under the current or future administrations.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The inability to obtain adequate financing from debt or capital sources in the future could force us to self-fund strategic initiatives or even forego certain opportunities, which in turn could potentially harm our performance.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      8
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>We have limited experience in assembling and testing our products and may encounter problems or delays in the assembly of our products or fail to meet certain regulatory requirements which could result in an adverse effect on our business and financial results.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We have limited experience in assembling and testing our planned device and no experience in doing so on a commercial scale. To become profitable, we must assemble and test our planned device in commercial quantities in compliance with regulatory requirements and at an acceptable cost. Increasing our capacity to assemble and test our products on a commercial scale will require us to improve internal efficiencies. We may encounter a number of difficulties in increasing our assembly and testing capacity, including:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">managing production yields;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">maintaining quality control and assurance;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">providing component and service availability;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">maintaining adequate control policies and procedures;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">hiring and retaining qualified personnel;&#160;and</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">complying with state, federal and foreign regulations.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">If we are unable to satisfy commercial demand for our planned device due to our inability to assemble and test our planned device, our ability to generate revenue would be impaired, market acceptance of our products could be adversely affected and customers may instead purchase or use, our competitors&#8217; products.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Rapidly changing technology in life sciences could make the products we are developing obsolete.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The medical device and life-science industry in general is characterized by rapid and significant technological changes, frequent new product introductions and enhancements and evolving industry standards. Our future success will depend on our ability to continually develop and then improve the products that we design and to develop and introduce new products that address the evolving needs of our customers on a timely and cost-effective basis.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Adverse developments affecting the financial services industry, such as actual events or concerns involving liquidity, defaults, or</i></b>&#160;<b><i>non-performance</i></b>&#160;<b><i>by financial institutions or transactional counterparties, could adversely affect our current and projected business operations and our financial condition and results of operations.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Actual events involving limited liquidity, defaults,&#160;non-performance,&#160;or other adverse developments that affect financial institutions, transactional counterparties or other companies in the financial services industry or the financial services industry generally or concerns or rumors about any events of these kinds or other similar risks, have in the past and may in the future lead to market-wide liquidity problems. For example, on March 10, 2023, Silicon Valley Bank (&#8220;SVB&#8221;) (now a division of First Citizens Bank), was closed by the California Department of Financial Protection and Innovation, which appointed the Federal Deposit Insurance Corporation, or the&#160;FDIC, as receiver, which has been followed by the collapse of Signature Bank Corp. (&#8220;Signature&#8221;), Silvergate Capital Corp. and First Republic Bank. Although we were not a borrower under or party to any material letter of credit or any other such instruments with SVB, Signature or any other financial institution, if we enter into any such instruments and any of our lenders or counterparties to such instruments were to be placed into receivership, we may be unable to access such funds. In addition, if any of our partners, suppliers or other parties with whom we conduct business are unable to access funds pursuant to such instruments or lending arrangements with such a financial institution, such parties&#8217; ability to pay their obligations to us or to enter into new commercial arrangements requiring additional payments to us could be adversely affected. In this regard, counterparties to credit agreements and arrangements with these financial institutions, and third parties such as beneficiaries of letters of credit (among others), may experience direct impacts from the closure of these financial institutions and uncertainty remains over liquidity concerns in the broader financial services industry. Similar impacts have occurred in the past, such as during the 2008-2010 financial crisis. Inflation and rapid increases in interest rates have led to a decline in the trading value of previously issued government securities with interest rates below current market interest rates.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Our access to funding sources and other credit arrangements in amounts adequate to finance or capitalize our current and projected future business operations could be significantly impaired by factors that affect us, any financial institutions with which we enter into credit agreements or arrangements directly, or the financial services industry or economy in general. These factors could include, among others, events such as liquidity constraints or failures, the ability to perform obligations under various types of financial, credit or liquidity agreements or arrangements, disruptions or instability in the financial services industry or financial markets or concerns or negative expectations about the prospects for companies in the financial services industry. These factors could involve financial institutions or financial services industry companies with which we have financial or business relationships but could also include factors involving financial markets or the financial services industry generally.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      9
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The results of events or concerns that involve one or more of these factors could include a variety of material and adverse impacts on our current and projected business operations and our financial condition and results of operations. These risks include, but may not be limited to, the following:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">delayed access to deposits or other financial assets or the uninsured loss of deposits or other financial assets;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">inability to enter into credit facilities or other working capital resources;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">potential or actual breach of contractual obligations that require us to maintain letters of credit or other credit support arrangements; or</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">termination of cash management arrangements and/or delays in accessing or actual loss of funds subject to cash management arrangements.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In addition, investor concerns regarding the U.S. or international financial systems could result in less favorable commercial financing terms, including higher interest rates or costs and tighter financial and operating covenants, or systemic limitations on access to credit and liquidity sources, thereby making it more difficult for us to acquire financing on acceptable terms or at all. Any decline in available funding or access to our cash and liquidity resources could, among other risks, adversely impact our ability to meet our operating expenses or other obligations, financial or otherwise, result in breaches of our financial and/or contractual obligations or result in violations of federal or state wage and hour laws. Any of these impacts, or any other impacts resulting from the factors described above or other related or similar factors, could have material adverse impacts on our liquidity and our current and/or projected business operations and financial condition and results of operations.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In addition, any further deterioration in the macroeconomic economy or financial services industry could lead to losses or defaults by our partners, vendors, or suppliers, which in turn, could have a material adverse effect on our current and/or projected business operations and results of operations and financial condition. For example, a partner may fail to make payments when due, default under their agreements with us, become insolvent or declare bankruptcy, or a supplier may determine that it will no longer deal with us as a customer. In addition, a vendor or supplier could be adversely affected by any of the liquidity or other risks that are described above as factors that could result in material adverse impacts on us, including but not limited to delayed access or loss of access to uninsured deposits or loss of the ability to draw on existing credit facilities involving a troubled or failed financial institution. The bankruptcy or insolvency of any partner, vendor or supplier, or the failure of any partner to make payments when due, or any breach or default by a partner, vendor or supplier, or the loss of any significant supplier relationships, could cause us to suffer material losses and may have a material adverse impact on our business.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>We may incur substantial costs as a result of litigation or other proceedings relating to patent and other intellectual property rights.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We may from time to time seek to enforce our intellectual property rights against infringers when we determine that a successful outcome is probable and may lead to an increase in the value of the intellectual property. If we choose to enforce our patent rights against a party, then that individual or company has the right to ask the court to rule that such patents are invalid or should not be enforced. Additionally, the validity of our patents and the patents we have licensed may be challenged if a petition for post grant proceedings such as inter-parties review and post grant review is filed within the statutorily applicable time with the U.S. Patent and Trademark Office (&#8220;USPTO&#8221;). These lawsuits and proceedings are expensive and would consume time and resources and divert the attention of managerial and scientific personnel even if we were successful in stopping the infringement of such patents. In addition, there is a risk that the court will decide that such patents are not valid and that we do not have the right to stop the other party from using the inventions. There is also the risk that, even if the validity of such patents is upheld, the court will refuse to stop the other party on the ground that such other party's activities do not infringe our intellectual property rights. In addition, in recent years the U.S. Supreme Court modified some tests used by the USPTO in granting patents over the past 20 years, which may decrease the likelihood that we will be able to obtain patents and increase the likelihood of a challenge of any patents we obtain or license.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Catastrophic events and disaster recovery may disrupt business continuity.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">A disruption or failure of our systems or operations in the event of a natural disaster or severe weather event, including, but not limited to, earthquakes, wildfires, droughts, flooding, tornadoes, hurricanes or tsunamis, health pandemic, such as an influenza outbreak within our workforce, or man-made catastrophic event could cause delays in completing sales, continuing production or performing other critical functions of our business, particularly if a catastrophic event were to occur at our premises. Global climate change could result in certain natural disasters occurring more frequently or with greater intensity. Any of these events could severely affect our ability to conduct normal business operations and, as a result, our operating results could be adversely affected. There may also be secondary impacts that are unforeseeable as well, such as impacts on our customers, which could cause delays in new orders, delays in completing sales or even order cancellations.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>We may fail to meet the Sarbanes-Oxley regulations and may lack the financial controls and safeguards required of public companies.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Ensuring that we have adequate internal financial and accounting controls and procedures in place to produce accurate financial statements on a timely basis is a costly and time-consuming effort that needs to be re-evaluated frequently. Our management has concluded that our internal controls over financial reporting are ineffective and has identified material weaknesses in our internal controls in areas such as the lack of segregation of duties; general technology controls; and financial statement reporting. While management is working to remediate the material weaknesses, there is no assurance that such changes, when economically feasible and sustainable, will remediate the identified material weaknesses or that the controls will prevent or detect future material weaknesses. If we are not able to maintain effective internal control over financial reporting, our financial statements, including related disclosures, may be inaccurate, which could have a material adverse effect on our business. We may discover additional material weaknesses in our internal financial and accounting controls and procedures that need improvement from time to time.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      10
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Management is responsible for establishing and maintaining adequate internal control over financial reporting to provide reasonable assurance regarding the reliability of our financial reporting and the preparation of financial statements for external purposes in accordance with United States generally accepted accounting principles. Management does not expect that our internal control over financial reporting will prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#8217;s objectives will be met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, within our company will have been detected.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We are required to comply with Section 404 of the Sarbanes-Oxley Act. We expect to expend significant resources in developing the necessary documentation and testing procedures required by Section 404. We cannot be certain that the actions we will be taking to improve our internal controls over financial reporting will be sufficient, or that we will be able to implement our planned processes and procedures in a timely manner. In addition, if we are unable to produce accurate financial statements on a timely basis, investors could lose confidence in the reliability of our financial statements, which could cause the market price of our common stock to decline and make it more difficult for us to finance our operations and growth.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>While our Company</i></b>&#8217;<b><i>s management is working to improve our internal controls and procedures, at present management has determined that our internal controls were deemed to be inadequate, which could cause our financial reporting to be unreliable and lead to misinformation being disseminated to the public.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">O&#65279;ur management is responsible for establishing and maintaining adequate internal control over financial reporting. As defined in Rule 13a-15(f) under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), internal control over financial reporting is a process designed by, or under the supervision of, the principal executive and principal financial officer and effected by the board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles and includes those policies and procedures that:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of our assets;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and/or directors of the Company; and</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company&#8217;s assets that could have a material effect on the financial statements.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We are required to include a report of management on the effectiveness of our internal control over financial reporting. We expect to incur additional expenses and diversion of management&#8217;s time as a result of performing the system and process evaluation, testing and remediation required in order to comply with the management certification requirements.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Presently, we do not have a sufficient number of employees to segregate responsibilities and may be unable to afford increasing our staff or engaging outside consultants or professionals to overcome our lack of employees. During the course of our testing, we may identify other deficiencies that we may not be able to timely remediate. If we cannot provide reliable financial reports or prevent fraud, our business and operating results could be harmed, investors could lose confidence in our reported financial information, and the trading price of our common stock, if a market ever develops, could drop significantly.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Because of the specialized nature of our business, the termination of relationships with our key employees, consultants and advisors may prevent us from successfully operating our business, including developing our products, conducting clinical studies, commercializing our products and obtaining any necessary financing.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We are highly dependent on the members of our executive team, the loss of whose services may adversely impact the achievement of our objectives. While we have entered into employment or consulting agreements with each of our key executives, any of them could leave our employment at any time. We do not have &#8220;key person&#8221; insurance on any of our employees. The loss of the services of one or more of our current employees might impede the achievement of our business objectives.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      11
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The competition for qualified personnel in the medical device fields is intense and we rely heavily on our ability to attract and retain qualified scientific, technical, and managerial personnel. Our future success depends upon our ability to attract, retain and motivate highly skilled employees. In order to commercialize our products successfully, we will be required to expand our workforce, particularly in the areas of research and development and clinical studies, finance, accounting and reporting, sales and marketing and supply chain management. These activities will require the addition of new personnel and the development of additional expertise by existing management personnel. We face intense competition for qualified individuals from numerous pharmaceutical, biopharmaceutical and biotechnology companies, as well as academic and other research institutions. We may not be able to attract and retain these individuals on acceptable terms or at all. Failure to do so could materially harm our business.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Our Certificate of Incorporation and Bylaws, each as amended to date, provide for indemnification of officers and directors at the expense of the Company and limit their liability that may result in a major cost to us and hurt the interests of our stockholders because corporate resources may be expended for the benefit of officers and/or directors.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Our Certificate of Incorporation and Bylaws, each as amended to date, provide for the indemnification of our officers and directors. We have been advised that, in the opinion of the SEC, indemnification for liabilities arising under federal securities laws is against public policy as expressed in the Securities Act and is therefore, unenforceable.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Risks Related to Government Regulation and Product Approvals</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Changes to United States federal and state regulatory agencies may cause disruptions and delays in approval of the government approval processes and regulation relating to our products.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">It is possible that the current administration could institute significant changes to certain regulatory agencies, including the Department of Government Efficiency ("DOGE"), which is tasked with making changes to eliminate regulations, cut expenditures and restructure federal agencies, some of which could impact public companies. For example, the current administration has discussed several changes to the reach and oversight of the Food and Drug Administration, which could affect its relationship with the pharmaceutical industry, transparency in decision making and ultimately the cost and availability of prescription drugs, as well as oversight over clinical trials and pharmaceutical development, all of which could pose risks (or opportunities) for companies in related industries. Similarly, there have been discussions of "reigning in" regulatory agencies such as the Federal Trade Commission, the Federal Communications Commission and the Federal Energy Regulatory Commission, all of which could impact how companies do business and could pose risks related to our business operations and financial outlook.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>There is no guarantee that the FDA will grant 510(k) or de novo clearance or a premarket approval application (</i></b>&#8220;<b><i>PMA</i></b>&#8221;<b><i>) of our future products and failure to obtain necessary clearances or approvals for our future products would adversely affect our ability to grow our business.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Our lead product candidate will require FDA clearance of a 510(k) or de novo application or may require FDA approval of a PMA. The FDA may not approve or clear these products for the indications that are necessary or desirable for successful commercialization. Indeed, the FDA may refuse our requests for premarket clearance or premarket approval of new products, new intended uses or modifications to existing products. Failure to receive clearance or approval for our products would have an adverse effect on our ability to continue or expand our business.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">If we fail to obtain and maintain regulatory approvals and clearances, or are unable to obtain, or experience significant delays in obtaining, FDA clearances or approvals for our device, our future products or product enhancements, our ability to commercially distribute and market these products could suffer.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Our products will be subject to rigorous regulation by the FDA and numerous other federal, state and foreign governmental authorities. The process of obtaining regulatory clearances or approvals to market a medical device can be costly and time consuming, and we may not be able to obtain these clearances or approvals on a timely basis, if at all. In particular, the FDA permits commercial distribution of a new medical device only after the device has received clearance under Section 510(k) of the Federal Food, Drug and Cosmetic Act, or is the subject of an approved premarket approval application, or PMA, unless the device is specifically exempt from those requirements. The FDA will clear marketing of a lower risk medical device through the 510(k) process if the manufacturer demonstrates that the new product is substantially equivalent to other 510(k)-cleared products or through a de novo process if substantial equivalence is not available. High risk devices deemed to pose the greatest risk, such as life-sustaining, life-supporting, or implantable devices, or devices not deemed substantially equivalent to a previously cleared device, require the approval of a PMA. The PMA process is more costly, lengthy and uncertain than the 510(k) or de novo clearance processes. A PMA application must be supported by extensive data, including, but not limited to, technical, preclinical, clinical trial, manufacturing and labeling data, to demonstrate to the FDA&#8217;s satisfaction the safety and efficacy of the device for its intended use. We believe our current product candidate will require clearance through the 510(k) or de novo process.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      12
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Our product development for our sensing and ablation technologies may not meet the necessary validation requirements to achieve regulatory approvals, or our internal specifications for commercial viability.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We are developing proprietary sensing and ablation technologies that represent novel applications within the medical device space. As such, these technologies are subject to stringent validation and verification processes, both internally and by regulatory bodies such as the FDA. There is no assurance that our products will meet the safety, efficacy, and performance criteria required to obtain regulatory approvals. Additionally, even if our technologies are shown to be safe and effective in preclinical or early-stage clinical studies, they may not meet the technical, usability, cost, or performance benchmarks necessary for commercial viability. Any delays or failures in validation, or changes in FDA requirements or guidance, could significantly impact our development timelines, increase our costs, and delay or prevent our ability to bring our products to market.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Modifications to our future products may require new regulatory clearances or approvals or may require us to recall or cease marketing our products until clearances or approvals are obtained.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Modifications to our future products may require new regulatory approvals or clearances, including 510(k) clearances or premarket approvals, or require us to recall or cease marketing the modified devices until these clearances or approvals are obtained. The FDA requires device manufacturers to initially make and document a determination of whether or not a modification requires a new approval, supplement or clearance. A manufacturer may determine that a modification could not significantly affect safety or efficacy and does not represent a major change in its intended use, so that no new 510(k) clearance is necessary. However, the FDA can review a manufacturer's decision and may disagree. The FDA may also on its own initiative determine that a new clearance or approval is required. Once we have a commercialized product, we may make modifications in the future that we believe do not or will not require additional clearances or approvals. If the FDA disagrees and requires new clearances or approvals for these modifications, we may be required to recall and to stop marketing our products as modified, which could require us to redesign our products and harm our operating results. In these circumstances, we may be subject to significant enforcement actions.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Where we determine that modifications to our products require a new 510(k) clearance or premarket approval application, we may not be able to obtain those additional clearances or approvals for the modifications or additional indications in a timely manner, or at all. Obtaining clearances and approvals can be a time-consuming process, and delays in obtaining required future clearances or approvals would adversely affect our ability to introduce new or enhanced products in a timely manner, which in turn would harm our future growth.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>The results of our future clinical trials may not support our product candidate claims or may result in the discovery of adverse side effects.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We have not completed any clinical trials and we cannot be certain that their results will support our product candidate claims or that the FDA will agree with our conclusions regarding them. Success in pre-clinical studies and early clinical trials does not ensure that later clinical trials will be successful, and we cannot be sure that the later trials will replicate the results of prior trials and pre-clinical studies. The clinical trial process may fail to demonstrate that our product candidates are safe and effective for the proposed indicated uses, which could cause us to abandon a product candidate and may delay development of others. Any delay or termination of our clinical trials will delay the filing of our product submissions and, ultimately, our ability to commercialize our product candidates and generate revenues. It is also possible that patients enrolled in clinical trials will experience adverse side effects that are not currently part of the product candidate&#8217;s profile.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>We are conducting our initial Proof of Concept trial outside the United States using commercially available RF ablation equipment in a new anatomical region to assess clinical response. We plan to present the relevant data from this trial to the FDA to support the clinical requirements for clearance in the United States. However, there is no assurance that the FDA will accept this data.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Human trials are often designed to begin with a Proof of Concept (&#8220;PoC&#8221;) trial and then progress to a &#8220;Pivotal&#8221; or approval, trial. We have started a PoC trial outside the United States using commercially available RF ablation devices, and upon completion, we intend to present the data to the FDA in a pre-submission meeting and use key learnings to inform the protocol for our US-based clinical trials. The first trial is not designed to replace the pivotal trial that will be required by the FDA to support clearance in the United States, but rather to potentially impact the size of that trial.&#160;There is no guarantee that our devices will perform the same as commercially available RF ablation equipment or that the results from this PoC trial will be replicated with our own devices. Additionally, there is no assurance that the FDA will accept the data from our international trial or that they will not require us to conduct additional Early Feasibility Studies (&#8220;EFS&#8221;) to supplement a pivotal trial. Any additional trials required by the FDA could be costly, time-consuming, and may necessitate raising additional financing, for which we have no commitments.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      13
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Our clinical studies could be delayed or otherwise adversely affected by many factors, including difficulties in enrolling patients.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Clinical testing can be costly and take many years and the outcome is uncertain and susceptible to varying interpretations. Moreover, success in pre-clinical and early clinical studies does not ensure that large-scale studies will be successful or predict final results. Acceptable results in early studies may not be replicable in later studies. A number of companies have suffered significant setbacks in advanced clinical studies, even after promising results in earlier studies. Negative or inconclusive results or adverse events or incidents during a clinical study could cause the clinical study to be redone or terminated. In addition, failure to appropriately construct clinical studies could result in high rates of adverse events or incidents, which could cause a clinical study to be suspended, redone or terminated. Our failure or the failure of third-party participants in our studies to comply with their obligations to follow protocols and/or legal requirements may also result in our inability to use the affected data in our submissions to regulatory authorities.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The timely completion of clinical studies depends, among other things, on our ability to enroll a sufficient number of patients who remain in the study until its conclusion. We may experience difficulties in patient enrollment in our clinical studies for a variety of reasons, including:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">the severity of the disease under investigation;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">the limited size and nature of the patient population;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">the patient eligibility criteria defined in our protocol and other clinical study protocols;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">the nature of the study protocol, including the attractiveness of, or the discomforts and risks associated with, the treatments received by enrolled subjects;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">difficulties and delays in clinical studies that may occur as a result of the COVID-19 pandemic;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">the ability to obtain institutional review board (&#8220;IRB&#8221;) approval at clinical study locations;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">clinicians&#8217;&#160;and patients&#8217;&#160;perceptions as to the potential advantages, disadvantages and side effects of our products in relation to other available therapies, including any new drugs or treatments that may be approved for the indications we are pursuing;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">the possibility or perception that enrolling in a product&#8217;s clinical study may limit the patient&#8217;s ability to enroll in future clinical studies for other therapies due to protocol restrictions;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">the possibility or perception that our software is not secure enough to maintain patient privacy;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">the ability to monitor patients adequately during and after treatment;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">the availability of appropriate clinical study investigators, support staff, drugs and other therapeutic supplies and proximity of patients to clinical sites;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">physicians&#8217;&#160;or our ability to obtain and maintain patient consents; and</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">the risk that patients enrolled in clinical studies will choose to withdraw from or otherwise not be able to complete a clinical study.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">If we have difficulty enrolling and retaining a sufficient number or diversity of patients to conduct our clinical studies as planned, or encounter other difficulties, we may need to delay, terminate or modify ongoing or planned clinical studies, any of which would have an adverse effect on our business.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>We may have limitations in generating statistically significant long-term clinical data and gaining extended-duration indications from clinical studies involving terminal patients.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Our clinical studies, particularly those involving terminal patients with pancreatic cancer, may face significant challenges in generating long-term data and developing extended indications. Given the nature of pancreatic cancer, many patients enrolled in our studies may have a limited life expectancy, which could hinder our ability to gather statistically significant long-term clinical data that may be crucial for establishing broader longer-term indications for our products. The inability to collect sufficient data from these patients may limit the scope of our clinical findings and the potential for additional indications beyond the initial use cases. As a result, the progress of our clinical trials, and the expansion of indications could be delayed and our ability to secure regulatory approvals for longer-term uses may be impacted.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Even if our products are cleared or approved by the FDA, if we or our suppliers fail to comply with ongoing FDA requirements, or if we experience unanticipated problems with our products, these products could be subject to restrictions or withdrawal from the market.</i></b>&#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Any product for which we obtain clearance or approval, and the manufacturing processes, reporting requirements, post-approval clinical data and promotional activities for such product, will be subject to continued regulatory review, oversight and periodic inspections by the FDA and other domestic and foreign regulatory bodies. In particular, we, and our suppliers, will be required to comply with FDA&#8217;s Quality System Regulations, or QSR, which covers the methods and documentation of the design, testing, production, control, quality assurance, labeling, packaging, storage and shipping of any product for which we obtain clearance or approval. FDA enforces the QSR and other regulations through periodic inspections. The failure by us or one of our suppliers to comply with applicable statutes and regulations administered by the FDA, or the failure to timely and adequately respond to any adverse inspectional observations or product safety issues, could result in, among other things, any of the following enforcement actions:&#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">untitled letters, warning letters, fines, injunctions, consent decrees and civil penalties;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">unanticipated expenditures to address or defend such actions;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">customer notifications for repair, replacement, refunds;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">recall, detention or seizure of our products;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      14
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">operating restrictions or partial suspension or total shutdown of production;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">refusing or delaying our requests for premarket clearance or premarket approval of new products or modified products;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">operating restrictions;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">withdrawing premarket clearances on PMA approvals that have already been granted;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">refusal to grant export approval for our products; or</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">criminal prosecution.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">If any of these actions were to occur, it would harm our reputation and cause our product sales and profitability to suffer and may prevent us from generating revenue. Furthermore, our key component suppliers may not be in compliance with all applicable regulatory requirements which could result in our failure to produce our products on a timely basis and in the required quantities, if at all.&#160;&#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Even if regulatory clearance or approval of a product is granted, such clearance or approval may be subject to limitations on the intended uses for which the product may be marketed and reduce our potential to successfully commercialize the product and generate revenue from the product. If the FDA determines that our promotional materials, labeling, training or other marketing or educational activities constitute promotion of an unapproved use, it could request that we cease or modify our training or promotional materials or subject us to regulatory enforcement actions. It is also possible that other federal, state or foreign enforcement authorities might take action if they consider our training or other promotional materials to constitute promotion of an unapproved use, which could result in significant fines or penalties under other statutory authorities, such as laws prohibiting false claims for reimbursement.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In addition, we may be required to conduct costly post-market testing and surveillance to monitor the safety or effectiveness of our products, and we must comply with medical device reporting requirements, including the reporting of adverse events and malfunctions related to our products. Later discovery of previously unknown problems with our products, including unanticipated adverse events or adverse events of unanticipated severity or frequency, manufacturing problems, or failure to comply with regulatory requirements such as QSR, may result in changes to labeling, restrictions on such products or manufacturing processes, withdrawal of the products from the market, voluntary or mandatory recalls, a requirement to repair, replace or refund the cost of any medical device we manufacture or distribute, fines, suspension of regulatory approvals, product seizures, injunctions or the imposition of civil or criminal penalties which would adversely affect our business, operating results and prospects.&#160;&#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Our products may in the future be subject to product recalls that could harm our reputation, business and financial results.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The FDA and similar foreign governmental authorities have the authority to require the recall of commercialized products in the event of material deficiencies or defects in design or manufacture. In the case of the FDA, the authority to require a recall must be based on an FDA finding that there is a reasonable probability that the device would cause serious injury or death. Manufacturers may, under their own initiative, recall a product if any material deficiency in a device is found. A government-mandated or voluntary recall by us or one of our distributors could occur as a result of component failures, manufacturing errors, design or labeling defects or other deficiencies and issues. Recalls of any of our products would divert managerial and financial resources and have an adverse effect on our financial condition and results of operations. The FDA requires that certain classifications of recalls be reported to FDA within 10 working days after the recall is initiated. Companies are required to maintain certain records of recalls, even if they are not reportable to the FDA. We may initiate voluntary recalls involving our products in the future that we determine do not require notification of the FDA. If the FDA disagrees with our determinations, they could require us to report those actions as recalls. A future recall announcement could harm our reputation with customers and negatively affect our sales. In addition, the FDA could take enforcement action for failing to report the recalls when they were conducted.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>If our products cause or contribute to a death or a serious injury, or malfunction in certain ways, we will be subject to medical device reporting regulations, which can result in voluntary corrective actions or agency enforcement actions.</i></b>&#160;&#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Under the FDA medical device reporting regulations, medical device manufacturers are required to report to the FDA information that a device has or may have caused or contributed to a death or serious injury or has malfunctioned in a way that would likely cause or contribute to death or serious injury if the malfunction of the device or one of our similar devices were to recur. If we fail to report these events to the FDA within the required timeframes, or at all, FDA could take enforcement action against us. Any such adverse event involving our products also could result in future voluntary corrective actions, such as recalls or customer notifications, or agency action, such as inspection or enforcement action. Any corrective action, whether voluntary or involuntary, as well as defending ourselves in a lawsuit, will require the dedication of our time and capital, distract management from operating our business, and may harm our reputation and financial results.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      15
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Certain parts used in the manufacturing of our equipment may experience shortages in global supply, which could impact our ability to manufacture our device for customers or maintain research and development timelines. </i></b>&#160;&#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">There are a number of component parts used in the manufacture of our device that are used by many manufacturers in a variety of products. We will compete with other manufacturers for the supply of these components. Additionally, certain parts that are currently in our design may be discontinued by our supplier requiring us to find alternative parts. This issue may require us to change the design of our device or purchase significant inventories of these parts in order to protect against manufacturing delays. We may not be able to procure alternative components or adequate raw material inventories which would result in an inability to produce our device.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>U.S. legislative or FDA regulatory reforms may make it more difficult and costly for us to obtain regulatory approval of our product candidates and to manufacture, market and distribute our products after approval is obtained.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">From time to time, legislation is drafted and introduced in Congress that could significantly change the statutory provisions governing the regulatory approval, manufacture and marketing of regulated products or the reimbursement thereof. In addition, FDA regulations and guidance are often revised or reinterpreted by the FDA in ways that may significantly affect our business and our products. Any new regulations or revisions or reinterpretations of existing regulations may impose additional costs or lengthen review times of future products. In addition, FDA regulations and guidance are often revised or reinterpreted by the agency in ways that may significantly affect our business and our products. It is impossible to predict whether legislative changes will be enacted, or FDA regulations, guidance or interpretations changed, and what the impact of such changes, if any, may be.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Failure to secure and maintain adequate coverage and reimbursement from third-party payers could adversely affect acceptance of our products, if approved, and reduce our revenues.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Assuming we receive approval of our products, we expect that the vast majority of our revenues will come from third-party payers, either directly to us in markets where we plan to provide our device candidates to patients, or indirectly via payments made to hospitals or other entities, which may in the future provide our device candidates to patients.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In the U.S., private payers cover the largest segment of the population, with the remainder either uninsured or covered by governmental payers. The majority of the third-party payers outside the U.S. are government agencies, government sponsored entities or other payers operating under significant regulatory requirements from national or regional governments.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Third-party payers may decline to cover and reimburse certain procedures, supplies or services. Additionally, some third-party payers may decline to cover and reimburse our products for a particular patient even if the payer has a favorable coverage policy addressing our products or previously approved reimbursement for our products. Additionally, private and government payers may consider the cost of a treatment in approving coverage or in setting reimbursement for the treatment.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Private and government payers around the world are increasingly challenging the prices charged for medical products and services. Additionally, the containment of healthcare costs has become a priority of governments around the world. Adoption of additional price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit our revenues and operating results. If third-party payers do not consider our products or the combination of our products with additional treatments to be cost-justified under a required cost-testing model, they may not cover our products for their populations or, if they do, the level of reimbursement may not be sufficient to allow us to sell our products on a profitable basis.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Reimbursement for the treatment of patients with medical devices around the world is governed by complex mechanisms established on a national or sub-national level in each country. These mechanisms vary widely among countries, can be informal, somewhat unpredictable, and evolve constantly, reflecting the efforts of these countries to reduce public spending on healthcare. As a result, obtaining and maintaining reimbursement for the treatment of patients with medical devices has become more challenging globally. We cannot guarantee that the use of our products will receive reimbursement approvals and cannot guarantee that our existing reimbursement approvals will be maintained in any country.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Because our technology introduces a novel approach to nerve sensing and ablation, including applications for conditions that are not well served by current therapies, third-party payers may require more extensive clinical and economic evidence than is typically needed for coverage of established technologies. In particular, demonstrating long-term safety, effectiveness, and cost-efficiency in real-world use may be necessary to obtain or maintain reimbursement. The absence of established coding, clinical guidelines, or historical reimbursement precedents for our system may further complicate this process. As a result, lack of adequate reimbursement could delay or limit commercial adoption of our products, even if we obtain regulatory clearance or approval.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Our failure to secure or maintain adequate coverage or reimbursement for our products by third-party payers in the U.S., or in the other jurisdictions in which we market our products, could have a material adverse effect on our business, revenues and results of operations.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      16
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>We may not be successful in securing and maintaining reimbursement codes necessary to facilitate accurate and timely billing for our products or physician services attendant to our products</i></b><b>.</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Third-party payers, healthcare systems, government agencies or other groups often issue reimbursement codes to facilitate billing for products and physician services used in the delivery of healthcare. Within the U.S., the billing codes most directly related to our products are contained in the Healthcare Common Procedure Coding System (&#8220;HCPCS code set&#8221;). The HCPCS code set contains Level I codes that describe physician services, also known as Common Procedural Terminology codes (&#8220;CPT codes&#8221;) and Level II codes that primarily describe products. Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;) is responsible for issuing the HCPCS Level II codes. The American Medical Association issues HCPCS Level I codes.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">No HCPCS codes or CPT codes currently exist to describe physician services related to the delivery of therapy using our products. We may not be able to secure HCPCS codes and CPT codes for physician services related to our products. Our future revenues and results may be affected by the absence of CPT codes, as physicians may be less likely to prescribe the therapy when there is no certainty that adequate reimbursement will be available for the time, effort, skill, practice expense and malpractice costs required to provide the therapy to patients.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Outside the U.S., we have not secured codes to describe our products or to document physician services related to the delivery of therapy using our products. The failure to obtain and maintain these codes could affect the future growth of our business.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>If we are unable to establish good relationships with physicians, our business could be negatively affected.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Our business model will require us to build and maintain good relationships with physicians who will have a significant source of patients that will generate treatment revenues for both the physician and the Company. If we are unable to establish good relationships with physicians and maintain them, it will jeopardize our ability to generate future revenues.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>There is no assurance that Medicare or the Medicare Administrative Contractors will provide coverage or adequate payment rates for our products.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We anticipate that a significant portion of patients using our products will be beneficiaries under the Medicare fee-for-service program. Failure to secure or maintain coverage or maintain adequate reimbursement from Medicare would reduce our revenues and may also affect the coverage and reimbursement decisions of other third-party payers in the U.S. and elsewhere.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Medicare may classify our medical device as durable medical equipment (&#8220;DME&#8221;). Medicare has the authority to issue national coverage determinations or to defer coverage decisions to its regional Medicare Administrative Contractors (&#8220;MACs&#8221;). The fact that only two MACs administer the entire DME program may negatively affect our ability to petition individual medical policy decision-makers at the MACs for coverage. The absence of a positive coverage determination or a future restriction to existing coverage from Medicare or the DME MACs would materially affect our future revenues.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Additionally, Medicare has the authority to publish the reimbursement amounts for DME products. Medicare may in the future publish reimbursement amounts for our products that do not reflect then-current prices for our products. Medicare fee schedules are frequently referenced by private payers in the U.S. and around the world. Medicare&#8217;s publication of reimbursement amounts for our products that are below our products&#8217; established prices could materially reduce our revenues and operating results with respect to non-Medicare payers in the U.S. and our other active markets.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Even if our products were authorized by Medicare, CMS requires prior authorization for certain DME items. Claims for such items that did not receive prior authorization before they were furnished to a beneficiary will be automatically denied. In the event Medicare adds one of our products to the list of items requiring prior authorization, our ability to bill and secure reimbursement for patients who would otherwise be covered to use our product under the Medicare fee-for-service program may be reduced.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We cannot provide any assurance that we can access transitional, expedited, or expanded Medicare coverage for our products. CMS is expected to issue rules regarding coverage of emerging technologies; however, no specific information is available about the content of the expected rules and we cannot provide any assurance that any new rules regarding emerging technologies would be applicable to our future products.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Risks Related to Intellectual Property</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>If third parties claim that our products infringe their intellectual property rights, we may be forced to expend significant financial resources and management time defending against such actions and our financial condition and our results of operations could suffer.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Third parties may claim that our products infringe their patents and other intellectual property rights. Identifying third-party patent rights can be particularly difficult because, in general, patent applications can be maintained in secrecy for a prolonged period after their earliest priority date. Historically, there has been substantial litigation regarding patents and other intellectual property rights in the medical device and related industries. If a competitor were to challenge our patents or other intellectual property rights, or assert that our products infringe its patent or other intellectual property rights, we could incur substantial litigation costs, be forced to make expensive changes to our product design, pay royalties or other fees to license rights in order to continue manufacturing and selling our products, or pay substantial damages. Third-party infringement claims, regardless of their outcome, would not only consume our financial resources but also divert our management&#8217;s time and effort.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      17
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>If we are unable to protect the intellectual property used in our products, others may be able to copy our innovations which may impair our ability to compete effectively in our markets.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The strength of our patents involves complex legal and scientific questions and can be uncertain. These patent applications may be challenged or fail to result in issued patents, or if issued, these patents and our existing patents may be too narrow to prevent third-parties from developing or designing around our intellectual property and in that event, we may lose competitive advantage, which could result in harm to our business.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>We may be subject to claims that our employees have wrongfully used or disclosed alleged trade secrets of their former employers.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">As is common in the medical device industry, we may employ individuals who were previously employed at other medical device companies, including our competitors or potential competitors. We may be subject to claims that these employees, or we, have used or disclosed trade secrets or other proprietary information of their former employers. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>If we are unable to protect the confidentiality of our proprietary information and know-how, the value of our technology and products could be adversely affected.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In addition to patented technology, we rely upon, among other things, unpatented proprietary technology, processes, trade secrets and know-how. Any involuntary disclosure to or misappropriation by third-parties of our confidential or proprietary information could enable competitors to duplicate or surpass our technological achievements, potentially eroding our competitive position in our market. We seek to protect confidential or proprietary information in part by confidentiality agreements with our employees, consultants and third-parties. While we require all of our employees, consultants, advisors and any third-parties who have access to our proprietary know-how, information and technology to enter into confidentiality agreements, we cannot be certain that this know-how, information and technology will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. These agreements may be terminated or breached, and we may not have adequate remedies for any such termination or breach. Furthermore, these agreements may not provide meaningful protection for our trade secrets and know-how in the event of unauthorized use or disclosure. To the extent that any of our staff were previously employed by other pharmaceutical, medical technology or biotechnology companies, those employers may allege violations of trade secrets and other similar claims in relation to their medical device development activities for us.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>We may not be able to protect our intellectual property rights throughout the world.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We are dependent on patents. Filing, prosecuting and defending patents in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States may be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These infringing products may compete with the product candidates we may develop, without any available recourse.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The laws of some other countries do not protect intellectual property rights to the same extent as the laws of the United States. Patent protection must ultimately be sought on a country-by-country basis, which is an expensive and time-consuming process with uncertain outcomes. Accordingly, we may choose not to seek patent protection in certain countries, and we will not have the benefit of patent protection in such countries. In addition, the legal systems of some countries, particularly developing countries, do not favor the enforcement of patents and other intellectual property protection. As a result, many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. Because the legal systems of many foreign countries do not favor the enforcement of patents and other intellectual property protection, it could be difficult for us to stop the infringement, misappropriation or violation of our patents or our licensors&#8217; patents or marketing of competing products in violation of our proprietary rights. Proceedings to enforce our intellectual property and other proprietary rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents or the patents of our licensors at risk of being invalidated or interpreted narrowly, could put our patent applications or the patent applications of our licensors at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      18
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Risks Related to Information Technology</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Our business and operations would suffer in the event of third-party computer system failures, cyberattacks on third-party systems or deficiency in our cybersecurity.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We rely on information technology (&#8220;IT&#8221;) systems, including third-party &#8220;cloud based&#8221; service providers, to keep financial records, maintain laboratory data, clinical data, and corporate records, to communicate with staff and external parties and to operate other critical functions. This includes critical systems such as email, other communication tools, electronic document repositories and archives. If any of these third-party information technology providers are compromised due to computer viruses, unauthorized access, malware, natural disasters, fire, terrorism, war and telecommunication failures, electrical failures, cyberattacks or cyber-intrusions over the internet, then sensitive emails or documents could be exposed or deleted. Similarly, we could incur business disruption if our access to the internet is compromised, and we are unable to connect with third-party IT providers. The risk of a security breach or disruption, particularly through cyberattacks or cyber-intrusion, including by computer hackers, foreign governments and cyber terrorists, has generally increased as the number, intensity and sophistication of attempted attacks and intrusions from around the world have increased. In addition, we rely on those third parties to safeguard important confidential personal data regarding our employees and subjects enrolled in our clinical trials. If a disruption event were to occur and cause interruptions in a third-party IT provider&#8217;s operation, it could result in a disruption of our drug development programs. For example, the loss of clinical trial data from completed, ongoing or planned clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach results in a loss of or damage to our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and development of our product candidates could be delayed or could fail.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Artificial intelligence presents risks and challenges that can impact our business, including by posing security risks to our confidential information, proprietary information and personal data.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Issues in the development and use of artificial intelligence, combined with an uncertain regulatory environment, may result in reputational harm, liability, or other adverse consequences to our business operations. As with many technological innovations, artificial intelligence presents risks and challenges that could impact our business. We may adopt and integrate generative artificial intelligence tools into our systems for specific use cases reviewed by legal and information security. Our vendors may incorporate generative artificial intelligence tools into their offerings without disclosing this use to us, and the providers of these generative artificial intelligence tools may not meet existing or rapidly evolving regulatory or industry standards with respect to privacy and data protection and may inhibit our or our vendors&#8217; ability to maintain an adequate level of service and experience. If we, our vendors, or our third-party partners experience an actual or perceived breach or privacy or security incident because of the use of generative artificial intelligence, we may lose valuable intellectual property and confidential information and our reputation and the public perception of the effectiveness of our security measures could be harmed. Further, bad actors around the world use increasingly sophisticated methods, including the use of artificial intelligence, to engage in illegal activities involving the theft and misuse of personal information, confidential information, and intellectual property. Any of these outcomes could damage our reputation, result in the loss of valuable property and information, and adversely impact our business.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Cybersecurity risks and cyber incidents could adversely affect our business and disrupt operations.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Cyber incidents can result from deliberate attacks or unintentional events. These incidents can include, but are not limited to, gaining unauthorized access to digital systems for purposes of misappropriating assets or sensitive information, corrupting data, or causing operational disruption. The result of these incidents could include, but are not limited to, disrupted operations, misstated financial data, liability for stolen assets or information, increased cybersecurity protection costs, litigation and reputational damage adversely affecting customer or investor confidence. We are in the process of implementing systems and processes to focus on identification, prevention, mitigation and resolution. However, these measures cannot provide absolute security, and our systems may be vulnerable to cybersecurity breaches such as viruses, hacking, and similar disruptions from unauthorized intrusions. In addition, we rely on third party service providers to perform certain services, such as payroll and tax services. Any failure of our systems or third-party systems may compromise our sensitive information and/or personally identifiable information of our employees or patient health information subject to HIPAA confidentiality requirements. While we are in the process of securing cyber insurance to potentially cover certain risks associated with cyber incidents, there can be no assurance the insurance will be sufficient to cover any such liability.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      19
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Risks Related to our Common Stock</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Concentration of ownership of our common stock among our existing executive officers and directors may prevent new investors from influencing significant corporate decisions.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Our executive officers and directors, and their affiliates, who are our principal stockholders, in the aggregate, beneficially own approximately&#160;5.8% of our outstanding common stock as of the date hereof. As a result, these persons, acting together, would be able to significantly influence all matters requiring stockholder approval, including the election and removal of directors, any merger, consolidation, sale of all or substantially all of our assets, or other significant corporate transactions. The minority stockholders have no way of overriding decisions made by our principal stockholders. This level of control may also have an adverse impact on the market value of our shares because our principal stockholders may institute or undertake transactions, policies or programs that result in losses and may not take any steps to increase our visibility in the financial community and/or may sell sufficient numbers of shares to significantly decrease our price per share.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>We do not intend to pay cash dividends on our common stock in the foreseeable future.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We have never declared or paid cash dividends on our capital stock. Subject to any series of preferred stock we may issue in the future, we intend to retain all available funds and any future earnings for use in the operation and expansion of our business and do not anticipate paying any cash dividends on our common stock in the foreseeable future. Accordingly, shareholders may have to sell some or all of their shares of our common stock in order to generate cash flow from an investment in our common stock.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>If our stock price fluctuates, you could lose a significant part of your investment.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The market price of our common stock may be subject to wide fluctuations in response to, among other things, the risk factors described in this prospectus and other factors beyond our control, such as fluctuations in the valuation of companies perceived by investors to be comparable to us. Furthermore, the stock markets have experienced price and volume fluctuations that have affected and continue to affect the market prices of equity securities of many companies. These fluctuations often have been unrelated or disproportionate to the operating performance of those companies. These broad market and industry fluctuations, as well as general economic, political, and market conditions, such as recessions, interest rate changes or international currency fluctuations, may negatively affect the market price of our common stock. In the past, many companies that have experienced volatility in the market price of their stock have been subject to securities class action litigation. We may be the target of this type of litigation in the future. Securities litigation against us could result in substantial costs and divert our management&#8217;s attention from other business concerns, which could seriously harm our business.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Techniques employed by short sellers may in the future drive down the market price of our common stock.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Short selling is the practice of selling securities that the seller does not own but rather has borrowed from a third-party with the intention of buying identical securities back at a later date to return to the lender. The short seller hopes to profit from a decline in the value of the securities between the sale of the borrowed securities and the purchase of the replacement shares, as the short seller expects to pay less in that purchase than it received in the sale. As it is in the short seller&#8217;s best interests for the price of the stock to decline, many short sellers publish, or arrange for the publication of, negative opinions regarding the relevant issuer and its business prospects in order to create negative market momentum and generate profits for themselves after selling a stock short. These short attacks have led to selling of shares in the market. Issuers that have common stock with limited trading volumes and/or have been susceptible to relatively high volatility levels, can be particularly vulnerable to such short seller attacks. The publication of any such articles regarding us in the future may bring about a temporary, or possibly long-term, decline in the market price of our common stock. If we continue to be the subject of unfavorable allegations, we may have to expend a significant amount of resources to investigate such allegations and/or defend ourselves. While we would strongly defend against any such short seller attacks, we may be constrained in the manner in which we can proceed against the relevant short seller by applicable state law or issues of commercial confidentiality. Such a situation could be costly, and time-consuming, and could be distracting for our management team.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>If securities or industry analysts do not publish research or reports about us, or if they adversely change their recommendations regarding our common stock, then our stock price and trading volume could decline.</i></b>&#160;&#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The trading market for our common stock is influenced by the research and reports that industry or securities analysts publish about us, our industry and our market. If no analyst elects to cover us and publish research or reports about us, the market for our common stock could be severely limited and our stock price could be adversely affected. As a small-cap company, we are more likely than our larger competitors to lack coverage from securities analysts. In addition, even if we receive analyst coverage, if one or more analysts ceases coverage of us or fails to regularly publish reports on us, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline. If one or more analysts who elect to cover us issue negative reports or adversely change their recommendations regarding our common stock, our stock price could decline.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      20
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>The market price of our stock may be highly volatile, and you could lose all or part of your investment.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The market for our common stock may be characterized by significant price volatility when compared to the shares of larger, more established companies that have large public floats, and we expect that our stock price will be more volatile than the shares of such larger, more established companies for the indefinite future. The stock market in general, and the market for stocks of technology companies in particular, has recently been highly volatile. Furthermore, there have been recent instances of extreme stock price run-ups followed by rapid price declines and stock price volatility following a number of recent initial public offerings, particularly among companies with relatively smaller public floats. We may also experience such volatility, including stock run-ups, which may be unrelated to our actual or expected operating performance and financial condition or prospects, making it difficult for prospective investors to assess the rapidly changing value of our common stock.&#160;&#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Your ownership may be diluted if additional capital stock is issued to raise capital, to finance acquisitions or in connection with strategic transactions.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We intend to seek to raise additional funds, finance acquisitions or develop strategic relationships by issuing equity or convertible debt securities, which would reduce the percentage ownership of our existing stockholders. Our board of directors has the authority, without action or vote of the stockholders, to issue all or any part of our authorized but unissued shares of common or preferred stock. Our certificate of incorporation authorizes us to issue up to 500,000,000 shares of common stock and 10,000,000 shares of preferred stock. Future issuances of common or preferred stock would reduce your influence over matters on which stockholders vote and would be dilutive to earnings per share. In addition, any newly issued preferred stock could have rights, preferences and privileges senior to those of the common stock. Those rights, preferences and privileges could include, among other things, the establishment of dividends that must be paid prior to declaring or paying dividends or other distributions to holders of our common stock or providing for preferential liquidation rights. These rights, preferences and privileges could negatively affect the rights of holders of our common stock, and the right to convert such preferred stock into shares of our common stock at a rate or price that would have a dilutive effect on the outstanding shares of our common stock.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>We may be required to issue up to 271,846 shares of common stock in connection with the reverse stock split we completed on October 24, 2024, and we may be subject to potential liability if it is determined that we are required to issue such shares and we fail to issue such shares on a timely basis.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">On October 24, 2024, we completed a one-for-twenty reverse stock split of our common stock. In connection with the approval of the reverse stock split, we agreed that no fractional shares will be issued in connection with the reverse stock split and that we would issue one full share of the post-reverse stock split common stock to any shareholder who would have been entitled to receive a fractional share as a result of the process. On November 1, 2024, we received notice from DTCC on behalf of the brokerage firms that hold the shares of our common stock held in &#8220;street name&#8221; that in connection with the foregoing rounding of shares we would need to issue 271,846 shares of common stock.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We do not believe the number of shares being requested is correct based on the historical number of shareholders of our common stock and have begun an inquiry into the calculations set forth in the request. During the pendency of this inquiry, we do not expect to issue any shares in connection with the fractional shares being requested. We may face potential liability for our failure to issue the shares of common stock if it is determined that we are required to issue such shares. In addition, our shareholders will be diluted to the extent of any issuances of shares of common stock in connection with the foregoing.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>If we are unable to maintain compliance with the listing requirements of The Nasdaq Capital Market, our common stock may be delisted from The Nasdaq Capital Market which could have a material adverse effect on our financial condition and could make it more difficult for you to sell your shares.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Our common stock is listed on The Nasdaq Capital Market, and we are therefore subject to its continued listing requirements, including requirements with respect to the market value of publicly held shares, market value of listed shares, minimum bid price per share, and minimum stockholder's equity, among others, and requirements relating to board and committee independence. If we fail to satisfy one or more of the requirements, we may be delisted from The Nasdaq Capital Market.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We have in the past, and we may again in the future,&#160;fail to comply with the continued listing requirements of the Nasdaq Capital Market, which would subject our common stock to being delisted. Delisting from The Nasdaq Capital Market would adversely affect our ability to raise additional financing through the public or private sale of equity securities, may significantly affect the ability of investors to trade our securities and may negatively affect the value and liquidity of our common stock. Delisting also could have other negative results, including the potential loss of employee confidence, the loss of institutional investors or interest in business development opportunities.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Provisions of the Series A and Series B Warrants we issued in prior offerings could discourage an acquisition of us by a third party.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Series A and B Warrants we have issued in prior offerings provide that in the event of a &#8220;Fundamental Transaction&#8221; (as defined in the related warrant agreement, which generally includes any merger with another entity, the sale, transfer or other disposition of all or substantially all of our assets to another entity, or the acquisition by a person of more than 50% of our common stock), each warrant holder will have the right at any time prior to the consummation of the Fundamental Transaction to require us to repurchase the common warrant for a purchase price in cash equal to the Black-Scholes value (as calculated under the warrant agreement) of the then remaining unexercised portion of such warrant on the date of such Fundamental Transaction, which may materially adversely affect our financial condition and/or results of operations and may prevent or deter a third party from acquiring us.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      21
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>General Risks</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Shareholder activism could cause material disruption to our business.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Publicly traded companies have increasingly become subject to campaigns by activist investors advocating corporate actions such as actions related to environment, social and governance (ESG) matters, among other issues. Responding to proxy contests and other actions by such activist investors or others in the future could be costly and time-consuming, disrupt our operations and divert the attention of our Board of Directors and senior management from the pursuit of our business strategies, which could adversely affect our results of operations and financial condition.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>As an </i></b>&#8220;<b><i>emerging growth company</i></b>&#8221;<b><i> under the Jumpstart Our Business Startups Act, or JOBS Act, we are permitted to, and intend to, rely on exemptions from certain disclosure requirements.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">As an &#8220;emerging growth company&#8221; under the JOBS Act, we are permitted to, and intend to, rely on exemptions from certain disclosure requirements. We are an emerging growth company until the earliest of:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">the last day of the fiscal year during which we have total annual gross revenues of $1.235 billion or more;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">the last day of the fiscal year following the fifth anniversary of the date of the first sale of our common equity pursuant to an effective registration statement under the Securities Act of 1933;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">the date on which we have, during the previous 3-year period, issued more than $1 billion in non-convertible debt; or</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">the date on which we are deemed a &#8220;large accelerated issuer&#8221;&#160;as defined under the federal securities laws.&#160;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">For so long as we remain an emerging growth company, we will not be required to:&#160;&#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">have an auditor report on our internal control over financial reporting pursuant to the Sarbanes-Oxley Act of 2002;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#8217;s report providing additional information about the audit and the financial statements (auditor discussion and analysis);</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">submit certain executive compensation matters to shareholders advisory votes pursuant to the &#8220;say on frequency&#8221;&#160;and &#8220;say on pay&#8221;&#160;provisions (requiring a non-binding shareholder vote to approve compensation of certain executive officers) and the &#8220;say on golden parachute&#8221;&#160;provisions (requiring a non-binding shareholder vote to approve golden parachute arrangements for certain executive officers in connection with mergers and certain other business combinations) of the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">include detailed compensation discussion and analysis in our filings under the Securities Exchange Act of 1934, as amended, and instead may provide a reduced level of disclosure concerning executive compensation;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">may present only two years of audited financial statements and only two years of related Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations, or MD&amp;A; and</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">are eligible to claim longer phase-in periods for the adoption of new or revised financial accounting standards under &#167;107 of the JOBS Act.&#160;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We intend to take advantage of all of these reduced reporting requirements and exemptions.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Certain of these reduced reporting requirements and exemptions will already be available to us due to the fact that we also qualify as a &#8220;smaller reporting company&#8221;&#160;under Commission rules. For instance, smaller reporting companies are not required to obtain an auditor attestation and report regarding management&#8217;s assessment of internal control over financial reporting; are not required to provide a compensation discussion and analysis; are not required to provide a pay-for-performance graph or CEO pay ratio disclosure; and may present only two years of audited financial statements and related MD&amp;A disclosure.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We cannot predict if investors will find our securities less attractive due to our reliance on these exemptions. If investors were to find our common stock less attractive as a result of our election, we may have difficulty raising all of the proceeds in any future offering.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      22
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Our Certificate of Incorporation includes a forum selection provision, which could result in less favorable outcomes to the plaintiff(s) in any action against us.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Our Certificate of Incorporation includes a forum selection provision that requires any claims against us by stockholders not arising under the federal securities laws to be brought in the Court of Chancery State in the state of Delaware. This forum selection provision may limit investors&#8217; ability to bring claims in judicial forums that they find favorable to such disputes and may discourage lawsuits with respect to such claims. In addition, this forum selection provision may impose additional litigation costs on stockholders in pursuing the claims identified above, particularly if the stockholders do not reside in or near the State of Delaware.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>The requirements of being a public company may strain our resources, divert management</i></b>&#8217;<b><i>s attention and affect our ability to attract and retain qualified board members. </i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">As a public company, we incur accounting, legal and other expenses that we did not incur as a private company. We incur costs associated with our public company reporting requirements. We also incur costs associated with corporate governance requirements, including requirements under the Sarbanes-Oxley Act of 2002, as well as rules and regulations implemented by the United States Security and Exchange Commission (&#8220;SEC&#8221;) and Nasdaq. We expect these rules and regulations to increase our legal and financial compliance costs and to make some activities more time-consuming and costly. Furthermore, these rules and regulations could make it more difficult or costlier for us to obtain certain types of insurance, including director and officer liability insurance, and we may be forced to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. The impact of these requirements could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, our board committees or as executive officers. We are currently evaluating and monitoring developments with respect to these rules and regulations and we cannot predict or estimate the amount of additional costs we may incur or the timing of such costs.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>We may be at an increased risk of securities class action litigation. </i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Historically, securities class action litigation has often been brought against a company following a decline in the market price of its securities. This risk is especially relevant for us because biotechnology companies have experienced significant stock price volatility in recent years. If we were to be sued, it could result in substantial costs and a diversion of management&#8217;s attention and resources, which could harm our business.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      23
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="caution" href="#"></a>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">This prospectus contains certain forward-looking statements that involve substantial risks and uncertainties. All statements contained in this prospectus, other than statements of historical facts, are forward-looking statements including statements regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans, objectives of management and expected market growth. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The words &#8220;anticipate&#8221;, &#8220;believe&#8221;, &#8220;estimate&#8221;, &#8220;expect&#8221;, &#8220;intend&#8221;, &#8220;may&#8221;, &#8220;plan&#8221;, &#8220;predict&#8221;, &#8220;project&#8221;, &#8220;target&#8221;, &#8220;potential&#8221;, &#8220;will&#8221;, &#8220;would&#8221;, &#8220;could&#8221;, &#8220;should&#8221;, &#8220;continue&#8221; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, among other things, statements about:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">our ability to continue as a going concern in the near term is dependent upon us successfully raising additional equity or debt financing to fund our operations;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">the success of our future clinical trials;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">we currently have no source of product sales revenue;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">competition from existing products or new products that may emerge;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">if we fail to comply with U.S. and foreign regulatory requirements, regulatory authorities could limit or withdraw any marketing or commercialization approvals we may receive and subject us to other penalties that could materially harm our business;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">we may be unable to obtain U.S. or foreign regulatory approval and, as a result, unable to commercialize our product candidates;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">the implementation of our business model and strategic plans for our business, technologies and product candidates;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">potential product liability claims;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">our dependency on third-party supply and manufacturing partners to supply the materials and components for, and manufacture, our research and development, preclinical and clinical trial devices;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">our ability to establish or maintain collaborations, licensing or other arrangements and retain commercial rights for our product candidates subject to collaborations;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">our ability and third parties&#8217;&#160;abilities to protect intellectual property rights and our ability to operate our business without infringing the intellectual property rights of others;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">our ability to adequately support future growth;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">our estimates of our expenses, ongoing losses, future revenue and capital requirements;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">our ability to attract and retain key management personnel and technical personnel to manage our business effectively;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">risks associated with our identification of material weaknesses in our control over financial reporting;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">our use of net proceeds received by us from any subsequent private placement or public financing;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">natural disasters affecting us, our primary manufacturer or our suppliers;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">our ability to establish relationships with health care professionals and organizations;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">general economic uncertainty that adversely affects spending on medical procedures;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">volatility in the market price of our stock; and</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">potential dilution to current stockholders from the issuance of equity awards.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">These forward-looking statements are only predictions and we may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, so you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our business, financial condition and operating results. We have included important factors in the cautionary statements included in this prospectus that could cause actual future results or events to differ materially from the forward-looking statements that we make. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments we may make.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">You should read this prospectus with the understanding that our actual future results may be materially different from what we expect. We do not assume any obligation to update any forward-looking statements whether as a result of new information, future events or otherwise, except as required by applicable law.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      24
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="lincoln" href="#"></a>THE LINCOLN PARK TRANSACTION</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">This prospectus covers the resale by the selling stockholder of up to 2,500,000 shares of our common stock, comprised of: (i) up to 2,238,068 shares of our common stock that we have reserved for sale to Lincoln Park under the Purchase Agreement from time to time after the date of this prospectus, if and when we determine to sell additional shares of our common stock to Lincoln Park under the Purchase Agreement and (ii) 261,932 Commitment Shares that we have already issued to Lincoln Park as a fee for making its irrevocable commitment to purchase our common stock under the Purchase Agreement.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>General</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">On August 25, 2025, we entered into the Purchase Agreement with Lincoln Park, pursuant to which Lincoln Park has agreed to purchase from us up to an aggregate of $15.0 million of our common stock (subject to certain limitations) from time to time over the term of the Purchase Agreement. Pursuant to the Purchase Agreement we issued 261,932 Commitment Shares to Lincoln Park as a fee for making its irrevocable commitment to purchase our common stock under the Purchase Agreement (for which Commitment Shares we have not and will not receive any cash consideration).</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">On August 25, 2025, we entered into the Registration Rights Agreement, pursuant to which we filed with the SEC the registration statement that includes this prospectus to register for resale under the Securities Act, the shares of our common stock that have been or may be issued to Lincoln Park under the Purchase Agreement, for which we have not and will not receive any cash consideration.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We do not have the right to commence any sales of our common stock to Lincoln Park under the Purchase Agreement until all of the conditions set forth in the Purchase Agreement have been satisfied, including that the SEC has declared effective the registration statement that includes this prospectus and the final form of this prospectus has been filed with the SEC, which we refer to in this prospectus as the "commencement", and the date on which the commencement occurs we refer to as the "Commencement Date". From and after the commencement, we may, from time to time and at our sole discretion for a period of 24-months, on any business day on which the closing sale price of our common stock is not below $0.25, direct Lincoln Park to purchase up to 30,000 shares of our common stock, which maximum share limitation may be increased in certain incremental amounts depending on the last closing sale price of our common stock at the time of sale, subject to a maximum commitment of $500,000 per purchase, which we refer to in this prospectus as &#8220;Regular Purchases".&#160;In addition to Regular Purchases, if we direct Lincoln Park to purchase the maximum number of shares of our common stock that we may sell in a Regular Purchase on the applicable business day we initiate such Regular Purchase, then, in addition to such Regular Purchase,&#160;we may also direct Lincoln Park to purchase certain additional amounts of our common stock as &#8220;accelerated purchases&#8221; and as &#8220;additional accelerated purchases.&#8221;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We will control the timing and amount of any sales of our common stock to Lincoln Park. The purchase price of the shares of our common stock that may be sold to Lincoln Park in Regular Purchases, accelerated purchases, and additional accelerated purchases under the Purchase Agreement will be based on the market price of our common stock at or prior to the time of sale as computed under the Purchase Agreement. The purchase price per share will be equitably adjusted as provided in the Purchase Agreement for any reorganization, recapitalization, non-cash dividend, stock split, or other similar transaction as set forth in the Purchase Agreement. We may at any time in our sole discretion terminate the Purchase Agreement without fee, penalty or cost upon one business day notice. Actual sales of shares of our common stock to Lincoln Park under the Purchase Agreement will depend on a variety of factors to be determined by us from time to time, including, among others, market conditions, the trading price of our common stock and determinations by us as to the appropriate sources of funding for our operations.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">As of September 19, 2025, there were 6,194,147 shares of our common stock outstanding, which includes the Commitment Shares. Although the Purchase Agreement provides that we may sell up to an aggregate of $15.0 million of our common stock to Lincoln Park, 2,500,000 shares of our common stock are being registered under the Securities Act for resale by Lincoln Park under the registration statement that includes this prospectus, which represents the 261,932 Commitment Shares that we issued to Lincoln Park on August 25, 2025 as a fee for making its irrevocable commitment to purchase our common stock at our direction under the Purchase Agreement and an additional 2,238,068 shares of our common stock that we may issue and sell to Lincoln Park as Purchase Shares from and after the commencement under the Purchase Agreement, if and when we elect to sell shares of our common stock to Lincoln Park under the Purchase Agreement. Depending on the market prices of our common stock at the time we elect to issue and sell shares of our common stock to Lincoln Park under the Purchase Agreement, we may need to register under the Securities Act for resale by Lincoln Park additional shares of our common stock in order to receive aggregate gross proceeds equal to the $15.0 million total commitment available to us under the Purchase Agreement. If, in addition to the 261,932 Commitment Shares that we have already issued to Lincoln Park, all of the 2,238,068 shares of our common stock that we may elect to issue and sell to Lincoln Park in the future as Purchase Shares that are being registered under the Securities Act for resale by Lincoln Park in the registration statement that includes this prospectus were issued and outstanding (without taking into account the Exchange Cap or the Beneficial Ownership Cap limitations described below), such shares of our common stock, together with the 261,932 Commitment Shares would represent approximately 29.6% of the total number of shares of our common stock outstanding and approximately 30.9% of the total number of outstanding shares held by non-affiliates of the Company, in each case as of September 19, 2025. If we elect to issue and sell to Lincoln Park under the Purchase Agreement more than the 2,238,068 shares of our common stock that we may elect to issue and sell to Lincoln Park in the future as Purchase Shares that are being registered under the Securities Act for resale by Lincoln Park in the registration statement that includes this prospectus, which we have the right, but not the obligation, to do, we must first register under the Securities Act for resale by Lincoln Park any such additional shares of our common stock, which could cause additional substantial dilution to our stockholders. The number of shares of our common stock ultimately offered for resale by Lincoln Park is dependent upon the number of shares of our common stock we ultimately decide to sell to Lincoln Park under the Purchase Agreement.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      25
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Under applicable Nasdaq rules, in no event may we issue or sell to Lincoln Park under the Purchase Agreement shares of our common stock in excess of 1,075,767 shares (including the Commitment Shares), which represented 19.99% of the shares of our common stock outstanding immediately prior to the execution of the Purchase Agreement, which limitation we refer to as the Exchange Cap, unless (i) we obtain stockholder approval to issue shares of our common stock in excess of the Exchange Cap or (ii) the average price of all applicable sales of our common stock to Lincoln Park under the Purchase Agreement equals or exceeds $1.3351 per share Base Price, representing the lower of (A) the official closing price of our common stock on Nasdaq on the trading day immediately preceding the date of the Purchase Agreement and (B) the average official closing price of our common stock on Nasdaq for the five consecutive trading days ending on the trading day immediately preceding the date of the Purchase Agreement, as adjusted under applicable Nasdaq rules to take into account the issuance of the Commitment Shares to Lincoln Park for non-cash consideration as payment of the commitment fee described below, so that the Exchange Cap would not apply under applicable Nasdaq rules to issuances and sales of our common stock to Lincoln Park under the Purchase Agreement.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">At the 2025 annual meeting of our stockholders to be held on October 30, 2025, among other things, we are seeking the requisite stockholder authorization in accordance with applicable Nasdaq listing rules to issue and sell shares of our common stock in excess of the 1,075,767 share Exchange Cap referred to above, if we so choose, to Lincoln Park under the Purchase Agreement. Accordingly, if such requisite stockholder approval is obtained, we would be able to issue and sell to Lincoln Park, in addition to the 261,932 Commitment Shares we have already issued to Lincoln Park on August 25, 2025, all of the 2,238,068 shares of common stock as Purchase Shares under the Purchase Agreement that are being registered under the Securities Act for resale by Lincoln Park under the registration statement that includes this prospectus, at purchase prices averaging less than the Base Price, without any further aggregate share issuance limitations under Nasdaq rules.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Purchase Agreement also prohibits us from directing Lincoln Park to purchase any shares of our common stock if those shares of our common stock, when aggregated with all other shares of our common stock then beneficially owned by Lincoln Park and its affiliates, would result in Lincoln Park having beneficial ownership, at any single point in time, of more than 4.99% of the then total outstanding shares of our common stock, as calculated pursuant to Section 13(d) of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and Rule 13d-3 thereunder, which limitation we refer to as the Beneficial Ownership Cap.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Issuances of our common stock to Lincoln Park under the Purchase Agreement will not affect the rights or privileges of our existing stockholders, except that the economic and voting interests of each of our existing stockholders will be diluted as a result of any such issuance. Although the number of shares of our common stock that our existing stockholders own will not decrease, the shares of our common stock owned by our existing stockholders will represent a smaller percentage of our total outstanding shares of our common stock after any such issuance of shares of our common stock to Lincoln Park under the Purchase Agreement. There are substantial risks to our stockholders as a result of the sale and issuance of common stock to Lincoln Park under the Purchase Agreement. See &#8220;Risk Factors.&#8221;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Purchase of Shares of our Common Stock Under the Purchase Agreement</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Regular Purchases</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">From and after the Commencement Date, provided the last closing sale price of our common stock on the applicable &#8220;regular purchase date&#8221; (as defined in the Purchase Agreement) is not below $0.25 (and provided all shares of common stock subject to all prior Regular Purchases have been properly delivered to Lincoln Park in accordance with the Purchase Agreement) (the &#8220;Regular Purchase Date&#8221;), we may, by written notice delivered by us to Lincoln Park within the time periods on such Regular Purchase Date, direct Lincoln Park to purchase up to 30,000 shares of our common stock in a Regular Purchase;&#160;provided that this amount shall be increased to (i) 40,000 shares of our common stock, if the closing sale price of our common stock on the applicable Regular Purchase Date is not below $1.00, (ii) to 50,000 shares of our common stock, if the closing sale price of our common stock on the applicable Regular Purchase Date is not below $1.50, and (iii) to 75,000 shares of our common stock, if the closing sale price of our common stock on the applicable Regular Purchase Date is not below $2.00 (all of which share and dollar amounts shall be appropriately proportionately adjusted for any reorganization, recapitalization, non-cash dividend, stock split or other similar transaction) (such share amount limitation, the &#8220;Regular Purchase Share Limit&#8221;).</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The purchase price per share for each Regular Purchase will be 97.0% of the lower of:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#9679; &#160; &#160; &#160; &#160; the lowest sale price for our common stock on the applicable Regular Purchase Date for such shares of our common stock; and</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#9679; &#160; &#160; &#160; &#160; the average of the three lowest closing sale prices of our common stock during the 10-business day period immediately preceding the applicable Regular Purchase Date for such shares of our common stock.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Accelerated Purchases</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">In addition to Regular Purchases described above, we may also direct Lincoln Park, on any Regular Purchase Date on which we have properly submitted a Regular Purchase notice directing Lincoln Park to purchase the maximum number of shares of our common stock that we are then permitted to include in a single Regular Purchase notice (and provided all shares of common stock subject to all prior Regular Purchases, Accelerated Purchases and Additional Accelerated Purchases effected prior to such Regular Purchase Date have been properly delivered to Lincoln Park in accordance with the Purchase Agreement), to purchase an additional amount of our common stock, which we refer to as an &#8220;Accelerated Purchase&#8221;, on the business day immediately following the applicable Regular Purchase Date for such corresponding Regular Purchase, which we refer to as the &#8220;Accelerated Purchase Date,&#8221; not to exceed the lesser of:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#9679; &#160; &#160; &#160; &#160; &#160;30% of the aggregate number of shares of our common stock traded during all or, if certain trading volume or market price thresholds specified in the Purchase Agreement are crossed on the applicable Accelerated Purchase Date, the portion of the normal trading hours on the applicable Accelerated Purchase Date prior to such time that any one of such thresholds is crossed, which period of time on the applicable Accelerated Purchase Date we refer to as the Accelerated Purchase Measurement Period; and</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      26
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#9679; &#160; &#160; &#160; &#160; 300% of the number of purchase shares purchased pursuant to the corresponding Regular Purchase.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The purchase price per share for the shares subject to an Accelerated Purchase will be equal to 97% of the lower of:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#9679; &#160; &#160; &#160; &#160; the volume weighted average price of our common stock during the Accelerated Purchase Measurement Period on the applicable Accelerated Purchase Date; and</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">&#9679; &#160; &#160; &#160; &#160; the closing sale price of our common stock on the applicable Accelerated Purchase Date.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Additional Accelerated Purchases</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We may also direct Lincoln Park, by written notice delivered to Lincoln Park, not later than 1:00 p.m., eastern time, on the same Accelerated Purchase Date on which an Accelerated Purchase Measurement Period for an Accelerated Purchase has ended prior to such time (and provided all shares of common stock subject to all prior Regular Purchases, Accelerated Purchases and Additional Accelerated Purchases, including those prior Accelerated Purchases and Additional Accelerated Purchases effected on the same Accelerated Purchase Date as the applicable Additional Accelerated Purchase have been properly delivered to Lincoln Park in accordance with the Purchase Agreement prior to such time), to purchase an additional amount of our common stock on such same Accelerated Purchase Date, which we refer to as an Additional Accelerated Purchase, of up to the lesser of:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 72pt;">&#9679;&#160; &#160; &#160; &#160;30% of the aggregate number of shares of our common stock traded during the portion of the normal trading hours on the applicable Accelerated Purchase Date determined in accordance with the Purchase Agreement, which period of time on the applicable Accelerated Purchase Date we refer to as the Additional Accelerated Purchase Measurement Period; and</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 72pt;">&#9679;&#160; &#160; &#160; &#160; &#160;300% of the number of purchase shares purchased pursuant to the Regular Purchase corresponding to the Accelerated Purchase effected on such same Accelerated Purchase Date.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The purchase price per share for the shares subject to an Additional Accelerated Purchase will be equal to 97% of the lower of:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 72pt;">&#9679; &#160; &#160; &#160; &#160; the volume weighted average price of our common stock during the applicable Additional Accelerated Purchase Measurement Period for such Additional Accelerated Purchase; and</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 72pt;">&#9679; &#160; &#160; &#160; &#160; the closing sale price of our common stock on the applicable same Accelerated Purchase Date.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We may, in our sole discretion, submit multiple Additional Accelerated Purchase notices to Lincoln Park prior to 1:00 p.m., eastern time, on a single Accelerated Purchase Date, again provided all shares of common stock subject to all prior Regular Purchases, Accelerated Purchases and Additional Accelerated Purchases, including those prior Accelerated Purchases and Additional Accelerated Purchases effected on the same Accelerated Purchase Date as the applicable Additional Accelerated Purchase, have been properly delivered to Lincoln Park in accordance with the Purchase Agreement prior to such time.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">In the case of Regular Purchases, Accelerated Purchases and Additional Accelerated Purchases, the purchase price per share will be equitably adjusted for any reorganization, recapitalization, non-cash dividend, stock split, reverse stock split or other similar transaction occurring during the business days used to compute the purchase price.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Other than as described above, there are no trading volume requirements or restrictions under the Purchase Agreement, and we will control the timing and amount of any sales of our common stock to Lincoln Park.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Suspension Events</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Suspension events under the Purchase Agreement include the following:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:72pt;">&#9679;&#160; &#160; &#160; &#160; the effectiveness of the registration statement of which this prospectus forms a part lapses for any reason (including, without limitation, the issuance of a stop order), or any required prospectus supplement and accompanying prospectus are unavailable for the resale by Lincoln Park of our common stock offered hereby, and such lapse or unavailability continues for a period of 10 consecutive business days or for more than an aggregate of 30 business days in any 365-day period;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      27
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:72pt;">&#9679; &#160; &#160; &#160; &#160; suspension by our principal market of our common stock from trading for a period of one business day;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:72pt;">&#9679;&#160; &#160; &#160; &#160; the delisting of our common stock from The Nasdaq Capital Market, our principal market, provided our common stock is not immediately thereafter trading on The Nasdaq Global Market, The Nasdaq Global Select Market, the New York Stock Exchange, the NYSE American, the NYSE Arca, or The OTCQX Best Market or The OTCQB Venture Market operated by OTC Markets Group, Inc. (or any nationally recognized successor to any of the foregoing);</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:72pt;">&#9679;&#160; &#160; &#160; &#160; &#160;the failure of our transfer agent to issue to Lincoln Park shares of our common stock within two business days after the applicable date on which Lincoln Park is entitled to receive such shares of our common stock;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:72pt;">&#9679;&#160; &#160; &#160; &#160; &#160;any breach of the representations or warranties or covenants contained in the Purchase Agreement or Registration Rights Agreement that has or could have a material adverse effect on us and, in the case of a breach of a covenant that is reasonably curable, that is not cured within five business days;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:72pt;">&#9679;&#160; &#160; &#160; &#160; &#160;any voluntary or involuntary participation or threatened participation in insolvency or bankruptcy proceedings by or against us;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:72pt;">&#9679;&#160; &#160; &#160; &#160; &#160;if at any time we are not eligible to transfer our common stock electronically;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:72pt;">&#9679;&#160; &#160; &#160; &#160; &#160;if at any time the Exchange Cap (to the extent applicable under the terms of the Purchase Agreement) is reached and our stockholders have not approved the issuance of common stock in excess of the Exchange Cap in accordance with the applicable Nasdaq rules; or</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:72pt;">&#9679;&#160; &#160; &#160; &#160; &#160;if at any time Lincoln Park&#8217;s broker is unable to accept shares of our common stock for deposit for reasons not within Lincoln Park&#8217;s control.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Following the Commencement Date, Lincoln Park does not have the right to terminate the Purchase Agreement upon any of the suspension events set forth above, although the Purchase Agreement would automatically terminate in the event of any voluntary or involuntary participation or threatened participation in insolvency or bankruptcy proceedings by or against us that are not discharged within 90 days. So long as a suspension event has occurred and is continuing, or if any event which, after notice and/or lapse of time, would reasonably be expected to become a suspension event has occurred and is continuing, we may not direct Lincoln Park to purchase any shares of our common stock under the Purchase Agreement.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Our Termination Rights</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We have the unconditional right, at any time, for any reason and without any payment or liability to us, to terminate the Purchase Agreement upon one business day&#8217;s prior written notice to Lincoln Park. In the event of any voluntary or involuntary bankruptcy proceedings by or against us that are not discharged within 90 days, the Purchase Agreement would automatically terminate without any action by us or Lincoln Park. No termination of the Purchase Agreement will be effective during the pendency of any Regular Purchase, Accelerated Purchase or Additional Accelerated Purchase that has not then fully settled in accordance with the Purchase Agreement.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>No Short-Selling or Hedging by Lincoln Park</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Lincoln Park has represented to us that at no time prior to the time of execution of the Purchase Agreement has Lincoln Park or its agents, representatives or affiliates engaged in or effected, in any manner whatsoever, directly or indirectly, any short sale (as such term is defined in Rule 200 of Regulation SHO under the Exchange Act) of our common stock or any hedging transaction, which establishes a net short position with respect to our common stock. Lincoln Park agreed that during the term of the Purchase Agreement, it, its agents, representatives or affiliates will not enter into or effect, directly or indirectly, any of the foregoing transactions.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Prohibitions on Certain Substantially Similar Transactions</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">There are no restrictions on future financings, rights of first refusal, participation rights, penalties or liquidated damages in the Purchase Agreement or Registration Rights Agreement, except we are prohibited (with certain specified exceptions set forth in the Purchase Agreement) from effecting or entering into an agreement to effect an &#8220;equity line of credit&#8221; or other substantially similar offering whereby an investor is irrevocably bound to purchase securities over a period of time from us at a price based on the market price of our common stock at the time of each such purchase.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      28
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Effect of Performance of the Purchase Agreement on Our Stockholders</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">All of the shares of our common stock being registered for resale hereunder which have been or may be issued or sold by us to Lincoln Park under the Purchase Agreement are expected to be freely tradable. It is anticipated that shares registered in this offering will be sold from time to time over a period of up to 24-months commencing on the date that the registration statement of which this prospectus forms a part becomes effective. The sale by Lincoln Park of a significant amount of shares of our common stock registered in this offering at any given time could cause the market price of our common stock to decline and to be highly volatile. Sales of our common stock to Lincoln Park, if any, will depend upon market conditions and other factors to be determined by us. We may ultimately decide to sell to Lincoln Park all, some or none of the additional shares of our common stock that may be available for us to sell pursuant to the Purchase Agreement. If and when we do sell additional shares of our common stock to Lincoln Park, after Lincoln Park has acquired the shares of our common stock, Lincoln Park may resell all, some or none of those shares of our common stock at any time or from time to time in its discretion. Therefore, sales to Lincoln Park by us under the Purchase Agreement may result in substantial dilution to the interests of other holders of our common stock. In addition, if we sell a substantial number of shares of our common stock to Lincoln Park under the Purchase Agreement, or if investors expect that we will do so, the actual sales of shares of our common stock or the mere existence of our arrangement with Lincoln Park may make it more difficult for us to sell equity or equity-related securities in the future at a time and at a price that we might otherwise wish to effect such sales. However, we have the right to control the timing and amount of any additional sales of our common stock to Lincoln Park and the Purchase Agreement may be terminated by us at any time at our discretion without any cost to us.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Pursuant to the terms of the Purchase Agreement, from and after commencement, we have the right, but not the obligation, from time to time to direct Lincoln Park to purchase up to $15.0 million of our common stock. Depending on the price per share at which we sell our common stock to Lincoln Park pursuant to the Purchase Agreement, we may need to sell to Lincoln Park under the Purchase Agreement more shares of our common stock than are being offered under this prospectus in order to receive aggregate gross proceeds equal to the $15.0 million total commitment available to us under the Purchase Agreement. If we choose to do so, we must first register for resale under the Securities Act such additional shares of our common stock, which could cause additional substantial dilution to our stockholders. The number of shares of our common stock ultimately offered for resale by Lincoln Park under this prospectus is dependent upon the number of shares of our common stock we direct Lincoln Park to purchase under the Purchase Agreement.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The following table sets forth the amount of gross proceeds we would receive from Lincoln Park from our sale of common stock to Lincoln Park under the Purchase Agreement at varying purchase prices:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Assumed</b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Average</b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Purchase Price</b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Per Share</b></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Number of Registered</b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Shares of our</b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Common Stock to be</b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Issued if Full</b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Purchase (1)</b></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Percentage of Outstanding</b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Shares of our Common</b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Stock After Giving Effect to</b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>the Issuance to</b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Lincoln Park (2)</b></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Gross Proceeds from the</b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Sale of Shares of our</b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Common Stock to Lincoln</b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Park Under the</b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Purchase Agreement (1)</b></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$</p> </td>
     <td style="vertical-align: bottom; width: 22%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">0.25</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 22%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">2,500,000</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 22%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">29.6</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$</p> </td>
     <td style="vertical-align: bottom; width: 22%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">559,517.00</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255);">
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$</p> </td>
     <td style="vertical-align: bottom; width: 22%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">0.50</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 22%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">2,500,000</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 22%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">29.6</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$</p> </td>
     <td style="vertical-align: bottom; width: 22%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">1,119,034.00</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$</p> </td>
     <td style="vertical-align: bottom; width: 22%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">1.06</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(3)&#160;</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 22%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">2,500,000</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 22%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">29.6</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$</p> </td>
     <td style="vertical-align: bottom; width: 22%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">2,372,352.08</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255);">
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$</p> </td>
     <td style="vertical-align: bottom; width: 22%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">2.00</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 22%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">2,500,000</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 22%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">29.6</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$</p> </td>
     <td style="vertical-align: bottom; width: 22%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">4,476,136.00</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$</p> </td>
     <td style="vertical-align: bottom; width: 22%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">3.00</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 22%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">2,500,000</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 22%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">29.6</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$</p> </td>
     <td style="vertical-align: bottom; width: 22%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">6,714,204.00</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">(1)</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Although the Purchase Agreement provides that we may sell up to $15.0 million of our common stock to Lincoln Park, we are only registering 2,500,000 shares of our common stock for resale under this prospectus, including 261,932 Commitment Shares that we have already issued to Lincoln Park as a fee for making its irrevocable commitment to purchase our common stock under the Purchase Agreement (for which we have not and will not receive any cash consideration), which may or may not cover all the shares of our common stock we ultimately sell to Lincoln Park under the Purchase Agreement, depending on the purchase price per share. Accordingly, the gross proceeds reflected in the fourth column from the left are calculated by multiplying only the 2,238,068 shares of common stock may be issued and sold by us to Lincoln Park in the future as Purchase Shares under the Purchase Agreement that are being registered under the Securities Act for resale by Lincoln Park in the registration statement that includes this prospectus, by the assumed average price per share set forth in the first column on the left, because we have not and will not receive any cash consideration for the 261,932 shares of common stock that we issued to Lincoln Park as Commitment Shares on August 25, 2025. Additionally, under applicable Nasdaq rules, in no event may we issue or sell to Lincoln Park under the Purchase Agreement shares of our common stock (including the Commitment Shares) in excess of the Exchange Cap (or 1,075,767 shares of common stock representing 19.99% of the shares of our common stock outstanding immediately prior to the execution of the Purchase Agreement), unless (i) we obtain stockholder approval to issue shares of our common stock to Lincoln Park under the Purchase Agreement in excess of the Exchange Cap or (ii) the average price of all applicable sales of our common stock to Lincoln Park under the Purchase Agreement equals or exceeds $1.3351 per share Base Price, so that the Exchange Cap would not apply under applicable Nasdaq rules to issuances and sales of our common stock to Lincoln Park under the Purchase Agreement. At the 2025 annual meeting of our stockholders to be held on October 30, 2025, among other things, we are seeking the requisite stockholder authorization in accordance with applicable Nasdaq listing rules to issue and sell shares of our common stock in excess of the 1,075,767 share Exchange Cap referred to above, if we so choose, to Lincoln Park under the Purchase Agreement. Accordingly, if such requisite stockholder approval is obtained, we would be able to issue and sell to Lincoln Park, in addition to the 261,932 Commitment Shares we have already issued to Lincoln Park on August 25, 2025, all of the 2,238,068 shares of common stock as Purchase Shares under the Purchase Agreement that are being registered under the Securities Act for resale by Lincoln Park under the registration statement that includes this prospectus, at purchase prices averaging less than the Base Price, without any further aggregate share issuance limitations under Nasdaq rules. The number of registered shares of common stock to be issued reflected in the second column from the left does not give effect to the limitations on the amount of shares we may be permitted to issue to Lincoln Park from time to time under the Purchase Agreement as a result of the Beneficial Ownership Cap or the Exchange Cap.</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">(2)</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">The denominator is based on 6,194,147 shares of our common stock outstanding as of September 19, 2025 (including the 261,932 Commitment Shares that we issued to Lincoln Park upon execution of the Purchase Agreement on August 25, 2025), adjusted to include the 2,238,068 shares of our common stock (which are included in the 2,500,000 shares of common stock set forth in the adjacent column to the left) that we would have sold to Lincoln Park as Purchase Shares pursuant to the Purchase Agreement, assuming such Purchase Shares are sold to Lincoln Park at the assumed average purchase price per share set forth in the first column on the left. The numerator is based on the number of shares of our common stock issuable under the Purchase Agreement at the corresponding assumed average purchase price per share set forth in the first column on the left, without giving effect to the Exchange Cap or the Beneficial Ownership Cap.</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">(3)</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">The closing sale price per share of our common stock on September 19, 2025</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      29
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="proceeds" href="#"></a>USE OF PROCEEDS</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">This prospectus relates to shares of our common stock that may be offered and sold from time to time by Lincoln Park. We will receive no proceeds from the sale of shares of common stock by Lincoln Park in this offering. We may receive up to $15.0 million in gross proceeds under the Purchase Agreement from any sales we make to Lincoln Park pursuant to the Purchase Agreement after the date of this prospectus. We estimate that the net proceeds to us from the sale of our common stock to Lincoln Park pursuant to the Purchase Agreement could be up to approximately $14.9 million over an approximately 24-month period, assuming that we sell the full amount of our common stock that we have the right, but not the obligation, to sell to Lincoln Park under the Purchase Agreement, and after other estimated fees and expenses. See &#8220;Plan of Distribution&#8221; elsewhere in this prospectus for more information.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Any proceeds from the selling stockholder that we receive under the Purchase Agreement are expected to be used for working capital and general corporate purposes. The amounts and timing of these expenditures will depend on a number of factors, such as the timing and progress of our clinical trials and any regulatory approvals. As we are unable to predict the timing or amount of potential issuances of all of the additional shares issuable to the Purchase Agreement, we cannot specify with certainty all of the particular uses for the net proceeds that we will have from the sale of such additional shares. Accordingly, our management will have broad discretion in the application of the net proceeds. We may use the proceeds for purposes that are not contemplated at the time of this offering. Pending use of the net proceeds as described above, we expect to invest the net proceeds in short- and intermediate-term, interest-bearing obligations, investment-grade instruments, certificates of deposit or direct or guaranteed obligations of the U.S. government. It is possible that no additional shares will be issued under the Purchase Agreement.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="dividend_policy" href="#"></a>DIVIDEND POLICY</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">To date, we have not paid any dividends on our common stock and do not anticipate paying any dividends in the foreseeable future. The declaration and payment of dividends on the common stock is at the discretion of our Board of Directors and will depend on, among other things, our operating results, financial condition, capital requirements, contractual restrictions or such other factors as our Board of Directors may deem relevant. We currently expect to use all available funds to finance the future development and expansion of our business and do not anticipate paying dividends on our common stock in the foreseeable future.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      30
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="dilution" href="#"></a>DILUTION</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The sale of common stock to Lincoln Park pursuant to the Purchase Agreement will have a dilutive impact on our stockholders. In addition, the lower the price of our common stock is at the time we exercise our right to sell shares to Lincoln Park, the more shares of our common stock we will issue to raise our desired amount of proceeds from the sale, and the greater the dilution to our existing shareholders.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The price that Lincoln Park will pay for our common stock to be resold pursuant to this prospectus will depend upon the timing of sales and will fluctuate based on the trading price of common stock.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">As of June 30, 2025, we had a net tangible book value of $7.0 million, or $1.75 per share of common stock. Our net tangible book value per share represents total tangible assets less total liabilities, divided by the number of shares of our common stock outstanding as of June 30, 2025.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Our pro forma net tangible book value as of June 30, 2025 was $10.1 million, or $1.56 per share of common stock. Pro forma net tangible book value gives effect to (i) 1,909,590 shares of common stock issued since June 30, 2025; (ii) 261,932 Commitment Shares issued to Lincoln Park pursuant to the Purchase Agreement, and (iii) 271,846 shares potentially issuable after the date of this prospectus in connection with the rounding of fractional shares in connection with the reverse stock split completed October 24, 2024 to the holders of our shares held in "street name".</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Dilution represents the difference between the amount per share paid by purchasers in this offering and the pro forma as adjusted net tangible book value per share of common stock after the offering. After giving effect to the 2,238,068 shares of common stock issuable to Lincoln Park pursuant to the Purchase Agreement at an assumed price of $1.06 per share, the closing price of our common stock on Nasdaq on September 19, 2025, and after deducting commissions and estimated aggregate offering expenses payable by us, our pro forma as adjusted net tangible book value as of June 30, 2025 would have been $12.4 million, or $1.42&#160;per share. This represents an immediate decrease in net tangible book value of $0.14&#160;per share to existing stockholders on a pro forma as adjusted basis and immediate increase in net tangible book value of $0.36 per share to new investors purchasing our common stock in this offering.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The following table illustrates this dilution on a per share basis:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align: bottom; width: 70%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Assumed public offering price per share</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 12%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$</p> </td>
     <td style="vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">1.06</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255);">
     <td style="vertical-align: bottom; width: 70%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Historical net tangible book value per share of common stock as of June 30, 2025</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$</p> </td>
     <td style="vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">1.75</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 12%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align: middle; width: 70%;">&#160;</td>
     <td style="vertical-align: middle; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 12%;">&#160;</td>
     <td style="vertical-align: middle; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 12%;">&#160;</td>
     <td style="vertical-align: middle; width: 1%;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255);">
     <td style="vertical-align: middle; width: 70%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Pro forma net tangible book value per share at June 30, 2025</p> </td>
     <td style="vertical-align: middle; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$</p> </td>
     <td style="vertical-align: middle; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">1.56&#65279;</p> </td>
     <td style="vertical-align: middle; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 12%;">&#160;</td>
     <td style="vertical-align: middle; width: 1%;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align: bottom; width: 70%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Decrease in pro forma net tangible book value per share to existing stockholders attributable to this offering on a pro forma basis</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">(0.14)</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 12%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255);">
     <td style="vertical-align: bottom; width: 70%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Pro forma as adjusted net tangible book value per share after this offering</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 12%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">1.42</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align: bottom; width: 70%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Increase in net tangible book value per share to new investors purchasing shares in this offering</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 12%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="border-bottom: 3px double rgb(0, 0, 0); vertical-align: bottom; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$</p> </td>
     <td style="border-bottom: 3px double rgb(0, 0, 0); vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">0.36</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The table and discussion above are based on 4,022,625 shares of our common stock outstanding as June 30, 2025 (6,465,993 shares of common stock outstanding on a pro forma basis after March 31, 2025 but prior to this offering), and excludes, as of such date, the following:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#9679;&#160; &#160; &#160; &#160; &#160; &#160;112,534 shares of common stock underlying outstanding warrants at a weighted average exercise price of $8.262 per share;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#9679;&#160; &#160; &#160; &#160; &#160; &#160;248,483 shares of common stock underlying outstanding options with a weighted average exercise price of $32.098 per share;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#9679;&#160; &#160; &#160; &#160; &#160; &#160;200,485 shares available for future issuance under the Autonomix Medical, Inc. 2023 Stock Plan; and</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#9679;&#160; &#160; &#160; &#160; &#160; &#160;1,533,096 shares of common stock underlying outstanding Series A warrants in connection with the November 2025 public offering at a weighted average exercise price of $6.540 per share;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#9679;&#160; &#160; &#160; &#160; &#160; &#160;91,985 shares of common stock underlying the Representative Warrants issuable to the underwriters in connection with the November 2024 public offering at a weighted average exercise price of $10.137.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      31
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="mda" href="#"></a>MANAGEMENT</b>&#8217;<b>S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND&#160;RESULTS OF OPERATIONS</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><i>You should read the following discussion and analysis of our financial condition and results of operations in conjunction with the financial statements and the related notes appearing elsewhere in this prospectus. This discussion contains forward-looking statements reflecting our current expectations that involve risks and uncertainties, including those set forth under "Cautionary Statement About Forward-Looking Statements."</i>&#160;<i>Actual results and the timing of events could differ materially from those discussed and other expectations expressed in our forward-looking statements as a result of many factors, including but not limited to those discussed herein and in the "Risk Factors</i>&#8221;<i> section above. </i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Overview</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We are a development-stage medical device company pioneering a first-in-class technology platform designed to sense and treat disorders of the nervous system. Our lead system in development is a catheter-based solution that combines diagnostic sensing and therapeutic radiofrequency ("RF") ablation. Initially developed to target intractable pain associated with pancreatic cancer, our platform is intended to provide minimally invasive access to deep neural structures and has the potential to address a wide range of clinical indications, including chronic pain, hypertension, cardiovascular disease, and other nerve-related disorders.&#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">A key differentiator of our technology is its ability to detect neural signals with greater sensitivity than commercially available systems. This performance advantage stems from two core innovations. First, our proprietary antenna array is engineered to capture extremely low-amplitude neural signals that may not be detected by conventional devices. Second, and equally important, our system processes these signals at the point of detection using a proprietary microchip embedded within the catheter. This local signal processing minimizes degradation and noise that typically occur during transmission to external consoles, allowing for high-fidelity, real-time signal capture and interpretation. Together, these capabilities enable more precise identification and targeting of nerve activity and represent a fundamental advancement in transvascular neuromodulation.&#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Our product development strategy is centered around two integrated functions: diagnostic sensing to identify pathological nerve signals, and therapeutic RF ablation to treat the identified targets. In preclinical animal models, our system has demonstrated the ability to detect signals from specific nerve bundles before ablation and confirm signal termination after ablation. We are now refining the catheter design to meet regulatory and manufacturing standards for human use.&#160;&#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In parallel, we have advanced our clinical strategy. In the second quarter of 2025, we completed our initial first-in-human proof-of-concept study ("PoC 1") evaluating the safety and feasibility of transvascular RF ablation in patients with pancreatic cancer pain. Based on the positive clinical outcomes, we have initiated a follow-on study ("PoC 2") that expands the protocol to include patients with pain associated with additional visceral cancers such as gallbladder, liver, and bile duct, as well as earlier-stage pancreatic cancer patients experiencing moderate to severe pain. This expansion reflects our goal of broadening the platform&#8217;s utility across oncology, gastroenterology, and other applicable sectors.&#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">As a development-stage company, our technology remains investigational, and there is no guarantee that our clinical trials will produce favorable outcomes or that our products will ultimately receive regulatory approval. One of the most challenging aspects of our commercialization plan will be scaling from our current prototype, which is built using hand-assembled and 3D-printed components, to a fully integrated commercial-grade device. While we have not yet assembled or tested the final commercial version, ongoing development efforts are focused on improving design robustness and manufacturability to support future clinical and commercial deployment.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Recent Developments</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In April 2025, we announced the completion of enrollment in our PoC 1, which evaluated the safety and feasibility of the Autonomix Elpis System in patients with late-stage pancreatic cancer experiencing severe pain. Preliminary results demonstrated statistically significant reductions in pain, with responding patients reporting improvement within 24 hours of the procedure and sustained responses observed at 4 to 6 weeks. Among responders, the mean pain reduction reached 59.2%, and 73% of the responders remained opioid-free during follow-up. No device-related serious adverse events were reported. These data supported the clinical potential of our platform and informed the next phase of development.&#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In May 2025, we received Ethics Committee approval to expand our proof-of-concept study into PoC 2, broadening the clinical focus to include patients with earlier-stage pancreatic cancer as well as those with other visceral cancers, such as gallbladder, bile duct, and liver cancers. This expansion is expected to double the potential addressable market for the platform.&#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We treated the first patient in the PoC 2 study in June 2025, marking the initiation of this market expansion phase. The study is designed to further evaluate the safety and feasibility of our system across a broader population and generate data to support both regulatory submissions and future commercial adoption.&#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      32
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In parallel, we held a formal pre-submission meeting with the U.S. Food and Drug Administration ("FDA") in May 2025 under the Q-Submission Program to discuss the regulatory requirements for initiating a U.S. clinical study under an Investigational Device Exemption ("IDE"). Based on FDA guidance, we have finalized the design of our Good Laboratory Practices ("GLP") preclinical study, including 90-day and 180-day safety endpoints. The FDA indicated that favorable 90-day data may support the initiation of an Early Feasibility Study ("EFS") in the United States, with the 180-day cohort supporting a future marketing application. Feedback was also provided on pivotal trial design, including recommendations regarding appropriate control arms, concurrent therapy tracking, and anatomical safety assessment. We have incorporated this guidance into our development plan and are targeting potential De Novo approval in 2028, following completion of the EFS and subsequent pivotal study. We anticipate submitting our 90-day GLP data by the end of 2025 and initiating the EFS in the first half of 2026.&#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We also made continued progress on product development. Engineering refinements to the ablation catheter during the quarter focused on improving steerability, vessel wall contact, and energy delivery precision, particularly in the complex anatomy of the celiac region. In parallel, development continued on our sensing catheter, with design modifications underway to support future activation of its sensing capabilities for targeted nerve localization. These enhancements are being guided by physician feedback and preclinical learnings and will be incorporated into our clinical-stage configurations.&#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Additionally, we strengthened our intellectual property portfolio with the issuance of two new U.S. patents during the quarter. U.S. Patent No. 12,257,071 relates to controlled sympathectomy and micro-ablation systems and methods, while U.S. Patent No. 12,279,889 B2 covers technologies for mapping, evaluating, and modifying neurological activity. These patents support our long-term strategy to protect our innovations and expand into adjacent indications within interventional neuromodulation.&#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">On July 21, 2025, the Company entered into a warrant exercise inducement offer letter (the "Inducement Letter") with the holders ("Holders") of certain existing warrants issued in the Offering from November 2024 to purchase up to 1,477,596 shares of the Company's common stock (the "Existing Warrants"). Pursuant to the Inducement Letter, the Company agreed to reduce the exercise price of the Existing Warrants to $1.723 per share, and the Holders agreed: (i) to exercise Existing Warrants to purchase 855,000 shares of Company common stock; and (ii) to prepay $1.722 per share of the reduced exercise price for Existing Warrants to purchase 622,596 shares of Company common stock in consideration of the Company further reducing the exercise price of such Existing Warrants to purchase 622,596 shares of Company common stock to $0.001 per share with an exercise term of 5.5 years. In consideration of the foregoing, the Company agreed to issue the Holders new warrants to purchase up to a number of shares of Company common stock equal to 100% of the number of shares of Company common stock underlying the Existing Warrants, comprised of new Series B warrants to purchase up to 1,477,596 shares of Company common stock (the &#8220;Inducement Warrants&#8221; and the shares of Company common stock underlying the Inducement Warrants, the &#8220;Inducement Warrant Shares&#8221;) at $1.723 per share with an exercise term of 5.5 years from the initial exercise date. In addition, the Company issued 88,656 Representative's Warrants at $2.6707 per share with an exercise term of 5 years. The Company received total gross proceeds of approximately $2.6 million, less expenses paid to the Placement Agent of approximately $0.3 million.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In July 2025, the Company entered into stock option cancellation agreements with certain employees to cancel an aggregate of 57,331 stock options. Employees that elected to cancel their stock options were granted severance agreements for three, six or nine months of their base salary (under certain conditions). On August 11, 2025, the Company entered into stock option cancellation agreements with Board members and certain officers of the Company to cancel an aggregate of 177,652 stock options. The Company's Board members included Mr. Walter Klemp, Chairman of the Board; Ms. Lori Bisson, Executive Vice Chairman of the Board; and Mr. Chris Capelli, Director, respectively, and included amounts of 8,773; 65,542; and 3,750, respectively. The Company's officers included Mr. Brad Hauser, Chief Executive Officer and President; Mr. Landy Toth, Chief Technology Officer; Mr. Robert Schwartz, Chief Medical Officer; and Mr. Trent Smith, Chief Financial Officer, respectively, and included amounts of 45,000; 8,773; 13,159; and 32,655, respectively. Mr. Hauser was granted three months of his base salary, in addition to the twelve months of his base salary per his July 17, 2024 employment agreement. Mr. Toth and Mr. Schwartz were granted severance agreements that amounted to nine months of their base salary. Mr. Smith was granted three months of his base salary, in addition to the nine months of his base salary per his July 24, 2023 employment agreement.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Results of Operations for the</b>&#160;<b>Three Months Ended June 30, 2025</b>&#160;<b>Compared to the</b>&#160;<b>Three Months Ended June 30, 2024</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Below is a summary of the results of operations (in thousands) (unaudited):</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: bottom; width: 52%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td colspan="14" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 37%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Three Months Ended June 30,</b></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: bottom; width: 52%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 9%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td colspan="2" style="vertical-align: bottom; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>2024</b></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td colspan="2" style="vertical-align: bottom; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Change</b></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td colspan="2" style="vertical-align: bottom; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Change</b></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: bottom; width: 52%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>2025</b></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(as revised)</b></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>( $ )</b></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>( % )</b></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align: bottom; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Operating expenses:</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 9%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 9%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 9%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 9%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255);">
     <td style="vertical-align: bottom; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Research and development</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$</p> </td>
     <td style="vertical-align: bottom; width: 9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">1,593</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$</p> </td>
     <td style="vertical-align: bottom; width: 9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">954</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$</p> </td>
     <td style="vertical-align: bottom; width: 9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">639</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">67</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align: bottom; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">General and administrative</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">1,828</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">1,799</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">29</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">2</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255);">
     <td style="vertical-align: bottom; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Total operating expenses</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="border-bottom: 3px double rgb(0, 0, 0); vertical-align: bottom; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$</p> </td>
     <td style="border-bottom: 3px double rgb(0, 0, 0); vertical-align: bottom; width: 9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">3,421</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="border-bottom: 3px double rgb(0, 0, 0); vertical-align: bottom; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$</p> </td>
     <td style="border-bottom: 3px double rgb(0, 0, 0); vertical-align: bottom; width: 9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">2,753</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="border-bottom: 3px double rgb(0, 0, 0); vertical-align: bottom; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$</p> </td>
     <td style="border-bottom: 3px double rgb(0, 0, 0); vertical-align: bottom; width: 9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">668</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="border-bottom: 3px double rgb(0, 0, 0); vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="border-bottom: 3px double rgb(0, 0, 0); vertical-align: bottom; width: 9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">24</p> </td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Research and Development Expense</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Research and development expense was $1.6 million for the three months ended June 30, 2025 compared to $1.0 million for the same period in 2024. The increase in research and development expenses during the current year was mainly attributed to our clinical trial and product development costs. We expect to incur increased research and development costs in the future as we continue with our clinical trial and product development costs.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><i>General and Administrative Expense</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">General and administrative expense was $1.8&#160;million for the three months ended June 30, 2025 compared to $1.8&#160;million for the same period in 2024. This was driven primarily by an increase in legal and professional fees of $0.1 million, offset by a decrease in officer and employee compensation and benefits of $0.1 million.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      33
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Interest expense</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">For the three months ended June 30, 2025 and 2024, we had interest expense of $0.0 and less than $0.1 million, respectively, related to the amortization of debt discount.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Interest income</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">For the three months ended June 30, 2025 and 2024, we had interest income of less than $0.1 million, respectively.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Results of Operations for the Year Ended</b>&#160;<b>March 31, 2025 Compared to the Year Ended March 31, 2024</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Below is a summary of the results of operations (in thousands):</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">
   <tbody>
    <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Year Ended March 31,</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
    </tr>

    <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
     <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
     <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Change</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Change</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>( $ )</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>( % )</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
    </tr>

    <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Operating expenses:</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">General and administrative</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6,863</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,249</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,614</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">31</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
    </tr>

    <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Research and development</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,725</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,225</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,500</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">112</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
    </tr>

    <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Warrant expense - termination agreement</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
     <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4,556</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(4,556</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(100</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)%</td>
    </tr>

    <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total operating expenses</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">11,588</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">12,030</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(442</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-4</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      34
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><i>General and Administrative ("G&amp;A"). </i>G&amp;A expenses increased by&#160;$1.6 million compared to the same period in 2024, primarily due to increases in officer and employee compensation and benefits of $1.5 million, stock-based compensation of $0.9 million, legal and professional fees of $0.4&#160;million, insurance expense of $0.3 million, franchise tax of $0.3 million, board of directors compensation of $0.1 million offset by a decrease in advertising expense of $1.8&#160;million related to our IPO in 2024 and travel and entertainment expense of $0.1 million.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><i>Research and Development ("R&amp;D").</i>&#160;R&amp;D expenses increased by $2.5&#160;million compared to the same period in 2024, primarily due to clinical trial execution and product development cost. We expect to incur increased research and development costs in the future as we continue our clinical trial and product development efforts.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><i>Warrant expense </i>&#8211;<i> termination agreement </i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Warrant Expense &#8211; termination agreement was $0 in 2025. Warrant Expense &#8211; termination agreement was $4.6 million in 2024. related to a license termination agreement. See <i>Note 2 - Warrant Liability and Fair Value of Financial Instruments</i> to the financial statements for additional information.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><i>Other Income/Expense</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><i>Warrant liability mark-to-market</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Warrant Liability - mark-to market adjustment was $0 in 2025. Warrant Liability - mark-to market adjustment was $3.4 million in 2024.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><i>Interest expense</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Interest expense was $0.2 million in 2025 and $0.1 million in 2024 related to the amortization of debt discounts.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><i>Interest income</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Interest income was&#160;$0.4 million in 2025 and $0.1 million in 2024 due to relatively higher cash balances throughout the year in 2025 as compared to 2024.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Liquidity and Capital Resources</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">On June 30, 2025, we had cash of $8.6 million, and working capital of $7.0 million. We have historically funded our operations from proceeds from debt and equity sales. We estimate our current cash resources are sufficient to fund our operations into but not beyond the second&#160;calendar quarter of 2026.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We will need to raise additional capital to meet our obligations and execute our business plan. We estimate that we will require additional financing of approximately $32&#160;to $40&#160;million to fund our operations to commercialization of our first indication. The timing and costs of clinical trials are difficult to predict and trial plans may change in response to evolving circumstances and as such the foregoing estimates may prove to be inaccurate. If we are unable to raise sufficient funds, we will be required to develop and implement an alternative plan to further extend payables, reduce overhead or scale back our business plan until sufficient additional capital is raised to support further operations. There can be no assurance that such a plan will be successful. We recognize the need to raise additional capital to continue to execute&#160;our business plan, including obtaining regulatory clearance for our products currently under development and commercializing and generating revenues from products under development. There is no assurance that additional financing will be available when needed or that management will be able to obtain financing on terms acceptable to us. A failure to raise sufficient capital, generate sufficient product revenues, control expenditures and regulatory matters, among other factors, will adversely impact our ability to meet our financial obligations as they become due and payable and to achieve our intended business objectives. If we are unable to raise sufficient additional funds, we will have to scale back our operations.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Summary of Cash Flows</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Cash used in operating activities</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Net cash used in operating activities was $2.6 million during the three months ended June 30, 2025, consisting of a net loss of $3.3 million, a decrease in operating assets of $0.1 million and an increase in operating liabilities of $0.2&#160;million. The change in operating assets and liabilities included sources of cash from a decrease in other current assets of $0.1&#160;million and a net increase in accounts payable and accrued expenses of $0.2 million. The increase in accounts payable and accrued expenses was&#160;driven primarily by increases in research and development expenses. Non-cash items primarily consisted of stock-based compensation of $0.4 million.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      35
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Cash used in investing activities</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Net cash used in investing activities was $0 for the three months ended June 30, 2025.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Net cash used in investing activities was $5 thousand for the three months ended June 30, 2024 related to the purchase of computer hardware and software.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Cash provided by financing activities</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Net cash provided by financing activities was $2.1 million&#160;for the three months ended June 30, 2025. On February 28, 2025, we entered into an At Market Issuances Sales Agreement (the &#8220;Agreement&#8221;) with Ladenburg Thalmann &amp; Co. Inc. (the &#8220;Agent&#8221;). Pursuant to the terms of the Agreement, we were able to sell $2.1 million of our common stock, before deducting Agent commissions and other estimated expenses payable by the Company. During the three months ended June 30, 2025, we also paid less than $0.1&#160;million in issuance costs related to the Agreement.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Net cash provided by financing activities was $0.0 for the three months ended June 30, 2024.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Contractual Obligations and Commitments</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">None.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Employment Arrangements</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We have agreements with key employees to provide certain benefits, including salary and other wage-related benefits, in the event of termination. In addition, the Company has adopted a severance policy for certain key members of executive management to provide certain benefits, including salary and other wage-related benefits, in the event of termination. In total, these benefits would amount to a range of $1.2 million to $1.7 million using the rate of compensation in effect at June 30, 2025.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      36
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Off-balance Sheet Arrangements</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">As of June 30, 2025 and March 31, 2025, we did not have any relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special purpose entities, established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Critical Accounting Policies and Significant Judgments and Estimates</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The financial statements in this prospectus have been prepared in accordance with generally accepted accounting principles in the United States of America (&#8220;GAAP&#8221;). The preparation of financial statements in conformity with GAAP requires management to make estimates, assumptions and judgments that affect the amounts reported in the financial statements, including the notes thereto. We consider critical accounting policies to be those that require more significant judgments and estimates in the preparation of our financial statements, including the following: research and development expenses, warrants, and stock-based compensation. Management relies on historical experience and other assumptions believed to be reasonable in making its judgments and estimates. Actual results could differ materially from those estimates.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Management believes its application of accounting policies, and the estimates inherently required therein, are reasonable. These accounting policies and estimates are periodically reevaluated, and adjustments are made when facts and circumstances dictate a change.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Our accounting policies are more fully described under the heading &#8220;Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies&#8221; in Note 1 to our Financial Statements included in this prospectus.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We believe that the following accounting policies are the most critical to aid in fully understanding and evaluating our reported financial results, and they require our most difficult, subjective or complex judgments, resulting from the need to make estimates about the effect of matters that are inherently uncertain.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Components of our Results of Operations and Financial Condition</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><b><i>Operating expenses</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We classify our operating expenses into three categories: (i) research and development, (ii) general and administrative and (iii) warrant expense &#8211; termination agreement.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><i>Research and development.</i> Research and development expenses consist primarily of:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 36pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">costs incurred to conduct research, such as animal research;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 36pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">costs related to the design and development of our technology, including fees paid to contract engineering firms and contract manufacturers;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 36pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">salaries and expenses, including stock-based compensation, related to our employees primarily engaged in research and development activities;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 36pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">fees paid to clinical consultants, clinical trial sites and vendors, including clinical research organizations, in preparation for clinical trials and our applications with the FDA;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 36pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">costs to develop our intellectual property; and</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 36pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">costs related to compliance with regulatory requirements.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We expect our research and development expenses to increase in the future as we advance our product into and through clinical trials,&#160;pursue additional regulatory approvals of our product in the United States, and continue commercial development of our device(s). The process of conducting the necessary clinical research to obtain regulatory approval is costly and time-consuming. The probability of success for our technology may be affected by a variety of factors including: the quality of our product, early clinical data, investment in our clinical program, competition, manufacturing capability and commercial viability. We may not succeed in achieving all necessary regulatory approvals for our product candidates. As a result of the uncertainties discussed above, we are unable to determine the duration and completion costs of our research and development process&#160;or when and to what extent, if any, we will generate revenue from the commercialization and sale of our device.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><i>General and administrative</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">General and administrative expenses consist of personnel related costs, which include salaries, as well as the costs of professional services, such as accounting and legal, facilities, information technology, stock-based compensation for general and administrative personnel, insurance, travel costs and other administrative expenses and costs to defend our patents. We expect our general and administrative expenses to increase due to the anticipated growth of our business and related infrastructure, as well as accounting, insurance, investor relations and other costs associated with being a public company.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      37
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><i>Advertising</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">It is our policy to expense advertising costs as incurred. Advertising&#160;expenses are included within general and administrative expenses within the statement of operations. For the years ended March 31, 2025 and 2024, the Company recorded less than $0.1&#160;million and $1.8 million, respectively.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><i>Stock-based compensation</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Stock-based compensation transactions are recognized as compensation expense in the statements of operations based on their fair values on the date of the grant. The expense for equity awards expected to vest is recognized over the applicable vesting period of the stock award using either the straight-line method or the accelerated method, depending on the vesting structure, and is included in general and administrative. We estimate the fair value of options granted using the Black-Scholes option pricing model. This estimate uses assumptions regarding a number of inputs that require us to make significant estimates and judgments. The expected volatility assumption was based on industry peer information.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><b>Accounting for Warrants</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We issued warrants to purchase shares of common stock (i) in connection with the Bridge Offering, (ii) in connection with the Exclusive License Termination Agreement (the &#8220;Termination Agreement&#8221;), (iii) in connection with our November 2024 and July 2025 offerings, and (iv) &#65279;as part of selling agent compensation in our IPO, the November 2024 offering and the July 2025 warrant inducement offering. We accounted for such warrants in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) Topic 480-10, <i>Distinguishing Liabilities from Equity </i>and ASC Topic 815-40<i>, Derivatives and Hedging </i>&#8211;<i> Contracts in Entity</i>&#8217;<i>s Own Equity. </i>Based on this guidance, we determined that warrants issued in connection with the Termination Agreement should be accounted for as a liability and the remaining warrants issued meet the requirements for equity classification. Liability classified warrants are subject to remeasurement at each balance sheet date, while equity classified warrants are valued at inception only.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><i>Bridge Financing Warrants</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The fair value of the Bridge Financing Warrants is estimated using a Monte Carlo simulation model with probability-weighted expected return method ("PWERM") based on the probabilities of different potential outcomes for the Notes issued with the Bridge Financing Warrants. The outcomes considered included (i) qualified financing as part of our planned IPO at various points in time and (ii) repayment in cash at maturity. Any increase in the amount of time expected until a qualified financing event and/or a reduction in the likelihood of a qualified financing event occurring during the term of the Notes would likely increase the fair value of the warrant, while the inverse of each scenario would have the opposite effect. The significant judgments and assumptions to the Monte Carlo simulation include the Company&#8217;s stock price, volatility based on a selection of publicly held peer companies, discount rate, and a discount for lack of marketability.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><i>Common Stock Fair Value </i>&#8211;<i> </i>The fair value of our common stock price was determined through a back solve, solving for the stock price that results in the average total value of the Notes and the warrants being equal to the cash proceeds received in the transaction it was issued at across one million iterations of the simulation.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><i>Historical Volatility</i> &#8211; We determine the expected volatility by weighing the historical average volatilities of publicly traded industry peers. Our intention is to consistently apply this methodology using the same or similar public companies until a sufficient amount of historical information regarding the volatility of our common stock becomes available. We will monitor our peer group for circumstances that may require a change to the composition or make-up of the entities and will identify if/when more suitable companies whose stock prices are publicly available would be utilized in the calculation.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><i>Discount Rate - </i>The rate is chosen based on private equity rates of return as described in the AICPA Practice Aid on Valuation of Privately-Held-Company Equity securities Issued as Compensation, choosing the rate at the lower end of the range.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><i>Credit Rating </i>&#8211;<i> </i>Our credit rating impacts the identification and calculation of the discount rate.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><i>Discount for lack of marketability</i> &#8211; Subsequent to the IPO, any shares issued pursuant to an exercise of the Bridge Financing Warrants, would be subject to a six-month lock-up. Consistent with AICPA&#8217;s Accounting and Valuation Guide: Valuation of Privately-Held-Company Equity Securities Issued as Compensation, the Finnerty model was used to estimate the discount for lack of marketability.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The fair value of the Notes and Bridge Financing Warrants is calculated such that they will combine to equal the cash purchase price of the Bridge Offering. Any changes in these assumptions will impact how the transaction price from the Bridge Offering is distributed between the Notes and the Bridge Financing Warrants.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      38
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><i>Termination Agreement Warrants</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The fair value of the Termination Agreement Warrants is estimated using a discounted cash flow model under various scenarios and used the probability-weighted expected return method (&#8220;PWERM&#8221;) comparing the probabilities of different outcomes. The outcomes considered included (i) qualified financing as part of our planned IPO at various points in time and (ii) possibility of default whereby the investor receives nothing. Any increase in the amount of time expected until a qualified financing event and/or a reduction in the likelihood of a qualified financing event occurring during the term of the warrant would decrease the fair value of the warrant, while the inverse of each scenario would have the opposite effect.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Additional significant assumptions and judgments used in preparing the discounted cash flow model include:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><i>Discount Rate - </i>The rate is chosen based on private equity rates of return as described in the AICPA Practice Aid on Valuation of Privately-Held-Company Equity Securities Issued as Compensation, choosing the rate at the lower end of the range.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><i>Credit Rating </i>&#8211;<i> </i>Our credit rating impacts the identification and calculation of the discount rate.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Any ongoing improvements in our credit rating would have the effect of driving down the discount rate used in the periodic re-measurement of the Termination Agreement warrants. Reductions in the Company&#8217;s discount rate would increase the fair value of the Termination Agreement warrants, while an increase in this factor will have an opposite effect.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><i>Other Warrants</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The fair value of equity-based warrants issued is estimated using the Black-Scholes option pricing model. The significant judgments and assumptions used in applying the Black-Scholes option pricing model include the underlying common stock at the measurement dates, the expected term, expected dividend yield and historical volatility of comparable companies&#8217; stock.&#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><i>Common Stock Fair Value </i>&#8211;<i> </i>Prior to our IPO, we periodically sold shares of our common stock for cash in an arms-length transaction. We consider these transactions as indicative of the fair value of our common stock when applying the Black-Scholes option pricing model. Subsequent to our IPO, we base the value of our shares on observable share data.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><i>Expected Term</i> &#8211; The estimate of the expected term of awards was determined in accordance with the contractual term of the arrangement.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><i>Expected Dividend Yield</i> &#8211; We have not declared or paid any cash dividends and do not presently intend to pay any in the foreseeable future. We have no plans or expectations that this assumption will change in the foreseeable future.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><i>Historical Volatility</i> &#8211; We determine the expected volatility by weighing the historical average volatilities of publicly traded industry peers. Our intention is to consistently apply this methodology using the same or similar public companies until a sufficient amount of historical information regarding the volatility of our common stock becomes available. We will monitor our peer group for circumstances that may require a change to the composition or make-up of the entities and will identify if/when more suitable companies whose stock prices are publicly available would be utilized in the calculation.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">A decrease in volatility and expected term will decrease the estimated fair value of the warrant, while an increase in these factors will have an opposite effect.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      39
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="business" href="#"></a>BUSINESS</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Overview</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Autonomix Medical, Inc. is a development-stage medical device company pioneering a first-in-class technology platform designed to sense and treat disorders of the nervous system. Our lead system in development is a catheter-based solution that combines diagnostic sensing and therapeutic radiofrequency ("RF") ablation. Initially developed to target intractable pain associated with pancreatic cancer, our platform is intended to provide minimally invasive access to deep neural structures and has the potential to address a wide range of clinical indications, including chronic pain, hypertension, cardiovascular disease, and other nerve-related disorders.&#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">A key differentiator of our technology is its ability to detect neural signals with greater sensitivity than commercially available systems. This performance advantage stems from two core innovations. First, our proprietary antenna array is engineered to capture extremely low-amplitude neural signals that may not be detected by conventional devices. Second, and equally important, our system processes these signals at the point of detection using a proprietary microchip embedded within the catheter. This local signal processing minimizes degradation and noise that typically occur during transmission to external consoles, allowing for high-fidelity, real-time signal capture and interpretation. Together, these capabilities enable more precise identification and targeting of nerve activity and represent a fundamental advancement in transvascular neuromodulation.&#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Our product development strategy is centered around two integrated functions: diagnostic sensing to identify pathological nerve signals, and therapeutic RF ablation to treat the identified targets. In preclinical animal models, our system has demonstrated the ability to detect signals from specific nerve bundles before ablation and confirm signal termination after ablation. We are now refining the catheter design to meet regulatory and manufacturing standards for human use.&#160;&#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In parallel, we have advanced our clinical strategy. In the second quarter of 2025, we completed our initial first-in-human proof-of-concept study ("PoC 1") evaluating the safety and feasibility of transvascular RF ablation in patients with pancreatic cancer pain. Based on the positive clinical outcomes, we have initiated a follow-on study ("PoC 2") that expands the protocol to include patients with pain associated with additional visceral cancers such as gallbladder, liver, and bile duct, as well as earlier-stage pancreatic cancer patients experiencing moderate to severe pain. This expansion reflects our goal of broadening the platform&#8217;s utility across oncology, gastroenterology, and other applicable sectors.&#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">As a development-stage company, our technology remains investigational, and there is no guarantee that our clinical trials will produce favorable outcomes or that our products will ultimately receive regulatory approval. One of the most challenging aspects of our commercialization plan will be scaling from our current prototype, which is built using hand-assembled and 3D-printed components, to a fully integrated commercial-grade device. While we have not yet assembled or tested the final commercial version, ongoing development efforts are focused on improving design robustness and manufacturability to support future clinical and commercial deployment.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Recent Developments</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In April 2025, we announced the completion of enrollment in our PoC 1, which evaluated the safety and feasibility of the Autonomix Elpis System in patients with late-stage pancreatic cancer experiencing severe pain. Preliminary results demonstrated statistically significant reductions in pain, with responding patients reporting improvement within 24 hours of the procedure and sustained responses observed at 4 to 6 weeks. Among responders, the mean pain reduction reached 59.2%, and 73% and the responders remained opioid-free during follow-up. No device-related serious adverse events were reported. These data supported the clinical potential of our platform and informed the next phase of development.&#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In May 2025, we received Ethics Committee approval to expand our proof-of-concept study into PoC 2, broadening the clinical focus to include patients with earlier-stage pancreatic cancer as well as those with other visceral cancers, such as gallbladder, bile duct, and liver cancers. This expansion is expected to double the potential addressable market for the platform.&#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We treated the first patient in the PoC 2 study in June 2025, marking the initiation of this market expansion phase. The study is designed to further evaluate the safety and feasibility of our system across a broader population and generate data to support both regulatory submissions and future commercial adoption.&#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In parallel, we held a formal pre-submission meeting with the U.S. Food and Drug Administration ("FDA") in May 2025 under the Q-Submission Program to discuss the regulatory requirements for initiating a U.S. clinical study under an Investigational Device Exemption ("IDE"). Based on FDA guidance, we have finalized our Good Laboratory Practices ("GLP") preclinical study, including 90-day and 180-day safety endpoints. The FDA indicated that favorable 90-day data may support the initiation of an Early Feasibility Study ("EFS") in the United States, with the 180-day cohort supporting a future marketing application. Feedback was also provided on pivotal trial design, including recommendations regarding appropriate control arms, concurrent therapy tracking, and anatomical safety assessment. We have incorporated this guidance into our development plan and are targeting potential De Novo approval in 2028, following completion of the EFS and subsequent pivotal study. We anticipate submitting our 90-day GLP data by the end of 2025 and initiating the EFS in the first half of 2026.&#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      40
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We also made continued progress on product development. Engineering refinements to the ablation catheter during the quarter focused on improving steerability, vessel wall contact, and energy delivery precision, particularly in the complex anatomy of the celiac region. In parallel, development continued on our sensing catheter, with design modifications underway to support future activation of its sensing capabilities for targeted nerve localization. These enhancements are being guided by physician feedback and preclinical learnings and will be incorporated into our clinical-stage configurations.&#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Additionally, we strengthened our intellectual property portfolio with the issuance of two new U.S. patents during the quarter. U.S. Patent No. 12,257,071 relates to controlled sympathectomy and micro-ablation systems and methods, while U.S. Patent No. 12,279,889 B2 covers technologies for mapping, evaluating, and modifying neurological activity. These patents support our long-term strategy to protect our innovations and expand into adjacent indications within interventional neuromodulation.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">As of June 30, 2025, we had an accumulated deficit of $53.7&#160;million, negative cash flows from operating activities of $2.6&#160;million and working capital of $7.0 million, which raises substantial doubt about our ability to continue as a going concern. Further, we have incurred and expect to continue to incur significant costs in pursuit of our business plans. We cannot assure you that we will be successful in raising additional funds. These factors, among others, raise substantial doubt about our ability to continue as a going concern.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      41
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Our Technology</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Targeting the Peripheral Nervous System</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The peripheral nervous system comprises a vast network of nerve fibers extending throughout the human body and interacting with every organ. Peripheral nerves can be further classified as autonomic (supplying sympathetic and parasympathetic nerve signals from the brain to tissue and organs, i.e., fear inducing production of adrenaline) and somatosensory (supplying signals to the brain from tissue and organs, i.e., the sensation of pain). Whether as a root cause or a manifestation of resulting symptoms, these nerves play a role in virtually all diseases.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="text-align:center;font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><img alt="a01.jpg" src="a01.jpg"/></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Unfortunately, we believe that very few tools currently exist for the sensing and targeting of nerve fibers within the peripheral nervous system. At Autonomix, our primary goal is to provide a breakthrough in sensing technology that will become an indispensable tool for diagnosing, targeting, and treating disorders relating to the peripheral nervous system. And, although our Company&#8217;s name hails from the autonomic subgroup of the peripheral nervous system, our technology is intended for both the autonomic and somatosensory systems and could eventually find uses within the central nervous system.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Exploiting the Vascular Superhighway</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Autonomix system we are developing is primarily catheter based, meaning that our sensing equipment will be delivered to its targeted location via a lumen within the body. While this could include oral, urethral, and other natural openings of the body, our primary focus is using the vasculature, most often arteries, to reach our target. Fortunately, nature has endowed us with &#8220;superhighway&#8221; access in the form of our arterial structure, as most of the peripheral nerves travel along our arteries. As can be seen in this cross-sectional view of the kidney and renal artery, the web of peripheral nerve fibers (shown in yellow) parallels the renal artery, and this form of nerve pathway development is typical throughout the body.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="text-align:center;font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><img alt="a02.jpg" src="a02.jpg"/></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Our sensing catheter has been designed to be introduced by a small incision into an artery (such as the femoral artery) and with a conventional guide wire or sheath be directed to any organ in the body where it will be close enough to the nerve fibers servicing that organ to sense, target and treat the nerves associated with that targeted disorder, and to confirm that the intended treatment was successful.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      42
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>The Sensing Problem</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Although this vascular superhighway has long been utilized for certain catheter-based evaluation and intervention, we believe its use throughout the body has been limited by the lack of adequate sophistication of catheter systems. According to a Markets and Markets report, titled &#8220;Electrophysiology Market Global Forecast to 2027&#8221; published in February 2023, the global electrophysiology market in terms of revenue was estimated to be $6.8 billion in 2021 and is expected to reach $11.6 billion by 2027. The report cites as a driver for such market the increased incidence of cardiovascular disease and the use of catheters to deliver corrective ablation in the field of cardiology. Most commonly, radio frequency (RF) energy is emitted from inside the walls of the heart or arteries sufficient to ablate (destroy) a cardiomyocyte or nerve within its path. This &#8220;transvascular&#8221; use of ablation forms the basis for treating atrial fibrillation, for example.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">More recently, companies like Medtronic have successfully used transvascular ablation of the nerves surrounding the renal artery to treat refractory hypertension (high blood pressure that has been resistant to standard drug therapy). One of the challenges they face however is that the nerves they are targeting operate at much lower voltage levels than, say, the level emitted by a cardiomyocyte. In cardiology, there are sensing systems capable of sensing down to a level of about 10 to 15 microvolts. That&#8217;s more than enough sensitivity to detect (and target) a cardiomyocyte that is emitting 100 microvolts per pulse, but the nerves around the renal artery (and around most peripheral nerve targets throughout the body) are operating at around 1 to 2 microvolts; much too low to be detected by existing sensing technology.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">What this means is that the ablation of nerves from within the renal artery is essentially conducted &#8220;blind.&#8221; Without a sensing system capable of detecting and targeting signals from nerves within the nervous system, clinicians cannot see the nerves causing hypertension in the patient. As a result, they are forced to hypothesize and treat one small area at a time, hoping they hit the desired target without hitting an unintended target. Over-treating the area could relegate the patient to life in a wheelchair by destroying their ability to regulate blood pressure.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>The Autonomix Solution</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We believe the reason no one has commercialized a sensing system capable of solving this problem is that the physics involved demanded a major technological breakthrough. By their very nature, electrical signals from the body are analog and even though a 10-milivolt signal can be detected and transmitted down the roughly 2 meters of wire required to travel along the catheter, outside the patient, and into the necessary processing equipment shown in this picture below of a typical catheter lab, this isn&#8217;t feasible with the 10 to 500 microvolt signal from a typical peripheral nerve. Given the cacophony of other signals emitted throughout the body and by other equipment in the lab as well as degradation of the signal due to the distance traveled along the catheter, these faint signals become lost or are rendered meaningless.&#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We are seeking to solve this problem through our design, which is still in development, of a proprietary sensor comprised of multiple key components, such as an electrode antenna and a microchip that processes data acquired through the antenna. Each antenna spline is comprised of 2 small differential electrodes and 1 reference electrode that can detect the presence of voltage down to as little as 2 microvolts, giving us sufficient sensitivity to register the impulse of a nearby nerve bundle that might typically be generating 10 to 500 microvolts, depending on the type of nerve fiber (i.e., parasympathetic, sympathetic, somatic, etc.). Our current design connects 8 splines to our proprietary chipset, which is designed to handle up to 16 differential electrodes,&#160;where an onboard amplifier and analog to digital converter convert each signal into a digital form. The chipset also includes a digital domain intended to enable the transmission of data from each of the antennae simultaneously down the catheter body to the catheter handle. The Wi-Fi handpiece then transmits this data to a nearby laptop for viewing and analysis by the clinician.&#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      43
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In a typical catheter lab, these signal conversion functions are often carried out by &#8220;briefcase&#8221; sized devices processing the raw analog signals that must travel the full length of the catheter, outside the patient&#8217;s body and then from the patient to the equipment. While this is feasible for higher voltage signals from the heart, the signals from peripheral nerve bundles are often too faint to travel all this distance without loss or corruption and yet the typical catheter lab equipment is far too big to fit inside a catheter. The patented Autonomix solution shrinks these processes down to a microchip small enough to place immediately adjacent to the antennae detecting the signals, greatly reducing the distance the signals must travel. The picture of the &#8220;proprietary chipset&#8221; below is our actual chipset and is not a rendering.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div style="text-align: center;">
   <img alt="a03.jpg" src="a03.jpg"/></div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">As shown in the diagram below, this basket antenna array is built from a micro-thin, laser-cut flexible circuit board. We believe the special arrangement of the antennae will make it possible to effectively geolocate the nerve in 3-dimensional space for targeting treatment.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div style="text-align: center;">
   <img alt="a04.jpg" src="a04.jpg"/></div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Sense, Ablate, Confirm</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">This sensing system is currently being developed to be deployed alongside a separate radio frequency ablation catheter system for a combined diagnostic and therapeutic solution which will require the use of two separate catheters that will be used during the procedure. However, our longer-term design is intended to combine the two catheters into one device so that the combined system could be capable of sensing, treating (ablating) and confirming successful treatment all with one relatively simple and minimally invasive procedure.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Focus on Pancreatic Cancer Patients</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We believe the Autonomix sensing technology has the potential to provide a level of detail and resolution in navigating the peripheral nervous system that until now has simply not been possible. As such, we believe this platform, if shown to be effective, could be applied to a wide range of disorders throughout the body. With that said, our experience tells us that the best way to develop a new technology like this is to narrowly focus on a proof of concept that we think will reflect the capabilities of our system while providing the most expeditious pathway to regulatory clearance, commercialization and revenue generation.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">For this reason, we are initially focusing on the treatment of pain associated with pancreatic cancer and we have designed our commercialization efforts around this as our first proposed indication for use.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      44
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We believe this is a good choice for several reasons:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Significant Unmet Need</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">According to a report by The Oncologist, titled &#8220;Pancreas Cancer-Associated Pain Management&#8221; first published April 22, 2021, &#8220;[p]ain is highly prevalent in patients with pancreas cancer,&#8221; &#8220;90% of these patients reported discussing pain with their health care provider,&#8221; and &#8220;50% of the respondents reported visits to the emergency room for symptoms related to pain.&#8221; One of the tragedies of this condition is that most pancreatic cancer patients have a short time to live and the debilitating pain resulting from the tumor can significantly reduce the quality of that remaining time. Moreover, we believe that prolonged pain can diminish a patient&#8217;s will to live, making that remaining time even shorter.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The standard of care for managing chronic abdominal pain due to pancreatic cancer typically begins with medical management, including non-opioid medications such as acetaminophen and NSAIDs. When this approach fails to provide adequate relief, second-line therapy often involves opioid pharmacotherapy. However, long-term opioid use is associated with tolerance, dependency, and adverse side effects that can ultimately outweigh the benefits.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The most common alternative method of treatment is a neurolytic celiac plexus blockade (&#8220;NCPB&#8221;), which is a percutaneous (via needle through the skin) ethanol injection guided by imaging, such as ultrasound or CT scan, to attempt to direct the ethanol (which will destroy neural tissue on contact) to the area of the pancreatic tumor and related peripheral nerves. Regardless of this initial targeting, the varied structure of the abdominal cavity leads to the potential for ethanol to either miss the intended target or migrate to unintended areas creating unwanted side effects.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Furthermore, according to a study titled &#8220;Neurolytic Celiac Plexus Block for Pain Control in Unresectable Pancreatic Cancer&#8221; published by the American Journal of Gastroenterology, 2007, Vol.102 (2), p.430-438, Article 430, meta-analysis from multiple randomized controlled trials suggests that patient benefits from NCPB are only marginally better than opioids and may not be outweighed by the potential risks. The most common side effects are diarrhea, transient hypotension, constipation, nausea and vomiting, and lethargy while rare major adverse events reported in the literature include infectious complications, bowel perforation, intraabdominal hemorrhage, fistula formation, stomach paralysis, partial paralysis of the lower limbs or loss of other motor function, chronic diarrhea, arterial damage, water on the lung, and death.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In contrast, we believe the Autonomix procedure could represent a much safer and more reliable treatment. This has the potential to significantly increase remaining quality of life for pancreatic cancer patients, and in so doing, even potentially extend overall survival.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">To begin with, our entire approach is via arterial catheter, inserted in most cases via the femoral or brachial artery. We believe this method of access should significantly reduce the potential for complications as compared with NCPB. We believe our sensing technology has the potential to identify and target the nerves that are responsible for the pain signal and with the ability to focus the ablative energy on that target, we should have a much greater degree of accuracy, control and reliability as compared with NCPB.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">When comparing to the use of opioids, we believe the potential benefits are even more obvious. The Autonomix procedure we are developing is, by design, targeted directly to the nerves responsible for the pain being treated and offers the potential for &#8220;one and done&#8221; durability, whereas opioids are systemic treatments subjecting the entire body to unnecessary exposure, requiring constant dosing, and inducing debilitating chronic systemic side effects as a consequence.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Beneficial Clinical Trial Dynamics/Expedited Regulatory Process</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Despite the significant unmet need, there are very few clinical trials worldwide focused on improving pain management for pancreatic cancer patients and currently none that we are aware of in the proposed location of our planned first-in-human proof of concept study. We believe this means there is limited competition for such patients, making it theoretically easier to recruit for our trial.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">At the same time, because we are focusing on palliative care for patients whose lives are being limited by a rare cancer, we believe regulatory authorities are willing to consider lower preclinical hurdles and smaller and simpler trial designs to help encourage trial sponsors to seek improved treatment options. However, these decisions are under the exclusive control of regulatory authorities and there is no guarantee that our trial designs will be approved. If regulatory authorities are willing to consider lower preclinical hurdles and smaller and simpler trial designs, this would translate into lower preclinical and clinical trial cost, as well as shorter completion times. Furthermore, study duration is also shortened by the very nature of the indication and primary efficacy endpoint: reduction of pain associated with pancreatic cancer.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Specifically, we intend for each patient to need only one treatment and we expect we will be able to immediately determine if there is any reduction of pain from our procedure such that an initial indication of pain reduction will likely be provided by patients upon conclusion of that treatment. Although follow-up visits will be required to assess continuing safety and durability of efficacy over a span of several months, an initial indication of efficacy will be available almost as quickly as patients are treated. For this reason, we are hopeful that the overall duration of this first trial will be measured in months rather than years, as is often the case for clinical trials with longer treatment durations or where a clinically significant response takes more time to be produced.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      45
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Meaningful Commercial Market</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Although pancreatic cancer is considered a rare disease, according to the American Cancer Society &#8220;Key Statistics for Pancreatic Cancer&#8221; (https://www.cancer.org/cancer/types/pancreatic-cancer/about/key-statistics.html), the American Cancer Society estimates in 2023 that approximately 64,000 will be diagnosed with pancreatic cancer in the U.S. on an annual basis and an article in the International Journal of Cancer (Int. J. Cancer. 2021;149:993&#8211;1001) indicates that annual new cases in the European Union reached 109,000 in 2019 and are expected to grow. A market analysis published by Precedence Research (https://www.precedenceresearch.com/ pancreatic-cancer-market) reported that the global market for treatment of pancreatic cancer in 2022 was estimated to be $2.2 billion. Published research by The Oncologist, titled &#8220;Pancreas Cancer-Associated Pain Management&#8221; stated that &#8220;90% of patients [with pancreatic cancer] reported discussing pain with their health care provider&#8221;. As a point of reference, a one-month course of Abraxane (a commonly prescribed drug for the treatment of pancreatic cancer) has a retail price of more than $10,000. While this should not be considered an indicator of how an Autonomix procedure will ultimately be priced, we believe it reflects the magnitude of potential market size and helps form the basis for expecting a significant revenue opportunity from this indication.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The incidence of pancreatitis, a non-cancerous condition that can also result in chronic pain, is estimated to be as much as three times that of pancreatic cancer. We believe that, if our procedure is cleared for use in treating pancreatic cancer pain, we should be able to eventually expand that clearance to include pain resulting from pancreatitis.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>The Potential to Impact Cancer</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Recent independent research has indicated that neural pathways may play an insidious role in cancer progression. An article published in Metastatic Cancer: Clinical and Biological Perspectives, titled &#8220;Sympathetic Nervous System Regulation of Metastasis&#8221; demonstrates that as pancreatic tumors progress to invade the liver (a common occurrence in patients with pancreatic cancer and a significant driver of morbidity) they do so by traveling along local neural pathways. Our development team speculated that disruption of these pathways might have the potential to slow or stop the progression of the primary tumor.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In collaboration with a specialist in pancreatic cancer, we conducted a study in mice to see if ablation (in this study, ethanol ablation was used, similar to its use with NCPB in humans) of the nerve fibers around the pancreas might have an effect on tumor progression. As can be seen in this study summary, there was a reduction in tumor progression in this model. This was a small study, and we can&#8217;t be certain that these results are indicative of the potential for impacting tumor progression in humans, but we do see this as encouraging further study and may represent a future opportunity beyond pain management.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div style="text-align: center;">
   <img alt="a05.jpg" src="a05.jpg"/></div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Indicative of Additional Market Potential</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We believe pancreatic cancer pain management is a &#8220;proof of concept,&#8221; and we believe success here will be indicative of the potential of our system in a wide range of disorders where the peripheral nervous system is involved.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      46
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Examples of future potential additional uses include expanding to other visceral cancers that transmit pain through the celiac plexus, like pancreatic, gall bladder, liver, and bile duct, renal denervation for treating hypertension, addressing other sources of pain including lower back and other joint locations, Complex Regional Pain Syndrome (&#8220;CRPS&#8221;), and pelvic pain, pulmonary disorders such as chronic obstructive pulmonary disease, and urinary tract and digestive disorders, and enabling more targeted treatments in cardiology, just to name a few.&#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div style="text-align: center;">
   <img alt="a06.jpg" src="a06.jpg"/></div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">A Markets and Markets report, titled &#8220;Electrophysiology Market Global Forecast to 2027&#8221; published in February 2023 describes the global electrophysiology (EP) market as representing approximately $6.8 billion in 2021 in annual global revenue, and is expected to reach $11.6 billion by 2027. The vast majority of this market today is represented by cardiology related diagnosis and intervention. Our vision for the Autonomix technology is to help expand electrophysiology well beyond cardiology to include nearly all reaches of the peripheral nervous system and we believe doing so will ultimately result in a market opportunity much greater than the current projections for the EP.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We believe enabling targeted transvascular treatment of pain will enable us to access the $75 billion pain management market, as cited in the Mordor Intelligence Pain Management Market Industry Report (https://www.mordorintelligence.com/industry-reports/pain-management-market). Additionally, facilitating a safer, more targeted method for renal denervation should enable us to access the $23 billion hypertension market, as indicated by Polaris Market Research (https://www.polarismarketresearch.com/industry-analysis/global-hypertension-drug-market). When additional indications such as COPD, irritable bowel syndrome, and overactive bladder are included, we believe the Autonomix platform has the potential to address more than $100 billion in market opportunities.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Commercialization Plan</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Regulatory Pathway</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The most likely regulatory pathway for our technology is the De Novo classification request. This pathway is distinct from the more common 510(k) clearance process, which is only applicable when a legally marketed &#8220;predicate&#8221; device exists that performs the same function in a substantially equivalent manner. It is also different from the more rigorous Premarket Approval ("PMA") pathway, which is typically reserved for high-risk devices with no prior precedent or those requiring extensive clinical validation.&#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In our case, while sensing and ablation technologies are well-established, there is no existing device that combines our level of signal sensitivity or targets the specific indications we are pursuing. As such, we anticipate that the De Novo pathway&#8212;designed for novel, moderate-risk devices without a direct predicate&#8212;will be the most likely route to market.&#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Whether in the United States or EU, we must demonstrate that our technology is safe and effective. The safety standard is ultimately met through a combination of animal studies, independent laboratory testing, a design history file documenting compliance with established standards and, ultimately, human clinical trials. Many of these requirements are staged such that not all must be met on the front end of development. In addition, efficacy must be based on a sound scientific rationale and ultimately demonstrated in a human clinical trial.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Human trials are often designed to begin with a Proof of Concept (&#8220;PoC&#8221;); the US Food and Drug Administration (&#8220;FDA&#8221;) sometimes refers to these as Early Feasibility Studies (&#8220;EFS&#8221;) and then progress to a Pivotal, or approval, Trial ("Pivotal Trial"). The design and endpoints of Pivotal Clinical Trials are often negotiated with the relevant regulatory authority (i.e., FDA in the United States, EMA or country-specific Competent Authority (&#8220;CA&#8221;) in Europe). Our regulatory package for authorization to conduct our initial phase of our first-in-human proof of concept trial ("PoC 1") was approved by the Ethics Committee (&#8220;EC&#8221;) at our intended clinical site hospital outside the United States. This approval allowed the initial PoC trial to begin. The regulatory package submitted included not only a detailed clinical protocol for conducting the study, but also an extensive Investigator&#8217;s Brochure (&#8220;IB&#8221;) setting forth details about the equipment to be used, historical safety of human procedures conducted with this equipment and details of our animal studies using this equipment for the first time in the area of the pancreas. With the success of our PoC 1, we will initiate a follow-on PoC 2 phase in a market expansion opportunity that has the potential to double the addressable market beyond pancreatic cancer pain by evaluating additional visceral cancers that signal pain through the celiac plexus and earlier stage pancreatic cancers with moderate to severe pain. The PoC 1 trial protocol will be amended to include the gathering of additional interventional pain management information that will continue to advance key learnings and used to inform future clinical studies.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      47
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We are actively engaging with the FDA through the pre-submission process as we work toward initiating our U.S.-based IDE clinical trials. We intend to start with a small, single-site EFS study leading into a larger, multi-centered pivotal trial. The first PoC trial is not designed to replace the pivotal trial that will be required by the FDA to support our submissions for clearance in the United States, but rather to provide key learnings and procedural knowledge going into our FDA clinical trials.&#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">According to an article by Applied Clinical Trials, titled &#8220;Medical Device Development: U.S. and EU Differences&#8221; published August 1, 2006 &#8220;[t]he way in which devices are regulated in the EU is very different from the way they are regulated in the United States,&#8230; [which] has introduced significant differences in time-to-market approval for the United States versus the EU, particularly in the case of high-risk Class III and Class IIb implantable devices.&#8221; While this is changing based on the advent of a new EU regulation called Medical Device Regulation (&#8220;MDR&#8221;) that is expected to make the EU process more like the FDA process, MDR is being rolled out country by country. We believe the approval process in some EU countries for utilizing CE marked devices off label is less demanding than in the US. As a result, we have decided to conduct the PoC in Europe instead of the US.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Once the PoC is established, however, there are compelling reasons to focus the approval process first and foremost in the US. One reason is that therapeutic procedures in the US will usually command higher prices and once those prices are set, EU pricing authorities will often index off of the US price. Another is that product launches are usually easier in the US where a single sales force can serve the entire region (as opposed to country-specific distribution teams in the EU) and where one regulatory standard applies across the board.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Upon completion of the Pivotal Trial, we expect to be in a position to submit our de novo application to the FDA, the review of which is expected to require approximately 170 days. We believe this entire timeline supports an ultimate FDA clearance (applications like this are not technically &#8220;approved&#8221; but rather &#8220;allowed&#8221; or &#8220;cleared&#8221;) in 2027. The foregoing timeline is not guaranteed and is subject to many of the risks and uncertainties disclosed in this prospectus and is subject to change.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Technology Development</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Commercialization of our technology can be thought of in three distinct phases: (1) sensing, (2) ablation, and (3) the combination of these two technologies into an integrated device. We believe that commercial success can be achieved with either of the two technologies and is not dependent upon successful integration (meaning two distinct systems, one for sensing and one for ablation could also be viable, even if not optimal).</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Similarly, our clinical development plan reflects the fact that the sensing and ablation systems are at different stages of development. Extensive testing in pigs (whose abdominal structure is considered similar to humans) has demonstrated that our sensing technology is capable of locating and targeting individual nerves around the renal artery. Considering the similarity in anatomy, both between pigs and humans and between the renal artery (supplying the kidneys) and the celiac and related arteries supplying the pancreas, we believe our sensing system may also be effective in humans and that the primary remaining risk relating to the sensing system is commercial execution.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Specifically, we believe one of the most demanding aspects of our commercialization plan will be scaling up from our existing sensing prototype to a robust commercial version. Today, our sensing device is hand built and includes a combination of hand-crafted and 3D printed parts, but we are actively engaged in the development of a more robust version which will meet requirements to be used in human clinical trials. We will divide this device into two subsets: (a) an electronics package (subassembly) that relies on semi-automated production of printed flexible circuit boards and electrical leads that is supplied to (b) a qualified catheter production process that will be contracted to a catheter production facility already experienced and certified in the &#8220;art&#8221; of catheter assembly. We expect the human clinical version to be completed in 2026 and the commercial scale up process to be completed by mid-2027, although there is no assurance that we will be able to meet such timeline.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Regarding the ablation system, safe and reliable off-the-shelf RF systems are currently available for use in cardiology and other electrophysiology indications. We are currently using one of these existing systems &#8220;off label&#8221; (in an area of the body for which the system is not yet approved by the relevant regulatory agency) in our proof-of-concept study to ablate the nerves near the pancreas of pancreatic cancer patients to demonstrate, for the first time ever, that transvascular ablation of those nerves may reduce pain in this patient population. The regulatory package submitted includes not only a detailed clinical protocol for conducting the study, but also an extensive Investigator&#8217;s Brochure (IB) setting forth details about the equipment to be used, historical safety of human procedures conducted with this equipment and details of our animal studies using this equipment for the first time in the area of the pancreas. To be clear, this first PoC trial is being conducted without the benefit of our sensing system because it has not yet been cleared by the FDA for use in humans.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      48
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The fact that this first PoC is essentially being performed &#8220;blind&#8221; (as all denervation procedures are currently done) simply means that it will not be as accurate as it could be. However, we believe if we successfully demonstrate that transvascular ablation is capable of mitigating pancreatic cancer pain, this would be a medical &#8220;first&#8221; and would represent an important breakthrough for the electrophysiology community. Likewise, we believe it could help support a request to the FDA to be granted &#8220;Breakthrough&#8221; status, which could accelerate our future commercialization efforts.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Also, what we are learning in the trial, about how to optimize ablation catheters for use outside the cardiology space, is being incorporated into the design of a customized RF catheter design for use in our own therapeutic device.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">It is possible to receive clearance from the FDA (and EMA) based on a prototype system that is not optimized for manufacturing and for the necessary design for manufacturability process to be running in the background with the goal of having the commercial version ready for launch shortly after the prototype platform is FDA cleared. We would then use our existing de novo cleared device as our own predicate for 510(k) clearance of the commercial version.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Our plan is then to launch the commercial version of our system, most likely to a controlled region or list of KOLs (Key Opinion Leaders) to debug and optimize the commercial strategy before committing to a national/global launch.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Accordingly, our planning considers both the possibility of a stand-alone commercial launch or a licensing arrangement with a larger player. As we get closer to an actual FDA device clearance, our strategy approach will be reviewed and adjusted for practicality. The Autonomix management team, however, has experience with both approaches.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The following graphic sets forth our planned development timeline, however, these timeframes are not guarantees and this timeline is subject to many of the risks and uncertainties disclosed in this prospectus and is subject to change:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="text-align:center;font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><img alt="a07.jpg" src="a07.jpg"/></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Revenue Model</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We envision our device revenue model on several levels: (a) purely as a targeted therapy for disorders associated with pancreatic tumors (and pancreatitis), (b) as a standalone sensing technology for broad based diagnostics use and/or use in conjunction with other ablation systems or (c) as a combined sensing and ablation system targeting a wide array of disorders throughout the body.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">There are four key elements of our device that will be provided to the user (hospital) to facilitate our technology: (1) a disposable sensing catheter with a handpiece (that connects to the catheter and could be partially or entirely disposable), (2) an RF catheter designed to reach the target nerves in the peripheral nervous system, (3) an RF energy source to power our custom RF ablation catheter, and (4) a user interface comprised primarily of software (translating data received from the catheter microchip and activating ablative energy in integrated systems) that could reside on existing hospital personal computer, or PC, systems or a dedicated PC system.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In general, we believe that hospitals place a high premium on disposability (maximizes patient safety, avoids complications of on-site sterilization) and that, if we can avoid the need for a significant outlay in &#8220;capital equipment&#8221; we should, since high-dollar capital equipment authorizations often involve additional bureaucracies within the hospital and complicate the sell-in process.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">An important benefit of the Autonomix platform will be that it will rely on catheter systems and techniques that are familiar to interventional radiologists (our expected primary users) and should require a minimum of training for successful use.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Our selection of radio frequency as an energy source was made based upon what we believe is the well-understood status of the technology within the industry and the FDA.&#160;Additionally, we have found in pre-clinical testing that this energy source appears to provide a very effective method of ablating neural tissue. The software required in our device&#8217;s user interface will likely be provided at no or a nominal charge.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      49
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">For the reasons described above, we believe the primary revenue model for Autonomix will be the sale of single-use disposable catheters to existing hospital catheter labs and that revenue volume will likely be a direct function of the number of procedures performed.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Intellectual Property</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><b><i>Patents and Pending Patent Applications</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company has 18 patent families (representing various inventions relating to different aspects of its technology) comprising 82 issued patents (44 in the US thus far) and 39 pending patent applications. All patents and patent applications were originated by our co-founders, Mr. Toth and/or Dr. Schwartz, with filing dates ranging from 2012 through 2025.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The following table shows our material patents and the expiration dates (assuming maintenance/annuity fees are paid as required) as of September 19, 2025:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><b><i>Issued Patents</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Patent No.</b></p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Jurisdiction</b></p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Title</b></p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Patent Expiration Date</b></p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2013211951</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Australia</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Controlled Sympathectomy and Micro-Ablation Systems and Methods</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">1/25/2033</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2,862,862</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Canada</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Controlled Sympathectomy and Micro-Ablation Systems and Methods</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">1/25/2033</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">3,151,885</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Canada</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Controlled Sympathectomy and Micro-Ablation Systems and Methods</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">1/25/2033</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">ZL201380016637.3</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">China</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Controlled Sympathectomy and Micro-Ablation Systems and Methods</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">1/25/2033</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">ZL201710440397.X</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">China</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Controlled Sympathectomy and Micro-Ablation Systems and Methods</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">1/25/2033</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2,804,527</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">European Patent Ratified in France, Germany, Ireland, Netherlands, UK</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Controlled Sympathectomy and Micro-Ablation Systems and Methods</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">1/25/2033</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">497881</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">India</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Controlled Sympathectomy and Micro-Ablation Systems and Methods</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">1/25/2033</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">347625</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Mexico</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Controlled Sympathectomy and Micro-Ablation Systems and Methods</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">1/25/2033</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">372926</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Mexico</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Controlled Sympathectomy and Micro-Ablation Systems and Methods</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">1/25/2033</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">11201406006X</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Singapore</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Controlled Sympathectomy and Micro-Ablation Systems and Methods</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">1/25/2033</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10,470,684</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">United States of America</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Controlled Sympathectomy and Micro-Ablation Systems and Methods</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">11/10/2034</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">12,376,757</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">United States of America</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Controlled Sympathectomy and Micro-Ablation Systems and Methods</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2/7/2035</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">9,649,064</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">United States of America</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Controlled Sympathectomy and Micro-Ablation Systems and Methods</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">4/28/2033</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10,022,085</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">United States of America</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Controlled Sympathectomy and Micro-Ablation Systems and Methods</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">1/25/2033</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">11,013,459</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">United States of America</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Controlled Sympathectomy and Micro-Ablation Systems and Methods</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">6/30/2033</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">12,257,071</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">United States of America</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Controlled Sympathectomy and Micro-Ablation Systems and Methods</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">11/12/2033</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2,874,620</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Canada</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Endoscopic Sympathectomy Systems and Methods</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">5/28/2033</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      50
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2,852,339</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">European Patent Ratified in France; Germany; Ireland; UK</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Endoscopic Sympathectomy Systems and Methods</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">5/28/2033</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">11201407873R</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Singapore</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Endoscopic Sympathectomy Systems and Methods</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">5/28/2033</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">9,968,790</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">United States of America</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Endoscopic Sympathectomy Systems and Methods</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">7/14/2033</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10,226,633</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">United States of America</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Endoscopic Sympathectomy Systems and Methods</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">5/28/2033</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">11,344,731</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">United States of America</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Endoscopic Sympathectomy Systems and Methods</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">5/28/2033</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">12,053,634</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">United States of America</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Endoscopic Sympathectomy Systems and Methods</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">5/28/2033</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2,876,080</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Canada</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Devices, Systems, and Methods for Diagnosis and Treatment of Overactive Bladder</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">6/13/2033</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2,861,145</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">European Patent Ratified in France; Germany; Ireland; Netherlands; UK</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Devices, Systems, and Methods for Diagnosis and Treatment of Overactive Bladder</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">6/13/2033</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">6,335,888</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Japan</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Devices, Systems, and Methods for Diagnosis and Treatment of Overactive Bladder</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">6/13/2033</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">6,672,370</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Japan</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Devices, Systems, and Methods for Diagnosis and Treatment of Overactive Bladder</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">6/13/2033</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">11201408219T</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Singapore</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Devices, Systems, and Methods for Diagnosis and Treatment of Overactive Bladder</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">6/13/2033</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10,206,616</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">United States of America</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Devices, Systems, and Methods for Diagnosis and Treatment of Overactive Bladder</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">9/10/2034</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">11,564,616</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">United States of America</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Devices, Systems, and Methods for Diagnosis and Treatment of Overactive Bladder</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">8/18/2033</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2,889,674</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Canada</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Systems and Methods for Treatment of Tissues Within and/or Through a Lumen Wall</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10/31/2033</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2,914,334</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">European Patent Ratified in France; Germany; UK</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Systems and Methods for Treatment of Tissues Within and/or Through a Lumen Wall</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10/31/2033</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">9,956,034</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">United States of America</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Systems and Methods for Treatment of Tissues Within and/or Through a Lumen Wall</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10/18/2034</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10,905,495</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">United States of America</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Systems and Methods for Treatment of Tissues Within and/or Through a Lumen Wall</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">11/6/2033</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">12,011,214</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">United States of America</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Systems and Methods for Treatment of Tissues Within and/or Through a Lumen Wall</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">5/13/2034</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2013354932</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Australia</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Systems and Methods for Regulating Organ and/or Tumor Growth Rates, Function, and/or Development</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">12/9/2033</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2,892,449</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Canada</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Systems and Methods for Regulating Organ and/or Tumor Growth Rates, Function, and/or Development</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">12/9/2033</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">388850</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">India</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Systems and Methods for Regulating Organ and/or Tumor Growth Rates, Function, and/or Development</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">12/9/2033</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">11201504119V</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Singapore</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Systems and Methods for Regulating Organ and/or Tumor Growth Rates, Function, and/or Development</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">12/9/2033</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      51
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:9.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10,674,963</p> </td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:0.5%;">&#160;</td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:14.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">United States of America</p> </td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:0.5%;">&#160;</td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:14.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Systems and Methods for Regulating Organ and/or Tumor Growth Rates, Function, and/or Development</p> </td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:0.5%;">&#160;</td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:6.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">6/1/2036</p> </td>
    </tr>

    <tr>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:9.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">12,369,859</p> </td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:0.5%;">&#160;</td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:14.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">United States of America</p> </td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:0.5%;">&#160;</td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:14.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Systems and Methods for Regulating Organ and/or Tumor Growth Rates, Function, and/or Development</p> </td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:0.5%;">&#160;</td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:6.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">12/8/2035</p> </td>
    </tr>

    <tr>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:9.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10,363,359</p> </td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:0.5%;">&#160;</td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:14.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">United States of America</p> </td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:0.5%;">&#160;</td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:14.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Systems and Methods for Regulating Organ and/or Tumor Growth Rates, Function, and/or Development</p> </td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:0.5%;">&#160;</td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:6.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2/25/2036</p> </td>
    </tr>

    <tr>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:9.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">11,478,582</p> </td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:0.5%;">&#160;</td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:14.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">United States of America</p> </td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:0.5%;">&#160;</td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:14.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Systems and Methods for Regulating Organ and/or Tumor Growth Rates, Function, and/or Development</p> </td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:0.5%;">&#160;</td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:6.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">8/2/2034</p> </td>
    </tr>

    <tr>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:9.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2,907,625</p> </td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:0.5%;">&#160;</td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:14.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Canada</p> </td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:0.5%;">&#160;</td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:14.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Systems and Methods for Neurological Traffic and/or Receptor Functional Evaluation and/or Modification</p> </td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:0.5%;">&#160;</td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:6.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">3/27/2034</p> </td>
    </tr>

    <tr>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:9.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2,978,372</p> </td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:0.5%;">&#160;</td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:14.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">European Patent Ratified in France; Germany; Ireland; Italy; UK</p> </td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:0.5%;">&#160;</td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:14.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Systems and Methods for Neurological Traffic and/or Receptor Functional Evaluation and/or Modification</p> </td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:0.5%;">&#160;</td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:6.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">3/27/2034</p> </td>
    </tr>

    <tr>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:9.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">11201507936U</p> </td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:0.5%;">&#160;</td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:14.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Singapore</p> </td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:0.5%;">&#160;</td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:14.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Neurological Traffic and Receptor Functional Evaluation and Modification</p> </td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:0.5%;">&#160;</td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:6.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">3/27/2034</p> </td>
    </tr>

    <tr>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:9.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10,004,458</p> </td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:0.5%;">&#160;</td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:14.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">United States of America</p> </td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:0.5%;">&#160;</td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:14.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Systems and Methods for Neurological Traffic and/or Receptor Functional Evaluation and/or Modification</p> </td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:0.5%;">&#160;</td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:6.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">1/16/2035</p> </td>
    </tr>

    <tr>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:9.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10,765,370</p> </td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:0.5%;">&#160;</td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:14.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">United States of America</p> </td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:0.5%;">&#160;</td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:14.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Systems and Methods for Neurological Traffic and/or Receptor Functional Evaluation and/or Modification</p> </td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:0.5%;">&#160;</td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:6.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">4/10/2034</p> </td>
    </tr>

    <tr>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:9.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">11,589,820</p> </td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:0.5%;">&#160;</td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:14.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">United States of America</p> </td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:0.5%;">&#160;</td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:14.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Systems and Methods for Neurological Traffic and/or Receptor Functional Evaluation and/or Modification</p> </td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:0.5%;">&#160;</td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:6.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">12/4/2034</p> </td>
    </tr>

    <tr>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:9.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">12,279,889</p> </td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:0.5%;">&#160;</td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:14.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">United States of America</p> </td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:0.5%;">&#160;</td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:14.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Systems and Methods for Neurological Traffic and/or Receptor Functional Evaluation and/or Modification</p> </td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:0.5%;">&#160;</td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:6.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">3/27/2034</p> </td>
    </tr>

    <tr>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:9.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2,926,088</p> </td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:0.5%;">&#160;</td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:14.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Canada</p> </td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:0.5%;">&#160;</td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:14.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Systems and Methods for Treating Cancer and/or Augmenting Organ Function</p> </td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:0.5%;">&#160;</td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:6.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10/14/2034</p> </td>
    </tr>

    <tr>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:9.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10,143,419</p> </td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:0.5%;">&#160;</td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:14.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">United States of America</p> </td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:0.5%;">&#160;</td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:14.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Systems and Methods for Treating Cancer and/or Augmenting Organ Function</p> </td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:0.5%;">&#160;</td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:6.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2/6/2035</p> </td>
    </tr>

    <tr>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:9.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">11,272,877</p> </td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:0.5%;">&#160;</td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:14.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">United States of America</p> </td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:0.5%;">&#160;</td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:14.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Systems and Methods for Treating Cancer and/or Augmenting Organ Function</p> </td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:0.5%;">&#160;</td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:6.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2/6/2035</p> </td>
    </tr>

    <tr>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:9.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">12,064,256</p> </td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:0.5%;">&#160;</td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:14.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">United Sates of America</p> </td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:0.5%;">&#160;</td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:14.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Systems and Methods for Treating Cancer and/or Augmenting Organ Function</p> </td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:0.5%;">&#160;</td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:6.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">3/6/2035</p> </td>
    </tr>

    <tr>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:9.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10,136,944</p> </td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:0.5%;">&#160;</td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:14.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">United States of America</p> </td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:0.5%;">&#160;</td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:14.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Systems and Methods for Treating Cancer and/or Augmenting Organ Function</p> </td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:0.5%;">&#160;</td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:6.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">5/24/2035</p> </td>
    </tr>

    <tr>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:9.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">11,382,687</p> </td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:0.5%;">&#160;</td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:14.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">United States of America</p> </td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:0.5%;">&#160;</td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:14.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Systems and Methods for Treating Cancer and/or Augmenting Organ Function</p> </td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:0.5%;">&#160;</td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:6.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">4/3/2035</p> </td>
    </tr>

    <tr>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:9.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2015302050</p> </td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:0.5%;">&#160;</td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:14.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Australia</p> </td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:0.5%;">&#160;</td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:14.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">ANS Assessment Systems, Kits, and Methods</p> </td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:0.5%;">&#160;</td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:6.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">8/7/2035</p> </td>
    </tr>

    <tr>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:9.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2,957,766</p> </td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:0.5%;">&#160;</td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:14.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Canada</p> </td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:0.5%;">&#160;</td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:14.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">ANS Assessment Systems, Kits, and Methods</p> </td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:0.5%;">&#160;</td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:6.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">8/7/2035</p> </td>
    </tr>

    <tr>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:9.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">3,177,201</p> </td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:0.5%;">&#160;</td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:14.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">European Patent Ratified as Unitary Patent</p> </td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:0.5%;">&#160;</td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:14.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">ANS Assessment Systems, Kits, and Methods</p> </td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:0.5%;">&#160;</td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:6.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">8/7/2035</p> </td>
    </tr>

    <tr>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:9.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">11201701018P</p> </td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:0.5%;">&#160;</td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:14.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Singapore</p> </td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:0.5%;">&#160;</td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:14.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">ANS Assessment Systems, Kits, and Methods</p> </td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:0.5%;">&#160;</td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:6.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">8/7/2035</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      52
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10,791,924</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">United States of America</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">ANS Assessment Systems, Kits, and Methods</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">9/2/2037</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">11,883,103</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">United States of America</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">ANS Assessment Systems, Kits, and Methods</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10/13/2036</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">3,226,792</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">European Patent Ratified as Unitary Patent and in Ireland and UK</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Systems And Methods for Regulating Organ and/or Tumor Growth Rates, Function, and/or Development</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">12/4/2035</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">3,364,869</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">European Patent Ratified as Unitary Patent</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Controlled and Precise Treatment of Cardiac Tissues</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10/20/2036</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">4,230,133</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">European Patent to be Ratified as Unitary Patent and in Ireland and UK</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Controlled and Precise Treatment of Cardiac Tissues</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10/20/2036</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">11,154,239</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">United States of America</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Controlled and Precise Treatment of Cardiac Tissues</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">5/28/2038</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">12,369,852</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">United States of America</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Controlled and Precise Treatment of Cardiac Tissues</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">6/6/2039</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">3,697,298</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">European Patent to be Ratified as Unitary Patent and in Ireland and UK</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Medical Devices with Circuitry for Capturing and Processing Physiological Signals</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10/17/2038</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">11,521,738</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">United States of America</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Medical Devices with Circuitry for Capturing and Processing Physiological Signals</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">4/14/2039</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">11,848,078</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">United States of America</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Medical Devices with Circuitry for Capturing and Processing Physiological Signals</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10/17/2038</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">12,217,863</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">United States of America</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Medical Devices with Circuitry for Capturing and Processing Physiological Signals</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10/17/2038</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">3,304,565</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">European Patent Ratified as Unitary Patent and in Ireland and UK</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Elongated Conductors and Methods of Making and Using the Same</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">5/19/2036</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">9,730,639</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">United States of America</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Elongated Conductors and Methods of Making and Using the Same</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">5/19/2036</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10,092,241</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">United States of America</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Elongated Conductors and Methods of Making and Using the Same</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">5/19/2036</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10,238,340</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">United States of America</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Elongated Conductors and Methods of Making and Using the Same</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">5/19/2036</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10,485,484</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">United States of America</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Elongated Conductors and Methods of Making and Using the Same</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">5/19/2036</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10,869,635</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">United States of America</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Elongated Conductors and Methods of Making and Using the Same</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">5/19/2036</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">11,445,979</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">United States of America</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Elongated Conductors and Methods of Making and Using the Same</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">5/19/2036</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">12,070,334</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">United States of America</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Elongated Conductors and Methods of Making and Using the Same</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">5/19/2036</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10,874,830</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">United States of America</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Smart Torquer and Methods of Using the Same</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">6/14/2037</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">12,295,646</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">United States of America</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Smart Torquer and Methods of Using the Same</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">6/14/2037</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">3,359,026</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">European Patent to be Ratified as Unitary Patent and in Ireland and UK</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Smart Torquer and Methods of Using the Same</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">9/21/2036</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      53
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The following table shows our material pending patent applications as of September 19, 2025, (note that no expiration dates are specified for the pending patent applications since, in certain jurisdictions, e.g., United States of America, the patent expiration date is calculated at the time of issue/grant):</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><b><i>Pending Patent Applications</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Application No.</b></p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 14%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Filing Date</b></p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Jurisdiction</b></p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 48%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Title</b></p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">3239581</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 14%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">5/24/2024</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Canada</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 48%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Controlled Sympathectomy and Micro-Ablation Systems and Methods</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">21168169.7</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 14%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">5/13/2021</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">European Patent Office</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 48%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Controlled Sympathectomy and Micro-Ablation Systems and Methods</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">19/258,286</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 14%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">7/2/2025</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">United States of America</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 48%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Controlled Sympathectomy and Micro-Ablation Systems and Methods</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">19/054,104</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 14%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2/14/2025</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">United States of America</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 48%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Controlled Sympathectomy and Micro-Ablation Systems and Methods</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">3158197</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 14%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">5/4/2022</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Canada</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 48%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Endoscopic Sympathectomy Systems and Methods</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">18/771,099</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 14%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">7/12/2024</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">United States of America</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 48%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Endoscopic Sympathectomy Systems and Methods</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">3184524</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 14%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">12/15/2022</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Canada</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 48%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Devices, Systems, and Methods for Diagnosis and Treatment of Overactive Bladder</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">202448028613</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 14%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">4/8/2024</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">India</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 48%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Devices, Systems, and Methods for Diagnosis and Treatment of Overactive Bladder</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">18/079,361</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 14%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">12/12/2022</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">United States of America</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 48%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Devices, Systems, and Methods for Diagnosis and Treatment of Overactive Bladder</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">3183802</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 14%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">12/9/2022</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Canada</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 48%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Systems and Methods for Treatment of Tissues Within and/or Through a Lumen Wall</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">18/656,031</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 14%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">5/6/2024</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">United States of America</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 48%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Systems and Methods for Treatment of Tissues Within and/or Through a Lumen Wall</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">3151434</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 14%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">3/9/2022</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Canada</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 48%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Systems and Methods for Regulating Organ and/or Tumor&#160;&#160;Growth Rates, Function, and/or Development</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">24170108.5</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 14%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">4/12/2024</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">European Patent Office</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 48%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Systems and Methods for Regulating Organ and/or Tumor&#160;&#160;Growth Rates, Function, and/or Development</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">19/258,543</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 14%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">7/2/2025</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">United States of America</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 48%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Systems and Methods for Regulating Organ and/or Tumor&#160;&#160;Growth Rates, Function, and/or Development</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">17/971,202</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 14%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10/21/2022</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">United States of America</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 48%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Systems and Methods for Regulating Organ and/or Tumor&#160;&#160;Growth Rates, Function, and/or Development</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">3,205,904</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 14%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">7/10/2023</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Canada</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 48%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Systems and Methods for Neurological Traffic and/or Receptor Functional Evaluation and/or Modification</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">202348081808</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 14%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">12/1/2023</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">India</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 48%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Systems and Methods for Neurological Traffic and/or Receptor Functional Evaluation and/or Modification</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">19/169,668</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 14%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">4/3/2025</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">United States of America</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 48%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Systems and Methods for Neurological Traffic and/or Receptor Functional Evaluation and/or Modification</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">3182302</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 14%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">11/28/2022</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Canada</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 48%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Systems and Methods for Treating Cancer and/or Augmenting Organ Function</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">22175617.4</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 14%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">5/26/2022</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">European Patent Office</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 48%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Systems and Methods for Treating Cancer and/or Augmenting Organ Function</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">18/772,819</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 14%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">7/15/2024</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">United States of America</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 48%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Systems and Methods for Treating Cancer and/or Augmenting Organ Function</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">17/833,964</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 14%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">6/7/2022</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">United States of America</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 48%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Systems and Methods for Treating Cancer and/or Augmenting Organ Function</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">19/323,501</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 14%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">9/9/2025</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">United States of America</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 48%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Systems and Methods for Treating Cancer and/or Augmenting Organ Function</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">23182480.6</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 14%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">6/29/2023</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">European Patent Office</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 48%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">ANS Assessment Systems, Kits, and Methods</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">3,210,898</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 14%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">9/1/2023</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Canada</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 48%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">ANS Assessment Systems, Kits, and Methods</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10202300654X</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 14%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">3/10/2023</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Singapore</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 48%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">ANS Assessment Systems, Kits, and Methods</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">18/543,538</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 14%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">12/18/2023</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">United States of America</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 48%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">ANS Assessment Systems, Kits, and Methods</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">23171646.5</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 14%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">5/4/2023</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">European Patent Office</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 48%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Systems and Methods for Treating Cancer and/or Augmenting Organ Function</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">25151120.0</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 14%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">1/10/2025</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">European Patent Office</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 48%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Systems and Methods for Regulating Organ and/or Tumor&#160;&#160;Growth Rates, Function, and/or Development</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">19/258,484</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 14%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">7/2/2025</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">United States of America</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 48%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Controlled and Precise Treatment of Cardiac Tissues</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">19/004,748</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 14%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">12/30/2024</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">United States of America</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 48%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Medical Devices with Circuitry for Capturing and Processing Physiological Signals</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">3,264,031</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 14%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2/3/2025</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Canada</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 48%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Medical Devices Configured for Therapeutic Electroporation of Biologic Tissues</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">23853213.9</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 14%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2/28/2025</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">European Patent Office</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 48%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Medical Devices Configured for Therapeutic Electroporation of Biologic Tissues</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">19/099,897</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 14%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">1/30/2025</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">United States of America</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 48%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Medical Devices Configured for Therapeutic Electroporation of Biologic Tissues</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">18/779,387</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 14%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">7/22/2024</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">United States of America</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 48%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Elongated Conductors and Methods of Making and Using the Same</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">19/180,938</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 14%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">4/16/2025</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">United States of America</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 48%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Smart Torquer and Methods of Using the Same</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">PCT/US2025/025299</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 14%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">4/18/2025</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Patent Cooperation Treaty (PCT) / United States of America, Receiving Office</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 48%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Medical Devices Configured for Temperature-Controlled Therapeutic Electroporation</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">PCT/US2025/025305</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 14%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">4/18/2025</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Patent Cooperation Treaty (PCT)/ United States of America, Receiving Office</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 48%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Medical Devices Configured for Therapeutic Electroporation with Adjustable Sections of an Elongate Member</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">PCT/US2025/025307</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 14%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">4/18/2025</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Patent Cooperation Treaty (PCT)/ United States of America, Receiving Office</p> </td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 48%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Medical Device Guide Sheaths with Return Electrodes for Bipolar Therapeutic Electroporation</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      54
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><b><i>Trademarks</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company has one trademark for the mark &#8220;AUTONOMIX&#8221; in the United States, Australia, China, the European Union, India, Japan, Mexico, and Singapore. The registrations of these trademarks are effective for varying periods of time and may be renewed periodically provided we comply with all applicable renewal requirements, including, where necessary, the&#160;continued use of the trademarks in the applicable jurisdictions in connection with certain goods and services.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><b>Competition</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The electrophysiology market is served by a number of very large players including, for example, Medtronic and Boston Scientific, all of whom have substantially greater resources than Autonomix.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">While the current standards of care for treating pancreatic cancer pain are comprised largely of generic drugs and injections, we are not aware of any person or company working on a transvascular sensing and ablation method for treating this indication. Although competitors like Medtronic are expanding the use of transvascular ablation techniques, we are not aware of anyone developing a sensing technology similar in capability to our technology.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Recent tests using Endoscopic Ultrasound-Guided Ablation to treat pancreatic cancer pain have claimed outcomes that may be better than NCPB, however this is still a percutaneous technique that we believe involves similar inherent risks of infection and internal damage as does NCPB. Conversely, we believe these risks are significantly reduced using a transvascular approach such as the Autonomix technology.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:-18pt;"><b>Description of Property </b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company leases office space as its headquarters in Texas and has access to a research and development facility in Pennsylvania.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      55
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:-18pt;"><b>Employees</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">As of June 30, 2025, we have 12 employees providing services to the Company, nine&#160;on a full-time basis and three on a part-time basis. Accordingly, a high percentage of the work performed for our development projects is conducted by qualified part-time staff and independent contractors.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:-18pt;"><b>Legal Proceedings</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">From time to time, we may become involved in litigation matters relating to claims arising from the ordinary course of business. While the results of such claims and legal actions cannot be predicted with certainty, our management does not believe that there are claims or actions, pending or threatened against us, the ultimate disposition of which would have a material adverse effect on our business, results of operations, financial condition, or cash flows.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;text-indent:9pt;"><b>Regulation of Our Business</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Our product candidate and operations are subject to extensive and rigorous regulation by the U.S. Food and Drug Administration (&#8220;FDA&#8221;), under the Federal Food, Drug, and Cosmetic Act (&#8220;FDCA&#8221;), and it&#8217;s implementing regulations, guidance documentation, and standards. Our sensing device and catheters are regulated by the FDA as medical devices. The FDA regulates the design, development, research, testing, manufacturing, safety, labeling, storage, record keeping, promotion, distribution, sale and advertising of medical devices in the United States to ensure that medical products distributed domestically are safe and effective for their intended uses. The FDA also regulates the export of medical devices manufactured in the United States to international markets. Any violations of these laws and regulations could result in a material adverse effect on our business, financial condition and results of operations. In addition, if there is a change in law, regulation or judicial interpretation, we may be required to change our business practices, which could have a material adverse effect on our business, financial condition and results of operations.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Unless an exemption applies, before we can commercially distribute medical devices in the United States, we must obtain, depending on the type of device, either prior premarket clearance or premarket approval (PMA), from the FDA. The FDA classifies medical devices into one of three classes:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Class&#160;I devices, which are subject to only general controls (e.g., labeling, medical devices reporting, and prohibitions against adulteration and misbranding) and, in some cases, to the premarket clearance requirements;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Class&#160;II devices, generally requiring premarket clearance before they may be commercially marketed in the United States; and</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Class&#160;III devices, consisting of devices deemed by the FDA to pose the greatest risk, such as life-sustaining, life-supporting or implantable devices, or devices deemed not substantially equivalent to a predicate device, generally requiring submission of a PMA supported by clinical trial data.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Our current product candidates are all class&#160;II&#160;devices and will require submission of a premarket notification.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>510(k) Clearance Pathway</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">When a 510(k) clearance is required, we must submit a premarket notification demonstrating that our proposed device is substantially equivalent to a previously cleared 510(k) device or a device that was in commercial distribution before May&#160;28, 1976 for which the FDA has not yet called for the submission of PMAs. By regulation, the FDA is required to clear or deny a 510(k) premarket notification within 90&#160;days of submission of the application. As a practical matter, clearance may take longer. The FDA may require further information, including clinical data, to make a determination regarding substantial equivalence.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Any modification to a 510(k)-cleared device that would constitute a major change in its intended use, or any change that could significantly affect the safety or effectiveness of the device, requires a new 510(k) clearance and may even, in some circumstances, require a PMA, if the change raises complex or novel scientific issues or the product has a new intended use. The FDA requires every manufacturer to make the determination regarding the need for a new 510(k) submission in the first instance, but the FDA may review any manufacturer's decision.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>PMA Pathway</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">A PMA must be submitted to the FDA if the device cannot be cleared through the 510(k) process. A PMA must be supported by extensive data, including but not limited to, technical, preclinical, clinical trials, manufacturing and labeling to demonstrate to the FDA's satisfaction the safety and effectiveness of the device for its intended use. During the review period, the FDA will typically request additional information or clarification of the information already provided. Also, an advisory panel of experts from outside the FDA may be convened to review and evaluate the application and provide recommendations to the FDA as to the approvability of the device. The FDA may or may not accept the panel's recommendation. In addition, the FDA will generally conduct a pre-approval inspection of the manufacturing facility or facilities to ensure compliance with the QSRs.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">New PMAs or PMA supplements are required for modifications that affect the safety or effectiveness of the device, including, for example, certain types of modifications to the device's indication for use, manufacturing process, labeling and design. PMA supplements often require submission of the same type of information as a PMA, except that the supplement is limited to information needed to support any changes from the device covered by the original PMA and may not require as extensive clinical data or the convening of an advisory panel.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      56
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>de novo Classification</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Medical device types that the FDA has not previously classified as Class I, II or III are automatically classified into Class III regardless of the level of risk they pose. The FDA Modernization Act of 1997 established a new route to market for low to moderate risk medical devices that are automatically placed into Class III due to the absence of a predicate device, called the &#8220;Request for Evaluation of Automatic Class III Designation,&#8221; or the de novo classification procedure. This procedure allows a manufacturer whose novel device is automatically classified into Class III to request down-classification of its medical device into Class I or Class II on the basis that the device presents low or moderate risk, rather than requiring the submission and approval of a PMA application. Prior to the enactment of the FDA Safety and Innovation Act of 2012, or the FDASIA, a medical device could only be eligible for de novo classification if the manufacturer first submitted a 510(k) premarket notification and received a determination from the FDA that the device was not substantially equivalent. FDASIA streamlined the de novo classification pathway by permitting manufacturers to request de novo classification directly without first submitting a 510(k) premarket notification to the FDA and receiving a not substantially equivalent determination. Under FDASIA, the FDA is required to classify the device within 120 days following receipt of the de novo application. If the manufacturer seeks reclassification into Class II, the manufacturer must include a draft proposal for special controls that are necessary to provide a reasonable assurance of the safety and effectiveness of the medical device. In addition, the FDA may reject the reclassification petition if it identifies a legally marketed predicate device that would be appropriate for a 510(k) or determines that the device is not low to moderate risk or that general controls would be inadequate to control the risks and special controls cannot be developed.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Clinical Trials</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Clinical trials are generally required to support a PMA application and are sometimes required for 510(k) or de novo clearance. Such trials generally require an investigational device exemption application, or IDE, approved in advance by the FDA for a specified number of patients and study sites, unless the product is deemed a nonsignificant risk device eligible for more abbreviated IDE requirements. Clinical trials are subject to extensive monitoring, record keeping and reporting requirements. Clinical trials must be conducted under the oversight of an institutional review board, or IRB, for the relevant clinical trial sites and must comply with FDA regulations, including but not limited to those relating to good clinical practices. To conduct a clinical trial, we also are required to obtain the patients' informed consent in form and substance that complies with both FDA requirements and state and federal privacy and human subject protection regulations. We, the FDA or the IRB could suspend a clinical trial at any time for various reasons, including a belief that the risks to study subjects outweigh the anticipated benefits. Even if a trial is completed, the results of clinical testing may not adequately demonstrate the safety and efficacy of the device or may otherwise not be sufficient to obtain FDA approval to market the product in the U.S. Similarly, in Europe the clinical study must be approved by a local ethics committee (EC) and in some cases, including studies with high-risk devices, by the ministry of health in the applicable country.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Pervasive and Continuing Regulation</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">After a device is placed on the market, numerous regulatory requirements apply. These&#160;include:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Product listing and establishment registration, which helps facilitate FDA inspections and other regulatory action;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Quality System Regulation, or QSR, which requires manufacturers, including third-party manufacturers, to follow stringent design, testing, control, documentation and other quality assurance procedures during all aspects of the manufacturing process;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">labeling regulations and FDA prohibitions against the promotion of products for uncleared, unapproved or off-label use or indication;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">clearance of product modifications that could significantly affect safety or efficacy or that would constitute a major change in intended use of one of our cleared devices;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">approval of product modifications that affect the safety or effectiveness of one of our approved devices;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">medical device reporting regulations, which require that manufacturers comply with FDA requirements to report if their device may have caused or contributed to a death or serious injury, or has malfunctioned in a way that would likely cause or contribute to a death or serious injury if the malfunction of the device or a similar device were to recur;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">post-approval restrictions or conditions, including post-approval study commitments;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">post-market surveillance regulations, which apply when necessary to protect the public health or to provide additional safety and effectiveness data for the device;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">the FDA's recall authority, whereby it can ask, or under certain conditions order, device manufacturers to recall from the market a product that is in violation of governing laws and regulations;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">regulations pertaining to voluntary recalls; and</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">notices of corrections or removals.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Advertising and promotion of medical devices, in addition to being regulated by the FDA, are also regulated by the Federal Trade Commission and by state regulatory and enforcement authorities. Recently, promotional activities for FDA-regulated products of other companies have been the subject of enforcement action brought under healthcare reimbursement laws and consumer protection statutes. In addition, under the federal Lanham Act and similar state laws, competitors and others can initiate litigation relating to&#160;advertising&#160;claims. In addition, we are required to meet regulatory requirements in countries outside the U.S., which can change rapidly with relatively short notice. If the FDA determines that our promotional materials or training constitutes promotion of an unapproved use, it could request that we modify our training or promotional materials or subject us to regulatory or enforcement actions.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      57
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Furthermore, our products could be subject to voluntary recall if we or the FDA determine, for any reason, that our products pose a risk of injury or are otherwise defective. Moreover, the FDA can order a mandatory recall if there is a reasonable probability that our device would cause serious adverse health consequences or death.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The FDA has broad post-market and regulatory enforcement powers. Once we have a marketed product, we will be subject to unannounced inspections by the FDA to determine our compliance with the QSR and other regulations, and these inspections may include the manufacturing facilities of some of our subcontractors. Failure by us or by our suppliers to comply with applicable regulatory requirements can result in enforcement action by the FDA or other regulatory authorities, which may result in sanctions including, but not limited to:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">untitled letters, warning letters, fines, injunctions, consent decrees and civil penalties;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">unanticipated expenditures to address or defend such actions</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">customer notifications for repair, replacement, refunds;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">recall, detention or seizure of our products;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">operating restrictions or partial suspension or total shutdown of production;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">refusing or delaying our requests for premarket clearance or premarket approval of new products or modified products;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">operating restrictions;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">withdrawing premarket clearances or PMA approvals that have already been granted;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">refusal to grant export approval for our products; or</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">criminal prosecution.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:-18pt;"><b>Glossary</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Unless we otherwise indicate, or unless the context requires otherwise, any references in this prospectus to the following medical terms have the respective meanings set forth below:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><b>ablation</b>: the removal or destruction of a body part or tissue or its function. This is often conducted with energy-based devices utilizing radio frequency or pulsed electrical field energy.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><b>cardiomyocyte</b>: the cell responsible for the contraction of the heart.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><b>catheter</b>: a thin tube made from medical grade materials serving a broad range of functions; catheters are medical devices that can be inserted in the body to treat diseases or perform a surgical procedure.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><b>celiac plexus</b>: also known as the solar plexus because of its radiating nerve fibers, is a complex network of nerves located in the abdomen, near where the celiac trunk, and other arteries branch from the abdominal aorta.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><b>electrophysiology</b>: the branch of physiology that deals with the electrical phenomena associated with nervous and other bodily activity.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><b>hypertension</b>: high blood pressure.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><b>microvolt</b>: one millionth of a volt.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><b>palliative care</b>: specialized medical care for people living with a serious illness focused on providing relief from the symptoms and stress of serious illness.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><b>renal artery</b>: the main blood vessel that supplies blood to a kidney.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><b>transvascular</b>: across the wall of a blood vessel (or similar vessel).</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><b>unresectable</b>: unable to be removed with surgery.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 45pt;text-indent:-27pt;"><b>Available Information</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Our Internet address is <span style="text-decoration: underline; ">www.autonomix.com</span>. On this website, we post the following filings as soon as reasonably practicable after they are electronically filed with or furnished to the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;): our Annual Reports on Form 10-K; our Quarterly Reports on Form 10-Q; our Current Reports on Form 8-K; our proxy statements related to our annual stockholders&#8217; meetings; and any amendments to those reports or statements. All such filings are available on our Web site free of charge. The charters of our audit, nominating and governance and compensation committees and our Code of Business Conduct and Ethics Policy are also available on our Web site and in print to any stockholder who requests them. The content on our Web site is not incorporated by reference into this prospectus.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      58
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="management" href="#"></a>MANAGEMENT</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The following table sets forth the names and ages of all of our directors and executive officers as of September 19, 2025. Our officers are appointed by, and serve at the pleasure of, the Board of Directors.&#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:80%;margin-left:0pt;margin-right:auto;">
   <tbody>
    <tr>
     <td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:19.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Name</b></p> </td>
     <td style="vertical-align:bottom;width:0.6%;">&#160;</td>
     <td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:8.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Age</b></p> </td>
     <td style="vertical-align:bottom;width:0.6%;">&#160;</td>
     <td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:28.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Position</b></p> </td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align:top;width:19.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Brad Hauser</p> </td>
     <td style="vertical-align:top;width:0.6%;">&#160;</td>
     <td style="vertical-align:top;width:8.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">48</p> </td>
     <td style="vertical-align:top;width:0.6%;">&#160;</td>
     <td style="vertical-align:top;width:28.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Chief Executive Officer</p> </td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255);">
     <td style="vertical-align:top;width:19.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Lori Bisson</p> </td>
     <td style="vertical-align:top;width:0.6%;">&#160;</td>
     <td style="vertical-align:top;width:8.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">55</p> </td>
     <td style="vertical-align:top;width:0.6%;">&#160;</td>
     <td style="vertical-align:top;width:28.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Executive Vice Chairman</p> </td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align:top;width:19.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Dr. Robert Schwartz</p> </td>
     <td style="vertical-align:top;width:0.6%;">&#160;</td>
     <td style="vertical-align:top;width:8.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">74</p> </td>
     <td style="vertical-align:top;width:0.6%;">&#160;</td>
     <td style="vertical-align:top;width:28.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Chief Medical Officer</p> </td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255);">
     <td style="vertical-align:top;width:19.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Landy Toth</p> </td>
     <td style="vertical-align:top;width:0.6%;">&#160;</td>
     <td style="vertical-align:top;width:8.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">48</p> </td>
     <td style="vertical-align:top;width:0.6%;">&#160;</td>
     <td style="vertical-align:top;width:28.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Chief Technology Officer</p> </td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align:top;width:19.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Trent Smith</p> </td>
     <td style="vertical-align:top;width:0.6%;">&#160;</td>
     <td style="vertical-align:top;width:8.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">56</p> </td>
     <td style="vertical-align:top;width:0.6%;">&#160;</td>
     <td style="vertical-align:top;width:28.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Chief Financial Officer</p> </td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255);">
     <td style="vertical-align:top;width:19.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Walter V. Klemp</p> </td>
     <td style="vertical-align:top;width:0.6%;">&#160;</td>
     <td style="vertical-align:top;width:8.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">66</p> </td>
     <td style="vertical-align:top;width:0.6%;">&#160;</td>
     <td style="vertical-align:top;width:28.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Executive Chairman</p> </td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align:top;width:19.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Jonathan P. Foster</p> </td>
     <td style="vertical-align:top;width:0.6%;">&#160;</td>
     <td style="vertical-align:top;width:8.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">61</p> </td>
     <td style="vertical-align:top;width:0.6%;">&#160;</td>
     <td style="vertical-align:top;width:28.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Director</p> </td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255);">
     <td style="vertical-align:top;width:19.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">David Robins</p> </td>
     <td style="vertical-align:top;width:0.6%;">&#160;</td>
     <td style="vertical-align:top;width:8.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">56</p> </td>
     <td style="vertical-align:top;width:0.6%;">&#160;</td>
     <td style="vertical-align:top;width:28.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Director</p> </td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align:top;width:19.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Christopher Capelli</p> </td>
     <td style="vertical-align:top;width:0.6%;">&#160;</td>
     <td style="vertical-align:top;width:8.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">65</p> </td>
     <td style="vertical-align:top;width:0.6%;">&#160;</td>
     <td style="vertical-align:top;width:28.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Director</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Set forth below is biographical information about each of the individuals named in the table above:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><b><i>Bradley Hauser, Chief Executive Officer.</i></b> Mr. Hauser became our President and Chief Executive Officer effective June 17, 2024. Prior to his appointment as President and Chief Executive Officer, Mr. Hauser served as the Chief Operating Officer at Beauty Health from January 2023 to June 2024. Mr. Hauser previously served as the President and Chief Executive Officer of Soliton, Inc., a medical device company focused on developing new technology for use in aesthetics, from November 2020 to December 2021. Soliton was purchased by AbbVie in 2021 and he continued to provide transition support post-acquisition as the President and Chief Executive Officer of Soliton with Allergan Aesthetics, an AbbVie company, until July 2022. Mr. Hauser previously served as Vice President, Research and Development and General Manager for CoolSculpting at Allergan Pharmaceuticals since ZELTIQ Aesthetics, Inc. was acquired by Allergan in April 2017. Previously, he served as the Senior Vice President of Research and Development at ZELTIQ Aesthetics, Inc. from January 2017 to April 2017 and as its Vice President of Research and Development from July 2015 to January 2017. Mr. Hauser joined ZELTIQ in December 2013 as Vice President of Product and Clinical Strategy. Prior to joining ZELTIQ, he held multiple roles in the aesthetic industry, including Executive Vice President of Commercial Operations for Cutera, Director of Research and Development at Medicis and Managing Director of Product and Clinical Marketing at Solta Medical. Mr. Hauser received his B.A. degree in Human Biology from Stanford University.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><b><i>Lori Bisson, Executive Vice Chairman.</i></b> Ms. Bisson joined us in July 2023 as a director and served as our Chief Executive Officer from July 2023 until June 2024 and as Executive Vice Chairman since June 2024. From January 2015 until June 2022, Ms. Bisson served as Chief Financial Officer of Soliton, Inc., a medical device company focused on developing new technology for use in aesthetics. Soliton was purchased by AbbVie in 2021 and she continued to provide transition support post-acquisition. Prior to joining Soliton, Ms. Bisson worked as a financial and business development consultant as a shareholder in Condon &amp; Company, PC, from 2009 through December 2014, where she advised a number of life science companies. From 2005 to 2009, Ms. Bisson served as the Chief Financial Officer and Vice President of Operations for Zeno Corporation, a medical device company focused on new technology in the aesthetics area. Ms. Bisson previously served as the Chief Financial Officer of Gulfstream Trading, Ltd., an international oil trading organization from 2001 to 2005. From 1995 to 2001, Ms. Bisson held various positions with Drypers Corporation, a publicly traded multinational consumer products company, where she ultimately held the title of Vice President of Integrated Solutions and oversaw accounting, information technology, and logistics for the U.S. operation. Ms. Bisson began her career at Arthur Andersen, LLP as an auditor focused on consumer products companies. Ms. Bisson also serves as an advisor to Moleculin Biotech, Inc., a clinical stage pharmaceutical company focused on the development of oncology drug candidates. Ms. Bisson is a Certified Public Accountant and holds a B.A. degree in Accounting from Baylor University. We believe that Ms. Bisson&#8217;s extensive experience in the medical device field provides her with the qualifications to serve as a director.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><b><i>Dr. Robert Schwartz, Chief Medical Officer.</i></b> Dr. Schwartz was a co-founder of our company, has served as our Chief Medical Officer since June 2023, and served as our Chief Executive Officer from February 2022 until June 2023. Dr. Schwartz is President of the Jon DeHaan Center for Medical Innovation. He was previously Director at the Center for Applied Vascular Biology and Interventions, Mayo Foundation. Dr. Schwartz has also served as Professor and Associate Professor at the Mayo Medical School. He holds Board Certifications on the National Board of Medical Examiners, American Board of Internal Medicine, and the American Board of Internal Medicine, Cardiovascular Diseases. He has published numerous articles in peer review journals dealing with various topics in interventional cardiology. Dr. Schwartz is the recipient of various awards including the Andreas Gruentzig Award for Basic Research in Coronary Restenosis from the Thoraxcenter/European Society of Cardiology. He holds professional memberships as Fellow of the American College of Cardiology, American Heart Association, and The Society for Cardiac Angiography and Interventions. Dr. Schwartz is also a member of the Society of Atherosclerosis Imaging. Dr. Schwartz received a Master&#8217;s Degree in Electrical Engineering, and his doctorate from the University of Colorado-Denver and continued his internship, residency, and Fellowship at the Mayo Graduate School of Medicine. Dr. Schwartz has agreed to provide services to us on a part-time basis of 25% of his working time.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      59
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><b><i>Landy Toth, Chief Technology Officer. </i></b>Mr. Toth is a key inventor and is responsible for Autonomix&#8217;s development efforts to date. Mr. Toth founded Tricord Holdings, LLC in 2012 and Autonomix in August 2014 and has been the Chief Technology Officer since that time. In addition to these efforts, he founded and has filled the role of Chief Technology Officer of LifeLens Technologies, Inc. since September 2016. Over the past 20 years, Mr. Toth has successfully commercialized medical device technologies within startup environments. His focus has been the development and commercialization of wearable and interventional diagnostic medical technologies. He presently has 647 publications across 56 patent families. His portfolio has a grant rate greater than 70% after 2 years. Mr. Toth holds a MASc from the University of Toronto and a BASc from the University of Waterloo. Mr. Toth has also been an employee of Davos Chemical Corporation since January 2011. Mr. Toth has agreed to provide services to us on a part-time basis of 25% of his working time.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><b><i>Trent Smith, Chief Financial Officer.</i></b> Mr. Smith joined us in July 2023 as our Chief Financial Officer. Mr. Smith has extensive management, accounting, financial and international experience. From June 2018 to September 2022, Mr. Smith served as the Corporate Controller and Vice-President of Soliton, Inc., a medical device company focused on developing new technology for use in aesthetics that was acquired by AbbVie, Inc. in December 2021 and he continued to provide transition support post acquisition. From 2011 to 2018, Mr. Smith held various positions with InfuSystem Holdings, Inc., a national provider of infusion pumps and related services to the healthcare industry, where he served as Corporate Controller and Vice-President before a promotion to Chief Accounting Officer and Executive Vice President. From 2010 to 2011, Mr. Smith served as the Director of External Reporting of Syncreon Holdings, Inc., an international leader in global supply chain management, where he was responsible for creating the external reporting department to be compliant with SEC type reporting. From 2006 to 2010, Mr. Smith served as the Director of Accounting and Financial Reporting of Champion Homes, Inc., a leader in the manufactured housing industry and one of the largest modular homebuilders in North America. From 2005 to 2006, Mr. Smith served as the Director of External Financial Reporting for Dura Automotive Systems, a Tier 1 international designer and manufacturer of automotive components headquartered in Auburn Hills, MI. From 1999 to 2006, Mr. Smith served in various roles and divisions for Valeo, Inc., an international Tier 1 automotive supplier, including as Financial Controller and Treasurer of Valeo Distribution North America and Director of Accounting and Internal Controls for Valeo Wiper Systems, Valoe&#8217;s largest division in North America. Mr. Smith began his professional career as an auditor with Deloitte &amp; Touche, LLP in 1995. Mr. Smith served on active duty in the United States Navy from 1987 through 1991 and the reserves until 1993. Mr. Smith is a Certified Public Accountant and a graduate of the University of Illinois where he earned a Bachelor of Science in Accounting.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><b><i>Walter V. Klemp, Executive Chairman. </i></b>Mr. Klemp joined us in January 2022 as our Executive Chairman. Mr. Klemp is a co-founder of Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, and has served as its Chairman of the Board and Chief Executive Officer since July 2015 and as president since August 2017. From July 2018 until December 2021, Mr. Klemp served as Executive Chairman on the Board of Directors of Soliton, Inc., a medical device company focused on developing new technology for use in aesthetics. In December 2021 Soliton, Inc. was acquired by AbbVie, Inc. From November 2011 to July 2018, Mr. Klemp served as Chief Executive Officer of Soliton. Mr. Klemp served as President and Chief Executive Officer of Zeno Corporation from 2004 to April 2011, where he developed and marketed dermatology devices and drugs from concept through FDA approval and market launch. From 1987 to 2000, Mr. Klemp served as Chief Executive Officer and Chairman of Drypers Corporation, a publicly traded multinational consumer products company that was listed as #1 on the INC 500 List of America&#8217;s Fastest Growing Companies. We believe that Mr. Klemp&#8217;s extensive experience in the medical device field provide him with the qualifications to serve as a Chairman of the Board.&#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><b><i>Jonathan P. Foster, Director.</i></b> Mr. Foster joined us in January 2022 as a director. Mr. Foster has served as the Chief Financial Officer and Executive Vice President of Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, since August 2016. Mr. Foster brings more than 30 years in financial experience holding a variety of executive and senior financial positions with public, private, start-up to large corporate and international companies. From February 2012 to August 2016, Mr. Foster served as Chief Financial Officer and Executive Vice President of InfuSystem Holdings, Inc., a national provider of infusion pumps and related services to the healthcare industry. From May 2011 to January 2012, Mr. Foster served as a consultant to the Chief Financial Officer of LSG Sky Chefs, USA, Inc., a subsidiary of Deutsche Lufthansa AG. Prior to that Mr. Foster served in various C-suite capacities with public and private companies with his start beginning as Manager at Deloitte &amp; Touche, LLP. Mr. Foster served on the Board of Financial Institutions for the State of South Carolina from 2006 to 2012 and from June 2018 until December 2021 served on the Board of Directors of Soliton, Inc., a medical device company focused on developing new technology for use in aesthetics, where he was the Chairman of the Audit and Compensation Committees and the past Chairman of the Nominating &amp; Governance Committee. In December 2021 Soliton, Inc. was acquired by AbbVie, Inc. Since June 2021, Mr. Foster has served on the Board of Directors of Volcon, Inc. where he is the past Chairman and current member of the Audit Committee, a member of the Nominating &amp; Governance Committee and is the Chairman of the Compensation Committee. Mr. Foster is a Certified Public Accountant (South Carolina) and holds the designation of Chartered Global Management Accountant from the American Institute of Certified Public Accountants. He received his BS in Accounting from Clemson University in 1985. We believe that Mr. Foster&#8217;s extensive experience in the medical field provide him with the qualifications to serve as a director.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      60
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><b><i>David Robins, Director</i></b>. Mr. Robins was a co-founder of our company and has served as a director since February 2022. Mr. Robins is also a founder and board member of LifeLens that is currently developing on the body sensing devices. Since 2013, Mr. Robins has served as co-CEO of DavosPharma, a privately held corporation that focuses on supporting biotechnology and medical device companies with manufacturing their products for clinical trials and commercialization. He received his BS in Engineering Chemistry from Queen&#8217;s University in Kingston, Ontario and a MS in Chemical Engineering from Syracuse University. Mr. Robins has a significant background in taking medical devices and drugs from clinical trials to commercialization and FDA approvals. We believe that Mr. Robins&#8217; extensive experience in medical device development provide him with the qualifications to serve as a director.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><b><i>Christopher Capelli, Director</i></b>. Dr. Capelli currently works at AbbVie as the Scientific Officer &amp; Medical Device Advisor/Soliton for Allergan Aesthetics R&amp;D Surgical Devices. Prior to being acquired by AbbVie in December 2021, he was the Vice Chairman of the Board, Chief Science Officer and Co-founder for Soliton, Inc., a medical device company that was commercializing RESONIC&#8482; for the dermatologic esthetics marketplace based on its Rapid Acoustic Pulse (&#8220;RAP&#8221;) technology. Dr. Capelli is the lead inventor in Soliton&#8217;s RAP technology. A graduate of Massachusetts Institute of Technology (&#8220;MIT&#8221;) with a Bachelor of Science degree in Mechanical Engineering, Dr. Capelli earned his MD from the University of Wisconsin Medical School and maintains a medical license in the State of Wisconsin. As a result of his scientific work since graduating from MIT, Dr. Capelli holds over 100 issued patents and patent applications worldwide. These patents served as the basis for the creation of five companies having a total market capitalization greater than $36 billion. As a businessman, Dr. Capelli has been directly involved in the start-up of numerous venture-capital backed biomedical company ventures. We believe that Dr. Capelli&#8217;s extensive experience in medical device development provide him with the qualifications to serve as a director.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">No director is related to any other director or executive officer of our company or our subsidiaries, and, there are no arrangements or understandings between a director and any other person pursuant to which such person was elected as director.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="exe_comp" href="#"></a>EXECUTIVE AND DIRECTOR COMPENSATION</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Director Independence</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The rules of the Nasdaq Stock Market, or the Nasdaq Rules, require a majority of a listed company&#8217;s board of directors to be composed of independent directors. In addition, the Nasdaq Rules require that, subject to specified exceptions, each member of a listed company&#8217;s audit, compensation and nominating and governance committees be independent. Under the Nasdaq Rules, a director will only qualify as an independent director if, in the opinion of our Board of Directors, that person does not have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. The Nasdaq Rules also require that audit committee members satisfy independence criteria set forth in Rule 10A-3 under the Securities Exchange Act of 1934, as amended, or the Exchange Act. In order to be considered independent for purposes of Rule 10A-3, a member of an audit committee of a listed company may not, other than in his or her capacity as a member of the audit committee, the board of directors, or any other board committee, accept, directly or indirectly, any consulting, advisory, or other compensatory fee from the listed company or any of its subsidiaries or otherwise be an affiliated person of the listed company or any of its subsidiaries. In considering the independence of compensation committee members, the Nasdaq Rules require that our board of directors must consider additional factors relevant to the duties of a compensation committee member, including the source of any compensation we pay to the director and any affiliations with our company.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Our board of directors undertook a review of the composition of our board of directors and its committees and the independence of each director. Based upon information requested from and provided by each director concerning his or her background, employment and affiliations, including family relationships, our board of directors has determined that each of our directors, with the exception of Ms. Bisson and Mr. Klemp, are independent as defined under the Nasdaq Rules.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      61
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Executive Officer Compensation </b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Summary Compensation Table </b>&#8211;<b> Fiscal 2025 and 2024</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 28%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Name and Principal Position</b></p> </td>
     <td style="vertical-align: bottom; width: 3%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Year</b></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Salary</b><br/> <b>( $ )</b></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Non-Equity </b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Incentive Plan</b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Compensation</b><br/> <b>( $ )</b></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Option</b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Awards</b><br/> <b>( $ ) (1)</b></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>All Other </b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Compensation</b><br/> <b>( $ ) (2)</b></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Total</b><br/> <b>( $ )</b></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: bottom; width: 28%;">&#160;</td>
     <td style="vertical-align: bottom; width: 3%;">&#160;</td>
     <td style="vertical-align: bottom; width: 7%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 10%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 10%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 8%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 10%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 8%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align: bottom; width: 28%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Brad Hauser - Chief Executive Officer</p> </td>
     <td style="vertical-align: bottom; width: 3%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">(3)</p> </td>
     <td style="vertical-align: bottom; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2025</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">356,250</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">202,350</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">1,103,961</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">-</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">1,662,561</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255);">
     <td style="vertical-align: bottom; width: 28%;">&#160;</td>
     <td style="vertical-align: bottom; width: 3%;">&#160;</td>
     <td style="vertical-align: bottom; width: 7%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 10%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 10%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 8%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 10%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 8%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align: bottom; width: 28%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Lori Bisson - Former Chief Executive Officer</p> </td>
     <td style="vertical-align: bottom; width: 3%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">(4)</p> </td>
     <td style="vertical-align: bottom; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2025</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">210,000</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">93,813</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">355,285</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">-</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">659,098</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align: bottom; width: 28%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">and current Executive Vice Chairman</p> </td>
     <td style="vertical-align: bottom; width: 3%;">&#160;</td>
     <td style="vertical-align: bottom; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2024</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">225,000</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">150,000</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">1,468,725</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">17,505</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">1,861,230</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255);">
     <td style="vertical-align: bottom; width: 28%;">&#160;</td>
     <td style="vertical-align: bottom; width: 3%;">&#160;</td>
     <td style="vertical-align: bottom; width: 7%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 10%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 10%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 8%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 10%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 8%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align: bottom; width: 28%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Dr. Robert Schwartz, Former Chief Executive Officer</p> </td>
     <td style="vertical-align: bottom; width: 3%;">&#160;</td>
     <td style="vertical-align: bottom; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2025</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">100,000</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">33,250</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">247,861</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">-</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">381,111</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align: bottom; width: 28%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">and current Chief Medical Officer</p> </td>
     <td style="vertical-align: bottom; width: 3%;">&#160;</td>
     <td style="vertical-align: bottom; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2024</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">100,000</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">35,000</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">-</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">-</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">135,000</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255);">
     <td style="vertical-align: bottom; width: 28%;">&#160;</td>
     <td style="vertical-align: bottom; width: 3%;">&#160;</td>
     <td style="vertical-align: bottom; width: 7%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 10%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 10%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 8%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 10%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 8%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align: bottom; width: 28%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Landy Toth - Chief Technology Officer</p> </td>
     <td style="vertical-align: bottom; width: 3%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">(5)</p> </td>
     <td style="vertical-align: bottom; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2025</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">147,917</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">-</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">165,241</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 10%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">313,158</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align: bottom; width: 28%;">&#160;</td>
     <td style="vertical-align: bottom; width: 3%;">&#160;</td>
     <td style="vertical-align: bottom; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2024</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">187,500</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">-</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">-</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">-</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">187,500</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255);">
     <td style="vertical-align: bottom; width: 28%;">&#160;</td>
     <td style="vertical-align: bottom; width: 3%;">&#160;</td>
     <td style="vertical-align: bottom; width: 7%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 10%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 10%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 8%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 10%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 8%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align: bottom; width: 28%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Trent Smith - Chief Financial Officer</p> </td>
     <td style="vertical-align: bottom; width: 3%;">&#160;</td>
     <td style="vertical-align: bottom; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2025</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">295,000</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">108,300</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">214,831</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">-</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">618,131</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align: bottom; width: 28%;">&#160;</td>
     <td style="vertical-align: bottom; width: 3%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">(6)</p> </td>
     <td style="vertical-align: bottom; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2024</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">159,375</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">74,250</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">673,783</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">18,114</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">925,522</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255);">
     <td style="vertical-align: bottom; width: 28%;">&#160;</td>
     <td style="vertical-align: bottom; width: 3%;">&#160;</td>
     <td style="vertical-align: bottom; width: 7%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 10%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 10%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 8%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 10%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 8%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align: bottom; width: 28%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Walter Klemp - Executive Chairman</p> </td>
     <td style="vertical-align: bottom; width: 3%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">(7)</p> </td>
     <td style="vertical-align: bottom; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2025</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">160,417</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">-</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">165,241</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">-</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">325,658</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align: bottom; width: 28%;">&#160;</td>
     <td style="vertical-align: bottom; width: 3%;">&#160;</td>
     <td style="vertical-align: bottom; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2024</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">200,000</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">-</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">-</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">-</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">200,000</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">(1)</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Represents the full grant date fair value of the option award our board approved and granted to each non-employee director, calculated in accordance with FASB ASC Topic 718. These option awards have been updated from the prior year 10-K/A filed on July 26, 2024 to reflect the option awards broken down for fiscal years 2025 and 2024. These amounts do not necessarily correspond to the actual value that may be realized by the named executive officer or director. For a summary of the assumptions made in the valuation of the awards, please see Note 4 to our financial statements as of and for the period ended March 31, 2025 included in the Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on May 29, 2025.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">(2)</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Other compensation amount represents healthcare insurance costs the Company currently pays for all employees, including $12,634 each for Ms. Bisson and Mr. Smith in fiscal year 2024. In addition, during fiscal year 2024, the Company reimbursed Ms. Bisson $4,871 and Mr. Smith $5,480 each for COBRA reimbursements.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">(3)</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Mr. Hauser joined the Company on June 17, 2024. Mr. Hauser's annual base salary was $450,000.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">(4)</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Ms. Bisson joined the Company on July 1, 2023. Ms. Bisson's annual base salary was $300,000. Ms. Bisson's annual base salary was increased to $375,000 on February 1, 2024. Ms. Bisson's annual base salary was decreased to $150,000 on June 17, 2024 upon transitioning to Executive Vice Chairman.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">(5)</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Mr. Toth took voluntary pay reductions in 2024-25 as follows: $50,000 in June 2024 and an additional $87,500 effective April 2025, which resulted in Mr. Toth&#8217;s annual salary being $50,000 on a go-forward basis.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">(6)</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Mr. Smith joined the Company on July 24, 2023. Mr. Smith's annual base salary was $225,000. Mr. Smith's base salary was increased to $285,000 on February 1, 2024.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">(7)</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Mr. Klemp took voluntary pay reductions in 2024-25 as follows: $50,000 in June 2024 and an additional $100,000 effective April 2025, which resulted in Mr. Klemp&#8217;s annual salary being $50,000 on a go-forward basis.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Employment Agreements</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><i>Brad Hauser Employment Agreement</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">On June 17, 2024, we entered into an employment agreement with Brad Hauser pursuant to which Mr. Hauser agreed to serve as our chief executive officer and president for an initial three-year period, which may be extended on a year-to-year basis. Mr. Hauser&#8217;s agreement provides for an initial annual base salary of $450,000 (subject to an annual review and increase at the discretion of our Compensation Committee) and a target annual bonus of 60% of his base salary. Pursuant to the agreement, Mr. Hauser was granted a ten-year option (the &#8220;Inducement Options&#8221;) to purchase 45,000 shares of common stock at an exercise price equal to the closing price of our common stock on the date of the employment agreement. The option vests in four equal annual installments (or 11,250 shares each installment) on each of the succeeding four anniversary dates of the execution of the employment agreement, provided Mr. Hauser is employed by us on each vesting date. In the event of a &#8220;change of control&#8221; or the termination of the agreement by us without &#8220;cause&#8221; or by Mr. Hauser for &#8220;good reason,&#8221; all of the unvested options shall immediately vest. The Inducement Options were granted outside of our 2023 Stock Plan as an inducement material to Mr. Hauser&#8217;s entering into employment with us in accordance with Nasdaq Stock Market Listing Rule 5635(c)(4). Commencing with the year ending March 31, 2025, Mr. Hauser will be eligible to receive annual option grants as determined by the Compensation Committee of the Board of Directors, based on criteria established by the Compensation Committee. The number of shares underlying the target annual option grant will be equal to $1,000,000 divided by the Black-Scholes value per share of our common stock on the date of grant.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">If Mr. Hauser&#8217;s employment is terminated at our election without &#8220;cause,&#8221; or by Mr. Hauser for &#8220;good reason,&#8221; Mr. Hauser shall be entitled to receive severance payments equal to twelve months of Mr. Hauser&#8217;s base salary and 100% of the target bonus for the year in which such termination occurs; provided that such amounts shall be increased by 50% if Mr. Hauser&#8217;s agreement is terminated without &#8220;cause&#8221; or by Mr. Hauser for &#8220;good reason&#8221; within three months prior to or twelve months after a &#8220;change of control.&#8221; In the event that any payments or benefits provided to Mr. Hauser would trigger the excise tax under Section 4999 of the Internal Revenue Code or any similar provision, the Company agreed to provide Mr. Hauser with a gross-up payment to ensure that, after payment of all taxes (including the excise tax, federal, state, and local income taxes, and employment taxes) imposed on the gross-up payment, Mr. Hauser receives a net amount equal to the payments or benefits Mr. Hauser would have received if the excise tax didn't apply.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      62
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><i>Lori Bisson </i>&#8211;<i> Executive Vice Chairman (former Chief Executive Officer)</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">On June 17, 2024, we entered into an employment agreement with Lori Bisson pursuant to which Ms. Bisson agreed to serve as our Executive Vice Chairman and Strategic Adviser to the Chief Executive Officer for a two-year period. Ms. Bisson&#8217;s agreement provides for an initial annual base salary of $150,000 (subject to an annual review and increase at the discretion of our Compensation Committee) and a target annual bonus of 50% of her base salary. Pursuant to the agreement, Ms. Bisson continued to vest in the option grants issued to Ms. Bisson in her role as chief executive officer and president in accordance with the vesting schedule set out in her initial employment agreement. In the event of a &#8220;change of control&#8221; or the termination of the agreement by us without &#8220;cause&#8221; or by Ms. Bisson for &#8220;good reason,&#8221; all of the unvested options shall immediately vest. Ms. Bisson is entitled to receive any compensation, including incentive compensation, for the fiscal year ended March 31, 2024 that has not been paid as of the date of the agreement. Commencing with the year ending March 31, 2025, Ms. Bisson will be eligible to receive annual option grants as determined by the Compensation Committee of the Board of Directors, based on criteria established by the Compensation Committee. Ms. Bisson agreed to waive any severance payments due to her in connection with the termination of the prior employment agreement that we entered into with her on June 30, 2023.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">On June 30, 2023, we entered into an employment agreement (the &#8220;prior agreement&#8221;) with Lori Bisson pursuant to which Ms. Bisson agreed to serve as our Chief Executive Officer commencing July 1, 2023 for an initial term of three years, which would have been automatically renewed for additional one-year terms unless either party chose not to renew the prior agreement. The prior agreement provided for an initial annual base salary of $300,000. Ms. Bisson was eligible to receive an annual bonus of up to 50% of her base salary, provided that the final determination on the amount of the annual bonus, if any, would be made by the Compensation Committee of the Board of Directors, based on criteria established by the Compensation Committee.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Pursuant to the prior agreement, Ms. Bisson was granted a ten-year option to purchase 46,680 shares of our common stock at an exercise price of $40.00 per share. The option vests in 48 equal installments (or approximately 973 shares each installment) on each of the succeeding forty-eight monthly anniversary dates of the execution of the prior agreement, provided Ms. Bisson is either CEO or a member of the Board of Directors on such vesting date. In the event of a &#8220;change of control&#8221; or the termination of the prior agreement by us without &#8220;cause&#8221; or by Ms. Bisson for &#8220;good reason,&#8221; all of the unvested options shall immediately vest. Commencing with the first full compensation year subsequent to the completion of this offering, Ms. Bisson was eligible to receive annual option grants as determined by the Compensation Committee of the Board of Directors, based on criteria established by the Compensation Committee. The number of shares underlying the target annual option grant for the initial grant after the completion of the IPO was to be equal to $300,000 divided by the Black-Scholes value per share of our common stock on the date of grant. In the event Ms. Bisson&#8217;s prior agreement was terminated without &#8220;cause&#8221; or by Ms. Bisson for &#8220;good reason&#8221; within three months prior to or twelve months after of a &#8220;change of control&#8221;, all of the unvested options shall immediately vest.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">If Ms. Bisson&#8217;s employment was terminated at our election without &#8220;cause&#8221;, which required 90 days advance notice, or by Ms. Bisson for &#8220;good reason,&#8221; Ms. Bisson was entitled to receive severance payments equal to twelve months of Ms. Bisson&#8217;s base salary and 100% of the target bonus for the year in which such termination occurs; provided that such amounts would have been increased by 50% if Ms. Bisson&#8217;s agreement was terminated without &#8220;cause&#8221; or by Ms. Bisson for &#8220;good reason&#8221; within three months prior to or twelve months after of a &#8220;change of control.&#8221; Ms. Bisson agreed not to compete with us until twelve months after the termination of her employment.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><i>Trent Smith </i>&#8211;<i> Chief Financial Officer</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">On July 24, 2023, we entered into an employment agreement with Trent Smith pursuant to which Mr. Smith agreed to serve as our Chief Financial Officer for an initial term of three years, which will be automatically renewed for additional one-year terms unless either party provides 90 days written notice to the other party of its decision not to renew the agreement. The agreement provided for an initial annual base salary of $225,000. Mr. Smith is eligible to receive an annual bonus of up to 33% of his base salary, provided that the final determination on the amount of the annual bonus, if any, will be made by the Compensation Committee of the Board of Directors, based on criteria established by the Compensation Committee.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Pursuant to the agreement, Mr. Smith was granted a ten-year option to purchase 21,250 shares of our common stock at an exercise price of $40.00 per share. The option vests vest in four equal annual installments (or approximately 5,313 shares each installment) on each of the succeeding four anniversary dates of the execution of the employment agreement, provided Mr. Smith is CFO on such vesting date. In the event of a &#8220;change of control&#8221; or the termination of the agreement by us without &#8220;cause&#8221; or by Mr. Smith for &#8220;good reason,&#8221; all of the unvested options shall immediately vest. Commencing with the fiscal year ended March 31, 2025, Mr. Smith will be eligible to receive annual option grants as determined by the Compensation Committee of the Board of Directors, based on criteria established by the Compensation Committee.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">If Mr. Smith&#8217;s employment is terminated upon his disability or death, at our election without &#8220;cause&#8221;, which requires 90 days advance notice, or by Mr. Smith for &#8220;good reason,&#8221; which requires 30 days advance notice, Mr. Smith shall be entitled to receive severance payments equal to nine months of Mr. Smith&#8217;s base salary and 100% of the target bonus for the year in which such termination occurs; provided that such amounts shall be increased to thirteen and one-half months of Mr. Smith&#8217;s base salary and 125% of the target bonus for the year in which such termination occurs if Mr. Smith&#8217;s agreement is terminated without &#8220;cause&#8221; or by Mr. Smith for &#8220;good reason&#8221; within three months prior to or twelve months after a &#8220;change of control.&#8221; Mr. Smith agreed not to compete with us until twelve months after the termination of his employment.&#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      63
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Other Agreements</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In January 2022, we entered into an at-will employment letter with Dr. Schwartz to serve as our acting Chief Executive Officer on a part-time basis comprising 25% of his working time until we identified a full-time Chief Executive Officer, at which time Dr. Schwartz would become our Chief Medical Officer. Pursuant to the letter, we agreed to pay Dr. Schwartz a base salary of $100,000 per year, and to pay Dr. Schwartz an annual incentive cash bonus of up to 35% of his base salary subject to the achievement of agreed upon goals and objectives and the approved of our Board of Directors or Compensation Committee. In connection with the employment letter, we issued Dr. Schwartz a grant of 20,000 shares of our common stock. Upon the appointment of Ms. Bisson as Chief Executive Officer, Dr. Schwartz agreed to serve as our Chief Medical Officer on a part-time basis comprising 25% of his working time.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Effective January 2022, we entered into an amended and restated consulting agreement with Mr. Toth to provide services to us on a part-time basis comprising 25% of his working time. Pursuant to the consulting agreement, we agreed to pay Mr. Toth a base salary of $187,500 per year commencing in June 2022. In connection with the consulting agreement, we issued Mr. Toth a stock grant of 77,500 shares of common stock. The consulting agreement may be terminated by either party on 30 days&#8217; notice.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In January 2022, we entered into a director offer letter with Mr. Klemp to serve as our Executive Chairman. Pursuant to the letter, we agreed to pay Mr. Klemp annual board fees of $200,000 per year. In connection with Mr. Klemp&#8217;s appointment to the Board, we issued Mr. Klemp a stock grant of 144,500 shares of common stock.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Narrative Disclosure to Summary Compensation Table</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We have established for compensation purposes a compensation year that matches our fiscal year that ends March 31. Subsequent to the end of the fiscal year, our Compensation Committee completes its annual review of executive compensation and determines, after researching comparable companies, the compensation arrangements for the next compensation year.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We review compensation annually for all employees, including our executives. In setting executive base salaries and bonuses and granting equity incentive awards, we consider compensation for comparable positions in the market, the individual executive&#8217;s performance as compared to our expectations and objectives, our desire to motivate our employees to achieve short and long-term results that are in the best interests of our stockholders and a long-term commitment to our company. We do not target a specific competitive position or a specific mix of compensation among base salary, bonus or long-term incentives. Our Compensation Committee typically reviews and discusses management&#8217;s proposed compensation with the Chief Executive Officer for all executives other than the Chief Executive Officer. Based on those discussions and its discretion, the Compensation Committee then determines the compensation for each executive officer. Our Compensation Committee, without members of management present, discusses and ultimately approves the compensation of our executive officers.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><i>Annual Base Salary</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">For the 2025 fiscal year, the base salaries for Ms. Bisson, Dr. Schwartz, Mr. Toth, Mr. Smith, Mr. Klemp and Mr. Hauser were $375,000, $100,000, $137,500, $285,000, $150,000, and $450,000, respectively. Upon Ms. Bisson&#8217;s change in responsibilities in June 2024, her annual base salary was reduced to $150,000. For the 2026 fiscal year, the base salaries for Ms. Bisson, Dr. Schwartz, Mr. Toth, Mr. Smith, Mr. Klemp and Mr. Hauser will be $150,000, $50,000, $50,000, $296,400, $50,000, and $468,000, respectively.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><i>Annual Bonus and Non-Equity Incentive Plan Compensation.</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We seek to motivate and reward our executives for achievements relative to our corporate goals and objectives, and with respect to their respective individual goals, for each fiscal year. For the last fiscal year, the target bonus for Ms. Bisson, Dr. Schwartz, Mr. Toth, Mr. Smith and Mr. Klemp and Mr. Hauser were 50%, 35%, 0%, 40%, 0%, and 60%, respectively, of their base salary. For the 2026&#160;fiscal year, the target bonus each year for Ms. Bisson, Dr. Schwartz, Mr. Toth, Mr. Smith, Mr. Klemp and Mr. Hauser are 50%, 35%, 0%, 40%, 0%, and 60%, respectively, of their base salary.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The actual performance-based annual bonus paid is calculated by multiplying the executive&#8217;s annual base salary, target bonus percentage, the percentage attainment of the corporate goals established by the Board for such year, which represents the total potential bonus payable to our named executive officers, and the percentage attainment of the individual goals approved by our Compensation Committee with respect to our other executive officers. However, the Compensation Committee is not required to calculate bonuses in this manner and retains discretion in the amounts it awards and the factors it takes into consideration in determining bonus amounts. At the end of the fiscal year, the Compensation Committee reviews our performance against our goals and objectives and approves the extent to which we achieved each of our corporate and individual goals and objectives, and, for each named executive officer, the amount of the bonus awarded.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">For the last fiscal year, bonuses were awarded based on our achievement of specified corporate goals, including securing strategic partnerships, progress on our pivotal trial, completion of financings, and completion of the ongoing clinical proof of concept trial. These corporate goals account for 100% of our base line bonuses. In addition, our Compensation Committee specified a series of &#8220;stretch goals,&#8221; that, if achieved, would result in an additional 20%. Based on the level of achievement, our Compensation Committee awarded Ms. Bisson, Dr. Schwartz, Mr. Smith and Mr. Hauser 95%, respectively, of their potential bonuses for the year. These actual bonus amounts are reflected in the "Non-Equity Incentive Plan Compensation" column of the Summary Compensation Table above.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      64
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">For the 2026&#160;fiscal year, bonuses will be awarded based on our achievement of specified corporate goals, including securing strategic partnerships, progress on our pivotal trial, completion of financings, design lock for catheter and completion of the second phase of the clinical proof of concept trial. These corporate goals account for 100% of our base line bonuses. In addition, our Compensation Committee specified a series of &#8220;stretch goals,&#8221; that, if achieved, would result in an additional 20%.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><i>Long-Term Incentives </i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Our 2023 Stock Plan provides for the grant of stock options, stock awards, stock unit awards and stock appreciation rights to key employees, non-employee directors and consultants.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Each year our Compensation Committee establishes a value for the expected equity grant issuable to each of our named executive officers. For options, we typically set the option exercise price and grant date fair value based on the closing price of our common stock on Nasdaq on the date of grant, however, there may be instances where we may use an average closing price, up to five days, to set the option exercise price. The shares underlying options typically vest in four equal annual installments. For other equity awards, the grant date fair value is based on the closing price of our common stock on Nasdaq on the date of grant.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">As of September 19, 2025, no equity grants for Ms. Bisson, Mr. Smith, Mr. Klemp and Mr. Hauser have been granted for fiscal year 2026. The final determination for any equity grants remain at the discretion of the Compensation Committee.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Equity Awards</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The following table sets forth certain information concerning our outstanding equity&#160;awards for our named executive officers at March 31, 2025.&#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 16pt;"><b>Outstanding Equity Awards At Fiscal Year-End</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: bottom; width: 30%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 12%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td colspan="12" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 44%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Option Awards</b></p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 30%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Name and Principal Position</b></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Grant</b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Date of </b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Equity</b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Award</b></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Number of </b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Securities</b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Underlying </b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Unexercised </b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Options</b><br/> <b>( # )</b><br/> <b>Exercisable (1)</b></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Number of </b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Securities </b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Underlying </b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Unexercised </b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Options</b><br/> <b>( # )</b><br/> <b>Unexercisable </b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(1)</b></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Option</b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Exercise </b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Price</b><br/> <b>( $ )</b></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Option </b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Expiration</b><br/> <b>Date</b></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: bottom; width: 30%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 12%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 12%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 12%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 12%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 12%;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align: bottom; width: 30%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Brad Hauser - Chief Executive Officer</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">06/17/24</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">-</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">45,000</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$</p> </td>
     <td style="vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">27.00</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">06/17/34</p> </td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255);">
     <td style="vertical-align: bottom; width: 30%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 12%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 12%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 12%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 12%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 12%;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align: bottom; width: 30%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Lori Bisson - Former Chief Executive Officer and</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">06/21/24</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">-</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">18,862</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$</p> </td>
     <td style="vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">26.56</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">06/21/34</p> </td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align: bottom; width: 30%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">current Executive Vice Chairman</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">06/30/23</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">20,423</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">26,257</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$</p> </td>
     <td style="vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">40.00</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">06/30/33</p> </td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255);">
     <td style="vertical-align: bottom; width: 30%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 12%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 12%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 12%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 12%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 12%;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align: bottom; width: 30%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Dr. Robert Schwartz, Former Chief Executive Officer and current Chief Medical Officer</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">06/21/24</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">-</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">13,159</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$</p> </td>
     <td style="vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">26.56</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">06/21/34</p> </td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255);">
     <td style="vertical-align: bottom; width: 30%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 12%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 12%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 12%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 12%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 12%;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align: bottom; width: 30%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Landy Toth - Chief Technology Officer</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">06/21/24</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">-</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">8,773</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$</p> </td>
     <td style="vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">26.56</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">06/21/34</p> </td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255);">
     <td style="vertical-align: bottom; width: 30%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 12%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 12%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 12%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 12%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 12%;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align: bottom; width: 30%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Trent Smith - Chief Financial Officer</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">06/21/24</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">-</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">11,405</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$</p> </td>
     <td style="vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">26.56</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">06/21/34</p> </td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align: bottom; width: 30%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">07/24/23</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">5,313</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">15,937</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$</p> </td>
     <td style="vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">40.00</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">07/24/33</p> </td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255);">
     <td style="vertical-align: bottom; width: 30%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 12%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 12%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 12%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 12%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 12%;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align: bottom; width: 30%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Walter Klemp - Executive Chairman</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">06/21/24</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">-</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">8,773</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">$</p> </td>
     <td style="vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">26.56</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">06/21/34</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">(1)</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">The shares underlying the options granted on June 30, 2023 for Ms. Bisson vest in equal monthly installments over a four-year period (i.e., 1/48<sup style="vertical-align:top;line-height:120%;">th</sup>&#160;of each grant vests each month on the anniversary of the grant date). All other shares underlying the options granted vest in annual installments over a four-year period (i.e., one-quarter of each grant vests on the first, second, third and fourth anniversary of the grant date), subject to continued service with us through each applicable vesting date.&#160;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      65
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Director Compensation</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In January 2022, we entered into a director offer letter with Mr. Klemp to serve as our Executive Chairman. Pursuant to the letter, we agreed to pay Mr. Klemp annual board fees of $200,000 per year commencing April 1, 2022. In connection with Mr. Klemp&#8217;s appointment to the Board, we issued Mr. Klemp a stock grant of 144,500 shares of common stock.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In January 2022, we entered into a director offer letter with Mr. Foster to serve as a director. Pursuant to the letter, we agreed to pay Mr. Foster annual board fees of $50,000 per year. In connection with Mr. Foster&#8217;s appointment to the Board, we issued Mr. Foster a stock grant of 35,000 shares of common stock.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In February 2022, we entered into a director offer letter with Mr. Robins to serve as a director. In connection with Mr. Robins&#8217; appointment to the Board, we issued Mr. Robins a stock grant of 5,000 shares of common stock.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In September 2023, we entered into a director offer letter with Mr. Capelli to serve as a director. In connection with Mr. Capelli&#8217;s appointment to the Board, we issued Mr. Capelli a stock option to purchase up to 3,750 shares of common stock.&#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Commencing upon the closing of our IPO in January 2024, our non-employee directors began to receive annual compensation of $50,000.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In May 2024, the Board of Directors approved an updated non-employee director compensation plan, pursuant to which upon the initial appointment (or election) of an non-employee director to the Board, the non-employee director shall be issued a 10-year option to purchase 3,750 shares of the Company&#8217;s common stock, under the 2023 Stock Plan, that will vest in three equal annual installments over a three-year period. In addition, on the date of our annual meeting, each non-employee director that is re-elected at the Annual Shareholder Meeting will be issued a 10-year option to purchase 2,500 shares of the Company&#8217;s common stock, under the 2023 Stock Plan that will vest quarterly over a one-year period. In addition, each non-employee director will receive an annual compensation of $40,000 and special service pay amounts based on service for committee responsibilities as follows: Audit Committee Chairman&#160;- $15,000; Compensation Committee Chairman - $10,000; and Nominating and Governance Chairman - $7,500. Each non-chairman committee member will also receive the following compensations: Audit Committee member - $7,500; Compensation Committee member - $5,000; and Nominating and Governance Committee member - $3,750.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The following table sets forth the total compensation earned by our non-employee directors in fiscal year 2025. Mr. Klemp&#8217;s compensation is fully reflected in the &#8220;<i>Summary Compensation Table</i>&#8221; above:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:19.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Name of Director</b></p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#160;</td>
     <td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:5.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Year</b></p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#160;</td>
     <td colspan="2" style="border-bottom:solid 1px #000000;vertical-align:bottom;width:0.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Fees earned</b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>or paid in </b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>cash</b><br/> <b>( $ )</b></p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#160;</td>
     <td style="vertical-align:bottom;width:0.5%;">&#160;</td>
     <td colspan="2" style="border-bottom:solid 1px #000000;vertical-align:bottom;width:0.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Option </b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>awards</b><br/> <b>( $ ) (1)</b></p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#160;</td>
     <td style="vertical-align:bottom;width:0.5%;">&#160;</td>
     <td colspan="2" style="border-bottom:solid 1px #000000;vertical-align:bottom;width:0.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Total</b><br/> <b>( $ )</b></p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:19.4%;">&#160;</td>
     <td style="vertical-align:bottom;width:0.5%;">&#160;</td>
     <td style="vertical-align:bottom;width:5.6%;">&#160;</td>
     <td style="vertical-align:bottom;width:0.5%;">&#160;</td>
     <td style="vertical-align:bottom;width:0.5%;">&#160;</td>
     <td style="vertical-align:bottom;width:5.6%;">&#160;</td>
     <td style="vertical-align:bottom;width:0.5%;">&#160;</td>
     <td style="vertical-align:bottom;width:0.5%;">&#160;</td>
     <td style="vertical-align:bottom;width:0.5%;">&#160;</td>
     <td style="vertical-align:bottom;width:5.6%;">&#160;</td>
     <td style="vertical-align:bottom;width:0.5%;">&#160;</td>
     <td style="vertical-align:bottom;width:0.5%;">&#160;</td>
     <td style="vertical-align:bottom;width:0.5%;">&#160;</td>
     <td style="vertical-align:bottom;width:5.6%;">&#160;</td>
     <td style="vertical-align:bottom;width:0.5%;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align:bottom;width:19.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Jonathan P. Foster</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#160;</td>
     <td style="vertical-align:bottom;width:5.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2025</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#160;</td>
     <td style="vertical-align:bottom;width:0.5%;">&#160;</td>
     <td style="vertical-align:bottom;width:5.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">68,750</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#160;</td>
     <td style="vertical-align:bottom;width:0.5%;">&#160;</td>
     <td style="vertical-align:bottom;width:0.5%;">&#160;</td>
     <td style="vertical-align:bottom;width:5.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">-</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#160;</td>
     <td style="vertical-align:bottom;width:0.5%;">&#160;</td>
     <td style="vertical-align:bottom;width:0.5%;">&#160;</td>
     <td style="vertical-align:bottom;width:5.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">68,750</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255);">
     <td style="vertical-align:bottom;width:19.4%;">&#160;</td>
     <td style="vertical-align:bottom;width:0.5%;">&#160;</td>
     <td style="vertical-align:bottom;width:5.6%;">&#160;</td>
     <td style="vertical-align:bottom;width:0.5%;">&#160;</td>
     <td style="vertical-align:bottom;width:0.5%;">&#160;</td>
     <td style="vertical-align:bottom;width:5.6%;">&#160;</td>
     <td style="vertical-align:bottom;width:0.5%;">&#160;</td>
     <td style="vertical-align:bottom;width:0.5%;">&#160;</td>
     <td style="vertical-align:bottom;width:0.5%;">&#160;</td>
     <td style="vertical-align:bottom;width:5.6%;">&#160;</td>
     <td style="vertical-align:bottom;width:0.5%;">&#160;</td>
     <td style="vertical-align:bottom;width:0.5%;">&#160;</td>
     <td style="vertical-align:bottom;width:0.5%;">&#160;</td>
     <td style="vertical-align:bottom;width:5.6%;">&#160;</td>
     <td style="vertical-align:bottom;width:0.5%;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align:bottom;width:19.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">David Robins</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#160;</td>
     <td style="vertical-align:bottom;width:5.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2025</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#160;</td>
     <td style="vertical-align:bottom;width:0.5%;">&#160;</td>
     <td style="vertical-align:bottom;width:5.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">60,000</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#160;</td>
     <td style="vertical-align:bottom;width:0.5%;">&#160;</td>
     <td style="vertical-align:bottom;width:0.5%;">&#160;</td>
     <td style="vertical-align:bottom;width:5.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">-</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#160;</td>
     <td style="vertical-align:bottom;width:0.5%;">&#160;</td>
     <td style="vertical-align:bottom;width:0.5%;">&#160;</td>
     <td style="vertical-align:bottom;width:5.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">60,000</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255);">
     <td style="vertical-align:bottom;width:19.4%;">&#160;</td>
     <td style="vertical-align:bottom;width:0.5%;">&#160;</td>
     <td style="vertical-align:bottom;width:5.6%;">&#160;</td>
     <td style="vertical-align:bottom;width:0.5%;">&#160;</td>
     <td style="vertical-align:bottom;width:0.5%;">&#160;</td>
     <td style="vertical-align:bottom;width:5.6%;">&#160;</td>
     <td style="vertical-align:bottom;width:0.5%;">&#160;</td>
     <td style="vertical-align:bottom;width:0.5%;">&#160;</td>
     <td style="vertical-align:bottom;width:0.5%;">&#160;</td>
     <td style="vertical-align:bottom;width:5.6%;">&#160;</td>
     <td style="vertical-align:bottom;width:0.5%;">&#160;</td>
     <td style="vertical-align:bottom;width:0.5%;">&#160;</td>
     <td style="vertical-align:bottom;width:0.5%;">&#160;</td>
     <td style="vertical-align:bottom;width:5.6%;">&#160;</td>
     <td style="vertical-align:bottom;width:0.5%;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align:bottom;width:19.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Christopher Capelli</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#160;</td>
     <td style="vertical-align:bottom;width:5.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2025</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#160;</td>
     <td style="vertical-align:bottom;width:0.5%;">&#160;</td>
     <td style="vertical-align:bottom;width:5.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">56,250</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#160;</td>
     <td style="vertical-align:bottom;width:0.5%;">&#160;</td>
     <td style="vertical-align:bottom;width:0.5%;">&#160;</td>
     <td style="vertical-align:bottom;width:5.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">-</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#160;</td>
     <td style="vertical-align:bottom;width:0.5%;">&#160;</td>
     <td style="vertical-align:bottom;width:0.5%;">&#160;</td>
     <td style="vertical-align:bottom;width:5.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">56,250</p> </td>
     <td style="vertical-align:bottom;width:0.5%;">&#160;</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">(1)</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">As of March 31, 2025, the aggregate number of shares outstanding under all options to purchase our common stock held by our non-employee directors were: Mr. Capelli &#8211;&#160;3,750 shares.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      66
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="certain" href="#"></a>CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In addition to the compensation arrangements, including employment, termination of employment and change in control arrangements, with our directors and executive officers, including those discussed in the sections titled &#8220;Management&#8221; and &#8220;Executive and Director Compensation,&#8221; the following is a description of each transaction since April 1, 2023 or any currently proposed transaction in which:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">we have been or are to be a party to;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">the amount involved exceeded or exceeds $120,000 or 1% of the average of our total assets as of the end of the last two completed fiscal years; and</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">any of our directors, executive officers or holders of more than 5% of our outstanding capital stock, or any immediate family member of, or person sharing the household with, any of these individuals or entities, had or will have a direct or indirect material interest.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In December 2021, we granted a company affiliated with certain early investors in the Company a license to our technology for use in the field of cardiology. In July 2023, we entered into a termination agreement for the license agreement in exchange for the issuance, upon the closing of our IPO, of a warrant to purchase 80,000 shares of our common stock at an exercise price of $0.02 per share. The shares underlying the warrant are subject to a lockup agreement for a period of six months after the closing of the IPO with respect to 12.5% of the shares and twelve months after the closing of the IPO for the remainder of the shares. We agreed to provide demand registration rights to the licensee with respect to the resale of the shares of common stock underlying the warrants. One of our directors, David Robins, holds a 20% interest in the company receiving the warrant.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In September 2023, we commenced a private placement for up to $2.0 million in principal amount of convertible notes with a maturity date of December 31, 2025. For each dollar in principal amount of convertible notes purchased, we issued a warrant to purchase 0.0125 shares of our common stock, with an exercise price of $20.00 per share. On the closing of our IPO, the principal amount of the convertible notes converted into our common stock at a conversion price of $40.00 per share. Subsequent to September 30, 2023, members of the Company&#8217;s management, Board of Directors and an immediate family member of the Company&#8217;s management, collectively purchased $500,000 ($400,000 (for management and members of the Board of Directors) and $100,000 (for the immediate family member of a member of the Company&#8217;s management, respectively) in principal amount of convertible notes in the private placement.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Policies and Procedures for Related Party Transactions</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Our audit committee charter provides that our audit committee is responsible for reviewing and approving in advance any related party transaction. This will cover, with certain exceptions set forth in Item 404 of Regulation S-K under the Securities Act, any transaction, arrangement or relationship, or any series of similar transactions, arrangements or relationships in which we were or will be a participant to, where the amount involved exceeds the lesser of $120,000 or one percent of the average of our total assets at year-end for the last two completed fiscal years, and a related person had or will have a direct or indirect material interest, including, without limitation, purchases of goods or services by or from the related person or entities in which the related person has a material interest, indebtedness, guarantees of indebtedness and employment by us of a related person. In determining whether to approve a proposed transaction, our audit committee will consider all relevant facts and circumstances including: (i) the materiality and character of the related party&#8217;s direct or indirect interest; (ii) the commercial reasonableness of the terms; (iii) the benefit or perceived benefit, or lack thereof, to us; (iv) the opportunity cost of alternate transactions; and (v) the actual or apparent conflict of interest of the related party.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      67
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="security_ownership" href="#"></a>SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The following table sets forth information, as of September 19, 2025, regarding beneficial ownership of our common stock by:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">each of our directors;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">each of our named executive officers;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">all directors and current executive officers as a group; and</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 36pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">each person, or group of affiliated persons, known by us to beneficially own more than five percent of our shares of common stock.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The percentage of beneficial ownership before the offering is based on 6,194,147 shares outstanding as of September 19, 2025. Beneficial ownership is determined according to the rules of the SEC, and generally means that person has beneficial ownership of a security if he or she possesses sole or shared voting or investment power of that security and includes options that are currently exercisable or exercisable within 60 days. Each director or officer, as the case may be, has furnished us with information with respect to beneficial ownership. Except as otherwise indicated, we believe that the beneficial owners of common stock listed below, based on the information each of them has given to us, have sole investment and voting power with respect to their shares, except where community property laws may apply. Except as otherwise noted below, the address for each person or entity listed in the table is c/o Autonomix Medical, Inc., 21 Waterway Avenue, Suite 300, The Woodlands, TX 77380.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 18pt; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">
   <tbody>
    <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 64.1%; border-bottom: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Name of Beneficial Owner</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Shares </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>beneficially </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>owned (1)</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Percent<br/> of<br/> Class</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
    </tr>

    <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Executive officers and directors:</i></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&#160;</i></td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&#160;</i></td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&#160;</i></td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&#160;</i></td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&#160;</i></td>
    </tr>

    <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Lori Bisson</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,750</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">*</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
    </tr>

    <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Dr. Robert Schwartz</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">35,765</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">*</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
    </tr>

    <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Landy Toth</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">101,315</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.6</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
    </tr>

    <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Walter Klemp</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">150,750</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2.4</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
    </tr>

    <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Jonathan P. Foster</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">36,563</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">*</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
    </tr>

    <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">David Robins</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">26,582</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1.9%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">(2)</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">*</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
    </tr>

    <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Trent Smith</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
     <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,750</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
     <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">*</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
    </tr>

    <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
    </tr>

    <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>All Executive Officers and Directors as a group (9 persons)</b></p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"><b>&#160;</b></td>
     <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>358,475</b></td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double black;"><b>&#160;</b></td>
     <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"><b>5.8</b></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding: 0px 0px 3px;"><b>%</b></td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">* Less than 1%</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">(1)</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Consists of shares of common stock, underlying warrants to purchase common stock.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">(2)</p> </td>
     <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Includes a portion of 15,600 warrants to purchase shares of the Company&#8217;s common stock that is held by Portsmouth Therapeutics, Inc., an entity in which Mr. Robins also owns a 33.33% interest.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      68
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="cap_stock" href="#"></a>DESCRIPTION OF CAPITAL STOCK</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><i>The following summary of the rights of our capital stock is not complete and is subject to and qualified in its entirety by reference to our certificate of incorporation and bylaws, copies of which are filed as exhibits to the registration statement of which this prospectus forms a part, which are incorporated by reference herein, and the applicable provisions of the Delaware General Corporation Law.</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Common Stock</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We are authorized to issue up to 500,000,000 shares of common stock. Shares of our common stock have the following rights, preferences and privileges:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><i>Voting</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Each holder of common stock is entitled to one vote for each share of common stock held on all matters submitted to a vote of stockholders. Any action at a meeting at which a quorum is present will be decided by a majority in voting power of the votes cast (excluding abstentions and broker non-votes), except in the case of any election of directors, which will be decided by a plurality of votes cast. There is no cumulative voting.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><i>Dividends</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Holders of our common stock are entitled to receive dividends when, as and if declared by our board of directors out of funds legally available for payment, subject to the rights of holders, if any, of any class of stock having preference over the common stock. Any decision to pay dividends on our common stock will be at the discretion of our board of directors. Our board of directors may or may not determine to declare dividends in the future. The board&#8217;s determination to issue dividends will depend upon our profitability and financial condition any contractual restrictions, restrictions imposed by applicable law and the SEC, and other factors that our board of directors deems relevant.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><i>Liquidation Rights</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In the event of a voluntary or involuntary liquidation, dissolution or winding up of the company, the holders of our common stock will be entitled to share ratably on the basis of the number of shares held in any of the assets available for distribution after we have paid in full, or provided for payment of, all of our debts and after the holders of all outstanding series of any class of stock have preference over the common stock, if any, have received their liquidation preferences in full.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><i>Number of Holders</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">There are approximately 7,200 holders of our common stock as of&#160;September 2, 2025.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><i>Other</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Our issued and outstanding shares of common stock are fully paid and nonassessable. Holders of shares of our common stock are not entitled to preemptive rights. Shares of our common stock are not convertible into shares of any other class of capital stock, nor are they subject to any redemption or sinking fund provisions.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Preferred Stock</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We are authorized to issue up to 10,000,000 shares of preferred stock. Our certificate of incorporation authorizes the board to issue these shares in one or more series, to determine the designations and the powers, preferences and relative, participating, optional or other special rights and the qualifications, limitations and restrictions thereof, including the dividend rights, conversion or exchange rights, voting rights (including the number of votes per share), redemption rights and terms, liquidation preferences, sinking fund provisions and the number of shares constituting the series. Our board of directors could, without stockholder approval, issue preferred stock with voting and other rights that could adversely affect the voting power and other rights of the holders of common stock and which could have the effect of making it more difficult for a third party to acquire, or of discouraging a third party from attempting to acquire, a majority of our outstanding voting stock.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      69
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Convertible Notes Payable</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">On September 9, 2023, our Board of Directors authorized an offering up to $2.0 million in unsecured, non-interest bearing convertible promissory notes (the &#8220;Notes&#8221;) and accompanying warrants (the &#8220;Bridge Financing Warrants&#8221;) (collectively, the &#8220;Bridge Offering&#8221;) that will mature on December 31, 2025. $670,000 of these Notes were converted into common stock on January 26, 2024 and the remaining $1,330,000 of these Notes were converted into common stock on March 28, 2025. The Notes provide that, on the closing date of the IPO, the outstanding principal would be&#160;automatically converted into common stock at the conversion price of $40.00, provided that certain holders of the Notes are not permitted to convert such Notes to the extent that the holders or any of its affiliates would beneficially own in excess of 4.99% (the &#8220;Beneficial Ownership Limit&#8221;) of our common stock after such conversion. Each dollar in principal amount of the convertible notes purchased were&#160;accompanied by a five-year Bridge Financing Warrant to purchase approximately 0.0125 shares of common stock with an exercise price of $20.00 per share as discussed in &#8220;<i>Warrants </i>&#8211;<i> Pre-IPO Warrants</i>&#8221; below.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Warrants</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>License Termination Warrants</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">As of the date hereof, we have outstanding warrants to purchase 25,600 shares of our common stock at an exercise price of $0.02&#160;per share expiring January 2029. The shares underlying the warrant are subject to a lockup agreement for a period of six months after the closing of our IPO with respect to 12.5% of the shares issued and twelve months after the closing of our IPO for the remainder of the shares. We agreed to provide demand registration rights to the licensee with respect to the resale of the shares of common stock underlying the warrants.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Pre-IPO Warrants</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">As of the date hereof, we have outstanding warrants to purchase 4,542&#160;shares of our common stock at a weighted average exercise price of $11.99 per share expiring through March 2032 and Bridge Financing Warrants to purchase an aggregate of 25,003 shares of our common stock at an exercise price of $20.00 per share expiring through October 2028. The foregoing warrants provide that no holder of these warrants will be permitted to exercise such warrants to the extent that the holder or any of its affiliates would beneficially own in excess of 4.99% of our common stock after such exercise.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Selling Agent Warrants</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In connection with our IPO, we issued approximately 2,989 shares of our common stock issuable upon exercise of warrants issued to the selling agent in our IPO (the &#8220;Selling Agent&#8217;s Warrants&#8221;). The Selling Agent&#8217;s Warrants are exercisable commencing six months after the date of commencement of sales in our IPO and will be exercisable until the fifth anniversary of such date. The exercise price for the Selling Agent&#8217;s Warrants is $125.00 per share. The Selling Agent&#8217;s Warrants are not redeemable.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Series A Warrants</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><b><i>Duration and Exercise Price</i></b>. Each Series A Warrant was issued on November 22, 2024 and has an initial exercise price per share equal to $6.54, subject to adjustment.&#160;The exercise price and number of shares of common stock issuable upon exercise for each Series A Warrant is subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting our shares of common stock and the exercise price. The Series A Warrants will expire five and one-half years from the issuance date.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><b><i>Exercisability</i></b>. The Series A Warrants are exercisable, at the option of the holder, in whole or in part, by delivering to us a duly-executed exercise notice, with payment in full for the number of shares of common stock purchased upon such exercise (except in the case of a cashless exercise as discussed below) due prior to issuance of the common stock.&#160; A holder (together with its affiliates) may not exercise any portion of the Series A Warrant to the extent that the holder would own more than 4.99% (or, at the election of the holder, prior to issuance, 9.99%) of the outstanding shares of common stock immediately after exercise, referred to herein as the beneficial ownership limitation. However, upon notice from the holder to us, the holder may decrease or increase the beneficial ownership limitation, which may not exceed 9.99% of the number of shares of common stock outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the Series A Warrants, provided that any increase in the beneficial ownership limitation will not take effect until 61 days following notice to us. No fractional shares of common stock will be issued in connection with the exercise of a Series A Warrant. In lieu of fractional shares, we will either pay the holder an amount in cash equal to the fractional amount multiplied by the exercise price or round up to the next whole share.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><b><i>Cashless Exercise</i></b>. If there is no registration statement registering, or the prospectus contained therein is not available for, the resale of the shares of common stock underlying the Series A warrants, in lieu of making the cash payment otherwise contemplated to be made to us upon such exercise, the holder may elect instead to receive upon such exercise (either in whole or in part) the net number of the shares of common stock determined according to a formula set forth in the warrants.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      70
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><b><i>Right as a Stockholder</i></b>.&#160; Except as otherwise provided in the Series A Warrants, including as described below under &#8220;Pro Rata Distributions,&#8221; or by virtue of such holder&#8217;s ownership of our shares of common stock, the holders of the Series A Warrants do not have the rights or privileges of holders of our shares of common stock, including any voting rights, until they exercise their Series A Warrants.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><b><i>Subsequent Rights Offerings</i></b>. In addition to in the event of stock dividends, stock splits, reorganizations or similar events affecting our shares of common stock and the exercise price, if at any time the Company grants, issues or sells any specified common stock equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any class of shares of Common Stock (the &#8220;Purchase Rights&#8221;), then the holder of a Series A Warrant will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the holder could have acquired if the holder had held the number of shares of common stock acquirable upon complete exercise of the holder&#8217;s Series A Warrant, without regard to any limitations on exercise hereof, including without limitation, the beneficial ownership limitation, &#160;immediately before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of common stock are to be determined for the grant, issue or sale of such Purchase Rights (provided, however, that, to the extent that the holder&#8217;s right to participate in any such Purchase Right would result in the holder exceeding the beneficial ownership limitation, then the holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such shares of common stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the holder until such time, if ever, as its right thereto would not result in the holder exceeding the beneficial ownership limitation).</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><b><i>Pro Rata Distributions</i></b>. During such time as a Series A Warrant is outstanding and has not reached its termination date, if the Company shall declare or make any dividend or other distribution of its assets (or rights to acquire its assets) to holders of shares of common stock, by way of return of capital or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a &#8220;Distribution&#8221;), at any time after the issuance of the Series A Warrants, then, in each such case, the holder of a Series A Warrant shall be entitled to participate in such Distribution to the same extent that the holder would have participated therein if the holder had held the number of shares of common stock acquirable upon complete exercise of the Series A Warrant (without regard to any limitations on exercise hereof, including without limitation, the beneficial ownership limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of shares of common stock are to be determined for the participation in such Distribution (provided, however, that, to the extent that the holder&#8217;s right to participate in any such Distribution would result in the holder exceeding the beneficial ownership limitation, then the holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership of any shares of common stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the holder until such time, if ever, as its right thereto would not result in such Holder exceeding the beneficial ownership limitation).</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><b><i>Fundamental Transaction</i></b>. In the event of a fundamental transaction, as described in the Series A Warrants and generally including any reorganization, recapitalization or reclassification of our shares of common stock, the sale, transfer or other disposition of all or substantially all of our properties or assets, our consolidation or merger with or into another person, the acquisition of more than 50% of our outstanding shares of common stock, or any person or group becoming the beneficial owner of 50% of the voting power represented by our outstanding shares of common stock, the holders of the Series A Warrants will be entitled to receive upon exercise of the Series A Warrants the kind and amount of securities, cash or other property that the holders would have received had they exercised the Series A Warrants immediately prior to such fundamental transaction.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><b><i>Change in Control</i></b><b>.</b>&#160;In the event of a Change in Control, as defined in the Series A Warrants, warrant holders may require the company to purchase the remaining unexercised portion of a Series A Warrant for an amount equal to the Black-Scholes Value (as defined in the relevant warrant) of that portion, as of the date of the Change of Control, unless the Change of Control is not within the Company&#8217;s control, as described in the warrant.&#160; In that event, holders will instead be entitled to receive the same type or form of consideration (and in the same proportion), at the Black-Scholes Value of the unexercised portion of the warrant, that is being offered and paid to the common shareholders.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><b><i>Series A Warrant </i></b>&#8211;<b><i> Inducement Transaction.</i></b> On July 21, 2025, we entered into a warrant exercise inducement offer letter (the &#8220;Inducement Letter&#8221;) with the holders of certain existing Series A warrants to purchase up to 1,477,596 shares of common stock (the &#8220;Existing Warrants&#8221;). Pursuant to the Inducement Letter, we agreed to reduce the exercise price of the Existing Warrants to $1.723 per share, and the holders agreed: (i) to exercise Existing Warrants to purchase 855,000 shares of common stock; and (ii) to prepay $1.722 per share of the reduced exercise price for Existing Warrants to purchase 622,596 shares of common stock in consideration of us further reducing the exercise price of such Existing Warrants to purchase 622,596 shares of common stock to $0.001 per share. In consideration of the foregoing, we agreed to issue the holders new warrants to purchase up to a number of shares of common stock equal to 100% of the number of shares of common stock underlying the Existing Warrants, comprised of new Series B Warrants to purchase up to 1,477,596 shares of common stock with an exercise term of 5.5 years from the initial exercise date.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      71
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Series B Warrants</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><b><i>Duration and Exercise Price</i></b>. Each Series B Warrant was issued on July 21, 2025 and has an initial exercise price per share equal to $1.723, subject to adjustment.&#160;The exercise price and number of shares of common stock issuable upon exercise for each Series B Warrant is subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting our shares of common stock and the exercise price. The Series B Warrants will expire five and one-half years from the issuance date.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><b><i>Exercisability</i></b>. The Series B Warrants are exercisable, at the option of the holder, in whole or in part, by delivering to us a duly-executed exercise notice, with payment in full for the number of shares of common stock purchased upon such exercise (except in the case of a cashless exercise as discussed below) due prior to issuance of the common stock.&#160; A holder (together with its affiliates) may not exercise any portion of the Series B Warrant to the extent that the holder would own more than 4.99% (or, at the election of the holder, prior to issuance, 9.99%) of the outstanding shares of common stock immediately after exercise, referred to herein as the beneficial ownership limitation. However, upon notice from the holder to us, the holder may decrease or increase the beneficial ownership limitation, which may not exceed 9.99% of the number of shares of common stock outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the Series B Warrants, provided that any increase in the beneficial ownership limitation will not take effect until 61 days following notice to us. No fractional shares of common stock will be issued in connection with the exercise of a Series B Warrant. In lieu of fractional shares, we will either pay the holder an amount in cash equal to the fractional amount multiplied by the exercise price or round up to the next whole share.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><b><i>Cashless Exercise</i></b>. If, commencing six months after issuance, there is no registration statement registering, or the prospectus contained therein is not available for, the resale of the shares of common stock underlying the Series B warrants, in lieu of making the cash payment otherwise contemplated to be made to us upon such exercise, the holder may elect instead to receive upon such exercise (either in whole or in part) the net number of the shares of common stock determined according to a formula set forth in the warrants.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><b><i>Right as a Stockholder</i></b>.&#160; Except as otherwise provided in the Series B Warrants, including as described below under &#8220;Pro Rata Distributions,&#8221; or by virtue of such holder&#8217;s ownership of our shares of common stock, the holders of the Series B Warrants do not have the rights or privileges of holders of our shares of common stock, including any voting rights, until they exercise their Series B Warrants.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><b><i>Subsequent Rights Offerings</i></b>. In addition to in the event of stock dividends, stock splits, reorganizations or similar events affecting our shares of common stock and the exercise price, if at any time the Company grants, issues or sells any specified common stock equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any class of shares of Common Stock (the &#8220;Purchase Rights&#8221;), then the holder of a Series B Warrant will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the holder could have acquired if the holder had held the number of shares of common stock acquirable upon complete exercise of the holder&#8217;s Series B Warrant, without regard to any limitations on exercise hereof, including without limitation, the beneficial ownership limitation, &#160;immediately before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of common stock are to be determined for the grant, issue or sale of such Purchase Rights (provided, however, that, to the extent that the holder&#8217;s right to participate in any such Purchase Right would result in the holder exceeding the beneficial ownership limitation, then the holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such shares of common stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the holder until such time, if ever, as its right thereto would not result in the holder exceeding the beneficial ownership limitation).</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><b><i>Pro Rata Distributions</i></b>. During such time as a Series B Warrant is outstanding and has not reached its termination date, if the Company shall declare or make any dividend or other distribution of its assets (or rights to acquire its assets) to holders of shares of common stock, by way of return of capital or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a &#8220;Distribution&#8221;), at any time after the issuance of the Series B Warrants, then, in each such case, the holder of a Series B Warrant shall be entitled to participate in such Distribution to the same extent that the holder would have participated therein if the holder had held the number of shares of common stock acquirable upon complete exercise of the Series B Warrant (without regard to any limitations on exercise hereof, including without limitation, the beneficial ownership limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of shares of common stock are to be determined for the participation in such Distribution (provided, however, that, to the extent that the holder&#8217;s right to participate in any such Distribution would result in the holder exceeding the beneficial ownership limitation, then the holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership of any shares of common stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the holder until such time, if ever, as its right thereto would not result in such Holder exceeding the beneficial ownership limitation).</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><b><i>Fundamental Transaction</i></b>. In the event of a fundamental transaction, as described in the Series B Warrants and generally including any reorganization, recapitalization or reclassification of our shares of common stock, the sale, transfer or other disposition of all or substantially all of our properties or assets, our consolidation or merger with or into another person, the acquisition of more than 50% of our outstanding shares of common stock, or any person or group becoming the beneficial owner of 50% of the voting power represented by our outstanding shares of common stock, the holders of the Series B Warrants will be entitled to receive upon exercise of the Series B Warrants the kind and amount of securities, cash or other property that the holders would have received had they exercised the Series B Warrants immediately prior to such fundamental transaction.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      72
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><b><i>Change in Control</i></b><b>.</b>&#160;In the event of a Change in Control, as defined in the Series B Warrants, warrant holders may require the company to purchase the remaining unexercised portion of a Series B Warrant for an amount equal to the Black-Scholes Value (as defined in the relevant warrant) of that portion, as of the date of the Change of Control, unless the Change of Control is not within the Company&#8217;s control, as described in the warrant.&#160; In that event, holders will instead be entitled to receive the same type or form of consideration (and in the same proportion), at the Black-Scholes Value of the unexercised portion of the warrant, that is being offered and paid to the common shareholders.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Limitations on Liability and Indemnification of Officers and Directors</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Our certificate of incorporation and bylaws limit the liability of our officers and directors and provide that we will indemnify our officers and directors, in each case, to the fullest extent permitted by the Delaware General Corporation Law.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We have entered into&#160;separate indemnification agreements with each of our directors and executive officers. Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors or executive officers, we have been informed that in the opinion of the Commission such indemnification is against public policy and is therefore unenforceable.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Certificate of Incorporation and Bylaw Provisions</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Our certificate of incorporation and bylaws include a number of anti-takeover provisions that may have the effect of encouraging persons considering unsolicited tender offers or other unilateral takeover proposals to negotiate with our board of directors rather than pursue non-negotiated takeover attempts. These provisions include:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><i>Advance Notice Requirements.</i>&#160;Our bylaws establish advance notice procedures with regard to stockholder proposals relating to the nomination of candidates for election as directors or new business to be brought before meetings of stockholders. These procedures provide that notice of stockholder proposals must be timely and given in writing to our corporate Secretary. Generally, to be timely, notice must be received at our principal executive offices not less than 90 days nor more than 120 days prior to the one-year anniversary of the preceding year&#8217;s annual meeting. The notice must contain the information required by the bylaws, including information regarding the proposal and the proponent.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><i>Special Meetings of Stockholders</i>. Our certificate of incorporation provides that special meetings of stockholders may be called at any time by, or at the direction of, only the Chairman of the Board, the Chief Executive Officer, the President or the board of directors.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><i>No Written Consent of Stockholders</i>. Our certificate of incorporation provides that any action required or permitted to be taken by stockholders must be effected at a duly called annual or special meeting of stockholders and may not be effected by any consent in writing by such stockholders.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      73
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><i>Exclusive Forum Provision</i>. Our certificate of incorporation provides that the Court of Chancery of the State of Delaware shall be the sole and exclusive forum for (i) any derivative action or proceeding brought on our behalf, (ii) any action asserting a claim of breach of a fiduciary duty owed by any of our directors or officers to us or our stockholders, (iii) any action asserting a claim against us arising pursuant to any provision of the Delaware General Corporation Law (the &#8220;DGCL&#8221;), or our certificate of incorporation or the bylaws, and (iv) any action asserting a claim against us governed by the internal affairs doctrine. This provision would not apply to suits brought to enforce a duty or liability created by the Exchange Act or Securities Act.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">This choice of forum provision may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage such lawsuits against us and our directors, officers and employees. In addition, this forum selection provision may impose additional litigation costs on stockholders in pursuing the claims identified above, particularly if the stockholders do not reside in or near the State of Delaware. Alternatively, a court could find these provisions of our certificate of incorporation to be inapplicable or unenforceable in respect of one or more of the specified types of actions or proceedings, which may require us to incur additional costs associated with resolving such matters in other jurisdictions, which could adversely affect our business and financial condition.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><i>Amendment of Bylaws</i>. Our stockholders may amend any provisions of our bylaws by obtaining the affirmative vote of the holders of at least a majority of the voting power of all the then-outstanding shares of our voting stock with the power to vote generally in an election of directors, voting together as a single class.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><i>Preferred Stock</i>. Our certificate of incorporation authorizes our board of directors to create and issue rights entitling our stockholders to purchase shares of our stock or other securities. The ability of our board to establish the rights and issue substantial amounts of preferred stock without the need for stockholder approval may delay or deter a change in control of us. See &#8220;<span style="text-decoration: underline; ">Preferred Stock</span>&#8221; above.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Delaware Takeover Statute</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We are subject to Section 203 of the DGCL which, subject to certain exceptions, prohibits a Delaware corporation from engaging in any &#8220;business combination&#8221; (as defined below) with any interested stockholder for a period of three years following the date that such stockholder became an interested stockholder, unless: (1) prior to such date, the board of directors of the corporation approved either the business combination or the transaction that resulted in the stockholder becoming an interested stockholder; (2) on consummation of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the voting stock outstanding those shares owned (a) by persons who are directors and also officers and (b) by employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to this plan will be tendered in a tender or exchange offer; or (3) on or subsequent to such date, the business combination is approved by the board of directors and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least 66 2&#8260;3% of the outstanding voting stock that is not owned by the interested stockholder.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Section 203 of the DGCL defines generally &#8220;business combination&#8221; to include: (1) any merger or consolidation involving the corporation and the interested stockholder; (2) any sale, transfer, pledge or other disposition of 10% or more of the assets of the corporation involving the interested stockholder; (3) subject to certain exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder; (4) any transaction involving the corporation that has the effect of increasing the proportionate share of the stock of any class or series of the corporation beneficially owned by the interested stockholder; or (5) the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided by or through the corporation. In general, Section 203 defines an &#8220;interested stockholder&#8221; as any entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity or person affiliated with or controlling or controlled by such entity or person.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Transfer Agent</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The transfer agent for our common stock is Equity Stock Transfer, LLC.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      74
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="selling" href="#"></a>SELLING STOCKHOLDER</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">This prospectus relates to the possible resale by the selling stockholder, Lincoln Park, of shares of our common stock that have been and may be issued to Lincoln Park pursuant to the Purchase Agreement. We are filing the registration statement of which this prospectus is a part pursuant to the provisions of the Registration Rights Agreements, which we entered into with Lincoln Park on August 25, 2025 concurrently with our execution of the Purchase Agreement, in which we agreed to provide certain registration rights with respect to sales by Lincoln Park of the shares of our common stock that may be issued to Lincoln Park under the Purchase Agreement.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Lincoln Park, as the selling stockholder, may, from time to time, offer and sell pursuant to this prospectus up to 2,500,000 shares of our common stock that we have issued or may issue to Lincoln Park. The selling stockholder may sell some, all or none of the shares of common stock. We do not know how long the selling stockholder will hold the shares of our common stock before selling them, and we currently have no agreements, arrangements or understandings with the selling stockholder regarding the sale of any of the shares of common stock. See &#8220;Plan of Distribution.&#8221;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The table below sets forth, to our knowledge, information concerning the beneficial ownership of shares of our common stock by the selling stockholder as of September 8, 2025. The percentages of shares owned before and after the offering are based on 6,194,147 shares of common stock outstanding as of September 8, 2025, which includes the 261,932 Commitment Shares that we issued to Lincoln Park upon execution of the Purchase Agreement. The information in the table below with respect to the selling stockholder has been obtained from the selling stockholder.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Beneficial ownership is determined in accordance with the rules of the SEC and includes voting or investment power with respect to shares. Unless otherwise indicated below, to our knowledge, all persons named in the table have sole voting and investment power with respect to their shares of common stock. The inclusion of any shares in this table does not constitute an admission of beneficial ownership for the person named below.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Throughout this prospectus, when we refer to the shares of common stock being offered for resale by the selling stockholder through this prospectus, we are referring to the shares of common stock that have been and may be issued and sold by us to Lincoln Park pursuant to the Purchase Agreement, unless otherwise indicated.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">
   <tbody>
    <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 40%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Name of Selling </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Stockholder</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 0%; padding: 0px;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Number of Shares of Common</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Stock Owned Prior to</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Offering<sup style="vertical-align:top;line-height:120%;">(2)</sup></b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 0%; padding-top: 0px; padding-left: 0px; padding-right: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Maximum Number of Shares of </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Common Stock to be Offered </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Pursuant to this Prospectus<sup style="vertical-align:top;line-height:120%;">(3)</sup></b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 0%; padding: 0px;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Number of Shares of Common</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Stock Owned After Offering<sup style="vertical-align:top;line-height:120%;">(4)</sup></b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
    </tr>

    <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Number</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Percent</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
     <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Number</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Percent</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
    </tr>

    <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Lincoln Park Capital Fund, LLC<sup style="vertical-align:top;line-height:120%;">(1)</sup></p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">261,932</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.2</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,500,000</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(1) Josh Scheinfeld and Jonathan Cope, the Managing Members of Lincoln Park Capital, LLC, the manager of Lincoln Park, are deemed to be beneficial owners of all of the shares of common stock owned directly by Lincoln Park. Messrs. Cope and Scheinfeld have shared voting and investment power over the shares of common stock being offered under the registration statement filed with the SEC in connection with the transactions contemplated under the Purchase Agreement and Registration Rights Agreement. Neither Lincoln Park Capital, LLC nor Lincoln Park is a licensed broker dealer or an affiliate of a licensed broker dealer.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(2) Represents the 261,932 Commitment Shares already issued to Lincoln Park upon execution of the Purchase Agreement on August 25, 2025. In accordance with Rule 13d-3(d) under the Exchange Act, we have excluded from the number of shares of our common stock beneficially owned prior to the offering all of the 2,238,068 shares of our common stock that we may issue and sell to Lincoln Park pursuant to the Purchase Agreement from and after commencement that are being registered for resale under the registration statement that includes this prospectus, because the issuance and sale of such shares to Lincoln Park under the Purchase Agreement is solely at our discretion and is subject to certain conditions, the satisfaction of all of which are outside of Lincoln Park&#8217;s control, including the registration statement that includes this prospectus becoming and remaining effective under the Securities Act. Furthermore, under the terms of the Purchase Agreement, issuances and sales of shares of our common stock to Lincoln Park under the Purchase Agreement are subject to certain limitations on the amounts we may sell to Lincoln Park at any time, including the Exchange Cap and the Beneficial Ownership Cap.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(3) Although the Purchase Agreement provides that we may sell up to $15.0 million of our common stock to Lincoln Park, we are only registering 2,500,000 shares of our common stock for resale under this prospectus, including the 261,932 Commitment Shares we issued to Lincoln Park upon execution of the Purchase Agreement on August 25, 2025 (for which we did not receive any cash consideration). Therefore, only 2,238,068 of such shares represent shares that we may issue and sell to Lincoln Park as Purchase Shares for cash consideration under the Purchase Agreement from time to time, at our sole discretion, during the 24-month period commencing on the Commencement Date. Depending on the price per share at which we sell our common stock to Lincoln Park pursuant to the Purchase Agreement, we may need to sell to Lincoln Park under the Purchase Agreement more shares of our common stock than are offered under this prospectus in order to receive aggregate gross proceeds equal to the full $15.0 million available to us under the Purchase Agreement. If we choose to do so, we must first register for resale under the Securities Act such additional shares. The number of shares ultimately offered for resale by Lincoln Park is dependent upon the number of shares we sell to Lincoln Park under the Purchase Agreement. Additionally, under applicable Nasdaq rules, in no event may we issue or sell to Lincoln Park under the Purchase Agreement shares of our common stock in excess of 1,075,767 share Exchange Cap (which includes the 261,932 Commitment Shares), representing 19.99% of the shares of our common stock outstanding immediately prior to the execution of the Purchase Agreement, unless (i) we obtain stockholder approval to issue shares of our common stock in excess of the Exchange Cap or (ii) the average price of all applicable sales of our common stock to Lincoln Park under the Purchase Agreement equals or exceeds the $1.3351 Base Price so that the Exchange Cap limitation would not apply to issuances and sales of common stock under the Purchase Agreement pursuant to the rules and regulations of Nasdaq. At the 2025 annual meeting of our stockholders to be held on October 30, 2025, among other things, we&#160;are seeking the requisite stockholder authorization in accordance with applicable Nasdaq listing rules to issue and sell shares of our&#160;common stock in excess of the 1,075,767 share Exchange Cap referred to above, if we so choose, to Lincoln Park under the Purchase&#160;Agreement. Accordingly, if such requisite stockholder approval is obtained, we would be able to issue and sell to Lincoln Park, in&#160;addition to the 261,932 Commitment Shares we have already issued to Lincoln Park on August 25, 2025, all of the 2,238,068 shares of&#160;common stock as Purchase Shares under the Purchase Agreement that are being registered under the Securities Act for resale by&#160;Lincoln Park under the registration statement that includes this prospectus, at purchase prices averaging less than the Base Price,&#160;without any further aggregate share issuance limitations under Nasdaq rules.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(4) Assumes the sale of all shares of our common stock registered for resale by the selling stockholder pursuant to the registration statement that includes this prospectus, although the selling stockholder is under no obligation known to us to sell any shares of common stock at any particular time.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      75
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="plan_distribution" href="#"></a>PLAN OF DISTRIBUTION</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The shares of our common stock offered by this prospectus are being offered by the selling stockholder, Lincoln Park Capital Fund, LLC. The shares may be sold or distributed from time to time by the selling stockholder directly to one or more purchasers or through brokers, dealers, or underwriters who may act solely as agents at market prices prevailing at the time of sale, at prices related to the prevailing market prices, at negotiated prices, or at fixed prices, which may be changed. The sale of our common stock offered by this prospectus could be effected in one or more of the following methods:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;">&#9679;&#160; &#160; &#160; &#160; ordinary brokers&#8217; transactions;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;">&#9679;&#160; &#160; &#160; &#160; transactions involving cross or block trades;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;">&#9679;&#160; &#160; &#160; &#160; through brokers, dealers, or underwriters who may act solely as agents;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;">&#9679;&#160; &#160; &#160; &#160; &#8220;at the market&#8221; into an existing market for the shares of our common stock;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;">&#9679;&#160; &#160; &#160; &#160; in other ways not involving market makers or established business markets, including direct sales to purchasers or sales effected through agents;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;">&#9679;&#160; &#160; &#160; &#160; in privately negotiated transactions; or</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;">&#9679;&#160; &#160; &#160; &#160; any combination of the foregoing.&#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">In order to comply with the securities laws of certain states, if applicable, the shares of our common stock offered by this prospectus may be sold only through registered or licensed brokers or dealers. In addition, in certain states, the shares of our common stock offered by this prospectus may not be sold unless they have been registered or qualified for sale in the state or an exemption from the state&#8217;s registration or qualification requirement is available and complied with.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Lincoln Park is an &#8220;underwriter&#8221; within the meaning of Section 2(a)(11) of the Securities Act.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Lincoln Park has informed us that it intends to use an unaffiliated broker-dealer to effectuate all sales, if any, of our common stock that it has acquired and may in the future acquire from us pursuant to the Purchase Agreement. Such sales will be made at prices and at terms then prevailing or at prices related to the then current market price. Each such unaffiliated broker-dealer will be an underwriter within the meaning of Section 2(a)(11) of the Securities Act. Lincoln Park has informed us that each such broker-dealer will receive commissions from Lincoln Park that will not exceed customary brokerage commissions.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Brokers, dealers, underwriters or agents participating in the distribution of the shares of our common stock offered by this prospectus may receive compensation in the form of commissions, discounts, or concessions from the selling stockholder and/or the purchasers, for whom the broker-dealers may act as agent. The compensation paid to any such particular broker-dealer may be less than or in excess of customary commissions. Neither we nor Lincoln Park can presently estimate the amount of compensation that any agent will receive from the selling stockholder or from any purchasers of shares of our common stock sold by Lincoln Park.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We know of no existing arrangements between Lincoln Park or any other stockholder, broker, dealer, underwriter or agent relating to the sale or distribution of the shares of our common stock offered by this prospectus.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We may from time to time file with the SEC one or more supplements to this prospectus or amendments to the registration statement that includes this prospectus to amend, supplement or update information contained in this prospectus, including, if and when required under the Securities Act, to disclose certain information relating to a particular sale of shares of our common stock offered by this prospectus by the selling stockholder, including the names of any brokers, dealers, underwriters or agents participating in the distribution of such shares of our common stock by the selling stockholder, any compensation paid by Lincoln Park to any such brokers, dealers, underwriters or agents, and any other required information.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We will pay the expenses incident to the registration under the Securities Act of the offer and sale of the shares of our common stock included in this prospectus by Lincoln Park. We estimate that the total expenses for the offering will be approximately $100,000. We have agreed to indemnify Lincoln Park and certain other persons against certain liabilities in connection with the offering of shares of our common stock offered by this prospectus, including liabilities arising under the Securities Act or, if such indemnity is unavailable, to contribute amounts required to be paid in respect of such liabilities. Lincoln Park has agreed to indemnify us against liabilities under the Securities Act that may arise from certain written information furnished to us by Lincoln Park specifically for use in this prospectus or, if such indemnity is unavailable, to contribute amounts required to be paid in respect of such liabilities.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      76
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Lincoln Park has represented to us that at no time prior to the Purchase Agreement has Lincoln Park or its agents, representatives or affiliates engaged in or effected, in any manner whatsoever, directly or indirectly, any short sale (as such term is defined in Rule 200 of Regulation SHO of the Exchange Act) of our common stock or any hedging transaction, which establishes a net short position with respect to our common stock. Lincoln Park agreed that during the term of the Purchase Agreement, it, its agents, representatives or affiliates will not enter into or effect, directly or indirectly, any of the foregoing transactions.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We have advised Lincoln Park that it is required to comply with Regulation M promulgated under the Exchange Act. With certain exceptions, Regulation M precludes the selling stockholder, any affiliated purchasers, and any broker-dealer or other person who participates in the distribution from bidding for or purchasing, or attempting to induce any person to bid for or purchase any security which is the subject of the distribution until the entire distribution is complete. Regulation M also prohibits any bids or purchases made in order to stabilize the price of a security in connection with the distribution of that security. All of the foregoing may affect the marketability of the securities offered by this prospectus.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">This offering will terminate on the date that all shares of our common stock offered by this prospectus have been sold by Lincoln Park.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Our common stock is listed on Nasdaq under the symbols &#8220;AMIX&#8221;.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      77
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="legal" href="#"></a>LEGAL MATTERS</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The validity of the securities offered hereby will be passed upon for us by ArentFox Schiff LLP, Washington, DC.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="expert" href="#"></a>EXPERTS</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The financial statements of Autonomix Medical, Inc. (the &#8220;Company&#8221;) as of March 31, 2025 and 2024 and for the fiscal years then ended, have been audited by Forvis Mazars, LLP, independent registered public accounting firm, as set forth in their report thereon, included in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended March 31, 2025, and included herein. Such financial statements have been included herein in reliance upon such report given on the authority of such firm as experts in accounting and auditing. The report of Forvis&#160;Mazars,&#160;LLP contains an explanatory paragraph regarding substantial doubt about the Company&#8217;s ability to continue as a going concern.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="where" href="#"></a>WHERE YOU CAN FIND MORE INFORMATION </b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We have filed with the SEC a registration statement on Form S-1 under the Securities Act for the securities being offered by this prospectus. This prospectus, which is part of the registration statement, does not contain all of the information included in the registration statement and the exhibits. For further information about us and the securities offered by this prospectus, you should refer to the registration statement and its exhibits. References in this prospectus to any of our contracts or other documents are not necessarily complete, and you should refer to the exhibits attached to the registration statement for copies of the actual contract or document. SEC filings are also available to the public at the SEC&#8217;s website at <i>www.sec.gov</i>.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We are subject to the reporting and information requirements of the Exchange Act and, as a result, we file periodic and current reports, proxy statements and other information with the SEC. We make our periodic reports and other information filed with or furnished to the SEC, available, free of charge, through our website as soon as reasonably practicable after those reports and other information are filed with or furnished to the SEC. Additionally, these periodic reports, proxy statements and other information are available at the SEC&#8217;s website at <i>www.sec.gov</i>.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      78
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <div>
   &#160;
  </div>
  <div>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="financials" href="#"></a>Index to Financial Statements</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
    <tbody>
     <tr>
      <td style="vertical-align:bottom;width:44%;">&#160;</td>
      <td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:2.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Page</b></p> </td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:44%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#audit_rpt" style="-sec-extract:exhibit;">Report of Independent Registered Public Accounting Firm</a></p> </td>
      <td style="vertical-align:bottom;width:2.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><a class="tocPGNUM" href="#audit_rpt">80</a></p> </td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:44%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#balsheet" style="-sec-extract:exhibit;">Balance Sheets as of March 31, 2025 and 2024</a></p> </td>
      <td style="vertical-align:bottom;width:2.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><a class="tocPGNUM" href="#balsheet">81</a></p> </td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:44%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#ops" style="-sec-extract:exhibit;">Statements of Operations for the years ended March 31, 2025 and 2024</a></p> </td>
      <td style="vertical-align:bottom;width:2.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><a class="tocPGNUM" href="#ops">82</a></p> </td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:44%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#equity" style="-sec-extract:exhibit;">Statements of Changes in Stockholders' Equity for the years ended March 31, 2025 and 2024</a></p> </td>
      <td style="vertical-align:bottom;width:2.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><a class="tocPGNUM" href="#equity">83</a></p> </td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:44%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#cashflow" style="-sec-extract:exhibit;">Statements of Cash Flows for the years ended March 31, 2025 and 2024</a></p> </td>
      <td style="vertical-align:bottom;width:2.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><a class="tocPGNUM" href="#cashflow">84</a></p> </td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:44%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#notes" style="-sec-extract:exhibit;">Notes to Financial Statements</a></p> </td>
      <td style="vertical-align:bottom;width:2.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><a class="tocPGNUM" href="#notes">85</a></p> </td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:44%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#ucbal" style="-sec-extract:exhibit;">Unaudited Condensed Balance Sheets as of June 30, 2025 and March 31, 2025</a></p> </td>
      <td style="vertical-align:bottom;width:2.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><a class="tocPGNUM" href="#ucbal">103</a></p> </td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:44%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#ucops" style="-sec-extract:exhibit;">Unaudited Condensed Statements of Operations for the three months ended June 30, 2025 and 2024</a></p> </td>
      <td style="vertical-align:bottom;width:2.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><a class="tocPGNUM" href="#ucops">104</a></p> </td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:44%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#ucequity" style="-sec-extract:exhibit;">Unaudited Condensed Statements of Stockholders&#8217;&#160;Equity for the three months ended June 30, 2025 and 2024</a></p> </td>
      <td style="vertical-align:bottom;width:2.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><a class="tocPGNUM" href="#ucequity">105</a></p> </td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:44%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#uccash" style="-sec-extract:exhibit;">Unaudited Condensed Statements of Cash Flows for the three months ended June 30, 2025 and 2024</a></p> </td>
      <td style="vertical-align:bottom;width:2.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><a class="tocPGNUM" href="#uccash">106</a></p> </td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:44%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#ucnotes" style="-sec-extract:exhibit;">Notes to the Unaudited Condensed Financial Statements</a></p> </td>
      <td style="vertical-align:bottom;width:2.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><a class="tocPGNUM" href="#ucnotes">107</a></p> </td>
     </tr>

    </tbody>
   </table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       79
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </div>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  </div>
  <div>
   &#160;
  </div>
  <div><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="audit_rpt" href="#"></a>Report of Independent Registered Public Accounting Firm</b></p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">To the Shareholders, Board of Directors, and Audit Committee</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Autonomix Medical, Inc.</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Opinion on the Financial Statements</i></b></p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We have audited the accompanying balance sheets of Autonomix Medical, Inc. (the &#8220;Company&#8221;) as of March&#160;31,&#160;2025 and 2024, the related statements of operations, changes in stockholders&#8217; equity, and cash flows for each of the years in the two-year period ended March 31, 2025, and the related notes (collectively referred to as the &#8220;financial statements&#8221;).&#160; In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of the Company as of March 31, 2025 and 2024, and the results of its operations and its cash flows for each of the years in the two-year period ended March 31, 2025, in conformity with accounting principles generally accepted in the United States of America.</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Going Concern</i></b></p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company has an accumulated deficit since inception, has not generated revenue from operations, and does not expect to experience positive cash flows from operating activities in the near term. These conditions raise substantial doubt about the Company&#8217;s ability to continue as a going concern. Management&#8217;s plans in regard to this matter are also described in Note 1. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Basis for Opinion</i></b></p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">These financial statements are the responsibility of the Company&#8217;s management.&#160;Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits.</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements.&#160;We believe that our audits provide a reasonable basis for our opinion.</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/ Forvis&#160;Mazars, LLP</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We have served as the Company&#8217;s auditor since 2022.</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Atlanta, Georgia</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">May 29, 2025</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
 <div class="PGFTR" style="text-align: center; width: 100%">
  <div class="hf-row">
   <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
    80
   </div>
  </div>
 </div>
 <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
 <div class="PGHDR" style="text-align: left; width: 100%">
  <div class="hf-row">
   <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
    <a style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;" href="#toc">Table of Contents</a>
   </div>
  </div>
 </div>
</div>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p></div>
  <div>
   &#160;
  </div>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="balsheet" href="#"></a>Autonomix Medical, Inc.</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Balance Sheets</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div>
   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>(in thousands, except par value and share data)</i></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">As of</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">March 31,</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2025</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2024</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>Assets</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Current assets:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Cash and cash equivalents</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563565" contextRef="i_2025-03-31" unitRef="USD" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" format="ixt:num-dot-decimal" decimals="-3">9,136</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563566" contextRef="i_2024-03-31" unitRef="USD" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" format="ixt:num-dot-decimal" decimals="-3">8,608</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Other current assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c134563567" contextRef="i_2025-03-31" unitRef="USD" name="us-gaap:OtherAssetsCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">473</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c134563568" contextRef="i_2024-03-31" unitRef="USD" name="us-gaap:OtherAssetsCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">783</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total current assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563569" contextRef="i_2025-03-31" unitRef="USD" name="us-gaap:AssetsCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">9,609</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563570" contextRef="i_2024-03-31" unitRef="USD" name="us-gaap:AssetsCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">9,391</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Long-term assets:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Fixed assets, net</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563571" contextRef="i_2025-03-31" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" format="ixt:num-dot-decimal" decimals="-3">21</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563572" contextRef="i_2024-03-31" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" format="ixt:num-dot-decimal" decimals="-3">16</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Deferred offering costs</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c134563573" contextRef="i_2025-03-31" unitRef="USD" name="us-gaap:DeferredCosts" scale="3" format="ixt:num-dot-decimal" decimals="-3">176</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c134563574" contextRef="i_2024-03-31" unitRef="USD" name="us-gaap:DeferredCosts" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total long-term assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c134563575" contextRef="i_2025-03-31" unitRef="USD" name="us-gaap:AssetsNoncurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">197</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c134563576" contextRef="i_2024-03-31" unitRef="USD" name="us-gaap:AssetsNoncurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">16</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Total Assets</b></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b><ix:nonFraction id="c134563577" contextRef="i_2025-03-31" unitRef="USD" name="us-gaap:Assets" scale="3" format="ixt:num-dot-decimal" decimals="-3">9,806</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b><ix:nonFraction id="c134563578" contextRef="i_2024-03-31" unitRef="USD" name="us-gaap:Assets" scale="3" format="ixt:num-dot-decimal" decimals="-3">9,407</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>Liabilities and Stockholders' Equity</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Current liabilities:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Accounts payable</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563579" contextRef="i_2025-03-31" unitRef="USD" name="us-gaap:AccountsPayableCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">676</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563580" contextRef="i_2024-03-31" unitRef="USD" name="us-gaap:AccountsPayableCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">492</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Accrued expenses</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c134563581" contextRef="i_2025-03-31" unitRef="USD" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,031</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c134563582" contextRef="i_2024-03-31" unitRef="USD" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">285</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total current liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563583" contextRef="i_2025-03-31" unitRef="USD" name="us-gaap:LiabilitiesCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,707</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563584" contextRef="i_2024-03-31" unitRef="USD" name="us-gaap:LiabilitiesCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">777</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Long-term liabilities:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Long term debt - convertible notes, net of unamortized debt discount</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c134563585" contextRef="i_2025-03-31" unitRef="USD" name="us-gaap:ConvertibleLongTermNotesPayable" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c134563586" contextRef="i_2024-03-31" unitRef="USD" name="us-gaap:ConvertibleLongTermNotesPayable" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,002</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total long-term liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c134563587" contextRef="i_2025-03-31" unitRef="USD" name="us-gaap:LiabilitiesNoncurrent" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c134563588" contextRef="i_2024-03-31" unitRef="USD" name="us-gaap:LiabilitiesNoncurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,002</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Total Liabilities</b></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&#160;</b></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b><ix:nonFraction id="c134563589" contextRef="i_2025-03-31" unitRef="USD" name="us-gaap:Liabilities" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,707</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&#160;</b></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b><ix:nonFraction id="c134563590" contextRef="i_2024-03-31" unitRef="USD" name="us-gaap:Liabilities" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,779</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Commitments and contingencies (Note 5)</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;<span style="-sec-ix-hidden:c134565227">&#160;</span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;<span style="-sec-ix-hidden:c134565228">&#160;</span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Stockholders' equity:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Preferred stock, $<span style="-sec-ix-hidden:c134565133"><span style="-sec-ix-hidden:c134565134">0.001</span></span> par value, <span style="-sec-ix-hidden:c134565135"><span style="-sec-ix-hidden:c134565136">10,000,000</span></span> shares authorized, <span style="-sec-ix-hidden:c134565137"><span style="-sec-ix-hidden:c134565139"><span style="-sec-ix-hidden:c134565138"><span style="-sec-ix-hidden:c134565140">no</span></span></span></span> shares issued and outstanding as of March 31, 2025 and March 31, 2024, respectively.</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563591" contextRef="i_2025-03-31" unitRef="USD" name="us-gaap:PreferredStockValue" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563592" contextRef="i_2024-03-31" unitRef="USD" name="us-gaap:PreferredStockValue" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Common stock, $<span style="-sec-ix-hidden:c134565141"><span style="-sec-ix-hidden:c134565142">0.001</span></span> par value, <span style="-sec-ix-hidden:c134565143"><span style="-sec-ix-hidden:c134565144">500,000,000</span></span> shares authorized, <span style="-sec-ix-hidden:c134565145"><span style="-sec-ix-hidden:c134565147">2,497,033</span></span> and <span style="-sec-ix-hidden:c134565146"><span style="-sec-ix-hidden:c134565148">942,575</span></span> shares issued and outstanding as of March 31, 2025 and March 31, 2024, respectively.</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563593" contextRef="i_2025-03-31" unitRef="USD" name="us-gaap:CommonStockValue" scale="3" format="ixt:num-dot-decimal" decimals="-3">2</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563594" contextRef="i_2024-03-31" unitRef="USD" name="us-gaap:CommonStockValue" scale="3" format="ixt:num-dot-decimal" decimals="-3">1</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Additional paid-in capital</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563595" contextRef="i_2025-03-31" unitRef="USD" name="us-gaap:AdditionalPaidInCapital" scale="3" format="ixt:num-dot-decimal" decimals="-3">58,476</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563596" contextRef="i_2024-03-31" unitRef="USD" name="us-gaap:AdditionalPaidInCapital" scale="3" format="ixt:num-dot-decimal" decimals="-3">46,596</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Accumulated deficit</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c134563597" contextRef="i_2025-03-31" unitRef="USD" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">50,379</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c134563598" contextRef="i_2024-03-31" unitRef="USD" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">38,969</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"><b>Total Stockholders' Equity</b></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&#160;</b></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b><ix:nonFraction id="c134563599" contextRef="i_2025-03-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">8,099</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&#160;</b></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b><ix:nonFraction id="c134563600" contextRef="i_2024-03-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">7,628</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Total Liabilities and Stockholders' Equity</b></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b><ix:nonFraction id="c134563601" contextRef="i_2025-03-31" unitRef="USD" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">9,806</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b><ix:nonFraction id="c134563602" contextRef="i_2024-03-31" unitRef="USD" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">9,407</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">See accompanying notes to the financial statements</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      81
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <div>
   &#160;
  </div>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="ops" href="#"></a>Autonomix Medical, Inc.</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Statements of Operations</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div>
   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">For the Years Ended</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">March 31,</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>(in thousands, except share and per share data)</i></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2025</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2024</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Operating expenses:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">General and administrative</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563611" contextRef="d_2024-04-01_2025-03-31" unitRef="USD" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">6,863</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563612" contextRef="d_2023-04-01_2024-03-31" unitRef="USD" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">5,249</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Research and development</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563613" contextRef="d_2024-04-01_2025-03-31" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">4,725</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563614" contextRef="d_2023-04-01_2024-03-31" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,225</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Warrant expense - termination agreement</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c134563615" contextRef="d_2024-04-01_2025-03-31" unitRef="USD" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="3" format="ixt:fixed-zero" decimals="-3" sign="-">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c134563616" contextRef="d_2023-04-01_2024-03-31" unitRef="USD" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">4,556</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total operating expenses</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c134563617" contextRef="d_2024-04-01_2025-03-31" unitRef="USD" name="us-gaap:OperatingExpenses" scale="3" format="ixt:num-dot-decimal" decimals="-3">11,588</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c134563618" contextRef="d_2023-04-01_2024-03-31" unitRef="USD" name="us-gaap:OperatingExpenses" scale="3" format="ixt:num-dot-decimal" decimals="-4">12,030</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Loss from operations</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c134563619" contextRef="d_2024-04-01_2025-03-31" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">11,588</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c134563620" contextRef="d_2023-04-01_2024-03-31" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-4" sign="-">12,030</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Other income (expense):</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Warrant liability - mark-to-market</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c134563621" contextRef="d_2024-04-01_2025-03-31" unitRef="USD" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" format="ixt:fixed-zero" decimals="-3" sign="-">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c134563622" contextRef="d_2023-04-01_2024-03-31" unitRef="USD" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" format="ixt:num-dot-decimal" decimals="-3">3,444</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Interest expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c134563623" contextRef="d_2024-04-01_2025-03-31" unitRef="USD" name="us-gaap:InterestExpenseNonoperating" scale="3" format="ixt:num-dot-decimal" decimals="-3">176</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c134563624" contextRef="d_2023-04-01_2024-03-31" unitRef="USD" name="us-gaap:InterestExpenseNonoperating" scale="3" format="ixt:num-dot-decimal" decimals="-3">79</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Interest income</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c134563625" contextRef="d_2024-04-01_2025-03-31" unitRef="USD" name="us-gaap:InvestmentIncomeInterest" scale="3" format="ixt:num-dot-decimal" decimals="-3">354</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c134563626" contextRef="d_2023-04-01_2024-03-31" unitRef="USD" name="us-gaap:InvestmentIncomeInterest" scale="3" format="ixt:num-dot-decimal" decimals="-3">127</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total other income (expense)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c134563627" contextRef="d_2024-04-01_2025-03-31" unitRef="USD" name="us-gaap:NonoperatingIncomeExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">178</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c134563628" contextRef="d_2023-04-01_2024-03-31" unitRef="USD" name="us-gaap:NonoperatingIncomeExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">3,396</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Loss before income taxes</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c134563629" contextRef="d_2024-04-01_2025-03-31" unitRef="USD" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" format="ixt:num-dot-decimal" decimals="-4" sign="-">11,410</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c134563630" contextRef="d_2023-04-01_2024-03-31" unitRef="USD" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">15,426</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Income taxes</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c134563631" contextRef="d_2024-04-01_2025-03-31" unitRef="USD" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c134563632" contextRef="d_2023-04-01_2024-03-31" unitRef="USD" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net loss</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c134563633" contextRef="d_2024-04-01_2025-03-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-4" sign="-">11,410</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c134563634" contextRef="d_2023-04-01_2024-03-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">15,426</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Loss per share - basic and diluted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c134563635" contextRef="d_2024-04-01_2025-03-31" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasic" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">6.46</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c134563636" contextRef="d_2023-04-01_2024-03-31" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasic" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">14.82</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Weighted average shares outstanding - basic and diluted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563637" contextRef="d_2024-04-01_2025-03-31" unitRef="Share" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,766,425</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563638" contextRef="d_2023-04-01_2024-03-31" unitRef="Share" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,040,720</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">See accompanying notes to the financial statements</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      82
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <div>
   &#160;
  </div>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="equity" href="#"></a>Autonomix Medical, Inc.</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Statements of Changes in Stockholders' Equity</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div>
   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Additional</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Total</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Common Stock</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Paid-in</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Accumulated</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Stockholders'</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 40%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>(in thousands)</i></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Shares</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Amount</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Capital</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Deficit</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Equity</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Balance March 31, 2023</b></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b><ix:nonFraction id="c134563641" contextRef="i_2023-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="3" format="ixt:num-dot-decimal" decimals="-3">617</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>$</b></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b><ix:nonFraction id="c134563642" contextRef="i_2023-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">1</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>$</b></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b><ix:nonFraction id="c134563643" contextRef="i_2023-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">24,186</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>$</b></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>(<ix:nonFraction id="c134563644" contextRef="i_2023-03-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">23,543</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>)</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>$</b></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b><ix:nonFraction id="c134563645" contextRef="i_2023-03-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">644</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net loss</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c134563647" contextRef="d_2023-04-01_2024-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c134563648" contextRef="d_2023-04-01_2024-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c134563649" contextRef="d_2023-04-01_2024-03-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">15,426</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c134563650" contextRef="d_2023-04-01_2024-03-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">15,426</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock-based compensation</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c134563652" contextRef="d_2023-04-01_2024-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563653" contextRef="d_2023-04-01_2024-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" format="ixt:num-dot-decimal" decimals="-3">618</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c134563654" contextRef="d_2023-04-01_2024-03-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563655" contextRef="d_2023-04-01_2024-03-31" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" format="ixt:num-dot-decimal" decimals="-3">618</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Issuance of common stock</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563656" contextRef="d_2023-04-01_2024-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="3" format="ixt:num-dot-decimal" decimals="-3">105</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c134563657" contextRef="d_2023-04-01_2024-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563658" contextRef="d_2023-04-01_2024-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:num-dot-decimal" decimals="-4">2,840</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c134563659" contextRef="d_2023-04-01_2024-03-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563660" contextRef="d_2023-04-01_2024-03-31" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:num-dot-decimal" decimals="-4">2,840</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Issuance of common stock from IPO, net of costs</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563661" contextRef="d_2023-04-01_2024-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="amix:StockIssuedDuringPeriodSharesInitialPublicOffering" scale="3" format="ixt:num-dot-decimal" decimals="-3">111</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c134563662" contextRef="d_2023-04-01_2024-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="amix:StockIssuedDuringPeriodValueInitialPublicOffering" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563663" contextRef="d_2023-04-01_2024-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="amix:StockIssuedDuringPeriodValueInitialPublicOffering" scale="3" format="ixt:num-dot-decimal" decimals="-3">9,875</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c134563664" contextRef="d_2023-04-01_2024-03-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="amix:StockIssuedDuringPeriodValueInitialPublicOffering" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563665" contextRef="d_2023-04-01_2024-03-31" unitRef="USD" name="amix:StockIssuedDuringPeriodValueInitialPublicOffering" scale="3" format="ixt:num-dot-decimal" decimals="-3">9,875</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Issuance of common stock for extinguishment of convertible debt</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563666" contextRef="d_2023-04-01_2024-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="3" format="ixt:num-dot-decimal" decimals="-3">17</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c134563667" contextRef="d_2023-04-01_2024-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563668" contextRef="d_2023-04-01_2024-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" format="ixt:num-dot-decimal" decimals="-5">500</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c134563669" contextRef="d_2023-04-01_2024-03-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563670" contextRef="d_2023-04-01_2024-03-31" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" format="ixt:num-dot-decimal" decimals="-5">500</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Issuance of common stock - warrants exercised</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563671" contextRef="d_2023-04-01_2024-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="amix:StockIssuedDuringPeriodSharesWarrantsExercised" scale="3" format="ixt:num-dot-decimal" decimals="-3">91</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c134563672" contextRef="d_2023-04-01_2024-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="amix:StockIssuedDuringPeriodValueWarrantsExercised" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c134563673" contextRef="d_2023-04-01_2024-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="amix:StockIssuedDuringPeriodValueWarrantsExercised" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c134563674" contextRef="d_2023-04-01_2024-03-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="amix:StockIssuedDuringPeriodValueWarrantsExercised" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c134563675" contextRef="d_2023-04-01_2024-03-31" unitRef="USD" name="amix:StockIssuedDuringPeriodValueWarrantsExercised" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Issuance of restricted common stock</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563676" contextRef="d_2023-04-01_2024-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="3" format="ixt:num-dot-decimal" decimals="-3">2</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c134563677" contextRef="d_2023-04-01_2024-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c134563678" contextRef="d_2023-04-01_2024-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c134563679" contextRef="d_2023-04-01_2024-03-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c134563680" contextRef="d_2023-04-01_2024-03-31" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Warrants issued for debt issuance costs</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c134563682" contextRef="d_2023-04-01_2024-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563683" contextRef="d_2023-04-01_2024-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" format="ixt:num-dot-decimal" decimals="-3">577</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c134563684" contextRef="d_2023-04-01_2024-03-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563685" contextRef="d_2023-04-01_2024-03-31" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" format="ixt:num-dot-decimal" decimals="-3">577</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Fair value of warrants issued - termination agreement</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c134563687" contextRef="d_2023-04-01_2024-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="amix:WarrantsIssuedFairValueIssuedForTerminationAgreement" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c134563688" contextRef="d_2023-04-01_2024-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="amix:WarrantsIssuedFairValueIssuedForTerminationAgreement" scale="3" format="ixt:num-dot-decimal" decimals="-6">8,000</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c134563689" contextRef="d_2023-04-01_2024-03-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="amix:WarrantsIssuedFairValueIssuedForTerminationAgreement" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c134563690" contextRef="d_2023-04-01_2024-03-31" unitRef="USD" name="amix:WarrantsIssuedFairValueIssuedForTerminationAgreement" scale="3" format="ixt:num-dot-decimal" decimals="-6">8,000</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Balance March 31, 2024</b></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"><b>&#160;</b></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b><ix:nonFraction id="c134563691" contextRef="i_2024-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="3" format="ixt:num-dot-decimal" decimals="-3">943</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"><b>&#160;</b></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b><ix:nonFraction id="c134563692" contextRef="i_2024-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">1</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"><b>&#160;</b></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b><ix:nonFraction id="c134563693" contextRef="i_2024-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">46,596</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"><b>&#160;</b></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>(<ix:nonFraction id="c134563694" contextRef="i_2024-03-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">38,969</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"><b>)</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"><b>&#160;</b></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b><ix:nonFraction id="c134563695" contextRef="i_2024-03-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">7,628</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net loss</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c134563697" contextRef="d_2024-04-01_2025-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c134563698" contextRef="d_2024-04-01_2025-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c134563699" contextRef="d_2024-04-01_2025-03-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-4" sign="-">11,410</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c134563700" contextRef="d_2024-04-01_2025-03-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-4" sign="-">11,410</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock-based compensation</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c134563702" contextRef="d_2024-04-01_2025-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563703" contextRef="d_2024-04-01_2025-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,628</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c134563704" contextRef="d_2024-04-01_2025-03-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563705" contextRef="d_2024-04-01_2025-03-31" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,628</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Issuance of common stock</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563706" contextRef="d_2024-04-01_2025-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="3" format="ixt:num-dot-decimal" decimals="-3">13</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c134563707" contextRef="d_2024-04-01_2025-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563708" contextRef="d_2024-04-01_2025-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:num-dot-decimal" decimals="-3">103</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c134563709" contextRef="d_2024-04-01_2025-03-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563710" contextRef="d_2024-04-01_2025-03-31" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:num-dot-decimal" decimals="-3">103</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Issuance of common stock - warrants exercised</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563711" contextRef="d_2024-04-01_2025-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="amix:StockIssuedDuringPeriodSharesWarrantsExercised" scale="3" format="ixt:num-dot-decimal" decimals="-3">892</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563712" contextRef="d_2024-04-01_2025-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="amix:StockIssuedDuringPeriodValueWarrantsExercised" scale="3" format="ixt:num-dot-decimal" decimals="-3">1</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c134563713" contextRef="d_2024-04-01_2025-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="amix:StockIssuedDuringPeriodValueWarrantsExercised" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c134563714" contextRef="d_2024-04-01_2025-03-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="amix:StockIssuedDuringPeriodValueWarrantsExercised" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563715" contextRef="d_2024-04-01_2025-03-31" unitRef="USD" name="amix:StockIssuedDuringPeriodValueWarrantsExercised" scale="3" format="ixt:num-dot-decimal" decimals="-3">1</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Issuance of common shares and equity classified warrants, net of offering costs</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563716" contextRef="d_2024-04-01_2025-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="amix:StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants" scale="3" format="ixt:num-dot-decimal" decimals="-3">616</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c134563717" contextRef="d_2024-04-01_2025-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="amix:StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563718" contextRef="d_2024-04-01_2025-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="amix:StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants" scale="3" format="ixt:num-dot-decimal" decimals="-3">8,972</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c134563719" contextRef="d_2024-04-01_2025-03-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="amix:StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563720" contextRef="d_2024-04-01_2025-03-31" unitRef="USD" name="amix:StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants" scale="3" format="ixt:num-dot-decimal" decimals="-3">8,972</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Issuance of common stock for extinguishment of convertible debt</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c134563721" contextRef="d_2024-04-01_2025-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="3" format="ixt:num-dot-decimal" decimals="-3">33</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c134563722" contextRef="d_2024-04-01_2025-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c134563723" contextRef="d_2024-04-01_2025-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,177</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c134563724" contextRef="d_2024-04-01_2025-03-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c134563725" contextRef="d_2024-04-01_2025-03-31" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,177</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Balance March 31, 2025</b></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"><b>&#160;</b></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b><ix:nonFraction id="c134563726" contextRef="i_2025-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,497</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b><ix:nonFraction id="c134563727" contextRef="i_2025-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">2</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b><ix:nonFraction id="c134563728" contextRef="i_2025-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">58,476</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>(<ix:nonFraction id="c134563729" contextRef="i_2025-03-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">50,379</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"><b>)</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b><ix:nonFraction id="c134563730" contextRef="i_2025-03-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">8,099</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">See accompanying notes to the financial statements</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      83
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <div>
   &#160;
  </div>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="cashflow" href="#"></a>Autonomix Medical, Inc.</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Statements of Cash Flows</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div>
   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">For the Years Ended March 31,</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>(in thousands)</i></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2025</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2024</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Cash Flows from Operating Activities:</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net loss</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c134563731" contextRef="d_2024-04-01_2025-03-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-4" sign="-">11,410</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c134563732" contextRef="d_2023-04-01_2024-03-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">15,426</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Adjustments to reconcile net loss to net cash used in operating activities:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Stock-based compensation</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563733" contextRef="d_2024-04-01_2025-03-31" unitRef="USD" name="us-gaap:ShareBasedCompensation" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,628</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563734" contextRef="d_2023-04-01_2024-03-31" unitRef="USD" name="us-gaap:ShareBasedCompensation" scale="3" format="ixt:num-dot-decimal" decimals="-3">618</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Depreciation and amortization expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563735" contextRef="d_2024-04-01_2025-03-31" unitRef="USD" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" format="ixt:num-dot-decimal" decimals="-3">183</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563736" contextRef="d_2023-04-01_2024-03-31" unitRef="USD" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" format="ixt:num-dot-decimal" decimals="-3">81</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Issuance of common stock, net of discount for lack of marketability</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563737" contextRef="d_2024-04-01_2025-03-31" unitRef="USD" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" scale="3" format="ixt:num-dot-decimal" decimals="-3">101</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c134563738" contextRef="d_2023-04-01_2024-03-31" unitRef="USD" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Warrant expense - termination agreement</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c134563739" contextRef="d_2024-04-01_2025-03-31" unitRef="USD" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="3" format="ixt:fixed-zero" decimals="-3" sign="-">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563740" contextRef="d_2023-04-01_2024-03-31" unitRef="USD" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">4,556</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Warrant liability - mark-to-market</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c134563741" contextRef="d_2024-04-01_2025-03-31" unitRef="USD" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563742" contextRef="d_2023-04-01_2024-03-31" unitRef="USD" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" format="ixt:num-dot-decimal" decimals="-3">3,444</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Changes in operating assets - (increase)/decrease:</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Other current assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563743" contextRef="d_2024-04-01_2025-03-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" scale="3" format="ixt:num-dot-decimal" decimals="-4" sign="-">310</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c134563744" contextRef="d_2023-04-01_2024-03-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" scale="3" format="ixt:num-dot-decimal" decimals="-3">478</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Changes in operating liabilities - increase:</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Accounts payable</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563745" contextRef="d_2024-04-01_2025-03-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" scale="3" format="ixt:num-dot-decimal" decimals="-3">184</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563746" contextRef="d_2023-04-01_2024-03-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" scale="3" format="ixt:num-dot-decimal" decimals="-4">320</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Accrued expenses</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c134563747" contextRef="d_2024-04-01_2025-03-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" format="ixt:num-dot-decimal" decimals="-3">746</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c134563748" contextRef="d_2023-04-01_2024-03-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" format="ixt:num-dot-decimal" decimals="-3">237</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Net cash used in operating activities</b></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>(<ix:nonFraction id="c134563749" contextRef="d_2024-04-01_2025-03-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">8,258</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>)</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>(<ix:nonFraction id="c134563750" contextRef="d_2023-04-01_2024-03-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">6,648</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>)</b></td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Cash Flows from Investing Activities:</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Purchase of property and equipment</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c134563751" contextRef="d_2024-04-01_2025-03-31" unitRef="USD" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" format="ixt:num-dot-decimal" decimals="-3">14</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c134563752" contextRef="d_2023-04-01_2024-03-31" unitRef="USD" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" format="ixt:num-dot-decimal" decimals="-3">19</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Net cash used in investing activities</b></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>(<ix:nonFraction id="c134563753" contextRef="d_2024-04-01_2025-03-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">14</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>)</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c134563754" contextRef="d_2023-04-01_2024-03-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">19</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Cash Flows from Financing Activities (increase/decrease):</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Issuance of common stock, pre-funded and common warrants</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563755" contextRef="d_2024-04-01_2025-03-31" unitRef="USD" name="amix:ProceedsFromIssuanceOfCommonStockAndWarrants" scale="3" format="ixt:num-dot-decimal" decimals="-3">10,025</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c134563756" contextRef="d_2023-04-01_2024-03-31" unitRef="USD" name="amix:ProceedsFromIssuanceOfCommonStockAndWarrants" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Payment of issuance costs for financing</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c134563757" contextRef="d_2024-04-01_2025-03-31" unitRef="USD" name="us-gaap:PaymentsOfFinancingCosts" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,052</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c134563758" contextRef="d_2023-04-01_2024-03-31" unitRef="USD" name="us-gaap:PaymentsOfFinancingCosts" scale="3" format="ixt:fixed-zero" decimals="-3" sign="-">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Payment of issuance costs for registration statement</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c134563759" contextRef="d_2024-04-01_2025-03-31" unitRef="USD" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" format="ixt:num-dot-decimal" decimals="-3">176</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c134563760" contextRef="d_2023-04-01_2024-03-31" unitRef="USD" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" format="ixt:fixed-zero" decimals="-3" sign="-">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Proceeds from exercise of warrants</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563761" contextRef="d_2024-04-01_2025-03-31" unitRef="USD" name="us-gaap:ProceedsFromWarrantExercises" scale="3" format="ixt:num-dot-decimal" decimals="-3">1</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c134563762" contextRef="d_2023-04-01_2024-03-31" unitRef="USD" name="us-gaap:ProceedsFromWarrantExercises" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Proceeds from sales of common stock</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563763" contextRef="d_2024-04-01_2025-03-31_SubsidiarySaleOfStockAxis-ATMAgreementMember" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" format="ixt:num-dot-decimal" decimals="-3">2</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c134563764" contextRef="d_2023-04-01_2024-03-31_SubsidiarySaleOfStockAxis-ATMAgreementMember" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Issuance of common stock</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c134563765" contextRef="d_2024-04-01_2025-03-31_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563766" contextRef="d_2023-04-01_2024-03-31_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" format="ixt:num-dot-decimal" decimals="-4">2,840</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Issuance of convertible debt</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c134563767" contextRef="d_2024-04-01_2025-03-31" unitRef="USD" name="us-gaap:ProceedsFromConvertibleDebt" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563768" contextRef="d_2023-04-01_2024-03-31" unitRef="USD" name="us-gaap:ProceedsFromConvertibleDebt" scale="3" format="ixt:num-dot-decimal" decimals="-6">2,000</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Issuance of common stock from IPO</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c134563769" contextRef="d_2024-04-01_2025-03-31" unitRef="USD" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563770" contextRef="d_2023-04-01_2024-03-31" unitRef="USD" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" scale="3" format="ixt:num-dot-decimal" decimals="-3">10,866</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Payment of issuance costs for IPO</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c134563771" contextRef="d_2024-04-01_2025-03-31" unitRef="USD" name="amix:PaymentsForInitialPublicOfferingIssuanceCosts" scale="3" format="ixt:fixed-zero" decimals="-3" sign="-">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c134563772" contextRef="d_2023-04-01_2024-03-31" unitRef="USD" name="amix:PaymentsForInitialPublicOfferingIssuanceCosts" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,296</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Net cash provided by financing activities</b></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b><ix:nonFraction id="c134563773" contextRef="d_2024-04-01_2025-03-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" format="ixt:num-dot-decimal" decimals="-5">8,800</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563774" contextRef="d_2023-04-01_2024-03-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" format="ixt:num-dot-decimal" decimals="-4">14,410</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net change in cash and cash equivalents</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563775" contextRef="d_2024-04-01_2025-03-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" format="ixt:num-dot-decimal" decimals="-3">528</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563776" contextRef="d_2023-04-01_2024-03-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" format="ixt:num-dot-decimal" decimals="-3">7,743</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Cash and cash equivalents, at beginning of period</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c134563777" contextRef="i_2024-03-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" format="ixt:num-dot-decimal" decimals="-3">8,608</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c134563778" contextRef="i_2023-03-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" format="ixt:num-dot-decimal" decimals="-3">865</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Cash and cash equivalents, at end of period</b></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b><ix:nonFraction id="c134563779" contextRef="i_2025-03-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" format="ixt:num-dot-decimal" decimals="-3">9,136</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b><ix:nonFraction id="c134563780" contextRef="i_2024-03-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" format="ixt:num-dot-decimal" decimals="-3">8,608</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><span style="text-decoration: underline; ">Supplemental cash flow disclosures:</span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Non-cash financing activities:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Warrants issued for equity issuance costs</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563781" contextRef="d_2024-04-01_2025-03-31" unitRef="USD" name="amix:WarrantsIssuedForEquityCosts" scale="3" format="ixt:num-dot-decimal" decimals="-3">479</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c134563782" contextRef="d_2023-04-01_2024-03-31" unitRef="USD" name="amix:WarrantsIssuedForEquityCosts" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Proceeds from cashless exercise of warrants</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563783" contextRef="d_2024-04-01_2025-03-31" unitRef="USD" name="us-gaap:StockIssued1" scale="3" format="ixt:num-dot-decimal" decimals="-3">39</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563784" contextRef="d_2023-04-01_2024-03-31" unitRef="USD" name="us-gaap:StockIssued1" scale="3" format="ixt:num-dot-decimal" decimals="-3">2</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Warrants issued for debt issuance costs</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c134563785" contextRef="d_2024-04-01_2025-03-31" unitRef="USD" name="amix:WarrantsIssuedForDebtIssuanceCosts" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563786" contextRef="d_2023-04-01_2024-03-31" unitRef="USD" name="amix:WarrantsIssuedForDebtIssuanceCosts" scale="3" format="ixt:num-dot-decimal" decimals="-3">577</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Fair value of warrants issued for issuance costs as part of IPO</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c134563787" contextRef="d_2024-04-01_2025-03-31" unitRef="USD" name="amix:ClassOfWarrantOrRightFairValueIssuedForIssuanceCostsFromIpo" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563788" contextRef="d_2023-04-01_2024-03-31" unitRef="USD" name="amix:ClassOfWarrantOrRightFairValueIssuedForIssuanceCostsFromIpo" scale="3" format="ixt:num-dot-decimal" decimals="-3">225</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Holdback of IPO proceeds</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c134563789" contextRef="d_2024-04-01_2025-03-31" unitRef="USD" name="amix:IpoProceedsHoldbackProvision" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563790" contextRef="d_2023-04-01_2024-03-31" unitRef="USD" name="amix:IpoProceedsHoldbackProvision" scale="3" format="ixt:num-dot-decimal" decimals="-3">305</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Convertible notes converted into common stock</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563791" contextRef="d_2024-04-01_2025-03-31_DebtConversionByUniqueDescriptionAxis-IssuanceOfCommonStockForExtinguishmentOfConvertibleDebtMember" unitRef="USD" name="us-gaap:DebtConversionOriginalDebtAmount1" scale="3" format="ixt:num-dot-decimal" decimals="-4">1,330</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563792" contextRef="d_2023-04-01_2024-03-31_DebtConversionByUniqueDescriptionAxis-IssuanceOfCommonStockForExtinguishmentOfConvertibleDebtMember" unitRef="USD" name="us-gaap:DebtConversionOriginalDebtAmount1" scale="3" format="ixt:num-dot-decimal" decimals="-4">670</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Settlement/conversion to common shares for debt issuance costs</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c134563793" contextRef="d_2024-04-01_2025-03-31_DebtConversionByUniqueDescriptionAxis-IssuanceOfCommonStockForExtinguishmentOfConvertibleDebtMember" unitRef="USD" name="amix:DebtConversionDebtIssuanceCostsConvertedCommonShares" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">153</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c134563794" contextRef="d_2023-04-01_2024-03-31_DebtConversionByUniqueDescriptionAxis-IssuanceOfCommonStockForExtinguishmentOfConvertibleDebtMember" unitRef="USD" name="amix:DebtConversionDebtIssuanceCostsConvertedCommonShares" scale="3" format="ixt:num-dot-decimal" decimals="-4" sign="-">170</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
</tbody></table>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">See accompanying notes to the financial statements</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      84
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="notes" href="#"></a>Autonomix Medical, Inc.</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Notes to the Financial Statements</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div>
   &#160;
  </div>
  <ix:nonNumeric contextRef="d_2024-04-01_2025-03-31" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" id="c3016953" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Note <em style="font: inherit;">1</em> </b>&#8211;<b> Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies </b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Description of the Business</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Autonomix Medical, Inc (&#8220;we,&#8221; &#8220;our,&#8221; the &#8220;Company&#8221;) is a medical device company organized as a Delaware corporation on <em style="font: inherit;"> June 10, 2014. </em>The Company is a pre-revenue, clinical stage life sciences company focused on advancing innovative technologies for sensing and treating disorders relating to the peripheral nervous system.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <ix:nonNumeric contextRef="d_2024-04-01_2025-03-31" name="amix:ReverseStockSplitPolicyTextBlock" id="c134565403" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Reverse Stock Split</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company&#160;held its annual meeting of stockholders (the "Annual Meeting") on&#160;<em style="font: inherit;"> October 17, 2024</em><i>.</i>&#160;In that Annual Meeting, stockholders of the Company approved an amendment to the Company&#8217;s amended and restated certificate of incorporation (the "Amendment&#8221;) to effect the reverse stock split at a ratio in the range of&#160;<em style="font: inherit;">1</em>-for-<ix:nonFraction id="c134564306" contextRef="d_2024-10-17_2024-10-17_NonmonetaryTransactionTypeAxis-ReverseStockSplitMember_RangeAxis-MinimumMember" unitRef="Pure" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" format="ixt:num-dot-decimal" decimals="INF">2</ix:nonFraction>&#160;to&#160;<em style="font: inherit;">1</em>-for-<ix:nonFraction id="c134564308" contextRef="d_2024-10-17_2024-10-17_NonmonetaryTransactionTypeAxis-ReverseStockSplitMember_RangeAxis-MaximumMember" unitRef="Pure" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" format="ixt:num-dot-decimal" decimals="INF">50</ix:nonFraction>, with such ratio to be determined in the discretion of the Company&#8217;s board of directors and with such reverse stock split to be effected at such time and date, if at all, as determined by the Company&#8217;s board of directors in its sole discretion prior to the&#160;<em style="font: inherit;">one</em>-year anniversary of the Annual Meeting.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Pursuant to such authority granted by the Company&#8217;s stockholders, the Company&#8217;s board of directors approved a&#160;<em style="font: inherit;">one</em>-for-&#160;<span style="-sec-ix-hidden:c134564311">twenty</span>&#160;(<em style="font: inherit;">1:20</em>) reverse stock split (the "Reverse Stock Split&#8221;) of the Company&#8217;s common stock and the filing of the Amendment to effectuate the Reverse Stock Split. The Amendment was filed with the Secretary of State of the State of Delaware and the Reverse Stock Split became effective in accordance with the terms of the Amendment at&#160;<em style="font: inherit;">11:59</em>&#160;p.m. Eastern Time on&#160;<em style="font: inherit;"> October 24, 2024 (</em>the "Effective Time&#8221;), and the Company&#8217;s common stock opened&#160;for trading on The Nasdaq Capital Market on&#160;<em style="font: inherit;"> October 25, 2024&#160;</em>on a post-split basis, under the existing ticker symbol "AMIX&#8221; but with a new CUSIP number&#160;<em style="font: inherit;">05330T205.</em>&#160;The Amendment provided that, at the Effective Time, every&#160;<span style="-sec-ix-hidden:c134564315">twenty</span>&#160;shares of the Company&#8217;s issued and outstanding common stock automatically combined into&#160;<em style="font: inherit;">one</em>&#160;issued and outstanding share of common stock, without any change in par value per share, which remained $<ix:nonFraction id="c134564317" contextRef="i_2024-10-24" unitRef="USDPerShare" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.001</ix:nonFraction>.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The number of authorized shares of common stock remained&#160;at&#160;<ix:nonFraction id="c134564318" contextRef="i_2024-10-24" unitRef="Share" name="us-gaap:CommonStockSharesAuthorized" scale="6" format="ixt:num-dot-decimal" decimals="-8">500</ix:nonFraction>&#160;million shares. As a result of the Reverse Stock Split, proportionate adjustments were made to the per share exercise price and/or the number of shares issuable upon the exercise or vesting of all outstanding stock options, restricted stock unit awards, warrants and convertible notes, which resulted in a proportional decrease in the number of shares of the Company&#8217;s common stock reserved for issuance upon exercise or vesting of such stock options, restricted stock unit awards, warrants and convertible notes and, in the case of stock options and warrants, a proportional increase in the exercise price of all such stock options and warrants.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company&#8217;s stock option awards did <em style="font: inherit;">not</em> automatically adjust for the Reverse Stock Split.&#160;However, the Company chose to exercise its rights under the agreements to adjust the exercise price and number of shares exercisable or issuable upon vesting proportionately for the Reverse Stock Split.&#160;Based on the analysis performed, the Company does <em style="font: inherit;">not</em> need to recognize any additional compensation expense as a result of the modification.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">In addition, the number of shares reserved for issuance under the Company&#8217;s equity compensation plan immediately prior to the Effective Time was reduced proportionately.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><em style="font: inherit;">No</em>&#160;fractional shares were issued as a result of the Reverse Stock Split. Any stockholder who would have been entitled to receive a fractional share as a result of the process was entitled to the rounding up of the fractional share to the nearest whole number. See "&#160;Fractional Shares" in Note&#160;<em style="font: inherit;">5</em>&#160;for further disclosure regarding fractional shares.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Reverse Stock Split has been retroactively adjusted throughout these interim financial statements and footnotes for all periods presented, including exercise prices and share data. As a result of the Reverse Stock Split, the Company reclassified approximately $<ix:nonFraction id="c134564323" contextRef="d_2024-10-24_2024-10-24" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit" scale="3" format="ixt:num-dot-decimal" decimals="-3">18</ix:nonFraction>&#160;thousand between common stock par value and additional paid-in capital.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p></ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <ix:nonNumeric contextRef="d_2024-04-01_2025-03-31" name="amix:SubstantialDoubtAboutGoingConcernPolicyPolicyTextBlock" id="c134565404" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Liquidity and Going Concern</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company's&#65279; financial statements are prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The Company is an early-stage company that is subject to all the risks associated with early-stage and emerging growth companies and has incurred losses since inception.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
    <ix:exclude>
     <div class="PGFTR" style="text-align: center; width: 100%">
      <div class="hf-row">
       <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
        <em style="font: inherit;">85</em>
       </div>
      </div>
     </div>
     <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
     <div class="PGHDR" style="text-align: left; width: 100%">
      <div class="hf-row">
       <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
        <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
       </div>
      </div>
     </div>
    </ix:exclude> <ix:exclude>&#160;</ix:exclude> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">For the years ended <em style="font: inherit;"> March 31, 2025 </em>and <em style="font: inherit;">2024,</em> the Company has net losses of approximately $<ix:nonFraction id="c134564326" contextRef="d_2024-04-01_2025-03-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="6" format="ixt:num-dot-decimal" decimals="-5" sign="-">11.4</ix:nonFraction> million and $<ix:nonFraction id="c134564327" contextRef="d_2023-04-01_2024-03-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="6" format="ixt:num-dot-decimal" decimals="-5" sign="-">15.4</ix:nonFraction> million, respectively and had net cash flows used in operating activities of $<ix:nonFraction id="c134564328" contextRef="d_2024-04-01_2025-03-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" format="ixt:num-dot-decimal" decimals="-5" sign="-">8.3</ix:nonFraction>&#160;million&#160;and $<ix:nonFraction id="c134564329" contextRef="d_2023-04-01_2024-03-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" format="ixt:num-dot-decimal" decimals="-5" sign="-">6.6</ix:nonFraction> million, respectively. The Company had <ix:nonFraction id="c134564330" contextRef="d_2024-04-01_2025-03-31" unitRef="USD" name="us-gaap:Revenues" scale="6" format="ixt-sec:numwordsen" decimals="-3">no</ix:nonFraction> revenues for the years ended <em style="font: inherit;"> March 31, 2025 </em>and <em style="font: inherit;">2024,</em> respectively. The Company had an accumulated deficit of $<ix:nonFraction id="c134564332" contextRef="i_2025-03-31" unitRef="USD" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" format="ixt:num-dot-decimal" decimals="-5" sign="-">50.4</ix:nonFraction> million and working capital of approximately $<ix:nonFraction id="c134564333" contextRef="i_2025-03-31" unitRef="USD" name="amix:WorkingCapitalDeficit" scale="6" format="ixt:num-dot-decimal" decimals="-5">7.9</ix:nonFraction> million as of <em style="font: inherit;"> March 31, 2025. </em>The Company does <em style="font: inherit;">not</em> expect to generate positive cash flows from operating activities in the near future. These conditions, and the Company's ability to comply with such conditions, raise substantial doubt about the Company's ability to continue as a going concern within <em style="font: inherit;">one</em> year after the date that the financial statements are issued. The accompanying financial statements have been prepared on a going concern basis and do <em style="font: inherit;">not</em> include any adjustments that might be necessary if the Company is unable to continue as a going concern.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> January 26, 2024, </em>the Company completed its IPO, pursuant to which it sold a total of <ix:nonFraction id="c134564337" contextRef="d_2024-01-26_2024-01-26_SubsidiarySaleOfStockAxis-IPOMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:num-dot-decimal" decimals="INF">111,962</ix:nonFraction>&#160;shares of common stock at a purchase price of $<ix:nonFraction id="c134564338" contextRef="i_2024-01-26_SubsidiarySaleOfStockAxis-IPOMember" unitRef="USDPerShare" name="us-gaap:SharesIssuedPricePerShare" scale="0" format="ixt:num-dot-decimal" decimals="INF">100.00</ix:nonFraction> per share for gross proceeds of $<ix:nonFraction id="c134564339" contextRef="d_2024-01-26_2024-01-26_SubsidiarySaleOfStockAxis-IPOMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" format="ixt:num-dot-decimal" decimals="-5">11.2</ix:nonFraction> million and net proceeds of $<ix:nonFraction id="c134564340" contextRef="d_2024-01-26_2024-01-26_SubsidiarySaleOfStockAxis-IPOMember" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" format="ixt:num-dot-decimal" decimals="-5">9.8</ix:nonFraction> million.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> November 22, 2024, </em>the Company completed a firm commitment underwritten public offering (the &#8220;Offering&#8221;) of: (i) <ix:nonFraction id="c134564341" contextRef="d_2024-11-22_2024-11-25_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember" unitRef="Share" name="amix:NumberOfCommonUnitsIssued" scale="0" format="ixt:num-dot-decimal" decimals="INF">458,691</ix:nonFraction> common units (the &#8220;Common Units&#8221;), each Common Unit consisting of <span style="-sec-ix-hidden:c134564342">one</span> share of Company common stock and <span style="-sec-ix-hidden:c134564343">one</span> series A warrant to purchase <span style="-sec-ix-hidden:c134564344">one</span> share of common stock (the &#8220;Series A Warrants&#8221;); and (ii) <ix:nonFraction id="c134564345" contextRef="d_2024-11-22_2024-11-25_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember" unitRef="Share" name="amix:NumberOfPrefundedUnitsIssued" scale="0" format="ixt:num-dot-decimal" decimals="INF">917,596</ix:nonFraction> pre-funded units (the &#8220;Pre-Funded Units&#8221;) and together with the Common Units, the "Units", each Pre-Funded Unit consisting of <span style="-sec-ix-hidden:c134564346">one</span> pre-funded warrant to purchase <span style="-sec-ix-hidden:c134564347">one</span> share of common stock (the &#8220;Pre-Funded Warrant&#8221;) and <span style="-sec-ix-hidden:c134564348">one</span> Series A Warrant. The purchase price of each Common Unit was $<ix:nonFraction id="c134564349" contextRef="d_2024-11-22_2024-11-25_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember" unitRef="USDPerShare" name="amix:CommonUnitsIssuedPurchasePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">6.540</ix:nonFraction>, and the purchase price of each Pre-Funded Unit was $<ix:nonFraction id="c134564350" contextRef="d_2024-11-22_2024-11-25_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember" unitRef="USDPerShare" name="amix:PrefundedUnitsIssuedPurchasePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">6.539</ix:nonFraction>.&#160;In addition, the Company granted the underwriters in the Offering a <ix:nonNumeric contextRef="d_2024-11-22_2024-11-22_CounterpartyNameAxis-UnderwritersMember_SubsidiarySaleOfStockAxis-OverAllotmentOptionMember" name="amix:EquityOfferingOptionPeriod" id="c134564351" format="ixt-sec:durday">45</ix:nonNumeric>-day option to purchase an additional <ix:nonFraction id="c134564352" contextRef="i_2024-11-22_CounterpartyNameAxis-UnderwritersMember_SubsidiarySaleOfStockAxis-OverAllotmentOptionMember" unitRef="Share" name="amix:EquityOfferingOptionMaximumShares" scale="0" format="ixt:num-dot-decimal" decimals="INF">206,422</ix:nonFraction> shares of common stock, and/or an additional <ix:nonFraction id="c134564353" contextRef="i_2024-11-22_ClassOfWarrantOrRightAxis-SeriesAWarrantsMember_CounterpartyNameAxis-UnderwritersMember" unitRef="Share" name="amix:EquityOfferingOptionMaximumWarrants" scale="0" format="ixt:num-dot-decimal" decimals="INF">206,422</ix:nonFraction> Series A Warrants, solely to cover over-allotments, if any. The Pre-Funded Warrants have an exercise price of $<ix:nonFraction id="c134564354" contextRef="i_2024-11-25_ClassOfWarrantOrRightAxis-PrefundedWarrantsMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.001</ix:nonFraction> per share, are immediately exercisable and <em style="font: inherit;"> may </em>be exercised at any time until all of the Pre-Funded Warrants are exercised in full. The Series A Warrants have an exercise price of $<ix:nonFraction id="c134564355" contextRef="i_2024-11-25_ClassOfWarrantOrRightAxis-SeriesAWarrantsMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:num-dot-decimal" decimals="INF">6.540</ix:nonFraction> per share, are immediately exercisable and <em style="font: inherit;"> may </em>be exercised at any time until the <span style="-sec-ix-hidden:c134564356">five</span>-year anniversary of the date of issuance. Both the Pre-Funded Warrants and the Series A Warrants are subject to a beneficial ownership limitation of <ix:nonFraction id="c134564357" contextRef="i_2024-11-25_ClassOfWarrantOrRightAxis-PrefundedAndSeriesAWarrantsMember" unitRef="Pure" name="amix:ClassOfWarrantsOrRightsMaximumBeneficialOwnership" scale="-2" format="ixt:num-dot-decimal" decimals="4">4.99</ix:nonFraction>%. The Offering closed on <em style="font: inherit;"> November 25, 2024. </em>On <em style="font: inherit;"> November 22, 2024, </em>the underwriters partially exercised their over-allotment option with respect to <ix:nonFraction id="c134564358" contextRef="d_2024-11-22_2024-11-22_CounterpartyNameAxis-UnderwritersMember_SubsidiarySaleOfStockAxis-OverAllotmentOptionMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:num-dot-decimal" decimals="INF">156,809</ix:nonFraction> shares of common stock and <ix:nonFraction id="c134564359" contextRef="d_2024-11-22_2024-11-22_ClassOfWarrantOrRightAxis-SeriesAWarrantsMember_CounterpartyNameAxis-UnderwritersMember" unitRef="Share" name="amix:ClassOfWarrantOrRightIssuedDuringPeriod" scale="0" format="ixt:num-dot-decimal" decimals="INF">156,809</ix:nonFraction> Series A Warrants. The aggregate gross proceeds to the Company, including the partial exercise of the over-allotment option, were approximately $<ix:nonFraction id="c134564360" contextRef="d_2024-11-22_2024-11-25_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="6" format="ixt:num-dot-decimal" decimals="-7">10.0</ix:nonFraction> million, before deducting underwriting discounts and other expenses by the Company of $<ix:nonFraction id="c134564361" contextRef="d_2024-11-22_2024-11-25_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="6" format="ixt:num-dot-decimal" decimals="-5">1.5</ix:nonFraction> million, including $<ix:nonFraction id="c134564362" contextRef="d_2024-11-22_2024-11-25_NatureOfExpenseAxis-NoncashExpensesMember_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.5</ix:nonFraction> million of non-cash expenses. The net cash proceeds to the Company were approximately $<ix:nonFraction id="c134564363" contextRef="d_2024-11-22_2024-11-25_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember" unitRef="USD" name="amix:ProceedsFromIssuanceOrSaleOfEquityNet" scale="6" format="ixt:num-dot-decimal" decimals="-6">9.0</ix:nonFraction> million.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> February 28, 2025, </em>the Company entered into an At Market Issuances Sales Agreement (the &#8220;ATM Agreement&#8221;) with Ladenburg Thalmann &amp; Co. Inc. (the &#8220;Agent&#8221;). Pursuant to the terms of the ATM Agreement, the Company <em style="font: inherit;"> may </em>sell from time to time through the Agent, as sales agent or principal, shares of the Company&#8217;s common stock with an initial aggregate sales price of up to $<ix:nonFraction id="c134564364" contextRef="i_2025-02-28_SubsidiarySaleOfStockAxis-ATMAgreementMember" unitRef="USD" name="amix:EquityOfferingMaximumOfferingAmount" scale="6" format="ixt:num-dot-decimal" decimals="-5">2.1</ix:nonFraction> million (the &#8220;Shares&#8221;). Any sale of Shares pursuant to the Agreement will be made under the Company&#8217;s &#8220;shelf&#8221; registration statement (the &#8220;Registration Statement&#8221;) on Form S-<em style="font: inherit;">3</em> filed on <em style="font: inherit;"> February 28, 2025 </em>with the Securities and Exchange Commission (the &#8220;SEC&#8221;). Under the ATM Agreement, the Company <em style="font: inherit;"> may </em>sell Shares through the Agent by any method that is deemed an &#8220;at the market offering&#8221; (as defined in Rule <em style="font: inherit;">415</em>(a)(<em style="font: inherit;">4</em>) under the Securities Act of <em style="font: inherit;">1933,</em> as amended). Under the ATM Agreement, the Agent will also be able to sell shares of Common Stock by any other method permitted by law, including in negotiated transactions with the Company&#8217;s prior written consent. The Company will pay a commission to the Agent of <ix:nonFraction id="c134564369" contextRef="i_2025-02-28_CounterpartyNameAxis-SellingAgentMember_SubsidiarySaleOfStockAxis-ATMAgreementMember" unitRef="Pure" name="amix:CommissionPercentage" scale="-2" format="ixt:num-dot-decimal" decimals="2">3.0</ix:nonFraction>% of the gross proceeds of the sale of the Shares sold under the ATM Agreement and reimburse the Agent for certain expenses. As of <em style="font: inherit;"> March 31, 2025, </em>the Company sold <ix:nonFraction id="c134564370" contextRef="d_2025-03-01_2025-03-31_SubsidiarySaleOfStockAxis-ATMAgreementMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:num-dot-decimal" decimals="INF">800</ix:nonFraction> shares pursuant to the ATM Agreement for net proceeds of approximately $<ix:nonFraction id="c134564371" contextRef="d_2025-03-01_2025-03-31_SubsidiarySaleOfStockAxis-ATMAgreementMember" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,746</ix:nonFraction>.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company estimates its current cash resources are sufficient to fund its operations into but <em style="font: inherit;">not</em> beyond the <em style="font: inherit;">first</em> calendar quarter of <em style="font: inherit;">2026.</em> The Company recognizes it will need to raise additional capital to continue to execute its business plan, including obtaining regulatory clearance for its products currently under development and commercializing and generating revenues from products under development. There is <em style="font: inherit;">no</em> assurance that additional financing will be available when needed or that management will be able to obtain financing on terms acceptable to the Company. A failure to raise sufficient capital, generate sufficient product revenues, control expenditures and regulatory matters, among other factors, will adversely impact the Company&#8217;s ability to meet its financial obligations as they become due and payable and to achieve its intended business objectives. If the Company is unable to raise sufficient additional funds, it will have to scale back its operations.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p></ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <ix:nonNumeric contextRef="d_2024-04-01_2025-03-31" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="c134565405" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Basis of Presentation</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The annual financial statements and disclosures have been prepared using the accrual basis of accounting in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;).</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p></ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       <em style="font: inherit;">86</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <ix:nonNumeric contextRef="d_2024-04-01_2025-03-31" name="us-gaap:UseOfEstimates" id="c134565406" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Use of Estimates in Financial Statement Presentation</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The preparation of these financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The Company's significant estimates and assumptions include the valuation of equity related instruments, and initial and recurring fair value measurements for the warrant liability. Although the Company believes that its estimates and assumptions are reasonable, they are based upon information available at the time the estimates and assumptions were made. Some of these judgments can be subjective and complex, and, consequently, actual results could differ from those estimates.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p></ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <ix:nonNumeric contextRef="d_2024-04-01_2025-03-31" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="c134565407" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Cash and Cash Equivalents</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company considers all highly liquid accounts with original maturities of <em style="font: inherit;">three</em> months or less at the date of acquisition to be cash equivalents.&#160;Periodically, the Company <em style="font: inherit;"> may </em>carry cash balances at financial institutions in excess of the federally insured limit of <em style="font: inherit;">$250,000.</em> The Company has <em style="font: inherit;">not</em> experienced losses on these accounts and management believes, based upon the quality of the financial institutions, that the credit risk with regard to these deposits is <em style="font: inherit;">not</em> significant.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p></ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <ix:nonNumeric contextRef="d_2024-04-01_2025-03-31" name="amix:OfferingCostsPolicyPolicyTextBlock" id="c134565408" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Offering and Financing Costs</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Offering costs consist of professional costs incurred through the balance sheet date that were direct and incremental to the Company&#8217;s equity financing activities. Specifically, offering costs were incurred on the Company's IPO, the Offering and the Registration Statement. The costs for the Registration Statement are recorded in deferred offering costs on the balance sheet as of <em style="font: inherit;"> March 31, 2025. </em>Costs associated with salaries and other period costs were expensed as incurred.&#160;</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">During the year ended <em style="font: inherit;"> March 31, 2024, </em>the Company paid $<ix:nonFraction id="c134564381" contextRef="d_2023-04-01_2024-03-31" unitRef="USD" name="amix:PaymentsForInitialPublicOfferingIssuanceCosts" scale="6" format="ixt:num-dot-decimal" decimals="-5">1.3</ix:nonFraction> million of issuance&#160;costs related to its IPO.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">During the year ended <em style="font: inherit;"> March 31, 2025, </em>the Company paid $<ix:nonFraction id="c134564382" contextRef="d_2024-04-01_2025-03-31" unitRef="USD" name="us-gaap:PaymentsOfFinancingCosts" scale="6" format="ixt:num-dot-decimal" decimals="-5">1.1</ix:nonFraction> million of issuance costs related to its Offering and $<ix:nonFraction id="c134564383" contextRef="d_2024-04-01_2025-03-31" unitRef="USD" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.2</ix:nonFraction> million of offering costs related to its Registration Statement.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p></ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <ix:nonNumeric contextRef="d_2024-04-01_2025-03-31" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="c134565409" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Property and Equipment</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Property and equipment are stated at historical cost and depreciated on a straight-line basis over their estimated useful lives, generally&#160;<span style="-sec-ix-hidden:c134564384">three</span> years. Upon disposition of the assets, the costs and related accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the results of operations.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p></ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <ix:nonNumeric contextRef="d_2024-04-01_2025-03-31" name="us-gaap:DebtPolicyTextBlock" id="c134565410" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Convertible Notes</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company evaluates embedded redemption, conversion and other features within its debt to determine whether any embedded features should be bifurcated from the host instrument and accounted for as a derivative at fair value, with changes in fair value recorded in the statement of operations.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company&#8217;s debt is carried on the balance sheet on a historical cost basis net of unamortized discounts and premiums because the Company has <em style="font: inherit;">not</em> elected the fair value option of accounting. Costs associated with acquiring debt, including detachable warrants issued in connection with the financing, are capitalized as a debt discount. The debt discount is presented in the balance sheet as a direct deduction from the carrying amount of the debt liability. The costs are amortized over the estimated contractual life of the related debt instrument using the effective interest method and are included in interest expense in the statement of operations.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">If the Company incurs costs associated with its convertible notes, in advance of the receipt of proceeds, the Company will record a deferred asset. Upon receipt of proceeds the Company will reclassify the deferred asset as a direct deduction from the carrying amount, as described above.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">In addition, since the instruments included a substantive conversion feature at the time of issuance, the issuance of equity securities were accounted for as a contractual conversion with <em style="font: inherit;">no</em> gain or loss recognized related to the equity securities issued to settle the instrument. &#160;</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p></ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <ix:nonNumeric contextRef="d_2024-04-01_2025-03-31" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="c134565411" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Fair Value of Financial Instruments</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs. The Company utilizes a <em style="font: inherit;">three</em>-level valuation hierarchy for disclosures of fair value measurements, defined as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Level <em style="font: inherit;">1</em> &#8211; inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
    <ix:exclude>
     <div class="PGNUM" style="width: 100%; text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      <em style="font: inherit;">87</em>
     </div>
     <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
     <div class="PGHDR" style="text-align: left; width: 100%">
      <div class="hf-row">
       <div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;">
        <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
       </div>
      </div>
     </div>
    </ix:exclude> <ix:exclude>&#160;</ix:exclude> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Level <em style="font: inherit;">2</em> &#8211; inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the assets or liability, either directly or indirectly, for substantially the full term of the financial instruments.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Level <em style="font: inherit;">3</em> &#8211; inputs to the valuation methodology are unobservable and significant to the fair value and require significant judgment and estimation.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Financial assets and financial liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. While the Company believes that its valuation methods are appropriate, the Company recognizes that the use of different methodologies or assumptions to determine the fair value could result in a different estimate of fair value at the reporting date. The primary assumptions that would significantly affect the fair values are the probability weighting of the different settlement outcomes used.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company did <em style="font: inherit;">not</em> have any assets or liabilities measured at fair value as of <em style="font: inherit;"> March 31, 2025 </em>and <em style="font: inherit;">2024,</em> respectively. In the <em style="font: inherit;">fourth</em> quarter of the Company's fiscal year ended <em style="font: inherit;"> March 31, 2024 </em>there was a transfer out of Level <em style="font: inherit;">3</em>&#160;for the warrant liability, for the settlement and reclassification to equity of the instrument, that occurred in the&#160;<em style="font: inherit;">three</em> months ended&#160;<em style="font: inherit;"> March 31, 2024. </em>For additional information, see&#160;<i>Note <em style="font: inherit;">2</em> - Warrant Liability and Fair Value of Financial Instruments</i>.&#65279;</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The carrying value of short-term instruments, including cash, accounts payable, accrued expenses and convertible notes included in long-term debt, approximate fair value due to the relatively short period to maturity for these instruments.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p></ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <ix:nonNumeric contextRef="d_2024-04-01_2025-03-31" name="amix:RelatedPartyTransactionsPolicyPolicyTextBlock" id="c134565412" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Related Parties</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company follows ASC <em style="font: inherit;">850,</em>&#160;<i>Related Party Disclosures</i>,&#160;for the identification of related parties and disclosure of related party transactions. See further discussion in the Notes below on this matter.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p></ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <ix:nonNumeric contextRef="d_2024-04-01_2025-03-31" name="us-gaap:IncomeTaxPolicyTextBlock" id="c134565413" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Income Taxes</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting and the tax basis of reported assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company must then assess the likelihood that the resulting deferred tax assets will be realized. A valuation allowance is provided when it is more likely than <em style="font: inherit;">not</em> that some portion or all of a deferred tax asset will <em style="font: inherit;">not</em> be realized. As of&#160;<em style="font: inherit;"> March 31, 2025 </em>and&#160;<em style="font: inherit;"> March 31, 2024 </em>the Company determined a full valuation allowance was required to offset its deferred tax assets as a result of recurring operating losses.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company accounts for uncertain tax positions in accordance with the provisions of ASC <em style="font: inherit;">740</em>-<em style="font: inherit;">10</em> which prescribes a recognition threshold and measurement attribute for financial statement disclosure of tax positions taken, or expected to be taken, on its tax return. The Company evaluates and records any uncertain tax positions based on the amount that management deems is more likely than <em style="font: inherit;">not</em> to be sustained upon examination and ultimate settlement with the tax authorities in the tax jurisdictions in which it operates. As of <em style="font: inherit;"> March 31, 2025 </em>and&#160;<em style="font: inherit;"> March 31, 2024 </em>the Company had <ix:nonFraction id="c134564404" contextRef="i_2025-03-31" unitRef="USD" name="us-gaap:LiabilityForUncertainTaxPositionsCurrent" scale="6" format="ixt-sec:numwordsen" decimals="-3">no</ix:nonFraction> uncertain tax positions.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p></ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <ix:nonNumeric contextRef="d_2024-04-01_2025-03-31" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="c134565414" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Stock-based Compensation</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Employee share-based compensation is measured at the grant date, based on the fair value of the award, and is recognized as an expense over the requisite service period.&#160;For awards with a performance condition, compensation expense is recognized over the requisite service period if it is probable that the performance condition will be satisfied. For awards to non-employees, the Company recognizes compensation expense in the same manner as if the Company had paid cash for the goods or services. The Company estimates the fair value of options and equity classified warrants granted using an options pricing model. Expense is recognized within general and administrative and research and development expenses and forfeitures are recognized as they are incurred.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p></ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <ix:nonNumeric contextRef="d_2024-04-01_2025-03-31" name="amix:WarrantsPolicyPolicyTextBlock" id="c134565415" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Warrants</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s specific terms and applicable authoritative guidance in FASB ASC <em style="font: inherit;">480,</em> Distinguishing Liabilities from Equity (&#8220;ASC <em style="font: inherit;">480&#8221;</em>) and ASC <em style="font: inherit;">815,</em> Derivatives and Hedging (&#8220;ASC <em style="font: inherit;">815&#8221;</em>). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC <em style="font: inherit;">480,</em> meet the definition of a liability pursuant to ASC <em style="font: inherit;">480,</em> and whether the warrants meet all of the requirements for equity classification under ASC <em style="font: inherit;">815,</em> including whether the warrants are indexed to the Company&#8217;s own ordinary shares and whether the warrant holders could potentially require &#8220;net cash settlement&#8221; in a circumstance outside of the Company&#8217;s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
    <ix:exclude>
     <div class="PGNUM" style="width: 100%; text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      <em style="font: inherit;">88</em>
     </div>
     <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
     <div class="PGHDR" style="text-align: left; width: 100%">
      <div class="hf-row">
       <div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;">
        <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
       </div>
      </div>
     </div>
    </ix:exclude> <ix:exclude>&#160;</ix:exclude> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do <em style="font: inherit;">not</em> meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss on the&#160;statements of operations. The fair value of the warrants is estimated using a Black-Scholes pricing model or a Monte Carlo simulation.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company&#65279; issued warrants to purchase shares of common stock (i) in connection with the Bridge Offering, (ii) as part of selling agent compensation in <em style="font: inherit;">2024,</em> (iii) in connection with the Exclusive License Termination Agreement (the &#8220;Termination Agreement&#8221;), and (iv) as part of the Offering&#65279;. Based on the guidance noted above, we determined that warrants issued in connection with the Termination Agreement should be accounted for as a liability and the remaining warrants issued meet the requirements for equity classification. Liability classified warrants are subject to remeasurement at each balance sheet date, while equity classified warrants are valued at inception only. As discussed in Note <em style="font: inherit;">2,</em> the liability warrants subsequently met the requirements for equity classification.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p></ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <ix:nonNumeric contextRef="d_2024-04-01_2025-03-31" name="us-gaap:EarningsPerSharePolicyTextBlock" id="c134565416" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Loss Per Common Share</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Basic loss per common share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period, which includes shares issuable for little to <em style="font: inherit;">no</em> consideration upon the exercise of certain equity-classified warrants. Diluted loss per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. In periods when losses are reported, the weighted-average number of common shares outstanding excludes common stock equivalents, because their inclusion would be anti-dilutive. Generally, the Company&#8217;s outstanding warrants are non-participating securities as they are <em style="font: inherit;">not</em> entitled to non-forfeitable rights to dividends or dividend equivalents during the vesting term and have <em style="font: inherit;">no</em> obligation to fund losses.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">However, the Company's warrants d&#65279;escribed in Note&#160;<em style="font: inherit;">2</em>&#160;and the warrants issued in connection with the Offering, are participating securities as the holders receive the right to dividends, but they are <em style="font: inherit;">not</em> obligated to fund losses. In periods of loss, since <em style="font: inherit;">no</em> income is allocated to these securities, the Company's use of the "treasury stock method" derives the same result. The dilutive effect of convertible securities is calculated using the &#8220;if-converted method.&#8221; Under the if-converted method, securities are assumed to be converted at the beginning of the period, and the resulting common shares are included in the denominator of the diluted calculation for the entire period being presented.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
    <ix:exclude>
     <div class="PGNUM" style="width: 100%; text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      <em style="font: inherit;">89</em>
     </div>
     <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
     <div class="PGHDR" style="text-align: left; width: 100%">
      <div class="hf-row">
       <div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;">
        <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
       </div>
      </div>
     </div>
    </ix:exclude> <ix:exclude>&#160;</ix:exclude> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">For the <em style="font: inherit;">twelve</em> months ended <em style="font: inherit;"> March 31, 2025&#160;</em>and <em style="font: inherit;">2024,</em> dilutive securities that were <em style="font: inherit;">not</em> included in the calculations of the loss per common share because they would be anti-dilutive included the following:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
    <ix:nonNumeric contextRef="d_2024-04-01_2025-03-31" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="c3016954" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 5%; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>March 31,</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(as revised)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Equity based warrants to purchase common shares</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563967" contextRef="d_2024-04-01_2025-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:num-dot-decimal" decimals="INF">87,531</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted"><ix:nonFraction id="c134563968" contextRef="d_2023-04-01_2024-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:num-dot-decimal" decimals="INF">4,334</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Convertible Notes - common shares (1)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563969" contextRef="d_2024-04-01_2025-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-ConvertibleDebtSecuritiesMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:fixed-zero" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted"><ix:nonFraction id="c134563970" contextRef="d_2023-04-01_2024-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-ConvertibleDebtSecuritiesMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:num-dot-decimal" decimals="INF">33,250</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Convertible Notes - equity-based warrants to purchase common shares</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563971" contextRef="d_2024-04-01_2025-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-ConvertibleNotesToWarrantsMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:num-dot-decimal" decimals="INF">25,003</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted"><ix:nonFraction id="c134563972" contextRef="d_2023-04-01_2024-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-ConvertibleNotesToWarrantsMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:num-dot-decimal" decimals="INF">25,003</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock options granted under Company's incentive plan</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563973" contextRef="d_2024-04-01_2025-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:num-dot-decimal" decimals="INF">243,483</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted"><ix:nonFraction id="c134563974" contextRef="d_2023-04-01_2024-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:num-dot-decimal" decimals="INF">100,180</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Series A Warrants</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563975" contextRef="d_2024-04-01_2025-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-SeriesAWarrantsMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,533,096</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted"><ix:nonFraction id="c134563976" contextRef="d_2023-04-01_2024-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-SeriesAWarrantsMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:fixed-zero" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Representative Warrants</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c134563977" contextRef="d_2024-04-01_2025-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-RepresentativesWarrantsMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:num-dot-decimal" decimals="INF">91,985</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted"><ix:nonFraction id="c134563978" contextRef="d_2023-04-01_2024-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-RepresentativesWarrantsMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:fixed-zero" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total potentially dilutive securities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c134563979" contextRef="d_2024-04-01_2025-03-31" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,981,098</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted"><ix:nonFraction id="c134563980" contextRef="d_2023-04-01_2024-03-31" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:num-dot-decimal" decimals="INF">162,767</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   </ix:nonNumeric> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 108pt;">(<em style="font: inherit;">1</em>) Shares for the convertible note proceeds received</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p></ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <ix:nonNumeric contextRef="d_2024-04-01_2025-03-31" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="c134565417" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Research and Development Costs</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Research and development costs are expensed as incurred.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p></ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <ix:nonNumeric contextRef="d_2024-04-01_2025-03-31" name="us-gaap:AdvertisingCostsPolicyTextBlock" id="c134565418" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Advertising</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">It is our policy to expense advertising costs as incurred. Advertising&#160;expenses are included within general and administrative expenses within the statement of operations. For the years ended <em style="font: inherit;"> March 31, 2025 </em>and <em style="font: inherit;">2024,</em> the Company recorded less than $<ix:nonFraction id="c134564428" contextRef="d_2024-04-01_2025-03-31" unitRef="USD" name="us-gaap:AdvertisingExpense" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.1</ix:nonFraction>&#160;million and $<ix:nonFraction id="c134564429" contextRef="d_2023-04-01_2024-03-31" unitRef="USD" name="us-gaap:AdvertisingExpense" scale="6" format="ixt:num-dot-decimal" decimals="-5">1.8</ix:nonFraction>&#160;million, respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p></ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <ix:nonNumeric contextRef="d_2024-04-01_2025-03-31" name="us-gaap:StockholdersEquityPolicyTextBlock" id="c134565419" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Fair Value of Common Stock</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Prior to establishing a public market for the Company&#8217;s common stock, the estimated fair value of the Company&#8217;s common stock was determined by the Company&#8217;s Board of Directors (the "Board") as of the date of each option grant, with input from management, considering the Company&#8217;s most recently available <em style="font: inherit;">third</em>-party valuations of common stock, recent sales of common stock to <em style="font: inherit;">third</em> parties, and the Company&#8217;s board of directors&#8217; assessment of additional objective and subjective factors that it believed were relevant and which <em style="font: inherit;"> may </em>have changed from the date of the most recent valuation through the date of the grant.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p></ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <ix:nonNumeric contextRef="d_2024-04-01_2025-03-31" name="amix:JumpstartOurBusinessStartupsJobsActAccountingElectionPolicyPolicyTextBlock" id="c134565420" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>JOBS Act Accounting Election</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company qualifies as an emerging growth company ("EGC"), as defined in the Jumpstart Our Business Startups Act of <em style="font: inherit;">2012</em> (the &#8220;JOBS Act&#8221;). The JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected <em style="font: inherit;">not</em> to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This <em style="font: inherit;"> may </em>make comparison of the Company&#8217;s financial statements with another public company which is neither an early-stage company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p></ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <ix:nonNumeric contextRef="d_2024-04-01_2025-03-31" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="c134565421" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Segments</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker ("CODM"), or decision-making group, in deciding how to allocate resources in assessing performance. Management has determined that the Company operates in&#160;<span style="-sec-ix-hidden:c134564434">one</span>&#160;reportable segment, which is advancing the development of innovative technologies for sensing and treating disorders relating to the nervous system. The Company is initially focused on developing the technology for patients with pancreatic cancer, however, the Company believes the technology constitutes a platform with the potential to address several indications, including chronic pain management, hypertension, cardiovascular disease and a wide range of other nerve-related disorders. The Company's CODM is its Chief Executive Officer.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
    <ix:exclude>
     <div class="PGNUM" style="width: 100%; text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      <em style="font: inherit;">90</em>
     </div>
     <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
     <div class="PGHDR" style="text-align: left; width: 100%">
      <div class="hf-row">
       <div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;">
        <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
       </div>
      </div>
     </div>
    </ix:exclude> <ix:exclude>&#160;</ix:exclude> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The accounting policies of the segment are the same as those described in the summary of significant accounting policies. The CODM assesses performance based on net loss, which is reported on the Statements of Operations. The measure of segment assets is reported on the balance sheet as total assets.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">To date, the Company has <em style="font: inherit;">not</em> generated any product revenue. The Company expects to continue to incur significant expenses and operating losses for the foreseeable future as it advances its' technology through all stages of development and clinical trials and, ultimately, seek regulatory approval.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">As such, the CODM primarily evaluates performance of the Company using various financial metrics, including the combined net income (loss) from operations, also shown on the Statements of Operations, forecasted cash expenditures and existing and forecasted cash balances. These financial metrics are used by the CODM to make key operating decisions, such as the assessment of segment performance and allocation of resources. The significant expense categories within net loss from operations that the CODM regularly reviews are expenses related to research and development, general and administrative, and depreciation and amortization. The significant expense categories and subcategories are reported on the Statements of Operations.&#160;Other expenses included in the Company&#8217;s net loss include change in fair value of warrant liabilities, other income (expense), interest income, net, and any additional non-operating expenses that are reported on the Statements of Operations.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p></ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <ix:nonNumeric contextRef="d_2024-04-01_2025-03-31" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="c134565422" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Recent Accounting Pronouncements</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">In&#160;<em style="font: inherit;"> November 2024 </em>and <em style="font: inherit;"> January 2025,&#160;</em>FASB issued ASU&#160;<em style="font: inherit;">2024</em>-<em style="font: inherit;">03</em> and ASU <em style="font: inherit;">2025</em>-<em style="font: inherit;">01,</em>&#160;Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic&#160;<em style="font: inherit;">220</em>-<em style="font: inherit;">40</em>): Disaggregation of Income Statement Expenses, which requires disclosure in the notes to the financial statements of specified information about certain costs and expenses. The amendments to the standards are effective for fiscal years beginning after&#160;<em style="font: inherit;"> December 15, 2026,&#160;</em>and for interim periods within fiscal years beginning after&#160;<em style="font: inherit;"> December 15, 2027.&#160;</em>Early adoption is permitted. The amendments should be applied either prospectively to financial statements issued for reporting periods after the effective date of this ASU or retrospectively to any or all prior periods presented in the financial statements. The Company is currently evaluating the new guidance to determine the impact it&#160;<em style="font: inherit;"> may&#160;</em>have on its financial statements and related disclosures.&#160;</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">In <em style="font: inherit;"> December 2023, </em>the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update, or ASU <em style="font: inherit;">2023</em>-<em style="font: inherit;">09,</em> Income Taxes (Topic <em style="font: inherit;">740</em>): Improvements to Income Tax Disclosures. ASU <em style="font: inherit;">2023</em>-<em style="font: inherit;">09</em>&#160;improves the transparency of income tax disclosures by requiring consistent categories and greater disaggregation of information in the effective tax rate reconciliation and income taxes paid disaggregated by jurisdiction. It also includes certain other amendments to improve the effectiveness of income tax disclosures. This guidance will be effective for the annual periods beginning after the year ended <em style="font: inherit;"> December 31, 2024. </em>The Company is currently assessing the impact of ASU <em style="font: inherit;">2023</em>-<em style="font: inherit;">09</em> on its disclosures.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">In <em style="font: inherit;"> November 2023, </em>the FASB issued ASU <em style="font: inherit;">No.</em> <em style="font: inherit;">2023</em>-<em style="font: inherit;">07,</em> Improvements to Reportable Segment Disclosures (ASU <em style="font: inherit;">2023</em>-<em style="font: inherit;">07</em>) which is intended to improve reportable segment disclosures primarily through enhanced disclosure of reportable segment expenses and requires that a public entity that has a single reportable segment provide all the disclosures required by ASU <em style="font: inherit;">2023</em>-<em style="font: inherit;">07</em> and all existing segment disclosures in Topic <em style="font: inherit;">280.</em> The new guidance is required to be applied retrospectively to all prior periods presented in the financial statements and is effective for the Company for fiscal periods beginning after <em style="font: inherit;"> December 15, 2023 </em>and interim periods within fiscal years beginning after <em style="font: inherit;"> December 15, 2024. </em>The Company adopted ASU <em style="font: inherit;">2023</em>-<em style="font: inherit;">07</em> during the year ended <em style="font: inherit;"> March 31, 2025. </em>There was <em style="font: inherit;">no</em> impact upon adoption of ASU <em style="font: inherit;">2023</em>-<em style="font: inherit;">07.</em>&#160;The Company views its operations and manages its business in&#160;<span style="-sec-ix-hidden:c134564463">one</span>&#160;operating segment.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">There are <em style="font: inherit;">no</em> other effective pronouncements, or pronouncements issued but <em style="font: inherit;">not</em> yet effective, if adopted, that would have a material effect on the accompanying financial statements.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p></ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <ix:nonNumeric contextRef="d_2024-04-01_2025-03-31" name="amix:CorrectionOfAnImmaterialErrorPolicyTextBlock" id="c134565423" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Correction of an Immaterial Error in the Prior Period Financial Statements</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">D&#65279;uring the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> December 31, 2024, </em>the Company determined that previously filed quarterly and annual financial statements had an immaterial earnings per share error resulting from the exclusion of certain unexercised equity based warrants to purchase common shares that had an exercise price of approximately $<ix:nonFraction id="c134564467" contextRef="i_2024-12-31_ClassOfWarrantOrRightAxis-EquitybasedWarrantsMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.01</ix:nonFraction> or less from the basic earnings per share calculations in accordance with <i>ASC <em style="font: inherit;">260</em>-<em style="font: inherit;">10</em>-<em style="font: inherit;">45</em>-<em style="font: inherit;">13</em></i>. As a&#160;result, the prior year earnings per share calculations have been revised for consistency with the current year presentation. The Company assessed the materiality of this change in presentation on prior period financial statements in accordance with <i>SEC Staff Accounting Bulletin <em style="font: inherit;">No.</em> <em style="font: inherit;">99</em></i>, &#8220;<i>Materiality</i>,&#8221; (<i>ASC Topic <em style="font: inherit;">250,</em> Accounting Changes and Error Corrections</i>). Based on this assessment, the Company concluded that this error correction in its&#160;<i>Statements of Operations</i>&#160;and <i>Note <em style="font: inherit;">1</em> </i>&#8211;<i> Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies (Loss Per Common Share)</i> is <em style="font: inherit;">not</em> material to any previously presented financial statements based upon overall considerations of both quantitative and qualitative factors. The corrections had <em style="font: inherit;">no</em> impact in the comparative period Balance Sheet,&#160;Statements of Cash Flows, or Statement of Changes in Stockholders&#8217;&#160;Equity. Further, the immaterial correction did <em style="font: inherit;">not</em> result in a change in operating losses or net loss in the Statement of Operations and the effects of including unexercised warrants in the earnings per share calculation have an antidilutive effect reducing the net loss per share amount. Accordingly, the Company corrected the previously reported earnings per share calculation for the <em style="font: inherit;">twelve</em> months ended <em style="font: inherit;"> March 31, 2024 </em>in this Annual Report on Form <em style="font: inherit;">10</em>-K.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
    <ix:exclude>
     <div class="PGNUM" style="width: 100%; text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      <em style="font: inherit;">91</em>
     </div>
     <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
     <div class="PGHDR" style="text-align: left; width: 100%">
      <div class="hf-row">
       <div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;">
        <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
       </div>
      </div>
     </div>
    </ix:exclude> <ix:exclude>&#160;</ix:exclude> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">A summary of the impact of the Company&#8217;s Reverse Stock Split and immaterial corrections reflecting the prior period impact to the Company&#8217;s Statement of Operations and earnings per share are shown below:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
    <ix:nonNumeric contextRef="d_2024-04-01_2025-03-31" name="us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" id="c463F7915-270B-4FCB-A5DA-407E83B25EB3" escape="true" continuedAt="c4455E16A-1AED-4EFB-A9EE-05C93A07B3E9">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Twelve Months Ended March 31, 2024</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Originally</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Filed</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Adjusted </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>for 1-for-20 </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Reverse </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Stock Split</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Correction</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>As Revised</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net Loss (in thousands)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted">(<ix:nonFraction id="c134563981" contextRef="d_2023-04-01_2024-03-31_RestatementAxis-ScenarioPreviouslyReportedMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">15,426</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563982" contextRef="d_2023-04-01_2024-03-31_RestatementAxis-ReverseStockSplitAdjustmentMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:fixed-zero" decimals="-3">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563983" contextRef="d_2023-04-01_2024-03-31_RestatementAxis-RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:fixed-zero" decimals="-3">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c134563984" contextRef="d_2023-04-01_2024-03-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">15,426</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Loss per share - basic and diluted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted">(<ix:nonFraction id="c134563985" contextRef="d_2023-04-01_2024-03-31_RestatementAxis-ScenarioPreviouslyReportedMember" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasic" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">1.05</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c134563986" contextRef="d_2023-04-01_2024-03-31_RestatementAxis-ReverseStockSplitAdjustmentMember" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasic" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">21.09</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563987" contextRef="d_2023-04-01_2024-03-31_RestatementAxis-RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasic" scale="0" format="ixt:num-dot-decimal" decimals="INF">6.27</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c134563988" contextRef="d_2023-04-01_2024-03-31" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasic" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">14.82</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Weighted average shares outstanding - basic and diluted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted"><ix:nonFraction id="c134563989" contextRef="d_2023-04-01_2024-03-31_RestatementAxis-ScenarioPreviouslyReportedMember" unitRef="Share" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" format="ixt:num-dot-decimal" decimals="INF">14,626,282</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563990" contextRef="d_2023-04-01_2024-03-31_RestatementAxis-ReverseStockSplitAdjustmentMember" unitRef="Share" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" format="ixt:num-dot-decimal" decimals="INF">731,372</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563991" contextRef="d_2023-04-01_2024-03-31_RestatementAxis-RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" unitRef="Share" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" format="ixt:num-dot-decimal" decimals="INF">309,348</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563992" contextRef="d_2023-04-01_2024-03-31" unitRef="Share" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,040,720</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   </ix:nonNumeric> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">A summary of the impact of the Company&#8217;s Reverse Stock Split and immaterial corrections reflecting the prior period impact to the disclosure of dilutive securities that were <em style="font: inherit;">not</em> included in the calculations of the loss per common share because they would be anti-dilutive are shown below:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
    <ix:continuation id="c4455E16A-1AED-4EFB-A9EE-05C93A07B3E9">
     <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Twelve Months Ended March 31, 2024</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Originally </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Filed</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Adjusted f</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>or 1-for-20 </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Reverse </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Stock Split</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Correction</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>As Revised</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Equity based warrants to purchase common shares</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563993" contextRef="d_2023-04-01_2024-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember_RestatementAxis-ScenarioPreviouslyReportedMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:num-dot-decimal" decimals="INF">5,744,569</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563994" contextRef="d_2023-04-01_2024-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember_RestatementAxis-ReverseStockSplitAdjustmentMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:num-dot-decimal" decimals="INF">287,231</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c134563995" contextRef="d_2023-04-01_2024-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember_RestatementAxis-RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">282,897</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted"><ix:nonFraction id="c134563996" contextRef="d_2023-04-01_2024-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:num-dot-decimal" decimals="INF">4,334</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Convertible Notes - common shares</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563997" contextRef="d_2023-04-01_2024-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-ConvertibleDebtSecuritiesMember_RestatementAxis-ScenarioPreviouslyReportedMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:num-dot-decimal" decimals="INF">665,000</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563998" contextRef="d_2023-04-01_2024-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-ConvertibleDebtSecuritiesMember_RestatementAxis-ReverseStockSplitAdjustmentMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:num-dot-decimal" decimals="INF">33,250</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563999" contextRef="d_2023-04-01_2024-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-ConvertibleDebtSecuritiesMember_RestatementAxis-RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:fixed-zero" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted"><ix:nonFraction id="c134564000" contextRef="d_2023-04-01_2024-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-ConvertibleDebtSecuritiesMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:num-dot-decimal" decimals="INF">33,250</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Convertible Notes - equity-based warrants to purchase common shares</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134564001" contextRef="d_2023-04-01_2024-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-ConvertibleNotesToWarrantsMember_RestatementAxis-ScenarioPreviouslyReportedMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:num-dot-decimal" decimals="INF">500,000</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134564002" contextRef="d_2023-04-01_2024-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-ConvertibleNotesToWarrantsMember_RestatementAxis-ReverseStockSplitAdjustmentMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:num-dot-decimal" decimals="INF">25,003</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134564003" contextRef="d_2023-04-01_2024-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-ConvertibleNotesToWarrantsMember_RestatementAxis-RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:fixed-zero" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted"><ix:nonFraction id="c134564004" contextRef="d_2023-04-01_2024-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-ConvertibleNotesToWarrantsMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:num-dot-decimal" decimals="INF">25,003</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock options granted under Company's incentive plan</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c134564005" contextRef="d_2023-04-01_2024-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember_RestatementAxis-ScenarioPreviouslyReportedMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:num-dot-decimal" decimals="INF">2,003,600</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c134564006" contextRef="d_2023-04-01_2024-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember_RestatementAxis-ReverseStockSplitAdjustmentMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:num-dot-decimal" decimals="INF">100,180</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c134564007" contextRef="d_2023-04-01_2024-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember_RestatementAxis-RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:fixed-zero" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted"><ix:nonFraction id="c134564008" contextRef="d_2023-04-01_2024-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:num-dot-decimal" decimals="INF">100,180</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Total potentially dilutive securities</b></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"><b>&#160;</b></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b><ix:nonFraction id="c134564009" contextRef="d_2023-04-01_2024-03-31_RestatementAxis-ScenarioPreviouslyReportedMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:num-dot-decimal" decimals="INF">8,913,169</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"><b>&#160;</b></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b><ix:nonFraction id="c134564010" contextRef="d_2023-04-01_2024-03-31_RestatementAxis-ReverseStockSplitAdjustmentMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:num-dot-decimal" decimals="INF">445,664</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"><b>&#160;</b></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>(<ix:nonFraction id="c134564011" contextRef="d_2023-04-01_2024-03-31_RestatementAxis-RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">282,897</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"><b>)</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"><b>&#160;</b></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted"><b><ix:nonFraction id="c134564012" contextRef="d_2023-04-01_2024-03-31" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:num-dot-decimal" decimals="INF">162,767</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
    </ix:continuation> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p></ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <ix:exclude>
    <div class="PGNUM" style="width: 100%; text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
     <em style="font: inherit;">92</em>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
  </ix:nonNumeric>
  <div>
   &#160;
  </div>
  <ix:nonNumeric contextRef="d_2024-04-01_2025-03-31" name="us-gaap:FairValueDisclosuresTextBlock" id="c3016957" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Note <em style="font: inherit;">2</em> </b>&#8211;<b> Warrant Liability and Fair Value of Financial Instruments</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Financial assets and financial liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. While the Company believes that its valuation methods are appropriate, the Company recognizes that the use of different methodologies or assumptions to determine the fair value could result in a different estimate of fair value at the reporting date. The primary assumptions that would significantly affect the fair values are the probability weighting of the different settlement outcomes used.&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">There were <ix:nonFraction id="c134564485" contextRef="i_2025-03-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member" unitRef="USD" name="us-gaap:AssetsFairValueDisclosure" scale="0" format="ixt-sec:numwordsen" decimals="-3">no</ix:nonFraction> outstanding instruments classified as Level <em style="font: inherit;">3</em> measurements as of <em style="font: inherit;"> March 31, 2025 </em>or &#160;<em style="font: inherit;"> March 31, 2024.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">There were <em style="font: inherit;">not</em> any transfers into or out of Level <em style="font: inherit;">3</em> as of <em style="font: inherit;"> March 31, 2025 </em>and <em style="font: inherit;"> March 31, 2024.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The following table summarizes the activity of the Level <em style="font: inherit;">3</em> fair value measurements during the <em style="font: inherit;">twelve</em> months ended <em style="font: inherit;"> March 31, 2024&#160;(</em>in thousands):</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:nonNumeric contextRef="d_2024-04-01_2025-03-31" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" id="c3016958" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 5%; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Warrant</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Liabilities</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 84%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance as of March 31, 2023</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted"><ix:nonFraction id="c134564013" contextRef="i_2023-03-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByLiabilityClassAxis-WarrantMember" unitRef="USD" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Additions</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted"><ix:nonFraction id="c134564014" contextRef="d_2023-04-01_2024-03-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByLiabilityClassAxis-WarrantMember" unitRef="USD" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements" scale="3" format="ixt:num-dot-decimal" decimals="-3">4,556</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Change in fair value measurements - warrants mark-to-market</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted"><ix:nonFraction id="c134564015" contextRef="d_2023-04-01_2024-03-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByLiabilityClassAxis-WarrantMember" unitRef="USD" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" format="ixt:num-dot-decimal" decimals="-3">3,444</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Settlement and reclassification to equity</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted">(<ix:nonFraction id="c134564016" contextRef="d_2023-04-01_2024-03-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByLiabilityClassAxis-WarrantMember" unitRef="USD" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" scale="3" format="ixt:num-dot-decimal" decimals="-6">8,000</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance as of March 31, 2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted"><ix:nonFraction id="c134564017" contextRef="i_2024-03-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByLiabilityClassAxis-WarrantMember" unitRef="USD" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company recognized the initial warrant expense as a component of operating expenses on the statement of operations under <i>warrant expense </i>&#8211;<i> termination agreement</i> for $<ix:nonFraction id="c134564491" contextRef="d_2023-04-01_2024-03-31" unitRef="USD" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="6" format="ixt:num-dot-decimal" decimals="-5" sign="-">4.6</ix:nonFraction> million and the changes in the fair value under <i>warrant liability </i>&#8211;<i> mark-to-market </i>for $<ix:nonFraction id="c134564492" contextRef="d_2023-04-01_2024-03-31" unitRef="USD" name="us-gaap:FairValueAdjustmentOfWarrants" scale="6" format="ixt:num-dot-decimal" decimals="-5">3.4</ix:nonFraction>&#160;million. There were <em style="font: inherit;">no</em> changes to the valuation approaches or techniques used for Level <em style="font: inherit;">3</em> measurements.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Warrant Liabilities</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">As more fully detailed in <i>Note <em style="font: inherit;">6</em> </i>&#8211;<i> Related Party Transactions</i>, on <em style="font: inherit;"> July 7, 2023, </em>the Company entered into an Exclusive License Termination Agreement (the &#8220;Termination Agreement&#8221;) with a licensee in exchange for the issuance, upon the closing of the Company&#8217;s IPO within <em style="font: inherit;">one</em> year of the agreement&#8217;s execution, of a warrant (the "Warrant") to purchase shares of the Company for a variable number of shares.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The fair value of the warrant liability has been estimated using a discounted cash flow model under various scenarios and used the probability-weighted expected return method (&#8220;PWERM&#8221;) comparing the probabilities of different outcomes. The outcomes considered included (i) the closing of a qualified financing as part of the Company&#8217;s IPO at various points in time and (ii) the possibility of default whereby the licensee receives nothing. Key assumptions for the model were as follows for the initial measurement:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:nonNumeric contextRef="d_2024-04-01_2025-03-31" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="c3016959" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 83%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Discount rate at issuance (1)</p> </td><td style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted"><em style="font: inherit;">&#160;</em></td><td style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted"><span style="-sec-ix-hidden:c134565294">20.00</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 83%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Probability (2)</p> </td><td style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted"><span style="-sec-ix-hidden:c134565295">&#160;70%</span></td><td style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">-</td><td style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;"><span style="-sec-ix-hidden:c134565296">10%</span></td><td style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">-</td><td style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="-sec-ix-hidden:c134565297">20</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 83%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Payment (3)</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 3%;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 3%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 3%; text-align: center;"><span style="-sec-ix-hidden:c134565299">$0</span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 3%; text-align: center;">-</td><td colspan="1" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 4%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><span style="-sec-ix-hidden:c134565300">&#160;$8,000,000</span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 83%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected term (in years)</p> </td><td style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted">&#160;</td><td style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;"><span style="-sec-ix-hidden:c134565302">0.48</span></td><td style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted">-</td><td style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="-sec-ix-hidden:c134565303">0.98</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">(<em style="font: inherit;">1</em>)</p> </td><td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">The initial discount rate was chosen based on private equity rates of return as described in the AICPA Practice Aid on Valuation of Privately-Held-Company Equity securities issued as compensation. For the recurring fair value measurement, the Company updated the discount rate based upon yield curves estimated to be similar in credit quality to the Company;</p> </td></tr>
<tr style="vertical-align: top;"><td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">(<em style="font: inherit;">2</em>)</p> </td><td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Scenario probability as of issuance was based on timing expectations of management that a qualified offering occurring as of <em style="font: inherit;"> December 31, 2023 </em>was estimated at <ix:nonFraction id="c134564499" contextRef="i_2023-12-31_MeasurementInputTypeAxis-MeasurementInputProbabilityRateMember_StatementScenarioAxis-QualifiedOfferingOccurringOneMember_ValuationTechniqueAxis-ValuationProbabilityweightedExpectedReturnMethodPWERMMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" format="ixt:num-dot-decimal" decimals="1">70</ix:nonFraction>%, respectively; a qualified offering occurring as of <em style="font: inherit;"> June 30, 2024 </em>was estimated at <span style="-sec-ix-hidden:c134564500">10%;</span> and <em style="font: inherit;">no</em> qualified offering occurring was estimated at <span style="-sec-ix-hidden:c134564502">20%;</span></p> </td></tr>
<tr style="vertical-align: top;"><td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">(<em style="font: inherit;">3</em>)</p> </td><td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">The warrant has a $<ix:nonFraction id="c134564504" contextRef="i_2023-12-31" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.02</ix:nonFraction>&#160;strike price, however, the strike price is low relative to the stock price, making the warrant value close to the value of a stock unit. The agreement has a fixed payment value of $<ix:nonFraction id="c134564505" contextRef="d_2023-07-07_2023-07-07_ClassOfWarrantOrRightAxis-TheWarrantMember_RelatedPartyTransactionAxis-TerminationAgreementMember" unitRef="USD" name="amix:ClassOfWarrantOrRightValueOfSecuritiesCalledByWarrantsOrRights" scale="6" format="ixt:num-dot-decimal" decimals="-6">8.0</ix:nonFraction> million, see Note <em style="font: inherit;">6</em> &#8211;&#160;Related Party Transactions.</p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> January 29, 2024, </em>the Company issued <ix:nonFraction id="c134564507" contextRef="i_2024-01-29_ClassOfWarrantOrRightAxis-TheWarrantMember_RelatedPartyTransactionAxis-TerminationAgreementMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" format="ixt:num-dot-decimal" decimals="INF">80,000</ix:nonFraction> warrant shares pursuant to the Termination Agreement.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The completion of the Company&#8217;s IPO fixed the number of warrant shares issuable and the Company re-classified the Warrant to additional-paid in capital as it met the requirements for equity classification. Upon reclassification, the Company valued the warrant at $<ix:nonFraction id="c134564508" contextRef="i_2024-01-29_ClassOfWarrantOrRightAxis-TheWarrantMember_RelatedPartyTransactionAxis-TerminationAgreementMember" unitRef="USD" name="us-gaap:WarrantsAndRightsOutstanding" scale="6" format="ixt:num-dot-decimal" decimals="-6">8.0</ix:nonFraction> million, which represented the fair value of the shares issued on that date.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>
   <ix:exclude>
    <div class="PGNUM" style="width: 100%; text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
     <em style="font: inherit;">93</em>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
  </ix:nonNumeric>
  <div>
   &#160;
  </div>
  <ix:nonNumeric contextRef="d_2024-04-01_2025-03-31" name="us-gaap:DebtDisclosureTextBlock" id="c3016960" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b>Note <em style="font: inherit;">3</em> </b>&#8211;<b> Convertible Notes Payable</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> September 9, 2023, </em>the Company's Board authorized an offering up to $<ix:nonFraction id="c134564511" contextRef="i_2023-09-09_DebtInstrumentAxis-TheNotesMember_RangeAxis-MaximumMember" unitRef="USD" name="us-gaap:DebtInstrumentFaceAmount" scale="6" format="ixt:num-dot-decimal" decimals="-6">2.0</ix:nonFraction> million in unsecured, non-interest bearing convertible promissory notes (the &#8220;Notes&#8221;) and accompanying warrants (the &#8220;Bridge Financing Warrants&#8221;) (collectively, the &#8220;Bridge Offering&#8221;) that will mature on <em style="font: inherit;"> December 31, 2025. </em>The Notes provided that, on the closing date of the IPO, the outstanding principal would be&#160;automatically converted into common stock at the conversion price of $<ix:nonFraction id="c134564512" contextRef="i_2023-09-09_DebtInstrumentAxis-TheNotesMember" unitRef="USDPerShare" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" format="ixt:num-dot-decimal" decimals="INF">40.00</ix:nonFraction>. Each dollar in principal amount of Notes purchased were&#160;accompanied by a <span style="-sec-ix-hidden:c134564513">five</span>-year Bridge Financing Warrant to purchase <ix:nonFraction id="c134564514" contextRef="i_2023-09-09_ClassOfWarrantOrRightAxis-BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.0125</ix:nonFraction> shares of Common stock with an exercise price of $<ix:nonFraction id="c134564515" contextRef="i_2023-09-09_ClassOfWarrantOrRightAxis-BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:num-dot-decimal" decimals="INF">20.00</ix:nonFraction> per share. The Company records the Bridge Financing Warrants as a discount to the Notes.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Bridge Financing Warrants can be exercised from the date of Notes issuance through the <em style="font: inherit;">five</em>-year anniversary of the issuance of the Notes. The shares issuable pursuant to the Notes and Bridge Financing Warrants had a <ix:nonNumeric contextRef="d_2023-09-09_2023-09-09_ClassOfWarrantOrRightAxis-BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember" name="amix:ClassOfWarrantOrRightLockupAgreementTermOfUnderlyingShares" id="c134564517" format="ixt-sec:durday">180</ix:nonNumeric>-day lock-up after the Company&#8217;s IPO. Thereafter, the foregoing lock-up agreement ceased to apply to <ix:nonFraction id="c134564518" contextRef="d_2023-09-09_2023-09-09_ClassOfWarrantOrRightAxis-BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember" unitRef="Pure" name="amix:ClassOfWarrantOrRightPercentageOfOutstandingStock" scale="-2" format="ixt:num-dot-decimal" decimals="2">25</ix:nonFraction>% of the purchased shares each month for a period of <em style="font: inherit;">four</em> months. The Note holders were <em style="font: inherit;">not</em> permitted to convert their Notes when the holders or any of their affiliates would beneficially own in excess of <ix:nonFraction id="c134564521" contextRef="i_2023-09-09_DebtInstrumentAxis-TheNotesMember" unitRef="Pure" name="amix:DebtInstrumentConvertibleMaximumBeneficialOwnershipPercentage" scale="-2" format="ixt:num-dot-decimal" decimals="4">4.99</ix:nonFraction>% of the Company&#8217;s common stock after such conversion.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">As of <em style="font: inherit;"> March 31, 2024, </em>the Company received proceeds of $<ix:nonFraction id="c134564522" contextRef="d_2023-09-10_2024-03-31_DebtInstrumentAxis-TheNotesMember" unitRef="USD" name="us-gaap:ProceedsFromConvertibleDebt" scale="6" format="ixt:num-dot-decimal" decimals="-6">2.0</ix:nonFraction> million of Notes executed from the Bridge Offering.&#160;Upon the closing of the IPO, certain notes were to be automatically converted according to their terms into the Company&#8217;s common stock to the extent and provided that certain holders of these notes are <em style="font: inherit;">not</em> permitted to convert such notes to the extent that the holders or any of its affiliates would beneficially own in excess of <ix:nonFraction id="c134564524" contextRef="i_2024-01-26_DebtInstrumentAxis-TheNotesMember" unitRef="Pure" name="amix:DebtInstrumentConvertibleMaximumBeneficialOwnershipPercentage" scale="-2" format="ixt:num-dot-decimal" decimals="4">4.99</ix:nonFraction>% of the Company&#8217;s common stock after such conversion. Due to this <ix:nonFraction id="c134564525" contextRef="i_2024-01-26_DebtInstrumentAxis-TheNotesMember" unitRef="Pure" name="amix:DebtInstrumentConvertibleMaximumBeneficialOwnershipPercentage" scale="-2" format="ixt:num-dot-decimal" decimals="4">4.99</ix:nonFraction>% limitation, principal representing $<ix:nonFraction id="c134564526" contextRef="i_2025-03-31_DebtInstrumentAxis-ConvertibleDebtWith499PercentBeneficialOwnershipLimitationMember" unitRef="USD" name="us-gaap:ConvertibleNotesPayable" scale="6" format="ixt:num-dot-decimal" decimals="-5">1.3</ix:nonFraction> million, or <ix:nonFraction id="c134564527" contextRef="d_2024-04-01_2025-03-31_DebtInstrumentAxis-ConvertibleDebtWith499PercentBeneficialOwnershipLimitationMember" unitRef="Pure" name="us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments" scale="0" format="ixt:num-dot-decimal" decimals="INF">33,250</ix:nonFraction> shares, of these notes remained outstanding.&#160;As discussed in Note <em style="font: inherit;">1,</em> the remaining notes converted into common stock in accordance with their original terms on the IPO. During the year ended <em style="font: inherit;"> March 31, 2025, </em>the remaining Notes were converted into <ix:nonFraction id="c134564529" contextRef="d_2024-04-01_2025-03-31_DebtConversionByUniqueDescriptionAxis-ConversionOfConvertibleNotesToCommonStockMember" unitRef="Share" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" scale="0" format="ixt:num-dot-decimal" decimals="INF">33,250</ix:nonFraction> shares.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company&#8217;s effective interest rate for the Notes was <ix:nonFraction id="c134564530" contextRef="i_2025-03-31_DebtInstrumentAxis-ConvertibleDebtWith499PercentBeneficialOwnershipLimitationMember" unitRef="Pure" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" format="ixt:num-dot-decimal" decimals="3">15.3</ix:nonFraction>% due to the amortization of the discount stemming from the issuance of the Bridge Financing Warrants.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The following table presents a summary of activity for the Company&#8217;s <em style="font: inherit;">zero</em>-coupon convertible notes payable (in thousands):</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:nonNumeric contextRef="d_2024-04-01_2025-03-31" name="us-gaap:ConvertibleDebtTableTextBlock" id="c3016961" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 5%; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Principal Amount</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Amortized Debt</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Discount</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Net Carrying</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Amount</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding, March 31, 2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134564038" contextRef="i_2024-03-31_DebtInstrumentAxis-TheNotesMember_LongtermDebtTypeAxis-ConvertibleDebtMember" unitRef="USD" name="us-gaap:DebtInstrumentFaceAmount" scale="3" format="ixt:num-dot-decimal" decimals="-4">1,330</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c134564039" contextRef="i_2024-03-31_DebtInstrumentAxis-TheNotesMember_LongtermDebtTypeAxis-ConvertibleDebtMember" unitRef="USD" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet" scale="3" format="ixt:num-dot-decimal" decimals="-3">328</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134564040" contextRef="i_2024-03-31_DebtInstrumentAxis-TheNotesMember_LongtermDebtTypeAxis-ConvertibleDebtMember" unitRef="USD" name="us-gaap:ConvertibleLongTermNotesPayable" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,002</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Amortization of debt discount</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted"><ix:nonFraction id="c134564042" contextRef="d_2024-04-01_2025-03-31_DebtInstrumentAxis-TheNotesMember_LongtermDebtTypeAxis-ConvertibleDebtMember" unitRef="USD" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" format="ixt:num-dot-decimal" decimals="-3">175</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134564043" contextRef="d_2024-04-01_2025-03-31_DebtInstrumentAxis-TheNotesMember_LongtermDebtTypeAxis-ConvertibleDebtMember" unitRef="USD" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" format="ixt:num-dot-decimal" decimals="-3">175</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Issuance of common stock for extinguishment of convertible debt</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c134564044" contextRef="d_2024-04-01_2025-03-31_DebtConversionByUniqueDescriptionAxis-IssuanceOfCommonStockForExtinguishmentOfConvertibleDebtMember" unitRef="USD" name="us-gaap:DebtConversionOriginalDebtAmount1" scale="3" format="ixt:num-dot-decimal" decimals="-4">1,330</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c134564045" contextRef="d_2024-04-01_2025-03-31_DebtConversionByUniqueDescriptionAxis-IssuanceOfCommonStockForExtinguishmentOfConvertibleDebtMember" unitRef="USD" name="amix:DebtConversionDebtIssuanceCostsConvertedCommonShares" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">153</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c134564046" contextRef="d_2024-04-01_2025-03-31_DebtConversionByUniqueDescriptionAxis-IssuanceOfCommonStockForExtinguishmentOfConvertibleDebtMember" unitRef="USD" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,177</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding, March 31, 2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c134564047" contextRef="i_2025-03-31_DebtInstrumentAxis-TheNotesMember_LongtermDebtTypeAxis-ConvertibleDebtMember" unitRef="USD" name="us-gaap:DebtInstrumentFaceAmount" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c134564048" contextRef="i_2025-03-31_DebtInstrumentAxis-TheNotesMember_LongtermDebtTypeAxis-ConvertibleDebtMember" unitRef="USD" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet" scale="3" format="ixt:fixed-zero" decimals="-3" sign="-">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c134564049" contextRef="i_2025-03-31_DebtInstrumentAxis-TheNotesMember_LongtermDebtTypeAxis-ConvertibleDebtMember" unitRef="USD" name="us-gaap:ConvertibleLongTermNotesPayable" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Warrants</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company issued the Notes with detachable warrants for the purchase of shares of the Company&#8217;s common stock. The Company utilized a Monte Carlo simulation model to determine the fair value of each Bridge Offering Warrant. During the year ended <em style="font: inherit;"> March 31, 2024, </em>the Company issued warrants valued at $<ix:nonFraction id="c134564532" contextRef="i_2024-03-31_ClassOfWarrantOrRightAxis-BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember" unitRef="USD" name="us-gaap:WarrantsAndRightsOutstanding" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.6</ix:nonFraction> million. The key inputs to the Monte Carlo simulation used to determine the fair value of each warrant include, the Company&#8217;s stock price fair value which was determined through a back solve calculation such that the stock price results in the average total value of the Notes and the Bridge Offering Warrants being equal to the cash proceeds received, volatility based on a selection of publicly held peer companies of <ix:nonFraction id="c134564533" contextRef="i_2024-03-31_ClassOfWarrantOrRightAxis-BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" format="ixt:num-dot-decimal" decimals="4">101.88</ix:nonFraction>%, expected term of <ix:nonFraction id="c134564534" contextRef="i_2024-03-31_ClassOfWarrantOrRightAxis-BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember" unitRef="Year" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" format="ixt:num-dot-decimal" decimals="INF">5</ix:nonFraction> years, risk free rate of <ix:nonFraction id="c134564535" contextRef="i_2024-03-31_ClassOfWarrantOrRightAxis-BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" format="ixt:num-dot-decimal" decimals="3">4.40</ix:nonFraction>%, discount rate of <ix:nonFraction id="c134564536" contextRef="i_2024-03-31_ClassOfWarrantOrRightAxis-BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember_MeasurementInputTypeAxis-MeasurementInputDiscountRateMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" format="ixt:num-dot-decimal" decimals="1">20.00</ix:nonFraction>% and a discount for lack of marketability of <ix:nonFraction id="c134564537" contextRef="i_2023-12-31_ClassOfWarrantOrRightAxis-BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember_MeasurementInputTypeAxis-MeasurementInputDiscountForLackOfMarketabilityMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" format="ixt:num-dot-decimal" decimals="4">15.77</ix:nonFraction>%.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">During the year ended <em style="font: inherit;"> March 31, 2025, </em>the Company recorded less than $<ix:nonFraction id="c134564538" contextRef="d_2024-04-01_2025-03-31_DebtInstrumentAxis-TheNotesMember_RangeAxis-MaximumMember" unitRef="USD" name="us-gaap:InterestExpenseDebt" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.2</ix:nonFraction> million in interest expense related to the amortization of the debt discount.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The following table presents a summary of activity for the warrants issued in connection with the Company&#8217;s Notes:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:nonNumeric contextRef="d_2024-04-01_2025-03-31" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="c3016962" escape="true">
    <table cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 0pt; margin-right: 0pt;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Warrants</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted-</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Average </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Exercise </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Price Per </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Share</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Remaining </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Life (In </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Years)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Aggregate </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Intrinsic </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Value*</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 48%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding and exercisable, March 31, 2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134564050" contextRef="i_2024-03-31" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">25,003</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134564051" contextRef="i_2024-03-31" unitRef="USDPerShare" name="amix:ClassOfWarrantOrRightOutstandingOutstandingWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">20.00</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted"><ix:nonNumeric contextRef="d_2023-04-01_2024-03-31" name="amix:ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm" id="c134564052" format="ixt-sec:duryear">4.48</ix:nonNumeric></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134564053" contextRef="i_2024-03-31" unitRef="USD" name="amix:ClassOfWarrantOrRightAggregateIntrinsicValueOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,010,000</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c134564054" contextRef="d_2024-04-01_2025-03-31" unitRef="Share" name="amix:ClassOfWarrantOrRightGrantsInPeriod" scale="0" format="ixt:fixed-zero" decimals="INF">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c134564055" contextRef="d_2024-04-01_2025-03-31" unitRef="USDPerShare" name="amix:ClassOfWarrantOrRightGrantsInPeriodWeightedAverageExercise" scale="0" format="ixt:fixed-zero" decimals="INF">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Exercised</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c134564058" contextRef="d_2024-04-01_2025-03-31" unitRef="Share" name="amix:ClassOfWarrantOrRightExercisesInPeriod" scale="0" format="ixt:fixed-zero" decimals="INF" sign="-">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c134564059" contextRef="d_2024-04-01_2025-03-31" unitRef="USDPerShare" name="amix:ClassOfWarrantOrRightExercisesInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:fixed-zero" decimals="INF">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Forfeited/Cancelled</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c134564062" contextRef="d_2024-04-01_2025-03-31" unitRef="Share" name="amix:ClassOfWarrantOrRightForfeituresInPeriod" scale="0" format="ixt:fixed-zero" decimals="INF" sign="-">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c134564063" contextRef="d_2024-04-01_2025-03-31" unitRef="USDPerShare" name="amix:ClassOfWarrantOrRightForfeituresInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:fixed-zero" decimals="INF">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Expired</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c134564066" contextRef="d_2024-04-01_2025-03-31" unitRef="Share" name="amix:ClassOfWarrantOrRightExpirationsInPeriod" scale="0" format="ixt:fixed-zero" decimals="INF" sign="-">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c134564067" contextRef="d_2024-04-01_2025-03-31" unitRef="USDPerShare" name="amix:ClassOfWarrantOrRightExpirationsInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:fixed-zero" decimals="INF">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding, March 31, 2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c134564070" contextRef="i_2025-03-31" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">25,003</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c134564071" contextRef="i_2025-03-31" unitRef="USDPerShare" name="amix:ClassOfWarrantOrRightOutstandingOutstandingWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">20.00</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonNumeric contextRef="d_2024-04-01_2025-03-31" name="amix:ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm" id="c134564072" format="ixt-sec:duryear">3.48</ix:nonNumeric></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c134564073" contextRef="i_2025-03-31" unitRef="USD" name="amix:ClassOfWarrantOrRightAggregateIntrinsicValueOutstanding" scale="0" format="ixt:fixed-zero" decimals="INF">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Exercisable, March 31, 2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c134564074" contextRef="i_2025-03-31" unitRef="Share" name="amix:ClassOfWarrantOrRightExercisableNumber" scale="0" format="ixt:num-dot-decimal" decimals="INF">25,003</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c134564075" contextRef="d_2024-04-01_2025-03-31" unitRef="USDPerShare" name="amix:ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">20.00</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonNumeric contextRef="d_2024-04-01_2025-03-31" name="amix:ClassOfWarrantOrRightExercisableWeightedAverageRemainingContractualTerm" id="c134564076" format="ixt-sec:duryear">3.48</ix:nonNumeric></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c134564077" contextRef="i_2025-03-31" unitRef="USD" name="amix:ClassOfWarrantOrRightAggregateIntrinsicValueExercisable" scale="0" format="ixt:fixed-zero" decimals="INF">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">*Aggregate Intrinsic Value = Excess of market value over the exercise price of all in-the-money warrants.&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:exclude>
    <div class="PGNUM" style="width: 100%; text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
     <em style="font: inherit;">94</em>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
  </ix:nonNumeric>
  <div>
   &#160;
  </div>
  <ix:nonNumeric contextRef="d_2024-04-01_2025-03-31" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="c3016963" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Note <em style="font: inherit;">4</em> </b>&#8211;<b> Equity</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> November 29, 2023, </em>the Company&#8217;s Board of Directors and applicable shareholders approved to amend and restate the Company&#8217;s certificate of incorporation and increased the authorized shares to <ix:nonFraction id="c134564541" contextRef="i_2023-11-29" unitRef="Share" name="us-gaap:CommonStockSharesAuthorized" scale="0" format="ixt:num-dot-decimal" decimals="INF">500,000,000</ix:nonFraction> shares of common stock, with a par value of <span style="-sec-ix-hidden:c134564542">$.001</span> per share, and <ix:nonFraction id="c134564543" contextRef="i_2023-11-29" unitRef="Share" name="us-gaap:PreferredStockSharesAuthorized" scale="0" format="ixt:num-dot-decimal" decimals="INF">10,000,000</ix:nonFraction> shares of preferred stock, with a par value of <span style="-sec-ix-hidden:c134564544">$.001</span> per share. The specific rights of the preferred stock shall be determined by the Board of Directors.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Preferred Stock </i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">As of <em style="font: inherit;"> March 31, 2025, </em>the Company had <ix:nonFraction id="c134564545" contextRef="i_2025-03-31" unitRef="Share" name="us-gaap:PreferredStockSharesOutstanding" scale="0" format="ixt-sec:numwordsen" decimals="-3">no</ix:nonFraction> shares of preferred stock outstanding.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Restricted Stock</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> February 15, 2024, </em>the Company issued&#160;<ix:nonFraction id="c134564546" contextRef="d_2024-02-15_2024-02-15_AwardTypeAxis-RestrictedStockMember_TitleOfIndividualAxis-MarketingConsultantMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,750</ix:nonFraction> restricted shares of common stock to the Company's marketing consultant at the closing price of $<ix:nonFraction id="c134564547" contextRef="i_2024-02-15_AwardTypeAxis-RestrictedStockMember_TitleOfIndividualAxis-MarketingConsultantMember" unitRef="USDPerShare" name="us-gaap:SharesIssuedPricePerShare" scale="0" format="ixt:num-dot-decimal" decimals="INF">76.00</ix:nonFraction> of the Company's common stock. The total value of these shares is $<ix:nonFraction id="c134564548" contextRef="d_2024-02-15_2024-02-15_AwardTypeAxis-RestrictedStockMember_TitleOfIndividualAxis-MarketingConsultantMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" format="ixt:num-dot-decimal" decimals="INF">133,000</ix:nonFraction>. These shares vest monthly over a <ix:nonNumeric contextRef="d_2024-02-15_2024-02-15_AwardTypeAxis-RestrictedStockMember_TitleOfIndividualAxis-MarketingConsultantMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="c134564549" format="ixt-sec:durmonth">12</ix:nonNumeric>-month period beginning on the issue&#160;date.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:nonNumeric contextRef="d_2024-04-01_2025-03-31" name="amix:RestrictedStockExpensesGeneralAndAdministrativeTableTextBlock" id="c3016964" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Year ended March 31,</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Recognized in general and administrative expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c134564078" contextRef="d_2024-04-01_2025-03-31_AwardTypeAxis-RestrictedStockMember_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" format="ixt:num-dot-decimal" decimals="INF">116,375</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted"><ix:nonFraction id="c134564079" contextRef="d_2023-04-01_2024-03-31_AwardTypeAxis-RestrictedStockMember_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" format="ixt:num-dot-decimal" decimals="INF">16,625</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c134564080" contextRef="d_2024-04-01_2025-03-31_AwardTypeAxis-RestrictedStockMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" format="ixt:num-dot-decimal" decimals="INF">116,375</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted"><ix:nonFraction id="c134564081" contextRef="d_2023-04-01_2024-03-31_AwardTypeAxis-RestrictedStockMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" format="ixt:num-dot-decimal" decimals="INF">16,625</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">For the year ended <em style="font: inherit;"> March 31, 2025, </em>there was <ix:nonFraction id="c134564550" contextRef="i_2025-03-31_AwardTypeAxis-RestrictedStockMember" unitRef="USD" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="0" format="ixt-sec:numwordsen" decimals="-3">no</ix:nonFraction> unrecognized stock-based compensation expense related to unvested Restricted Stock.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">A summary of activity regarding Restricted Stock issued is as follows:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:nonNumeric contextRef="d_2024-04-01_2025-03-31" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" id="c3016965" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Grant Date</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Number of </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Shares</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Fair Value Per </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Share</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding, March 31, 2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted"><ix:nonFraction id="c134564082" contextRef="i_2024-03-31_AwardTypeAxis-RestrictedStockMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,604</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134564083" contextRef="i_2024-03-31_AwardTypeAxis-RestrictedStockMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" format="ixt:num-dot-decimal" decimals="INF">76.00</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted"><ix:nonFraction id="c134564084" contextRef="d_2024-04-01_2025-03-31_AwardTypeAxis-RestrictedStockMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" format="ixt:fixed-zero" decimals="INF">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c134564085" contextRef="d_2024-04-01_2025-03-31_AwardTypeAxis-RestrictedStockMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" format="ixt:fixed-zero" decimals="INF">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Vested</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted">(<ix:nonFraction id="c134564086" contextRef="d_2024-04-01_2025-03-31_AwardTypeAxis-RestrictedStockMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,604</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c134564087" contextRef="d_2024-04-01_2025-03-31_AwardTypeAxis-RestrictedStockMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" format="ixt:num-dot-decimal" decimals="INF">76.00</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding, March 31, 2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted"><ix:nonFraction id="c134564088" contextRef="i_2025-03-31_AwardTypeAxis-RestrictedStockMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" format="ixt:fixed-zero" decimals="INF">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c134564089" contextRef="i_2025-03-31_AwardTypeAxis-RestrictedStockMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" format="ixt:fixed-zero" decimals="INF">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Common Stock </i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> April 6, 2023, </em>the Board of Directors approved a private placement offering of up to <ix:nonFraction id="c134564551" contextRef="i_2023-04-06_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="Share" name="amix:EquityOfferingMaximumSharesToBeIssued" scale="0" format="ixt:num-dot-decimal" decimals="INF">100,000</ix:nonFraction> common shares at a price of $<ix:nonFraction id="c134564552" contextRef="i_2023-04-06_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="USDPerShare" name="us-gaap:SharesIssuedPricePerShare" scale="0" format="ixt:num-dot-decimal" decimals="INF">40.00</ix:nonFraction> per share. During the year ended <em style="font: inherit;"> March 31, 2024, </em>the Company sold <ix:nonFraction id="c134564553" contextRef="d_2023-04-01_2024-03-31_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:num-dot-decimal" decimals="INF">71,000</ix:nonFraction> shares for cash proceeds of $<ix:nonFraction id="c134564554" contextRef="d_2023-04-01_2024-03-31_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" format="ixt:num-dot-decimal" decimals="INF">2,840,000</ix:nonFraction>. The Company did <span style="-sec-ix-hidden:c134564555">not</span> incur any costs that were direct and incremental to the private placement.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> September 9, 2023, </em>the Board approved a Bridge Offering. See Note <em style="font: inherit;">3</em> <i>Convertible Notes Payable</i> for additional detail as these notes are convertible into common stock.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> February 28, 2025, </em>the Company entered into an ATM Agreement. Pursuant to the terms of the Agreement, the Company <em style="font: inherit;"> may </em>sell from time to time, the Company&#8217;s Common Stock, par value $<ix:nonFraction id="c134564557" contextRef="i_2025-02-28" unitRef="USDPerShare" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.001</ix:nonFraction> per share, with an initial aggregate sales price of up to $<ix:nonFraction id="c134564558" contextRef="i_2025-02-28_SubsidiarySaleOfStockAxis-ATMAgreementMember" unitRef="USD" name="amix:EquityOfferingMaximumOfferingAmount" scale="6" format="ixt:num-dot-decimal" decimals="-5">2.1</ix:nonFraction> million. As of <em style="font: inherit;"> March 31, 2025, </em>the Company sold <ix:nonFraction id="c134564559" contextRef="d_2025-03-01_2025-03-31_SubsidiarySaleOfStockAxis-ATMAgreementMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:num-dot-decimal" decimals="INF">800</ix:nonFraction> shares pursuant to the ATM Agreement for net proceeds of approximately $<ix:nonFraction id="c134564560" contextRef="d_2025-03-01_2025-03-31_SubsidiarySaleOfStockAxis-ATMAgreementMember" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,746</ix:nonFraction>.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Stock Plan and Stock Options</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">In <em style="font: inherit;"> June 2023, </em>the Company adopted, and the Company&#8217;s shareholders approved, the Autonomix Medical, Inc. <em style="font: inherit;">2023</em> Stock Plan (the &#8220;Plan&#8221;). The Plan is a stock-based compensation plan that provides for discretionary grants of stock options, stock awards and stock unit awards to key employees, non-employee directors, and consultants, subject to certain individual threshold limitations. The Plan provides for up to <ix:nonFraction id="c134564562" contextRef="i_2023-06-30_PlanNameAxis-The2023StockPlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" format="ixt:num-dot-decimal" decimals="INF">200,000</ix:nonFraction> shares to be issued. Shares that are surrendered because of forfeiture, expiration, termination, or cancellation are available for re-issuance. As of <em style="font: inherit;"> March 31, 2025, </em>there were <ix:nonFraction id="c134564563" contextRef="i_2025-03-31_PlanNameAxis-The2023StockPlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" format="ixt:num-dot-decimal" decimals="INF">75,633</ix:nonFraction> shares remaining available in the Plan.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:exclude>
    <div class="PGNUM" style="width: 100%; text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
     <em style="font: inherit;">95</em>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">In <em style="font: inherit;"> August 2023, </em>the Plan was amended to allow for an automatic increase of the available shares for issuance, whereby on the <em style="font: inherit;">1st</em> of each fiscal year, beginning on <em style="font: inherit;"> April 1, 2024 </em>and ending on (and including) <em style="font: inherit;"> April 1, 2033 </em>in an amount equal to <em style="font: inherit;">five</em> percent (<ix:nonFraction id="c134564567" contextRef="d_2023-08-01_2023-08-31_PlanNameAxis-The2023StockPlanMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" scale="-2" format="ixt:num-dot-decimal" decimals="2">5</ix:nonFraction>%) of the total number of shares of Common Stock outstanding on the <em style="font: inherit;"> March </em><em style="font: inherit;">31st</em> immediately preceding the applicable date. However, the Board <em style="font: inherit;"> may </em>act prior to the automatic increase of a given year to provide that there will be <em style="font: inherit;">no</em> increase for such year, or that the increase for such year will be a lesser number of shares of Common Stock. On <em style="font: inherit;"> April 1, 2024, </em>the Plan was increased by <ix:nonFraction id="c134564570" contextRef="d_2024-04-01_2024-04-01_PlanNameAxis-The2023StockPlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" format="ixt:num-dot-decimal" decimals="INF">47,116</ix:nonFraction> shares and on <em style="font: inherit;"> April 1, 2025, </em>the Plan was increased by <ix:nonFraction id="c134564571" contextRef="d_2025-04-01_2025-04-01_PlanNameAxis-The2023StockPlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" format="ixt:num-dot-decimal" decimals="INF">124,852</ix:nonFraction> shares.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The following table summarizes the stock option activity for the year ended <em style="font: inherit;"> March 31, 2025.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:nonNumeric contextRef="d_2024-04-01_2025-03-31" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="c3016966" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Options</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted-</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Average </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Exercise </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Price </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Per Share</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted-</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Average </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Remaining</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Life </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(In Years)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Aggregate </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Intrinsic </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Value*</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding, March 31, 2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134564090" contextRef="i_2024-03-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" format="ixt:num-dot-decimal" decimals="INF">100,180</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134564091" contextRef="i_2024-03-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">46.59</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonNumeric contextRef="d_2023-04-01_2024-03-31" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="c134564092" format="ixt-sec:duryear">9.35</ix:nonNumeric></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134564093" contextRef="i_2024-04-01" unitRef="USD" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,680,672</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134564094" contextRef="d_2024-04-01_2025-03-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" format="ixt:num-dot-decimal" decimals="INF">143,303</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134564095" contextRef="d_2024-04-01_2025-03-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">23.02</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Exercised</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c134564098" contextRef="d_2024-04-01_2025-03-31" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" format="ixt:fixed-zero" decimals="INF">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c134564099" contextRef="d_2024-04-01_2025-03-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:fixed-zero" decimals="INF">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Forfeited/Cancelled</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c134564102" contextRef="d_2024-04-01_2025-03-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" format="ixt:fixed-zero" decimals="INF" sign="-">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c134564103" contextRef="d_2024-04-01_2025-03-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:fixed-zero" decimals="INF">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Expired</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c134564106" contextRef="d_2024-04-01_2025-03-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="0" format="ixt:fixed-zero" decimals="INF" sign="-">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c134564107" contextRef="d_2024-04-01_2025-03-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:fixed-zero" decimals="INF">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding, March 31, 2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c134564110" contextRef="i_2025-03-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" format="ixt:num-dot-decimal" decimals="INF">243,483</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c134564111" contextRef="i_2025-03-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">32.72</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonNumeric contextRef="d_2024-04-01_2025-03-31" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="c134564112" format="ixt-sec:duryear">8.92</ix:nonNumeric></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c134564113" contextRef="i_2025-03-31" unitRef="USD" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" format="ixt:fixed-zero" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Exercisable, March 31, 2025*</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c134564114" contextRef="i_2025-03-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" format="ixt:num-dot-decimal" decimals="INF">37,923</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c134564115" contextRef="i_2025-03-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">44.35</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonNumeric contextRef="d_2024-04-01_2025-03-31" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="c134564116" format="ixt-sec:duryear">8.20</ix:nonNumeric></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c134564117" contextRef="i_2025-03-31" unitRef="USD" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="0" format="ixt:fixed-zero" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">*Aggregate Intrinsic Value = Excess of market value over the exercise price of all in-the-money stock.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:exclude>
    <div class="PGNUM" style="width: 100%; text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
     <em style="font: inherit;">96</em>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">During the year ended <em style="font: inherit;"> March 31, 2025, </em>the Company granted certain&#160;individuals options to purchase <ix:nonFraction id="c134564573" contextRef="d_2024-04-01_2025-03-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2023StockPlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" format="ixt:num-dot-decimal" decimals="INF">143,303</ix:nonFraction> shares of common stock with contractual terms&#160;of <span style="-sec-ix-hidden:c134564574">ten</span> years, and vesting periods of annually over <span style="-sec-ix-hidden:c134564575">four</span> years. The options had an aggregate grant date fair value of $<ix:nonFraction id="c134564576" contextRef="i_2025-03-31_AwardTypeAxis-EmployeeStockOptionMember_ValuationTechniqueAxis-BlackscholesModelMember" unitRef="USD" name="amix:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantDateFairValue" scale="6" format="ixt:num-dot-decimal" decimals="-5">2.6</ix:nonFraction>&#160;million that was calculated using the Black-Scholes option pricing model. Variables used in the Black-Scholes option pricing model included the following: (<em style="font: inherit;">1</em>) fair value of common stock on the measurement date ranging from $<ix:nonFraction id="c134564578" contextRef="i_2025-03-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MinimumMember_ValuationTechniqueAxis-BlackscholesModelMember" unitRef="USDPerShare" name="us-gaap:SharePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">1.99</ix:nonFraction> and $<ix:nonFraction id="c134564579" contextRef="i_2025-03-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MaximumMember_ValuationTechniqueAxis-BlackscholesModelMember" unitRef="USDPerShare" name="us-gaap:SharePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">56.20</ix:nonFraction> per share; (<em style="font: inherit;">2</em>) discount rate ranging from <ix:nonFraction id="c134564581" contextRef="d_2024-04-01_2025-03-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MinimumMember_ValuationTechniqueAxis-BlackscholesModelMember" unitRef="Pure" name="amix:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsDiscountRate" scale="-2" format="ixt:num-dot-decimal" decimals="4">4.17</ix:nonFraction>% to <ix:nonFraction id="c134564582" contextRef="d_2024-04-01_2025-03-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MaximumMember_ValuationTechniqueAxis-BlackscholesModelMember" unitRef="Pure" name="amix:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsDiscountRate" scale="-2" format="ixt:num-dot-decimal" decimals="4">4.39</ix:nonFraction>% based on the daily yield curve rates for U.S. Treasury obligations, (<em style="font: inherit;">3</em>) expected life of <ix:nonNumeric contextRef="d_2024-04-01_2025-03-31_AwardTypeAxis-EmployeeStockOptionMember_ValuationTechniqueAxis-BlackscholesModelMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="c134564584" format="ixt-sec:duryear">6.25</ix:nonNumeric> years based on the simplified method (vesting plus contractual term divided by <em style="font: inherit;">two</em>), and (<em style="font: inherit;">4</em>) expected volatility ranging from <ix:nonFraction id="c134564587" contextRef="d_2024-04-01_2025-03-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MinimumMember_ValuationTechniqueAxis-BlackscholesModelMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" format="ixt:num-dot-decimal" decimals="1">110</ix:nonFraction>% to <ix:nonFraction id="c134564588" contextRef="d_2024-04-01_2025-03-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MaximumMember_ValuationTechniqueAxis-BlackscholesModelMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" format="ixt:num-dot-decimal" decimals="2">138</ix:nonFraction>% based on the historical volatility of comparable companies' stock.&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">All options issued and outstanding are being amortized over their respective vesting periods. The unrecognized compensation expense at <em style="font: inherit;"> March 31, 2025 </em>was $<ix:nonFraction id="c134564589" contextRef="i_2025-03-31_AwardTypeAxis-EmployeeStockOptionMember" unitRef="USD" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" format="ixt:num-dot-decimal" decimals="-5">4.3</ix:nonFraction> million. During the year ended <em style="font: inherit;"> March 31, 2025, </em>the Company recorded stock-based compensation - option expense of $<ix:nonFraction id="c134564590" contextRef="d_2024-04-01_2025-03-31_AwardTypeAxis-EmployeeStockOptionMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" format="ixt:num-dot-decimal" decimals="-5">1.5</ix:nonFraction> million, of which $<ix:nonFraction id="c134564591" contextRef="d_2024-04-01_2025-03-31_AwardTypeAxis-EmployeeStockOptionMember_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" format="ixt:num-dot-decimal" decimals="-5">1.3</ix:nonFraction> million was recorded&#160;in general and administrative expenses and $<ix:nonFraction id="c134564592" contextRef="d_2024-04-01_2025-03-31_AwardTypeAxis-EmployeeStockOptionMember_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.2</ix:nonFraction> million was recorded in research and development expenses in the statements of operations. The unrecognized compensation expense at <em style="font: inherit;"> March 31, 2024 </em>was $<ix:nonFraction id="c134564593" contextRef="i_2024-03-31_AwardTypeAxis-EmployeeStockOptionMember" unitRef="USD" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" format="ixt:num-dot-decimal" decimals="-5">3.1</ix:nonFraction> million. During the year ended <em style="font: inherit;"> March 31, 2024, </em>the Company recorded stock-based compensation - option expense of $<ix:nonFraction id="c134564594" contextRef="d_2023-04-01_2024-03-31_AwardTypeAxis-EmployeeStockOptionMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.6</ix:nonFraction> million, of which $<ix:nonFraction id="c134564595" contextRef="d_2023-04-01_2024-03-31_AwardTypeAxis-EmployeeStockOptionMember_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.5</ix:nonFraction> million was recorded&#160;in general and administrative expenses and $<ix:nonFraction id="c134564596" contextRef="d_2023-04-01_2024-03-31_AwardTypeAxis-EmployeeStockOptionMember_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.1</ix:nonFraction> million was recorded in research and development expenses in the statements of operations.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>License Agreement</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> July 10, 2024, </em>we entered into a license agreement (the &#8220;Agreement&#8221;) with RF Innovations, Inc. (&#8220;RFI&#8221;), a privately held medical technology company, to license products utilizing RFI&#8217;s intellectual property related to its Apex <em style="font: inherit;">6</em> Radiofrequency Generator (the &#8220;Licensed Products&#8221;). The Apex <em style="font: inherit;">6</em> Generator is a United States Food and Drug Administration (&#8220;FDA&#8221;) cleared ablation technology designed to lesion neural tissue for pain management in the peripheral nervous system. Pursuant to the Agreement, RFI granted us a perpetual non-exclusive worldwide royalty free fully paid license related to the Licensed Products, provided that the license did <em style="font: inherit;">not</em> include the right to sell certain products to customers for the treatment of spine pain. In connection with the Agreement, we issued RFI <ix:nonFraction id="c134564600" contextRef="d_2024-07-10_2024-07-10_CounterpartyNameAxis-RfInnovationsIncMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:num-dot-decimal" decimals="INF">12,500</ix:nonFraction> unregistered shares of our common stock as consideration for the license. The Company determined that the fair value of the shares granted was $<ix:nonFraction id="c134564601" contextRef="d_2024-07-10_2024-07-10_CounterpartyNameAxis-RfInnovationsIncMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.1</ix:nonFraction> million, which represented its stock price on the date of the Agreement less a <ix:nonFraction id="c134564602" contextRef="i_2024-07-10_CounterpartyNameAxis-RfInnovationsIncMember" unitRef="Pure" name="amix:CommonStockDiscountForLackOfMarketability" scale="-2" format="ixt:num-dot-decimal" decimals="3">25.6</ix:nonFraction>% discount for lack of marketability (&#8220;DLOM&#8221;).&#160; The Company concluded a discount for lack of marketability was appropriate as the shares are subject to an initial lock-up period of <em style="font: inherit;">six</em>-months until they are eligible for registration pursuant to SEC Rule <em style="font: inherit;">144</em> followed by restrictions that allow for a maximum of <ix:nonFraction id="c134564605" contextRef="i_2024-07-10_CounterpartyNameAxis-RfInnovationsIncMember" unitRef="Pure" name="amix:MaximumPercentageOfSharesSoldInThirtyDays" scale="-2" format="ixt:num-dot-decimal" decimals="1">10</ix:nonFraction>% of total shares to be sold within a <em style="font: inherit;">30</em>-day period.&#160;The DLOM effectively reflects the value of an average strike put option relative to our stock price and was calculated based on the Finnerty average put model.&#160;The Company concluded that the licensed technology qualified as a research and development expense pursuant to ASC Topic <em style="font: inherit;">730,</em> Research and Development, as the Company does <em style="font: inherit;">not</em> have an alternative future use for the technology and the Company does <em style="font: inherit;">not</em> have a plan to otherwise monetize the Licensed Products.&#160;The Company recognized $<ix:nonFraction id="c134564610" contextRef="d_2024-10-01_2024-12-31_CounterpartyNameAxis-RfInnovationsIncMember_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.1</ix:nonFraction> million in Research and Development expense in its condensed statement of income for the <em style="font: inherit;">three</em> and <em style="font: inherit;">nine</em>-months ended <em style="font: inherit;"> December 31, 2024.&#160;</em>The Agreement provides RFI the right to terminate the license if we breach any representation, warranty or covenant contained in the Agreement, subject to any relevant cure periods, or if we are subject to a bankruptcy or insolvency event.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Offering Agreement </i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> November 22, 2024, </em>the Company entered into the Offering, which consisted of: (i) <ix:nonFraction id="c134564613" contextRef="d_2024-11-22_2024-11-25_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember" unitRef="Share" name="amix:NumberOfCommonUnitsIssued" scale="0" format="ixt:num-dot-decimal" decimals="INF">458,691</ix:nonFraction> Common Units, each Common Unit consisting of <span style="-sec-ix-hidden:c134564614">one</span> share of common stock, par value $<ix:nonFraction id="c134564615" contextRef="i_2024-11-25_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember" unitRef="USDPerShare" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.001</ix:nonFraction> per share, and <span style="-sec-ix-hidden:c134564616">one</span> Series A Warrant to purchase <span style="-sec-ix-hidden:c134564617">one</span> share of common stock; and (ii) <ix:nonFraction id="c134564618" contextRef="d_2024-11-22_2024-11-25_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember" unitRef="Share" name="amix:NumberOfPrefundedUnitsIssued" scale="0" format="ixt:num-dot-decimal" decimals="INF">917,596</ix:nonFraction> Pre-Funded Units, each Pre-Funded Unit consisting of <span style="-sec-ix-hidden:c134564619">one</span> Pre-Funded Warrant to purchase <span style="-sec-ix-hidden:c134564620">one</span> share of common stock and <span style="-sec-ix-hidden:c134564621">one</span> Series A Warrant. The purchase price of each Common Unit was $<ix:nonFraction id="c134564622" contextRef="d_2024-11-22_2024-11-25_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember" unitRef="USDPerShare" name="amix:CommonUnitsIssuedPurchasePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">6.540</ix:nonFraction>, and the purchase price of each Pre-Funded Unit was $<ix:nonFraction id="c134564623" contextRef="d_2024-11-22_2024-11-25_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember" unitRef="USDPerShare" name="amix:PrefundedUnitsIssuedPurchasePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">6.539</ix:nonFraction>.&#160;In addition, the Company granted the Underwriters a <ix:nonNumeric contextRef="d_2024-11-22_2024-11-22_CounterpartyNameAxis-UnderwritersMember_SubsidiarySaleOfStockAxis-OverAllotmentOptionMember" name="amix:EquityOfferingOptionPeriod" id="c134564624" format="ixt-sec:durday">45</ix:nonNumeric>-day option to purchase additional <ix:nonFraction id="c134564625" contextRef="i_2024-11-22_CounterpartyNameAxis-UnderwritersMember_SubsidiarySaleOfStockAxis-OverAllotmentOptionMember" unitRef="Share" name="amix:EquityOfferingOptionMaximumShares" scale="0" format="ixt:num-dot-decimal" decimals="INF">206,422</ix:nonFraction> shares of common stock, and/or additional <ix:nonFraction id="c134564626" contextRef="i_2024-11-22_ClassOfWarrantOrRightAxis-SeriesAWarrantsMember_CounterpartyNameAxis-UnderwritersMember" unitRef="Share" name="amix:EquityOfferingOptionMaximumWarrants" scale="0" format="ixt:num-dot-decimal" decimals="INF">206,422</ix:nonFraction> Series A Warrants, solely to cover over-allotments, if any. The Offering closed on <em style="font: inherit;"> November 25, 2024. </em>On <em style="font: inherit;"> November 22, 2024, </em>the Underwriters partially exercised their over-allotment option with respect to <ix:nonFraction id="c134564627" contextRef="d_2024-11-22_2024-11-22_CounterpartyNameAxis-UnderwritersMember_SubsidiarySaleOfStockAxis-OverAllotmentOptionMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:num-dot-decimal" decimals="INF">156,809</ix:nonFraction> shares of Common Stock and <ix:nonFraction id="c134564628" contextRef="d_2024-11-22_2024-11-22_ClassOfWarrantOrRightAxis-SeriesAWarrantsMember_CounterpartyNameAxis-UnderwritersMember" unitRef="Share" name="amix:ClassOfWarrantOrRightIssuedDuringPeriod" scale="0" format="ixt:num-dot-decimal" decimals="INF">156,809</ix:nonFraction> Series A Warrants. The Company received gross proceeds of $<ix:nonFraction id="c134564629" contextRef="d_2024-11-22_2024-11-25_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="6" format="ixt:num-dot-decimal" decimals="-7">10.0</ix:nonFraction>&#160;million, before deducting the placement agent's fees and other offering expenses payable by the Company.&#160;Under the terms of the Underwriting Agreement, the Underwriters received an underwriting discount of <ix:nonFraction id="c134564630" contextRef="i_2024-11-25_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember" unitRef="Pure" name="amix:CommissionPercentage" scale="-2" format="ixt:num-dot-decimal" decimals="2">8.0</ix:nonFraction>% to the public offering price for the Units.&#160; The Company also issued to the Representative&#8217;s Warrants to purchase up to <ix:nonFraction id="c134564631" contextRef="d_2024-11-22_2024-11-25_ClassOfWarrantOrRightAxis-RepresentativesWarrantsMember_CounterpartyNameAxis-UnderwritersMember" unitRef="Share" name="amix:ClassOfWarrantOrRightIssuedDuringPeriod" scale="0" format="ixt:num-dot-decimal" decimals="INF">91,985</ix:nonFraction> shares of Common Stock.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Pre-Funded Warrants have an exercise price of $<ix:nonFraction id="c134564632" contextRef="i_2024-11-25_ClassOfWarrantOrRightAxis-PrefundedWarrantsMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.001</ix:nonFraction> per share, are immediately exercisable and <em style="font: inherit;"> may </em>be exercised at any time until all of the Pre-Funded Warrants are exercised in full, subject to a beneficial ownership limitation of <ix:nonFraction id="c134564633" contextRef="i_2024-11-25_ClassOfWarrantOrRightAxis-PrefundedWarrantsMember" unitRef="Pure" name="amix:ClassOfWarrantsOrRightsMaximumBeneficialOwnership" scale="-2" format="ixt:num-dot-decimal" decimals="4">4.99</ix:nonFraction>%. The Series A Warrants have an exercise price of $<ix:nonFraction id="c134564634" contextRef="i_2024-11-25_ClassOfWarrantOrRightAxis-SeriesAWarrantsMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:num-dot-decimal" decimals="INF">6.540</ix:nonFraction> per share and <em style="font: inherit;"> may </em>be exercised at any time until the <span style="-sec-ix-hidden:c134564635">five</span>-year anniversary of the date of issuance, subject to a beneficial ownership limitation of <ix:nonFraction id="c134564636" contextRef="i_2024-11-25_ClassOfWarrantOrRightAxis-SeriesAWarrantsMember" unitRef="Pure" name="amix:ClassOfWarrantsOrRightsMaximumBeneficialOwnership" scale="-2" format="ixt:num-dot-decimal" decimals="4">4.99</ix:nonFraction>%. The Pre-Funded Warrants and Series A Warrants were issued pursuant a Warrant Agency Agreement between the Company and Equity Stock Transfer, LLC.&#160;The Series A Warrants and the Representative&#8217;s Warrants, largely have the same terms and conditions, except the Representative&#8217;s Warrants were <em style="font: inherit;">not</em> exercisable until <em style="font: inherit;"> May 21, 2025 </em>and were subject to a <ix:nonNumeric contextRef="d_2024-11-22_2024-11-25_ClassOfWarrantOrRightAxis-RepresentativesWarrantsMember" name="amix:ClassOfWarrantOrRightLockupPeriod" id="c134564638" format="ixt-sec:durday">180</ix:nonNumeric>-day lock-up prior to being transferable.&#160;The Series A Warrants and Representative&#8217;s Warrants <em style="font: inherit;"> may, </em>at the option of the holder be settled upon a change of control at the Black-Scholes value, as defined in the agreement.&#160;Upon a change of control the holder <em style="font: inherit;"> may </em>receive cash, other assets or shares of the successor entity, depending on the specific nature of the change of control transaction and the settlement options afforded to the holders of Common Stock.&#160;The Company analyzed the Pre-Funded Warrants, the Series A Warrants, and the Representative&#8217;s Warrants (collectively the &#8220;Offering Warrants&#8221;) in accordance with ASC Topic <em style="font: inherit;">480,</em> Distinguishing Liabilities from Equity and ASC Topic <em style="font: inherit;">815,</em> Derivatives and Hedging.&#160;Management concluded that the Offering Warrants meet all the requirements for equity classification.&#160;Since the Offering Warrants meet the requirements for equity classification and the Offering represents an arms-length cash transaction, the Common Units and Pre-Funded Units were recorded in equity based on the proceeds received, net of issuance costs.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:exclude>
    <div class="PGNUM" style="width: 100%; text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
     <em style="font: inherit;">97</em>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">At issuance the Pre-Funded Warrants had a fair value of $<ix:nonFraction id="c134564642" contextRef="i_2024-11-25_ClassOfWarrantOrRightAxis-PrefundedWarrantsMember" unitRef="USDPerShare" name="amix:ClassOfWarrantOrRightFairValuePerShare" scale="0" format="ixt:num-dot-decimal" decimals="INF">6.3290</ix:nonFraction> per share, which represented the common stock issuance price less the $<ix:nonFraction id="c134564643" contextRef="i_2024-11-25_ClassOfWarrantOrRightAxis-PrefundedWarrantsMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.001</ix:nonFraction> exercise price.&#160;At issuance, the Series A Warrants and the Representative&#8217;s Warrants had&#160;a fair value of $<ix:nonFraction id="c134564644" contextRef="i_2024-11-25_ClassOfWarrantOrRightAxis-SeriesAWarrantsMember" unitRef="USDPerShare" name="amix:ClassOfWarrantOrRightFairValuePerShare" scale="0" format="ixt:num-dot-decimal" decimals="INF">5.3597</ix:nonFraction> and $<ix:nonFraction id="c134564645" contextRef="i_2024-11-25_ClassOfWarrantOrRightAxis-RepresentativesWarrantsMember" unitRef="USDPerShare" name="amix:ClassOfWarrantOrRightFairValuePerShare" scale="0" format="ixt:num-dot-decimal" decimals="INF">5.2125</ix:nonFraction>&#160;per share, respectively, which was determined using a Black-Scholes option pricing model.&#160;Variables used in the Black-Scholes option pricing model included the following: (<em style="font: inherit;">1</em>) fair value of common stock on the measurement date; (<em style="font: inherit;">2</em>) discount rate of <ix:nonFraction id="c134564648" contextRef="i_2024-11-25_ClassOfWarrantOrRightAxis-SeriesAWarrantsAndTheRepresentativesWarrantsMember_MeasurementInputTypeAxis-ValuationTechniqueDiscountedCashFlowMember_ValuationTechniqueAxis-BlackscholesModelMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" format="ixt:num-dot-decimal" decimals="4">4.17</ix:nonFraction>% based on the daily yield curve rates for U.S. Treasury obligations, (<em style="font: inherit;">3</em>) the contractual term of the warrants and (<em style="font: inherit;">4</em>) expected volatility of <ix:nonFraction id="c134564651" contextRef="i_2024-11-25_ClassOfWarrantOrRightAxis-SeriesAWarrantsAndTheRepresentativesWarrantsMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember_ValuationTechniqueAxis-BlackscholesModelMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" format="ixt:num-dot-decimal" decimals="4">144.15</ix:nonFraction>% based on the historical volatility of comparable companies' stock. Due to the relative volume of Series A Warrants and Representative&#8217;s Warrants issued compared with the Company&#8217;s outstanding shares, the Company's stock price was adjusted for the effects of dilution.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">In connection with the Offering, the Company incurred total offering costs of $<ix:nonFraction id="c134564652" contextRef="d_2024-11-22_2024-11-25_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="6" format="ixt:num-dot-decimal" decimals="-5">1.5</ix:nonFraction> million.&#160;This was comprised of $<ix:nonFraction id="c134564653" contextRef="d_2024-11-22_2024-11-25_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember" unitRef="USD" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" format="ixt:num-dot-decimal" decimals="-6">1.0</ix:nonFraction> million in cash offering costs and $<ix:nonFraction id="c134564654" contextRef="d_2024-11-22_2024-11-25_NatureOfExpenseAxis-NoncashExpensesMember_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.5</ix:nonFraction> million&#160;for the fair value of the Representative&#8217;s Warrant issued.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Equity-Based Stock Warrants</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> January 26, 2024, </em>the Company issued <span style="-sec-ix-hidden:c134564655">five</span>-year warrants to the selling agent in the Company's IPO to purchase <ix:nonFraction id="c134564656" contextRef="i_2024-01-26_ClassOfWarrantOrRightAxis-EquitybasedWarrantsMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" format="ixt:num-dot-decimal" decimals="INF">2,988</ix:nonFraction> shares of common stock at an exercise price of $<ix:nonFraction id="c134564657" contextRef="i_2024-01-26_ClassOfWarrantOrRightAxis-EquitybasedWarrantsMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:num-dot-decimal" decimals="INF">125.00</ix:nonFraction>. Under the fair value method, the fair value of these warrants was estimated on the grant date using the Black-Scholes option pricing model. Variables used in the Black-Scholes warrant pricing model included the following: (<em style="font: inherit;">1</em>) fair value of common stock on the measurement date of $<ix:nonFraction id="c134564659" contextRef="i_2024-01-26" unitRef="USDPerShare" name="us-gaap:SharePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">100.00</ix:nonFraction> split-adjusted per share; (<em style="font: inherit;">2</em>) discount rate of <ix:nonFraction id="c134564661" contextRef="i_2024-01-26_ClassOfWarrantOrRightAxis-EquitybasedWarrantsMember_MeasurementInputTypeAxis-MeasurementInputDiscountRateMember_ValuationTechniqueAxis-BlackscholesModelMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" format="ixt:num-dot-decimal" decimals="4">4.04</ix:nonFraction>% based on the daily yield curve rates for U.S. Treasury obligations; (<em style="font: inherit;">3</em>) expected life of <ix:nonFraction id="c134564663" contextRef="i_2024-01-26_ClassOfWarrantOrRightAxis-EquitybasedWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember_ValuationTechniqueAxis-BlackscholesModelMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" format="ixt:num-dot-decimal" decimals="INF">5</ix:nonFraction> years and (<em style="font: inherit;">4</em>) expected volatility of <ix:nonFraction id="c134564665" contextRef="i_2024-01-26_ClassOfWarrantOrRightAxis-EquitybasedWarrantsMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember_ValuationTechniqueAxis-BlackscholesModelMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" format="ixt:num-dot-decimal" decimals="2">104</ix:nonFraction>% based on the historical volatility of comparable companies' stock. The costs associated with these shares were reclassified to additional paid-in capital upon completion of the Company&#8217;s IPO on <em style="font: inherit;"> January 26, 2024.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company will periodically grant warrants to investors in connection with equity financing or to <em style="font: inherit;">third</em>-party service providers in exchange for services rendered. The following table summarizes the stock warrant activity for the year ended <em style="font: inherit;"> March 31, 2025:</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:nonNumeric contextRef="d_2024-04-01_2025-03-31" name="us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" id="c3016967" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Warrants</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted-</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Average </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Exercise </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Price Per </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Share</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted-</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Average </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Remaining </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Life (In </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Years)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Aggregate </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Intrinsic </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Value*</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding and exercisable, March 31, 2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134564118" contextRef="i_2024-03-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" scale="0" format="ixt:num-dot-decimal" decimals="INF">287,231</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134564119" contextRef="i_2024-03-31" unitRef="USDPerShare" name="amix:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">1.64</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonNumeric contextRef="d_2023-04-01_2024-03-31" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" id="c134564120" format="ixt-sec:duryear">4.80</ix:nonNumeric></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134564121" contextRef="i_2024-04-01" unitRef="USD" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">17,072,147</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134564122" contextRef="d_2024-04-01_2025-03-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" scale="0" format="ixt:num-dot-decimal" decimals="INF">2,542,677</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134564123" contextRef="d_2024-04-01_2025-03-31" unitRef="USDPerShare" name="amix:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">4.31</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Exercised**</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c134564126" contextRef="d_2024-04-01_2025-03-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" scale="0" format="ixt:num-dot-decimal" decimals="INF">892,432</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134564127" contextRef="d_2024-04-01_2025-03-31" unitRef="USDPerShare" name="amix:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.04</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Forfeited/Cancelled</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c134564130" contextRef="d_2024-04-01_2025-03-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" scale="0" format="ixt:num-dot-decimal" decimals="INF">2,602</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134564131" contextRef="d_2024-04-01_2025-03-31" unitRef="USDPerShare" name="amix:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.20</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Expired</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c134564134" contextRef="d_2024-04-01_2025-03-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" scale="0" format="ixt:fixed-zero" decimals="INF" sign="-">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c134564135" contextRef="d_2024-04-01_2025-03-31" unitRef="USDPerShare" name="amix:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:fixed-zero" decimals="INF">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding, March 31, 2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c134564138" contextRef="i_2025-03-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,934,874</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c134564139" contextRef="i_2025-03-31" unitRef="USDPerShare" name="amix:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">5.89</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonNumeric contextRef="d_2024-04-01_2025-03-31" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" id="c134564140" format="ixt-sec:duryear">4.09</ix:nonNumeric></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c134564141" contextRef="i_2025-03-31" unitRef="USD" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">532,060</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Exercisable, March 31, 2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c134564142" contextRef="i_2025-03-31" unitRef="Share" name="amix:SharebasedCompensationArrangementBySharebasedPaymentAwardNonoptionEquityInstrumentsExercisableNumberOutstandingNumber" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,842,889</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c134564143" contextRef="i_2025-03-31" unitRef="USDPerShare" name="amix:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">5.67</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonNumeric contextRef="d_2024-04-01_2025-03-31" name="amix:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerm" id="c134564144" format="ixt-sec:duryear">4.06</ix:nonNumeric></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c134564145" contextRef="d_2024-04-01_2025-03-31" unitRef="USD" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" scale="0" format="ixt:num-dot-decimal" decimals="INF">532,060</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">*Aggregate Intrinsic Value = Excess of market value over the exercise price of all in-the-money stock.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><span style="-sec-ix-hidden:c134564667">**197,098</span>&#160;exercised shares utilized the &#8220;cashless exercise&#8221; option and <ix:nonFraction id="c134564668" contextRef="d_2024-04-01_2025-03-31_ClassOfWarrantOrRightAxis-EquitybasedWarrantsMember" unitRef="Share" name="amix:ClassOfWarrantOrRightExercisedInPeriodCash" scale="0" format="ixt:num-dot-decimal" decimals="INF">695,334</ix:nonFraction> exercised shares were paid in cash.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The unrecognized compensation expense at <em style="font: inherit;"> March 31, 2025 </em>was $<ix:nonFraction id="c134564669" contextRef="i_2025-03-31_AwardTypeAxis-WarrantMember" unitRef="USD" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>. During the year ended <em style="font: inherit;"> March 31, 2025, </em>the Company recorded stock-based compensation - warrant expense of less than $<ix:nonFraction id="c134564670" contextRef="d_2024-04-01_2025-03-31_AwardTypeAxis-WarrantMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.1</ix:nonFraction> million. The unrecognized compensation expense at <em style="font: inherit;"> March 31, 2024 </em>was less than <span style="-sec-ix-hidden:c134564671">$0.1</span> million.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">During the year ended <em style="font: inherit;"> March 31, 2024, </em>the Company recorded stock-based compensation - warrant expense of less than $<ix:nonFraction id="c134564672" contextRef="d_2023-04-01_2024-03-31_AwardTypeAxis-WarrantMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.1</ix:nonFraction> million.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Under the fair value method, the fair value of each warrant was estimated on the grant date using the Black-Scholes option pricing model. Variables used in the Black-Scholes warrant pricing model included the following:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:nonNumeric contextRef="d_2024-04-01_2025-03-31" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="c3016968" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 71%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="7" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 23%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Range</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 71%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2025</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 8%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2024</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 71%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Fair value of common stock on the measurement date (per share)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8211;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">$<ix:nonFraction id="c134564146" contextRef="i_2024-03-31_AwardTypeAxis-WarrantMember_RangeAxis-MinimumMember_ValuationTechniqueAxis-BlackscholesModelMember" unitRef="USDPerShare" name="us-gaap:SharePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">2.00</ix:nonFraction></td><td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">to</em></td><td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134564148" contextRef="i_2024-03-31_AwardTypeAxis-WarrantMember_RangeAxis-MaximumMember_ValuationTechniqueAxis-BlackscholesModelMember" unitRef="USDPerShare" name="us-gaap:SharePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">5.00</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 71%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Discount rate based on the daily yield curve rates for U.S. Treasury obligations</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8211;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted"><ix:nonFraction id="c134564149" contextRef="d_2023-04-01_2024-03-31_AwardTypeAxis-WarrantMember_RangeAxis-MinimumMember_ValuationTechniqueAxis-BlackscholesModelMember" unitRef="Pure" name="amix:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsDiscountRate" scale="-2" format="ixt:num-dot-decimal" decimals="4">4.04</ix:nonFraction>%</td><td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;"><em style="font: inherit;">to</em></td><td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134564151" contextRef="d_2023-04-01_2024-03-31_AwardTypeAxis-WarrantMember_RangeAxis-MaximumMember_ValuationTechniqueAxis-BlackscholesModelMember" unitRef="Pure" name="amix:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsDiscountRate" scale="-2" format="ixt:num-dot-decimal" decimals="4">4.54</ix:nonFraction>%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 71%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected life (in years)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8211;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted"><ix:nonNumeric contextRef="d_2023-04-01_2024-03-31_AwardTypeAxis-WarrantMember_RangeAxis-MinimumMember_ValuationTechniqueAxis-BlackscholesModelMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="c134564152" format="ixt-sec:duryear">3</ix:nonNumeric></td><td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;"><em style="font: inherit;">to</em></td><td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonNumeric contextRef="d_2023-04-01_2024-03-31_AwardTypeAxis-WarrantMember_RangeAxis-MaximumMember_ValuationTechniqueAxis-BlackscholesModelMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="c134564154" format="ixt-sec:duryear">5</ix:nonNumeric></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 71%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected volatility based on the historical volatility of comparable companies' stock</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8211;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted"><ix:nonFraction id="c134564155" contextRef="d_2023-04-01_2024-03-31_AwardTypeAxis-WarrantMember_RangeAxis-MinimumMember_ValuationTechniqueAxis-BlackscholesModelMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" format="ixt:num-dot-decimal" decimals="2">104</ix:nonFraction>%</td><td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;"><em style="font: inherit;">to</em></td><td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134564157" contextRef="d_2023-04-01_2024-03-31_AwardTypeAxis-WarrantMember_RangeAxis-MaximumMember_ValuationTechniqueAxis-BlackscholesModelMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" format="ixt:num-dot-decimal" decimals="2">119</ix:nonFraction>%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  </ix:nonNumeric>
  <div>
   &#160;
  </div>
  <ix:nonNumeric contextRef="d_2024-04-01_2025-03-31" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="c3016969" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Note <em style="font: inherit;">5</em> </b>&#8211;<b> Commitments and Contingencies</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Legal Proceedings</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">From time to time, we <em style="font: inherit;"> may </em>be involved in claims that arise during the ordinary course of business. Although the results of litigation and claims cannot be predicted with certainty, we do <span style="-sec-ix-hidden:c134564674">not</span> currently have any pending litigation to which we are a party or to which our property is subject that we believe to be material. Regardless of the outcome, litigation can be costly and time consuming, and it can divert management&#8217;s attention from important business matters and initiatives, negatively impacting our overall operations.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:exclude>
    <div class="PGNUM" style="width: 100%; text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
     <em style="font: inherit;">98</em>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Employment Agreements</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company has agreements with key employees to provide certain benefits, including salary and other wage-related benefits, in the event of termination. In addition, the Company has adopted a severance policy for certain key members of executive management to provide certain benefits, including salary and other wage-related benefits, in the event of termination without cause. In total, these benefits would amount to a range of $<ix:nonFraction id="c134564676" contextRef="d_2024-04-01_2025-03-31_RangeAxis-MinimumMember_TypeOfArrangementAxis-EmploymentContractsMember" unitRef="USD" name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" scale="6" format="ixt:num-dot-decimal" decimals="-5">1.1</ix:nonFraction> million to $<ix:nonFraction id="c134564677" contextRef="d_2024-04-01_2025-03-31_RangeAxis-MaximumMember_TypeOfArrangementAxis-EmploymentContractsMember" unitRef="USD" name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" scale="6" format="ixt:num-dot-decimal" decimals="-5">1.6</ix:nonFraction> million&#160;using the rate of compensation in effect at <em style="font: inherit;"> March 31, 2025.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Brad Hauser - Chief Executive Officer</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> June 17, 2024, </em>we entered into an employment agreement with Brad Hauser pursuant to which Mr. Hauser agreed to serve as our chief executive officer and president for an initial <span style="-sec-ix-hidden:c134564678">three</span>-year period, which <em style="font: inherit;"> may </em>be extended on a year-to-year basis. Mr. Hauser&#8217;s agreement provides for an initial annual base salary of $<ix:nonFraction id="c134564679" contextRef="d_2024-06-17_2024-06-17_TitleOfIndividualAxis-ChiefExecutiveOfficerMember_TypeOfArrangementAxis-EmploymentContractsMember" unitRef="USD" name="amix:AnnualBaseSalary" scale="0" format="ixt:num-dot-decimal" decimals="INF">450,000</ix:nonFraction> (subject to an annual review and increase at the discretion of our Compensation Committee) and a target annual bonus of <ix:nonFraction id="c134564680" contextRef="d_2024-06-17_2024-06-17_TitleOfIndividualAxis-ChiefExecutiveOfficerMember_TypeOfArrangementAxis-EmploymentContractsMember" unitRef="Pure" name="amix:EmploymentAgreementBonusAsAPercentageOfAnnualBaseCompensation" scale="-2" format="ixt:num-dot-decimal" decimals="1">60</ix:nonFraction>% of his base salary. Pursuant to the agreement, Mr. Hauser was granted a <span style="-sec-ix-hidden:c134564681">ten</span>-year option (the &#8220;Inducement Options&#8221;) to purchase <ix:nonFraction id="c134564682" contextRef="d_2024-06-17_2024-06-17_AwardTypeAxis-InducementOptionsMember_TitleOfIndividualAxis-ChiefExecutiveOfficerMember_TypeOfArrangementAxis-EmploymentContractsMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" format="ixt:num-dot-decimal" decimals="INF">45,000</ix:nonFraction> shares of common stock at an exercise price equal to the closing price of our common stock on the date of the employment agreement. The option vests in <em style="font: inherit;">four</em> equal annual installments (or <ix:nonFraction id="c134564684" contextRef="d_2024-06-17_2024-06-17_AwardTypeAxis-InducementOptionsMember_TitleOfIndividualAxis-ChiefExecutiveOfficerMember_TypeOfArrangementAxis-EmploymentContractsMember_VestingAxis-ShareBasedCompensationAwardTrancheOneMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" format="ixt:num-dot-decimal" decimals="INF">11,250</ix:nonFraction> shares each installment) on each of the succeeding <em style="font: inherit;">four</em> anniversary dates of the execution of the employment agreement, provided Mr. Hauser is employed by us on each vesting date. In the event of a &#8220;change of control&#8221; or the termination of the agreement by us without &#8220;cause&#8221; or by Mr. Hauser for &#8220;good reason,&#8221; all of the unvested options shall immediately vest. The Inducement Options were granted outside of our <em style="font: inherit;">2023</em> Stock Plan as an inducement material to Mr. Hauser&#8217;s entering into employment with us in accordance with Nasdaq Stock Market Listing Rule <em style="font: inherit;">5635</em>(c)(<em style="font: inherit;">4</em>). Commencing with the year ending <em style="font: inherit;"> March 31, 2025, </em>Mr. Hauser will be eligible to receive annual option grants as determined by the Compensation Committee of the Board of Directors, based on criteria established by the Compensation Committee. The number of shares underlying the target annual option grant will be equal to $<ix:nonFraction id="c134564689" contextRef="d_2024-06-17_2024-06-17_TitleOfIndividualAxis-ChiefExecutiveOfficerMember_TypeOfArrangementAxis-EmploymentContractsMember" unitRef="USD" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,000,000</ix:nonFraction> divided by the Black-Scholes value per share of our common stock on the date of grant.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">If Mr. Hauser&#8217;s employment is terminated at our election without &#8220;cause,&#8221; or by Mr. Hauser for &#8220;good reason,&#8221; Mr. Hauser shall be entitled to receive severance payments equal to <em style="font: inherit;">twelve</em> months of Mr. Hauser&#8217;s base salary and <ix:nonFraction id="c134564691" contextRef="d_2024-06-17_2024-06-17_StatementScenarioAxis-ScenarioContractTerminationMember_TitleOfIndividualAxis-ChiefExecutiveOfficerMember_TypeOfArrangementAxis-EmploymentContractsMember" unitRef="Pure" name="amix:EmploymentAgreementBonusAsAPercentageOfAnnualBaseCompensation" scale="-2" format="ixt:num-dot-decimal" decimals="0">100</ix:nonFraction>% of the target bonus for the year in which such termination occurs; provided that such amounts shall be increased by <ix:nonFraction id="c134564692" contextRef="d_2024-06-17_2024-06-17_StatementScenarioAxis-ScenarioContractTerminationWithoutCauseMember_TitleOfIndividualAxis-ChiefExecutiveOfficerMember_TypeOfArrangementAxis-EmploymentContractsMember" unitRef="Pure" name="amix:EmploymentAgreementBonusAsAPercentageOfAnnualBaseCompensation" scale="-2" format="ixt:num-dot-decimal" decimals="1">50</ix:nonFraction>% if Mr. Hauser&#8217;s agreement is terminated without &#8220;cause&#8221; or by Mr. Hauser for &#8220;good reason&#8221; within <em style="font: inherit;">three</em> months prior to or <em style="font: inherit;">twelve</em> months after a &#8220;change of control.&#8221; In the event that any payments or benefits provided to Mr. Hauser would trigger the excise tax under Section <em style="font: inherit;">4999</em> of the Internal Revenue Code or any similar provision, the Company agreed to provide Mr. Hauser with a gross-up payment to ensure that, after payment of all taxes (including the excise tax, federal, state, and local income taxes, and employment taxes) imposed on the gross-up payment, Mr. Hauser receives a net amount equal to the payments or benefits Mr. Hauser would have received if the excise tax didn't apply.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Lori Bisson</i>&#160;-&#160;Executive <i>Vice Chairman (former Chief Executive Officer)</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> June 17, 2024, </em>we entered into an employment agreement with Lori Bisson pursuant to which Ms. Bisson agreed to serve as our Executive Vice Chairman and Strategic Adviser to the Chief Executive Officer for a <span style="-sec-ix-hidden:c134564696">two</span>-year period. Ms. Bisson&#8217;s agreement provides for an initial annual base salary of $<ix:nonFraction id="c134564697" contextRef="d_2024-06-17_2024-06-17_TitleOfIndividualAxis-ExecutiveViceChairAndStrategicAdvisorToTheChiefExecutiveOfficerMember_TypeOfArrangementAxis-EmploymentContractsMember" unitRef="USD" name="amix:AnnualBaseSalary" scale="0" format="ixt:num-dot-decimal" decimals="INF">150,000</ix:nonFraction> (subject to an annual review and increase at the discretion of our Compensation Committee) and a target annual bonus of <ix:nonFraction id="c134564698" contextRef="d_2024-06-17_2024-06-17_TitleOfIndividualAxis-ExecutiveViceChairAndStrategicAdvisorToTheChiefExecutiveOfficerMember_TypeOfArrangementAxis-EmploymentContractsMember" unitRef="Pure" name="amix:EmploymentAgreementBonusAsAPercentageOfAnnualBaseCompensation" scale="-2" format="ixt:num-dot-decimal" decimals="1">50</ix:nonFraction>% of her base salary. Pursuant to the agreement, Ms. Bisson continued to vest in the option grants issued to Ms. Bisson in her role as chief executive officer and president in accordance with the vesting schedule set out in her initial employment agreement. In the event of a &#8220;change of control&#8221; or the termination of the agreement by us without &#8220;cause&#8221; or by Ms. Bisson for &#8220;good reason,&#8221; all of the unvested options shall immediately vest. Ms. Bisson is entitled to receive any compensation, including incentive compensation, for the fiscal year ended <em style="font: inherit;"> March 31, 2024 </em>that has <em style="font: inherit;">not</em> been paid as of the date of the agreement. Commencing with the year ending <em style="font: inherit;"> March 31, 2025, </em>Ms. Bisson will be eligible to receive annual option grants as determined by the Compensation Committee of the Board of Directors, based on criteria established by the Compensation Committee. Ms. Bisson agreed to waive any severance payments due to her in connection with the termination of the prior employment agreement that we entered into with her on <em style="font: inherit;"> June 30, 2023.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Fractional Shares</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">See <i>Note <em style="font: inherit;">1</em> - Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies</i> - "<i>Reverse Stock Split</i>" for additional information.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> November 1, 2024, </em>the Company received notice from the Depository Trust and Clearing Corporation ("DTCC") on behalf of the brokerage firms that hold the shares of Company common stock held in &#8220;street name&#8221; that in connection with the rounding of fractional shares in connection with the Reverse Stock Split, the Company would need to issue <ix:nonFraction id="c134564701" contextRef="i_2024-11-01" unitRef="Share" name="amix:StockRequiredToBeIssuedForStockSplitShares" scale="0" format="ixt:num-dot-decimal" decimals="INF">271,846</ix:nonFraction> shares of common stock (the &#8220;Shares&#8221;) for the rounding of shares. The Company does <em style="font: inherit;">not</em> believe the number of Shares being requested is correct based on the historical number of shareholders of its common stock and is aware of similar anomalies in recent months for other companies completing a Reverse Stock Split. As such, the Company has begun an inquiry into the calculations set forth in the request. During the pendency of this inquiry, the Company does <em style="font: inherit;">not</em> intend to issue any shares in connection with the fractional shares being requested and has concluded that an obligation should <em style="font: inherit;">not</em> be recorded in its financial statements. The Company is <em style="font: inherit;">not</em> currently subject to any pending litigation as a result of the fractional roundup shares.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       99
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
  </ix:nonNumeric>
  <div>
   &#160;
  </div>
  <ix:nonNumeric contextRef="d_2024-04-01_2025-03-31" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="c3016970" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Note <em style="font: inherit;">6</em> </b>&#8211;<b> Related Party Transactions</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company utilizes a consulting firm that is owned by the Company&#8217;s former Chief Financial Officer to provide accounting and financial reporting services and pays certain expenses on behalf of the Company. During the year ended <em style="font: inherit;"> March 31, 2025 </em>and <em style="font: inherit;">2024,</em> the Company incurred fees of less than $<ix:nonFraction id="c134564709" contextRef="d_2024-04-01_2025-03-31_RangeAxis-MaximumMember_RelatedPartyTransactionAxis-AccountingAndFinancialReportingServicesMember_RelatedPartyTransactionsByRelatedPartyAxis-ConsultingFirmOwnedByFormerCFOMember" unitRef="USD" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.1</ix:nonFraction> million, respectively, for these services, excluding officer compensation. As of <em style="font: inherit;"> March 31, 2025 </em>and <em style="font: inherit;"> March 31, 2024, </em>the Company owed the consulting firm $<ix:nonFraction id="c134564710" contextRef="i_2025-03-31_RelatedPartyTransactionAxis-AccountingAndFinancialReportingServicesMember_RelatedPartyTransactionsByRelatedPartyAxis-ConsultingFirmOwnedByFormerCFOMember" unitRef="USD" name="us-gaap:AccountsPayableCurrentAndNoncurrent" scale="6" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction> and less than $<ix:nonFraction id="c134564711" contextRef="i_2024-03-31_RelatedPartyTransactionAxis-AccountingAndFinancialReportingServicesMember_RelatedPartyTransactionsByRelatedPartyAxis-ConsultingFirmOwnedByFormerCFOMember" unitRef="USD" name="us-gaap:AccountsPayableCurrentAndNoncurrent" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.1</ix:nonFraction> million, respectively, for services and expenses.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">As of <em style="font: inherit;"> March 31, 2025, </em>members of the Company&#8217;s management/Board and an immediate family member of the Company&#8217;s management (related party), collectively purchased $<ix:nonFraction id="c134564712" contextRef="d_2024-04-01_2025-03-31_DebtInstrumentAxis-TheBridgeOfferingMember_RelatedPartyTransactionsByRelatedPartyAxis-ManagementBoardOfDirectorFamilyMember" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.5</ix:nonFraction> million ($<ix:nonFraction id="c134564713" contextRef="d_2024-04-01_2025-03-31_DebtInstrumentAxis-TheBridgeOfferingMember_RelatedPartyTransactionsByRelatedPartyAxis-ManagementMember" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.4</ix:nonFraction> million and $<ix:nonFraction id="c134564714" contextRef="d_2024-04-01_2025-03-31_DebtInstrumentAxis-TheBridgeOfferingMember_RelatedPartyTransactionsByRelatedPartyAxis-RelatedPartyMember" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.1</ix:nonFraction> million, respectively) of the Bridge Offering.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> December 21, 2021, </em>the Company entered into a perpetual, worldwide, exclusive license agreement (the &#8220;License&#8221; or &#8220;License Agreement&#8221;) with a company controlled by a significant stockholder of the Company (the &#8220;Licensee&#8221;). The License allows the Licensee to use certain intellectual property and technology related to the diagnosis and treatment of cardiovascular conditions held by the Company. Upon <em style="font: inherit;">90</em> days following the completion of an IPO or special purpose acquisition company transaction, the Licensee <em style="font: inherit;"> may </em>enter into sublicenses of the licensed intellectual property and technology.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:exclude>
    <div class="PGNUM" style="width: 100%; text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
     100
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> July 7, 2023, </em>the Company and the Licensee entered into an Exclusive License Termination Agreement (the &#8220;Termination Agreement&#8221;) in exchange for the issuance, upon the closing of the Company&#8217;s IPO within <em style="font: inherit;">one</em> year of the agreement&#8217;s execution, of a warrant to purchase shares of the Company for a variable number of shares. Upon the Company's closing of its IPO on <em style="font: inherit;"> January 29, 2024, </em><ix:nonFraction id="c134564718" contextRef="i_2024-01-29_ClassOfWarrantOrRightAxis-TheWarrantMember_RelatedPartyTransactionAxis-TerminationAgreementMember" unitRef="Share" name="us-gaap:CommonStockSharesIssued" scale="0" format="ixt:num-dot-decimal" decimals="INF">80,000</ix:nonFraction>&#160;warrant shares were issued at $<ix:nonFraction id="c134564719" contextRef="i_2024-01-29_ClassOfWarrantOrRightAxis-TheWarrantMember_RelatedPartyTransactionAxis-TerminationAgreementMember" unitRef="USDPerShare" name="us-gaap:SharesIssuedPricePerShare" scale="0" format="ixt:num-dot-decimal" decimals="INF">100.00</ix:nonFraction> per share for a fixed value of $<ix:nonFraction id="c134564720" contextRef="d_2023-07-07_2023-07-07_ClassOfWarrantOrRightAxis-TheWarrantMember_RelatedPartyTransactionAxis-TerminationAgreementMember" unitRef="USD" name="amix:ClassOfWarrantOrRightValueOfSecuritiesCalledByWarrantsOrRights" scale="6" format="ixt:num-dot-decimal" decimals="-6">8.0</ix:nonFraction> million. The warrants are&#160;exercisable at a price of $<ix:nonFraction id="c134564721" contextRef="i_2023-07-07_ClassOfWarrantOrRightAxis-TheWarrantMember_RelatedPartyTransactionAxis-TerminationAgreementMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.02</ix:nonFraction> per share and <em style="font: inherit;"> may </em>be exercised any time after the issuance date, subject to a beneficial ownership limitation, and expire <span style="-sec-ix-hidden:c134564722">five</span> years from the original issuance. The warrants contain dividend rights commensurate with the holders of common stock. The warrants do <em style="font: inherit;">not</em> include any other stockholder rights or privileges prior to exercise.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The shares underlying the warrant will be subject to a lockup agreement for a period of <span style="-sec-ix-hidden:c134564724">six</span> months after the closing of the IPO with respect to <ix:nonFraction id="c134564725" contextRef="d_2023-07-07_2023-07-07_ClassOfWarrantOrRightAxis-TheWarrantMember_RelatedPartyTransactionAxis-TerminationAgreementMember_UnderlyingAssetClassAxis-CommonStock6MonthsLockupPeriodMember" unitRef="Pure" name="amix:ClassOfWarrantOrRightPercentageOfOutstandingStock" scale="-2" format="ixt:num-dot-decimal" decimals="3">12.5</ix:nonFraction>% of the shares issued and <span style="-sec-ix-hidden:c134564726">twelve</span> months after the closing of the IPO for the remainder of the shares. In connection with the Termination Agreement, the Company agreed to register the resale of the shares of common stock. One of the Company&#8217;s directors holds a <ix:nonFraction id="c134564727" contextRef="i_2023-07-07_ClassOfWarrantOrRightAxis-TheWarrantMember_RelatedPartyTransactionAxis-TerminationAgreementMember" unitRef="Pure" name="amix:InterestHeldInCompanyReceivingWarrants" scale="-2" format="ixt:num-dot-decimal" decimals="1">20</ix:nonFraction>% interest in the company receiving the warrant.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  </ix:nonNumeric>
  <div>
   &#160;
  </div>
  <ix:nonNumeric contextRef="d_2024-04-01_2025-03-31" name="us-gaap:IncomeTaxDisclosureTextBlock" id="c3016971" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Note <em style="font: inherit;">7</em> </b>&#8211;<b> Income Taxes</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company files U.S. federal and various U.S. state income tax returns. Due to the Company&#8217;s losses, there was <em style="font: inherit;">no</em> income tax expense for the years ended <em style="font: inherit;"> March 31, 2025 </em>and <em style="font: inherit;">2024</em> (in thousands):</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:nonNumeric contextRef="d_2024-04-01_2025-06-30" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="c3016972" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>March 31,</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>March 31,</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Amount</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">%</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Amount</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">%</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Tax benefit at the U.S. federal statutory rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c134564158" contextRef="d_2024-04-01_2025-03-31" unitRef="USD" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">2,396</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134564159" contextRef="d_2024-04-01_2025-03-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" format="ixt:num-dot-decimal" decimals="2">21.00</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c134564160" contextRef="d_2023-04-01_2024-03-31" unitRef="USD" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">3,239</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134564161" contextRef="d_2023-04-01_2024-03-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" format="ixt:num-dot-decimal" decimals="2">21.00</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Tax rate change</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c134564162" contextRef="d_2024-04-01_2025-03-31" unitRef="USD" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c134564163" contextRef="d_2024-04-01_2025-03-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" scale="-2" format="ixt:fixed-zero" decimals="0">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c134564164" contextRef="d_2023-04-01_2024-03-31" unitRef="USD" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c134564165" contextRef="d_2023-04-01_2024-03-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" scale="-2" format="ixt:fixed-zero" decimals="0">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Permanent differences</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134564166" contextRef="d_2024-04-01_2025-03-31" unitRef="USD" name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">5</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c134564167" contextRef="d_2024-04-01_2025-03-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" scale="-2" format="ixt:num-dot-decimal" decimals="4" sign="-">0.05</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134564168" contextRef="d_2023-04-01_2024-03-31" unitRef="USD" name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,697</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c134564169" contextRef="d_2023-04-01_2024-03-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" scale="-2" format="ixt:num-dot-decimal" decimals="4" sign="-">11.01</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)%</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Return to provision</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c134564170" contextRef="d_2024-04-01_2025-03-31" unitRef="USD" name="us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">44</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134564171" contextRef="d_2024-04-01_2025-03-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" scale="-2" format="ixt:num-dot-decimal" decimals="4">0.39</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c134564172" contextRef="d_2023-04-01_2024-03-31" unitRef="USD" name="us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">69</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134564173" contextRef="d_2023-04-01_2024-03-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" scale="-2" format="ixt:num-dot-decimal" decimals="4">0.45</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Change in state rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134564174" contextRef="d_2024-04-01_2025-03-31" unitRef="USD" name="amix:EffectiveIncomeTaxRateReconciliationChangeInStateRateAmount" scale="3" format="ixt:num-dot-decimal" decimals="-3">234</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c134564175" contextRef="d_2024-04-01_2025-03-31" unitRef="Pure" name="amix:EffectiveIncomeTaxRateReconciliationChangeInStateRatePercent" scale="-2" format="ixt:num-dot-decimal" decimals="4" sign="-">2.05</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c134564176" contextRef="d_2023-04-01_2024-03-31" unitRef="USD" name="amix:EffectiveIncomeTaxRateReconciliationChangeInStateRateAmount" scale="3" format="ixt:num-dot-decimal" decimals="-4" sign="-">190</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134564177" contextRef="d_2023-04-01_2024-03-31" unitRef="Pure" name="amix:EffectiveIncomeTaxRateReconciliationChangeInStateRatePercent" scale="-2" format="ixt:num-dot-decimal" decimals="4">1.23</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">State tax (net of federal benefit)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c134564178" contextRef="d_2024-04-01_2025-03-31" unitRef="USD" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">63</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134564179" contextRef="d_2024-04-01_2025-03-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" format="ixt:num-dot-decimal" decimals="4">0.55</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c134564180" contextRef="d_2023-04-01_2024-03-31" unitRef="USD" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">192</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134564181" contextRef="d_2023-04-01_2024-03-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" format="ixt:num-dot-decimal" decimals="4">1.24</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Valuation allowance</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c134564182" contextRef="d_2024-04-01_2025-03-31" unitRef="USD" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,264</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c134564183" contextRef="d_2024-04-01_2025-03-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" format="ixt:num-dot-decimal" decimals="4" sign="-">19.84</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c134564184" contextRef="d_2023-04-01_2024-03-31" unitRef="USD" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,993</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c134564185" contextRef="d_2023-04-01_2024-03-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" format="ixt:num-dot-decimal" decimals="4" sign="-">12.91</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)%</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Effective income tax rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c134564186" contextRef="d_2024-04-01_2025-03-31" unitRef="USD" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c134564187" contextRef="d_2024-04-01_2025-03-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" format="ixt:fixed-zero" decimals="0">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c134564188" contextRef="d_2023-04-01_2024-03-31" unitRef="USD" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c134564189" contextRef="d_2023-04-01_2024-03-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" format="ixt:fixed-zero" decimals="0">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The effective income tax rate varied from the statutory rate in <em style="font: inherit;">2025</em> primarily due to permanent differences and the increase in the valuation allowance.&#160;The effective income tax rate varied from the statutory rate in <em style="font: inherit;">2024</em> primarily as a result of the increase&#160;in the valuation allowance.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Deferred tax assets and liabilities consist of the following (in thousands):</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:nonNumeric contextRef="d_2024-04-01_2025-03-31" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="c3016973" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>March 31,</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>March 31,</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Assets related to:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Capitalized R&amp;D costs</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted"><ix:nonFraction id="c134564190" contextRef="i_2025-03-31" unitRef="USD" name="amix:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,380</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134564191" contextRef="i_2024-03-31" unitRef="USD" name="amix:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" scale="0" format="ixt:num-dot-decimal" decimals="INF">602</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Net operating losses</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted"><ix:nonFraction id="c134564192" contextRef="i_2025-03-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="0" format="ixt:num-dot-decimal" decimals="INF">761</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134564193" contextRef="i_2024-03-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="0" format="ixt:num-dot-decimal" decimals="INF">2,643</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Accruals and reserves</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted"><ix:nonFraction id="c134564194" contextRef="i_2025-03-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" scale="0" format="ixt:num-dot-decimal" decimals="INF">3,438</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134564195" contextRef="i_2024-03-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" scale="0" format="ixt:num-dot-decimal" decimals="INF">72</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Stock-based compensation</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted"><ix:nonFraction id="c134564196" contextRef="i_2025-03-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="0" format="ixt:num-dot-decimal" decimals="INF">450</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c134564197" contextRef="i_2024-03-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="0" format="ixt:num-dot-decimal" decimals="INF">142</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total deferred tax assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted"><ix:nonFraction id="c134564198" contextRef="i_2025-03-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsGross" scale="0" format="ixt:num-dot-decimal" decimals="INF">6,029</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134564199" contextRef="i_2024-03-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsGross" scale="0" format="ixt:num-dot-decimal" decimals="INF">3,459</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Valuation allowance for deferred tax assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted">(<ix:nonFraction id="c134564200" contextRef="i_2025-03-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" format="ixt:num-dot-decimal" decimals="INF">5,723</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c134564201" contextRef="i_2024-03-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" format="ixt:num-dot-decimal" decimals="INF">3,459</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net deferred tax assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted"><ix:nonFraction id="c134564202" contextRef="i_2025-03-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsNet" scale="0" format="ixt:num-dot-decimal" decimals="INF">306</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c134564203" contextRef="i_2024-03-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsNet" scale="0" format="ixt:fixed-zero" decimals="INF">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Liabilities related to:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Section 481A method change</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted">(<ix:nonFraction id="c134564204" contextRef="i_2025-03-31" unitRef="USD" name="amix:DeferredTaxLiabilitiesChangeInAccountingMethod" scale="0" format="ixt:num-dot-decimal" decimals="INF">306</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c134564205" contextRef="i_2024-03-31" unitRef="USD" name="amix:DeferredTaxLiabilitiesChangeInAccountingMethod" scale="0" format="ixt:fixed-zero" decimals="INF" sign="-">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net deferred tax liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted">(<ix:nonFraction id="c134564206" contextRef="i_2025-03-31" unitRef="USD" name="us-gaap:DeferredTaxLiabilities" scale="0" format="ixt:num-dot-decimal" decimals="INF">306</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c134564207" contextRef="i_2024-03-31" unitRef="USD" name="us-gaap:DeferredTaxLiabilities" scale="0" format="ixt:fixed-zero" decimals="INF" sign="-">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net deferred tax</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted"><ix:nonFraction id="c134564208" contextRef="i_2025-03-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="0" format="ixt:fixed-zero" decimals="INF">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c134564209" contextRef="i_2024-03-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="0" format="ixt:fixed-zero" decimals="INF">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:exclude>
    <div class="PGNUM" style="width: 100%; text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
     <em style="font: inherit;">101</em>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">At <em style="font: inherit;"> March 31, 2025, </em>the Company had U.S. federal net operating loss ("NOL") carry forwards of $<ix:nonFraction id="c134564734" contextRef="i_2025-03-31" unitRef="USD" name="us-gaap:OperatingLossCarryforwards" scale="6" format="ixt:num-dot-decimal" decimals="-5">3.6</ix:nonFraction> million. Approximately $<ix:nonFraction id="c134564735" contextRef="i_2025-03-31_TaxPeriodAxis-ExpirationCommencingTaxYear20342037Member" unitRef="USD" name="us-gaap:OperatingLossCarryforwards" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.9</ix:nonFraction> million of the U.S. federal NOLs will start expiring in <em style="font: inherit;">2037.</em> Additionally, the Company generated a U.S. federal NOL carry-forward of approximately $<ix:nonFraction id="c134564737" contextRef="i_2025-03-31_TaxPeriodAxis-NolGeneratedDuring20172024Member" unitRef="USD" name="us-gaap:OperatingLossCarryforwards" scale="6" format="ixt:num-dot-decimal" decimals="-5">2.7</ix:nonFraction> million post-<em style="font: inherit;">2017</em> to <em style="font: inherit;">2024.</em> Under the new Tax Act, post-<em style="font: inherit;">2017</em> federal NOL carry forwards do <em style="font: inherit;">not</em> expire, but can only offset <em style="font: inherit;">80%</em> of taxable income in the year the loss carry forward is used.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Sections <em style="font: inherit;">382</em> and <em style="font: inherit;">383</em> of the Internal Revenue Code limit the annual use of NOL &#160;carry-forwards and tax credit carry forwards, respectively, following an ownership change. NOL carry-forwards <em style="font: inherit;"> may </em>be subject to annual limitations under Internal Revenue Code Section <em style="font: inherit;">382</em> (Section <em style="font: inherit;">382</em>) (or comparable provisions of state law) if certain changes in ownership were to occur.&#160;Determination of ownership change, or limitation hasn&#8217;t been calculated; however, the Company will perform the NOL limitation analysis under Section&#160;<em style="font: inherit;">382</em>&#160;before any NOLs are expected to be utilized.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company has recorded a full valuation allowance against its net total deferred tax assets as of <em style="font: inherit;"> March 31, 2025 </em>and <em style="font: inherit;">2024</em> because management determined that it is <span style="-sec-ix-hidden:c134564749">not</span> more-likely-than <em style="font: inherit;">not</em> that those assets will be realized. In assessing the realization of deferred tax assets, management considers whether it is more likely than <em style="font: inherit;">not</em> that some portion or all of deferred assets will <em style="font: inherit;">not</em> be realized. The ultimate realization of the deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. During the year ended <em style="font: inherit;"> March 31, 2025, </em>the valuation allowance increased by $<ix:nonFraction id="c134564753" contextRef="d_2024-04-01_2025-03-31" unitRef="USD" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="6" format="ixt:num-dot-decimal" decimals="-5">2.3</ix:nonFraction> million mainly due to additional capitalized R&amp;D and Start-up Costs.&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company is subject to income taxes in the U.S. federal jurisdiction and various state jurisdictions. Tax regulations within each jurisdiction are subject to the interpretation of the related tax laws and regulations and require significant judgment to apply. As of <em style="font: inherit;"> March 31, 2025, </em>all of the tax years remained open to examination by the federal and state taxing authorities, for <em style="font: inherit;">three</em> or <em style="font: inherit;">four</em> years from the tax year in which net operating losses or tax credits are utilized completely.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">As of <em style="font: inherit;"> March 31, 2025, </em>the Company has <em style="font: inherit;">no</em> uncertain tax positions.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  </ix:nonNumeric>
  <div>
   &#160;
  </div>
  <ix:nonNumeric contextRef="d_2024-04-01_2025-03-31" name="us-gaap:SubsequentEventsTextBlock" id="c3016974" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Note <em style="font: inherit;">8</em> </b>&#8211;<b> Subsequent Events</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">As of <em style="font: inherit;"> May 28, 2025, </em>the Company has sold <ix:nonFraction id="c134564758" contextRef="d_2025-04-01_2025-05-28_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-ATMAgreementMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:num-dot-decimal" decimals="INF">289,144</ix:nonFraction> shares pursuant to the ATM Agreement for net proceeds of approximately $<ix:nonFraction id="c134564759" contextRef="d_2025-04-01_2025-05-28_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-ATMAgreementMember" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.6</ix:nonFraction> million.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> April 17, 2025, </em>we granted a new employee a <span style="-sec-ix-hidden:c134564760">ten</span>-year option (the &#8220;Inducement Options&#8221;) to purchase <ix:nonFraction id="c134564761" contextRef="d_2025-04-17_2025-04-17_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_SubsequentEventTypeAxis-SubsequentEventMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" format="ixt:num-dot-decimal" decimals="INF">5,000</ix:nonFraction> shares of common stock at an exercise price equal to the closing price of our common stock on the date of the employment. The option vests in <em style="font: inherit;">four</em> equal annual installments (or <ix:nonFraction id="c134564763" contextRef="d_2025-04-17_2025-04-17_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_SubsequentEventTypeAxis-SubsequentEventMember_VestingAxis-ShareBasedCompensationAwardTrancheOneMember" unitRef="Share" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,250</ix:nonFraction> shares each installment) on each of the succeeding <em style="font: inherit;">four</em> anniversary dates of the execution of the date of employment, provided the employee is employed by us on each vesting date.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:exclude>
    <div class="PGNUM" style="width: 100%; text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
     <em style="font: inherit;">102</em>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
  </ix:nonNumeric>
  <div>
   &#160;
  </div>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="ucbal" href="#"></a>Autonomix Medical, Inc.</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Condensed Balance Sheets</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Unaudited)</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div>
   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 70%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>(in thousands, except par value and share data)</i></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>As of</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>June 30,</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>March 31,</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Assets</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Current assets:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Cash and cash equivalents</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563803" contextRef="i_2025-06-30" unitRef="USD" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" format="ixt:num-dot-decimal" decimals="-3">8,589</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563804" contextRef="i_2025-03-31" unitRef="USD" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" format="ixt:num-dot-decimal" decimals="-3">9,136</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Other current assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c134563805" contextRef="i_2025-06-30" unitRef="USD" name="us-gaap:OtherAssetsCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">389</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c134563806" contextRef="i_2025-03-31" unitRef="USD" name="us-gaap:OtherAssetsCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">473</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total current assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563807" contextRef="i_2025-06-30" unitRef="USD" name="us-gaap:AssetsCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">8,978</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563808" contextRef="i_2025-03-31" unitRef="USD" name="us-gaap:AssetsCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">9,609</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Long term assets:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Fixed assets, net</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563809" contextRef="i_2025-06-30" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" format="ixt:num-dot-decimal" decimals="-3">19</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563810" contextRef="i_2025-03-31" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" format="ixt:num-dot-decimal" decimals="-3">21</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Deferred offering costs</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c134563811" contextRef="i_2025-06-30" unitRef="USD" name="us-gaap:DeferredCosts" scale="3" format="ixt:fixed-zero" decimals="-3">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c134563812" contextRef="i_2025-03-31" unitRef="USD" name="us-gaap:DeferredCosts" scale="3" format="ixt:num-dot-decimal" decimals="-3">176</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total long term assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c134563813" contextRef="i_2025-06-30" unitRef="USD" name="us-gaap:AssetsNoncurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">19</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c134563814" contextRef="i_2025-03-31" unitRef="USD" name="us-gaap:AssetsNoncurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">197</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total Assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c134563815" contextRef="i_2025-06-30" unitRef="USD" name="us-gaap:Assets" scale="3" format="ixt:num-dot-decimal" decimals="-3">8,997</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c134563816" contextRef="i_2025-03-31" unitRef="USD" name="us-gaap:Assets" scale="3" format="ixt:num-dot-decimal" decimals="-3">9,806</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Liabilities and Stockholders' Equity</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Current liabilities:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Accounts payable</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563817" contextRef="i_2025-06-30" unitRef="USD" name="us-gaap:AccountsPayableCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">815</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563818" contextRef="i_2025-03-31" unitRef="USD" name="us-gaap:AccountsPayableCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">676</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Accrued expenses</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c134563819" contextRef="i_2025-06-30" unitRef="USD" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-4">1,150</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c134563820" contextRef="i_2025-03-31" unitRef="USD" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,031</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total current liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c134563821" contextRef="i_2025-06-30" unitRef="USD" name="us-gaap:LiabilitiesCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,965</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c134563822" contextRef="i_2025-03-31" unitRef="USD" name="us-gaap:LiabilitiesCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,707</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total Liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c134563823" contextRef="i_2025-06-30" unitRef="USD" name="us-gaap:Liabilities" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,965</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c134563824" contextRef="i_2025-03-31" unitRef="USD" name="us-gaap:Liabilities" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,707</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Commitments and contingencies (Note 4)</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;<span style="-sec-ix-hidden:c134565269">&#160;</span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;<span style="-sec-ix-hidden:c134565270">&#160;</span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Stockholders' equity:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 18pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Preferred stock, $<span style="-sec-ix-hidden:c134565149"><span style="-sec-ix-hidden:c134565150">0.001</span></span> par value, <span style="-sec-ix-hidden:c134565151"><span style="-sec-ix-hidden:c134565152">10,000,000</span></span> shares authorized, <span style="-sec-ix-hidden:c134565153"><span style="-sec-ix-hidden:c134565155"><span style="-sec-ix-hidden:c134565154"><span style="-sec-ix-hidden:c134565156">no</span></span></span></span> shares issued and outstanding as of June 30, 2025 and March 31, 2025, respectively</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563825" contextRef="i_2025-06-30" unitRef="USD" name="us-gaap:PreferredStockValue" scale="3" format="ixt:fixed-zero" decimals="-3">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563826" contextRef="i_2025-03-31" unitRef="USD" name="us-gaap:PreferredStockValue" scale="3" format="ixt:fixed-zero" decimals="-3">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 18pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Common stock, $<span style="-sec-ix-hidden:c134565157"><span style="-sec-ix-hidden:c134565158">0.001</span></span> par value, <span style="-sec-ix-hidden:c134565159"><span style="-sec-ix-hidden:c134565160">500,000,000</span></span> shares authorized, <span style="-sec-ix-hidden:c134565161"><span style="-sec-ix-hidden:c134565163">4,022,625</span></span> and <span style="-sec-ix-hidden:c134565162"><span style="-sec-ix-hidden:c134565164">2,497,033</span></span> shares issued and outstanding as of June 30, 2025 and March 31, 2025, respectively</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563827" contextRef="i_2025-06-30" unitRef="USD" name="us-gaap:CommonStockValue" scale="3" format="ixt:num-dot-decimal" decimals="-3">4</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563828" contextRef="i_2025-03-31" unitRef="USD" name="us-gaap:CommonStockValue" scale="3" format="ixt:num-dot-decimal" decimals="-3">2</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Additional paid-in capital</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563829" contextRef="i_2025-06-30" unitRef="USD" name="us-gaap:AdditionalPaidInCapital" scale="3" format="ixt:num-dot-decimal" decimals="-3">60,744</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563830" contextRef="i_2025-03-31" unitRef="USD" name="us-gaap:AdditionalPaidInCapital" scale="3" format="ixt:num-dot-decimal" decimals="-3">58,476</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Accumulated deficit</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c134563831" contextRef="i_2025-06-30" unitRef="USD" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">53,716</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c134563832" contextRef="i_2025-03-31" unitRef="USD" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">50,379</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total Stockholders' Equity</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c134563833" contextRef="i_2025-06-30" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">7,032</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c134563834" contextRef="i_2025-03-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">8,099</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total Liabilities and Stockholders' Equity</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c134563835" contextRef="i_2025-06-30" unitRef="USD" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">8,997</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c134563836" contextRef="i_2025-03-31" unitRef="USD" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">9,806</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">See accompanying notes to the unaudited condensed financial statements.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="width: 100%; text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
    103
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div>
   &#160;
  </div>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="ucops" href="#"></a>Autonomix Medical, Inc.</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Condensed Statements of Operations</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Unaudited)</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div>
   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Three Months Ended</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>June 30,</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 70%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">(in thousands, except share and per share data)</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Operating expenses:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Research and development</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563844" contextRef="d_2025-04-01_2025-06-30" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,593</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted"><ix:nonFraction id="c134563845" contextRef="d_2024-04-01_2024-06-30" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">954</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">General and administrative</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c134563846" contextRef="d_2025-04-01_2025-06-30" unitRef="USD" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,828</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted"><ix:nonFraction id="c134563847" contextRef="d_2024-04-01_2024-06-30" unitRef="USD" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,799</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total operating expenses</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c134563848" contextRef="d_2025-04-01_2025-06-30" unitRef="USD" name="us-gaap:OperatingExpenses" scale="3" format="ixt:num-dot-decimal" decimals="-3">3,421</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted"><ix:nonFraction id="c134563849" contextRef="d_2024-04-01_2024-06-30" unitRef="USD" name="us-gaap:OperatingExpenses" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,753</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Loss from operations</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c134563850" contextRef="d_2025-04-01_2025-06-30" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">3,421</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted">(<ix:nonFraction id="c134563851" contextRef="d_2024-04-01_2024-06-30" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">2,753</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Other income (expense):</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Interest expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563852" contextRef="d_2025-04-01_2025-06-30" unitRef="USD" name="us-gaap:InterestExpenseNonoperating" scale="3" format="ixt:fixed-zero" decimals="-3" sign="-">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted">(<ix:nonFraction id="c134563853" contextRef="d_2024-04-01_2024-06-30" unitRef="USD" name="us-gaap:InterestExpenseNonoperating" scale="3" format="ixt:num-dot-decimal" decimals="-3">41</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Interest income</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c134563854" contextRef="d_2025-04-01_2025-06-30" unitRef="USD" name="us-gaap:InvestmentIncomeInterest" scale="3" format="ixt:num-dot-decimal" decimals="-3">84</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted"><ix:nonFraction id="c134563855" contextRef="d_2024-04-01_2024-06-30" unitRef="USD" name="us-gaap:InvestmentIncomeInterest" scale="3" format="ixt:num-dot-decimal" decimals="-3">95</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total other income (expense)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c134563856" contextRef="d_2025-04-01_2025-06-30" unitRef="USD" name="us-gaap:NonoperatingIncomeExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">84</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted"><ix:nonFraction id="c134563857" contextRef="d_2024-04-01_2024-06-30" unitRef="USD" name="us-gaap:NonoperatingIncomeExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">54</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Loss before income taxes</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c134563858" contextRef="d_2025-04-01_2025-06-30" unitRef="USD" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">3,337</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted">(<ix:nonFraction id="c134563859" contextRef="d_2024-04-01_2024-06-30" unitRef="USD" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">2,699</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Income taxes</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c134563860" contextRef="d_2025-04-01_2025-06-30" unitRef="USD" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" format="ixt:fixed-zero" decimals="-3">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted"><ix:nonFraction id="c134563861" contextRef="d_2024-04-01_2024-06-30" unitRef="USD" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" format="ixt:fixed-zero" decimals="-3">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net loss</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c134563862" contextRef="d_2025-04-01_2025-06-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">3,337</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted">(<ix:nonFraction id="c134563863" contextRef="d_2024-04-01_2024-06-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">2,699</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Loss per share - basic and diluted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c134563864" contextRef="d_2025-04-01_2025-06-30" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasic" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">1.07</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted">(<ix:nonFraction id="c134563865" contextRef="d_2024-04-01_2024-06-30" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasic" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">2.20</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Weighted average shares outstanding - basic and diluted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563866" contextRef="d_2025-04-01_2025-06-30" unitRef="Share" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" format="ixt:num-dot-decimal" decimals="INF">3,105,156</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted"><ix:nonFraction id="c134563867" contextRef="d_2024-04-01_2024-06-30" unitRef="Share" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,225,423</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">See accompanying notes to the unaudited condensed financial statements.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="width: 100%; text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
    104
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div>
   &#160;
  </div>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="ucequity" href="#"></a>Autonomix Medical, Inc.</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Condensed Statements of Changes in Stockholders' Equity</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Unaudited)</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div>
   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Additional</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Total</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Common Stock</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Paid-in</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Accumulated</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Stockholders'</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 40%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>(in thousands)</i></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Shares</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Amount</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Capital</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Deficit</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Equity</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance March 31, 2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563870" contextRef="i_2024-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="3" format="ixt:num-dot-decimal" decimals="-3">943</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563871" contextRef="i_2024-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">1</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563872" contextRef="i_2024-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">46,596</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c134563873" contextRef="i_2024-03-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">38,969</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563874" contextRef="i_2024-03-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">7,628</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net loss</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563876" contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:fixed-zero" decimals="-3">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563877" contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:fixed-zero" decimals="-3">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c134563878" contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">2,699</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c134563879" contextRef="d_2024-04-01_2024-06-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">2,699</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock-based compensation</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563881" contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" format="ixt:fixed-zero" decimals="-3">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563882" contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" format="ixt:num-dot-decimal" decimals="-4">360</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563883" contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" format="ixt:fixed-zero" decimals="-3">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563884" contextRef="d_2024-04-01_2024-06-30" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" format="ixt:num-dot-decimal" decimals="-4">360</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Issuance of common stock - warrants exercised</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c134563885" contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="amix:StockIssuedDuringPeriodSharesWarrantsExercised" scale="3" format="ixt:num-dot-decimal" decimals="-4">20</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c134563886" contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="amix:StockIssuedDuringPeriodValueWarrantsExercised" scale="3" format="ixt:fixed-zero" decimals="-3">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c134563887" contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="amix:StockIssuedDuringPeriodValueWarrantsExercised" scale="3" format="ixt:fixed-zero" decimals="-3">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c134563888" contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="amix:StockIssuedDuringPeriodValueWarrantsExercised" scale="3" format="ixt:fixed-zero" decimals="-3">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c134563889" contextRef="d_2024-04-01_2024-06-30" unitRef="USD" name="amix:StockIssuedDuringPeriodValueWarrantsExercised" scale="3" format="ixt:fixed-zero" decimals="-3">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance June 30, 2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c134563890" contextRef="i_2024-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="3" format="ixt:num-dot-decimal" decimals="-3">963</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c134563891" contextRef="i_2024-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">1</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c134563892" contextRef="i_2024-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">46,956</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c134563893" contextRef="i_2024-06-30_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">41,668</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c134563894" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">5,289</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance March 31, 2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563895" contextRef="i_2025-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,497</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563896" contextRef="i_2025-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">2</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563897" contextRef="i_2025-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">58,476</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c134563898" contextRef="i_2025-03-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">50,379</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563899" contextRef="i_2025-03-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">8,099</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net loss</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563901" contextRef="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:fixed-zero" decimals="-3">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563902" contextRef="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:fixed-zero" decimals="-3">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c134563903" contextRef="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">3,337</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c134563904" contextRef="d_2025-04-01_2025-06-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">3,337</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock-based compensation</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563906" contextRef="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" format="ixt:fixed-zero" decimals="-3">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563907" contextRef="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" format="ixt:num-dot-decimal" decimals="-3">388</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563908" contextRef="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" format="ixt:fixed-zero" decimals="-3">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563909" contextRef="d_2025-04-01_2025-06-30" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" format="ixt:num-dot-decimal" decimals="-3">388</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Issuance of common stock, net of offering costs</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563910" contextRef="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,304</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563911" contextRef="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:num-dot-decimal" decimals="-3">2</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563912" contextRef="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:num-dot-decimal" decimals="-4">1,880</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563913" contextRef="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:fixed-zero" decimals="-3">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563914" contextRef="d_2025-04-01_2025-06-30" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,882</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Issuance of common stock - warrants exercised</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c134563915" contextRef="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="amix:StockIssuedDuringPeriodSharesWarrantsExercised" scale="3" format="ixt:num-dot-decimal" decimals="-3">222</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c134563916" contextRef="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="amix:StockIssuedDuringPeriodValueWarrantsExercised" scale="3" format="ixt:fixed-zero" decimals="-3">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c134563917" contextRef="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="amix:StockIssuedDuringPeriodValueWarrantsExercised" scale="3" format="ixt:fixed-zero" decimals="-3">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c134563918" contextRef="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="amix:StockIssuedDuringPeriodValueWarrantsExercised" scale="3" format="ixt:fixed-zero" decimals="-3">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c134563919" contextRef="d_2025-04-01_2025-06-30" unitRef="USD" name="amix:StockIssuedDuringPeriodValueWarrantsExercised" scale="3" format="ixt:fixed-zero" decimals="-3">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance June 30, 2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c134563920" contextRef="i_2025-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="3" format="ixt:num-dot-decimal" decimals="-3">4,023</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c134563921" contextRef="i_2025-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">4</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c134563922" contextRef="i_2025-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">60,744</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c134563923" contextRef="i_2025-06-30_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">53,716</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c134563924" contextRef="i_2025-06-30" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">7,032</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">See accompanying notes to the unaudited condensed financial statements.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="width: 100%; text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
    105
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div>
   &#160;
  </div>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="uccash" href="#"></a>Autonomix Medical, Inc.</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Condensed Statements of Cash Flows</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Unaudited)</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div>
   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Three Months Ended June 30,</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>(in thousands)</i></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Cash Flows from Operating Activities:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Net loss</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c134563925" contextRef="d_2025-04-01_2025-06-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">3,337</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted">(<ix:nonFraction id="c134563926" contextRef="d_2024-04-01_2024-06-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">2,699</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Adjustments to reconcile net loss to net cash used in operating activities:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Stock-based compensation</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563927" contextRef="d_2025-04-01_2025-06-30" unitRef="USD" name="us-gaap:ShareBasedCompensation" scale="3" format="ixt:num-dot-decimal" decimals="-3">388</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted"><ix:nonFraction id="c134563928" contextRef="d_2024-04-01_2024-06-30" unitRef="USD" name="us-gaap:ShareBasedCompensation" scale="3" format="ixt:num-dot-decimal" decimals="-4">360</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Depreciation and amortization expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563929" contextRef="d_2025-04-01_2025-06-30" unitRef="USD" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" format="ixt:num-dot-decimal" decimals="-3">3</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted"><ix:nonFraction id="c134563930" contextRef="d_2024-04-01_2024-06-30" unitRef="USD" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" format="ixt:num-dot-decimal" decimals="-3">43</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Changes in operating assets - decrease:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Other current assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563931" contextRef="d_2025-04-01_2025-06-30" unitRef="USD" name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">84</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted"><ix:nonFraction id="c134563932" contextRef="d_2024-04-01_2024-06-30" unitRef="USD" name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">458</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Changes in operating liabilities - (decrease)/increase:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Accounts payable</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563933" contextRef="d_2025-04-01_2025-06-30" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" scale="3" format="ixt:num-dot-decimal" decimals="-4">140</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted">(<ix:nonFraction id="c134563934" contextRef="d_2024-04-01_2024-06-30" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">205</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Accrued expenses</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c134563935" contextRef="d_2025-04-01_2025-06-30" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" format="ixt:num-dot-decimal" decimals="-3">118</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted"><ix:nonFraction id="c134563936" contextRef="d_2024-04-01_2024-06-30" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" format="ixt:num-dot-decimal" decimals="-3">191</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net cash used in operating activities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c134563937" contextRef="d_2025-04-01_2025-06-30" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">2,604</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted">(<ix:nonFraction id="c134563938" contextRef="d_2024-04-01_2024-06-30" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">1,852</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Cash Flows from Investing Activities:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Purchase of property and equipment</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c134563939" contextRef="d_2025-04-01_2025-06-30" unitRef="USD" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" format="ixt:fixed-zero" decimals="-3" sign="-">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted">(<ix:nonFraction id="c134563940" contextRef="d_2024-04-01_2024-06-30" unitRef="USD" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" format="ixt:num-dot-decimal" decimals="-3">5</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net cash used in investing activities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563941" contextRef="d_2025-04-01_2025-06-30" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" format="ixt:fixed-zero" decimals="-3">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted">(<ix:nonFraction id="c134563942" contextRef="d_2024-04-01_2024-06-30" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">5</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Cash Flows from Financing Activities:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Issuance of common stock</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563943" contextRef="d_2025-04-01_2025-06-30_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,121</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted"><ix:nonFraction id="c134563944" contextRef="d_2024-04-01_2024-06-30_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" format="ixt:fixed-zero" decimals="-3">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Direct financing costs from issuance of common stock</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c134563945" contextRef="d_2025-04-01_2025-06-30" unitRef="USD" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" format="ixt:num-dot-decimal" decimals="-3">64</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted"><ix:nonFraction id="c134563946" contextRef="d_2024-04-01_2024-06-30" unitRef="USD" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" format="ixt:fixed-zero" decimals="-3" sign="-">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net cash provided by financing activities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c134563947" contextRef="d_2025-04-01_2025-06-30" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,057</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted"><ix:nonFraction id="c134563948" contextRef="d_2024-04-01_2024-06-30" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" format="ixt:fixed-zero" decimals="-3">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net increase in cash and cash equivalents</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c134563949" contextRef="d_2025-04-01_2025-06-30" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">547</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted">(<ix:nonFraction id="c134563950" contextRef="d_2024-04-01_2024-06-30" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">1,857</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Cash and cash equivalents, at beginning of period</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c134563951" contextRef="i_2025-03-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" format="ixt:num-dot-decimal" decimals="-3">9,136</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted"><ix:nonFraction id="c134563952" contextRef="i_2024-03-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" format="ixt:num-dot-decimal" decimals="-3">8,608</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Cash and cash equivalents, at end of period</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c134563953" contextRef="i_2025-06-30" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" format="ixt:num-dot-decimal" decimals="-3">8,589</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted"><ix:nonFraction id="c134563954" contextRef="i_2024-06-30" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" format="ixt:num-dot-decimal" decimals="-3">6,751</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><span style="text-decoration: underline; ">Supplemental cash flow disclosures:</span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Non-cash financing activities:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Recognition of deferred financing costs associated with issuance of common stock</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c134563955" contextRef="d_2025-04-01_2025-06-30" unitRef="USD" name="amix:DeferredFinancingCostsRelatedToTheIssuanceOfCommonStock" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">176</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted"><ix:nonFraction id="c134563956" contextRef="d_2024-04-01_2024-06-30" unitRef="USD" name="amix:DeferredFinancingCostsRelatedToTheIssuanceOfCommonStock" scale="3" format="ixt:fixed-zero" decimals="-3">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Proceeds from cashless exercise of warrants</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134563957" contextRef="d_2025-04-01_2025-06-30" unitRef="USD" name="us-gaap:StockIssued1" scale="3" format="ixt:fixed-zero" decimals="-3">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted"><ix:nonFraction id="c134563958" contextRef="d_2024-04-01_2024-06-30" unitRef="USD" name="us-gaap:StockIssued1" scale="3" format="ixt:num-dot-decimal" decimals="-3">4</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">See accompanying notes to the unaudited condensed financial statements.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="width: 100%; text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
    106
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="ucnotes" href="#"></a>Autonomix Medical, Inc.</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Notes to the Unaudited Condensed Financial Statements</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div>
   &#160;
  </div>
  <ix:nonNumeric contextRef="d_2025-04-01_2025-06-30" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" id="c3016975" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Note <em style="font: inherit;">1</em> </b>&#8211;<b> Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies </b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Description of the Business</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Autonomix Medical, Inc. (&#8220;we,&#8221; &#8220;our,&#8221; the &#8220;Company&#8221;) is a medical device company organized as a Delaware corporation on <em style="font: inherit;"> June 10, 2014. </em>The Company is a pre-revenue, clinical stage life sciences company focused on advancing innovative technologies for sensing and treating disorders relating to the peripheral nervous system.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <ix:nonNumeric contextRef="d_2025-04-01_2025-06-30" name="amix:ReverseStockSplitPolicyTextBlock" id="c134565383" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Reverse Stock Split</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company&#160;held its annual meeting of stockholders (the "Annual Meeting") on <em style="font: inherit;"> October 17, 2024. </em>In that Annual Meeting, stockholders of the Company approved an amendment to the Company&#8217;s amended and restated certificate of incorporation (the "Amendment&#8221;) to effect the reverse stock split at a ratio in the range of <em style="font: inherit;">1</em>-for-<ix:nonFraction id="c134564768" contextRef="d_2024-10-17_2024-10-17_NonmonetaryTransactionTypeAxis-ReverseStockSplitMember_RangeAxis-MinimumMember" unitRef="Pure" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" format="ixt:num-dot-decimal" decimals="INF">2</ix:nonFraction> to <em style="font: inherit;">1</em>-for-<ix:nonFraction id="c134564770" contextRef="d_2024-10-17_2024-10-17_NonmonetaryTransactionTypeAxis-ReverseStockSplitMember_RangeAxis-MaximumMember" unitRef="Pure" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" format="ixt:num-dot-decimal" decimals="INF">50</ix:nonFraction>, with such ratio to be determined in the discretion of the Company&#8217;s Board of Directors (the "Board") and with such reverse stock split to be effected at such time and date, if at all, as determined by the Company&#8217;s Board in its sole discretion prior to the <em style="font: inherit;">one</em>-year anniversary of the Annual Meeting.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Pursuant to such authority granted by the Company&#8217;s stockholders, the Company&#8217;s Board approved a <em style="font: inherit;">one</em>-for-<span style="-sec-ix-hidden:c134564773">twenty</span> (<em style="font: inherit;">1:20</em>) reverse stock split (the "Reverse Stock Split&#8221;) of the Company&#8217;s common stock and the filing of the Amendment to effectuate the Reverse Stock Split. The Amendment was filed with the Secretary of State of the State of Delaware and the Reverse Stock Split became effective in accordance with the terms of the Amendment at <em style="font: inherit;">11:59</em> p.m. Eastern Time on <em style="font: inherit;"> October 24, 2024 (</em>the "Effective Time&#8221;), and the Company&#8217;s common stock opened&#160;for trading on The Nasdaq Capital Market on <em style="font: inherit;"> October 25, 2024 </em>on a post-split basis, under the existing ticker symbol "AMIX&#8221; but with a new CUSIP number <em style="font: inherit;">05330T205.</em> The Amendment provides that, at the Effective Time, every <span style="-sec-ix-hidden:c134564777">twenty</span> shares of the Company&#8217;s issued and outstanding common stock was automatically combined into <em style="font: inherit;">one</em> issued and outstanding share of common stock, without any change in par value per share, which will remain $<ix:nonFraction id="c134564779" contextRef="i_2024-10-24" unitRef="USDPerShare" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.001</ix:nonFraction>.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The number of authorized shares of common stock remained&#160;at <ix:nonFraction id="c134564780" contextRef="i_2024-10-24" unitRef="Share" name="us-gaap:CommonStockSharesAuthorized" scale="6" format="ixt:num-dot-decimal" decimals="-8">500</ix:nonFraction> million shares. As a result of the Reverse Stock Split, proportionate adjustments were made to the per share exercise price and/or the number of shares issuable upon the exercise or vesting of all outstanding stock options, restricted stock unit awards, warrants and convertible notes, which resulted in a proportional decrease in the number of shares of the Company&#8217;s common stock reserved for issuance upon exercise or vesting of such stock options, restricted stock unit awards, warrants and convertible notes and, in the case of stock options and warrants, a proportional increase in the exercise price of all such stock options and warrants.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company&#8217;s stock option awards did <em style="font: inherit;">not</em> automatically adjust for the Reverse Stock Split.&#160;However, the Company chose to exercise its rights under the agreements to adjust the exercise price and number of shares exercisable or issuable upon vesting proportionately for the Reverse Stock Split.&#160;Based on the analysis performed, the Company does <em style="font: inherit;">not</em> need to recognize any additional compensation expense as a result of the modification.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">In addition, the number of shares reserved for issuance under the Company&#8217;s equity compensation plan immediately prior to the Effective Time was reduced proportionately.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><em style="font: inherit;">No</em> fractional shares were issued as a result of the Reverse Stock Split. Any stockholder who would have been entitled to receive a fractional share as a result of the process was entitled to the rounding up of the fractional share to the nearest whole number. See "<i>Fractional Shares</i>" in Note <em style="font: inherit;">4</em> for further disclosure regarding fractional shares.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Reverse Stock Split has been retroactively adjusted throughout these interim financial statements and footnotes for all periods presented, including exercise prices and share data. As a result of the Reverse Stock Split, the Company reclassified approximately $<ix:nonFraction id="c134564785" contextRef="d_2024-10-24_2024-10-24" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit" scale="3" format="ixt:num-dot-decimal" decimals="-3">18</ix:nonFraction> thousand between common stock par value and additional paid-in capital.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p></ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <ix:nonNumeric contextRef="d_2025-04-01_2025-06-30" name="amix:SubstantialDoubtAboutGoingConcernPolicyPolicyTextBlock" id="c134565384" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Liquidity and Going Concern</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company's financial statements are prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The Company is an early-stage company that is subject to all the risks associated with early-stage and emerging growth companies and has incurred losses since inception.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">O&#65279;n <em style="font: inherit;"> February 28, 2025,&#160;</em>the Company entered into an At Market Issuances Sales Agreement (the &#8220;ATM Agreement&#8221;) with Ladenburg Thalmann &amp; Co. Inc. (the &#8220;Agent&#8221;). Pursuant to the terms of the ATM Agreement, The Company <em style="font: inherit;"> may </em>sell from time to time through the Agent, as sales agent or principal, shares of its common stock with an initial aggregate sales price of up to $<ix:nonFraction id="c134564786" contextRef="i_2025-02-28_SubsidiarySaleOfStockAxis-ATMAgreementMember" unitRef="USD" name="amix:EquityOfferingMaximumOfferingAmount" scale="6" format="ixt:num-dot-decimal" decimals="-5">2.1</ix:nonFraction> million (the &#8220;Shares&#8221;). As of <em style="font: inherit;"> June 30, 2025, </em>the Company sold <ix:nonFraction id="c134564787" contextRef="d_2025-04-01_2025-06-30_SubsidiarySaleOfStockAxis-ATMAgreementMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,304,260</ix:nonFraction> Shares pursuant to the ATM Agreement for net proceeds of approximately $<ix:nonFraction id="c134564788" contextRef="d_2025-04-01_2025-06-30_SubsidiarySaleOfStockAxis-ATMAgreementMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" format="ixt:num-dot-decimal" decimals="-5">2.1</ix:nonFraction> million.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
    <ix:exclude>
     <div class="PGNUM" style="width: 100%; text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      <em style="font: inherit;">107</em>
     </div>
     <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
     <div class="PGHDR" style="text-align: left; width: 100%">
      <div class="hf-row">
       <div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;">
        <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
       </div>
      </div>
     </div>
    </ix:exclude> <ix:exclude>&#160;</ix:exclude> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> November 22, 2024, </em>the Company entered into&#160;an Underwriting Agreement (the &#8220;Underwriting Agreement&#8221;) with Ladenburg Thalmann &amp; Co. Inc., as representative of the several underwriters, if any, named on Schedule I of the Underwriting Agreement (the &#8220;Underwriters&#8221;), in connection with a firm commitment underwritten public offering (the &#8220;Offering&#8221;) of: (i) <ix:nonFraction id="c134564790" contextRef="d_2024-11-22_2024-11-25_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember" unitRef="Share" name="amix:NumberOfCommonUnitsIssued" scale="0" format="ixt:num-dot-decimal" decimals="INF">458,691</ix:nonFraction> common units (the &#8220;Common Units&#8221;), each Common Unit consisting of <span style="-sec-ix-hidden:c134564791">one</span> share of Company common stock and <span style="-sec-ix-hidden:c134564792">one</span> series A warrant to purchase <span style="-sec-ix-hidden:c134564793">one</span> share of common stock (the &#8220;Series A Warrants&#8221;); and (ii) <ix:nonFraction id="c134564794" contextRef="d_2024-11-22_2024-11-25_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember" unitRef="Share" name="amix:NumberOfPrefundedUnitsIssued" scale="0" format="ixt:num-dot-decimal" decimals="INF">917,596</ix:nonFraction> pre-funded units (the &#8220;Pre-Funded Units&#8221;) and together with the Common Units, the "Units", each Pre-Funded Unit consisting of <span style="-sec-ix-hidden:c134564795">one</span> pre-funded warrant to purchase <span style="-sec-ix-hidden:c134564796">one</span> share of common stock (the &#8220;Pre-Funded Warrant&#8221;) and <span style="-sec-ix-hidden:c134564797">one</span> Series A Warrant. The purchase price of each Common Unit was $<ix:nonFraction id="c134564798" contextRef="d_2024-11-22_2024-11-25_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember" unitRef="USDPerShare" name="amix:CommonUnitsIssuedPurchasePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">6.540</ix:nonFraction>, and the purchase price of each Pre-Funded Unit was $<ix:nonFraction id="c134564799" contextRef="d_2024-11-22_2024-11-25_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember" unitRef="USDPerShare" name="amix:PrefundedUnitsIssuedPurchasePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">6.539</ix:nonFraction>.&#160;In addition, the Company granted the Underwriters a <ix:nonNumeric contextRef="d_2024-11-22_2024-11-22_CounterpartyNameAxis-UnderwritersMember_SubsidiarySaleOfStockAxis-OverAllotmentOptionMember" name="amix:EquityOfferingOptionPeriod" id="c134564800" format="ixt-sec:durday">45</ix:nonNumeric>-day option to purchase an additional <ix:nonFraction id="c134564801" contextRef="i_2024-11-22_CounterpartyNameAxis-UnderwritersMember_SubsidiarySaleOfStockAxis-OverAllotmentOptionMember" unitRef="Share" name="amix:EquityOfferingOptionMaximumShares" scale="0" format="ixt:num-dot-decimal" decimals="INF">206,422</ix:nonFraction> shares of common stock, and/or an additional <ix:nonFraction id="c134564802" contextRef="i_2024-11-22_ClassOfWarrantOrRightAxis-SeriesAWarrantsMember_CounterpartyNameAxis-UnderwritersMember" unitRef="Share" name="amix:EquityOfferingOptionMaximumWarrants" scale="0" format="ixt:num-dot-decimal" decimals="INF">206,422</ix:nonFraction> Series A Warrants, solely to cover over-allotments, if any. The Pre-Funded Warrants have an exercise price of $<ix:nonFraction id="c134564803" contextRef="i_2024-11-25_ClassOfWarrantOrRightAxis-PrefundedWarrantsMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.001</ix:nonFraction> per share, are immediately exercisable and <em style="font: inherit;"> may </em>be exercised at any time until all of the Pre-Funded Warrants are exercised in full. The Series A Warrants have an exercise price of $<ix:nonFraction id="c134564804" contextRef="i_2024-11-25_ClassOfWarrantOrRightAxis-SeriesAWarrantsMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:num-dot-decimal" decimals="INF">6.540</ix:nonFraction> per share, are immediately exercisable and <em style="font: inherit;"> may </em>be exercised at any time until the <span style="-sec-ix-hidden:c134564805">five</span>-year anniversary of the date of issuance. Both the Pre-Funded Warrants and the Series A Warrants are subject to a beneficial ownership limitation of <ix:nonFraction id="c134564806" contextRef="i_2024-11-25_ClassOfWarrantOrRightAxis-PrefundedAndSeriesAWarrantsMember" unitRef="Pure" name="amix:ClassOfWarrantsOrRightsMaximumBeneficialOwnership" scale="-2" format="ixt:num-dot-decimal" decimals="4">4.99</ix:nonFraction>%. The Pre-Funded Warrants and Series A Warrants were issued pursuant to a warrant agency agreement between the Company and Equity Stock Transfer, LLC (the &#8220;Warrant Agency Agreement&#8221;). The Offering closed on <em style="font: inherit;"> November 25, 2024. </em>On <em style="font: inherit;"> November 22, 2024, </em>the Underwriters partially exercised their over-allotment option with respect to <ix:nonFraction id="c134564807" contextRef="d_2024-11-22_2024-11-22_CounterpartyNameAxis-UnderwritersMember_SubsidiarySaleOfStockAxis-OverAllotmentOptionMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:num-dot-decimal" decimals="INF">156,809</ix:nonFraction> shares of common stock and <ix:nonFraction id="c134564808" contextRef="d_2024-11-22_2024-11-22_ClassOfWarrantOrRightAxis-SeriesAWarrantsMember_CounterpartyNameAxis-UnderwritersMember" unitRef="Share" name="amix:ClassOfWarrantOrRightIssuedDuringPeriod" scale="0" format="ixt:num-dot-decimal" decimals="INF">156,809</ix:nonFraction> Series A Warrants. The aggregate gross proceeds to the Company, including the partial exercise of the over-allotment option, were approximately $<ix:nonFraction id="c134564809" contextRef="d_2024-11-22_2024-11-25_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="6" format="ixt:num-dot-decimal" decimals="-7">10.0</ix:nonFraction> million, before deducting underwriting discounts and other expenses by the Company of $<ix:nonFraction id="c134564810" contextRef="d_2024-11-22_2024-11-25_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="6" format="ixt:num-dot-decimal" decimals="-5">1.5</ix:nonFraction> million, including $<ix:nonFraction id="c134564811" contextRef="d_2024-11-22_2024-11-25_NatureOfExpenseAxis-NoncashExpensesMember_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.5</ix:nonFraction> million of non-cash expenses. The net cash proceeds to the Company were approximately $<ix:nonFraction id="c134564812" contextRef="d_2024-11-22_2024-11-25_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember" unitRef="USD" name="amix:ProceedsFromIssuanceOrSaleOfEquityNet" scale="6" format="ixt:num-dot-decimal" decimals="-6">9.0</ix:nonFraction> million. See Note <em style="font: inherit;">6</em> - Subsequent Events for additional information regarding events occurring after <em style="font: inherit;"> June 30, 2025.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">For the&#160;<em style="font: inherit;">three</em> months ended <em style="font: inherit;"> June 30, 2025 </em>and <em style="font: inherit;">2024,</em> the Company incurred net losses of $<ix:nonFraction id="c134564816" contextRef="d_2025-04-01_2025-06-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="6" format="ixt:num-dot-decimal" decimals="-5" sign="-">3.3</ix:nonFraction> million and $<ix:nonFraction id="c134564817" contextRef="d_2024-04-01_2024-06-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="6" format="ixt:num-dot-decimal" decimals="-5" sign="-">2.7</ix:nonFraction> million, respectively, and had net cash flows used in operating activities of $<ix:nonFraction id="c134564818" contextRef="d_2025-04-01_2025-06-30" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" format="ixt:num-dot-decimal" decimals="-5" sign="-">2.6</ix:nonFraction> million and $<ix:nonFraction id="c134564819" contextRef="d_2024-04-01_2024-06-30" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" format="ixt:num-dot-decimal" decimals="-5" sign="-">1.9</ix:nonFraction>&#160;million, respectively. The Company had <ix:nonFraction id="c134564820" contextRef="d_2025-04-01_2025-06-30" unitRef="USD" name="us-gaap:Revenues" scale="6" format="ixt-sec:numwordsen" decimals="-3">no</ix:nonFraction> revenues for the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> June 30, 2025 </em>and <em style="font: inherit;">2024,</em> respectively, and an accumulated deficit of $<ix:nonFraction id="c134564823" contextRef="i_2025-06-30" unitRef="USD" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" format="ixt:num-dot-decimal" decimals="-5" sign="-">53.7</ix:nonFraction>&#160;million, working capital of $<ix:nonFraction id="c134564824" contextRef="i_2025-06-30" unitRef="USD" name="amix:WorkingCapitalDeficit" scale="6" format="ixt:num-dot-decimal" decimals="-6">7.0</ix:nonFraction> million and cash of $<ix:nonFraction id="c134564825" contextRef="i_2025-06-30" unitRef="USD" name="us-gaap:Cash" scale="6" format="ixt:num-dot-decimal" decimals="-5">8.6</ix:nonFraction> million as of <em style="font: inherit;"> June 30, 2025. </em>The Company does <em style="font: inherit;">not</em> expect to&#160;generate&#160;positive cash flows from operating activities in the near future.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company estimates its current cash resources&#160;are sufficient to fund its operations into but <em style="font: inherit;">not</em> beyond the <em style="font: inherit;">second</em> calendar quarter of <em style="font: inherit;">2026.</em> The Company recognizes it will need to raise additional capital to continue to execute its business plan, including obtaining regulatory clearance for its products currently under development and commercializing and generating revenues from products under development. There is <em style="font: inherit;">no</em> assurance that additional financing will be available when needed or that management will be able to obtain financing on terms acceptable to the Company. A failure to raise sufficient capital, generate sufficient product revenues, control expenditures and regulatory matters, among other factors, will adversely impact the Company&#8217;s ability to meet its financial obligations as they become due and payable and to achieve its intended business objectives. If the Company is unable to raise sufficient additional funds, it will have to scale back its operations.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">These factors raise substantial doubt about the Company's ability to continue as a going concern within <em style="font: inherit;">one</em> year after the date the financial statements are issued. The accompanying condensed financial statements have been prepared on a going concern basis and do <em style="font: inherit;">not</em> include any adjustments that might be necessary if the Company is unable to continue as a going concern.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p></ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <ix:nonNumeric contextRef="d_2025-04-01_2025-06-30" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="c134565385" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Basis of Presentation</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The accompanying condensed interim financial statements are unaudited. These unaudited condensed interim financial statements have been prepared in accordance with the rules and regulations of the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) for interim financial information. Accordingly, they do <em style="font: inherit;">not</em> include all the information and notes required by generally accepted accounting principles in the United States of America (&#8220;GAAP&#8221;) for complete financial statements. The Company&#8217;s fiscal year end is <em style="font: inherit;"> March 31</em><sup style="vertical-align:top;line-height:120%;">st</sup>. These unaudited condensed interim financial statements should be read in conjunction with the audited financial statements and accompanying notes for the year ended <em style="font: inherit;"> March 31, 2025 </em>as found in the Annual Report in the Company's Form <em style="font: inherit;">10</em>-K filed with the SEC on <em style="font: inherit;"> May 29, 2025. </em>In the opinion of management, the unaudited condensed interim financial statements reflect all the adjustments (consisting of normal recurring adjustments) necessary to state fairly the Company&#8217;s financial position, results of operations and cash flows for the quarterly and year-to-date periods, as applicable. The interim results of operations are <em style="font: inherit;">not</em> necessarily indicative of the results that <em style="font: inherit;"> may </em>occur for the full fiscal year. The <em style="font: inherit;"> March 31, 2025 </em>audited condensed balance sheet included herein was derived from the audited financial statements, but does <em style="font: inherit;">not</em> include all disclosures, including notes, required by GAAP for complete financial statements.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p></ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <ix:nonNumeric contextRef="d_2025-04-01_2025-06-30" name="us-gaap:UseOfEstimates" id="c134565386" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Use of Estimates in Financial Statement Presentation</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The preparation of these unaudited condensed interim financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The Company's significant estimates and assumptions include work performed but <em style="font: inherit;">not</em> yet billed by contract manufacturers, engineers and research organizations and the valuation of equity related instruments. Although the Company believes that its estimates and assumptions are reasonable, they are based upon information available at the time the estimates and assumptions were made. Some of these judgments can be subjective and complex, and, consequently, actual results could differ from those estimates.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p></ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       <em style="font: inherit;">108</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <ix:nonNumeric contextRef="d_2025-04-01_2025-06-30" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="c134565387" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Cash and Cash Equivalents</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company considers all highly liquid accounts with original maturities of <em style="font: inherit;">three</em> months or less at the date of acquisition to be cash equivalents.&#160;Periodically, the Company <em style="font: inherit;"> may </em>carry cash balances at financial institutions in excess of the federally insured limit of <em style="font: inherit;">$250</em> thousand. The Company has <em style="font: inherit;">not</em> experienced losses on these accounts and management believes, based upon the quality of the financial institutions, that the credit risk with regard to these deposits is <em style="font: inherit;">not</em> significant.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p></ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <ix:nonNumeric contextRef="d_2025-04-01_2025-06-30" name="amix:OfferingCostsPolicyPolicyTextBlock" id="c134565388" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Offering and Financing Costs</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Offering costs consist of professional costs incurred through the balance sheet date that are direct and incremental related to the Company&#8217;s equity financing activities. Specifically, offering costs were incurred during the Company&#8217;s initial public offering ("IPO"), Offering from <em style="font: inherit;"> November 2024 </em>and ATM Agreement. The Company includes offering costs in additional paid-in capital, to the extent there is sufficient cash proceeds, upon completion of the sale of equity. Costs associated with salaries and other period costs are expensed as incurred.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p></ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;text-indent:9pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;text-indent:9pt;"><i></i></p>
   <ix:nonNumeric contextRef="d_2025-04-01_2025-06-30" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="c134565389" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;text-indent:9pt;"><i>Property and Equipment</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Property and equipment (comprised of computer and IT equipment) are stated at historical cost and depreciated on a straight-line basis over their estimated useful lives, generally&#160;<span style="-sec-ix-hidden:c134564843">three</span> years. Upon disposition of the assets, the costs and related accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the results of operations.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p></ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <ix:nonNumeric contextRef="d_2025-04-01_2025-06-30" name="us-gaap:DebtPolicyTextBlock" id="c134565390" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Convertible Notes</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">For the period ended <em style="font: inherit;"> March 31, 2025, </em>the Company evaluated embedded redemption, conversion and other features within its debt to determine whether any embedded features should be bifurcated from the host instrument and accounted for as a derivative at fair value, with changes in fair value recorded in the condensed statements of operations. The Company&#8217;s debt was carried on the condensed balance sheets on a historical cost basis, net of unamortized discounts and premiums, because the Company did <em style="font: inherit;">not</em> elect the fair value option of accounting. Costs associated with acquiring debt, including detachable warrants issued in connection with the financing, were&#160;capitalized as a debt discount. The debt discount was&#160;presented in the condensed balance sheets, in prior year periods, as a direct deduction from the carrying amount of the debt liability. The costs were&#160;amortized over the estimated contractual life of the related debt instrument using the effective interest method and were&#160;included in interest expense in the condensed statements of operations.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">In addition, since the instruments included a substantive conversion feature as of time of issuance, the issuance of equity securities to settle the outstanding notes with the conversion were accounted for as a contractual conversion with <em style="font: inherit;">no</em> gain or loss recognized related to the equity securities issued to settle the instrument. See <i>Note <em style="font: inherit;">2</em> - Convertible Notes Payable</i> for additional information.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p></ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <ix:nonNumeric contextRef="d_2025-04-01_2025-06-30" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="c134565391" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Fair Value of Financial Instruments</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs. The Company utilizes a <em style="font: inherit;">three</em>-level valuation hierarchy for disclosures of fair value measurements, defined as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Level <em style="font: inherit;">1</em> &#8211; inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Level <em style="font: inherit;">2</em> &#8211; inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the assets or liability, either directly or indirectly, for substantially the full term of the financial instrument</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">Level <em style="font: inherit;">3</em> &#8211; inputs to the valuation methodology are unobservable and significant to the fair value and require significant judgment and estimation</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Financial assets and financial liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. While the Company believes that its valuation methods are appropriate, the Company recognizes that the use of different methodologies or assumptions to determine the fair value could result in a different estimate of fair value at the reporting date. The primary assumptions that would significantly affect the fair values are the probability weighting of the different settlement outcomes used.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
    <ix:exclude>
     <div class="PGNUM" style="width: 100%; text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      <em style="font: inherit;">109</em>
     </div>
     <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
     <div class="PGHDR" style="text-align: left; width: 100%">
      <div class="hf-row">
       <div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;">
        <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
       </div>
      </div>
     </div>
    </ix:exclude> <ix:exclude>&#160;</ix:exclude> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company did <em style="font: inherit;">not</em> have any assets or liabilities measured at fair value as of <em style="font: inherit;"> June 30, 2025 </em>and <em style="font: inherit;"> March 31, 2025.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">The carrying value of short-term instruments, including cash, accounts payable and accrued expenses, approximate fair value due to the relatively short period to maturity for these instruments.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p></ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;"><i></i></p>
   <ix:nonNumeric contextRef="d_2025-04-01_2025-06-30" name="amix:RelatedPartyTransactionsPolicyPolicyTextBlock" id="c134565392" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;"><i>Related Parties</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company follows Accounting Standards Codification ("ASC") <em style="font: inherit;">850,</em> <i>Related Party Disclosures</i>, for the identification of related parties and disclosure of related party transactions. See further discussion in Note <em style="font: inherit;">5</em> below on this matter.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p></ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <ix:nonNumeric contextRef="d_2025-04-01_2025-06-30" name="us-gaap:IncomeTaxPolicyTextBlock" id="c134565393" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Income Taxes</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting and the tax basis of reported assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company must then assess the likelihood that the resulting deferred tax assets will be realized. A valuation allowance is provided when it is more likely than <em style="font: inherit;">not</em> that some portion or all of a deferred tax asset will <em style="font: inherit;">not</em> be realized. As of <em style="font: inherit;"> June 30, 2025 </em>and <em style="font: inherit;"> March 31, 2025 </em>the Company determined a full valuation allowance was required to offset its deferred tax assets as a result of recurring operating losses.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company accounts for uncertain tax positions in accordance with the provisions of ASC <em style="font: inherit;">740</em>-<em style="font: inherit;">10</em> which prescribes a recognition threshold and measurement attribute for financial statement disclosure of tax positions taken, or expected to be taken, on its tax return. The Company evaluates and records any uncertain tax positions based on the amount that management deems is more likely than <em style="font: inherit;">not</em> to be sustained upon examination and ultimate settlement with the tax authorities in the tax jurisdictions in which it operates. As of <em style="font: inherit;"> June 30, 2025 </em>and <em style="font: inherit;"> March 31, 2025 </em>the Company had <ix:nonFraction id="c134564860" contextRef="i_2025-06-30" unitRef="USD" name="us-gaap:LiabilityForUncertainTaxPositionsCurrent" scale="6" format="ixt-sec:numwordsen" decimals="-3">no</ix:nonFraction> uncertain tax positions.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company does&#160;<em style="font: inherit;">not</em>&#160;expect to pay any significant federal, state, or foreign income taxes in&#160;its fiscal year <em style="font: inherit;">2026</em> (ending <em style="font: inherit;"> March 31, 2026) </em>as a result of the losses recorded during the&#160;<em style="font: inherit;">three</em> months ended <em style="font: inherit;"> June 30, 2025&#160;</em>and the additional losses expected for the remainder of&#160;its fiscal year <em style="font: inherit;">2026</em>&#160;and cumulative net operating loss carryforwards. Accounting standards require the consideration of a valuation allowance for deferred tax assets if it is &#8220;more likely than&#160;<em style="font: inherit;">not&#8221;</em>&#160;that some component or all of the benefits of deferred tax assets will <em style="font: inherit;">not</em> be realized.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company recorded&#160;<em style="font: inherit;">no</em>&#160;income tax provision for the&#160;<em style="font: inherit;">three</em> months ended <em style="font: inherit;"> June 30, 2025 </em>and <em style="font: inherit;">2024,</em> respectively. The effective tax rate for the&#160;<em style="font: inherit;">three</em> months ended <em style="font: inherit;"> June 30, 2025 </em>and <em style="font: inherit;">2024</em>&#160;is zero.&#160;The Company estimates its annual effective tax rate at the end of each quarterly period. Jurisdictions with a projected loss for the year where&#160;<em style="font: inherit;">no</em>&#160;tax benefit can be recognized due to the valuation allowance could result in a higher or lower effective tax rate during a particular quarter depending on the mix and timing of actual earnings versus annual projections.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p></ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <ix:nonNumeric contextRef="d_2025-04-01_2025-06-30" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="c134565394" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Stock-based Compensation</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Employee and non-employee share-based compensation is measured at the grant date, based on the fair value of the award, and is recognized as an expense over the requisite service period. For awards with a performance condition, compensation expense is recognized over the requisite service period if it is probable that the performance condition will be satisfied. For awards to non-employees, the Company recognizes compensation expense in the same manner as if the Company had paid cash for the goods or services. The Company estimates the fair value of options and equity classified warrants granted using an options pricing model. Expense is recognized within general and administrative and research and development expenses and forfeitures are recognized as they are incurred.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p></ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <ix:nonNumeric contextRef="d_2025-04-01_2025-06-30" name="amix:WarrantsPolicyPolicyTextBlock" id="c134565395" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Warrants</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s specific terms and applicable authoritative guidance in FASB ASC <em style="font: inherit;">480,</em> Distinguishing Liabilities from Equity (&#8220;ASC <em style="font: inherit;">480&#8221;</em>) and ASC <em style="font: inherit;">815,</em> Derivatives and Hedging (&#8220;ASC <em style="font: inherit;">815&#8221;</em>). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC <em style="font: inherit;">480,</em> meet the definition of a liability pursuant to ASC <em style="font: inherit;">480,</em> and whether the warrants meet all of the requirements for equity classification under ASC <em style="font: inherit;">815,</em> including whether the warrants are indexed to the Company&#8217;s own ordinary shares and whether the warrant holders could potentially require &#8220;net cash settlement&#8221; in a circumstance outside of the Company&#8217;s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do <em style="font: inherit;">not</em> meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss on the&#160;statements of operations. The fair value of the warrants is estimated using a Black-Scholes pricing model or a Monte Carlo simulation.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p></ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <ix:exclude>
    <div class="PGNUM" style="width: 100%; text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
     <em style="font: inherit;">110</em>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <ix:nonNumeric contextRef="d_2025-04-01_2025-06-30" name="us-gaap:EarningsPerSharePolicyTextBlock" id="c134565396" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Loss Per Common Share</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Basic loss per common share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period, which includes shares issuable for little to <em style="font: inherit;">no</em> consideration upon the exercise of certain equity-classified warrants. Diluted loss per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. In periods when losses are reported, the weighted-average number of common shares outstanding excludes common stock equivalents, because their inclusion would be anti-dilutive. Generally, the Company&#8217;s outstanding warrants are non-participating securities as they are <em style="font: inherit;">not</em> entitled to non-forfeitable rights to dividends or dividend equivalents during the vesting term and have <em style="font: inherit;">no</em> obligation to fund losses.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">However, the Company's warrants described in Note&#160;<em style="font: inherit;">2</em>&#160;and the warrants issued in connection with the Offering, are participating securities as the holders receive the right to dividends, but they are <em style="font: inherit;">not</em> obligated to fund losses. In periods of loss, since <em style="font: inherit;">no</em> income is allocated to these securities, the Company's use of the "treasury stock method" derives the same result. The dilutive effect of convertible securities is calculated using the &#8220;if-converted method.&#8221; Under the if-converted method, securities are assumed to be converted at the beginning of the period, and the resulting common shares are included in the denominator of the diluted calculation for the entire period being presented.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">For the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> June 30, 2025 </em>and <em style="font: inherit;">2024,</em> dilutive securities that were <em style="font: inherit;">not</em> included in the calculations of the loss per common share because they would be anti-dilutive included the following:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
    <ix:nonNumeric contextRef="d_2025-04-01_2025-06-30" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="c3016976" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 5%; margin-left: 54pt; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>June 30,</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(as revised)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Equity based warrants to purchase common shares</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134564212" contextRef="d_2025-04-01_2025-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:num-dot-decimal" decimals="INF">87,531</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted"><ix:nonFraction id="c134564213" contextRef="d_2024-04-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:num-dot-decimal" decimals="INF">4,334</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Convertible Notes - common shares (1)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134564214" contextRef="d_2025-04-01_2025-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-ConvertibleDebtSecuritiesMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:fixed-zero" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted"><ix:nonFraction id="c134564215" contextRef="d_2024-04-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-ConvertibleDebtSecuritiesMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:num-dot-decimal" decimals="INF">33,250</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Convertible Notes - equity-based warrants to purchase common shares</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134564216" contextRef="d_2025-04-01_2025-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-ConvertibleNotesToWarrantsMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:num-dot-decimal" decimals="INF">25,003</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted"><ix:nonFraction id="c134564217" contextRef="d_2024-04-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-ConvertibleNotesToWarrantsMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:num-dot-decimal" decimals="INF">25,003</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock options granted under Company's incentive plan</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134564218" contextRef="d_2025-04-01_2025-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:num-dot-decimal" decimals="INF">248,483</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted"><ix:nonFraction id="c134564219" contextRef="d_2024-04-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:num-dot-decimal" decimals="INF">216,483</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Series A Warrants</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134564220" contextRef="d_2025-04-01_2025-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-SeriesAWarrantsMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,533,096</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted"><ix:nonFraction id="c134564221" contextRef="d_2024-04-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-SeriesAWarrantsMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:fixed-zero" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Representative Warrants</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c134564222" contextRef="d_2025-04-01_2025-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-RepresentativesWarrantsMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:num-dot-decimal" decimals="INF">91,985</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted"><ix:nonFraction id="c134564223" contextRef="d_2024-04-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-RepresentativesWarrantsMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:fixed-zero" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total potentially dilutive securities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c134564224" contextRef="d_2025-04-01_2025-06-30" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,986,098</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted"><ix:nonFraction id="c134564225" contextRef="d_2024-04-01_2024-06-30" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:num-dot-decimal" decimals="INF">279,070</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   </ix:nonNumeric> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 54pt;">(<em style="font: inherit;">1</em>) Shares for the convertible note proceeds received</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p></ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <ix:nonNumeric contextRef="d_2025-04-01_2025-06-30" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="c134565397" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Research and Development Costs</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Research and development costs are expensed as incurred.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p></ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <ix:nonNumeric contextRef="d_2025-04-01_2025-06-30" name="us-gaap:AdvertisingCostsPolicyTextBlock" id="c134565398" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Advertising</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">It is the Company's policy to expense advertising costs as incurred. Advertising&#160;expenses are included within general and administrative expenses within the statement of operations. For the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> June 30, 2025 </em>and <em style="font: inherit;">2024,</em> the Company recorded $<ix:nonFraction id="c134564894" contextRef="d_2025-04-01_2025-06-30" unitRef="USD" name="us-gaap:AdvertisingExpense" scale="6" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction> and less than $<ix:nonFraction id="c134564895" contextRef="d_2024-04-01_2024-06-30" unitRef="USD" name="us-gaap:AdvertisingExpense" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.1</ix:nonFraction>&#160;million, respectively, of advertising expenses.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p></ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <ix:nonNumeric contextRef="d_2025-04-01_2025-06-30" name="amix:JumpstartOurBusinessStartupsJobsActAccountingElectionPolicyPolicyTextBlock" id="c134565399" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>JOBS Act Accounting Election</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company qualifies as an emerging growth company (&#8220;EGC&#8221;), as defined in the Jumpstart Our Business Startups Act of <em style="font: inherit;">2012</em> (the &#8220;JOBS Act&#8221;). The JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected <em style="font: inherit;">not</em> to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This <em style="font: inherit;"> may </em>make comparison of the Company&#8217;s financial statements with another public company which is neither an early-stage company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p></ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <ix:exclude>
    <div class="PGNUM" style="width: 100%; text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
     <em style="font: inherit;">111</em>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><i></i></p>
   <ix:nonNumeric contextRef="d_2025-04-01_2025-06-30" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="c134565400" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><i>Segments</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker ("CODM"), or decision-making group, in deciding how to allocate resources in assessing performance. Management has determined that the Company operates in&#160;<span style="-sec-ix-hidden:c134564899">one</span>&#160;reportable segment, which is advancing the development of innovative technologies for sensing and treating disorders relating to the nervous system. The Company is initially focused on developing the technology for patients with pancreatic cancer, however, the Company believes the technology constitutes a platform with the potential to address several indications, including chronic pain management, hypertension, cardiovascular disease and a wide range of other nerve-related disorders. The Company's CODM is its Chief Executive Officer.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The accounting policies of the segment are the same as those described in the summary of significant accounting policies. The CODM assesses performance based on net loss, which is reported on the Statements of Operations. The measure of segment assets is reported on the balance sheet as total assets.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">To date, the Company has <em style="font: inherit;">not</em> generated any product revenue. The Company expects to continue to incur significant expenses and operating losses for the foreseeable future as it advances its' technology through all stages of development and clinical trials and, ultimately, seek regulatory approval.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">As such, the CODM primarily evaluates performance of the Company using various financial metrics, including the combined net income (loss) from operations, also shown on the Statements of Operations, forecasted cash expenditures and existing and forecasted cash balances. These financial metrics are used by the CODM to make key operating decisions, such as the assessment of segment performance and allocation of resources. All of the Company's assets are located in the United States. The significant expense categories within net loss from operations that the CODM regularly reviews are expenses related to research and development, general and administrative, and depreciation and amortization. The significant expense categories and subcategories are reported on the Statements of Operations.&#160;Other expenses included in the Company&#8217;s net loss include other income (expense), interest income, net, and any additional non-operating expenses that are reported on the Statements of Operations.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p></ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <ix:nonNumeric contextRef="d_2025-04-01_2025-06-30" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="c134565401" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Recent Accounting Pronouncements</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">In&#160;<em style="font: inherit;"> November 2024 </em>and <em style="font: inherit;"> January 2025,&#160;</em>FASB issued ASU&#160;<em style="font: inherit;">2024</em>-<em style="font: inherit;">03</em> and ASU <em style="font: inherit;">2025</em>-<em style="font: inherit;">01,</em>&#160;Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic&#160;<em style="font: inherit;">220</em>-<em style="font: inherit;">40</em>): Disaggregation of Income Statement Expenses, which requires disclosure in the notes to the financial statements of specified information about certain costs and expenses. The amendments to the standards are effective for fiscal years beginning after&#160;<em style="font: inherit;"> December 15, 2026,&#160;</em>and for interim periods within fiscal years beginning after&#160;<em style="font: inherit;"> December 15, 2027.&#160;</em>Early adoption is permitted. The amendments should be applied either prospectively to financial statements issued for reporting periods after the effective date of this ASU or retrospectively to any or all prior periods presented in the financial statements. The Company is currently evaluating the new guidance to determine the impact it&#160;<em style="font: inherit;"> may&#160;</em>have on its financial statements and related disclosures.&#160;</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">In <em style="font: inherit;"> December 2023, </em>the FASB issued <i>ASU <em style="font: inherit;">2023</em>-<em style="font: inherit;">09,</em> </i>&#8220;<i>Income Taxes (Topic <em style="font: inherit;">740</em>): Improvements to Income Tax Disclosures,</i>&#8221; which requires disaggregated information about a reporting entity&#8217;s effective tax rate reconciliation as well as information on income taxes paid. The guidance is effective for the Company&#8217;s fiscal years beginning after <em style="font: inherit;"> December 15, 2024. </em>The Company is currently evaluating the new guidance to determine the impact it&#160;<em style="font: inherit;"> may&#160;</em>have on its financial statements and related disclosures.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">In <em style="font: inherit;"> November 2023, </em>the FASB issued <i>ASU <em style="font: inherit;">No.</em> <em style="font: inherit;">2023</em>-<em style="font: inherit;">07,</em> Segment Reporting (Topic <em style="font: inherit;">280</em>): Improvements to Reportable Segment Disclosures.</i> The ASU updates reportable segment disclosure requirements, primarily through requiring enhanced disclosures about significant segment expenses and information used to assess segment performance and allocate resources. The guidance is effective for fiscal years beginning after <em style="font: inherit;"> December 15, 2023 </em>and interim periods for fiscal years beginning after <em style="font: inherit;"> December 15, 2024, </em>on a retrospective basis. There was <em style="font: inherit;">no</em> material impact upon the adoption of <i>ASU <em style="font: inherit;">2023</em>-<em style="font: inherit;">07</em></i> on the Company's interim disclosures.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">There are <em style="font: inherit;">no</em> other effective pronouncements, or pronouncements issued but <em style="font: inherit;">not</em> yet effective, if adopted, that would have a material effect on the accompanying financial statements.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p></ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;text-indent:9pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;text-indent:9pt;"><i></i></p>
   <ix:nonNumeric contextRef="d_2025-04-01_2025-06-30" name="amix:CorrectionOfAnImmaterialErrorPolicyTextBlock" id="c134565402" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;text-indent:9pt;"><i>Correction of an Immaterial Error in the Prior Period Financial Statements</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">D&#65279;uring the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> December 31, 2024, </em>the Company determined that previously filed quarterly and annual financial statements had an immaterial earnings per share error resulting from the exclusion of certain unexercised equity based warrants to purchase common shares that had an exercise price of approximately $<ix:nonFraction id="c134564920" contextRef="i_2024-12-31_ClassOfWarrantOrRightAxis-EquitybasedWarrantsMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.01</ix:nonFraction> or less from the basic earnings per share calculations in accordance with <i>ASC <em style="font: inherit;">260</em>-<em style="font: inherit;">10</em>-<em style="font: inherit;">45</em>-<em style="font: inherit;">13</em></i>. As a&#160;result, the prior year earnings per share calculations have been revised for consistency with the current year presentation. The Company assessed the materiality of this change in presentation on prior period financial statements in accordance with <i>SEC Staff Accounting Bulletin <em style="font: inherit;">No.</em> <em style="font: inherit;">99</em></i>, &#8220;<i>Materiality</i>,&#8221; (<i>ASC Topic <em style="font: inherit;">250,</em> Accounting Changes and Error Corrections</i>). Based on this assessment, the Company concluded that this error correction in its&#160;<i>Statements of Operations</i>&#160;and <i>Note <em style="font: inherit;">1</em> </i>&#8211;<i> Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies (Loss Per Common Share)</i> is <em style="font: inherit;">not</em> material to any previously presented financial statements based upon overall considerations of both quantitative and qualitative factors. The corrections had <em style="font: inherit;">no</em> impact in the comparative period Balance Sheet,&#160;Statements of Cash Flows, or Statement of Changes in Stockholders&#8217;&#160;Equity. Further, the immaterial correction did <em style="font: inherit;">not</em> result in a change in operating losses or net loss in the Statement of Operations and the effects of including unexercised warrants in the earnings per share calculation have an antidilutive effect reducing the net loss per share amount. Accordingly, the Company corrected the previously reported earnings per share calculation for the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> June 30, 2024 </em>in this Quarterly Report on Form <em style="font: inherit;">10</em>-Q.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
    <ix:exclude>
     <div class="PGNUM" style="width: 100%; text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      <em style="font: inherit;">112</em>
     </div>
     <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
     <div class="PGHDR" style="text-align: left; width: 100%">
      <div class="hf-row">
       <div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;">
        <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
       </div>
      </div>
     </div>
    </ix:exclude> <ix:exclude>&#160;</ix:exclude> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">A summary of the impact of the Company&#8217;s Reverse Stock Split and immaterial corrections reflecting the prior period impact to the Company&#8217;s Statement of Operations and earnings per share are shown below:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
    <ix:nonNumeric contextRef="d_2025-04-01_2025-06-30" name="us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" id="EDBFCD1B-5AC0-4A4A-9FF1-7B073398C2A1" escape="true" continuedAt="E5A521EB-2792-45CA-8FD9-B028E96456BE">
     <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Three Months Ended June 30, 2024</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Originally </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Filed</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Adjusted </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>for 1-for-20 </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Reverse </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Stock Split</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Correction</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>As Revised</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net Loss (in thousands)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c134564226" contextRef="d_2024-04-01_2024-06-30_RestatementAxis-ScenarioPreviouslyReportedMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">2,699</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted"><ix:nonFraction id="c134564227" contextRef="d_2024-04-01_2024-06-30_RestatementAxis-ReverseStockSplitAdjustmentMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:fixed-zero" decimals="-3">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134564228" contextRef="d_2024-04-01_2024-06-30_RestatementAxis-RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:fixed-zero" decimals="-3">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c134564229" contextRef="d_2024-04-01_2024-06-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">2,699</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Loss per share - basic and diluted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c134564230" contextRef="d_2024-04-01_2024-06-30_RestatementAxis-ScenarioPreviouslyReportedMember" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasic" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">0.14</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted">(<ix:nonFraction id="c134564231" contextRef="d_2024-04-01_2024-06-30_RestatementAxis-ReverseStockSplitAdjustmentMember" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasic" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">2.85</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c134564232" contextRef="d_2024-04-01_2024-06-30_RestatementAxis-RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasic" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.65</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c134564233" contextRef="d_2024-04-01_2024-06-30" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasic" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">2.20</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Weighted average shares outstanding - basic and diluted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c134564234" contextRef="d_2024-04-01_2024-06-30_RestatementAxis-ScenarioPreviouslyReportedMember" unitRef="Share" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" format="ixt:num-dot-decimal" decimals="INF">18,902,248</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted"><ix:nonFraction id="c134564235" contextRef="d_2024-04-01_2024-06-30_RestatementAxis-ReverseStockSplitAdjustmentMember" unitRef="Share" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" format="ixt:num-dot-decimal" decimals="INF">945,382</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c134564236" contextRef="d_2024-04-01_2024-06-30_RestatementAxis-RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" unitRef="Share" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" format="ixt:num-dot-decimal" decimals="INF">280,041</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c134564237" contextRef="d_2024-04-01_2024-06-30" unitRef="Share" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,225,423</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
    </ix:nonNumeric> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">A summary of the impact of the Company&#8217;s Reverse Stock Split and immaterial corrections reflecting the prior period impact are shown below:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
    <ix:continuation id="E5A521EB-2792-45CA-8FD9-B028E96456BE">
     <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Three Months Ended June 30, 2024</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Originally </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Filed</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Adjusted </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>for 1-for-20 </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Reverse </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Stock Split</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Correction</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>As Revised</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Equity based warrants to purchase common shares</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134564238" contextRef="d_2024-04-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember_RestatementAxis-ScenarioPreviouslyReportedMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:num-dot-decimal" decimals="INF">5,344,569</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134564239" contextRef="d_2024-04-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember_RestatementAxis-ReverseStockSplitAdjustmentMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:num-dot-decimal" decimals="INF">267,231</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c134564240" contextRef="d_2024-04-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember_RestatementAxis-RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">262,897</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted"><ix:nonFraction id="c134564241" contextRef="d_2024-04-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:num-dot-decimal" decimals="INF">4,334</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Convertible Notes - common shares</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134564242" contextRef="d_2024-04-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-ConvertibleDebtSecuritiesMember_RestatementAxis-ScenarioPreviouslyReportedMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:num-dot-decimal" decimals="INF">665,000</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134564243" contextRef="d_2024-04-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-ConvertibleDebtSecuritiesMember_RestatementAxis-ReverseStockSplitAdjustmentMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:num-dot-decimal" decimals="INF">33,250</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134564244" contextRef="d_2024-04-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-ConvertibleDebtSecuritiesMember_RestatementAxis-RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:fixed-zero" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted"><ix:nonFraction id="c134564245" contextRef="d_2024-04-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-ConvertibleDebtSecuritiesMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:num-dot-decimal" decimals="INF">33,250</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Convertible Notes - equity-based warrants to purchase common shares</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134564246" contextRef="d_2024-04-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-ConvertibleNotesToWarrantsMember_RestatementAxis-ScenarioPreviouslyReportedMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:num-dot-decimal" decimals="INF">500,000</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134564247" contextRef="d_2024-04-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-ConvertibleNotesToWarrantsMember_RestatementAxis-ReverseStockSplitAdjustmentMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:num-dot-decimal" decimals="INF">25,003</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134564248" contextRef="d_2024-04-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-ConvertibleNotesToWarrantsMember_RestatementAxis-RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:fixed-zero" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted"><ix:nonFraction id="c134564249" contextRef="d_2024-04-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-ConvertibleNotesToWarrantsMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:num-dot-decimal" decimals="INF">25,003</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock options granted under Company's incentive plan</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c134564250" contextRef="d_2024-04-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember_RestatementAxis-ScenarioPreviouslyReportedMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:num-dot-decimal" decimals="INF">4,329,579</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c134564251" contextRef="d_2024-04-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember_RestatementAxis-ReverseStockSplitAdjustmentMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:num-dot-decimal" decimals="INF">216,483</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c134564252" contextRef="d_2024-04-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember_RestatementAxis-RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:fixed-zero" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted"><ix:nonFraction id="c134564253" contextRef="d_2024-04-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:num-dot-decimal" decimals="INF">216,483</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total potentially dilutive securities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c134564254" contextRef="d_2024-04-01_2024-06-30_RestatementAxis-ScenarioPreviouslyReportedMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:num-dot-decimal" decimals="INF">10,839,148</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c134564255" contextRef="d_2024-04-01_2024-06-30_RestatementAxis-ReverseStockSplitAdjustmentMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:num-dot-decimal" decimals="INF">541,967</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c134564256" contextRef="d_2024-04-01_2024-06-30_RestatementAxis-RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">262,897</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted"><ix:nonFraction id="c134564257" contextRef="d_2024-04-01_2024-06-30" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:num-dot-decimal" decimals="INF">279,070</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
    </ix:continuation> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p></ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
  </ix:nonNumeric>
  <div>
   &#160;
  </div>
  <ix:nonNumeric contextRef="d_2025-04-01_2025-06-30" name="us-gaap:DebtDisclosureTextBlock" id="c3016979" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Note <em style="font: inherit;">2</em></b>&#160;&#8211;<b> Convertible Notes Payable</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> September 9, 2023, </em>the Company's Board authorized an offering of up to $<ix:nonFraction id="c134564936" contextRef="i_2023-09-09_DebtInstrumentAxis-TheNotesMember_RangeAxis-MaximumMember" unitRef="USD" name="us-gaap:DebtInstrumentFaceAmount" scale="6" format="ixt:num-dot-decimal" decimals="-6">2.0</ix:nonFraction> million in unsecured, non-interest bearing convertible promissory notes (the &#8220;Notes&#8221;) and accompanying warrants (the &#8220;Bridge Financing Warrants&#8221;) (collectively, the &#8220;Bridge Offering&#8221;) that mature on <em style="font: inherit;"> December 31, 2025. </em>The Notes provided that, on the closing date of the IPO, the outstanding principal would be automatically converted into common stock at the conversion price of $<ix:nonFraction id="c134564937" contextRef="i_2023-09-09_DebtInstrumentAxis-TheNotesMember" unitRef="USDPerShare" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" format="ixt:num-dot-decimal" decimals="INF">40.00</ix:nonFraction>. Each dollar in principal amount of Notes purchased were accompanied by a <span style="-sec-ix-hidden:c134564938">five</span>-year Bridge Financing Warrant to purchase approximately <ix:nonFraction id="c134564939" contextRef="i_2023-09-09_ClassOfWarrantOrRightAxis-BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.0125</ix:nonFraction> shares of Common stock with an exercise price of $<ix:nonFraction id="c134564940" contextRef="i_2023-09-09_ClassOfWarrantOrRightAxis-BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:num-dot-decimal" decimals="INF">20.00</ix:nonFraction> per share. The Company records the Bridge Financing Warrants as a discount to the Notes.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Bridge Financing Warrants can be exercised from the date of Notes issuance through the <em style="font: inherit;">five</em>-year anniversary of the issuance of the Notes. The Note holders are <em style="font: inherit;">not</em> permitted to convert their Notes when the holders or any of their affiliates would beneficially own in excess of <ix:nonFraction id="c134564943" contextRef="i_2023-09-09_DebtInstrumentAxis-TheNotesMember" unitRef="Pure" name="amix:DebtInstrumentConvertibleMaximumBeneficialOwnershipPercentage" scale="-2" format="ixt:num-dot-decimal" decimals="4">4.99</ix:nonFraction>% of the Company&#8217;s common stock after such conversion.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company received proceeds of $<ix:nonFraction id="c134564944" contextRef="d_2023-09-09_2024-03-31_DebtInstrumentAxis-TheNotesMember" unitRef="USD" name="us-gaap:ProceedsFromConvertibleDebt" scale="6" format="ixt:num-dot-decimal" decimals="-6">2.0</ix:nonFraction> million of Notes from the Bridge Offering. The Company&#8217;s effective interest rate for the Notes was <ix:nonFraction id="c134564945" contextRef="i_2025-06-30_DebtInstrumentAxis-ConvertibleDebtWith499PercentBeneficialOwnershipLimitationMember" unitRef="Pure" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" format="ixt:num-dot-decimal" decimals="3">15.3</ix:nonFraction>% due to the amortization of the discount stemming from the issuance of the Bridge Financing Warrants. On <em style="font: inherit;"> January 26, 2024, </em>the Company consummated its initial public offering (&#8220;IPO&#8221;). In connection with the closing of the IPO, a portion of the Notes were converted into <ix:nonFraction id="c134564946" contextRef="d_2024-01-26_2024-01-26_DebtConversionByUniqueDescriptionAxis-ConversionOfConvertibleNotesToCommonStockMember" unitRef="Share" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" scale="0" format="ixt:num-dot-decimal" decimals="INF">16,750</ix:nonFraction> shares of common stock. Upon the closing of the IPO, certain Notes that were to be automatically converted according to their terms into &#65279;common stock were <em style="font: inherit;">not</em> converted due to restrictions on the holders of the Notes or any of their affiliates beneficially owning in excess of <ix:nonFraction id="c134564948" contextRef="i_2024-01-26_DebtInstrumentAxis-TheNotesMember" unitRef="Pure" name="amix:DebtInstrumentConvertibleMaximumBeneficialOwnershipPercentage" scale="-2" format="ixt:num-dot-decimal" decimals="4">4.99</ix:nonFraction>% of the Company's common stock after such conversion. The remaining portion of the N&#65279;otes was converted into <ix:nonFraction id="c134564949" contextRef="d_2025-03-28_2025-03-28_DebtInstrumentAxis-ConvertibleDebtWith499PercentBeneficialOwnershipLimitationMember" unitRef="Pure" name="us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments" scale="0" format="ixt:num-dot-decimal" decimals="INF">33,250</ix:nonFraction> shares of common stock on <em style="font: inherit;"> March 28, 2025.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Warrants - Convertible Promissory Notes</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">During <em style="font: inherit;"> September </em>to <em style="font: inherit;"> December 2023, </em>the Company issued the Notes with the detachable Bridge Financing Warrants. The Company utilized a Monte Carlo simulation model to determine the fair value of each Bridge Offering Warrant. The key inputs to the Monte Carlo simulation used to determine the fair value of each warrant include, the Company&#8217;s stock price fair value which was determined through a back solve calculation such that the stock price results in the average total value of the Notes and the Bridge Offering Warrants being equal to the cash proceeds received, volatility based on a selection of publicly held peer companies of <ix:nonFraction id="c134564950" contextRef="i_2024-03-31_ClassOfWarrantOrRightAxis-BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" format="ixt:num-dot-decimal" decimals="4">101.88</ix:nonFraction>%, expected term of <ix:nonFraction id="c134564951" contextRef="i_2024-03-31_ClassOfWarrantOrRightAxis-BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember" unitRef="Year" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" format="ixt:num-dot-decimal" decimals="INF">5</ix:nonFraction> years, risk free rate of <ix:nonFraction id="c134564952" contextRef="i_2024-03-31_ClassOfWarrantOrRightAxis-BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" format="ixt:num-dot-decimal" decimals="3">4.40</ix:nonFraction>%, discount rate of <ix:nonFraction id="c134564953" contextRef="i_2024-03-31_ClassOfWarrantOrRightAxis-BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember_MeasurementInputTypeAxis-MeasurementInputDiscountRateMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" format="ixt:num-dot-decimal" decimals="1">20.00</ix:nonFraction>% and a discount for lack of marketability of <ix:nonFraction id="c134564954" contextRef="i_2023-12-31_ClassOfWarrantOrRightAxis-BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember_MeasurementInputTypeAxis-MeasurementInputDiscountForLackOfMarketabilityMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" format="ixt:num-dot-decimal" decimals="4">15.77</ix:nonFraction>%.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:exclude>
    <div class="PGNUM" style="width: 100%; text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
     <em style="font: inherit;">113</em>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">During the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> June 30, 2025 </em>and <em style="font: inherit;">2024,</em> the Company recorded $<ix:nonFraction id="c134564958" contextRef="d_2025-04-01_2025-06-30_DebtInstrumentAxis-TheNotesMember" unitRef="USD" name="us-gaap:InterestExpenseDebt" scale="6" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction> and less than $<ix:nonFraction id="c134564959" contextRef="d_2024-04-01_2024-06-30_DebtInstrumentAxis-TheNotesMember" unitRef="USD" name="us-gaap:InterestExpenseDebt" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.1</ix:nonFraction> million, respectively, in interest expense related to the amortization of the debt discount.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The following table presents a summary of activity for the warrants issued in connection with the Company&#8217;s Notes:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:nonNumeric contextRef="d_2025-04-01_2025-06-30" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="c3016980" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted-</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Average</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Exercise Price</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Warrants</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Per Share</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding and exercisable, March 31, 2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134564258" contextRef="i_2025-03-31" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">25,003</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted"><ix:nonFraction id="c134564259" contextRef="i_2025-03-31" unitRef="USDPerShare" name="amix:ClassOfWarrantOrRightOutstandingOutstandingWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">20.00</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134564260" contextRef="d_2025-04-01_2025-06-30" unitRef="Share" name="amix:ClassOfWarrantOrRightGrantsInPeriod" scale="0" format="ixt:fixed-zero" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted"><ix:nonFraction id="c134564261" contextRef="d_2025-04-01_2025-06-30" unitRef="USDPerShare" name="amix:ClassOfWarrantOrRightGrantsInPeriodWeightedAverageExercise" scale="0" format="ixt:fixed-zero" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Exercised</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134564262" contextRef="d_2025-04-01_2025-06-30" unitRef="Share" name="amix:ClassOfWarrantOrRightExercisesInPeriod" scale="0" format="ixt:fixed-zero" decimals="INF" sign="-">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted"><ix:nonFraction id="c134564263" contextRef="d_2025-04-01_2025-06-30" unitRef="USDPerShare" name="amix:ClassOfWarrantOrRightExercisesInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:fixed-zero" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Forfeited/Cancelled</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134564264" contextRef="d_2025-04-01_2025-06-30" unitRef="Share" name="amix:ClassOfWarrantOrRightForfeituresInPeriod" scale="0" format="ixt:fixed-zero" decimals="INF" sign="-">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted"><ix:nonFraction id="c134564265" contextRef="d_2025-04-01_2025-06-30" unitRef="USDPerShare" name="amix:ClassOfWarrantOrRightForfeituresInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:fixed-zero" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Expired</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c134564266" contextRef="d_2025-04-01_2025-06-30" unitRef="Share" name="amix:ClassOfWarrantOrRightExpirationsInPeriod" scale="0" format="ixt:fixed-zero" decimals="INF" sign="-">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted"><ix:nonFraction id="c134564267" contextRef="d_2025-04-01_2025-06-30" unitRef="USDPerShare" name="amix:ClassOfWarrantOrRightExpirationsInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:fixed-zero" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding, June 30, 2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c134564268" contextRef="i_2025-06-30" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">25,003</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted"><ix:nonFraction id="c134564269" contextRef="i_2025-06-30" unitRef="USDPerShare" name="amix:ClassOfWarrantOrRightOutstandingOutstandingWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">20.00</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Exercisable, June 30, 2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c134564270" contextRef="i_2025-06-30" unitRef="Share" name="amix:ClassOfWarrantOrRightExercisableNumber" scale="0" format="ixt:num-dot-decimal" decimals="INF">25,003</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted"><ix:nonFraction id="c134564271" contextRef="d_2025-04-01_2025-06-30" unitRef="USDPerShare" name="amix:ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">20.00</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  </ix:nonNumeric>
  <div>
   &#160;
  </div>
  <ix:nonNumeric contextRef="d_2025-04-01_2025-06-30" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="c3016981" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Note <em style="font: inherit;">3</em></b>&#160;&#8211;<b> Equity</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> November 29, 2023, </em>the Company&#8217;s Board and applicable shareholders approved to amend and restate the Company&#8217;s certificate of incorporation and increased the authorized shares to <ix:nonFraction id="c134564961" contextRef="i_2023-11-29" unitRef="Share" name="us-gaap:CommonStockSharesAuthorized" scale="0" format="ixt:num-dot-decimal" decimals="INF">500,000,000</ix:nonFraction> shares of common stock and <ix:nonFraction id="c134564962" contextRef="i_2023-11-29" unitRef="Share" name="us-gaap:PreferredStockSharesAuthorized" scale="0" format="ixt:num-dot-decimal" decimals="INF">10,000,000</ix:nonFraction> shares of preferred stock, each with a par value of $<ix:nonFraction id="c134564963" contextRef="i_2023-11-29" unitRef="USDPerShare" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.001</ix:nonFraction> per share. The specific rights of the preferred stock shall be determined by the Board.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;text-indent:9pt;"><i>Preferred Stock </i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;text-indent:9pt;">As of <em style="font: inherit;"> June 30, 2025, </em>the Company had <ix:nonFraction id="c134564964" contextRef="i_2025-06-30" unitRef="Share" name="us-gaap:PreferredStockSharesOutstanding" scale="0" format="ixt-sec:numwordsen" decimals="-3">no</ix:nonFraction> shares of preferred stock outstanding.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Restricted Stock</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> February 15, 2024, </em>the Company issued&#160;<ix:nonFraction id="c134564965" contextRef="d_2024-02-15_2024-02-15_AwardTypeAxis-RestrictedStockMember_TitleOfIndividualAxis-MarketingConsultantMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,750</ix:nonFraction> restricted shares of common stock to the Company's marketing consultant at the closing price of $<ix:nonFraction id="c134564966" contextRef="i_2024-02-15_AwardTypeAxis-RestrictedStockMember_TitleOfIndividualAxis-MarketingConsultantMember" unitRef="USDPerShare" name="us-gaap:SharesIssuedPricePerShare" scale="0" format="ixt:num-dot-decimal" decimals="INF">76.00</ix:nonFraction> of the Company's common stock. The total value of these shares is $<ix:nonFraction id="c134564967" contextRef="d_2024-02-15_2024-02-15_AwardTypeAxis-RestrictedStockMember_TitleOfIndividualAxis-MarketingConsultantMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" format="ixt:num-dot-decimal" decimals="INF">133,000</ix:nonFraction>. These shares vested monthly over a <ix:nonNumeric contextRef="d_2024-02-15_2024-02-15_AwardTypeAxis-RestrictedStockMember_TitleOfIndividualAxis-MarketingConsultantMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="c134564968" format="ixt-sec:durmonth">12</ix:nonNumeric>-month period beginning on the issue&#160;date.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:nonNumeric contextRef="d_2025-04-01_2025-06-30" name="amix:RestrictedStockExpensesGeneralAndAdministrativeTableTextBlock" id="c3016982" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Three Months Ended June 30,</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Recognized in general and administrative expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c134564272" contextRef="d_2025-04-01_2025-06-30_AwardTypeAxis-RestrictedStockMember_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" format="ixt:fixed-zero" decimals="INF">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c134564273" contextRef="d_2024-04-01_2024-06-30_AwardTypeAxis-RestrictedStockMember_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" format="ixt:num-dot-decimal" decimals="INF">33,250</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c134564274" contextRef="d_2025-04-01_2025-06-30_AwardTypeAxis-RestrictedStockMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" format="ixt:fixed-zero" decimals="INF">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c134564275" contextRef="d_2024-04-01_2024-06-30_AwardTypeAxis-RestrictedStockMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" format="ixt:num-dot-decimal" decimals="INF">33,250</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">As of <em style="font: inherit;"> June 30, 2025, </em>there was $<ix:nonFraction id="c134564969" contextRef="i_2025-06-30_AwardTypeAxis-RestrictedStockMember" unitRef="USD" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction> of unrecognized stock-based compensation expense related to Restricted Stock.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Common Stock </i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> February 28, 2025, </em>the Company entered into an ATM Agreement. Pursuant to the terms of the Agreement, the Company was permitted to sell from time to time shares of Company&#8217;s common stock, with an initial aggregate sales price of up to $<ix:nonFraction id="c134564970" contextRef="i_2025-02-28_SubsidiarySaleOfStockAxis-ATMAgreementMember" unitRef="USD" name="amix:EquityOfferingMaximumOfferingAmount" scale="6" format="ixt:num-dot-decimal" decimals="-5">2.1</ix:nonFraction> million. As of <em style="font: inherit;"> June 30, 2025, </em>the Company sold <ix:nonFraction id="c134564971" contextRef="d_2025-04-01_2025-06-30_SubsidiarySaleOfStockAxis-ATMAgreementMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,304,260</ix:nonFraction> shares pursuant to the ATM Agreement for net proceeds of approximately $<ix:nonFraction id="c134564972" contextRef="d_2025-04-01_2025-06-30_SubsidiarySaleOfStockAxis-ATMAgreementMember" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" format="ixt:num-dot-decimal" decimals="-5">2.1</ix:nonFraction> million.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Stock Plan and Stock Options</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">In <em style="font: inherit;"> June 2023, </em>the Company adopted, and the Company&#8217;s shareholders approved, the Autonomix Medical, Inc. <em style="font: inherit;">2023</em> Stock Plan (the &#8220;Plan&#8221;). The Plan is a stock-based compensation plan that provides for discretionary grants of stock options, stock awards and stock unit awards to key employees, non-employee directors, and consultants, subject to certain individual threshold limitations. The Plan initially provided for up to <ix:nonFraction id="c134564974" contextRef="i_2023-06-30_PlanNameAxis-The2023StockPlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" format="ixt:num-dot-decimal" decimals="INF">200,000</ix:nonFraction> shares to be issued, subject to adjustments as provided in the Plan. Shares that are surrendered because of forfeiture, expiration, termination, or cancellation are available for re-issuance.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:exclude>
    <div class="PGNUM" style="width: 100%; text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
     <em style="font: inherit;">114</em>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">In <em style="font: inherit;"> August 2023, </em>the Plan was amended to allow for an automatic increase of the available shares for issuance, whereby on the <em style="font: inherit;">1st</em> of each fiscal year, beginning on <em style="font: inherit;"> April 1, 2024 </em>and ending on (and including) <em style="font: inherit;"> April 1, 2033 </em>in an amount equal to <em style="font: inherit;">five</em> percent (<ix:nonFraction id="c134564978" contextRef="d_2023-08-01_2023-08-31_PlanNameAxis-The2023StockPlanMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" scale="-2" format="ixt:num-dot-decimal" decimals="2">5</ix:nonFraction>%) of the total number of shares of Common Stock outstanding on the <em style="font: inherit;"> March </em><em style="font: inherit;">31st</em> immediately preceding the applicable date. However, the Board <em style="font: inherit;"> may </em>act prior to the automatic increase of a given year to provide that there will be <em style="font: inherit;">no</em> increase for such year, or that the increase for such year will be a lesser number of shares of Common Stock. On <em style="font: inherit;"> April 1, 2025, </em>the Plan was increased by <ix:nonFraction id="c134564981" contextRef="d_2025-04-01_2025-04-01_PlanNameAxis-The2023StockPlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" format="ixt:num-dot-decimal" decimals="INF">124,852</ix:nonFraction> shares.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The following table summarizes the stock option activity for the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> June 30, 2025:</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:nonNumeric contextRef="d_2025-04-01_2025-06-30" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="c3016983" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted-</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Average</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Exercise Price</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Options</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Per Share</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding, March 31, 2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134564276" contextRef="i_2025-03-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" format="ixt:num-dot-decimal" decimals="INF">243,483</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134564277" contextRef="i_2025-03-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">32.72</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134564278" contextRef="d_2025-04-01_2025-06-30" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" format="ixt:num-dot-decimal" decimals="INF">5,000</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134564279" contextRef="d_2025-04-01_2025-06-30" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">1.85</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Exercised</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134564280" contextRef="d_2025-04-01_2025-06-30" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" format="ixt:fixed-zero" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134564281" contextRef="d_2025-04-01_2025-06-30" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:fixed-zero" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Forfeited/Cancelled</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134564282" contextRef="d_2025-04-01_2025-06-30" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" format="ixt:fixed-zero" decimals="INF" sign="-">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134564283" contextRef="d_2025-04-01_2025-06-30" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:fixed-zero" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Expired</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c134564284" contextRef="d_2025-04-01_2025-06-30" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="0" format="ixt:fixed-zero" decimals="INF" sign="-">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c134564285" contextRef="d_2025-04-01_2025-06-30" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:fixed-zero" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding, June 30, 2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c134564286" contextRef="i_2025-06-30" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" format="ixt:num-dot-decimal" decimals="INF">248,483</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c134564287" contextRef="i_2025-06-30" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">32.10</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Exercisable, June 30, 2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c134564288" contextRef="i_2025-06-30" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" format="ixt:num-dot-decimal" decimals="INF">69,916</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c134564289" contextRef="i_2025-06-30" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">37.24</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company&#8217;s stock option awards did <em style="font: inherit;">not</em> automatically adjust for the Reverse Stock Split.&#160;However, the Company chose to exercise its rights under the Plan to adjust the exercise price and number of shares exercisable or issuable upon vesting proportionately for the Reverse Stock Split.&#160;Based on the analysis performed, the Company does <em style="font: inherit;">not</em> need to recognize any additional compensation expense as a result of the modification.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">During the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> June 30, 2025, </em>the Company granted&#160;options to purchase <ix:nonFraction id="c134564986" contextRef="d_2025-04-01_2025-06-30_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2023StockPlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" format="ixt:num-dot-decimal" decimals="INF">5,000</ix:nonFraction> shares of common stock with a contractual term that vests&#65279; annually over <span style="-sec-ix-hidden:c134564987">four</span> years on the anniversary date. The options had an aggregate grant date fair value of $<ix:nonFraction id="c134564988" contextRef="i_2025-06-30_AwardTypeAxis-EmployeeStockOptionMember_ValuationTechniqueAxis-BlackscholesModelMember" unitRef="USD" name="amix:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantDateFairValue" scale="0" format="ixt:num-dot-decimal" decimals="INF">9</ix:nonFraction> thousand that was calculated using the Black-Scholes option pricing model. Variables used in the Black-Scholes option pricing model included the following: (<em style="font: inherit;">1</em>) fair value of common stock on the measurement date; (<em style="font: inherit;">2</em>) discount rate ranging of <ix:nonFraction id="c134564991" contextRef="d_2025-04-01_2025-06-30_AwardTypeAxis-EmployeeStockOptionMember_ValuationTechniqueAxis-BlackscholesModelMember" unitRef="Pure" name="amix:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsDiscountRate" scale="-2" format="ixt:num-dot-decimal" decimals="4">4.06</ix:nonFraction>% based on the daily yield curve rates for U.S. Treasury obligations, (<em style="font: inherit;">3</em>) expected life of <ix:nonNumeric contextRef="d_2025-04-01_2025-06-30_AwardTypeAxis-EmployeeStockOptionMember_ValuationTechniqueAxis-BlackscholesModelMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="c134564993" format="ixt-sec:duryear">6.25</ix:nonNumeric> years based on the simplified method (vesting plus contractual term divided by <em style="font: inherit;">two</em>) and (<em style="font: inherit;">4</em>) expected volatility of <ix:nonFraction id="c134564996" contextRef="d_2025-04-01_2025-06-30_AwardTypeAxis-EmployeeStockOptionMember_ValuationTechniqueAxis-BlackscholesModelMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" format="ixt:num-dot-decimal" decimals="2">139</ix:nonFraction>%&#160;based on the historical volatility of comparable companies' stock.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">All options issued and outstanding are being amortized over their respective vesting periods. The unrecognized compensation expense at <em style="font: inherit;"> June 30, 2025 </em>was $<ix:nonFraction id="c134564997" contextRef="i_2025-06-30_AwardTypeAxis-EmployeeStockOptionMember" unitRef="USD" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" format="ixt:num-dot-decimal" decimals="-5">3.9</ix:nonFraction> million. During the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> June 30, 2025, </em>the Company recorded stock-based compensation - option expense of $<ix:nonFraction id="c134564999" contextRef="d_2025-04-01_2025-06-30_AwardTypeAxis-EmployeeStockOptionMember_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.3</ix:nonFraction> million in general and administrative expense and less than $<ix:nonFraction id="c134565000" contextRef="d_2025-04-01_2025-06-30_AwardTypeAxis-EmployeeStockOptionMember_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.1</ix:nonFraction> million in research and development expense. During the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> June 30, 2024,&#160;</em>the Company recorded stock-based compensation - option expense of $<ix:nonFraction id="c134565002" contextRef="d_2024-04-01_2024-06-30_AwardTypeAxis-EmployeeStockOptionMember_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.3</ix:nonFraction> million in general and administrative expense and less than $<ix:nonFraction id="c134565003" contextRef="d_2024-04-01_2024-06-30_AwardTypeAxis-EmployeeStockOptionMember_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.1</ix:nonFraction> million in research and development expense
    <span style="text-decoration: line-through; ">
      .
    </span></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;text-indent:9pt;"><i>License Agreement</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> July 10, 2024, </em>the Company entered into a license agreement (the &#8220;Agreement&#8221;) with RF Innovations, Inc. (&#8220;RFI&#8221;), a privately held medical technology company, to license products utilizing RFI&#8217;s intellectual property related to its Apex <em style="font: inherit;">6</em> Radiofrequency Generator (the &#8220;Licensed Products&#8221;). The Apex <em style="font: inherit;">6</em> Generator is a United States Food and Drug Administration (&#8220;FDA&#8221;) cleared ablation technology designed to lesion neural tissue for pain management in the peripheral nervous system. Pursuant to the Agreement, RFI granted us a perpetual non-exclusive worldwide royalty free fully paid license related to the Licensed Products, provided that the license did <em style="font: inherit;">not</em> include the right to sell certain products to customers for the treatment of spine pain. In connection with the Agreement, the Company issued RFI <ix:nonFraction id="c134565007" contextRef="d_2024-07-10_2024-07-10_CounterpartyNameAxis-RfInnovationsIncMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:num-dot-decimal" decimals="INF">12,500</ix:nonFraction> unregistered shares of its common stock as consideration for the license. The Company determined that the fair value of the shares granted was $<ix:nonFraction id="c134565008" contextRef="d_2024-07-10_2024-07-10_CounterpartyNameAxis-RfInnovationsIncMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.1</ix:nonFraction> million, which represented its stock price on the date of the Agreement less a <ix:nonFraction id="c134565009" contextRef="i_2024-07-10_CounterpartyNameAxis-RfInnovationsIncMember" unitRef="Pure" name="amix:CommonStockDiscountForLackOfMarketability" scale="-2" format="ixt:num-dot-decimal" decimals="3">25.6</ix:nonFraction>% discount for lack of marketability (&#8220;DLOM&#8221;). The Company concluded a DLOM was appropriate as the shares were subject to an initial lock-up period of <em style="font: inherit;">six</em> months followed by restrictions that allow for a maximum of <ix:nonFraction id="c134565011" contextRef="i_2024-07-10_CounterpartyNameAxis-RfInnovationsIncMember" unitRef="Pure" name="amix:MaximumPercentageOfSharesSoldInThirtyDays" scale="-2" format="ixt:num-dot-decimal" decimals="1">10</ix:nonFraction>% of total shares to be sold within a <em style="font: inherit;">30</em>-day period.&#160;The DLOM effectively reflects the value of an average strike put option relative to the Company's stock price and was calculated based on the Finnerty average put model.&#160;The Company concluded that the licensed technology qualified as a research and development expense pursuant to ASC Topic <em style="font: inherit;">730,</em> <i>Research and Development</i>, as the Company does <em style="font: inherit;">not</em> have an alternative future use for the technology and the Company does <em style="font: inherit;">not</em> have a plan to otherwise monetize the Licensed Products.&#160;The Agreement provides RFI the right to terminate the license if we breach any representation, warranty or covenant contained in the Agreement, subject to any relevant cure periods, or if we are subject to a bankruptcy or insolvency event.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       <em style="font: inherit;">115</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Offering Agreement </i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> November 22, 2024, </em>the Company entered into the Offering, which consisted of: (i) <ix:nonFraction id="c134565017" contextRef="d_2024-11-22_2024-11-25_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember" unitRef="Share" name="amix:NumberOfCommonUnitsIssued" scale="0" format="ixt:num-dot-decimal" decimals="INF">458,691</ix:nonFraction> Common Units, each Common Unit consisting of <span style="-sec-ix-hidden:c134565018">one</span> share of common stock and <span style="-sec-ix-hidden:c134565019">one</span> Series A Warrant to purchase <span style="-sec-ix-hidden:c134565020">one</span> share of common stock; and (ii) <ix:nonFraction id="c134565021" contextRef="d_2024-11-22_2024-11-25_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember" unitRef="Share" name="amix:NumberOfPrefundedUnitsIssued" scale="0" format="ixt:num-dot-decimal" decimals="INF">917,596</ix:nonFraction> Pre-Funded Units, each Pre-Funded Unit consisting of <span style="-sec-ix-hidden:c134565022">one</span> Pre-Funded Warrant to purchase <span style="-sec-ix-hidden:c134565023">one</span> share of common stock and <span style="-sec-ix-hidden:c134565024">one</span> Series A Warrant. The purchase price of each Common Unit was $<ix:nonFraction id="c134565025" contextRef="d_2024-11-22_2024-11-25_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember" unitRef="USDPerShare" name="amix:CommonUnitsIssuedPurchasePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">6.540</ix:nonFraction>, and the purchase price of each Pre-Funded Unit was $<ix:nonFraction id="c134565026" contextRef="d_2024-11-22_2024-11-25_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember" unitRef="USDPerShare" name="amix:PrefundedUnitsIssuedPurchasePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">6.539</ix:nonFraction>.&#160;In addition, the Company granted the Underwriters a <ix:nonNumeric contextRef="d_2024-11-22_2024-11-22_CounterpartyNameAxis-UnderwritersMember_SubsidiarySaleOfStockAxis-OverAllotmentOptionMember" name="amix:EquityOfferingOptionPeriod" id="c134565027" format="ixt-sec:durday">45</ix:nonNumeric>-day option to purchase additional <ix:nonFraction id="c134565028" contextRef="i_2024-11-22_CounterpartyNameAxis-UnderwritersMember_SubsidiarySaleOfStockAxis-OverAllotmentOptionMember" unitRef="Share" name="amix:EquityOfferingOptionMaximumShares" scale="0" format="ixt:num-dot-decimal" decimals="INF">206,422</ix:nonFraction> shares of common stock, and/or additional <ix:nonFraction id="c134565029" contextRef="i_2024-11-22_ClassOfWarrantOrRightAxis-SeriesAWarrantsMember_CounterpartyNameAxis-UnderwritersMember" unitRef="Share" name="amix:EquityOfferingOptionMaximumWarrants" scale="0" format="ixt:num-dot-decimal" decimals="INF">206,422</ix:nonFraction> Series A Warrants, solely to cover over-allotments, if any. The Offering closed on <em style="font: inherit;"> November 25, 2024. </em>On <em style="font: inherit;"> November 22, 2024, </em>the Underwriters partially exercised their over-allotment option with respect to <ix:nonFraction id="c134565030" contextRef="d_2024-11-22_2024-11-22_CounterpartyNameAxis-UnderwritersMember_SubsidiarySaleOfStockAxis-OverAllotmentOptionMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:num-dot-decimal" decimals="INF">156,809</ix:nonFraction> shares of Common Stock and <ix:nonFraction id="c134565031" contextRef="d_2024-11-22_2024-11-22_ClassOfWarrantOrRightAxis-SeriesAWarrantsMember_CounterpartyNameAxis-UnderwritersMember" unitRef="Share" name="amix:ClassOfWarrantOrRightIssuedDuringPeriod" scale="0" format="ixt:num-dot-decimal" decimals="INF">156,809</ix:nonFraction> Series A Warrants. The Company received gross proceeds of $<ix:nonFraction id="c134565032" contextRef="d_2024-11-22_2024-11-25_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="6" format="ixt:num-dot-decimal" decimals="-7">10.0</ix:nonFraction>&#160;million, before deducting the Underwriter's fees and other offering expenses payable by the Company.&#160;Under the terms of the Underwriting Agreement, the Underwriters received an underwriting discount of <ix:nonFraction id="c134565033" contextRef="i_2024-11-25_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember" unitRef="Pure" name="amix:CommissionPercentage" scale="-2" format="ixt:num-dot-decimal" decimals="2">8.0</ix:nonFraction>% to the public offering price for the Units. The Company also issued to the representative of the Underwriters (the "Representative") Representative's Warrants to purchase up to <ix:nonFraction id="c134565034" contextRef="d_2024-11-22_2024-11-25_ClassOfWarrantOrRightAxis-RepresentativesWarrantsMember_CounterpartyNameAxis-UnderwritersMember" unitRef="Share" name="amix:ClassOfWarrantOrRightIssuedDuringPeriod" scale="0" format="ixt:num-dot-decimal" decimals="INF">91,985</ix:nonFraction> shares of common stock.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Pre-Funded Warrants have an exercise price of $<ix:nonFraction id="c134565035" contextRef="i_2024-11-25_ClassOfWarrantOrRightAxis-PrefundedWarrantsMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.001</ix:nonFraction> per share, are immediately exercisable and <em style="font: inherit;"> may </em>be exercised at any time until all of the Pre-Funded Warrants are exercised in full, subject to a beneficial ownership limitation of <ix:nonFraction id="c134565036" contextRef="i_2024-11-25_ClassOfWarrantOrRightAxis-PrefundedWarrantsMember" unitRef="Pure" name="amix:ClassOfWarrantsOrRightsMaximumBeneficialOwnership" scale="-2" format="ixt:num-dot-decimal" decimals="4">4.99</ix:nonFraction>%. The Series A Warrants have an exercise price of $<ix:nonFraction id="c134565037" contextRef="i_2024-11-25_ClassOfWarrantOrRightAxis-SeriesAWarrantsMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:num-dot-decimal" decimals="INF">6.540</ix:nonFraction> per share and <em style="font: inherit;"> may </em>be exercised at any time until the <span style="-sec-ix-hidden:c134565038">five</span>-year anniversary of the date of issuance, subject to a beneficial ownership limitation of <ix:nonFraction id="c134565039" contextRef="i_2024-11-25_ClassOfWarrantOrRightAxis-SeriesAWarrantsMember" unitRef="Pure" name="amix:ClassOfWarrantsOrRightsMaximumBeneficialOwnership" scale="-2" format="ixt:num-dot-decimal" decimals="4">4.99</ix:nonFraction>%. The Pre-Funded Warrants and Series A Warrants were issued pursuant a Warrant Agency Agreement between the Company and Equity Stock Transfer, LLC.&#160;The Series A Warrants and the Representative&#8217;s Warrants, largely have the same terms and conditions, except the Representative&#8217;s Warrants were <em style="font: inherit;">not</em> exercisable until <em style="font: inherit;"> May 21, 2025 </em>and are subject to a <ix:nonNumeric contextRef="d_2024-11-22_2024-11-25_ClassOfWarrantOrRightAxis-RepresentativesWarrantsMember" name="amix:ClassOfWarrantOrRightLockupPeriod" id="c134565041" format="ixt-sec:durday">180</ix:nonNumeric>-day lock-up prior to being transferable.&#160;The Series A Warrants and Representative&#8217;s Warrants <em style="font: inherit;"> may, </em>at the option of the holder be settled upon a change of control at the Black-Scholes value, as defined in the agreement.&#160;Upon a change of control the holder <em style="font: inherit;"> may </em>receive cash, other assets or shares of the successor entity, depending on the specific nature of the change of control transaction and the settlement options afforded to the holders of common stock.&#160;The Company analyzed the Pre-Funded Warrants, the Series A Warrants, and the Representative&#8217;s Warrants (collectively the &#8220;Offering Warrants&#8221;) in accordance with ASC Topic <em style="font: inherit;">480,</em> Distinguishing Liabilities from Equity and ASC Topic <em style="font: inherit;">815,</em> Derivatives and Hedging.&#160;Management concluded that the Offering Warrants meet all the requirements for equity classification.&#160;Since the Offering Warrants meet the requirements for equity classification and the Offering represents an arms-length cash transaction, the Common Units and Pre-Funded Units will be recorded in equity based on the proceeds received, net of issuance costs.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">At issuance the Pre-Funded Warrants had a fair value of $<ix:nonFraction id="c134565044" contextRef="i_2024-11-25_ClassOfWarrantOrRightAxis-PrefundedWarrantsMember" unitRef="USDPerShare" name="amix:ClassOfWarrantOrRightFairValuePerShare" scale="0" format="ixt:num-dot-decimal" decimals="INF">6.3290</ix:nonFraction> per share, which represented the common stock issuance price less the $<ix:nonFraction id="c134565045" contextRef="i_2024-11-25_ClassOfWarrantOrRightAxis-PrefundedWarrantsMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.001</ix:nonFraction> exercise price.&#160;At issuance, the Series A Warrants and the Representative&#8217;s Warrants had&#160;a fair value of $<ix:nonFraction id="c134565046" contextRef="i_2024-11-25_ClassOfWarrantOrRightAxis-SeriesAWarrantsMember" unitRef="USDPerShare" name="amix:ClassOfWarrantOrRightFairValuePerShare" scale="0" format="ixt:num-dot-decimal" decimals="INF">5.3597</ix:nonFraction> and $<ix:nonFraction id="c134565047" contextRef="i_2024-11-25_ClassOfWarrantOrRightAxis-RepresentativesWarrantsMember" unitRef="USDPerShare" name="amix:ClassOfWarrantOrRightFairValuePerShare" scale="0" format="ixt:num-dot-decimal" decimals="INF">5.2125</ix:nonFraction>&#160;per share, respectively, which was determined using a Black-Scholes option pricing model.&#160;Variables used in the Black-Scholes option pricing model included the following: (<em style="font: inherit;">1</em>) fair value of common stock on the measurement date; (<em style="font: inherit;">2</em>) discount rate of <ix:nonFraction id="c134565050" contextRef="i_2025-06-30_ClassOfWarrantOrRightAxis-SeriesAWarrantsAndTheRepresentativesWarrantsMember_MeasurementInputTypeAxis-MeasurementInputDiscountRateMember_ValuationTechniqueAxis-BlackscholesModelMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" format="ixt:num-dot-decimal" decimals="INF">4.17</ix:nonFraction>% based on the daily yield curve rates for U.S. Treasury obligations, (<em style="font: inherit;">3</em>) the contractual term of the warrants and (<em style="font: inherit;">4</em>) expected volatility of <ix:nonFraction id="c134565053" contextRef="i_2025-06-30_ClassOfWarrantOrRightAxis-SeriesAWarrantsAndTheRepresentativesWarrantsMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember_ValuationTechniqueAxis-BlackscholesModelMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" format="ixt:num-dot-decimal" decimals="INF">144.15</ix:nonFraction>% based on the historical volatility of comparable companies' stock. Due to the relative volume of Series A Warrants and Representative&#8217;s Warrants issued compared with the Company&#8217;s outstanding shares, the Company's stock price was adjusted for the effects of dilution.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">In connection with the Offering, the Company incurred total offering costs of $<ix:nonFraction id="c134565054" contextRef="d_2024-11-22_2024-11-25_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="6" format="ixt:num-dot-decimal" decimals="-5">1.5</ix:nonFraction> million.&#160;This was comprised of $<ix:nonFraction id="c134565055" contextRef="d_2024-11-22_2024-11-25_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember" unitRef="USD" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" format="ixt:num-dot-decimal" decimals="-6">1.0</ix:nonFraction> million in cash offering costs and $<ix:nonFraction id="c134565056" contextRef="d_2024-11-22_2024-11-25_NatureOfExpenseAxis-NoncashExpensesMember_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.5</ix:nonFraction> million&#160;for the fair value of the Representative&#8217;s Warrant issued.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Equity-Based Stock Warrants</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company will periodically grant warrants to investors in connection with equity financing or to <em style="font: inherit;">third</em>-party service providers in exchange for services rendered. The following table summarizes the stock warrant activity for the&#160;<em style="font: inherit;">three</em> months ended <em style="font: inherit;"> June 30, 2025:</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:nonNumeric contextRef="d_2025-04-01_2025-06-30" name="us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" id="c3016984" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted-</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Average</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Exercise Price</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Warrants</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Per Share</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding, March 31, 2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134564290" contextRef="i_2025-03-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,934,874</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="-sec-ix-hidden:c134564291">5.8860</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134564292" contextRef="d_2025-04-01_2025-06-30" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" scale="0" format="ixt:fixed-zero" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134564293" contextRef="d_2025-04-01_2025-06-30" unitRef="USDPerShare" name="amix:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:fixed-zero" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Exercised</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c134564294" contextRef="d_2025-04-01_2025-06-30" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" scale="0" format="ixt:num-dot-decimal" decimals="INF">222,132</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134564295" contextRef="d_2025-04-01_2025-06-30" unitRef="USDPerShare" name="amix:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.0010</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Forfeited/Cancelled</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c134564296" contextRef="d_2025-04-01_2025-06-30" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" scale="0" format="ixt:num-dot-decimal" decimals="INF">130</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c134564297" contextRef="d_2025-04-01_2025-06-30" unitRef="USDPerShare" name="amix:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.0010</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Expired</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c134564298" contextRef="d_2025-04-01_2025-06-30" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" scale="0" format="ixt:fixed-zero" decimals="INF" sign="-">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c134564299" contextRef="d_2025-04-01_2025-06-30" unitRef="USDPerShare" name="amix:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:fixed-zero" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding, June 30, 2025*</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c134564300" contextRef="i_2025-06-30" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,712,612</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c134564301" contextRef="i_2025-06-30" unitRef="USDPerShare" name="amix:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">6.6498</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Exercisable, June 30, 2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c134564302" contextRef="i_2025-06-30" unitRef="Share" name="amix:SharebasedCompensationArrangementBySharebasedPaymentAwardNonoptionEquityInstrumentsExercisableNumberOutstandingNumber" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,712,612</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c134564303" contextRef="i_2025-06-30" unitRef="USDPerShare" name="amix:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">6.6498</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">*</p> </td><td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Amount includes <ix:nonFraction id="c134565059" contextRef="i_2025-06-30_ClassOfWarrantOrRightAxis-CommonWarrantsMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">87,531</ix:nonFraction> common warrants; <ix:nonFraction id="c134565060" contextRef="i_2025-06-30_ClassOfWarrantOrRightAxis-RepresentativesWarrantsMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">91,985</ix:nonFraction> Representative's Warrants and <ix:nonFraction id="c134565061" contextRef="i_2025-06-30_ClassOfWarrantOrRightAxis-SeriesAWarrantsMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,533,096</ix:nonFraction> Series A Warrants.</p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       <em style="font: inherit;">116</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The unrecognized compensation expense at <em style="font: inherit;"> June 30, 2025 </em>for warrants issued to <em style="font: inherit;">third</em>-party service providers was $<ix:nonFraction id="c134565064" contextRef="i_2025-06-30_AwardTypeAxis-WarrantMember" unitRef="USD" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>. During the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> June 30, 2025 </em>and <em style="font: inherit;">2024,</em> the Company recorded stock-based compensation - warrant expense of $<ix:nonFraction id="c134565067" contextRef="d_2025-04-01_2025-06-30_AwardTypeAxis-WarrantMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction> and less than $<ix:nonFraction id="c134565068" contextRef="d_2024-04-01_2024-06-30_AwardTypeAxis-WarrantMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.1</ix:nonFraction> million, respectively.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  </ix:nonNumeric>
  <div>
   &#160;
  </div>
  <ix:nonNumeric contextRef="d_2025-04-01_2025-06-30" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="c3016985" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Note <em style="font: inherit;">4</em></b>&#160;&#8211;<b> Commitments and Contingencies</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Legal Proceedings</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">From time to time, the Company <em style="font: inherit;"> may </em>be involved in claims that arise during the ordinary course of business. Although the results of litigation and claims cannot be predicted with certainty, the Company does <span style="-sec-ix-hidden:c134565070">not</span> currently have any pending litigation to which it is a party or to which its property is subject that we believe to be material. There are <em style="font: inherit;">no</em> legal matters for which a reasonably estimated range of losses can be determined. Regardless of the outcome, litigation can be costly and time consuming, and it can divert management&#8217;s attention from important business matters and initiatives, negatively impacting our overall operations.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Employment Agreements</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company has agreements with key employees to provide certain benefits, including salary and other wage-related benefits, in the event of termination. In addition, the Company has adopted a severance policy for certain key members of executive management to provide certain benefits, including salary and other wage-related benefits, in the event of termination. In total, these benefits would amount to a range of $<ix:nonFraction id="c134565072" contextRef="d_2025-04-01_2025-06-30_RangeAxis-MinimumMember_TypeOfArrangementAxis-EmploymentContractsMember" unitRef="USD" name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" scale="6" format="ixt:num-dot-decimal" decimals="-5">1.2</ix:nonFraction>&#160;million to $<ix:nonFraction id="c134565073" contextRef="d_2025-04-01_2025-06-30_RangeAxis-MaximumMember_TypeOfArrangementAxis-EmploymentContractsMember" unitRef="USD" name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" scale="6" format="ixt:num-dot-decimal" decimals="-5">1.7</ix:nonFraction> million using the rate of compensation in effect at <em style="font: inherit;"> June 30, 2025. </em>See Note <em style="font: inherit;">6</em> - Subsequent Events for additional information regarding events occurring after <em style="font: inherit;"> June 30, 2025.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Fractional Shares</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">See <i>Note <em style="font: inherit;">1</em> - Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies</i> - "<i>Reverse Stock Split</i>" for additional information.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> November 1, 2024, </em>the Company received notice from the Depository Trust and Clearing Corporation ("DTCC") on behalf of the brokerage firms that hold the shares of Company common stock held in &#8220;street name&#8221; that in connection with the rounding of fractional shares in connection with the Reverse Stock Split, the Company would need to issue <ix:nonFraction id="c134565076" contextRef="i_2024-11-01" unitRef="Share" name="amix:StockRequiredToBeIssuedForStockSplitShares" scale="0" format="ixt:num-dot-decimal" decimals="INF">271,846</ix:nonFraction> shares of common stock (the &#8220;Shares&#8221;) for the rounding of shares. The Company does <em style="font: inherit;">not</em> believe the number of Shares being requested is correct based on the historical number of shareholders of its common stock and is aware of similar anomalies in recent months for other companies completing a Reverse Stock Split. As such, the Company has begun an inquiry into the calculations set forth in the request. During the pendency of this inquiry, the Company does <em style="font: inherit;">not</em> intend to issue any shares in connection with the fractional shares being requested and has concluded that an obligation should <em style="font: inherit;">not</em> be recorded in its financial statements. The Company is <em style="font: inherit;">not</em> currently subject to any pending litigation as a result of the fractional roundup shares.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  </ix:nonNumeric>
  <div>
   &#160;
  </div>
  <ix:nonNumeric contextRef="d_2025-04-01_2025-06-30" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="c3016986" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Note <em style="font: inherit;">5</em></b>&#160;&#8211;<b> Related Party Transactions</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> December 21, 2021, </em>the Company entered into a license agreement with a company controlled by a significant stockholder of the Company (&#8220;Licensee&#8221;). On <em style="font: inherit;"> July 7, 2023, </em>the Company and the Licensee entered into an Exclusive License Termination Agreement (the &#8220;Termination Agreement&#8221;) in exchange for the issuance, upon the closing of the Company&#8217;s initial public offering within <em style="font: inherit;">one</em> year of the agreement&#8217;s execution, of a warrant to purchase shares of the Company for a variable number of shares. The variable number of shares issued was based upon a fixed value of $<ix:nonFraction id="c134565083" contextRef="d_2023-07-07_2023-07-07_ClassOfWarrantOrRightAxis-TheWarrantMember_RelatedPartyTransactionAxis-TerminationAgreementMember" unitRef="USD" name="amix:ClassOfWarrantOrRightValueOfSecuritiesCalledByWarrantsOrRights" scale="6" format="ixt:num-dot-decimal" decimals="-6">8.0</ix:nonFraction> million divided by the price per share in the offering. The warrants were exercisable at a price of $<ix:nonFraction id="c134565084" contextRef="i_2023-07-07_ClassOfWarrantOrRightAxis-TheWarrantMember_RelatedPartyTransactionAxis-TerminationAgreementMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.02</ix:nonFraction> per share and <em style="font: inherit;"> may </em>be exercised any time after the issuance date, subject to a beneficial ownership limitation, and expired <span style="-sec-ix-hidden:c134565085">five</span> years from the original issuance. The warrants did <em style="font: inherit;">not</em> provide voting rights, dividend rights, and other rights of a shareholder prior to exercise. The shares underlying the warrant were subject to a lockup agreement for a period of <span style="-sec-ix-hidden:c134565087">six</span> months after the closing of the offering with respect to <ix:nonFraction id="c134565088" contextRef="d_2023-07-07_2023-07-07_ClassOfWarrantOrRightAxis-TheWarrantMember_RelatedPartyTransactionAxis-TerminationAgreementMember_UnderlyingAssetClassAxis-CommonStock6MonthsLockupPeriodMember" unitRef="Pure" name="amix:ClassOfWarrantOrRightPercentageOfOutstandingStock" scale="-2" format="ixt:num-dot-decimal" decimals="3">12.5</ix:nonFraction>% of the shares issued and <span style="-sec-ix-hidden:c134565089">twelve</span> months after the closing of the offering for the remainder of the shares. The Company agreed to register the resale of the shares of common stock underlying the warrant upon a notice of <em style="font: inherit;">20</em> business days by the Warrant holder.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> January 29, 2024, </em>pursuant to the Termination Agreement, the Company issued a warrant to purchase <ix:nonFraction id="c134565091" contextRef="i_2024-01-29_ClassOfWarrantOrRightAxis-TheWarrantMember_RelatedPartyTransactionAxis-TerminationAgreementMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" format="ixt:num-dot-decimal" decimals="INF">80,000</ix:nonFraction> shares (the &#8220;Warrant&#8221;) pursuant to the Termination Agreement to the Licensee<i>.</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The completion of the Company&#8217;s IPO fixed the number of warrant shares issuable and the Company re-classified the Warrant to additional-paid in capital as it met the requirements for equity classification. Upon reclassification, the Company valued the warrant at $<ix:nonFraction id="c134565092" contextRef="i_2024-01-29_ClassOfWarrantOrRightAxis-TheWarrantMember_RelatedPartyTransactionAxis-TerminationAgreementMember" unitRef="USD" name="us-gaap:WarrantsAndRightsOutstanding" scale="6" format="ixt:num-dot-decimal" decimals="-6">8.0</ix:nonFraction>&#160;million, which represented the fair value of the shares issued on that date.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       <em style="font: inherit;">117</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
  </ix:nonNumeric>
  <div>
   &#160;
  </div>
  <ix:nonNumeric contextRef="d_2025-04-01_2025-06-30" name="us-gaap:SubsequentEventsTextBlock" id="c3016987" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Note <em style="font: inherit;">6</em></b>&#160;&#8211;<b> Subsequent Events</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> July 21, 2025, </em>the Company entered into a warrant exercise inducement offer letter (the "Inducement Letter") with the holders ("Holders") of certain existing warrants issued in the Offering from <em style="font: inherit;"> November 2024 </em>to purchase up to <ix:nonFraction id="c134565095" contextRef="i_2025-07-21_ClassOfWarrantOrRightAxis-ExistingWarrantsMember_SubsequentEventTypeAxis-SubsequentEventMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,477,596</ix:nonFraction> shares of the Company's common stock (the "Existing Warrants"). Pursuant to the Inducement Letter, the Company agreed to reduce the exercise price of the Existing Warrants to $<ix:nonFraction id="c134565096" contextRef="i_2025-07-21_ClassOfWarrantOrRightAxis-ExistingWarrantsAt1723ExercisePriceMember_SubsequentEventTypeAxis-SubsequentEventMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:num-dot-decimal" decimals="INF">1.723</ix:nonFraction> per share, and the Holders agreed: (i) to exercise Existing Warrants to purchase <ix:nonFraction id="c134565097" contextRef="d_2025-07-21_2025-07-21_ClassOfWarrantOrRightAxis-ExistingWarrantsAt1723ExercisePriceMember_SubsequentEventTypeAxis-SubsequentEventMember" unitRef="Share" name="amix:ClassOfWarrantOrRightExercisesInPeriod" scale="0" format="ixt:num-dot-decimal" decimals="INF">855,000</ix:nonFraction> shares of Company common stock; and (ii) to prepay $<ix:nonFraction id="c134565098" contextRef="i_2025-07-21_ClassOfWarrantOrRightAxis-ExistingWarrantsAt1722ExercisePriceMember_SubsequentEventTypeAxis-SubsequentEventMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:num-dot-decimal" decimals="INF">1.722</ix:nonFraction> per share of the reduced exercise price for Existing Warrants to purchase <ix:nonFraction id="c134565099" contextRef="i_2025-07-21_ClassOfWarrantOrRightAxis-ExistingWarrantsAt1722ExercisePriceMember_SubsequentEventTypeAxis-SubsequentEventMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" format="ixt:num-dot-decimal" decimals="INF">622,596</ix:nonFraction> shares of Company common stock in consideration of the Company further reducing the exercise price of such Existing Warrants to purchase <ix:nonFraction id="c134565100" contextRef="i_2025-07-21_ClassOfWarrantOrRightAxis-ExistingWarrantsAt1722ExercisePriceMember_SubsequentEventTypeAxis-SubsequentEventMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" format="ixt:num-dot-decimal" decimals="INF">622,596</ix:nonFraction> shares of Company common stock to $<ix:nonFraction id="c134565101" contextRef="i_2025-07-21_SubsequentEventTypeAxis-SubsequentEventMember" unitRef="USDPerShare" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.001</ix:nonFraction> per share with an exercise term of <ix:nonNumeric contextRef="i_2025-07-21_ClassOfWarrantOrRightAxis-ExistingWarrantsAt1722ExercisePriceMember_SubsequentEventTypeAxis-SubsequentEventMember" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="c134565102" format="ixt-sec:duryear">5.5</ix:nonNumeric> years. In consideration of the foregoing, the Company agreed to issue the Holders new warrants to purchase up to a number of shares of Company common stock equal to <ix:nonFraction id="c134565103" contextRef="i_2025-07-21_ClassOfWarrantOrRightAxis-ExistingWarrantsMember_SubsequentEventTypeAxis-SubsequentEventMember" unitRef="Pure" name="amix:ClassOfWarrantOrRightExchangesPercentageOfUnderlyingShares" scale="-2" format="ixt:num-dot-decimal" decimals="0">100</ix:nonFraction>% of the number of shares of Company common stock underlying the Existing Warrants, comprised of new Series B warrants to purchase up to <ix:nonFraction id="c134565104" contextRef="i_2025-07-21_ClassOfWarrantOrRightAxis-SeriesBWarrantsMember_SubsequentEventTypeAxis-SubsequentEventMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,477,596</ix:nonFraction> shares of Company common stock (the &#8220;Inducement Warrants&#8221; and the shares of Company common stock underlying the Inducement Warrants, the &#8220;Inducement Warrant Shares&#8221;) at $<ix:nonFraction id="c134565105" contextRef="i_2025-07-21_ClassOfWarrantOrRightAxis-SeriesBWarrantsMember_SubsequentEventTypeAxis-SubsequentEventMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:num-dot-decimal" decimals="INF">1.723</ix:nonFraction> per share with an exercise term of <ix:nonNumeric contextRef="i_2025-07-21_ClassOfWarrantOrRightAxis-SeriesBWarrantsMember_SubsequentEventTypeAxis-SubsequentEventMember" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="c134565106" format="ixt-sec:duryear">5.5</ix:nonNumeric> years from the initial exercise date. In addition, the Company issued <ix:nonFraction id="c134565107" contextRef="i_2025-07-21_ClassOfWarrantOrRightAxis-RepresentativesWarrantsMember_SubsequentEventTypeAxis-SubsequentEventMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" format="ixt:num-dot-decimal" decimals="INF">88,656</ix:nonFraction> Representative's Warrants at $<ix:nonFraction id="c134565108" contextRef="i_2025-07-21_ClassOfWarrantOrRightAxis-RepresentativesWarrantsMember_SubsequentEventTypeAxis-SubsequentEventMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:num-dot-decimal" decimals="INF">2.6707</ix:nonFraction> per share with an exercise term of <ix:nonNumeric contextRef="i_2025-07-21_ClassOfWarrantOrRightAxis-RepresentativesWarrantsMember_SubsequentEventTypeAxis-SubsequentEventMember" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="c134565109" format="ixt-sec:duryear">5</ix:nonNumeric>&#160;years. The Company received total gross proceeds of approximately $<ix:nonFraction id="c134565110" contextRef="d_2025-07-21_2025-07-21_ClassOfWarrantOrRightAxis-ExistingWarrantsMember_SubsequentEventTypeAxis-SubsequentEventMember" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfWarrants" scale="6" format="ixt:num-dot-decimal" decimals="-5">2.6</ix:nonFraction> million, less expenses paid to the Placement Agent of approximately $<ix:nonFraction id="c134565111" contextRef="d_2025-07-21_2025-07-21_ClassOfWarrantOrRightAxis-ExistingWarrantsMember_SubsequentEventTypeAxis-SubsequentEventMember" unitRef="USD" name="amix:PaymentsForWarrantIssuanceFees" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.3</ix:nonFraction> million.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In <em style="font: inherit;"> July 2025, </em>of the <ix:nonFraction id="c134565112" contextRef="i_2025-07-01_ClassOfWarrantOrRightAxis-SeriesAWarrantsMember_SubsequentEventTypeAxis-SubsequentEventMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">622,596</ix:nonFraction> Amended Series A Warrants above, <ix:nonFraction id="c134565113" contextRef="d_2025-07-01_2025-07-31_ClassOfWarrantOrRightAxis-SeriesAWarrantsMember_SubsequentEventTypeAxis-SubsequentEventMember" unitRef="Share" name="amix:ClassOfWarrantOrRightExercisesInPeriod" scale="0" format="ixt:num-dot-decimal" decimals="INF">268,072</ix:nonFraction> were exercised, leaving <ix:nonFraction id="c134565114" contextRef="i_2025-07-31_ClassOfWarrantOrRightAxis-SeriesAWarrantsMember_SubsequentEventTypeAxis-SubsequentEventMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">354,524</ix:nonFraction> of the Amended Series A Warrants at the time of this filing.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> August 5, 2025, </em><ix:nonFraction id="c134565115" contextRef="d_2025-08-05_2025-08-05_ClassOfWarrantOrRightAxis-PreipoWarrantsMember_SubsequentEventTypeAxis-SubsequentEventMember" unitRef="Share" name="amix:ClassOfWarrantOrRightExercisesInPeriod" scale="0" format="ixt:num-dot-decimal" decimals="INF">54,400</ix:nonFraction> of pre-IPO warrants were exercised on a cashless basis.&#65279;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In <em style="font: inherit;"> July 2025, </em>the Company entered into stock option cancellation agreements with certain employees to cancel an aggregate of <ix:nonFraction id="c134565116" contextRef="d_2025-07-01_2025-07-31_SubsequentEventTypeAxis-SubsequentEventMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" format="ixt:num-dot-decimal" decimals="INF">57,331</ix:nonFraction> stock options. Employees that elected to cancel their stock options were granted severance agreements for three, <em style="font: inherit;">six</em> or <em style="font: inherit;">nine</em> months of their base salary (under certain conditions). On <em style="font: inherit;"> August 11, 2025, </em>the Company entered into stock option cancellation agreements with Board members and certain officers of the Company to cancel an aggregate of <span style="-sec-ix-hidden:c134565119">177,652</span> stock options. The Company's Board members included Mr. Walter Klemp, Chairman of the Board; Ms. Lori Bisson, Executive Vice Chairman of the Board; and Mr. Chris Capelli, Director, respectively, and included amounts of <span style="-sec-ix-hidden:c134565120">8,773;</span> <span style="-sec-ix-hidden:c134565121">65,542;</span> and <span style="-sec-ix-hidden:c134565122">3,750,</span> respectively. The Company's officers included Mr. Brad Hauser, Chief Executive Officer and President; Mr. Landy Toth, Chief Technology Officer; Mr. Robert Schwartz, Chief Medical Officer; and Mr. Trent Smith, Chief Financial Officer, respectively, and included amounts of <span style="-sec-ix-hidden:c134565123">45,000;</span> <span style="-sec-ix-hidden:c134565124">8,773;</span> <span style="-sec-ix-hidden:c134565125">13,159;</span> and <span style="-sec-ix-hidden:c134565126">32,655,</span> respectively. Mr. Hauser was granted <em style="font: inherit;">three</em> months of his base salary, in addition to the <em style="font: inherit;">twelve</em> months of his base salary per his <em style="font: inherit;"> July 17, 2024 </em>employment agreement. Mr. Toth and Mr. Schwartz were granted severance agreements that amounted to <em style="font: inherit;">nine</em> months of their base salary. Mr. Smith was granted <em style="font: inherit;">three</em> months of his base salary, in addition to the <em style="font: inherit;">nine</em> months of his base salary per his <em style="font: inherit;"> July 24, 2023 </em>employment agreement.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       <em style="font: inherit;">118</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>
     &#160;
   </ix:exclude>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>
  </ix:nonNumeric>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>2,500,000 Shares of Common Stock Issuable </b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="text-align:center;font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><img alt="amix20251001c_424b3img010.jpg" src="amix20251001c_424b3img010.jpg" style="width:224;height:126;"/></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>PROSPECTUS</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>September 30, 2025</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="LAST-PAGE-BREAK">
   <div class="PGFTR">
    <div class="hf-row">
     <div class="hf-cell PGNUM">
      &#160;
     </div>
    </div>
   </div>
  </div>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>2
<FILENAME>amix-20250630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 03:06PM UTC 2025-10-04--><xsd:schema xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:amix="http://autonomix.com/20250630" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:currency="http://xbrl.sec.gov/currency/2025" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:exch="http://xbrl.sec.gov/exch/2025" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2025" xmlns:sic="http://xbrl.sec.gov/sic/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:srt-types="http://fasb.org/srt-types/2025" xmlns:stpr="http://xbrl.sec.gov/stpr/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:us-types="http://fasb.org/us-types/2025" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://autonomix.com/20250630">
  <xsd:import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/ecd/2025" schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/exch/2025" schemaLocation="https://xbrl.sec.gov/exch/2025/exch-2025.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2025" schemaLocation="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"/>
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/currency/2025" schemaLocation="https://xbrl.sec.gov/currency/2025/currency-2025.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/naics/2025" schemaLocation="https://xbrl.sec.gov/naics/2025/naics-2025.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/country/2025" schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xsd:import namespace="http://xbrl.org/2020/extensible-enumerations-2.0" schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd"/>
  <xsd:import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/sic/2025" schemaLocation="https://xbrl.sec.gov/sic/2025/sic-2025.xsd"/>
  <xsd:import namespace="http://fasb.org/us-types/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd"/>
  <xsd:import namespace="http://fasb.org/srt-types/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="amix-20250630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="amix-20250630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="amix-20250630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="amix-20250630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="statement-document-and-entity-information" roleURI="http://autonomix.com/20250630/role/statement-document-and-entity-information">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-balance-sheets" roleURI="http://autonomix.com/20250630/role/statement-balance-sheets">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">001 - Statement - Balance Sheets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-balance-sheets-parentheticals" roleURI="http://autonomix.com/20250630/role/statement-balance-sheets-parentheticals">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">002 - Statement - Balance Sheets (Parentheticals)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-statements-of-operations" roleURI="http://autonomix.com/20250630/role/statement-statements-of-operations">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">003 - Statement - Statements of Operations</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-statements-of-changes-in-stockholders-equity" roleURI="http://autonomix.com/20250630/role/statement-statements-of-changes-in-stockholders-equity">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">004 - Statement - Statements of Changes in Stockholders' Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-statements-of-cash-flows" roleURI="http://autonomix.com/20250630/role/statement-statements-of-cash-flows">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">005 - Statement - Statements of Cash Flows</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-condensed-balance-sheets-unaudited-" roleURI="http://autonomix.com/20250630/role/statement-condensed-balance-sheets-unaudited-">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">006 - Statement - Condensed Balance Sheets (Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-condensed-balance-sheets-unaudited-parentheticals" roleURI="http://autonomix.com/20250630/role/statement-condensed-balance-sheets-unaudited-parentheticals">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">007 - Statement - Condensed Balance Sheets (Unaudited) (Parentheticals)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-condensed-statements-of-operations-unaudited" roleURI="http://autonomix.com/20250630/role/statement-condensed-statements-of-operations-unaudited">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">008 - Statement - Condensed Statements of Operations (Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-condensed-statements-of-changes-in-stockholders-equity-unaudited" roleURI="http://autonomix.com/20250630/role/statement-condensed-statements-of-changes-in-stockholders-equity-unaudited">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">009 - Statement - Condensed Statements of Changes in Stockholders' Equity (Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-condensed-statements-of-cash-flows-unaudited" roleURI="http://autonomix.com/20250630/role/statement-condensed-statements-of-cash-flows-unaudited">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">010 - Statement - Condensed Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies" roleURI="http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">011 - Disclosure - Note 1 - Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-warrant-liability-and-fair-value-of-financial-instruments" roleURI="http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">012 - Disclosure - Note 2 - Warrant Liability and Fair Value of Financial Instruments</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-convertible-notes-payable" roleURI="http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">013 - Disclosure - Note 3 - Convertible Notes Payable</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-equity" roleURI="http://autonomix.com/20250630/role/statement-note-4-equity">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">014 - Disclosure - Note 4 - Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-commitments-and-contingencies" roleURI="http://autonomix.com/20250630/role/statement-note-5-commitments-and-contingencies">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">015 - Disclosure - Note 5 - Commitments and Contingencies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-related-party-transactions" roleURI="http://autonomix.com/20250630/role/statement-note-6-related-party-transactions">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">016 - Disclosure - Note 6 - Related Party Transactions</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-income-taxes" roleURI="http://autonomix.com/20250630/role/statement-note-7-income-taxes">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">017 - Disclosure - Note 7 - Income Taxes</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-subsequent-events" roleURI="http://autonomix.com/20250630/role/statement-note-8-subsequent-events">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">018 - Disclosure - Note 8 - Subsequent Events</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q" roleURI="http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">019 - Disclosure - Note 1 - Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies - 10-Q</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-convertible-notes-payable-10q" roleURI="http://autonomix.com/20250630/role/statement-note-2-convertible-notes-payable-10q">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">020 - Disclosure - Note 2 - Convertible Notes Payable - 10Q</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-equity-10q" roleURI="http://autonomix.com/20250630/role/statement-note-3-equity-10q">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">021 - Disclosure - Note 3 - Equity - 10Q</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-commitments-and-contingencies-10q" roleURI="http://autonomix.com/20250630/role/statement-note-4-commitments-and-contingencies-10q">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">022 - Disclosure - Note 4 - Commitments and Contingencies - 10Q</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-related-party-transactions-10q" roleURI="http://autonomix.com/20250630/role/statement-note-5-related-party-transactions-10q">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">023 - Disclosure - Note 5 - Related Party Transactions - 10Q</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-subsequent-events-10q" roleURI="http://autonomix.com/20250630/role/statement-note-6-subsequent-events-10q">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">024 - Disclosure - Note 6 - Subsequent Events - 10Q</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-significant-accounting-policies-policies" roleURI="http://autonomix.com/20250630/role/statement-significant-accounting-policies-policies">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">025 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-tables" roleURI="http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">026 - Disclosure - Note 1 - Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-tables" roleURI="http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">027 - Disclosure - Note 2 - Warrant Liability and Fair Value of Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-convertible-notes-payable-tables" roleURI="http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">028 - Disclosure - Note 3 - Convertible Notes Payable (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-equity-tables" roleURI="http://autonomix.com/20250630/role/statement-note-4-equity-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">029 - Disclosure - Note 4 - Equity (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-income-taxes-tables" roleURI="http://autonomix.com/20250630/role/statement-note-7-income-taxes-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">030 - Disclosure - Note 7 - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q-tables" roleURI="http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">031 - Disclosure - Note 1 - Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies - 10-Q (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-convertible-notes-payable-10q-tables" roleURI="http://autonomix.com/20250630/role/statement-note-2-convertible-notes-payable-10q-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">032 - Disclosure - Note 2 - Convertible Notes Payable - 10Q (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-equity-10q-tables" roleURI="http://autonomix.com/20250630/role/statement-note-3-equity-10q-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">033 - Disclosure - Note 3 - Equity - 10Q (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual" roleURI="http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">034 - Disclosure - Note 1 - Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-antidilutive-securities-details" roleURI="http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-antidilutive-securities-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">035 - Disclosure - Note 1 - Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies - Anti-dilutive Securities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-prior-period-corrections-details" roleURI="http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-prior-period-corrections-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">036 - Disclosure - Note 1 - Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies - Prior Period Corrections (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-details-textual" roleURI="http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">037 - Disclosure - Note 2 - Warrant Liability and Fair Value of Financial Instruments (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-schedule-of-fair-value-measurements-details" roleURI="http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-schedule-of-fair-value-measurements-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">038 - Disclosure - Note 2 - Warrant Liability and Fair Value of Financial Instruments - Schedule of Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-fair-value-measurement-inputs-and-valuation-techniques-details" roleURI="http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-fair-value-measurement-inputs-and-valuation-techniques-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">039 - Disclosure - Note 2 - Warrant Liability and Fair Value of Financial Instruments - Fair Value Measurement Inputs and Valuation Techniques (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-convertible-notes-payable-details-textual" roleURI="http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">040 - Disclosure - Note 3 - Convertible Notes Payable (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-convertible-notes-payable-schedule-of-convertible-notes-payable-details" roleURI="http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable-schedule-of-convertible-notes-payable-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">041 - Disclosure - Note 3 - Convertible Notes Payable - Schedule of Convertible Notes Payable (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-convertible-notes-payable-schedule-of-detachable-warrants-details" roleURI="http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable-schedule-of-detachable-warrants-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">042 - Disclosure - Note 3 - Convertible Notes Payable - Schedule of Detachable Warrants (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-equity-details-textual" roleURI="http://autonomix.com/20250630/role/statement-note-4-equity-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">043 - Disclosure - Note 4 - Equity (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-equity-general-and-administrative-expense-details" roleURI="http://autonomix.com/20250630/role/statement-note-4-equity-general-and-administrative-expense-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">044 - Disclosure - Note 4 - Equity - General and Administrative Expense (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-equity-restricted-stock-activity-details" roleURI="http://autonomix.com/20250630/role/statement-note-4-equity-restricted-stock-activity-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">045 - Disclosure - Note 4 - Equity - Restricted Stock Activity (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-equity-schedule-of-stock-option-activity-details" roleURI="http://autonomix.com/20250630/role/statement-note-4-equity-schedule-of-stock-option-activity-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">046 - Disclosure - Note 4 - Equity - Schedule of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-equity-schedule-of-equitybased-stock-warrants-details" roleURI="http://autonomix.com/20250630/role/statement-note-4-equity-schedule-of-equitybased-stock-warrants-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">047 - Disclosure - Note 4 - Equity - Schedule of Equity-Based Stock Warrants (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-equity-blackscholes-option-pricing-model-details" roleURI="http://autonomix.com/20250630/role/statement-note-4-equity-blackscholes-option-pricing-model-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">048 - Disclosure - Note 4 - Equity - Black-Scholes Option Pricing Model (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-commitments-and-contingencies-details-textual" roleURI="http://autonomix.com/20250630/role/statement-note-5-commitments-and-contingencies-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">049 - Disclosure - Note 5 - Commitments and Contingencies (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-related-party-transactions-details-textual" roleURI="http://autonomix.com/20250630/role/statement-note-6-related-party-transactions-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">050 - Disclosure - Note 6 - Related Party Transactions (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-income-taxes-details-textual" roleURI="http://autonomix.com/20250630/role/statement-note-7-income-taxes-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">051 - Disclosure - Note 7 - Income Taxes (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-income-taxes-schedule-of-reconciliation-details" roleURI="http://autonomix.com/20250630/role/statement-note-7-income-taxes-schedule-of-reconciliation-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">052 - Disclosure - Note 7 - Income Taxes - Schedule of Reconciliation (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" roleURI="http://autonomix.com/20250630/role/statement-note-7-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">053 - Disclosure - Note 7 - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-subsequent-events-details-textual" roleURI="http://autonomix.com/20250630/role/statement-note-8-subsequent-events-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">054 - Disclosure - Note 8 - Subsequent Events (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q-details-textual" roleURI="http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">055 - Disclosure - Note 1 - Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies - 10-Q (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-10q-details" roleURI="http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-10q-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">056 - Disclosure - Note 1 - Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Anti-dilutive Securities - 10Q (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-schedule-of-prior-period-corrections-10q-details" roleURI="http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-schedule-of-prior-period-corrections-10q-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">057 - Disclosure - Note 1 - Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Prior Period Corrections - 10Q (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-convertible-notes-payable-10q-details-textual" roleURI="http://autonomix.com/20250630/role/statement-note-2-convertible-notes-payable-10q-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">058 - Disclosure - Note 2 - Convertible Notes Payable - 10Q (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-convertible-notes-payable-schedule-of-detachable-warrants-10q-details" roleURI="http://autonomix.com/20250630/role/statement-note-2-convertible-notes-payable-schedule-of-detachable-warrants-10q-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">059 - Disclosure - Note 2 - Convertible Notes Payable - Schedule of Detachable Warrants - 10Q (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-equity-10q-details-textual" roleURI="http://autonomix.com/20250630/role/statement-note-3-equity-10q-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">060 - Disclosure - Note 3 - Equity - 10Q (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-equity-general-and-administrative-expense-10q-details" roleURI="http://autonomix.com/20250630/role/statement-note-3-equity-general-and-administrative-expense-10q-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">061 - Disclosure - Note 3 - Equity - General and Administrative Expense - 10Q (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-equity-schedule-of-stock-option-activity-10q-details" roleURI="http://autonomix.com/20250630/role/statement-note-3-equity-schedule-of-stock-option-activity-10q-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">062 - Disclosure - Note 3 - Equity - Schedule of Stock Option Activity - 10Q (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-equity-schedule-of-equitybased-stock-warrants-10q-details" roleURI="http://autonomix.com/20250630/role/statement-note-3-equity-schedule-of-equitybased-stock-warrants-10q-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">063 - Disclosure - Note 3 - Equity - Schedule of Equity-Based Stock Warrants - 10Q (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-commitments-and-contingencies-10q-details-textual" roleURI="http://autonomix.com/20250630/role/statement-note-4-commitments-and-contingencies-10q-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">064 - Disclosure - Note 4 - Commitments and Contingencies - 10Q (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-related-party-transactions-10q-details-textual" roleURI="http://autonomix.com/20250630/role/statement-note-5-related-party-transactions-10q-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">065 - Disclosure - Note 5 - Related Party Transactions - 10Q (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-subsequent-events-10q-details-textual" roleURI="http://autonomix.com/20250630/role/statement-note-6-subsequent-events-10q-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">066 - Disclosure - Note 6 - Subsequent Events - 10Q (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element abstract="true" id="amix_ATMAgreementMember" name="ATMAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="amix_AccountingAndFinancialReportingServicesMember" name="AccountingAndFinancialReportingServicesMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="amix_AnnualBaseSalary" name="AnnualBaseSalary" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="amix_BlackscholesModelMember" name="BlackscholesModelMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="amix_BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember" name="BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="amix_ChiefMedicalOfficerMember" name="ChiefMedicalOfficerMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="amix_ChiefTechnologyOfficerMember" name="ChiefTechnologyOfficerMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="amix_ClassOfWarrantOrRightAggregateIntrinsicValueExercisable" name="ClassOfWarrantOrRightAggregateIntrinsicValueExercisable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="amix_ClassOfWarrantOrRightAggregateIntrinsicValueOutstanding" name="ClassOfWarrantOrRightAggregateIntrinsicValueOutstanding" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="amix_ClassOfWarrantOrRightExchangesPercentageOfUnderlyingShares" name="ClassOfWarrantOrRightExchangesPercentageOfUnderlyingShares" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="instant"/>
  <xsd:element id="amix_ClassOfWarrantOrRightExercisableNumber" name="ClassOfWarrantOrRightExercisableNumber" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant"/>
  <xsd:element id="amix_ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice" name="ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType" xbrli:periodType="duration"/>
  <xsd:element id="amix_ClassOfWarrantOrRightExercisableWeightedAverageRemainingContractualTerm" name="ClassOfWarrantOrRightExercisableWeightedAverageRemainingContractualTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="amix_ClassOfWarrantOrRightExercisedInPeriodCash" name="ClassOfWarrantOrRightExercisedInPeriodCash" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="amix_ClassOfWarrantOrRightExercisedInPeriodCashless" name="ClassOfWarrantOrRightExercisedInPeriodCashless" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="amix_ClassOfWarrantOrRightExercisesInPeriod" name="ClassOfWarrantOrRightExercisesInPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="amix_ClassOfWarrantOrRightExercisesInPeriodWeightedAverageExercisePrice" name="ClassOfWarrantOrRightExercisesInPeriodWeightedAverageExercisePrice" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType" xbrli:periodType="duration"/>
  <xsd:element id="amix_ClassOfWarrantOrRightExpirationsInPeriod" name="ClassOfWarrantOrRightExpirationsInPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="amix_ClassOfWarrantOrRightExpirationsInPeriodWeightedAverageExercisePrice" name="ClassOfWarrantOrRightExpirationsInPeriodWeightedAverageExercisePrice" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType" xbrli:periodType="duration"/>
  <xsd:element id="amix_ClassOfWarrantOrRightFairValueIssuedForIssuanceCostsFromIpo" name="ClassOfWarrantOrRightFairValueIssuedForIssuanceCostsFromIpo" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="amix_ClassOfWarrantOrRightFairValuePerShare" name="ClassOfWarrantOrRightFairValuePerShare" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType" xbrli:periodType="instant"/>
  <xsd:element id="amix_ClassOfWarrantOrRightForfeituresInPeriod" name="ClassOfWarrantOrRightForfeituresInPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="amix_ClassOfWarrantOrRightForfeituresInPeriodWeightedAverageExercisePrice" name="ClassOfWarrantOrRightForfeituresInPeriodWeightedAverageExercisePrice" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType" xbrli:periodType="duration"/>
  <xsd:element id="amix_ClassOfWarrantOrRightGrantsInPeriod" name="ClassOfWarrantOrRightGrantsInPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="amix_ClassOfWarrantOrRightGrantsInPeriodWeightedAverageExercise" name="ClassOfWarrantOrRightGrantsInPeriodWeightedAverageExercise" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType" xbrli:periodType="duration"/>
  <xsd:element id="amix_ClassOfWarrantOrRightIssuedDuringPeriod" name="ClassOfWarrantOrRightIssuedDuringPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="amix_ClassOfWarrantOrRightLockupAgreementTermOfUnderlyingShares" name="ClassOfWarrantOrRightLockupAgreementTermOfUnderlyingShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="amix_ClassOfWarrantOrRightLockupPeriod" name="ClassOfWarrantOrRightLockupPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="amix_ClassOfWarrantOrRightOutstandingOutstandingWeightedAverageExercisePrice" name="ClassOfWarrantOrRightOutstandingOutstandingWeightedAverageExercisePrice" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType" xbrli:periodType="instant"/>
  <xsd:element id="amix_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm" name="ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="amix_ClassOfWarrantOrRightPercentageOfOutstandingStock" name="ClassOfWarrantOrRightPercentageOfOutstandingStock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="duration"/>
  <xsd:element id="amix_ClassOfWarrantOrRightValueOfSecuritiesCalledByWarrantsOrRights" name="ClassOfWarrantOrRightValueOfSecuritiesCalledByWarrantsOrRights" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="amix_ClassOfWarrantsOrRightsMaximumBeneficialOwnership" name="ClassOfWarrantsOrRightsMaximumBeneficialOwnership" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="instant"/>
  <xsd:element id="amix_CommissionPercentage" name="CommissionPercentage" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="amix_CommonStock12MonthsLockupPeriodMember" name="CommonStock12MonthsLockupPeriodMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="amix_CommonStock6MonthsLockupPeriodMember" name="CommonStock6MonthsLockupPeriodMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="amix_CommonStockDiscountForLackOfMarketability" name="CommonStockDiscountForLackOfMarketability" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="instant"/>
  <xsd:element id="amix_CommonUnitsIssuedPurchasePrice" name="CommonUnitsIssuedPurchasePrice" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="amix_CommonWarrantsMember" name="CommonWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="amix_ConsultingFirmOwnedByFormerCFOMember" name="ConsultingFirmOwnedByFormerCFOMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="amix_ConversionOfConvertibleNotesToCommonStockMember" name="ConversionOfConvertibleNotesToCommonStockMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="amix_ConvertibleDebtWith499PercentBeneficialOwnershipLimitationMember" name="ConvertibleDebtWith499PercentBeneficialOwnershipLimitationMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="amix_ConvertibleNotesToWarrantsMember" name="ConvertibleNotesToWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="amix_CorrectionOfAnImmaterialErrorPolicyTextBlock" name="CorrectionOfAnImmaterialErrorPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="amix_DebtConversionDebtIssuanceCostsConvertedCommonShares" name="DebtConversionDebtIssuanceCostsConvertedCommonShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="amix_DebtInstrumentConvertibleMaximumBeneficialOwnershipPercentage" name="DebtInstrumentConvertibleMaximumBeneficialOwnershipPercentage" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="instant"/>
  <xsd:element id="amix_DeferredFinancingCostsRelatedToTheIssuanceOfCommonStock" name="DeferredFinancingCostsRelatedToTheIssuanceOfCommonStock" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="amix_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" name="DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="amix_DeferredTaxLiabilitiesChangeInAccountingMethod" name="DeferredTaxLiabilitiesChangeInAccountingMethod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="amix_DocumentAndEntityInformation" name="DocumentAndEntityInformation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element id="amix_EffectiveIncomeTaxRateReconciliationChangeInStateRateAmount" name="EffectiveIncomeTaxRateReconciliationChangeInStateRateAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="amix_EffectiveIncomeTaxRateReconciliationChangeInStateRatePercent" name="EffectiveIncomeTaxRateReconciliationChangeInStateRatePercent" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="duration"/>
  <xsd:element id="amix_EmploymentAgreementBonusAsAPercentageOfAnnualBaseCompensation" name="EmploymentAgreementBonusAsAPercentageOfAnnualBaseCompensation" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="duration"/>
  <xsd:element id="amix_EmploymentAgreementTermOfContract" name="EmploymentAgreementTermOfContract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="amix_EquityOfferingMaximumOfferingAmount" name="EquityOfferingMaximumOfferingAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="amix_EquityOfferingMaximumSharesToBeIssued" name="EquityOfferingMaximumSharesToBeIssued" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant"/>
  <xsd:element id="amix_EquityOfferingOptionMaximumShares" name="EquityOfferingOptionMaximumShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant"/>
  <xsd:element id="amix_EquityOfferingOptionMaximumWarrants" name="EquityOfferingOptionMaximumWarrants" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant"/>
  <xsd:element id="amix_EquityOfferingOptionPeriod" name="EquityOfferingOptionPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="amix_EquitybasedWarrantsMember" name="EquitybasedWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="amix_ExecutiveChairOfTheBoardMember" name="ExecutiveChairOfTheBoardMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="amix_ExecutiveViceChairAndStrategicAdvisorToTheChiefExecutiveOfficerMember" name="ExecutiveViceChairAndStrategicAdvisorToTheChiefExecutiveOfficerMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="amix_ExistingWarrantsAt1722ExercisePriceMember" name="ExistingWarrantsAt1722ExercisePriceMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="amix_ExistingWarrantsAt1723ExercisePriceMember" name="ExistingWarrantsAt1723ExercisePriceMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="amix_ExistingWarrantsMember" name="ExistingWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="amix_ExpirationCommencingTaxYear20342037Member" name="ExpirationCommencingTaxYear20342037Member" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="amix_InducementOptionsMember" name="InducementOptionsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="amix_InterestHeldInCompanyReceivingWarrants" name="InterestHeldInCompanyReceivingWarrants" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="instant"/>
  <xsd:element id="amix_IpoProceedsHoldbackProvision" name="IpoProceedsHoldbackProvision" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="amix_IssuanceOfCommonStockForExtinguishmentOfConvertibleDebtMember" name="IssuanceOfCommonStockForExtinguishmentOfConvertibleDebtMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="amix_JumpstartOurBusinessStartupsJobsActAccountingElectionPolicyPolicyTextBlock" name="JumpstartOurBusinessStartupsJobsActAccountingElectionPolicyPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="amix_ManagementBoardOfDirectorFamilyMember" name="ManagementBoardOfDirectorFamilyMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="amix_MarketingConsultantMember" name="MarketingConsultantMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="amix_MaximumPercentageOfSharesSoldInThirtyDays" name="MaximumPercentageOfSharesSoldInThirtyDays" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="amix_MeasurementInputFixedPriceMember" name="MeasurementInputFixedPriceMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="amix_MeasurementInputProbabilityRateMember" name="MeasurementInputProbabilityRateMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="amix_NoQualifiedOfferingOccurringMember" name="NoQualifiedOfferingOccurringMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="amix_NolGeneratedDuring20172024Member" name="NolGeneratedDuring20172024Member" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="amix_NoncashExpensesMember" name="NoncashExpensesMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="amix_NoteToFinancialStatementDetailsTextual" name="NoteToFinancialStatementDetailsTextual" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="amix_NotesToFinancialStatements" name="NotesToFinancialStatements" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="amix_NotesToFinancialStatementsAbstract" name="NotesToFinancialStatementsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element id="amix_NumberOfCommonUnitsIssued" name="NumberOfCommonUnitsIssued" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="amix_NumberOfPrefundedUnitsIssued" name="NumberOfPrefundedUnitsIssued" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="amix_NumberOfSharesPerCommonUnit" name="NumberOfSharesPerCommonUnit" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant"/>
  <xsd:element id="amix_NumberOfWarrantsPerCommonUnit" name="NumberOfWarrantsPerCommonUnit" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant"/>
  <xsd:element id="amix_NumberOfWarrantsPerPrefundedUnit" name="NumberOfWarrantsPerPrefundedUnit" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant"/>
  <xsd:element id="amix_OfferingCostsPolicyPolicyTextBlock" name="OfferingCostsPolicyPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="amix_PaymentsForInitialPublicOfferingIssuanceCosts" name="PaymentsForInitialPublicOfferingIssuanceCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="amix_PaymentsForWarrantIssuanceFees" name="PaymentsForWarrantIssuanceFees" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="amix_PrefundedAndSeriesAWarrantsMember" name="PrefundedAndSeriesAWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="amix_PrefundedUnitsIssuedPurchasePrice" name="PrefundedUnitsIssuedPurchasePrice" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="amix_PrefundedWarrantsMember" name="PrefundedWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="amix_PreipoWarrantsMember" name="PreipoWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="amix_ProceedsFromIssuanceOfCommonStockAndWarrants" name="ProceedsFromIssuanceOfCommonStockAndWarrants" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="amix_ProceedsFromIssuanceOrSaleOfEquityNet" name="ProceedsFromIssuanceOrSaleOfEquityNet" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="amix_QualifiedOfferingOccurringOneMember" name="QualifiedOfferingOccurringOneMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="amix_QualifiedOfferingOccurringTwoMember" name="QualifiedOfferingOccurringTwoMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="amix_RelatedPartyTransactionsPolicyPolicyTextBlock" name="RelatedPartyTransactionsPolicyPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="amix_RepresentativesWarrantsMember" name="RepresentativesWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="amix_ReserveForUncertainTaxPositions" name="ReserveForUncertainTaxPositions" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="amix_RestrictedStockExpensesGeneralAndAdministrativeTableTextBlock" name="RestrictedStockExpensesGeneralAndAdministrativeTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="amix_ReverseStockSplitAdjustmentMember" name="ReverseStockSplitAdjustmentMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="amix_ReverseStockSplitMember" name="ReverseStockSplitMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="amix_ReverseStockSplitPolicyTextBlock" name="ReverseStockSplitPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="amix_RfInnovationsIncMember" name="RfInnovationsIncMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="amix_ScenarioContractTerminationMember" name="ScenarioContractTerminationMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="amix_ScenarioContractTerminationWithoutCauseMember" name="ScenarioContractTerminationWithoutCauseMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="amix_SellingAgentMember" name="SellingAgentMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="amix_SeriesAWarrantsAndTheRepresentativesWarrantsMember" name="SeriesAWarrantsAndTheRepresentativesWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="amix_SeriesAWarrantsMember" name="SeriesAWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="amix_SeriesBWarrantsMember" name="SeriesBWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice" name="SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType" xbrli:periodType="instant"/>
  <xsd:element id="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerm" name="SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice" name="SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType" xbrli:periodType="duration"/>
  <xsd:element id="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriodWeightedAverageExercisePrice" name="SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriodWeightedAverageExercisePrice" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType" xbrli:periodType="duration"/>
  <xsd:element id="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice" name="SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType" xbrli:periodType="duration"/>
  <xsd:element id="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice" name="SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType" xbrli:periodType="duration"/>
  <xsd:element id="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" name="SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType" xbrli:periodType="instant"/>
  <xsd:element id="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsDiscountRate" name="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsDiscountRate" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="duration"/>
  <xsd:element id="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardNonoptionEquityInstrumentsExercisableNumberOutstandingNumber" name="SharebasedCompensationArrangementBySharebasedPaymentAwardNonoptionEquityInstrumentsExercisableNumberOutstandingNumber" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant"/>
  <xsd:element id="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantDateFairValue" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantDateFairValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="amix_StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants" name="StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="amix_StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants" name="StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="amix_StockIssuedDuringPeriodSharesInitialPublicOffering" name="StockIssuedDuringPeriodSharesInitialPublicOffering" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="amix_StockIssuedDuringPeriodSharesWarrantsExercised" name="StockIssuedDuringPeriodSharesWarrantsExercised" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="amix_StockIssuedDuringPeriodValueInitialPublicOffering" name="StockIssuedDuringPeriodValueInitialPublicOffering" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="amix_StockIssuedDuringPeriodValueWarrantsExercised" name="StockIssuedDuringPeriodValueWarrantsExercised" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="amix_StockRequiredToBeIssuedForStockSplitShares" name="StockRequiredToBeIssuedForStockSplitShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant"/>
  <xsd:element id="amix_SubstantialDoubtAboutGoingConcernPolicyPolicyTextBlock" name="SubstantialDoubtAboutGoingConcernPolicyPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="amix_TerminationAgreementMember" name="TerminationAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="amix_The2023StockPlanMember" name="The2023StockPlanMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="amix_TheBridgeOfferingMember" name="TheBridgeOfferingMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="amix_TheNotesMember" name="TheNotesMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="amix_TheWarrantMember" name="TheWarrantMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="amix_UnderwritersMember" name="UnderwritersMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="amix_UnderwrittenPublicOfferingMember" name="UnderwrittenPublicOfferingMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="amix_ValuationProbabilityweightedExpectedReturnMethodPWERMMember" name="ValuationProbabilityweightedExpectedReturnMethodPWERMMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="amix_WarrantsIssuedFairValueIssuedForTerminationAgreement" name="WarrantsIssuedFairValueIssuedForTerminationAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="amix_WarrantsIssuedForDebtIssuanceCosts" name="WarrantsIssuedForDebtIssuanceCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="amix_WarrantsIssuedForEquityCosts" name="WarrantsIssuedForEquityCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="amix_WarrantsPolicyPolicyTextBlock" name="WarrantsPolicyPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="amix_WorkingCapitalDeficit" name="WorkingCapitalDeficit" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="amix_statement-statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q-tables" name="statement-statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="amix_statement-statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-antidilutive-securities-details" name="statement-statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-antidilutive-securities-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="amix_statement-statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-prior-period-corrections-details" name="statement-statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-prior-period-corrections-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="amix_statement-statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-10q-details" name="statement-statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-10q-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="amix_statement-statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-schedule-of-prior-period-corrections-10q-details" name="statement-statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-schedule-of-prior-period-corrections-10q-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="amix_statement-statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-tables" name="statement-statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="amix_statement-statement-note-2-convertible-notes-payable-10q-tables" name="statement-statement-note-2-convertible-notes-payable-10q-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="amix_statement-statement-note-2-convertible-notes-payable-schedule-of-detachable-warrants-10q-details" name="statement-statement-note-2-convertible-notes-payable-schedule-of-detachable-warrants-10q-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="amix_statement-statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-fair-value-measurement-inputs-and-valuation-techniques-details" name="statement-statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-fair-value-measurement-inputs-and-valuation-techniques-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="amix_statement-statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-schedule-of-fair-value-measurements-details" name="statement-statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-schedule-of-fair-value-measurements-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="amix_statement-statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-tables" name="statement-statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="amix_statement-statement-note-3-convertible-notes-payable-schedule-of-convertible-notes-payable-details" name="statement-statement-note-3-convertible-notes-payable-schedule-of-convertible-notes-payable-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="amix_statement-statement-note-3-convertible-notes-payable-schedule-of-detachable-warrants-details" name="statement-statement-note-3-convertible-notes-payable-schedule-of-detachable-warrants-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="amix_statement-statement-note-3-convertible-notes-payable-tables" name="statement-statement-note-3-convertible-notes-payable-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="amix_statement-statement-note-3-equity-10q-tables" name="statement-statement-note-3-equity-10q-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="amix_statement-statement-note-3-equity-general-and-administrative-expense-10q-details" name="statement-statement-note-3-equity-general-and-administrative-expense-10q-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="amix_statement-statement-note-3-equity-schedule-of-equitybased-stock-warrants-10q-details" name="statement-statement-note-3-equity-schedule-of-equitybased-stock-warrants-10q-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="amix_statement-statement-note-3-equity-schedule-of-stock-option-activity-10q-details" name="statement-statement-note-3-equity-schedule-of-stock-option-activity-10q-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="amix_statement-statement-note-4-equity-blackscholes-option-pricing-model-details" name="statement-statement-note-4-equity-blackscholes-option-pricing-model-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="amix_statement-statement-note-4-equity-general-and-administrative-expense-details" name="statement-statement-note-4-equity-general-and-administrative-expense-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="amix_statement-statement-note-4-equity-restricted-stock-activity-details" name="statement-statement-note-4-equity-restricted-stock-activity-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="amix_statement-statement-note-4-equity-schedule-of-equitybased-stock-warrants-details" name="statement-statement-note-4-equity-schedule-of-equitybased-stock-warrants-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="amix_statement-statement-note-4-equity-schedule-of-stock-option-activity-details" name="statement-statement-note-4-equity-schedule-of-stock-option-activity-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="amix_statement-statement-note-4-equity-tables" name="statement-statement-note-4-equity-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="amix_statement-statement-note-7-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" name="statement-statement-note-7-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="amix_statement-statement-note-7-income-taxes-schedule-of-reconciliation-details" name="statement-statement-note-7-income-taxes-schedule-of-reconciliation-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="amix_statement-statement-note-7-income-taxes-tables" name="statement-statement-note-7-income-taxes-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="amix_statement-statement-significant-accounting-policies-policies" name="statement-statement-significant-accounting-policies-policies" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>3
<FILENAME>amix-20250630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 03:06PM UTC 2025-10-04--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-note-7-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" xlink:href="amix-20250630.xsd#statement-note-7-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://autonomix.com/20250630/role/statement-note-7-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="amix-20250630.xsd#amix_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" xlink:label="amix_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_DeferredTaxLiabilitiesChangeInAccountingMethod" xlink:label="amix_DeferredTaxLiabilitiesChangeInAccountingMethod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="amix_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="amix_DeferredTaxLiabilitiesChangeInAccountingMethod" xlink:type="arc"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxLiabilities" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsNet" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-statements-of-cash-flows" xlink:href="amix-20250630.xsd#statement-statements-of-cash-flows" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://autonomix.com/20250630/role/statement-statements-of-cash-flows" xlink:type="extended">
    <link:loc xlink:href="amix-20250630.xsd#amix_PaymentsForInitialPublicOfferingIssuanceCosts" xlink:label="amix_PaymentsForInitialPublicOfferingIssuanceCosts" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:label="amix_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" xlink:type="arc"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:type="arc"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:type="arc"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromConvertibleDebt" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromWarrantExercises" xlink:type="arc"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfFinancingCosts" xlink:type="arc"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="arc"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="amix_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:type="arc"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="amix_PaymentsForInitialPublicOfferingIssuanceCosts" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-condensed-statements-of-cash-flows-unaudited" xlink:href="amix-20250630.xsd#statement-condensed-statements-of-cash-flows-unaudited" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://autonomix.com/20250630/role/statement-condensed-statements-of-cash-flows-unaudited" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:type="arc"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-note-7-income-taxes-schedule-of-reconciliation-details" xlink:href="amix-20250630.xsd#statement-note-7-income-taxes-schedule-of-reconciliation-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://autonomix.com/20250630/role/statement-note-7-income-taxes-schedule-of-reconciliation-details" xlink:type="extended">
    <link:loc xlink:href="amix-20250630.xsd#amix_EffectiveIncomeTaxRateReconciliationChangeInStateRateAmount" xlink:label="amix_EffectiveIncomeTaxRateReconciliationChangeInStateRateAmount" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_EffectiveIncomeTaxRateReconciliationChangeInStateRatePercent" xlink:label="amix_EffectiveIncomeTaxRateReconciliationChangeInStateRatePercent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="amix_EffectiveIncomeTaxRateReconciliationChangeInStateRateAmount" xlink:type="arc"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="amix_EffectiveIncomeTaxRateReconciliationChangeInStateRatePercent" xlink:type="arc"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-statements-of-operations" xlink:href="amix-20250630.xsd#statement-statements-of-operations" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://autonomix.com/20250630/role/statement-statements-of-operations" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="us-gaap_InterestExpenseNonoperating" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" xlink:type="arc"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InterestExpenseNonoperating" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InvestmentIncomeInterest" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_NonoperatingIncomeExpense" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-condensed-statements-of-operations-unaudited" xlink:href="amix-20250630.xsd#statement-condensed-statements-of-operations-unaudited" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://autonomix.com/20250630/role/statement-condensed-statements-of-operations-unaudited" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="us-gaap_InterestExpenseNonoperating" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" xlink:type="arc"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InterestExpenseNonoperating" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InvestmentIncomeInterest" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_NonoperatingIncomeExpense" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" xlink:type="arc"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-balance-sheets" xlink:href="amix-20250630.xsd#statement-balance-sheets" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://autonomix.com/20250630/role/statement-balance-sheets" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="us-gaap_ConvertibleLongTermNotesPayable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCosts" xlink:label="us-gaap_DeferredCosts" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_DeferredCosts" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_ConvertibleLongTermNotesPayable" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-condensed-balance-sheets-unaudited-" xlink:href="amix-20250630.xsd#statement-condensed-balance-sheets-unaudited-" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://autonomix.com/20250630/role/statement-condensed-balance-sheets-unaudited-" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCosts" xlink:label="us-gaap_DeferredCosts" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_DeferredCosts" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>4
<FILENAME>amix-20250630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 03:06PM UTC 2025-10-04--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-document-and-entity-information" xlink:href="amix-20250630.xsd#statement-document-and-entity-information" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://autonomix.com/20250630/role/statement-document-and-entity-information" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-balance-sheets-parentheticals" xlink:href="amix-20250630.xsd#statement-balance-sheets-parentheticals" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://autonomix.com/20250630/role/statement-balance-sheets-parentheticals" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-condensed-balance-sheets-unaudited-parentheticals" xlink:href="amix-20250630.xsd#statement-condensed-balance-sheets-unaudited-parentheticals" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://autonomix.com/20250630/role/statement-condensed-balance-sheets-unaudited-parentheticals" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies" xlink:href="amix-20250630.xsd#statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies" xlink:type="extended">
    <link:loc xlink:href="amix-20250630.xsd#amix_ATMAgreementMember" xlink:label="amix_ATMAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_EquitybasedWarrantsMember" xlink:label="amix_EquitybasedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_NoncashExpensesMember" xlink:label="amix_NoncashExpensesMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_PrefundedAndSeriesAWarrantsMember" xlink:label="amix_PrefundedAndSeriesAWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_PrefundedWarrantsMember" xlink:label="amix_PrefundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ReverseStockSplitMember" xlink:label="amix_ReverseStockSplitMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_SellingAgentMember" xlink:label="amix_SellingAgentMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_SeriesAWarrantsMember" xlink:label="amix_SeriesAWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_UnderwritersMember" xlink:label="amix_UnderwritersMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_UnderwrittenPublicOfferingMember" xlink:label="amix_UnderwrittenPublicOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="us-gaap_InterimPeriodCostsNotAllocableDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NatureOfExpenseAxis" xlink:label="us-gaap_NatureOfExpenseAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonmonetaryTransactionTypeAxis" xlink:label="us-gaap_NonmonetaryTransactionTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonmonetaryTransactionTypeDomain" xlink:label="us-gaap_NonmonetaryTransactionTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonmonetaryTransactionTypeDomain" xlink:label="us-gaap_NonmonetaryTransactionTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_NonmonetaryTransactionTypeAxis" xlink:to="us-gaap_NonmonetaryTransactionTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_NonmonetaryTransactionTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonmonetaryTransactionTypeDomain" xlink:to="amix_ReverseStockSplitMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_NonmonetaryTransactionTypeAxis" xlink:to="us-gaap_NonmonetaryTransactionTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="amix_UnderwrittenPublicOfferingMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="amix_SeriesAWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="amix_PrefundedWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="amix_UnderwritersMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="amix_PrefundedAndSeriesAWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_NatureOfExpenseAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:to="amix_NoncashExpensesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="us-gaap_InterimPeriodCostsNotAllocableDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="amix_ATMAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="amix_SellingAgentMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="amix_EquitybasedWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments" xlink:href="amix-20250630.xsd#statement-note-2-warrant-liability-and-fair-value-of-financial-instruments" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments" xlink:type="extended">
    <link:loc xlink:href="amix-20250630.xsd#amix_MeasurementInputProbabilityRateMember" xlink:label="amix_MeasurementInputProbabilityRateMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_NoQualifiedOfferingOccurringMember" xlink:label="amix_NoQualifiedOfferingOccurringMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_QualifiedOfferingOccurringOneMember" xlink:label="amix_QualifiedOfferingOccurringOneMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_QualifiedOfferingOccurringTwoMember" xlink:label="amix_QualifiedOfferingOccurringTwoMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_TerminationAgreementMember" xlink:label="amix_TerminationAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_TheWarrantMember" xlink:label="amix_TheWarrantMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ValuationProbabilityweightedExpectedReturnMethodPWERMMember" xlink:label="amix_ValuationProbabilityweightedExpectedReturnMethodPWERMMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="us-gaap_ValuationTechniqueAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="us-gaap_ValuationTechniqueDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="us-gaap_ValuationTechniqueDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_MeasurementInputTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="amix_MeasurementInputProbabilityRateMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ValuationTechniqueAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationTechniqueDomain" xlink:to="amix_ValuationProbabilityweightedExpectedReturnMethodPWERMMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="amix_QualifiedOfferingOccurringOneMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="amix_QualifiedOfferingOccurringTwoMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="amix_NoQualifiedOfferingOccurringMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="amix_TheWarrantMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="amix_TerminationAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable" xlink:href="amix-20250630.xsd#statement-note-3-convertible-notes-payable" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable" xlink:type="extended">
    <link:loc xlink:href="amix-20250630.xsd#amix_BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember" xlink:label="amix_BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ConversionOfConvertibleNotesToCommonStockMember" xlink:label="amix_ConversionOfConvertibleNotesToCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ConvertibleDebtWith499PercentBeneficialOwnershipLimitationMember" xlink:label="amix_ConvertibleDebtWith499PercentBeneficialOwnershipLimitationMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_TheNotesMember" xlink:label="amix_TheNotesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember" xlink:label="us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="us-gaap_MeasurementInputDiscountRateMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="amix_TheNotesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="amix_BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="amix_ConvertibleDebtWith499PercentBeneficialOwnershipLimitationMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionNameDomain" xlink:to="amix_ConversionOfConvertibleNotesToCommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_MeasurementInputTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedTermMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-note-4-equity" xlink:href="amix-20250630.xsd#statement-note-4-equity" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://autonomix.com/20250630/role/statement-note-4-equity" xlink:type="extended">
    <link:loc xlink:href="amix-20250630.xsd#amix_ATMAgreementMember" xlink:label="amix_ATMAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_BlackscholesModelMember" xlink:label="amix_BlackscholesModelMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_EquitybasedWarrantsMember" xlink:label="amix_EquitybasedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_MarketingConsultantMember" xlink:label="amix_MarketingConsultantMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_NoncashExpensesMember" xlink:label="amix_NoncashExpensesMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_PrefundedWarrantsMember" xlink:label="amix_PrefundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_RepresentativesWarrantsMember" xlink:label="amix_RepresentativesWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_RfInnovationsIncMember" xlink:label="amix_RfInnovationsIncMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_SeriesAWarrantsAndTheRepresentativesWarrantsMember" xlink:label="amix_SeriesAWarrantsAndTheRepresentativesWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_SeriesAWarrantsMember" xlink:label="amix_SeriesAWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_The2023StockPlanMember" xlink:label="amix_The2023StockPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_UnderwritersMember" xlink:label="amix_UnderwritersMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_UnderwrittenPublicOfferingMember" xlink:label="amix_UnderwrittenPublicOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="us-gaap_InterimPeriodCostsNotAllocableDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="us-gaap_MeasurementInputDiscountRateMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NatureOfExpenseAxis" xlink:label="us-gaap_NatureOfExpenseAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="us-gaap_ValuationTechniqueAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:label="us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="us-gaap_ValuationTechniqueDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="us-gaap_ValuationTechniqueDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="amix_MarketingConsultantMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="amix_ATMAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="amix_The2023StockPlanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ValuationTechniqueAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationTechniqueDomain" xlink:to="amix_BlackscholesModelMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueDomain-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="amix_RfInnovationsIncMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="amix_UnderwrittenPublicOfferingMember" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="amix_SeriesAWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="amix_PrefundedWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="amix_UnderwritersMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="amix_RepresentativesWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="amix_SeriesAWarrantsAndTheRepresentativesWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_MeasurementInputTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_NatureOfExpenseAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:to="amix_NoncashExpensesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="us-gaap_InterimPeriodCostsNotAllocableDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="amix_EquitybasedWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedTermMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_WarrantMember" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-note-5-commitments-and-contingencies" xlink:href="amix-20250630.xsd#statement-note-5-commitments-and-contingencies" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://autonomix.com/20250630/role/statement-note-5-commitments-and-contingencies" xlink:type="extended">
    <link:loc xlink:href="amix-20250630.xsd#amix_ExecutiveViceChairAndStrategicAdvisorToTheChiefExecutiveOfficerMember" xlink:label="amix_ExecutiveViceChairAndStrategicAdvisorToTheChiefExecutiveOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_InducementOptionsMember" xlink:label="amix_InducementOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ScenarioContractTerminationMember" xlink:label="amix_ScenarioContractTerminationMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ScenarioContractTerminationWithoutCauseMember" xlink:label="amix_ScenarioContractTerminationWithoutCauseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmploymentContractsMember" xlink:label="us-gaap_EmploymentContractsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LitigationStatusAxis" xlink:label="us-gaap_LitigationStatusAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LitigationStatusDomain" xlink:label="us-gaap_LitigationStatusDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LitigationStatusDomain" xlink:label="us-gaap_LitigationStatusDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PendingLitigationMember" xlink:label="us-gaap_PendingLitigationMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LitigationStatusAxis" xlink:to="us-gaap_LitigationStatusDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LitigationStatusAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LitigationStatusDomain" xlink:to="us-gaap_PendingLitigationMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LitigationStatusAxis" xlink:to="us-gaap_LitigationStatusDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_EmploymentContractsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefExecutiveOfficerMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="amix_InducementOptionsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VestingAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain-default" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="amix_ScenarioContractTerminationMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="amix_ScenarioContractTerminationWithoutCauseMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="amix_ExecutiveViceChairAndStrategicAdvisorToTheChiefExecutiveOfficerMember" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-note-6-related-party-transactions" xlink:href="amix-20250630.xsd#statement-note-6-related-party-transactions" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://autonomix.com/20250630/role/statement-note-6-related-party-transactions" xlink:type="extended">
    <link:loc xlink:href="amix-20250630.xsd#amix_AccountingAndFinancialReportingServicesMember" xlink:label="amix_AccountingAndFinancialReportingServicesMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_CommonStock12MonthsLockupPeriodMember" xlink:label="amix_CommonStock12MonthsLockupPeriodMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_CommonStock6MonthsLockupPeriodMember" xlink:label="amix_CommonStock6MonthsLockupPeriodMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ConsultingFirmOwnedByFormerCFOMember" xlink:label="amix_ConsultingFirmOwnedByFormerCFOMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ManagementBoardOfDirectorFamilyMember" xlink:label="amix_ManagementBoardOfDirectorFamilyMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_TerminationAgreementMember" xlink:label="amix_TerminationAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_TheBridgeOfferingMember" xlink:label="amix_TheBridgeOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_TheWarrantMember" xlink:label="amix_TheWarrantMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ManagementMember" xlink:label="srt_ManagementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnderlyingAssetClassAxis" xlink:label="us-gaap_UnderlyingAssetClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnderlyingAssetClassDomain" xlink:label="us-gaap_UnderlyingAssetClassDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnderlyingAssetClassDomain" xlink:label="us-gaap_UnderlyingAssetClassDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_UnderlyingAssetClassAxis" xlink:to="us-gaap_UnderlyingAssetClassDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="amix_ConsultingFirmOwnedByFormerCFOMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="amix_AccountingAndFinancialReportingServicesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="amix_ManagementBoardOfDirectorFamilyMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="amix_TheBridgeOfferingMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="srt_ManagementMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="amix_TheWarrantMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="amix_TerminationAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_UnderlyingAssetClassAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_UnderlyingAssetClassDomain" xlink:to="amix_CommonStock6MonthsLockupPeriodMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_UnderlyingAssetClassAxis" xlink:to="us-gaap_UnderlyingAssetClassDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_UnderlyingAssetClassDomain" xlink:to="amix_CommonStock12MonthsLockupPeriodMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-note-7-income-taxes" xlink:href="amix-20250630.xsd#statement-note-7-income-taxes" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://autonomix.com/20250630/role/statement-note-7-income-taxes" xlink:type="extended">
    <link:loc xlink:href="amix-20250630.xsd#amix_ExpirationCommencingTaxYear20342037Member" xlink:label="amix_ExpirationCommencingTaxYear20342037Member" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_NolGeneratedDuring20172024Member" xlink:label="amix_NolGeneratedDuring20172024Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TaxPeriodAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="amix_ExpirationCommencingTaxYear20342037Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="amix_NolGeneratedDuring20172024Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-note-8-subsequent-events" xlink:href="amix-20250630.xsd#statement-note-8-subsequent-events" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://autonomix.com/20250630/role/statement-note-8-subsequent-events" xlink:type="extended">
    <link:loc xlink:href="amix-20250630.xsd#amix_ATMAgreementMember" xlink:label="amix_ATMAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="amix_ATMAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_GranteeStatusAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VestingAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q" xlink:href="amix-20250630.xsd#statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q" xlink:type="extended">
    <link:loc xlink:href="amix-20250630.xsd#amix_ATMAgreementMember" xlink:label="amix_ATMAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_EquitybasedWarrantsMember" xlink:label="amix_EquitybasedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_NoncashExpensesMember" xlink:label="amix_NoncashExpensesMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_PrefundedAndSeriesAWarrantsMember" xlink:label="amix_PrefundedAndSeriesAWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_PrefundedWarrantsMember" xlink:label="amix_PrefundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ReverseStockSplitMember" xlink:label="amix_ReverseStockSplitMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_SeriesAWarrantsMember" xlink:label="amix_SeriesAWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_UnderwritersMember" xlink:label="amix_UnderwritersMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_UnderwrittenPublicOfferingMember" xlink:label="amix_UnderwrittenPublicOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="us-gaap_InterimPeriodCostsNotAllocableDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NatureOfExpenseAxis" xlink:label="us-gaap_NatureOfExpenseAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonmonetaryTransactionTypeAxis" xlink:label="us-gaap_NonmonetaryTransactionTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonmonetaryTransactionTypeDomain" xlink:label="us-gaap_NonmonetaryTransactionTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonmonetaryTransactionTypeDomain" xlink:label="us-gaap_NonmonetaryTransactionTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_NonmonetaryTransactionTypeAxis" xlink:to="us-gaap_NonmonetaryTransactionTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_NonmonetaryTransactionTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonmonetaryTransactionTypeDomain" xlink:to="amix_ReverseStockSplitMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_NonmonetaryTransactionTypeAxis" xlink:to="us-gaap_NonmonetaryTransactionTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="amix_ATMAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="amix_UnderwrittenPublicOfferingMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="amix_SeriesAWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="amix_PrefundedWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="amix_UnderwritersMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="amix_PrefundedAndSeriesAWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_NatureOfExpenseAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:to="amix_NoncashExpensesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="us-gaap_InterimPeriodCostsNotAllocableDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="amix_EquitybasedWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-note-2-convertible-notes-payable-10q" xlink:href="amix-20250630.xsd#statement-note-2-convertible-notes-payable-10q" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://autonomix.com/20250630/role/statement-note-2-convertible-notes-payable-10q" xlink:type="extended">
    <link:loc xlink:href="amix-20250630.xsd#amix_BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember" xlink:label="amix_BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ConversionOfConvertibleNotesToCommonStockMember" xlink:label="amix_ConversionOfConvertibleNotesToCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ConvertibleDebtWith499PercentBeneficialOwnershipLimitationMember" xlink:label="amix_ConvertibleDebtWith499PercentBeneficialOwnershipLimitationMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_TheNotesMember" xlink:label="amix_TheNotesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember" xlink:label="us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="us-gaap_MeasurementInputDiscountRateMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="amix_TheNotesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="amix_BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="amix_ConvertibleDebtWith499PercentBeneficialOwnershipLimitationMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionNameDomain" xlink:to="amix_ConversionOfConvertibleNotesToCommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_MeasurementInputTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedTermMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-note-3-equity-10q" xlink:href="amix-20250630.xsd#statement-note-3-equity-10q" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://autonomix.com/20250630/role/statement-note-3-equity-10q" xlink:type="extended">
    <link:loc xlink:href="amix-20250630.xsd#amix_ATMAgreementMember" xlink:label="amix_ATMAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_BlackscholesModelMember" xlink:label="amix_BlackscholesModelMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_CommonWarrantsMember" xlink:label="amix_CommonWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_MarketingConsultantMember" xlink:label="amix_MarketingConsultantMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_NoncashExpensesMember" xlink:label="amix_NoncashExpensesMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_PrefundedWarrantsMember" xlink:label="amix_PrefundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_RepresentativesWarrantsMember" xlink:label="amix_RepresentativesWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_RfInnovationsIncMember" xlink:label="amix_RfInnovationsIncMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_SeriesAWarrantsAndTheRepresentativesWarrantsMember" xlink:label="amix_SeriesAWarrantsAndTheRepresentativesWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_SeriesAWarrantsMember" xlink:label="amix_SeriesAWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_The2023StockPlanMember" xlink:label="amix_The2023StockPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_UnderwritersMember" xlink:label="amix_UnderwritersMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_UnderwrittenPublicOfferingMember" xlink:label="amix_UnderwrittenPublicOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="us-gaap_InterimPeriodCostsNotAllocableDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="us-gaap_MeasurementInputDiscountRateMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NatureOfExpenseAxis" xlink:label="us-gaap_NatureOfExpenseAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="us-gaap_ValuationTechniqueAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="us-gaap_ValuationTechniqueDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="us-gaap_ValuationTechniqueDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="amix_MarketingConsultantMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="amix_ATMAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="amix_The2023StockPlanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ValuationTechniqueAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationTechniqueDomain" xlink:to="amix_BlackscholesModelMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueDomain-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="amix_RfInnovationsIncMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="amix_UnderwrittenPublicOfferingMember" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="amix_SeriesAWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="amix_PrefundedWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="amix_UnderwritersMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="amix_RepresentativesWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="amix_SeriesAWarrantsAndTheRepresentativesWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_MeasurementInputTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_NatureOfExpenseAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:to="amix_NoncashExpensesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="us-gaap_InterimPeriodCostsNotAllocableDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="amix_CommonWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_WarrantMember" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-note-4-commitments-and-contingencies-10q" xlink:href="amix-20250630.xsd#statement-note-4-commitments-and-contingencies-10q" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://autonomix.com/20250630/role/statement-note-4-commitments-and-contingencies-10q" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmploymentContractsMember" xlink:label="us-gaap_EmploymentContractsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LitigationStatusAxis" xlink:label="us-gaap_LitigationStatusAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LitigationStatusDomain" xlink:label="us-gaap_LitigationStatusDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LitigationStatusDomain" xlink:label="us-gaap_LitigationStatusDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PendingLitigationMember" xlink:label="us-gaap_PendingLitigationMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LitigationStatusAxis" xlink:to="us-gaap_LitigationStatusDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LitigationStatusAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LitigationStatusDomain" xlink:to="us-gaap_PendingLitigationMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LitigationStatusAxis" xlink:to="us-gaap_LitigationStatusDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_EmploymentContractsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-note-5-related-party-transactions-10q" xlink:href="amix-20250630.xsd#statement-note-5-related-party-transactions-10q" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://autonomix.com/20250630/role/statement-note-5-related-party-transactions-10q" xlink:type="extended">
    <link:loc xlink:href="amix-20250630.xsd#amix_CommonStock12MonthsLockupPeriodMember" xlink:label="amix_CommonStock12MonthsLockupPeriodMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_CommonStock6MonthsLockupPeriodMember" xlink:label="amix_CommonStock6MonthsLockupPeriodMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_TerminationAgreementMember" xlink:label="amix_TerminationAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_TheWarrantMember" xlink:label="amix_TheWarrantMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnderlyingAssetClassAxis" xlink:label="us-gaap_UnderlyingAssetClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnderlyingAssetClassDomain" xlink:label="us-gaap_UnderlyingAssetClassDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnderlyingAssetClassDomain" xlink:label="us-gaap_UnderlyingAssetClassDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_UnderlyingAssetClassAxis" xlink:to="us-gaap_UnderlyingAssetClassDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="amix_TheWarrantMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="amix_TerminationAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_UnderlyingAssetClassAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_UnderlyingAssetClassDomain" xlink:to="amix_CommonStock6MonthsLockupPeriodMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_UnderlyingAssetClassAxis" xlink:to="us-gaap_UnderlyingAssetClassDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_UnderlyingAssetClassDomain" xlink:to="amix_CommonStock12MonthsLockupPeriodMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-note-6-subsequent-events-10q" xlink:href="amix-20250630.xsd#statement-note-6-subsequent-events-10q" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://autonomix.com/20250630/role/statement-note-6-subsequent-events-10q" xlink:type="extended">
    <link:loc xlink:href="amix-20250630.xsd#amix_ChiefMedicalOfficerMember" xlink:label="amix_ChiefMedicalOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ChiefTechnologyOfficerMember" xlink:label="amix_ChiefTechnologyOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ExecutiveChairOfTheBoardMember" xlink:label="amix_ExecutiveChairOfTheBoardMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ExistingWarrantsAt1722ExercisePriceMember" xlink:label="amix_ExistingWarrantsAt1722ExercisePriceMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ExistingWarrantsAt1723ExercisePriceMember" xlink:label="amix_ExistingWarrantsAt1723ExercisePriceMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ExistingWarrantsMember" xlink:label="amix_ExistingWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_PreipoWarrantsMember" xlink:label="amix_PreipoWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_RepresentativesWarrantsMember" xlink:label="amix_RepresentativesWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_SeriesAWarrantsMember" xlink:label="amix_SeriesAWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_SeriesBWarrantsMember" xlink:label="amix_SeriesBWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_BoardOfDirectorsChairmanMember" xlink:label="srt_BoardOfDirectorsChairmanMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ChiefFinancialOfficerMember" xlink:label="srt_ChiefFinancialOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="amix_ExistingWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="amix_ExistingWarrantsAt1723ExercisePriceMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="amix_ExistingWarrantsAt1722ExercisePriceMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="amix_SeriesBWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="amix_RepresentativesWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="amix_SeriesAWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="amix_PreipoWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_BoardOfDirectorsChairmanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="amix_ExecutiveChairOfTheBoardMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_DirectorMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefExecutiveOfficerMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="amix_ChiefTechnologyOfficerMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="amix_ChiefMedicalOfficerMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefFinancialOfficerMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-significant-accounting-policies-policies" xlink:href="amix-20250630.xsd#statement-significant-accounting-policies-policies" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://autonomix.com/20250630/role/statement-significant-accounting-policies-policies" xlink:type="extended">
    <link:loc xlink:href="amix-20250630.xsd#amix_CorrectionOfAnImmaterialErrorPolicyTextBlock" xlink:label="amix_CorrectionOfAnImmaterialErrorPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_JumpstartOurBusinessStartupsJobsActAccountingElectionPolicyPolicyTextBlock" xlink:label="amix_JumpstartOurBusinessStartupsJobsActAccountingElectionPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_OfferingCostsPolicyPolicyTextBlock" xlink:label="amix_OfferingCostsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_RelatedPartyTransactionsPolicyPolicyTextBlock" xlink:label="amix_RelatedPartyTransactionsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ReverseStockSplitPolicyTextBlock" xlink:label="amix_ReverseStockSplitPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_SubstantialDoubtAboutGoingConcernPolicyPolicyTextBlock" xlink:label="amix_SubstantialDoubtAboutGoingConcernPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_WarrantsPolicyPolicyTextBlock" xlink:label="amix_WarrantsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdvertisingCostsPolicyTextBlock" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="us-gaap_DebtPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityPolicyTextBlock" xlink:label="us-gaap_StockholdersEquityPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PolicyTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="amix_ReverseStockSplitPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="amix_SubstantialDoubtAboutGoingConcernPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="amix_OfferingCostsPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DebtPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="amix_RelatedPartyTransactionsPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="amix_WarrantsPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AdvertisingCostsPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_StockholdersEquityPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="amix_JumpstartOurBusinessStartupsJobsActAccountingElectionPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="amix_CorrectionOfAnImmaterialErrorPolicyTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-tables" xlink:href="amix-20250630.xsd#statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:label="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-tables" xlink:href="amix-20250630.xsd#statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable-tables" xlink:href="amix-20250630.xsd#statement-note-3-convertible-notes-payable-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebtTableTextBlock" xlink:label="us-gaap_ConvertibleDebtTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ConvertibleDebtTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-note-4-equity-tables" xlink:href="amix-20250630.xsd#statement-note-4-equity-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://autonomix.com/20250630/role/statement-note-4-equity-tables" xlink:type="extended">
    <link:loc xlink:href="amix-20250630.xsd#amix_RestrictedStockExpensesGeneralAndAdministrativeTableTextBlock" xlink:label="amix_RestrictedStockExpensesGeneralAndAdministrativeTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="amix_RestrictedStockExpensesGeneralAndAdministrativeTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-note-7-income-taxes-tables" xlink:href="amix-20250630.xsd#statement-note-7-income-taxes-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://autonomix.com/20250630/role/statement-note-7-income-taxes-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q-tables" xlink:href="amix-20250630.xsd#statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:label="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-note-2-convertible-notes-payable-10q-tables" xlink:href="amix-20250630.xsd#statement-note-2-convertible-notes-payable-10q-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://autonomix.com/20250630/role/statement-note-2-convertible-notes-payable-10q-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-note-3-equity-10q-tables" xlink:href="amix-20250630.xsd#statement-note-3-equity-10q-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://autonomix.com/20250630/role/statement-note-3-equity-10q-tables" xlink:type="extended">
    <link:loc xlink:href="amix-20250630.xsd#amix_RestrictedStockExpensesGeneralAndAdministrativeTableTextBlock" xlink:label="amix_RestrictedStockExpensesGeneralAndAdministrativeTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="amix_RestrictedStockExpensesGeneralAndAdministrativeTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual" xlink:href="amix-20250630.xsd#statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual" xlink:type="extended">
    <link:loc xlink:href="amix-20250630.xsd#amix_ATMAgreementMember" xlink:label="amix_ATMAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:label="amix_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantsOrRightsMaximumBeneficialOwnership" xlink:label="amix_ClassOfWarrantsOrRightsMaximumBeneficialOwnership" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_CommissionPercentage" xlink:label="amix_CommissionPercentage" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_CommonUnitsIssuedPurchasePrice" xlink:label="amix_CommonUnitsIssuedPurchasePrice" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_EquityOfferingMaximumOfferingAmount" xlink:label="amix_EquityOfferingMaximumOfferingAmount" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_EquityOfferingOptionMaximumShares" xlink:label="amix_EquityOfferingOptionMaximumShares" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_EquityOfferingOptionMaximumWarrants" xlink:label="amix_EquityOfferingOptionMaximumWarrants" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_EquityOfferingOptionPeriod" xlink:label="amix_EquityOfferingOptionPeriod" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_EquitybasedWarrantsMember" xlink:label="amix_EquitybasedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_NoncashExpensesMember" xlink:label="amix_NoncashExpensesMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_NumberOfCommonUnitsIssued" xlink:label="amix_NumberOfCommonUnitsIssued" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_NumberOfPrefundedUnitsIssued" xlink:label="amix_NumberOfPrefundedUnitsIssued" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_NumberOfSharesPerCommonUnit" xlink:label="amix_NumberOfSharesPerCommonUnit" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_NumberOfWarrantsPerCommonUnit" xlink:label="amix_NumberOfWarrantsPerCommonUnit" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_NumberOfWarrantsPerPrefundedUnit" xlink:label="amix_NumberOfWarrantsPerPrefundedUnit" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_PaymentsForInitialPublicOfferingIssuanceCosts" xlink:label="amix_PaymentsForInitialPublicOfferingIssuanceCosts" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_PrefundedAndSeriesAWarrantsMember" xlink:label="amix_PrefundedAndSeriesAWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_PrefundedUnitsIssuedPurchasePrice" xlink:label="amix_PrefundedUnitsIssuedPurchasePrice" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_PrefundedWarrantsMember" xlink:label="amix_PrefundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ProceedsFromIssuanceOrSaleOfEquityNet" xlink:label="amix_ProceedsFromIssuanceOrSaleOfEquityNet" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ReverseStockSplitMember" xlink:label="amix_ReverseStockSplitMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_SellingAgentMember" xlink:label="amix_SellingAgentMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_SeriesAWarrantsMember" xlink:label="amix_SeriesAWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_UnderwritersMember" xlink:label="amix_UnderwritersMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_UnderwrittenPublicOfferingMember" xlink:label="amix_UnderwrittenPublicOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_WorkingCapitalDeficit" xlink:label="amix_WorkingCapitalDeficit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdvertisingExpense" xlink:label="us-gaap_AdvertisingExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="us-gaap_InterimPeriodCostsNotAllocableDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NatureOfExpenseAxis" xlink:label="us-gaap_NatureOfExpenseAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonmonetaryTransactionTypeAxis" xlink:label="us-gaap_NonmonetaryTransactionTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonmonetaryTransactionTypeDomain" xlink:label="us-gaap_NonmonetaryTransactionTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonmonetaryTransactionTypeDomain" xlink:label="us-gaap_NonmonetaryTransactionTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_NonmonetaryTransactionTypeAxis" xlink:to="us-gaap_NonmonetaryTransactionTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_NonmonetaryTransactionTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonmonetaryTransactionTypeDomain" xlink:to="amix_ReverseStockSplitMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_NonmonetaryTransactionTypeAxis" xlink:to="us-gaap_NonmonetaryTransactionTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="amix_UnderwrittenPublicOfferingMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="amix_SeriesAWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="amix_PrefundedWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="amix_UnderwritersMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="amix_PrefundedAndSeriesAWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_NatureOfExpenseAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:to="amix_NoncashExpensesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="us-gaap_InterimPeriodCostsNotAllocableDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="amix_ATMAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="amix_SellingAgentMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="amix_EquitybasedWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Revenues" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_WorkingCapitalDeficit" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_NumberOfCommonUnitsIssued" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_NumberOfSharesPerCommonUnit" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_NumberOfWarrantsPerCommonUnit" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_NumberOfPrefundedUnitsIssued" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_NumberOfWarrantsPerPrefundedUnit" xlink:type="arc"/>
    <link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_CommonUnitsIssuedPurchasePrice" xlink:type="arc"/>
    <link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_PrefundedUnitsIssuedPurchasePrice" xlink:type="arc"/>
    <link:definitionArc order="22" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_EquityOfferingOptionPeriod" xlink:type="arc"/>
    <link:definitionArc order="23" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_EquityOfferingOptionMaximumShares" xlink:type="arc"/>
    <link:definitionArc order="24" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_EquityOfferingOptionMaximumWarrants" xlink:type="arc"/>
    <link:definitionArc order="25" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc"/>
    <link:definitionArc order="26" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="arc"/>
    <link:definitionArc order="27" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_ClassOfWarrantsOrRightsMaximumBeneficialOwnership" xlink:type="arc"/>
    <link:definitionArc order="28" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:type="arc"/>
    <link:definitionArc order="29" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc"/>
    <link:definitionArc order="30" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc"/>
    <link:definitionArc order="31" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_ProceedsFromIssuanceOrSaleOfEquityNet" xlink:type="arc"/>
    <link:definitionArc order="32" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_EquityOfferingMaximumOfferingAmount" xlink:type="arc"/>
    <link:definitionArc order="33" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_CommissionPercentage" xlink:type="arc"/>
    <link:definitionArc order="34" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_PaymentsForInitialPublicOfferingIssuanceCosts" xlink:type="arc"/>
    <link:definitionArc order="35" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsOfFinancingCosts" xlink:type="arc"/>
    <link:definitionArc order="36" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc"/>
    <link:definitionArc order="37" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc"/>
    <link:definitionArc order="38" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:type="arc"/>
    <link:definitionArc order="39" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdvertisingExpense" xlink:type="arc"/>
    <link:definitionArc order="40" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NumberOfReportableSegments" xlink:type="arc"/>
    <link:definitionArc order="41" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-details-textual" xlink:href="amix-20250630.xsd#statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-details-textual" xlink:type="extended">
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightValueOfSecuritiesCalledByWarrantsOrRights" xlink:label="amix_ClassOfWarrantOrRightValueOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_MeasurementInputProbabilityRateMember" xlink:label="amix_MeasurementInputProbabilityRateMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_NoQualifiedOfferingOccurringMember" xlink:label="amix_NoQualifiedOfferingOccurringMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_QualifiedOfferingOccurringOneMember" xlink:label="amix_QualifiedOfferingOccurringOneMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_QualifiedOfferingOccurringTwoMember" xlink:label="amix_QualifiedOfferingOccurringTwoMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_TerminationAgreementMember" xlink:label="amix_TerminationAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_TheWarrantMember" xlink:label="amix_TheWarrantMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ValuationProbabilityweightedExpectedReturnMethodPWERMMember" xlink:label="amix_ValuationProbabilityweightedExpectedReturnMethodPWERMMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="us-gaap_ValuationTechniqueAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="us-gaap_ValuationTechniqueDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="us-gaap_ValuationTechniqueDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_MeasurementInputTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="amix_MeasurementInputProbabilityRateMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ValuationTechniqueAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationTechniqueDomain" xlink:to="amix_ValuationProbabilityweightedExpectedReturnMethodPWERMMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="amix_QualifiedOfferingOccurringOneMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="amix_QualifiedOfferingOccurringTwoMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="amix_NoQualifiedOfferingOccurringMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="amix_TheWarrantMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="amix_TerminationAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_ClassOfWarrantOrRightValueOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable-details-textual" xlink:href="amix-20250630.xsd#statement-note-3-convertible-notes-payable-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable-details-textual" xlink:type="extended">
    <link:loc xlink:href="amix-20250630.xsd#amix_BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember" xlink:label="amix_BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightLockupAgreementTermOfUnderlyingShares" xlink:label="amix_ClassOfWarrantOrRightLockupAgreementTermOfUnderlyingShares" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightPercentageOfOutstandingStock" xlink:label="amix_ClassOfWarrantOrRightPercentageOfOutstandingStock" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ConversionOfConvertibleNotesToCommonStockMember" xlink:label="amix_ConversionOfConvertibleNotesToCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ConvertibleDebtWith499PercentBeneficialOwnershipLimitationMember" xlink:label="amix_ConvertibleDebtWith499PercentBeneficialOwnershipLimitationMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_DebtInstrumentConvertibleMaximumBeneficialOwnershipPercentage" xlink:label="amix_DebtInstrumentConvertibleMaximumBeneficialOwnershipPercentage" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_TheNotesMember" xlink:label="amix_TheNotesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="us-gaap_ConvertibleNotesPayable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:label="us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember" xlink:label="us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="us-gaap_MeasurementInputDiscountRateMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="amix_TheNotesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="amix_BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="amix_ConvertibleDebtWith499PercentBeneficialOwnershipLimitationMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionNameDomain" xlink:to="amix_ConversionOfConvertibleNotesToCommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_MeasurementInputTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedTermMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_ClassOfWarrantOrRightLockupAgreementTermOfUnderlyingShares" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_ClassOfWarrantOrRightPercentageOfOutstandingStock" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_DebtInstrumentConvertibleMaximumBeneficialOwnershipPercentage" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromConvertibleDebt" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConvertibleNotesPayable" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestExpenseDebt" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-note-4-equity-details-textual" xlink:href="amix-20250630.xsd#statement-note-4-equity-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://autonomix.com/20250630/role/statement-note-4-equity-details-textual" xlink:type="extended">
    <link:loc xlink:href="amix-20250630.xsd#amix_ATMAgreementMember" xlink:label="amix_ATMAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_BlackscholesModelMember" xlink:label="amix_BlackscholesModelMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightExercisedInPeriodCash" xlink:label="amix_ClassOfWarrantOrRightExercisedInPeriodCash" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightExercisedInPeriodCashless" xlink:label="amix_ClassOfWarrantOrRightExercisedInPeriodCashless" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightFairValuePerShare" xlink:label="amix_ClassOfWarrantOrRightFairValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:label="amix_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightLockupPeriod" xlink:label="amix_ClassOfWarrantOrRightLockupPeriod" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantsOrRightsMaximumBeneficialOwnership" xlink:label="amix_ClassOfWarrantsOrRightsMaximumBeneficialOwnership" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_CommissionPercentage" xlink:label="amix_CommissionPercentage" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_CommonStockDiscountForLackOfMarketability" xlink:label="amix_CommonStockDiscountForLackOfMarketability" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_CommonUnitsIssuedPurchasePrice" xlink:label="amix_CommonUnitsIssuedPurchasePrice" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_EquityOfferingMaximumOfferingAmount" xlink:label="amix_EquityOfferingMaximumOfferingAmount" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_EquityOfferingMaximumSharesToBeIssued" xlink:label="amix_EquityOfferingMaximumSharesToBeIssued" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_EquityOfferingOptionMaximumShares" xlink:label="amix_EquityOfferingOptionMaximumShares" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_EquityOfferingOptionMaximumWarrants" xlink:label="amix_EquityOfferingOptionMaximumWarrants" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_EquityOfferingOptionPeriod" xlink:label="amix_EquityOfferingOptionPeriod" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_EquitybasedWarrantsMember" xlink:label="amix_EquitybasedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_MarketingConsultantMember" xlink:label="amix_MarketingConsultantMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_MaximumPercentageOfSharesSoldInThirtyDays" xlink:label="amix_MaximumPercentageOfSharesSoldInThirtyDays" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_NoncashExpensesMember" xlink:label="amix_NoncashExpensesMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_NumberOfCommonUnitsIssued" xlink:label="amix_NumberOfCommonUnitsIssued" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_NumberOfPrefundedUnitsIssued" xlink:label="amix_NumberOfPrefundedUnitsIssued" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_NumberOfSharesPerCommonUnit" xlink:label="amix_NumberOfSharesPerCommonUnit" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_NumberOfWarrantsPerCommonUnit" xlink:label="amix_NumberOfWarrantsPerCommonUnit" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_NumberOfWarrantsPerPrefundedUnit" xlink:label="amix_NumberOfWarrantsPerPrefundedUnit" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_PrefundedUnitsIssuedPurchasePrice" xlink:label="amix_PrefundedUnitsIssuedPurchasePrice" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_PrefundedWarrantsMember" xlink:label="amix_PrefundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_RepresentativesWarrantsMember" xlink:label="amix_RepresentativesWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_RfInnovationsIncMember" xlink:label="amix_RfInnovationsIncMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_SeriesAWarrantsAndTheRepresentativesWarrantsMember" xlink:label="amix_SeriesAWarrantsAndTheRepresentativesWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_SeriesAWarrantsMember" xlink:label="amix_SeriesAWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsDiscountRate" xlink:label="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsDiscountRate" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantDateFairValue" xlink:label="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_The2023StockPlanMember" xlink:label="amix_The2023StockPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_UnderwritersMember" xlink:label="amix_UnderwritersMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_UnderwrittenPublicOfferingMember" xlink:label="amix_UnderwrittenPublicOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="us-gaap_InterimPeriodCostsNotAllocableDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="us-gaap_MeasurementInputDiscountRateMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NatureOfExpenseAxis" xlink:label="us-gaap_NatureOfExpenseAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="us-gaap_ValuationTechniqueAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:label="us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="us-gaap_ValuationTechniqueDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="us-gaap_ValuationTechniqueDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="amix_MarketingConsultantMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="amix_ATMAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="amix_The2023StockPlanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ValuationTechniqueAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationTechniqueDomain" xlink:to="amix_BlackscholesModelMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueDomain-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="amix_RfInnovationsIncMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="amix_UnderwrittenPublicOfferingMember" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="amix_SeriesAWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="amix_PrefundedWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="amix_UnderwritersMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="amix_RepresentativesWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="amix_SeriesAWarrantsAndTheRepresentativesWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_MeasurementInputTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_NatureOfExpenseAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:to="amix_NoncashExpensesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="us-gaap_InterimPeriodCostsNotAllocableDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="amix_EquitybasedWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedTermMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_WarrantMember" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_EquityOfferingMaximumSharesToBeIssued" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_EquityOfferingMaximumOfferingAmount" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:type="arc"/>
    <link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc"/>
    <link:definitionArc order="22" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc"/>
    <link:definitionArc order="23" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantDateFairValue" xlink:type="arc"/>
    <link:definitionArc order="24" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharePrice" xlink:type="arc"/>
    <link:definitionArc order="25" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsDiscountRate" xlink:type="arc"/>
    <link:definitionArc order="26" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc"/>
    <link:definitionArc order="27" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc"/>
    <link:definitionArc order="28" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc"/>
    <link:definitionArc order="29" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc"/>
    <link:definitionArc order="30" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_CommonStockDiscountForLackOfMarketability" xlink:type="arc"/>
    <link:definitionArc order="31" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_MaximumPercentageOfSharesSoldInThirtyDays" xlink:type="arc"/>
    <link:definitionArc order="32" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_NumberOfCommonUnitsIssued" xlink:type="arc"/>
    <link:definitionArc order="33" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_NumberOfSharesPerCommonUnit" xlink:type="arc"/>
    <link:definitionArc order="34" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_NumberOfWarrantsPerCommonUnit" xlink:type="arc"/>
    <link:definitionArc order="35" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="arc"/>
    <link:definitionArc order="36" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_NumberOfPrefundedUnitsIssued" xlink:type="arc"/>
    <link:definitionArc order="37" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_NumberOfWarrantsPerPrefundedUnit" xlink:type="arc"/>
    <link:definitionArc order="38" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_CommonUnitsIssuedPurchasePrice" xlink:type="arc"/>
    <link:definitionArc order="39" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_PrefundedUnitsIssuedPurchasePrice" xlink:type="arc"/>
    <link:definitionArc order="40" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_EquityOfferingOptionPeriod" xlink:type="arc"/>
    <link:definitionArc order="41" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_EquityOfferingOptionMaximumShares" xlink:type="arc"/>
    <link:definitionArc order="42" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_EquityOfferingOptionMaximumWarrants" xlink:type="arc"/>
    <link:definitionArc order="43" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:type="arc"/>
    <link:definitionArc order="44" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc"/>
    <link:definitionArc order="45" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_CommissionPercentage" xlink:type="arc"/>
    <link:definitionArc order="46" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc"/>
    <link:definitionArc order="47" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_ClassOfWarrantsOrRightsMaximumBeneficialOwnership" xlink:type="arc"/>
    <link:definitionArc order="48" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="arc"/>
    <link:definitionArc order="49" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_ClassOfWarrantOrRightLockupPeriod" xlink:type="arc"/>
    <link:definitionArc order="50" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_ClassOfWarrantOrRightFairValuePerShare" xlink:type="arc"/>
    <link:definitionArc order="51" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:type="arc"/>
    <link:definitionArc order="52" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc"/>
    <link:definitionArc order="53" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc"/>
    <link:definitionArc order="54" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_ClassOfWarrantOrRightExercisedInPeriodCashless" xlink:type="arc"/>
    <link:definitionArc order="55" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_ClassOfWarrantOrRightExercisedInPeriodCash" xlink:type="arc"/>
    <link:definitionArc order="56" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-note-5-commitments-and-contingencies-details-textual" xlink:href="amix-20250630.xsd#statement-note-5-commitments-and-contingencies-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://autonomix.com/20250630/role/statement-note-5-commitments-and-contingencies-details-textual" xlink:type="extended">
    <link:loc xlink:href="amix-20250630.xsd#amix_AnnualBaseSalary" xlink:label="amix_AnnualBaseSalary" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_EmploymentAgreementBonusAsAPercentageOfAnnualBaseCompensation" xlink:label="amix_EmploymentAgreementBonusAsAPercentageOfAnnualBaseCompensation" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_EmploymentAgreementTermOfContract" xlink:label="amix_EmploymentAgreementTermOfContract" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ExecutiveViceChairAndStrategicAdvisorToTheChiefExecutiveOfficerMember" xlink:label="amix_ExecutiveViceChairAndStrategicAdvisorToTheChiefExecutiveOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_InducementOptionsMember" xlink:label="amix_InducementOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ScenarioContractTerminationMember" xlink:label="amix_ScenarioContractTerminationMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ScenarioContractTerminationWithoutCauseMember" xlink:label="amix_ScenarioContractTerminationWithoutCauseMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_StockRequiredToBeIssuedForStockSplitShares" xlink:label="amix_StockRequiredToBeIssuedForStockSplitShares" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmploymentContractsMember" xlink:label="us-gaap_EmploymentContractsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LitigationStatusAxis" xlink:label="us-gaap_LitigationStatusAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LitigationStatusDomain" xlink:label="us-gaap_LitigationStatusDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LitigationStatusDomain" xlink:label="us-gaap_LitigationStatusDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyPendingClaimsNumber" xlink:label="us-gaap_LossContingencyPendingClaimsNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PendingLitigationMember" xlink:label="us-gaap_PendingLitigationMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LitigationStatusAxis" xlink:to="us-gaap_LitigationStatusDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LitigationStatusAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LitigationStatusDomain" xlink:to="us-gaap_PendingLitigationMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LitigationStatusAxis" xlink:to="us-gaap_LitigationStatusDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_EmploymentContractsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefExecutiveOfficerMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="amix_InducementOptionsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VestingAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain-default" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="amix_ScenarioContractTerminationMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="amix_ScenarioContractTerminationWithoutCauseMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="amix_ExecutiveViceChairAndStrategicAdvisorToTheChiefExecutiveOfficerMember" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LossContingencyPendingClaimsNumber" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_EmploymentAgreementTermOfContract" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_AnnualBaseSalary" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_EmploymentAgreementBonusAsAPercentageOfAnnualBaseCompensation" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_StockRequiredToBeIssuedForStockSplitShares" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-note-6-related-party-transactions-details-textual" xlink:href="amix-20250630.xsd#statement-note-6-related-party-transactions-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://autonomix.com/20250630/role/statement-note-6-related-party-transactions-details-textual" xlink:type="extended">
    <link:loc xlink:href="amix-20250630.xsd#amix_AccountingAndFinancialReportingServicesMember" xlink:label="amix_AccountingAndFinancialReportingServicesMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightLockupAgreementTermOfUnderlyingShares" xlink:label="amix_ClassOfWarrantOrRightLockupAgreementTermOfUnderlyingShares" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightPercentageOfOutstandingStock" xlink:label="amix_ClassOfWarrantOrRightPercentageOfOutstandingStock" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightValueOfSecuritiesCalledByWarrantsOrRights" xlink:label="amix_ClassOfWarrantOrRightValueOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_CommonStock12MonthsLockupPeriodMember" xlink:label="amix_CommonStock12MonthsLockupPeriodMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_CommonStock6MonthsLockupPeriodMember" xlink:label="amix_CommonStock6MonthsLockupPeriodMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ConsultingFirmOwnedByFormerCFOMember" xlink:label="amix_ConsultingFirmOwnedByFormerCFOMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_InterestHeldInCompanyReceivingWarrants" xlink:label="amix_InterestHeldInCompanyReceivingWarrants" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ManagementBoardOfDirectorFamilyMember" xlink:label="amix_ManagementBoardOfDirectorFamilyMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_TerminationAgreementMember" xlink:label="amix_TerminationAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_TheBridgeOfferingMember" xlink:label="amix_TheBridgeOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_TheWarrantMember" xlink:label="amix_TheWarrantMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ManagementMember" xlink:label="srt_ManagementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnderlyingAssetClassAxis" xlink:label="us-gaap_UnderlyingAssetClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnderlyingAssetClassDomain" xlink:label="us-gaap_UnderlyingAssetClassDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnderlyingAssetClassDomain" xlink:label="us-gaap_UnderlyingAssetClassDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_UnderlyingAssetClassAxis" xlink:to="us-gaap_UnderlyingAssetClassDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="amix_ConsultingFirmOwnedByFormerCFOMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="amix_AccountingAndFinancialReportingServicesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="amix_ManagementBoardOfDirectorFamilyMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="amix_TheBridgeOfferingMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="srt_ManagementMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="amix_TheWarrantMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="amix_TerminationAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_UnderlyingAssetClassAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_UnderlyingAssetClassDomain" xlink:to="amix_CommonStock6MonthsLockupPeriodMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_UnderlyingAssetClassAxis" xlink:to="us-gaap_UnderlyingAssetClassDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_UnderlyingAssetClassDomain" xlink:to="amix_CommonStock12MonthsLockupPeriodMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_ClassOfWarrantOrRightValueOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_ClassOfWarrantOrRightLockupAgreementTermOfUnderlyingShares" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_ClassOfWarrantOrRightPercentageOfOutstandingStock" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_InterestHeldInCompanyReceivingWarrants" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-note-7-income-taxes-details-textual" xlink:href="amix-20250630.xsd#statement-note-7-income-taxes-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://autonomix.com/20250630/role/statement-note-7-income-taxes-details-textual" xlink:type="extended">
    <link:loc xlink:href="amix-20250630.xsd#amix_ExpirationCommencingTaxYear20342037Member" xlink:label="amix_ExpirationCommencingTaxYear20342037Member" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_NolGeneratedDuring20172024Member" xlink:label="amix_NolGeneratedDuring20172024Member" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ReserveForUncertainTaxPositions" xlink:label="amix_ReserveForUncertainTaxPositions" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TaxPeriodAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="amix_ExpirationCommencingTaxYear20342037Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="amix_NolGeneratedDuring20172024Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_ReserveForUncertainTaxPositions" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-note-8-subsequent-events-details-textual" xlink:href="amix-20250630.xsd#statement-note-8-subsequent-events-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://autonomix.com/20250630/role/statement-note-8-subsequent-events-details-textual" xlink:type="extended">
    <link:loc xlink:href="amix-20250630.xsd#amix_ATMAgreementMember" xlink:label="amix_ATMAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="amix_ATMAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_GranteeStatusAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VestingAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q-details-textual" xlink:href="amix-20250630.xsd#statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q-details-textual" xlink:type="extended">
    <link:loc xlink:href="amix-20250630.xsd#amix_ATMAgreementMember" xlink:label="amix_ATMAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:label="amix_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantsOrRightsMaximumBeneficialOwnership" xlink:label="amix_ClassOfWarrantsOrRightsMaximumBeneficialOwnership" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_CommonUnitsIssuedPurchasePrice" xlink:label="amix_CommonUnitsIssuedPurchasePrice" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_EquityOfferingMaximumOfferingAmount" xlink:label="amix_EquityOfferingMaximumOfferingAmount" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_EquityOfferingOptionMaximumShares" xlink:label="amix_EquityOfferingOptionMaximumShares" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_EquityOfferingOptionMaximumWarrants" xlink:label="amix_EquityOfferingOptionMaximumWarrants" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_EquityOfferingOptionPeriod" xlink:label="amix_EquityOfferingOptionPeriod" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_EquitybasedWarrantsMember" xlink:label="amix_EquitybasedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_NoncashExpensesMember" xlink:label="amix_NoncashExpensesMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_NumberOfCommonUnitsIssued" xlink:label="amix_NumberOfCommonUnitsIssued" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_NumberOfPrefundedUnitsIssued" xlink:label="amix_NumberOfPrefundedUnitsIssued" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_NumberOfSharesPerCommonUnit" xlink:label="amix_NumberOfSharesPerCommonUnit" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_NumberOfWarrantsPerCommonUnit" xlink:label="amix_NumberOfWarrantsPerCommonUnit" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_NumberOfWarrantsPerPrefundedUnit" xlink:label="amix_NumberOfWarrantsPerPrefundedUnit" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_PrefundedAndSeriesAWarrantsMember" xlink:label="amix_PrefundedAndSeriesAWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_PrefundedUnitsIssuedPurchasePrice" xlink:label="amix_PrefundedUnitsIssuedPurchasePrice" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_PrefundedWarrantsMember" xlink:label="amix_PrefundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ProceedsFromIssuanceOrSaleOfEquityNet" xlink:label="amix_ProceedsFromIssuanceOrSaleOfEquityNet" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ReverseStockSplitMember" xlink:label="amix_ReverseStockSplitMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_SeriesAWarrantsMember" xlink:label="amix_SeriesAWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_UnderwritersMember" xlink:label="amix_UnderwritersMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_UnderwrittenPublicOfferingMember" xlink:label="amix_UnderwrittenPublicOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_WorkingCapitalDeficit" xlink:label="amix_WorkingCapitalDeficit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdvertisingExpense" xlink:label="us-gaap_AdvertisingExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="us-gaap_InterimPeriodCostsNotAllocableDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NatureOfExpenseAxis" xlink:label="us-gaap_NatureOfExpenseAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonmonetaryTransactionTypeAxis" xlink:label="us-gaap_NonmonetaryTransactionTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonmonetaryTransactionTypeDomain" xlink:label="us-gaap_NonmonetaryTransactionTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonmonetaryTransactionTypeDomain" xlink:label="us-gaap_NonmonetaryTransactionTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_NonmonetaryTransactionTypeAxis" xlink:to="us-gaap_NonmonetaryTransactionTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_NonmonetaryTransactionTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonmonetaryTransactionTypeDomain" xlink:to="amix_ReverseStockSplitMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_NonmonetaryTransactionTypeAxis" xlink:to="us-gaap_NonmonetaryTransactionTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="amix_ATMAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="amix_UnderwrittenPublicOfferingMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="amix_SeriesAWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="amix_PrefundedWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="amix_UnderwritersMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="amix_PrefundedAndSeriesAWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_NatureOfExpenseAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:to="amix_NoncashExpensesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="us-gaap_InterimPeriodCostsNotAllocableDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="amix_EquitybasedWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_EquityOfferingMaximumOfferingAmount" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_NumberOfCommonUnitsIssued" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_NumberOfSharesPerCommonUnit" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_NumberOfWarrantsPerCommonUnit" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_NumberOfPrefundedUnitsIssued" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_NumberOfWarrantsPerPrefundedUnit" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_CommonUnitsIssuedPurchasePrice" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_PrefundedUnitsIssuedPurchasePrice" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_EquityOfferingOptionPeriod" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_EquityOfferingOptionMaximumShares" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_EquityOfferingOptionMaximumWarrants" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc"/>
    <link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="arc"/>
    <link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_ClassOfWarrantsOrRightsMaximumBeneficialOwnership" xlink:type="arc"/>
    <link:definitionArc order="22" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:type="arc"/>
    <link:definitionArc order="23" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc"/>
    <link:definitionArc order="24" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc"/>
    <link:definitionArc order="25" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_ProceedsFromIssuanceOrSaleOfEquityNet" xlink:type="arc"/>
    <link:definitionArc order="26" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="27" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc"/>
    <link:definitionArc order="28" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Revenues" xlink:type="arc"/>
    <link:definitionArc order="29" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:definitionArc order="30" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_WorkingCapitalDeficit" xlink:type="arc"/>
    <link:definitionArc order="31" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Cash" xlink:type="arc"/>
    <link:definitionArc order="32" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc"/>
    <link:definitionArc order="33" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:type="arc"/>
    <link:definitionArc order="34" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdvertisingExpense" xlink:type="arc"/>
    <link:definitionArc order="35" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NumberOfReportableSegments" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-note-2-convertible-notes-payable-10q-details-textual" xlink:href="amix-20250630.xsd#statement-note-2-convertible-notes-payable-10q-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://autonomix.com/20250630/role/statement-note-2-convertible-notes-payable-10q-details-textual" xlink:type="extended">
    <link:loc xlink:href="amix-20250630.xsd#amix_BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember" xlink:label="amix_BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ConversionOfConvertibleNotesToCommonStockMember" xlink:label="amix_ConversionOfConvertibleNotesToCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ConvertibleDebtWith499PercentBeneficialOwnershipLimitationMember" xlink:label="amix_ConvertibleDebtWith499PercentBeneficialOwnershipLimitationMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_DebtInstrumentConvertibleMaximumBeneficialOwnershipPercentage" xlink:label="amix_DebtInstrumentConvertibleMaximumBeneficialOwnershipPercentage" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_TheNotesMember" xlink:label="amix_TheNotesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:label="us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember" xlink:label="us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="us-gaap_MeasurementInputDiscountRateMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="amix_TheNotesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="amix_BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="amix_ConvertibleDebtWith499PercentBeneficialOwnershipLimitationMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionNameDomain" xlink:to="amix_ConversionOfConvertibleNotesToCommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_MeasurementInputTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedTermMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_DebtInstrumentConvertibleMaximumBeneficialOwnershipPercentage" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromConvertibleDebt" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestExpenseDebt" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-note-3-equity-10q-details-textual" xlink:href="amix-20250630.xsd#statement-note-3-equity-10q-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://autonomix.com/20250630/role/statement-note-3-equity-10q-details-textual" xlink:type="extended">
    <link:loc xlink:href="amix-20250630.xsd#amix_ATMAgreementMember" xlink:label="amix_ATMAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_BlackscholesModelMember" xlink:label="amix_BlackscholesModelMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightFairValuePerShare" xlink:label="amix_ClassOfWarrantOrRightFairValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:label="amix_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightLockupPeriod" xlink:label="amix_ClassOfWarrantOrRightLockupPeriod" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantsOrRightsMaximumBeneficialOwnership" xlink:label="amix_ClassOfWarrantsOrRightsMaximumBeneficialOwnership" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_CommissionPercentage" xlink:label="amix_CommissionPercentage" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_CommonStockDiscountForLackOfMarketability" xlink:label="amix_CommonStockDiscountForLackOfMarketability" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_CommonUnitsIssuedPurchasePrice" xlink:label="amix_CommonUnitsIssuedPurchasePrice" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_CommonWarrantsMember" xlink:label="amix_CommonWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_EquityOfferingMaximumOfferingAmount" xlink:label="amix_EquityOfferingMaximumOfferingAmount" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_EquityOfferingOptionMaximumShares" xlink:label="amix_EquityOfferingOptionMaximumShares" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_EquityOfferingOptionMaximumWarrants" xlink:label="amix_EquityOfferingOptionMaximumWarrants" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_EquityOfferingOptionPeriod" xlink:label="amix_EquityOfferingOptionPeriod" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_MarketingConsultantMember" xlink:label="amix_MarketingConsultantMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_MaximumPercentageOfSharesSoldInThirtyDays" xlink:label="amix_MaximumPercentageOfSharesSoldInThirtyDays" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_NoncashExpensesMember" xlink:label="amix_NoncashExpensesMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_NumberOfCommonUnitsIssued" xlink:label="amix_NumberOfCommonUnitsIssued" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_NumberOfPrefundedUnitsIssued" xlink:label="amix_NumberOfPrefundedUnitsIssued" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_NumberOfSharesPerCommonUnit" xlink:label="amix_NumberOfSharesPerCommonUnit" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_NumberOfWarrantsPerCommonUnit" xlink:label="amix_NumberOfWarrantsPerCommonUnit" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_NumberOfWarrantsPerPrefundedUnit" xlink:label="amix_NumberOfWarrantsPerPrefundedUnit" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_PrefundedUnitsIssuedPurchasePrice" xlink:label="amix_PrefundedUnitsIssuedPurchasePrice" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_PrefundedWarrantsMember" xlink:label="amix_PrefundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_RepresentativesWarrantsMember" xlink:label="amix_RepresentativesWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_RfInnovationsIncMember" xlink:label="amix_RfInnovationsIncMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_SeriesAWarrantsAndTheRepresentativesWarrantsMember" xlink:label="amix_SeriesAWarrantsAndTheRepresentativesWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_SeriesAWarrantsMember" xlink:label="amix_SeriesAWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsDiscountRate" xlink:label="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsDiscountRate" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantDateFairValue" xlink:label="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_The2023StockPlanMember" xlink:label="amix_The2023StockPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_UnderwritersMember" xlink:label="amix_UnderwritersMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_UnderwrittenPublicOfferingMember" xlink:label="amix_UnderwrittenPublicOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="us-gaap_InterimPeriodCostsNotAllocableDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="us-gaap_MeasurementInputDiscountRateMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NatureOfExpenseAxis" xlink:label="us-gaap_NatureOfExpenseAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="us-gaap_ValuationTechniqueAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="us-gaap_ValuationTechniqueDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="us-gaap_ValuationTechniqueDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="amix_MarketingConsultantMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="amix_ATMAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="amix_The2023StockPlanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ValuationTechniqueAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationTechniqueDomain" xlink:to="amix_BlackscholesModelMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueDomain-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="amix_RfInnovationsIncMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="amix_UnderwrittenPublicOfferingMember" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="amix_SeriesAWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="amix_PrefundedWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="amix_UnderwritersMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="amix_RepresentativesWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="amix_SeriesAWarrantsAndTheRepresentativesWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_MeasurementInputTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_NatureOfExpenseAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:to="amix_NoncashExpensesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="us-gaap_InterimPeriodCostsNotAllocableDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="amix_CommonWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_WarrantMember" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_EquityOfferingMaximumOfferingAmount" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantDateFairValue" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsDiscountRate" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc"/>
    <link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc"/>
    <link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc"/>
    <link:definitionArc order="22" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc"/>
    <link:definitionArc order="23" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc"/>
    <link:definitionArc order="24" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_CommonStockDiscountForLackOfMarketability" xlink:type="arc"/>
    <link:definitionArc order="25" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_MaximumPercentageOfSharesSoldInThirtyDays" xlink:type="arc"/>
    <link:definitionArc order="26" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_NumberOfCommonUnitsIssued" xlink:type="arc"/>
    <link:definitionArc order="27" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_NumberOfSharesPerCommonUnit" xlink:type="arc"/>
    <link:definitionArc order="28" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_NumberOfWarrantsPerCommonUnit" xlink:type="arc"/>
    <link:definitionArc order="29" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="arc"/>
    <link:definitionArc order="30" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_NumberOfPrefundedUnitsIssued" xlink:type="arc"/>
    <link:definitionArc order="31" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_NumberOfWarrantsPerPrefundedUnit" xlink:type="arc"/>
    <link:definitionArc order="32" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_CommonUnitsIssuedPurchasePrice" xlink:type="arc"/>
    <link:definitionArc order="33" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_PrefundedUnitsIssuedPurchasePrice" xlink:type="arc"/>
    <link:definitionArc order="34" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_EquityOfferingOptionPeriod" xlink:type="arc"/>
    <link:definitionArc order="35" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_EquityOfferingOptionMaximumShares" xlink:type="arc"/>
    <link:definitionArc order="36" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_EquityOfferingOptionMaximumWarrants" xlink:type="arc"/>
    <link:definitionArc order="37" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:type="arc"/>
    <link:definitionArc order="38" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc"/>
    <link:definitionArc order="39" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_CommissionPercentage" xlink:type="arc"/>
    <link:definitionArc order="40" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc"/>
    <link:definitionArc order="41" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_ClassOfWarrantsOrRightsMaximumBeneficialOwnership" xlink:type="arc"/>
    <link:definitionArc order="42" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="arc"/>
    <link:definitionArc order="43" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_ClassOfWarrantOrRightLockupPeriod" xlink:type="arc"/>
    <link:definitionArc order="44" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_ClassOfWarrantOrRightFairValuePerShare" xlink:type="arc"/>
    <link:definitionArc order="45" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:type="arc"/>
    <link:definitionArc order="46" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc"/>
    <link:definitionArc order="47" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc"/>
    <link:definitionArc order="48" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc"/>
    <link:definitionArc order="49" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc"/>
    <link:definitionArc order="50" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-note-4-commitments-and-contingencies-10q-details-textual" xlink:href="amix-20250630.xsd#statement-note-4-commitments-and-contingencies-10q-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://autonomix.com/20250630/role/statement-note-4-commitments-and-contingencies-10q-details-textual" xlink:type="extended">
    <link:loc xlink:href="amix-20250630.xsd#amix_StockRequiredToBeIssuedForStockSplitShares" xlink:label="amix_StockRequiredToBeIssuedForStockSplitShares" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmploymentContractsMember" xlink:label="us-gaap_EmploymentContractsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LitigationStatusAxis" xlink:label="us-gaap_LitigationStatusAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LitigationStatusDomain" xlink:label="us-gaap_LitigationStatusDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LitigationStatusDomain" xlink:label="us-gaap_LitigationStatusDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyPendingClaimsNumber" xlink:label="us-gaap_LossContingencyPendingClaimsNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PendingLitigationMember" xlink:label="us-gaap_PendingLitigationMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LitigationStatusAxis" xlink:to="us-gaap_LitigationStatusDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LitigationStatusAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LitigationStatusDomain" xlink:to="us-gaap_PendingLitigationMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LitigationStatusAxis" xlink:to="us-gaap_LitigationStatusDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_EmploymentContractsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LossContingencyPendingClaimsNumber" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_StockRequiredToBeIssuedForStockSplitShares" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-note-5-related-party-transactions-10q-details-textual" xlink:href="amix-20250630.xsd#statement-note-5-related-party-transactions-10q-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://autonomix.com/20250630/role/statement-note-5-related-party-transactions-10q-details-textual" xlink:type="extended">
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightLockupAgreementTermOfUnderlyingShares" xlink:label="amix_ClassOfWarrantOrRightLockupAgreementTermOfUnderlyingShares" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightPercentageOfOutstandingStock" xlink:label="amix_ClassOfWarrantOrRightPercentageOfOutstandingStock" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightValueOfSecuritiesCalledByWarrantsOrRights" xlink:label="amix_ClassOfWarrantOrRightValueOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_CommonStock12MonthsLockupPeriodMember" xlink:label="amix_CommonStock12MonthsLockupPeriodMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_CommonStock6MonthsLockupPeriodMember" xlink:label="amix_CommonStock6MonthsLockupPeriodMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_TerminationAgreementMember" xlink:label="amix_TerminationAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_TheWarrantMember" xlink:label="amix_TheWarrantMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnderlyingAssetClassAxis" xlink:label="us-gaap_UnderlyingAssetClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnderlyingAssetClassDomain" xlink:label="us-gaap_UnderlyingAssetClassDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnderlyingAssetClassDomain" xlink:label="us-gaap_UnderlyingAssetClassDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_UnderlyingAssetClassAxis" xlink:to="us-gaap_UnderlyingAssetClassDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="amix_TheWarrantMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="amix_TerminationAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_UnderlyingAssetClassAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_UnderlyingAssetClassDomain" xlink:to="amix_CommonStock6MonthsLockupPeriodMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_UnderlyingAssetClassAxis" xlink:to="us-gaap_UnderlyingAssetClassDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_UnderlyingAssetClassDomain" xlink:to="amix_CommonStock12MonthsLockupPeriodMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_ClassOfWarrantOrRightValueOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_ClassOfWarrantOrRightLockupAgreementTermOfUnderlyingShares" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_ClassOfWarrantOrRightPercentageOfOutstandingStock" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-note-6-subsequent-events-10q-details-textual" xlink:href="amix-20250630.xsd#statement-note-6-subsequent-events-10q-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://autonomix.com/20250630/role/statement-note-6-subsequent-events-10q-details-textual" xlink:type="extended">
    <link:loc xlink:href="amix-20250630.xsd#amix_ChiefMedicalOfficerMember" xlink:label="amix_ChiefMedicalOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ChiefTechnologyOfficerMember" xlink:label="amix_ChiefTechnologyOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightExchangesPercentageOfUnderlyingShares" xlink:label="amix_ClassOfWarrantOrRightExchangesPercentageOfUnderlyingShares" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightExercisesInPeriod" xlink:label="amix_ClassOfWarrantOrRightExercisesInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ExecutiveChairOfTheBoardMember" xlink:label="amix_ExecutiveChairOfTheBoardMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ExistingWarrantsAt1722ExercisePriceMember" xlink:label="amix_ExistingWarrantsAt1722ExercisePriceMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ExistingWarrantsAt1723ExercisePriceMember" xlink:label="amix_ExistingWarrantsAt1723ExercisePriceMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ExistingWarrantsMember" xlink:label="amix_ExistingWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_PaymentsForWarrantIssuanceFees" xlink:label="amix_PaymentsForWarrantIssuanceFees" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_PreipoWarrantsMember" xlink:label="amix_PreipoWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_RepresentativesWarrantsMember" xlink:label="amix_RepresentativesWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_SeriesAWarrantsMember" xlink:label="amix_SeriesAWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_SeriesBWarrantsMember" xlink:label="amix_SeriesBWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_BoardOfDirectorsChairmanMember" xlink:label="srt_BoardOfDirectorsChairmanMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ChiefFinancialOfficerMember" xlink:label="srt_ChiefFinancialOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="amix_ExistingWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="amix_ExistingWarrantsAt1723ExercisePriceMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="amix_ExistingWarrantsAt1722ExercisePriceMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="amix_SeriesBWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="amix_RepresentativesWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="amix_SeriesAWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="amix_PreipoWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_BoardOfDirectorsChairmanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="amix_ExecutiveChairOfTheBoardMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_DirectorMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefExecutiveOfficerMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="amix_ChiefTechnologyOfficerMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="amix_ChiefMedicalOfficerMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefFinancialOfficerMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_ClassOfWarrantOrRightExercisesInPeriod" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_ClassOfWarrantOrRightExchangesPercentageOfUnderlyingShares" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_PaymentsForWarrantIssuanceFees" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-fair-value-measurement-inputs-and-valuation-techniques-details" xlink:href="amix-20250630.xsd#statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-fair-value-measurement-inputs-and-valuation-techniques-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-fair-value-measurement-inputs-and-valuation-techniques-details" xlink:type="extended">
    <link:loc xlink:href="amix-20250630.xsd#amix_MeasurementInputFixedPriceMember" xlink:label="amix_MeasurementInputFixedPriceMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_MeasurementInputProbabilityRateMember" xlink:label="amix_MeasurementInputProbabilityRateMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_NoQualifiedOfferingOccurringMember" xlink:label="amix_NoQualifiedOfferingOccurringMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_QualifiedOfferingOccurringOneMember" xlink:label="amix_QualifiedOfferingOccurringOneMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_QualifiedOfferingOccurringTwoMember" xlink:label="amix_QualifiedOfferingOccurringTwoMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ValuationProbabilityweightedExpectedReturnMethodPWERMMember" xlink:label="amix_ValuationProbabilityweightedExpectedReturnMethodPWERMMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="us-gaap_MeasurementInputDiscountRateMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PercentageOfFIFOInventory" xlink:label="us-gaap_PercentageOfFIFOInventory" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="us-gaap_ValuationTechniqueAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="us-gaap_ValuationTechniqueDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="us-gaap_ValuationTechniqueDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_MeasurementInputTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="amix_MeasurementInputProbabilityRateMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ValuationTechniqueAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationTechniqueDomain" xlink:to="amix_ValuationProbabilityweightedExpectedReturnMethodPWERMMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="amix_QualifiedOfferingOccurringOneMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="amix_QualifiedOfferingOccurringTwoMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="amix_NoQualifiedOfferingOccurringMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="amix_MeasurementInputFixedPriceMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedTermMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PercentageOfFIFOInventory" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-note-7-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" xlink:href="amix-20250630.xsd#statement-note-7-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://autonomix.com/20250630/role/statement-note-7-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="amix-20250630.xsd#amix_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" xlink:label="amix_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_DeferredTaxLiabilitiesChangeInAccountingMethod" xlink:label="amix_DeferredTaxLiabilitiesChangeInAccountingMethod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:to="amix_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="amix_DeferredTaxLiabilitiesChangeInAccountingMethod" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilities" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-schedule-of-fair-value-measurements-details" xlink:href="amix-20250630.xsd#statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-schedule-of-fair-value-measurements-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-schedule-of-fair-value-measurements-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="us-gaap_WarrantMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable-schedule-of-convertible-notes-payable-details" xlink:href="amix-20250630.xsd#statement-note-3-convertible-notes-payable-schedule-of-convertible-notes-payable-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable-schedule-of-convertible-notes-payable-details" xlink:type="extended">
    <link:loc xlink:href="amix-20250630.xsd#amix_DebtConversionDebtIssuanceCostsConvertedCommonShares" xlink:label="amix_DebtConversionDebtIssuanceCostsConvertedCommonShares" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_IssuanceOfCommonStockForExtinguishmentOfConvertibleDebtMember" xlink:label="amix_IssuanceOfCommonStockForExtinguishmentOfConvertibleDebtMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_TheNotesMember" xlink:label="amix_TheNotesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebtMember" xlink:label="us-gaap_ConvertibleDebtMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="us-gaap_ConvertibleLongTermNotesPayable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="amix_TheNotesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LongtermDebtTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_ConvertibleDebtMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionNameDomain" xlink:to="amix_IssuanceOfCommonStockForExtinguishmentOfConvertibleDebtMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConvertibleLongTermNotesPayable" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_DebtConversionDebtIssuanceCostsConvertedCommonShares" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable-schedule-of-detachable-warrants-details" xlink:href="amix-20250630.xsd#statement-note-3-convertible-notes-payable-schedule-of-detachable-warrants-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable-schedule-of-detachable-warrants-details" xlink:type="extended">
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightAggregateIntrinsicValueExercisable" xlink:label="amix_ClassOfWarrantOrRightAggregateIntrinsicValueExercisable" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightAggregateIntrinsicValueOutstanding" xlink:label="amix_ClassOfWarrantOrRightAggregateIntrinsicValueOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightExercisableNumber" xlink:label="amix_ClassOfWarrantOrRightExercisableNumber" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice" xlink:label="amix_ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightExercisableWeightedAverageRemainingContractualTerm" xlink:label="amix_ClassOfWarrantOrRightExercisableWeightedAverageRemainingContractualTerm" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightExercisesInPeriod" xlink:label="amix_ClassOfWarrantOrRightExercisesInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightExercisesInPeriodWeightedAverageExercisePrice" xlink:label="amix_ClassOfWarrantOrRightExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightExpirationsInPeriod" xlink:label="amix_ClassOfWarrantOrRightExpirationsInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="amix_ClassOfWarrantOrRightExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightForfeituresInPeriod" xlink:label="amix_ClassOfWarrantOrRightForfeituresInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="amix_ClassOfWarrantOrRightForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightGrantsInPeriod" xlink:label="amix_ClassOfWarrantOrRightGrantsInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightGrantsInPeriodWeightedAverageExercise" xlink:label="amix_ClassOfWarrantOrRightGrantsInPeriodWeightedAverageExercise" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightOutstandingOutstandingWeightedAverageExercisePrice" xlink:label="amix_ClassOfWarrantOrRightOutstandingOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm" xlink:label="amix_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_ClassOfWarrantOrRightOutstandingOutstandingWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_ClassOfWarrantOrRightAggregateIntrinsicValueOutstanding" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_ClassOfWarrantOrRightGrantsInPeriod" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_ClassOfWarrantOrRightGrantsInPeriodWeightedAverageExercise" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_ClassOfWarrantOrRightExercisesInPeriod" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_ClassOfWarrantOrRightExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_ClassOfWarrantOrRightForfeituresInPeriod" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_ClassOfWarrantOrRightForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_ClassOfWarrantOrRightExpirationsInPeriod" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_ClassOfWarrantOrRightExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_ClassOfWarrantOrRightExercisableNumber" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_ClassOfWarrantOrRightExercisableWeightedAverageRemainingContractualTerm" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_ClassOfWarrantOrRightAggregateIntrinsicValueExercisable" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-note-4-equity-general-and-administrative-expense-details" xlink:href="amix-20250630.xsd#statement-note-4-equity-general-and-administrative-expense-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://autonomix.com/20250630/role/statement-note-4-equity-general-and-administrative-expense-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-note-4-equity-restricted-stock-activity-details" xlink:href="amix-20250630.xsd#statement-note-4-equity-restricted-stock-activity-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://autonomix.com/20250630/role/statement-note-4-equity-restricted-stock-activity-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-note-4-equity-schedule-of-stock-option-activity-details" xlink:href="amix-20250630.xsd#statement-note-4-equity-schedule-of-stock-option-activity-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://autonomix.com/20250630/role/statement-note-4-equity-schedule-of-stock-option-activity-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-note-4-equity-schedule-of-equitybased-stock-warrants-details" xlink:href="amix-20250630.xsd#statement-note-4-equity-schedule-of-equitybased-stock-warrants-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://autonomix.com/20250630/role/statement-note-4-equity-schedule-of-equitybased-stock-warrants-details" xlink:type="extended">
    <link:loc xlink:href="amix-20250630.xsd#amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice" xlink:label="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerm" xlink:label="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerm" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:label="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_SharebasedCompensationArrangementBySharebasedPaymentAwardNonoptionEquityInstrumentsExercisableNumberOutstandingNumber" xlink:label="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardNonoptionEquityInstrumentsExercisableNumberOutstandingNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardNonoptionEquityInstrumentsExercisableNumberOutstandingNumber" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerm" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-note-3-equity-general-and-administrative-expense-10q-details" xlink:href="amix-20250630.xsd#statement-note-3-equity-general-and-administrative-expense-10q-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://autonomix.com/20250630/role/statement-note-3-equity-general-and-administrative-expense-10q-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-note-4-equity-blackscholes-option-pricing-model-details" xlink:href="amix-20250630.xsd#statement-note-4-equity-blackscholes-option-pricing-model-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://autonomix.com/20250630/role/statement-note-4-equity-blackscholes-option-pricing-model-details" xlink:type="extended">
    <link:loc xlink:href="amix-20250630.xsd#amix_BlackscholesModelMember" xlink:label="amix_BlackscholesModelMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsDiscountRate" xlink:label="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsDiscountRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="us-gaap_ValuationTechniqueAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="us-gaap_ValuationTechniqueDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="us-gaap_ValuationTechniqueDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ValuationTechniqueAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationTechniqueDomain" xlink:to="amix_BlackscholesModelMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_WarrantMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharePrice" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsDiscountRate" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-statements-of-cash-flows" xlink:href="amix-20250630.xsd#statement-statements-of-cash-flows" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://autonomix.com/20250630/role/statement-statements-of-cash-flows" xlink:type="extended">
    <link:loc xlink:href="amix-20250630.xsd#amix_ATMAgreementMember" xlink:label="amix_ATMAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightFairValueIssuedForIssuanceCostsFromIpo" xlink:label="amix_ClassOfWarrantOrRightFairValueIssuedForIssuanceCostsFromIpo" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_DebtConversionDebtIssuanceCostsConvertedCommonShares" xlink:label="amix_DebtConversionDebtIssuanceCostsConvertedCommonShares" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_IpoProceedsHoldbackProvision" xlink:label="amix_IpoProceedsHoldbackProvision" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_IssuanceOfCommonStockForExtinguishmentOfConvertibleDebtMember" xlink:label="amix_IssuanceOfCommonStockForExtinguishmentOfConvertibleDebtMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_PaymentsForInitialPublicOfferingIssuanceCosts" xlink:label="amix_PaymentsForInitialPublicOfferingIssuanceCosts" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:label="amix_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_WarrantsIssuedForDebtIssuanceCosts" xlink:label="amix_WarrantsIssuedForDebtIssuanceCosts" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_WarrantsIssuedForEquityCosts" xlink:label="amix_WarrantsIssuedForEquityCosts" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssued1" xlink:label="us-gaap_StockIssued1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="amix_ATMAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionNameDomain" xlink:to="amix_IssuanceOfCommonStockForExtinguishmentOfConvertibleDebtMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="amix_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfFinancingCosts" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromWarrantExercises" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromConvertibleDebt" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="amix_PaymentsForInitialPublicOfferingIssuanceCosts" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="amix_WarrantsIssuedForEquityCosts" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_StockIssued1" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="amix_WarrantsIssuedForDebtIssuanceCosts" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="amix_ClassOfWarrantOrRightFairValueIssuedForIssuanceCostsFromIpo" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="amix_IpoProceedsHoldbackProvision" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="amix_DebtConversionDebtIssuanceCostsConvertedCommonShares" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-condensed-statements-of-cash-flows-unaudited" xlink:href="amix-20250630.xsd#statement-condensed-statements-of-cash-flows-unaudited" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://autonomix.com/20250630/role/statement-condensed-statements-of-cash-flows-unaudited" xlink:type="extended">
    <link:loc xlink:href="amix-20250630.xsd#amix_DeferredFinancingCostsRelatedToTheIssuanceOfCommonStock" xlink:label="amix_DeferredFinancingCostsRelatedToTheIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssued1" xlink:label="us-gaap_StockIssued1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="amix_DeferredFinancingCostsRelatedToTheIssuanceOfCommonStock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_StockIssued1" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-prior-period-corrections-details" xlink:href="amix-20250630.xsd#statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-prior-period-corrections-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-prior-period-corrections-details" xlink:type="extended">
    <link:loc xlink:href="amix-20250630.xsd#amix_ConvertibleNotesToWarrantsMember" xlink:label="amix_ConvertibleNotesToWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ReverseStockSplitAdjustmentMember" xlink:label="amix_ReverseStockSplitAdjustmentMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" xlink:label="srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="srt_ScenarioPreviouslyReportedMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RestatementAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RestatementDomain" xlink:to="srt_ScenarioPreviouslyReportedMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RestatementDomain" xlink:to="amix_ReverseStockSplitAdjustmentMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RestatementDomain" xlink:to="srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_ConvertibleDebtSecuritiesMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="amix_ConvertibleNotesToWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-note-7-income-taxes-schedule-of-reconciliation-details" xlink:href="amix-20250630.xsd#statement-note-7-income-taxes-schedule-of-reconciliation-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://autonomix.com/20250630/role/statement-note-7-income-taxes-schedule-of-reconciliation-details" xlink:type="extended">
    <link:loc xlink:href="amix-20250630.xsd#amix_EffectiveIncomeTaxRateReconciliationChangeInStateRateAmount" xlink:label="amix_EffectiveIncomeTaxRateReconciliationChangeInStateRateAmount" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_EffectiveIncomeTaxRateReconciliationChangeInStateRatePercent" xlink:label="amix_EffectiveIncomeTaxRateReconciliationChangeInStateRatePercent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_EffectiveIncomeTaxRateReconciliationChangeInStateRateAmount" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_EffectiveIncomeTaxRateReconciliationChangeInStateRatePercent" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-schedule-of-prior-period-corrections-10q-details" xlink:href="amix-20250630.xsd#statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-schedule-of-prior-period-corrections-10q-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-schedule-of-prior-period-corrections-10q-details" xlink:type="extended">
    <link:loc xlink:href="amix-20250630.xsd#amix_ConvertibleNotesToWarrantsMember" xlink:label="amix_ConvertibleNotesToWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ReverseStockSplitAdjustmentMember" xlink:label="amix_ReverseStockSplitAdjustmentMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" xlink:label="srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="srt_ScenarioPreviouslyReportedMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RestatementAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RestatementDomain" xlink:to="srt_ScenarioPreviouslyReportedMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RestatementDomain" xlink:to="amix_ReverseStockSplitAdjustmentMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RestatementDomain" xlink:to="srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_ConvertibleDebtSecuritiesMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="amix_ConvertibleNotesToWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-statements-of-operations" xlink:href="amix-20250630.xsd#statement-statements-of-operations" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://autonomix.com/20250630/role/statement-statements-of-operations" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="us-gaap_InterestExpenseNonoperating" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingCostsAndExpensesAbstract" xlink:label="us-gaap_OperatingCostsAndExpensesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingCostsAndExpensesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestExpenseNonoperating" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_EarningsPerShareBasic" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-condensed-statements-of-operations-unaudited" xlink:href="amix-20250630.xsd#statement-condensed-statements-of-operations-unaudited" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://autonomix.com/20250630/role/statement-condensed-statements-of-operations-unaudited" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="us-gaap_InterestExpenseNonoperating" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingCostsAndExpensesAbstract" xlink:label="us-gaap_OperatingCostsAndExpensesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingCostsAndExpensesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestExpenseNonoperating" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_EarningsPerShareBasic" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-statements-of-changes-in-stockholders-equity" xlink:href="amix-20250630.xsd#statement-statements-of-changes-in-stockholders-equity" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://autonomix.com/20250630/role/statement-statements-of-changes-in-stockholders-equity" xlink:type="extended">
    <link:loc xlink:href="amix-20250630.xsd#amix_StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants" xlink:label="amix_StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants" xlink:label="amix_StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_StockIssuedDuringPeriodSharesInitialPublicOffering" xlink:label="amix_StockIssuedDuringPeriodSharesInitialPublicOffering" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="amix_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_StockIssuedDuringPeriodValueInitialPublicOffering" xlink:label="amix_StockIssuedDuringPeriodValueInitialPublicOffering" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="amix_StockIssuedDuringPeriodValueWarrantsExercised" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_WarrantsIssuedFairValueIssuedForTerminationAgreement" xlink:label="amix_WarrantsIssuedFairValueIssuedForTerminationAgreement" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_StockIssuedDuringPeriodSharesInitialPublicOffering" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_StockIssuedDuringPeriodValueInitialPublicOffering" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_StockIssuedDuringPeriodValueWarrantsExercised" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_WarrantsIssuedFairValueIssuedForTerminationAgreement" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-condensed-statements-of-changes-in-stockholders-equity-unaudited" xlink:href="amix-20250630.xsd#statement-condensed-statements-of-changes-in-stockholders-equity-unaudited" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://autonomix.com/20250630/role/statement-condensed-statements-of-changes-in-stockholders-equity-unaudited" xlink:type="extended">
    <link:loc xlink:href="amix-20250630.xsd#amix_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="amix_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="amix_StockIssuedDuringPeriodValueWarrantsExercised" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_StockIssuedDuringPeriodValueWarrantsExercised" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-antidilutive-securities-details" xlink:href="amix-20250630.xsd#statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-antidilutive-securities-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-antidilutive-securities-details" xlink:type="extended">
    <link:loc xlink:href="amix-20250630.xsd#amix_ConvertibleNotesToWarrantsMember" xlink:label="amix_ConvertibleNotesToWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_RepresentativesWarrantsMember" xlink:label="amix_RepresentativesWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_SeriesAWarrantsMember" xlink:label="amix_SeriesAWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_ConvertibleDebtSecuritiesMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="amix_ConvertibleNotesToWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="amix_SeriesAWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="amix_RepresentativesWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-10q-details" xlink:href="amix-20250630.xsd#statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-10q-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-10q-details" xlink:type="extended">
    <link:loc xlink:href="amix-20250630.xsd#amix_ConvertibleNotesToWarrantsMember" xlink:label="amix_ConvertibleNotesToWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_RepresentativesWarrantsMember" xlink:label="amix_RepresentativesWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_SeriesAWarrantsMember" xlink:label="amix_SeriesAWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_ConvertibleDebtSecuritiesMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="amix_ConvertibleNotesToWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="amix_SeriesAWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="amix_RepresentativesWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-note-2-convertible-notes-payable-schedule-of-detachable-warrants-10q-details" xlink:href="amix-20250630.xsd#statement-note-2-convertible-notes-payable-schedule-of-detachable-warrants-10q-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://autonomix.com/20250630/role/statement-note-2-convertible-notes-payable-schedule-of-detachable-warrants-10q-details" xlink:type="extended">
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightExercisableNumber" xlink:label="amix_ClassOfWarrantOrRightExercisableNumber" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice" xlink:label="amix_ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightExercisesInPeriod" xlink:label="amix_ClassOfWarrantOrRightExercisesInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightExercisesInPeriodWeightedAverageExercisePrice" xlink:label="amix_ClassOfWarrantOrRightExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightExpirationsInPeriod" xlink:label="amix_ClassOfWarrantOrRightExpirationsInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="amix_ClassOfWarrantOrRightExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightForfeituresInPeriod" xlink:label="amix_ClassOfWarrantOrRightForfeituresInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="amix_ClassOfWarrantOrRightForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightGrantsInPeriod" xlink:label="amix_ClassOfWarrantOrRightGrantsInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightGrantsInPeriodWeightedAverageExercise" xlink:label="amix_ClassOfWarrantOrRightGrantsInPeriodWeightedAverageExercise" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightOutstandingOutstandingWeightedAverageExercisePrice" xlink:label="amix_ClassOfWarrantOrRightOutstandingOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_ClassOfWarrantOrRightOutstandingOutstandingWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_ClassOfWarrantOrRightGrantsInPeriod" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_ClassOfWarrantOrRightGrantsInPeriodWeightedAverageExercise" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_ClassOfWarrantOrRightExercisesInPeriod" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_ClassOfWarrantOrRightExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_ClassOfWarrantOrRightForfeituresInPeriod" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_ClassOfWarrantOrRightForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_ClassOfWarrantOrRightExpirationsInPeriod" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_ClassOfWarrantOrRightExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_ClassOfWarrantOrRightExercisableNumber" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-note-3-equity-schedule-of-stock-option-activity-10q-details" xlink:href="amix-20250630.xsd#statement-note-3-equity-schedule-of-stock-option-activity-10q-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://autonomix.com/20250630/role/statement-note-3-equity-schedule-of-stock-option-activity-10q-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-note-3-equity-schedule-of-equitybased-stock-warrants-10q-details" xlink:href="amix-20250630.xsd#statement-note-3-equity-schedule-of-equitybased-stock-warrants-10q-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://autonomix.com/20250630/role/statement-note-3-equity-schedule-of-equitybased-stock-warrants-10q-details" xlink:type="extended">
    <link:loc xlink:href="amix-20250630.xsd#amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice" xlink:label="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:label="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_SharebasedCompensationArrangementBySharebasedPaymentAwardNonoptionEquityInstrumentsExercisableNumberOutstandingNumber" xlink:label="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardNonoptionEquityInstrumentsExercisableNumberOutstandingNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardNonoptionEquityInstrumentsExercisableNumberOutstandingNumber" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-balance-sheets" xlink:href="amix-20250630.xsd#statement-balance-sheets" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://autonomix.com/20250630/role/statement-balance-sheets" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="us-gaap_ConvertibleLongTermNotesPayable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCosts" xlink:label="us-gaap_DeferredCosts" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrentAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsCurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsNoncurrentAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_DeferredCosts" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_Assets" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_ConvertibleLongTermNotesPayable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_Liabilities" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-condensed-balance-sheets-unaudited-" xlink:href="amix-20250630.xsd#statement-condensed-balance-sheets-unaudited-" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://autonomix.com/20250630/role/statement-condensed-balance-sheets-unaudited-" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCosts" xlink:label="us-gaap_DeferredCosts" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrentAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsCurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsNoncurrentAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_DeferredCosts" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_Assets" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_Liabilities" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>amix-20250630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 03:06PM UTC 2025-10-04--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="amix-20250630.xsd#amix_DocumentAndEntityInformation" xlink:label="amix_DocumentAndEntityInformation" xlink:type="locator"/>
    <link:label xlink:label="amix_DocumentAndEntityInformation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document And Entity Information</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_DocumentAndEntityInformation" xlink:to="amix_DocumentAndEntityInformation-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_NumberOfCommonUnitsIssued" xlink:label="amix_NumberOfCommonUnitsIssued" xlink:type="locator"/>
    <link:label xlink:label="amix_NumberOfCommonUnitsIssued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">amix_NumberOfCommonUnitsIssued</link:label>
    <link:label xlink:label="amix_NumberOfCommonUnitsIssued-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Common Units Issued (in shares)</link:label>
    <link:label xlink:label="amix_NumberOfCommonUnitsIssued-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The number of common units issued.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_NumberOfCommonUnitsIssued" xlink:to="amix_NumberOfCommonUnitsIssued-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_UnderwrittenPublicOfferingMember" xlink:label="amix_UnderwrittenPublicOfferingMember" xlink:type="locator"/>
    <link:label xlink:label="amix_UnderwrittenPublicOfferingMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underwritten Public Offering [Member]</link:label>
    <link:label xlink:label="amix_UnderwrittenPublicOfferingMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the underwritten public offering.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_UnderwrittenPublicOfferingMember" xlink:to="amix_UnderwrittenPublicOfferingMember-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_NoteToFinancialStatementDetailsTextual" xlink:label="amix_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:label xlink:label="amix_NoteToFinancialStatementDetailsTextual-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note To Financial Statement Details Textual</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_NoteToFinancialStatementDetailsTextual" xlink:to="amix_NoteToFinancialStatementDetailsTextual-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_NumberOfWarrantsPerCommonUnit" xlink:label="amix_NumberOfWarrantsPerCommonUnit" xlink:type="locator"/>
    <link:label xlink:label="amix_NumberOfWarrantsPerCommonUnit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">amix_NumberOfWarrantsPerCommonUnit</link:label>
    <link:label xlink:label="amix_NumberOfWarrantsPerCommonUnit-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Warrants Per Common Unit (in shares)</link:label>
    <link:label xlink:label="amix_NumberOfWarrantsPerCommonUnit-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The number of warrants per common unit.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_NumberOfWarrantsPerCommonUnit" xlink:to="amix_NumberOfWarrantsPerCommonUnit-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_statement-statement-significant-accounting-policies-policies" xlink:label="amix_statement-statement-significant-accounting-policies-policies" xlink:type="locator"/>
    <link:label xlink:label="amix_statement-statement-significant-accounting-policies-policies-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_statement-statement-significant-accounting-policies-policies" xlink:to="amix_statement-statement-significant-accounting-policies-policies-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_NumberOfSharesPerCommonUnit" xlink:label="amix_NumberOfSharesPerCommonUnit" xlink:type="locator"/>
    <link:label xlink:label="amix_NumberOfSharesPerCommonUnit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">amix_NumberOfSharesPerCommonUnit</link:label>
    <link:label xlink:label="amix_NumberOfSharesPerCommonUnit-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Shares Per Common Unit (in shares)</link:label>
    <link:label xlink:label="amix_NumberOfSharesPerCommonUnit-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The number of shares per common unit.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_NumberOfSharesPerCommonUnit" xlink:to="amix_NumberOfSharesPerCommonUnit-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_statement-statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-tables" xlink:label="amix_statement-statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-tables" xlink:type="locator"/>
    <link:label xlink:label="amix_statement-statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 1 - Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_statement-statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-tables" xlink:to="amix_statement-statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax benefit at the U.S. federal statutory rate, amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_statement-statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-tables" xlink:label="amix_statement-statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-tables" xlink:type="locator"/>
    <link:label xlink:label="amix_statement-statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 2 - Warrant Liability and Fair Value of Financial Instruments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_statement-statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-tables" xlink:to="amix_statement-statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants" xlink:label="amix_StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants" xlink:type="locator"/>
    <link:label xlink:label="amix_StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common shares and equity classified warrants, net of offering costs</link:label>
    <link:label xlink:label="amix_StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Value of common stock and warrants for common stock issued.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants" xlink:to="amix_StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_statement-statement-note-3-convertible-notes-payable-tables" xlink:label="amix_statement-statement-note-3-convertible-notes-payable-tables" xlink:type="locator"/>
    <link:label xlink:label="amix_statement-statement-note-3-convertible-notes-payable-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 3 - Convertible Notes Payable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_statement-statement-note-3-convertible-notes-payable-tables" xlink:to="amix_statement-statement-note-3-convertible-notes-payable-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_WarrantsIssuedForDebtIssuanceCosts" xlink:label="amix_WarrantsIssuedForDebtIssuanceCosts" xlink:type="locator"/>
    <link:label xlink:label="amix_WarrantsIssuedForDebtIssuanceCosts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">amix_WarrantsIssuedForDebtIssuanceCosts</link:label>
    <link:label xlink:label="amix_WarrantsIssuedForDebtIssuanceCosts-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants issued for debt issuance costs</link:label>
    <link:label xlink:label="amix_WarrantsIssuedForDebtIssuanceCosts-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of warrants issued for debt issuance costs in noncash or part noncash transaction.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_WarrantsIssuedForDebtIssuanceCosts" xlink:to="amix_WarrantsIssuedForDebtIssuanceCosts-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_EquitybasedWarrantsMember" xlink:label="amix_EquitybasedWarrantsMember" xlink:type="locator"/>
    <link:label xlink:label="amix_EquitybasedWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity-based Warrants [Member]</link:label>
    <link:label xlink:label="amix_EquitybasedWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents equity-based warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_EquitybasedWarrantsMember" xlink:to="amix_EquitybasedWarrantsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_statement-statement-note-4-equity-tables" xlink:label="amix_statement-statement-note-4-equity-tables" xlink:type="locator"/>
    <link:label xlink:label="amix_statement-statement-note-4-equity-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 4 - Equity</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_statement-statement-note-4-equity-tables" xlink:to="amix_statement-statement-note-4-equity-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_statement-statement-note-7-income-taxes-tables" xlink:label="amix_statement-statement-note-7-income-taxes-tables" xlink:type="locator"/>
    <link:label xlink:label="amix_statement-statement-note-7-income-taxes-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 7 - Income Taxes</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_statement-statement-note-7-income-taxes-tables" xlink:to="amix_statement-statement-note-7-income-taxes-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants" xlink:label="amix_StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants" xlink:type="locator"/>
    <link:label xlink:label="amix_StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common shares and equity classified warrants, net of offering costs (in shares)</link:label>
    <link:label xlink:label="amix_StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of shares of common stock and warrants for common stock issued.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants" xlink:to="amix_StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_PrefundedUnitsIssuedPurchasePrice" xlink:label="amix_PrefundedUnitsIssuedPurchasePrice" xlink:type="locator"/>
    <link:label xlink:label="amix_PrefundedUnitsIssuedPurchasePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">amix_PrefundedUnitsIssuedPurchasePrice</link:label>
    <link:label xlink:label="amix_PrefundedUnitsIssuedPurchasePrice-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-funded Units Issued, Purchase Price (in dollars per share)</link:label>
    <link:label xlink:label="amix_PrefundedUnitsIssuedPurchasePrice-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Per share or per unit price of pre-funded units issued.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_PrefundedUnitsIssuedPurchasePrice" xlink:to="amix_PrefundedUnitsIssuedPurchasePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_statement-statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q-tables" xlink:label="amix_statement-statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q-tables" xlink:type="locator"/>
    <link:label xlink:label="amix_statement-statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 1 - Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies - 10-Q</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_statement-statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q-tables" xlink:to="amix_statement-statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesNoncurrentAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term liabilities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_CommonUnitsIssuedPurchasePrice" xlink:label="amix_CommonUnitsIssuedPurchasePrice" xlink:type="locator"/>
    <link:label xlink:label="amix_CommonUnitsIssuedPurchasePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">amix_CommonUnitsIssuedPurchasePrice</link:label>
    <link:label xlink:label="amix_CommonUnitsIssuedPurchasePrice-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Units Issued, Purchase Price (in dollars per share)</link:label>
    <link:label xlink:label="amix_CommonUnitsIssuedPurchasePrice-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Per share or per unit price of common units issued.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_CommonUnitsIssuedPurchasePrice" xlink:to="amix_CommonUnitsIssuedPurchasePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ConsultingFirmOwnedByFormerCFOMember" xlink:label="amix_ConsultingFirmOwnedByFormerCFOMember" xlink:type="locator"/>
    <link:label xlink:label="amix_ConsultingFirmOwnedByFormerCFOMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consulting Firm Owned by Former CFO [MEmber]</link:label>
    <link:label xlink:label="amix_ConsultingFirmOwnedByFormerCFOMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the consulting firm owned by the former CFO.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_ConsultingFirmOwnedByFormerCFOMember" xlink:to="amix_ConsultingFirmOwnedByFormerCFOMember-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_statement-statement-note-2-convertible-notes-payable-10q-tables" xlink:label="amix_statement-statement-note-2-convertible-notes-payable-10q-tables" xlink:type="locator"/>
    <link:label xlink:label="amix_statement-statement-note-2-convertible-notes-payable-10q-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 2 - Convertible Notes Payable - 10Q</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_statement-statement-note-2-convertible-notes-payable-10q-tables" xlink:to="amix_statement-statement-note-2-convertible-notes-payable-10q-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_EquityOfferingOptionMaximumShares" xlink:label="amix_EquityOfferingOptionMaximumShares" xlink:type="locator"/>
    <link:label xlink:label="amix_EquityOfferingOptionMaximumShares-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">amix_EquityOfferingOptionMaximumShares</link:label>
    <link:label xlink:label="amix_EquityOfferingOptionMaximumShares-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Offering, Option, Maximum Shares (in shares)</link:label>
    <link:label xlink:label="amix_EquityOfferingOptionMaximumShares-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The maximum shares to be issued in option under equity offering.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_EquityOfferingOptionMaximumShares" xlink:to="amix_EquityOfferingOptionMaximumShares-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_StockRequiredToBeIssuedForStockSplitShares" xlink:label="amix_StockRequiredToBeIssuedForStockSplitShares" xlink:type="locator"/>
    <link:label xlink:label="amix_StockRequiredToBeIssuedForStockSplitShares-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">amix_StockRequiredToBeIssuedForStockSplitShares</link:label>
    <link:label xlink:label="amix_StockRequiredToBeIssuedForStockSplitShares-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Required to be Issued for Stock Split, Shares (in shares)</link:label>
    <link:label xlink:label="amix_StockRequiredToBeIssuedForStockSplitShares-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The number of shares required to be issued for the stock split.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_StockRequiredToBeIssuedForStockSplitShares" xlink:to="amix_StockRequiredToBeIssuedForStockSplitShares-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_statement-statement-note-3-equity-10q-tables" xlink:label="amix_statement-statement-note-3-equity-10q-tables" xlink:type="locator"/>
    <link:label xlink:label="amix_statement-statement-note-3-equity-10q-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 3 - Equity - 10Q</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_statement-statement-note-3-equity-10q-tables" xlink:to="amix_statement-statement-note-3-equity-10q-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_EquityOfferingOptionPeriod" xlink:label="amix_EquityOfferingOptionPeriod" xlink:type="locator"/>
    <link:label xlink:label="amix_EquityOfferingOptionPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">amix_EquityOfferingOptionPeriod</link:label>
    <link:label xlink:label="amix_EquityOfferingOptionPeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Offering, Option Period (Day)</link:label>
    <link:label xlink:label="amix_EquityOfferingOptionPeriod-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Period of the option in the equity offering.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_EquityOfferingOptionPeriod" xlink:to="amix_EquityOfferingOptionPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_statement-statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-antidilutive-securities-details" xlink:label="amix_statement-statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-antidilutive-securities-details" xlink:type="locator"/>
    <link:label xlink:label="amix_statement-statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-antidilutive-securities-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 1 - Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies - Anti-dilutive Securities (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_statement-statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-antidilutive-securities-details" xlink:to="amix_statement-statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-antidilutive-securities-details-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_NumberOfPrefundedUnitsIssued" xlink:label="amix_NumberOfPrefundedUnitsIssued" xlink:type="locator"/>
    <link:label xlink:label="amix_NumberOfPrefundedUnitsIssued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">amix_NumberOfPrefundedUnitsIssued</link:label>
    <link:label xlink:label="amix_NumberOfPrefundedUnitsIssued-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Pre-funded Units Issued (in shares)</link:label>
    <link:label xlink:label="amix_NumberOfPrefundedUnitsIssued-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The number of pre-funded units issued.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_NumberOfPrefundedUnitsIssued" xlink:to="amix_NumberOfPrefundedUnitsIssued-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_statement-statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-prior-period-corrections-details" xlink:label="amix_statement-statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-prior-period-corrections-details" xlink:type="locator"/>
    <link:label xlink:label="amix_statement-statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-prior-period-corrections-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 1 - Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies - Prior Period Corrections (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_statement-statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-prior-period-corrections-details" xlink:to="amix_statement-statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-prior-period-corrections-details-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_SeriesAWarrantsMember" xlink:label="amix_SeriesAWarrantsMember" xlink:type="locator"/>
    <link:label xlink:label="amix_SeriesAWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series A Warrants [Member]</link:label>
    <link:label xlink:label="amix_SeriesAWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents Series A Warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_SeriesAWarrantsMember" xlink:to="amix_SeriesAWarrantsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_statement-statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-schedule-of-fair-value-measurements-details" xlink:label="amix_statement-statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-schedule-of-fair-value-measurements-details" xlink:type="locator"/>
    <link:label xlink:label="amix_statement-statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-schedule-of-fair-value-measurements-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 2 - Warrant Liability and Fair Value of Financial Instruments - Schedule of Fair Value Measurements (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_statement-statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-schedule-of-fair-value-measurements-details" xlink:to="amix_statement-statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-schedule-of-fair-value-measurements-details-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_NumberOfWarrantsPerPrefundedUnit" xlink:label="amix_NumberOfWarrantsPerPrefundedUnit" xlink:type="locator"/>
    <link:label xlink:label="amix_NumberOfWarrantsPerPrefundedUnit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">amix_NumberOfWarrantsPerPrefundedUnit</link:label>
    <link:label xlink:label="amix_NumberOfWarrantsPerPrefundedUnit-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Warrants Per Pre-funded Unit (in shares)</link:label>
    <link:label xlink:label="amix_NumberOfWarrantsPerPrefundedUnit-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The number of warrants per pre-funded unit.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_NumberOfWarrantsPerPrefundedUnit" xlink:to="amix_NumberOfWarrantsPerPrefundedUnit-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_statement-statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-fair-value-measurement-inputs-and-valuation-techniques-details" xlink:label="amix_statement-statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-fair-value-measurement-inputs-and-valuation-techniques-details" xlink:type="locator"/>
    <link:label xlink:label="amix_statement-statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-fair-value-measurement-inputs-and-valuation-techniques-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 2 - Warrant Liability and Fair Value of Financial Instruments - Fair Value Measurement Inputs and Valuation Techniques (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_statement-statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-fair-value-measurement-inputs-and-valuation-techniques-details" xlink:to="amix_statement-statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-fair-value-measurement-inputs-and-valuation-techniques-details-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_statement-statement-note-3-convertible-notes-payable-schedule-of-convertible-notes-payable-details" xlink:label="amix_statement-statement-note-3-convertible-notes-payable-schedule-of-convertible-notes-payable-details" xlink:type="locator"/>
    <link:label xlink:label="amix_statement-statement-note-3-convertible-notes-payable-schedule-of-convertible-notes-payable-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 3 - Convertible Notes Payable - Schedule of Convertible Notes Payable (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_statement-statement-note-3-convertible-notes-payable-schedule-of-convertible-notes-payable-details" xlink:to="amix_statement-statement-note-3-convertible-notes-payable-schedule-of-convertible-notes-payable-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LiabilitiesCurrent</link:label>
    <link:label xlink:label="us-gaap_LiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:label="amix_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:type="locator"/>
    <link:label xlink:label="amix_ClassOfWarrantOrRightIssuedDuringPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">amix_ClassOfWarrantOrRightIssuedDuringPeriod</link:label>
    <link:label xlink:label="amix_ClassOfWarrantOrRightIssuedDuringPeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Issued During Period (in shares)</link:label>
    <link:label xlink:label="amix_ClassOfWarrantOrRightIssuedDuringPeriod-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The number of warrants or rights issued during the period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:to="amix_ClassOfWarrantOrRightIssuedDuringPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_statement-statement-note-3-convertible-notes-payable-schedule-of-detachable-warrants-details" xlink:label="amix_statement-statement-note-3-convertible-notes-payable-schedule-of-detachable-warrants-details" xlink:type="locator"/>
    <link:label xlink:label="amix_statement-statement-note-3-convertible-notes-payable-schedule-of-detachable-warrants-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 3 - Convertible Notes Payable - Schedule of Detachable Warrants (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_statement-statement-note-3-convertible-notes-payable-schedule-of-detachable-warrants-details" xlink:to="amix_statement-statement-note-3-convertible-notes-payable-schedule-of-detachable-warrants-details-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_PrefundedAndSeriesAWarrantsMember" xlink:label="amix_PrefundedAndSeriesAWarrantsMember" xlink:type="locator"/>
    <link:label xlink:label="amix_PrefundedAndSeriesAWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-funded and Series A Warrants [Member]</link:label>
    <link:label xlink:label="amix_PrefundedAndSeriesAWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents pre-funded and Series A warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_PrefundedAndSeriesAWarrantsMember" xlink:to="amix_PrefundedAndSeriesAWarrantsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_statement-statement-note-4-equity-general-and-administrative-expense-details" xlink:label="amix_statement-statement-note-4-equity-general-and-administrative-expense-details" xlink:type="locator"/>
    <link:label xlink:label="amix_statement-statement-note-4-equity-general-and-administrative-expense-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 4 - Equity - General and Administrative Expense (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_statement-statement-note-4-equity-general-and-administrative-expense-details" xlink:to="amix_statement-statement-note-4-equity-general-and-administrative-expense-details-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_NoncashExpensesMember" xlink:label="amix_NoncashExpensesMember" xlink:type="locator"/>
    <link:label xlink:label="amix_NoncashExpensesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-cash Expenses [Member]</link:label>
    <link:label xlink:label="amix_NoncashExpensesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents non-cash expenses.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_NoncashExpensesMember" xlink:to="amix_NoncashExpensesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebtTableTextBlock" xlink:label="us-gaap_ConvertibleDebtTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConvertibleDebtTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debt [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtTableTextBlock" xlink:to="us-gaap_ConvertibleDebtTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_statement-statement-note-4-equity-restricted-stock-activity-details" xlink:label="amix_statement-statement-note-4-equity-restricted-stock-activity-details" xlink:type="locator"/>
    <link:label xlink:label="amix_statement-statement-note-4-equity-restricted-stock-activity-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 4 - Equity - Restricted Stock Activity (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_statement-statement-note-4-equity-restricted-stock-activity-details" xlink:to="amix_statement-statement-note-4-equity-restricted-stock-activity-details-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ProceedsFromIssuanceOrSaleOfEquityNet" xlink:label="amix_ProceedsFromIssuanceOrSaleOfEquityNet" xlink:type="locator"/>
    <link:label xlink:label="amix_ProceedsFromIssuanceOrSaleOfEquityNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">amix_ProceedsFromIssuanceOrSaleOfEquityNet</link:label>
    <link:label xlink:label="amix_ProceedsFromIssuanceOrSaleOfEquityNet-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance or Sale of Equity, Net</link:label>
    <link:label xlink:label="amix_ProceedsFromIssuanceOrSaleOfEquityNet-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_ProceedsFromIssuanceOrSaleOfEquityNet" xlink:to="amix_ProceedsFromIssuanceOrSaleOfEquityNet-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_statement-statement-note-4-equity-schedule-of-stock-option-activity-details" xlink:label="amix_statement-statement-note-4-equity-schedule-of-stock-option-activity-details" xlink:type="locator"/>
    <link:label xlink:label="amix_statement-statement-note-4-equity-schedule-of-stock-option-activity-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 4 - Equity - Schedule of Stock Option Activity (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_statement-statement-note-4-equity-schedule-of-stock-option-activity-details" xlink:to="amix_statement-statement-note-4-equity-schedule-of-stock-option-activity-details-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_UnderwritersMember" xlink:label="amix_UnderwritersMember" xlink:type="locator"/>
    <link:label xlink:label="amix_UnderwritersMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underwriters [Member]</link:label>
    <link:label xlink:label="amix_UnderwritersMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the Underwriters.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_UnderwritersMember" xlink:to="amix_UnderwritersMember-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_statement-statement-note-4-equity-schedule-of-equitybased-stock-warrants-details" xlink:label="amix_statement-statement-note-4-equity-schedule-of-equitybased-stock-warrants-details" xlink:type="locator"/>
    <link:label xlink:label="amix_statement-statement-note-4-equity-schedule-of-equitybased-stock-warrants-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 4 - Equity - Schedule of Equity-Based Stock Warrants (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_statement-statement-note-4-equity-schedule-of-equitybased-stock-warrants-details" xlink:to="amix_statement-statement-note-4-equity-schedule-of-equitybased-stock-warrants-details-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_EquityOfferingOptionMaximumWarrants" xlink:label="amix_EquityOfferingOptionMaximumWarrants" xlink:type="locator"/>
    <link:label xlink:label="amix_EquityOfferingOptionMaximumWarrants-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">amix_EquityOfferingOptionMaximumWarrants</link:label>
    <link:label xlink:label="amix_EquityOfferingOptionMaximumWarrants-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Offering, Option, Maximum Warrants (in shares)</link:label>
    <link:label xlink:label="amix_EquityOfferingOptionMaximumWarrants-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The maximum warrants to be issued in option of equity offering.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_EquityOfferingOptionMaximumWarrants" xlink:to="amix_EquityOfferingOptionMaximumWarrants-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_statement-statement-note-4-equity-blackscholes-option-pricing-model-details" xlink:label="amix_statement-statement-note-4-equity-blackscholes-option-pricing-model-details" xlink:type="locator"/>
    <link:label xlink:label="amix_statement-statement-note-4-equity-blackscholes-option-pricing-model-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 4 - Equity - Black-Scholes Option Pricing Model (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_statement-statement-note-4-equity-blackscholes-option-pricing-model-details" xlink:to="amix_statement-statement-note-4-equity-blackscholes-option-pricing-model-details-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantsOrRightsMaximumBeneficialOwnership" xlink:label="amix_ClassOfWarrantsOrRightsMaximumBeneficialOwnership" xlink:type="locator"/>
    <link:label xlink:label="amix_ClassOfWarrantsOrRightsMaximumBeneficialOwnership-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">amix_ClassOfWarrantsOrRightsMaximumBeneficialOwnership</link:label>
    <link:label xlink:label="amix_ClassOfWarrantsOrRightsMaximumBeneficialOwnership-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrants or Rights, Maximum Beneficial Ownership</link:label>
    <link:label xlink:label="amix_ClassOfWarrantsOrRightsMaximumBeneficialOwnership-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of maximum beneficial ownership of warrants or rights.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_ClassOfWarrantsOrRightsMaximumBeneficialOwnership" xlink:to="amix_ClassOfWarrantsOrRightsMaximumBeneficialOwnership-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding, warrants, weighted average remaining contractual term (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_statement-statement-note-7-income-taxes-schedule-of-reconciliation-details" xlink:label="amix_statement-statement-note-7-income-taxes-schedule-of-reconciliation-details" xlink:type="locator"/>
    <link:label xlink:label="amix_statement-statement-note-7-income-taxes-schedule-of-reconciliation-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 7 - Income Taxes - Schedule of Reconciliation (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_statement-statement-note-7-income-taxes-schedule-of-reconciliation-details" xlink:to="amix_statement-statement-note-7-income-taxes-schedule-of-reconciliation-details-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_PrefundedWarrantsMember" xlink:label="amix_PrefundedWarrantsMember" xlink:type="locator"/>
    <link:label xlink:label="amix_PrefundedWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-funded Warrants [Member]</link:label>
    <link:label xlink:label="amix_PrefundedWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the pre-funded warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_PrefundedWarrantsMember" xlink:to="amix_PrefundedWarrantsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_statement-statement-note-7-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" xlink:label="amix_statement-statement-note-7-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" xlink:type="locator"/>
    <link:label xlink:label="amix_statement-statement-note-7-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 7 - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_statement-statement-note-7-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" xlink:to="amix_statement-statement-note-7-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnderlyingAssetClassDomain" xlink:label="us-gaap_UnderlyingAssetClassDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_UnderlyingAssetClassDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underlying Asset Class [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnderlyingAssetClassDomain" xlink:to="us-gaap_UnderlyingAssetClassDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_statement-statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-10q-details" xlink:label="amix_statement-statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-10q-details" xlink:type="locator"/>
    <link:label xlink:label="amix_statement-statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-10q-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 1 - Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Anti-dilutive Securities - 10Q (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_statement-statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-10q-details" xlink:to="amix_statement-statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-10q-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_statement-statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-schedule-of-prior-period-corrections-10q-details" xlink:label="amix_statement-statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-schedule-of-prior-period-corrections-10q-details" xlink:type="locator"/>
    <link:label xlink:label="amix_statement-statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-schedule-of-prior-period-corrections-10q-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 1 - Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Prior Period Corrections - 10Q (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_statement-statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-schedule-of-prior-period-corrections-10q-details" xlink:to="amix_statement-statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-schedule-of-prior-period-corrections-10q-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding, warrants, aggregate intrinsic value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_statement-statement-note-2-convertible-notes-payable-schedule-of-detachable-warrants-10q-details" xlink:label="amix_statement-statement-note-2-convertible-notes-payable-schedule-of-detachable-warrants-10q-details" xlink:type="locator"/>
    <link:label xlink:label="amix_statement-statement-note-2-convertible-notes-payable-schedule-of-detachable-warrants-10q-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 2 - Convertible Notes Payable - Schedule of Detachable Warrants - 10Q (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_statement-statement-note-2-convertible-notes-payable-schedule-of-detachable-warrants-10q-details" xlink:to="amix_statement-statement-note-2-convertible-notes-payable-schedule-of-detachable-warrants-10q-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercisable, warrants, aggregate intrinsic value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_statement-statement-note-3-equity-general-and-administrative-expense-10q-details" xlink:label="amix_statement-statement-note-3-equity-general-and-administrative-expense-10q-details" xlink:type="locator"/>
    <link:label xlink:label="amix_statement-statement-note-3-equity-general-and-administrative-expense-10q-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 3 - Equity - General and Administrative Expense - 10Q (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_statement-statement-note-3-equity-general-and-administrative-expense-10q-details" xlink:to="amix_statement-statement-note-3-equity-general-and-administrative-expense-10q-details-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ReverseStockSplitAdjustmentMember" xlink:label="amix_ReverseStockSplitAdjustmentMember" xlink:type="locator"/>
    <link:label xlink:label="amix_ReverseStockSplitAdjustmentMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reverse Stock Split Adjustment [Member]</link:label>
    <link:label xlink:label="amix_ReverseStockSplitAdjustmentMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the reverse stock split adjustment.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_ReverseStockSplitAdjustmentMember" xlink:to="amix_ReverseStockSplitAdjustmentMember-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_RepresentativesWarrantsMember" xlink:label="amix_RepresentativesWarrantsMember" xlink:type="locator"/>
    <link:label xlink:label="amix_RepresentativesWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Representative's Warrants [Member]</link:label>
    <link:label xlink:label="amix_RepresentativesWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents Representative's Warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_RepresentativesWarrantsMember" xlink:to="amix_RepresentativesWarrantsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_statement-statement-note-3-equity-schedule-of-stock-option-activity-10q-details" xlink:label="amix_statement-statement-note-3-equity-schedule-of-stock-option-activity-10q-details" xlink:type="locator"/>
    <link:label xlink:label="amix_statement-statement-note-3-equity-schedule-of-stock-option-activity-10q-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 3 - Equity - Schedule of Stock Option Activity - 10Q (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_statement-statement-note-3-equity-schedule-of-stock-option-activity-10q-details" xlink:to="amix_statement-statement-note-3-equity-schedule-of-stock-option-activity-10q-details-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_statement-statement-note-3-equity-schedule-of-equitybased-stock-warrants-10q-details" xlink:label="amix_statement-statement-note-3-equity-schedule-of-equitybased-stock-warrants-10q-details" xlink:type="locator"/>
    <link:label xlink:label="amix_statement-statement-note-3-equity-schedule-of-equitybased-stock-warrants-10q-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 3 - Equity - Schedule of Equity-Based Stock Warrants - 10Q (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_statement-statement-note-3-equity-schedule-of-equitybased-stock-warrants-10q-details" xlink:to="amix_statement-statement-note-3-equity-schedule-of-equitybased-stock-warrants-10q-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilityForUncertainTaxPositionsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LiabilityForUncertainTaxPositionsCurrent</link:label>
    <link:label xlink:label="us-gaap_LiabilityForUncertainTaxPositionsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liability for Uncertainty in Income Taxes, Current</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:to="us-gaap_LiabilityForUncertainTaxPositionsCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_NotesToFinancialStatements" xlink:label="amix_NotesToFinancialStatements" xlink:type="locator"/>
    <link:label xlink:label="amix_NotesToFinancialStatements-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes To Financial Statements</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_NotesToFinancialStatements" xlink:to="amix_NotesToFinancialStatements-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnderlyingAssetClassAxis" xlink:label="us-gaap_UnderlyingAssetClassAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_UnderlyingAssetClassAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underlying Asset Class [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnderlyingAssetClassAxis" xlink:to="us-gaap_UnderlyingAssetClassAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_NotesToFinancialStatementsAbstract" xlink:label="amix_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:label xlink:label="amix_NotesToFinancialStatementsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes To Financial Statements [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_NotesToFinancialStatementsAbstract" xlink:to="amix_NotesToFinancialStatementsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightFairValuePerShare" xlink:label="amix_ClassOfWarrantOrRightFairValuePerShare" xlink:type="locator"/>
    <link:label xlink:label="amix_ClassOfWarrantOrRightFairValuePerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">amix_ClassOfWarrantOrRightFairValuePerShare</link:label>
    <link:label xlink:label="amix_ClassOfWarrantOrRightFairValuePerShare-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Fair Value Per Share (in dollars per share)</link:label>
    <link:label xlink:label="amix_ClassOfWarrantOrRightFairValuePerShare-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Per share or per unit fair value price of warrants or rights.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_ClassOfWarrantOrRightFairValuePerShare" xlink:to="amix_ClassOfWarrantOrRightFairValuePerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Granted, unvested restricted stock units, weighted average grant date fair value (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightLockupPeriod" xlink:label="amix_ClassOfWarrantOrRightLockupPeriod" xlink:type="locator"/>
    <link:label xlink:label="amix_ClassOfWarrantOrRightLockupPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">amix_ClassOfWarrantOrRightLockupPeriod</link:label>
    <link:label xlink:label="amix_ClassOfWarrantOrRightLockupPeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Lock-up Period (Day)</link:label>
    <link:label xlink:label="amix_ClassOfWarrantOrRightLockupPeriod-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Period of lock-up for warrants or rights.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_ClassOfWarrantOrRightLockupPeriod" xlink:to="amix_ClassOfWarrantOrRightLockupPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vested restricted stock units, weighted average grant date fair value (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_SeriesAWarrantsAndTheRepresentativesWarrantsMember" xlink:label="amix_SeriesAWarrantsAndTheRepresentativesWarrantsMember" xlink:type="locator"/>
    <link:label xlink:label="amix_SeriesAWarrantsAndTheRepresentativesWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series A Warrants and the Representative's Warrants [Member]</link:label>
    <link:label xlink:label="amix_SeriesAWarrantsAndTheRepresentativesWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the Series A Warrants and the Representative's Warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_SeriesAWarrantsAndTheRepresentativesWarrantsMember" xlink:to="amix_SeriesAWarrantsAndTheRepresentativesWarrantsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance, unvested restricted stock units, weighted average grant date fair value (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance, unvested restricted stock units, weighted average grant date fair value (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance, unvested restricted stock units, shares (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance, unvested restricted stock units, shares (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Outstanding Award, Activity, Excluding Option [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Granted, unvested restricted stock units, shares (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Vested restricted stock units, shares (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_CommonWarrantsMember" xlink:label="amix_CommonWarrantsMember" xlink:type="locator"/>
    <link:label xlink:label="amix_CommonWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Warrants [Member]</link:label>
    <link:label xlink:label="amix_CommonWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents common warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_CommonWarrantsMember" xlink:to="amix_CommonWarrantsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercisable, options, weighted average exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercisable, options, Weighted average remaining contractual term (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercisable, aggregate intrinsic value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercisable, options (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding, options, Weighted average remaining contractual term (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding, aggregate intrinsic value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, options, weighted average exercise price (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, options, weighted average exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forfeited/Cancelled, options, weighted average exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expired, options, weighted average exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, warrants (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, warrants (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Granted, options, weighted average exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercised, options, weighted average exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ExecutiveChairOfTheBoardMember" xlink:label="amix_ExecutiveChairOfTheBoardMember" xlink:type="locator"/>
    <link:label xlink:label="amix_ExecutiveChairOfTheBoardMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Executive Chair of the Board [Member]</link:label>
    <link:label xlink:label="amix_ExecutiveChairOfTheBoardMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to the Executive Chair of the Board.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_ExecutiveChairOfTheBoardMember" xlink:to="amix_ExecutiveChairOfTheBoardMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccruedLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ChiefMedicalOfficerMember" xlink:label="amix_ChiefMedicalOfficerMember" xlink:type="locator"/>
    <link:label xlink:label="amix_ChiefMedicalOfficerMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Chief Medical Officer [Member]</link:label>
    <link:label xlink:label="amix_ChiefMedicalOfficerMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to Chief Medical Officer.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_ChiefMedicalOfficerMember" xlink:to="amix_ChiefMedicalOfficerMember-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ChiefTechnologyOfficerMember" xlink:label="amix_ChiefTechnologyOfficerMember" xlink:type="locator"/>
    <link:label xlink:label="amix_ChiefTechnologyOfficerMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Chief Technology Officer [Member]</link:label>
    <link:label xlink:label="amix_ChiefTechnologyOfficerMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to Chief Technology Officer.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_ChiefTechnologyOfficerMember" xlink:to="amix_ChiefTechnologyOfficerMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Exercised, warrants (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Forfeited/Cancelled, warrants (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Expired, warrants (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsPayableCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, options (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, options (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Granted, warrants (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Expired, options (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PolicyTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PolicyTextBlockAbstract</link:label>
    <link:label xlink:label="us-gaap_PolicyTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_PolicyTextBlockAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyPendingClaimsNumber" xlink:label="us-gaap_LossContingencyPendingClaimsNumber" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LossContingencyPendingClaimsNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LossContingencyPendingClaimsNumber</link:label>
    <link:label xlink:label="us-gaap_LossContingencyPendingClaimsNumber-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingency, Pending Claims, Number</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyPendingClaimsNumber" xlink:to="us-gaap_LossContingencyPendingClaimsNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssued1" xlink:label="us-gaap_StockIssued1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssued1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from cashless exercise of warrants</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssued1" xlink:to="us-gaap_StockIssued1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</link:label>
    <link:label xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchase of property and equipment</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Month)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GranteeStatusDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Grantee Status [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_GranteeStatusDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GranteeStatusAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Grantee Status [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesCurrentAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_VestingAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_VestingDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Tranche One [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Assets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_Assets</link:label>
    <link:label xlink:label="us-gaap_Assets-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PlanNameAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PlanNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</link:label>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmploymentContractsMember" xlink:label="us-gaap_EmploymentContractsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmploymentContractsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employment Contracts [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmploymentContractsMember" xlink:to="us-gaap_EmploymentContractsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</link:label>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</link:label>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_AnnualBaseSalary" xlink:label="amix_AnnualBaseSalary" xlink:type="locator"/>
    <link:label xlink:label="amix_AnnualBaseSalary-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">amix_AnnualBaseSalary</link:label>
    <link:label xlink:label="amix_AnnualBaseSalary-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual Base Salary</link:label>
    <link:label xlink:label="amix_AnnualBaseSalary-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the annual base salary.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_AnnualBaseSalary" xlink:to="amix_AnnualBaseSalary-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_RfInnovationsIncMember" xlink:label="amix_RfInnovationsIncMember" xlink:type="locator"/>
    <link:label xlink:label="amix_RfInnovationsIncMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">RF Innovations, Inc. [Member]</link:label>
    <link:label xlink:label="amix_RfInnovationsIncMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information pertaining to RF Innovations, Inc.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_RfInnovationsIncMember" xlink:to="amix_RfInnovationsIncMember-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ExecutiveViceChairAndStrategicAdvisorToTheChiefExecutiveOfficerMember" xlink:label="amix_ExecutiveViceChairAndStrategicAdvisorToTheChiefExecutiveOfficerMember" xlink:type="locator"/>
    <link:label xlink:label="amix_ExecutiveViceChairAndStrategicAdvisorToTheChiefExecutiveOfficerMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Executive Vice Chair and Strategic Advisor to the Chief Executive Officer [Member]</link:label>
    <link:label xlink:label="amix_ExecutiveViceChairAndStrategicAdvisorToTheChiefExecutiveOfficerMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information pertaining to the executive vice chair and strategic advisor to the CEO.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_ExecutiveViceChairAndStrategicAdvisorToTheChiefExecutiveOfficerMember" xlink:to="amix_ExecutiveViceChairAndStrategicAdvisorToTheChiefExecutiveOfficerMember-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_InducementOptionsMember" xlink:label="amix_InducementOptionsMember" xlink:type="locator"/>
    <link:label xlink:label="amix_InducementOptionsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inducement Options [Member]</link:label>
    <link:label xlink:label="amix_InducementOptionsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information pertaining to inducement options.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_InducementOptionsMember" xlink:to="amix_InducementOptionsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:label="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Error Corrections and Prior Period Adjustments [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:to="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net Loss (in thousands)</link:label>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AwardTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RestrictedStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConvertibleDebtSecuritiesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debt Securities [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtSecuritiesMember" xlink:to="us-gaap_ConvertibleDebtSecuritiesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeStockOptionMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_WarrantMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LitigationStatusAxis" xlink:label="us-gaap_LitigationStatusAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LitigationStatusAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Status [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LitigationStatusAxis" xlink:to="us-gaap_LitigationStatusAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LitigationStatusDomain" xlink:label="us-gaap_LitigationStatusDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LitigationStatusDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Status [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LitigationStatusDomain" xlink:to="us-gaap_LitigationStatusDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PendingLitigationMember" xlink:label="us-gaap_PendingLitigationMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PendingLitigationMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pending Litigation [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PendingLitigationMember" xlink:to="us-gaap_PendingLitigationMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fixed assets, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LongtermDebtTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LongtermDebtTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_LongtermDebtTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flows from Investing Activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebtMember" xlink:label="us-gaap_ConvertibleDebtMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConvertibleDebtMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debt [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtMember" xlink:to="us-gaap_ConvertibleDebtMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_RelatedPartyTransactionAmountsOfTransaction</link:label>
    <link:label xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Amounts of Transaction</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInAccruedLiabilities</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income taxes</link:label>
    <link:label xlink:label="us-gaap_IncomeTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Effective income tax rate, Total, amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GainLossOnDerivativeInstrumentsNetPretax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_GainLossOnDerivativeInstrumentsNetPretax</link:label>
    <link:label xlink:label="us-gaap_GainLossOnDerivativeInstrumentsNetPretax-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Derivative Instruments, Net, Pretax</link:label>
    <link:label xlink:label="us-gaap_GainLossOnDerivativeInstrumentsNetPretax-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Warrant expense - termination agreement</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:to="us-gaap_GainLossOnDerivativeInstrumentsNetPretax-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingExpenses-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingExpenses</link:label>
    <link:label xlink:label="us-gaap_OperatingExpenses-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInAccountsPayableTrade</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GeneralAndAdministrativeExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Cash-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_Cash</link:label>
    <link:label xlink:label="us-gaap_Cash-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="us-gaap_InterestExpenseNonoperating" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InterestExpenseNonoperating-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_InterestExpenseNonoperating</link:label>
    <link:label xlink:label="us-gaap_InterestExpenseNonoperating-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseNonoperating" xlink:to="us-gaap_InterestExpenseNonoperating-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DebtInstrumentConvertibleConversionPrice1</link:label>
    <link:label xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AllocatedShareBasedCompensationExpense</link:label>
    <link:label xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:label="us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments</link:label>
    <link:label xlink:label="us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Number of Equity Instruments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:to="us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in fair value measurements - warrants mark-to-market</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:label xlink:label="dei_AmendmentFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_UseOfEstimates-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharesOutstanding</link:label>
    <link:label xlink:label="us-gaap_SharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label xlink:label="us-gaap_SharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, outstanding (in shares)</link:label>
    <link:label xlink:label="us-gaap_PreferredStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changes in operating liabilities - increase:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DebtInstrumentInterestRateEffectivePercentage</link:label>
    <link:label xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentFaceAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DebtInstrumentFaceAmount</link:label>
    <link:label xlink:label="us-gaap_DebtInstrumentFaceAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:label xlink:label="us-gaap_DebtInstrumentFaceAmount-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, principal amount</link:label>
    <link:label xlink:label="us-gaap_DebtInstrumentFaceAmount-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, principal amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentType-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InterimPeriodCostsNotAllocableDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interim Period, Costs Not Allocable [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:to="us-gaap_InterimPeriodCostsNotAllocableDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:to="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentInformationLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentInformationTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NatureOfExpenseAxis" xlink:label="us-gaap_NatureOfExpenseAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NatureOfExpenseAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nature of Expense [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="us-gaap_NatureOfExpenseAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</link:label>
    <link:label xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additions</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="amix_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="locator"/>
    <link:label xlink:label="amix_StockIssuedDuringPeriodSharesWarrantsExercised-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common stock - warrants exercised (in shares)</link:label>
    <link:label xlink:label="amix_StockIssuedDuringPeriodSharesWarrantsExercised-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of warrants exercised during the current period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:to="amix_StockIssuedDuringPeriodSharesWarrantsExercised-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="amix_StockIssuedDuringPeriodValueWarrantsExercised" xlink:type="locator"/>
    <link:label xlink:label="amix_StockIssuedDuringPeriodValueWarrantsExercised-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common stock - warrants exercised</link:label>
    <link:label xlink:label="amix_StockIssuedDuringPeriodValueWarrantsExercised-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Value of stock issued as a result of the exercise of warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_StockIssuedDuringPeriodValueWarrantsExercised" xlink:to="amix_StockIssuedDuringPeriodValueWarrantsExercised-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit</link:label>
    <link:label xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Split</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_TheWarrantMember" xlink:label="amix_TheWarrantMember" xlink:type="locator"/>
    <link:label xlink:label="amix_TheWarrantMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The Warrant [Member]</link:label>
    <link:label xlink:label="amix_TheWarrantMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_TheWarrantMember" xlink:to="amix_TheWarrantMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants issued for debt issuance costs</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ConvertibleDebtWith499PercentBeneficialOwnershipLimitationMember" xlink:label="amix_ConvertibleDebtWith499PercentBeneficialOwnershipLimitationMember" xlink:type="locator"/>
    <link:label xlink:label="amix_ConvertibleDebtWith499PercentBeneficialOwnershipLimitationMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debt with 4.99% Beneficial Ownership Limitation [Member]</link:label>
    <link:label xlink:label="amix_ConvertibleDebtWith499PercentBeneficialOwnershipLimitationMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to the convertible debt.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_ConvertibleDebtWith499PercentBeneficialOwnershipLimitationMember" xlink:to="amix_ConvertibleDebtWith499PercentBeneficialOwnershipLimitationMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ConversionOfConvertibleNotesToCommonStockMember" xlink:label="amix_ConversionOfConvertibleNotesToCommonStockMember" xlink:type="locator"/>
    <link:label xlink:label="amix_ConversionOfConvertibleNotesToCommonStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of Convertible Notes to Common Stock [Member]</link:label>
    <link:label xlink:label="amix_ConversionOfConvertibleNotesToCommonStockMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The name of the original debt issue that has been converted in a noncash (or part noncash) transaction during the accounting period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_ConversionOfConvertibleNotesToCommonStockMember" xlink:to="amix_ConversionOfConvertibleNotesToCommonStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCentralIndexKey-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityRegistrantName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueByLiabilityClassAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueByLiabilityClassAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightLockupAgreementTermOfUnderlyingShares" xlink:label="amix_ClassOfWarrantOrRightLockupAgreementTermOfUnderlyingShares" xlink:type="locator"/>
    <link:label xlink:label="amix_ClassOfWarrantOrRightLockupAgreementTermOfUnderlyingShares-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">amix_ClassOfWarrantOrRightLockupAgreementTermOfUnderlyingShares</link:label>
    <link:label xlink:label="amix_ClassOfWarrantOrRightLockupAgreementTermOfUnderlyingShares-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Lock-up Agreement Term of Underlying Shares (Day)</link:label>
    <link:label xlink:label="amix_ClassOfWarrantOrRightLockupAgreementTermOfUnderlyingShares-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pertains to the term of the lock-up agreement associated with the shares underlying the warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_ClassOfWarrantOrRightLockupAgreementTermOfUnderlyingShares" xlink:to="amix_ClassOfWarrantOrRightLockupAgreementTermOfUnderlyingShares-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:label xlink:label="dei_LegalEntityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightPercentageOfOutstandingStock" xlink:label="amix_ClassOfWarrantOrRightPercentageOfOutstandingStock" xlink:type="locator"/>
    <link:label xlink:label="amix_ClassOfWarrantOrRightPercentageOfOutstandingStock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">amix_ClassOfWarrantOrRightPercentageOfOutstandingStock</link:label>
    <link:label xlink:label="amix_ClassOfWarrantOrRightPercentageOfOutstandingStock-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Percentage of Outstanding Stock</link:label>
    <link:label xlink:label="amix_ClassOfWarrantOrRightPercentageOfOutstandingStock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the warrants as a proportion of outstanding capital stock.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_ClassOfWarrantOrRightPercentageOfOutstandingStock" xlink:to="amix_ClassOfWarrantOrRightPercentageOfOutstandingStock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</link:label>
    <link:label xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements</link:label>
    <link:label xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Settlement and reclassification to equity</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_CommonStock12MonthsLockupPeriodMember" xlink:label="amix_CommonStock12MonthsLockupPeriodMember" xlink:type="locator"/>
    <link:label xlink:label="amix_CommonStock12MonthsLockupPeriodMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, 12 Months Lock-up Period [Member]</link:label>
    <link:label xlink:label="amix_CommonStock12MonthsLockupPeriodMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pertains to the shares underlying the warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_CommonStock12MonthsLockupPeriodMember" xlink:to="amix_CommonStock12MonthsLockupPeriodMember-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_CommonStock6MonthsLockupPeriodMember" xlink:label="amix_CommonStock6MonthsLockupPeriodMember" xlink:type="locator"/>
    <link:label xlink:label="amix_CommonStock6MonthsLockupPeriodMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, 6 Months Lock-up Period [Member]</link:label>
    <link:label xlink:label="amix_CommonStock6MonthsLockupPeriodMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pertains to the shares underlying the warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_CommonStock6MonthsLockupPeriodMember" xlink:to="amix_CommonStock6MonthsLockupPeriodMember-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_AccountingAndFinancialReportingServicesMember" xlink:label="amix_AccountingAndFinancialReportingServicesMember" xlink:type="locator"/>
    <link:label xlink:label="amix_AccountingAndFinancialReportingServicesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting and Financial Reporting Services [Member]</link:label>
    <link:label xlink:label="amix_AccountingAndFinancialReportingServicesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Transaction between related party.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_AccountingAndFinancialReportingServicesMember" xlink:to="amix_AccountingAndFinancialReportingServicesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightValueOfSecuritiesCalledByWarrantsOrRights" xlink:label="amix_ClassOfWarrantOrRightValueOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator"/>
    <link:label xlink:label="amix_ClassOfWarrantOrRightValueOfSecuritiesCalledByWarrantsOrRights-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">amix_ClassOfWarrantOrRightValueOfSecuritiesCalledByWarrantsOrRights</link:label>
    <link:label xlink:label="amix_ClassOfWarrantOrRightValueOfSecuritiesCalledByWarrantsOrRights-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Value of Securities Called by Warrants or Rights</link:label>
    <link:label xlink:label="amix_ClassOfWarrantOrRightValueOfSecuritiesCalledByWarrantsOrRights-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Value of securities into which the class of warrant or right may be converted.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_ClassOfWarrantOrRightValueOfSecuritiesCalledByWarrantsOrRights" xlink:to="amix_ClassOfWarrantOrRightValueOfSecuritiesCalledByWarrantsOrRights-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_TerminationAgreementMember" xlink:label="amix_TerminationAgreementMember" xlink:type="locator"/>
    <link:label xlink:label="amix_TerminationAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Termination Agreement [Member]</link:label>
    <link:label xlink:label="amix_TerminationAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information by type of related party transaction.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_TerminationAgreementMember" xlink:to="amix_TerminationAgreementMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdvertisingExpense" xlink:label="us-gaap_AdvertisingExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdvertisingExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AdvertisingExpense</link:label>
    <link:label xlink:label="us-gaap_AdvertisingExpense-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Advertising Expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvertisingExpense" xlink:to="us-gaap_AdvertisingExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_The2023StockPlanMember" xlink:label="amix_The2023StockPlanMember" xlink:type="locator"/>
    <link:label xlink:label="amix_The2023StockPlanMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The 2023 Stock Plan [Member]</link:label>
    <link:label xlink:label="amix_The2023StockPlanMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Plan name for share-based payment arrangement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_The2023StockPlanMember" xlink:to="amix_The2023StockPlanMember-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_TheBridgeOfferingMember" xlink:label="amix_TheBridgeOfferingMember" xlink:type="locator"/>
    <link:label xlink:label="amix_TheBridgeOfferingMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The Bridge Offering [Member]</link:label>
    <link:label xlink:label="amix_TheBridgeOfferingMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_TheBridgeOfferingMember" xlink:to="amix_TheBridgeOfferingMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInOtherCurrentAssets</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ManagementBoardOfDirectorFamilyMember" xlink:label="amix_ManagementBoardOfDirectorFamilyMember" xlink:type="locator"/>
    <link:label xlink:label="amix_ManagementBoardOfDirectorFamilyMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Management, Board of Director, and Family [Member]</link:label>
    <link:label xlink:label="amix_ManagementBoardOfDirectorFamilyMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pertains to the related party.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_ManagementBoardOfDirectorFamilyMember" xlink:to="amix_ManagementBoardOfDirectorFamilyMember-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_SubstantialDoubtAboutGoingConcernPolicyPolicyTextBlock" xlink:label="amix_SubstantialDoubtAboutGoingConcernPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="amix_SubstantialDoubtAboutGoingConcernPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Substantial Doubt About Going Concern Policy [Policy Text Block]</link:label>
    <link:label xlink:label="amix_SubstantialDoubtAboutGoingConcernPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of the accounting policy for substantial doubt about the ability to continue as a going concern.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_SubstantialDoubtAboutGoingConcernPolicyPolicyTextBlock" xlink:to="amix_SubstantialDoubtAboutGoingConcernPolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_JumpstartOurBusinessStartupsJobsActAccountingElectionPolicyPolicyTextBlock" xlink:label="amix_JumpstartOurBusinessStartupsJobsActAccountingElectionPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="amix_JumpstartOurBusinessStartupsJobsActAccountingElectionPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Jumpstart Our Business Startups (JOBS) Act Accounting Election Policy [Policy Text Block]</link:label>
    <link:label xlink:label="amix_JumpstartOurBusinessStartupsJobsActAccountingElectionPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of accounting policy regarding the Jumpstart Our Business Startups Act (the &#8220;JOBS Act&#8221;).</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_JumpstartOurBusinessStartupsJobsActAccountingElectionPolicyPolicyTextBlock" xlink:to="amix_JumpstartOurBusinessStartupsJobsActAccountingElectionPolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_RelatedPartyTransactionsPolicyPolicyTextBlock" xlink:label="amix_RelatedPartyTransactionsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="amix_RelatedPartyTransactionsPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions Policy [Policy Text Block]</link:label>
    <link:label xlink:label="amix_RelatedPartyTransactionsPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of accounting policy for related party transactions.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_RelatedPartyTransactionsPolicyPolicyTextBlock" xlink:to="amix_RelatedPartyTransactionsPolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_MeasurementInputProbabilityRateMember" xlink:label="amix_MeasurementInputProbabilityRateMember" xlink:type="locator"/>
    <link:label xlink:label="amix_MeasurementInputProbabilityRateMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Probability Rate [Member]</link:label>
    <link:label xlink:label="amix_MeasurementInputProbabilityRateMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Measurement input using probability.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_MeasurementInputProbabilityRateMember" xlink:to="amix_MeasurementInputProbabilityRateMember-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ValuationProbabilityweightedExpectedReturnMethodPWERMMember" xlink:label="amix_ValuationProbabilityweightedExpectedReturnMethodPWERMMember" xlink:type="locator"/>
    <link:label xlink:label="amix_ValuationProbabilityweightedExpectedReturnMethodPWERMMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation, Probability-weighted Expected Return Method (PWERM) [Member]</link:label>
    <link:label xlink:label="amix_ValuationProbabilityweightedExpectedReturnMethodPWERMMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information by valuation approach and technique.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_ValuationProbabilityweightedExpectedReturnMethodPWERMMember" xlink:to="amix_ValuationProbabilityweightedExpectedReturnMethodPWERMMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common stock for extinguishment of convertible debt</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_MeasurementInputFixedPriceMember" xlink:label="amix_MeasurementInputFixedPriceMember" xlink:type="locator"/>
    <link:label xlink:label="amix_MeasurementInputFixedPriceMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Fixed Price [Member]</link:label>
    <link:label xlink:label="amix_MeasurementInputFixedPriceMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Measurement input using fixed payment value.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_MeasurementInputFixedPriceMember" xlink:to="amix_MeasurementInputFixedPriceMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common stock for extinguishment of convertible debt (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_WorkingCapitalDeficit" xlink:label="amix_WorkingCapitalDeficit" xlink:type="locator"/>
    <link:label xlink:label="amix_WorkingCapitalDeficit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">amix_WorkingCapitalDeficit</link:label>
    <link:label xlink:label="amix_WorkingCapitalDeficit-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Working Capital (Deficit)</link:label>
    <link:label xlink:label="amix_WorkingCapitalDeficit-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to capital available to meet current, short-term obligations.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_WorkingCapitalDeficit" xlink:to="amix_WorkingCapitalDeficit-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ConvertibleNotesToWarrantsMember" xlink:label="amix_ConvertibleNotesToWarrantsMember" xlink:type="locator"/>
    <link:label xlink:label="amix_ConvertibleNotesToWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Notes to Warrant [Member]</link:label>
    <link:label xlink:label="amix_ConvertibleNotesToWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents convertible notes to warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_ConvertibleNotesToWarrantsMember" xlink:to="amix_ConvertibleNotesToWarrantsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercised, options (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_TableTextBlock</link:label>
    <link:label xlink:label="us-gaap_TableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes Tables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_TableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_TheNotesMember" xlink:label="amix_TheNotesMember" xlink:type="locator"/>
    <link:label xlink:label="amix_TheNotesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The Notes [Member]</link:label>
    <link:label xlink:label="amix_TheNotesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information by type of debt instrument, including, but not limited to, draws against credit facilities.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_TheNotesMember" xlink:to="amix_TheNotesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_QualifiedOfferingOccurringTwoMember" xlink:label="amix_QualifiedOfferingOccurringTwoMember" xlink:type="locator"/>
    <link:label xlink:label="amix_QualifiedOfferingOccurringTwoMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Qualified Offering Occurring, Two [Member]</link:label>
    <link:label xlink:label="amix_QualifiedOfferingOccurringTwoMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_QualifiedOfferingOccurringTwoMember" xlink:to="amix_QualifiedOfferingOccurringTwoMember-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_QualifiedOfferingOccurringOneMember" xlink:label="amix_QualifiedOfferingOccurringOneMember" xlink:type="locator"/>
    <link:label xlink:label="amix_QualifiedOfferingOccurringOneMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Qualified Offering Occurring, One [Member]</link:label>
    <link:label xlink:label="amix_QualifiedOfferingOccurringOneMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_QualifiedOfferingOccurringOneMember" xlink:to="amix_QualifiedOfferingOccurringOneMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of restricted common stock (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_NoQualifiedOfferingOccurringMember" xlink:label="amix_NoQualifiedOfferingOccurringMember" xlink:type="locator"/>
    <link:label xlink:label="amix_NoQualifiedOfferingOccurringMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">No Qualified Offering Occurring [Member]</link:label>
    <link:label xlink:label="amix_NoQualifiedOfferingOccurringMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_NoQualifiedOfferingOccurringMember" xlink:to="amix_NoQualifiedOfferingOccurringMember-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightExercisesInPeriod" xlink:label="amix_ClassOfWarrantOrRightExercisesInPeriod" xlink:type="locator"/>
    <link:label xlink:label="amix_ClassOfWarrantOrRightExercisesInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">amix_ClassOfWarrantOrRightExercisesInPeriod</link:label>
    <link:label xlink:label="amix_ClassOfWarrantOrRightExercisesInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercises in Period (in shares)</link:label>
    <link:label xlink:label="amix_ClassOfWarrantOrRightExercisesInPeriod-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Exercised, outstanding (in shares)</link:label>
    <link:label xlink:label="amix_ClassOfWarrantOrRightExercisesInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of warrants exercised during the current period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_ClassOfWarrantOrRightExercisesInPeriod" xlink:to="amix_ClassOfWarrantOrRightExercisesInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightExpirationsInPeriod" xlink:label="amix_ClassOfWarrantOrRightExpirationsInPeriod" xlink:type="locator"/>
    <link:label xlink:label="amix_ClassOfWarrantOrRightExpirationsInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">amix_ClassOfWarrantOrRightExpirationsInPeriod</link:label>
    <link:label xlink:label="amix_ClassOfWarrantOrRightExpirationsInPeriod-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Expired, outstanding (in shares)</link:label>
    <link:label xlink:label="amix_ClassOfWarrantOrRightExpirationsInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of warrants for which the right to exercise has lapsed under the terms of the plan agreements.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_ClassOfWarrantOrRightExpirationsInPeriod" xlink:to="amix_ClassOfWarrantOrRightExpirationsInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of restricted common stock</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightForfeituresInPeriod" xlink:label="amix_ClassOfWarrantOrRightForfeituresInPeriod" xlink:type="locator"/>
    <link:label xlink:label="amix_ClassOfWarrantOrRightForfeituresInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">amix_ClassOfWarrantOrRightForfeituresInPeriod</link:label>
    <link:label xlink:label="amix_ClassOfWarrantOrRightForfeituresInPeriod-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Forfeited/Cancelled, outstanding (in shares)</link:label>
    <link:label xlink:label="amix_ClassOfWarrantOrRightForfeituresInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of warrants that were cancelled during the period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_ClassOfWarrantOrRightForfeituresInPeriod" xlink:to="amix_ClassOfWarrantOrRightForfeituresInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember" xlink:label="amix_BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember" xlink:type="locator"/>
    <link:label xlink:label="amix_BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bridge Financing Warrants in Connection with Convertible Notes [Member[</link:label>
    <link:label xlink:label="amix_BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information by type of warrant or right issued.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember" xlink:to="amix_BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related and Nonrelated Parties [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RelatedPartyDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related and Nonrelated Parties [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightGrantsInPeriod" xlink:label="amix_ClassOfWarrantOrRightGrantsInPeriod" xlink:type="locator"/>
    <link:label xlink:label="amix_ClassOfWarrantOrRightGrantsInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Granted, outstanding (in shares)</link:label>
    <link:label xlink:label="amix_ClassOfWarrantOrRightGrantsInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The number of warrants granted during the period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_ClassOfWarrantOrRightGrantsInPeriod" xlink:to="amix_ClassOfWarrantOrRightGrantsInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="amix_ClassOfWarrantOrRightForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="amix_ClassOfWarrantOrRightForfeituresInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forfeited/Cancelled, weighted average exercise price (in dollars per share)</link:label>
    <link:label xlink:label="amix_ClassOfWarrantOrRightForfeituresInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted average price at which holders could have acquired the underlying shares with respect to warrants that were terminated.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_ClassOfWarrantOrRightForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="amix_ClassOfWarrantOrRightForfeituresInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PercentageOfFIFOInventory" xlink:label="us-gaap_PercentageOfFIFOInventory" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PercentageOfFIFOInventory-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discount rate at issuance (1)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PercentageOfFIFOInventory" xlink:to="us-gaap_PercentageOfFIFOInventory-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice" xlink:label="amix_ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="amix_ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercisable, weighted average exercise price (in dollars per share)</link:label>
    <link:label xlink:label="amix_ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The weighted-average price as of the balance sheet date at which holders can acquire the shares on warrants outstanding and currently exercisable.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice" xlink:to="amix_ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="amix_ClassOfWarrantOrRightExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="amix_ClassOfWarrantOrRightExpirationsInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expired, weighted average exercise price (in dollars per share)</link:label>
    <link:label xlink:label="amix_ClassOfWarrantOrRightExpirationsInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted average price at which holders could have acquired the underlying shares with respect to the warrants that expired.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_ClassOfWarrantOrRightExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="amix_ClassOfWarrantOrRightExpirationsInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightOutstandingOutstandingWeightedAverageExercisePrice" xlink:label="amix_ClassOfWarrantOrRightOutstandingOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="amix_ClassOfWarrantOrRightOutstandingOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">amix_ClassOfWarrantOrRightOutstandingOutstandingWeightedAverageExercisePrice</link:label>
    <link:label xlink:label="amix_ClassOfWarrantOrRightOutstandingOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, weighted average exercise price (in dollars per share)</link:label>
    <link:label xlink:label="amix_ClassOfWarrantOrRightOutstandingOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, weighted average exercise price (in dollars per share)</link:label>
    <link:label xlink:label="amix_ClassOfWarrantOrRightOutstandingOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted average price at which holders can acquire the shares reserved for issuance under the warrant plan.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_ClassOfWarrantOrRightOutstandingOutstandingWeightedAverageExercisePrice" xlink:to="amix_ClassOfWarrantOrRightOutstandingOutstandingWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Granted, options (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightExercisableNumber" xlink:label="amix_ClassOfWarrantOrRightExercisableNumber" xlink:type="locator"/>
    <link:label xlink:label="amix_ClassOfWarrantOrRightExercisableNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercisable (in shares)</link:label>
    <link:label xlink:label="amix_ClassOfWarrantOrRightExercisableNumber-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The number of shares into which fully or partially vested warrants outstanding as of the balance sheet date can be currently converted under the option plan.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_ClassOfWarrantOrRightExercisableNumber" xlink:to="amix_ClassOfWarrantOrRightExercisableNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant measurement input</link:label>
    <link:label xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants and Rights Outstanding, Measurement Input</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Forfeited/Cancelled, options (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightExercisesInPeriodWeightedAverageExercisePrice" xlink:label="amix_ClassOfWarrantOrRightExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="amix_ClassOfWarrantOrRightExercisesInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercised, weighted average exercise price (in dollars per share)</link:label>
    <link:label xlink:label="amix_ClassOfWarrantOrRightExercisesInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted average price at which warrant holders acquired shares when converting their warrants into shares.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_ClassOfWarrantOrRightExercisesInPeriodWeightedAverageExercisePrice" xlink:to="amix_ClassOfWarrantOrRightExercisesInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_WarrantsAndRightsOutstandingTerm</link:label>
    <link:label xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants and Rights Outstanding, Term (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightGrantsInPeriodWeightedAverageExercise" xlink:label="amix_ClassOfWarrantOrRightGrantsInPeriodWeightedAverageExercise" xlink:type="locator"/>
    <link:label xlink:label="amix_ClassOfWarrantOrRightGrantsInPeriodWeightedAverageExercise-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Granted, weighted average exercise price (in dollars per share)</link:label>
    <link:label xlink:label="amix_ClassOfWarrantOrRightGrantsInPeriodWeightedAverageExercise-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted average per share amount at which holders can acquire shares of common stock by exercise of warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_ClassOfWarrantOrRightGrantsInPeriodWeightedAverageExercise" xlink:to="amix_ClassOfWarrantOrRightGrantsInPeriodWeightedAverageExercise-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerm" xlink:label="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerm" xlink:type="locator"/>
    <link:label xlink:label="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerm-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercisable, warrants, weighted average remaining contractual term ( (Year)</link:label>
    <link:label xlink:label="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerm-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted average remaining contractual term for equity-based awards excluding options, currently exercisable, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerm" xlink:to="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerm-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common stock (in shares)</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Issued for Services</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_SharebasedCompensationArrangementBySharebasedPaymentAwardNonoptionEquityInstrumentsExercisableNumberOutstandingNumber" xlink:label="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardNonoptionEquityInstrumentsExercisableNumberOutstandingNumber" xlink:type="locator"/>
    <link:label xlink:label="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardNonoptionEquityInstrumentsExercisableNumberOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercisable, warrants (in shares)</link:label>
    <link:label xlink:label="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardNonoptionEquityInstrumentsExercisableNumberOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The number of shares into which equity instruments other than options can be currently converted.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardNonoptionEquityInstrumentsExercisableNumberOutstandingNumber" xlink:to="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardNonoptionEquityInstrumentsExercisableNumberOutstandingNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LiabilitiesAndStockholdersEquity</link:label>
    <link:label xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Liabilities and Stockholders' Equity</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common stock</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RelatedPartyTransactionAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RelatedPartyTransactionDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changes in operating assets - (increase)/decrease:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetsNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AssetsNoncurrent</link:label>
    <link:label xlink:label="us-gaap_AssetsNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total long-term assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingCostsAndExpensesAbstract" xlink:label="us-gaap_OperatingCostsAndExpensesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingCostsAndExpensesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_OperatingCostsAndExpensesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="us-gaap_MeasurementInputDiscountRateMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MeasurementInputDiscountRateMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputDiscountRateMember" xlink:to="us-gaap_MeasurementInputDiscountRateMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MeasurementInputPriceVolatilityMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Price Volatility [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InterestExpenseDebt-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_InterestExpenseDebt</link:label>
    <link:label xlink:label="us-gaap_InterestExpenseDebt-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DisclosureTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DisclosureTextBlockAbstract</link:label>
    <link:label xlink:label="us-gaap_DisclosureTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes to Financial Statements</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureTextBlockAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Granted, warrants, weighted average exercise price (in dollars per share)</link:label>
    <link:label xlink:label="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted average per share amount at which holders can acquire shares of common stock by exercise of warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:label="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice</link:label>
    <link:label xlink:label="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, warrants, weighted average exercise price (in dollars per share)</link:label>
    <link:label xlink:label="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, warrants, weighted average exercise price (in dollars per share)</link:label>
    <link:label xlink:label="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted average price at which holders can acquire the shares under the warrant plan.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:to="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsequentEventMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MeasurementInputExpectedTermMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Expected Term [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember" xlink:label="us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Discount for Lack of Marketability [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember" xlink:to="us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm" xlink:label="amix_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm" xlink:type="locator"/>
    <link:label xlink:label="amix_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding, remaining term (Year)</link:label>
    <link:label xlink:label="amix_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted average remaining contractual term for warrants outstanding.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm" xlink:to="amix_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice" xlink:label="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercisable, warrants, weighted average exercise price (in dollars per share)</link:label>
    <link:label xlink:label="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The weighted-average price at which holders can acquire the shares on vested portions of warrants outstanding and currently exercisable.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice" xlink:to="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsequentEventTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightExercisableWeightedAverageRemainingContractualTerm" xlink:label="amix_ClassOfWarrantOrRightExercisableWeightedAverageRemainingContractualTerm" xlink:type="locator"/>
    <link:label xlink:label="amix_ClassOfWarrantOrRightExercisableWeightedAverageRemainingContractualTerm-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercisable, remaining term (Year)</link:label>
    <link:label xlink:label="amix_ClassOfWarrantOrRightExercisableWeightedAverageRemainingContractualTerm-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted average remaining contractual term for vested portions of warrants currently exercisable or convertible.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_ClassOfWarrantOrRightExercisableWeightedAverageRemainingContractualTerm" xlink:to="amix_ClassOfWarrantOrRightExercisableWeightedAverageRemainingContractualTerm-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsequentEventTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercised, warrants, weighted average exercise price (in dollars per share)</link:label>
    <link:label xlink:label="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted average price at which warrant holders acquired shares when converting their warrants into shares.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expired, warrants, weighted average exercise price (in dollars per share)</link:label>
    <link:label xlink:label="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted average price at which holders could have acquired the underlying shares with respect to warrants of the plan that expired.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCosts" xlink:label="us-gaap_DeferredCosts" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredCosts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred offering costs</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCosts" xlink:to="us-gaap_DeferredCosts-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsequentEventsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forfeited/Cancelled, warrants, weighted average exercise price (in dollars per share)</link:label>
    <link:label xlink:label="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted average price at which holders could have acquired the underlying shares with respect to warrants that were terminated.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ScenarioContractTerminationWithoutCauseMember" xlink:label="amix_ScenarioContractTerminationWithoutCauseMember" xlink:type="locator"/>
    <link:label xlink:label="amix_ScenarioContractTerminationWithoutCauseMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario, Contract Termination, Without Cause [Member]</link:label>
    <link:label xlink:label="amix_ScenarioContractTerminationWithoutCauseMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to contract termination.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_ScenarioContractTerminationWithoutCauseMember" xlink:to="amix_ScenarioContractTerminationWithoutCauseMember-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_EmploymentAgreementBonusAsAPercentageOfAnnualBaseCompensation" xlink:label="amix_EmploymentAgreementBonusAsAPercentageOfAnnualBaseCompensation" xlink:type="locator"/>
    <link:label xlink:label="amix_EmploymentAgreementBonusAsAPercentageOfAnnualBaseCompensation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">amix_EmploymentAgreementBonusAsAPercentageOfAnnualBaseCompensation</link:label>
    <link:label xlink:label="amix_EmploymentAgreementBonusAsAPercentageOfAnnualBaseCompensation-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employment Agreement, Bonus as a Percentage of Annual Base Compensation</link:label>
    <link:label xlink:label="amix_EmploymentAgreementBonusAsAPercentageOfAnnualBaseCompensation-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commitment made to pay an annual bonus expressed as a percentage of the individual's base salary.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_EmploymentAgreementBonusAsAPercentageOfAnnualBaseCompensation" xlink:to="amix_EmploymentAgreementBonusAsAPercentageOfAnnualBaseCompensation-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MeasurementInputTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MeasurementInputTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EmployeeBenefitsAndShareBasedCompensation</link:label>
    <link:label xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Benefits and Share-Based Compensation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightAggregateIntrinsicValueOutstanding" xlink:label="amix_ClassOfWarrantOrRightAggregateIntrinsicValueOutstanding" xlink:type="locator"/>
    <link:label xlink:label="amix_ClassOfWarrantOrRightAggregateIntrinsicValueOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding, intrinsic value</link:label>
    <link:label xlink:label="amix_ClassOfWarrantOrRightAggregateIntrinsicValueOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Intrinsic value of outstanding warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_ClassOfWarrantOrRightAggregateIntrinsicValueOutstanding" xlink:to="amix_ClassOfWarrantOrRightAggregateIntrinsicValueOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_EmploymentAgreementTermOfContract" xlink:label="amix_EmploymentAgreementTermOfContract" xlink:type="locator"/>
    <link:label xlink:label="amix_EmploymentAgreementTermOfContract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">amix_EmploymentAgreementTermOfContract</link:label>
    <link:label xlink:label="amix_EmploymentAgreementTermOfContract-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employment Agreement, Term of Contract (Year)</link:label>
    <link:label xlink:label="amix_EmploymentAgreementTermOfContract-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pertains to the terms of the employment agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_EmploymentAgreementTermOfContract" xlink:to="amix_EmploymentAgreementTermOfContract-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightAggregateIntrinsicValueExercisable" xlink:label="amix_ClassOfWarrantOrRightAggregateIntrinsicValueExercisable" xlink:type="locator"/>
    <link:label xlink:label="amix_ClassOfWarrantOrRightAggregateIntrinsicValueExercisable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercisable, intrinsic value</link:label>
    <link:label xlink:label="amix_ClassOfWarrantOrRightAggregateIntrinsicValueExercisable-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Intrinsic value of warrants currently exercisable.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_ClassOfWarrantOrRightAggregateIntrinsicValueExercisable" xlink:to="amix_ClassOfWarrantOrRightAggregateIntrinsicValueExercisable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:label="us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ValuationTechniqueDiscountedCashFlowMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Technique, Discounted Cash Flow [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:to="us-gaap_ValuationTechniqueDiscountedCashFlowMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="us-gaap_ValuationTechniqueAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ValuationTechniqueAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Approach and Technique [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="us-gaap_ValuationTechniqueDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ValuationTechniqueDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Approach and Technique [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationTechniqueDomain" xlink:to="us-gaap_ValuationTechniqueDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common stock, net of discount for lack of marketability</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Employee [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueAdjustmentOfWarrants-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant liability - mark-to-market</link:label>
    <link:label xlink:label="us-gaap_FairValueAdjustmentOfWarrants-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Adjustment of Warrants</link:label>
    <link:label xlink:label="us-gaap_FairValueAdjustmentOfWarrants-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Warrant liability - mark-to-market</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DebtConversionConvertedInstrumentAmount1</link:label>
    <link:label xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock for extinguishment of convertible debt</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensation</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</link:label>
    <link:label xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Conversion, Converted Instrument, Shares Issued (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerSharePolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtConversionOriginalDebtAmount1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible notes converted into common stock</link:label>
    <link:label xlink:label="us-gaap_DebtConversionOriginalDebtAmount1-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock for extinguishment of convertible debt</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionOriginalDebtAmount1" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Revenues-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_Revenues</link:label>
    <link:label xlink:label="us-gaap_Revenues-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Conversion Description [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsDiscountRate" xlink:label="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsDiscountRate" xlink:type="locator"/>
    <link:label xlink:label="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsDiscountRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">amix_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsDiscountRate</link:label>
    <link:label xlink:label="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsDiscountRate-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Discount Rate</link:label>
    <link:label xlink:label="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsDiscountRate-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The interest rate assumption that is used in valuing an option on its own shares.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsDiscountRate" xlink:to="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsDiscountRate-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtConversionNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Conversion, Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionNameDomain" xlink:to="us-gaap_DebtConversionNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ScenarioContractTerminationMember" xlink:label="amix_ScenarioContractTerminationMember" xlink:type="locator"/>
    <link:label xlink:label="amix_ScenarioContractTerminationMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario, Contract Termination [Member]</link:label>
    <link:label xlink:label="amix_ScenarioContractTerminationMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to the termination of the employment contract.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_ScenarioContractTerminationMember" xlink:to="amix_ScenarioContractTerminationMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AmortizationOfDebtDiscountPremium-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of debt discount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_BlackscholesModelMember" xlink:label="amix_BlackscholesModelMember" xlink:type="locator"/>
    <link:label xlink:label="amix_BlackscholesModelMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Black-Scholes Model [Member]</link:label>
    <link:label xlink:label="amix_BlackscholesModelMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Black-Scholes-Merton used to estimate fair value of award under share-based payment arrangement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_BlackscholesModelMember" xlink:to="amix_BlackscholesModelMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetsFairValueDisclosure-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AssetsFairValueDisclosure</link:label>
    <link:label xlink:label="us-gaap_AssetsFairValueDisclosure-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DepreciationDepletionAndAmortization-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation and amortization expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharesIssuedPricePerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharesIssuedPricePerShare</link:label>
    <link:label xlink:label="us-gaap_SharesIssuedPricePerShare-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares Issued, Price Per Share (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AssetsCurrent</link:label>
    <link:label xlink:label="us-gaap_AssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetsNoncurrentAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term assets:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdvertisingCostsPolicyTextBlock" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Advertising Cost [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvertisingCostsPolicyTextBlock" xlink:to="us-gaap_AdvertisingCostsPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, $0.001 par value, 500,000,000 shares authorized, 2,497,033 and 942,575 shares issued and outstanding as of March 31, 2025 and March 31, 2024, respectively.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueMeasurementFrequencyDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueMeasurementsRecurringMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, authorized (in shares)</link:label>
    <link:label xlink:label="us-gaap_CommonStockSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesIssued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, issued (in shares)</link:label>
    <link:label xlink:label="us-gaap_CommonStockSharesIssued-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockParOrStatedValuePerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_CommonStockParOrStatedValuePerShare-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityPolicyTextBlock" xlink:label="us-gaap_StockholdersEquityPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquityPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityPolicyTextBlock" xlink:to="us-gaap_StockholdersEquityPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</link:label>
    <link:label xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_RestatementAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revision of Prior Period [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain" xlink:type="locator"/>
    <link:label xlink:label="srt_RestatementDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revision of Prior Period [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementDomain" xlink:to="srt_RestatementDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="srt_ScenarioPreviouslyReportedMember" xlink:type="locator"/>
    <link:label xlink:label="srt_ScenarioPreviouslyReportedMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Previously Reported [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioPreviouslyReportedMember" xlink:to="srt_ScenarioPreviouslyReportedMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxAssetsValuationAllowance</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance for deferred tax assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:label xlink:label="srt_RangeMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:label xlink:label="srt_MaximumMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-cash financing activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:label xlink:label="srt_MinimumMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherAssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxAssetsNet</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsNet-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_RangeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="us-gaap_DebtPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtPolicyTextBlock" xlink:to="us-gaap_DebtPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, $0.001 par value, 10,000,000 shares authorized, no shares issued and outstanding as of March 31, 2025 and March 31, 2024, respectively.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxAssetsLiabilitiesNet</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockSharesIssued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, issued (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxAssetsGross</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsGross-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, authorized (in shares)</link:label>
    <link:label xlink:label="us-gaap_PreferredStockSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueInputsLevel3Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accruals and reserves</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PropertyPlantAndEquipmentUsefulLife</link:label>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" xlink:label="srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" xlink:type="locator"/>
    <link:label xlink:label="srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revision of Prior Period, Error Correction, Adjustment [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" xlink:to="srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flows from Operating Activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_WarrantsAndRightsOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_WarrantsAndRightsOutstanding</link:label>
    <link:label xlink:label="us-gaap_WarrantsAndRightsOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants and Rights Outstanding</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NumberOfOperatingSegments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NumberOfOperatingSegments</link:label>
    <link:label xlink:label="us-gaap_NumberOfOperatingSegments-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NumberOfReportableSegments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NumberOfReportableSegments</link:label>
    <link:label xlink:label="us-gaap_NumberOfReportableSegments-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdditionalPaidInCapital-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquityAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' equity:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_BoardOfDirectorsChairmanMember" xlink:label="srt_BoardOfDirectorsChairmanMember" xlink:type="locator"/>
    <link:label xlink:label="srt_BoardOfDirectorsChairmanMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Board of Directors Chairman [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_BoardOfDirectorsChairmanMember" xlink:to="srt_BoardOfDirectorsChairmanMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NonoperatingIncomeExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NonoperatingIncomeExpense</link:label>
    <link:label xlink:label="us-gaap_NonoperatingIncomeExpense-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other income (expense)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net operating losses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ChiefFinancialOfficerMember" xlink:label="srt_ChiefFinancialOfficerMember" xlink:type="locator"/>
    <link:label xlink:label="srt_ChiefFinancialOfficerMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Chief Financial Officer [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefFinancialOfficerMember" xlink:to="srt_ChiefFinancialOfficerMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember" xlink:type="locator"/>
    <link:label xlink:label="srt_ChiefExecutiveOfficerMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Chief Executive Officer [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefExecutiveOfficerMember" xlink:to="srt_ChiefExecutiveOfficerMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetsCurrentAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueDisclosuresTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</link:label>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, at beginning of period</link:label>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, at end of period</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IPOMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">IPO [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PrivatePlacementMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Private Placement [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InvestmentIncomeInterest-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</link:label>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net change in cash and cash equivalents</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OverAllotmentOptionMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets related to:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInFinancingActivities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Liabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_Liabilities</link:label>
    <link:label xlink:label="us-gaap_Liabilities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommitmentsAndContingencies-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and contingencies (Note 5)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsidiarySaleOfStockAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember" xlink:type="locator"/>
    <link:label xlink:label="srt_DirectorMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Director [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingIncomeLoss</link:label>
    <link:label xlink:label="us-gaap_OperatingIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInOperatingActivities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other income (expense):</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxLiabilities</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxLiabilities-label" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInInvestingActivities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_CounterpartyNameAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:label xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ManagementMember" xlink:label="srt_ManagementMember" xlink:type="locator"/>
    <link:label xlink:label="srt_ManagementMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Management [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ManagementMember" xlink:to="srt_ManagementMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PaymentsOfStockIssuanceCosts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PaymentsOfStockIssuanceCosts</link:label>
    <link:label xlink:label="us-gaap_PaymentsOfStockIssuanceCosts-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:label xlink:label="us-gaap_PaymentsOfStockIssuanceCosts-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payment of issuance costs for registration statement</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AccountsPayableCurrentAndNoncurrent</link:label>
    <link:label xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Payable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:to="us-gaap_AccountsPayableCurrentAndNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities related to:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance or Sale of Equity</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:label xlink:label="srt_ScenarioUnspecifiedDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ProceedsFromIssuanceOfWarrants</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Warrants</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromWarrantExercises-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from exercise of warrants</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RetainedEarningsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common stock from IPO</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of common stock</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of common stock</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:label xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title and Position [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_TitleOfIndividualAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title and Position [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_StatementScenarioAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdditionalPaidInCapitalMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementEquityComponentsAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EquityComponentDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</link:label>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_DeferredTaxLiabilitiesChangeInAccountingMethod" xlink:label="amix_DeferredTaxLiabilitiesChangeInAccountingMethod" xlink:type="locator"/>
    <link:label xlink:label="amix_DeferredTaxLiabilitiesChangeInAccountingMethod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">amix_DeferredTaxLiabilitiesChangeInAccountingMethod</link:label>
    <link:label xlink:label="amix_DeferredTaxLiabilitiesChangeInAccountingMethod-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Section 481A method change</link:label>
    <link:label xlink:label="amix_DeferredTaxLiabilitiesChangeInAccountingMethod-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of deferred tax liability attributable to taxable temporary differences from Section 481A method change.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_DeferredTaxLiabilitiesChangeInAccountingMethod" xlink:to="amix_DeferredTaxLiabilitiesChangeInAccountingMethod-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ATMAgreementMember" xlink:label="amix_ATMAgreementMember" xlink:type="locator"/>
    <link:label xlink:label="amix_ATMAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ATM Agreement [Member]</link:label>
    <link:label xlink:label="amix_ATMAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the ATM Agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_ATMAgreementMember" xlink:to="amix_ATMAgreementMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</link:label>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ClassOfWarrantOrRightOutstanding</link:label>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Outstanding (in shares)</link:label>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance, outstanding (in shares)</link:label>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance, outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="us-gaap_ConvertibleNotesPayable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConvertibleNotesPayable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ConvertibleNotesPayable</link:label>
    <link:label xlink:label="us-gaap_ConvertibleNotesPayable-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Notes Payable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayable" xlink:to="us-gaap_ConvertibleNotesPayable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</link:label>
    <link:label xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss before income taxes</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</link:label>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PaymentsOfFinancingCosts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PaymentsOfFinancingCosts</link:label>
    <link:label xlink:label="us-gaap_PaymentsOfFinancingCosts-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments of Financing Costs</link:label>
    <link:label xlink:label="us-gaap_PaymentsOfFinancingCosts-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payment of issuance costs for financing</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfFinancingCosts" xlink:to="us-gaap_PaymentsOfFinancingCosts-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet-label" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, amortized debt discount</link:label>
    <link:label xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet-label" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, amortized debt discount</link:label>
    <link:label xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountingPoliciesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RelatedPartyMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_EquityOfferingMaximumOfferingAmount" xlink:label="amix_EquityOfferingMaximumOfferingAmount" xlink:type="locator"/>
    <link:label xlink:label="amix_EquityOfferingMaximumOfferingAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">amix_EquityOfferingMaximumOfferingAmount</link:label>
    <link:label xlink:label="amix_EquityOfferingMaximumOfferingAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Offering, Maximum Offering Amount</link:label>
    <link:label xlink:label="amix_EquityOfferingMaximumOfferingAmount-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Maximum value of company's equity authorized for issuance under equity offering.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_EquityOfferingMaximumOfferingAmount" xlink:to="amix_EquityOfferingMaximumOfferingAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromConvertibleDebt-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of convertible debt</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromConvertibleDebt-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Convertible Debt</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeStatementLocationAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeStatementLocationDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonmonetaryTransactionTypeDomain" xlink:label="us-gaap_NonmonetaryTransactionTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NonmonetaryTransactionTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonmonetary Transaction Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonmonetaryTransactionTypeDomain" xlink:to="us-gaap_NonmonetaryTransactionTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_SeriesBWarrantsMember" xlink:label="amix_SeriesBWarrantsMember" xlink:type="locator"/>
    <link:label xlink:label="amix_SeriesBWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series B Warrants [Member]</link:label>
    <link:label xlink:label="amix_SeriesBWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the series B warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_SeriesBWarrantsMember" xlink:to="amix_SeriesBWarrantsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TypeOfArrangementAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_PreipoWarrantsMember" xlink:label="amix_PreipoWarrantsMember" xlink:type="locator"/>
    <link:label xlink:label="amix_PreipoWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-IPO Warrants [Member]</link:label>
    <link:label xlink:label="amix_PreipoWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pre-IPO warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_PreipoWarrantsMember" xlink:to="amix_PreipoWarrantsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ExistingWarrantsAt1722ExercisePriceMember" xlink:label="amix_ExistingWarrantsAt1722ExercisePriceMember" xlink:type="locator"/>
    <link:label xlink:label="amix_ExistingWarrantsAt1722ExercisePriceMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Existing Warrants at 1.722 Exercise Price [Member]</link:label>
    <link:label xlink:label="amix_ExistingWarrantsAt1722ExercisePriceMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the existing warrants with an exercise price of $1.722.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_ExistingWarrantsAt1722ExercisePriceMember" xlink:to="amix_ExistingWarrantsAt1722ExercisePriceMember-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ExistingWarrantsAt1723ExercisePriceMember" xlink:label="amix_ExistingWarrantsAt1723ExercisePriceMember" xlink:type="locator"/>
    <link:label xlink:label="amix_ExistingWarrantsAt1723ExercisePriceMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Existing Warrants at 1.723 Exercise Price [Member]</link:label>
    <link:label xlink:label="amix_ExistingWarrantsAt1723ExercisePriceMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the existing warrants at an exercise price of $1.723.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_ExistingWarrantsAt1723ExercisePriceMember" xlink:to="amix_ExistingWarrantsAt1723ExercisePriceMember-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightExercisedInPeriodCashless" xlink:label="amix_ClassOfWarrantOrRightExercisedInPeriodCashless" xlink:type="locator"/>
    <link:label xlink:label="amix_ClassOfWarrantOrRightExercisedInPeriodCashless-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">amix_ClassOfWarrantOrRightExercisedInPeriodCashless</link:label>
    <link:label xlink:label="amix_ClassOfWarrantOrRightExercisedInPeriodCashless-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant Or Right Exercised In Period, Cashless (in shares)</link:label>
    <link:label xlink:label="amix_ClassOfWarrantOrRightExercisedInPeriodCashless-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of warrants exercised during the current period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_ClassOfWarrantOrRightExercisedInPeriodCashless" xlink:to="amix_ClassOfWarrantOrRightExercisedInPeriodCashless-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TaxPeriodDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Period [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_TaxPeriodDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonmonetaryTransactionTypeAxis" xlink:label="us-gaap_NonmonetaryTransactionTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NonmonetaryTransactionTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonmonetary Transaction Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonmonetaryTransactionTypeAxis" xlink:to="us-gaap_NonmonetaryTransactionTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightExercisedInPeriodCash" xlink:label="amix_ClassOfWarrantOrRightExercisedInPeriodCash" xlink:type="locator"/>
    <link:label xlink:label="amix_ClassOfWarrantOrRightExercisedInPeriodCash-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">amix_ClassOfWarrantOrRightExercisedInPeriodCash</link:label>
    <link:label xlink:label="amix_ClassOfWarrantOrRightExercisedInPeriodCash-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant Or Right Exercised In Period, Cash (in shares)</link:label>
    <link:label xlink:label="amix_ClassOfWarrantOrRightExercisedInPeriodCash-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of warrants exercised during the current period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_ClassOfWarrantOrRightExercisedInPeriodCash" xlink:to="amix_ClassOfWarrantOrRightExercisedInPeriodCash-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ExistingWarrantsMember" xlink:label="amix_ExistingWarrantsMember" xlink:type="locator"/>
    <link:label xlink:label="amix_ExistingWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Existing Warrants [Member]</link:label>
    <link:label xlink:label="amix_ExistingWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the existing warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_ExistingWarrantsMember" xlink:to="amix_ExistingWarrantsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightExchangesPercentageOfUnderlyingShares" xlink:label="amix_ClassOfWarrantOrRightExchangesPercentageOfUnderlyingShares" xlink:type="locator"/>
    <link:label xlink:label="amix_ClassOfWarrantOrRightExchangesPercentageOfUnderlyingShares-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">amix_ClassOfWarrantOrRightExchangesPercentageOfUnderlyingShares</link:label>
    <link:label xlink:label="amix_ClassOfWarrantOrRightExchangesPercentageOfUnderlyingShares-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exchanges, Percentage of Underlying Shares</link:label>
    <link:label xlink:label="amix_ClassOfWarrantOrRightExchangesPercentageOfUnderlyingShares-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The percent of underlying shares related to the exchange of warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_ClassOfWarrantOrRightExchangesPercentageOfUnderlyingShares" xlink:to="amix_ClassOfWarrantOrRightExchangesPercentageOfUnderlyingShares-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TaxPeriodAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Period [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_DeferredFinancingCostsRelatedToTheIssuanceOfCommonStock" xlink:label="amix_DeferredFinancingCostsRelatedToTheIssuanceOfCommonStock" xlink:type="locator"/>
    <link:label xlink:label="amix_DeferredFinancingCostsRelatedToTheIssuanceOfCommonStock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recognition of deferred financing costs associated with issuance of common stock</link:label>
    <link:label xlink:label="amix_DeferredFinancingCostsRelatedToTheIssuanceOfCommonStock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of deferred financing costs related to the issuance of common stock.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_DeferredFinancingCostsRelatedToTheIssuanceOfCommonStock" xlink:to="amix_DeferredFinancingCostsRelatedToTheIssuanceOfCommonStock-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_PaymentsForWarrantIssuanceFees" xlink:label="amix_PaymentsForWarrantIssuanceFees" xlink:type="locator"/>
    <link:label xlink:label="amix_PaymentsForWarrantIssuanceFees-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">amix_PaymentsForWarrantIssuanceFees</link:label>
    <link:label xlink:label="amix_PaymentsForWarrantIssuanceFees-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments for Warrant Issuance Fees</link:label>
    <link:label xlink:label="amix_PaymentsForWarrantIssuanceFees-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The cash outflow for the payment of warrant issuance fees.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_PaymentsForWarrantIssuanceFees" xlink:to="amix_PaymentsForWarrantIssuanceFees-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharePrice</link:label>
    <link:label xlink:label="us-gaap_SharePrice-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive securities (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_IssuanceOfCommonStockForExtinguishmentOfConvertibleDebtMember" xlink:label="amix_IssuanceOfCommonStockForExtinguishmentOfConvertibleDebtMember" xlink:type="locator"/>
    <link:label xlink:label="amix_IssuanceOfCommonStockForExtinguishmentOfConvertibleDebtMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of Common Stock for Extinguishment of Convertible Debt [Member]</link:label>
    <link:label xlink:label="amix_IssuanceOfCommonStockForExtinguishmentOfConvertibleDebtMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the issuance of common stock for extinguishment of convertible debt.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_IssuanceOfCommonStockForExtinguishmentOfConvertibleDebtMember" xlink:to="amix_IssuanceOfCommonStockForExtinguishmentOfConvertibleDebtMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLossCarryforwards-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingLossCarryforwards</link:label>
    <link:label xlink:label="us-gaap_OperatingLossCarryforwards-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfFinancialPositionAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted average shares outstanding - basic and diluted (in shares)</link:label>
    <link:label xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average shares outstanding - basic and diluted (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ExpirationCommencingTaxYear20342037Member" xlink:label="amix_ExpirationCommencingTaxYear20342037Member" xlink:type="locator"/>
    <link:label xlink:label="amix_ExpirationCommencingTaxYear20342037Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expiration Commencing, Tax Year 2034-2037 [Member]</link:label>
    <link:label xlink:label="amix_ExpirationCommencingTaxYear20342037Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The identified tax year, period, for the expiration of the net operating loss carryforward.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_ExpirationCommencingTaxYear20342037Member" xlink:to="amix_ExpirationCommencingTaxYear20342037Member-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EffectiveIncomeTaxRateContinuingOperations</link:label>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Effective income tax rate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerShareBasic-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Loss per share - basic and diluted (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_EarningsPerShareBasic-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss per share - basic and diluted (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax rate change, percent</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Return to provision, percent</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation allowance, percent</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" xlink:label="amix_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" xlink:type="locator"/>
    <link:label xlink:label="amix_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capitalized R&amp;D costs</link:label>
    <link:label xlink:label="amix_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from research and development costs.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" xlink:to="amix_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfCashFlowsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_EffectiveIncomeTaxRateReconciliationChangeInStateRatePercent" xlink:label="amix_EffectiveIncomeTaxRateReconciliationChangeInStateRatePercent" xlink:type="locator"/>
    <link:label xlink:label="amix_EffectiveIncomeTaxRateReconciliationChangeInStateRatePercent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in state rate, percent</link:label>
    <link:label xlink:label="amix_EffectiveIncomeTaxRateReconciliationChangeInStateRatePercent-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to the change in state rate.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_EffectiveIncomeTaxRateReconciliationChangeInStateRatePercent" xlink:to="amix_EffectiveIncomeTaxRateReconciliationChangeInStateRatePercent-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_PaymentsForInitialPublicOfferingIssuanceCosts" xlink:label="amix_PaymentsForInitialPublicOfferingIssuanceCosts" xlink:type="locator"/>
    <link:label xlink:label="amix_PaymentsForInitialPublicOfferingIssuanceCosts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">amix_PaymentsForInitialPublicOfferingIssuanceCosts</link:label>
    <link:label xlink:label="amix_PaymentsForInitialPublicOfferingIssuanceCosts-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments for Initial Public Offering Issuance Costs</link:label>
    <link:label xlink:label="amix_PaymentsForInitialPublicOfferingIssuanceCosts-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payment of issuance costs for IPO</link:label>
    <link:label xlink:label="amix_PaymentsForInitialPublicOfferingIssuanceCosts-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the payments for the issuance costs from an initial public offering.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_PaymentsForInitialPublicOfferingIssuanceCosts" xlink:to="amix_PaymentsForInitialPublicOfferingIssuanceCosts-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_NolGeneratedDuring20172024Member" xlink:label="amix_NolGeneratedDuring20172024Member" xlink:type="locator"/>
    <link:label xlink:label="amix_NolGeneratedDuring20172024Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">NOL Generated During 2017-2024 [Member]</link:label>
    <link:label xlink:label="amix_NolGeneratedDuring20172024Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The NOL generated from 2017 through 2024.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_NolGeneratedDuring20172024Member" xlink:to="amix_NolGeneratedDuring20172024Member-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfStockholdersEquityAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_EffectiveIncomeTaxRateReconciliationChangeInStateRateAmount" xlink:label="amix_EffectiveIncomeTaxRateReconciliationChangeInStateRateAmount" xlink:type="locator"/>
    <link:label xlink:label="amix_EffectiveIncomeTaxRateReconciliationChangeInStateRateAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in state rate, amount</link:label>
    <link:label xlink:label="amix_EffectiveIncomeTaxRateReconciliationChangeInStateRateAmount-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to the change in stat rate.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_EffectiveIncomeTaxRateReconciliationChangeInStateRateAmount" xlink:to="amix_EffectiveIncomeTaxRateReconciliationChangeInStateRateAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ReserveForUncertainTaxPositions" xlink:label="amix_ReserveForUncertainTaxPositions" xlink:type="locator"/>
    <link:label xlink:label="amix_ReserveForUncertainTaxPositions-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">amix_ReserveForUncertainTaxPositions</link:label>
    <link:label xlink:label="amix_ReserveForUncertainTaxPositions-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reserve for Uncertain Tax Positions</link:label>
    <link:label xlink:label="amix_ReserveForUncertainTaxPositions-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of money reserved for uncertain tax positions.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_ReserveForUncertainTaxPositions" xlink:to="amix_ReserveForUncertainTaxPositions-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeStatementAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_DebtConversionDebtIssuanceCostsConvertedCommonShares" xlink:label="amix_DebtConversionDebtIssuanceCostsConvertedCommonShares" xlink:type="locator"/>
    <link:label xlink:label="amix_DebtConversionDebtIssuanceCostsConvertedCommonShares-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Settlement/conversion to common shares for debt issuance costs</link:label>
    <link:label xlink:label="amix_DebtConversionDebtIssuanceCostsConvertedCommonShares-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock for extinguishment of convertible debt, amortized debt discuont</link:label>
    <link:label xlink:label="amix_DebtConversionDebtIssuanceCostsConvertedCommonShares-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the debt issuance costs that were converted into common shares.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_DebtConversionDebtIssuanceCostsConvertedCommonShares" xlink:to="amix_DebtConversionDebtIssuanceCostsConvertedCommonShares-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_IpoProceedsHoldbackProvision" xlink:label="amix_IpoProceedsHoldbackProvision" xlink:type="locator"/>
    <link:label xlink:label="amix_IpoProceedsHoldbackProvision-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Holdback of IPO proceeds</link:label>
    <link:label xlink:label="amix_IpoProceedsHoldbackProvision-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the portion of proceeds from initial public offering that is under holdback.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_IpoProceedsHoldbackProvision" xlink:to="amix_IpoProceedsHoldbackProvision-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_StockIssuedDuringPeriodSharesInitialPublicOffering" xlink:label="amix_StockIssuedDuringPeriodSharesInitialPublicOffering" xlink:type="locator"/>
    <link:label xlink:label="amix_StockIssuedDuringPeriodSharesInitialPublicOffering-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common stock from IPO, net of costs (in shares)</link:label>
    <link:label xlink:label="amix_StockIssuedDuringPeriodSharesInitialPublicOffering-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the stock issued during the period from initial public offerings in shares.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_StockIssuedDuringPeriodSharesInitialPublicOffering" xlink:to="amix_StockIssuedDuringPeriodSharesInitialPublicOffering-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_RestrictedStockExpensesGeneralAndAdministrativeTableTextBlock" xlink:label="amix_RestrictedStockExpensesGeneralAndAdministrativeTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="amix_RestrictedStockExpensesGeneralAndAdministrativeTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Expenses, General and Administrative [Table Text Block]</link:label>
    <link:label xlink:label="amix_RestrictedStockExpensesGeneralAndAdministrativeTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tabular disclosure of the general and administrative costs for restricted stock.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_RestrictedStockExpensesGeneralAndAdministrativeTableTextBlock" xlink:to="amix_RestrictedStockExpensesGeneralAndAdministrativeTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfDebt-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ProceedsFromIssuanceOfDebt</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfDebt-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Debt</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_InterestHeldInCompanyReceivingWarrants" xlink:label="amix_InterestHeldInCompanyReceivingWarrants" xlink:type="locator"/>
    <link:label xlink:label="amix_InterestHeldInCompanyReceivingWarrants-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">amix_InterestHeldInCompanyReceivingWarrants</link:label>
    <link:label xlink:label="amix_InterestHeldInCompanyReceivingWarrants-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest Held in Company Receiving Warrants</link:label>
    <link:label xlink:label="amix_InterestHeldInCompanyReceivingWarrants-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The percentage of interest held in the company receiving warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_InterestHeldInCompanyReceivingWarrants" xlink:to="amix_InterestHeldInCompanyReceivingWarrants-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightFairValueIssuedForIssuanceCostsFromIpo" xlink:label="amix_ClassOfWarrantOrRightFairValueIssuedForIssuanceCostsFromIpo" xlink:type="locator"/>
    <link:label xlink:label="amix_ClassOfWarrantOrRightFairValueIssuedForIssuanceCostsFromIpo-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair value of warrants issued for issuance costs as part of IPO</link:label>
    <link:label xlink:label="amix_ClassOfWarrantOrRightFairValueIssuedForIssuanceCostsFromIpo-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the fair value of the warrants or rights issued for issuance costs from an initial public offering.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_ClassOfWarrantOrRightFairValueIssuedForIssuanceCostsFromIpo" xlink:to="amix_ClassOfWarrantOrRightFairValueIssuedForIssuanceCostsFromIpo-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_StockIssuedDuringPeriodValueInitialPublicOffering" xlink:label="amix_StockIssuedDuringPeriodValueInitialPublicOffering" xlink:type="locator"/>
    <link:label xlink:label="amix_StockIssuedDuringPeriodValueInitialPublicOffering-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common stock from IPO, net of costs</link:label>
    <link:label xlink:label="amix_StockIssuedDuringPeriodValueInitialPublicOffering-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the value of the stock issued during the period from the initial public offering.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_StockIssuedDuringPeriodValueInitialPublicOffering" xlink:to="amix_StockIssuedDuringPeriodValueInitialPublicOffering-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_WarrantsIssuedFairValueIssuedForTerminationAgreement" xlink:label="amix_WarrantsIssuedFairValueIssuedForTerminationAgreement" xlink:type="locator"/>
    <link:label xlink:label="amix_WarrantsIssuedFairValueIssuedForTerminationAgreement-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair value of warrants issued - termination agreement</link:label>
    <link:label xlink:label="amix_WarrantsIssuedFairValueIssuedForTerminationAgreement-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the fair value of the warrants issued for termination agreements.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_WarrantsIssuedFairValueIssuedForTerminationAgreement" xlink:to="amix_WarrantsIssuedFairValueIssuedForTerminationAgreement-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_SellingAgentMember" xlink:label="amix_SellingAgentMember" xlink:type="locator"/>
    <link:label xlink:label="amix_SellingAgentMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling Agent [Member]</link:label>
    <link:label xlink:label="amix_SellingAgentMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Refers to the selling agent.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_SellingAgentMember" xlink:to="amix_SellingAgentMember-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_WarrantsPolicyPolicyTextBlock" xlink:label="amix_WarrantsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="amix_WarrantsPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants, Policy [Policy Text Block]</link:label>
    <link:label xlink:label="amix_WarrantsPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of Warrant related activity.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_WarrantsPolicyPolicyTextBlock" xlink:to="amix_WarrantsPolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_OfferingCostsPolicyPolicyTextBlock" xlink:label="amix_OfferingCostsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="amix_OfferingCostsPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Offering Costs, Policy [Policy Text Block]</link:label>
    <link:label xlink:label="amix_OfferingCostsPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">In reference to offering costs in the period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_OfferingCostsPolicyPolicyTextBlock" xlink:to="amix_OfferingCostsPolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_CommissionPercentage" xlink:label="amix_CommissionPercentage" xlink:type="locator"/>
    <link:label xlink:label="amix_CommissionPercentage-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">amix_CommissionPercentage</link:label>
    <link:label xlink:label="amix_CommissionPercentage-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commission Percentage</link:label>
    <link:label xlink:label="amix_CommissionPercentage-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Refers to the amount of commission percentage.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_CommissionPercentage" xlink:to="amix_CommissionPercentage-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Permanent differences, percent</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">State tax (net of federal benefit)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LiabilitiesNoncurrent</link:label>
    <link:label xlink:label="us-gaap_LiabilitiesNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total long-term liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flows from Financing Activities (increase/decrease):</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax benefit at the U.S. federal statutory rate, percent</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax rate change, amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Return to provision, amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation allowance, amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockholdersEquity</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Stockholders' Equity</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Permanent differences, amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementClassOfStockAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_CorrectionOfAnImmaterialErrorPolicyTextBlock" xlink:label="amix_CorrectionOfAnImmaterialErrorPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="amix_CorrectionOfAnImmaterialErrorPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Correction of an Immaterial Error [Policy Text Block]</link:label>
    <link:label xlink:label="amix_CorrectionOfAnImmaterialErrorPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of accounting policy for correction of an immaterial error.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_CorrectionOfAnImmaterialErrorPolicyTextBlock" xlink:to="amix_CorrectionOfAnImmaterialErrorPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ReverseStockSplitMember" xlink:label="amix_ReverseStockSplitMember" xlink:type="locator"/>
    <link:label xlink:label="amix_ReverseStockSplitMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reverse Stock Split [Member]</link:label>
    <link:label xlink:label="amix_ReverseStockSplitMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents reverse stock split.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_ReverseStockSplitMember" xlink:to="amix_ReverseStockSplitMember-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ReverseStockSplitPolicyTextBlock" xlink:label="amix_ReverseStockSplitPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="amix_ReverseStockSplitPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reverse Stock Split [Policy Text Block]</link:label>
    <link:label xlink:label="amix_ReverseStockSplitPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of accounting policy for reverse stock split.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_ReverseStockSplitPolicyTextBlock" xlink:to="amix_ReverseStockSplitPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_MaximumPercentageOfSharesSoldInThirtyDays" xlink:label="amix_MaximumPercentageOfSharesSoldInThirtyDays" xlink:type="locator"/>
    <link:label xlink:label="amix_MaximumPercentageOfSharesSoldInThirtyDays-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">amix_MaximumPercentageOfSharesSoldInThirtyDays</link:label>
    <link:label xlink:label="amix_MaximumPercentageOfSharesSoldInThirtyDays-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum Percentage of Shares Sold in Thirty Days</link:label>
    <link:label xlink:label="amix_MaximumPercentageOfSharesSoldInThirtyDays-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The maximum percentage of shares allowed to be sold within 30 days.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_MaximumPercentageOfSharesSoldInThirtyDays" xlink:to="amix_MaximumPercentageOfSharesSoldInThirtyDays-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantDateFairValue" xlink:label="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantDateFairValue" xlink:type="locator"/>
    <link:label xlink:label="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">amix_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantDateFairValue</link:label>
    <link:label xlink:label="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grant Date Fair Value</link:label>
    <link:label xlink:label="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The grant-date fair value of options as calculated by applying the disclosed option pricing methodology.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantDateFairValue" xlink:to="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantDateFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_WarrantsIssuedForEquityCosts" xlink:label="amix_WarrantsIssuedForEquityCosts" xlink:type="locator"/>
    <link:label xlink:label="amix_WarrantsIssuedForEquityCosts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants issued for equity issuance costs</link:label>
    <link:label xlink:label="amix_WarrantsIssuedForEquityCosts-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of warrants issued for equity costs in noncash or part noncash transaction.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_WarrantsIssuedForEquityCosts" xlink:to="amix_WarrantsIssuedForEquityCosts-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_CommonStockDiscountForLackOfMarketability" xlink:label="amix_CommonStockDiscountForLackOfMarketability" xlink:type="locator"/>
    <link:label xlink:label="amix_CommonStockDiscountForLackOfMarketability-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">amix_CommonStockDiscountForLackOfMarketability</link:label>
    <link:label xlink:label="amix_CommonStockDiscountForLackOfMarketability-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock, Discount for Lack of Marketability</link:label>
    <link:label xlink:label="amix_CommonStockDiscountForLackOfMarketability-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of discount for lack of marketability on common stock.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_CommonStockDiscountForLackOfMarketability" xlink:to="amix_CommonStockDiscountForLackOfMarketability-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="us-gaap_ConvertibleLongTermNotesPayable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConvertibleLongTermNotesPayable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ConvertibleLongTermNotesPayable</link:label>
    <link:label xlink:label="us-gaap_ConvertibleLongTermNotesPayable-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long term debt - convertible notes, net of unamortized debt discount</link:label>
    <link:label xlink:label="us-gaap_ConvertibleLongTermNotesPayable-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, net carrying amount</link:label>
    <link:label xlink:label="us-gaap_ConvertibleLongTermNotesPayable-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, net carrying amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleLongTermNotesPayable" xlink:to="us-gaap_ConvertibleLongTermNotesPayable-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:label="amix_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:type="locator"/>
    <link:label xlink:label="amix_ProceedsFromIssuanceOfCommonStockAndWarrants-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common stock, pre-funded and common warrants</link:label>
    <link:label xlink:label="amix_ProceedsFromIssuanceOfCommonStockAndWarrants-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The cash inflow from the additional capital contribution to the entity and issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:to="amix_ProceedsFromIssuanceOfCommonStockAndWarrants-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">State tax (net of federal benefit), amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_DebtInstrumentConvertibleMaximumBeneficialOwnershipPercentage" xlink:label="amix_DebtInstrumentConvertibleMaximumBeneficialOwnershipPercentage" xlink:type="locator"/>
    <link:label xlink:label="amix_DebtInstrumentConvertibleMaximumBeneficialOwnershipPercentage-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">amix_DebtInstrumentConvertibleMaximumBeneficialOwnershipPercentage</link:label>
    <link:label xlink:label="amix_DebtInstrumentConvertibleMaximumBeneficialOwnershipPercentage-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Maximum Beneficial Ownership, Percentage</link:label>
    <link:label xlink:label="amix_DebtInstrumentConvertibleMaximumBeneficialOwnershipPercentage-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of maximum beneficial ownership upon conversion of the debt instrument.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_DebtInstrumentConvertibleMaximumBeneficialOwnershipPercentage" xlink:to="amix_DebtInstrumentConvertibleMaximumBeneficialOwnershipPercentage-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_EquityOfferingMaximumSharesToBeIssued" xlink:label="amix_EquityOfferingMaximumSharesToBeIssued" xlink:type="locator"/>
    <link:label xlink:label="amix_EquityOfferingMaximumSharesToBeIssued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">amix_EquityOfferingMaximumSharesToBeIssued</link:label>
    <link:label xlink:label="amix_EquityOfferingMaximumSharesToBeIssued-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Offering, Maximum Shares to be Issued (in shares)</link:label>
    <link:label xlink:label="amix_EquityOfferingMaximumSharesToBeIssued-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The maximum number of shares to be issued in the equity offering.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_EquityOfferingMaximumSharesToBeIssued" xlink:to="amix_EquityOfferingMaximumSharesToBeIssued-label" xlink:type="arc"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_MarketingConsultantMember" xlink:label="amix_MarketingConsultantMember" xlink:type="locator"/>
    <link:label xlink:label="amix_MarketingConsultantMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketing Consultant [Member]</link:label>
    <link:label xlink:label="amix_MarketingConsultantMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents marketing consultant.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amix_MarketingConsultantMember" xlink:to="amix_MarketingConsultantMember-label" xlink:type="arc"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>amix-20250630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 03:06PM UTC 2025-10-04--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-document-and-entity-information" xlink:href="amix-20250630.xsd#statement-document-and-entity-information" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://autonomix.com/20250630/role/statement-document-and-entity-information" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-balance-sheets-parentheticals" xlink:href="amix-20250630.xsd#statement-balance-sheets-parentheticals" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://autonomix.com/20250630/role/statement-balance-sheets-parentheticals" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-condensed-balance-sheets-unaudited-parentheticals" xlink:href="amix-20250630.xsd#statement-condensed-balance-sheets-unaudited-parentheticals" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://autonomix.com/20250630/role/statement-condensed-balance-sheets-unaudited-parentheticals" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies" xlink:href="amix-20250630.xsd#statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies" xlink:type="extended">
    <link:loc xlink:href="amix-20250630.xsd#amix_ATMAgreementMember" xlink:label="amix_ATMAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_EquitybasedWarrantsMember" xlink:label="amix_EquitybasedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_NoncashExpensesMember" xlink:label="amix_NoncashExpensesMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_NotesToFinancialStatementsAbstract" xlink:label="amix_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_PrefundedAndSeriesAWarrantsMember" xlink:label="amix_PrefundedAndSeriesAWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_PrefundedWarrantsMember" xlink:label="amix_PrefundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ReverseStockSplitMember" xlink:label="amix_ReverseStockSplitMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_SellingAgentMember" xlink:label="amix_SellingAgentMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_SeriesAWarrantsMember" xlink:label="amix_SeriesAWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_UnderwritersMember" xlink:label="amix_UnderwritersMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_UnderwrittenPublicOfferingMember" xlink:label="amix_UnderwrittenPublicOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NatureOfExpenseAxis" xlink:label="us-gaap_NatureOfExpenseAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonmonetaryTransactionTypeAxis" xlink:label="us-gaap_NonmonetaryTransactionTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonmonetaryTransactionTypeDomain" xlink:label="us-gaap_NonmonetaryTransactionTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amix_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonmonetaryTransactionTypeAxis" xlink:to="us-gaap_NonmonetaryTransactionTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_NonmonetaryTransactionTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonmonetaryTransactionTypeAxis" xlink:to="amix_ReverseStockSplitMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_IPOMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="amix_UnderwrittenPublicOfferingMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="amix_SeriesAWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="amix_PrefundedWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_OverAllotmentOptionMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="amix_UnderwritersMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="amix_PrefundedAndSeriesAWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_NatureOfExpenseAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="amix_NoncashExpensesMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="amix_ATMAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="amix_SellingAgentMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="amix_EquitybasedWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments" xlink:href="amix-20250630.xsd#statement-note-2-warrant-liability-and-fair-value-of-financial-instruments" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments" xlink:type="extended">
    <link:loc xlink:href="amix-20250630.xsd#amix_MeasurementInputProbabilityRateMember" xlink:label="amix_MeasurementInputProbabilityRateMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_NoQualifiedOfferingOccurringMember" xlink:label="amix_NoQualifiedOfferingOccurringMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_NotesToFinancialStatementsAbstract" xlink:label="amix_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_QualifiedOfferingOccurringOneMember" xlink:label="amix_QualifiedOfferingOccurringOneMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_QualifiedOfferingOccurringTwoMember" xlink:label="amix_QualifiedOfferingOccurringTwoMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_TerminationAgreementMember" xlink:label="amix_TerminationAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_TheWarrantMember" xlink:label="amix_TheWarrantMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ValuationProbabilityweightedExpectedReturnMethodPWERMMember" xlink:label="amix_ValuationProbabilityweightedExpectedReturnMethodPWERMMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="us-gaap_ValuationTechniqueAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="us-gaap_ValuationTechniqueDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amix_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel3Member" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_MeasurementInputTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="amix_MeasurementInputProbabilityRateMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ValuationTechniqueAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="amix_ValuationProbabilityweightedExpectedReturnMethodPWERMMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="amix_QualifiedOfferingOccurringOneMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="amix_QualifiedOfferingOccurringTwoMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="amix_NoQualifiedOfferingOccurringMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="amix_TheWarrantMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="amix_TerminationAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable" xlink:href="amix-20250630.xsd#statement-note-3-convertible-notes-payable" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable" xlink:type="extended">
    <link:loc xlink:href="amix-20250630.xsd#amix_BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember" xlink:label="amix_BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ConversionOfConvertibleNotesToCommonStockMember" xlink:label="amix_ConversionOfConvertibleNotesToCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ConvertibleDebtWith499PercentBeneficialOwnershipLimitationMember" xlink:label="amix_ConvertibleDebtWith499PercentBeneficialOwnershipLimitationMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_NotesToFinancialStatementsAbstract" xlink:label="amix_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_TheNotesMember" xlink:label="amix_TheNotesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember" xlink:label="us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="us-gaap_MeasurementInputDiscountRateMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amix_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="amix_TheNotesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="amix_BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="amix_ConvertibleDebtWith499PercentBeneficialOwnershipLimitationMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="amix_ConversionOfConvertibleNotesToCommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_MeasurementInputTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputExpectedTermMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-note-4-equity" xlink:href="amix-20250630.xsd#statement-note-4-equity" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://autonomix.com/20250630/role/statement-note-4-equity" xlink:type="extended">
    <link:loc xlink:href="amix-20250630.xsd#amix_ATMAgreementMember" xlink:label="amix_ATMAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_BlackscholesModelMember" xlink:label="amix_BlackscholesModelMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_EquitybasedWarrantsMember" xlink:label="amix_EquitybasedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_MarketingConsultantMember" xlink:label="amix_MarketingConsultantMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_NoncashExpensesMember" xlink:label="amix_NoncashExpensesMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_NotesToFinancialStatementsAbstract" xlink:label="amix_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_PrefundedWarrantsMember" xlink:label="amix_PrefundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_RepresentativesWarrantsMember" xlink:label="amix_RepresentativesWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_RfInnovationsIncMember" xlink:label="amix_RfInnovationsIncMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_SeriesAWarrantsAndTheRepresentativesWarrantsMember" xlink:label="amix_SeriesAWarrantsAndTheRepresentativesWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_SeriesAWarrantsMember" xlink:label="amix_SeriesAWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_The2023StockPlanMember" xlink:label="amix_The2023StockPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_UnderwritersMember" xlink:label="amix_UnderwritersMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_UnderwrittenPublicOfferingMember" xlink:label="amix_UnderwrittenPublicOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="us-gaap_MeasurementInputDiscountRateMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NatureOfExpenseAxis" xlink:label="us-gaap_NatureOfExpenseAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="us-gaap_ValuationTechniqueAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:label="us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="us-gaap_ValuationTechniqueDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amix_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="amix_MarketingConsultantMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_PrivatePlacementMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="amix_ATMAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="amix_The2023StockPlanMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ValuationTechniqueAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="amix_BlackscholesModelMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="amix_RfInnovationsIncMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="amix_UnderwrittenPublicOfferingMember" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="amix_SeriesAWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="amix_PrefundedWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_OverAllotmentOptionMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="amix_UnderwritersMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="amix_RepresentativesWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="amix_SeriesAWarrantsAndTheRepresentativesWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_MeasurementInputTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_NatureOfExpenseAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="amix_NoncashExpensesMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="amix_EquitybasedWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputExpectedTermMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_WarrantMember" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-note-5-commitments-and-contingencies" xlink:href="amix-20250630.xsd#statement-note-5-commitments-and-contingencies" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://autonomix.com/20250630/role/statement-note-5-commitments-and-contingencies" xlink:type="extended">
    <link:loc xlink:href="amix-20250630.xsd#amix_ExecutiveViceChairAndStrategicAdvisorToTheChiefExecutiveOfficerMember" xlink:label="amix_ExecutiveViceChairAndStrategicAdvisorToTheChiefExecutiveOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_InducementOptionsMember" xlink:label="amix_InducementOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_NotesToFinancialStatementsAbstract" xlink:label="amix_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ScenarioContractTerminationMember" xlink:label="amix_ScenarioContractTerminationMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ScenarioContractTerminationWithoutCauseMember" xlink:label="amix_ScenarioContractTerminationWithoutCauseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmploymentContractsMember" xlink:label="us-gaap_EmploymentContractsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LitigationStatusAxis" xlink:label="us-gaap_LitigationStatusAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LitigationStatusDomain" xlink:label="us-gaap_LitigationStatusDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PendingLitigationMember" xlink:label="us-gaap_PendingLitigationMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amix_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LitigationStatusAxis" xlink:to="us-gaap_LitigationStatusDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LitigationStatusAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LitigationStatusAxis" xlink:to="us-gaap_PendingLitigationMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_EmploymentContractsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_ChiefExecutiveOfficerMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="amix_InducementOptionsMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VestingAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="amix_ScenarioContractTerminationMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="amix_ScenarioContractTerminationWithoutCauseMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="amix_ExecutiveViceChairAndStrategicAdvisorToTheChiefExecutiveOfficerMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-note-6-related-party-transactions" xlink:href="amix-20250630.xsd#statement-note-6-related-party-transactions" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://autonomix.com/20250630/role/statement-note-6-related-party-transactions" xlink:type="extended">
    <link:loc xlink:href="amix-20250630.xsd#amix_AccountingAndFinancialReportingServicesMember" xlink:label="amix_AccountingAndFinancialReportingServicesMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_CommonStock12MonthsLockupPeriodMember" xlink:label="amix_CommonStock12MonthsLockupPeriodMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_CommonStock6MonthsLockupPeriodMember" xlink:label="amix_CommonStock6MonthsLockupPeriodMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ConsultingFirmOwnedByFormerCFOMember" xlink:label="amix_ConsultingFirmOwnedByFormerCFOMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ManagementBoardOfDirectorFamilyMember" xlink:label="amix_ManagementBoardOfDirectorFamilyMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_NotesToFinancialStatementsAbstract" xlink:label="amix_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_TerminationAgreementMember" xlink:label="amix_TerminationAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_TheBridgeOfferingMember" xlink:label="amix_TheBridgeOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_TheWarrantMember" xlink:label="amix_TheWarrantMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ManagementMember" xlink:label="srt_ManagementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnderlyingAssetClassAxis" xlink:label="us-gaap_UnderlyingAssetClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnderlyingAssetClassDomain" xlink:label="us-gaap_UnderlyingAssetClassDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amix_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_UnderlyingAssetClassAxis" xlink:to="us-gaap_UnderlyingAssetClassDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="amix_ConsultingFirmOwnedByFormerCFOMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="amix_AccountingAndFinancialReportingServicesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="amix_ManagementBoardOfDirectorFamilyMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="amix_TheBridgeOfferingMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="srt_ManagementMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="amix_TheWarrantMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="amix_TerminationAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_UnderlyingAssetClassAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_UnderlyingAssetClassAxis" xlink:to="amix_CommonStock6MonthsLockupPeriodMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_UnderlyingAssetClassAxis" xlink:to="amix_CommonStock12MonthsLockupPeriodMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-note-7-income-taxes" xlink:href="amix-20250630.xsd#statement-note-7-income-taxes" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://autonomix.com/20250630/role/statement-note-7-income-taxes" xlink:type="extended">
    <link:loc xlink:href="amix-20250630.xsd#amix_ExpirationCommencingTaxYear20342037Member" xlink:label="amix_ExpirationCommencingTaxYear20342037Member" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_NolGeneratedDuring20172024Member" xlink:label="amix_NolGeneratedDuring20172024Member" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_NotesToFinancialStatementsAbstract" xlink:label="amix_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amix_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TaxPeriodAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="amix_ExpirationCommencingTaxYear20342037Member" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="amix_NolGeneratedDuring20172024Member" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-note-8-subsequent-events" xlink:href="amix-20250630.xsd#statement-note-8-subsequent-events" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://autonomix.com/20250630/role/statement-note-8-subsequent-events" xlink:type="extended">
    <link:loc xlink:href="amix-20250630.xsd#amix_ATMAgreementMember" xlink:label="amix_ATMAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_NotesToFinancialStatementsAbstract" xlink:label="amix_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amix_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="amix_ATMAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_GranteeStatusAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VestingAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q" xlink:href="amix-20250630.xsd#statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q" xlink:type="extended">
    <link:loc xlink:href="amix-20250630.xsd#amix_ATMAgreementMember" xlink:label="amix_ATMAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_EquitybasedWarrantsMember" xlink:label="amix_EquitybasedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_NoncashExpensesMember" xlink:label="amix_NoncashExpensesMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_NotesToFinancialStatementsAbstract" xlink:label="amix_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_PrefundedAndSeriesAWarrantsMember" xlink:label="amix_PrefundedAndSeriesAWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_PrefundedWarrantsMember" xlink:label="amix_PrefundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ReverseStockSplitMember" xlink:label="amix_ReverseStockSplitMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_SeriesAWarrantsMember" xlink:label="amix_SeriesAWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_UnderwritersMember" xlink:label="amix_UnderwritersMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_UnderwrittenPublicOfferingMember" xlink:label="amix_UnderwrittenPublicOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NatureOfExpenseAxis" xlink:label="us-gaap_NatureOfExpenseAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonmonetaryTransactionTypeAxis" xlink:label="us-gaap_NonmonetaryTransactionTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonmonetaryTransactionTypeDomain" xlink:label="us-gaap_NonmonetaryTransactionTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amix_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonmonetaryTransactionTypeAxis" xlink:to="us-gaap_NonmonetaryTransactionTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_NonmonetaryTransactionTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonmonetaryTransactionTypeAxis" xlink:to="amix_ReverseStockSplitMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="amix_ATMAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="amix_UnderwrittenPublicOfferingMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="amix_SeriesAWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="amix_PrefundedWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_OverAllotmentOptionMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="amix_UnderwritersMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="amix_PrefundedAndSeriesAWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_NatureOfExpenseAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="amix_NoncashExpensesMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="amix_EquitybasedWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-note-2-convertible-notes-payable-10q" xlink:href="amix-20250630.xsd#statement-note-2-convertible-notes-payable-10q" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://autonomix.com/20250630/role/statement-note-2-convertible-notes-payable-10q" xlink:type="extended">
    <link:loc xlink:href="amix-20250630.xsd#amix_BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember" xlink:label="amix_BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ConversionOfConvertibleNotesToCommonStockMember" xlink:label="amix_ConversionOfConvertibleNotesToCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ConvertibleDebtWith499PercentBeneficialOwnershipLimitationMember" xlink:label="amix_ConvertibleDebtWith499PercentBeneficialOwnershipLimitationMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_NotesToFinancialStatementsAbstract" xlink:label="amix_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_TheNotesMember" xlink:label="amix_TheNotesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember" xlink:label="us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="us-gaap_MeasurementInputDiscountRateMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amix_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="amix_TheNotesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="amix_BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="amix_ConvertibleDebtWith499PercentBeneficialOwnershipLimitationMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="amix_ConversionOfConvertibleNotesToCommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_MeasurementInputTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputExpectedTermMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-note-3-equity-10q" xlink:href="amix-20250630.xsd#statement-note-3-equity-10q" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://autonomix.com/20250630/role/statement-note-3-equity-10q" xlink:type="extended">
    <link:loc xlink:href="amix-20250630.xsd#amix_ATMAgreementMember" xlink:label="amix_ATMAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_BlackscholesModelMember" xlink:label="amix_BlackscholesModelMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_CommonWarrantsMember" xlink:label="amix_CommonWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_MarketingConsultantMember" xlink:label="amix_MarketingConsultantMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_NoncashExpensesMember" xlink:label="amix_NoncashExpensesMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_NotesToFinancialStatementsAbstract" xlink:label="amix_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_PrefundedWarrantsMember" xlink:label="amix_PrefundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_RepresentativesWarrantsMember" xlink:label="amix_RepresentativesWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_RfInnovationsIncMember" xlink:label="amix_RfInnovationsIncMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_SeriesAWarrantsAndTheRepresentativesWarrantsMember" xlink:label="amix_SeriesAWarrantsAndTheRepresentativesWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_SeriesAWarrantsMember" xlink:label="amix_SeriesAWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_The2023StockPlanMember" xlink:label="amix_The2023StockPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_UnderwritersMember" xlink:label="amix_UnderwritersMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_UnderwrittenPublicOfferingMember" xlink:label="amix_UnderwrittenPublicOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="us-gaap_MeasurementInputDiscountRateMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NatureOfExpenseAxis" xlink:label="us-gaap_NatureOfExpenseAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="us-gaap_ValuationTechniqueAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="us-gaap_ValuationTechniqueDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amix_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="amix_MarketingConsultantMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="amix_ATMAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="amix_The2023StockPlanMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ValuationTechniqueAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="amix_BlackscholesModelMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="amix_RfInnovationsIncMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="amix_UnderwrittenPublicOfferingMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="amix_SeriesAWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="amix_PrefundedWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_OverAllotmentOptionMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="amix_UnderwritersMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="amix_RepresentativesWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="amix_SeriesAWarrantsAndTheRepresentativesWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_MeasurementInputTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_NatureOfExpenseAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="amix_NoncashExpensesMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="amix_CommonWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_WarrantMember" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-note-4-commitments-and-contingencies-10q" xlink:href="amix-20250630.xsd#statement-note-4-commitments-and-contingencies-10q" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://autonomix.com/20250630/role/statement-note-4-commitments-and-contingencies-10q" xlink:type="extended">
    <link:loc xlink:href="amix-20250630.xsd#amix_NotesToFinancialStatementsAbstract" xlink:label="amix_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmploymentContractsMember" xlink:label="us-gaap_EmploymentContractsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LitigationStatusAxis" xlink:label="us-gaap_LitigationStatusAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LitigationStatusDomain" xlink:label="us-gaap_LitigationStatusDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PendingLitigationMember" xlink:label="us-gaap_PendingLitigationMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amix_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LitigationStatusAxis" xlink:to="us-gaap_LitigationStatusDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LitigationStatusAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LitigationStatusAxis" xlink:to="us-gaap_PendingLitigationMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_EmploymentContractsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-note-5-related-party-transactions-10q" xlink:href="amix-20250630.xsd#statement-note-5-related-party-transactions-10q" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://autonomix.com/20250630/role/statement-note-5-related-party-transactions-10q" xlink:type="extended">
    <link:loc xlink:href="amix-20250630.xsd#amix_CommonStock12MonthsLockupPeriodMember" xlink:label="amix_CommonStock12MonthsLockupPeriodMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_CommonStock6MonthsLockupPeriodMember" xlink:label="amix_CommonStock6MonthsLockupPeriodMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_NotesToFinancialStatementsAbstract" xlink:label="amix_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_TerminationAgreementMember" xlink:label="amix_TerminationAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_TheWarrantMember" xlink:label="amix_TheWarrantMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnderlyingAssetClassAxis" xlink:label="us-gaap_UnderlyingAssetClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnderlyingAssetClassDomain" xlink:label="us-gaap_UnderlyingAssetClassDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amix_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_UnderlyingAssetClassAxis" xlink:to="us-gaap_UnderlyingAssetClassDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="amix_TheWarrantMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="amix_TerminationAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_UnderlyingAssetClassAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_UnderlyingAssetClassAxis" xlink:to="amix_CommonStock6MonthsLockupPeriodMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_UnderlyingAssetClassAxis" xlink:to="amix_CommonStock12MonthsLockupPeriodMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-note-6-subsequent-events-10q" xlink:href="amix-20250630.xsd#statement-note-6-subsequent-events-10q" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://autonomix.com/20250630/role/statement-note-6-subsequent-events-10q" xlink:type="extended">
    <link:loc xlink:href="amix-20250630.xsd#amix_ChiefMedicalOfficerMember" xlink:label="amix_ChiefMedicalOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ChiefTechnologyOfficerMember" xlink:label="amix_ChiefTechnologyOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ExecutiveChairOfTheBoardMember" xlink:label="amix_ExecutiveChairOfTheBoardMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ExistingWarrantsAt1722ExercisePriceMember" xlink:label="amix_ExistingWarrantsAt1722ExercisePriceMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ExistingWarrantsAt1723ExercisePriceMember" xlink:label="amix_ExistingWarrantsAt1723ExercisePriceMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ExistingWarrantsMember" xlink:label="amix_ExistingWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_NotesToFinancialStatementsAbstract" xlink:label="amix_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_PreipoWarrantsMember" xlink:label="amix_PreipoWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_RepresentativesWarrantsMember" xlink:label="amix_RepresentativesWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_SeriesAWarrantsMember" xlink:label="amix_SeriesAWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_SeriesBWarrantsMember" xlink:label="amix_SeriesBWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_BoardOfDirectorsChairmanMember" xlink:label="srt_BoardOfDirectorsChairmanMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ChiefFinancialOfficerMember" xlink:label="srt_ChiefFinancialOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amix_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="amix_ExistingWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="amix_ExistingWarrantsAt1723ExercisePriceMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="amix_ExistingWarrantsAt1722ExercisePriceMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="amix_SeriesBWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="amix_RepresentativesWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="amix_SeriesAWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="amix_PreipoWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_BoardOfDirectorsChairmanMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="amix_ExecutiveChairOfTheBoardMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_DirectorMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_ChiefExecutiveOfficerMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="amix_ChiefTechnologyOfficerMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="amix_ChiefMedicalOfficerMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_ChiefFinancialOfficerMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-significant-accounting-policies-policies" xlink:href="amix-20250630.xsd#statement-significant-accounting-policies-policies" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://autonomix.com/20250630/role/statement-significant-accounting-policies-policies" xlink:type="extended">
    <link:loc xlink:href="amix-20250630.xsd#amix_CorrectionOfAnImmaterialErrorPolicyTextBlock" xlink:label="amix_CorrectionOfAnImmaterialErrorPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_JumpstartOurBusinessStartupsJobsActAccountingElectionPolicyPolicyTextBlock" xlink:label="amix_JumpstartOurBusinessStartupsJobsActAccountingElectionPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_OfferingCostsPolicyPolicyTextBlock" xlink:label="amix_OfferingCostsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_RelatedPartyTransactionsPolicyPolicyTextBlock" xlink:label="amix_RelatedPartyTransactionsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ReverseStockSplitPolicyTextBlock" xlink:label="amix_ReverseStockSplitPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_SubstantialDoubtAboutGoingConcernPolicyPolicyTextBlock" xlink:label="amix_SubstantialDoubtAboutGoingConcernPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_WarrantsPolicyPolicyTextBlock" xlink:label="amix_WarrantsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_statement-statement-significant-accounting-policies-policies" xlink:label="amix_statement-statement-significant-accounting-policies-policies" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdvertisingCostsPolicyTextBlock" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="us-gaap_DebtPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityPolicyTextBlock" xlink:label="us-gaap_StockholdersEquityPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amix_statement-statement-significant-accounting-policies-policies" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PolicyTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="amix_ReverseStockSplitPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="amix_SubstantialDoubtAboutGoingConcernPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="amix_OfferingCostsPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DebtPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="amix_RelatedPartyTransactionsPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="amix_WarrantsPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AdvertisingCostsPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_StockholdersEquityPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="amix_JumpstartOurBusinessStartupsJobsActAccountingElectionPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="amix_CorrectionOfAnImmaterialErrorPolicyTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-tables" xlink:href="amix-20250630.xsd#statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-tables" xlink:type="extended">
    <link:loc xlink:href="amix-20250630.xsd#amix_statement-statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-tables" xlink:label="amix_statement-statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:label="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amix_statement-statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-tables" xlink:href="amix-20250630.xsd#statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-tables" xlink:type="extended">
    <link:loc xlink:href="amix-20250630.xsd#amix_statement-statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-tables" xlink:label="amix_statement-statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amix_statement-statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable-tables" xlink:href="amix-20250630.xsd#statement-note-3-convertible-notes-payable-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable-tables" xlink:type="extended">
    <link:loc xlink:href="amix-20250630.xsd#amix_statement-statement-note-3-convertible-notes-payable-tables" xlink:label="amix_statement-statement-note-3-convertible-notes-payable-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebtTableTextBlock" xlink:label="us-gaap_ConvertibleDebtTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amix_statement-statement-note-3-convertible-notes-payable-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ConvertibleDebtTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-note-4-equity-tables" xlink:href="amix-20250630.xsd#statement-note-4-equity-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://autonomix.com/20250630/role/statement-note-4-equity-tables" xlink:type="extended">
    <link:loc xlink:href="amix-20250630.xsd#amix_RestrictedStockExpensesGeneralAndAdministrativeTableTextBlock" xlink:label="amix_RestrictedStockExpensesGeneralAndAdministrativeTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_statement-statement-note-4-equity-tables" xlink:label="amix_statement-statement-note-4-equity-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amix_statement-statement-note-4-equity-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="amix_RestrictedStockExpensesGeneralAndAdministrativeTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-note-7-income-taxes-tables" xlink:href="amix-20250630.xsd#statement-note-7-income-taxes-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://autonomix.com/20250630/role/statement-note-7-income-taxes-tables" xlink:type="extended">
    <link:loc xlink:href="amix-20250630.xsd#amix_statement-statement-note-7-income-taxes-tables" xlink:label="amix_statement-statement-note-7-income-taxes-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amix_statement-statement-note-7-income-taxes-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q-tables" xlink:href="amix-20250630.xsd#statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q-tables" xlink:type="extended">
    <link:loc xlink:href="amix-20250630.xsd#amix_statement-statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q-tables" xlink:label="amix_statement-statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:label="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amix_statement-statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-note-2-convertible-notes-payable-10q-tables" xlink:href="amix-20250630.xsd#statement-note-2-convertible-notes-payable-10q-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://autonomix.com/20250630/role/statement-note-2-convertible-notes-payable-10q-tables" xlink:type="extended">
    <link:loc xlink:href="amix-20250630.xsd#amix_statement-statement-note-2-convertible-notes-payable-10q-tables" xlink:label="amix_statement-statement-note-2-convertible-notes-payable-10q-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amix_statement-statement-note-2-convertible-notes-payable-10q-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-note-3-equity-10q-tables" xlink:href="amix-20250630.xsd#statement-note-3-equity-10q-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://autonomix.com/20250630/role/statement-note-3-equity-10q-tables" xlink:type="extended">
    <link:loc xlink:href="amix-20250630.xsd#amix_RestrictedStockExpensesGeneralAndAdministrativeTableTextBlock" xlink:label="amix_RestrictedStockExpensesGeneralAndAdministrativeTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_statement-statement-note-3-equity-10q-tables" xlink:label="amix_statement-statement-note-3-equity-10q-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amix_statement-statement-note-3-equity-10q-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="amix_RestrictedStockExpensesGeneralAndAdministrativeTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual" xlink:href="amix-20250630.xsd#statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual" xlink:type="extended">
    <link:loc xlink:href="amix-20250630.xsd#amix_ATMAgreementMember" xlink:label="amix_ATMAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:label="amix_ClassOfWarrantOrRightIssuedDuringPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantsOrRightsMaximumBeneficialOwnership" xlink:label="amix_ClassOfWarrantsOrRightsMaximumBeneficialOwnership-2" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_CommissionPercentage" xlink:label="amix_CommissionPercentage-2" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_CommonUnitsIssuedPurchasePrice" xlink:label="amix_CommonUnitsIssuedPurchasePrice-2" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_EquityOfferingMaximumOfferingAmount" xlink:label="amix_EquityOfferingMaximumOfferingAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_EquityOfferingOptionMaximumShares" xlink:label="amix_EquityOfferingOptionMaximumShares-2" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_EquityOfferingOptionMaximumWarrants" xlink:label="amix_EquityOfferingOptionMaximumWarrants-2" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_EquityOfferingOptionPeriod" xlink:label="amix_EquityOfferingOptionPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_EquitybasedWarrantsMember" xlink:label="amix_EquitybasedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_NoncashExpensesMember" xlink:label="amix_NoncashExpensesMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_NoteToFinancialStatementDetailsTextual" xlink:label="amix_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_NumberOfCommonUnitsIssued" xlink:label="amix_NumberOfCommonUnitsIssued-2" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_NumberOfPrefundedUnitsIssued" xlink:label="amix_NumberOfPrefundedUnitsIssued-2" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_NumberOfSharesPerCommonUnit" xlink:label="amix_NumberOfSharesPerCommonUnit-2" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_NumberOfWarrantsPerCommonUnit" xlink:label="amix_NumberOfWarrantsPerCommonUnit-2" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_NumberOfWarrantsPerPrefundedUnit" xlink:label="amix_NumberOfWarrantsPerPrefundedUnit-2" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_PaymentsForInitialPublicOfferingIssuanceCosts" xlink:label="amix_PaymentsForInitialPublicOfferingIssuanceCosts-2" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_PrefundedAndSeriesAWarrantsMember" xlink:label="amix_PrefundedAndSeriesAWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_PrefundedUnitsIssuedPurchasePrice" xlink:label="amix_PrefundedUnitsIssuedPurchasePrice-2" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_PrefundedWarrantsMember" xlink:label="amix_PrefundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ProceedsFromIssuanceOrSaleOfEquityNet" xlink:label="amix_ProceedsFromIssuanceOrSaleOfEquityNet-2" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ReverseStockSplitMember" xlink:label="amix_ReverseStockSplitMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_SellingAgentMember" xlink:label="amix_SellingAgentMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_SeriesAWarrantsMember" xlink:label="amix_SeriesAWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_UnderwritersMember" xlink:label="amix_UnderwritersMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_UnderwrittenPublicOfferingMember" xlink:label="amix_UnderwrittenPublicOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_WorkingCapitalDeficit" xlink:label="amix_WorkingCapitalDeficit-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdvertisingExpense" xlink:label="us-gaap_AdvertisingExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsCurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NatureOfExpenseAxis" xlink:label="us-gaap_NatureOfExpenseAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-n2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss-n2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonmonetaryTransactionTypeAxis" xlink:label="us-gaap_NonmonetaryTransactionTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonmonetaryTransactionTypeDomain" xlink:label="us-gaap_NonmonetaryTransactionTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit-n2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amix_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonmonetaryTransactionTypeAxis" xlink:to="us-gaap_NonmonetaryTransactionTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_NonmonetaryTransactionTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonmonetaryTransactionTypeAxis" xlink:to="amix_ReverseStockSplitMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_IPOMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="amix_UnderwrittenPublicOfferingMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="amix_SeriesAWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="amix_PrefundedWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_OverAllotmentOptionMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="amix_UnderwritersMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="amix_PrefundedAndSeriesAWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_NatureOfExpenseAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="amix_NoncashExpensesMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="amix_ATMAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="amix_SellingAgentMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="amix_EquitybasedWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss-n2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities-n2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Revenues-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit-n2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_WorkingCapitalDeficit-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_NumberOfCommonUnitsIssued-2" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_NumberOfSharesPerCommonUnit-2" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_NumberOfWarrantsPerCommonUnit-2" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight-2" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_NumberOfPrefundedUnitsIssued-2" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_NumberOfWarrantsPerPrefundedUnit-2" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_CommonUnitsIssuedPurchasePrice-2" xlink:type="arc"/>
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_PrefundedUnitsIssuedPurchasePrice-2" xlink:type="arc"/>
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_EquityOfferingOptionPeriod-2" xlink:type="arc"/>
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_EquityOfferingOptionMaximumShares-2" xlink:type="arc"/>
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_EquityOfferingOptionMaximumWarrants-2" xlink:type="arc"/>
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-2" xlink:type="arc"/>
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm-2" xlink:type="arc"/>
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_ClassOfWarrantsOrRightsMaximumBeneficialOwnership-2" xlink:type="arc"/>
    <link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_ClassOfWarrantOrRightIssuedDuringPeriod-2" xlink:type="arc"/>
    <link:presentationArc order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity-2" xlink:type="arc"/>
    <link:presentationArc order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts-2" xlink:type="arc"/>
    <link:presentationArc order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_ProceedsFromIssuanceOrSaleOfEquityNet-2" xlink:type="arc"/>
    <link:presentationArc order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_EquityOfferingMaximumOfferingAmount-2" xlink:type="arc"/>
    <link:presentationArc order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_CommissionPercentage-2" xlink:type="arc"/>
    <link:presentationArc order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_PaymentsForInitialPublicOfferingIssuanceCosts-2" xlink:type="arc"/>
    <link:presentationArc order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsOfFinancingCosts-2" xlink:type="arc"/>
    <link:presentationArc order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts-2" xlink:type="arc"/>
    <link:presentationArc order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife-2" xlink:type="arc"/>
    <link:presentationArc order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilityForUncertainTaxPositionsCurrent-2" xlink:type="arc"/>
    <link:presentationArc order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdvertisingExpense-2" xlink:type="arc"/>
    <link:presentationArc order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NumberOfReportableSegments-2" xlink:type="arc"/>
    <link:presentationArc order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NumberOfOperatingSegments-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-details-textual" xlink:href="amix-20250630.xsd#statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-details-textual" xlink:type="extended">
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightValueOfSecuritiesCalledByWarrantsOrRights" xlink:label="amix_ClassOfWarrantOrRightValueOfSecuritiesCalledByWarrantsOrRights-2" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_MeasurementInputProbabilityRateMember" xlink:label="amix_MeasurementInputProbabilityRateMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_NoQualifiedOfferingOccurringMember" xlink:label="amix_NoQualifiedOfferingOccurringMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_NoteToFinancialStatementDetailsTextual" xlink:label="amix_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_QualifiedOfferingOccurringOneMember" xlink:label="amix_QualifiedOfferingOccurringOneMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_QualifiedOfferingOccurringTwoMember" xlink:label="amix_QualifiedOfferingOccurringTwoMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_TerminationAgreementMember" xlink:label="amix_TerminationAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_TheWarrantMember" xlink:label="amix_TheWarrantMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ValuationProbabilityweightedExpectedReturnMethodPWERMMember" xlink:label="amix_ValuationProbabilityweightedExpectedReturnMethodPWERMMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="us-gaap_GainLossOnDerivativeInstrumentsNetPretax-n2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="us-gaap_ValuationTechniqueAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="us-gaap_ValuationTechniqueDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amix_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel3Member" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_MeasurementInputTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="amix_MeasurementInputProbabilityRateMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ValuationTechniqueAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="amix_ValuationProbabilityweightedExpectedReturnMethodPWERMMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="amix_QualifiedOfferingOccurringOneMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="amix_QualifiedOfferingOccurringTwoMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="amix_NoQualifiedOfferingOccurringMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="amix_TheWarrantMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="amix_TerminationAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GainLossOnDerivativeInstrumentsNetPretax-n2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_ClassOfWarrantOrRightValueOfSecuritiesCalledByWarrantsOrRights-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable-details-textual" xlink:href="amix-20250630.xsd#statement-note-3-convertible-notes-payable-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable-details-textual" xlink:type="extended">
    <link:loc xlink:href="amix-20250630.xsd#amix_BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember" xlink:label="amix_BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightLockupAgreementTermOfUnderlyingShares" xlink:label="amix_ClassOfWarrantOrRightLockupAgreementTermOfUnderlyingShares-2" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightPercentageOfOutstandingStock" xlink:label="amix_ClassOfWarrantOrRightPercentageOfOutstandingStock-2" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ConversionOfConvertibleNotesToCommonStockMember" xlink:label="amix_ConversionOfConvertibleNotesToCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ConvertibleDebtWith499PercentBeneficialOwnershipLimitationMember" xlink:label="amix_ConvertibleDebtWith499PercentBeneficialOwnershipLimitationMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_DebtInstrumentConvertibleMaximumBeneficialOwnershipPercentage" xlink:label="amix_DebtInstrumentConvertibleMaximumBeneficialOwnershipPercentage-2" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_NoteToFinancialStatementDetailsTextual" xlink:label="amix_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_TheNotesMember" xlink:label="amix_TheNotesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="us-gaap_ConvertibleNotesPayable-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:label="us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember" xlink:label="us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="us-gaap_MeasurementInputDiscountRateMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amix_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="amix_TheNotesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="amix_BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="amix_ConvertibleDebtWith499PercentBeneficialOwnershipLimitationMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="amix_ConversionOfConvertibleNotesToCommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_MeasurementInputTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputExpectedTermMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_ClassOfWarrantOrRightLockupAgreementTermOfUnderlyingShares-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_ClassOfWarrantOrRightPercentageOfOutstandingStock-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_DebtInstrumentConvertibleMaximumBeneficialOwnershipPercentage-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromConvertibleDebt-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConvertibleNotesPayable-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding-2" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput-2" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestExpenseDebt-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-note-4-equity-details-textual" xlink:href="amix-20250630.xsd#statement-note-4-equity-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://autonomix.com/20250630/role/statement-note-4-equity-details-textual" xlink:type="extended">
    <link:loc xlink:href="amix-20250630.xsd#amix_ATMAgreementMember" xlink:label="amix_ATMAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_BlackscholesModelMember" xlink:label="amix_BlackscholesModelMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightExercisedInPeriodCash" xlink:label="amix_ClassOfWarrantOrRightExercisedInPeriodCash-2" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightExercisedInPeriodCashless" xlink:label="amix_ClassOfWarrantOrRightExercisedInPeriodCashless-2" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightFairValuePerShare" xlink:label="amix_ClassOfWarrantOrRightFairValuePerShare-2" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:label="amix_ClassOfWarrantOrRightIssuedDuringPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightLockupPeriod" xlink:label="amix_ClassOfWarrantOrRightLockupPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantsOrRightsMaximumBeneficialOwnership" xlink:label="amix_ClassOfWarrantsOrRightsMaximumBeneficialOwnership-2" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_CommissionPercentage" xlink:label="amix_CommissionPercentage-2" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_CommonStockDiscountForLackOfMarketability" xlink:label="amix_CommonStockDiscountForLackOfMarketability-2" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_CommonUnitsIssuedPurchasePrice" xlink:label="amix_CommonUnitsIssuedPurchasePrice-2" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_EquityOfferingMaximumOfferingAmount" xlink:label="amix_EquityOfferingMaximumOfferingAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_EquityOfferingMaximumSharesToBeIssued" xlink:label="amix_EquityOfferingMaximumSharesToBeIssued-2" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_EquityOfferingOptionMaximumShares" xlink:label="amix_EquityOfferingOptionMaximumShares-2" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_EquityOfferingOptionMaximumWarrants" xlink:label="amix_EquityOfferingOptionMaximumWarrants-2" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_EquityOfferingOptionPeriod" xlink:label="amix_EquityOfferingOptionPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_EquitybasedWarrantsMember" xlink:label="amix_EquitybasedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_MarketingConsultantMember" xlink:label="amix_MarketingConsultantMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_MaximumPercentageOfSharesSoldInThirtyDays" xlink:label="amix_MaximumPercentageOfSharesSoldInThirtyDays-2" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_NoncashExpensesMember" xlink:label="amix_NoncashExpensesMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_NoteToFinancialStatementDetailsTextual" xlink:label="amix_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_NumberOfCommonUnitsIssued" xlink:label="amix_NumberOfCommonUnitsIssued-2" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_NumberOfPrefundedUnitsIssued" xlink:label="amix_NumberOfPrefundedUnitsIssued-2" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_NumberOfSharesPerCommonUnit" xlink:label="amix_NumberOfSharesPerCommonUnit-2" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_NumberOfWarrantsPerCommonUnit" xlink:label="amix_NumberOfWarrantsPerCommonUnit-2" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_NumberOfWarrantsPerPrefundedUnit" xlink:label="amix_NumberOfWarrantsPerPrefundedUnit-2" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_PrefundedUnitsIssuedPurchasePrice" xlink:label="amix_PrefundedUnitsIssuedPurchasePrice-2" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_PrefundedWarrantsMember" xlink:label="amix_PrefundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_RepresentativesWarrantsMember" xlink:label="amix_RepresentativesWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_RfInnovationsIncMember" xlink:label="amix_RfInnovationsIncMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_SeriesAWarrantsAndTheRepresentativesWarrantsMember" xlink:label="amix_SeriesAWarrantsAndTheRepresentativesWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_SeriesAWarrantsMember" xlink:label="amix_SeriesAWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsDiscountRate" xlink:label="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsDiscountRate-2" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantDateFairValue" xlink:label="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantDateFairValue-2" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_The2023StockPlanMember" xlink:label="amix_The2023StockPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_UnderwritersMember" xlink:label="amix_UnderwritersMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_UnderwrittenPublicOfferingMember" xlink:label="amix_UnderwrittenPublicOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="us-gaap_MeasurementInputDiscountRateMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NatureOfExpenseAxis" xlink:label="us-gaap_NatureOfExpenseAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="us-gaap_ValuationTechniqueAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:label="us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="us-gaap_ValuationTechniqueDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amix_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="amix_MarketingConsultantMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_PrivatePlacementMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="amix_ATMAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="amix_The2023StockPlanMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ValuationTechniqueAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="amix_BlackscholesModelMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="amix_RfInnovationsIncMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="amix_UnderwrittenPublicOfferingMember" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="amix_SeriesAWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="amix_PrefundedWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_OverAllotmentOptionMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="amix_UnderwritersMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="amix_RepresentativesWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="amix_SeriesAWarrantsAndTheRepresentativesWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_MeasurementInputTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_NatureOfExpenseAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="amix_NoncashExpensesMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="amix_EquitybasedWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputExpectedTermMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_WarrantMember" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_EquityOfferingMaximumSharesToBeIssued-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts-2" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_EquityOfferingMaximumOfferingAmount-2" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock-2" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-2" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-2" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum-2" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized-2" xlink:type="arc"/>
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-2" xlink:type="arc"/>
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-2" xlink:type="arc"/>
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantDateFairValue-2" xlink:type="arc"/>
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharePrice-2" xlink:type="arc"/>
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsDiscountRate-2" xlink:type="arc"/>
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1-2" xlink:type="arc"/>
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate-2" xlink:type="arc"/>
    <link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions-2" xlink:type="arc"/>
    <link:presentationArc order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense-2" xlink:type="arc"/>
    <link:presentationArc order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_CommonStockDiscountForLackOfMarketability-2" xlink:type="arc"/>
    <link:presentationArc order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_MaximumPercentageOfSharesSoldInThirtyDays-2" xlink:type="arc"/>
    <link:presentationArc order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_NumberOfCommonUnitsIssued-2" xlink:type="arc"/>
    <link:presentationArc order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_NumberOfSharesPerCommonUnit-2" xlink:type="arc"/>
    <link:presentationArc order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_NumberOfWarrantsPerCommonUnit-2" xlink:type="arc"/>
    <link:presentationArc order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight-2" xlink:type="arc"/>
    <link:presentationArc order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_NumberOfPrefundedUnitsIssued-2" xlink:type="arc"/>
    <link:presentationArc order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_NumberOfWarrantsPerPrefundedUnit-2" xlink:type="arc"/>
    <link:presentationArc order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_CommonUnitsIssuedPurchasePrice-2" xlink:type="arc"/>
    <link:presentationArc order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_PrefundedUnitsIssuedPurchasePrice-2" xlink:type="arc"/>
    <link:presentationArc order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_EquityOfferingOptionPeriod-2" xlink:type="arc"/>
    <link:presentationArc order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_EquityOfferingOptionMaximumShares-2" xlink:type="arc"/>
    <link:presentationArc order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_EquityOfferingOptionMaximumWarrants-2" xlink:type="arc"/>
    <link:presentationArc order="42" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_ClassOfWarrantOrRightIssuedDuringPeriod-2" xlink:type="arc"/>
    <link:presentationArc order="43" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity-2" xlink:type="arc"/>
    <link:presentationArc order="44" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_CommissionPercentage-2" xlink:type="arc"/>
    <link:presentationArc order="45" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-2" xlink:type="arc"/>
    <link:presentationArc order="46" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_ClassOfWarrantsOrRightsMaximumBeneficialOwnership-2" xlink:type="arc"/>
    <link:presentationArc order="47" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm-2" xlink:type="arc"/>
    <link:presentationArc order="48" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_ClassOfWarrantOrRightLockupPeriod-2" xlink:type="arc"/>
    <link:presentationArc order="49" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_ClassOfWarrantOrRightFairValuePerShare-2" xlink:type="arc"/>
    <link:presentationArc order="50" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput-2" xlink:type="arc"/>
    <link:presentationArc order="51" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts-2" xlink:type="arc"/>
    <link:presentationArc order="52" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-2" xlink:type="arc"/>
    <link:presentationArc order="53" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_ClassOfWarrantOrRightExercisedInPeriodCashless-2" xlink:type="arc"/>
    <link:presentationArc order="54" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_ClassOfWarrantOrRightExercisedInPeriodCash-2" xlink:type="arc"/>
    <link:presentationArc order="55" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-note-5-commitments-and-contingencies-details-textual" xlink:href="amix-20250630.xsd#statement-note-5-commitments-and-contingencies-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://autonomix.com/20250630/role/statement-note-5-commitments-and-contingencies-details-textual" xlink:type="extended">
    <link:loc xlink:href="amix-20250630.xsd#amix_AnnualBaseSalary" xlink:label="amix_AnnualBaseSalary-2" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_EmploymentAgreementBonusAsAPercentageOfAnnualBaseCompensation" xlink:label="amix_EmploymentAgreementBonusAsAPercentageOfAnnualBaseCompensation-2" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_EmploymentAgreementTermOfContract" xlink:label="amix_EmploymentAgreementTermOfContract-2" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ExecutiveViceChairAndStrategicAdvisorToTheChiefExecutiveOfficerMember" xlink:label="amix_ExecutiveViceChairAndStrategicAdvisorToTheChiefExecutiveOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_InducementOptionsMember" xlink:label="amix_InducementOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_NoteToFinancialStatementDetailsTextual" xlink:label="amix_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ScenarioContractTerminationMember" xlink:label="amix_ScenarioContractTerminationMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ScenarioContractTerminationWithoutCauseMember" xlink:label="amix_ScenarioContractTerminationWithoutCauseMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_StockRequiredToBeIssuedForStockSplitShares" xlink:label="amix_StockRequiredToBeIssuedForStockSplitShares-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmploymentContractsMember" xlink:label="us-gaap_EmploymentContractsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LitigationStatusAxis" xlink:label="us-gaap_LitigationStatusAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LitigationStatusDomain" xlink:label="us-gaap_LitigationStatusDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyPendingClaimsNumber" xlink:label="us-gaap_LossContingencyPendingClaimsNumber-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PendingLitigationMember" xlink:label="us-gaap_PendingLitigationMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amix_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LitigationStatusAxis" xlink:to="us-gaap_LitigationStatusDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LitigationStatusAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LitigationStatusAxis" xlink:to="us-gaap_PendingLitigationMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_EmploymentContractsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_ChiefExecutiveOfficerMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="amix_InducementOptionsMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VestingAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="amix_ScenarioContractTerminationMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="amix_ScenarioContractTerminationWithoutCauseMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="amix_ExecutiveViceChairAndStrategicAdvisorToTheChiefExecutiveOfficerMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LossContingencyPendingClaimsNumber-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_EmploymentAgreementTermOfContract-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_AnnualBaseSalary-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_EmploymentAgreementBonusAsAPercentageOfAnnualBaseCompensation-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_StockRequiredToBeIssuedForStockSplitShares-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-note-6-related-party-transactions-details-textual" xlink:href="amix-20250630.xsd#statement-note-6-related-party-transactions-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://autonomix.com/20250630/role/statement-note-6-related-party-transactions-details-textual" xlink:type="extended">
    <link:loc xlink:href="amix-20250630.xsd#amix_AccountingAndFinancialReportingServicesMember" xlink:label="amix_AccountingAndFinancialReportingServicesMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightLockupAgreementTermOfUnderlyingShares" xlink:label="amix_ClassOfWarrantOrRightLockupAgreementTermOfUnderlyingShares-2" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightPercentageOfOutstandingStock" xlink:label="amix_ClassOfWarrantOrRightPercentageOfOutstandingStock-2" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightValueOfSecuritiesCalledByWarrantsOrRights" xlink:label="amix_ClassOfWarrantOrRightValueOfSecuritiesCalledByWarrantsOrRights-2" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_CommonStock12MonthsLockupPeriodMember" xlink:label="amix_CommonStock12MonthsLockupPeriodMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_CommonStock6MonthsLockupPeriodMember" xlink:label="amix_CommonStock6MonthsLockupPeriodMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ConsultingFirmOwnedByFormerCFOMember" xlink:label="amix_ConsultingFirmOwnedByFormerCFOMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_InterestHeldInCompanyReceivingWarrants" xlink:label="amix_InterestHeldInCompanyReceivingWarrants-2" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ManagementBoardOfDirectorFamilyMember" xlink:label="amix_ManagementBoardOfDirectorFamilyMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_NoteToFinancialStatementDetailsTextual" xlink:label="amix_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_TerminationAgreementMember" xlink:label="amix_TerminationAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_TheBridgeOfferingMember" xlink:label="amix_TheBridgeOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_TheWarrantMember" xlink:label="amix_TheWarrantMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ManagementMember" xlink:label="srt_ManagementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnderlyingAssetClassAxis" xlink:label="us-gaap_UnderlyingAssetClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnderlyingAssetClassDomain" xlink:label="us-gaap_UnderlyingAssetClassDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amix_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_UnderlyingAssetClassAxis" xlink:to="us-gaap_UnderlyingAssetClassDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="amix_ConsultingFirmOwnedByFormerCFOMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="amix_AccountingAndFinancialReportingServicesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="amix_ManagementBoardOfDirectorFamilyMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="amix_TheBridgeOfferingMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="srt_ManagementMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="amix_TheWarrantMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="amix_TerminationAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_UnderlyingAssetClassAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_UnderlyingAssetClassAxis" xlink:to="amix_CommonStock6MonthsLockupPeriodMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_UnderlyingAssetClassAxis" xlink:to="amix_CommonStock12MonthsLockupPeriodMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountsPayableCurrentAndNoncurrent-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_ClassOfWarrantOrRightValueOfSecuritiesCalledByWarrantsOrRights-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_ClassOfWarrantOrRightLockupAgreementTermOfUnderlyingShares-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_ClassOfWarrantOrRightPercentageOfOutstandingStock-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_InterestHeldInCompanyReceivingWarrants-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-note-7-income-taxes-details-textual" xlink:href="amix-20250630.xsd#statement-note-7-income-taxes-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://autonomix.com/20250630/role/statement-note-7-income-taxes-details-textual" xlink:type="extended">
    <link:loc xlink:href="amix-20250630.xsd#amix_ExpirationCommencingTaxYear20342037Member" xlink:label="amix_ExpirationCommencingTaxYear20342037Member" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_NolGeneratedDuring20172024Member" xlink:label="amix_NolGeneratedDuring20172024Member" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_NoteToFinancialStatementDetailsTextual" xlink:label="amix_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ReserveForUncertainTaxPositions" xlink:label="amix_ReserveForUncertainTaxPositions-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amix_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TaxPeriodAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="amix_ExpirationCommencingTaxYear20342037Member" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="amix_NolGeneratedDuring20172024Member" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLossCarryforwards-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_ReserveForUncertainTaxPositions-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-note-8-subsequent-events-details-textual" xlink:href="amix-20250630.xsd#statement-note-8-subsequent-events-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://autonomix.com/20250630/role/statement-note-8-subsequent-events-details-textual" xlink:type="extended">
    <link:loc xlink:href="amix-20250630.xsd#amix_ATMAgreementMember" xlink:label="amix_ATMAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_NoteToFinancialStatementDetailsTextual" xlink:label="amix_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amix_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="amix_ATMAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_GranteeStatusAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VestingAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q-details-textual" xlink:href="amix-20250630.xsd#statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q-details-textual" xlink:type="extended">
    <link:loc xlink:href="amix-20250630.xsd#amix_ATMAgreementMember" xlink:label="amix_ATMAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:label="amix_ClassOfWarrantOrRightIssuedDuringPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantsOrRightsMaximumBeneficialOwnership" xlink:label="amix_ClassOfWarrantsOrRightsMaximumBeneficialOwnership-2" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_CommonUnitsIssuedPurchasePrice" xlink:label="amix_CommonUnitsIssuedPurchasePrice-2" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_EquityOfferingMaximumOfferingAmount" xlink:label="amix_EquityOfferingMaximumOfferingAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_EquityOfferingOptionMaximumShares" xlink:label="amix_EquityOfferingOptionMaximumShares-2" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_EquityOfferingOptionMaximumWarrants" xlink:label="amix_EquityOfferingOptionMaximumWarrants-2" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_EquityOfferingOptionPeriod" xlink:label="amix_EquityOfferingOptionPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_EquitybasedWarrantsMember" xlink:label="amix_EquitybasedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_NoncashExpensesMember" xlink:label="amix_NoncashExpensesMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_NoteToFinancialStatementDetailsTextual" xlink:label="amix_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_NumberOfCommonUnitsIssued" xlink:label="amix_NumberOfCommonUnitsIssued-2" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_NumberOfPrefundedUnitsIssued" xlink:label="amix_NumberOfPrefundedUnitsIssued-2" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_NumberOfSharesPerCommonUnit" xlink:label="amix_NumberOfSharesPerCommonUnit-2" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_NumberOfWarrantsPerCommonUnit" xlink:label="amix_NumberOfWarrantsPerCommonUnit-2" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_NumberOfWarrantsPerPrefundedUnit" xlink:label="amix_NumberOfWarrantsPerPrefundedUnit-2" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_PrefundedAndSeriesAWarrantsMember" xlink:label="amix_PrefundedAndSeriesAWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_PrefundedUnitsIssuedPurchasePrice" xlink:label="amix_PrefundedUnitsIssuedPurchasePrice-2" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_PrefundedWarrantsMember" xlink:label="amix_PrefundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ProceedsFromIssuanceOrSaleOfEquityNet" xlink:label="amix_ProceedsFromIssuanceOrSaleOfEquityNet-2" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ReverseStockSplitMember" xlink:label="amix_ReverseStockSplitMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_SeriesAWarrantsMember" xlink:label="amix_SeriesAWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_UnderwritersMember" xlink:label="amix_UnderwritersMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_UnderwrittenPublicOfferingMember" xlink:label="amix_UnderwrittenPublicOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_WorkingCapitalDeficit" xlink:label="amix_WorkingCapitalDeficit-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdvertisingExpense" xlink:label="us-gaap_AdvertisingExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsCurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NatureOfExpenseAxis" xlink:label="us-gaap_NatureOfExpenseAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-n2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss-n2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonmonetaryTransactionTypeAxis" xlink:label="us-gaap_NonmonetaryTransactionTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonmonetaryTransactionTypeDomain" xlink:label="us-gaap_NonmonetaryTransactionTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit-n2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amix_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonmonetaryTransactionTypeAxis" xlink:to="us-gaap_NonmonetaryTransactionTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_NonmonetaryTransactionTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonmonetaryTransactionTypeAxis" xlink:to="amix_ReverseStockSplitMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="amix_ATMAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="amix_UnderwrittenPublicOfferingMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="amix_SeriesAWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="amix_PrefundedWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_OverAllotmentOptionMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="amix_UnderwritersMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="amix_PrefundedAndSeriesAWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_NatureOfExpenseAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="amix_NoncashExpensesMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="amix_EquitybasedWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_EquityOfferingMaximumOfferingAmount-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_NumberOfCommonUnitsIssued-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_NumberOfSharesPerCommonUnit-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_NumberOfWarrantsPerCommonUnit-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_NumberOfPrefundedUnitsIssued-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_NumberOfWarrantsPerPrefundedUnit-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_CommonUnitsIssuedPurchasePrice-2" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_PrefundedUnitsIssuedPurchasePrice-2" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_EquityOfferingOptionPeriod-2" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_EquityOfferingOptionMaximumShares-2" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_EquityOfferingOptionMaximumWarrants-2" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-2" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm-2" xlink:type="arc"/>
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_ClassOfWarrantsOrRightsMaximumBeneficialOwnership-2" xlink:type="arc"/>
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_ClassOfWarrantOrRightIssuedDuringPeriod-2" xlink:type="arc"/>
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity-2" xlink:type="arc"/>
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts-2" xlink:type="arc"/>
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_ProceedsFromIssuanceOrSaleOfEquityNet-2" xlink:type="arc"/>
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss-n2" xlink:type="arc"/>
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities-n2" xlink:type="arc"/>
    <link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Revenues-2" xlink:type="arc"/>
    <link:presentationArc order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit-n2" xlink:type="arc"/>
    <link:presentationArc order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_WorkingCapitalDeficit-2" xlink:type="arc"/>
    <link:presentationArc order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Cash-2" xlink:type="arc"/>
    <link:presentationArc order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife-2" xlink:type="arc"/>
    <link:presentationArc order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilityForUncertainTaxPositionsCurrent-2" xlink:type="arc"/>
    <link:presentationArc order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdvertisingExpense-2" xlink:type="arc"/>
    <link:presentationArc order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NumberOfReportableSegments-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-note-2-convertible-notes-payable-10q-details-textual" xlink:href="amix-20250630.xsd#statement-note-2-convertible-notes-payable-10q-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://autonomix.com/20250630/role/statement-note-2-convertible-notes-payable-10q-details-textual" xlink:type="extended">
    <link:loc xlink:href="amix-20250630.xsd#amix_BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember" xlink:label="amix_BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ConversionOfConvertibleNotesToCommonStockMember" xlink:label="amix_ConversionOfConvertibleNotesToCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ConvertibleDebtWith499PercentBeneficialOwnershipLimitationMember" xlink:label="amix_ConvertibleDebtWith499PercentBeneficialOwnershipLimitationMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_DebtInstrumentConvertibleMaximumBeneficialOwnershipPercentage" xlink:label="amix_DebtInstrumentConvertibleMaximumBeneficialOwnershipPercentage-2" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_NoteToFinancialStatementDetailsTextual" xlink:label="amix_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_TheNotesMember" xlink:label="amix_TheNotesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:label="us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember" xlink:label="us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="us-gaap_MeasurementInputDiscountRateMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amix_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="amix_TheNotesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="amix_BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="amix_ConvertibleDebtWith499PercentBeneficialOwnershipLimitationMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="amix_ConversionOfConvertibleNotesToCommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_MeasurementInputTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputExpectedTermMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_DebtInstrumentConvertibleMaximumBeneficialOwnershipPercentage-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromConvertibleDebt-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestExpenseDebt-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-note-3-equity-10q-details-textual" xlink:href="amix-20250630.xsd#statement-note-3-equity-10q-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://autonomix.com/20250630/role/statement-note-3-equity-10q-details-textual" xlink:type="extended">
    <link:loc xlink:href="amix-20250630.xsd#amix_ATMAgreementMember" xlink:label="amix_ATMAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_BlackscholesModelMember" xlink:label="amix_BlackscholesModelMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightFairValuePerShare" xlink:label="amix_ClassOfWarrantOrRightFairValuePerShare-2" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:label="amix_ClassOfWarrantOrRightIssuedDuringPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightLockupPeriod" xlink:label="amix_ClassOfWarrantOrRightLockupPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantsOrRightsMaximumBeneficialOwnership" xlink:label="amix_ClassOfWarrantsOrRightsMaximumBeneficialOwnership-2" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_CommissionPercentage" xlink:label="amix_CommissionPercentage-2" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_CommonStockDiscountForLackOfMarketability" xlink:label="amix_CommonStockDiscountForLackOfMarketability-2" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_CommonUnitsIssuedPurchasePrice" xlink:label="amix_CommonUnitsIssuedPurchasePrice-2" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_CommonWarrantsMember" xlink:label="amix_CommonWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_EquityOfferingMaximumOfferingAmount" xlink:label="amix_EquityOfferingMaximumOfferingAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_EquityOfferingOptionMaximumShares" xlink:label="amix_EquityOfferingOptionMaximumShares-2" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_EquityOfferingOptionMaximumWarrants" xlink:label="amix_EquityOfferingOptionMaximumWarrants-2" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_EquityOfferingOptionPeriod" xlink:label="amix_EquityOfferingOptionPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_MarketingConsultantMember" xlink:label="amix_MarketingConsultantMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_MaximumPercentageOfSharesSoldInThirtyDays" xlink:label="amix_MaximumPercentageOfSharesSoldInThirtyDays-2" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_NoncashExpensesMember" xlink:label="amix_NoncashExpensesMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_NoteToFinancialStatementDetailsTextual" xlink:label="amix_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_NumberOfCommonUnitsIssued" xlink:label="amix_NumberOfCommonUnitsIssued-2" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_NumberOfPrefundedUnitsIssued" xlink:label="amix_NumberOfPrefundedUnitsIssued-2" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_NumberOfSharesPerCommonUnit" xlink:label="amix_NumberOfSharesPerCommonUnit-2" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_NumberOfWarrantsPerCommonUnit" xlink:label="amix_NumberOfWarrantsPerCommonUnit-2" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_NumberOfWarrantsPerPrefundedUnit" xlink:label="amix_NumberOfWarrantsPerPrefundedUnit-2" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_PrefundedUnitsIssuedPurchasePrice" xlink:label="amix_PrefundedUnitsIssuedPurchasePrice-2" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_PrefundedWarrantsMember" xlink:label="amix_PrefundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_RepresentativesWarrantsMember" xlink:label="amix_RepresentativesWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_RfInnovationsIncMember" xlink:label="amix_RfInnovationsIncMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_SeriesAWarrantsAndTheRepresentativesWarrantsMember" xlink:label="amix_SeriesAWarrantsAndTheRepresentativesWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_SeriesAWarrantsMember" xlink:label="amix_SeriesAWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsDiscountRate" xlink:label="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsDiscountRate-2" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantDateFairValue" xlink:label="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantDateFairValue-2" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_The2023StockPlanMember" xlink:label="amix_The2023StockPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_UnderwritersMember" xlink:label="amix_UnderwritersMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_UnderwrittenPublicOfferingMember" xlink:label="amix_UnderwrittenPublicOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="us-gaap_MeasurementInputDiscountRateMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NatureOfExpenseAxis" xlink:label="us-gaap_NatureOfExpenseAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="us-gaap_ValuationTechniqueAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="us-gaap_ValuationTechniqueDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amix_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="amix_MarketingConsultantMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="amix_ATMAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="amix_The2023StockPlanMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ValuationTechniqueAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="amix_BlackscholesModelMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="amix_RfInnovationsIncMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="amix_UnderwrittenPublicOfferingMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="amix_SeriesAWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="amix_PrefundedWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_OverAllotmentOptionMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="amix_UnderwritersMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="amix_RepresentativesWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="amix_SeriesAWarrantsAndTheRepresentativesWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_MeasurementInputTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_NatureOfExpenseAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="amix_NoncashExpensesMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="amix_CommonWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_WarrantMember" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_EquityOfferingMaximumOfferingAmount-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum-2" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized-2" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-2" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantDateFairValue-2" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsDiscountRate-2" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1-2" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate-2" xlink:type="arc"/>
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions-2" xlink:type="arc"/>
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense-2" xlink:type="arc"/>
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues-2" xlink:type="arc"/>
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_CommonStockDiscountForLackOfMarketability-2" xlink:type="arc"/>
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_MaximumPercentageOfSharesSoldInThirtyDays-2" xlink:type="arc"/>
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_NumberOfCommonUnitsIssued-2" xlink:type="arc"/>
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_NumberOfSharesPerCommonUnit-2" xlink:type="arc"/>
    <link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_NumberOfWarrantsPerCommonUnit-2" xlink:type="arc"/>
    <link:presentationArc order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight-2" xlink:type="arc"/>
    <link:presentationArc order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_NumberOfPrefundedUnitsIssued-2" xlink:type="arc"/>
    <link:presentationArc order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_NumberOfWarrantsPerPrefundedUnit-2" xlink:type="arc"/>
    <link:presentationArc order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_CommonUnitsIssuedPurchasePrice-2" xlink:type="arc"/>
    <link:presentationArc order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_PrefundedUnitsIssuedPurchasePrice-2" xlink:type="arc"/>
    <link:presentationArc order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_EquityOfferingOptionPeriod-2" xlink:type="arc"/>
    <link:presentationArc order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_EquityOfferingOptionMaximumShares-2" xlink:type="arc"/>
    <link:presentationArc order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_EquityOfferingOptionMaximumWarrants-2" xlink:type="arc"/>
    <link:presentationArc order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_ClassOfWarrantOrRightIssuedDuringPeriod-2" xlink:type="arc"/>
    <link:presentationArc order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity-2" xlink:type="arc"/>
    <link:presentationArc order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_CommissionPercentage-2" xlink:type="arc"/>
    <link:presentationArc order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-2" xlink:type="arc"/>
    <link:presentationArc order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_ClassOfWarrantsOrRightsMaximumBeneficialOwnership-2" xlink:type="arc"/>
    <link:presentationArc order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm-2" xlink:type="arc"/>
    <link:presentationArc order="42" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_ClassOfWarrantOrRightLockupPeriod-2" xlink:type="arc"/>
    <link:presentationArc order="43" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_ClassOfWarrantOrRightFairValuePerShare-2" xlink:type="arc"/>
    <link:presentationArc order="44" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput-2" xlink:type="arc"/>
    <link:presentationArc order="45" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts-2" xlink:type="arc"/>
    <link:presentationArc order="46" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts-2" xlink:type="arc"/>
    <link:presentationArc order="47" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding-2" xlink:type="arc"/>
    <link:presentationArc order="48" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-2" xlink:type="arc"/>
    <link:presentationArc order="49" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-note-4-commitments-and-contingencies-10q-details-textual" xlink:href="amix-20250630.xsd#statement-note-4-commitments-and-contingencies-10q-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://autonomix.com/20250630/role/statement-note-4-commitments-and-contingencies-10q-details-textual" xlink:type="extended">
    <link:loc xlink:href="amix-20250630.xsd#amix_NoteToFinancialStatementDetailsTextual" xlink:label="amix_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_StockRequiredToBeIssuedForStockSplitShares" xlink:label="amix_StockRequiredToBeIssuedForStockSplitShares-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmploymentContractsMember" xlink:label="us-gaap_EmploymentContractsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LitigationStatusAxis" xlink:label="us-gaap_LitigationStatusAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LitigationStatusDomain" xlink:label="us-gaap_LitigationStatusDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyPendingClaimsNumber" xlink:label="us-gaap_LossContingencyPendingClaimsNumber-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PendingLitigationMember" xlink:label="us-gaap_PendingLitigationMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amix_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LitigationStatusAxis" xlink:to="us-gaap_LitigationStatusDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LitigationStatusAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LitigationStatusAxis" xlink:to="us-gaap_PendingLitigationMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_EmploymentContractsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LossContingencyPendingClaimsNumber-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_StockRequiredToBeIssuedForStockSplitShares-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-note-5-related-party-transactions-10q-details-textual" xlink:href="amix-20250630.xsd#statement-note-5-related-party-transactions-10q-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://autonomix.com/20250630/role/statement-note-5-related-party-transactions-10q-details-textual" xlink:type="extended">
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightLockupAgreementTermOfUnderlyingShares" xlink:label="amix_ClassOfWarrantOrRightLockupAgreementTermOfUnderlyingShares-2" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightPercentageOfOutstandingStock" xlink:label="amix_ClassOfWarrantOrRightPercentageOfOutstandingStock-2" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightValueOfSecuritiesCalledByWarrantsOrRights" xlink:label="amix_ClassOfWarrantOrRightValueOfSecuritiesCalledByWarrantsOrRights-2" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_CommonStock12MonthsLockupPeriodMember" xlink:label="amix_CommonStock12MonthsLockupPeriodMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_CommonStock6MonthsLockupPeriodMember" xlink:label="amix_CommonStock6MonthsLockupPeriodMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_NoteToFinancialStatementDetailsTextual" xlink:label="amix_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_TerminationAgreementMember" xlink:label="amix_TerminationAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_TheWarrantMember" xlink:label="amix_TheWarrantMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnderlyingAssetClassAxis" xlink:label="us-gaap_UnderlyingAssetClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnderlyingAssetClassDomain" xlink:label="us-gaap_UnderlyingAssetClassDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amix_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_UnderlyingAssetClassAxis" xlink:to="us-gaap_UnderlyingAssetClassDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="amix_TheWarrantMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="amix_TerminationAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_UnderlyingAssetClassAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_UnderlyingAssetClassAxis" xlink:to="amix_CommonStock6MonthsLockupPeriodMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_UnderlyingAssetClassAxis" xlink:to="amix_CommonStock12MonthsLockupPeriodMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_ClassOfWarrantOrRightValueOfSecuritiesCalledByWarrantsOrRights-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_ClassOfWarrantOrRightLockupAgreementTermOfUnderlyingShares-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_ClassOfWarrantOrRightPercentageOfOutstandingStock-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-note-6-subsequent-events-10q-details-textual" xlink:href="amix-20250630.xsd#statement-note-6-subsequent-events-10q-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://autonomix.com/20250630/role/statement-note-6-subsequent-events-10q-details-textual" xlink:type="extended">
    <link:loc xlink:href="amix-20250630.xsd#amix_ChiefMedicalOfficerMember" xlink:label="amix_ChiefMedicalOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ChiefTechnologyOfficerMember" xlink:label="amix_ChiefTechnologyOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightExchangesPercentageOfUnderlyingShares" xlink:label="amix_ClassOfWarrantOrRightExchangesPercentageOfUnderlyingShares-2" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightExercisesInPeriod" xlink:label="amix_ClassOfWarrantOrRightExercisesInPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ExecutiveChairOfTheBoardMember" xlink:label="amix_ExecutiveChairOfTheBoardMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ExistingWarrantsAt1722ExercisePriceMember" xlink:label="amix_ExistingWarrantsAt1722ExercisePriceMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ExistingWarrantsAt1723ExercisePriceMember" xlink:label="amix_ExistingWarrantsAt1723ExercisePriceMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ExistingWarrantsMember" xlink:label="amix_ExistingWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_NoteToFinancialStatementDetailsTextual" xlink:label="amix_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_PaymentsForWarrantIssuanceFees" xlink:label="amix_PaymentsForWarrantIssuanceFees-2" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_PreipoWarrantsMember" xlink:label="amix_PreipoWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_RepresentativesWarrantsMember" xlink:label="amix_RepresentativesWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_SeriesAWarrantsMember" xlink:label="amix_SeriesAWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_SeriesBWarrantsMember" xlink:label="amix_SeriesBWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_BoardOfDirectorsChairmanMember" xlink:label="srt_BoardOfDirectorsChairmanMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ChiefFinancialOfficerMember" xlink:label="srt_ChiefFinancialOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amix_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="amix_ExistingWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="amix_ExistingWarrantsAt1723ExercisePriceMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="amix_ExistingWarrantsAt1722ExercisePriceMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="amix_SeriesBWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="amix_RepresentativesWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="amix_SeriesAWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="amix_PreipoWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_BoardOfDirectorsChairmanMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="amix_ExecutiveChairOfTheBoardMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_DirectorMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_ChiefExecutiveOfficerMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="amix_ChiefTechnologyOfficerMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="amix_ChiefMedicalOfficerMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_ChiefFinancialOfficerMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_ClassOfWarrantOrRightExercisesInPeriod-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_ClassOfWarrantOrRightExchangesPercentageOfUnderlyingShares-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_PaymentsForWarrantIssuanceFees-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-fair-value-measurement-inputs-and-valuation-techniques-details" xlink:href="amix-20250630.xsd#statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-fair-value-measurement-inputs-and-valuation-techniques-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-fair-value-measurement-inputs-and-valuation-techniques-details" xlink:type="extended">
    <link:loc xlink:href="amix-20250630.xsd#amix_MeasurementInputFixedPriceMember" xlink:label="amix_MeasurementInputFixedPriceMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_MeasurementInputProbabilityRateMember" xlink:label="amix_MeasurementInputProbabilityRateMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_NoQualifiedOfferingOccurringMember" xlink:label="amix_NoQualifiedOfferingOccurringMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_QualifiedOfferingOccurringOneMember" xlink:label="amix_QualifiedOfferingOccurringOneMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_QualifiedOfferingOccurringTwoMember" xlink:label="amix_QualifiedOfferingOccurringTwoMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ValuationProbabilityweightedExpectedReturnMethodPWERMMember" xlink:label="amix_ValuationProbabilityweightedExpectedReturnMethodPWERMMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_statement-statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-fair-value-measurement-inputs-and-valuation-techniques-details" xlink:label="amix_statement-statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-fair-value-measurement-inputs-and-valuation-techniques-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="us-gaap_MeasurementInputDiscountRateMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PercentageOfFIFOInventory" xlink:label="us-gaap_PercentageOfFIFOInventory" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="us-gaap_ValuationTechniqueAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="us-gaap_ValuationTechniqueDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amix_statement-statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-fair-value-measurement-inputs-and-valuation-techniques-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_MeasurementInputTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="amix_MeasurementInputProbabilityRateMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ValuationTechniqueAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="amix_ValuationProbabilityweightedExpectedReturnMethodPWERMMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="amix_QualifiedOfferingOccurringOneMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="amix_QualifiedOfferingOccurringTwoMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="amix_NoQualifiedOfferingOccurringMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="amix_MeasurementInputFixedPriceMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputExpectedTermMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PercentageOfFIFOInventory" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-note-7-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" xlink:href="amix-20250630.xsd#statement-note-7-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://autonomix.com/20250630/role/statement-note-7-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="amix-20250630.xsd#amix_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" xlink:label="amix_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_DeferredTaxLiabilitiesChangeInAccountingMethod" xlink:label="amix_DeferredTaxLiabilitiesChangeInAccountingMethod-n8" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_statement-statement-note-7-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" xlink:label="amix_statement-statement-note-7-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities-n10" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amix_statement-statement-note-7-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:to="amix_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross-3" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance-n8" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet-3" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="amix_DeferredTaxLiabilitiesChangeInAccountingMethod-n8" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilities-n10" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-schedule-of-fair-value-measurements-details" xlink:href="amix-20250630.xsd#statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-schedule-of-fair-value-measurements-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-schedule-of-fair-value-measurements-details" xlink:type="extended">
    <link:loc xlink:href="amix-20250630.xsd#amix_statement-statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-schedule-of-fair-value-measurements-details" xlink:label="amix_statement-statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-schedule-of-fair-value-measurements-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amix_statement-statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-schedule-of-fair-value-measurements-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel3Member" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_WarrantMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements-n8" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue-5" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable-schedule-of-convertible-notes-payable-details" xlink:href="amix-20250630.xsd#statement-note-3-convertible-notes-payable-schedule-of-convertible-notes-payable-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable-schedule-of-convertible-notes-payable-details" xlink:type="extended">
    <link:loc xlink:href="amix-20250630.xsd#amix_DebtConversionDebtIssuanceCostsConvertedCommonShares" xlink:label="amix_DebtConversionDebtIssuanceCostsConvertedCommonShares-n9" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_IssuanceOfCommonStockForExtinguishmentOfConvertibleDebtMember" xlink:label="amix_IssuanceOfCommonStockForExtinguishmentOfConvertibleDebtMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_TheNotesMember" xlink:label="amix_TheNotesMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_statement-statement-note-3-convertible-notes-payable-schedule-of-convertible-notes-payable-details" xlink:label="amix_statement-statement-note-3-convertible-notes-payable-schedule-of-convertible-notes-payable-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebtMember" xlink:label="us-gaap_ConvertibleDebtMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="us-gaap_ConvertibleLongTermNotesPayable-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="us-gaap_ConvertibleLongTermNotesPayable-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1-n9" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1-n9" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet-n11" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet-n12" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amix_statement-statement-note-3-convertible-notes-payable-schedule-of-convertible-notes-payable-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="amix_TheNotesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LongtermDebtTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_ConvertibleDebtMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="amix_IssuanceOfCommonStockForExtinguishmentOfConvertibleDebtMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet-n11" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConvertibleLongTermNotesPayable-4" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1-n9" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_DebtConversionDebtIssuanceCostsConvertedCommonShares-n9" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1-n9" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount-5" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet-n12" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConvertibleLongTermNotesPayable-5" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable-schedule-of-detachable-warrants-details" xlink:href="amix-20250630.xsd#statement-note-3-convertible-notes-payable-schedule-of-detachable-warrants-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable-schedule-of-detachable-warrants-details" xlink:type="extended">
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightAggregateIntrinsicValueExercisable" xlink:label="amix_ClassOfWarrantOrRightAggregateIntrinsicValueExercisable" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightAggregateIntrinsicValueOutstanding" xlink:label="amix_ClassOfWarrantOrRightAggregateIntrinsicValueOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightExercisableNumber" xlink:label="amix_ClassOfWarrantOrRightExercisableNumber" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice" xlink:label="amix_ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightExercisableWeightedAverageRemainingContractualTerm" xlink:label="amix_ClassOfWarrantOrRightExercisableWeightedAverageRemainingContractualTerm" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightExercisesInPeriod" xlink:label="amix_ClassOfWarrantOrRightExercisesInPeriod-n8" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightExercisesInPeriodWeightedAverageExercisePrice" xlink:label="amix_ClassOfWarrantOrRightExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightExpirationsInPeriod" xlink:label="amix_ClassOfWarrantOrRightExpirationsInPeriod-n8" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="amix_ClassOfWarrantOrRightExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightForfeituresInPeriod" xlink:label="amix_ClassOfWarrantOrRightForfeituresInPeriod-n8" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="amix_ClassOfWarrantOrRightForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightGrantsInPeriod" xlink:label="amix_ClassOfWarrantOrRightGrantsInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightGrantsInPeriodWeightedAverageExercise" xlink:label="amix_ClassOfWarrantOrRightGrantsInPeriodWeightedAverageExercise" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightOutstandingOutstandingWeightedAverageExercisePrice" xlink:label="amix_ClassOfWarrantOrRightOutstandingOutstandingWeightedAverageExercisePrice-4" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightOutstandingOutstandingWeightedAverageExercisePrice" xlink:label="amix_ClassOfWarrantOrRightOutstandingOutstandingWeightedAverageExercisePrice-5" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm" xlink:label="amix_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_statement-statement-note-3-convertible-notes-payable-schedule-of-detachable-warrants-details" xlink:label="amix_statement-statement-note-3-convertible-notes-payable-schedule-of-detachable-warrants-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amix_statement-statement-note-3-convertible-notes-payable-schedule-of-detachable-warrants-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_ClassOfWarrantOrRightOutstandingOutstandingWeightedAverageExercisePrice-4" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_ClassOfWarrantOrRightAggregateIntrinsicValueOutstanding" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_ClassOfWarrantOrRightGrantsInPeriod" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_ClassOfWarrantOrRightGrantsInPeriodWeightedAverageExercise" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_ClassOfWarrantOrRightExercisesInPeriod-n8" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_ClassOfWarrantOrRightExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_ClassOfWarrantOrRightForfeituresInPeriod-n8" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_ClassOfWarrantOrRightForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_ClassOfWarrantOrRightExpirationsInPeriod-n8" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_ClassOfWarrantOrRightExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding-5" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_ClassOfWarrantOrRightOutstandingOutstandingWeightedAverageExercisePrice-5" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_ClassOfWarrantOrRightExercisableNumber" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_ClassOfWarrantOrRightExercisableWeightedAverageRemainingContractualTerm" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_ClassOfWarrantOrRightAggregateIntrinsicValueExercisable" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-note-4-equity-general-and-administrative-expense-details" xlink:href="amix-20250630.xsd#statement-note-4-equity-general-and-administrative-expense-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://autonomix.com/20250630/role/statement-note-4-equity-general-and-administrative-expense-details" xlink:type="extended">
    <link:loc xlink:href="amix-20250630.xsd#amix_statement-statement-note-4-equity-general-and-administrative-expense-details" xlink:label="amix_statement-statement-note-4-equity-general-and-administrative-expense-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amix_statement-statement-note-4-equity-general-and-administrative-expense-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-note-4-equity-restricted-stock-activity-details" xlink:href="amix-20250630.xsd#statement-note-4-equity-restricted-stock-activity-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://autonomix.com/20250630/role/statement-note-4-equity-restricted-stock-activity-details" xlink:type="extended">
    <link:loc xlink:href="amix-20250630.xsd#amix_statement-statement-note-4-equity-restricted-stock-activity-details" xlink:label="amix_statement-statement-note-4-equity-restricted-stock-activity-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amix_statement-statement-note-4-equity-restricted-stock-activity-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue-4" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod-n8" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-5" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue-5" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-note-4-equity-schedule-of-stock-option-activity-details" xlink:href="amix-20250630.xsd#statement-note-4-equity-schedule-of-stock-option-activity-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://autonomix.com/20250630/role/statement-note-4-equity-schedule-of-stock-option-activity-details" xlink:type="extended">
    <link:loc xlink:href="amix-20250630.xsd#amix_statement-statement-note-4-equity-schedule-of-stock-option-activity-details" xlink:label="amix_statement-statement-note-4-equity-schedule-of-stock-option-activity-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amix_statement-statement-note-4-equity-schedule-of-stock-option-activity-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-4" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-n8" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod-n8" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-5" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-5" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-note-4-equity-schedule-of-equitybased-stock-warrants-details" xlink:href="amix-20250630.xsd#statement-note-4-equity-schedule-of-equitybased-stock-warrants-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://autonomix.com/20250630/role/statement-note-4-equity-schedule-of-equitybased-stock-warrants-details" xlink:type="extended">
    <link:loc xlink:href="amix-20250630.xsd#amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice" xlink:label="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerm" xlink:label="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerm" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:label="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice-4" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:label="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice-5" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_SharebasedCompensationArrangementBySharebasedPaymentAwardNonoptionEquityInstrumentsExercisableNumberOutstandingNumber" xlink:label="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardNonoptionEquityInstrumentsExercisableNumberOutstandingNumber" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_statement-statement-note-4-equity-schedule-of-equitybased-stock-warrants-details" xlink:label="amix_statement-statement-note-4-equity-schedule-of-equitybased-stock-warrants-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amix_statement-statement-note-4-equity-schedule-of-equitybased-stock-warrants-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice-4" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised-n8" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures-n8" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations-n8" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber-5" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice-5" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardNonoptionEquityInstrumentsExercisableNumberOutstandingNumber" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerm" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-note-3-equity-general-and-administrative-expense-10q-details" xlink:href="amix-20250630.xsd#statement-note-3-equity-general-and-administrative-expense-10q-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://autonomix.com/20250630/role/statement-note-3-equity-general-and-administrative-expense-10q-details" xlink:type="extended">
    <link:loc xlink:href="amix-20250630.xsd#amix_statement-statement-note-3-equity-general-and-administrative-expense-10q-details" xlink:label="amix_statement-statement-note-3-equity-general-and-administrative-expense-10q-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amix_statement-statement-note-3-equity-general-and-administrative-expense-10q-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-note-4-equity-blackscholes-option-pricing-model-details" xlink:href="amix-20250630.xsd#statement-note-4-equity-blackscholes-option-pricing-model-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://autonomix.com/20250630/role/statement-note-4-equity-blackscholes-option-pricing-model-details" xlink:type="extended">
    <link:loc xlink:href="amix-20250630.xsd#amix_BlackscholesModelMember" xlink:label="amix_BlackscholesModelMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsDiscountRate" xlink:label="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsDiscountRate-2" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_statement-statement-note-4-equity-blackscholes-option-pricing-model-details" xlink:label="amix_statement-statement-note-4-equity-blackscholes-option-pricing-model-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="us-gaap_ValuationTechniqueAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="us-gaap_ValuationTechniqueDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amix_statement-statement-note-4-equity-blackscholes-option-pricing-model-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ValuationTechniqueAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="amix_BlackscholesModelMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_WarrantMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharePrice-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsDiscountRate-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-statements-of-cash-flows" xlink:href="amix-20250630.xsd#statement-statements-of-cash-flows" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://autonomix.com/20250630/role/statement-statements-of-cash-flows" xlink:type="extended">
    <link:loc xlink:href="amix-20250630.xsd#amix_ATMAgreementMember" xlink:label="amix_ATMAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightFairValueIssuedForIssuanceCostsFromIpo" xlink:label="amix_ClassOfWarrantOrRightFairValueIssuedForIssuanceCostsFromIpo" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_DebtConversionDebtIssuanceCostsConvertedCommonShares" xlink:label="amix_DebtConversionDebtIssuanceCostsConvertedCommonShares" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_IpoProceedsHoldbackProvision" xlink:label="amix_IpoProceedsHoldbackProvision" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_IssuanceOfCommonStockForExtinguishmentOfConvertibleDebtMember" xlink:label="amix_IssuanceOfCommonStockForExtinguishmentOfConvertibleDebtMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_PaymentsForInitialPublicOfferingIssuanceCosts" xlink:label="amix_PaymentsForInitialPublicOfferingIssuanceCosts-n8" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:label="amix_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_WarrantsIssuedForDebtIssuanceCosts" xlink:label="amix_WarrantsIssuedForDebtIssuanceCosts-2" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_WarrantsIssuedForEquityCosts" xlink:label="amix_WarrantsIssuedForEquityCosts" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="us-gaap_GainLossOnDerivativeInstrumentsNetPretax-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssued1" xlink:label="us-gaap_StockIssued1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="amix_ATMAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_PrivatePlacementMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="amix_IssuanceOfCommonStockForExtinguishmentOfConvertibleDebtMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnDerivativeInstrumentsNetPretax-n8" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets-n8" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-n8" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="amix_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfFinancingCosts-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts-n8" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromWarrantExercises" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock-1" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromConvertibleDebt" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="amix_PaymentsForInitialPublicOfferingIssuanceCosts-n8" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-3" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-4" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-5" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="amix_WarrantsIssuedForEquityCosts" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_StockIssued1" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="amix_WarrantsIssuedForDebtIssuanceCosts-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="amix_ClassOfWarrantOrRightFairValueIssuedForIssuanceCostsFromIpo" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="amix_IpoProceedsHoldbackProvision" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="amix_DebtConversionDebtIssuanceCostsConvertedCommonShares" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-condensed-statements-of-cash-flows-unaudited" xlink:href="amix-20250630.xsd#statement-condensed-statements-of-cash-flows-unaudited" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://autonomix.com/20250630/role/statement-condensed-statements-of-cash-flows-unaudited" xlink:type="extended">
    <link:loc xlink:href="amix-20250630.xsd#amix_DeferredFinancingCostsRelatedToTheIssuanceOfCommonStock" xlink:label="amix_DeferredFinancingCostsRelatedToTheIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssued1" xlink:label="us-gaap_StockIssued1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_PrivatePlacementMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets-n8" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-n8" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock-1" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-4" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-5" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="amix_DeferredFinancingCostsRelatedToTheIssuanceOfCommonStock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_StockIssued1" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-prior-period-corrections-details" xlink:href="amix-20250630.xsd#statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-prior-period-corrections-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-prior-period-corrections-details" xlink:type="extended">
    <link:loc xlink:href="amix-20250630.xsd#amix_ConvertibleNotesToWarrantsMember" xlink:label="amix_ConvertibleNotesToWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ReverseStockSplitAdjustmentMember" xlink:label="amix_ReverseStockSplitAdjustmentMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_statement-statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-prior-period-corrections-details" xlink:label="amix_statement-statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-prior-period-corrections-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" xlink:label="srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="srt_ScenarioPreviouslyReportedMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic-1" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amix_statement-statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-prior-period-corrections-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RestatementAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementAxis" xlink:to="srt_ScenarioPreviouslyReportedMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_WarrantMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementAxis" xlink:to="amix_ReverseStockSplitAdjustmentMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementAxis" xlink:to="srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_ConvertibleDebtSecuritiesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="amix_ConvertibleNotesToWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss-1" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic-1" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic-1" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-note-7-income-taxes-schedule-of-reconciliation-details" xlink:href="amix-20250630.xsd#statement-note-7-income-taxes-schedule-of-reconciliation-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://autonomix.com/20250630/role/statement-note-7-income-taxes-schedule-of-reconciliation-details" xlink:type="extended">
    <link:loc xlink:href="amix-20250630.xsd#amix_EffectiveIncomeTaxRateReconciliationChangeInStateRateAmount" xlink:label="amix_EffectiveIncomeTaxRateReconciliationChangeInStateRateAmount" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_EffectiveIncomeTaxRateReconciliationChangeInStateRatePercent" xlink:label="amix_EffectiveIncomeTaxRateReconciliationChangeInStateRatePercent" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_statement-statement-note-7-income-taxes-schedule-of-reconciliation-details" xlink:label="amix_statement-statement-note-7-income-taxes-schedule-of-reconciliation-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amix_statement-statement-note-7-income-taxes-schedule-of-reconciliation-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_EffectiveIncomeTaxRateReconciliationChangeInStateRateAmount" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_EffectiveIncomeTaxRateReconciliationChangeInStateRatePercent" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit-3" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-schedule-of-prior-period-corrections-10q-details" xlink:href="amix-20250630.xsd#statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-schedule-of-prior-period-corrections-10q-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-schedule-of-prior-period-corrections-10q-details" xlink:type="extended">
    <link:loc xlink:href="amix-20250630.xsd#amix_ConvertibleNotesToWarrantsMember" xlink:label="amix_ConvertibleNotesToWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ReverseStockSplitAdjustmentMember" xlink:label="amix_ReverseStockSplitAdjustmentMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_statement-statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-schedule-of-prior-period-corrections-10q-details" xlink:label="amix_statement-statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-schedule-of-prior-period-corrections-10q-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" xlink:label="srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="srt_ScenarioPreviouslyReportedMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic-1" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amix_statement-statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-schedule-of-prior-period-corrections-10q-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RestatementAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementAxis" xlink:to="srt_ScenarioPreviouslyReportedMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_WarrantMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementAxis" xlink:to="amix_ReverseStockSplitAdjustmentMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementAxis" xlink:to="srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_ConvertibleDebtSecuritiesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="amix_ConvertibleNotesToWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss-1" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic-1" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic-1" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-statements-of-operations" xlink:href="amix-20250630.xsd#statement-statements-of-operations" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://autonomix.com/20250630/role/statement-statements-of-operations" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="us-gaap_GainLossOnDerivativeInstrumentsNetPretax-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="us-gaap_InterestExpenseNonoperating-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingCostsAndExpensesAbstract" xlink:label="us-gaap_OperatingCostsAndExpensesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingCostsAndExpensesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_GainLossOnDerivativeInstrumentsNetPretax-n8" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_OperatingExpenses-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss-3" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants-n8" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestExpenseNonoperating-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest-3" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NetIncomeLoss-3" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_EarningsPerShareBasic" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-condensed-statements-of-operations-unaudited" xlink:href="amix-20250630.xsd#statement-condensed-statements-of-operations-unaudited" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://autonomix.com/20250630/role/statement-condensed-statements-of-operations-unaudited" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="us-gaap_InterestExpenseNonoperating-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingCostsAndExpensesAbstract" xlink:label="us-gaap_OperatingCostsAndExpensesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingCostsAndExpensesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_OperatingExpenses-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss-3" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestExpenseNonoperating-n8" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NetIncomeLoss-3" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_EarningsPerShareBasic" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-statements-of-changes-in-stockholders-equity" xlink:href="amix-20250630.xsd#statement-statements-of-changes-in-stockholders-equity" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://autonomix.com/20250630/role/statement-statements-of-changes-in-stockholders-equity" xlink:type="extended">
    <link:loc xlink:href="amix-20250630.xsd#amix_StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants" xlink:label="amix_StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants" xlink:label="amix_StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_StockIssuedDuringPeriodSharesInitialPublicOffering" xlink:label="amix_StockIssuedDuringPeriodSharesInitialPublicOffering" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="amix_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_StockIssuedDuringPeriodValueInitialPublicOffering" xlink:label="amix_StockIssuedDuringPeriodValueInitialPublicOffering" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="amix_StockIssuedDuringPeriodValueWarrantsExercised" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_WarrantsIssuedFairValueIssuedForTerminationAgreement" xlink:label="amix_WarrantsIssuedFairValueIssuedForTerminationAgreement" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-5" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity-4" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_StockIssuedDuringPeriodSharesInitialPublicOffering" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_StockIssuedDuringPeriodValueInitialPublicOffering" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_StockIssuedDuringPeriodValueWarrantsExercised" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_WarrantsIssuedFairValueIssuedForTerminationAgreement" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding-5" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity-5" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-condensed-statements-of-changes-in-stockholders-equity-unaudited" xlink:href="amix-20250630.xsd#statement-condensed-statements-of-changes-in-stockholders-equity-unaudited" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://autonomix.com/20250630/role/statement-condensed-statements-of-changes-in-stockholders-equity-unaudited" xlink:type="extended">
    <link:loc xlink:href="amix-20250630.xsd#amix_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="amix_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="amix_StockIssuedDuringPeriodValueWarrantsExercised" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-5" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity-4" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_StockIssuedDuringPeriodValueWarrantsExercised" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding-5" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity-5" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-antidilutive-securities-details" xlink:href="amix-20250630.xsd#statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-antidilutive-securities-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-antidilutive-securities-details" xlink:type="extended">
    <link:loc xlink:href="amix-20250630.xsd#amix_ConvertibleNotesToWarrantsMember" xlink:label="amix_ConvertibleNotesToWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_RepresentativesWarrantsMember" xlink:label="amix_RepresentativesWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_SeriesAWarrantsMember" xlink:label="amix_SeriesAWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_statement-statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-antidilutive-securities-details" xlink:label="amix_statement-statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-antidilutive-securities-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amix_statement-statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-antidilutive-securities-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_WarrantMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_ConvertibleDebtSecuritiesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="amix_ConvertibleNotesToWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="amix_SeriesAWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="amix_RepresentativesWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-10q-details" xlink:href="amix-20250630.xsd#statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-10q-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-10q-details" xlink:type="extended">
    <link:loc xlink:href="amix-20250630.xsd#amix_ConvertibleNotesToWarrantsMember" xlink:label="amix_ConvertibleNotesToWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_RepresentativesWarrantsMember" xlink:label="amix_RepresentativesWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_SeriesAWarrantsMember" xlink:label="amix_SeriesAWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_statement-statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-10q-details" xlink:label="amix_statement-statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-10q-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amix_statement-statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-10q-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_WarrantMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_ConvertibleDebtSecuritiesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="amix_ConvertibleNotesToWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="amix_SeriesAWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="amix_RepresentativesWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-note-2-convertible-notes-payable-schedule-of-detachable-warrants-10q-details" xlink:href="amix-20250630.xsd#statement-note-2-convertible-notes-payable-schedule-of-detachable-warrants-10q-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://autonomix.com/20250630/role/statement-note-2-convertible-notes-payable-schedule-of-detachable-warrants-10q-details" xlink:type="extended">
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightExercisableNumber" xlink:label="amix_ClassOfWarrantOrRightExercisableNumber" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice" xlink:label="amix_ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightExercisesInPeriod" xlink:label="amix_ClassOfWarrantOrRightExercisesInPeriod-n8" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightExercisesInPeriodWeightedAverageExercisePrice" xlink:label="amix_ClassOfWarrantOrRightExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightExpirationsInPeriod" xlink:label="amix_ClassOfWarrantOrRightExpirationsInPeriod-n8" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="amix_ClassOfWarrantOrRightExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightForfeituresInPeriod" xlink:label="amix_ClassOfWarrantOrRightForfeituresInPeriod-n8" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="amix_ClassOfWarrantOrRightForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightGrantsInPeriod" xlink:label="amix_ClassOfWarrantOrRightGrantsInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightGrantsInPeriodWeightedAverageExercise" xlink:label="amix_ClassOfWarrantOrRightGrantsInPeriodWeightedAverageExercise" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightOutstandingOutstandingWeightedAverageExercisePrice" xlink:label="amix_ClassOfWarrantOrRightOutstandingOutstandingWeightedAverageExercisePrice-4" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_ClassOfWarrantOrRightOutstandingOutstandingWeightedAverageExercisePrice" xlink:label="amix_ClassOfWarrantOrRightOutstandingOutstandingWeightedAverageExercisePrice-5" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_statement-statement-note-2-convertible-notes-payable-schedule-of-detachable-warrants-10q-details" xlink:label="amix_statement-statement-note-2-convertible-notes-payable-schedule-of-detachable-warrants-10q-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amix_statement-statement-note-2-convertible-notes-payable-schedule-of-detachable-warrants-10q-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_ClassOfWarrantOrRightOutstandingOutstandingWeightedAverageExercisePrice-4" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_ClassOfWarrantOrRightGrantsInPeriod" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_ClassOfWarrantOrRightGrantsInPeriodWeightedAverageExercise" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_ClassOfWarrantOrRightExercisesInPeriod-n8" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_ClassOfWarrantOrRightExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_ClassOfWarrantOrRightForfeituresInPeriod-n8" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_ClassOfWarrantOrRightForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_ClassOfWarrantOrRightExpirationsInPeriod-n8" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_ClassOfWarrantOrRightExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding-5" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_ClassOfWarrantOrRightOutstandingOutstandingWeightedAverageExercisePrice-5" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_ClassOfWarrantOrRightExercisableNumber" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-note-3-equity-schedule-of-stock-option-activity-10q-details" xlink:href="amix-20250630.xsd#statement-note-3-equity-schedule-of-stock-option-activity-10q-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://autonomix.com/20250630/role/statement-note-3-equity-schedule-of-stock-option-activity-10q-details" xlink:type="extended">
    <link:loc xlink:href="amix-20250630.xsd#amix_statement-statement-note-3-equity-schedule-of-stock-option-activity-10q-details" xlink:label="amix_statement-statement-note-3-equity-schedule-of-stock-option-activity-10q-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amix_statement-statement-note-3-equity-schedule-of-stock-option-activity-10q-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-4" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-n8" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod-n8" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-5" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-5" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-note-3-equity-schedule-of-equitybased-stock-warrants-10q-details" xlink:href="amix-20250630.xsd#statement-note-3-equity-schedule-of-equitybased-stock-warrants-10q-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://autonomix.com/20250630/role/statement-note-3-equity-schedule-of-equitybased-stock-warrants-10q-details" xlink:type="extended">
    <link:loc xlink:href="amix-20250630.xsd#amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice" xlink:label="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:label="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice-4" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:label="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice-5" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_SharebasedCompensationArrangementBySharebasedPaymentAwardNonoptionEquityInstrumentsExercisableNumberOutstandingNumber" xlink:label="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardNonoptionEquityInstrumentsExercisableNumberOutstandingNumber" xlink:type="locator"/>
    <link:loc xlink:href="amix-20250630.xsd#amix_statement-statement-note-3-equity-schedule-of-equitybased-stock-warrants-10q-details" xlink:label="amix_statement-statement-note-3-equity-schedule-of-equitybased-stock-warrants-10q-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amix_statement-statement-note-3-equity-schedule-of-equitybased-stock-warrants-10q-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice-4" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised-n8" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures-n8" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations-n8" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber-5" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice-5" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardNonoptionEquityInstrumentsExercisableNumberOutstandingNumber" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-balance-sheets" xlink:href="amix-20250630.xsd#statement-balance-sheets" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://autonomix.com/20250630/role/statement-balance-sheets" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="us-gaap_ConvertibleLongTermNotesPayable-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCosts" xlink:label="us-gaap_DeferredCosts" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrentAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsCurrent" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent-3" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsNoncurrentAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_DeferredCosts" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrent-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_Assets-3" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_ConvertibleLongTermNotesPayable-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrent-3" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_Liabilities-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity-3" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://autonomix.com/20250630/role/statement-condensed-balance-sheets-unaudited-" xlink:href="amix-20250630.xsd#statement-condensed-balance-sheets-unaudited-" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://autonomix.com/20250630/role/statement-condensed-balance-sheets-unaudited-" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCosts" xlink:label="us-gaap_DeferredCosts" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrentAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsCurrent" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent-3" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsNoncurrentAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_DeferredCosts" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrent-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_Assets-3" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_Liabilities-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity-3" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity-3" xlink:type="arc"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>a01.jpg
<TEXT>
begin 644 a01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!P17AI9@  34T *@    @ !@$Q  (
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M^/GZ_]H # ,!  (1 Q$ /P#]_**** "BBB@ HHS0: "BBB@ HHS10 444;J
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M$VO%'Q>_8J^(OPG^(WQJ\4>.-0^(C@R:[<V,,#:7&&5A'!"F%5<KSSS72_M
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M#Y-?0GCCJ*** "BBB@#YZ_X*M-M_X)I_'+_L3=1_]$M70_\ !/PY_86^#_\
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MP[\/^&O$'B;PU>^)?"M_H.I->65X;5-\UE-N 9957G< 01TH ^T%VJ_S!L\
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M.:R]7_;6^%.@_%B'P'??$+P?9^,YG\I='EU6);H.>B$9P'/]TG/M7PU#\)M
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MHKUCSPHHHH ^>?\ @J[_ ,HTOCE_V)NH_P#HEJZ+_@GU_P F+_!__L3]+_\
M2:.N=_X*N_\ *-+XY?\ 8FZC_P"B6KHO^"?7_)B_P?\ ^Q/TO_TFCK;_ )=?
M,#V-EWKCUJEK.@6NOZ3<65];P7MG=1-!<6\T0DBGC((*LIR"#GH:NEL+GVS7
M'?'3XT:;\!?@KXJ\;:Q'(VF^%=*N-4N4C8!I%BC+E%/]XXP/<UB!Y?\ #S_@
MF!^SY\(]8AN_#?PA\$Z3>0ZBFK17,>GKO@NE;<DD;'E""2<+@5ZAX5^ /A'P
M/KOBK5-)T'3[+4/'$_VG7YXX_GU:39LS(>_R\?2O$_\ @F[^U7\4OVNOA/\
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M7X9Z]XDD^&_Q%^$FLZ]JWAJ\U66^CT&]MD817,)D8R0M(,@C(R>17V?\:?\
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MWIB_9+4);1R-/!$N '3<Q"="0!4GA/\ ;_\ CI^R5H?[5G@?X@:CHWQ4\7?
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MG_%#PWX7TGQA>LOC"1+72-:FTV:'1[VY<9%NETP">;VV^M?*WQ,MKBW^._\
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MD+QXXW'[Q/<U]":UH\>E?\'&7AB6ULFMXYOA!<P2S16[+$P2Z!2,L!MXZ@4
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M-=)^P9_P3U^)'[.O[7OQ(^,?Q*^)%CX^U[XF:7:6MQ%:69MH--D@./*A7/\
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M6C?-)'%R221G'%?=WPJ^*6E_&;X<^'_%>@S+=Z)XEL(=2LI@?OPRQAU)'KR
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MA;\9+SXX>./%_C+Q]H7]HZW:WFO+<:;KT]P@D<):GB/[.QP-F-NWFOI3P?\
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MLQ/F:KJT&G1L3_!%'D_J:X\%K&Z.C$:/E.]_X.E?"\%[^PCX9U)X5-UI?BB
MQ2XSY/F AA^/ K\-EUI[KPO'IN5CMY+^-S&!_K#N &?QK^B7_@X.^%"_$S_@
MEUXZD8,\WAV6WUB';ZQR#/Z-^E?SF>'A]O\ $6D*BEO,O+?: -VXEE/3O6V(
MC^[U,Z'Q6/OS_@B]X<3Q9_P6_M7F51_8FEW$Z#T9;=5QCVSUK^A8*0?Y<5_/
MK_P2NOKKPI_P72\.W4$$5O:^*+2^A&TYR%B ;\25SCWK^@K?S4X/WJ*L/$*T
M]1U%%%=A@%%%% !1110!\\_\%7?^4:7QR_[$W4?_ $2U=%_P3Z_Y,7^#_P#V
M)^E_^DT=<[_P5=_Y1I?'+_L3=1_]$M71?\$^O^3%_@__ -B?I?\ Z31UK_RZ
M^?Z >R8XIICW?CV[4XG KC_CA\=/#O[.GPHUSQMXMN_[-\,^';<W5_=[2WD1
M# +8_&L@.J6TVD8=LYR??_"A+38/O_-W.,9Z]J^6_A5_P6D_9X^-?QKTOP'X
M<\<+=ZQX@^71KF:SFM].UF3;N,5O<NHCD<#^$'.1BM#]I3_@KM\#_P!E#XD3
M>$_%OB*]_MK3X4NM6CTW3IKZ/0H6^[)=O&"L(/7DY Y( H ^DVM=D;?.P7&>
MF3^?6HE57=?F8[2 &!R ?3TKQ7X]_P#!23X-_LU_#OPGXL\7^--.T_PQXZR-
M"U.,^=!J'[KS1L*YZKT'4GBO)?A_^W9H_P"T[^T]\%=6\#_%232?!WC32]6E
MC\(7WAV2*^\1R6IPTP>0!H53.>1\PZ4 ?:!.!4*76\+\I]QZ5\>^-/\ @O+^
MS+X+N);>\\<3-):7TNFZGY.F3S)HLL;[&^ULJXA7/=C@BN#_ ."F'[<UO\ O
MVC_V3_$T'Q$7P_\ "WQ%JM_>:Y<PN7M-9LS:AK=<*"SEF8$ #- 'Z"45X-^R
M?_P4E^$O[:>E^(KGP+XB::7PBQ_MJSU*V?3[O34P2)9(Y0"$(&0W3'-<A\+_
M /@L_P#L]_&#XRV'@C1?&4KZAK5X^GZ1?W&GSV^EZS<I]Z&WNG41R-P0 #SC
MC- 'U12,VU2?05\P?M$_\%A/@3^R[\5+_P "^+/$UY'XST^6TC?1;'3IKR\<
M7'W)%1%),8_B;H*S?B__ ,%J_@#\$_B;=>$]>\2:K#=Z=/'::E?0:/<S:=I,
MLBAD6XN FR/(8=3]<4 ?54=XS!"T3+NQGG.":L5\1^,?C]XDO?\ @M5\)?"N
MB^)[J3X?^(OAK?ZW-IT#!K.]D$P$-P#]#7VY0 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 !.!7DO[:O[8OAK]AC]F_Q%\3/%4-Y
M=:3H*)MM;-=UU?2NX188E[N2>GM7K$J[XF7^\"*_.'_@J1\5=?\ BY^WQ\$_
MA/X-\%W'Q,_X0!I/B'XMT*&\BMD>-08;196D^7_6,S!2#GCZT ?;W[.O[2OA
MW]IC]G_PO\2-!D:'P]XHTZ/4(6NF$;6X;JDF> RMD$=B#7:2:_;0RJDDT,9F
M!:+?*J^<H&25SUP.3V K\5O"7Q$\4?#C_@GY^V?\!=>T'5O!?BCP+-+XTT/0
M4N_M%U8:%J,PG!B>/JD3!\[?N@FO=]7_ &B? O[0'[?G[&'AOPWXUTWQ0)/!
MNHR:M9:??F9'A?38T_?["1DD,-K'<#F@#[T_9[_:P\#_ +4.C:K?^#=8AU2'
M1=6N=$NE7[Z75NVV5=O4J#T8<&NUTOQA8:\9UT^\T^\EMFV3)!<I*83Z-MSM
MZ=Z_#_X0Z-X9_9W_ .":'[5.K_"V1?#OQ8T7Q=JFBZHVGW;2:QH>@G48U>80
M;B4Q"7;S0N>^:]M\'>!_A#\"/V\?V6%_9C\2R:E=^,+*]A\8V>FZU)J-MJ.C
MK:>9]MO1O8)*)L$.<$G(Q0!^J@\6:>;^&V.H6(N;H$V\/VA/,N,9SM7.6QCG
M%&K>,M/\/>1_:5]9:>L[F-3<W"0AF'8;B-W/'&:_#+2/V>_"_A[_ ()8:M^T
M##K7B)OB7I/Q2D?3M=DUNX)TN-=9\K[/"N[:L31DAE(.0<5]"^.]%^$G[1?_
M  46_:*L?VF/$WV.'PCX?TU_!NF:EK#Z?9V>F2V?F3WUH RAIO.ZD%B#VH _
M5"[U^UL58S36\*JAD)DF5!M'4\]O?I5,>/-+,%C(=0TT0ZDQ2UD^UQ[;D]A&
M<X?/^SFOQA^#OAF]_:E^''[!_A?XB:UXIO-*US7/$D<8?4);2\U[280_V07.
M"'>,Q@#D\CG/-9MY^Q)\/3\'_P!N1VO/$7V7X%ZK.G@2U;7;D0^"RMN+C=;#
M?E27P>2W0CO0!^PGB/XW:AH/Q\\/^#(_!^MWFFZUIUQ?S>(HV06&FM$P402@
MG<9')X"@BNPM?%EC?ZI-8V]Y8SWMJP%Q;QW*-+;YZ;U!RI/H?6ORS^,WQB\8
M3_&3X%^)='U+4KCQE<?LZ:UK5K#%.Q^V7XM(RLOEYVM(#N8'&<UW_P#P2(^&
M/[-.G>$/@WXR\+^,X=9^,WB3P_)-J,[:]+<:CK%R\8:]^UP%S@QON WA=N.,
MT ?I"C[Q3J;$?EIU !1110 4444 %!Z44'D4 ,+_ "_A7X:?\'*_C2U\8?M[
M?"WPO#(BW/A_0WNKULY*+))D #UP/6OW,,>1Z^U?S8_\%RO&EQKO_!7[QE-(
MVXZ*+&QA'HGE@X_$UAB(MP=C6C\:/"/CT6G^%?@#4F5C'J;:C(CL<L=DX4+^
M7.:_:_\ X-D?!K>&/^";<>H-&0VN>(KV?)_B52%4_I7XM_M Q>9^S_X+C:18
MYM#GOE> C!19"'S^.:_?C_@A3X3E\&?\$M/A/#,OER7UE)>$ ?>\R5V!_+%<
MF6OW/0UQBM4NST[_ (*3>#O^$^_8(^+6E-_RV\,W9'R[LE$+]/\ @-?RZ_ .
M13\2_!;,HVRZA;)\W16+@<_3%?UK?&'0!XI^$?BK3&C\Y;[2+J H1]\M$PQ7
M\H/P%\+M<?';2;61E@ATS696??\ P;'8@8^HQ73BG:EJ9X?^(?6W_!-[QA#\
M-?\ @J]\,-6N+@7%OJ'B;5-%;S/^69D+HK ]N>V/QK^BY7W/^.#[5_*C!XJF
M\(_M2^ ;VSDDCNK/Q@E\"GR[2UVO\P:_JFL+DW,4$O3S8U;ZDX-89<_W5S3%
M+]X7****] Y0HHHH **** /GG_@J[_RC2^.7_8FZC_Z):NB_X)]?\F+_  ?_
M .Q/TO\ ])HZYW_@J[_RC2^.7_8FZC_Z):NB_P""?7_)B_P?_P"Q/TO_ -)H
MZV_Y=?,#V*1=R$>U?)__  6^B:Z_X)._'2/Y)-WAR0;2< _.A(KZR8X%>1?M
MR_LQC]L;]D_QK\,/[6;01XPT\V(U!(O,:U^96W[<C=C;TS^?0X@?E5\5_P!J
M+X4_ML?LY_L@_!_X-Z7=3_$K2_%&@:E)IEMHKVUQX3M;1 ;NYF.T+$K;<YS\
MV:R/#6K+\ /VK_VK/"?Q,^/FI? >^\8>*;K4VMKWPK'J5KXKTR>$)'/'.Z'>
M?+W)Y:G@\CFOV)^"GP$T?X0^"M#T^"STNXU;2])MM+NM62RBCN+\0QK&&=@-
MQSMSC/4UM^+?A%X;\?-:-KN@:'K4EB0;=K^PCN##_NE@<4 ?E!\5_P!G;P%X
M'^$W_!._P/X?U34OB-\/;?QZ9+&]UFR;S+Z,QO*C2H5^10QP,\=*^C?VJ+);
M#_@NG^RZL-NT<2^%/$2*8H#Y40\M>"5&U<XX!]*^X9?!6FS"RS8V.[36W6;&
MW0_8SC \H8PF!Z5//X<L9M2COI+6U>[A#".=X@9(@P^8*W5<]\&@#\.OV2_V
MX?@5^S[^QS^UMX#\;6*KX\\0>*_$L$=B='>YF\6&X+QVT,$@4B8JS 8)&W.:
M] T#X':AX(T;_@F'X'^(>C37FK:;<7<M[I]];&;[*WV7S(UEX(4QY4#=T*XK
M[]_8>_X)WZ+^R5X*UK2M6N]/\:WFJ>+-1\465]>Z=$TVEF[DWF*,L&("] 1^
ME?0]WX:L[^]@N;BVM;BXM6+V\LL"NT!(P2I/*Y]B* /RG_:L^%NK>/?^"D'[
M8GASP7I4W]N>)/@3;Q01P1-"-1N06 C## 9RORC!!YKPK]G@_#/]I;]FSX&_
M#WQI^U-KFGW'AO4M(%M\/$\&QVNIZ5JMK)_Q[ED02*H<8,I."#DFOW-C\,V<
M.IR7T=K:KJ$D2P-="(><R+T4OU('IFLV/X2>&(?%)UZ/P[H*:XW!U$:?"+H_
M]M-N[]: /A7]F/P-I/B7_@OK^TCK%_I-M<ZAI?A+0K>QO9[7<T*LAWB-F&,G
MC./>OB_]OW]O3Q)\:?AQ^U-X/\5>/+/X5IH=S>Z'I?PPT_P:+O5/%5NFT)>R
M7++N(EX)=3\H!K]S(/#%G:ZG-?1VMM'>W*A)KA856:8#. SCD@9[UGWWPL\.
MZKK?]J7FAZ)>:HT7DM>S:?$]PR'@J7(SM(XQZ4 ?FG^S;YT?_!3/]D%9H;I9
M$^ #))F-B(F.P[6;& W'0\U^IE9MIX0TVRO;>YBT^QCN+.+[/!*ENHDAB_N*
MV,A?8<5I4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%%  >E<UIWPB\.Z3X[U#Q5;:1IUOXFU:VCL[W58[=5NKJ&,Y2-GZE0<G'O72
MT4 <I>?!+PMJ/C2X\1W&@Z/-KUY8'2KF_DM%>>XM"<F!V.2T9_NG(KEOA?\
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M%<_\-OV-?A9\'OB/J?C#POX!\*Z#XHU@$7FI6.GI#/+GKR/NY[[<9[UZ910
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MKL,@HHHH **** /GG_@J[_RC2^.7_8FZC_Z):NB_X)]?\F+_  ?_ .Q/TO\
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M?]B/POK'PK\/:EX1\)V]S<6*Z)>.TDFF7,4A$T._)W*KY 8'!%?4% !1110
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M  SHL?EVEC;K\J9.68D\LQ/)).2:[:BB@ HHHH **** "BBB@ HHHH ****
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B^B@",VY/\9W=<X%/V_\ ZZ6B@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>a02.jpg
<TEXT>
begin 644 a02.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!P17AI9@  34T *@    @ !@$Q  (
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MQ/X'_9#L=;;PA;ZE=:IXDG6?6-9U2_?4-2U)D7;&))I.2J#*A>P)KG?VB/\
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MX)+?!?X9>%/&6BMH.L>)[/QUIPTC67\2:U<ZI/<6:_=A5Y&S&JG!7;@Y .:
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M]QVE2<8Q@U]T>*?@QX8\:_!^[\!ZQX?T^Z\'WFGC1YM(DC_T=[4*$$0 Z*%
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M^CO[/GC#3?B%\&O"^NZ+KTWBC1]5TJWGM-6EX?44*#$S# PS=QZ@UXI\3O\
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MGAGQ3\.],T33+HSKOFO(48/"8^JJ">#T.>];7_!._P#9V\7? ;_@FQHOP_\
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MX)V?&CXF?'C1-4\7^#?$GA&SN/AMK?A'Q!K_ (@\7?VQ>WVJWD>W[3%'D^7
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M2J^(G@?QY\"-<TF_T6RM])9X/B3IP?='J#1+*+.^@[><GF;6[E0/2N<^'_\
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M\-/C#X7^,-I>7'A?7M-UZWT^=K6YDLYA*L4HZJ2*Z:OE_P#X)B?L]^/OV<_
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M."#ZUU5J-6E9R5T^J/B,1A*M&7+-&INHSS4<<PSM[XS3P036*E?8YA:***H
MHHHH **** "@G%%-DZ4,!=X-)),L8J)YEB'S5%<W4?E;MP5%Y+9X ]S4<\>F
MI/-W)I+I0OWN^*KZCJ4-E:--<2QPPQ@LTDC;50#N2>@KXK_;@_X+;_#7]EG5
M;CPWX=D7XB>/H@5&FZ9,IM[5^<>?-]U /3.:_+7]I#_@H3\8OVT=?DA\5^++
MC1?#S,1_8.@2&WM5!_ADE'S2$ D>]?387AG$NBL3B_W4'LY:-^B,'B;RY*:;
M9^NO[3W_  61^!_[-=Q-I\OB ^*_$$7"Z?HJ_:VW8/#2#Y5].3U(KXZ\=?\
M!<CXO?&'6X=.\#^%?#_@'3;^3RHK[67-S<1@YPVU>/>O@#0-%T^PU1;>QLXK
M>./M&/F;G^)SRWXUVNKS[X5CCRJQIYF_NI7FO-QF;9;@8M86'M)+J]5]Q]%E
M?#L\7)?6'9/L?5OB:Z^.GQ(UV.'Q+\<?$EP)!N,6BH+.!Q@] !G%>+^*O!.I
M6FJ^7<^*O&%^K2%6DN-5E;>?S'Z5[K^SM,?%OPTTZ^U#4)H]2EMS#B(9>%3C
M;^?%87Q3\-P^$8(].95FU&%]TSMT )R-H]^I^E?GF,\1LS;M1:BK[))'UL>"
M<LA'WJ=WYMGD/@OP9'#J\T-YJ?B.-6)\MX=3F7/(]Z]8\)>%M6T;Q/;KIOCS
MQSI#3 $3QZH[C;[ Y![5S5GI2W/BV*UW,I,F\'MBNXT+7GFO[FPDCC-GIYS"
M_1XP.H)[YS64./,T?Q3OY6,9<&Y;+[!VOAW]KWXW?!9KJ>Q^(,/BS2=/;YH]
M=M!YC+_O+S_^NO</@A_P6ATW5YX;/Q]X;O-!D(&[4-/!N+4#(^8J,D#WKY6^
M+5_'%I%\MJJF'4K4.4]QBO(;34&AAC:WG=,!0%^\#ZY!X(]C7MX#C2E7]W&4
M5?NM'_D=$?"EXG#NK@ZW*^SV_(_<[X9?%WPW\6-$CU;P[K5CK%C(.9;682!3
MZ,!]T^QP:ZB*[C:3:&Y[BOPW^%?Q=\2?!OQ<-:\+ZA)H-XA#%8&/V.ZZ9$L/
MW<'CD<U^D7[%O_!1K1_C^(=!\0QP:%XM"[1#O_T>^(ZF%CZ]=IY]*^F]E1Q-
M/VV"GS]UU7KW/S;,L!CLFK_5\SARI[2Z,^K&D5>IH\U?6J,-VEQ\RONQVJ:+
M]Y]WIC-<OEU)C-27/!W3[%H'-%"C HH+"BBB@ HHHH **** "BBB@ HHHH *
M*** &0_='T%/ID/W1]!3Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?XBC\12+')%<7UJACDV=H'!&04SMYZ@5\'>+?VFOV:_%%Q#]EO/'^E_<'G-
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M7_ 5I/ 3BN:#/3GGE!2]C6BKG:77[''CJT\1V]BVFO:V]R<B^N@%@6/_ )Z
MG[RCVS7VM^SK^RW<?#']GO[/I,8N[W2;[[?8:B#YFY9 ?.C1E_@) ..U<#XS
MF\5>&O#1MO&GAB/Q!X=G96M=;T-I#>:,I^^&A)^:,9/ !Z5UGPP\?^-_V<?$
M:V_@O7--\1:1@3C2B^Z"_A9<AO+/S+UY*\ \5Q2QT^=0KH)9)1QL'+#25WT/
M3-<TFXNM+ANK[P7'--''YD,ACVR,<?,I/?OU]J^9_%G@_6OV<_%O_"4>";B>
M/3]6+-?:!J*$VLV>7CY]>W&,BOTF_8[_ &I_ GQKT"WT"ZAAT7Q=;LPDTO4
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M0@G?ETNCR*\^)JCQ+K?A7Q!'9OI_B&W,=G?"("73[L#Y)/\ :YR!GN0:T_\
M@G5>G]K3X'?%C]E#6I1I/B/4;@^,?AG+=N \>LVV3-;%F^]).H[D#K@UX_\
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M^A!-?JG^Q_\ %V:^^ 3>'=:MTL-<T/3A*&BXANK0+M5E_P!I3P1UYZ5^7?Q
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MEC5?J?!1B$6MW _YXVT(0CME37T1^QA\3+>#]GSQU:ZMC5&^';OK&D:?=#?
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M^SX/P4I5G7E\,=3X/CO,HTZ#IQ9^PW_!#W]A^3]@[]@/PGX9U"W6+Q)K$?\
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MTWA_7/$WAQ;99(9C!J2VB#B<@[&QV! (.3CI7UM^V#X9LV\-_"/R?])NM/\
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M@]A7(?\ !1']@;Q9XGGFU;PVVN:Y9^*/%6GZKJZ:8L:W^CPVMF8 T!++OWD
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MA:%0OS848&>__P"JIJ** "BBB@!D/W1]!3Z** "BBB@ HHHH **** "BBB@
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-HHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>a03.jpg
<TEXT>
begin 644 a03.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!P17AI9@  34T *@    @ !@$Q  (
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHILF?+;&,XXSTH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P"+_@7PM\/_  !\'=7M_%&K:OINKB^/BJ_AA"P"VA',4)SEMW0DU^@7QW^
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MPO->U_MJZE9V7[3/C/R5BNH9+U75U;<C9':OG;7_ !3JB^)$C261+5B (UZ
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M'+AT#F1OG[U]]@\XJQPD;)'#[&1[#\>]!O=8^(1\468T/PA;ZM(MY8VXN?\
MCW48R/QQ7-ZKI.M:MJT6L:UXB\/S&Z3;"YOU#';TQ7EGCGQHOBC3;>SBAU:X
M5E ^T3 [5QV%<9J=E<6UO);R0W$BY#1%X^_M7EUJD:CO-:>I7U=3:E);'T'\
M6[CQ!XZ^&.FQ:AKUC??8)"EO')?_ "(OM6?\%K"'PY\8/#L5O(LGVB"6-_WJ
MNF\QD<&O)X=3D?P/:PSXB96/#CGVKL/V<M62+XU^%I'&U//*L5&XL-G.!WKE
MJRI2A:*.BG*S/UJ^%MK)IGP!TO3+.95FM].D\R16W" -"4W8[XW9QWQ7??&O
MPB_[._[.OPR^ \6O2:_IO@?35O[N]5/)%W<W1,NPKWVYKX?\:?\ !0SP+X2\
M):YX8T?2=?CUJ^L!;VPE(\F29BI!W]ANQQ7O5IXL^(GQG\6W'Q"^)/@W4?#4
ME[IEI8:-$\3)9+Y2*"RGNSK_ #KPL1B%0AS[G91PSK5>1',ZSI=K:>+O[+>'
MR6N4,T#'N!UK-\73W>@:-=>3NM[]86:$I_& #BNMUO0;KQ9>:;+J#QV/V&22
M2/ROO.'&,&GZG:Z-:6Z?VG-#>;?ECC<=3V%9QSZ.(I6C3;9Z<<AKT*C<GH9/
MAKQU=?%7P7I>MK#(\FH6:&0]")$;:#GZBOT;_95_:CTKQ!I^H>(/%&HA]4^'
MOAR'2O*\[,UP6^9R@/\ &V M?F#\6/C1K?@+P[-<:/I]E!(K".QMYE C ]:F
MTKQ;>>*?B?'J5U9VMMINEI:S7%P+K;&+CR\\ =>>U>S0P>+E1YZL+)D1ITJ+
M<F[L_1L?M*VOQ1^(=KXUGTVXL]4M4:WLH3(%6"(=F'J>M=-X/^-M]IEW)/;V
MT:WUU$<D'!8$]*^0_@=;3>(?$DVNB.^L;5$\N"V8_NI\]9%KZ \.0_8-9BM_
MF($6_P"8],UXM3"TX2Y4CR8R<G=GO'AWXVS7\6VY=[69>N9\8KSOQA^S'I?Q
M0\>-XB/CK5K-V^_!-*KC_@/^S6;%9_:I"N0-W&3VJ;P]\(=&\86,"ZLNMS,K
MMN%I=>6I3N/RK3ZK36J15.HH;,V=3_9@^']I9R)JO]DZD_'^GMJ'E,/]X+7'
M:G^S_P""-8\;"&WUUI;&* I*EE,J@''"[FY-=!XA^#WPZ_M&$6/A^_56&V1+
MF_+-D=_O55\7>!_#OA[PY)'I?ANSL/,(".LSNUNW8M]358>IR3O(J,DY7/$_
M#7[$O]FV'BSPCHOV;6+[2=874[#5+VZ6,I93KD6Q3OM;G-6;?_@GUXHBUG>\
MFAM#( '5IUVJ?:L^;PAK&I_$WQ3<:=J-Q;SP06R, ^$)(YP:ZW]D#XMZ3X]\
M9W7A>ZU2R\4I.KRZ?(JO;W6FS0?+-;3 \-QDAJ[LSS"%*2?<JK33E=FSX _9
M#\5>#O#7B"SN/!NCZY=LI;2KV748XH;)L' <#G!./PK[(_X)._"+Q3\$_P!C
M30]!\9S6<WB*.]NKBX:TE\V!?,E)"HWLN*^7/B5^S+<>./B?H.MZ;XPUC0=)
MLV_T_1(&+6NH@<\GL>,5]G?L'I&_P L9(A^Y>^N&0!B5 $C*,?UKBP6.5>I[
MIRU*;B>W4445ZYF%%%% !1110 4444 %%%% !1110 4444 0[OD/7\*_+/\
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MBUB?=Z[KQS1P_!)RDNACBMKGW]1117U1PA1110 4444 %%%% !1110 4444
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M2S3B,]J@EO.:I7%Y][Z5GS:IY9QQS75&+9G*M9FM)JGEMM]>*E@U0K]U@6[
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M\D_>0QE1)Y'I\W:OFSXU?MIZY\.OC?I.ESR3&.73?M8C@3Y5R<#-?F_\+_\
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M5]1N+[4@'\Z1I"@;:D'L37F?C#_@H%J'[(OQ&D@^':V!U^% E_<7L :)D/\
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MF;Q08W\1R75[-=^088+4*DKKP%);H">,^]=F%K7C[Q\_6I7V(?A5K_A/P_\
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MEB/]Y-C^$_7I7,^$/!LWQ0^*N@:/)YD*:I<QK>2[OF@CW#*D]N*^4?CCX_\
M&J^&VUC0M0\0:LEU'$SZ9'(4FM)&7YFR.65CW'*UUG[+_B/XY_#;X?:A:Z+X
M!,UUJVI)J@U*19;B>([5PN3W]J[N0Y*-:K.?*S]D-6/AG]FGX=,8;;^S]$TW
MR[9FA3S&F9L?,Q^M:'AGXCZ)XJ55L=5BE=E5T5SM(!KQ;X ?M?WGQ)^&J+\0
MO!-]H,_EI;W7VR#,-R0,%O+/:NQO_P!G_P +^/;%;WPKJLFD23#<!$?-AS_U
MS_A%53E?5G1*-MCUJ"9U7=C:O]X'.ZNX\"R^;X>B_P!XU\AZ]8_$[X&65U?6
MUI>>(M/LXFD;^S'^U2NB@D_N3SD@=!R>E>W?L/?'^P_:=_9\T?QA81ZC%#>S
M21M%>V+V=Q#(C;75HFY7IT-35\B3VBBBBN< HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "@]*** (QU
MKX[_ ."T*[_V=_#ZMT;7H@?^^'K[&DYC;KT[5Y3^U/\ LMZ3^U3X*L]!U;4+
MS3K>UNQ=H]M]\L!@9KGK0YX\I<)6:9^-\NA&=&SGS,<?2LJ[T%H6P.N:_3+_
M (<S^#?^AK\2?FM12?\ !%SP7*P/_"5>)/S6O%>73._ZU _,>:RDC.,?I56Y
MT^1QC;U[[J_3Z;_@BCX*F.?^$J\2?FE5YO\ @B'X'EY_X2OQ)^!2H_LZMV)^
MLQ/R[ETME;:/UJC=:3L?+>7N'-?J4_\ P0[\".W/B[Q0/^_=13?\$+O <I_Y
M&[Q5]?W=..!FN@_K5,_+2ZTMI(\CYJSK_3!@>9&V?89K]6?^'%?@,_\ ,Y>*
MORCJ*;_@@[X!FZ^,O%G_ )#K3^SY$_6('YG>%?$HTO35M+K1;.\AR"&4[)?_
M -=:5FFCZGK-M>:?J=YIVJV(*VXF<P21@]0&'!'UXK]&E_X(,^ 48-_PF?B[
M@Y_Y9U-/_P $(?A_<I\_B[Q0R]"&$?(KKHT:D-S*52+ZGP[I'QD\:^#(4\ZX
MCURSR.+M<C'M(./QKP[]NOQE/^T#%I5K:Z3'IEQ#"!=RSR;XU.>"ON*_5?3/
M^"%?@S0SFQ\>>-+=?^>9=6B/X>E8/C7_ (-Z?A]X_P!;FO-0\=>,FCF0*UO&
M(T5CZXKMY5V.?F/RH_X)U_L9?#CQ3X\NM4\47%UX@UW2VWPAB?L[!3U<#NO:
MON6]^"_AW6;2;[/8Z?':S%6'DH-R;>GO7TQ\)O\ @ASX#^"^I1W6C^+/$\05
M=IC98RK_ %I\?_!%#0;7QE<:Q;_$SQM EQ)YC6H,9CSUQBK]D53JR@K19\C>
M._A]9>)()(98H6A\ORI2YP0 ,"O#]?\ A/;SW%]IM]-9W]G<(UL4,W5",;?R
M.*_5;3_^"5.AV^B75I=>,O$%])<*0D[QQ[H01CCW%>>^'/\ @@?\-]!GNIKK
MQ9XPU"YNIO/,LTBX4YS@"LO8ON7'$21^<W@']EWPC\,_ DL>AZ38V5NL1D6?
M9YERSD\J/:N>76M TRTCA\F^OKRVG#0O.WEQ12CH#[9Q7ZO7_P#P1F\+7.C_
M &2'QMXJM\<1R*L9\L>E>>Q_\&[W@7S;AI/B)XTF^U.7D&V+DUE4HN1?UF35
MF?D+\=/#.D_$!-0UBUOKVRUF\'V6]+Q^;;:1(1CY5'(!'\1Z=:^.]"_9"\6:
M'\4;>&2&U^QVUTMQ]I+=4)R2/4D5_1=XA_X-N?ASK6LKJ$'Q \:Z?.J>6Y@\
MO$R]]WK]*B/_  ;8_#NYN4GN/B+XWEFCZ86)>/RI>QG:R0I3@WN?G-\$-"?5
M]6TG2K>2&&XNF$?F2#(R!BO?O$7A:;X6Z7J%K>>,H-$TNUC@:[F6U^T>;<R,
M BI_=4D@$]A7USI7_!O9X T(QO%X\\:+)&P9&_=[E(Y!'O7>^./^"-/@GXC:
M$ECK'B;Q!=1O!'#<XV_Z44.4=O<=:SP^":ES,*E9RC:Y^0/CW'ACQ[XX;Q1:
MV\=_:3PZK&UJWF1")@%65?[JGJ1]:R-1\&Z9-<+JEM&+B&X@)N;9.DY(X./6
MOUOU#_@@M\.M4\0P:A=^*_%%Q-;Z.VB$.RL)82VY=_J1VKF]4_X-V/AWJ5G]
MEC\>>,[>W4B6W2(Q[K>8<AP?0'!Q[5Z48V5C#F/S6TVRLYM%ADAMX8UD3!"I
MAUQ_"U<=XDM+71-2^T-MD;.0JK\RX]/>OUVA_P""!/@/R%63QMXPDDVA7D/E
M[I&'<U@Z]_P;F_#OQ#=>>WC[QG&R\?+Y>*N+Y0YCXK\"_M6'X:^#]'U32='T
M76;6.1#(\T&)$"\N#(>.@/RFL7XC_P#!:KXM>(X+Z3P_'X?\'Z;YLJQ36UOO
MD;;QSV_*OO;P;_P;P> /!+30P^/O&5QI]T");6;RVC8G@G%'@+_@W1^$_@K4
MX+AO$GB34EA9W6.=8V0LW(('^S3Y@YNQ^-/[5G_!23XL^'=1T5/$OB_Q!8ZQ
M? W$#P,%GM(<@B9TZ$.N0 >M=I^QS^W=K&E_Z7X3^,E]8ZVS>;<P:_.98KA^
MN!&>%R>.*^_/B%_P:*_"_P"*WBW5M;UWXN?$B^U35IQ)),XB(BC!^6-..%7I
M6&W_  9D?!7<'_X6E\2MW;_4_P"%3)M[!&5MSI_A[_P6RUSX#VVG)\:?#G]G
M64\8D_M_3#Y\ 7L[*O**1R2>@K]'?V3OCSX9_:5^"^D>,O!^J6VKZ#K!=H;J
M' $I!YZ#J/?FOSR\#?\ !K7X9^&>HZ7<:;\??BM=)I3$VUGJ2PWEGL/5&C88
M93T(/:OT)_9-_9>\/_LA_!;2_!'AM=NFV,LDY80K#OED;<S;%^49/84*_4D]
M4HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH ****GE 3=[&D+<=Z=15:@1[J,U)BBC4-"/
M*$]*=N'I3J* T&[AZ4%@1TIU% :$,C!4/TKY_P!<_P""C'PX\._'1?AS>0^+
M(_$S/@0_V)/Y&P.%,OF8V^7DYWGC!KZ$F7=$P]CTKYA_:(_9BU;XR_M73ZC>
MQ>1X%U;X=:AX;U&^BN/+F@EFE5U*XZ$8S^% :'T3JOBK3=$C:6^U&QM8X4\R
M1IYQ&$4]&.3TK$F^+&DQ^-],T-1-/-JUG+?VUS#A[,QQXW'S<XS@U^46E>&/
M&GQ%^ OPU\<^-_"MYXZ\0>*/B7;:#'H4-U);PZMHVG1300-\_P JF789&W<,
M6]*]?@_8&^-!^#^GZ;IM@VB.= U^.UTQ=9)&DQ75XDT&FF3)SNB#)N!PN<4
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M6]UI^KQPE5E:UBZLQ1=RB3"[CSD5Y5^SW^P7\0?AIXO^&?BG7OAJFJ2Z/?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "FRHLD3*RAE8$$$9R*** *4>D6Z+;Q_9[4+"2T:B(8C/JO]T_2
MK?D444  AP:>0,444 -$2@_2G%<@^]%% #/(H$.#110!)1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>a04.jpg
<TEXT>
begin 644 a04.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!P17AI9@  34T *@    @ !@$Q  (
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M2V!E_<&OO*SPVWO^-?323NI+X7U/SG&86IAZOLYHM4444'.%-E&Z,BG4C=*
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M*0N ?_K4KH!:* <BBCF0!106Q2;A2YD M%)N%&X50"T4 YHH **** "BBB@
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MT55#*LJ[?XN*FC(W5LI:V9\^[+0DHHHJ@"BBB@ HHHH **** "BBB@ HHHH
M*AOG\N!FZ;>:FKG?BSJC:)\--=O%;:]K8S2J?=4)'\JJFKR2+IQO-+S/Y[_V
MROB@_P </VN_B=XFD;SDGUIK&T/]V"'*+_(UYW'IV]=VWFEM;MKF^O+ATVR7
M=[<SR-_>9I6-:MM#YJU\OGV+:Q')V/TRG17)&"[&6-.]5XJ-M,#2?*/F[9K>
MNH%ACW,QV]\#)KUCX"?L8Z[\6K2/4]4;_A&?"K.,75T<7%VO?8.U>'1G.H]
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M/YE;*)HH'#=%FEC;_?65@:VK"261HH8(Y)IIF"1QHNYG8\ 8]_7MUKHOB_\
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M;;?"WA>6-5,OV2>,LO +9%?8/[.&NSR? [P6RR;6ETBTC +?*3M R1WKXO\
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MTK[BN6Q"W7+<# S7GGQJ_9V\._'O5/".H:]#-)-X'U=-<TQH9=H%P@(Y'XT
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M /FC]ES_ (*/^*OVJ?B9\(_#>CZ5I=KJ5YI=]J/Q(B)+/H,MNWDK /[I>7+
M=P:^V$;)9AEE8X4CL..M?+_[ '[$5U^SS\??CI\1]:L--T_6/BMXF:\M8;-]
MPAL8EVQ[NV]SESCUKZLHWT8%.\MUFBVMT85\8_MN_P#!%[X=?M7WT^NZ4K>"
M_%LP/F7UA$!#>,?^>L?1OJ.1UK[:Q39#A*GENN6>J['5@\=6PLN>B[,_G?\
MVG/^".?QT_9WN6E7P^/%6G(6$=]H>9&=!T\R,?,#]:^0_%MMJ'A/47M]9L;_
M $N\C8JZ7EL\;*1]1BOZUIU608V]>,XS7#?$7]G/P3\6+;R?$7A/0-97HS7-
MDCMCZXS7BXKAK 5WS\MF?:X'CJO"-JROW/Y1KKQ):N>+J/\  UDW.N@!\7"[
M2#_%BOZ;O$'_  2,_9SUP$R_"OPRK9W#9 4R?H*\)_8#_P"":WP/\81>/KR]
M^'GA[4IM)\7:AIML;B R>1!&_P B 'CC)KGAP3A)P<U.UO+_ ()[4>-L/.E*
M2B]#\!M.M+[Q%<QV^CZ;J6L7# *$M[9I2Q)Z# KZI_9A_P""'G[07[4U]:W#
M^&E\#Z*[*3>:Q^Z?8>=RQ]6_^O7]$/P[_9J\#_">UCA\.^$O#FCQKT%K81J1
M^.,UWML(TFV+M.WLJ\+7I87(\'02]V[1X6/XVK5(\M%6/A/]@3_@@Y\)_P!C
MB\M]>U:%_''C)<%M1U% T%NX_P">,1X'?FON>TMA#M5 %V^BX 'H*OXYHKTI
M:KE6B/C<5C*V(ES597(0NTT]/O4^BIBK;G+HM@HHHJ@"BBB@ HHHH **** "
MBD+ 4GFKC_ZU &3XQ?RM!O6](CBOEGQ1&SK+D<L2:^I?&<J'P[>;F W)@9KY
MP\1:<S.WIFOE>(.A]EPE)+F/.;C2_(L+F5E/"\&OI;]D2U\KX.V>W^.:0G\S
M7BTFA?;8VC_@=<?C7OG[-^G?V+\-[>U;[T,K9_'.*X^'T_;-G=Q74O145W/'
M/^"OMK)=_L0ZXL:DE+JW8X[ .*^5?!4FSP5IRLV08E(/J,9KZ^_X*FSPQ?L<
M^)(9I%7[0888P>[%^,>]?$?PW\4I?^$M/LY6:.:VC"'*]<<5CQ(KS217"/\
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M/Q:\,^!_&FL:;9S6T5@MQIS00ZK%<2!1=1MSO3 .!QDX'>N%^!W[&G[0$?Q
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MQD'L6X)JS)^R7\8O$S,VL_M :Y:A^&BTC2H8$'K@G)H ^EY<>6=V />L^_\
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M!TG,OY"NG+O]ZB>=F+2P\[]C[R@XB6G4R!MT2T^OU.G\)^./<****L04444
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MG),A(%>X>%/ FB^#84ATG2--TF-1C9:VJ0C'_ 137LT!\K_\-C?M$_%J.1?
M_P !7T.W?B*\\5Z@+;'HWEKR1[5$W[.'[4OQ@.?%WQFT'P;:RH ;7PQINYE/
M=?,?T'>OLFC&*7-V ^1-'_X)#>!=8O/M7CSQ3X^^(U[MVM)JVK.(2>^$7C\*
M]C^'/[%GPI^%*QMX?^'_ (9L9(E""8V*O*<=RS G->L44N:0%6SMH[2%8X52
M*-1A8U4*J_0 5-4E%3KU CI4^]3Z*.4KF"BBBERDA1115 %%%% !1110 444
M4 %%%% !1110 4444 %,G_U?XT^FOR* *K=&_&O'?V8_^2M_%+_L-)_Z)6O8
MW'R5XY^S-_R6#XH_]A>'_P!$BM\/&U.1XF,_WNB_4]NHHHK ]L**** "BBB@
M HHHH **** "BBB@#G/B3+Y/AJZ8],+7G7@&Y6#XA*N[_CXA)'O7H_Q'A:?P
MKJ 5=V(LCZUXYH^H_P!D>*M%O';:K 1L??IBO4PNM-GS>9)^V1)\2)OL/BZW
MD/RK#+G/H<UU'Q?MUO/#]A,W\:@9^HS67\:M($M[(RKAF02J/P%:%N__  G'
MPBA91NFLV&<=0!FJE\46<\*;;E&1P_@'7GL/%NF7C-\L<QMF^A)KH?VBO%]Q
MI-VVGLW^CW4?F)GV]*XO3;62PUJ[LV5E64B:)O\ :&*[GXB>&_\ A;?PRM;M
M5_T_2#\X'WF XP:TQ'NU%(ZL'3YX.#+?AOQ(MQX<T"X5Q^[8*3Z=JS?B3:?8
M/B V3B.^C\]6[9'%4OACX=NI](FTF<,BS8EC;^XP[5Z1>>#X?%^@PK.NV[M1
MY>[O@5-6K!2NCBEETYIP?35'PK^WGX7^U?'/2=4@7_6:?%(V!]\AL&N>\#Z,
M/%?C;POH,R_N]2U>.8^CE.=OZ5[C^W[X#FTEO".O1QX2.1K&5?[PYQ7(^!_
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MNZ]>:PI?'NEVGBBST>:ZBCU*^A-Q!!GYI$7O_GTKY6\._'GXD>"_!NO:U?\
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MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ;/\
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M:0M>L>I? ^;/>BB@"/2?A5X:\,>)9=8TOPWH^FZM-&(7O;2QCCG=.NW<!_\
MKJ1/A5X9B\02:U_PCNAG5I\&6\^PQ^<^/5L9S110 [0?AIX>\+ZG?:CI6@Z3
MIVH:L=U[/:V4<,UW_OD#YOJ:F\.>!-%\'6UQ%H^DZ?I-M=R&:YBM;5(EF<_>
M+A1AB:** )(/!.CI;VT*Z5IL<-JYF@C$"A87/5EXX)YSBM"^1OLS#O("I*'!
M48QQ[^E%% 'DO[+_ .QYX+_9>\+K9Z+86]]J"WEW<KJES:QF^C-PYD9#)C=C
M)QP>U>A3_#3P[<^+8?$$WA_1Y->@&%U,V49N4^DF-_\ ]:BB@"[9Z!9Z:UY)
M:6D%L]])YMPT,0S<L>"S>N1QSS69HWPQ\-:#:M:V/A_1[.U^U&\,45I&J>>>
ML@P,>8?6BB@"2]^&/AO5_%-OKUWH.D7.NVH_<W\ME&UU%V'SXR,58N?!>DW$
MD[S:9ITDERXDF,ENN9I%Y#Y/4@XP3Z"BB@"K?_"_P[JOBN#Q!<^']%N-;M5"
M17TUDC740'^WC/3/2NAMAY<V"=S,,ECCG\*** +-%%% !1110 4444 %%%%
C!1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>a05.jpg
<TEXT>
begin 644 a05.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!P17AI9@  34T *@    @ !@$Q  (
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MN*?*^P'KE%>=? _XXS?%KX)Z/XQUC0=1\!-JD1EFTW6WCCN-. <K^\8$KD@
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M3:Z2_KY'V;_;]D/^7RW_ ._@_P :/^$AL1_R^6__ ']%>9S_ +'_ ,/K5?\
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MOIOVEK[XF&+45GU>4:DLZ:J%6RDLBV!;K"!@%,<YSFOHS]NKXH^+/V(/C_\
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MTDFU<9)&,@>O\A^-.P%O'-%5?M3*^UF"L#A@??ICO0)I G)R6) 8+V]<9YI
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MJ<46IF..\6(_<\U!NVGLQ]J^U]?TCX<^+/"\>AZI8>$]0T6%@\=A<10RVT;
MY!6-@5!!YX%:4&L^#[748;R*308;NW@^RQ3QF-9(X<Y\M2!D)Q]T<>U$I75N
M6P?6*?<_*3XS?$?POX.\2_'#Q3\3/#_AWQE\7M!\>"&/0_%>ISV-P-"\R-;(
MZ*J<,2&+$I@D[LD]_6OC)^V%\9O =]\>/%VD^+4L_"_@35-)\+Z/HG]CB:+1
M([N*'S=1GD/SR^2)">#MXYS@U]W>)="^&OC/7[35M8T_PCJVJ:>0;:\NX(9K
MB#'(VNP+#'UK1;4/!<\%_&QT!H]6)^W(1&5O,C!\P8^?CCG/%-5$EL'UBG_,
M?GWX=_X*#>.OAMK=Q8W'Q-TWQU\/_#7Q#T;2KKQX;.-+>6QNX-UQ;3-&-@*.
M0!*O3(!-9FO_ /!1_P :?$N;PG##\8M!^'_A7Q5X_P#$NC1^*)--1XY+.RB+
MVD<1<;<,1RY^]FOT$M_#/PTM/!4OAJ'2_!\?AR8EI-+%O +.0DY),6-I.?45
MQ/Q"_9G^#_Q(\5^#=4U+3_#KVW@7[0--TP"$:<&N%V,9(<;3C P<<'TI^T3W
MB'UBGW%_X)I_'3Q1^T9^QMX4\6>,/+DUJ^\^)KR. P)J<44SQQW00_=$J*&Q
MTYXKW*Y7S <^E8&C^,O#FC:=%:VU]I=M;VZ^7'%'(L<<:C@!5'  QVJ:X^(F
MBD?+JFGMGC'GBN;V;<[HFIB*?(]3&^!4:Q:;K:J,#^V+G_T*LK]KKX\6O[,O
M[.OC+QU<_,/#>E2W,4:KO::<C;#&!ZO(54>YIOP5\>:3::9JWF:E8JTFJ3O_
M *]><D5TFO\ B+PKXHL&L]4N-'U"TD(9H+ATDC8@Y!*D$'!&1GN*UJ1DI7:,
M<+B*?LT[GXOZ!XI\5? []EGX[_#OQ=H?CCPW=?$KPE%\0;)_$^9=FJF=/[06
M#:W^JC!C8("/NG  KU76OCWKGQ4\%?\ "'ZAX\M?BUX3\)^+O!MSI/B:RL5A
M5+B8@RV3F+(;:!N/<;@#7ZAZS?\ @KQ&\;:C_8.H-"ACC-R8Y#&K  J-PX!P
M,CH:HZ#H/PU\+Z(NFZ7I_A+3=.2Y%ZMK:P0Q0K.#D2[5 &\'^+K71[:-OA.K
MZU2[GYF^-OV]_'GQP\7?%SPKX8\>:]<^%M<\$Z_J>GW,MM!%?Z/=V$VS;#%'
M\\:_*PQ+@L!D>M:VJ?M=^*?@K\-O!_B#PWK]A\1M8L?@S#J">*;BT$T\<DMW
M%%+-+LP&6 ,Q* Y^4YSS7Z.:7H/PWT+7;[4['3_"-GJ>I[OM=W#!#'-<AOO;
MW RV>^3S4ND6/P[\/:;'9V%GX4L[6.)[=888H8XQ&_+IM  VL>2.A-)5HW^$
M'BJ5MS\]K_\ ;=^+&F^&_%WA3PG\7--\=6T?B'PWIVF>/H])BD6$ZDV+JU"Q
M_([H/F0X^4, U>Y?!?XS_%KQ/^R%^T%I$FKKXO\ B)\--2UC0-!U:.S%K-J;
M16X>%C&OR^:-Q (&"0.M?2GA[2?AOX1T&'2]+T_PAINF6]P+J.UMH8(H4F!R
M) JC&[WZUIV.O>$M->9[.ZT:T-Q,;B9H)$C,LIZNV/O-[GFLYSNM$3]8I]S\
MOOV4OBQ\,_AWXO\ @DW@G0?#/B37_$F@:A-?^()]4N'\6:9K$5L\MTU_"_'E
M>:I4!^ .F.*ZOPY^U7\8K/X&_!5O&_QGM?#<?QF?4=6U/QE)HT,-IX?2W0M!
MIT08!1OZ[Y,D[2!UK[_TSPW\,]&\47NN66E^#[76-21H[N^AMX$N+E6X8.X&
M6SWSUJ77M+^'GB?PS'HNJ6?A?4=%B*F.PN(H9;:,KR-L; J,>PHY_(/K%/N?
MGAH7_!6?Q]X5^%^H:QXY\2Z3H6[X9W^J^'[ZZL?L\'B'4K>\>*"YC7!+>;$%
M;R1TSG'-9WQG_P""C/Q2\,^-?$4UO\5M)T?5/"NB>%=1T3P:^EQR7'BZ:_6/
M[5G^/;ECA4P5]A7Z->(M"^'/BF+38]2TWP?J2Z1D:>EW;02K9#C(BROR= .,
M=!7':#^SS\*]#^.WB'XBM'H][XGU[[/NN;SRIOL'DILC\C<#LP!CY<57-%Z.
M(?6*?<]F\.:A-J.DVTUQ%]FN)HHY)83_ ,L79 2OX$UI*<US=G\1-#,>6U;3
MRV>=LXP/I5[3/%^GZU<^39W]K<2*,E(Y S8KCY6MQJM!Z)FM14:2%L\]_3I3
MT.10:IW*TS;0,\ANGL<5^,?[=GQ D^)W[>GQ,_9_TF:UTO6/&-DTS:M?P>=;
MVL9C&=JCG?P>?<5^SEP.?[N,$?6OQJ^-/PN>]_X+MZ_XD-Y:V^;%;3RV.' :
M/ERW10,]?8UI&[I2Y>AG1C!X^BJCLKGRYH'_  ;Y>./"UI#+'\4]'DTA1Y*S
M2V3R*S'\<@D]C736?_! 7XAW[26T/Q"TV=H\)*8=-;=$>2-W.!Z_B*_4KPE\
M((O &G+);^)O#NN0Y+F&]OT\OYC]_@X)7U]JZ/X;>"K'3/!?BS2KKQIH-A/K
M<O\ HM_;:A')(<CGJ>W3Z"O*C6JV2>Q^@X["Y<G*I%W>A^0WAG_@W.\81?$[
M1?$UQXVAO[/2YP\T<>DNWF@'KG..#D\5^E?PA^&]G\,_!_V6:76+Z6WB$,VH
MP6&[&T]#SP1Z5Z+\-/@Y9>&-&\)1WWQ8223PR\GFP0W\7EW^YB0)1D^OY8K2
M^&]Z?"&F^)K6XOO!K0ZIJDMS;1#5%.8V '.3D'(IRK3L>9+#X22]Q?@97AKX
ML^']!B6&9=2O5NAE3):;6D"]QSU%>-?'_P""6I?M!^*U\0:%K$TT%N&:TL[K
M1Q) TAR "PYR/>O6-/\ @WI^J^$H[?4/$OAE;J/S;B-8[U"Z3L?D4'(^4 =!
MUSSFL/P]\*-9MOB!#J7_  GFAZ787#HTMG:7R&*R*C!8#/)8^O3%8^VJ[GKK
M+<KJTM':7FF?*/B3_@G[XJN$N'O[K2O#ES>?<>"UEA66;L,$XP3UQ7F?QH_8
MJ^('AS]G_P 57FI^--!\RSLI/.86KM&0HYC';=CN>.:_075_A-JUYHK1:A\1
MO#GBB:8W,/F75]'#]@27 1MH/)4#ZUYA^T)\';C3?V4/&GAM?$6@ZEJ&N:<-
M,M!%?HQF/3S<=0,_RI1J5'+5:!' Y=]7]R?O+U/Y]R%CT65O)A\NXBDC,14$
MC@@DCWYK^IK_ ()"6D=C_P $S/@Q#$OEQIX<@PN,>M?SW^//^"5OQ(^&_P ,
M)KS3[K0/$5];6SM/9:?,'F4<_,%ZFOZ&/^"2NEWFC?\ !-WX/V>H026UY;^'
MH8Y8I%VO&06X(KUH6LFCX*M=2<4>]^(GSH-WC_GDV?R-?#GPTU63Q+K?PQT^
M&^GT^:/4Y6$\(!90 ^5.>QK[?UTG^P;W/01/_P"@FOS;^!NHV/B+XJ?#RQU*
MX-O9+JUP2ZS^2RLN_:-W&1[5^&>*.'4\XRR7]\^1SS.7A*V'I1=O:.Q^F-L^
M8UZ\<9/4U,!BJ\!^7;QM5>,'.?0YJ9MV.*_;HQ]U'U"U1\W?\%@?._X=F_&9
MK6X>TND\.3M#,APR.,8(K\QO^"<?P$\&?$7]BWP)>>,M!L+_ ,1:Q#Y,U]<3
MR)+=D 98E3QMR"-N*_4/_@K A/\ P3D^+Z^7YA;P_*-I_BY'3WK\Y?\ @G)^
MTY\!_A+^RMX3TGXH>,+73=:M;;?9VT:N[6^0,EMH(!R/TK+$*>\3Z#(O8:O$
M*Z/HOP)\*-#^ NBZLFFVL.HZ+<P^6EYJ9ENEN@!AX4!.5[#/6N9O_P#@F/\
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M** "H;KH:FJ&ZZ&G'<SJ_ SC/@><:;K?_87N?_0J[>/H?K7#_ __ )!NN?\
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M1*(\XY!X/>H;7Y8=V[VX'2IB6Y]*SNMS]_C?EN^I\T_\%>-T7_!.7XM.N?\
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M=37ZTI;,#A_CS_R)*_\ 7Y;_ /HP5VMG_J!7%?'G_D25_P"ORW_]&"NUL_\
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MM[Q5AC@_?,TA*(=R#.><$YS[UVMK;I%$JJNU5&T =A7YO%.[1^O;)11\V_\
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M  5)N=0\'>/O@'XWC\+>(O$^B^!_&$E_JRZ-8F\N;2%K5T#^6.2-Q XKP_\
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MPR#+?SXK,TWPW8:!-<?8+&VM?MTK7%P8(@C2R'J[D?>8],GGB@#XR_X)E_\
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M"_&'B"/P'X3FEC3P3ILVB"2Q\?IY)>2-=1.%@NA)P(B1D8(Z\?;MZ&W?=QM
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M0  !^ JQ0 4444 %%%% !1110!7GZ#Z_XU_.?_P6\=C_ ,%+?&VW=Q'#T/\
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M4 ]2GI]E#91,L,:QAG+D*,9).2:M1C H$2KTIP&* BDE9!1110 4A0,<TM%
M$;6T;#!5?7ZT);1IT7J,$GG/U]:DHH ;'&L2X48%.HHH **** "BBB@ HHHH
M K7"Y8?Y]:_FB_X. _"EOXE_X*:^,TFL/M7[F !\$D$CY5 'J:_I>FK^<O\
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M\VMJ-<OI],T37;G3VAT;7+N $RV]O.3\SC:PQCJ#7R/_ ,$^_P!ESXR?M"?
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M^W]\/?&NG?"FXL[Z^*_&83_\(R'MRIN/)C:1]_\ <P%/6O/_ (1?\%D?@_\
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M%TEO$$=C#K_V2+^TH[(EK9+C8/,$9/.P-G'M0!NT444 %%%% !1110 4444
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MD^W1ZFTT%^XN5P/M9WK\ZCWY_*OY_=/N()H(98OF01H%+<'[HS^N:_H\N/\
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M\3O%G[0_PY^'7A/Q)8>';6SL=!>XM/[/C_L^[L)H/,NW::4[UN!C;&B\,?T
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M59(Y(Y(V *LK!@0>0<CC\CBI@[&3D[?:OS!\2?MZ?$#PQX<_XDGC+P[X(A\
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MH00.*](_;E_9;\;?$VV^"=_!X$TWXH1^![&[AUS2;O51:-)<RV2PI*).C;9
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M^%_[->@_"OXO^/?'-G]INO$7Q"N+>;4KB=07$<$8CAA0C^!%S@>YKQCX]?\
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MF(VM>+K^WN/'-RW@:;6]0\3Z5HB6:++9ZG=(ZEFN.K1IO9@F>I]"!71?'/\
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MHUEU Z:/W+I-G=$68 D#\.M9_C[_ ()"S>,+/1-/B^)FJ0Z+I]PTUS8268:
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M?MSKOB74O$&C>.;O0M:NM9T75[:46"216S:?!]G\LQ_QK(F[.>A.?2@#T/\
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M_P#@GM\;5^!EOX#TSQ-X0MM#TW6M8F6V@:>W76K"]#F'[0R*&5X&D.54X8
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M/B6GCBRL;ZV*V[VAM1;RP/MZ/_$"/0=Z]H^,'[-E]\3_ -IWX6_$"6?2VM?
M=IJ,5S;2V_FRR/=0B/?"2"%*GD'J0*]IB16C(D5>ZDC[ISUJ58UQC''H: /S
MW^"W_!(G4O -IX@\-ZU_PCMYI;V&M66B>*UOKA]4LDU$L6!MS^Z'+ ,1V XX
MS42?\$Q?BYX^\-Z['XFUSX>:;J$/@NP\+:'_ &582!7EL+I9X9[HD<APH!49
M K]"G7RSC:0, !NH H"1E=IPPS]0?6@#X-U7_@GQ\9/$#ZYXUU;7/A_<?$2?
MQE8^+]/T^.VD&CRK;6WD&VEW?,Q(.X,<X-=E\0_V/OBI\1/B6GB2;4/ ]K<>
M*/A]>>#_ !-##"X73Y9"SPRVI/)7+;6#>G%?8$D,,B[F&[C&?0>GTILJ[9%"
MG:I'KW[8]: /@7Q?_P $QOB,EAJN@^']>\%?\(_\1/#VDZ'XJGU"V>2[TPV*
MA2;'C;M=<MAONMDCFNTTK_@FYJNBV%K'#JVA>=9_$Z'QM#<- ?M#6<4*Q>2[
MXR9"!R?I7V1%$O/RCY2> .Q]NE-E&R10N-R@D<9.: /E3]M?]@W6_P!J3X@Z
MYK.FZIHMC;ZMX.;PP8KR!G8N;M)B7[%"J8QW[UZ)\"_V;;SX/_M#_$3Q@\VF
MMIOC.STFTM;*T@\IK=K2W,3%ATPQY'L!7L-O>1WD&Z*6.:'E&D5PW3CJ,C(/
M!SZ4NEW]MK%AYT-Q#<PLS)YD4@=20<'!'H1^!H ^&K/]@'XJ>#/#=K%HFN^!
M9=0\!?$"Y\7>%9;B*2--2M[K?YD%YM^[(ID(4KUVBM'X3?\ !,[Q7X:M?"LW
MB36_">I:II-GXFAO3%9'[.;C5I-RF%&!V[,X)[XK[=:"&1]S*I;L2.:AE180
M(XU=4.22B\K_ /KH ^&=;_X)+:KK_P *=)\.QZ[H.E_V;\.?^$05[2VV*]XM
MVMRCN /FA)4!UZ\MZTEU_P $X_B!\7I=:\0>.M0\!V_B37M2T#S]-TJU=M+C
ML=+F#@D./GEDR3R" -H&,5]TI"MSCS &/48)P??%/,48'?:/4\4 >-_M8?LV
M7'[0C_#M;*?3;>U\&^+['Q'<QW4.];F*WS^[0=,X/&>F*\6T7_@FWK_AW4M"
MO+'5O#FGWVC_ !#UOQFMS#9?O0M['(D*\8W,A92<\84#MBOLXHI7CVYJ.2"(
M8W*&"]%(SCMQZ4 ?GQ\+O^"8WQ$T>\\?:KXZNO!/Q U#Q1X3B\-O9WT]R8-7
MEBG:7[3*V/\ 1R,C:(^%(R,9K3B_X)W_ !BBT7X8M_PFGA]O&G@^Z9IO&?G3
M-JFG:<9MYTQ/EVW</EX0&7!XSU&:^Z)M9T^UO9+>2\M%N(]K21F959<G"Y&>
MA/'N:MI90R%G\M,L<GW/OZT .TN/RK?'R_>[#G/<GW)Y_&K-5FR'VKT&">>>
M>.>/\XI+#4([]'\F>&=8V*$QL& (Z@X)YH M44T/G_\ 52&8!<_A0 ^BD4Y%
M+0 4R2W65LL*-QHW&IY@$-HA Z_*,#F@6D8'W?S-*S9]J6/I570>8TVD>TC;
MC/IQ0+6,-NV\DYJ2B@",6L85AMX;KSUH%G&I^[[9S4E% $;6L;=5'7)]Z;]A
MBSG;SZ@\_P">:FHH C^RQG^!3]>_<4?9HRI&W[W7WJ2B@"/[-&"?E'(Q3F@5
M\;ESCH#TIU% $?V6/(^7ITY_&FO8Q2#YESU[GC/6IJ* (_LL>S;M^7I@]*&M
MHW'S*#GCWJ2B@"/[-'G[HILEA#*?FC5OK4U% $9M8RP.WE>GMVH-LA_AJ2B@
M",6<:C[O<'KZ=*/LT?\ =_\ KU)10 S[.F5^7[O0TU[**3&Y VWH3UJ6B@"/
M[-'NW;>?YT?8XPN-BJ,@X''3I4E% $:VD:@81?E.1]:7[.N.GY&GT4 1BUC4
M\*!@8&*#:QL/F7<,8P3FI** &^2N.GZTX#%%% !1110 5'*<&I*CF0N:!/8Y
M^?XCZ=:^*X=%:9C?S+N5,<8Y'7\#6U<A7!!R0<+D'_/O4)T"S.HB[:UA-THP
M)2OS ?6KD<"A?N]*#*DFOB/SG\':+!XT_P""N'Q8EU:+PI?6NAZAIWD7.K>(
M);74-+/V7=_HEMG9*H;DY&/O=\UQMC_P59^*USX'^-C?\)#X-L[SX3B*TTO4
MI[(_9/%:3WGEG5X\X_T>%28V"9&]#7Z)>(/V9?AYXI\>Q^*-2\%^';SQ)#M*
M:I+8H;M=H('[S&[@$]^YKF?CY^Q=X%^.OPL?PC=:+9Z7IYA6W633[6..:. 3
M+*T*''$;L,LO0YH-CXQ\:_\ !2'XH_#C1=?\*VWB30/'$T?BS2="M_'&FV4:
M6]I#>V_G.A1B(6F0C:N2!EP&Z5T&B?MG_&77O$7@'P3XN\6>!_A9JMS:W^J:
MAXAN?L]W;ZS#;W(CMH =_E13.AS(H)P0=O:OM+1/V:OA_H7PTN?"%KX-\-P>
M&;TEKG3$L(UMKACC+.@&"W'WNH(J/4_V5/AKK7A#1] O/ OA>ZT70)#-IMG-
MI\<D5DY.2T8(^4GOCK0!\-^'/VG_ !1\&/%_[1UWXH^,VUK;Q3IVFZ-91Z7'
M<2:=]ICBVO"C'_5/DA7D^08)SS7/_#;]K;XG?M"^/?@-J6I_$JW\)):^,-?\
M-ZPBVL0M?$ MHB8ED 8IYCKA<*<9R1UK]$/$'[./@'QAJ6JWFJ>#_#M_=:Y:
MQV6H2S6*.UY#']Q')'S!>V>G:HG_ &9_AZ- TW25\%^&UTW1[L:A8VRV$:QV
M=P/^6L8 ^5_5AR>^: /@+P7^V?XRMOAWX5\+Z#XJ\)_"FUET_P 0^(+G6]4M
M_M-O=2VEVZ16<8D; !'S2<E\?=Q2:[_P4;^.7BKP;JGCK3=4\-^&M*\"^%-#
M\1:EH5UI7F2:O)>3&.9?,+9CC(&Y".<$9-?H#XL_9P^'_CO1+'3=9\&>&]2T
M[3;EKNTMI["-HK>5CEG5<8!)Y/KWK6NOA-X8U*.^6X\/Z/,NJ01VMVKVJ,MS
M%'_JT<8^95[ ],<4 ?._[:_[3OBKP/K/PC\-^'_$&C> 8_B9<3+>>)M4@6:'
M2UBMO/$2;B(_-<\+OXP#WKYO^&GC[Q9^VI^U+^S-X@\4:YI<]KIK>(E6VCTX
MM8:^]E(L2ZC$&^[YBX*GL0<=J_13XA_!KPK\6O"Z:'XF\/:3KVCQLLB6=[;+
M-$C+]UE4C@CL1R*DM/AOX>T&73&L]%TNUDT2V>WTXQ6RI]BB.-RQX'RJ<#@4
M ?$'[=O[;OQ'^#G[1OCK0_#GCKPAX5TOP'X3L_$UII6I6 FN_$T[S%6MD8D$
M*V F5RVYLBLP?\%(O$^N?M>^%-#L=<BU3P[XIOY/#VMZ+<Z?';1Z+=?8/M#+
M"^[SY61CM9BNTY&#P:^JM>_8B\!^,_VC+SXF:]HUEX@URZL;:RM8]1M8YHM.
M$#%EDCW X;)[>@KM%_9^\#3>/9/%3>$_#LGB23KJ9L4^U$XVD[\9!QD9':@#
M\Z?"G[7_ ,7E^%<<?@77/"_A/3_"/@&[\:7UI<:<;R34)DOY(_*W,V40HO)Q
MD$\5[;_P44^+/B[5?V6O@KXP\/\ C8?#F37O$^AMJM]%$LENL5SC<)&8_+$"
M>I]J^N+'X,^$["WFBA\-Z+%'/9G3Y%6T0"2V+;C">.4+$DKT).:G\5_"CPSX
MY\$MX;UC0M+U/0&1$_L^XMUDMPJ8*@(1@;<#&.F* /@SXF?MV?&#X<:)\>O'
M%OK&BZYX=^'FN0>%-$T>VTU5D=Y?*W:C/-NQQO9E7A".OM3\3_MT?%CP-\#9
M+7Q1XLTW2/$6J:Q<1>$=3LK2SN[CQ!;16GGNMRJR&WMV5N/O99<8YK[]A^%7
MAFTTB^T^/P_HZV.J#%Y;BU3R[K@+\XQAN !SV%<Y:?LD?#&T\#0^&H_ ?A==
M M[O[='8_8$,*S]#)C'WL<9].* /A+X'_M??$7XG?'CPGX^U+Q]9Z7I^M?!J
M?Q)_PBHMT^SZK>P/(C-"2>6W ,0I/RCTQ698?MB_M*WWA:"]E^(W@=?MGPT/
MQ.?R- +F)8Y,&RCYY1E&&<\AB<8Q7Z+O\ ? \EUHLQ\)^'_.\.0O;Z6XL8P=
M/C<89(N/E4C@@<5<_P"%1>%O)6/_ (1W1_+6Q.F!3:)@6IY,'3_5G^[TH ^#
M$_X*&_&KXJ?M(Q:;X1TG1[73]#_L%[C2;R:WMTU>WOHUDN)?-D82 J#B,1Y!
M(YS4/AK]L/XU>*M=MKN^\8>'9?#OC[6_$OA/3;"RTWR[G2#90RM#="7/SRJ4
MPR]#QBON?6/V<O ?B#Q9H^O7OA'P_<ZSH$:1:=>O9H9K)$^XJ-C*A>WIVQ6K
M9_"OPUI[6;0:#I,+:?<R7EJ4M4'V>:3/F2)Q\KMDY8<G)SUH ^4?V)O'7Q%\
M0?\ !)^WUS2O'=GX^^(BZ1<W=CJ,\"X^T(69;>51U8;2I!&1FO"_A?\ \%D?
M'7Q^^*>CZ'H-KI5OIOQ4O--T_P !73V;.TDUK_R'Q+QR(65PI] *_2'P-\*O
M#?PQTVYL_#NB:;HEG>7#W<UO90+#%),_WW*K@;CW.*JZ'\#O!OAB327T[PKX
M?L7T%IGTUH+".-K!IL^:8B!\ADR=Q7&[/.: /SM^"GQ9\4>(?VF_A!]@\>6?
M@WPGJ>I^++2ZT**+=!KKP3[0#)(>)6'*_3BL/]F7]JOXH?LD_ _PWJ"ZEH_B
MOPSXNLO%5[I.@):%+C3)+*>1U8S9+2]27'8 X[8_2F^^ '@C4ETL3>%-!D_L
M6];4=/\ ]#0?8[ACEI8\#Y6)ZD=:OV_PG\,VGV#R] TE/[+\W['BU3_1O-_U
MNSCY=^3NQ][OF@#\\4_X*,?%'X<^"O%$UQXX\'_$!(?"&E>+AJ^GZ>L</AM[
MB[2*:UGVD@H(RQ4D;QC)IO[8'[9OBSXPV'C*+P3\4M)\,:#X&^(7AK3H==TY
M%GB,%S$KSI/)]TH';C' S@FOOKPI^S7\/_ WAW5M)T?P9X;T[3->+G4K:"PC
M6._W_>\T8^<'T.156T_99^&VF> [[PM;^!?"L/AW5 GVS3DTV(6]T5^Z77&&
M([$\B@#Q']N#]HCQ5\*-4^%'@WP_XPT7PE)\0KR:"]\9:E:I+;6RP0^;A49A
M'OF_AR<8KPWXA?\ !0WXD:%XQ\57=CXZ\';?AEJNDZ.OA^6R7S_'JW)19;N'
M!WJ&#GRQ'D90Y.*^\_&WP/\ !WQ*\$1>&O$'AG1=9\/P!!%I]W:K-;Q;!A=J
ML,# XXJI-^S;\/[SQ/HNMS>#?#<FK^'84M]+O&L(S-81H,(D;8RH4= .E 'P
MWK_[6?[0'C'XF[M"\;^#]#T'Q!\2;OX>V>GW.C>=<Z5"D!E%R7SAYU88VGY<
M=:S]2_X*#_%+Q'X6^&^FW'Q'\#_#^\U/3_$?]L:[?V"O#J%QI<YBB,*L<*9
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M<5W5,ODJ4:D6G=7T>QU3PK4%.ZU/8IKC8.6VX&2>P_'I4D$V5Y.>>H%?,/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
FHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>a06.jpg
<TEXT>
begin 644 a06.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!P17AI9@  34T *@    @ !@$Q  (
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M#<J,:U=.W.UH=-KW[:/C'P3X\*^'9-*TSP_X?N&L]/TYM/294ABRAW.1O^8
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M*R:3X.^$OP\M;JS\??%CQ=XXTO4-:L$T31!%<75O:7#I-YL60(@F" <_,%H
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ME3:\%KT:9A_>E89 [**Q==^'&N?M'V#+XJ6]T'PHV##H\4FVZN^<B2Y8=!D
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M>*O'=CX3B5+B9IKE^$MX5W32GTV]OK6&-.\0?$"(OJ;OH.DN-JV4)W7$P/\
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MB7/T;&[\*A^"_BB\\;?"CP]K.J1PQZEJ6GPSW*QYV!G4'@59\9_#G2?'%O\
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MC^S#\2_"6A^,F\*WFGW<'B+2F,J_O9 ?+GBVL/XE&<8ZYK[#,O#_ "Q4(X_
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M#^)]:_F[-LOG@<94PCVB['],\.YHLRP5''+[25ST",Y2G=Z\'^,?_!0SX4_
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M%!SM&?7%<3EK9;'IQIV?,]Q:",BBBD:@!BBBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH 1UW+44D "?4YJ:FS'Y*AW6J JWNF6^IV_E7,,-Q&?X94
M#K^1K#D^%WAMY3(V@Z*\G<FR3G_QVE\<>.-+\ :)<:IK%U#I]E;=9')Y.<
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M^&'[/OP7T?1O#=CI&O:#J^HZIXM2WO<R3RW%O<*LCR9S)EG3DY"_A6%\-_\
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MXY/OFMA!AA3@OL.>O%.Q6'*V[R#F"BBBK)"C%%% !1110 4444 %-D&4IU%
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MC2BAF,TJ#YJ7?]: P)J=33T'44$X%-,@J@'44T/DTXF@ HI,XI<T %%&<T4
M%%%% !1110 4444 %%%% !1110 4V1MJ$TZO-_VPKW^SOV4_B-<?:I+'R?#E
M](+B-BK0$0.0X(Y!'7(Z4 >@372QQDNZQKW)8 "J\^IP6C1K-,D?V@XC61P'
MD/7"C//X<U^3?[-WQBUJ_P#V1_%WB#XC7UY)\9+*R\/:=/X<OKJ1M/T[19)X
M5LY[4*1YBS*2[S==YVGI79>)OVFO%7QT_:O^&-QJOC#PW:Z-IGQ/O=(M/!%O
M$5U:T2SM) LLC[MS*^-Q##;AEP30!^GD3895X7'(Y^]4V<5^:'A[_@H[\:_
MGP^M_&OB.X\,>++7Q9X2US7--T73;!HI--FL9RD7S]9 5^^.Q'I6GX)_;X^-
MGA#X$ZI\1/%2Z!J7@_PCJ&EZKJM^GD_:KC2;A?\ 3%$43-Y?D$@JYY89R* /
MT:)S4-_(L<+,WW44L?H.:_/+0_\ @H3\2Y/'?PQ\0^*-9T?P_P#"_P"(M\TF
MES66G"XOVBN)RMC!=0$^8B21@,)U4C)&<#FOT!UF.8V4RQCYC&P!;YL\'&*+
M7T*CJ['X@_\ !;/Q)J/B'XB>#[Z;S(]+UJ6_OH>?D>57$8Y_W%!'>OAUIVM9
M?.0M&\?SJZ]8V'(/X=:_6S_@ISX?\$O_ ,$T_#NL>*M,OM2U+2;]X-,>V/E7
M%O<M*ZD%C_#@'.>HK\ET<F96CQNC&XG^X<]O[Q%?WYX$YRL9PZZ-.%I0NO4_
MK7PQS&.*R9TH*THZ'WI^Q_\ #SQ'\6-4^%6K/\5-?^&?C5=,EMK*_)5;'5D\
MPF.W\AL+)(5^8]\"OUQ^ >F^/-%\$1VOQ$U31M:UV&0HMYI<+6\,\8^ZSH>!
M(>X'%?CI^SJ^M?MR_L%^.+'4I/M/CSX)747B'PMJMO'LG@:-?,$9"^JH5/J#
M7Z_?LD?%?_A??[+_ ()\7,W[S7-(@N9-N<K*4PW_ (]GZ5_*?BIAYQS2K[16
M<9M-=NJ^\_"/$*\L=.36J=CG?VO?VT_AA^RY\/=4;QQXDTV*2:V=1I2RK+?7
MF5/[M85RV6Z#M7\^O[3?PI\'^!)]-U_PMJVI6]CXVC;5[3PUJ5KY=[I5N[L5
M,CYQM;G@>U?MA_P4^^(W@K]ECP:OBJS^'N@^+OBEXYO8M!T*&:V1KC4)VPH5
MG.2NU23D#MS7Y4_\%9?A]8^"?B3X>CO?$UCJ/C6UTI+75]-5O-FM4/SQ(7Z?
M)E@>_ K]"^CPU0S:"IWC[2_S2_0]3P[E&A5?+NSQ']F/]KWQ=^QK\1+?Q9X-
MDLX;A9D.HJR;I-1MU(+0$]EQG'N!7]!/[+OQ:L?B[\2M'\8:6!'9?$#PE!J;
MIU^=& 'XJ&VFOYN- \(ZOX[U2WT;0=,OM6U2^<6T$%O%O9F;@97TYR3Z U_0
MM_P3[^#E]\!$^'?@F^7S+_PKX&5;]P<K#-+*I*#TP0:^F^DSE.5T<32Q%*RK
MROS>?F=/B-1PZ:G#XCZ^0<TZFQ_<%.K^1S\B"BBB@ HHHH **** "BBB@ IK
MG"TZFN>*3V AG.Z)QCL>V:^5_P!MK]A7PO\ \%$?#WC3X?\ BZ:XM+<-8WFF
M:A:C;=:5.N<O&?7C&>V:^JKA=\./[W6N#9_^$=_:!#,=L/B#3MJ>GF0G./\
MODDUTX/%5L/456@^62ZF=;H?E;^VA_P23_:B^#WB7PS;_LU?$+Q%=>%+.TBB
MF2[\0.NH&\48-Q,[G#QGC*#@CC%?8WP3_94^(WA[X?:3'KG@WX-)XHUK2H[;
MQGJ\=GMNM6F8%9@#&H .#GW.:^R@H*]/:HY@JQ,?NCJ:][,.+L;BL/3HU%%.
M'VDK2?JUN:QLUJ?RU_MR?LN7W[&/[6?C#X?WL;K:6MXU_I+L"$FLY3E3'GG"
MDE?K7%^ _!VI?$3QCI/AK1H9+K7/$-U'96D<8.[=(P7><=EZGZ5^A7_!R_\
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M8K%X>FX)*VO4Y^*N(*.955*FC5C/RTZBBOR0^1"BBB@ HHHH **** "BBB@
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D@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>a07.jpg
<TEXT>
begin 644 a07.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!P17AI9@  34T *@    @ !@$Q  (
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MBX_7[;2^YGWVO_!67]M!1S=::W_<-TW_ .-TX?\ !6+]M!US]JTT?]PS3?\
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M &V@W-UI>U1GC3M,Y_\ (=?GPVF7:'_CTU(?6.7_  IDNE74F/\ 0=0;'/\
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M_+/\3]+;C_@MU_P4&5?EO=(/TTK2#_[2J%O^"W__  4("_\ ']I*_72=(_\
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MOM"T>24"[O+)2;A(_P"+R\<[L<>X-:4<56E42E-V]6<^*HT:=-N$$WZ'6O\
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M9.LMOY<$BG(98EQ_*H@,4A7=N^;"XYYZU5/,L8G=3?WLF6782<7S07W(]O\
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M8B<86Y)MZ=SGHRJST<$M>QDBWM3\R6>FLK<_\>D?'_CM(T$(/%CIO_@''_\
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MQ,W4J0]Y[Z'T.#XQS;"P5.E4T6VIZ4O[24S#C1XO^_\ 2-^T?-G_ )!$*_\
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M^?FZ_P"_S?XTX74X4G[1=?\ ?YO\:7L<7Y![3!G1+\"O&A)_XIVZ_P"_L?\
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M).?^FX_PH_VSR#V>!\SE#X-UH?=T'7L>VGS'_P!EH3PKK49Q_8.O?^ $H_\
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M/B?2/%?[=]WX1M/[/^(WB+P/\ V\-^(42[#0Z]J"8W6;3< MSMW Y]Z_/_\
M;G^"FJ?#G1O#LL_[/EA\ H[N"2WB@M=4-[_:Q(SSEF*E>G&,YHIUG?4=;#Q5
MK#O@Q_P3L^)7QR^'.G^+K%O"OAKP]K$QM](N?$VLQZ<=<D4A2+=6Y9=W\73F
ML+Q5^Q=\1_A]:?$N77]"31YOA"MO<>)8+FX^989V*QR08'[V,G!WKQBOI']K
M;]G+QC^WU\(_@#XJ^$&BP^,O#>A>%;;P[=Z7:WL<;>'-31MKL\3,"BN0"7]J
MW7^%/B>V^$G[6GPY?X@#XL>.K7P?HL?VI;D>8JPR;I[**0MAA N0<9S[U<JL
M[Z$_5X/1'Q'\6_A;?_!#7[73=<O]'NIK[3H-5C?3+D748AE4,H+#A6Y&0?:F
M_"+X7ZA\:O&+Z+H]WI-G<_9);POJMQ]CA5(U#'YFY#$= 1S7Z/))I/PX_:*^
M*.K:-H7AN>;1_P!GS2]3L+2YLH'LXKT(O[P*<JT@QD@#.153X/ZE9_M :W^S
M;X\\6:3X4OO%GBSX;^*5UFXBL8+6"^:&-A 6AP%#*>%.!G\*R=:78/JM/JS\
MPC=*%D9DD40N5F*J76+!QD, 00<<$XS3KBYCDR(-SMM^8QH[+%G&">.,\]3U
MK]*/@;H'Q"TK]GOX"VWP'\(^ ]>^'VL:#J#>/Y]?AMWMO[1#-YR:A,Q\R$(H
M'E[2.<=N*[#_ ()S?#R;P?\ "OX4K:V]MJGAWQGXIU/^V!H&DVMY916ZRF,0
MZK<W&76( ?)LPV,'O5+$2[$QPD;Z,_-36?@7XBT?X#:3\3I([5O!^NZK+HMI
M(LH,YN8ERP*_D?QKC)8RTAZ;NZC^'VK[>_:Q^'2C_@G1JUCX9L(9-'^'7QFU
MHWMM;2Q_\26U<[8VVD[O*.X8/O7Q&G"X],?-G.\'D'\C6].3>K,,1%1=D,5=
MM=G\)#G0_'7_ & '_P#0UKD67</>NO\ A%$PT?QUG_H O_Z&*\_./X-^ESLR
MG^/9;M'$%L,%[8''X4K+MZ5[O\$?V/[?X]_L^+K5CJ1TWQ+'?20(9QFVN%4#
M"^QYQQ[5Y/\ $KX5^(/A%K36?B33[C3Y&;;',5_T>;D@;7Z=NAYKR\!Q/@:M
M9X6=1*2TL>KCN&<=2H+%0IMQEK<YWRV>ZMR.@E3/_?:UUW[0W'QP\2;>GVA/
M_1:UR]J&6XC5UVE98P><Y^85U7[08!^-OB+_ *[I_P"BUKT]'CHOR.&/^Z-,
MXMF ZUZ3^S/^Q[XT_;"U3Q#;>#/[#C_X1.Q74M3N-6OQ9V\$!;;DNW'7-></
M"".G^>:^OO\ @DWK^E^$_A_^TU?:YX?L_%6DVW@-)9M&NYC#%J2B;YHRZD$<
M>AS7HSE)*\3SL/&+=I'G>E_\$N/B7XE^+<'@G2=:^'>LZQ)H\NNO-8^((I[*
MUM8R%=YI5X3!.<9Z#/>N5_:)_8%^)G[+_@FQ\5>(+/0]4\)ZA<&TBU_P_JL>
MI:='<8R(I63)C)'3/<U],?\ !+_Q#X=^/'[17Q*M_A]\,]%^&\>J?"?4]*M?
M#^F7K7$5Y<R@!6\R9LAF^[C/\-5?@)^RIXV_9?\ ^"??Q4^''Q)M8/#OB'X\
M7>F>'?!WA":^BN+PW7G@2WOE*Q$053RW'2N-U)O5H[%1I\UD?+.O_LA?$#PW
M^RCH?QHU#1_)^'FO7IL;:\+@W"L&*B1T[(Y4@-4/[+G['WC+]L?Q/X@T?P>N
MAPS>&=/&KZE=:K>BSM;.UW;=Q=OP-?I[XLD^$/QG\3^-_P!F+0_B=<:IJT?@
M./P?H_A0Z=Y.F6FK:8AE-Q'=$[7E=]P.",GUZ5\B?\$@/A_JWCD?M*>%+.Q?
M4O$VH?#6ZTJ*P+(MQ/<";:8?F8 MN![GC%$9R=]!U*,;JS/ _P!I;]A+XE?L
MI^'=-UGQ18Z/=>&M8D\BRU[1-02_TV:3/W#*A(5\#[I X(/>O%UG:YF\M&;]
MX6,9"MB89_A+ +QWY)K[^\#_  2N_P!AW_@FIXJ\!_'=+/0;CXK>--$_LGPL
M]\EQ<6=M#,OVJ]949O*7:""..!]*^CO^"@6@:'=_ OXV:--X!U";X>>']&M9
MO!^IW,&G66A6)*KY4VESQ@3SR,!\RL3S4QE)]"IT5;1GY>_!G]C;X@?M'?!_
MQUXV\'Z;%K&B_#>,2ZW''+MNC&1N+PQX)<(H);V^E<]<_L_^(9/V9;7XO,MB
MO@/4=;;P]!>I/^]^U(F]@8ST0 XW'GKZ5]>_\$U_VD/$7[)__!//X^?$+PZ]
MO-K6@^)= EEL9U41ZI;/E)[9U;G$D>0>M>[?&7P!\#1^R_\  O4M'U"V;X+_
M !2^-]OXJU'3+MPBZ"L\/[ZR<9RJ)-GK@!2*EU&G:QI3I1<;7/R)W0C/S3^6
MR;H0\4BM,!UV94;AZ%<U7N(H5@4MM7S 6&'+A@/0@>_).,$8K]>OVB?$_CSX
M<_"KX_>*_C5X1\#Z+H?PQ\5Z??\ P:FATZTC6Y\N<;;>U,>6N(9+?EB^1G-9
M7[0/@#X1_L_1R>+IF\-S>%?VQO&VASPJBH[>'M 58Y;]58?ZD-.Q5L8QDC(J
ME5?8GZKYGY'1L+A;=8?-'F$F(R1/'YA!P0NX 'IV)IMQ:L\S,WS;OXA]UOI[
M=N>X-?KG^V7X7\67_P '?VJK7XR>#_!^A_"OPV+8_!B^M+2TM97E#_Z.EI+%
MAY@\.&8MD9S7Y,+"T42AFW2;0SG;M.2,G/OS6D/>=V8U(\NACW<!$,H_V6_]
M!->@?'^(#PG\+2[;5;PJJGW_ 'K5QMU;YADS_</\J]EU'PU9^*OB#\!=)U&%
MKG3=2TFWMKF)#AGC:9LX/;ZUY>:XB-"2K5-HH];)Z,Z\)4(;R9\_+"TBMGYE
MW-@X[9-0FUW=?>ON#]J#_@DEJGA2\OM8^&=W)KEB)69M"NF$=U&.I$3]&[<'
MGK7QGKNAW.@ZM<:?J%K<:;J5FQ2>TNT,,\1]"IZ_A7+E/$F"Q^E"HK]C;-.&
M<?@-:T'R]SKO@9%Y/A/XJ#'+>%\9]/WRUYM]G553=_"BC('7BO5?@3;J/!?Q
M4P<[O#'<<C]\O%>;QV!VA>RJN/R%>A@[_6:E^Z.'&?[O37DS/EMPP_=L=O<5
M";9B>Z_C6E%;%9.FZB2'*9QSG%>@X-L\^[L9OV;^]S]:CEM@LG '3TK2*#[N
MWYO6F36#"/=G/-5MH/VEBG9VC7]Y;V<:CSKR>."')VAG=@JKGMDD<U]2?&?_
M ((V_%K]G7PCKFK>,/$'PBTV30;--1NM(;Q9#_:R1. Z@0?>9BI QCO7S;H=
ML/\ A+_#[(LBLFK6;L5;# "=.GO_ (5^@O\ P7P^.OPU_P"&L_B3X0D^!?A7
M4/&S:=I/D^/XM:F>\,C00E9/(4F+Y5&T@CMR.]9U+G1AXQD]3R?_ (<5?M"G
M1-/DLT^'&H:UJ>F1:U:>'X?$D*ZQ<6DB>8K);,0S.5(PHZUXK^RU^Q+\2/VU
M?CO+\-? ^A[O&UC%<2W]EJ9^R+IRP,5<2DY*-N& #U)K](_VS/\ @G;\8?C_
M /\ !2OX+?%+PCIMIH7@/P_X8\+WE_XXN=4AM+72H[:-'GW/OW[MN> /0>U;
M.I_%GX1^!(OVF/VC+[XF7WPPL_CSX^@\/^"O$FAZ9_:5[<VFFLDMU-% A#>7
M/)&P+<=:Q5:2Z'9]6I]S\??$?AZ_\&>)]4T74+=[/4-%O)=/O8&&##/$Y1Q]
M-P.#Z57",W.,_49K['_X+>?##PWIG[8]C\3O =U;:EX!^.^@VWB[2+R(",27
M!14N5D3K&S.I8J>AS7R#:(LT*E265B<-_>Y/_P"JNB,KJYQ5(\LFD5EBR_0?
ME2QQ_-T'Y5;2#:.>M-$7S],5J8MNX)%N6G")SPI-31Q';4D2,&HLA7.V_9D3
M'Q]\.;=V<S@\_P#3%ZXM%&9L_>\Z3_T,UWG[,$0'[0'AWCO.?_(+5Q*0!IIN
M&_UTG3_?->?1_P!Z:.NO_NUS^A;_ (--UV_\$Z/&7_91K[_TV:713O\ @T^7
M;_P3K\9=?^2C7W7_ +!FET5S8C^(SV,+_!CZ'BG_  <S-C]J;P#[>%@?_)JZ
MK\_OA(V[XJ>&_P#:OX\U^@/_  <T*Q_:D\ [1DMX750.[$W=R ![\U^?WPPM
M+C2?C+X?M;B.2&>WU*-)(Y!AE/H:[I_[F?/2E_PH.QE:\W_%2:F?^GV;_P!#
M-&AZ/-XDU_3]-LH]]YJEY%9VJ%MJR2.VT GMR11XC'_%2ZHOI>S?^AFM3X*R
M>5\;/ YW*G_%1V"AF/W<S+S[_I71AY2]DK(Y:T8RKOF[GN'Q;_X)3_%SX0Z!
MKFH22>"O$DOA6 SZSINB:NEUJ&EQ$ ^;+!G=M4')QP*^:A=V^HV$<R_-$S Q
MS2*WV<R <%'(VGW&:_03]L_]K[X=_LY_ME?&R'P9\-=0MO'GC)XO#GB/Q7=Z
MN)H&L91&)S!;J2-Q0G [<UZA\5O"&I?VQ\5-%UC0_!L?[)-G\-@WA348[:VC
MB^VBW7RF@F!\TW+7!(92?2DL142L;UL-2;23/B'X)?\ !._XC?'GX:67BZ&Z
M\&^$_#.LSM;Z7>>*=42Q.MR@\FV1N67=\I8\>G2O-OB3\ /%7P$^*5YX$\1:
M#>:/XL@F2W6Q0^8)F<CRF@(&'63C##M7UC^TM^SKXL_X* ? W]GOQ)\*=)M_
M%^C^&_"$7AS4-$@OHK>3PYJ49Q++*K$!5;.[>!]*\3_:3^&WC#P?^U9HW@^S
M\?S?$KQYI:6%E:ZA%+N;3;X8,=FLF<.D3=7!P :%)O5F-3#QA*R96^-/_!-_
MXH?LY_#RX\7>)_#>CPZ98O$FHC3K^.XNM#>3F,742_-"6SR3C.>:H? #]C3Q
MA^T;X9UCQ!IEWX6\-^%-'N4L;S6O$FHK86(NGQM@21N&<Y!QTP17U1^T_P#L
MY_$3]CG]DSQQX=ATW5_&WB+XG26^N?%CQ]-<Q/8VB(?DM+92Y:20,1DXZ?2N
M%_X)_P"G?$#4/V3/&EOX9\%^!_CGX1N-9A36OAEJK;=37 &+^W<D=N, \<^U
M-U)I:&D<+3<M6>"_$?\ 8R^(WP@\<:]X;U#PI-/?>&=-77+Z33'6XM1IK'_C
M\C=21(F>@'/6O*I+6UNMTD=L&9CO^6'AC_"Z^ON.HSBOUL^'FCO^SO\ M!?$
MGP+\(]3;3_$/B[X2MJ]OX/U2^AU63P]K0($=A'/*2"H3(\HL1UR.E>6?"']G
MSQ-\>/ '['/B#3_#NDWW_")^)K\?$*X9K:$:7,+G=+'=C/S9Q@+@@ C%3&M)
M*[0ZF&CM&1^=+)!&K)Y+232,F^.*%F9B2%RX ^4*>Y]*]7^*?[&7BKX1:QXP
MM?$4OA*UU3P#I]GJ5]$+[]Y>6]VH>/[-QF1MI&1GCGFOM6PL?%NF?#?XKWGP
M#T/PUJ7Q"D^,US:>*$EM[:62QT7<&CVK+\JVQYRR8QVJU^W?8Z;K&N_MH7=_
M:Z:]Q!X8\*9DB,<CV@.Q;@6S9^7C< %SP.:KZP^B)C@XVUD?F6GERVJE1-'#
M(X5'$3;-[\JH(&W]:<TBB)61)&5B8V<HX2)AQ]\C8>1TSFOUV^,>D^&H_A;X
MDTG1_!]QJ?P5E^&<<]C>@6-OX<MV6 %YX[@#SS?+)_ 3SZ5RFE^'+CQ[^P[)
MIE_H.F>"M-T_X;B\ANGL[74/!^M!!E9DG'[Z'42",H3U[=,$<1*^Q/U-)-W/
MRV1F* -MW#KBFW,C>5^0_44VW.S3K;/#F)6(!RH!'8^E1RLTC?[/'\ZVJ.]"
M39S45:HO4^EO@1ND_;G7@-G1H^HZ?N5KZL$.S=,TJPK&,M(_RJ,=RW;ZU\7Z
M+\4+/X,?M53^(+^WN+N*UTB*..WAX,SM"N 3V%<W\9_VHO%GQF::&XG_ +)T
MB0X&GVCE>/\ IHW4GVSC@5^ \1\!8[.\TIUJ>D5U\C^AN&>/,)DN5SHRLY2>
MW?0]._;)^*OPV\5136-II9UCQ1&VU-1L2(X[9^X<C'F$=<\\$5XE81LG[.U\
M&<2.FOQ98=SY9KFHT56BVJHV<+@?=^E=1 /(_9YU#;QN\0Q9/K^[-?IV7Y#_
M &9AX47/FM9'Y/C,^>9XFI5<%&]]CCFX9O7-)'$S/GM2RD>><U*L@5*^S;OJ
M?&RT>AJ> _#6O>.O&=EH/AF&]N/$&L;K:R@M)?*DN<C+)NR.,#IGFO2O''[&
MG[0'P=\ ZCK>N>"_'7AGPOID?F7<CWQAM((N.0B/@C)SD5XV]Y-8;[JSN+JT
MN;=&=;FVE,,UN<$!E<<KU/2OT0\9:;+\6/B%^P1X9\27NJ:WH?BC0VMM7T^>
M]F>#6$:1A^_7/[PXZ,<XKFK5'%K0Z\/#F6K/@SX?>!_%7B#P_KFM>%(=8DL_
M"< O-6OK"Y,#VD3M]YVW L"<>M96J^)[S7FB6_U;4+]8R2J7EZTYC)!SM5FR
M&;'48Z"OM2^L/"?Q:T3]L&'0/A[H?@>U^'NEIHNAV.ES2NDDGV[R_.N?FPTA
MZ GY5 7CBO6O&7[''P]N/@M\3/A_K'@?PCH^N^"?ALGB,1Z98W-QJUA?B(.)
M[C43B&7?D_NESM%+ZQ'^4U]BWU/SK\4>%_&OP-FMH=27Q!X-?7+!-1B5)WM5
MO[68?)(P1@""/7G@US&E7DEB/M%K=W5KN4H]S:SMNF0_>SM.3[ACSFOTC^(7
MA;P[XM_;)^"^L>//!>L>*O"MO\%+"Z6>UTV2\M;":.(XNI(D.Z>&(Y+HIS7S
MK_P5+^$FE_#N_P#A_P"(M T;PA8:1XXT9[J*_P##@DL[/7I$DQYWV.7Y[9@K
M<J>#QWZ/ZUY$O#Z[GA?Q*\$^+/A7JL.G^*(-4TB\U2QCN(H[BY.ZXLG7]WM(
M8_NR/X6Z<\5B1:S=K:+);:CJ42PJ4C,-TRK#V*Q8(V*0.0, ]\U^COC?X(?#
M[P#\4OBQKFK> ]+\66O@?X+:)XCL[#47E*->-C+E\[@IZ$ @8KYF_P""CGAG
MPS>_"_X*_$#P_P"#='\$W'Q6\(2ZCJFEZ6&%BDZ2;=T0;D';BI^L>1$L/9IM
MGCOB7X;^-OA5?:?H6IV?B#06\5007EGIZ3/%'JD$IQ$X0,%;<Q Y')S73^#/
MV4?C3XG\<ZU\/_#GA/QK)KF@!;C6-)M;LPP6A8!HWE^8("R] >217U!^W'\*
M?%GQ;_:-_9/UCPUX=UOQ'I>J>$=!L[6_L;=[BV\R"5?-5F4$(5 R=Q&*]#^-
M?Q)U"U^-G[6RZEX!\0?$CX)ZUXAL;#Q1=>$M3:WU[1KV&!55X1&=[1@C!QQ4
M_6/(UC0N]&?G?\2?AUXN^!_BF^\.^*])\0^&]4DVR76G7Y>,:@IY#2#.)1GH
M>>E<U)\S8RI"\ #HH]*^H_\ @J%\-[[P!K/PJU:3Q3XP\2>'/$GA@7/A^Q\6
MP"+7_#UK&<+;7' 9\DDAGR2#]:^7#$8%\OY<I_$._?\ K753E>-SEQ%U*PU_
MD7(KL/A)*PTOQM_M:"W_ *,%<F$5QR*ZSX2_\@?QT>I707VCT_>+7FYQ_NS7
M<[<G_P!X4GT/J;_@G:^[]G%L\[M2F SVX'^>*]B\::/HNN^$[R'Q1#83:.BG
MSWU#!C0=]A/*M[CVKY+_ &=OVL] ^ 7P 735M+C6/$37TDL5FOR1H"  SMZ9
M!X'/%>3?%GXX>*?C?JWG:]?[88WW165NVV"'\!C<>>IS7X*_#_'8S.Y8M-QC
M>]UH?OK\0\LP>11PDH\T[6L]1?C5I_@?3/B)Y?@*\U"\T=9E:43+\L;>8!A&
M/++C&#[GTJM\?GW_ !I\0_\ 7=/_ $!:YB-?],A0_P#/5!QQD;A76?'U5_X7
M5XAW=?.C_P#1:U^V8'#RPU>%.4G*RM=GXCBL='$TIU81Y;O8XT'Y::UW)I\4
M_E75Q:K<((Y6CE:-609)#X^\OL>,U(^W/RU'<Q+-:/'(?+60A5?.,-D 9]1D
MC(XX-?12ENT>%'='JFC?L6?'";X9-X]TGX?>,K70&MQ.FH6;&.5;8X)FV(WF
ME -I&!CDUY1-K%]?ZJ-0DU34+C44^9;Q[UY+JT(Z'>S97KT&.:_5?P@GB3X[
M?M!^ _"_C#PY\6O@K\<K?PC%8:-XR\)W1O\ PE?:<(25^TPG,,:,O!SSFO ]
M,_8\L]?\"?LEW&F^#5\3:AXB\=ZGI?C;4M*LWF@U6.*^V_OBN0B%=QYP.:X_
M;]SO^KWUN?&I\&^)K'X?P^/C::E!X8DU,Z7_ ,) D_E9O0"S!9<YW$=>23NK
M#M=9O-$E%S:ZA?:?)-\YGL[@VLC_ $<,-W7)'J<]:_3SXAM9_LZ?LC_$RW\-
M_!G2?B=IOAWX]7-EI?AZYMIKNQT>-D52QACY)*M@9R <$]JROB_^S=\)OV6=
M1_:L\40_"W0_$5OX#T30==TCPYJ\SO#X=N[T#S+<[3D*&((4GCD52Q%MD4\-
MIN?F?=:K)J]RMU=7UQ>W,R%?/N;DRRLHZJK.Q(XZCO72^)? OB[2/A=X=U;6
MDUZ/P7KQ9M#-U?.]G-Y?W@D98@8.>H%?IAIOPM^#_C3]JSX<_#W_ (4+X)L[
M?XZ?#8^+]<OX9YOM.CW(MF9/L*Y(B4,H)QUYKR7X-_ 3P/>?#;]D&Z\6>"=:
M\::;J+>)6URPTY'GN;M;>1A#.+<D!HXP SJF"P]:GZT^B)]AIJS\_P"VOY&L
M)%BNYH]-=A)<0B7="Y'W3+'G:2O\.>F:T/AS\-_$GQGUY/"_A.QO?%&H7"37
M46DV\H\MPJ[I)0K-L!"Y]#Q7Z+>-?V</AOJO[0_P+\;3?#70_&'PX\60ZJ;M
M_!%C<6B:J;<,8Y)-,EQ*GV? \Q1]_G&:Z7PU^R_X/\6_MB? WQ-IWA+P7-X2
M\>:1X@QJ7AF"ZT>#77MK:0QB6QDQ+#(F,,> Q H]LGNBE1FOA9^5.LZG>:A#
M:VVJ:OJ=Y%IN8;6&^NGE^RD<%8P[84J00"!Q535-3-Q#''>7;7%K;1%(X+J=
MFCM8VZJB,<*#W"CD\U^@WP ^$GA+X/? /]G^]L?@IHGQKO/CMXJO=(\5ZEJ%
MM-<3:' EV8EMHO+X@=5^;>_:M+QS\)/A1^PW\ _B-XDM/A=X1^*4WA?XW'P9
MHTWB"1Y(K2QD5"T+.A"RE#N5?0_6I]MV1I&@VM6?G-J6JW^L6%G:WVJ:IJ%K
M9KBU@NKN2>"W';RPY(&!P".G:L^[M&E;<Q^;N<=:^D_^"J_P,\._L]_M\^./
M#?A'3?[%\/K!9ZC:V )*6C3VZ2.B9YV@L0!Z5\]MDI[_ $KHCJKG+/1V,&ZM
M=L4B]1L/->V6MKCXP_L]L,\:=:]#_P!-VKRB6V,\<BM_</\ *O5M3UJS\(>.
MO@CJVH&1=-TO2[>:X,8S($65B=OUKYKB3#RQ%)T([N,K'T?#>(^KUE6E\*E&
MY^H=R&EU*:./<TDDA 55+=.Y]/K7RY_P4$\4_!!_#DUCXX@CUSQ>J$6,&BE1
M?Q/S@O*/E" YX;)ZUXQ^TM_P4T\4?%.*\TSP9"?">@3.RF[!S?7B9/?G;GVQ
MWKY=N4GO9I)I#-(\QW.TS>8\A/=B>OXU^4<$^&^+HXCZW7FX=;)M'ZUQGXDX
M6KAOJ>'@IZ6O:]CK/@C:;_#'Q2X95D\.DKN.6V^>N ?>O-?*WP_+S(H QZC%
M>K?!&S9?"?Q,W?=/AW_VLM><-8@$-MZ #K7[3@(*-><5W1^*9A-RHPEY,S+>
M%G+;?EP>>.E$ML9E;:=Q49P.I_SQ6LEFKN<?+Q5>XT]D@=8>)&#!2.H..OZ5
MZW1GFP.T_9__ &+_ (K?M5F\?X;>!-?\:6VED1WMW91K':V\I'">;(54DGL#
MFL^Y_99^(UOXJ\4>'YO _B.UU_P38OJ6OV%Q;&*;1[<$ 33*>D?( 8$@^M?8
M7[4VF^.M8_X)%_LMM\)K;Q)<^!;,7Z^*X/"9F,PUPR_)]J$/SLVT@J6X&!Z"
MO8_A7H'QXBOOC-I_QBGL=:\?3_LW2'2;2RA,VM+IXE4Q1WZ* \DXY.#EL8]Z
MY?:'9'#Q:NS\GI)8Y9+<JRK(RY2-]H;)')'/Y&EOM1DFD\R^O)+N:;*M+?2F
M2:0=/G9CEB.@';%?L#\*?V,?V>?!7PE^#O@'5O"NF>)(_B=\/'U[5+N+PU=Z
MAXANKXQ.[2VM]&1;VRP,HS$^",'(YKF?^";'['7P^_X5K\%=&\<?#OP3J,_Q
MDUC4[4W^K6%UJVL:[802-&C0R0_NM.,:C):0Y+ ]<T_;+J5]6:^%GY5WOB/6
M+^SCL9_$GB"XL5*J+675)FC./NA8BV-O;&, "H1>R7"Q6JWTDBVK$P6(GW)
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MK<$F^!.295.0Y)SRP)IA^!7C0'Y?#=YC_?3_ .*H_P"%$^,L?-X;O/P=,?\
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M&G^)$&/L?B=OK!/1_9/B)_\ ES\3#_MA/7V%_P .F/VUL_\ (N^(/_"NTO\
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MDQ[VT]1R^'-?FC99M+\13*W!1K6=E/X'BOLP_P#!);]ML=/#OB#_ ,*_2O\
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M]%[XV7C/C3G_ &+B@7GC@CEO&G_?%Q7U\?\ @D;^V_MR/#OB+=_V.&D__)=
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9** "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>amix20251001c_424b3img010.jpg
<TEXT>
begin 644 amix20251001c_424b3img010.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !^ . # 2(  A$! Q$!_\0
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M'T4458@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
MC)XI&=40EF '<FFRRI#$TCMA5&237%ZQK4FH2^1;Y6$'MU<UP8S&PPZ[M]#:
MC0E4>FQVD<J2+N1@P]0<TXL%3FL7P]8S6-FQG."_S!3_  U5UK6B"UM:MR.&
M<=JSJ8Z,*"G/1OH-4'*IRQU1EZI>RW%[)ESL5B%4'BM+P[=S-<- S%DVY /\
M-5--T62^C,DC&-<\'J36BTEMH";(P99FZC->#A_;QK+$5':)W594W#V4%=G1
M]:.M4]/O/MML)=NWVJV*^MIU(U(J4=F>6TT[,?1116@@HHHH **** "BBB@
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MZ?X0U>_O].N[DI>9WV[XV+SGCZ5/XS\":3XVM8HM0\R*:'_53Q'#+GM]*!G
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7 HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>logolrg.jpg
<TEXT>
begin 644 logolrg.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!P17AI9@  34T *@    @ !@$Q  (
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M(/\ _!4CPG\$?'7C:^^(7PJ\?30P0-<S-*(XI7V07**Y+I(C<,!D&LC]DO\
M:G_:N_X-_P!?$7PC\2?!/5OB1X,74'NM&NK..1H &/S212H#\C8'!&0:Z_\
M9,_92_:$_P""S'_!3+PM^T1\;/!]Q\/OA[X%=)=+LKN'[.62-]\=M"K?,PW\
MLYZ^@H'RG[6_M*?$2/X1_L_>./%4TGE1:#H=W>[\_=*0L0?Y5_.U_P $!?\
M@HOXB^ __!0RW?X@>*->F\!_%""\BDO-6O))+.VF+--$8V8X&,;2!T_2OVG_
M ."WWB#Q%8_\$P_BE;^%=%U;7-;UFP72K:QTZ$S7$IE?8WRCMMK\FOBU_P $
MFO&7B+_@WC^%&LZ;X/U9?BAX%U2ZU&72WMV74)X;N;RGC9!SN& P'8?6@@\:
MTW_@H_XS^+'_  6[\/\ Q8?6O$5KX*U+X@KH]E:BZE2QDLE81;0F=K$D@GC@
M'O7],OQ'N<_#OQ"Z/MVZ9<,I0\_ZIB"#7X+_ /!33_@E?XH_9G_X)9?LMV?@
MSPEK.N>-/!NLKK.O_P!EVK37?FW!6:0MCG@@+STQ7[>>#?$5WX]_98L-4FT^
M^M=0U3PJ)'M9DQ.DK6W,97^^&XQ0!^4W_!I+XSU[QIJ'[0RZUKFKZPMOK44<
M'VV[DG,*[I>%+$X_"OM#_@M7_P $^M5_;P_9/OX_!OB#5/"_Q"\)(^H:!=65
MZ]NMP4!+V\NTC(;'4]#7R%_P:C_!?QM\'-2_: _X2_P;XB\+KJ6LPRV9U.T:
MW^U+NE^YNZ]:]D_X. ?VR?BSX(^&$/P8^!W@KQAKOC+Q_%]GU#6M-LG:'2+6
M0;,>:. []">-H'>@#\N/@U^T9^T-_P %D?%7P:_9AMO$-]X;7X?I(OB/5[2^
M>*>YAA;9)-,P(+D(,  G/6OZ/?@;\%=+_9\^$'A_P3H<]Y-IGA^SCM89+F4S
M3RA>"[L3EB?T]Z_!?XZ?\$6?C!_P2:^$WP9^/7P?N/$/BCXJ^'[J-O&FFV :
M<L9L-LC0<M&,E&SGGGVK]Q/V,OVE3^U7^S_X:\;W/AO6O"6I:K;;;W2M7@,%
MU97"@"1&7T!Z'O0!Z9C,^T?*9"02.H.!R/?DU(%X#<[MNXG/4YQ110!#*2L,
MFYFDVAL!O]D?G]:;-\FUO^>FQ2I^Z%)QC'I110:$D%G%"<1QQQ+D9$:A<C/3
MCM5YQLB_"BB@S*BRL;;=G'R-@#H,8Q5[^#\*** ,RYMDG+1NH:-URZ,-RO\
M4'@TZWL(X2L,:K'"JC"(H10?7@#!^E%%!H6C_K9%P"% 7D=14#2F1&W8;;DC
M/8Y-%%!F10%G7?N;]WG SP<C/-6GA!"IDG=W/4444&A3EMENHF\P+(L9PJLB
ML!R.>13DB 11V.(P.R@=P.@HHH D5VEGD7<5V'8"/IG/UIRQ[HU;+;@1SGN>
M_IFBB@S'"/RX&92VYG'?/?'>HWXD"Y)X+9[Y'>BB@"21=T*%OF+*&Y[&FQGR
MOG7JV&;W)R?T[444 0,/LTK,N=^<;B<G#/@BE6%9)A&PSN."V,,<#.?J:**
#/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001617867<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Autonomix Medical, Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">424B3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 9,136<span></span>
</td>
<td class="nump">$ 8,608<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">473<span></span>
</td>
<td class="nump">783<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">9,609<span></span>
</td>
<td class="nump">9,391<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Long-term assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Fixed assets, net</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCosts', window );">Deferred offering costs</a></td>
<td class="nump">176<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total long-term assets</a></td>
<td class="nump">197<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">9,806<span></span>
</td>
<td class="nump">9,407<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">676<span></span>
</td>
<td class="nump">492<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">1,031<span></span>
</td>
<td class="nump">285<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">1,707<span></span>
</td>
<td class="nump">777<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Long-term liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleLongTermNotesPayable', window );">Long term debt - convertible notes, net of unamortized debt discount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,002<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total long-term liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,002<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">1,707<span></span>
</td>
<td class="nump">1,779<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 5)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value, 10,000,000 shares authorized, no shares issued and outstanding as of March 31, 2025 and March 31, 2024, respectively.</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value, 500,000,000 shares authorized, 2,497,033 and 942,575 shares issued and outstanding as of March 31, 2025 and March 31, 2024, respectively.</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">58,476<span></span>
</td>
<td class="nump">46,596<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(50,379)<span></span>
</td>
<td class="num">(38,969)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders' Equity</a></td>
<td class="nump">8,099<span></span>
</td>
<td class="nump">7,628<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders' Equity</a></td>
<td class="nump">$ 9,806<span></span>
</td>
<td class="nump">$ 9,407<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleLongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleLongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred cost, excluding capitalized cost related to contract with customer; classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Feb. 28, 2025</div></th>
<th class="th"><div>Oct. 24, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Nov. 29, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized (in shares)</a></td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued (in shares)</a></td>
<td class="nump">4,022,625<span></span>
</td>
<td class="nump">2,497,033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">942,575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding (in shares)</a></td>
<td class="nump">4,022,625<span></span>
</td>
<td class="nump">2,497,033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">942,575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">$ 1,828<span></span>
</td>
<td class="nump">$ 1,799<span></span>
</td>
<td class="nump">$ 6,863<span></span>
</td>
<td class="nump">$ 5,249<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">1,593<span></span>
</td>
<td class="nump">954<span></span>
</td>
<td class="nump">4,725<span></span>
</td>
<td class="nump">2,225<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Warrant expense - termination agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,556<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">3,421<span></span>
</td>
<td class="nump">2,753<span></span>
</td>
<td class="nump">11,588<span></span>
</td>
<td class="nump">12,030<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(3,421)<span></span>
</td>
<td class="num">(2,753)<span></span>
</td>
<td class="num">(11,588)<span></span>
</td>
<td class="num">(12,030)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Warrant liability - mark-to-market</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(3,444)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(41)<span></span>
</td>
<td class="num">(176)<span></span>
</td>
<td class="num">(79)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">84<span></span>
</td>
<td class="nump">95<span></span>
</td>
<td class="nump">354<span></span>
</td>
<td class="nump">127<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense)</a></td>
<td class="nump">84<span></span>
</td>
<td class="nump">54<span></span>
</td>
<td class="nump">178<span></span>
</td>
<td class="num">(3,396)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(3,337)<span></span>
</td>
<td class="num">(2,699)<span></span>
</td>
<td class="num">(11,410)<span></span>
</td>
<td class="num">(15,426)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (3,337)<span></span>
</td>
<td class="num">$ (2,699)<span></span>
</td>
<td class="num">$ (11,410)<span></span>
</td>
<td class="num">$ (15,426)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Loss per share - basic and diluted (in dollars per share)</a></td>
<td class="num">$ (1.07)<span></span>
</td>
<td class="num">$ (2.2)<span></span>
</td>
<td class="num">$ (6.46)<span></span>
</td>
<td class="num">$ (14.82)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding - basic and diluted (in shares)</a></td>
<td class="nump">3,105,156<span></span>
</td>
<td class="nump">1,225,423<span></span>
</td>
<td class="nump">1,766,425<span></span>
</td>
<td class="nump">1,040,720<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDerivativeInstrumentsNetPretax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingCostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingCostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Statements of Changes in Stockholders' Equity - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Mar. 31, 2023</a></td>
<td class="nump">617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2023</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 24,186<span></span>
</td>
<td class="num">$ (23,543)<span></span>
</td>
<td class="nump">$ 644<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(15,426)<span></span>
</td>
<td class="num">(15,426)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">618<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">618<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares)</a></td>
<td class="nump">105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">2,840<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,840<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_StockIssuedDuringPeriodSharesInitialPublicOffering', window );">Issuance of common stock from IPO, net of costs (in shares)</a></td>
<td class="nump">111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_StockIssuedDuringPeriodValueInitialPublicOffering', window );">Issuance of common stock from IPO, net of costs</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">9,875<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">9,875<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common stock for extinguishment of convertible debt (in shares)</a></td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issuance of common stock for extinguishment of convertible debt</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Issuance of common stock - warrants exercised (in shares)</a></td>
<td class="nump">91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_StockIssuedDuringPeriodValueWarrantsExercised', window );">Issuance of common stock - warrants exercised</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of restricted common stock (in shares)</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance of restricted common stock</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Warrants issued for debt issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">577<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">577<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_WarrantsIssuedFairValueIssuedForTerminationAgreement', window );">Fair value of warrants issued - termination agreement</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">8,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Mar. 31, 2024</a></td>
<td class="nump">943<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2024</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">46,596<span></span>
</td>
<td class="num">(38,969)<span></span>
</td>
<td class="nump">7,628<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,699)<span></span>
</td>
<td class="num">(2,699)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">360<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">360<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Issuance of common stock - warrants exercised (in shares)</a></td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_StockIssuedDuringPeriodValueWarrantsExercised', window );">Issuance of common stock - warrants exercised</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Jun. 30, 2024</a></td>
<td class="nump">963<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2024</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">46,956<span></span>
</td>
<td class="num">(41,668)<span></span>
</td>
<td class="nump">5,289<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Mar. 31, 2024</a></td>
<td class="nump">943<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2024</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">46,596<span></span>
</td>
<td class="num">(38,969)<span></span>
</td>
<td class="nump">7,628<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(11,410)<span></span>
</td>
<td class="num">(11,410)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,628<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,628<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares)</a></td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">103<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">103<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common stock for extinguishment of convertible debt (in shares)</a></td>
<td class="nump">33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issuance of common stock for extinguishment of convertible debt</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,177<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,177<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Issuance of common stock - warrants exercised (in shares)</a></td>
<td class="nump">892<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_StockIssuedDuringPeriodValueWarrantsExercised', window );">Issuance of common stock - warrants exercised</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants', window );">Issuance of common shares and equity classified warrants, net of offering costs (in shares)</a></td>
<td class="nump">616<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants', window );">Issuance of common shares and equity classified warrants, net of offering costs</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">8,972<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,972<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Mar. 31, 2025</a></td>
<td class="nump">2,497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2025</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">58,476<span></span>
</td>
<td class="num">(50,379)<span></span>
</td>
<td class="nump">8,099<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(3,337)<span></span>
</td>
<td class="num">(3,337)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">388<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">388<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares)</a></td>
<td class="nump">1,304<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">1,880<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,882<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Issuance of common stock - warrants exercised (in shares)</a></td>
<td class="nump">222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_StockIssuedDuringPeriodValueWarrantsExercised', window );">Issuance of common stock - warrants exercised</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Jun. 30, 2025</a></td>
<td class="nump">4,023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2025</a></td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 60,744<span></span>
</td>
<td class="num">$ (53,716)<span></span>
</td>
<td class="nump">$ 7,032<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock and warrants for common stock issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of common stock and warrants for common stock issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_StockIssuedDuringPeriodSharesInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the stock issued during the period from initial public offerings in shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_StockIssuedDuringPeriodSharesInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_StockIssuedDuringPeriodSharesWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_StockIssuedDuringPeriodSharesWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_StockIssuedDuringPeriodValueInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the value of the stock issued during the period from the initial public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_StockIssuedDuringPeriodValueInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_StockIssuedDuringPeriodValueWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_StockIssuedDuringPeriodValueWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_WarrantsIssuedFairValueIssuedForTerminationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the fair value of the warrants issued for termination agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_WarrantsIssuedFairValueIssuedForTerminationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481284/470-20-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows from Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (11,410,000)<span></span>
</td>
<td class="num">$ (15,426,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">1,628,000<span></span>
</td>
<td class="nump">618,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">183,000<span></span>
</td>
<td class="nump">81,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Issuance of common stock, net of discount for lack of marketability</a></td>
<td class="nump">101,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Warrant expense - termination agreement</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,556,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Warrant liability - mark-to-market</a></td>
<td class="nump">(0)<span></span>
</td>
<td class="nump">3,444,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract', window );"><strong>Changes in operating assets - (increase)/decrease:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets', window );">Other current assets</a></td>
<td class="nump">310,000<span></span>
</td>
<td class="num">(478,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract', window );"><strong>Changes in operating liabilities - increase:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade', window );">Accounts payable</a></td>
<td class="nump">184,000<span></span>
</td>
<td class="nump">320,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">746,000<span></span>
</td>
<td class="nump">237,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(8,258,000)<span></span>
</td>
<td class="num">(6,648,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows from Investing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(14,000)<span></span>
</td>
<td class="num">(19,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(14,000)<span></span>
</td>
<td class="num">(19,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows from Financing Activities (increase/decrease):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_ProceedsFromIssuanceOfCommonStockAndWarrants', window );">Issuance of common stock, pre-funded and common warrants</a></td>
<td class="nump">10,025,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Payment of issuance costs for financing</a></td>
<td class="num">(1,052,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of issuance costs for registration statement</a></td>
<td class="num">(176,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Issuance of convertible debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Issuance of common stock from IPO</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,866,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_PaymentsForInitialPublicOfferingIssuanceCosts', window );">Payment of issuance costs for IPO</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,296,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">8,800,000<span></span>
</td>
<td class="nump">14,410,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash and cash equivalents</a></td>
<td class="nump">528,000<span></span>
</td>
<td class="nump">7,743,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents, at beginning of period</a></td>
<td class="nump">8,608,000<span></span>
</td>
<td class="nump">865,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents, at end of period</a></td>
<td class="nump">9,136,000<span></span>
</td>
<td class="nump">8,608,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Non-cash financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_WarrantsIssuedForEquityCosts', window );">Warrants issued for equity issuance costs</a></td>
<td class="nump">479,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Proceeds from cashless exercise of warrants</a></td>
<td class="nump">39,000<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_WarrantsIssuedForDebtIssuanceCosts', window );">Warrants issued for debt issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">577,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_ClassOfWarrantOrRightFairValueIssuedForIssuanceCostsFromIpo', window );">Fair value of warrants issued for issuance costs as part of IPO</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">225,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_IpoProceedsHoldbackProvision', window );">Holdback of IPO proceeds</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">305,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionByUniqueDescriptionAxis=amix_IssuanceOfCommonStockForExtinguishmentOfConvertibleDebtMember', window );">Issuance of Common Stock for Extinguishment of Convertible Debt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Non-cash financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Convertible notes converted into common stock</a></td>
<td class="nump">1,330,000<span></span>
</td>
<td class="nump">670,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_DebtConversionDebtIssuanceCostsConvertedCommonShares', window );">Settlement/conversion to common shares for debt issuance costs</a></td>
<td class="num">(153,000)<span></span>
</td>
<td class="num">(170,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=amix_ATMAgreementMember', window );">ATM Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows from Financing Activities (increase/decrease):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows from Financing Activities (increase/decrease):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of issuance costs for registration statement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,840,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,840,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_ClassOfWarrantOrRightFairValueIssuedForIssuanceCostsFromIpo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the fair value of the warrants or rights issued for issuance costs from an initial public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_ClassOfWarrantOrRightFairValueIssuedForIssuanceCostsFromIpo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_DebtConversionDebtIssuanceCostsConvertedCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the debt issuance costs that were converted into common shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_DebtConversionDebtIssuanceCostsConvertedCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_IpoProceedsHoldbackProvision">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the portion of proceeds from initial public offering that is under holdback.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_IpoProceedsHoldbackProvision</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_PaymentsForInitialPublicOfferingIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the payments for the issuance costs from an initial public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_PaymentsForInitialPublicOfferingIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_ProceedsFromIssuanceOfCommonStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity and issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_ProceedsFromIssuanceOfCommonStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_WarrantsIssuedForDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of warrants issued for debt issuance costs in noncash or part noncash transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_WarrantsIssuedForDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_WarrantsIssuedForEquityCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of warrants issued for equity costs in noncash or part noncash transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_WarrantsIssuedForEquityCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionOriginalDebtAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionOriginalDebtAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDerivativeInstrumentsNetPretax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableTrade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionByUniqueDescriptionAxis=amix_IssuanceOfCommonStockForExtinguishmentOfConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionByUniqueDescriptionAxis=amix_IssuanceOfCommonStockForExtinguishmentOfConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=amix_ATMAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=amix_ATMAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Balance Sheets (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 8,589<span></span>
</td>
<td class="nump">$ 9,136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">389<span></span>
</td>
<td class="nump">473<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">783<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">8,978<span></span>
</td>
<td class="nump">9,609<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,391<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Long-term assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Fixed assets, net</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCosts', window );">Deferred offering costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total long-term assets</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">8,997<span></span>
</td>
<td class="nump">9,806<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">815<span></span>
</td>
<td class="nump">676<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">492<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">1,150<span></span>
</td>
<td class="nump">1,031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">1,965<span></span>
</td>
<td class="nump">1,707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">777<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">1,965<span></span>
</td>
<td class="nump">1,707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,779<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 5)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value, 10,000,000 shares authorized, no shares issued and outstanding as of March 31, 2025 and March 31, 2024, respectively.</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value, 500,000,000 shares authorized, 2,497,033 and 942,575 shares issued and outstanding as of March 31, 2025 and March 31, 2024, respectively.</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">60,744<span></span>
</td>
<td class="nump">58,476<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(53,716)<span></span>
</td>
<td class="num">(50,379)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(38,969)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders' Equity</a></td>
<td class="nump">7,032<span></span>
</td>
<td class="nump">8,099<span></span>
</td>
<td class="nump">$ 5,289<span></span>
</td>
<td class="nump">7,628<span></span>
</td>
<td class="nump">$ 644<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders' Equity</a></td>
<td class="nump">$ 8,997<span></span>
</td>
<td class="nump">$ 9,806<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred cost, excluding capitalized cost related to contract with customer; classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Balance Sheets (Unaudited) (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Feb. 28, 2025</div></th>
<th class="th"><div>Oct. 24, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Nov. 29, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized (in shares)</a></td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued (in shares)</a></td>
<td class="nump">4,022,625<span></span>
</td>
<td class="nump">2,497,033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">942,575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding (in shares)</a></td>
<td class="nump">4,022,625<span></span>
</td>
<td class="nump">2,497,033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">942,575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Statements of Operations (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 1,593<span></span>
</td>
<td class="nump">$ 954<span></span>
</td>
<td class="nump">$ 4,725<span></span>
</td>
<td class="nump">$ 2,225<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">1,828<span></span>
</td>
<td class="nump">1,799<span></span>
</td>
<td class="nump">6,863<span></span>
</td>
<td class="nump">5,249<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">3,421<span></span>
</td>
<td class="nump">2,753<span></span>
</td>
<td class="nump">11,588<span></span>
</td>
<td class="nump">12,030<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(3,421)<span></span>
</td>
<td class="num">(2,753)<span></span>
</td>
<td class="num">(11,588)<span></span>
</td>
<td class="num">(12,030)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(41)<span></span>
</td>
<td class="num">(176)<span></span>
</td>
<td class="num">(79)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">84<span></span>
</td>
<td class="nump">95<span></span>
</td>
<td class="nump">354<span></span>
</td>
<td class="nump">127<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense)</a></td>
<td class="nump">84<span></span>
</td>
<td class="nump">54<span></span>
</td>
<td class="nump">178<span></span>
</td>
<td class="num">(3,396)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(3,337)<span></span>
</td>
<td class="num">(2,699)<span></span>
</td>
<td class="num">(11,410)<span></span>
</td>
<td class="num">(15,426)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (3,337)<span></span>
</td>
<td class="num">$ (2,699)<span></span>
</td>
<td class="num">$ (11,410)<span></span>
</td>
<td class="num">$ (15,426)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Loss per share - basic and diluted (in dollars per share)</a></td>
<td class="num">$ (1.07)<span></span>
</td>
<td class="num">$ (2.2)<span></span>
</td>
<td class="num">$ (6.46)<span></span>
</td>
<td class="num">$ (14.82)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding - basic and diluted (in shares)</a></td>
<td class="nump">3,105,156<span></span>
</td>
<td class="nump">1,225,423<span></span>
</td>
<td class="nump">1,766,425<span></span>
</td>
<td class="nump">1,040,720<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingCostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingCostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Statements of Changes in Stockholders' Equity (Unaudited) - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Mar. 31, 2023</a></td>
<td class="nump">617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2023</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 24,186<span></span>
</td>
<td class="num">$ (23,543)<span></span>
</td>
<td class="nump">$ 644<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(15,426)<span></span>
</td>
<td class="num">(15,426)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">618<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">618<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Issuance of common stock - warrants exercised (in shares)</a></td>
<td class="nump">91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_StockIssuedDuringPeriodValueWarrantsExercised', window );">Issuance of common stock - warrants exercised</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares)</a></td>
<td class="nump">105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">2,840<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,840<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Mar. 31, 2024</a></td>
<td class="nump">943<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2024</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">46,596<span></span>
</td>
<td class="num">(38,969)<span></span>
</td>
<td class="nump">7,628<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,699)<span></span>
</td>
<td class="num">(2,699)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">360<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">360<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Issuance of common stock - warrants exercised (in shares)</a></td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_StockIssuedDuringPeriodValueWarrantsExercised', window );">Issuance of common stock - warrants exercised</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Jun. 30, 2024</a></td>
<td class="nump">963<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2024</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">46,956<span></span>
</td>
<td class="num">(41,668)<span></span>
</td>
<td class="nump">5,289<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Mar. 31, 2024</a></td>
<td class="nump">943<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2024</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">46,596<span></span>
</td>
<td class="num">(38,969)<span></span>
</td>
<td class="nump">7,628<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(11,410)<span></span>
</td>
<td class="num">(11,410)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,628<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,628<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Issuance of common stock - warrants exercised (in shares)</a></td>
<td class="nump">892<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_StockIssuedDuringPeriodValueWarrantsExercised', window );">Issuance of common stock - warrants exercised</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares)</a></td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">103<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">103<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Mar. 31, 2025</a></td>
<td class="nump">2,497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2025</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">58,476<span></span>
</td>
<td class="num">(50,379)<span></span>
</td>
<td class="nump">8,099<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(3,337)<span></span>
</td>
<td class="num">(3,337)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">388<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">388<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Issuance of common stock - warrants exercised (in shares)</a></td>
<td class="nump">222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_StockIssuedDuringPeriodValueWarrantsExercised', window );">Issuance of common stock - warrants exercised</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares)</a></td>
<td class="nump">1,304<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">1,880<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,882<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Jun. 30, 2025</a></td>
<td class="nump">4,023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2025</a></td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 60,744<span></span>
</td>
<td class="num">$ (53,716)<span></span>
</td>
<td class="nump">$ 7,032<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_StockIssuedDuringPeriodSharesWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_StockIssuedDuringPeriodSharesWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_StockIssuedDuringPeriodValueWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_StockIssuedDuringPeriodValueWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Statements of Cash Flows (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows from Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (3,337)<span></span>
</td>
<td class="num">$ (2,699)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">388<span></span>
</td>
<td class="nump">360<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract', window );"><strong>Changes in operating assets - (increase)/decrease:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets', window );">Other current assets</a></td>
<td class="nump">84<span></span>
</td>
<td class="nump">458<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract', window );"><strong>Changes in operating liabilities - increase:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade', window );">Accounts payable</a></td>
<td class="nump">140<span></span>
</td>
<td class="num">(205)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">118<span></span>
</td>
<td class="nump">191<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(2,604)<span></span>
</td>
<td class="num">(1,852)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows from Investing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows from Financing Activities (increase/decrease):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of issuance costs for registration statement</a></td>
<td class="num">(64)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">2,057<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash and cash equivalents</a></td>
<td class="num">(547)<span></span>
</td>
<td class="num">(1,857)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents, at beginning of period</a></td>
<td class="nump">9,136<span></span>
</td>
<td class="nump">8,608<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents, at end of period</a></td>
<td class="nump">8,589<span></span>
</td>
<td class="nump">6,751<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Non-cash financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_DeferredFinancingCostsRelatedToTheIssuanceOfCommonStock', window );">Recognition of deferred financing costs associated with issuance of common stock</a></td>
<td class="num">(176)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Proceeds from cashless exercise of warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows from Financing Activities (increase/decrease):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">$ 2,121<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_DeferredFinancingCostsRelatedToTheIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of deferred financing costs related to the issuance of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_DeferredFinancingCostsRelatedToTheIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableTrade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 1 - Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Note <em style="font: inherit;">1</em> </b>&#8211;<b> Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies </b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Description of the Business</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Autonomix Medical, Inc. (&#8220;we,&#8221; &#8220;our,&#8221; the &#8220;Company&#8221;) is a medical device company organized as a Delaware corporation on <em style="font: inherit;"> June 10, 2014. </em>The Company is a pre-revenue, clinical stage life sciences company focused on advancing innovative technologies for sensing and treating disorders relating to the peripheral nervous system.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Reverse Stock Split</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company&#160;held its annual meeting of stockholders (the "Annual Meeting") on <em style="font: inherit;"> October 17, 2024. </em>In that Annual Meeting, stockholders of the Company approved an amendment to the Company&#8217;s amended and restated certificate of incorporation (the "Amendment&#8221;) to effect the reverse stock split at a ratio in the range of <em style="font: inherit;">1</em>-for-2 to <em style="font: inherit;">1</em>-for-50, with such ratio to be determined in the discretion of the Company&#8217;s Board of Directors (the "Board") and with such reverse stock split to be effected at such time and date, if at all, as determined by the Company&#8217;s Board in its sole discretion prior to the <em style="font: inherit;">one</em>-year anniversary of the Annual Meeting.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Pursuant to such authority granted by the Company&#8217;s stockholders, the Company&#8217;s Board approved a <em style="font: inherit;">one</em>-for-<span style="-sec-ix-hidden:c134564773">twenty</span> (<em style="font: inherit;">1:20</em>) reverse stock split (the "Reverse Stock Split&#8221;) of the Company&#8217;s common stock and the filing of the Amendment to effectuate the Reverse Stock Split. The Amendment was filed with the Secretary of State of the State of Delaware and the Reverse Stock Split became effective in accordance with the terms of the Amendment at <em style="font: inherit;">11:59</em> p.m. Eastern Time on <em style="font: inherit;"> October 24, 2024 (</em>the "Effective Time&#8221;), and the Company&#8217;s common stock opened&#160;for trading on The Nasdaq Capital Market on <em style="font: inherit;"> October 25, 2024 </em>on a post-split basis, under the existing ticker symbol "AMIX&#8221; but with a new CUSIP number <em style="font: inherit;">05330T205.</em> The Amendment provides that, at the Effective Time, every <span style="-sec-ix-hidden:c134564777">twenty</span> shares of the Company&#8217;s issued and outstanding common stock was automatically combined into <em style="font: inherit;">one</em> issued and outstanding share of common stock, without any change in par value per share, which will remain $0.001.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The number of authorized shares of common stock remained&#160;at 500 million shares. As a result of the Reverse Stock Split, proportionate adjustments were made to the per share exercise price and/or the number of shares issuable upon the exercise or vesting of all outstanding stock options, restricted stock unit awards, warrants and convertible notes, which resulted in a proportional decrease in the number of shares of the Company&#8217;s common stock reserved for issuance upon exercise or vesting of such stock options, restricted stock unit awards, warrants and convertible notes and, in the case of stock options and warrants, a proportional increase in the exercise price of all such stock options and warrants.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company&#8217;s stock option awards did <em style="font: inherit;">not</em> automatically adjust for the Reverse Stock Split.&#160;However, the Company chose to exercise its rights under the agreements to adjust the exercise price and number of shares exercisable or issuable upon vesting proportionately for the Reverse Stock Split.&#160;Based on the analysis performed, the Company does <em style="font: inherit;">not</em> need to recognize any additional compensation expense as a result of the modification.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">In addition, the number of shares reserved for issuance under the Company&#8217;s equity compensation plan immediately prior to the Effective Time was reduced proportionately.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><em style="font: inherit;">No</em> fractional shares were issued as a result of the Reverse Stock Split. Any stockholder who would have been entitled to receive a fractional share as a result of the process was entitled to the rounding up of the fractional share to the nearest whole number. See "<i>Fractional Shares</i>" in Note <em style="font: inherit;">4</em> for further disclosure regarding fractional shares.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Reverse Stock Split has been retroactively adjusted throughout these interim financial statements and footnotes for all periods presented, including exercise prices and share data. As a result of the Reverse Stock Split, the Company reclassified approximately $18 thousand between common stock par value and additional paid-in capital.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Liquidity and Going Concern</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company's financial statements are prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The Company is an early-stage company that is subject to all the risks associated with early-stage and emerging growth companies and has incurred losses since inception.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">O&#65279;n <em style="font: inherit;"> February 28, 2025,&#160;</em>the Company entered into an At Market Issuances Sales Agreement (the &#8220;ATM Agreement&#8221;) with Ladenburg Thalmann &amp; Co. Inc. (the &#8220;Agent&#8221;). Pursuant to the terms of the ATM Agreement, The Company <em style="font: inherit;"> may </em>sell from time to time through the Agent, as sales agent or principal, shares of its common stock with an initial aggregate sales price of up to $2.1 million (the &#8220;Shares&#8221;). As of <em style="font: inherit;"> June 30, 2025, </em>the Company sold 1,304,260 Shares pursuant to the ATM Agreement for net proceeds of approximately $2.1 million.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
      <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> November 22, 2024, </em>the Company entered into&#160;an Underwriting Agreement (the &#8220;Underwriting Agreement&#8221;) with Ladenburg Thalmann &amp; Co. Inc., as representative of the several underwriters, if any, named on Schedule I of the Underwriting Agreement (the &#8220;Underwriters&#8221;), in connection with a firm commitment underwritten public offering (the &#8220;Offering&#8221;) of: (i) 458,691 common units (the &#8220;Common Units&#8221;), each Common Unit consisting of <span style="-sec-ix-hidden:c134564791">one</span> share of Company common stock and <span style="-sec-ix-hidden:c134564792">one</span> series A warrant to purchase <span style="-sec-ix-hidden:c134564793">one</span> share of common stock (the &#8220;Series A Warrants&#8221;); and (ii) 917,596 pre-funded units (the &#8220;Pre-Funded Units&#8221;) and together with the Common Units, the "Units", each Pre-Funded Unit consisting of <span style="-sec-ix-hidden:c134564795">one</span> pre-funded warrant to purchase <span style="-sec-ix-hidden:c134564796">one</span> share of common stock (the &#8220;Pre-Funded Warrant&#8221;) and <span style="-sec-ix-hidden:c134564797">one</span> Series A Warrant. The purchase price of each Common Unit was $6.540, and the purchase price of each Pre-Funded Unit was $6.539.&#160;In addition, the Company granted the Underwriters a 45-day option to purchase an additional 206,422 shares of common stock, and/or an additional 206,422 Series A Warrants, solely to cover over-allotments, if any. The Pre-Funded Warrants have an exercise price of $0.001 per share, are immediately exercisable and <em style="font: inherit;"> may </em>be exercised at any time until all of the Pre-Funded Warrants are exercised in full. The Series A Warrants have an exercise price of $6.540 per share, are immediately exercisable and <em style="font: inherit;"> may </em>be exercised at any time until the <span style="-sec-ix-hidden:c134564805">five</span>-year anniversary of the date of issuance. Both the Pre-Funded Warrants and the Series A Warrants are subject to a beneficial ownership limitation of 4.99%. The Pre-Funded Warrants and Series A Warrants were issued pursuant to a warrant agency agreement between the Company and Equity Stock Transfer, LLC (the &#8220;Warrant Agency Agreement&#8221;). The Offering closed on <em style="font: inherit;"> November 25, 2024. </em>On <em style="font: inherit;"> November 22, 2024, </em>the Underwriters partially exercised their over-allotment option with respect to 156,809 shares of common stock and 156,809 Series A Warrants. The aggregate gross proceeds to the Company, including the partial exercise of the over-allotment option, were approximately $10.0 million, before deducting underwriting discounts and other expenses by the Company of $1.5 million, including $0.5 million of non-cash expenses. The net cash proceeds to the Company were approximately $9.0 million. See Note <em style="font: inherit;">6</em> - Subsequent Events for additional information regarding events occurring after <em style="font: inherit;"> June 30, 2025.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">For the&#160;<em style="font: inherit;">three</em> months ended <em style="font: inherit;"> June 30, 2025 </em>and <em style="font: inherit;">2024,</em> the Company incurred net losses of $3.3 million and $2.7 million, respectively, and had net cash flows used in operating activities of $2.6 million and $1.9&#160;million, respectively. The Company had no revenues for the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> June 30, 2025 </em>and <em style="font: inherit;">2024,</em> respectively, and an accumulated deficit of $53.7&#160;million, working capital of $7.0 million and cash of $8.6 million as of <em style="font: inherit;"> June 30, 2025. </em>The Company does <em style="font: inherit;">not</em> expect to&#160;generate&#160;positive cash flows from operating activities in the near future.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company estimates its current cash resources&#160;are sufficient to fund its operations into but <em style="font: inherit;">not</em> beyond the <em style="font: inherit;">second</em> calendar quarter of <em style="font: inherit;">2026.</em> The Company recognizes it will need to raise additional capital to continue to execute its business plan, including obtaining regulatory clearance for its products currently under development and commercializing and generating revenues from products under development. There is <em style="font: inherit;">no</em> assurance that additional financing will be available when needed or that management will be able to obtain financing on terms acceptable to the Company. A failure to raise sufficient capital, generate sufficient product revenues, control expenditures and regulatory matters, among other factors, will adversely impact the Company&#8217;s ability to meet its financial obligations as they become due and payable and to achieve its intended business objectives. If the Company is unable to raise sufficient additional funds, it will have to scale back its operations.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">These factors raise substantial doubt about the Company's ability to continue as a going concern within <em style="font: inherit;">one</em> year after the date the financial statements are issued. The accompanying condensed financial statements have been prepared on a going concern basis and do <em style="font: inherit;">not</em> include any adjustments that might be necessary if the Company is unable to continue as a going concern.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Basis of Presentation</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The accompanying condensed interim financial statements are unaudited. These unaudited condensed interim financial statements have been prepared in accordance with the rules and regulations of the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) for interim financial information. Accordingly, they do <em style="font: inherit;">not</em> include all the information and notes required by generally accepted accounting principles in the United States of America (&#8220;GAAP&#8221;) for complete financial statements. The Company&#8217;s fiscal year end is <em style="font: inherit;"> March 31</em><sup style="vertical-align:top;line-height:120%;">st</sup>. These unaudited condensed interim financial statements should be read in conjunction with the audited financial statements and accompanying notes for the year ended <em style="font: inherit;"> March 31, 2025 </em>as found in the Annual Report in the Company's Form <em style="font: inherit;">10</em>-K filed with the SEC on <em style="font: inherit;"> May 29, 2025. </em>In the opinion of management, the unaudited condensed interim financial statements reflect all the adjustments (consisting of normal recurring adjustments) necessary to state fairly the Company&#8217;s financial position, results of operations and cash flows for the quarterly and year-to-date periods, as applicable. The interim results of operations are <em style="font: inherit;">not</em> necessarily indicative of the results that <em style="font: inherit;"> may </em>occur for the full fiscal year. The <em style="font: inherit;"> March 31, 2025 </em>audited condensed balance sheet included herein was derived from the audited financial statements, but does <em style="font: inherit;">not</em> include all disclosures, including notes, required by GAAP for complete financial statements.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Use of Estimates in Financial Statement Presentation</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The preparation of these unaudited condensed interim financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The Company's significant estimates and assumptions include work performed but <em style="font: inherit;">not</em> yet billed by contract manufacturers, engineers and research organizations and the valuation of equity related instruments. Although the Company believes that its estimates and assumptions are reasonable, they are based upon information available at the time the estimates and assumptions were made. Some of these judgments can be subjective and complex, and, consequently, actual results could differ from those estimates.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Cash and Cash Equivalents</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company considers all highly liquid accounts with original maturities of <em style="font: inherit;">three</em> months or less at the date of acquisition to be cash equivalents.&#160;Periodically, the Company <em style="font: inherit;"> may </em>carry cash balances at financial institutions in excess of the federally insured limit of <em style="font: inherit;">$250</em> thousand. The Company has <em style="font: inherit;">not</em> experienced losses on these accounts and management believes, based upon the quality of the financial institutions, that the credit risk with regard to these deposits is <em style="font: inherit;">not</em> significant.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Offering and Financing Costs</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Offering costs consist of professional costs incurred through the balance sheet date that are direct and incremental related to the Company&#8217;s equity financing activities. Specifically, offering costs were incurred during the Company&#8217;s initial public offering ("IPO"), Offering from <em style="font: inherit;"> November 2024 </em>and ATM Agreement. The Company includes offering costs in additional paid-in capital, to the extent there is sufficient cash proceeds, upon completion of the sale of equity. Costs associated with salaries and other period costs are expensed as incurred.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;text-indent:9pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;text-indent:9pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;text-indent:9pt;"><i>Property and Equipment</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Property and equipment (comprised of computer and IT equipment) are stated at historical cost and depreciated on a straight-line basis over their estimated useful lives, generally&#160;<span style="-sec-ix-hidden:c134564843">three</span> years. Upon disposition of the assets, the costs and related accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the results of operations.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Convertible Notes</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">For the period ended <em style="font: inherit;"> March 31, 2025, </em>the Company evaluated embedded redemption, conversion and other features within its debt to determine whether any embedded features should be bifurcated from the host instrument and accounted for as a derivative at fair value, with changes in fair value recorded in the condensed statements of operations. The Company&#8217;s debt was carried on the condensed balance sheets on a historical cost basis, net of unamortized discounts and premiums, because the Company did <em style="font: inherit;">not</em> elect the fair value option of accounting. Costs associated with acquiring debt, including detachable warrants issued in connection with the financing, were&#160;capitalized as a debt discount. The debt discount was&#160;presented in the condensed balance sheets, in prior year periods, as a direct deduction from the carrying amount of the debt liability. The costs were&#160;amortized over the estimated contractual life of the related debt instrument using the effective interest method and were&#160;included in interest expense in the condensed statements of operations.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">In addition, since the instruments included a substantive conversion feature as of time of issuance, the issuance of equity securities to settle the outstanding notes with the conversion were accounted for as a contractual conversion with <em style="font: inherit;">no</em> gain or loss recognized related to the equity securities issued to settle the instrument. See <i>Note <em style="font: inherit;">2</em> - Convertible Notes Payable</i> for additional information.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Fair Value of Financial Instruments</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs. The Company utilizes a <em style="font: inherit;">three</em>-level valuation hierarchy for disclosures of fair value measurements, defined as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Level <em style="font: inherit;">1</em> &#8211; inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Level <em style="font: inherit;">2</em> &#8211; inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the assets or liability, either directly or indirectly, for substantially the full term of the financial instrument</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">Level <em style="font: inherit;">3</em> &#8211; inputs to the valuation methodology are unobservable and significant to the fair value and require significant judgment and estimation</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Financial assets and financial liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. While the Company believes that its valuation methods are appropriate, the Company recognizes that the use of different methodologies or assumptions to determine the fair value could result in a different estimate of fair value at the reporting date. The primary assumptions that would significantly affect the fair values are the probability weighting of the different settlement outcomes used.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
      <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company did <em style="font: inherit;">not</em> have any assets or liabilities measured at fair value as of <em style="font: inherit;"> June 30, 2025 </em>and <em style="font: inherit;"> March 31, 2025.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">The carrying value of short-term instruments, including cash, accounts payable and accrued expenses, approximate fair value due to the relatively short period to maturity for these instruments.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;"><i>Related Parties</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company follows Accounting Standards Codification ("ASC") <em style="font: inherit;">850,</em> <i>Related Party Disclosures</i>, for the identification of related parties and disclosure of related party transactions. See further discussion in Note <em style="font: inherit;">5</em> below on this matter.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Income Taxes</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting and the tax basis of reported assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company must then assess the likelihood that the resulting deferred tax assets will be realized. A valuation allowance is provided when it is more likely than <em style="font: inherit;">not</em> that some portion or all of a deferred tax asset will <em style="font: inherit;">not</em> be realized. As of <em style="font: inherit;"> June 30, 2025 </em>and <em style="font: inherit;"> March 31, 2025 </em>the Company determined a full valuation allowance was required to offset its deferred tax assets as a result of recurring operating losses.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company accounts for uncertain tax positions in accordance with the provisions of ASC <em style="font: inherit;">740</em>-<em style="font: inherit;">10</em> which prescribes a recognition threshold and measurement attribute for financial statement disclosure of tax positions taken, or expected to be taken, on its tax return. The Company evaluates and records any uncertain tax positions based on the amount that management deems is more likely than <em style="font: inherit;">not</em> to be sustained upon examination and ultimate settlement with the tax authorities in the tax jurisdictions in which it operates. As of <em style="font: inherit;"> June 30, 2025 </em>and <em style="font: inherit;"> March 31, 2025 </em>the Company had no uncertain tax positions.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company does&#160;<em style="font: inherit;">not</em>&#160;expect to pay any significant federal, state, or foreign income taxes in&#160;its fiscal year <em style="font: inherit;">2026</em> (ending <em style="font: inherit;"> March 31, 2026) </em>as a result of the losses recorded during the&#160;<em style="font: inherit;">three</em> months ended <em style="font: inherit;"> June 30, 2025&#160;</em>and the additional losses expected for the remainder of&#160;its fiscal year <em style="font: inherit;">2026</em>&#160;and cumulative net operating loss carryforwards. Accounting standards require the consideration of a valuation allowance for deferred tax assets if it is &#8220;more likely than&#160;<em style="font: inherit;">not&#8221;</em>&#160;that some component or all of the benefits of deferred tax assets will <em style="font: inherit;">not</em> be realized.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company recorded&#160;<em style="font: inherit;">no</em>&#160;income tax provision for the&#160;<em style="font: inherit;">three</em> months ended <em style="font: inherit;"> June 30, 2025 </em>and <em style="font: inherit;">2024,</em> respectively. The effective tax rate for the&#160;<em style="font: inherit;">three</em> months ended <em style="font: inherit;"> June 30, 2025 </em>and <em style="font: inherit;">2024</em>&#160;is zero.&#160;The Company estimates its annual effective tax rate at the end of each quarterly period. Jurisdictions with a projected loss for the year where&#160;<em style="font: inherit;">no</em>&#160;tax benefit can be recognized due to the valuation allowance could result in a higher or lower effective tax rate during a particular quarter depending on the mix and timing of actual earnings versus annual projections.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Stock-based Compensation</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Employee and non-employee share-based compensation is measured at the grant date, based on the fair value of the award, and is recognized as an expense over the requisite service period. For awards with a performance condition, compensation expense is recognized over the requisite service period if it is probable that the performance condition will be satisfied. For awards to non-employees, the Company recognizes compensation expense in the same manner as if the Company had paid cash for the goods or services. The Company estimates the fair value of options and equity classified warrants granted using an options pricing model. Expense is recognized within general and administrative and research and development expenses and forfeitures are recognized as they are incurred.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Warrants</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s specific terms and applicable authoritative guidance in FASB ASC <em style="font: inherit;">480,</em> Distinguishing Liabilities from Equity (&#8220;ASC <em style="font: inherit;">480&#8221;</em>) and ASC <em style="font: inherit;">815,</em> Derivatives and Hedging (&#8220;ASC <em style="font: inherit;">815&#8221;</em>). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC <em style="font: inherit;">480,</em> meet the definition of a liability pursuant to ASC <em style="font: inherit;">480,</em> and whether the warrants meet all of the requirements for equity classification under ASC <em style="font: inherit;">815,</em> including whether the warrants are indexed to the Company&#8217;s own ordinary shares and whether the warrant holders could potentially require &#8220;net cash settlement&#8221; in a circumstance outside of the Company&#8217;s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do <em style="font: inherit;">not</em> meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss on the&#160;statements of operations. The fair value of the warrants is estimated using a Black-Scholes pricing model or a Monte Carlo simulation.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Loss Per Common Share</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Basic loss per common share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period, which includes shares issuable for little to <em style="font: inherit;">no</em> consideration upon the exercise of certain equity-classified warrants. Diluted loss per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. In periods when losses are reported, the weighted-average number of common shares outstanding excludes common stock equivalents, because their inclusion would be anti-dilutive. Generally, the Company&#8217;s outstanding warrants are non-participating securities as they are <em style="font: inherit;">not</em> entitled to non-forfeitable rights to dividends or dividend equivalents during the vesting term and have <em style="font: inherit;">no</em> obligation to fund losses.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">However, the Company's warrants described in Note&#160;<em style="font: inherit;">2</em>&#160;and the warrants issued in connection with the Offering, are participating securities as the holders receive the right to dividends, but they are <em style="font: inherit;">not</em> obligated to fund losses. In periods of loss, since <em style="font: inherit;">no</em> income is allocated to these securities, the Company's use of the "treasury stock method" derives the same result. The dilutive effect of convertible securities is calculated using the &#8220;if-converted method.&#8221; Under the if-converted method, securities are assumed to be converted at the beginning of the period, and the resulting common shares are included in the denominator of the diluted calculation for the entire period being presented.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">For the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> June 30, 2025 </em>and <em style="font: inherit;">2024,</em> dilutive securities that were <em style="font: inherit;">not</em> included in the calculations of the loss per common share because they would be anti-dilutive included the following:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 5%; margin-left: 54pt; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>June 30,</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(as revised)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Equity based warrants to purchase common shares</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">87,531</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,334</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Convertible Notes - common shares (1)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">33,250</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Convertible Notes - equity-based warrants to purchase common shares</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">25,003</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">25,003</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock options granted under Company's incentive plan</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">248,483</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">216,483</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Series A Warrants</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,533,096</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Representative Warrants</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">91,985</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total potentially dilutive securities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,986,098</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">279,070</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
    <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 54pt;">(<em style="font: inherit;">1</em>) Shares for the convertible note proceeds received</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Research and Development Costs</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Research and development costs are expensed as incurred.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Advertising</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">It is the Company's policy to expense advertising costs as incurred. Advertising&#160;expenses are included within general and administrative expenses within the statement of operations. For the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> June 30, 2025 </em>and <em style="font: inherit;">2024,</em> the Company recorded $0 and less than $0.1&#160;million, respectively, of advertising expenses.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>JOBS Act Accounting Election</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company qualifies as an emerging growth company (&#8220;EGC&#8221;), as defined in the Jumpstart Our Business Startups Act of <em style="font: inherit;">2012</em> (the &#8220;JOBS Act&#8221;). The JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected <em style="font: inherit;">not</em> to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This <em style="font: inherit;"> may </em>make comparison of the Company&#8217;s financial statements with another public company which is neither an early-stage company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><i>Segments</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker ("CODM"), or decision-making group, in deciding how to allocate resources in assessing performance. Management has determined that the Company operates in&#160;<span style="-sec-ix-hidden:c134564899">one</span>&#160;reportable segment, which is advancing the development of innovative technologies for sensing and treating disorders relating to the nervous system. The Company is initially focused on developing the technology for patients with pancreatic cancer, however, the Company believes the technology constitutes a platform with the potential to address several indications, including chronic pain management, hypertension, cardiovascular disease and a wide range of other nerve-related disorders. The Company's CODM is its Chief Executive Officer.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The accounting policies of the segment are the same as those described in the summary of significant accounting policies. The CODM assesses performance based on net loss, which is reported on the Statements of Operations. The measure of segment assets is reported on the balance sheet as total assets.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">To date, the Company has <em style="font: inherit;">not</em> generated any product revenue. The Company expects to continue to incur significant expenses and operating losses for the foreseeable future as it advances its' technology through all stages of development and clinical trials and, ultimately, seek regulatory approval.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">As such, the CODM primarily evaluates performance of the Company using various financial metrics, including the combined net income (loss) from operations, also shown on the Statements of Operations, forecasted cash expenditures and existing and forecasted cash balances. These financial metrics are used by the CODM to make key operating decisions, such as the assessment of segment performance and allocation of resources. All of the Company's assets are located in the United States. The significant expense categories within net loss from operations that the CODM regularly reviews are expenses related to research and development, general and administrative, and depreciation and amortization. The significant expense categories and subcategories are reported on the Statements of Operations.&#160;Other expenses included in the Company&#8217;s net loss include other income (expense), interest income, net, and any additional non-operating expenses that are reported on the Statements of Operations.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Recent Accounting Pronouncements</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">In&#160;<em style="font: inherit;"> November 2024 </em>and <em style="font: inherit;"> January 2025,&#160;</em>FASB issued ASU&#160;<em style="font: inherit;">2024</em>-<em style="font: inherit;">03</em> and ASU <em style="font: inherit;">2025</em>-<em style="font: inherit;">01,</em>&#160;Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic&#160;<em style="font: inherit;">220</em>-<em style="font: inherit;">40</em>): Disaggregation of Income Statement Expenses, which requires disclosure in the notes to the financial statements of specified information about certain costs and expenses. The amendments to the standards are effective for fiscal years beginning after&#160;<em style="font: inherit;"> December 15, 2026,&#160;</em>and for interim periods within fiscal years beginning after&#160;<em style="font: inherit;"> December 15, 2027.&#160;</em>Early adoption is permitted. The amendments should be applied either prospectively to financial statements issued for reporting periods after the effective date of this ASU or retrospectively to any or all prior periods presented in the financial statements. The Company is currently evaluating the new guidance to determine the impact it&#160;<em style="font: inherit;"> may&#160;</em>have on its financial statements and related disclosures.&#160;</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">In <em style="font: inherit;"> December 2023, </em>the FASB issued <i>ASU <em style="font: inherit;">2023</em>-<em style="font: inherit;">09,</em> </i>&#8220;<i>Income Taxes (Topic <em style="font: inherit;">740</em>): Improvements to Income Tax Disclosures,</i>&#8221; which requires disaggregated information about a reporting entity&#8217;s effective tax rate reconciliation as well as information on income taxes paid. The guidance is effective for the Company&#8217;s fiscal years beginning after <em style="font: inherit;"> December 15, 2024. </em>The Company is currently evaluating the new guidance to determine the impact it&#160;<em style="font: inherit;"> may&#160;</em>have on its financial statements and related disclosures.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">In <em style="font: inherit;"> November 2023, </em>the FASB issued <i>ASU <em style="font: inherit;">No.</em> <em style="font: inherit;">2023</em>-<em style="font: inherit;">07,</em> Segment Reporting (Topic <em style="font: inherit;">280</em>): Improvements to Reportable Segment Disclosures.</i> The ASU updates reportable segment disclosure requirements, primarily through requiring enhanced disclosures about significant segment expenses and information used to assess segment performance and allocate resources. The guidance is effective for fiscal years beginning after <em style="font: inherit;"> December 15, 2023 </em>and interim periods for fiscal years beginning after <em style="font: inherit;"> December 15, 2024, </em>on a retrospective basis. There was <em style="font: inherit;">no</em> material impact upon the adoption of <i>ASU <em style="font: inherit;">2023</em>-<em style="font: inherit;">07</em></i> on the Company's interim disclosures.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">There are <em style="font: inherit;">no</em> other effective pronouncements, or pronouncements issued but <em style="font: inherit;">not</em> yet effective, if adopted, that would have a material effect on the accompanying financial statements.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;text-indent:9pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;text-indent:9pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;text-indent:9pt;"><i>Correction of an Immaterial Error in the Prior Period Financial Statements</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">D&#65279;uring the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> December 31, 2024, </em>the Company determined that previously filed quarterly and annual financial statements had an immaterial earnings per share error resulting from the exclusion of certain unexercised equity based warrants to purchase common shares that had an exercise price of approximately $0.01 or less from the basic earnings per share calculations in accordance with <i>ASC <em style="font: inherit;">260</em>-<em style="font: inherit;">10</em>-<em style="font: inherit;">45</em>-<em style="font: inherit;">13</em></i>. As a&#160;result, the prior year earnings per share calculations have been revised for consistency with the current year presentation. The Company assessed the materiality of this change in presentation on prior period financial statements in accordance with <i>SEC Staff Accounting Bulletin <em style="font: inherit;">No.</em> <em style="font: inherit;">99</em></i>, &#8220;<i>Materiality</i>,&#8221; (<i>ASC Topic <em style="font: inherit;">250,</em> Accounting Changes and Error Corrections</i>). Based on this assessment, the Company concluded that this error correction in its&#160;<i>Statements of Operations</i>&#160;and <i>Note <em style="font: inherit;">1</em> </i>&#8211;<i> Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies (Loss Per Common Share)</i> is <em style="font: inherit;">not</em> material to any previously presented financial statements based upon overall considerations of both quantitative and qualitative factors. The corrections had <em style="font: inherit;">no</em> impact in the comparative period Balance Sheet,&#160;Statements of Cash Flows, or Statement of Changes in Stockholders&#8217;&#160;Equity. Further, the immaterial correction did <em style="font: inherit;">not</em> result in a change in operating losses or net loss in the Statement of Operations and the effects of including unexercised warrants in the earnings per share calculation have an antidilutive effect reducing the net loss per share amount. Accordingly, the Company corrected the previously reported earnings per share calculation for the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> June 30, 2024 </em>in this Quarterly Report on Form <em style="font: inherit;">10</em>-Q.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
      <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">A summary of the impact of the Company&#8217;s Reverse Stock Split and immaterial corrections reflecting the prior period impact to the Company&#8217;s Statement of Operations and earnings per share are shown below:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

     <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Three Months Ended June 30, 2024</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Originally </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Filed</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Adjusted </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>for 1-for-20 </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Reverse </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Stock Split</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Correction</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>As Revised</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net Loss (in thousands)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(2,699</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(2,699</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Loss per share - basic and diluted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(0.14</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(2.85</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">0.65</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(2.20</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Weighted average shares outstanding - basic and diluted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">18,902,248</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">945,382</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">280,041</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,225,423</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
     <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">A summary of the impact of the Company&#8217;s Reverse Stock Split and immaterial corrections reflecting the prior period impact are shown below:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

     <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Three Months Ended June 30, 2024</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Originally </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Filed</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Adjusted </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>for 1-for-20 </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Reverse </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Stock Split</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Correction</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>As Revised</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Equity based warrants to purchase common shares</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,344,569</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">267,231</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(262,897</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,334</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Convertible Notes - common shares</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">665,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">33,250</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">33,250</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Convertible Notes - equity-based warrants to purchase common shares</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">500,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">25,003</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">25,003</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock options granted under Company's incentive plan</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4,329,579</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">216,483</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">216,483</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total potentially dilutive securities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">10,839,148</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">541,967</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(262,897</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">279,070</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
     <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
  <span></span>
</td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Note <em style="font: inherit;">1</em> </b>&#8211;<b> Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies </b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Description of the Business</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Autonomix Medical, Inc (&#8220;we,&#8221; &#8220;our,&#8221; the &#8220;Company&#8221;) is a medical device company organized as a Delaware corporation on <em style="font: inherit;"> June 10, 2014. </em>The Company is a pre-revenue, clinical stage life sciences company focused on advancing innovative technologies for sensing and treating disorders relating to the peripheral nervous system.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Reverse Stock Split</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company&#160;held its annual meeting of stockholders (the "Annual Meeting") on&#160;<em style="font: inherit;"> October 17, 2024</em><i>.</i>&#160;In that Annual Meeting, stockholders of the Company approved an amendment to the Company&#8217;s amended and restated certificate of incorporation (the "Amendment&#8221;) to effect the reverse stock split at a ratio in the range of&#160;<em style="font: inherit;">1</em>-for-2&#160;to&#160;<em style="font: inherit;">1</em>-for-50, with such ratio to be determined in the discretion of the Company&#8217;s board of directors and with such reverse stock split to be effected at such time and date, if at all, as determined by the Company&#8217;s board of directors in its sole discretion prior to the&#160;<em style="font: inherit;">one</em>-year anniversary of the Annual Meeting.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Pursuant to such authority granted by the Company&#8217;s stockholders, the Company&#8217;s board of directors approved a&#160;<em style="font: inherit;">one</em>-for-&#160;<span style="-sec-ix-hidden:c134564311">twenty</span>&#160;(<em style="font: inherit;">1:20</em>) reverse stock split (the "Reverse Stock Split&#8221;) of the Company&#8217;s common stock and the filing of the Amendment to effectuate the Reverse Stock Split. The Amendment was filed with the Secretary of State of the State of Delaware and the Reverse Stock Split became effective in accordance with the terms of the Amendment at&#160;<em style="font: inherit;">11:59</em>&#160;p.m. Eastern Time on&#160;<em style="font: inherit;"> October 24, 2024 (</em>the "Effective Time&#8221;), and the Company&#8217;s common stock opened&#160;for trading on The Nasdaq Capital Market on&#160;<em style="font: inherit;"> October 25, 2024&#160;</em>on a post-split basis, under the existing ticker symbol "AMIX&#8221; but with a new CUSIP number&#160;<em style="font: inherit;">05330T205.</em>&#160;The Amendment provided that, at the Effective Time, every&#160;<span style="-sec-ix-hidden:c134564315">twenty</span>&#160;shares of the Company&#8217;s issued and outstanding common stock automatically combined into&#160;<em style="font: inherit;">one</em>&#160;issued and outstanding share of common stock, without any change in par value per share, which remained $0.001.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The number of authorized shares of common stock remained&#160;at&#160;500&#160;million shares. As a result of the Reverse Stock Split, proportionate adjustments were made to the per share exercise price and/or the number of shares issuable upon the exercise or vesting of all outstanding stock options, restricted stock unit awards, warrants and convertible notes, which resulted in a proportional decrease in the number of shares of the Company&#8217;s common stock reserved for issuance upon exercise or vesting of such stock options, restricted stock unit awards, warrants and convertible notes and, in the case of stock options and warrants, a proportional increase in the exercise price of all such stock options and warrants.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company&#8217;s stock option awards did <em style="font: inherit;">not</em> automatically adjust for the Reverse Stock Split.&#160;However, the Company chose to exercise its rights under the agreements to adjust the exercise price and number of shares exercisable or issuable upon vesting proportionately for the Reverse Stock Split.&#160;Based on the analysis performed, the Company does <em style="font: inherit;">not</em> need to recognize any additional compensation expense as a result of the modification.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">In addition, the number of shares reserved for issuance under the Company&#8217;s equity compensation plan immediately prior to the Effective Time was reduced proportionately.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><em style="font: inherit;">No</em>&#160;fractional shares were issued as a result of the Reverse Stock Split. Any stockholder who would have been entitled to receive a fractional share as a result of the process was entitled to the rounding up of the fractional share to the nearest whole number. See "&#160;Fractional Shares" in Note&#160;<em style="font: inherit;">5</em>&#160;for further disclosure regarding fractional shares.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Reverse Stock Split has been retroactively adjusted throughout these interim financial statements and footnotes for all periods presented, including exercise prices and share data. As a result of the Reverse Stock Split, the Company reclassified approximately $18&#160;thousand between common stock par value and additional paid-in capital.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Liquidity and Going Concern</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company's&#65279; financial statements are prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The Company is an early-stage company that is subject to all the risks associated with early-stage and emerging growth companies and has incurred losses since inception.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
      <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">For the years ended <em style="font: inherit;"> March 31, 2025 </em>and <em style="font: inherit;">2024,</em> the Company has net losses of approximately $11.4 million and $15.4 million, respectively and had net cash flows used in operating activities of $8.3&#160;million&#160;and $6.6 million, respectively. The Company had no revenues for the years ended <em style="font: inherit;"> March 31, 2025 </em>and <em style="font: inherit;">2024,</em> respectively. The Company had an accumulated deficit of $50.4 million and working capital of approximately $7.9 million as of <em style="font: inherit;"> March 31, 2025. </em>The Company does <em style="font: inherit;">not</em> expect to generate positive cash flows from operating activities in the near future. These conditions, and the Company's ability to comply with such conditions, raise substantial doubt about the Company's ability to continue as a going concern within <em style="font: inherit;">one</em> year after the date that the financial statements are issued. The accompanying financial statements have been prepared on a going concern basis and do <em style="font: inherit;">not</em> include any adjustments that might be necessary if the Company is unable to continue as a going concern.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> January 26, 2024, </em>the Company completed its IPO, pursuant to which it sold a total of 111,962&#160;shares of common stock at a purchase price of $100.00 per share for gross proceeds of $11.2 million and net proceeds of $9.8 million.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> November 22, 2024, </em>the Company completed a firm commitment underwritten public offering (the &#8220;Offering&#8221;) of: (i) 458,691 common units (the &#8220;Common Units&#8221;), each Common Unit consisting of <span style="-sec-ix-hidden:c134564342">one</span> share of Company common stock and <span style="-sec-ix-hidden:c134564343">one</span> series A warrant to purchase <span style="-sec-ix-hidden:c134564344">one</span> share of common stock (the &#8220;Series A Warrants&#8221;); and (ii) 917,596 pre-funded units (the &#8220;Pre-Funded Units&#8221;) and together with the Common Units, the "Units", each Pre-Funded Unit consisting of <span style="-sec-ix-hidden:c134564346">one</span> pre-funded warrant to purchase <span style="-sec-ix-hidden:c134564347">one</span> share of common stock (the &#8220;Pre-Funded Warrant&#8221;) and <span style="-sec-ix-hidden:c134564348">one</span> Series A Warrant. The purchase price of each Common Unit was $6.540, and the purchase price of each Pre-Funded Unit was $6.539.&#160;In addition, the Company granted the underwriters in the Offering a 45-day option to purchase an additional 206,422 shares of common stock, and/or an additional 206,422 Series A Warrants, solely to cover over-allotments, if any. The Pre-Funded Warrants have an exercise price of $0.001 per share, are immediately exercisable and <em style="font: inherit;"> may </em>be exercised at any time until all of the Pre-Funded Warrants are exercised in full. The Series A Warrants have an exercise price of $6.540 per share, are immediately exercisable and <em style="font: inherit;"> may </em>be exercised at any time until the <span style="-sec-ix-hidden:c134564356">five</span>-year anniversary of the date of issuance. Both the Pre-Funded Warrants and the Series A Warrants are subject to a beneficial ownership limitation of 4.99%. The Offering closed on <em style="font: inherit;"> November 25, 2024. </em>On <em style="font: inherit;"> November 22, 2024, </em>the underwriters partially exercised their over-allotment option with respect to 156,809 shares of common stock and 156,809 Series A Warrants. The aggregate gross proceeds to the Company, including the partial exercise of the over-allotment option, were approximately $10.0 million, before deducting underwriting discounts and other expenses by the Company of $1.5 million, including $0.5 million of non-cash expenses. The net cash proceeds to the Company were approximately $9.0 million.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> February 28, 2025, </em>the Company entered into an At Market Issuances Sales Agreement (the &#8220;ATM Agreement&#8221;) with Ladenburg Thalmann &amp; Co. Inc. (the &#8220;Agent&#8221;). Pursuant to the terms of the ATM Agreement, the Company <em style="font: inherit;"> may </em>sell from time to time through the Agent, as sales agent or principal, shares of the Company&#8217;s common stock with an initial aggregate sales price of up to $2.1 million (the &#8220;Shares&#8221;). Any sale of Shares pursuant to the Agreement will be made under the Company&#8217;s &#8220;shelf&#8221; registration statement (the &#8220;Registration Statement&#8221;) on Form S-<em style="font: inherit;">3</em> filed on <em style="font: inherit;"> February 28, 2025 </em>with the Securities and Exchange Commission (the &#8220;SEC&#8221;). Under the ATM Agreement, the Company <em style="font: inherit;"> may </em>sell Shares through the Agent by any method that is deemed an &#8220;at the market offering&#8221; (as defined in Rule <em style="font: inherit;">415</em>(a)(<em style="font: inherit;">4</em>) under the Securities Act of <em style="font: inherit;">1933,</em> as amended). Under the ATM Agreement, the Agent will also be able to sell shares of Common Stock by any other method permitted by law, including in negotiated transactions with the Company&#8217;s prior written consent. The Company will pay a commission to the Agent of 3.0% of the gross proceeds of the sale of the Shares sold under the ATM Agreement and reimburse the Agent for certain expenses. As of <em style="font: inherit;"> March 31, 2025, </em>the Company sold 800 shares pursuant to the ATM Agreement for net proceeds of approximately $1,746.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company estimates its current cash resources are sufficient to fund its operations into but <em style="font: inherit;">not</em> beyond the <em style="font: inherit;">first</em> calendar quarter of <em style="font: inherit;">2026.</em> The Company recognizes it will need to raise additional capital to continue to execute its business plan, including obtaining regulatory clearance for its products currently under development and commercializing and generating revenues from products under development. There is <em style="font: inherit;">no</em> assurance that additional financing will be available when needed or that management will be able to obtain financing on terms acceptable to the Company. A failure to raise sufficient capital, generate sufficient product revenues, control expenditures and regulatory matters, among other factors, will adversely impact the Company&#8217;s ability to meet its financial obligations as they become due and payable and to achieve its intended business objectives. If the Company is unable to raise sufficient additional funds, it will have to scale back its operations.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Basis of Presentation</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The annual financial statements and disclosures have been prepared using the accrual basis of accounting in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;).</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Use of Estimates in Financial Statement Presentation</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The preparation of these financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The Company's significant estimates and assumptions include the valuation of equity related instruments, and initial and recurring fair value measurements for the warrant liability. Although the Company believes that its estimates and assumptions are reasonable, they are based upon information available at the time the estimates and assumptions were made. Some of these judgments can be subjective and complex, and, consequently, actual results could differ from those estimates.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Cash and Cash Equivalents</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company considers all highly liquid accounts with original maturities of <em style="font: inherit;">three</em> months or less at the date of acquisition to be cash equivalents.&#160;Periodically, the Company <em style="font: inherit;"> may </em>carry cash balances at financial institutions in excess of the federally insured limit of <em style="font: inherit;">$250,000.</em> The Company has <em style="font: inherit;">not</em> experienced losses on these accounts and management believes, based upon the quality of the financial institutions, that the credit risk with regard to these deposits is <em style="font: inherit;">not</em> significant.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Offering and Financing Costs</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Offering costs consist of professional costs incurred through the balance sheet date that were direct and incremental to the Company&#8217;s equity financing activities. Specifically, offering costs were incurred on the Company's IPO, the Offering and the Registration Statement. The costs for the Registration Statement are recorded in deferred offering costs on the balance sheet as of <em style="font: inherit;"> March 31, 2025. </em>Costs associated with salaries and other period costs were expensed as incurred.&#160;</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">During the year ended <em style="font: inherit;"> March 31, 2024, </em>the Company paid $1.3 million of issuance&#160;costs related to its IPO.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">During the year ended <em style="font: inherit;"> March 31, 2025, </em>the Company paid $1.1 million of issuance costs related to its Offering and $0.2 million of offering costs related to its Registration Statement.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Property and Equipment</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Property and equipment are stated at historical cost and depreciated on a straight-line basis over their estimated useful lives, generally&#160;<span style="-sec-ix-hidden:c134564384">three</span> years. Upon disposition of the assets, the costs and related accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the results of operations.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Convertible Notes</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company evaluates embedded redemption, conversion and other features within its debt to determine whether any embedded features should be bifurcated from the host instrument and accounted for as a derivative at fair value, with changes in fair value recorded in the statement of operations.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company&#8217;s debt is carried on the balance sheet on a historical cost basis net of unamortized discounts and premiums because the Company has <em style="font: inherit;">not</em> elected the fair value option of accounting. Costs associated with acquiring debt, including detachable warrants issued in connection with the financing, are capitalized as a debt discount. The debt discount is presented in the balance sheet as a direct deduction from the carrying amount of the debt liability. The costs are amortized over the estimated contractual life of the related debt instrument using the effective interest method and are included in interest expense in the statement of operations.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">If the Company incurs costs associated with its convertible notes, in advance of the receipt of proceeds, the Company will record a deferred asset. Upon receipt of proceeds the Company will reclassify the deferred asset as a direct deduction from the carrying amount, as described above.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">In addition, since the instruments included a substantive conversion feature at the time of issuance, the issuance of equity securities were accounted for as a contractual conversion with <em style="font: inherit;">no</em> gain or loss recognized related to the equity securities issued to settle the instrument. &#160;</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Fair Value of Financial Instruments</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs. The Company utilizes a <em style="font: inherit;">three</em>-level valuation hierarchy for disclosures of fair value measurements, defined as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Level <em style="font: inherit;">1</em> &#8211; inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
      <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Level <em style="font: inherit;">2</em> &#8211; inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the assets or liability, either directly or indirectly, for substantially the full term of the financial instruments.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Level <em style="font: inherit;">3</em> &#8211; inputs to the valuation methodology are unobservable and significant to the fair value and require significant judgment and estimation.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Financial assets and financial liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. While the Company believes that its valuation methods are appropriate, the Company recognizes that the use of different methodologies or assumptions to determine the fair value could result in a different estimate of fair value at the reporting date. The primary assumptions that would significantly affect the fair values are the probability weighting of the different settlement outcomes used.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company did <em style="font: inherit;">not</em> have any assets or liabilities measured at fair value as of <em style="font: inherit;"> March 31, 2025 </em>and <em style="font: inherit;">2024,</em> respectively. In the <em style="font: inherit;">fourth</em> quarter of the Company's fiscal year ended <em style="font: inherit;"> March 31, 2024 </em>there was a transfer out of Level <em style="font: inherit;">3</em>&#160;for the warrant liability, for the settlement and reclassification to equity of the instrument, that occurred in the&#160;<em style="font: inherit;">three</em> months ended&#160;<em style="font: inherit;"> March 31, 2024. </em>For additional information, see&#160;<i>Note <em style="font: inherit;">2</em> - Warrant Liability and Fair Value of Financial Instruments</i>.&#65279;</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The carrying value of short-term instruments, including cash, accounts payable, accrued expenses and convertible notes included in long-term debt, approximate fair value due to the relatively short period to maturity for these instruments.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Related Parties</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company follows ASC <em style="font: inherit;">850,</em>&#160;<i>Related Party Disclosures</i>,&#160;for the identification of related parties and disclosure of related party transactions. See further discussion in the Notes below on this matter.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Income Taxes</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting and the tax basis of reported assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company must then assess the likelihood that the resulting deferred tax assets will be realized. A valuation allowance is provided when it is more likely than <em style="font: inherit;">not</em> that some portion or all of a deferred tax asset will <em style="font: inherit;">not</em> be realized. As of&#160;<em style="font: inherit;"> March 31, 2025 </em>and&#160;<em style="font: inherit;"> March 31, 2024 </em>the Company determined a full valuation allowance was required to offset its deferred tax assets as a result of recurring operating losses.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company accounts for uncertain tax positions in accordance with the provisions of ASC <em style="font: inherit;">740</em>-<em style="font: inherit;">10</em> which prescribes a recognition threshold and measurement attribute for financial statement disclosure of tax positions taken, or expected to be taken, on its tax return. The Company evaluates and records any uncertain tax positions based on the amount that management deems is more likely than <em style="font: inherit;">not</em> to be sustained upon examination and ultimate settlement with the tax authorities in the tax jurisdictions in which it operates. As of <em style="font: inherit;"> March 31, 2025 </em>and&#160;<em style="font: inherit;"> March 31, 2024 </em>the Company had no uncertain tax positions.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Stock-based Compensation</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Employee share-based compensation is measured at the grant date, based on the fair value of the award, and is recognized as an expense over the requisite service period.&#160;For awards with a performance condition, compensation expense is recognized over the requisite service period if it is probable that the performance condition will be satisfied. For awards to non-employees, the Company recognizes compensation expense in the same manner as if the Company had paid cash for the goods or services. The Company estimates the fair value of options and equity classified warrants granted using an options pricing model. Expense is recognized within general and administrative and research and development expenses and forfeitures are recognized as they are incurred.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Warrants</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s specific terms and applicable authoritative guidance in FASB ASC <em style="font: inherit;">480,</em> Distinguishing Liabilities from Equity (&#8220;ASC <em style="font: inherit;">480&#8221;</em>) and ASC <em style="font: inherit;">815,</em> Derivatives and Hedging (&#8220;ASC <em style="font: inherit;">815&#8221;</em>). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC <em style="font: inherit;">480,</em> meet the definition of a liability pursuant to ASC <em style="font: inherit;">480,</em> and whether the warrants meet all of the requirements for equity classification under ASC <em style="font: inherit;">815,</em> including whether the warrants are indexed to the Company&#8217;s own ordinary shares and whether the warrant holders could potentially require &#8220;net cash settlement&#8221; in a circumstance outside of the Company&#8217;s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
      <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do <em style="font: inherit;">not</em> meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss on the&#160;statements of operations. The fair value of the warrants is estimated using a Black-Scholes pricing model or a Monte Carlo simulation.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company&#65279; issued warrants to purchase shares of common stock (i) in connection with the Bridge Offering, (ii) as part of selling agent compensation in <em style="font: inherit;">2024,</em> (iii) in connection with the Exclusive License Termination Agreement (the &#8220;Termination Agreement&#8221;), and (iv) as part of the Offering&#65279;. Based on the guidance noted above, we determined that warrants issued in connection with the Termination Agreement should be accounted for as a liability and the remaining warrants issued meet the requirements for equity classification. Liability classified warrants are subject to remeasurement at each balance sheet date, while equity classified warrants are valued at inception only. As discussed in Note <em style="font: inherit;">2,</em> the liability warrants subsequently met the requirements for equity classification.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Loss Per Common Share</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Basic loss per common share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period, which includes shares issuable for little to <em style="font: inherit;">no</em> consideration upon the exercise of certain equity-classified warrants. Diluted loss per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. In periods when losses are reported, the weighted-average number of common shares outstanding excludes common stock equivalents, because their inclusion would be anti-dilutive. Generally, the Company&#8217;s outstanding warrants are non-participating securities as they are <em style="font: inherit;">not</em> entitled to non-forfeitable rights to dividends or dividend equivalents during the vesting term and have <em style="font: inherit;">no</em> obligation to fund losses.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">However, the Company's warrants d&#65279;escribed in Note&#160;<em style="font: inherit;">2</em>&#160;and the warrants issued in connection with the Offering, are participating securities as the holders receive the right to dividends, but they are <em style="font: inherit;">not</em> obligated to fund losses. In periods of loss, since <em style="font: inherit;">no</em> income is allocated to these securities, the Company's use of the "treasury stock method" derives the same result. The dilutive effect of convertible securities is calculated using the &#8220;if-converted method.&#8221; Under the if-converted method, securities are assumed to be converted at the beginning of the period, and the resulting common shares are included in the denominator of the diluted calculation for the entire period being presented.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
      <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">For the <em style="font: inherit;">twelve</em> months ended <em style="font: inherit;"> March 31, 2025&#160;</em>and <em style="font: inherit;">2024,</em> dilutive securities that were <em style="font: inherit;">not</em> included in the calculations of the loss per common share because they would be anti-dilutive included the following:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 5%; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>March 31,</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(as revised)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Equity based warrants to purchase common shares</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">87,531</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,334</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Convertible Notes - common shares (1)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">33,250</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Convertible Notes - equity-based warrants to purchase common shares</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">25,003</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">25,003</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock options granted under Company's incentive plan</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">243,483</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">100,180</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Series A Warrants</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,533,096</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Representative Warrants</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">91,985</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total potentially dilutive securities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,981,098</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">162,767</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
    <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 108pt;">(<em style="font: inherit;">1</em>) Shares for the convertible note proceeds received</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Research and Development Costs</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Research and development costs are expensed as incurred.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Advertising</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">It is our policy to expense advertising costs as incurred. Advertising&#160;expenses are included within general and administrative expenses within the statement of operations. For the years ended <em style="font: inherit;"> March 31, 2025 </em>and <em style="font: inherit;">2024,</em> the Company recorded less than $0.1&#160;million and $1.8&#160;million, respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Fair Value of Common Stock</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Prior to establishing a public market for the Company&#8217;s common stock, the estimated fair value of the Company&#8217;s common stock was determined by the Company&#8217;s Board of Directors (the "Board") as of the date of each option grant, with input from management, considering the Company&#8217;s most recently available <em style="font: inherit;">third</em>-party valuations of common stock, recent sales of common stock to <em style="font: inherit;">third</em> parties, and the Company&#8217;s board of directors&#8217; assessment of additional objective and subjective factors that it believed were relevant and which <em style="font: inherit;"> may </em>have changed from the date of the most recent valuation through the date of the grant.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>JOBS Act Accounting Election</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company qualifies as an emerging growth company ("EGC"), as defined in the Jumpstart Our Business Startups Act of <em style="font: inherit;">2012</em> (the &#8220;JOBS Act&#8221;). The JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected <em style="font: inherit;">not</em> to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This <em style="font: inherit;"> may </em>make comparison of the Company&#8217;s financial statements with another public company which is neither an early-stage company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Segments</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker ("CODM"), or decision-making group, in deciding how to allocate resources in assessing performance. Management has determined that the Company operates in&#160;<span style="-sec-ix-hidden:c134564434">one</span>&#160;reportable segment, which is advancing the development of innovative technologies for sensing and treating disorders relating to the nervous system. The Company is initially focused on developing the technology for patients with pancreatic cancer, however, the Company believes the technology constitutes a platform with the potential to address several indications, including chronic pain management, hypertension, cardiovascular disease and a wide range of other nerve-related disorders. The Company's CODM is its Chief Executive Officer.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
      <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The accounting policies of the segment are the same as those described in the summary of significant accounting policies. The CODM assesses performance based on net loss, which is reported on the Statements of Operations. The measure of segment assets is reported on the balance sheet as total assets.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">To date, the Company has <em style="font: inherit;">not</em> generated any product revenue. The Company expects to continue to incur significant expenses and operating losses for the foreseeable future as it advances its' technology through all stages of development and clinical trials and, ultimately, seek regulatory approval.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">As such, the CODM primarily evaluates performance of the Company using various financial metrics, including the combined net income (loss) from operations, also shown on the Statements of Operations, forecasted cash expenditures and existing and forecasted cash balances. These financial metrics are used by the CODM to make key operating decisions, such as the assessment of segment performance and allocation of resources. The significant expense categories within net loss from operations that the CODM regularly reviews are expenses related to research and development, general and administrative, and depreciation and amortization. The significant expense categories and subcategories are reported on the Statements of Operations.&#160;Other expenses included in the Company&#8217;s net loss include change in fair value of warrant liabilities, other income (expense), interest income, net, and any additional non-operating expenses that are reported on the Statements of Operations.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Recent Accounting Pronouncements</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">In&#160;<em style="font: inherit;"> November 2024 </em>and <em style="font: inherit;"> January 2025,&#160;</em>FASB issued ASU&#160;<em style="font: inherit;">2024</em>-<em style="font: inherit;">03</em> and ASU <em style="font: inherit;">2025</em>-<em style="font: inherit;">01,</em>&#160;Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic&#160;<em style="font: inherit;">220</em>-<em style="font: inherit;">40</em>): Disaggregation of Income Statement Expenses, which requires disclosure in the notes to the financial statements of specified information about certain costs and expenses. The amendments to the standards are effective for fiscal years beginning after&#160;<em style="font: inherit;"> December 15, 2026,&#160;</em>and for interim periods within fiscal years beginning after&#160;<em style="font: inherit;"> December 15, 2027.&#160;</em>Early adoption is permitted. The amendments should be applied either prospectively to financial statements issued for reporting periods after the effective date of this ASU or retrospectively to any or all prior periods presented in the financial statements. The Company is currently evaluating the new guidance to determine the impact it&#160;<em style="font: inherit;"> may&#160;</em>have on its financial statements and related disclosures.&#160;</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">In <em style="font: inherit;"> December 2023, </em>the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update, or ASU <em style="font: inherit;">2023</em>-<em style="font: inherit;">09,</em> Income Taxes (Topic <em style="font: inherit;">740</em>): Improvements to Income Tax Disclosures. ASU <em style="font: inherit;">2023</em>-<em style="font: inherit;">09</em>&#160;improves the transparency of income tax disclosures by requiring consistent categories and greater disaggregation of information in the effective tax rate reconciliation and income taxes paid disaggregated by jurisdiction. It also includes certain other amendments to improve the effectiveness of income tax disclosures. This guidance will be effective for the annual periods beginning after the year ended <em style="font: inherit;"> December 31, 2024. </em>The Company is currently assessing the impact of ASU <em style="font: inherit;">2023</em>-<em style="font: inherit;">09</em> on its disclosures.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">In <em style="font: inherit;"> November 2023, </em>the FASB issued ASU <em style="font: inherit;">No.</em> <em style="font: inherit;">2023</em>-<em style="font: inherit;">07,</em> Improvements to Reportable Segment Disclosures (ASU <em style="font: inherit;">2023</em>-<em style="font: inherit;">07</em>) which is intended to improve reportable segment disclosures primarily through enhanced disclosure of reportable segment expenses and requires that a public entity that has a single reportable segment provide all the disclosures required by ASU <em style="font: inherit;">2023</em>-<em style="font: inherit;">07</em> and all existing segment disclosures in Topic <em style="font: inherit;">280.</em> The new guidance is required to be applied retrospectively to all prior periods presented in the financial statements and is effective for the Company for fiscal periods beginning after <em style="font: inherit;"> December 15, 2023 </em>and interim periods within fiscal years beginning after <em style="font: inherit;"> December 15, 2024. </em>The Company adopted ASU <em style="font: inherit;">2023</em>-<em style="font: inherit;">07</em> during the year ended <em style="font: inherit;"> March 31, 2025. </em>There was <em style="font: inherit;">no</em> impact upon adoption of ASU <em style="font: inherit;">2023</em>-<em style="font: inherit;">07.</em>&#160;The Company views its operations and manages its business in&#160;<span style="-sec-ix-hidden:c134564463">one</span>&#160;operating segment.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">There are <em style="font: inherit;">no</em> other effective pronouncements, or pronouncements issued but <em style="font: inherit;">not</em> yet effective, if adopted, that would have a material effect on the accompanying financial statements.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Correction of an Immaterial Error in the Prior Period Financial Statements</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">D&#65279;uring the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> December 31, 2024, </em>the Company determined that previously filed quarterly and annual financial statements had an immaterial earnings per share error resulting from the exclusion of certain unexercised equity based warrants to purchase common shares that had an exercise price of approximately $0.01 or less from the basic earnings per share calculations in accordance with <i>ASC <em style="font: inherit;">260</em>-<em style="font: inherit;">10</em>-<em style="font: inherit;">45</em>-<em style="font: inherit;">13</em></i>. As a&#160;result, the prior year earnings per share calculations have been revised for consistency with the current year presentation. The Company assessed the materiality of this change in presentation on prior period financial statements in accordance with <i>SEC Staff Accounting Bulletin <em style="font: inherit;">No.</em> <em style="font: inherit;">99</em></i>, &#8220;<i>Materiality</i>,&#8221; (<i>ASC Topic <em style="font: inherit;">250,</em> Accounting Changes and Error Corrections</i>). Based on this assessment, the Company concluded that this error correction in its&#160;<i>Statements of Operations</i>&#160;and <i>Note <em style="font: inherit;">1</em> </i>&#8211;<i> Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies (Loss Per Common Share)</i> is <em style="font: inherit;">not</em> material to any previously presented financial statements based upon overall considerations of both quantitative and qualitative factors. The corrections had <em style="font: inherit;">no</em> impact in the comparative period Balance Sheet,&#160;Statements of Cash Flows, or Statement of Changes in Stockholders&#8217;&#160;Equity. Further, the immaterial correction did <em style="font: inherit;">not</em> result in a change in operating losses or net loss in the Statement of Operations and the effects of including unexercised warrants in the earnings per share calculation have an antidilutive effect reducing the net loss per share amount. Accordingly, the Company corrected the previously reported earnings per share calculation for the <em style="font: inherit;">twelve</em> months ended <em style="font: inherit;"> March 31, 2024 </em>in this Annual Report on Form <em style="font: inherit;">10</em>-K.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
      <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">A summary of the impact of the Company&#8217;s Reverse Stock Split and immaterial corrections reflecting the prior period impact to the Company&#8217;s Statement of Operations and earnings per share are shown below:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Twelve Months Ended March 31, 2024</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Originally</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Filed</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Adjusted </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>for 1-for-20 </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Reverse </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Stock Split</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Correction</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>As Revised</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net Loss (in thousands)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(15,426</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(15,426</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Loss per share - basic and diluted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(1.05</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(21.09</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6.27</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(14.82</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Weighted average shares outstanding - basic and diluted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">14,626,282</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">731,372</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">309,348</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,040,720</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
    <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">A summary of the impact of the Company&#8217;s Reverse Stock Split and immaterial corrections reflecting the prior period impact to the disclosure of dilutive securities that were <em style="font: inherit;">not</em> included in the calculations of the loss per common share because they would be anti-dilutive are shown below:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

     <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Twelve Months Ended March 31, 2024</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Originally </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Filed</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Adjusted f</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>or 1-for-20 </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Reverse </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Stock Split</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Correction</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>As Revised</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Equity based warrants to purchase common shares</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,744,569</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">287,231</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(282,897</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,334</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Convertible Notes - common shares</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">665,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">33,250</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">33,250</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Convertible Notes - equity-based warrants to purchase common shares</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">500,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">25,003</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">25,003</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock options granted under Company's incentive plan</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,003,600</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">100,180</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">100,180</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Total potentially dilutive securities</b></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"><b>&#160;</b></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>8,913,169</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"><b>&#160;</b></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>445,664</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"><b>&#160;</b></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>(282,897</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"><b>)</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"><b>&#160;</b></td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>162,767</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
     <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>


  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Warrant Liability and Fair Value of Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Disclosures [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Note <em style="font: inherit;">2</em> </b>&#8211;<b> Warrant Liability and Fair Value of Financial Instruments</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Financial assets and financial liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. While the Company believes that its valuation methods are appropriate, the Company recognizes that the use of different methodologies or assumptions to determine the fair value could result in a different estimate of fair value at the reporting date. The primary assumptions that would significantly affect the fair values are the probability weighting of the different settlement outcomes used.&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">There were no outstanding instruments classified as Level <em style="font: inherit;">3</em> measurements as of <em style="font: inherit;"> March 31, 2025 </em>or &#160;<em style="font: inherit;"> March 31, 2024.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">There were <em style="font: inherit;">not</em> any transfers into or out of Level <em style="font: inherit;">3</em> as of <em style="font: inherit;"> March 31, 2025 </em>and <em style="font: inherit;"> March 31, 2024.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The following table summarizes the activity of the Level <em style="font: inherit;">3</em> fair value measurements during the <em style="font: inherit;">twelve</em> months ended <em style="font: inherit;"> March 31, 2024&#160;(</em>in thousands):</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 5%; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Warrant</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Liabilities</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 84%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance as of March 31, 2023</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Additions</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,556</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Change in fair value measurements - warrants mark-to-market</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,444</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Settlement and reclassification to equity</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(8,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance as of March 31, 2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company recognized the initial warrant expense as a component of operating expenses on the statement of operations under <i>warrant expense </i>&#8211;<i> termination agreement</i> for $4.6 million and the changes in the fair value under <i>warrant liability </i>&#8211;<i> mark-to-market </i>for $3.4&#160;million. There were <em style="font: inherit;">no</em> changes to the valuation approaches or techniques used for Level <em style="font: inherit;">3</em> measurements.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Warrant Liabilities</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">As more fully detailed in <i>Note <em style="font: inherit;">6</em> </i>&#8211;<i> Related Party Transactions</i>, on <em style="font: inherit;"> July 7, 2023, </em>the Company entered into an Exclusive License Termination Agreement (the &#8220;Termination Agreement&#8221;) with a licensee in exchange for the issuance, upon the closing of the Company&#8217;s IPO within <em style="font: inherit;">one</em> year of the agreement&#8217;s execution, of a warrant (the "Warrant") to purchase shares of the Company for a variable number of shares.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The fair value of the warrant liability has been estimated using a discounted cash flow model under various scenarios and used the probability-weighted expected return method (&#8220;PWERM&#8221;) comparing the probabilities of different outcomes. The outcomes considered included (i) the closing of a qualified financing as part of the Company&#8217;s IPO at various points in time and (ii) the possibility of default whereby the licensee receives nothing. Key assumptions for the model were as follows for the initial measurement:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 83%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Discount rate at issuance (1)</p> </td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="-sec-ix-hidden:c134565294">20.00</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 83%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Probability (2)</p> </td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="-sec-ix-hidden:c134565295">&#160;70%</span></td><td style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">-</td><td style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;"><span style="-sec-ix-hidden:c134565296">10%</span></td><td style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">-</td><td style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="-sec-ix-hidden:c134565297">20</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 83%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Payment (3)</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 3%;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 3%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 3%; text-align: center;"><span style="-sec-ix-hidden:c134565299">$0</span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 3%; text-align: center;">-</td><td colspan="1" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 4%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><span style="-sec-ix-hidden:c134565300">&#160;$8,000,000</span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 83%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected term (in years)</p> </td><td style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;"><span style="-sec-ix-hidden:c134565302">0.48</span></td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">-</td><td style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="-sec-ix-hidden:c134565303">0.98</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">(<em style="font: inherit;">1</em>)</p> </td><td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">The initial discount rate was chosen based on private equity rates of return as described in the AICPA Practice Aid on Valuation of Privately-Held-Company Equity securities issued as compensation. For the recurring fair value measurement, the Company updated the discount rate based upon yield curves estimated to be similar in credit quality to the Company;</p> </td></tr>
<tr style="vertical-align: top;"><td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">(<em style="font: inherit;">2</em>)</p> </td><td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Scenario probability as of issuance was based on timing expectations of management that a qualified offering occurring as of <em style="font: inherit;"> December 31, 2023 </em>was estimated at 70%, respectively; a qualified offering occurring as of <em style="font: inherit;"> June 30, 2024 </em>was estimated at <span style="-sec-ix-hidden:c134564500">10%;</span> and <em style="font: inherit;">no</em> qualified offering occurring was estimated at <span style="-sec-ix-hidden:c134564502">20%;</span></p> </td></tr>
<tr style="vertical-align: top;"><td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">(<em style="font: inherit;">3</em>)</p> </td><td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">The warrant has a $0.02&#160;strike price, however, the strike price is low relative to the stock price, making the warrant value close to the value of a stock unit. The agreement has a fixed payment value of $8.0 million, see Note <em style="font: inherit;">6</em> &#8211;&#160;Related Party Transactions.</p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> January 29, 2024, </em>the Company issued 80,000 warrant shares pursuant to the Termination Agreement.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The completion of the Company&#8217;s IPO fixed the number of warrant shares issuable and the Company re-classified the Warrant to additional-paid in capital as it met the requirements for equity classification. Upon reclassification, the Company valued the warrant at $8.0 million, which represented the fair value of the shares issued on that date.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>


  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Convertible Notes Payable<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Note <em style="font: inherit;">2</em></b>&#160;&#8211;<b> Convertible Notes Payable</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> September 9, 2023, </em>the Company's Board authorized an offering of up to $2.0 million in unsecured, non-interest bearing convertible promissory notes (the &#8220;Notes&#8221;) and accompanying warrants (the &#8220;Bridge Financing Warrants&#8221;) (collectively, the &#8220;Bridge Offering&#8221;) that mature on <em style="font: inherit;"> December 31, 2025. </em>The Notes provided that, on the closing date of the IPO, the outstanding principal would be automatically converted into common stock at the conversion price of $40.00. Each dollar in principal amount of Notes purchased were accompanied by a <span style="-sec-ix-hidden:c134564938">five</span>-year Bridge Financing Warrant to purchase approximately 0.0125 shares of Common stock with an exercise price of $20.00 per share. The Company records the Bridge Financing Warrants as a discount to the Notes.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Bridge Financing Warrants can be exercised from the date of Notes issuance through the <em style="font: inherit;">five</em>-year anniversary of the issuance of the Notes. The Note holders are <em style="font: inherit;">not</em> permitted to convert their Notes when the holders or any of their affiliates would beneficially own in excess of 4.99% of the Company&#8217;s common stock after such conversion.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company received proceeds of $2.0 million of Notes from the Bridge Offering. The Company&#8217;s effective interest rate for the Notes was 15.3% due to the amortization of the discount stemming from the issuance of the Bridge Financing Warrants. On <em style="font: inherit;"> January 26, 2024, </em>the Company consummated its initial public offering (&#8220;IPO&#8221;). In connection with the closing of the IPO, a portion of the Notes were converted into 16,750 shares of common stock. Upon the closing of the IPO, certain Notes that were to be automatically converted according to their terms into &#65279;common stock were <em style="font: inherit;">not</em> converted due to restrictions on the holders of the Notes or any of their affiliates beneficially owning in excess of 4.99% of the Company's common stock after such conversion. The remaining portion of the N&#65279;otes was converted into 33,250 shares of common stock on <em style="font: inherit;"> March 28, 2025.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Warrants - Convertible Promissory Notes</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">During <em style="font: inherit;"> September </em>to <em style="font: inherit;"> December 2023, </em>the Company issued the Notes with the detachable Bridge Financing Warrants. The Company utilized a Monte Carlo simulation model to determine the fair value of each Bridge Offering Warrant. The key inputs to the Monte Carlo simulation used to determine the fair value of each warrant include, the Company&#8217;s stock price fair value which was determined through a back solve calculation such that the stock price results in the average total value of the Notes and the Bridge Offering Warrants being equal to the cash proceeds received, volatility based on a selection of publicly held peer companies of 101.88%, expected term of 5 years, risk free rate of 4.40%, discount rate of 20.00% and a discount for lack of marketability of 15.77%.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">During the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> June 30, 2025 </em>and <em style="font: inherit;">2024,</em> the Company recorded $0 and less than $0.1 million, respectively, in interest expense related to the amortization of the debt discount.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The following table presents a summary of activity for the warrants issued in connection with the Company&#8217;s Notes:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted-</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Average</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Exercise Price</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Warrants</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Per Share</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding and exercisable, March 31, 2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">25,003</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">20.00</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Exercised</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Forfeited/Cancelled</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Expired</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding, June 30, 2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">25,003</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">20.00</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Exercisable, June 30, 2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">25,003</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">20.00</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <span></span>
</td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b>Note <em style="font: inherit;">3</em> </b>&#8211;<b> Convertible Notes Payable</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> September 9, 2023, </em>the Company's Board authorized an offering up to $2.0 million in unsecured, non-interest bearing convertible promissory notes (the &#8220;Notes&#8221;) and accompanying warrants (the &#8220;Bridge Financing Warrants&#8221;) (collectively, the &#8220;Bridge Offering&#8221;) that will mature on <em style="font: inherit;"> December 31, 2025. </em>The Notes provided that, on the closing date of the IPO, the outstanding principal would be&#160;automatically converted into common stock at the conversion price of $40.00. Each dollar in principal amount of Notes purchased were&#160;accompanied by a <span style="-sec-ix-hidden:c134564513">five</span>-year Bridge Financing Warrant to purchase 0.0125 shares of Common stock with an exercise price of $20.00 per share. The Company records the Bridge Financing Warrants as a discount to the Notes.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Bridge Financing Warrants can be exercised from the date of Notes issuance through the <em style="font: inherit;">five</em>-year anniversary of the issuance of the Notes. The shares issuable pursuant to the Notes and Bridge Financing Warrants had a 180-day lock-up after the Company&#8217;s IPO. Thereafter, the foregoing lock-up agreement ceased to apply to 25% of the purchased shares each month for a period of <em style="font: inherit;">four</em> months. The Note holders were <em style="font: inherit;">not</em> permitted to convert their Notes when the holders or any of their affiliates would beneficially own in excess of 4.99% of the Company&#8217;s common stock after such conversion.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">As of <em style="font: inherit;"> March 31, 2024, </em>the Company received proceeds of $2.0 million of Notes executed from the Bridge Offering.&#160;Upon the closing of the IPO, certain notes were to be automatically converted according to their terms into the Company&#8217;s common stock to the extent and provided that certain holders of these notes are <em style="font: inherit;">not</em> permitted to convert such notes to the extent that the holders or any of its affiliates would beneficially own in excess of 4.99% of the Company&#8217;s common stock after such conversion. Due to this 4.99% limitation, principal representing $1.3 million, or 33,250 shares, of these notes remained outstanding.&#160;As discussed in Note <em style="font: inherit;">1,</em> the remaining notes converted into common stock in accordance with their original terms on the IPO. During the year ended <em style="font: inherit;"> March 31, 2025, </em>the remaining Notes were converted into 33,250 shares.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company&#8217;s effective interest rate for the Notes was 15.3% due to the amortization of the discount stemming from the issuance of the Bridge Financing Warrants.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The following table presents a summary of activity for the Company&#8217;s <em style="font: inherit;">zero</em>-coupon convertible notes payable (in thousands):</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 5%; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Principal Amount</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Amortized Debt</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Discount</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Net Carrying</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Amount</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding, March 31, 2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,330</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(328</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,002</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Amortization of debt discount</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">175</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">175</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Issuance of common stock for extinguishment of convertible debt</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,330</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">153</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,177</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding, March 31, 2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Warrants</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company issued the Notes with detachable warrants for the purchase of shares of the Company&#8217;s common stock. The Company utilized a Monte Carlo simulation model to determine the fair value of each Bridge Offering Warrant. During the year ended <em style="font: inherit;"> March 31, 2024, </em>the Company issued warrants valued at $0.6 million. The key inputs to the Monte Carlo simulation used to determine the fair value of each warrant include, the Company&#8217;s stock price fair value which was determined through a back solve calculation such that the stock price results in the average total value of the Notes and the Bridge Offering Warrants being equal to the cash proceeds received, volatility based on a selection of publicly held peer companies of 101.88%, expected term of 5 years, risk free rate of 4.40%, discount rate of 20.00% and a discount for lack of marketability of 15.77%.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">During the year ended <em style="font: inherit;"> March 31, 2025, </em>the Company recorded less than $0.2 million in interest expense related to the amortization of the debt discount.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The following table presents a summary of activity for the warrants issued in connection with the Company&#8217;s Notes:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 0pt; margin-right: 0pt;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Warrants</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted-</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Average </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Exercise </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Price Per </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Share</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Remaining </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Life (In </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Years)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Aggregate </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Intrinsic </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Value*</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 48%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding and exercisable, March 31, 2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">25,003</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">20.00</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.48</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,010,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Exercised</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Forfeited/Cancelled</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Expired</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding, March 31, 2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">25,003</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">20.00</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3.48</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Exercisable, March 31, 2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">25,003</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">20.00</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3.48</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">*Aggregate Intrinsic Value = Excess of market value over the exercise price of all in-the-money warrants.&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Equity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Equity [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Note <em style="font: inherit;">3</em></b>&#160;&#8211;<b> Equity</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> November 29, 2023, </em>the Company&#8217;s Board and applicable shareholders approved to amend and restate the Company&#8217;s certificate of incorporation and increased the authorized shares to 500,000,000 shares of common stock and 10,000,000 shares of preferred stock, each with a par value of $0.001 per share. The specific rights of the preferred stock shall be determined by the Board.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;text-indent:9pt;"><i>Preferred Stock </i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;text-indent:9pt;">As of <em style="font: inherit;"> June 30, 2025, </em>the Company had no shares of preferred stock outstanding.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Restricted Stock</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> February 15, 2024, </em>the Company issued&#160;1,750 restricted shares of common stock to the Company's marketing consultant at the closing price of $76.00 of the Company's common stock. The total value of these shares is $133,000. These shares vested monthly over a 12-month period beginning on the issue&#160;date.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Three Months Ended June 30,</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Recognized in general and administrative expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">33,250</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">33,250</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">As of <em style="font: inherit;"> June 30, 2025, </em>there was $0 of unrecognized stock-based compensation expense related to Restricted Stock.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Common Stock </i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> February 28, 2025, </em>the Company entered into an ATM Agreement. Pursuant to the terms of the Agreement, the Company was permitted to sell from time to time shares of Company&#8217;s common stock, with an initial aggregate sales price of up to $2.1 million. As of <em style="font: inherit;"> June 30, 2025, </em>the Company sold 1,304,260 shares pursuant to the ATM Agreement for net proceeds of approximately $2.1 million.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Stock Plan and Stock Options</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">In <em style="font: inherit;"> June 2023, </em>the Company adopted, and the Company&#8217;s shareholders approved, the Autonomix Medical, Inc. <em style="font: inherit;">2023</em> Stock Plan (the &#8220;Plan&#8221;). The Plan is a stock-based compensation plan that provides for discretionary grants of stock options, stock awards and stock unit awards to key employees, non-employee directors, and consultants, subject to certain individual threshold limitations. The Plan initially provided for up to 200,000 shares to be issued, subject to adjustments as provided in the Plan. Shares that are surrendered because of forfeiture, expiration, termination, or cancellation are available for re-issuance.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">In <em style="font: inherit;"> August 2023, </em>the Plan was amended to allow for an automatic increase of the available shares for issuance, whereby on the <em style="font: inherit;">1st</em> of each fiscal year, beginning on <em style="font: inherit;"> April 1, 2024 </em>and ending on (and including) <em style="font: inherit;"> April 1, 2033 </em>in an amount equal to <em style="font: inherit;">five</em> percent (5%) of the total number of shares of Common Stock outstanding on the <em style="font: inherit;"> March </em><em style="font: inherit;">31st</em> immediately preceding the applicable date. However, the Board <em style="font: inherit;"> may </em>act prior to the automatic increase of a given year to provide that there will be <em style="font: inherit;">no</em> increase for such year, or that the increase for such year will be a lesser number of shares of Common Stock. On <em style="font: inherit;"> April 1, 2025, </em>the Plan was increased by 124,852 shares.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The following table summarizes the stock option activity for the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> June 30, 2025:</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted-</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Average</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Exercise Price</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Options</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Per Share</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding, March 31, 2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">243,483</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">32.72</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.85</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Exercised</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Forfeited/Cancelled</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Expired</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding, June 30, 2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">248,483</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">32.10</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Exercisable, June 30, 2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">69,916</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">37.24</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company&#8217;s stock option awards did <em style="font: inherit;">not</em> automatically adjust for the Reverse Stock Split.&#160;However, the Company chose to exercise its rights under the Plan to adjust the exercise price and number of shares exercisable or issuable upon vesting proportionately for the Reverse Stock Split.&#160;Based on the analysis performed, the Company does <em style="font: inherit;">not</em> need to recognize any additional compensation expense as a result of the modification.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">During the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> June 30, 2025, </em>the Company granted&#160;options to purchase 5,000 shares of common stock with a contractual term that vests&#65279; annually over <span style="-sec-ix-hidden:c134564987">four</span> years on the anniversary date. The options had an aggregate grant date fair value of $9 thousand that was calculated using the Black-Scholes option pricing model. Variables used in the Black-Scholes option pricing model included the following: (<em style="font: inherit;">1</em>) fair value of common stock on the measurement date; (<em style="font: inherit;">2</em>) discount rate ranging of 4.06% based on the daily yield curve rates for U.S. Treasury obligations, (<em style="font: inherit;">3</em>) expected life of 6.25 years based on the simplified method (vesting plus contractual term divided by <em style="font: inherit;">two</em>) and (<em style="font: inherit;">4</em>) expected volatility of 139%&#160;based on the historical volatility of comparable companies' stock.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">All options issued and outstanding are being amortized over their respective vesting periods. The unrecognized compensation expense at <em style="font: inherit;"> June 30, 2025 </em>was $3.9 million. During the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> June 30, 2025, </em>the Company recorded stock-based compensation - option expense of $0.3 million in general and administrative expense and less than $0.1 million in research and development expense. During the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> June 30, 2024,&#160;</em>the Company recorded stock-based compensation - option expense of $0.3 million in general and administrative expense and less than $0.1 million in research and development expense
    <span style="text-decoration: line-through; ">
      .
    </span></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;text-indent:9pt;"><i>License Agreement</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> July 10, 2024, </em>the Company entered into a license agreement (the &#8220;Agreement&#8221;) with RF Innovations, Inc. (&#8220;RFI&#8221;), a privately held medical technology company, to license products utilizing RFI&#8217;s intellectual property related to its Apex <em style="font: inherit;">6</em> Radiofrequency Generator (the &#8220;Licensed Products&#8221;). The Apex <em style="font: inherit;">6</em> Generator is a United States Food and Drug Administration (&#8220;FDA&#8221;) cleared ablation technology designed to lesion neural tissue for pain management in the peripheral nervous system. Pursuant to the Agreement, RFI granted us a perpetual non-exclusive worldwide royalty free fully paid license related to the Licensed Products, provided that the license did <em style="font: inherit;">not</em> include the right to sell certain products to customers for the treatment of spine pain. In connection with the Agreement, the Company issued RFI 12,500 unregistered shares of its common stock as consideration for the license. The Company determined that the fair value of the shares granted was $0.1 million, which represented its stock price on the date of the Agreement less a 25.6% discount for lack of marketability (&#8220;DLOM&#8221;). The Company concluded a DLOM was appropriate as the shares were subject to an initial lock-up period of <em style="font: inherit;">six</em> months followed by restrictions that allow for a maximum of 10% of total shares to be sold within a <em style="font: inherit;">30</em>-day period.&#160;The DLOM effectively reflects the value of an average strike put option relative to the Company's stock price and was calculated based on the Finnerty average put model.&#160;The Company concluded that the licensed technology qualified as a research and development expense pursuant to ASC Topic <em style="font: inherit;">730,</em> <i>Research and Development</i>, as the Company does <em style="font: inherit;">not</em> have an alternative future use for the technology and the Company does <em style="font: inherit;">not</em> have a plan to otherwise monetize the Licensed Products.&#160;The Agreement provides RFI the right to terminate the license if we breach any representation, warranty or covenant contained in the Agreement, subject to any relevant cure periods, or if we are subject to a bankruptcy or insolvency event.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Offering Agreement </i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> November 22, 2024, </em>the Company entered into the Offering, which consisted of: (i) 458,691 Common Units, each Common Unit consisting of <span style="-sec-ix-hidden:c134565018">one</span> share of common stock and <span style="-sec-ix-hidden:c134565019">one</span> Series A Warrant to purchase <span style="-sec-ix-hidden:c134565020">one</span> share of common stock; and (ii) 917,596 Pre-Funded Units, each Pre-Funded Unit consisting of <span style="-sec-ix-hidden:c134565022">one</span> Pre-Funded Warrant to purchase <span style="-sec-ix-hidden:c134565023">one</span> share of common stock and <span style="-sec-ix-hidden:c134565024">one</span> Series A Warrant. The purchase price of each Common Unit was $6.540, and the purchase price of each Pre-Funded Unit was $6.539.&#160;In addition, the Company granted the Underwriters a 45-day option to purchase additional 206,422 shares of common stock, and/or additional 206,422 Series A Warrants, solely to cover over-allotments, if any. The Offering closed on <em style="font: inherit;"> November 25, 2024. </em>On <em style="font: inherit;"> November 22, 2024, </em>the Underwriters partially exercised their over-allotment option with respect to 156,809 shares of Common Stock and 156,809 Series A Warrants. The Company received gross proceeds of $10.0&#160;million, before deducting the Underwriter's fees and other offering expenses payable by the Company.&#160;Under the terms of the Underwriting Agreement, the Underwriters received an underwriting discount of 8.0% to the public offering price for the Units. The Company also issued to the representative of the Underwriters (the "Representative") Representative's Warrants to purchase up to 91,985 shares of common stock.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Pre-Funded Warrants have an exercise price of $0.001 per share, are immediately exercisable and <em style="font: inherit;"> may </em>be exercised at any time until all of the Pre-Funded Warrants are exercised in full, subject to a beneficial ownership limitation of 4.99%. The Series A Warrants have an exercise price of $6.540 per share and <em style="font: inherit;"> may </em>be exercised at any time until the <span style="-sec-ix-hidden:c134565038">five</span>-year anniversary of the date of issuance, subject to a beneficial ownership limitation of 4.99%. The Pre-Funded Warrants and Series A Warrants were issued pursuant a Warrant Agency Agreement between the Company and Equity Stock Transfer, LLC.&#160;The Series A Warrants and the Representative&#8217;s Warrants, largely have the same terms and conditions, except the Representative&#8217;s Warrants were <em style="font: inherit;">not</em> exercisable until <em style="font: inherit;"> May 21, 2025 </em>and are subject to a 180-day lock-up prior to being transferable.&#160;The Series A Warrants and Representative&#8217;s Warrants <em style="font: inherit;"> may, </em>at the option of the holder be settled upon a change of control at the Black-Scholes value, as defined in the agreement.&#160;Upon a change of control the holder <em style="font: inherit;"> may </em>receive cash, other assets or shares of the successor entity, depending on the specific nature of the change of control transaction and the settlement options afforded to the holders of common stock.&#160;The Company analyzed the Pre-Funded Warrants, the Series A Warrants, and the Representative&#8217;s Warrants (collectively the &#8220;Offering Warrants&#8221;) in accordance with ASC Topic <em style="font: inherit;">480,</em> Distinguishing Liabilities from Equity and ASC Topic <em style="font: inherit;">815,</em> Derivatives and Hedging.&#160;Management concluded that the Offering Warrants meet all the requirements for equity classification.&#160;Since the Offering Warrants meet the requirements for equity classification and the Offering represents an arms-length cash transaction, the Common Units and Pre-Funded Units will be recorded in equity based on the proceeds received, net of issuance costs.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">At issuance the Pre-Funded Warrants had a fair value of $6.3290 per share, which represented the common stock issuance price less the $0.001 exercise price.&#160;At issuance, the Series A Warrants and the Representative&#8217;s Warrants had&#160;a fair value of $5.3597 and $5.2125&#160;per share, respectively, which was determined using a Black-Scholes option pricing model.&#160;Variables used in the Black-Scholes option pricing model included the following: (<em style="font: inherit;">1</em>) fair value of common stock on the measurement date; (<em style="font: inherit;">2</em>) discount rate of 4.17% based on the daily yield curve rates for U.S. Treasury obligations, (<em style="font: inherit;">3</em>) the contractual term of the warrants and (<em style="font: inherit;">4</em>) expected volatility of 144.15% based on the historical volatility of comparable companies' stock. Due to the relative volume of Series A Warrants and Representative&#8217;s Warrants issued compared with the Company&#8217;s outstanding shares, the Company's stock price was adjusted for the effects of dilution.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">In connection with the Offering, the Company incurred total offering costs of $1.5 million.&#160;This was comprised of $1.0 million in cash offering costs and $0.5 million&#160;for the fair value of the Representative&#8217;s Warrant issued.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Equity-Based Stock Warrants</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company will periodically grant warrants to investors in connection with equity financing or to <em style="font: inherit;">third</em>-party service providers in exchange for services rendered. The following table summarizes the stock warrant activity for the&#160;<em style="font: inherit;">three</em> months ended <em style="font: inherit;"> June 30, 2025:</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted-</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Average</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Exercise Price</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Warrants</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Per Share</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding, March 31, 2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,934,874</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="-sec-ix-hidden:c134564291">5.8860</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Exercised</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(222,132</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.0010</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Forfeited/Cancelled</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(130</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.0010</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Expired</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding, June 30, 2025*</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,712,612</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6.6498</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Exercisable, June 30, 2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,712,612</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6.6498</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">*</p> </td><td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Amount includes 87,531 common warrants; 91,985 Representative's Warrants and 1,533,096 Series A Warrants.</p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The unrecognized compensation expense at <em style="font: inherit;"> June 30, 2025 </em>for warrants issued to <em style="font: inherit;">third</em>-party service providers was $0. During the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> June 30, 2025 </em>and <em style="font: inherit;">2024,</em> the Company recorded stock-based compensation - warrant expense of $0 and less than $0.1 million, respectively.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <span></span>
</td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Note <em style="font: inherit;">4</em> </b>&#8211;<b> Equity</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> November 29, 2023, </em>the Company&#8217;s Board of Directors and applicable shareholders approved to amend and restate the Company&#8217;s certificate of incorporation and increased the authorized shares to 500,000,000 shares of common stock, with a par value of <span style="-sec-ix-hidden:c134564542">$.001</span> per share, and 10,000,000 shares of preferred stock, with a par value of <span style="-sec-ix-hidden:c134564544">$.001</span> per share. The specific rights of the preferred stock shall be determined by the Board of Directors.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Preferred Stock </i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">As of <em style="font: inherit;"> March 31, 2025, </em>the Company had no shares of preferred stock outstanding.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Restricted Stock</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> February 15, 2024, </em>the Company issued&#160;1,750 restricted shares of common stock to the Company's marketing consultant at the closing price of $76.00 of the Company's common stock. The total value of these shares is $133,000. These shares vest monthly over a 12-month period beginning on the issue&#160;date.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Year ended March 31,</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Recognized in general and administrative expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">116,375</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">16,625</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">116,375</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">16,625</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">For the year ended <em style="font: inherit;"> March 31, 2025, </em>there was no unrecognized stock-based compensation expense related to unvested Restricted Stock.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">A summary of activity regarding Restricted Stock issued is as follows:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Grant Date</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Number of </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Shares</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Fair Value Per </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Share</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding, March 31, 2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,604</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">76.00</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Vested</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,604</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">76.00</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding, March 31, 2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Common Stock </i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> April 6, 2023, </em>the Board of Directors approved a private placement offering of up to 100,000 common shares at a price of $40.00 per share. During the year ended <em style="font: inherit;"> March 31, 2024, </em>the Company sold 71,000 shares for cash proceeds of $2,840,000. The Company did <span style="-sec-ix-hidden:c134564555">not</span> incur any costs that were direct and incremental to the private placement.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> September 9, 2023, </em>the Board approved a Bridge Offering. See Note <em style="font: inherit;">3</em> <i>Convertible Notes Payable</i> for additional detail as these notes are convertible into common stock.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> February 28, 2025, </em>the Company entered into an ATM Agreement. Pursuant to the terms of the Agreement, the Company <em style="font: inherit;"> may </em>sell from time to time, the Company&#8217;s Common Stock, par value $0.001 per share, with an initial aggregate sales price of up to $2.1 million. As of <em style="font: inherit;"> March 31, 2025, </em>the Company sold 800 shares pursuant to the ATM Agreement for net proceeds of approximately $1,746.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Stock Plan and Stock Options</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">In <em style="font: inherit;"> June 2023, </em>the Company adopted, and the Company&#8217;s shareholders approved, the Autonomix Medical, Inc. <em style="font: inherit;">2023</em> Stock Plan (the &#8220;Plan&#8221;). The Plan is a stock-based compensation plan that provides for discretionary grants of stock options, stock awards and stock unit awards to key employees, non-employee directors, and consultants, subject to certain individual threshold limitations. The Plan provides for up to 200,000 shares to be issued. Shares that are surrendered because of forfeiture, expiration, termination, or cancellation are available for re-issuance. As of <em style="font: inherit;"> March 31, 2025, </em>there were 75,633 shares remaining available in the Plan.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">In <em style="font: inherit;"> August 2023, </em>the Plan was amended to allow for an automatic increase of the available shares for issuance, whereby on the <em style="font: inherit;">1st</em> of each fiscal year, beginning on <em style="font: inherit;"> April 1, 2024 </em>and ending on (and including) <em style="font: inherit;"> April 1, 2033 </em>in an amount equal to <em style="font: inherit;">five</em> percent (5%) of the total number of shares of Common Stock outstanding on the <em style="font: inherit;"> March </em><em style="font: inherit;">31st</em> immediately preceding the applicable date. However, the Board <em style="font: inherit;"> may </em>act prior to the automatic increase of a given year to provide that there will be <em style="font: inherit;">no</em> increase for such year, or that the increase for such year will be a lesser number of shares of Common Stock. On <em style="font: inherit;"> April 1, 2024, </em>the Plan was increased by 47,116 shares and on <em style="font: inherit;"> April 1, 2025, </em>the Plan was increased by 124,852 shares.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The following table summarizes the stock option activity for the year ended <em style="font: inherit;"> March 31, 2025.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Options</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted-</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Average </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Exercise </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Price </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Per Share</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted-</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Average </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Remaining</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Life </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(In Years)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Aggregate </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Intrinsic </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Value*</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding, March 31, 2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">100,180</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">46.59</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">9.35</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,680,672</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">143,303</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">23.02</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Exercised</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Forfeited/Cancelled</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Expired</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding, March 31, 2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">243,483</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">32.72</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">8.92</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Exercisable, March 31, 2025*</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">37,923</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">44.35</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">8.20</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">*Aggregate Intrinsic Value = Excess of market value over the exercise price of all in-the-money stock.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">During the year ended <em style="font: inherit;"> March 31, 2025, </em>the Company granted certain&#160;individuals options to purchase 143,303 shares of common stock with contractual terms&#160;of <span style="-sec-ix-hidden:c134564574">ten</span> years, and vesting periods of annually over <span style="-sec-ix-hidden:c134564575">four</span> years. The options had an aggregate grant date fair value of $2.6&#160;million that was calculated using the Black-Scholes option pricing model. Variables used in the Black-Scholes option pricing model included the following: (<em style="font: inherit;">1</em>) fair value of common stock on the measurement date ranging from $1.99 and $56.20 per share; (<em style="font: inherit;">2</em>) discount rate ranging from 4.17% to 4.39% based on the daily yield curve rates for U.S. Treasury obligations, (<em style="font: inherit;">3</em>) expected life of 6.25 years based on the simplified method (vesting plus contractual term divided by <em style="font: inherit;">two</em>), and (<em style="font: inherit;">4</em>) expected volatility ranging from 110% to 138% based on the historical volatility of comparable companies' stock.&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">All options issued and outstanding are being amortized over their respective vesting periods. The unrecognized compensation expense at <em style="font: inherit;"> March 31, 2025 </em>was $4.3 million. During the year ended <em style="font: inherit;"> March 31, 2025, </em>the Company recorded stock-based compensation - option expense of $1.5 million, of which $1.3 million was recorded&#160;in general and administrative expenses and $0.2 million was recorded in research and development expenses in the statements of operations. The unrecognized compensation expense at <em style="font: inherit;"> March 31, 2024 </em>was $3.1 million. During the year ended <em style="font: inherit;"> March 31, 2024, </em>the Company recorded stock-based compensation - option expense of $0.6 million, of which $0.5 million was recorded&#160;in general and administrative expenses and $0.1 million was recorded in research and development expenses in the statements of operations.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>License Agreement</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> July 10, 2024, </em>we entered into a license agreement (the &#8220;Agreement&#8221;) with RF Innovations, Inc. (&#8220;RFI&#8221;), a privately held medical technology company, to license products utilizing RFI&#8217;s intellectual property related to its Apex <em style="font: inherit;">6</em> Radiofrequency Generator (the &#8220;Licensed Products&#8221;). The Apex <em style="font: inherit;">6</em> Generator is a United States Food and Drug Administration (&#8220;FDA&#8221;) cleared ablation technology designed to lesion neural tissue for pain management in the peripheral nervous system. Pursuant to the Agreement, RFI granted us a perpetual non-exclusive worldwide royalty free fully paid license related to the Licensed Products, provided that the license did <em style="font: inherit;">not</em> include the right to sell certain products to customers for the treatment of spine pain. In connection with the Agreement, we issued RFI 12,500 unregistered shares of our common stock as consideration for the license. The Company determined that the fair value of the shares granted was $0.1 million, which represented its stock price on the date of the Agreement less a 25.6% discount for lack of marketability (&#8220;DLOM&#8221;).&#160; The Company concluded a discount for lack of marketability was appropriate as the shares are subject to an initial lock-up period of <em style="font: inherit;">six</em>-months until they are eligible for registration pursuant to SEC Rule <em style="font: inherit;">144</em> followed by restrictions that allow for a maximum of 10% of total shares to be sold within a <em style="font: inherit;">30</em>-day period.&#160;The DLOM effectively reflects the value of an average strike put option relative to our stock price and was calculated based on the Finnerty average put model.&#160;The Company concluded that the licensed technology qualified as a research and development expense pursuant to ASC Topic <em style="font: inherit;">730,</em> Research and Development, as the Company does <em style="font: inherit;">not</em> have an alternative future use for the technology and the Company does <em style="font: inherit;">not</em> have a plan to otherwise monetize the Licensed Products.&#160;The Company recognized $0.1 million in Research and Development expense in its condensed statement of income for the <em style="font: inherit;">three</em> and <em style="font: inherit;">nine</em>-months ended <em style="font: inherit;"> December 31, 2024.&#160;</em>The Agreement provides RFI the right to terminate the license if we breach any representation, warranty or covenant contained in the Agreement, subject to any relevant cure periods, or if we are subject to a bankruptcy or insolvency event.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Offering Agreement </i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> November 22, 2024, </em>the Company entered into the Offering, which consisted of: (i) 458,691 Common Units, each Common Unit consisting of <span style="-sec-ix-hidden:c134564614">one</span> share of common stock, par value $0.001 per share, and <span style="-sec-ix-hidden:c134564616">one</span> Series A Warrant to purchase <span style="-sec-ix-hidden:c134564617">one</span> share of common stock; and (ii) 917,596 Pre-Funded Units, each Pre-Funded Unit consisting of <span style="-sec-ix-hidden:c134564619">one</span> Pre-Funded Warrant to purchase <span style="-sec-ix-hidden:c134564620">one</span> share of common stock and <span style="-sec-ix-hidden:c134564621">one</span> Series A Warrant. The purchase price of each Common Unit was $6.540, and the purchase price of each Pre-Funded Unit was $6.539.&#160;In addition, the Company granted the Underwriters a 45-day option to purchase additional 206,422 shares of common stock, and/or additional 206,422 Series A Warrants, solely to cover over-allotments, if any. The Offering closed on <em style="font: inherit;"> November 25, 2024. </em>On <em style="font: inherit;"> November 22, 2024, </em>the Underwriters partially exercised their over-allotment option with respect to 156,809 shares of Common Stock and 156,809 Series A Warrants. The Company received gross proceeds of $10.0&#160;million, before deducting the placement agent's fees and other offering expenses payable by the Company.&#160;Under the terms of the Underwriting Agreement, the Underwriters received an underwriting discount of 8.0% to the public offering price for the Units.&#160; The Company also issued to the Representative&#8217;s Warrants to purchase up to 91,985 shares of Common Stock.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Pre-Funded Warrants have an exercise price of $0.001 per share, are immediately exercisable and <em style="font: inherit;"> may </em>be exercised at any time until all of the Pre-Funded Warrants are exercised in full, subject to a beneficial ownership limitation of 4.99%. The Series A Warrants have an exercise price of $6.540 per share and <em style="font: inherit;"> may </em>be exercised at any time until the <span style="-sec-ix-hidden:c134564635">five</span>-year anniversary of the date of issuance, subject to a beneficial ownership limitation of 4.99%. The Pre-Funded Warrants and Series A Warrants were issued pursuant a Warrant Agency Agreement between the Company and Equity Stock Transfer, LLC.&#160;The Series A Warrants and the Representative&#8217;s Warrants, largely have the same terms and conditions, except the Representative&#8217;s Warrants were <em style="font: inherit;">not</em> exercisable until <em style="font: inherit;"> May 21, 2025 </em>and were subject to a 180-day lock-up prior to being transferable.&#160;The Series A Warrants and Representative&#8217;s Warrants <em style="font: inherit;"> may, </em>at the option of the holder be settled upon a change of control at the Black-Scholes value, as defined in the agreement.&#160;Upon a change of control the holder <em style="font: inherit;"> may </em>receive cash, other assets or shares of the successor entity, depending on the specific nature of the change of control transaction and the settlement options afforded to the holders of Common Stock.&#160;The Company analyzed the Pre-Funded Warrants, the Series A Warrants, and the Representative&#8217;s Warrants (collectively the &#8220;Offering Warrants&#8221;) in accordance with ASC Topic <em style="font: inherit;">480,</em> Distinguishing Liabilities from Equity and ASC Topic <em style="font: inherit;">815,</em> Derivatives and Hedging.&#160;Management concluded that the Offering Warrants meet all the requirements for equity classification.&#160;Since the Offering Warrants meet the requirements for equity classification and the Offering represents an arms-length cash transaction, the Common Units and Pre-Funded Units were recorded in equity based on the proceeds received, net of issuance costs.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">At issuance the Pre-Funded Warrants had a fair value of $6.3290 per share, which represented the common stock issuance price less the $0.001 exercise price.&#160;At issuance, the Series A Warrants and the Representative&#8217;s Warrants had&#160;a fair value of $5.3597 and $5.2125&#160;per share, respectively, which was determined using a Black-Scholes option pricing model.&#160;Variables used in the Black-Scholes option pricing model included the following: (<em style="font: inherit;">1</em>) fair value of common stock on the measurement date; (<em style="font: inherit;">2</em>) discount rate of 4.17% based on the daily yield curve rates for U.S. Treasury obligations, (<em style="font: inherit;">3</em>) the contractual term of the warrants and (<em style="font: inherit;">4</em>) expected volatility of 144.15% based on the historical volatility of comparable companies' stock. Due to the relative volume of Series A Warrants and Representative&#8217;s Warrants issued compared with the Company&#8217;s outstanding shares, the Company's stock price was adjusted for the effects of dilution.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">In connection with the Offering, the Company incurred total offering costs of $1.5 million.&#160;This was comprised of $1.0 million in cash offering costs and $0.5 million&#160;for the fair value of the Representative&#8217;s Warrant issued.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Equity-Based Stock Warrants</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> January 26, 2024, </em>the Company issued <span style="-sec-ix-hidden:c134564655">five</span>-year warrants to the selling agent in the Company's IPO to purchase 2,988 shares of common stock at an exercise price of $125.00. Under the fair value method, the fair value of these warrants was estimated on the grant date using the Black-Scholes option pricing model. Variables used in the Black-Scholes warrant pricing model included the following: (<em style="font: inherit;">1</em>) fair value of common stock on the measurement date of $100.00 split-adjusted per share; (<em style="font: inherit;">2</em>) discount rate of 4.04% based on the daily yield curve rates for U.S. Treasury obligations; (<em style="font: inherit;">3</em>) expected life of 5 years and (<em style="font: inherit;">4</em>) expected volatility of 104% based on the historical volatility of comparable companies' stock. The costs associated with these shares were reclassified to additional paid-in capital upon completion of the Company&#8217;s IPO on <em style="font: inherit;"> January 26, 2024.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company will periodically grant warrants to investors in connection with equity financing or to <em style="font: inherit;">third</em>-party service providers in exchange for services rendered. The following table summarizes the stock warrant activity for the year ended <em style="font: inherit;"> March 31, 2025:</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Warrants</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted-</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Average </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Exercise </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Price Per </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Share</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted-</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Average </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Remaining </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Life (In </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Years)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Aggregate </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Intrinsic </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Value*</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding and exercisable, March 31, 2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">287,231</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.64</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.80</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">17,072,147</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,542,677</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.31</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Exercised**</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(892,432</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.04</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Forfeited/Cancelled</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(2,602</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.20</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Expired</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding, March 31, 2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,934,874</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5.89</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4.09</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">532,060</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Exercisable, March 31, 2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,842,889</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5.67</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4.06</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">532,060</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">*Aggregate Intrinsic Value = Excess of market value over the exercise price of all in-the-money stock.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><span style="-sec-ix-hidden:c134564667">**197,098</span>&#160;exercised shares utilized the &#8220;cashless exercise&#8221; option and 695,334 exercised shares were paid in cash.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The unrecognized compensation expense at <em style="font: inherit;"> March 31, 2025 </em>was $0. During the year ended <em style="font: inherit;"> March 31, 2025, </em>the Company recorded stock-based compensation - warrant expense of less than $0.1 million. The unrecognized compensation expense at <em style="font: inherit;"> March 31, 2024 </em>was less than <span style="-sec-ix-hidden:c134564671">$0.1</span> million.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">During the year ended <em style="font: inherit;"> March 31, 2024, </em>the Company recorded stock-based compensation - warrant expense of less than $0.1 million.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Under the fair value method, the fair value of each warrant was estimated on the grant date using the Black-Scholes option pricing model. Variables used in the Black-Scholes warrant pricing model included the following:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 71%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="7" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 23%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Range</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 71%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2025</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 8%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2024</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td></tr>
<tr class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 71%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Fair value of common stock on the measurement date (per share)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8211;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">$2.00</td><td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">to</em></td><td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5.00</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 71%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Discount rate based on the daily yield curve rates for U.S. Treasury obligations</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8211;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;">4.04%</td><td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;"><em style="font: inherit;">to</em></td><td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.54%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 71%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected life (in years)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8211;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;">3</td><td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;"><em style="font: inherit;">to</em></td><td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 71%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected volatility based on the historical volatility of comparable companies' stock</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8211;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;">104%</td><td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;"><em style="font: inherit;">to</em></td><td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">119%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 5 - Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Note <em style="font: inherit;">4</em></b>&#160;&#8211;<b> Commitments and Contingencies</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Legal Proceedings</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">From time to time, the Company <em style="font: inherit;"> may </em>be involved in claims that arise during the ordinary course of business. Although the results of litigation and claims cannot be predicted with certainty, the Company does <span style="-sec-ix-hidden:c134565070">not</span> currently have any pending litigation to which it is a party or to which its property is subject that we believe to be material. There are <em style="font: inherit;">no</em> legal matters for which a reasonably estimated range of losses can be determined. Regardless of the outcome, litigation can be costly and time consuming, and it can divert management&#8217;s attention from important business matters and initiatives, negatively impacting our overall operations.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Employment Agreements</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company has agreements with key employees to provide certain benefits, including salary and other wage-related benefits, in the event of termination. In addition, the Company has adopted a severance policy for certain key members of executive management to provide certain benefits, including salary and other wage-related benefits, in the event of termination. In total, these benefits would amount to a range of $1.2&#160;million to $1.7 million using the rate of compensation in effect at <em style="font: inherit;"> June 30, 2025. </em>See Note <em style="font: inherit;">6</em> - Subsequent Events for additional information regarding events occurring after <em style="font: inherit;"> June 30, 2025.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Fractional Shares</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">See <i>Note <em style="font: inherit;">1</em> - Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies</i> - "<i>Reverse Stock Split</i>" for additional information.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> November 1, 2024, </em>the Company received notice from the Depository Trust and Clearing Corporation ("DTCC") on behalf of the brokerage firms that hold the shares of Company common stock held in &#8220;street name&#8221; that in connection with the rounding of fractional shares in connection with the Reverse Stock Split, the Company would need to issue 271,846 shares of common stock (the &#8220;Shares&#8221;) for the rounding of shares. The Company does <em style="font: inherit;">not</em> believe the number of Shares being requested is correct based on the historical number of shareholders of its common stock and is aware of similar anomalies in recent months for other companies completing a Reverse Stock Split. As such, the Company has begun an inquiry into the calculations set forth in the request. During the pendency of this inquiry, the Company does <em style="font: inherit;">not</em> intend to issue any shares in connection with the fractional shares being requested and has concluded that an obligation should <em style="font: inherit;">not</em> be recorded in its financial statements. The Company is <em style="font: inherit;">not</em> currently subject to any pending litigation as a result of the fractional roundup shares.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <span></span>
</td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Note <em style="font: inherit;">5</em> </b>&#8211;<b> Commitments and Contingencies</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Legal Proceedings</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">From time to time, we <em style="font: inherit;"> may </em>be involved in claims that arise during the ordinary course of business. Although the results of litigation and claims cannot be predicted with certainty, we do <span style="-sec-ix-hidden:c134564674">not</span> currently have any pending litigation to which we are a party or to which our property is subject that we believe to be material. Regardless of the outcome, litigation can be costly and time consuming, and it can divert management&#8217;s attention from important business matters and initiatives, negatively impacting our overall operations.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Employment Agreements</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company has agreements with key employees to provide certain benefits, including salary and other wage-related benefits, in the event of termination. In addition, the Company has adopted a severance policy for certain key members of executive management to provide certain benefits, including salary and other wage-related benefits, in the event of termination without cause. In total, these benefits would amount to a range of $1.1 million to $1.6 million&#160;using the rate of compensation in effect at <em style="font: inherit;"> March 31, 2025.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Brad Hauser - Chief Executive Officer</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> June 17, 2024, </em>we entered into an employment agreement with Brad Hauser pursuant to which Mr. Hauser agreed to serve as our chief executive officer and president for an initial <span style="-sec-ix-hidden:c134564678">three</span>-year period, which <em style="font: inherit;"> may </em>be extended on a year-to-year basis. Mr. Hauser&#8217;s agreement provides for an initial annual base salary of $450,000 (subject to an annual review and increase at the discretion of our Compensation Committee) and a target annual bonus of 60% of his base salary. Pursuant to the agreement, Mr. Hauser was granted a <span style="-sec-ix-hidden:c134564681">ten</span>-year option (the &#8220;Inducement Options&#8221;) to purchase 45,000 shares of common stock at an exercise price equal to the closing price of our common stock on the date of the employment agreement. The option vests in <em style="font: inherit;">four</em> equal annual installments (or 11,250 shares each installment) on each of the succeeding <em style="font: inherit;">four</em> anniversary dates of the execution of the employment agreement, provided Mr. Hauser is employed by us on each vesting date. In the event of a &#8220;change of control&#8221; or the termination of the agreement by us without &#8220;cause&#8221; or by Mr. Hauser for &#8220;good reason,&#8221; all of the unvested options shall immediately vest. The Inducement Options were granted outside of our <em style="font: inherit;">2023</em> Stock Plan as an inducement material to Mr. Hauser&#8217;s entering into employment with us in accordance with Nasdaq Stock Market Listing Rule <em style="font: inherit;">5635</em>(c)(<em style="font: inherit;">4</em>). Commencing with the year ending <em style="font: inherit;"> March 31, 2025, </em>Mr. Hauser will be eligible to receive annual option grants as determined by the Compensation Committee of the Board of Directors, based on criteria established by the Compensation Committee. The number of shares underlying the target annual option grant will be equal to $1,000,000 divided by the Black-Scholes value per share of our common stock on the date of grant.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">If Mr. Hauser&#8217;s employment is terminated at our election without &#8220;cause,&#8221; or by Mr. Hauser for &#8220;good reason,&#8221; Mr. Hauser shall be entitled to receive severance payments equal to <em style="font: inherit;">twelve</em> months of Mr. Hauser&#8217;s base salary and 100% of the target bonus for the year in which such termination occurs; provided that such amounts shall be increased by 50% if Mr. Hauser&#8217;s agreement is terminated without &#8220;cause&#8221; or by Mr. Hauser for &#8220;good reason&#8221; within <em style="font: inherit;">three</em> months prior to or <em style="font: inherit;">twelve</em> months after a &#8220;change of control.&#8221; In the event that any payments or benefits provided to Mr. Hauser would trigger the excise tax under Section <em style="font: inherit;">4999</em> of the Internal Revenue Code or any similar provision, the Company agreed to provide Mr. Hauser with a gross-up payment to ensure that, after payment of all taxes (including the excise tax, federal, state, and local income taxes, and employment taxes) imposed on the gross-up payment, Mr. Hauser receives a net amount equal to the payments or benefits Mr. Hauser would have received if the excise tax didn't apply.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Lori Bisson</i>&#160;-&#160;Executive <i>Vice Chairman (former Chief Executive Officer)</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> June 17, 2024, </em>we entered into an employment agreement with Lori Bisson pursuant to which Ms. Bisson agreed to serve as our Executive Vice Chairman and Strategic Adviser to the Chief Executive Officer for a <span style="-sec-ix-hidden:c134564696">two</span>-year period. Ms. Bisson&#8217;s agreement provides for an initial annual base salary of $150,000 (subject to an annual review and increase at the discretion of our Compensation Committee) and a target annual bonus of 50% of her base salary. Pursuant to the agreement, Ms. Bisson continued to vest in the option grants issued to Ms. Bisson in her role as chief executive officer and president in accordance with the vesting schedule set out in her initial employment agreement. In the event of a &#8220;change of control&#8221; or the termination of the agreement by us without &#8220;cause&#8221; or by Ms. Bisson for &#8220;good reason,&#8221; all of the unvested options shall immediately vest. Ms. Bisson is entitled to receive any compensation, including incentive compensation, for the fiscal year ended <em style="font: inherit;"> March 31, 2024 </em>that has <em style="font: inherit;">not</em> been paid as of the date of the agreement. Commencing with the year ending <em style="font: inherit;"> March 31, 2025, </em>Ms. Bisson will be eligible to receive annual option grants as determined by the Compensation Committee of the Board of Directors, based on criteria established by the Compensation Committee. Ms. Bisson agreed to waive any severance payments due to her in connection with the termination of the prior employment agreement that we entered into with her on <em style="font: inherit;"> June 30, 2023.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Fractional Shares</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">See <i>Note <em style="font: inherit;">1</em> - Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies</i> - "<i>Reverse Stock Split</i>" for additional information.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> November 1, 2024, </em>the Company received notice from the Depository Trust and Clearing Corporation ("DTCC") on behalf of the brokerage firms that hold the shares of Company common stock held in &#8220;street name&#8221; that in connection with the rounding of fractional shares in connection with the Reverse Stock Split, the Company would need to issue 271,846 shares of common stock (the &#8220;Shares&#8221;) for the rounding of shares. The Company does <em style="font: inherit;">not</em> believe the number of Shares being requested is correct based on the historical number of shareholders of its common stock and is aware of similar anomalies in recent months for other companies completing a Reverse Stock Split. As such, the Company has begun an inquiry into the calculations set forth in the request. During the pendency of this inquiry, the Company does <em style="font: inherit;">not</em> intend to issue any shares in connection with the fractional shares being requested and has concluded that an obligation should <em style="font: inherit;">not</em> be recorded in its financial statements. The Company is <em style="font: inherit;">not</em> currently subject to any pending litigation as a result of the fractional roundup shares.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Note <em style="font: inherit;">5</em></b>&#160;&#8211;<b> Related Party Transactions</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> December 21, 2021, </em>the Company entered into a license agreement with a company controlled by a significant stockholder of the Company (&#8220;Licensee&#8221;). On <em style="font: inherit;"> July 7, 2023, </em>the Company and the Licensee entered into an Exclusive License Termination Agreement (the &#8220;Termination Agreement&#8221;) in exchange for the issuance, upon the closing of the Company&#8217;s initial public offering within <em style="font: inherit;">one</em> year of the agreement&#8217;s execution, of a warrant to purchase shares of the Company for a variable number of shares. The variable number of shares issued was based upon a fixed value of $8.0 million divided by the price per share in the offering. The warrants were exercisable at a price of $0.02 per share and <em style="font: inherit;"> may </em>be exercised any time after the issuance date, subject to a beneficial ownership limitation, and expired <span style="-sec-ix-hidden:c134565085">five</span> years from the original issuance. The warrants did <em style="font: inherit;">not</em> provide voting rights, dividend rights, and other rights of a shareholder prior to exercise. The shares underlying the warrant were subject to a lockup agreement for a period of <span style="-sec-ix-hidden:c134565087">six</span> months after the closing of the offering with respect to 12.5% of the shares issued and <span style="-sec-ix-hidden:c134565089">twelve</span> months after the closing of the offering for the remainder of the shares. The Company agreed to register the resale of the shares of common stock underlying the warrant upon a notice of <em style="font: inherit;">20</em> business days by the Warrant holder.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> January 29, 2024, </em>pursuant to the Termination Agreement, the Company issued a warrant to purchase 80,000 shares (the &#8220;Warrant&#8221;) pursuant to the Termination Agreement to the Licensee<i>.</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The completion of the Company&#8217;s IPO fixed the number of warrant shares issuable and the Company re-classified the Warrant to additional-paid in capital as it met the requirements for equity classification. Upon reclassification, the Company valued the warrant at $8.0&#160;million, which represented the fair value of the shares issued on that date.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


  <span></span>
</td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Note <em style="font: inherit;">6</em> </b>&#8211;<b> Related Party Transactions</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company utilizes a consulting firm that is owned by the Company&#8217;s former Chief Financial Officer to provide accounting and financial reporting services and pays certain expenses on behalf of the Company. During the year ended <em style="font: inherit;"> March 31, 2025 </em>and <em style="font: inherit;">2024,</em> the Company incurred fees of less than $0.1 million, respectively, for these services, excluding officer compensation. As of <em style="font: inherit;"> March 31, 2025 </em>and <em style="font: inherit;"> March 31, 2024, </em>the Company owed the consulting firm $0 and less than $0.1 million, respectively, for services and expenses.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">As of <em style="font: inherit;"> March 31, 2025, </em>members of the Company&#8217;s management/Board and an immediate family member of the Company&#8217;s management (related party), collectively purchased $0.5 million ($0.4 million and $0.1 million, respectively) of the Bridge Offering.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> December 21, 2021, </em>the Company entered into a perpetual, worldwide, exclusive license agreement (the &#8220;License&#8221; or &#8220;License Agreement&#8221;) with a company controlled by a significant stockholder of the Company (the &#8220;Licensee&#8221;). The License allows the Licensee to use certain intellectual property and technology related to the diagnosis and treatment of cardiovascular conditions held by the Company. Upon <em style="font: inherit;">90</em> days following the completion of an IPO or special purpose acquisition company transaction, the Licensee <em style="font: inherit;"> may </em>enter into sublicenses of the licensed intellectual property and technology.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> July 7, 2023, </em>the Company and the Licensee entered into an Exclusive License Termination Agreement (the &#8220;Termination Agreement&#8221;) in exchange for the issuance, upon the closing of the Company&#8217;s IPO within <em style="font: inherit;">one</em> year of the agreement&#8217;s execution, of a warrant to purchase shares of the Company for a variable number of shares. Upon the Company's closing of its IPO on <em style="font: inherit;"> January 29, 2024, </em>80,000&#160;warrant shares were issued at $100.00 per share for a fixed value of $8.0 million. The warrants are&#160;exercisable at a price of $0.02 per share and <em style="font: inherit;"> may </em>be exercised any time after the issuance date, subject to a beneficial ownership limitation, and expire <span style="-sec-ix-hidden:c134564722">five</span> years from the original issuance. The warrants contain dividend rights commensurate with the holders of common stock. The warrants do <em style="font: inherit;">not</em> include any other stockholder rights or privileges prior to exercise.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The shares underlying the warrant will be subject to a lockup agreement for a period of <span style="-sec-ix-hidden:c134564724">six</span> months after the closing of the IPO with respect to 12.5% of the shares issued and <span style="-sec-ix-hidden:c134564726">twelve</span> months after the closing of the IPO for the remainder of the shares. In connection with the Termination Agreement, the Company agreed to register the resale of the shares of common stock. One of the Company&#8217;s directors holds a 20% interest in the company receiving the warrant.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Tax Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Note <em style="font: inherit;">7</em> </b>&#8211;<b> Income Taxes</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company files U.S. federal and various U.S. state income tax returns. Due to the Company&#8217;s losses, there was <em style="font: inherit;">no</em> income tax expense for the years ended <em style="font: inherit;"> March 31, 2025 </em>and <em style="font: inherit;">2024</em> (in thousands):</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>March 31,</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>March 31,</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Amount</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">%</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Amount</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">%</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Tax benefit at the U.S. federal statutory rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(2,396</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">21.00</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(3,239</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">21.00</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Tax rate change</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Permanent differences</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(0.05</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,697</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(11.01</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)%</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Return to provision</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(44</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.39</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(69</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.45</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Change in state rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">234</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(2.05</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(190</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.23</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">State tax (net of federal benefit)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(63</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.55</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(192</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.24</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Valuation allowance</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,264</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(19.84</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,993</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(12.91</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)%</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Effective income tax rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The effective income tax rate varied from the statutory rate in <em style="font: inherit;">2025</em> primarily due to permanent differences and the increase in the valuation allowance.&#160;The effective income tax rate varied from the statutory rate in <em style="font: inherit;">2024</em> primarily as a result of the increase&#160;in the valuation allowance.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Deferred tax assets and liabilities consist of the following (in thousands):</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>March 31,</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>March 31,</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Assets related to:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Capitalized R&amp;D costs</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,380</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">602</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Net operating losses</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">761</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,643</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Accruals and reserves</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,438</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">72</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Stock-based compensation</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">450</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">142</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total deferred tax assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6,029</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,459</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Valuation allowance for deferred tax assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(5,723</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(3,459</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net deferred tax assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">306</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Liabilities related to:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Section 481A method change</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(306</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net deferred tax liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(306</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net deferred tax</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">At <em style="font: inherit;"> March 31, 2025, </em>the Company had U.S. federal net operating loss ("NOL") carry forwards of $3.6 million. Approximately $0.9 million of the U.S. federal NOLs will start expiring in <em style="font: inherit;">2037.</em> Additionally, the Company generated a U.S. federal NOL carry-forward of approximately $2.7 million post-<em style="font: inherit;">2017</em> to <em style="font: inherit;">2024.</em> Under the new Tax Act, post-<em style="font: inherit;">2017</em> federal NOL carry forwards do <em style="font: inherit;">not</em> expire, but can only offset <em style="font: inherit;">80%</em> of taxable income in the year the loss carry forward is used.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Sections <em style="font: inherit;">382</em> and <em style="font: inherit;">383</em> of the Internal Revenue Code limit the annual use of NOL &#160;carry-forwards and tax credit carry forwards, respectively, following an ownership change. NOL carry-forwards <em style="font: inherit;"> may </em>be subject to annual limitations under Internal Revenue Code Section <em style="font: inherit;">382</em> (Section <em style="font: inherit;">382</em>) (or comparable provisions of state law) if certain changes in ownership were to occur.&#160;Determination of ownership change, or limitation hasn&#8217;t been calculated; however, the Company will perform the NOL limitation analysis under Section&#160;<em style="font: inherit;">382</em>&#160;before any NOLs are expected to be utilized.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company has recorded a full valuation allowance against its net total deferred tax assets as of <em style="font: inherit;"> March 31, 2025 </em>and <em style="font: inherit;">2024</em> because management determined that it is <span style="-sec-ix-hidden:c134564749">not</span> more-likely-than <em style="font: inherit;">not</em> that those assets will be realized. In assessing the realization of deferred tax assets, management considers whether it is more likely than <em style="font: inherit;">not</em> that some portion or all of deferred assets will <em style="font: inherit;">not</em> be realized. The ultimate realization of the deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. During the year ended <em style="font: inherit;"> March 31, 2025, </em>the valuation allowance increased by $2.3 million mainly due to additional capitalized R&amp;D and Start-up Costs.&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company is subject to income taxes in the U.S. federal jurisdiction and various state jurisdictions. Tax regulations within each jurisdiction are subject to the interpretation of the related tax laws and regulations and require significant judgment to apply. As of <em style="font: inherit;"> March 31, 2025, </em>all of the tax years remained open to examination by the federal and state taxing authorities, for <em style="font: inherit;">three</em> or <em style="font: inherit;">four</em> years from the tax year in which net operating losses or tax credits are utilized completely.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">As of <em style="font: inherit;"> March 31, 2025, </em>the Company has <em style="font: inherit;">no</em> uncertain tax positions.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477617/942-740-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478822/944-740-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Note <em style="font: inherit;">6</em></b>&#160;&#8211;<b> Subsequent Events</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> July 21, 2025, </em>the Company entered into a warrant exercise inducement offer letter (the "Inducement Letter") with the holders ("Holders") of certain existing warrants issued in the Offering from <em style="font: inherit;"> November 2024 </em>to purchase up to 1,477,596 shares of the Company's common stock (the "Existing Warrants"). Pursuant to the Inducement Letter, the Company agreed to reduce the exercise price of the Existing Warrants to $1.723 per share, and the Holders agreed: (i) to exercise Existing Warrants to purchase 855,000 shares of Company common stock; and (ii) to prepay $1.722 per share of the reduced exercise price for Existing Warrants to purchase 622,596 shares of Company common stock in consideration of the Company further reducing the exercise price of such Existing Warrants to purchase 622,596 shares of Company common stock to $0.001 per share with an exercise term of 5.5 years. In consideration of the foregoing, the Company agreed to issue the Holders new warrants to purchase up to a number of shares of Company common stock equal to 100% of the number of shares of Company common stock underlying the Existing Warrants, comprised of new Series B warrants to purchase up to 1,477,596 shares of Company common stock (the &#8220;Inducement Warrants&#8221; and the shares of Company common stock underlying the Inducement Warrants, the &#8220;Inducement Warrant Shares&#8221;) at $1.723 per share with an exercise term of 5.5 years from the initial exercise date. In addition, the Company issued 88,656 Representative's Warrants at $2.6707 per share with an exercise term of 5&#160;years. The Company received total gross proceeds of approximately $2.6 million, less expenses paid to the Placement Agent of approximately $0.3 million.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In <em style="font: inherit;"> July 2025, </em>of the 622,596 Amended Series A Warrants above, 268,072 were exercised, leaving 354,524 of the Amended Series A Warrants at the time of this filing.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> August 5, 2025, </em>54,400 of pre-IPO warrants were exercised on a cashless basis.&#65279;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In <em style="font: inherit;"> July 2025, </em>the Company entered into stock option cancellation agreements with certain employees to cancel an aggregate of 57,331 stock options. Employees that elected to cancel their stock options were granted severance agreements for three, <em style="font: inherit;">six</em> or <em style="font: inherit;">nine</em> months of their base salary (under certain conditions). On <em style="font: inherit;"> August 11, 2025, </em>the Company entered into stock option cancellation agreements with Board members and certain officers of the Company to cancel an aggregate of <span style="-sec-ix-hidden:c134565119">177,652</span> stock options. The Company's Board members included Mr. Walter Klemp, Chairman of the Board; Ms. Lori Bisson, Executive Vice Chairman of the Board; and Mr. Chris Capelli, Director, respectively, and included amounts of <span style="-sec-ix-hidden:c134565120">8,773;</span> <span style="-sec-ix-hidden:c134565121">65,542;</span> and <span style="-sec-ix-hidden:c134565122">3,750,</span> respectively. The Company's officers included Mr. Brad Hauser, Chief Executive Officer and President; Mr. Landy Toth, Chief Technology Officer; Mr. Robert Schwartz, Chief Medical Officer; and Mr. Trent Smith, Chief Financial Officer, respectively, and included amounts of <span style="-sec-ix-hidden:c134565123">45,000;</span> <span style="-sec-ix-hidden:c134565124">8,773;</span> <span style="-sec-ix-hidden:c134565125">13,159;</span> and <span style="-sec-ix-hidden:c134565126">32,655,</span> respectively. Mr. Hauser was granted <em style="font: inherit;">three</em> months of his base salary, in addition to the <em style="font: inherit;">twelve</em> months of his base salary per his <em style="font: inherit;"> July 17, 2024 </em>employment agreement. Mr. Toth and Mr. Schwartz were granted severance agreements that amounted to <em style="font: inherit;">nine</em> months of their base salary. Mr. Smith was granted <em style="font: inherit;">three</em> months of his base salary, in addition to the <em style="font: inherit;">nine</em> months of his base salary per his <em style="font: inherit;"> July 24, 2023 </em>employment agreement.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>
  <span></span>
</td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Note <em style="font: inherit;">8</em> </b>&#8211;<b> Subsequent Events</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">As of <em style="font: inherit;"> May 28, 2025, </em>the Company has sold 289,144 shares pursuant to the ATM Agreement for net proceeds of approximately $0.6 million.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> April 17, 2025, </em>we granted a new employee a <span style="-sec-ix-hidden:c134564760">ten</span>-year option (the &#8220;Inducement Options&#8221;) to purchase 5,000 shares of common stock at an exercise price equal to the closing price of our common stock on the date of the employment. The option vests in <em style="font: inherit;">four</em> equal annual installments (or 1,250 shares each installment) on each of the succeeding <em style="font: inherit;">four</em> anniversary dates of the execution of the date of employment, provided the employee is employed by us on each vesting date.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 1 - Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies - 10-Q<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Note <em style="font: inherit;">1</em> </b>&#8211;<b> Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies </b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Description of the Business</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Autonomix Medical, Inc. (&#8220;we,&#8221; &#8220;our,&#8221; the &#8220;Company&#8221;) is a medical device company organized as a Delaware corporation on <em style="font: inherit;"> June 10, 2014. </em>The Company is a pre-revenue, clinical stage life sciences company focused on advancing innovative technologies for sensing and treating disorders relating to the peripheral nervous system.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Reverse Stock Split</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company&#160;held its annual meeting of stockholders (the "Annual Meeting") on <em style="font: inherit;"> October 17, 2024. </em>In that Annual Meeting, stockholders of the Company approved an amendment to the Company&#8217;s amended and restated certificate of incorporation (the "Amendment&#8221;) to effect the reverse stock split at a ratio in the range of <em style="font: inherit;">1</em>-for-2 to <em style="font: inherit;">1</em>-for-50, with such ratio to be determined in the discretion of the Company&#8217;s Board of Directors (the "Board") and with such reverse stock split to be effected at such time and date, if at all, as determined by the Company&#8217;s Board in its sole discretion prior to the <em style="font: inherit;">one</em>-year anniversary of the Annual Meeting.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Pursuant to such authority granted by the Company&#8217;s stockholders, the Company&#8217;s Board approved a <em style="font: inherit;">one</em>-for-<span style="-sec-ix-hidden:c134564773">twenty</span> (<em style="font: inherit;">1:20</em>) reverse stock split (the "Reverse Stock Split&#8221;) of the Company&#8217;s common stock and the filing of the Amendment to effectuate the Reverse Stock Split. The Amendment was filed with the Secretary of State of the State of Delaware and the Reverse Stock Split became effective in accordance with the terms of the Amendment at <em style="font: inherit;">11:59</em> p.m. Eastern Time on <em style="font: inherit;"> October 24, 2024 (</em>the "Effective Time&#8221;), and the Company&#8217;s common stock opened&#160;for trading on The Nasdaq Capital Market on <em style="font: inherit;"> October 25, 2024 </em>on a post-split basis, under the existing ticker symbol "AMIX&#8221; but with a new CUSIP number <em style="font: inherit;">05330T205.</em> The Amendment provides that, at the Effective Time, every <span style="-sec-ix-hidden:c134564777">twenty</span> shares of the Company&#8217;s issued and outstanding common stock was automatically combined into <em style="font: inherit;">one</em> issued and outstanding share of common stock, without any change in par value per share, which will remain $0.001.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The number of authorized shares of common stock remained&#160;at 500 million shares. As a result of the Reverse Stock Split, proportionate adjustments were made to the per share exercise price and/or the number of shares issuable upon the exercise or vesting of all outstanding stock options, restricted stock unit awards, warrants and convertible notes, which resulted in a proportional decrease in the number of shares of the Company&#8217;s common stock reserved for issuance upon exercise or vesting of such stock options, restricted stock unit awards, warrants and convertible notes and, in the case of stock options and warrants, a proportional increase in the exercise price of all such stock options and warrants.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company&#8217;s stock option awards did <em style="font: inherit;">not</em> automatically adjust for the Reverse Stock Split.&#160;However, the Company chose to exercise its rights under the agreements to adjust the exercise price and number of shares exercisable or issuable upon vesting proportionately for the Reverse Stock Split.&#160;Based on the analysis performed, the Company does <em style="font: inherit;">not</em> need to recognize any additional compensation expense as a result of the modification.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">In addition, the number of shares reserved for issuance under the Company&#8217;s equity compensation plan immediately prior to the Effective Time was reduced proportionately.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><em style="font: inherit;">No</em> fractional shares were issued as a result of the Reverse Stock Split. Any stockholder who would have been entitled to receive a fractional share as a result of the process was entitled to the rounding up of the fractional share to the nearest whole number. See "<i>Fractional Shares</i>" in Note <em style="font: inherit;">4</em> for further disclosure regarding fractional shares.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Reverse Stock Split has been retroactively adjusted throughout these interim financial statements and footnotes for all periods presented, including exercise prices and share data. As a result of the Reverse Stock Split, the Company reclassified approximately $18 thousand between common stock par value and additional paid-in capital.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Liquidity and Going Concern</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company's financial statements are prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The Company is an early-stage company that is subject to all the risks associated with early-stage and emerging growth companies and has incurred losses since inception.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">O&#65279;n <em style="font: inherit;"> February 28, 2025,&#160;</em>the Company entered into an At Market Issuances Sales Agreement (the &#8220;ATM Agreement&#8221;) with Ladenburg Thalmann &amp; Co. Inc. (the &#8220;Agent&#8221;). Pursuant to the terms of the ATM Agreement, The Company <em style="font: inherit;"> may </em>sell from time to time through the Agent, as sales agent or principal, shares of its common stock with an initial aggregate sales price of up to $2.1 million (the &#8220;Shares&#8221;). As of <em style="font: inherit;"> June 30, 2025, </em>the Company sold 1,304,260 Shares pursuant to the ATM Agreement for net proceeds of approximately $2.1 million.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
      <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> November 22, 2024, </em>the Company entered into&#160;an Underwriting Agreement (the &#8220;Underwriting Agreement&#8221;) with Ladenburg Thalmann &amp; Co. Inc., as representative of the several underwriters, if any, named on Schedule I of the Underwriting Agreement (the &#8220;Underwriters&#8221;), in connection with a firm commitment underwritten public offering (the &#8220;Offering&#8221;) of: (i) 458,691 common units (the &#8220;Common Units&#8221;), each Common Unit consisting of <span style="-sec-ix-hidden:c134564791">one</span> share of Company common stock and <span style="-sec-ix-hidden:c134564792">one</span> series A warrant to purchase <span style="-sec-ix-hidden:c134564793">one</span> share of common stock (the &#8220;Series A Warrants&#8221;); and (ii) 917,596 pre-funded units (the &#8220;Pre-Funded Units&#8221;) and together with the Common Units, the "Units", each Pre-Funded Unit consisting of <span style="-sec-ix-hidden:c134564795">one</span> pre-funded warrant to purchase <span style="-sec-ix-hidden:c134564796">one</span> share of common stock (the &#8220;Pre-Funded Warrant&#8221;) and <span style="-sec-ix-hidden:c134564797">one</span> Series A Warrant. The purchase price of each Common Unit was $6.540, and the purchase price of each Pre-Funded Unit was $6.539.&#160;In addition, the Company granted the Underwriters a 45-day option to purchase an additional 206,422 shares of common stock, and/or an additional 206,422 Series A Warrants, solely to cover over-allotments, if any. The Pre-Funded Warrants have an exercise price of $0.001 per share, are immediately exercisable and <em style="font: inherit;"> may </em>be exercised at any time until all of the Pre-Funded Warrants are exercised in full. The Series A Warrants have an exercise price of $6.540 per share, are immediately exercisable and <em style="font: inherit;"> may </em>be exercised at any time until the <span style="-sec-ix-hidden:c134564805">five</span>-year anniversary of the date of issuance. Both the Pre-Funded Warrants and the Series A Warrants are subject to a beneficial ownership limitation of 4.99%. The Pre-Funded Warrants and Series A Warrants were issued pursuant to a warrant agency agreement between the Company and Equity Stock Transfer, LLC (the &#8220;Warrant Agency Agreement&#8221;). The Offering closed on <em style="font: inherit;"> November 25, 2024. </em>On <em style="font: inherit;"> November 22, 2024, </em>the Underwriters partially exercised their over-allotment option with respect to 156,809 shares of common stock and 156,809 Series A Warrants. The aggregate gross proceeds to the Company, including the partial exercise of the over-allotment option, were approximately $10.0 million, before deducting underwriting discounts and other expenses by the Company of $1.5 million, including $0.5 million of non-cash expenses. The net cash proceeds to the Company were approximately $9.0 million. See Note <em style="font: inherit;">6</em> - Subsequent Events for additional information regarding events occurring after <em style="font: inherit;"> June 30, 2025.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">For the&#160;<em style="font: inherit;">three</em> months ended <em style="font: inherit;"> June 30, 2025 </em>and <em style="font: inherit;">2024,</em> the Company incurred net losses of $3.3 million and $2.7 million, respectively, and had net cash flows used in operating activities of $2.6 million and $1.9&#160;million, respectively. The Company had no revenues for the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> June 30, 2025 </em>and <em style="font: inherit;">2024,</em> respectively, and an accumulated deficit of $53.7&#160;million, working capital of $7.0 million and cash of $8.6 million as of <em style="font: inherit;"> June 30, 2025. </em>The Company does <em style="font: inherit;">not</em> expect to&#160;generate&#160;positive cash flows from operating activities in the near future.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company estimates its current cash resources&#160;are sufficient to fund its operations into but <em style="font: inherit;">not</em> beyond the <em style="font: inherit;">second</em> calendar quarter of <em style="font: inherit;">2026.</em> The Company recognizes it will need to raise additional capital to continue to execute its business plan, including obtaining regulatory clearance for its products currently under development and commercializing and generating revenues from products under development. There is <em style="font: inherit;">no</em> assurance that additional financing will be available when needed or that management will be able to obtain financing on terms acceptable to the Company. A failure to raise sufficient capital, generate sufficient product revenues, control expenditures and regulatory matters, among other factors, will adversely impact the Company&#8217;s ability to meet its financial obligations as they become due and payable and to achieve its intended business objectives. If the Company is unable to raise sufficient additional funds, it will have to scale back its operations.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">These factors raise substantial doubt about the Company's ability to continue as a going concern within <em style="font: inherit;">one</em> year after the date the financial statements are issued. The accompanying condensed financial statements have been prepared on a going concern basis and do <em style="font: inherit;">not</em> include any adjustments that might be necessary if the Company is unable to continue as a going concern.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Basis of Presentation</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The accompanying condensed interim financial statements are unaudited. These unaudited condensed interim financial statements have been prepared in accordance with the rules and regulations of the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) for interim financial information. Accordingly, they do <em style="font: inherit;">not</em> include all the information and notes required by generally accepted accounting principles in the United States of America (&#8220;GAAP&#8221;) for complete financial statements. The Company&#8217;s fiscal year end is <em style="font: inherit;"> March 31</em><sup style="vertical-align:top;line-height:120%;">st</sup>. These unaudited condensed interim financial statements should be read in conjunction with the audited financial statements and accompanying notes for the year ended <em style="font: inherit;"> March 31, 2025 </em>as found in the Annual Report in the Company's Form <em style="font: inherit;">10</em>-K filed with the SEC on <em style="font: inherit;"> May 29, 2025. </em>In the opinion of management, the unaudited condensed interim financial statements reflect all the adjustments (consisting of normal recurring adjustments) necessary to state fairly the Company&#8217;s financial position, results of operations and cash flows for the quarterly and year-to-date periods, as applicable. The interim results of operations are <em style="font: inherit;">not</em> necessarily indicative of the results that <em style="font: inherit;"> may </em>occur for the full fiscal year. The <em style="font: inherit;"> March 31, 2025 </em>audited condensed balance sheet included herein was derived from the audited financial statements, but does <em style="font: inherit;">not</em> include all disclosures, including notes, required by GAAP for complete financial statements.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Use of Estimates in Financial Statement Presentation</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The preparation of these unaudited condensed interim financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The Company's significant estimates and assumptions include work performed but <em style="font: inherit;">not</em> yet billed by contract manufacturers, engineers and research organizations and the valuation of equity related instruments. Although the Company believes that its estimates and assumptions are reasonable, they are based upon information available at the time the estimates and assumptions were made. Some of these judgments can be subjective and complex, and, consequently, actual results could differ from those estimates.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Cash and Cash Equivalents</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company considers all highly liquid accounts with original maturities of <em style="font: inherit;">three</em> months or less at the date of acquisition to be cash equivalents.&#160;Periodically, the Company <em style="font: inherit;"> may </em>carry cash balances at financial institutions in excess of the federally insured limit of <em style="font: inherit;">$250</em> thousand. The Company has <em style="font: inherit;">not</em> experienced losses on these accounts and management believes, based upon the quality of the financial institutions, that the credit risk with regard to these deposits is <em style="font: inherit;">not</em> significant.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Offering and Financing Costs</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Offering costs consist of professional costs incurred through the balance sheet date that are direct and incremental related to the Company&#8217;s equity financing activities. Specifically, offering costs were incurred during the Company&#8217;s initial public offering ("IPO"), Offering from <em style="font: inherit;"> November 2024 </em>and ATM Agreement. The Company includes offering costs in additional paid-in capital, to the extent there is sufficient cash proceeds, upon completion of the sale of equity. Costs associated with salaries and other period costs are expensed as incurred.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;text-indent:9pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;text-indent:9pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;text-indent:9pt;"><i>Property and Equipment</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Property and equipment (comprised of computer and IT equipment) are stated at historical cost and depreciated on a straight-line basis over their estimated useful lives, generally&#160;<span style="-sec-ix-hidden:c134564843">three</span> years. Upon disposition of the assets, the costs and related accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the results of operations.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Convertible Notes</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">For the period ended <em style="font: inherit;"> March 31, 2025, </em>the Company evaluated embedded redemption, conversion and other features within its debt to determine whether any embedded features should be bifurcated from the host instrument and accounted for as a derivative at fair value, with changes in fair value recorded in the condensed statements of operations. The Company&#8217;s debt was carried on the condensed balance sheets on a historical cost basis, net of unamortized discounts and premiums, because the Company did <em style="font: inherit;">not</em> elect the fair value option of accounting. Costs associated with acquiring debt, including detachable warrants issued in connection with the financing, were&#160;capitalized as a debt discount. The debt discount was&#160;presented in the condensed balance sheets, in prior year periods, as a direct deduction from the carrying amount of the debt liability. The costs were&#160;amortized over the estimated contractual life of the related debt instrument using the effective interest method and were&#160;included in interest expense in the condensed statements of operations.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">In addition, since the instruments included a substantive conversion feature as of time of issuance, the issuance of equity securities to settle the outstanding notes with the conversion were accounted for as a contractual conversion with <em style="font: inherit;">no</em> gain or loss recognized related to the equity securities issued to settle the instrument. See <i>Note <em style="font: inherit;">2</em> - Convertible Notes Payable</i> for additional information.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Fair Value of Financial Instruments</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs. The Company utilizes a <em style="font: inherit;">three</em>-level valuation hierarchy for disclosures of fair value measurements, defined as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Level <em style="font: inherit;">1</em> &#8211; inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Level <em style="font: inherit;">2</em> &#8211; inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the assets or liability, either directly or indirectly, for substantially the full term of the financial instrument</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">Level <em style="font: inherit;">3</em> &#8211; inputs to the valuation methodology are unobservable and significant to the fair value and require significant judgment and estimation</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Financial assets and financial liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. While the Company believes that its valuation methods are appropriate, the Company recognizes that the use of different methodologies or assumptions to determine the fair value could result in a different estimate of fair value at the reporting date. The primary assumptions that would significantly affect the fair values are the probability weighting of the different settlement outcomes used.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
      <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company did <em style="font: inherit;">not</em> have any assets or liabilities measured at fair value as of <em style="font: inherit;"> June 30, 2025 </em>and <em style="font: inherit;"> March 31, 2025.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">The carrying value of short-term instruments, including cash, accounts payable and accrued expenses, approximate fair value due to the relatively short period to maturity for these instruments.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;"><i>Related Parties</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company follows Accounting Standards Codification ("ASC") <em style="font: inherit;">850,</em> <i>Related Party Disclosures</i>, for the identification of related parties and disclosure of related party transactions. See further discussion in Note <em style="font: inherit;">5</em> below on this matter.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Income Taxes</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting and the tax basis of reported assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company must then assess the likelihood that the resulting deferred tax assets will be realized. A valuation allowance is provided when it is more likely than <em style="font: inherit;">not</em> that some portion or all of a deferred tax asset will <em style="font: inherit;">not</em> be realized. As of <em style="font: inherit;"> June 30, 2025 </em>and <em style="font: inherit;"> March 31, 2025 </em>the Company determined a full valuation allowance was required to offset its deferred tax assets as a result of recurring operating losses.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company accounts for uncertain tax positions in accordance with the provisions of ASC <em style="font: inherit;">740</em>-<em style="font: inherit;">10</em> which prescribes a recognition threshold and measurement attribute for financial statement disclosure of tax positions taken, or expected to be taken, on its tax return. The Company evaluates and records any uncertain tax positions based on the amount that management deems is more likely than <em style="font: inherit;">not</em> to be sustained upon examination and ultimate settlement with the tax authorities in the tax jurisdictions in which it operates. As of <em style="font: inherit;"> June 30, 2025 </em>and <em style="font: inherit;"> March 31, 2025 </em>the Company had no uncertain tax positions.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company does&#160;<em style="font: inherit;">not</em>&#160;expect to pay any significant federal, state, or foreign income taxes in&#160;its fiscal year <em style="font: inherit;">2026</em> (ending <em style="font: inherit;"> March 31, 2026) </em>as a result of the losses recorded during the&#160;<em style="font: inherit;">three</em> months ended <em style="font: inherit;"> June 30, 2025&#160;</em>and the additional losses expected for the remainder of&#160;its fiscal year <em style="font: inherit;">2026</em>&#160;and cumulative net operating loss carryforwards. Accounting standards require the consideration of a valuation allowance for deferred tax assets if it is &#8220;more likely than&#160;<em style="font: inherit;">not&#8221;</em>&#160;that some component or all of the benefits of deferred tax assets will <em style="font: inherit;">not</em> be realized.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company recorded&#160;<em style="font: inherit;">no</em>&#160;income tax provision for the&#160;<em style="font: inherit;">three</em> months ended <em style="font: inherit;"> June 30, 2025 </em>and <em style="font: inherit;">2024,</em> respectively. The effective tax rate for the&#160;<em style="font: inherit;">three</em> months ended <em style="font: inherit;"> June 30, 2025 </em>and <em style="font: inherit;">2024</em>&#160;is zero.&#160;The Company estimates its annual effective tax rate at the end of each quarterly period. Jurisdictions with a projected loss for the year where&#160;<em style="font: inherit;">no</em>&#160;tax benefit can be recognized due to the valuation allowance could result in a higher or lower effective tax rate during a particular quarter depending on the mix and timing of actual earnings versus annual projections.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Stock-based Compensation</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Employee and non-employee share-based compensation is measured at the grant date, based on the fair value of the award, and is recognized as an expense over the requisite service period. For awards with a performance condition, compensation expense is recognized over the requisite service period if it is probable that the performance condition will be satisfied. For awards to non-employees, the Company recognizes compensation expense in the same manner as if the Company had paid cash for the goods or services. The Company estimates the fair value of options and equity classified warrants granted using an options pricing model. Expense is recognized within general and administrative and research and development expenses and forfeitures are recognized as they are incurred.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Warrants</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s specific terms and applicable authoritative guidance in FASB ASC <em style="font: inherit;">480,</em> Distinguishing Liabilities from Equity (&#8220;ASC <em style="font: inherit;">480&#8221;</em>) and ASC <em style="font: inherit;">815,</em> Derivatives and Hedging (&#8220;ASC <em style="font: inherit;">815&#8221;</em>). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC <em style="font: inherit;">480,</em> meet the definition of a liability pursuant to ASC <em style="font: inherit;">480,</em> and whether the warrants meet all of the requirements for equity classification under ASC <em style="font: inherit;">815,</em> including whether the warrants are indexed to the Company&#8217;s own ordinary shares and whether the warrant holders could potentially require &#8220;net cash settlement&#8221; in a circumstance outside of the Company&#8217;s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do <em style="font: inherit;">not</em> meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss on the&#160;statements of operations. The fair value of the warrants is estimated using a Black-Scholes pricing model or a Monte Carlo simulation.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Loss Per Common Share</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Basic loss per common share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period, which includes shares issuable for little to <em style="font: inherit;">no</em> consideration upon the exercise of certain equity-classified warrants. Diluted loss per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. In periods when losses are reported, the weighted-average number of common shares outstanding excludes common stock equivalents, because their inclusion would be anti-dilutive. Generally, the Company&#8217;s outstanding warrants are non-participating securities as they are <em style="font: inherit;">not</em> entitled to non-forfeitable rights to dividends or dividend equivalents during the vesting term and have <em style="font: inherit;">no</em> obligation to fund losses.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">However, the Company's warrants described in Note&#160;<em style="font: inherit;">2</em>&#160;and the warrants issued in connection with the Offering, are participating securities as the holders receive the right to dividends, but they are <em style="font: inherit;">not</em> obligated to fund losses. In periods of loss, since <em style="font: inherit;">no</em> income is allocated to these securities, the Company's use of the "treasury stock method" derives the same result. The dilutive effect of convertible securities is calculated using the &#8220;if-converted method.&#8221; Under the if-converted method, securities are assumed to be converted at the beginning of the period, and the resulting common shares are included in the denominator of the diluted calculation for the entire period being presented.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">For the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> June 30, 2025 </em>and <em style="font: inherit;">2024,</em> dilutive securities that were <em style="font: inherit;">not</em> included in the calculations of the loss per common share because they would be anti-dilutive included the following:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 5%; margin-left: 54pt; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>June 30,</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(as revised)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Equity based warrants to purchase common shares</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">87,531</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,334</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Convertible Notes - common shares (1)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">33,250</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Convertible Notes - equity-based warrants to purchase common shares</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">25,003</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">25,003</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock options granted under Company's incentive plan</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">248,483</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">216,483</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Series A Warrants</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,533,096</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Representative Warrants</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">91,985</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total potentially dilutive securities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,986,098</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">279,070</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
    <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 54pt;">(<em style="font: inherit;">1</em>) Shares for the convertible note proceeds received</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Research and Development Costs</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Research and development costs are expensed as incurred.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Advertising</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">It is the Company's policy to expense advertising costs as incurred. Advertising&#160;expenses are included within general and administrative expenses within the statement of operations. For the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> June 30, 2025 </em>and <em style="font: inherit;">2024,</em> the Company recorded $0 and less than $0.1&#160;million, respectively, of advertising expenses.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>JOBS Act Accounting Election</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company qualifies as an emerging growth company (&#8220;EGC&#8221;), as defined in the Jumpstart Our Business Startups Act of <em style="font: inherit;">2012</em> (the &#8220;JOBS Act&#8221;). The JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected <em style="font: inherit;">not</em> to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This <em style="font: inherit;"> may </em>make comparison of the Company&#8217;s financial statements with another public company which is neither an early-stage company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><i>Segments</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker ("CODM"), or decision-making group, in deciding how to allocate resources in assessing performance. Management has determined that the Company operates in&#160;<span style="-sec-ix-hidden:c134564899">one</span>&#160;reportable segment, which is advancing the development of innovative technologies for sensing and treating disorders relating to the nervous system. The Company is initially focused on developing the technology for patients with pancreatic cancer, however, the Company believes the technology constitutes a platform with the potential to address several indications, including chronic pain management, hypertension, cardiovascular disease and a wide range of other nerve-related disorders. The Company's CODM is its Chief Executive Officer.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The accounting policies of the segment are the same as those described in the summary of significant accounting policies. The CODM assesses performance based on net loss, which is reported on the Statements of Operations. The measure of segment assets is reported on the balance sheet as total assets.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">To date, the Company has <em style="font: inherit;">not</em> generated any product revenue. The Company expects to continue to incur significant expenses and operating losses for the foreseeable future as it advances its' technology through all stages of development and clinical trials and, ultimately, seek regulatory approval.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">As such, the CODM primarily evaluates performance of the Company using various financial metrics, including the combined net income (loss) from operations, also shown on the Statements of Operations, forecasted cash expenditures and existing and forecasted cash balances. These financial metrics are used by the CODM to make key operating decisions, such as the assessment of segment performance and allocation of resources. All of the Company's assets are located in the United States. The significant expense categories within net loss from operations that the CODM regularly reviews are expenses related to research and development, general and administrative, and depreciation and amortization. The significant expense categories and subcategories are reported on the Statements of Operations.&#160;Other expenses included in the Company&#8217;s net loss include other income (expense), interest income, net, and any additional non-operating expenses that are reported on the Statements of Operations.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Recent Accounting Pronouncements</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">In&#160;<em style="font: inherit;"> November 2024 </em>and <em style="font: inherit;"> January 2025,&#160;</em>FASB issued ASU&#160;<em style="font: inherit;">2024</em>-<em style="font: inherit;">03</em> and ASU <em style="font: inherit;">2025</em>-<em style="font: inherit;">01,</em>&#160;Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic&#160;<em style="font: inherit;">220</em>-<em style="font: inherit;">40</em>): Disaggregation of Income Statement Expenses, which requires disclosure in the notes to the financial statements of specified information about certain costs and expenses. The amendments to the standards are effective for fiscal years beginning after&#160;<em style="font: inherit;"> December 15, 2026,&#160;</em>and for interim periods within fiscal years beginning after&#160;<em style="font: inherit;"> December 15, 2027.&#160;</em>Early adoption is permitted. The amendments should be applied either prospectively to financial statements issued for reporting periods after the effective date of this ASU or retrospectively to any or all prior periods presented in the financial statements. The Company is currently evaluating the new guidance to determine the impact it&#160;<em style="font: inherit;"> may&#160;</em>have on its financial statements and related disclosures.&#160;</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">In <em style="font: inherit;"> December 2023, </em>the FASB issued <i>ASU <em style="font: inherit;">2023</em>-<em style="font: inherit;">09,</em> </i>&#8220;<i>Income Taxes (Topic <em style="font: inherit;">740</em>): Improvements to Income Tax Disclosures,</i>&#8221; which requires disaggregated information about a reporting entity&#8217;s effective tax rate reconciliation as well as information on income taxes paid. The guidance is effective for the Company&#8217;s fiscal years beginning after <em style="font: inherit;"> December 15, 2024. </em>The Company is currently evaluating the new guidance to determine the impact it&#160;<em style="font: inherit;"> may&#160;</em>have on its financial statements and related disclosures.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">In <em style="font: inherit;"> November 2023, </em>the FASB issued <i>ASU <em style="font: inherit;">No.</em> <em style="font: inherit;">2023</em>-<em style="font: inherit;">07,</em> Segment Reporting (Topic <em style="font: inherit;">280</em>): Improvements to Reportable Segment Disclosures.</i> The ASU updates reportable segment disclosure requirements, primarily through requiring enhanced disclosures about significant segment expenses and information used to assess segment performance and allocate resources. The guidance is effective for fiscal years beginning after <em style="font: inherit;"> December 15, 2023 </em>and interim periods for fiscal years beginning after <em style="font: inherit;"> December 15, 2024, </em>on a retrospective basis. There was <em style="font: inherit;">no</em> material impact upon the adoption of <i>ASU <em style="font: inherit;">2023</em>-<em style="font: inherit;">07</em></i> on the Company's interim disclosures.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">There are <em style="font: inherit;">no</em> other effective pronouncements, or pronouncements issued but <em style="font: inherit;">not</em> yet effective, if adopted, that would have a material effect on the accompanying financial statements.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;text-indent:9pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;text-indent:9pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;text-indent:9pt;"><i>Correction of an Immaterial Error in the Prior Period Financial Statements</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">D&#65279;uring the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> December 31, 2024, </em>the Company determined that previously filed quarterly and annual financial statements had an immaterial earnings per share error resulting from the exclusion of certain unexercised equity based warrants to purchase common shares that had an exercise price of approximately $0.01 or less from the basic earnings per share calculations in accordance with <i>ASC <em style="font: inherit;">260</em>-<em style="font: inherit;">10</em>-<em style="font: inherit;">45</em>-<em style="font: inherit;">13</em></i>. As a&#160;result, the prior year earnings per share calculations have been revised for consistency with the current year presentation. The Company assessed the materiality of this change in presentation on prior period financial statements in accordance with <i>SEC Staff Accounting Bulletin <em style="font: inherit;">No.</em> <em style="font: inherit;">99</em></i>, &#8220;<i>Materiality</i>,&#8221; (<i>ASC Topic <em style="font: inherit;">250,</em> Accounting Changes and Error Corrections</i>). Based on this assessment, the Company concluded that this error correction in its&#160;<i>Statements of Operations</i>&#160;and <i>Note <em style="font: inherit;">1</em> </i>&#8211;<i> Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies (Loss Per Common Share)</i> is <em style="font: inherit;">not</em> material to any previously presented financial statements based upon overall considerations of both quantitative and qualitative factors. The corrections had <em style="font: inherit;">no</em> impact in the comparative period Balance Sheet,&#160;Statements of Cash Flows, or Statement of Changes in Stockholders&#8217;&#160;Equity. Further, the immaterial correction did <em style="font: inherit;">not</em> result in a change in operating losses or net loss in the Statement of Operations and the effects of including unexercised warrants in the earnings per share calculation have an antidilutive effect reducing the net loss per share amount. Accordingly, the Company corrected the previously reported earnings per share calculation for the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> June 30, 2024 </em>in this Quarterly Report on Form <em style="font: inherit;">10</em>-Q.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
      <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">A summary of the impact of the Company&#8217;s Reverse Stock Split and immaterial corrections reflecting the prior period impact to the Company&#8217;s Statement of Operations and earnings per share are shown below:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

     <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Three Months Ended June 30, 2024</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Originally </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Filed</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Adjusted </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>for 1-for-20 </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Reverse </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Stock Split</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Correction</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>As Revised</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net Loss (in thousands)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(2,699</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(2,699</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Loss per share - basic and diluted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(0.14</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(2.85</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">0.65</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(2.20</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Weighted average shares outstanding - basic and diluted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">18,902,248</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">945,382</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">280,041</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,225,423</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
     <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">A summary of the impact of the Company&#8217;s Reverse Stock Split and immaterial corrections reflecting the prior period impact are shown below:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

     <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Three Months Ended June 30, 2024</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Originally </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Filed</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Adjusted </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>for 1-for-20 </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Reverse </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Stock Split</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Correction</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>As Revised</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Equity based warrants to purchase common shares</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,344,569</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">267,231</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(262,897</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,334</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Convertible Notes - common shares</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">665,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">33,250</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">33,250</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Convertible Notes - equity-based warrants to purchase common shares</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">500,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">25,003</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">25,003</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock options granted under Company's incentive plan</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4,329,579</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">216,483</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">216,483</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total potentially dilutive securities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">10,839,148</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">541,967</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(262,897</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">279,070</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
     <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
  <span></span>
</td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Note <em style="font: inherit;">1</em> </b>&#8211;<b> Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies </b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Description of the Business</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Autonomix Medical, Inc (&#8220;we,&#8221; &#8220;our,&#8221; the &#8220;Company&#8221;) is a medical device company organized as a Delaware corporation on <em style="font: inherit;"> June 10, 2014. </em>The Company is a pre-revenue, clinical stage life sciences company focused on advancing innovative technologies for sensing and treating disorders relating to the peripheral nervous system.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Reverse Stock Split</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company&#160;held its annual meeting of stockholders (the "Annual Meeting") on&#160;<em style="font: inherit;"> October 17, 2024</em><i>.</i>&#160;In that Annual Meeting, stockholders of the Company approved an amendment to the Company&#8217;s amended and restated certificate of incorporation (the "Amendment&#8221;) to effect the reverse stock split at a ratio in the range of&#160;<em style="font: inherit;">1</em>-for-2&#160;to&#160;<em style="font: inherit;">1</em>-for-50, with such ratio to be determined in the discretion of the Company&#8217;s board of directors and with such reverse stock split to be effected at such time and date, if at all, as determined by the Company&#8217;s board of directors in its sole discretion prior to the&#160;<em style="font: inherit;">one</em>-year anniversary of the Annual Meeting.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Pursuant to such authority granted by the Company&#8217;s stockholders, the Company&#8217;s board of directors approved a&#160;<em style="font: inherit;">one</em>-for-&#160;<span style="-sec-ix-hidden:c134564311">twenty</span>&#160;(<em style="font: inherit;">1:20</em>) reverse stock split (the "Reverse Stock Split&#8221;) of the Company&#8217;s common stock and the filing of the Amendment to effectuate the Reverse Stock Split. The Amendment was filed with the Secretary of State of the State of Delaware and the Reverse Stock Split became effective in accordance with the terms of the Amendment at&#160;<em style="font: inherit;">11:59</em>&#160;p.m. Eastern Time on&#160;<em style="font: inherit;"> October 24, 2024 (</em>the "Effective Time&#8221;), and the Company&#8217;s common stock opened&#160;for trading on The Nasdaq Capital Market on&#160;<em style="font: inherit;"> October 25, 2024&#160;</em>on a post-split basis, under the existing ticker symbol "AMIX&#8221; but with a new CUSIP number&#160;<em style="font: inherit;">05330T205.</em>&#160;The Amendment provided that, at the Effective Time, every&#160;<span style="-sec-ix-hidden:c134564315">twenty</span>&#160;shares of the Company&#8217;s issued and outstanding common stock automatically combined into&#160;<em style="font: inherit;">one</em>&#160;issued and outstanding share of common stock, without any change in par value per share, which remained $0.001.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The number of authorized shares of common stock remained&#160;at&#160;500&#160;million shares. As a result of the Reverse Stock Split, proportionate adjustments were made to the per share exercise price and/or the number of shares issuable upon the exercise or vesting of all outstanding stock options, restricted stock unit awards, warrants and convertible notes, which resulted in a proportional decrease in the number of shares of the Company&#8217;s common stock reserved for issuance upon exercise or vesting of such stock options, restricted stock unit awards, warrants and convertible notes and, in the case of stock options and warrants, a proportional increase in the exercise price of all such stock options and warrants.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company&#8217;s stock option awards did <em style="font: inherit;">not</em> automatically adjust for the Reverse Stock Split.&#160;However, the Company chose to exercise its rights under the agreements to adjust the exercise price and number of shares exercisable or issuable upon vesting proportionately for the Reverse Stock Split.&#160;Based on the analysis performed, the Company does <em style="font: inherit;">not</em> need to recognize any additional compensation expense as a result of the modification.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">In addition, the number of shares reserved for issuance under the Company&#8217;s equity compensation plan immediately prior to the Effective Time was reduced proportionately.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><em style="font: inherit;">No</em>&#160;fractional shares were issued as a result of the Reverse Stock Split. Any stockholder who would have been entitled to receive a fractional share as a result of the process was entitled to the rounding up of the fractional share to the nearest whole number. See "&#160;Fractional Shares" in Note&#160;<em style="font: inherit;">5</em>&#160;for further disclosure regarding fractional shares.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Reverse Stock Split has been retroactively adjusted throughout these interim financial statements and footnotes for all periods presented, including exercise prices and share data. As a result of the Reverse Stock Split, the Company reclassified approximately $18&#160;thousand between common stock par value and additional paid-in capital.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Liquidity and Going Concern</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company's&#65279; financial statements are prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The Company is an early-stage company that is subject to all the risks associated with early-stage and emerging growth companies and has incurred losses since inception.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
      <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">For the years ended <em style="font: inherit;"> March 31, 2025 </em>and <em style="font: inherit;">2024,</em> the Company has net losses of approximately $11.4 million and $15.4 million, respectively and had net cash flows used in operating activities of $8.3&#160;million&#160;and $6.6 million, respectively. The Company had no revenues for the years ended <em style="font: inherit;"> March 31, 2025 </em>and <em style="font: inherit;">2024,</em> respectively. The Company had an accumulated deficit of $50.4 million and working capital of approximately $7.9 million as of <em style="font: inherit;"> March 31, 2025. </em>The Company does <em style="font: inherit;">not</em> expect to generate positive cash flows from operating activities in the near future. These conditions, and the Company's ability to comply with such conditions, raise substantial doubt about the Company's ability to continue as a going concern within <em style="font: inherit;">one</em> year after the date that the financial statements are issued. The accompanying financial statements have been prepared on a going concern basis and do <em style="font: inherit;">not</em> include any adjustments that might be necessary if the Company is unable to continue as a going concern.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> January 26, 2024, </em>the Company completed its IPO, pursuant to which it sold a total of 111,962&#160;shares of common stock at a purchase price of $100.00 per share for gross proceeds of $11.2 million and net proceeds of $9.8 million.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> November 22, 2024, </em>the Company completed a firm commitment underwritten public offering (the &#8220;Offering&#8221;) of: (i) 458,691 common units (the &#8220;Common Units&#8221;), each Common Unit consisting of <span style="-sec-ix-hidden:c134564342">one</span> share of Company common stock and <span style="-sec-ix-hidden:c134564343">one</span> series A warrant to purchase <span style="-sec-ix-hidden:c134564344">one</span> share of common stock (the &#8220;Series A Warrants&#8221;); and (ii) 917,596 pre-funded units (the &#8220;Pre-Funded Units&#8221;) and together with the Common Units, the "Units", each Pre-Funded Unit consisting of <span style="-sec-ix-hidden:c134564346">one</span> pre-funded warrant to purchase <span style="-sec-ix-hidden:c134564347">one</span> share of common stock (the &#8220;Pre-Funded Warrant&#8221;) and <span style="-sec-ix-hidden:c134564348">one</span> Series A Warrant. The purchase price of each Common Unit was $6.540, and the purchase price of each Pre-Funded Unit was $6.539.&#160;In addition, the Company granted the underwriters in the Offering a 45-day option to purchase an additional 206,422 shares of common stock, and/or an additional 206,422 Series A Warrants, solely to cover over-allotments, if any. The Pre-Funded Warrants have an exercise price of $0.001 per share, are immediately exercisable and <em style="font: inherit;"> may </em>be exercised at any time until all of the Pre-Funded Warrants are exercised in full. The Series A Warrants have an exercise price of $6.540 per share, are immediately exercisable and <em style="font: inherit;"> may </em>be exercised at any time until the <span style="-sec-ix-hidden:c134564356">five</span>-year anniversary of the date of issuance. Both the Pre-Funded Warrants and the Series A Warrants are subject to a beneficial ownership limitation of 4.99%. The Offering closed on <em style="font: inherit;"> November 25, 2024. </em>On <em style="font: inherit;"> November 22, 2024, </em>the underwriters partially exercised their over-allotment option with respect to 156,809 shares of common stock and 156,809 Series A Warrants. The aggregate gross proceeds to the Company, including the partial exercise of the over-allotment option, were approximately $10.0 million, before deducting underwriting discounts and other expenses by the Company of $1.5 million, including $0.5 million of non-cash expenses. The net cash proceeds to the Company were approximately $9.0 million.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> February 28, 2025, </em>the Company entered into an At Market Issuances Sales Agreement (the &#8220;ATM Agreement&#8221;) with Ladenburg Thalmann &amp; Co. Inc. (the &#8220;Agent&#8221;). Pursuant to the terms of the ATM Agreement, the Company <em style="font: inherit;"> may </em>sell from time to time through the Agent, as sales agent or principal, shares of the Company&#8217;s common stock with an initial aggregate sales price of up to $2.1 million (the &#8220;Shares&#8221;). Any sale of Shares pursuant to the Agreement will be made under the Company&#8217;s &#8220;shelf&#8221; registration statement (the &#8220;Registration Statement&#8221;) on Form S-<em style="font: inherit;">3</em> filed on <em style="font: inherit;"> February 28, 2025 </em>with the Securities and Exchange Commission (the &#8220;SEC&#8221;). Under the ATM Agreement, the Company <em style="font: inherit;"> may </em>sell Shares through the Agent by any method that is deemed an &#8220;at the market offering&#8221; (as defined in Rule <em style="font: inherit;">415</em>(a)(<em style="font: inherit;">4</em>) under the Securities Act of <em style="font: inherit;">1933,</em> as amended). Under the ATM Agreement, the Agent will also be able to sell shares of Common Stock by any other method permitted by law, including in negotiated transactions with the Company&#8217;s prior written consent. The Company will pay a commission to the Agent of 3.0% of the gross proceeds of the sale of the Shares sold under the ATM Agreement and reimburse the Agent for certain expenses. As of <em style="font: inherit;"> March 31, 2025, </em>the Company sold 800 shares pursuant to the ATM Agreement for net proceeds of approximately $1,746.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company estimates its current cash resources are sufficient to fund its operations into but <em style="font: inherit;">not</em> beyond the <em style="font: inherit;">first</em> calendar quarter of <em style="font: inherit;">2026.</em> The Company recognizes it will need to raise additional capital to continue to execute its business plan, including obtaining regulatory clearance for its products currently under development and commercializing and generating revenues from products under development. There is <em style="font: inherit;">no</em> assurance that additional financing will be available when needed or that management will be able to obtain financing on terms acceptable to the Company. A failure to raise sufficient capital, generate sufficient product revenues, control expenditures and regulatory matters, among other factors, will adversely impact the Company&#8217;s ability to meet its financial obligations as they become due and payable and to achieve its intended business objectives. If the Company is unable to raise sufficient additional funds, it will have to scale back its operations.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Basis of Presentation</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The annual financial statements and disclosures have been prepared using the accrual basis of accounting in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;).</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Use of Estimates in Financial Statement Presentation</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The preparation of these financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The Company's significant estimates and assumptions include the valuation of equity related instruments, and initial and recurring fair value measurements for the warrant liability. Although the Company believes that its estimates and assumptions are reasonable, they are based upon information available at the time the estimates and assumptions were made. Some of these judgments can be subjective and complex, and, consequently, actual results could differ from those estimates.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Cash and Cash Equivalents</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company considers all highly liquid accounts with original maturities of <em style="font: inherit;">three</em> months or less at the date of acquisition to be cash equivalents.&#160;Periodically, the Company <em style="font: inherit;"> may </em>carry cash balances at financial institutions in excess of the federally insured limit of <em style="font: inherit;">$250,000.</em> The Company has <em style="font: inherit;">not</em> experienced losses on these accounts and management believes, based upon the quality of the financial institutions, that the credit risk with regard to these deposits is <em style="font: inherit;">not</em> significant.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Offering and Financing Costs</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Offering costs consist of professional costs incurred through the balance sheet date that were direct and incremental to the Company&#8217;s equity financing activities. Specifically, offering costs were incurred on the Company's IPO, the Offering and the Registration Statement. The costs for the Registration Statement are recorded in deferred offering costs on the balance sheet as of <em style="font: inherit;"> March 31, 2025. </em>Costs associated with salaries and other period costs were expensed as incurred.&#160;</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">During the year ended <em style="font: inherit;"> March 31, 2024, </em>the Company paid $1.3 million of issuance&#160;costs related to its IPO.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">During the year ended <em style="font: inherit;"> March 31, 2025, </em>the Company paid $1.1 million of issuance costs related to its Offering and $0.2 million of offering costs related to its Registration Statement.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Property and Equipment</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Property and equipment are stated at historical cost and depreciated on a straight-line basis over their estimated useful lives, generally&#160;<span style="-sec-ix-hidden:c134564384">three</span> years. Upon disposition of the assets, the costs and related accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the results of operations.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Convertible Notes</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company evaluates embedded redemption, conversion and other features within its debt to determine whether any embedded features should be bifurcated from the host instrument and accounted for as a derivative at fair value, with changes in fair value recorded in the statement of operations.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company&#8217;s debt is carried on the balance sheet on a historical cost basis net of unamortized discounts and premiums because the Company has <em style="font: inherit;">not</em> elected the fair value option of accounting. Costs associated with acquiring debt, including detachable warrants issued in connection with the financing, are capitalized as a debt discount. The debt discount is presented in the balance sheet as a direct deduction from the carrying amount of the debt liability. The costs are amortized over the estimated contractual life of the related debt instrument using the effective interest method and are included in interest expense in the statement of operations.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">If the Company incurs costs associated with its convertible notes, in advance of the receipt of proceeds, the Company will record a deferred asset. Upon receipt of proceeds the Company will reclassify the deferred asset as a direct deduction from the carrying amount, as described above.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">In addition, since the instruments included a substantive conversion feature at the time of issuance, the issuance of equity securities were accounted for as a contractual conversion with <em style="font: inherit;">no</em> gain or loss recognized related to the equity securities issued to settle the instrument. &#160;</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Fair Value of Financial Instruments</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs. The Company utilizes a <em style="font: inherit;">three</em>-level valuation hierarchy for disclosures of fair value measurements, defined as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Level <em style="font: inherit;">1</em> &#8211; inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
      <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Level <em style="font: inherit;">2</em> &#8211; inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the assets or liability, either directly or indirectly, for substantially the full term of the financial instruments.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Level <em style="font: inherit;">3</em> &#8211; inputs to the valuation methodology are unobservable and significant to the fair value and require significant judgment and estimation.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Financial assets and financial liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. While the Company believes that its valuation methods are appropriate, the Company recognizes that the use of different methodologies or assumptions to determine the fair value could result in a different estimate of fair value at the reporting date. The primary assumptions that would significantly affect the fair values are the probability weighting of the different settlement outcomes used.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company did <em style="font: inherit;">not</em> have any assets or liabilities measured at fair value as of <em style="font: inherit;"> March 31, 2025 </em>and <em style="font: inherit;">2024,</em> respectively. In the <em style="font: inherit;">fourth</em> quarter of the Company's fiscal year ended <em style="font: inherit;"> March 31, 2024 </em>there was a transfer out of Level <em style="font: inherit;">3</em>&#160;for the warrant liability, for the settlement and reclassification to equity of the instrument, that occurred in the&#160;<em style="font: inherit;">three</em> months ended&#160;<em style="font: inherit;"> March 31, 2024. </em>For additional information, see&#160;<i>Note <em style="font: inherit;">2</em> - Warrant Liability and Fair Value of Financial Instruments</i>.&#65279;</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The carrying value of short-term instruments, including cash, accounts payable, accrued expenses and convertible notes included in long-term debt, approximate fair value due to the relatively short period to maturity for these instruments.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Related Parties</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company follows ASC <em style="font: inherit;">850,</em>&#160;<i>Related Party Disclosures</i>,&#160;for the identification of related parties and disclosure of related party transactions. See further discussion in the Notes below on this matter.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Income Taxes</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting and the tax basis of reported assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company must then assess the likelihood that the resulting deferred tax assets will be realized. A valuation allowance is provided when it is more likely than <em style="font: inherit;">not</em> that some portion or all of a deferred tax asset will <em style="font: inherit;">not</em> be realized. As of&#160;<em style="font: inherit;"> March 31, 2025 </em>and&#160;<em style="font: inherit;"> March 31, 2024 </em>the Company determined a full valuation allowance was required to offset its deferred tax assets as a result of recurring operating losses.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company accounts for uncertain tax positions in accordance with the provisions of ASC <em style="font: inherit;">740</em>-<em style="font: inherit;">10</em> which prescribes a recognition threshold and measurement attribute for financial statement disclosure of tax positions taken, or expected to be taken, on its tax return. The Company evaluates and records any uncertain tax positions based on the amount that management deems is more likely than <em style="font: inherit;">not</em> to be sustained upon examination and ultimate settlement with the tax authorities in the tax jurisdictions in which it operates. As of <em style="font: inherit;"> March 31, 2025 </em>and&#160;<em style="font: inherit;"> March 31, 2024 </em>the Company had no uncertain tax positions.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Stock-based Compensation</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Employee share-based compensation is measured at the grant date, based on the fair value of the award, and is recognized as an expense over the requisite service period.&#160;For awards with a performance condition, compensation expense is recognized over the requisite service period if it is probable that the performance condition will be satisfied. For awards to non-employees, the Company recognizes compensation expense in the same manner as if the Company had paid cash for the goods or services. The Company estimates the fair value of options and equity classified warrants granted using an options pricing model. Expense is recognized within general and administrative and research and development expenses and forfeitures are recognized as they are incurred.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Warrants</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s specific terms and applicable authoritative guidance in FASB ASC <em style="font: inherit;">480,</em> Distinguishing Liabilities from Equity (&#8220;ASC <em style="font: inherit;">480&#8221;</em>) and ASC <em style="font: inherit;">815,</em> Derivatives and Hedging (&#8220;ASC <em style="font: inherit;">815&#8221;</em>). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC <em style="font: inherit;">480,</em> meet the definition of a liability pursuant to ASC <em style="font: inherit;">480,</em> and whether the warrants meet all of the requirements for equity classification under ASC <em style="font: inherit;">815,</em> including whether the warrants are indexed to the Company&#8217;s own ordinary shares and whether the warrant holders could potentially require &#8220;net cash settlement&#8221; in a circumstance outside of the Company&#8217;s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
      <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do <em style="font: inherit;">not</em> meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss on the&#160;statements of operations. The fair value of the warrants is estimated using a Black-Scholes pricing model or a Monte Carlo simulation.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company&#65279; issued warrants to purchase shares of common stock (i) in connection with the Bridge Offering, (ii) as part of selling agent compensation in <em style="font: inherit;">2024,</em> (iii) in connection with the Exclusive License Termination Agreement (the &#8220;Termination Agreement&#8221;), and (iv) as part of the Offering&#65279;. Based on the guidance noted above, we determined that warrants issued in connection with the Termination Agreement should be accounted for as a liability and the remaining warrants issued meet the requirements for equity classification. Liability classified warrants are subject to remeasurement at each balance sheet date, while equity classified warrants are valued at inception only. As discussed in Note <em style="font: inherit;">2,</em> the liability warrants subsequently met the requirements for equity classification.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Loss Per Common Share</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Basic loss per common share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period, which includes shares issuable for little to <em style="font: inherit;">no</em> consideration upon the exercise of certain equity-classified warrants. Diluted loss per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. In periods when losses are reported, the weighted-average number of common shares outstanding excludes common stock equivalents, because their inclusion would be anti-dilutive. Generally, the Company&#8217;s outstanding warrants are non-participating securities as they are <em style="font: inherit;">not</em> entitled to non-forfeitable rights to dividends or dividend equivalents during the vesting term and have <em style="font: inherit;">no</em> obligation to fund losses.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">However, the Company's warrants d&#65279;escribed in Note&#160;<em style="font: inherit;">2</em>&#160;and the warrants issued in connection with the Offering, are participating securities as the holders receive the right to dividends, but they are <em style="font: inherit;">not</em> obligated to fund losses. In periods of loss, since <em style="font: inherit;">no</em> income is allocated to these securities, the Company's use of the "treasury stock method" derives the same result. The dilutive effect of convertible securities is calculated using the &#8220;if-converted method.&#8221; Under the if-converted method, securities are assumed to be converted at the beginning of the period, and the resulting common shares are included in the denominator of the diluted calculation for the entire period being presented.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
      <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">For the <em style="font: inherit;">twelve</em> months ended <em style="font: inherit;"> March 31, 2025&#160;</em>and <em style="font: inherit;">2024,</em> dilutive securities that were <em style="font: inherit;">not</em> included in the calculations of the loss per common share because they would be anti-dilutive included the following:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 5%; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>March 31,</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(as revised)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Equity based warrants to purchase common shares</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">87,531</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,334</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Convertible Notes - common shares (1)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">33,250</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Convertible Notes - equity-based warrants to purchase common shares</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">25,003</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">25,003</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock options granted under Company's incentive plan</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">243,483</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">100,180</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Series A Warrants</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,533,096</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Representative Warrants</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">91,985</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total potentially dilutive securities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,981,098</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">162,767</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
    <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 108pt;">(<em style="font: inherit;">1</em>) Shares for the convertible note proceeds received</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Research and Development Costs</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Research and development costs are expensed as incurred.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Advertising</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">It is our policy to expense advertising costs as incurred. Advertising&#160;expenses are included within general and administrative expenses within the statement of operations. For the years ended <em style="font: inherit;"> March 31, 2025 </em>and <em style="font: inherit;">2024,</em> the Company recorded less than $0.1&#160;million and $1.8&#160;million, respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Fair Value of Common Stock</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Prior to establishing a public market for the Company&#8217;s common stock, the estimated fair value of the Company&#8217;s common stock was determined by the Company&#8217;s Board of Directors (the "Board") as of the date of each option grant, with input from management, considering the Company&#8217;s most recently available <em style="font: inherit;">third</em>-party valuations of common stock, recent sales of common stock to <em style="font: inherit;">third</em> parties, and the Company&#8217;s board of directors&#8217; assessment of additional objective and subjective factors that it believed were relevant and which <em style="font: inherit;"> may </em>have changed from the date of the most recent valuation through the date of the grant.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>JOBS Act Accounting Election</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company qualifies as an emerging growth company ("EGC"), as defined in the Jumpstart Our Business Startups Act of <em style="font: inherit;">2012</em> (the &#8220;JOBS Act&#8221;). The JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected <em style="font: inherit;">not</em> to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This <em style="font: inherit;"> may </em>make comparison of the Company&#8217;s financial statements with another public company which is neither an early-stage company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Segments</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker ("CODM"), or decision-making group, in deciding how to allocate resources in assessing performance. Management has determined that the Company operates in&#160;<span style="-sec-ix-hidden:c134564434">one</span>&#160;reportable segment, which is advancing the development of innovative technologies for sensing and treating disorders relating to the nervous system. The Company is initially focused on developing the technology for patients with pancreatic cancer, however, the Company believes the technology constitutes a platform with the potential to address several indications, including chronic pain management, hypertension, cardiovascular disease and a wide range of other nerve-related disorders. The Company's CODM is its Chief Executive Officer.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
      <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The accounting policies of the segment are the same as those described in the summary of significant accounting policies. The CODM assesses performance based on net loss, which is reported on the Statements of Operations. The measure of segment assets is reported on the balance sheet as total assets.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">To date, the Company has <em style="font: inherit;">not</em> generated any product revenue. The Company expects to continue to incur significant expenses and operating losses for the foreseeable future as it advances its' technology through all stages of development and clinical trials and, ultimately, seek regulatory approval.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">As such, the CODM primarily evaluates performance of the Company using various financial metrics, including the combined net income (loss) from operations, also shown on the Statements of Operations, forecasted cash expenditures and existing and forecasted cash balances. These financial metrics are used by the CODM to make key operating decisions, such as the assessment of segment performance and allocation of resources. The significant expense categories within net loss from operations that the CODM regularly reviews are expenses related to research and development, general and administrative, and depreciation and amortization. The significant expense categories and subcategories are reported on the Statements of Operations.&#160;Other expenses included in the Company&#8217;s net loss include change in fair value of warrant liabilities, other income (expense), interest income, net, and any additional non-operating expenses that are reported on the Statements of Operations.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Recent Accounting Pronouncements</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">In&#160;<em style="font: inherit;"> November 2024 </em>and <em style="font: inherit;"> January 2025,&#160;</em>FASB issued ASU&#160;<em style="font: inherit;">2024</em>-<em style="font: inherit;">03</em> and ASU <em style="font: inherit;">2025</em>-<em style="font: inherit;">01,</em>&#160;Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic&#160;<em style="font: inherit;">220</em>-<em style="font: inherit;">40</em>): Disaggregation of Income Statement Expenses, which requires disclosure in the notes to the financial statements of specified information about certain costs and expenses. The amendments to the standards are effective for fiscal years beginning after&#160;<em style="font: inherit;"> December 15, 2026,&#160;</em>and for interim periods within fiscal years beginning after&#160;<em style="font: inherit;"> December 15, 2027.&#160;</em>Early adoption is permitted. The amendments should be applied either prospectively to financial statements issued for reporting periods after the effective date of this ASU or retrospectively to any or all prior periods presented in the financial statements. The Company is currently evaluating the new guidance to determine the impact it&#160;<em style="font: inherit;"> may&#160;</em>have on its financial statements and related disclosures.&#160;</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">In <em style="font: inherit;"> December 2023, </em>the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update, or ASU <em style="font: inherit;">2023</em>-<em style="font: inherit;">09,</em> Income Taxes (Topic <em style="font: inherit;">740</em>): Improvements to Income Tax Disclosures. ASU <em style="font: inherit;">2023</em>-<em style="font: inherit;">09</em>&#160;improves the transparency of income tax disclosures by requiring consistent categories and greater disaggregation of information in the effective tax rate reconciliation and income taxes paid disaggregated by jurisdiction. It also includes certain other amendments to improve the effectiveness of income tax disclosures. This guidance will be effective for the annual periods beginning after the year ended <em style="font: inherit;"> December 31, 2024. </em>The Company is currently assessing the impact of ASU <em style="font: inherit;">2023</em>-<em style="font: inherit;">09</em> on its disclosures.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">In <em style="font: inherit;"> November 2023, </em>the FASB issued ASU <em style="font: inherit;">No.</em> <em style="font: inherit;">2023</em>-<em style="font: inherit;">07,</em> Improvements to Reportable Segment Disclosures (ASU <em style="font: inherit;">2023</em>-<em style="font: inherit;">07</em>) which is intended to improve reportable segment disclosures primarily through enhanced disclosure of reportable segment expenses and requires that a public entity that has a single reportable segment provide all the disclosures required by ASU <em style="font: inherit;">2023</em>-<em style="font: inherit;">07</em> and all existing segment disclosures in Topic <em style="font: inherit;">280.</em> The new guidance is required to be applied retrospectively to all prior periods presented in the financial statements and is effective for the Company for fiscal periods beginning after <em style="font: inherit;"> December 15, 2023 </em>and interim periods within fiscal years beginning after <em style="font: inherit;"> December 15, 2024. </em>The Company adopted ASU <em style="font: inherit;">2023</em>-<em style="font: inherit;">07</em> during the year ended <em style="font: inherit;"> March 31, 2025. </em>There was <em style="font: inherit;">no</em> impact upon adoption of ASU <em style="font: inherit;">2023</em>-<em style="font: inherit;">07.</em>&#160;The Company views its operations and manages its business in&#160;<span style="-sec-ix-hidden:c134564463">one</span>&#160;operating segment.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">There are <em style="font: inherit;">no</em> other effective pronouncements, or pronouncements issued but <em style="font: inherit;">not</em> yet effective, if adopted, that would have a material effect on the accompanying financial statements.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i></i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Correction of an Immaterial Error in the Prior Period Financial Statements</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">D&#65279;uring the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> December 31, 2024, </em>the Company determined that previously filed quarterly and annual financial statements had an immaterial earnings per share error resulting from the exclusion of certain unexercised equity based warrants to purchase common shares that had an exercise price of approximately $0.01 or less from the basic earnings per share calculations in accordance with <i>ASC <em style="font: inherit;">260</em>-<em style="font: inherit;">10</em>-<em style="font: inherit;">45</em>-<em style="font: inherit;">13</em></i>. As a&#160;result, the prior year earnings per share calculations have been revised for consistency with the current year presentation. The Company assessed the materiality of this change in presentation on prior period financial statements in accordance with <i>SEC Staff Accounting Bulletin <em style="font: inherit;">No.</em> <em style="font: inherit;">99</em></i>, &#8220;<i>Materiality</i>,&#8221; (<i>ASC Topic <em style="font: inherit;">250,</em> Accounting Changes and Error Corrections</i>). Based on this assessment, the Company concluded that this error correction in its&#160;<i>Statements of Operations</i>&#160;and <i>Note <em style="font: inherit;">1</em> </i>&#8211;<i> Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies (Loss Per Common Share)</i> is <em style="font: inherit;">not</em> material to any previously presented financial statements based upon overall considerations of both quantitative and qualitative factors. The corrections had <em style="font: inherit;">no</em> impact in the comparative period Balance Sheet,&#160;Statements of Cash Flows, or Statement of Changes in Stockholders&#8217;&#160;Equity. Further, the immaterial correction did <em style="font: inherit;">not</em> result in a change in operating losses or net loss in the Statement of Operations and the effects of including unexercised warrants in the earnings per share calculation have an antidilutive effect reducing the net loss per share amount. Accordingly, the Company corrected the previously reported earnings per share calculation for the <em style="font: inherit;">twelve</em> months ended <em style="font: inherit;"> March 31, 2024 </em>in this Annual Report on Form <em style="font: inherit;">10</em>-K.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
      <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">A summary of the impact of the Company&#8217;s Reverse Stock Split and immaterial corrections reflecting the prior period impact to the Company&#8217;s Statement of Operations and earnings per share are shown below:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Twelve Months Ended March 31, 2024</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Originally</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Filed</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Adjusted </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>for 1-for-20 </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Reverse </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Stock Split</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Correction</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>As Revised</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net Loss (in thousands)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(15,426</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(15,426</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Loss per share - basic and diluted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(1.05</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(21.09</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6.27</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(14.82</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Weighted average shares outstanding - basic and diluted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">14,626,282</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">731,372</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">309,348</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,040,720</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
    <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">A summary of the impact of the Company&#8217;s Reverse Stock Split and immaterial corrections reflecting the prior period impact to the disclosure of dilutive securities that were <em style="font: inherit;">not</em> included in the calculations of the loss per common share because they would be anti-dilutive are shown below:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

     <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Twelve Months Ended March 31, 2024</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Originally </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Filed</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Adjusted f</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>or 1-for-20 </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Reverse </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Stock Split</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Correction</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>As Revised</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Equity based warrants to purchase common shares</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,744,569</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">287,231</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(282,897</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,334</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Convertible Notes - common shares</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">665,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">33,250</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">33,250</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Convertible Notes - equity-based warrants to purchase common shares</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">500,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">25,003</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">25,003</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock options granted under Company's incentive plan</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,003,600</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">100,180</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">100,180</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Total potentially dilutive securities</b></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"><b>&#160;</b></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>8,913,169</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"><b>&#160;</b></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>445,664</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"><b>&#160;</b></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>(282,897</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"><b>)</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"><b>&#160;</b></td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>162,767</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
     <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>


  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Convertible Notes Payable - 10Q<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Note <em style="font: inherit;">2</em></b>&#160;&#8211;<b> Convertible Notes Payable</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> September 9, 2023, </em>the Company's Board authorized an offering of up to $2.0 million in unsecured, non-interest bearing convertible promissory notes (the &#8220;Notes&#8221;) and accompanying warrants (the &#8220;Bridge Financing Warrants&#8221;) (collectively, the &#8220;Bridge Offering&#8221;) that mature on <em style="font: inherit;"> December 31, 2025. </em>The Notes provided that, on the closing date of the IPO, the outstanding principal would be automatically converted into common stock at the conversion price of $40.00. Each dollar in principal amount of Notes purchased were accompanied by a <span style="-sec-ix-hidden:c134564938">five</span>-year Bridge Financing Warrant to purchase approximately 0.0125 shares of Common stock with an exercise price of $20.00 per share. The Company records the Bridge Financing Warrants as a discount to the Notes.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Bridge Financing Warrants can be exercised from the date of Notes issuance through the <em style="font: inherit;">five</em>-year anniversary of the issuance of the Notes. The Note holders are <em style="font: inherit;">not</em> permitted to convert their Notes when the holders or any of their affiliates would beneficially own in excess of 4.99% of the Company&#8217;s common stock after such conversion.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company received proceeds of $2.0 million of Notes from the Bridge Offering. The Company&#8217;s effective interest rate for the Notes was 15.3% due to the amortization of the discount stemming from the issuance of the Bridge Financing Warrants. On <em style="font: inherit;"> January 26, 2024, </em>the Company consummated its initial public offering (&#8220;IPO&#8221;). In connection with the closing of the IPO, a portion of the Notes were converted into 16,750 shares of common stock. Upon the closing of the IPO, certain Notes that were to be automatically converted according to their terms into &#65279;common stock were <em style="font: inherit;">not</em> converted due to restrictions on the holders of the Notes or any of their affiliates beneficially owning in excess of 4.99% of the Company's common stock after such conversion. The remaining portion of the N&#65279;otes was converted into 33,250 shares of common stock on <em style="font: inherit;"> March 28, 2025.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Warrants - Convertible Promissory Notes</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">During <em style="font: inherit;"> September </em>to <em style="font: inherit;"> December 2023, </em>the Company issued the Notes with the detachable Bridge Financing Warrants. The Company utilized a Monte Carlo simulation model to determine the fair value of each Bridge Offering Warrant. The key inputs to the Monte Carlo simulation used to determine the fair value of each warrant include, the Company&#8217;s stock price fair value which was determined through a back solve calculation such that the stock price results in the average total value of the Notes and the Bridge Offering Warrants being equal to the cash proceeds received, volatility based on a selection of publicly held peer companies of 101.88%, expected term of 5 years, risk free rate of 4.40%, discount rate of 20.00% and a discount for lack of marketability of 15.77%.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">During the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> June 30, 2025 </em>and <em style="font: inherit;">2024,</em> the Company recorded $0 and less than $0.1 million, respectively, in interest expense related to the amortization of the debt discount.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The following table presents a summary of activity for the warrants issued in connection with the Company&#8217;s Notes:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted-</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Average</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Exercise Price</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Warrants</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Per Share</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding and exercisable, March 31, 2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">25,003</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">20.00</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Exercised</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Forfeited/Cancelled</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Expired</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding, June 30, 2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">25,003</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">20.00</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Exercisable, June 30, 2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">25,003</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">20.00</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <span></span>
</td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b>Note <em style="font: inherit;">3</em> </b>&#8211;<b> Convertible Notes Payable</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> September 9, 2023, </em>the Company's Board authorized an offering up to $2.0 million in unsecured, non-interest bearing convertible promissory notes (the &#8220;Notes&#8221;) and accompanying warrants (the &#8220;Bridge Financing Warrants&#8221;) (collectively, the &#8220;Bridge Offering&#8221;) that will mature on <em style="font: inherit;"> December 31, 2025. </em>The Notes provided that, on the closing date of the IPO, the outstanding principal would be&#160;automatically converted into common stock at the conversion price of $40.00. Each dollar in principal amount of Notes purchased were&#160;accompanied by a <span style="-sec-ix-hidden:c134564513">five</span>-year Bridge Financing Warrant to purchase 0.0125 shares of Common stock with an exercise price of $20.00 per share. The Company records the Bridge Financing Warrants as a discount to the Notes.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Bridge Financing Warrants can be exercised from the date of Notes issuance through the <em style="font: inherit;">five</em>-year anniversary of the issuance of the Notes. The shares issuable pursuant to the Notes and Bridge Financing Warrants had a 180-day lock-up after the Company&#8217;s IPO. Thereafter, the foregoing lock-up agreement ceased to apply to 25% of the purchased shares each month for a period of <em style="font: inherit;">four</em> months. The Note holders were <em style="font: inherit;">not</em> permitted to convert their Notes when the holders or any of their affiliates would beneficially own in excess of 4.99% of the Company&#8217;s common stock after such conversion.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">As of <em style="font: inherit;"> March 31, 2024, </em>the Company received proceeds of $2.0 million of Notes executed from the Bridge Offering.&#160;Upon the closing of the IPO, certain notes were to be automatically converted according to their terms into the Company&#8217;s common stock to the extent and provided that certain holders of these notes are <em style="font: inherit;">not</em> permitted to convert such notes to the extent that the holders or any of its affiliates would beneficially own in excess of 4.99% of the Company&#8217;s common stock after such conversion. Due to this 4.99% limitation, principal representing $1.3 million, or 33,250 shares, of these notes remained outstanding.&#160;As discussed in Note <em style="font: inherit;">1,</em> the remaining notes converted into common stock in accordance with their original terms on the IPO. During the year ended <em style="font: inherit;"> March 31, 2025, </em>the remaining Notes were converted into 33,250 shares.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company&#8217;s effective interest rate for the Notes was 15.3% due to the amortization of the discount stemming from the issuance of the Bridge Financing Warrants.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The following table presents a summary of activity for the Company&#8217;s <em style="font: inherit;">zero</em>-coupon convertible notes payable (in thousands):</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 5%; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Principal Amount</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Amortized Debt</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Discount</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Net Carrying</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Amount</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding, March 31, 2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,330</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(328</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,002</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Amortization of debt discount</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">175</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">175</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Issuance of common stock for extinguishment of convertible debt</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,330</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">153</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,177</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding, March 31, 2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Warrants</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company issued the Notes with detachable warrants for the purchase of shares of the Company&#8217;s common stock. The Company utilized a Monte Carlo simulation model to determine the fair value of each Bridge Offering Warrant. During the year ended <em style="font: inherit;"> March 31, 2024, </em>the Company issued warrants valued at $0.6 million. The key inputs to the Monte Carlo simulation used to determine the fair value of each warrant include, the Company&#8217;s stock price fair value which was determined through a back solve calculation such that the stock price results in the average total value of the Notes and the Bridge Offering Warrants being equal to the cash proceeds received, volatility based on a selection of publicly held peer companies of 101.88%, expected term of 5 years, risk free rate of 4.40%, discount rate of 20.00% and a discount for lack of marketability of 15.77%.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">During the year ended <em style="font: inherit;"> March 31, 2025, </em>the Company recorded less than $0.2 million in interest expense related to the amortization of the debt discount.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The following table presents a summary of activity for the warrants issued in connection with the Company&#8217;s Notes:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 0pt; margin-right: 0pt;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Warrants</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted-</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Average </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Exercise </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Price Per </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Share</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Remaining </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Life (In </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Years)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Aggregate </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Intrinsic </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Value*</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 48%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding and exercisable, March 31, 2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">25,003</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">20.00</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.48</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,010,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Exercised</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Forfeited/Cancelled</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Expired</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding, March 31, 2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">25,003</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">20.00</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3.48</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Exercisable, March 31, 2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">25,003</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">20.00</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3.48</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">*Aggregate Intrinsic Value = Excess of market value over the exercise price of all in-the-money warrants.&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Equity - 10Q<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Equity [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Note <em style="font: inherit;">3</em></b>&#160;&#8211;<b> Equity</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> November 29, 2023, </em>the Company&#8217;s Board and applicable shareholders approved to amend and restate the Company&#8217;s certificate of incorporation and increased the authorized shares to 500,000,000 shares of common stock and 10,000,000 shares of preferred stock, each with a par value of $0.001 per share. The specific rights of the preferred stock shall be determined by the Board.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;text-indent:9pt;"><i>Preferred Stock </i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;text-indent:9pt;">As of <em style="font: inherit;"> June 30, 2025, </em>the Company had no shares of preferred stock outstanding.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Restricted Stock</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> February 15, 2024, </em>the Company issued&#160;1,750 restricted shares of common stock to the Company's marketing consultant at the closing price of $76.00 of the Company's common stock. The total value of these shares is $133,000. These shares vested monthly over a 12-month period beginning on the issue&#160;date.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Three Months Ended June 30,</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Recognized in general and administrative expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">33,250</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">33,250</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">As of <em style="font: inherit;"> June 30, 2025, </em>there was $0 of unrecognized stock-based compensation expense related to Restricted Stock.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Common Stock </i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> February 28, 2025, </em>the Company entered into an ATM Agreement. Pursuant to the terms of the Agreement, the Company was permitted to sell from time to time shares of Company&#8217;s common stock, with an initial aggregate sales price of up to $2.1 million. As of <em style="font: inherit;"> June 30, 2025, </em>the Company sold 1,304,260 shares pursuant to the ATM Agreement for net proceeds of approximately $2.1 million.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Stock Plan and Stock Options</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">In <em style="font: inherit;"> June 2023, </em>the Company adopted, and the Company&#8217;s shareholders approved, the Autonomix Medical, Inc. <em style="font: inherit;">2023</em> Stock Plan (the &#8220;Plan&#8221;). The Plan is a stock-based compensation plan that provides for discretionary grants of stock options, stock awards and stock unit awards to key employees, non-employee directors, and consultants, subject to certain individual threshold limitations. The Plan initially provided for up to 200,000 shares to be issued, subject to adjustments as provided in the Plan. Shares that are surrendered because of forfeiture, expiration, termination, or cancellation are available for re-issuance.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">In <em style="font: inherit;"> August 2023, </em>the Plan was amended to allow for an automatic increase of the available shares for issuance, whereby on the <em style="font: inherit;">1st</em> of each fiscal year, beginning on <em style="font: inherit;"> April 1, 2024 </em>and ending on (and including) <em style="font: inherit;"> April 1, 2033 </em>in an amount equal to <em style="font: inherit;">five</em> percent (5%) of the total number of shares of Common Stock outstanding on the <em style="font: inherit;"> March </em><em style="font: inherit;">31st</em> immediately preceding the applicable date. However, the Board <em style="font: inherit;"> may </em>act prior to the automatic increase of a given year to provide that there will be <em style="font: inherit;">no</em> increase for such year, or that the increase for such year will be a lesser number of shares of Common Stock. On <em style="font: inherit;"> April 1, 2025, </em>the Plan was increased by 124,852 shares.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The following table summarizes the stock option activity for the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> June 30, 2025:</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted-</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Average</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Exercise Price</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Options</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Per Share</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding, March 31, 2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">243,483</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">32.72</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.85</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Exercised</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Forfeited/Cancelled</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Expired</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding, June 30, 2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">248,483</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">32.10</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Exercisable, June 30, 2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">69,916</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">37.24</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company&#8217;s stock option awards did <em style="font: inherit;">not</em> automatically adjust for the Reverse Stock Split.&#160;However, the Company chose to exercise its rights under the Plan to adjust the exercise price and number of shares exercisable or issuable upon vesting proportionately for the Reverse Stock Split.&#160;Based on the analysis performed, the Company does <em style="font: inherit;">not</em> need to recognize any additional compensation expense as a result of the modification.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">During the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> June 30, 2025, </em>the Company granted&#160;options to purchase 5,000 shares of common stock with a contractual term that vests&#65279; annually over <span style="-sec-ix-hidden:c134564987">four</span> years on the anniversary date. The options had an aggregate grant date fair value of $9 thousand that was calculated using the Black-Scholes option pricing model. Variables used in the Black-Scholes option pricing model included the following: (<em style="font: inherit;">1</em>) fair value of common stock on the measurement date; (<em style="font: inherit;">2</em>) discount rate ranging of 4.06% based on the daily yield curve rates for U.S. Treasury obligations, (<em style="font: inherit;">3</em>) expected life of 6.25 years based on the simplified method (vesting plus contractual term divided by <em style="font: inherit;">two</em>) and (<em style="font: inherit;">4</em>) expected volatility of 139%&#160;based on the historical volatility of comparable companies' stock.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">All options issued and outstanding are being amortized over their respective vesting periods. The unrecognized compensation expense at <em style="font: inherit;"> June 30, 2025 </em>was $3.9 million. During the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> June 30, 2025, </em>the Company recorded stock-based compensation - option expense of $0.3 million in general and administrative expense and less than $0.1 million in research and development expense. During the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> June 30, 2024,&#160;</em>the Company recorded stock-based compensation - option expense of $0.3 million in general and administrative expense and less than $0.1 million in research and development expense
    <span style="text-decoration: line-through; ">
      .
    </span></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;text-indent:9pt;"><i>License Agreement</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> July 10, 2024, </em>the Company entered into a license agreement (the &#8220;Agreement&#8221;) with RF Innovations, Inc. (&#8220;RFI&#8221;), a privately held medical technology company, to license products utilizing RFI&#8217;s intellectual property related to its Apex <em style="font: inherit;">6</em> Radiofrequency Generator (the &#8220;Licensed Products&#8221;). The Apex <em style="font: inherit;">6</em> Generator is a United States Food and Drug Administration (&#8220;FDA&#8221;) cleared ablation technology designed to lesion neural tissue for pain management in the peripheral nervous system. Pursuant to the Agreement, RFI granted us a perpetual non-exclusive worldwide royalty free fully paid license related to the Licensed Products, provided that the license did <em style="font: inherit;">not</em> include the right to sell certain products to customers for the treatment of spine pain. In connection with the Agreement, the Company issued RFI 12,500 unregistered shares of its common stock as consideration for the license. The Company determined that the fair value of the shares granted was $0.1 million, which represented its stock price on the date of the Agreement less a 25.6% discount for lack of marketability (&#8220;DLOM&#8221;). The Company concluded a DLOM was appropriate as the shares were subject to an initial lock-up period of <em style="font: inherit;">six</em> months followed by restrictions that allow for a maximum of 10% of total shares to be sold within a <em style="font: inherit;">30</em>-day period.&#160;The DLOM effectively reflects the value of an average strike put option relative to the Company's stock price and was calculated based on the Finnerty average put model.&#160;The Company concluded that the licensed technology qualified as a research and development expense pursuant to ASC Topic <em style="font: inherit;">730,</em> <i>Research and Development</i>, as the Company does <em style="font: inherit;">not</em> have an alternative future use for the technology and the Company does <em style="font: inherit;">not</em> have a plan to otherwise monetize the Licensed Products.&#160;The Agreement provides RFI the right to terminate the license if we breach any representation, warranty or covenant contained in the Agreement, subject to any relevant cure periods, or if we are subject to a bankruptcy or insolvency event.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Offering Agreement </i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> November 22, 2024, </em>the Company entered into the Offering, which consisted of: (i) 458,691 Common Units, each Common Unit consisting of <span style="-sec-ix-hidden:c134565018">one</span> share of common stock and <span style="-sec-ix-hidden:c134565019">one</span> Series A Warrant to purchase <span style="-sec-ix-hidden:c134565020">one</span> share of common stock; and (ii) 917,596 Pre-Funded Units, each Pre-Funded Unit consisting of <span style="-sec-ix-hidden:c134565022">one</span> Pre-Funded Warrant to purchase <span style="-sec-ix-hidden:c134565023">one</span> share of common stock and <span style="-sec-ix-hidden:c134565024">one</span> Series A Warrant. The purchase price of each Common Unit was $6.540, and the purchase price of each Pre-Funded Unit was $6.539.&#160;In addition, the Company granted the Underwriters a 45-day option to purchase additional 206,422 shares of common stock, and/or additional 206,422 Series A Warrants, solely to cover over-allotments, if any. The Offering closed on <em style="font: inherit;"> November 25, 2024. </em>On <em style="font: inherit;"> November 22, 2024, </em>the Underwriters partially exercised their over-allotment option with respect to 156,809 shares of Common Stock and 156,809 Series A Warrants. The Company received gross proceeds of $10.0&#160;million, before deducting the Underwriter's fees and other offering expenses payable by the Company.&#160;Under the terms of the Underwriting Agreement, the Underwriters received an underwriting discount of 8.0% to the public offering price for the Units. The Company also issued to the representative of the Underwriters (the "Representative") Representative's Warrants to purchase up to 91,985 shares of common stock.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Pre-Funded Warrants have an exercise price of $0.001 per share, are immediately exercisable and <em style="font: inherit;"> may </em>be exercised at any time until all of the Pre-Funded Warrants are exercised in full, subject to a beneficial ownership limitation of 4.99%. The Series A Warrants have an exercise price of $6.540 per share and <em style="font: inherit;"> may </em>be exercised at any time until the <span style="-sec-ix-hidden:c134565038">five</span>-year anniversary of the date of issuance, subject to a beneficial ownership limitation of 4.99%. The Pre-Funded Warrants and Series A Warrants were issued pursuant a Warrant Agency Agreement between the Company and Equity Stock Transfer, LLC.&#160;The Series A Warrants and the Representative&#8217;s Warrants, largely have the same terms and conditions, except the Representative&#8217;s Warrants were <em style="font: inherit;">not</em> exercisable until <em style="font: inherit;"> May 21, 2025 </em>and are subject to a 180-day lock-up prior to being transferable.&#160;The Series A Warrants and Representative&#8217;s Warrants <em style="font: inherit;"> may, </em>at the option of the holder be settled upon a change of control at the Black-Scholes value, as defined in the agreement.&#160;Upon a change of control the holder <em style="font: inherit;"> may </em>receive cash, other assets or shares of the successor entity, depending on the specific nature of the change of control transaction and the settlement options afforded to the holders of common stock.&#160;The Company analyzed the Pre-Funded Warrants, the Series A Warrants, and the Representative&#8217;s Warrants (collectively the &#8220;Offering Warrants&#8221;) in accordance with ASC Topic <em style="font: inherit;">480,</em> Distinguishing Liabilities from Equity and ASC Topic <em style="font: inherit;">815,</em> Derivatives and Hedging.&#160;Management concluded that the Offering Warrants meet all the requirements for equity classification.&#160;Since the Offering Warrants meet the requirements for equity classification and the Offering represents an arms-length cash transaction, the Common Units and Pre-Funded Units will be recorded in equity based on the proceeds received, net of issuance costs.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">At issuance the Pre-Funded Warrants had a fair value of $6.3290 per share, which represented the common stock issuance price less the $0.001 exercise price.&#160;At issuance, the Series A Warrants and the Representative&#8217;s Warrants had&#160;a fair value of $5.3597 and $5.2125&#160;per share, respectively, which was determined using a Black-Scholes option pricing model.&#160;Variables used in the Black-Scholes option pricing model included the following: (<em style="font: inherit;">1</em>) fair value of common stock on the measurement date; (<em style="font: inherit;">2</em>) discount rate of 4.17% based on the daily yield curve rates for U.S. Treasury obligations, (<em style="font: inherit;">3</em>) the contractual term of the warrants and (<em style="font: inherit;">4</em>) expected volatility of 144.15% based on the historical volatility of comparable companies' stock. Due to the relative volume of Series A Warrants and Representative&#8217;s Warrants issued compared with the Company&#8217;s outstanding shares, the Company's stock price was adjusted for the effects of dilution.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">In connection with the Offering, the Company incurred total offering costs of $1.5 million.&#160;This was comprised of $1.0 million in cash offering costs and $0.5 million&#160;for the fair value of the Representative&#8217;s Warrant issued.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Equity-Based Stock Warrants</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company will periodically grant warrants to investors in connection with equity financing or to <em style="font: inherit;">third</em>-party service providers in exchange for services rendered. The following table summarizes the stock warrant activity for the&#160;<em style="font: inherit;">three</em> months ended <em style="font: inherit;"> June 30, 2025:</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted-</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Average</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Exercise Price</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Warrants</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Per Share</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding, March 31, 2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,934,874</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="-sec-ix-hidden:c134564291">5.8860</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Exercised</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(222,132</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.0010</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Forfeited/Cancelled</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(130</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.0010</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Expired</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding, June 30, 2025*</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,712,612</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6.6498</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Exercisable, June 30, 2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,712,612</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6.6498</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">*</p> </td><td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Amount includes 87,531 common warrants; 91,985 Representative's Warrants and 1,533,096 Series A Warrants.</p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The unrecognized compensation expense at <em style="font: inherit;"> June 30, 2025 </em>for warrants issued to <em style="font: inherit;">third</em>-party service providers was $0. During the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> June 30, 2025 </em>and <em style="font: inherit;">2024,</em> the Company recorded stock-based compensation - warrant expense of $0 and less than $0.1 million, respectively.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <span></span>
</td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Note <em style="font: inherit;">4</em> </b>&#8211;<b> Equity</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> November 29, 2023, </em>the Company&#8217;s Board of Directors and applicable shareholders approved to amend and restate the Company&#8217;s certificate of incorporation and increased the authorized shares to 500,000,000 shares of common stock, with a par value of <span style="-sec-ix-hidden:c134564542">$.001</span> per share, and 10,000,000 shares of preferred stock, with a par value of <span style="-sec-ix-hidden:c134564544">$.001</span> per share. The specific rights of the preferred stock shall be determined by the Board of Directors.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Preferred Stock </i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">As of <em style="font: inherit;"> March 31, 2025, </em>the Company had no shares of preferred stock outstanding.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Restricted Stock</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> February 15, 2024, </em>the Company issued&#160;1,750 restricted shares of common stock to the Company's marketing consultant at the closing price of $76.00 of the Company's common stock. The total value of these shares is $133,000. These shares vest monthly over a 12-month period beginning on the issue&#160;date.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Year ended March 31,</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Recognized in general and administrative expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">116,375</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">16,625</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">116,375</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">16,625</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">For the year ended <em style="font: inherit;"> March 31, 2025, </em>there was no unrecognized stock-based compensation expense related to unvested Restricted Stock.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">A summary of activity regarding Restricted Stock issued is as follows:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Grant Date</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Number of </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Shares</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Fair Value Per </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Share</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding, March 31, 2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,604</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">76.00</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Vested</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,604</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">76.00</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding, March 31, 2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Common Stock </i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> April 6, 2023, </em>the Board of Directors approved a private placement offering of up to 100,000 common shares at a price of $40.00 per share. During the year ended <em style="font: inherit;"> March 31, 2024, </em>the Company sold 71,000 shares for cash proceeds of $2,840,000. The Company did <span style="-sec-ix-hidden:c134564555">not</span> incur any costs that were direct and incremental to the private placement.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> September 9, 2023, </em>the Board approved a Bridge Offering. See Note <em style="font: inherit;">3</em> <i>Convertible Notes Payable</i> for additional detail as these notes are convertible into common stock.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> February 28, 2025, </em>the Company entered into an ATM Agreement. Pursuant to the terms of the Agreement, the Company <em style="font: inherit;"> may </em>sell from time to time, the Company&#8217;s Common Stock, par value $0.001 per share, with an initial aggregate sales price of up to $2.1 million. As of <em style="font: inherit;"> March 31, 2025, </em>the Company sold 800 shares pursuant to the ATM Agreement for net proceeds of approximately $1,746.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Stock Plan and Stock Options</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">In <em style="font: inherit;"> June 2023, </em>the Company adopted, and the Company&#8217;s shareholders approved, the Autonomix Medical, Inc. <em style="font: inherit;">2023</em> Stock Plan (the &#8220;Plan&#8221;). The Plan is a stock-based compensation plan that provides for discretionary grants of stock options, stock awards and stock unit awards to key employees, non-employee directors, and consultants, subject to certain individual threshold limitations. The Plan provides for up to 200,000 shares to be issued. Shares that are surrendered because of forfeiture, expiration, termination, or cancellation are available for re-issuance. As of <em style="font: inherit;"> March 31, 2025, </em>there were 75,633 shares remaining available in the Plan.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">In <em style="font: inherit;"> August 2023, </em>the Plan was amended to allow for an automatic increase of the available shares for issuance, whereby on the <em style="font: inherit;">1st</em> of each fiscal year, beginning on <em style="font: inherit;"> April 1, 2024 </em>and ending on (and including) <em style="font: inherit;"> April 1, 2033 </em>in an amount equal to <em style="font: inherit;">five</em> percent (5%) of the total number of shares of Common Stock outstanding on the <em style="font: inherit;"> March </em><em style="font: inherit;">31st</em> immediately preceding the applicable date. However, the Board <em style="font: inherit;"> may </em>act prior to the automatic increase of a given year to provide that there will be <em style="font: inherit;">no</em> increase for such year, or that the increase for such year will be a lesser number of shares of Common Stock. On <em style="font: inherit;"> April 1, 2024, </em>the Plan was increased by 47,116 shares and on <em style="font: inherit;"> April 1, 2025, </em>the Plan was increased by 124,852 shares.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The following table summarizes the stock option activity for the year ended <em style="font: inherit;"> March 31, 2025.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Options</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted-</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Average </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Exercise </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Price </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Per Share</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted-</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Average </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Remaining</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Life </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(In Years)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Aggregate </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Intrinsic </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Value*</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding, March 31, 2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">100,180</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">46.59</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">9.35</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,680,672</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">143,303</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">23.02</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Exercised</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Forfeited/Cancelled</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Expired</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding, March 31, 2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">243,483</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">32.72</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">8.92</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Exercisable, March 31, 2025*</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">37,923</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">44.35</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">8.20</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">*Aggregate Intrinsic Value = Excess of market value over the exercise price of all in-the-money stock.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">During the year ended <em style="font: inherit;"> March 31, 2025, </em>the Company granted certain&#160;individuals options to purchase 143,303 shares of common stock with contractual terms&#160;of <span style="-sec-ix-hidden:c134564574">ten</span> years, and vesting periods of annually over <span style="-sec-ix-hidden:c134564575">four</span> years. The options had an aggregate grant date fair value of $2.6&#160;million that was calculated using the Black-Scholes option pricing model. Variables used in the Black-Scholes option pricing model included the following: (<em style="font: inherit;">1</em>) fair value of common stock on the measurement date ranging from $1.99 and $56.20 per share; (<em style="font: inherit;">2</em>) discount rate ranging from 4.17% to 4.39% based on the daily yield curve rates for U.S. Treasury obligations, (<em style="font: inherit;">3</em>) expected life of 6.25 years based on the simplified method (vesting plus contractual term divided by <em style="font: inherit;">two</em>), and (<em style="font: inherit;">4</em>) expected volatility ranging from 110% to 138% based on the historical volatility of comparable companies' stock.&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">All options issued and outstanding are being amortized over their respective vesting periods. The unrecognized compensation expense at <em style="font: inherit;"> March 31, 2025 </em>was $4.3 million. During the year ended <em style="font: inherit;"> March 31, 2025, </em>the Company recorded stock-based compensation - option expense of $1.5 million, of which $1.3 million was recorded&#160;in general and administrative expenses and $0.2 million was recorded in research and development expenses in the statements of operations. The unrecognized compensation expense at <em style="font: inherit;"> March 31, 2024 </em>was $3.1 million. During the year ended <em style="font: inherit;"> March 31, 2024, </em>the Company recorded stock-based compensation - option expense of $0.6 million, of which $0.5 million was recorded&#160;in general and administrative expenses and $0.1 million was recorded in research and development expenses in the statements of operations.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>License Agreement</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> July 10, 2024, </em>we entered into a license agreement (the &#8220;Agreement&#8221;) with RF Innovations, Inc. (&#8220;RFI&#8221;), a privately held medical technology company, to license products utilizing RFI&#8217;s intellectual property related to its Apex <em style="font: inherit;">6</em> Radiofrequency Generator (the &#8220;Licensed Products&#8221;). The Apex <em style="font: inherit;">6</em> Generator is a United States Food and Drug Administration (&#8220;FDA&#8221;) cleared ablation technology designed to lesion neural tissue for pain management in the peripheral nervous system. Pursuant to the Agreement, RFI granted us a perpetual non-exclusive worldwide royalty free fully paid license related to the Licensed Products, provided that the license did <em style="font: inherit;">not</em> include the right to sell certain products to customers for the treatment of spine pain. In connection with the Agreement, we issued RFI 12,500 unregistered shares of our common stock as consideration for the license. The Company determined that the fair value of the shares granted was $0.1 million, which represented its stock price on the date of the Agreement less a 25.6% discount for lack of marketability (&#8220;DLOM&#8221;).&#160; The Company concluded a discount for lack of marketability was appropriate as the shares are subject to an initial lock-up period of <em style="font: inherit;">six</em>-months until they are eligible for registration pursuant to SEC Rule <em style="font: inherit;">144</em> followed by restrictions that allow for a maximum of 10% of total shares to be sold within a <em style="font: inherit;">30</em>-day period.&#160;The DLOM effectively reflects the value of an average strike put option relative to our stock price and was calculated based on the Finnerty average put model.&#160;The Company concluded that the licensed technology qualified as a research and development expense pursuant to ASC Topic <em style="font: inherit;">730,</em> Research and Development, as the Company does <em style="font: inherit;">not</em> have an alternative future use for the technology and the Company does <em style="font: inherit;">not</em> have a plan to otherwise monetize the Licensed Products.&#160;The Company recognized $0.1 million in Research and Development expense in its condensed statement of income for the <em style="font: inherit;">three</em> and <em style="font: inherit;">nine</em>-months ended <em style="font: inherit;"> December 31, 2024.&#160;</em>The Agreement provides RFI the right to terminate the license if we breach any representation, warranty or covenant contained in the Agreement, subject to any relevant cure periods, or if we are subject to a bankruptcy or insolvency event.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Offering Agreement </i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> November 22, 2024, </em>the Company entered into the Offering, which consisted of: (i) 458,691 Common Units, each Common Unit consisting of <span style="-sec-ix-hidden:c134564614">one</span> share of common stock, par value $0.001 per share, and <span style="-sec-ix-hidden:c134564616">one</span> Series A Warrant to purchase <span style="-sec-ix-hidden:c134564617">one</span> share of common stock; and (ii) 917,596 Pre-Funded Units, each Pre-Funded Unit consisting of <span style="-sec-ix-hidden:c134564619">one</span> Pre-Funded Warrant to purchase <span style="-sec-ix-hidden:c134564620">one</span> share of common stock and <span style="-sec-ix-hidden:c134564621">one</span> Series A Warrant. The purchase price of each Common Unit was $6.540, and the purchase price of each Pre-Funded Unit was $6.539.&#160;In addition, the Company granted the Underwriters a 45-day option to purchase additional 206,422 shares of common stock, and/or additional 206,422 Series A Warrants, solely to cover over-allotments, if any. The Offering closed on <em style="font: inherit;"> November 25, 2024. </em>On <em style="font: inherit;"> November 22, 2024, </em>the Underwriters partially exercised their over-allotment option with respect to 156,809 shares of Common Stock and 156,809 Series A Warrants. The Company received gross proceeds of $10.0&#160;million, before deducting the placement agent's fees and other offering expenses payable by the Company.&#160;Under the terms of the Underwriting Agreement, the Underwriters received an underwriting discount of 8.0% to the public offering price for the Units.&#160; The Company also issued to the Representative&#8217;s Warrants to purchase up to 91,985 shares of Common Stock.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Pre-Funded Warrants have an exercise price of $0.001 per share, are immediately exercisable and <em style="font: inherit;"> may </em>be exercised at any time until all of the Pre-Funded Warrants are exercised in full, subject to a beneficial ownership limitation of 4.99%. The Series A Warrants have an exercise price of $6.540 per share and <em style="font: inherit;"> may </em>be exercised at any time until the <span style="-sec-ix-hidden:c134564635">five</span>-year anniversary of the date of issuance, subject to a beneficial ownership limitation of 4.99%. The Pre-Funded Warrants and Series A Warrants were issued pursuant a Warrant Agency Agreement between the Company and Equity Stock Transfer, LLC.&#160;The Series A Warrants and the Representative&#8217;s Warrants, largely have the same terms and conditions, except the Representative&#8217;s Warrants were <em style="font: inherit;">not</em> exercisable until <em style="font: inherit;"> May 21, 2025 </em>and were subject to a 180-day lock-up prior to being transferable.&#160;The Series A Warrants and Representative&#8217;s Warrants <em style="font: inherit;"> may, </em>at the option of the holder be settled upon a change of control at the Black-Scholes value, as defined in the agreement.&#160;Upon a change of control the holder <em style="font: inherit;"> may </em>receive cash, other assets or shares of the successor entity, depending on the specific nature of the change of control transaction and the settlement options afforded to the holders of Common Stock.&#160;The Company analyzed the Pre-Funded Warrants, the Series A Warrants, and the Representative&#8217;s Warrants (collectively the &#8220;Offering Warrants&#8221;) in accordance with ASC Topic <em style="font: inherit;">480,</em> Distinguishing Liabilities from Equity and ASC Topic <em style="font: inherit;">815,</em> Derivatives and Hedging.&#160;Management concluded that the Offering Warrants meet all the requirements for equity classification.&#160;Since the Offering Warrants meet the requirements for equity classification and the Offering represents an arms-length cash transaction, the Common Units and Pre-Funded Units were recorded in equity based on the proceeds received, net of issuance costs.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">At issuance the Pre-Funded Warrants had a fair value of $6.3290 per share, which represented the common stock issuance price less the $0.001 exercise price.&#160;At issuance, the Series A Warrants and the Representative&#8217;s Warrants had&#160;a fair value of $5.3597 and $5.2125&#160;per share, respectively, which was determined using a Black-Scholes option pricing model.&#160;Variables used in the Black-Scholes option pricing model included the following: (<em style="font: inherit;">1</em>) fair value of common stock on the measurement date; (<em style="font: inherit;">2</em>) discount rate of 4.17% based on the daily yield curve rates for U.S. Treasury obligations, (<em style="font: inherit;">3</em>) the contractual term of the warrants and (<em style="font: inherit;">4</em>) expected volatility of 144.15% based on the historical volatility of comparable companies' stock. Due to the relative volume of Series A Warrants and Representative&#8217;s Warrants issued compared with the Company&#8217;s outstanding shares, the Company's stock price was adjusted for the effects of dilution.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">In connection with the Offering, the Company incurred total offering costs of $1.5 million.&#160;This was comprised of $1.0 million in cash offering costs and $0.5 million&#160;for the fair value of the Representative&#8217;s Warrant issued.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Equity-Based Stock Warrants</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> January 26, 2024, </em>the Company issued <span style="-sec-ix-hidden:c134564655">five</span>-year warrants to the selling agent in the Company's IPO to purchase 2,988 shares of common stock at an exercise price of $125.00. Under the fair value method, the fair value of these warrants was estimated on the grant date using the Black-Scholes option pricing model. Variables used in the Black-Scholes warrant pricing model included the following: (<em style="font: inherit;">1</em>) fair value of common stock on the measurement date of $100.00 split-adjusted per share; (<em style="font: inherit;">2</em>) discount rate of 4.04% based on the daily yield curve rates for U.S. Treasury obligations; (<em style="font: inherit;">3</em>) expected life of 5 years and (<em style="font: inherit;">4</em>) expected volatility of 104% based on the historical volatility of comparable companies' stock. The costs associated with these shares were reclassified to additional paid-in capital upon completion of the Company&#8217;s IPO on <em style="font: inherit;"> January 26, 2024.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company will periodically grant warrants to investors in connection with equity financing or to <em style="font: inherit;">third</em>-party service providers in exchange for services rendered. The following table summarizes the stock warrant activity for the year ended <em style="font: inherit;"> March 31, 2025:</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Warrants</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted-</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Average </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Exercise </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Price Per </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Share</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted-</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Average </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Remaining </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Life (In </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Years)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Aggregate </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Intrinsic </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Value*</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding and exercisable, March 31, 2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">287,231</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.64</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.80</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">17,072,147</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,542,677</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.31</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Exercised**</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(892,432</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.04</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Forfeited/Cancelled</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(2,602</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.20</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Expired</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding, March 31, 2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,934,874</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5.89</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4.09</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">532,060</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Exercisable, March 31, 2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,842,889</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5.67</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4.06</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">532,060</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">*Aggregate Intrinsic Value = Excess of market value over the exercise price of all in-the-money stock.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><span style="-sec-ix-hidden:c134564667">**197,098</span>&#160;exercised shares utilized the &#8220;cashless exercise&#8221; option and 695,334 exercised shares were paid in cash.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The unrecognized compensation expense at <em style="font: inherit;"> March 31, 2025 </em>was $0. During the year ended <em style="font: inherit;"> March 31, 2025, </em>the Company recorded stock-based compensation - warrant expense of less than $0.1 million. The unrecognized compensation expense at <em style="font: inherit;"> March 31, 2024 </em>was less than <span style="-sec-ix-hidden:c134564671">$0.1</span> million.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">During the year ended <em style="font: inherit;"> March 31, 2024, </em>the Company recorded stock-based compensation - warrant expense of less than $0.1 million.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Under the fair value method, the fair value of each warrant was estimated on the grant date using the Black-Scholes option pricing model. Variables used in the Black-Scholes warrant pricing model included the following:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 71%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="7" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 23%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Range</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 71%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2025</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 8%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2024</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td></tr>
<tr class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 71%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Fair value of common stock on the measurement date (per share)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8211;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">$2.00</td><td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">to</em></td><td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5.00</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 71%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Discount rate based on the daily yield curve rates for U.S. Treasury obligations</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8211;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;">4.04%</td><td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;"><em style="font: inherit;">to</em></td><td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.54%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 71%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected life (in years)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8211;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;">3</td><td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;"><em style="font: inherit;">to</em></td><td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 71%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected volatility based on the historical volatility of comparable companies' stock</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8211;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;">104%</td><td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;"><em style="font: inherit;">to</em></td><td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">119%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Commitments and Contingencies - 10Q<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Note <em style="font: inherit;">4</em></b>&#160;&#8211;<b> Commitments and Contingencies</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Legal Proceedings</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">From time to time, the Company <em style="font: inherit;"> may </em>be involved in claims that arise during the ordinary course of business. Although the results of litigation and claims cannot be predicted with certainty, the Company does <span style="-sec-ix-hidden:c134565070">not</span> currently have any pending litigation to which it is a party or to which its property is subject that we believe to be material. There are <em style="font: inherit;">no</em> legal matters for which a reasonably estimated range of losses can be determined. Regardless of the outcome, litigation can be costly and time consuming, and it can divert management&#8217;s attention from important business matters and initiatives, negatively impacting our overall operations.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Employment Agreements</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company has agreements with key employees to provide certain benefits, including salary and other wage-related benefits, in the event of termination. In addition, the Company has adopted a severance policy for certain key members of executive management to provide certain benefits, including salary and other wage-related benefits, in the event of termination. In total, these benefits would amount to a range of $1.2&#160;million to $1.7 million using the rate of compensation in effect at <em style="font: inherit;"> June 30, 2025. </em>See Note <em style="font: inherit;">6</em> - Subsequent Events for additional information regarding events occurring after <em style="font: inherit;"> June 30, 2025.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Fractional Shares</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">See <i>Note <em style="font: inherit;">1</em> - Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies</i> - "<i>Reverse Stock Split</i>" for additional information.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> November 1, 2024, </em>the Company received notice from the Depository Trust and Clearing Corporation ("DTCC") on behalf of the brokerage firms that hold the shares of Company common stock held in &#8220;street name&#8221; that in connection with the rounding of fractional shares in connection with the Reverse Stock Split, the Company would need to issue 271,846 shares of common stock (the &#8220;Shares&#8221;) for the rounding of shares. The Company does <em style="font: inherit;">not</em> believe the number of Shares being requested is correct based on the historical number of shareholders of its common stock and is aware of similar anomalies in recent months for other companies completing a Reverse Stock Split. As such, the Company has begun an inquiry into the calculations set forth in the request. During the pendency of this inquiry, the Company does <em style="font: inherit;">not</em> intend to issue any shares in connection with the fractional shares being requested and has concluded that an obligation should <em style="font: inherit;">not</em> be recorded in its financial statements. The Company is <em style="font: inherit;">not</em> currently subject to any pending litigation as a result of the fractional roundup shares.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <span></span>
</td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Note <em style="font: inherit;">5</em> </b>&#8211;<b> Commitments and Contingencies</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Legal Proceedings</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">From time to time, we <em style="font: inherit;"> may </em>be involved in claims that arise during the ordinary course of business. Although the results of litigation and claims cannot be predicted with certainty, we do <span style="-sec-ix-hidden:c134564674">not</span> currently have any pending litigation to which we are a party or to which our property is subject that we believe to be material. Regardless of the outcome, litigation can be costly and time consuming, and it can divert management&#8217;s attention from important business matters and initiatives, negatively impacting our overall operations.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Employment Agreements</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company has agreements with key employees to provide certain benefits, including salary and other wage-related benefits, in the event of termination. In addition, the Company has adopted a severance policy for certain key members of executive management to provide certain benefits, including salary and other wage-related benefits, in the event of termination without cause. In total, these benefits would amount to a range of $1.1 million to $1.6 million&#160;using the rate of compensation in effect at <em style="font: inherit;"> March 31, 2025.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Brad Hauser - Chief Executive Officer</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> June 17, 2024, </em>we entered into an employment agreement with Brad Hauser pursuant to which Mr. Hauser agreed to serve as our chief executive officer and president for an initial <span style="-sec-ix-hidden:c134564678">three</span>-year period, which <em style="font: inherit;"> may </em>be extended on a year-to-year basis. Mr. Hauser&#8217;s agreement provides for an initial annual base salary of $450,000 (subject to an annual review and increase at the discretion of our Compensation Committee) and a target annual bonus of 60% of his base salary. Pursuant to the agreement, Mr. Hauser was granted a <span style="-sec-ix-hidden:c134564681">ten</span>-year option (the &#8220;Inducement Options&#8221;) to purchase 45,000 shares of common stock at an exercise price equal to the closing price of our common stock on the date of the employment agreement. The option vests in <em style="font: inherit;">four</em> equal annual installments (or 11,250 shares each installment) on each of the succeeding <em style="font: inherit;">four</em> anniversary dates of the execution of the employment agreement, provided Mr. Hauser is employed by us on each vesting date. In the event of a &#8220;change of control&#8221; or the termination of the agreement by us without &#8220;cause&#8221; or by Mr. Hauser for &#8220;good reason,&#8221; all of the unvested options shall immediately vest. The Inducement Options were granted outside of our <em style="font: inherit;">2023</em> Stock Plan as an inducement material to Mr. Hauser&#8217;s entering into employment with us in accordance with Nasdaq Stock Market Listing Rule <em style="font: inherit;">5635</em>(c)(<em style="font: inherit;">4</em>). Commencing with the year ending <em style="font: inherit;"> March 31, 2025, </em>Mr. Hauser will be eligible to receive annual option grants as determined by the Compensation Committee of the Board of Directors, based on criteria established by the Compensation Committee. The number of shares underlying the target annual option grant will be equal to $1,000,000 divided by the Black-Scholes value per share of our common stock on the date of grant.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">If Mr. Hauser&#8217;s employment is terminated at our election without &#8220;cause,&#8221; or by Mr. Hauser for &#8220;good reason,&#8221; Mr. Hauser shall be entitled to receive severance payments equal to <em style="font: inherit;">twelve</em> months of Mr. Hauser&#8217;s base salary and 100% of the target bonus for the year in which such termination occurs; provided that such amounts shall be increased by 50% if Mr. Hauser&#8217;s agreement is terminated without &#8220;cause&#8221; or by Mr. Hauser for &#8220;good reason&#8221; within <em style="font: inherit;">three</em> months prior to or <em style="font: inherit;">twelve</em> months after a &#8220;change of control.&#8221; In the event that any payments or benefits provided to Mr. Hauser would trigger the excise tax under Section <em style="font: inherit;">4999</em> of the Internal Revenue Code or any similar provision, the Company agreed to provide Mr. Hauser with a gross-up payment to ensure that, after payment of all taxes (including the excise tax, federal, state, and local income taxes, and employment taxes) imposed on the gross-up payment, Mr. Hauser receives a net amount equal to the payments or benefits Mr. Hauser would have received if the excise tax didn't apply.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Lori Bisson</i>&#160;-&#160;Executive <i>Vice Chairman (former Chief Executive Officer)</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> June 17, 2024, </em>we entered into an employment agreement with Lori Bisson pursuant to which Ms. Bisson agreed to serve as our Executive Vice Chairman and Strategic Adviser to the Chief Executive Officer for a <span style="-sec-ix-hidden:c134564696">two</span>-year period. Ms. Bisson&#8217;s agreement provides for an initial annual base salary of $150,000 (subject to an annual review and increase at the discretion of our Compensation Committee) and a target annual bonus of 50% of her base salary. Pursuant to the agreement, Ms. Bisson continued to vest in the option grants issued to Ms. Bisson in her role as chief executive officer and president in accordance with the vesting schedule set out in her initial employment agreement. In the event of a &#8220;change of control&#8221; or the termination of the agreement by us without &#8220;cause&#8221; or by Ms. Bisson for &#8220;good reason,&#8221; all of the unvested options shall immediately vest. Ms. Bisson is entitled to receive any compensation, including incentive compensation, for the fiscal year ended <em style="font: inherit;"> March 31, 2024 </em>that has <em style="font: inherit;">not</em> been paid as of the date of the agreement. Commencing with the year ending <em style="font: inherit;"> March 31, 2025, </em>Ms. Bisson will be eligible to receive annual option grants as determined by the Compensation Committee of the Board of Directors, based on criteria established by the Compensation Committee. Ms. Bisson agreed to waive any severance payments due to her in connection with the termination of the prior employment agreement that we entered into with her on <em style="font: inherit;"> June 30, 2023.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Fractional Shares</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">See <i>Note <em style="font: inherit;">1</em> - Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies</i> - "<i>Reverse Stock Split</i>" for additional information.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> November 1, 2024, </em>the Company received notice from the Depository Trust and Clearing Corporation ("DTCC") on behalf of the brokerage firms that hold the shares of Company common stock held in &#8220;street name&#8221; that in connection with the rounding of fractional shares in connection with the Reverse Stock Split, the Company would need to issue 271,846 shares of common stock (the &#8220;Shares&#8221;) for the rounding of shares. The Company does <em style="font: inherit;">not</em> believe the number of Shares being requested is correct based on the historical number of shareholders of its common stock and is aware of similar anomalies in recent months for other companies completing a Reverse Stock Split. As such, the Company has begun an inquiry into the calculations set forth in the request. During the pendency of this inquiry, the Company does <em style="font: inherit;">not</em> intend to issue any shares in connection with the fractional shares being requested and has concluded that an obligation should <em style="font: inherit;">not</em> be recorded in its financial statements. The Company is <em style="font: inherit;">not</em> currently subject to any pending litigation as a result of the fractional roundup shares.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 5 - Related Party Transactions - 10Q<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Note <em style="font: inherit;">5</em></b>&#160;&#8211;<b> Related Party Transactions</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> December 21, 2021, </em>the Company entered into a license agreement with a company controlled by a significant stockholder of the Company (&#8220;Licensee&#8221;). On <em style="font: inherit;"> July 7, 2023, </em>the Company and the Licensee entered into an Exclusive License Termination Agreement (the &#8220;Termination Agreement&#8221;) in exchange for the issuance, upon the closing of the Company&#8217;s initial public offering within <em style="font: inherit;">one</em> year of the agreement&#8217;s execution, of a warrant to purchase shares of the Company for a variable number of shares. The variable number of shares issued was based upon a fixed value of $8.0 million divided by the price per share in the offering. The warrants were exercisable at a price of $0.02 per share and <em style="font: inherit;"> may </em>be exercised any time after the issuance date, subject to a beneficial ownership limitation, and expired <span style="-sec-ix-hidden:c134565085">five</span> years from the original issuance. The warrants did <em style="font: inherit;">not</em> provide voting rights, dividend rights, and other rights of a shareholder prior to exercise. The shares underlying the warrant were subject to a lockup agreement for a period of <span style="-sec-ix-hidden:c134565087">six</span> months after the closing of the offering with respect to 12.5% of the shares issued and <span style="-sec-ix-hidden:c134565089">twelve</span> months after the closing of the offering for the remainder of the shares. The Company agreed to register the resale of the shares of common stock underlying the warrant upon a notice of <em style="font: inherit;">20</em> business days by the Warrant holder.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> January 29, 2024, </em>pursuant to the Termination Agreement, the Company issued a warrant to purchase 80,000 shares (the &#8220;Warrant&#8221;) pursuant to the Termination Agreement to the Licensee<i>.</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The completion of the Company&#8217;s IPO fixed the number of warrant shares issuable and the Company re-classified the Warrant to additional-paid in capital as it met the requirements for equity classification. Upon reclassification, the Company valued the warrant at $8.0&#160;million, which represented the fair value of the shares issued on that date.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


  <span></span>
</td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Note <em style="font: inherit;">6</em> </b>&#8211;<b> Related Party Transactions</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company utilizes a consulting firm that is owned by the Company&#8217;s former Chief Financial Officer to provide accounting and financial reporting services and pays certain expenses on behalf of the Company. During the year ended <em style="font: inherit;"> March 31, 2025 </em>and <em style="font: inherit;">2024,</em> the Company incurred fees of less than $0.1 million, respectively, for these services, excluding officer compensation. As of <em style="font: inherit;"> March 31, 2025 </em>and <em style="font: inherit;"> March 31, 2024, </em>the Company owed the consulting firm $0 and less than $0.1 million, respectively, for services and expenses.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">As of <em style="font: inherit;"> March 31, 2025, </em>members of the Company&#8217;s management/Board and an immediate family member of the Company&#8217;s management (related party), collectively purchased $0.5 million ($0.4 million and $0.1 million, respectively) of the Bridge Offering.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> December 21, 2021, </em>the Company entered into a perpetual, worldwide, exclusive license agreement (the &#8220;License&#8221; or &#8220;License Agreement&#8221;) with a company controlled by a significant stockholder of the Company (the &#8220;Licensee&#8221;). The License allows the Licensee to use certain intellectual property and technology related to the diagnosis and treatment of cardiovascular conditions held by the Company. Upon <em style="font: inherit;">90</em> days following the completion of an IPO or special purpose acquisition company transaction, the Licensee <em style="font: inherit;"> may </em>enter into sublicenses of the licensed intellectual property and technology.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> July 7, 2023, </em>the Company and the Licensee entered into an Exclusive License Termination Agreement (the &#8220;Termination Agreement&#8221;) in exchange for the issuance, upon the closing of the Company&#8217;s IPO within <em style="font: inherit;">one</em> year of the agreement&#8217;s execution, of a warrant to purchase shares of the Company for a variable number of shares. Upon the Company's closing of its IPO on <em style="font: inherit;"> January 29, 2024, </em>80,000&#160;warrant shares were issued at $100.00 per share for a fixed value of $8.0 million. The warrants are&#160;exercisable at a price of $0.02 per share and <em style="font: inherit;"> may </em>be exercised any time after the issuance date, subject to a beneficial ownership limitation, and expire <span style="-sec-ix-hidden:c134564722">five</span> years from the original issuance. The warrants contain dividend rights commensurate with the holders of common stock. The warrants do <em style="font: inherit;">not</em> include any other stockholder rights or privileges prior to exercise.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The shares underlying the warrant will be subject to a lockup agreement for a period of <span style="-sec-ix-hidden:c134564724">six</span> months after the closing of the IPO with respect to 12.5% of the shares issued and <span style="-sec-ix-hidden:c134564726">twelve</span> months after the closing of the IPO for the remainder of the shares. In connection with the Termination Agreement, the Company agreed to register the resale of the shares of common stock. One of the Company&#8217;s directors holds a 20% interest in the company receiving the warrant.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Subsequent Events - 10Q<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Note <em style="font: inherit;">6</em></b>&#160;&#8211;<b> Subsequent Events</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> July 21, 2025, </em>the Company entered into a warrant exercise inducement offer letter (the "Inducement Letter") with the holders ("Holders") of certain existing warrants issued in the Offering from <em style="font: inherit;"> November 2024 </em>to purchase up to 1,477,596 shares of the Company's common stock (the "Existing Warrants"). Pursuant to the Inducement Letter, the Company agreed to reduce the exercise price of the Existing Warrants to $1.723 per share, and the Holders agreed: (i) to exercise Existing Warrants to purchase 855,000 shares of Company common stock; and (ii) to prepay $1.722 per share of the reduced exercise price for Existing Warrants to purchase 622,596 shares of Company common stock in consideration of the Company further reducing the exercise price of such Existing Warrants to purchase 622,596 shares of Company common stock to $0.001 per share with an exercise term of 5.5 years. In consideration of the foregoing, the Company agreed to issue the Holders new warrants to purchase up to a number of shares of Company common stock equal to 100% of the number of shares of Company common stock underlying the Existing Warrants, comprised of new Series B warrants to purchase up to 1,477,596 shares of Company common stock (the &#8220;Inducement Warrants&#8221; and the shares of Company common stock underlying the Inducement Warrants, the &#8220;Inducement Warrant Shares&#8221;) at $1.723 per share with an exercise term of 5.5 years from the initial exercise date. In addition, the Company issued 88,656 Representative's Warrants at $2.6707 per share with an exercise term of 5&#160;years. The Company received total gross proceeds of approximately $2.6 million, less expenses paid to the Placement Agent of approximately $0.3 million.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In <em style="font: inherit;"> July 2025, </em>of the 622,596 Amended Series A Warrants above, 268,072 were exercised, leaving 354,524 of the Amended Series A Warrants at the time of this filing.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> August 5, 2025, </em>54,400 of pre-IPO warrants were exercised on a cashless basis.&#65279;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In <em style="font: inherit;"> July 2025, </em>the Company entered into stock option cancellation agreements with certain employees to cancel an aggregate of 57,331 stock options. Employees that elected to cancel their stock options were granted severance agreements for three, <em style="font: inherit;">six</em> or <em style="font: inherit;">nine</em> months of their base salary (under certain conditions). On <em style="font: inherit;"> August 11, 2025, </em>the Company entered into stock option cancellation agreements with Board members and certain officers of the Company to cancel an aggregate of <span style="-sec-ix-hidden:c134565119">177,652</span> stock options. The Company's Board members included Mr. Walter Klemp, Chairman of the Board; Ms. Lori Bisson, Executive Vice Chairman of the Board; and Mr. Chris Capelli, Director, respectively, and included amounts of <span style="-sec-ix-hidden:c134565120">8,773;</span> <span style="-sec-ix-hidden:c134565121">65,542;</span> and <span style="-sec-ix-hidden:c134565122">3,750,</span> respectively. The Company's officers included Mr. Brad Hauser, Chief Executive Officer and President; Mr. Landy Toth, Chief Technology Officer; Mr. Robert Schwartz, Chief Medical Officer; and Mr. Trent Smith, Chief Financial Officer, respectively, and included amounts of <span style="-sec-ix-hidden:c134565123">45,000;</span> <span style="-sec-ix-hidden:c134565124">8,773;</span> <span style="-sec-ix-hidden:c134565125">13,159;</span> and <span style="-sec-ix-hidden:c134565126">32,655,</span> respectively. Mr. Hauser was granted <em style="font: inherit;">three</em> months of his base salary, in addition to the <em style="font: inherit;">twelve</em> months of his base salary per his <em style="font: inherit;"> July 17, 2024 </em>employment agreement. Mr. Toth and Mr. Schwartz were granted severance agreements that amounted to <em style="font: inherit;">nine</em> months of their base salary. Mr. Smith was granted <em style="font: inherit;">three</em> months of his base salary, in addition to the <em style="font: inherit;">nine</em> months of his base salary per his <em style="font: inherit;"> July 24, 2023 </em>employment agreement.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>
  <span></span>
</td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Note <em style="font: inherit;">8</em> </b>&#8211;<b> Subsequent Events</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">As of <em style="font: inherit;"> May 28, 2025, </em>the Company has sold 289,144 shares pursuant to the ATM Agreement for net proceeds of approximately $0.6 million.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> April 17, 2025, </em>we granted a new employee a <span style="-sec-ix-hidden:c134564760">ten</span>-year option (the &#8220;Inducement Options&#8221;) to purchase 5,000 shares of common stock at an exercise price equal to the closing price of our common stock on the date of the employment. The option vests in <em style="font: inherit;">four</em> equal annual installments (or 1,250 shares each installment) on each of the succeeding <em style="font: inherit;">four</em> anniversary dates of the execution of the date of employment, provided the employee is employed by us on each vesting date.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_ReverseStockSplitPolicyTextBlock', window );">Reverse Stock Split [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Reverse Stock Split</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company&#160;held its annual meeting of stockholders (the "Annual Meeting") on <em style="font: inherit;"> October 17, 2024. </em>In that Annual Meeting, stockholders of the Company approved an amendment to the Company&#8217;s amended and restated certificate of incorporation (the "Amendment&#8221;) to effect the reverse stock split at a ratio in the range of <em style="font: inherit;">1</em>-for-2 to <em style="font: inherit;">1</em>-for-50, with such ratio to be determined in the discretion of the Company&#8217;s Board of Directors (the "Board") and with such reverse stock split to be effected at such time and date, if at all, as determined by the Company&#8217;s Board in its sole discretion prior to the <em style="font: inherit;">one</em>-year anniversary of the Annual Meeting.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Pursuant to such authority granted by the Company&#8217;s stockholders, the Company&#8217;s Board approved a <em style="font: inherit;">one</em>-for-<span style="-sec-ix-hidden:c134564773">twenty</span> (<em style="font: inherit;">1:20</em>) reverse stock split (the "Reverse Stock Split&#8221;) of the Company&#8217;s common stock and the filing of the Amendment to effectuate the Reverse Stock Split. The Amendment was filed with the Secretary of State of the State of Delaware and the Reverse Stock Split became effective in accordance with the terms of the Amendment at <em style="font: inherit;">11:59</em> p.m. Eastern Time on <em style="font: inherit;"> October 24, 2024 (</em>the "Effective Time&#8221;), and the Company&#8217;s common stock opened&#160;for trading on The Nasdaq Capital Market on <em style="font: inherit;"> October 25, 2024 </em>on a post-split basis, under the existing ticker symbol "AMIX&#8221; but with a new CUSIP number <em style="font: inherit;">05330T205.</em> The Amendment provides that, at the Effective Time, every <span style="-sec-ix-hidden:c134564777">twenty</span> shares of the Company&#8217;s issued and outstanding common stock was automatically combined into <em style="font: inherit;">one</em> issued and outstanding share of common stock, without any change in par value per share, which will remain $0.001.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The number of authorized shares of common stock remained&#160;at 500 million shares. As a result of the Reverse Stock Split, proportionate adjustments were made to the per share exercise price and/or the number of shares issuable upon the exercise or vesting of all outstanding stock options, restricted stock unit awards, warrants and convertible notes, which resulted in a proportional decrease in the number of shares of the Company&#8217;s common stock reserved for issuance upon exercise or vesting of such stock options, restricted stock unit awards, warrants and convertible notes and, in the case of stock options and warrants, a proportional increase in the exercise price of all such stock options and warrants.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company&#8217;s stock option awards did <em style="font: inherit;">not</em> automatically adjust for the Reverse Stock Split.&#160;However, the Company chose to exercise its rights under the agreements to adjust the exercise price and number of shares exercisable or issuable upon vesting proportionately for the Reverse Stock Split.&#160;Based on the analysis performed, the Company does <em style="font: inherit;">not</em> need to recognize any additional compensation expense as a result of the modification.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">In addition, the number of shares reserved for issuance under the Company&#8217;s equity compensation plan immediately prior to the Effective Time was reduced proportionately.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><em style="font: inherit;">No</em> fractional shares were issued as a result of the Reverse Stock Split. Any stockholder who would have been entitled to receive a fractional share as a result of the process was entitled to the rounding up of the fractional share to the nearest whole number. See "<i>Fractional Shares</i>" in Note <em style="font: inherit;">4</em> for further disclosure regarding fractional shares.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Reverse Stock Split has been retroactively adjusted throughout these interim financial statements and footnotes for all periods presented, including exercise prices and share data. As a result of the Reverse Stock Split, the Company reclassified approximately $18 thousand between common stock par value and additional paid-in capital.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Reverse Stock Split</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company&#160;held its annual meeting of stockholders (the "Annual Meeting") on&#160;<em style="font: inherit;"> October 17, 2024</em><i>.</i>&#160;In that Annual Meeting, stockholders of the Company approved an amendment to the Company&#8217;s amended and restated certificate of incorporation (the "Amendment&#8221;) to effect the reverse stock split at a ratio in the range of&#160;<em style="font: inherit;">1</em>-for-2&#160;to&#160;<em style="font: inherit;">1</em>-for-50, with such ratio to be determined in the discretion of the Company&#8217;s board of directors and with such reverse stock split to be effected at such time and date, if at all, as determined by the Company&#8217;s board of directors in its sole discretion prior to the&#160;<em style="font: inherit;">one</em>-year anniversary of the Annual Meeting.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Pursuant to such authority granted by the Company&#8217;s stockholders, the Company&#8217;s board of directors approved a&#160;<em style="font: inherit;">one</em>-for-&#160;<span style="-sec-ix-hidden:c134564311">twenty</span>&#160;(<em style="font: inherit;">1:20</em>) reverse stock split (the "Reverse Stock Split&#8221;) of the Company&#8217;s common stock and the filing of the Amendment to effectuate the Reverse Stock Split. The Amendment was filed with the Secretary of State of the State of Delaware and the Reverse Stock Split became effective in accordance with the terms of the Amendment at&#160;<em style="font: inherit;">11:59</em>&#160;p.m. Eastern Time on&#160;<em style="font: inherit;"> October 24, 2024 (</em>the "Effective Time&#8221;), and the Company&#8217;s common stock opened&#160;for trading on The Nasdaq Capital Market on&#160;<em style="font: inherit;"> October 25, 2024&#160;</em>on a post-split basis, under the existing ticker symbol "AMIX&#8221; but with a new CUSIP number&#160;<em style="font: inherit;">05330T205.</em>&#160;The Amendment provided that, at the Effective Time, every&#160;<span style="-sec-ix-hidden:c134564315">twenty</span>&#160;shares of the Company&#8217;s issued and outstanding common stock automatically combined into&#160;<em style="font: inherit;">one</em>&#160;issued and outstanding share of common stock, without any change in par value per share, which remained $0.001.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The number of authorized shares of common stock remained&#160;at&#160;500&#160;million shares. As a result of the Reverse Stock Split, proportionate adjustments were made to the per share exercise price and/or the number of shares issuable upon the exercise or vesting of all outstanding stock options, restricted stock unit awards, warrants and convertible notes, which resulted in a proportional decrease in the number of shares of the Company&#8217;s common stock reserved for issuance upon exercise or vesting of such stock options, restricted stock unit awards, warrants and convertible notes and, in the case of stock options and warrants, a proportional increase in the exercise price of all such stock options and warrants.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company&#8217;s stock option awards did <em style="font: inherit;">not</em> automatically adjust for the Reverse Stock Split.&#160;However, the Company chose to exercise its rights under the agreements to adjust the exercise price and number of shares exercisable or issuable upon vesting proportionately for the Reverse Stock Split.&#160;Based on the analysis performed, the Company does <em style="font: inherit;">not</em> need to recognize any additional compensation expense as a result of the modification.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">In addition, the number of shares reserved for issuance under the Company&#8217;s equity compensation plan immediately prior to the Effective Time was reduced proportionately.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><em style="font: inherit;">No</em>&#160;fractional shares were issued as a result of the Reverse Stock Split. Any stockholder who would have been entitled to receive a fractional share as a result of the process was entitled to the rounding up of the fractional share to the nearest whole number. See "&#160;Fractional Shares" in Note&#160;<em style="font: inherit;">5</em>&#160;for further disclosure regarding fractional shares.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Reverse Stock Split has been retroactively adjusted throughout these interim financial statements and footnotes for all periods presented, including exercise prices and share data. As a result of the Reverse Stock Split, the Company reclassified approximately $18&#160;thousand between common stock par value and additional paid-in capital.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_SubstantialDoubtAboutGoingConcernPolicyPolicyTextBlock', window );">Substantial Doubt About Going Concern Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Liquidity and Going Concern</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company's financial statements are prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The Company is an early-stage company that is subject to all the risks associated with early-stage and emerging growth companies and has incurred losses since inception.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">O&#65279;n <em style="font: inherit;"> February 28, 2025,&#160;</em>the Company entered into an At Market Issuances Sales Agreement (the &#8220;ATM Agreement&#8221;) with Ladenburg Thalmann &amp; Co. Inc. (the &#8220;Agent&#8221;). Pursuant to the terms of the ATM Agreement, The Company <em style="font: inherit;"> may </em>sell from time to time through the Agent, as sales agent or principal, shares of its common stock with an initial aggregate sales price of up to $2.1 million (the &#8220;Shares&#8221;). As of <em style="font: inherit;"> June 30, 2025, </em>the Company sold 1,304,260 Shares pursuant to the ATM Agreement for net proceeds of approximately $2.1 million.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
      <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> November 22, 2024, </em>the Company entered into&#160;an Underwriting Agreement (the &#8220;Underwriting Agreement&#8221;) with Ladenburg Thalmann &amp; Co. Inc., as representative of the several underwriters, if any, named on Schedule I of the Underwriting Agreement (the &#8220;Underwriters&#8221;), in connection with a firm commitment underwritten public offering (the &#8220;Offering&#8221;) of: (i) 458,691 common units (the &#8220;Common Units&#8221;), each Common Unit consisting of <span style="-sec-ix-hidden:c134564791">one</span> share of Company common stock and <span style="-sec-ix-hidden:c134564792">one</span> series A warrant to purchase <span style="-sec-ix-hidden:c134564793">one</span> share of common stock (the &#8220;Series A Warrants&#8221;); and (ii) 917,596 pre-funded units (the &#8220;Pre-Funded Units&#8221;) and together with the Common Units, the "Units", each Pre-Funded Unit consisting of <span style="-sec-ix-hidden:c134564795">one</span> pre-funded warrant to purchase <span style="-sec-ix-hidden:c134564796">one</span> share of common stock (the &#8220;Pre-Funded Warrant&#8221;) and <span style="-sec-ix-hidden:c134564797">one</span> Series A Warrant. The purchase price of each Common Unit was $6.540, and the purchase price of each Pre-Funded Unit was $6.539.&#160;In addition, the Company granted the Underwriters a 45-day option to purchase an additional 206,422 shares of common stock, and/or an additional 206,422 Series A Warrants, solely to cover over-allotments, if any. The Pre-Funded Warrants have an exercise price of $0.001 per share, are immediately exercisable and <em style="font: inherit;"> may </em>be exercised at any time until all of the Pre-Funded Warrants are exercised in full. The Series A Warrants have an exercise price of $6.540 per share, are immediately exercisable and <em style="font: inherit;"> may </em>be exercised at any time until the <span style="-sec-ix-hidden:c134564805">five</span>-year anniversary of the date of issuance. Both the Pre-Funded Warrants and the Series A Warrants are subject to a beneficial ownership limitation of 4.99%. The Pre-Funded Warrants and Series A Warrants were issued pursuant to a warrant agency agreement between the Company and Equity Stock Transfer, LLC (the &#8220;Warrant Agency Agreement&#8221;). The Offering closed on <em style="font: inherit;"> November 25, 2024. </em>On <em style="font: inherit;"> November 22, 2024, </em>the Underwriters partially exercised their over-allotment option with respect to 156,809 shares of common stock and 156,809 Series A Warrants. The aggregate gross proceeds to the Company, including the partial exercise of the over-allotment option, were approximately $10.0 million, before deducting underwriting discounts and other expenses by the Company of $1.5 million, including $0.5 million of non-cash expenses. The net cash proceeds to the Company were approximately $9.0 million. See Note <em style="font: inherit;">6</em> - Subsequent Events for additional information regarding events occurring after <em style="font: inherit;"> June 30, 2025.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">For the&#160;<em style="font: inherit;">three</em> months ended <em style="font: inherit;"> June 30, 2025 </em>and <em style="font: inherit;">2024,</em> the Company incurred net losses of $3.3 million and $2.7 million, respectively, and had net cash flows used in operating activities of $2.6 million and $1.9&#160;million, respectively. The Company had no revenues for the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> June 30, 2025 </em>and <em style="font: inherit;">2024,</em> respectively, and an accumulated deficit of $53.7&#160;million, working capital of $7.0 million and cash of $8.6 million as of <em style="font: inherit;"> June 30, 2025. </em>The Company does <em style="font: inherit;">not</em> expect to&#160;generate&#160;positive cash flows from operating activities in the near future.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company estimates its current cash resources&#160;are sufficient to fund its operations into but <em style="font: inherit;">not</em> beyond the <em style="font: inherit;">second</em> calendar quarter of <em style="font: inherit;">2026.</em> The Company recognizes it will need to raise additional capital to continue to execute its business plan, including obtaining regulatory clearance for its products currently under development and commercializing and generating revenues from products under development. There is <em style="font: inherit;">no</em> assurance that additional financing will be available when needed or that management will be able to obtain financing on terms acceptable to the Company. A failure to raise sufficient capital, generate sufficient product revenues, control expenditures and regulatory matters, among other factors, will adversely impact the Company&#8217;s ability to meet its financial obligations as they become due and payable and to achieve its intended business objectives. If the Company is unable to raise sufficient additional funds, it will have to scale back its operations.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">These factors raise substantial doubt about the Company's ability to continue as a going concern within <em style="font: inherit;">one</em> year after the date the financial statements are issued. The accompanying condensed financial statements have been prepared on a going concern basis and do <em style="font: inherit;">not</em> include any adjustments that might be necessary if the Company is unable to continue as a going concern.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Liquidity and Going Concern</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company's&#65279; financial statements are prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The Company is an early-stage company that is subject to all the risks associated with early-stage and emerging growth companies and has incurred losses since inception.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
      <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">For the years ended <em style="font: inherit;"> March 31, 2025 </em>and <em style="font: inherit;">2024,</em> the Company has net losses of approximately $11.4 million and $15.4 million, respectively and had net cash flows used in operating activities of $8.3&#160;million&#160;and $6.6 million, respectively. The Company had no revenues for the years ended <em style="font: inherit;"> March 31, 2025 </em>and <em style="font: inherit;">2024,</em> respectively. The Company had an accumulated deficit of $50.4 million and working capital of approximately $7.9 million as of <em style="font: inherit;"> March 31, 2025. </em>The Company does <em style="font: inherit;">not</em> expect to generate positive cash flows from operating activities in the near future. These conditions, and the Company's ability to comply with such conditions, raise substantial doubt about the Company's ability to continue as a going concern within <em style="font: inherit;">one</em> year after the date that the financial statements are issued. The accompanying financial statements have been prepared on a going concern basis and do <em style="font: inherit;">not</em> include any adjustments that might be necessary if the Company is unable to continue as a going concern.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> January 26, 2024, </em>the Company completed its IPO, pursuant to which it sold a total of 111,962&#160;shares of common stock at a purchase price of $100.00 per share for gross proceeds of $11.2 million and net proceeds of $9.8 million.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> November 22, 2024, </em>the Company completed a firm commitment underwritten public offering (the &#8220;Offering&#8221;) of: (i) 458,691 common units (the &#8220;Common Units&#8221;), each Common Unit consisting of <span style="-sec-ix-hidden:c134564342">one</span> share of Company common stock and <span style="-sec-ix-hidden:c134564343">one</span> series A warrant to purchase <span style="-sec-ix-hidden:c134564344">one</span> share of common stock (the &#8220;Series A Warrants&#8221;); and (ii) 917,596 pre-funded units (the &#8220;Pre-Funded Units&#8221;) and together with the Common Units, the "Units", each Pre-Funded Unit consisting of <span style="-sec-ix-hidden:c134564346">one</span> pre-funded warrant to purchase <span style="-sec-ix-hidden:c134564347">one</span> share of common stock (the &#8220;Pre-Funded Warrant&#8221;) and <span style="-sec-ix-hidden:c134564348">one</span> Series A Warrant. The purchase price of each Common Unit was $6.540, and the purchase price of each Pre-Funded Unit was $6.539.&#160;In addition, the Company granted the underwriters in the Offering a 45-day option to purchase an additional 206,422 shares of common stock, and/or an additional 206,422 Series A Warrants, solely to cover over-allotments, if any. The Pre-Funded Warrants have an exercise price of $0.001 per share, are immediately exercisable and <em style="font: inherit;"> may </em>be exercised at any time until all of the Pre-Funded Warrants are exercised in full. The Series A Warrants have an exercise price of $6.540 per share, are immediately exercisable and <em style="font: inherit;"> may </em>be exercised at any time until the <span style="-sec-ix-hidden:c134564356">five</span>-year anniversary of the date of issuance. Both the Pre-Funded Warrants and the Series A Warrants are subject to a beneficial ownership limitation of 4.99%. The Offering closed on <em style="font: inherit;"> November 25, 2024. </em>On <em style="font: inherit;"> November 22, 2024, </em>the underwriters partially exercised their over-allotment option with respect to 156,809 shares of common stock and 156,809 Series A Warrants. The aggregate gross proceeds to the Company, including the partial exercise of the over-allotment option, were approximately $10.0 million, before deducting underwriting discounts and other expenses by the Company of $1.5 million, including $0.5 million of non-cash expenses. The net cash proceeds to the Company were approximately $9.0 million.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> February 28, 2025, </em>the Company entered into an At Market Issuances Sales Agreement (the &#8220;ATM Agreement&#8221;) with Ladenburg Thalmann &amp; Co. Inc. (the &#8220;Agent&#8221;). Pursuant to the terms of the ATM Agreement, the Company <em style="font: inherit;"> may </em>sell from time to time through the Agent, as sales agent or principal, shares of the Company&#8217;s common stock with an initial aggregate sales price of up to $2.1 million (the &#8220;Shares&#8221;). Any sale of Shares pursuant to the Agreement will be made under the Company&#8217;s &#8220;shelf&#8221; registration statement (the &#8220;Registration Statement&#8221;) on Form S-<em style="font: inherit;">3</em> filed on <em style="font: inherit;"> February 28, 2025 </em>with the Securities and Exchange Commission (the &#8220;SEC&#8221;). Under the ATM Agreement, the Company <em style="font: inherit;"> may </em>sell Shares through the Agent by any method that is deemed an &#8220;at the market offering&#8221; (as defined in Rule <em style="font: inherit;">415</em>(a)(<em style="font: inherit;">4</em>) under the Securities Act of <em style="font: inherit;">1933,</em> as amended). Under the ATM Agreement, the Agent will also be able to sell shares of Common Stock by any other method permitted by law, including in negotiated transactions with the Company&#8217;s prior written consent. The Company will pay a commission to the Agent of 3.0% of the gross proceeds of the sale of the Shares sold under the ATM Agreement and reimburse the Agent for certain expenses. As of <em style="font: inherit;"> March 31, 2025, </em>the Company sold 800 shares pursuant to the ATM Agreement for net proceeds of approximately $1,746.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company estimates its current cash resources are sufficient to fund its operations into but <em style="font: inherit;">not</em> beyond the <em style="font: inherit;">first</em> calendar quarter of <em style="font: inherit;">2026.</em> The Company recognizes it will need to raise additional capital to continue to execute its business plan, including obtaining regulatory clearance for its products currently under development and commercializing and generating revenues from products under development. There is <em style="font: inherit;">no</em> assurance that additional financing will be available when needed or that management will be able to obtain financing on terms acceptable to the Company. A failure to raise sufficient capital, generate sufficient product revenues, control expenditures and regulatory matters, among other factors, will adversely impact the Company&#8217;s ability to meet its financial obligations as they become due and payable and to achieve its intended business objectives. If the Company is unable to raise sufficient additional funds, it will have to scale back its operations.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Accounting, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Basis of Presentation</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The accompanying condensed interim financial statements are unaudited. These unaudited condensed interim financial statements have been prepared in accordance with the rules and regulations of the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) for interim financial information. Accordingly, they do <em style="font: inherit;">not</em> include all the information and notes required by generally accepted accounting principles in the United States of America (&#8220;GAAP&#8221;) for complete financial statements. The Company&#8217;s fiscal year end is <em style="font: inherit;"> March 31</em><sup style="vertical-align:top;line-height:120%;">st</sup>. These unaudited condensed interim financial statements should be read in conjunction with the audited financial statements and accompanying notes for the year ended <em style="font: inherit;"> March 31, 2025 </em>as found in the Annual Report in the Company's Form <em style="font: inherit;">10</em>-K filed with the SEC on <em style="font: inherit;"> May 29, 2025. </em>In the opinion of management, the unaudited condensed interim financial statements reflect all the adjustments (consisting of normal recurring adjustments) necessary to state fairly the Company&#8217;s financial position, results of operations and cash flows for the quarterly and year-to-date periods, as applicable. The interim results of operations are <em style="font: inherit;">not</em> necessarily indicative of the results that <em style="font: inherit;"> may </em>occur for the full fiscal year. The <em style="font: inherit;"> March 31, 2025 </em>audited condensed balance sheet included herein was derived from the audited financial statements, but does <em style="font: inherit;">not</em> include all disclosures, including notes, required by GAAP for complete financial statements.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Basis of Presentation</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The annual financial statements and disclosures have been prepared using the accrual basis of accounting in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;).</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Use of Estimates in Financial Statement Presentation</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The preparation of these unaudited condensed interim financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The Company's significant estimates and assumptions include work performed but <em style="font: inherit;">not</em> yet billed by contract manufacturers, engineers and research organizations and the valuation of equity related instruments. Although the Company believes that its estimates and assumptions are reasonable, they are based upon information available at the time the estimates and assumptions were made. Some of these judgments can be subjective and complex, and, consequently, actual results could differ from those estimates.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Use of Estimates in Financial Statement Presentation</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The preparation of these financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The Company's significant estimates and assumptions include the valuation of equity related instruments, and initial and recurring fair value measurements for the warrant liability. Although the Company believes that its estimates and assumptions are reasonable, they are based upon information available at the time the estimates and assumptions were made. Some of these judgments can be subjective and complex, and, consequently, actual results could differ from those estimates.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Cash and Cash Equivalents</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company considers all highly liquid accounts with original maturities of <em style="font: inherit;">three</em> months or less at the date of acquisition to be cash equivalents.&#160;Periodically, the Company <em style="font: inherit;"> may </em>carry cash balances at financial institutions in excess of the federally insured limit of <em style="font: inherit;">$250</em> thousand. The Company has <em style="font: inherit;">not</em> experienced losses on these accounts and management believes, based upon the quality of the financial institutions, that the credit risk with regard to these deposits is <em style="font: inherit;">not</em> significant.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Cash and Cash Equivalents</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company considers all highly liquid accounts with original maturities of <em style="font: inherit;">three</em> months or less at the date of acquisition to be cash equivalents.&#160;Periodically, the Company <em style="font: inherit;"> may </em>carry cash balances at financial institutions in excess of the federally insured limit of <em style="font: inherit;">$250,000.</em> The Company has <em style="font: inherit;">not</em> experienced losses on these accounts and management believes, based upon the quality of the financial institutions, that the credit risk with regard to these deposits is <em style="font: inherit;">not</em> significant.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_OfferingCostsPolicyPolicyTextBlock', window );">Offering Costs, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Offering and Financing Costs</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Offering costs consist of professional costs incurred through the balance sheet date that are direct and incremental related to the Company&#8217;s equity financing activities. Specifically, offering costs were incurred during the Company&#8217;s initial public offering ("IPO"), Offering from <em style="font: inherit;"> November 2024 </em>and ATM Agreement. The Company includes offering costs in additional paid-in capital, to the extent there is sufficient cash proceeds, upon completion of the sale of equity. Costs associated with salaries and other period costs are expensed as incurred.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Offering and Financing Costs</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Offering costs consist of professional costs incurred through the balance sheet date that were direct and incremental to the Company&#8217;s equity financing activities. Specifically, offering costs were incurred on the Company's IPO, the Offering and the Registration Statement. The costs for the Registration Statement are recorded in deferred offering costs on the balance sheet as of <em style="font: inherit;"> March 31, 2025. </em>Costs associated with salaries and other period costs were expensed as incurred.&#160;</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">During the year ended <em style="font: inherit;"> March 31, 2024, </em>the Company paid $1.3 million of issuance&#160;costs related to its IPO.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">During the year ended <em style="font: inherit;"> March 31, 2025, </em>the Company paid $1.1 million of issuance costs related to its Offering and $0.2 million of offering costs related to its Registration Statement.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Plant and Equipment, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;text-indent:9pt;"><i>Property and Equipment</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Property and equipment (comprised of computer and IT equipment) are stated at historical cost and depreciated on a straight-line basis over their estimated useful lives, generally&#160;<span style="-sec-ix-hidden:c134564843">three</span> years. Upon disposition of the assets, the costs and related accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the results of operations.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Property and Equipment</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Property and equipment are stated at historical cost and depreciated on a straight-line basis over their estimated useful lives, generally&#160;<span style="-sec-ix-hidden:c134564384">three</span> years. Upon disposition of the assets, the costs and related accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the results of operations.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtPolicyTextBlock', window );">Debt, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Convertible Notes</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">For the period ended <em style="font: inherit;"> March 31, 2025, </em>the Company evaluated embedded redemption, conversion and other features within its debt to determine whether any embedded features should be bifurcated from the host instrument and accounted for as a derivative at fair value, with changes in fair value recorded in the condensed statements of operations. The Company&#8217;s debt was carried on the condensed balance sheets on a historical cost basis, net of unamortized discounts and premiums, because the Company did <em style="font: inherit;">not</em> elect the fair value option of accounting. Costs associated with acquiring debt, including detachable warrants issued in connection with the financing, were&#160;capitalized as a debt discount. The debt discount was&#160;presented in the condensed balance sheets, in prior year periods, as a direct deduction from the carrying amount of the debt liability. The costs were&#160;amortized over the estimated contractual life of the related debt instrument using the effective interest method and were&#160;included in interest expense in the condensed statements of operations.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">In addition, since the instruments included a substantive conversion feature as of time of issuance, the issuance of equity securities to settle the outstanding notes with the conversion were accounted for as a contractual conversion with <em style="font: inherit;">no</em> gain or loss recognized related to the equity securities issued to settle the instrument. See <i>Note <em style="font: inherit;">2</em> - Convertible Notes Payable</i> for additional information.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Convertible Notes</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company evaluates embedded redemption, conversion and other features within its debt to determine whether any embedded features should be bifurcated from the host instrument and accounted for as a derivative at fair value, with changes in fair value recorded in the statement of operations.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company&#8217;s debt is carried on the balance sheet on a historical cost basis net of unamortized discounts and premiums because the Company has <em style="font: inherit;">not</em> elected the fair value option of accounting. Costs associated with acquiring debt, including detachable warrants issued in connection with the financing, are capitalized as a debt discount. The debt discount is presented in the balance sheet as a direct deduction from the carrying amount of the debt liability. The costs are amortized over the estimated contractual life of the related debt instrument using the effective interest method and are included in interest expense in the statement of operations.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">If the Company incurs costs associated with its convertible notes, in advance of the receipt of proceeds, the Company will record a deferred asset. Upon receipt of proceeds the Company will reclassify the deferred asset as a direct deduction from the carrying amount, as described above.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">In addition, since the instruments included a substantive conversion feature at the time of issuance, the issuance of equity securities were accounted for as a contractual conversion with <em style="font: inherit;">no</em> gain or loss recognized related to the equity securities issued to settle the instrument. &#160;</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Fair Value of Financial Instruments</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs. The Company utilizes a <em style="font: inherit;">three</em>-level valuation hierarchy for disclosures of fair value measurements, defined as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Level <em style="font: inherit;">1</em> &#8211; inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Level <em style="font: inherit;">2</em> &#8211; inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the assets or liability, either directly or indirectly, for substantially the full term of the financial instrument</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">Level <em style="font: inherit;">3</em> &#8211; inputs to the valuation methodology are unobservable and significant to the fair value and require significant judgment and estimation</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Financial assets and financial liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. While the Company believes that its valuation methods are appropriate, the Company recognizes that the use of different methodologies or assumptions to determine the fair value could result in a different estimate of fair value at the reporting date. The primary assumptions that would significantly affect the fair values are the probability weighting of the different settlement outcomes used.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
      <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company did <em style="font: inherit;">not</em> have any assets or liabilities measured at fair value as of <em style="font: inherit;"> June 30, 2025 </em>and <em style="font: inherit;"> March 31, 2025.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">The carrying value of short-term instruments, including cash, accounts payable and accrued expenses, approximate fair value due to the relatively short period to maturity for these instruments.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Fair Value of Financial Instruments</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs. The Company utilizes a <em style="font: inherit;">three</em>-level valuation hierarchy for disclosures of fair value measurements, defined as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Level <em style="font: inherit;">1</em> &#8211; inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
      <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Level <em style="font: inherit;">2</em> &#8211; inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the assets or liability, either directly or indirectly, for substantially the full term of the financial instruments.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Level <em style="font: inherit;">3</em> &#8211; inputs to the valuation methodology are unobservable and significant to the fair value and require significant judgment and estimation.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Financial assets and financial liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. While the Company believes that its valuation methods are appropriate, the Company recognizes that the use of different methodologies or assumptions to determine the fair value could result in a different estimate of fair value at the reporting date. The primary assumptions that would significantly affect the fair values are the probability weighting of the different settlement outcomes used.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company did <em style="font: inherit;">not</em> have any assets or liabilities measured at fair value as of <em style="font: inherit;"> March 31, 2025 </em>and <em style="font: inherit;">2024,</em> respectively. In the <em style="font: inherit;">fourth</em> quarter of the Company's fiscal year ended <em style="font: inherit;"> March 31, 2024 </em>there was a transfer out of Level <em style="font: inherit;">3</em>&#160;for the warrant liability, for the settlement and reclassification to equity of the instrument, that occurred in the&#160;<em style="font: inherit;">three</em> months ended&#160;<em style="font: inherit;"> March 31, 2024. </em>For additional information, see&#160;<i>Note <em style="font: inherit;">2</em> - Warrant Liability and Fair Value of Financial Instruments</i>.&#65279;</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The carrying value of short-term instruments, including cash, accounts payable, accrued expenses and convertible notes included in long-term debt, approximate fair value due to the relatively short period to maturity for these instruments.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_RelatedPartyTransactionsPolicyPolicyTextBlock', window );">Related Party Transactions Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;"><i>Related Parties</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company follows Accounting Standards Codification ("ASC") <em style="font: inherit;">850,</em> <i>Related Party Disclosures</i>, for the identification of related parties and disclosure of related party transactions. See further discussion in Note <em style="font: inherit;">5</em> below on this matter.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Related Parties</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company follows ASC <em style="font: inherit;">850,</em>&#160;<i>Related Party Disclosures</i>,&#160;for the identification of related parties and disclosure of related party transactions. See further discussion in the Notes below on this matter.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Tax, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Income Taxes</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting and the tax basis of reported assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company must then assess the likelihood that the resulting deferred tax assets will be realized. A valuation allowance is provided when it is more likely than <em style="font: inherit;">not</em> that some portion or all of a deferred tax asset will <em style="font: inherit;">not</em> be realized. As of <em style="font: inherit;"> June 30, 2025 </em>and <em style="font: inherit;"> March 31, 2025 </em>the Company determined a full valuation allowance was required to offset its deferred tax assets as a result of recurring operating losses.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company accounts for uncertain tax positions in accordance with the provisions of ASC <em style="font: inherit;">740</em>-<em style="font: inherit;">10</em> which prescribes a recognition threshold and measurement attribute for financial statement disclosure of tax positions taken, or expected to be taken, on its tax return. The Company evaluates and records any uncertain tax positions based on the amount that management deems is more likely than <em style="font: inherit;">not</em> to be sustained upon examination and ultimate settlement with the tax authorities in the tax jurisdictions in which it operates. As of <em style="font: inherit;"> June 30, 2025 </em>and <em style="font: inherit;"> March 31, 2025 </em>the Company had no uncertain tax positions.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company does&#160;<em style="font: inherit;">not</em>&#160;expect to pay any significant federal, state, or foreign income taxes in&#160;its fiscal year <em style="font: inherit;">2026</em> (ending <em style="font: inherit;"> March 31, 2026) </em>as a result of the losses recorded during the&#160;<em style="font: inherit;">three</em> months ended <em style="font: inherit;"> June 30, 2025&#160;</em>and the additional losses expected for the remainder of&#160;its fiscal year <em style="font: inherit;">2026</em>&#160;and cumulative net operating loss carryforwards. Accounting standards require the consideration of a valuation allowance for deferred tax assets if it is &#8220;more likely than&#160;<em style="font: inherit;">not&#8221;</em>&#160;that some component or all of the benefits of deferred tax assets will <em style="font: inherit;">not</em> be realized.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company recorded&#160;<em style="font: inherit;">no</em>&#160;income tax provision for the&#160;<em style="font: inherit;">three</em> months ended <em style="font: inherit;"> June 30, 2025 </em>and <em style="font: inherit;">2024,</em> respectively. The effective tax rate for the&#160;<em style="font: inherit;">three</em> months ended <em style="font: inherit;"> June 30, 2025 </em>and <em style="font: inherit;">2024</em>&#160;is zero.&#160;The Company estimates its annual effective tax rate at the end of each quarterly period. Jurisdictions with a projected loss for the year where&#160;<em style="font: inherit;">no</em>&#160;tax benefit can be recognized due to the valuation allowance could result in a higher or lower effective tax rate during a particular quarter depending on the mix and timing of actual earnings versus annual projections.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Income Taxes</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting and the tax basis of reported assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company must then assess the likelihood that the resulting deferred tax assets will be realized. A valuation allowance is provided when it is more likely than <em style="font: inherit;">not</em> that some portion or all of a deferred tax asset will <em style="font: inherit;">not</em> be realized. As of&#160;<em style="font: inherit;"> March 31, 2025 </em>and&#160;<em style="font: inherit;"> March 31, 2024 </em>the Company determined a full valuation allowance was required to offset its deferred tax assets as a result of recurring operating losses.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company accounts for uncertain tax positions in accordance with the provisions of ASC <em style="font: inherit;">740</em>-<em style="font: inherit;">10</em> which prescribes a recognition threshold and measurement attribute for financial statement disclosure of tax positions taken, or expected to be taken, on its tax return. The Company evaluates and records any uncertain tax positions based on the amount that management deems is more likely than <em style="font: inherit;">not</em> to be sustained upon examination and ultimate settlement with the tax authorities in the tax jurisdictions in which it operates. As of <em style="font: inherit;"> March 31, 2025 </em>and&#160;<em style="font: inherit;"> March 31, 2024 </em>the Company had no uncertain tax positions.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Payment Arrangement [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Stock-based Compensation</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Employee and non-employee share-based compensation is measured at the grant date, based on the fair value of the award, and is recognized as an expense over the requisite service period. For awards with a performance condition, compensation expense is recognized over the requisite service period if it is probable that the performance condition will be satisfied. For awards to non-employees, the Company recognizes compensation expense in the same manner as if the Company had paid cash for the goods or services. The Company estimates the fair value of options and equity classified warrants granted using an options pricing model. Expense is recognized within general and administrative and research and development expenses and forfeitures are recognized as they are incurred.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Stock-based Compensation</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Employee share-based compensation is measured at the grant date, based on the fair value of the award, and is recognized as an expense over the requisite service period.&#160;For awards with a performance condition, compensation expense is recognized over the requisite service period if it is probable that the performance condition will be satisfied. For awards to non-employees, the Company recognizes compensation expense in the same manner as if the Company had paid cash for the goods or services. The Company estimates the fair value of options and equity classified warrants granted using an options pricing model. Expense is recognized within general and administrative and research and development expenses and forfeitures are recognized as they are incurred.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_WarrantsPolicyPolicyTextBlock', window );">Warrants, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Warrants</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s specific terms and applicable authoritative guidance in FASB ASC <em style="font: inherit;">480,</em> Distinguishing Liabilities from Equity (&#8220;ASC <em style="font: inherit;">480&#8221;</em>) and ASC <em style="font: inherit;">815,</em> Derivatives and Hedging (&#8220;ASC <em style="font: inherit;">815&#8221;</em>). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC <em style="font: inherit;">480,</em> meet the definition of a liability pursuant to ASC <em style="font: inherit;">480,</em> and whether the warrants meet all of the requirements for equity classification under ASC <em style="font: inherit;">815,</em> including whether the warrants are indexed to the Company&#8217;s own ordinary shares and whether the warrant holders could potentially require &#8220;net cash settlement&#8221; in a circumstance outside of the Company&#8217;s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do <em style="font: inherit;">not</em> meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss on the&#160;statements of operations. The fair value of the warrants is estimated using a Black-Scholes pricing model or a Monte Carlo simulation.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Warrants</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s specific terms and applicable authoritative guidance in FASB ASC <em style="font: inherit;">480,</em> Distinguishing Liabilities from Equity (&#8220;ASC <em style="font: inherit;">480&#8221;</em>) and ASC <em style="font: inherit;">815,</em> Derivatives and Hedging (&#8220;ASC <em style="font: inherit;">815&#8221;</em>). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC <em style="font: inherit;">480,</em> meet the definition of a liability pursuant to ASC <em style="font: inherit;">480,</em> and whether the warrants meet all of the requirements for equity classification under ASC <em style="font: inherit;">815,</em> including whether the warrants are indexed to the Company&#8217;s own ordinary shares and whether the warrant holders could potentially require &#8220;net cash settlement&#8221; in a circumstance outside of the Company&#8217;s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
      <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do <em style="font: inherit;">not</em> meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss on the&#160;statements of operations. The fair value of the warrants is estimated using a Black-Scholes pricing model or a Monte Carlo simulation.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company&#65279; issued warrants to purchase shares of common stock (i) in connection with the Bridge Offering, (ii) as part of selling agent compensation in <em style="font: inherit;">2024,</em> (iii) in connection with the Exclusive License Termination Agreement (the &#8220;Termination Agreement&#8221;), and (iv) as part of the Offering&#65279;. Based on the guidance noted above, we determined that warrants issued in connection with the Termination Agreement should be accounted for as a liability and the remaining warrants issued meet the requirements for equity classification. Liability classified warrants are subject to remeasurement at each balance sheet date, while equity classified warrants are valued at inception only. As discussed in Note <em style="font: inherit;">2,</em> the liability warrants subsequently met the requirements for equity classification.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings Per Share, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Loss Per Common Share</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Basic loss per common share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period, which includes shares issuable for little to <em style="font: inherit;">no</em> consideration upon the exercise of certain equity-classified warrants. Diluted loss per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. In periods when losses are reported, the weighted-average number of common shares outstanding excludes common stock equivalents, because their inclusion would be anti-dilutive. Generally, the Company&#8217;s outstanding warrants are non-participating securities as they are <em style="font: inherit;">not</em> entitled to non-forfeitable rights to dividends or dividend equivalents during the vesting term and have <em style="font: inherit;">no</em> obligation to fund losses.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">However, the Company's warrants described in Note&#160;<em style="font: inherit;">2</em>&#160;and the warrants issued in connection with the Offering, are participating securities as the holders receive the right to dividends, but they are <em style="font: inherit;">not</em> obligated to fund losses. In periods of loss, since <em style="font: inherit;">no</em> income is allocated to these securities, the Company's use of the "treasury stock method" derives the same result. The dilutive effect of convertible securities is calculated using the &#8220;if-converted method.&#8221; Under the if-converted method, securities are assumed to be converted at the beginning of the period, and the resulting common shares are included in the denominator of the diluted calculation for the entire period being presented.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">For the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> June 30, 2025 </em>and <em style="font: inherit;">2024,</em> dilutive securities that were <em style="font: inherit;">not</em> included in the calculations of the loss per common share because they would be anti-dilutive included the following:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 5%; margin-left: 54pt; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>June 30,</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(as revised)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Equity based warrants to purchase common shares</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">87,531</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,334</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Convertible Notes - common shares (1)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">33,250</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Convertible Notes - equity-based warrants to purchase common shares</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">25,003</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">25,003</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock options granted under Company's incentive plan</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">248,483</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">216,483</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Series A Warrants</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,533,096</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Representative Warrants</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">91,985</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total potentially dilutive securities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,986,098</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">279,070</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
    <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 54pt;">(<em style="font: inherit;">1</em>) Shares for the convertible note proceeds received</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Loss Per Common Share</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Basic loss per common share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period, which includes shares issuable for little to <em style="font: inherit;">no</em> consideration upon the exercise of certain equity-classified warrants. Diluted loss per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. In periods when losses are reported, the weighted-average number of common shares outstanding excludes common stock equivalents, because their inclusion would be anti-dilutive. Generally, the Company&#8217;s outstanding warrants are non-participating securities as they are <em style="font: inherit;">not</em> entitled to non-forfeitable rights to dividends or dividend equivalents during the vesting term and have <em style="font: inherit;">no</em> obligation to fund losses.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">However, the Company's warrants d&#65279;escribed in Note&#160;<em style="font: inherit;">2</em>&#160;and the warrants issued in connection with the Offering, are participating securities as the holders receive the right to dividends, but they are <em style="font: inherit;">not</em> obligated to fund losses. In periods of loss, since <em style="font: inherit;">no</em> income is allocated to these securities, the Company's use of the "treasury stock method" derives the same result. The dilutive effect of convertible securities is calculated using the &#8220;if-converted method.&#8221; Under the if-converted method, securities are assumed to be converted at the beginning of the period, and the resulting common shares are included in the denominator of the diluted calculation for the entire period being presented.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
      <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">For the <em style="font: inherit;">twelve</em> months ended <em style="font: inherit;"> March 31, 2025&#160;</em>and <em style="font: inherit;">2024,</em> dilutive securities that were <em style="font: inherit;">not</em> included in the calculations of the loss per common share because they would be anti-dilutive included the following:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 5%; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>March 31,</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(as revised)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Equity based warrants to purchase common shares</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">87,531</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,334</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Convertible Notes - common shares (1)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">33,250</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Convertible Notes - equity-based warrants to purchase common shares</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">25,003</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">25,003</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock options granted under Company's incentive plan</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">243,483</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">100,180</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Series A Warrants</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,533,096</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Representative Warrants</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">91,985</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total potentially dilutive securities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,981,098</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">162,767</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
    <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 108pt;">(<em style="font: inherit;">1</em>) Shares for the convertible note proceeds received</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expense, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Research and Development Costs</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Research and development costs are expensed as incurred.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Research and Development Costs</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Research and development costs are expensed as incurred.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingCostsPolicyTextBlock', window );">Advertising Cost [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Advertising</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">It is the Company's policy to expense advertising costs as incurred. Advertising&#160;expenses are included within general and administrative expenses within the statement of operations. For the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> June 30, 2025 </em>and <em style="font: inherit;">2024,</em> the Company recorded $0 and less than $0.1&#160;million, respectively, of advertising expenses.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Advertising</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">It is our policy to expense advertising costs as incurred. Advertising&#160;expenses are included within general and administrative expenses within the statement of operations. For the years ended <em style="font: inherit;"> March 31, 2025 </em>and <em style="font: inherit;">2024,</em> the Company recorded less than $0.1&#160;million and $1.8&#160;million, respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityPolicyTextBlock', window );">Stockholders' Equity, Policy [Policy Text Block]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Fair Value of Common Stock</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Prior to establishing a public market for the Company&#8217;s common stock, the estimated fair value of the Company&#8217;s common stock was determined by the Company&#8217;s Board of Directors (the "Board") as of the date of each option grant, with input from management, considering the Company&#8217;s most recently available <em style="font: inherit;">third</em>-party valuations of common stock, recent sales of common stock to <em style="font: inherit;">third</em> parties, and the Company&#8217;s board of directors&#8217; assessment of additional objective and subjective factors that it believed were relevant and which <em style="font: inherit;"> may </em>have changed from the date of the most recent valuation through the date of the grant.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_JumpstartOurBusinessStartupsJobsActAccountingElectionPolicyPolicyTextBlock', window );">Jumpstart Our Business Startups (JOBS) Act Accounting Election Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>JOBS Act Accounting Election</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company qualifies as an emerging growth company (&#8220;EGC&#8221;), as defined in the Jumpstart Our Business Startups Act of <em style="font: inherit;">2012</em> (the &#8220;JOBS Act&#8221;). The JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected <em style="font: inherit;">not</em> to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This <em style="font: inherit;"> may </em>make comparison of the Company&#8217;s financial statements with another public company which is neither an early-stage company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>JOBS Act Accounting Election</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company qualifies as an emerging growth company ("EGC"), as defined in the Jumpstart Our Business Startups Act of <em style="font: inherit;">2012</em> (the &#8220;JOBS Act&#8221;). The JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected <em style="font: inherit;">not</em> to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This <em style="font: inherit;"> may </em>make comparison of the Company&#8217;s financial statements with another public company which is neither an early-stage company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><i>Segments</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker ("CODM"), or decision-making group, in deciding how to allocate resources in assessing performance. Management has determined that the Company operates in&#160;<span style="-sec-ix-hidden:c134564899">one</span>&#160;reportable segment, which is advancing the development of innovative technologies for sensing and treating disorders relating to the nervous system. The Company is initially focused on developing the technology for patients with pancreatic cancer, however, the Company believes the technology constitutes a platform with the potential to address several indications, including chronic pain management, hypertension, cardiovascular disease and a wide range of other nerve-related disorders. The Company's CODM is its Chief Executive Officer.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The accounting policies of the segment are the same as those described in the summary of significant accounting policies. The CODM assesses performance based on net loss, which is reported on the Statements of Operations. The measure of segment assets is reported on the balance sheet as total assets.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">To date, the Company has <em style="font: inherit;">not</em> generated any product revenue. The Company expects to continue to incur significant expenses and operating losses for the foreseeable future as it advances its' technology through all stages of development and clinical trials and, ultimately, seek regulatory approval.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">As such, the CODM primarily evaluates performance of the Company using various financial metrics, including the combined net income (loss) from operations, also shown on the Statements of Operations, forecasted cash expenditures and existing and forecasted cash balances. These financial metrics are used by the CODM to make key operating decisions, such as the assessment of segment performance and allocation of resources. All of the Company's assets are located in the United States. The significant expense categories within net loss from operations that the CODM regularly reviews are expenses related to research and development, general and administrative, and depreciation and amortization. The significant expense categories and subcategories are reported on the Statements of Operations.&#160;Other expenses included in the Company&#8217;s net loss include other income (expense), interest income, net, and any additional non-operating expenses that are reported on the Statements of Operations.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Segments</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker ("CODM"), or decision-making group, in deciding how to allocate resources in assessing performance. Management has determined that the Company operates in&#160;<span style="-sec-ix-hidden:c134564434">one</span>&#160;reportable segment, which is advancing the development of innovative technologies for sensing and treating disorders relating to the nervous system. The Company is initially focused on developing the technology for patients with pancreatic cancer, however, the Company believes the technology constitutes a platform with the potential to address several indications, including chronic pain management, hypertension, cardiovascular disease and a wide range of other nerve-related disorders. The Company's CODM is its Chief Executive Officer.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
      <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The accounting policies of the segment are the same as those described in the summary of significant accounting policies. The CODM assesses performance based on net loss, which is reported on the Statements of Operations. The measure of segment assets is reported on the balance sheet as total assets.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">To date, the Company has <em style="font: inherit;">not</em> generated any product revenue. The Company expects to continue to incur significant expenses and operating losses for the foreseeable future as it advances its' technology through all stages of development and clinical trials and, ultimately, seek regulatory approval.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">As such, the CODM primarily evaluates performance of the Company using various financial metrics, including the combined net income (loss) from operations, also shown on the Statements of Operations, forecasted cash expenditures and existing and forecasted cash balances. These financial metrics are used by the CODM to make key operating decisions, such as the assessment of segment performance and allocation of resources. The significant expense categories within net loss from operations that the CODM regularly reviews are expenses related to research and development, general and administrative, and depreciation and amortization. The significant expense categories and subcategories are reported on the Statements of Operations.&#160;Other expenses included in the Company&#8217;s net loss include change in fair value of warrant liabilities, other income (expense), interest income, net, and any additional non-operating expenses that are reported on the Statements of Operations.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncements, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Recent Accounting Pronouncements</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">In&#160;<em style="font: inherit;"> November 2024 </em>and <em style="font: inherit;"> January 2025,&#160;</em>FASB issued ASU&#160;<em style="font: inherit;">2024</em>-<em style="font: inherit;">03</em> and ASU <em style="font: inherit;">2025</em>-<em style="font: inherit;">01,</em>&#160;Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic&#160;<em style="font: inherit;">220</em>-<em style="font: inherit;">40</em>): Disaggregation of Income Statement Expenses, which requires disclosure in the notes to the financial statements of specified information about certain costs and expenses. The amendments to the standards are effective for fiscal years beginning after&#160;<em style="font: inherit;"> December 15, 2026,&#160;</em>and for interim periods within fiscal years beginning after&#160;<em style="font: inherit;"> December 15, 2027.&#160;</em>Early adoption is permitted. The amendments should be applied either prospectively to financial statements issued for reporting periods after the effective date of this ASU or retrospectively to any or all prior periods presented in the financial statements. The Company is currently evaluating the new guidance to determine the impact it&#160;<em style="font: inherit;"> may&#160;</em>have on its financial statements and related disclosures.&#160;</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">In <em style="font: inherit;"> December 2023, </em>the FASB issued <i>ASU <em style="font: inherit;">2023</em>-<em style="font: inherit;">09,</em> </i>&#8220;<i>Income Taxes (Topic <em style="font: inherit;">740</em>): Improvements to Income Tax Disclosures,</i>&#8221; which requires disaggregated information about a reporting entity&#8217;s effective tax rate reconciliation as well as information on income taxes paid. The guidance is effective for the Company&#8217;s fiscal years beginning after <em style="font: inherit;"> December 15, 2024. </em>The Company is currently evaluating the new guidance to determine the impact it&#160;<em style="font: inherit;"> may&#160;</em>have on its financial statements and related disclosures.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">In <em style="font: inherit;"> November 2023, </em>the FASB issued <i>ASU <em style="font: inherit;">No.</em> <em style="font: inherit;">2023</em>-<em style="font: inherit;">07,</em> Segment Reporting (Topic <em style="font: inherit;">280</em>): Improvements to Reportable Segment Disclosures.</i> The ASU updates reportable segment disclosure requirements, primarily through requiring enhanced disclosures about significant segment expenses and information used to assess segment performance and allocate resources. The guidance is effective for fiscal years beginning after <em style="font: inherit;"> December 15, 2023 </em>and interim periods for fiscal years beginning after <em style="font: inherit;"> December 15, 2024, </em>on a retrospective basis. There was <em style="font: inherit;">no</em> material impact upon the adoption of <i>ASU <em style="font: inherit;">2023</em>-<em style="font: inherit;">07</em></i> on the Company's interim disclosures.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">There are <em style="font: inherit;">no</em> other effective pronouncements, or pronouncements issued but <em style="font: inherit;">not</em> yet effective, if adopted, that would have a material effect on the accompanying financial statements.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Recent Accounting Pronouncements</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">In&#160;<em style="font: inherit;"> November 2024 </em>and <em style="font: inherit;"> January 2025,&#160;</em>FASB issued ASU&#160;<em style="font: inherit;">2024</em>-<em style="font: inherit;">03</em> and ASU <em style="font: inherit;">2025</em>-<em style="font: inherit;">01,</em>&#160;Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic&#160;<em style="font: inherit;">220</em>-<em style="font: inherit;">40</em>): Disaggregation of Income Statement Expenses, which requires disclosure in the notes to the financial statements of specified information about certain costs and expenses. The amendments to the standards are effective for fiscal years beginning after&#160;<em style="font: inherit;"> December 15, 2026,&#160;</em>and for interim periods within fiscal years beginning after&#160;<em style="font: inherit;"> December 15, 2027.&#160;</em>Early adoption is permitted. The amendments should be applied either prospectively to financial statements issued for reporting periods after the effective date of this ASU or retrospectively to any or all prior periods presented in the financial statements. The Company is currently evaluating the new guidance to determine the impact it&#160;<em style="font: inherit;"> may&#160;</em>have on its financial statements and related disclosures.&#160;</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">In <em style="font: inherit;"> December 2023, </em>the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update, or ASU <em style="font: inherit;">2023</em>-<em style="font: inherit;">09,</em> Income Taxes (Topic <em style="font: inherit;">740</em>): Improvements to Income Tax Disclosures. ASU <em style="font: inherit;">2023</em>-<em style="font: inherit;">09</em>&#160;improves the transparency of income tax disclosures by requiring consistent categories and greater disaggregation of information in the effective tax rate reconciliation and income taxes paid disaggregated by jurisdiction. It also includes certain other amendments to improve the effectiveness of income tax disclosures. This guidance will be effective for the annual periods beginning after the year ended <em style="font: inherit;"> December 31, 2024. </em>The Company is currently assessing the impact of ASU <em style="font: inherit;">2023</em>-<em style="font: inherit;">09</em> on its disclosures.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">In <em style="font: inherit;"> November 2023, </em>the FASB issued ASU <em style="font: inherit;">No.</em> <em style="font: inherit;">2023</em>-<em style="font: inherit;">07,</em> Improvements to Reportable Segment Disclosures (ASU <em style="font: inherit;">2023</em>-<em style="font: inherit;">07</em>) which is intended to improve reportable segment disclosures primarily through enhanced disclosure of reportable segment expenses and requires that a public entity that has a single reportable segment provide all the disclosures required by ASU <em style="font: inherit;">2023</em>-<em style="font: inherit;">07</em> and all existing segment disclosures in Topic <em style="font: inherit;">280.</em> The new guidance is required to be applied retrospectively to all prior periods presented in the financial statements and is effective for the Company for fiscal periods beginning after <em style="font: inherit;"> December 15, 2023 </em>and interim periods within fiscal years beginning after <em style="font: inherit;"> December 15, 2024. </em>The Company adopted ASU <em style="font: inherit;">2023</em>-<em style="font: inherit;">07</em> during the year ended <em style="font: inherit;"> March 31, 2025. </em>There was <em style="font: inherit;">no</em> impact upon adoption of ASU <em style="font: inherit;">2023</em>-<em style="font: inherit;">07.</em>&#160;The Company views its operations and manages its business in&#160;<span style="-sec-ix-hidden:c134564463">one</span>&#160;operating segment.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">There are <em style="font: inherit;">no</em> other effective pronouncements, or pronouncements issued but <em style="font: inherit;">not</em> yet effective, if adopted, that would have a material effect on the accompanying financial statements.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_CorrectionOfAnImmaterialErrorPolicyTextBlock', window );">Correction of an Immaterial Error [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;text-indent:9pt;"><i>Correction of an Immaterial Error in the Prior Period Financial Statements</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">D&#65279;uring the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> December 31, 2024, </em>the Company determined that previously filed quarterly and annual financial statements had an immaterial earnings per share error resulting from the exclusion of certain unexercised equity based warrants to purchase common shares that had an exercise price of approximately $0.01 or less from the basic earnings per share calculations in accordance with <i>ASC <em style="font: inherit;">260</em>-<em style="font: inherit;">10</em>-<em style="font: inherit;">45</em>-<em style="font: inherit;">13</em></i>. As a&#160;result, the prior year earnings per share calculations have been revised for consistency with the current year presentation. The Company assessed the materiality of this change in presentation on prior period financial statements in accordance with <i>SEC Staff Accounting Bulletin <em style="font: inherit;">No.</em> <em style="font: inherit;">99</em></i>, &#8220;<i>Materiality</i>,&#8221; (<i>ASC Topic <em style="font: inherit;">250,</em> Accounting Changes and Error Corrections</i>). Based on this assessment, the Company concluded that this error correction in its&#160;<i>Statements of Operations</i>&#160;and <i>Note <em style="font: inherit;">1</em> </i>&#8211;<i> Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies (Loss Per Common Share)</i> is <em style="font: inherit;">not</em> material to any previously presented financial statements based upon overall considerations of both quantitative and qualitative factors. The corrections had <em style="font: inherit;">no</em> impact in the comparative period Balance Sheet,&#160;Statements of Cash Flows, or Statement of Changes in Stockholders&#8217;&#160;Equity. Further, the immaterial correction did <em style="font: inherit;">not</em> result in a change in operating losses or net loss in the Statement of Operations and the effects of including unexercised warrants in the earnings per share calculation have an antidilutive effect reducing the net loss per share amount. Accordingly, the Company corrected the previously reported earnings per share calculation for the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> June 30, 2024 </em>in this Quarterly Report on Form <em style="font: inherit;">10</em>-Q.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
      <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">A summary of the impact of the Company&#8217;s Reverse Stock Split and immaterial corrections reflecting the prior period impact to the Company&#8217;s Statement of Operations and earnings per share are shown below:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

     <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Three Months Ended June 30, 2024</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Originally </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Filed</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Adjusted </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>for 1-for-20 </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Reverse </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Stock Split</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Correction</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>As Revised</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net Loss (in thousands)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(2,699</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(2,699</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Loss per share - basic and diluted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(0.14</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(2.85</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">0.65</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(2.20</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Weighted average shares outstanding - basic and diluted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">18,902,248</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">945,382</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">280,041</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,225,423</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
     <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">A summary of the impact of the Company&#8217;s Reverse Stock Split and immaterial corrections reflecting the prior period impact are shown below:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

     <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Three Months Ended June 30, 2024</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Originally </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Filed</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Adjusted </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>for 1-for-20 </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Reverse </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Stock Split</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Correction</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>As Revised</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Equity based warrants to purchase common shares</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,344,569</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">267,231</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(262,897</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,334</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Convertible Notes - common shares</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">665,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">33,250</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">33,250</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Convertible Notes - equity-based warrants to purchase common shares</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">500,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">25,003</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">25,003</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock options granted under Company's incentive plan</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4,329,579</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">216,483</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">216,483</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total potentially dilutive securities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">10,839,148</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">541,967</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(262,897</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">279,070</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
     <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Correction of an Immaterial Error in the Prior Period Financial Statements</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">D&#65279;uring the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> December 31, 2024, </em>the Company determined that previously filed quarterly and annual financial statements had an immaterial earnings per share error resulting from the exclusion of certain unexercised equity based warrants to purchase common shares that had an exercise price of approximately $0.01 or less from the basic earnings per share calculations in accordance with <i>ASC <em style="font: inherit;">260</em>-<em style="font: inherit;">10</em>-<em style="font: inherit;">45</em>-<em style="font: inherit;">13</em></i>. As a&#160;result, the prior year earnings per share calculations have been revised for consistency with the current year presentation. The Company assessed the materiality of this change in presentation on prior period financial statements in accordance with <i>SEC Staff Accounting Bulletin <em style="font: inherit;">No.</em> <em style="font: inherit;">99</em></i>, &#8220;<i>Materiality</i>,&#8221; (<i>ASC Topic <em style="font: inherit;">250,</em> Accounting Changes and Error Corrections</i>). Based on this assessment, the Company concluded that this error correction in its&#160;<i>Statements of Operations</i>&#160;and <i>Note <em style="font: inherit;">1</em> </i>&#8211;<i> Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies (Loss Per Common Share)</i> is <em style="font: inherit;">not</em> material to any previously presented financial statements based upon overall considerations of both quantitative and qualitative factors. The corrections had <em style="font: inherit;">no</em> impact in the comparative period Balance Sheet,&#160;Statements of Cash Flows, or Statement of Changes in Stockholders&#8217;&#160;Equity. Further, the immaterial correction did <em style="font: inherit;">not</em> result in a change in operating losses or net loss in the Statement of Operations and the effects of including unexercised warrants in the earnings per share calculation have an antidilutive effect reducing the net loss per share amount. Accordingly, the Company corrected the previously reported earnings per share calculation for the <em style="font: inherit;">twelve</em> months ended <em style="font: inherit;"> March 31, 2024 </em>in this Annual Report on Form <em style="font: inherit;">10</em>-K.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
      <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">A summary of the impact of the Company&#8217;s Reverse Stock Split and immaterial corrections reflecting the prior period impact to the Company&#8217;s Statement of Operations and earnings per share are shown below:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Twelve Months Ended March 31, 2024</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Originally</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Filed</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Adjusted </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>for 1-for-20 </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Reverse </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Stock Split</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Correction</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>As Revised</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net Loss (in thousands)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(15,426</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(15,426</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Loss per share - basic and diluted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(1.05</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(21.09</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6.27</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(14.82</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Weighted average shares outstanding - basic and diluted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">14,626,282</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">731,372</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">309,348</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,040,720</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
    <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">A summary of the impact of the Company&#8217;s Reverse Stock Split and immaterial corrections reflecting the prior period impact to the disclosure of dilutive securities that were <em style="font: inherit;">not</em> included in the calculations of the loss per common share because they would be anti-dilutive are shown below:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

     <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Twelve Months Ended March 31, 2024</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Originally </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Filed</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Adjusted f</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>or 1-for-20 </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Reverse </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Stock Split</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Correction</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>As Revised</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Equity based warrants to purchase common shares</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,744,569</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">287,231</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(282,897</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,334</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Convertible Notes - common shares</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">665,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">33,250</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">33,250</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Convertible Notes - equity-based warrants to purchase common shares</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">500,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">25,003</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">25,003</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock options granted under Company's incentive plan</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,003,600</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">100,180</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">100,180</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Total potentially dilutive securities</b></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"><b>&#160;</b></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>8,913,169</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"><b>&#160;</b></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>445,664</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"><b>&#160;</b></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>(282,897</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"><b>)</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"><b>&#160;</b></td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>162,767</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
     <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_CorrectionOfAnImmaterialErrorPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for correction of an immaterial error.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_CorrectionOfAnImmaterialErrorPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_JumpstartOurBusinessStartupsJobsActAccountingElectionPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding the Jumpstart Our Business Startups Act (the &#8220;JOBS Act&#8221;).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_JumpstartOurBusinessStartupsJobsActAccountingElectionPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_OfferingCostsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>In reference to offering costs in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_OfferingCostsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_RelatedPartyTransactionsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for related party transactions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_RelatedPartyTransactionsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_ReverseStockSplitPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reverse stock split.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_ReverseStockSplitPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_SubstantialDoubtAboutGoingConcernPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the accounting policy for substantial doubt about the ability to continue as a going concern.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_SubstantialDoubtAboutGoingConcernPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_WarrantsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of Warrant related activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_WarrantsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advertising cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 35<br> -Topic 720<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483406/720-35-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-4<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 1 - Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 5%; margin-left: 54pt; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>June 30,</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(as revised)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Equity based warrants to purchase common shares</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">87,531</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,334</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Convertible Notes - common shares (1)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">33,250</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Convertible Notes - equity-based warrants to purchase common shares</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">25,003</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">25,003</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock options granted under Company's incentive plan</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">248,483</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">216,483</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Series A Warrants</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,533,096</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Representative Warrants</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">91,985</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total potentially dilutive securities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,986,098</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">279,070</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 5%; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>March 31,</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(as revised)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Equity based warrants to purchase common shares</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">87,531</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,334</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Convertible Notes - common shares (1)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">33,250</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Convertible Notes - equity-based warrants to purchase common shares</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">25,003</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">25,003</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock options granted under Company's incentive plan</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">243,483</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">100,180</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Series A Warrants</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,533,096</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Representative Warrants</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">91,985</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total potentially dilutive securities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,981,098</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">162,767</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock', window );">Schedule of Error Corrections and Prior Period Adjustments [Table Text Block]</a></td>
<td class="text">
     <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Three Months Ended June 30, 2024</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Originally </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Filed</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Adjusted </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>for 1-for-20 </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Reverse </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Stock Split</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Correction</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>As Revised</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net Loss (in thousands)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(2,699</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(2,699</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Loss per share - basic and diluted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(0.14</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(2.85</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">0.65</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(2.20</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Weighted average shares outstanding - basic and diluted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">18,902,248</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">945,382</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">280,041</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,225,423</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

     <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Three Months Ended June 30, 2024</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Originally </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Filed</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Adjusted </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>for 1-for-20 </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Reverse </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Stock Split</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Correction</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>As Revised</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Equity based warrants to purchase common shares</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,344,569</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">267,231</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(262,897</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,334</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Convertible Notes - common shares</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">665,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">33,250</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">33,250</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Convertible Notes - equity-based warrants to purchase common shares</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">500,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">25,003</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">25,003</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock options granted under Company's incentive plan</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4,329,579</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">216,483</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">216,483</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total potentially dilutive securities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">10,839,148</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">541,967</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(262,897</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">279,070</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
    <span></span>
</td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Twelve Months Ended March 31, 2024</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Originally</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Filed</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Adjusted </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>for 1-for-20 </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Reverse </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Stock Split</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Correction</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>As Revised</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net Loss (in thousands)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(15,426</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(15,426</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Loss per share - basic and diluted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(1.05</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(21.09</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6.27</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(14.82</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Weighted average shares outstanding - basic and diluted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">14,626,282</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">731,372</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">309,348</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,040,720</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

     <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Twelve Months Ended March 31, 2024</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Originally </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Filed</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Adjusted f</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>or 1-for-20 </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Reverse </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Stock Split</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Correction</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>As Revised</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Equity based warrants to purchase common shares</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,744,569</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">287,231</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(282,897</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,334</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Convertible Notes - common shares</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">665,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">33,250</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">33,250</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Convertible Notes - equity-based warrants to purchase common shares</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">500,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">25,003</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">25,003</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock options granted under Company's incentive plan</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,003,600</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">100,180</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">100,180</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Total potentially dilutive securities</b></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"><b>&#160;</b></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>8,913,169</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"><b>&#160;</b></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>445,664</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"><b>&#160;</b></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>(282,897</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"><b>)</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"><b>&#160;</b></td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>162,767</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
    <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of prior period adjustments to previously issued financial statements including (1) the effect of the correction on each financial statement line item and any per-share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustments (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Warrant Liability and Fair Value of Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock', window );">Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 5%; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Warrant</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Liabilities</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 84%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance as of March 31, 2023</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Additions</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,556</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Change in fair value measurements - warrants mark-to-market</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,444</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Settlement and reclassification to equity</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(8,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance as of March 31, 2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 83%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Discount rate at issuance (1)</p> </td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="-sec-ix-hidden:c134565294">20.00</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 83%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Probability (2)</p> </td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="-sec-ix-hidden:c134565295">&#160;70%</span></td><td style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">-</td><td style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;"><span style="-sec-ix-hidden:c134565296">10%</span></td><td style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">-</td><td style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="-sec-ix-hidden:c134565297">20</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 83%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Payment (3)</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 3%;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 3%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 3%; text-align: center;"><span style="-sec-ix-hidden:c134565299">$0</span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 3%; text-align: center;">-</td><td colspan="1" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 4%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><span style="-sec-ix-hidden:c134565300">&#160;$8,000,000</span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 83%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected term (in years)</p> </td><td style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;"><span style="-sec-ix-hidden:c134565302">0.48</span></td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">-</td><td style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="-sec-ix-hidden:c134565303">0.98</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset) using recurring unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Convertible Notes Payable (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtTableTextBlock', window );">Convertible Debt [Table Text Block]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 5%; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Principal Amount</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Amortized Debt</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Discount</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Net Carrying</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Amount</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding, March 31, 2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,330</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(328</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,002</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Amortization of debt discount</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">175</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">175</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Issuance of common stock for extinguishment of convertible debt</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,330</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">153</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,177</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding, March 31, 2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted-</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Average</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Exercise Price</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Warrants</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Per Share</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding and exercisable, March 31, 2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">25,003</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">20.00</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Exercised</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Forfeited/Cancelled</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Expired</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding, June 30, 2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">25,003</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">20.00</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Exercisable, June 30, 2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">25,003</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">20.00</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
<td class="text">
    <table cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 0pt; margin-right: 0pt;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Warrants</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted-</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Average </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Exercise </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Price Per </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Share</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Remaining </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Life (In </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Years)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Aggregate </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Intrinsic </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Value*</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 48%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding and exercisable, March 31, 2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">25,003</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">20.00</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.48</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,010,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Exercised</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Forfeited/Cancelled</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Expired</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding, March 31, 2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">25,003</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">20.00</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3.48</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Exercisable, March 31, 2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">25,003</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">20.00</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3.48</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_RestrictedStockExpensesGeneralAndAdministrativeTableTextBlock', window );">Restricted Stock Expenses, General and Administrative [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Three Months Ended June 30,</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Recognized in general and administrative expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">33,250</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">33,250</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Year ended March 31,</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Recognized in general and administrative expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">116,375</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">16,625</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">116,375</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">16,625</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Grant Date</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Number of </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Shares</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Fair Value Per </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Share</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding, March 31, 2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,604</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">76.00</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Vested</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,604</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">76.00</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding, March 31, 2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted-</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Average</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Exercise Price</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Options</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Per Share</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding, March 31, 2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">243,483</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">32.72</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.85</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Exercised</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Forfeited/Cancelled</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Expired</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding, June 30, 2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">248,483</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">32.10</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Exercisable, June 30, 2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">69,916</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">37.24</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Options</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted-</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Average </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Exercise </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Price </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Per Share</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted-</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Average </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Remaining</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Life </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(In Years)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Aggregate </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Intrinsic </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Value*</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding, March 31, 2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">100,180</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">46.59</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">9.35</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,680,672</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">143,303</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">23.02</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Exercised</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Forfeited/Cancelled</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Expired</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding, March 31, 2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">243,483</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">32.72</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">8.92</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Exercisable, March 31, 2025*</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">37,923</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">44.35</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">8.20</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock', window );">Share-Based Payment Arrangement, Outstanding Award, Activity, Excluding Option [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted-</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Average</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Exercise Price</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Warrants</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Per Share</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding, March 31, 2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,934,874</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="-sec-ix-hidden:c134564291">5.8860</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Exercised</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(222,132</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.0010</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Forfeited/Cancelled</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(130</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.0010</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Expired</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding, June 30, 2025*</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,712,612</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6.6498</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Exercisable, June 30, 2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,712,612</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6.6498</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Warrants</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted-</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Average </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Exercise </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Price Per </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Share</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted-</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Average </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Remaining </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Life (In </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Years)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Aggregate </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Intrinsic </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Value*</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding and exercisable, March 31, 2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">287,231</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.64</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.80</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">17,072,147</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,542,677</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.31</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Exercised**</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(892,432</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.04</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Forfeited/Cancelled</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(2,602</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.20</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Expired</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding, March 31, 2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,934,874</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5.89</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4.09</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">532,060</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Exercisable, March 31, 2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,842,889</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5.67</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4.06</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">532,060</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 71%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="7" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 23%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Range</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 71%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2025</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td><td colspan="3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 8%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2024</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td></tr>
<tr class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 71%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Fair value of common stock on the measurement date (per share)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8211;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">$2.00</td><td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">to</em></td><td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5.00</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 71%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Discount rate based on the daily yield curve rates for U.S. Treasury obligations</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8211;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;">4.04%</td><td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;"><em style="font: inherit;">to</em></td><td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.54%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 71%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected life (in years)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8211;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;">3</td><td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;"><em style="font: inherit;">to</em></td><td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 71%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected volatility based on the historical volatility of comparable companies' stock</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8211;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;">104%</td><td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;"><em style="font: inherit;">to</em></td><td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">119%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_RestrictedStockExpensesGeneralAndAdministrativeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the general and administrative costs for restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_RestrictedStockExpensesGeneralAndAdministrativeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for outstanding award under share-based payment arrangement excluding share and unit options and nonvested award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1">15 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>March 31,</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>March 31,</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Amount</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">%</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Amount</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">%</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Tax benefit at the U.S. federal statutory rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(2,396</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">21.00</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(3,239</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">21.00</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Tax rate change</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Permanent differences</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(0.05</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,697</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(11.01</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)%</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Return to provision</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(44</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.39</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(69</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.45</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Change in state rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">234</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(2.05</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(190</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.23</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">State tax (net of federal benefit)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(63</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.55</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(192</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.24</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Valuation allowance</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,264</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(19.84</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,993</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(12.91</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)%</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Effective income tax rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>March 31,</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>March 31,</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Assets related to:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Capitalized R&amp;D costs</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,380</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">602</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Net operating losses</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">761</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,643</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Accruals and reserves</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,438</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">72</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Stock-based compensation</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">450</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">142</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total deferred tax assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6,029</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,459</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Valuation allowance for deferred tax assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(5,723</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(3,459</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net deferred tax assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">306</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Liabilities related to:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Section 481A method change</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(306</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net deferred tax liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(306</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net deferred tax</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 1 - Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies - 10-Q (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 5%; margin-left: 54pt; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>June 30,</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(as revised)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Equity based warrants to purchase common shares</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">87,531</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,334</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Convertible Notes - common shares (1)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">33,250</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Convertible Notes - equity-based warrants to purchase common shares</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">25,003</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">25,003</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock options granted under Company's incentive plan</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">248,483</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">216,483</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Series A Warrants</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,533,096</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Representative Warrants</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">91,985</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total potentially dilutive securities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,986,098</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">279,070</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 5%; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>March 31,</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(as revised)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Equity based warrants to purchase common shares</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">87,531</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,334</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Convertible Notes - common shares (1)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">33,250</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Convertible Notes - equity-based warrants to purchase common shares</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">25,003</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">25,003</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock options granted under Company's incentive plan</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">243,483</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">100,180</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Series A Warrants</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,533,096</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Representative Warrants</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">91,985</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total potentially dilutive securities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,981,098</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">162,767</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock', window );">Schedule of Error Corrections and Prior Period Adjustments [Table Text Block]</a></td>
<td class="text">
     <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Three Months Ended June 30, 2024</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Originally </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Filed</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Adjusted </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>for 1-for-20 </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Reverse </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Stock Split</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Correction</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>As Revised</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net Loss (in thousands)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(2,699</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(2,699</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Loss per share - basic and diluted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(0.14</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(2.85</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">0.65</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(2.20</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Weighted average shares outstanding - basic and diluted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">18,902,248</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">945,382</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">280,041</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,225,423</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

     <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Three Months Ended June 30, 2024</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Originally </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Filed</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Adjusted </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>for 1-for-20 </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Reverse </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Stock Split</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Correction</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>As Revised</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Equity based warrants to purchase common shares</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,344,569</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">267,231</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(262,897</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,334</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Convertible Notes - common shares</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">665,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">33,250</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">33,250</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Convertible Notes - equity-based warrants to purchase common shares</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">500,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">25,003</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">25,003</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock options granted under Company's incentive plan</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4,329,579</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">216,483</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">216,483</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total potentially dilutive securities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">10,839,148</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">541,967</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(262,897</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">279,070</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
    <span></span>
</td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Twelve Months Ended March 31, 2024</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Originally</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Filed</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Adjusted </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>for 1-for-20 </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Reverse </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Stock Split</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Correction</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>As Revised</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net Loss (in thousands)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(15,426</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(15,426</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Loss per share - basic and diluted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(1.05</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(21.09</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6.27</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(14.82</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Weighted average shares outstanding - basic and diluted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">14,626,282</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">731,372</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">309,348</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,040,720</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

     <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Twelve Months Ended March 31, 2024</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Originally </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Filed</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Adjusted f</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>or 1-for-20 </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Reverse </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Stock Split</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Correction</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>As Revised</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Equity based warrants to purchase common shares</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,744,569</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">287,231</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(282,897</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,334</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Convertible Notes - common shares</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">665,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">33,250</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">33,250</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Convertible Notes - equity-based warrants to purchase common shares</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">500,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">25,003</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">25,003</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock options granted under Company's incentive plan</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,003,600</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">100,180</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">100,180</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Total potentially dilutive securities</b></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"><b>&#160;</b></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>8,913,169</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"><b>&#160;</b></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>445,664</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"><b>&#160;</b></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>(282,897</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"><b>)</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"><b>&#160;</b></td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>162,767</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
    <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of prior period adjustments to previously issued financial statements including (1) the effect of the correction on each financial statement line item and any per-share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustments (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Convertible Notes Payable - 10Q (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted-</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Average</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Exercise Price</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Warrants</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Per Share</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding and exercisable, March 31, 2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">25,003</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">20.00</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Exercised</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Forfeited/Cancelled</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Expired</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding, June 30, 2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">25,003</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">20.00</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Exercisable, June 30, 2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">25,003</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">20.00</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
<td class="text">
    <table cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 0pt; margin-right: 0pt;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Warrants</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted-</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Average </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Exercise </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Price Per </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Share</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Remaining </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Life (In </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Years)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Aggregate </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Intrinsic </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Value*</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 48%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding and exercisable, March 31, 2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">25,003</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">20.00</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.48</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,010,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Exercised</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Forfeited/Cancelled</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Expired</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding, March 31, 2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">25,003</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">20.00</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3.48</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Exercisable, March 31, 2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">25,003</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">20.00</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3.48</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Equity - 10Q (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_RestrictedStockExpensesGeneralAndAdministrativeTableTextBlock', window );">Restricted Stock Expenses, General and Administrative [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Three Months Ended June 30,</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Recognized in general and administrative expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">33,250</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">33,250</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Year ended March 31,</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Recognized in general and administrative expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">116,375</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">16,625</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">116,375</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">16,625</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted-</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Average</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Exercise Price</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Options</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Per Share</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding, March 31, 2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">243,483</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">32.72</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.85</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Exercised</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Forfeited/Cancelled</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Expired</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding, June 30, 2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">248,483</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">32.10</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Exercisable, June 30, 2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">69,916</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">37.24</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Options</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted-</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Average </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Exercise </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Price </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Per Share</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted-</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Average </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Remaining</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Life </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(In Years)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Aggregate </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Intrinsic </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Value*</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding, March 31, 2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">100,180</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">46.59</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">9.35</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,680,672</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">143,303</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">23.02</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Exercised</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Forfeited/Cancelled</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Expired</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding, March 31, 2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">243,483</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">32.72</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">8.92</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Exercisable, March 31, 2025*</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">37,923</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">44.35</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">8.20</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock', window );">Share-Based Payment Arrangement, Outstanding Award, Activity, Excluding Option [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted-</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Average</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Exercise Price</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Warrants</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Per Share</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding, March 31, 2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,934,874</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="-sec-ix-hidden:c134564291">5.8860</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Exercised</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(222,132</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.0010</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Forfeited/Cancelled</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(130</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.0010</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Expired</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding, June 30, 2025*</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,712,612</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6.6498</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Exercisable, June 30, 2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,712,612</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6.6498</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Warrants</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted-</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Average </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Exercise </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Price Per </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Share</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted-</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Average </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Remaining </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Life (In </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Years)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Aggregate </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Intrinsic </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Value*</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding and exercisable, March 31, 2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">287,231</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.64</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.80</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">17,072,147</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,542,677</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.31</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Exercised**</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(892,432</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.04</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Forfeited/Cancelled</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(2,602</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.20</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Expired</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding, March 31, 2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,934,874</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5.89</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4.09</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">532,060</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Exercisable, March 31, 2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,842,889</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5.67</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4.06</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">532,060</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_RestrictedStockExpensesGeneralAndAdministrativeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the general and administrative costs for restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_RestrictedStockExpensesGeneralAndAdministrativeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for outstanding award under share-based payment arrangement excluding share and unit options and nonvested award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 1 - Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies (Details Textual)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 25, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 22, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 24, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th"><div>Oct. 17, 2024</div></th>
<th class="th">
<div>Jan. 26, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 28, 2025 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Nov. 29, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit', window );">Adjustments to Additional Paid in Capital, Stock Split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss) Attributable to Parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3,337,000)<span></span>
</td>
<td class="num">$ (2,699,000)<span></span>
</td>
<td class="num">$ (11,410,000)<span></span>
</td>
<td class="num">$ (15,426,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,604,000)<span></span>
</td>
<td class="num">(1,852,000)<span></span>
</td>
<td class="num">(8,258,000)<span></span>
</td>
<td class="num">(6,648,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained Earnings (Accumulated Deficit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (50,379,000)<span></span>
</td>
<td class="num">(53,716,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(50,379,000)<span></span>
</td>
<td class="num">(38,969,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_WorkingCapitalDeficit', window );">Working Capital (Deficit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,900,000<span></span>
</td>
<td class="nump">7,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,882,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">103,000<span></span>
</td>
<td class="nump">2,840,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_PaymentsForInitialPublicOfferingIssuanceCosts', window );">Payments for Initial Public Offering Issuance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">(0)<span></span>
</td>
<td class="nump">1,296,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Payments of Financing Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,052,000<span></span>
</td>
<td class="nump">(0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of Stock Issuance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64,000<span></span>
</td>
<td class="nump">(0)<span></span>
</td>
<td class="nump">$ 176,000<span></span>
</td>
<td class="nump">(0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUncertainTaxPositionsCurrent', window );">Liability for Uncertainty in Income Taxes, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of Reportable Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=amix_SeriesAWarrantsMember', window );">Series A Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | shares</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_NumberOfWarrantsPerPrefundedUnit', window );">Number of Warrants Per Pre-funded Unit (in shares) | shares</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 6.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and Rights Outstanding, Term (Year)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_ClassOfWarrantsOrRightsMaximumBeneficialOwnership', window );">Class of Warrants or Rights, Maximum Beneficial Ownership</a></td>
<td class="nump">4.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=amix_SeriesAWarrantsMember', window );">Series A Warrants [Member] | Underwriters [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_EquityOfferingOptionMaximumWarrants', window );">Equity Offering, Option, Maximum Warrants (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">206,422<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_ClassOfWarrantOrRightIssuedDuringPeriod', window );">Class of Warrant or Right, Issued During Period (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">156,809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=amix_PrefundedWarrantsMember', window );">Pre-funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | shares</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_NumberOfWarrantsPerPrefundedUnit', window );">Number of Warrants Per Pre-funded Unit (in shares) | shares</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_ClassOfWarrantsOrRightsMaximumBeneficialOwnership', window );">Class of Warrants or Rights, Maximum Beneficial Ownership</a></td>
<td class="nump">4.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=amix_PrefundedAndSeriesAWarrantsMember', window );">Pre-funded and Series A Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_ClassOfWarrantsOrRightsMaximumBeneficialOwnership', window );">Class of Warrants or Rights, Maximum Beneficial Ownership</a></td>
<td class="nump">4.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=amix_EquitybasedWarrantsMember', window );">Equity-based Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and Rights Outstanding, Term (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">111,962<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=amix_UnderwrittenPublicOfferingMember', window );">Underwritten Public Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_NumberOfCommonUnitsIssued', window );">Number of Common Units Issued (in shares) | shares</a></td>
<td class="nump">458,691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_NumberOfSharesPerCommonUnit', window );">Number of Shares Per Common Unit (in shares) | shares</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_NumberOfWarrantsPerCommonUnit', window );">Number of Warrants Per Common Unit (in shares) | shares</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_NumberOfPrefundedUnitsIssued', window );">Number of Pre-funded Units Issued (in shares) | shares</a></td>
<td class="nump">917,596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_CommonUnitsIssuedPurchasePrice', window );">Common Units Issued, Purchase Price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 6.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_PrefundedUnitsIssuedPurchasePrice', window );">Pre-funded Units Issued, Purchase Price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 6.539<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from Issuance or Sale of Equity</a></td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</a></td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_ProceedsFromIssuanceOrSaleOfEquityNet', window );">Proceeds from Issuance or Sale of Equity, Net</a></td>
<td class="nump">$ 9,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_CommissionPercentage', window );">Commission Percentage</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of Stock Issuance Costs</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=amix_UnderwrittenPublicOfferingMember', window );">Underwritten Public Offering [Member] | Non-cash Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option [Member] | Underwriters [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">156,809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_EquityOfferingOptionPeriod', window );">Equity Offering, Option Period (Day)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">45 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_EquityOfferingOptionMaximumShares', window );">Equity Offering, Option, Maximum Shares (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">206,422<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=amix_ATMAgreementMember', window );">ATM Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="nump">1,304,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,746<span></span>
</td>
<td class="nump">$ 2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from Issuance or Sale of Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,746<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_EquityOfferingMaximumOfferingAmount', window );">Equity Offering, Maximum Offering Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=amix_ATMAgreementMember', window );">ATM Agreement [Member] | Selling Agent [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_CommissionPercentage', window );">Commission Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonmonetaryTransactionTypeAxis=amix_ReverseStockSplitMember', window );">Reverse Stock Split [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stockholders' Equity Note, Stock Split, Conversion Ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonmonetaryTransactionTypeAxis=amix_ReverseStockSplitMember', window );">Reverse Stock Split [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stockholders' Equity Note, Stock Split, Conversion Ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonmonetaryTransactionTypeAxis=amix_ReverseStockSplitMember', window );">Reverse Stock Split [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stockholders' Equity Note, Stock Split, Conversion Ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_ClassOfWarrantOrRightIssuedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of warrants or rights issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_ClassOfWarrantOrRightIssuedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_ClassOfWarrantsOrRightsMaximumBeneficialOwnership">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of maximum beneficial ownership of warrants or rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_ClassOfWarrantsOrRightsMaximumBeneficialOwnership</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_CommissionPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Refers to the amount of commission percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_CommissionPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_CommonUnitsIssuedPurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit price of common units issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_CommonUnitsIssuedPurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_EquityOfferingMaximumOfferingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum value of company's equity authorized for issuance under equity offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_EquityOfferingMaximumOfferingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_EquityOfferingOptionMaximumShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum shares to be issued in option under equity offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_EquityOfferingOptionMaximumShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_EquityOfferingOptionMaximumWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum warrants to be issued in option of equity offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_EquityOfferingOptionMaximumWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_EquityOfferingOptionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of the option in the equity offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_EquityOfferingOptionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_NumberOfCommonUnitsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of common units issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_NumberOfCommonUnitsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_NumberOfPrefundedUnitsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of pre-funded units issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_NumberOfPrefundedUnitsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_NumberOfSharesPerCommonUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares per common unit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_NumberOfSharesPerCommonUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_NumberOfWarrantsPerCommonUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of warrants per common unit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_NumberOfWarrantsPerCommonUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_NumberOfWarrantsPerPrefundedUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of warrants per pre-funded unit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_NumberOfWarrantsPerPrefundedUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_PaymentsForInitialPublicOfferingIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the payments for the issuance costs from an initial public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_PaymentsForInitialPublicOfferingIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_PrefundedUnitsIssuedPurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit price of pre-funded units issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_PrefundedUnitsIssuedPurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_ProceedsFromIssuanceOrSaleOfEquityNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_ProceedsFromIssuanceOrSaleOfEquityNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_WorkingCapitalDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Information pertaining to capital available to meet current, short-term obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_WorkingCapitalDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from a stock split in which per-share par value or stated value is not changed proportionately.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 720<br> -SubTopic 35<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483385/720-35-55-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 35<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483406/720-35-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUncertainTaxPositionsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for uncertainty in income taxes classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUncertainTaxPositionsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=amix_SeriesAWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=amix_SeriesAWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=amix_UnderwritersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=amix_UnderwritersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=amix_PrefundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=amix_PrefundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=amix_PrefundedAndSeriesAWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=amix_PrefundedAndSeriesAWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=amix_EquitybasedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=amix_EquitybasedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=amix_UnderwrittenPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=amix_UnderwrittenPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfExpenseAxis=amix_NoncashExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfExpenseAxis=amix_NoncashExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=amix_ATMAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=amix_ATMAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=amix_SellingAgentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=amix_SellingAgentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonmonetaryTransactionTypeAxis=amix_ReverseStockSplitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonmonetaryTransactionTypeAxis=amix_ReverseStockSplitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Note 1 - Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies - Anti-dilutive Securities (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,986,098<span></span>
</td>
<td class="nump">279,070<span></span>
</td>
<td class="nump">1,981,098<span></span>
</td>
<td class="nump">162,767<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">87,531<span></span>
</td>
<td class="nump">4,334<span></span>
</td>
<td class="nump">87,531<span></span>
</td>
<td class="nump">4,334<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember', window );">Convertible Debt Securities [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">33,250<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">33,250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=amix_ConvertibleNotesToWarrantsMember', window );">Convertible Notes to Warrant [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">25,003<span></span>
</td>
<td class="nump">25,003<span></span>
</td>
<td class="nump">25,003<span></span>
</td>
<td class="nump">25,003<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">248,483<span></span>
</td>
<td class="nump">216,483<span></span>
</td>
<td class="nump">243,483<span></span>
</td>
<td class="nump">100,180<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=amix_SeriesAWarrantsMember', window );">Series A Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,533,096<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,533,096<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=amix_RepresentativesWarrantsMember', window );">Representative's Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">91,985<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">91,985<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Shares for the convertible note proceeds received</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=amix_ConvertibleNotesToWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=amix_ConvertibleNotesToWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=amix_SeriesAWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=amix_SeriesAWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=amix_RepresentativesWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=amix_RepresentativesWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Note 1 - Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies - Prior Period Corrections (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss (in thousands)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (3,337)<span></span>
</td>
<td class="num">$ (2,699)<span></span>
</td>
<td class="num">$ (11,410)<span></span>
</td>
<td class="num">$ (15,426)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Loss per share - basic and diluted (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (1.07)<span></span>
</td>
<td class="num">$ (2.2)<span></span>
</td>
<td class="num">$ (6.46)<span></span>
</td>
<td class="num">$ (14.82)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding - basic and diluted (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,105,156<span></span>
</td>
<td class="nump">1,225,423<span></span>
</td>
<td class="nump">1,766,425<span></span>
</td>
<td class="nump">1,040,720<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,986,098<span></span>
</td>
<td class="nump">279,070<span></span>
</td>
<td class="nump">1,981,098<span></span>
</td>
<td class="nump">162,767<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">87,531<span></span>
</td>
<td class="nump">4,334<span></span>
</td>
<td class="nump">87,531<span></span>
</td>
<td class="nump">4,334<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember', window );">Convertible Debt Securities [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">33,250<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">33,250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=amix_ConvertibleNotesToWarrantsMember', window );">Convertible Notes to Warrant [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">25,003<span></span>
</td>
<td class="nump">25,003<span></span>
</td>
<td class="nump">25,003<span></span>
</td>
<td class="nump">25,003<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">248,483<span></span>
</td>
<td class="nump">216,483<span></span>
</td>
<td class="nump">243,483<span></span>
</td>
<td class="nump">100,180<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">Previously Reported [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss (in thousands)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,699)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (15,426)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Loss per share - basic and diluted (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.14)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1.05)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding - basic and diluted (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,902,248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,626,282<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,839,148<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,913,169<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">Previously Reported [Member] | Warrant [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,344,569<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,744,569<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">Previously Reported [Member] | Convertible Debt Securities [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">665,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">665,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">Previously Reported [Member] | Convertible Notes to Warrant [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">Previously Reported [Member] | Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,329,579<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,003,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=amix_ReverseStockSplitAdjustmentMember', window );">Reverse Stock Split Adjustment [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss (in thousands)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Loss per share - basic and diluted (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2.85)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (21.09)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding - basic and diluted (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">945,382<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">731,372<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">541,967<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">445,664<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=amix_ReverseStockSplitAdjustmentMember', window );">Reverse Stock Split Adjustment [Member] | Warrant [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">267,231<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">287,231<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=amix_ReverseStockSplitAdjustmentMember', window );">Reverse Stock Split Adjustment [Member] | Convertible Debt Securities [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=amix_ReverseStockSplitAdjustmentMember', window );">Reverse Stock Split Adjustment [Member] | Convertible Notes to Warrant [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,003<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=amix_ReverseStockSplitAdjustmentMember', window );">Reverse Stock Split Adjustment [Member] | Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">216,483<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,180<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember', window );">Revision of Prior Period, Error Correction, Adjustment [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss (in thousands)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Loss per share - basic and diluted (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.27<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding - basic and diluted (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">280,041<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">309,348<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(262,897)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(282,897)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember', window );">Revision of Prior Period, Error Correction, Adjustment [Member] | Warrant [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(262,897)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(282,897)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember', window );">Revision of Prior Period, Error Correction, Adjustment [Member] | Convertible Debt Securities [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember', window );">Revision of Prior Period, Error Correction, Adjustment [Member] | Convertible Notes to Warrant [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember', window );">Revision of Prior Period, Error Correction, Adjustment [Member] | Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Shares for the convertible note proceeds received</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=amix_ConvertibleNotesToWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=amix_ConvertibleNotesToWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=amix_ReverseStockSplitAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=amix_ReverseStockSplitAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Warrant Liability and Fair Value of Financial Instruments (Details Textual)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th" colspan="2">
<div>Jul. 07, 2023 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 29, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Gain (Loss) on Derivative Instruments, Net, Pretax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ (0)<span></span>
</td>
<td class="num">$ (4,556)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair Value Adjustment of Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">(0)<span></span>
</td>
<td class="nump">$ 3,444<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.02<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=amix_TheWarrantMember', window );">The Warrant [Member] | Termination Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.02<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_ClassOfWarrantOrRightValueOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Value of Securities Called by Warrants or Rights</a></td>
<td class="nump">$ 8,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants and Rights Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=amix_MeasurementInputProbabilityRateMember', window );">Measurement Input, Probability Rate [Member] | Valuation, Probability-weighted Expected Return Method (PWERM) [Member] | Qualified Offering Occurring, One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="nump">0.70<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.70<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=amix_MeasurementInputProbabilityRateMember', window );">Measurement Input, Probability Rate [Member] | Valuation, Probability-weighted Expected Return Method (PWERM) [Member] | Qualified Offering Occurring, Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="nump">0.10<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.10<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=amix_MeasurementInputProbabilityRateMember', window );">Measurement Input, Probability Rate [Member] | Valuation, Probability-weighted Expected Return Method (PWERM) [Member] | No Qualified Offering Occurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="nump">0.20<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.20<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, Fair Value Disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Scenario probability as of issuance was based on timing expectations of management that a qualified offering occurring as of December 31, 2023 was estimated at 70%, respectively; a qualified offering occurring as of June 30, 2024 was estimated at 10%; and no qualified offering occurring was estimated at 20%;</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_ClassOfWarrantOrRightValueOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of securities into which the class of warrant or right may be converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_ClassOfWarrantOrRightValueOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDerivativeInstrumentsNetPretax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=amix_TheWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=amix_TheWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=amix_TerminationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=amix_TerminationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=amix_MeasurementInputProbabilityRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=amix_MeasurementInputProbabilityRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=amix_ValuationProbabilityweightedExpectedReturnMethodPWERMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=amix_ValuationProbabilityweightedExpectedReturnMethodPWERMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=amix_QualifiedOfferingOccurringOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=amix_QualifiedOfferingOccurringOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=amix_QualifiedOfferingOccurringTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=amix_QualifiedOfferingOccurringTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=amix_NoQualifiedOfferingOccurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=amix_NoQualifiedOfferingOccurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Warrant Liability and Fair Value of Financial Instruments - Schedule of Fair Value Measurements (Details) - Fair Value, Inputs, Level 3 [Member] - Warrant [Member]<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements', window );">Additions</a></td>
<td class="nump">4,556<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value measurements - warrants mark-to-market</a></td>
<td class="nump">3,444<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements', window );">Settlement and reclassification to equity</a></td>
<td class="num">(8,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of settlement of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 101<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-101<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchases, (sales), issuances and (settlements) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Note 2 - Warrant Liability and Fair Value of Financial Instruments - Fair Value Measurement Inputs and Valuation Techniques (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th" colspan="2"><div>Jul. 07, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember', window );">Measurement Input, Discount Rate [Member] | Fair Value, Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PercentageOfFIFOInventory', window );">Discount rate at issuance (1)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=amix_MeasurementInputProbabilityRateMember', window );">Measurement Input, Probability Rate [Member] | Valuation, Probability-weighted Expected Return Method (PWERM) [Member] | Qualified Offering Occurring, One [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement input</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.70<span></span>
</td>
<td class="nump">0.70<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=amix_MeasurementInputProbabilityRateMember', window );">Measurement Input, Probability Rate [Member] | Valuation, Probability-weighted Expected Return Method (PWERM) [Member] | Qualified Offering Occurring, Two [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement input</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.10<span></span>
</td>
<td class="nump">0.10<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=amix_MeasurementInputProbabilityRateMember', window );">Measurement Input, Probability Rate [Member] | Valuation, Probability-weighted Expected Return Method (PWERM) [Member] | No Qualified Offering Occurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement input</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.20<span></span>
</td>
<td class="nump">0.20<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=amix_MeasurementInputFixedPriceMember', window );">Measurement Input, Fixed Price [Member] | Valuation, Probability-weighted Expected Return Method (PWERM) [Member] | Minimum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement input</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=amix_MeasurementInputFixedPriceMember', window );">Measurement Input, Fixed Price [Member] | Valuation, Probability-weighted Expected Return Method (PWERM) [Member] | Maximum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement input</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Measurement Input, Expected Term [Member] | Fair Value, Recurring [Member] | Valuation, Probability-weighted Expected Return Method (PWERM) [Member] | Minimum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement input</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.48<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Measurement Input, Expected Term [Member] | Fair Value, Recurring [Member] | Valuation, Probability-weighted Expected Return Method (PWERM) [Member] | Maximum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement input</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.98<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The initial discount rate was chosen based on private equity rates of return as described in the AICPA Practice Aid on Valuation of Privately-Held-Company Equity securities issued as compensation. For the recurring fair value measurement, the Company updated the discount rate based upon yield curves estimated to be similar in credit quality to the Company;</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Scenario probability as of issuance was based on timing expectations of management that a qualified offering occurring as of December 31, 2023 was estimated at 70%, respectively; a qualified offering occurring as of June 30, 2024 was estimated at 10%; and no qualified offering occurring was estimated at 20%;</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">The warrant has a $0.02 strike price, however, the strike price is low relative to the stock price, making the warrant value close to the value of a stock unit. The agreement has a fixed payment value of $8.0 million, see Note 6 &#8211; Related Party Transactions.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PercentageOfFIFOInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of FIFO (first in first out) inventory to total inventory as of the balance sheet date if other than 100 percent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PercentageOfFIFOInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=amix_MeasurementInputProbabilityRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=amix_MeasurementInputProbabilityRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=amix_ValuationProbabilityweightedExpectedReturnMethodPWERMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=amix_ValuationProbabilityweightedExpectedReturnMethodPWERMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=amix_QualifiedOfferingOccurringOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=amix_QualifiedOfferingOccurringOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=amix_QualifiedOfferingOccurringTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=amix_QualifiedOfferingOccurringTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=amix_NoQualifiedOfferingOccurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=amix_NoQualifiedOfferingOccurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=amix_MeasurementInputFixedPriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=amix_MeasurementInputFixedPriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Convertible Notes Payable (Details Textual)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">7 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 28, 2025</div></th>
<th class="th">
<div>Jan. 26, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 09, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($) </div>
<div>yr</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($) </div>
<div>yr</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($) </div>
<div>yr</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.02<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionByUniqueDescriptionAxis=amix_ConversionOfConvertibleNotesToCommonStockMember', window );">Conversion of Convertible Notes to Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt Conversion, Converted Instrument, Shares Issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=amix_BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember', window );">Bridge Financing Warrants in Connection with Convertible Notes [Member[</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and Rights Outstanding, Term (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_ClassOfWarrantOrRightLockupAgreementTermOfUnderlyingShares', window );">Class of Warrant or Right, Lock-up Agreement Term of Underlying Shares (Day)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">180 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_ClassOfWarrantOrRightPercentageOfOutstandingStock', window );">Class of Warrant or Right, Percentage of Outstanding Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants and Rights Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=amix_BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember', window );">Bridge Financing Warrants in Connection with Convertible Notes [Member[ | Measurement Input, Price Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.0188<span></span>
</td>
<td class="nump">1.0188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.0188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=amix_BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember', window );">Bridge Financing Warrants in Connection with Convertible Notes [Member[ | Measurement Input, Expected Term [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input | yr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=amix_BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember', window );">Bridge Financing Warrants in Connection with Convertible Notes [Member[ | Measurement Input, Risk Free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.044<span></span>
</td>
<td class="nump">0.044<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.044<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=amix_BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember', window );">Bridge Financing Warrants in Connection with Convertible Notes [Member[ | Measurement Input, Discount Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.20<span></span>
</td>
<td class="nump">0.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=amix_BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember', window );">Bridge Financing Warrants in Connection with Convertible Notes [Member[ | Measurement Input, Discount for Lack of Marketability [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1577<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amix_TheNotesMember', window );">The Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_DebtInstrumentConvertibleMaximumBeneficialOwnershipPercentage', window );">Debt Instrument, Convertible, Maximum Beneficial Ownership, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.99%<span></span>
</td>
<td class="nump">4.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest Expense, Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amix_TheNotesMember', window );">The Notes [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest Expense, Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amix_ConvertibleDebtWith499PercentBeneficialOwnershipLimitationMember', window );">Convertible Debt with 4.99% Beneficial Ownership Limitation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Convertible Notes Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments', window );">Debt Instrument, Convertible, Number of Equity Instruments</a></td>
<td class="nump">33,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Debt Instrument, Interest Rate, Effective Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_ClassOfWarrantOrRightLockupAgreementTermOfUnderlyingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Pertains to the term of the lock-up agreement associated with the shares underlying the warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_ClassOfWarrantOrRightLockupAgreementTermOfUnderlyingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_ClassOfWarrantOrRightPercentageOfOutstandingStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the warrants as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_ClassOfWarrantOrRightPercentageOfOutstandingStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_DebtInstrumentConvertibleMaximumBeneficialOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of maximum beneficial ownership upon conversion of the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_DebtInstrumentConvertibleMaximumBeneficialOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity instruments that the holder of the debt instrument would receive if the debt was converted to equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-7<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionByUniqueDescriptionAxis=amix_ConversionOfConvertibleNotesToCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionByUniqueDescriptionAxis=amix_ConversionOfConvertibleNotesToCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=amix_BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=amix_BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amix_TheNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amix_TheNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amix_ConvertibleDebtWith499PercentBeneficialOwnershipLimitationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amix_ConvertibleDebtWith499PercentBeneficialOwnershipLimitationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Convertible Notes Payable - Schedule of Convertible Notes Payable (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleLongTermNotesPayable', window );">Outstanding, net carrying amount</a></td>
<td class="nump">$ 1,002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleLongTermNotesPayable', window );">Outstanding, net carrying amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 1,002<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionByUniqueDescriptionAxis=amix_IssuanceOfCommonStockForExtinguishmentOfConvertibleDebtMember', window );">Issuance of Common Stock for Extinguishment of Convertible Debt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Issuance of common stock for extinguishment of convertible debt</a></td>
<td class="num">(1,330)<span></span>
</td>
<td class="num">(670)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_DebtConversionDebtIssuanceCostsConvertedCommonShares', window );">Issuance of common stock for extinguishment of convertible debt, amortized debt discuont</a></td>
<td class="nump">153<span></span>
</td>
<td class="nump">170<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Issuance of common stock for extinguishment of convertible debt</a></td>
<td class="num">(1,177)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amix_TheNotesMember', window );">The Notes [Member] | Convertible Debt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Outstanding, principal amount</a></td>
<td class="nump">1,330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet', window );">Outstanding, amortized debt discount</a></td>
<td class="num">(328)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleLongTermNotesPayable', window );">Outstanding, net carrying amount</a></td>
<td class="nump">1,002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="nump">175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Outstanding, principal amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,330<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet', window );">Outstanding, amortized debt discount</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(328)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleLongTermNotesPayable', window );">Outstanding, net carrying amount</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,002<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_DebtConversionDebtIssuanceCostsConvertedCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the debt issuance costs that were converted into common shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_DebtConversionDebtIssuanceCostsConvertedCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleLongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleLongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionOriginalDebtAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionOriginalDebtAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount (premium).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionByUniqueDescriptionAxis=amix_IssuanceOfCommonStockForExtinguishmentOfConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionByUniqueDescriptionAxis=amix_IssuanceOfCommonStockForExtinguishmentOfConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amix_TheNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amix_TheNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Convertible Notes Payable - Schedule of Detachable Warrants (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Balance, outstanding (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">25,003<span></span>
</td>
<td class="nump">25,003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_ClassOfWarrantOrRightOutstandingOutstandingWeightedAverageExercisePrice', window );">Outstanding, weighted average exercise price (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 20<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm', window );">Outstanding, remaining term (Year)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 5 months 23 days<span></span>
</td>
<td class="text">4 years 5 months 23 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_ClassOfWarrantOrRightAggregateIntrinsicValueOutstanding', window );">Outstanding, intrinsic value</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,010,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_ClassOfWarrantOrRightGrantsInPeriod', window );">Granted, outstanding (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_ClassOfWarrantOrRightGrantsInPeriodWeightedAverageExercise', window );">Granted, weighted average exercise price (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_ClassOfWarrantOrRightExercisesInPeriod', window );">Exercised, outstanding (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_ClassOfWarrantOrRightExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised, weighted average exercise price (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_ClassOfWarrantOrRightForfeituresInPeriod', window );">Forfeited/Cancelled, outstanding (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_ClassOfWarrantOrRightForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited/Cancelled, weighted average exercise price (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_ClassOfWarrantOrRightExpirationsInPeriod', window );">Expired, outstanding (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_ClassOfWarrantOrRightExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired, weighted average exercise price (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Balance, outstanding (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">25,003<span></span>
</td>
<td class="nump">25,003<span></span>
</td>
<td class="nump">25,003<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_ClassOfWarrantOrRightOutstandingOutstandingWeightedAverageExercisePrice', window );">Outstanding, weighted average exercise price (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 20<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_ClassOfWarrantOrRightExercisableNumber', window );">Exercisable (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">25,003<span></span>
</td>
<td class="nump">25,003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice', window );">Exercisable, weighted average exercise price (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 20<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_ClassOfWarrantOrRightExercisableWeightedAverageRemainingContractualTerm', window );">Exercisable, remaining term (Year)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 5 months 23 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_ClassOfWarrantOrRightAggregateIntrinsicValueExercisable', window );">Exercisable, intrinsic value</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Aggregate Intrinsic Value = Excess of market value over the exercise price of all in-the-money warrants. No outstanding or exercisable warrants were in-the-money as of March 31, 2024.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_ClassOfWarrantOrRightAggregateIntrinsicValueExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of warrants currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_ClassOfWarrantOrRightAggregateIntrinsicValueExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_ClassOfWarrantOrRightAggregateIntrinsicValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of outstanding warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_ClassOfWarrantOrRightAggregateIntrinsicValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_ClassOfWarrantOrRightExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested warrants outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_ClassOfWarrantOrRightExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which holders can acquire the shares on warrants outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_ClassOfWarrantOrRightExercisableWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of warrants currently exercisable or convertible.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_ClassOfWarrantOrRightExercisableWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_ClassOfWarrantOrRightExercisesInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_ClassOfWarrantOrRightExercisesInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_ClassOfWarrantOrRightExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which warrant holders acquired shares when converting their warrants into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_ClassOfWarrantOrRightExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_ClassOfWarrantOrRightExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_ClassOfWarrantOrRightExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_ClassOfWarrantOrRightExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which holders could have acquired the underlying shares with respect to the warrants that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_ClassOfWarrantOrRightExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_ClassOfWarrantOrRightForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants that were cancelled during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_ClassOfWarrantOrRightForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_ClassOfWarrantOrRightForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which holders could have acquired the underlying shares with respect to warrants that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_ClassOfWarrantOrRightForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_ClassOfWarrantOrRightGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of warrants granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_ClassOfWarrantOrRightGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_ClassOfWarrantOrRightGrantsInPeriodWeightedAverageExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which holders can acquire shares of common stock by exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_ClassOfWarrantOrRightGrantsInPeriodWeightedAverageExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_ClassOfWarrantOrRightOutstandingOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which holders can acquire the shares reserved for issuance under the warrant plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_ClassOfWarrantOrRightOutstandingOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for warrants outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Equity (Details Textual)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 01, 2025 </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 25, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 22, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 10, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 01, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 15, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th"><div>Aug. 31, 2023</div></th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 28, 2025 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Oct. 24, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 26, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Nov. 29, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 06, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, Shares Authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, Shares Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,882,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 103,000<span></span>
</td>
<td class="nump">$ 2,840,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of Stock Issuance Costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ (0)<span></span>
</td>
<td class="nump">$ 176,000<span></span>
</td>
<td class="nump">$ (0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">143,303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=amix_SeriesAWarrantsMember', window );">Series A Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_NumberOfWarrantsPerPrefundedUnit', window );">Number of Warrants Per Pre-funded Unit (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_ClassOfWarrantsOrRightsMaximumBeneficialOwnership', window );">Class of Warrants or Rights, Maximum Beneficial Ownership</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and Rights Outstanding, Term (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_ClassOfWarrantOrRightFairValuePerShare', window );">Class of Warrant or Right, Fair Value Per Share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.3597<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=amix_PrefundedWarrantsMember', window );">Pre-funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_NumberOfWarrantsPerPrefundedUnit', window );">Number of Warrants Per Pre-funded Unit (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_ClassOfWarrantsOrRightsMaximumBeneficialOwnership', window );">Class of Warrants or Rights, Maximum Beneficial Ownership</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_ClassOfWarrantOrRightFairValuePerShare', window );">Class of Warrant or Right, Fair Value Per Share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.329<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=amix_RepresentativesWarrantsMember', window );">Representative's Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_ClassOfWarrantOrRightLockupPeriod', window );">Class of Warrant or Right, Lock-up Period (Day)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">180 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_ClassOfWarrantOrRightFairValuePerShare', window );">Class of Warrant or Right, Fair Value Per Share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.2125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=amix_EquitybasedWarrantsMember', window );">Equity-based Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and Rights Outstanding, Term (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,988<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_ClassOfWarrantOrRightExercisedInPeriodCashless', window );">Class of Warrant Or Right Exercised In Period, Cashless (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">197,098<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_ClassOfWarrantOrRightExercisedInPeriodCash', window );">Class of Warrant Or Right Exercised In Period, Cash (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">695,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=amix_RfInnovationsIncMember', window );">RF Innovations, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_CommonStockDiscountForLackOfMarketability', window );">Common Stock, Discount for Lack of Marketability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_MaximumPercentageOfSharesSoldInThirtyDays', window );">Maximum Percentage of Shares Sold in Thirty Days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=amix_UnderwritersMember', window );">Underwriters [Member] | Series A Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_EquityOfferingOptionMaximumWarrants', window );">Equity Offering, Option, Maximum Warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">206,422<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_ClassOfWarrantOrRightIssuedDuringPeriod', window );">Class of Warrant or Right, Issued During Period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">156,809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=amix_UnderwritersMember', window );">Underwriters [Member] | Representative's Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_ClassOfWarrantOrRightIssuedDuringPeriod', window );">Class of Warrant or Right, Issued During Period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91,985<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member] | RF Innovations, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-Based Payment Arrangement, Expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=amix_BlackscholesModelMember', window );">Black-Scholes Model [Member] | Series A Warrants and the Representative's Warrants [Member] | Valuation Technique, Discounted Cash Flow [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0417<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=amix_BlackscholesModelMember', window );">Black-Scholes Model [Member] | Series A Warrants and the Representative's Warrants [Member] | Measurement Input, Price Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.4415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">144.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=amix_BlackscholesModelMember', window );">Black-Scholes Model [Member] | Series A Warrants and the Representative's Warrants [Member] | Measurement Input, Discount Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=amix_BlackscholesModelMember', window );">Black-Scholes Model [Member] | Equity-based Warrants [Member] | Measurement Input, Price Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=amix_BlackscholesModelMember', window );">Black-Scholes Model [Member] | Equity-based Warrants [Member] | Measurement Input, Discount Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=amix_BlackscholesModelMember', window );">Black-Scholes Model [Member] | Equity-based Warrants [Member] | Measurement Input, Expected Term [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=amix_The2023StockPlanMember', window );">The 2023 Stock Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares)</a></td>
<td class="nump">124,852<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_EquityOfferingMaximumSharesToBeIssued', window );">Equity Offering, Maximum Shares to be Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,840,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of Stock Issuance Costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,121,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">2,840,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=amix_ATMAgreementMember', window );">ATM Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,304,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_EquityOfferingMaximumOfferingAmount', window );">Equity Offering, Maximum Offering Amount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,746<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from Issuance or Sale of Equity | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,746<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=amix_UnderwrittenPublicOfferingMember', window );">Underwritten Public Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of Stock Issuance Costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_NumberOfCommonUnitsIssued', window );">Number of Common Units Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">458,691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_NumberOfSharesPerCommonUnit', window );">Number of Shares Per Common Unit (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_NumberOfWarrantsPerCommonUnit', window );">Number of Warrants Per Common Unit (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_NumberOfPrefundedUnitsIssued', window );">Number of Pre-funded Units Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">917,596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_CommonUnitsIssuedPurchasePrice', window );">Common Units Issued, Purchase Price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_PrefundedUnitsIssuedPurchasePrice', window );">Pre-funded Units Issued, Purchase Price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.539<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from Issuance or Sale of Equity | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_CommissionPercentage', window );">Commission Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=amix_UnderwrittenPublicOfferingMember', window );">Underwritten Public Offering [Member] | Non-cash Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option [Member] | Underwriters [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">156,809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_EquityOfferingOptionPeriod', window );">Equity Offering, Option Period (Day)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">45 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_EquityOfferingOptionMaximumShares', window );">Equity Offering, Option, Maximum Shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">206,422<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-Based Payment Arrangement, Expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,250<span></span>
</td>
<td class="nump">116,375<span></span>
</td>
<td class="nump">16,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member] | General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-Based Payment Arrangement, Expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,250<span></span>
</td>
<td class="nump">116,375<span></span>
</td>
<td class="nump">16,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member] | Marketing Consultant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock Issued During Period, Shares, Issued for Services (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Stock Issued During Period, Value, Issued for Services | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 133,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Month)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,300,000<span></span>
</td>
<td class="nump">3,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-Based Payment Arrangement, Expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member] | General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-Based Payment Arrangement, Expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member] | Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-Based Payment Arrangement, Expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member] | Black-Scholes Model [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantDateFairValue', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grant Date Fair Value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsDiscountRate', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Discount Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.06%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">139.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member] | Black-Scholes Model [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsDiscountRate', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Discount Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.17%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member] | Black-Scholes Model [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsDiscountRate', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Discount Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.39%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">138.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member] | The 2023 Stock Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Month)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">143,303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-Based Payment Arrangement, Expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember', window );">Warrant [Member] | Black-Scholes Model [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsDiscountRate', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Discount Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.04%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember', window );">Warrant [Member] | Black-Scholes Model [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsDiscountRate', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Discount Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.54%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">119.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_ClassOfWarrantOrRightExercisedInPeriodCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_ClassOfWarrantOrRightExercisedInPeriodCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_ClassOfWarrantOrRightExercisedInPeriodCashless">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_ClassOfWarrantOrRightExercisedInPeriodCashless</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_ClassOfWarrantOrRightFairValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit fair value price of warrants or rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_ClassOfWarrantOrRightFairValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_ClassOfWarrantOrRightIssuedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of warrants or rights issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_ClassOfWarrantOrRightIssuedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_ClassOfWarrantOrRightLockupPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of lock-up for warrants or rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_ClassOfWarrantOrRightLockupPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_ClassOfWarrantsOrRightsMaximumBeneficialOwnership">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of maximum beneficial ownership of warrants or rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_ClassOfWarrantsOrRightsMaximumBeneficialOwnership</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_CommissionPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Refers to the amount of commission percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_CommissionPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_CommonStockDiscountForLackOfMarketability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of discount for lack of marketability on common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_CommonStockDiscountForLackOfMarketability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_CommonUnitsIssuedPurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit price of common units issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_CommonUnitsIssuedPurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_EquityOfferingMaximumOfferingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum value of company's equity authorized for issuance under equity offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_EquityOfferingMaximumOfferingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_EquityOfferingMaximumSharesToBeIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares to be issued in the equity offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_EquityOfferingMaximumSharesToBeIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_EquityOfferingOptionMaximumShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum shares to be issued in option under equity offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_EquityOfferingOptionMaximumShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_EquityOfferingOptionMaximumWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum warrants to be issued in option of equity offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_EquityOfferingOptionMaximumWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_EquityOfferingOptionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of the option in the equity offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_EquityOfferingOptionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_MaximumPercentageOfSharesSoldInThirtyDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum percentage of shares allowed to be sold within 30 days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_MaximumPercentageOfSharesSoldInThirtyDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_NumberOfCommonUnitsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of common units issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_NumberOfCommonUnitsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_NumberOfPrefundedUnitsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of pre-funded units issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_NumberOfPrefundedUnitsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_NumberOfSharesPerCommonUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares per common unit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_NumberOfSharesPerCommonUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_NumberOfWarrantsPerCommonUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of warrants per common unit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_NumberOfWarrantsPerCommonUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_NumberOfWarrantsPerPrefundedUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of warrants per pre-funded unit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_NumberOfWarrantsPerPrefundedUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_PrefundedUnitsIssuedPurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit price of pre-funded units issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_PrefundedUnitsIssuedPurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The grant-date fair value of options as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=amix_SeriesAWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=amix_SeriesAWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=amix_PrefundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=amix_PrefundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=amix_RepresentativesWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=amix_RepresentativesWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=amix_EquitybasedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=amix_EquitybasedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=amix_RfInnovationsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=amix_RfInnovationsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=amix_UnderwritersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=amix_UnderwritersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=amix_BlackscholesModelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=amix_BlackscholesModelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=amix_SeriesAWarrantsAndTheRepresentativesWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=amix_SeriesAWarrantsAndTheRepresentativesWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_ValuationTechniqueDiscountedCashFlowMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_ValuationTechniqueDiscountedCashFlowMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=amix_The2023StockPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=amix_The2023StockPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=amix_ATMAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=amix_ATMAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=amix_UnderwrittenPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=amix_UnderwrittenPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfExpenseAxis=amix_NoncashExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfExpenseAxis=amix_NoncashExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=amix_MarketingConsultantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=amix_MarketingConsultantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Equity - General and Administrative Expense (Details) - Restricted Stock [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-Based Payment Arrangement, Expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 33,250<span></span>
</td>
<td class="nump">$ 116,375<span></span>
</td>
<td class="nump">$ 16,625<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-Based Payment Arrangement, Expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 33,250<span></span>
</td>
<td class="nump">$ 116,375<span></span>
</td>
<td class="nump">$ 16,625<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Equity - Restricted Stock Activity (Details) - Restricted Stock [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2025 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Balance, unvested restricted stock units, shares (in shares) | shares</a></td>
<td class="nump">1,604<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Balance, unvested restricted stock units, weighted average grant date fair value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 76<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted, unvested restricted stock units, shares (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted, unvested restricted stock units, weighted average grant date fair value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested restricted stock units, shares (in shares) | shares</a></td>
<td class="num">(1,604)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested restricted stock units, weighted average grant date fair value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 76<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Balance, unvested restricted stock units, shares (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Balance, unvested restricted stock units, weighted average grant date fair value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Equity - Schedule of Stock Option Activity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Apr. 01, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, options (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">243,483<span></span>
</td>
<td class="nump">100,180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, options, weighted average exercise price (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 32.72<span></span>
</td>
<td class="nump">$ 46.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding, options, Weighted average remaining contractual term (Year)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 11 months 1 day<span></span>
</td>
<td class="text">9 years 4 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding, aggregate intrinsic value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,680,672<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted, options (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">143,303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted, options, weighted average exercise price (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1.85<span></span>
</td>
<td class="nump">$ 23.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised, options (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised, options, weighted average exercise price (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited/Cancelled, options (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited/Cancelled, options, weighted average exercise price (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expired, options (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired, options, weighted average exercise price (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, options (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">248,483<span></span>
</td>
<td class="nump">243,483<span></span>
</td>
<td class="nump">100,180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, options, weighted average exercise price (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 32.1<span></span>
</td>
<td class="nump">$ 32.72<span></span>
</td>
<td class="nump">$ 46.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable, options (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">69,916<span></span>
</td>
<td class="nump">37,923<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable, options, weighted average exercise price (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 37.24<span></span>
</td>
<td class="nump">$ 44.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable, options, Weighted average remaining contractual term (Year)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable, aggregate intrinsic value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Aggregate Intrinsic Value = Excess of market value over the exercise price of all in-the-money stock.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Equity - Schedule of Equity-Based Stock Warrants (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th" colspan="2"><div>Jun. 30, 2025</div></th>
<th class="th" colspan="2"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Apr. 01, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Outstanding, warrants (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,934,874<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">287,231<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, warrants, weighted average exercise price (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 5.89<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 1.64<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Outstanding, warrants, weighted average remaining contractual term (Year)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">4 years 1 month 2 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">4 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Outstanding, warrants, aggregate intrinsic value</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 532,060<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,072,147<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Granted, warrants (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,542,677<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted, warrants, weighted average exercise price (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 4.31<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Exercised, warrants (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(222,132)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(892,432)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised, warrants, weighted average exercise price (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 0.04<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures', window );">Forfeited/Cancelled, warrants (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(130)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(2,602)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited/Cancelled, warrants, weighted average exercise price (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations', window );">Expired, warrants (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired, warrants, weighted average exercise price (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Outstanding, warrants (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,712,612<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">1,934,874<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">287,231<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, warrants, weighted average exercise price (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 6.6498<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">$ 5.89<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 1.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_SharebasedCompensationArrangementBySharebasedPaymentAwardNonoptionEquityInstrumentsExercisableNumberOutstandingNumber', window );">Exercisable, warrants (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,712,612<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,842,889<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable, warrants, weighted average exercise price (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 6.6498<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 5.67<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerm', window );">Exercisable, warrants, weighted average remaining contractual term ( (Year)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">4 years 21 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested', window );">Exercisable, warrants, aggregate intrinsic value</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 532,060<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Aggregate Intrinsic Value = Excess of market value over the exercise price of all in-the-money stock.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">197,098 exercised shares utilized the &#8220;cashless exercise&#8221; option and 695,334 exercised shares were paid in cash.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">Amount includes 87,531 common warrants; 91,985 Representative's Warrants and 1,533,096 Series A Warrants.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price at which holders can acquire the shares on vested portions of warrants outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, currently exercisable, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which warrant holders acquired shares when converting their warrants into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which holders could have acquired the underlying shares with respect to warrants of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which holders could have acquired the underlying shares with respect to warrants that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which holders can acquire shares of common stock by exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which holders can acquire the shares under the warrant plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_SharebasedCompensationArrangementBySharebasedPaymentAwardNonoptionEquityInstrumentsExercisableNumberOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which equity instruments other than options can be currently converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_SharebasedCompensationArrangementBySharebasedPaymentAwardNonoptionEquityInstrumentsExercisableNumberOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements for which rights to exercise lapsed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Equity - Black-Scholes Option Pricing Model (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Jan. 26, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=amix_BlackscholesModelMember', window );">Black-Scholes Model [Member] | Warrant [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price (in dollars per share)</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsDiscountRate', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Discount Rate</a></td>
<td class="nump">4.04%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term (Year)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</a></td>
<td class="nump">104.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=amix_BlackscholesModelMember', window );">Black-Scholes Model [Member] | Warrant [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price (in dollars per share)</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsDiscountRate', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Discount Rate</a></td>
<td class="nump">4.54%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term (Year)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</a></td>
<td class="nump">119.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=amix_BlackscholesModelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=amix_BlackscholesModelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 5 - Commitments and Contingencies (Details Textual)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 17, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 01, 2024 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">143,303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_StockRequiredToBeIssuedForStockSplitShares', window );">Stock Required to be Issued for Stock Split, Shares (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">271,846<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_EmploymentContractsMember', window );">Employment Contracts [Member] | Chief Executive Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_EmploymentAgreementTermOfContract', window );">Employment Agreement, Term of Contract (Year)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_AnnualBaseSalary', window );">Annual Base Salary</a></td>
<td class="nump">$ 450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_EmploymentAgreementBonusAsAPercentageOfAnnualBaseCompensation', window );">Employment Agreement, Bonus as a Percentage of Annual Base Compensation</a></td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_EmploymentContractsMember', window );">Employment Contracts [Member] | Chief Executive Officer [Member] | Scenario, Contract Termination [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_EmploymentAgreementBonusAsAPercentageOfAnnualBaseCompensation', window );">Employment Agreement, Bonus as a Percentage of Annual Base Compensation</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_EmploymentContractsMember', window );">Employment Contracts [Member] | Chief Executive Officer [Member] | Scenario, Contract Termination, Without Cause [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_EmploymentAgreementBonusAsAPercentageOfAnnualBaseCompensation', window );">Employment Agreement, Bonus as a Percentage of Annual Base Compensation</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_EmploymentContractsMember', window );">Employment Contracts [Member] | Chief Executive Officer [Member] | Inducement Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares) | shares</a></td>
<td class="nump">45,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_EmploymentContractsMember', window );">Employment Contracts [Member] | Chief Executive Officer [Member] | Inducement Options [Member] | Share-Based Payment Arrangement, Tranche One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares) | shares</a></td>
<td class="nump">11,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_EmploymentContractsMember', window );">Employment Contracts [Member] | Executive Vice Chair and Strategic Advisor to the Chief Executive Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_EmploymentAgreementTermOfContract', window );">Employment Agreement, Term of Contract (Year)</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_AnnualBaseSalary', window );">Annual Base Salary</a></td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_EmploymentAgreementBonusAsAPercentageOfAnnualBaseCompensation', window );">Employment Agreement, Bonus as a Percentage of Annual Base Compensation</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_EmploymentContractsMember', window );">Employment Contracts [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation', window );">Employee Benefits and Share-Based Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_EmploymentContractsMember', window );">Employment Contracts [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation', window );">Employee Benefits and Share-Based Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember', window );">Pending Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Loss Contingency, Pending Claims, Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_AnnualBaseSalary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the annual base salary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_AnnualBaseSalary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_EmploymentAgreementBonusAsAPercentageOfAnnualBaseCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitment made to pay an annual bonus expressed as a percentage of the individual's base salary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_EmploymentAgreementBonusAsAPercentageOfAnnualBaseCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_EmploymentAgreementTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Pertains to the terms of the employment agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_EmploymentAgreementTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_StockRequiredToBeIssuedForStockSplitShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares required to be issued for the stock split.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_StockRequiredToBeIssuedForStockSplitShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for employee benefit and equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeBenefitsAndShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyPendingClaimsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of pending claims pertaining to a loss contingency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyPendingClaimsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_EmploymentContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_EmploymentContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=amix_ScenarioContractTerminationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=amix_ScenarioContractTerminationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=amix_ScenarioContractTerminationWithoutCauseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=amix_ScenarioContractTerminationWithoutCauseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=amix_InducementOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=amix_InducementOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=amix_ExecutiveViceChairAndStrategicAdvisorToTheChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=amix_ExecutiveViceChairAndStrategicAdvisorToTheChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Related Party Transactions (Details Textual) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 07, 2023</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Jan. 29, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares, Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,497,033<span></span>
</td>
<td class="nump">4,022,625<span></span>
</td>
<td class="nump">942,575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.02<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=amix_TerminationAgreementMember', window );">Termination Agreement [Member] | The Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares, Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_ClassOfWarrantOrRightValueOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Value of Securities Called by Warrants or Rights</a></td>
<td class="nump">$ 8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)</a></td>
<td class="nump">$ 0.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and Rights Outstanding, Term (Year)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_InterestHeldInCompanyReceivingWarrants', window );">Interest Held in Company Receiving Warrants</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=amix_TerminationAgreementMember', window );">Termination Agreement [Member] | The Warrant [Member] | Common Stock, 6 Months Lock-up Period [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_ClassOfWarrantOrRightLockupAgreementTermOfUnderlyingShares', window );">Class of Warrant or Right, Lock-up Agreement Term of Underlying Shares (Day)</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_ClassOfWarrantOrRightPercentageOfOutstandingStock', window );">Class of Warrant or Right, Percentage of Outstanding Stock</a></td>
<td class="nump">12.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=amix_TerminationAgreementMember', window );">Termination Agreement [Member] | The Warrant [Member] | Common Stock, 12 Months Lock-up Period [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_ClassOfWarrantOrRightLockupAgreementTermOfUnderlyingShares', window );">Class of Warrant or Right, Lock-up Agreement Term of Underlying Shares (Day)</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=amix_ConsultingFirmOwnedByFormerCFOMember', window );">Consulting Firm Owned by Former CFO [MEmber] | Accounting and Financial Reporting Services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrentAndNoncurrent', window );">Accounts Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=amix_ConsultingFirmOwnedByFormerCFOMember', window );">Consulting Firm Owned by Former CFO [MEmber] | Accounting and Financial Reporting Services [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Related Party Transaction, Amounts of Transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=amix_ManagementBoardOfDirectorFamilyMember', window );">Management, Board of Director, and Family [Member] | The Bridge Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from Issuance of Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ManagementMember', window );">Management [Member] | The Bridge Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from Issuance of Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member] | The Bridge Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from Issuance of Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_ClassOfWarrantOrRightLockupAgreementTermOfUnderlyingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Pertains to the term of the lock-up agreement associated with the shares underlying the warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_ClassOfWarrantOrRightLockupAgreementTermOfUnderlyingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_ClassOfWarrantOrRightPercentageOfOutstandingStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the warrants as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_ClassOfWarrantOrRightPercentageOfOutstandingStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_ClassOfWarrantOrRightValueOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of securities into which the class of warrant or right may be converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_ClassOfWarrantOrRightValueOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_InterestHeldInCompanyReceivingWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of interest held in the company receiving warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_InterestHeldInCompanyReceivingWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=amix_TerminationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=amix_TerminationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=amix_TheWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=amix_TheWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnderlyingAssetClassAxis=amix_CommonStock6MonthsLockupPeriodMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnderlyingAssetClassAxis=amix_CommonStock6MonthsLockupPeriodMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnderlyingAssetClassAxis=amix_CommonStock12MonthsLockupPeriodMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnderlyingAssetClassAxis=amix_CommonStock12MonthsLockupPeriodMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=amix_ConsultingFirmOwnedByFormerCFOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=amix_ConsultingFirmOwnedByFormerCFOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=amix_AccountingAndFinancialReportingServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=amix_AccountingAndFinancialReportingServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=amix_ManagementBoardOfDirectorFamilyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=amix_ManagementBoardOfDirectorFamilyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amix_TheBridgeOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amix_TheBridgeOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ManagementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ManagementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Income Taxes (Details Textual)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards</a></td>
<td class="nump">$ 3,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_ReserveForUncertainTaxPositions', window );">Reserve for Uncertain Tax Positions</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</a></td>
<td class="nump">2,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=amix_ExpirationCommencingTaxYear20342037Member', window );">Expiration Commencing, Tax Year 2034-2037 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards</a></td>
<td class="nump">900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=amix_NolGeneratedDuring20172024Member', window );">NOL Generated During 2017-2024 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards</a></td>
<td class="nump">$ 2,700<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_ReserveForUncertainTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of money reserved for uncertain tax positions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_ReserveForUncertainTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=amix_ExpirationCommencingTaxYear20342037Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=amix_ExpirationCommencingTaxYear20342037Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=amix_NolGeneratedDuring20172024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=amix_NolGeneratedDuring20172024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Income Taxes - Schedule of Reconciliation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Tax benefit at the U.S. federal statutory rate, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,396)<span></span>
</td>
<td class="num">$ (3,239)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Tax benefit at the U.S. federal statutory rate, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate', window );">Tax rate change, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate', window );">Tax rate change, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense', window );">Permanent differences, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 1,697<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense', window );">Permanent differences, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.05%)<span></span>
</td>
<td class="num">(11.01%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes', window );">Return to provision, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (44)<span></span>
</td>
<td class="num">$ (69)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes', window );">Return to provision, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.39%<span></span>
</td>
<td class="nump">0.45%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_EffectiveIncomeTaxRateReconciliationChangeInStateRateAmount', window );">Change in state rate, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 234<span></span>
</td>
<td class="num">$ (190)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_EffectiveIncomeTaxRateReconciliationChangeInStateRatePercent', window );">Change in state rate, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.05%)<span></span>
</td>
<td class="nump">1.23%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State tax (net of federal benefit), amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (63)<span></span>
</td>
<td class="num">$ (192)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State tax (net of federal benefit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.55%<span></span>
</td>
<td class="nump">1.24%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Valuation allowance, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,264<span></span>
</td>
<td class="nump">$ 1,993<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Valuation allowance, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19.84%)<span></span>
</td>
<td class="num">(12.91%)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Effective income tax rate, Total, amount</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_EffectiveIncomeTaxRateReconciliationChangeInStateRateAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to the change in stat rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_EffectiveIncomeTaxRateReconciliationChangeInStateRateAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_EffectiveIncomeTaxRateReconciliationChangeInStateRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to the change in state rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_EffectiveIncomeTaxRateReconciliationChangeInStateRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 7 - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract', window );"><strong>Assets related to:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts', window );">Capitalized R&amp;D costs</a></td>
<td class="nump">$ 1,380<span></span>
</td>
<td class="nump">$ 602<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="nump">761<span></span>
</td>
<td class="nump">2,643<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals', window );">Accruals and reserves</a></td>
<td class="nump">3,438<span></span>
</td>
<td class="nump">72<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">450<span></span>
</td>
<td class="nump">142<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">6,029<span></span>
</td>
<td class="nump">3,459<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance for deferred tax assets</a></td>
<td class="num">(5,723)<span></span>
</td>
<td class="num">(3,459)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="nump">306<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNetAbstract', window );"><strong>Liabilities related to:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_DeferredTaxLiabilitiesChangeInAccountingMethod', window );">Section 481A method change</a></td>
<td class="num">(306)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Net deferred tax liabilities</a></td>
<td class="num">(306)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from research and development costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_DeferredTaxLiabilitiesChangeInAccountingMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from Section 481A method change.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_DeferredTaxLiabilitiesChangeInAccountingMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Subsequent Events (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 17, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>May 28, 2025</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">143,303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=amix_ATMAgreementMember', window );">ATM Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,304,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,746<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100,000<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Share-Based Payment Arrangement, Employee [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Share-Based Payment Arrangement, Employee [Member] | Share-Based Payment Arrangement, Tranche One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares (in shares)</a></td>
<td class="nump">1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Share-Based Payment Arrangement, Employee [Member] | Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | ATM Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">289,144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=amix_ATMAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=amix_ATMAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 1 - Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies - 10-Q (Details Textual)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 25, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 22, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 24, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th"><div>Oct. 17, 2024</div></th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 28, 2025 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jan. 26, 2024 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Nov. 29, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit', window );">Adjustments to Additional Paid in Capital, Stock Split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,882,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 103,000<span></span>
</td>
<td class="nump">$ 2,840,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss) Attributable to Parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,337,000)<span></span>
</td>
<td class="num">$ (2,699,000)<span></span>
</td>
<td class="num">(11,410,000)<span></span>
</td>
<td class="num">(15,426,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,604,000)<span></span>
</td>
<td class="num">(1,852,000)<span></span>
</td>
<td class="num">(8,258,000)<span></span>
</td>
<td class="num">(6,648,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained Earnings (Accumulated Deficit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (50,379,000)<span></span>
</td>
<td class="num">(53,716,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(50,379,000)<span></span>
</td>
<td class="num">(38,969,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_WorkingCapitalDeficit', window );">Working Capital (Deficit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,900,000<span></span>
</td>
<td class="nump">7,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUncertainTaxPositionsCurrent', window );">Liability for Uncertainty in Income Taxes, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of Reportable Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=amix_SeriesAWarrantsMember', window );">Series A Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | shares</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_NumberOfWarrantsPerPrefundedUnit', window );">Number of Warrants Per Pre-funded Unit (in shares) | shares</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 6.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and Rights Outstanding, Term (Year)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_ClassOfWarrantsOrRightsMaximumBeneficialOwnership', window );">Class of Warrants or Rights, Maximum Beneficial Ownership</a></td>
<td class="nump">4.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=amix_SeriesAWarrantsMember', window );">Series A Warrants [Member] | Underwriters [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_EquityOfferingOptionMaximumWarrants', window );">Equity Offering, Option, Maximum Warrants (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">206,422<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_ClassOfWarrantOrRightIssuedDuringPeriod', window );">Class of Warrant or Right, Issued During Period (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">156,809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=amix_PrefundedWarrantsMember', window );">Pre-funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | shares</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_NumberOfWarrantsPerPrefundedUnit', window );">Number of Warrants Per Pre-funded Unit (in shares) | shares</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_ClassOfWarrantsOrRightsMaximumBeneficialOwnership', window );">Class of Warrants or Rights, Maximum Beneficial Ownership</a></td>
<td class="nump">4.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=amix_PrefundedAndSeriesAWarrantsMember', window );">Pre-funded and Series A Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_ClassOfWarrantsOrRightsMaximumBeneficialOwnership', window );">Class of Warrants or Rights, Maximum Beneficial Ownership</a></td>
<td class="nump">4.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=amix_EquitybasedWarrantsMember', window );">Equity-based Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and Rights Outstanding, Term (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=amix_ATMAgreementMember', window );">ATM Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_EquityOfferingMaximumOfferingAmount', window );">Equity Offering, Maximum Offering Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="nump">1,304,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from Issuance or Sale of Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,746<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=amix_UnderwrittenPublicOfferingMember', window );">Underwritten Public Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_NumberOfCommonUnitsIssued', window );">Number of Common Units Issued (in shares) | shares</a></td>
<td class="nump">458,691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_NumberOfSharesPerCommonUnit', window );">Number of Shares Per Common Unit (in shares) | shares</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_NumberOfWarrantsPerCommonUnit', window );">Number of Warrants Per Common Unit (in shares) | shares</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_NumberOfPrefundedUnitsIssued', window );">Number of Pre-funded Units Issued (in shares) | shares</a></td>
<td class="nump">917,596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_CommonUnitsIssuedPurchasePrice', window );">Common Units Issued, Purchase Price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 6.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_PrefundedUnitsIssuedPurchasePrice', window );">Pre-funded Units Issued, Purchase Price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 6.539<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from Issuance or Sale of Equity</a></td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</a></td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_ProceedsFromIssuanceOrSaleOfEquityNet', window );">Proceeds from Issuance or Sale of Equity, Net</a></td>
<td class="nump">9,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=amix_UnderwrittenPublicOfferingMember', window );">Underwritten Public Offering [Member] | Non-cash Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option [Member] | Underwriters [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">156,809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_EquityOfferingOptionPeriod', window );">Equity Offering, Option Period (Day)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">45 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_EquityOfferingOptionMaximumShares', window );">Equity Offering, Option, Maximum Shares (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">206,422<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonmonetaryTransactionTypeAxis=amix_ReverseStockSplitMember', window );">Reverse Stock Split [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stockholders' Equity Note, Stock Split, Conversion Ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonmonetaryTransactionTypeAxis=amix_ReverseStockSplitMember', window );">Reverse Stock Split [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stockholders' Equity Note, Stock Split, Conversion Ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonmonetaryTransactionTypeAxis=amix_ReverseStockSplitMember', window );">Reverse Stock Split [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stockholders' Equity Note, Stock Split, Conversion Ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_ClassOfWarrantOrRightIssuedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of warrants or rights issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_ClassOfWarrantOrRightIssuedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_ClassOfWarrantsOrRightsMaximumBeneficialOwnership">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of maximum beneficial ownership of warrants or rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_ClassOfWarrantsOrRightsMaximumBeneficialOwnership</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_CommonUnitsIssuedPurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit price of common units issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_CommonUnitsIssuedPurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_EquityOfferingMaximumOfferingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum value of company's equity authorized for issuance under equity offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_EquityOfferingMaximumOfferingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_EquityOfferingOptionMaximumShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum shares to be issued in option under equity offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_EquityOfferingOptionMaximumShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_EquityOfferingOptionMaximumWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum warrants to be issued in option of equity offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_EquityOfferingOptionMaximumWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_EquityOfferingOptionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of the option in the equity offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_EquityOfferingOptionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_NumberOfCommonUnitsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of common units issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_NumberOfCommonUnitsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_NumberOfPrefundedUnitsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of pre-funded units issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_NumberOfPrefundedUnitsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_NumberOfSharesPerCommonUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares per common unit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_NumberOfSharesPerCommonUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_NumberOfWarrantsPerCommonUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of warrants per common unit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_NumberOfWarrantsPerCommonUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_NumberOfWarrantsPerPrefundedUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of warrants per pre-funded unit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_NumberOfWarrantsPerPrefundedUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_PrefundedUnitsIssuedPurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit price of pre-funded units issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_PrefundedUnitsIssuedPurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_ProceedsFromIssuanceOrSaleOfEquityNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_ProceedsFromIssuanceOrSaleOfEquityNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_WorkingCapitalDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Information pertaining to capital available to meet current, short-term obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_WorkingCapitalDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from a stock split in which per-share par value or stated value is not changed proportionately.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 720<br> -SubTopic 35<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483385/720-35-55-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 35<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483406/720-35-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-21<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUncertainTaxPositionsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for uncertainty in income taxes classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUncertainTaxPositionsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=amix_SeriesAWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=amix_SeriesAWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=amix_UnderwritersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=amix_UnderwritersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=amix_PrefundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=amix_PrefundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=amix_PrefundedAndSeriesAWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=amix_PrefundedAndSeriesAWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=amix_EquitybasedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=amix_EquitybasedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=amix_ATMAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=amix_ATMAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=amix_UnderwrittenPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=amix_UnderwrittenPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfExpenseAxis=amix_NoncashExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfExpenseAxis=amix_NoncashExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonmonetaryTransactionTypeAxis=amix_ReverseStockSplitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonmonetaryTransactionTypeAxis=amix_ReverseStockSplitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Note 1 - Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Anti-dilutive Securities - 10Q (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,986,098<span></span>
</td>
<td class="nump">279,070<span></span>
</td>
<td class="nump">1,981,098<span></span>
</td>
<td class="nump">162,767<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">87,531<span></span>
</td>
<td class="nump">4,334<span></span>
</td>
<td class="nump">87,531<span></span>
</td>
<td class="nump">4,334<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember', window );">Convertible Debt Securities [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">33,250<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">33,250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=amix_ConvertibleNotesToWarrantsMember', window );">Convertible Notes to Warrant [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">25,003<span></span>
</td>
<td class="nump">25,003<span></span>
</td>
<td class="nump">25,003<span></span>
</td>
<td class="nump">25,003<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">248,483<span></span>
</td>
<td class="nump">216,483<span></span>
</td>
<td class="nump">243,483<span></span>
</td>
<td class="nump">100,180<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=amix_SeriesAWarrantsMember', window );">Series A Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,533,096<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,533,096<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=amix_RepresentativesWarrantsMember', window );">Representative's Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">91,985<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">91,985<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Shares for the convertible note proceeds received</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=amix_ConvertibleNotesToWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=amix_ConvertibleNotesToWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=amix_SeriesAWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=amix_SeriesAWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=amix_RepresentativesWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=amix_RepresentativesWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Note 1 - Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Prior Period Corrections - 10Q (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss (in thousands)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (3,337)<span></span>
</td>
<td class="num">$ (2,699)<span></span>
</td>
<td class="num">$ (11,410)<span></span>
</td>
<td class="num">$ (15,426)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Loss per share - basic and diluted (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (1.07)<span></span>
</td>
<td class="num">$ (2.2)<span></span>
</td>
<td class="num">$ (6.46)<span></span>
</td>
<td class="num">$ (14.82)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding - basic and diluted (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,105,156<span></span>
</td>
<td class="nump">1,225,423<span></span>
</td>
<td class="nump">1,766,425<span></span>
</td>
<td class="nump">1,040,720<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,986,098<span></span>
</td>
<td class="nump">279,070<span></span>
</td>
<td class="nump">1,981,098<span></span>
</td>
<td class="nump">162,767<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">87,531<span></span>
</td>
<td class="nump">4,334<span></span>
</td>
<td class="nump">87,531<span></span>
</td>
<td class="nump">4,334<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember', window );">Convertible Debt Securities [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">33,250<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">33,250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=amix_ConvertibleNotesToWarrantsMember', window );">Convertible Notes to Warrant [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">25,003<span></span>
</td>
<td class="nump">25,003<span></span>
</td>
<td class="nump">25,003<span></span>
</td>
<td class="nump">25,003<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">248,483<span></span>
</td>
<td class="nump">216,483<span></span>
</td>
<td class="nump">243,483<span></span>
</td>
<td class="nump">100,180<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">Previously Reported [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss (in thousands)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,699)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (15,426)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Loss per share - basic and diluted (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.14)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1.05)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding - basic and diluted (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,902,248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,626,282<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,839,148<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,913,169<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">Previously Reported [Member] | Warrant [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,344,569<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,744,569<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">Previously Reported [Member] | Convertible Debt Securities [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">665,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">665,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">Previously Reported [Member] | Convertible Notes to Warrant [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">Previously Reported [Member] | Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,329,579<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,003,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=amix_ReverseStockSplitAdjustmentMember', window );">Reverse Stock Split Adjustment [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss (in thousands)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Loss per share - basic and diluted (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2.85)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (21.09)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding - basic and diluted (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">945,382<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">731,372<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">541,967<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">445,664<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=amix_ReverseStockSplitAdjustmentMember', window );">Reverse Stock Split Adjustment [Member] | Warrant [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">267,231<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">287,231<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=amix_ReverseStockSplitAdjustmentMember', window );">Reverse Stock Split Adjustment [Member] | Convertible Debt Securities [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=amix_ReverseStockSplitAdjustmentMember', window );">Reverse Stock Split Adjustment [Member] | Convertible Notes to Warrant [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,003<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=amix_ReverseStockSplitAdjustmentMember', window );">Reverse Stock Split Adjustment [Member] | Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">216,483<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,180<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember', window );">Revision of Prior Period, Error Correction, Adjustment [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss (in thousands)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Loss per share - basic and diluted (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.27<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding - basic and diluted (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">280,041<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">309,348<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(262,897)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(282,897)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember', window );">Revision of Prior Period, Error Correction, Adjustment [Member] | Warrant [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(262,897)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(282,897)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember', window );">Revision of Prior Period, Error Correction, Adjustment [Member] | Convertible Debt Securities [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember', window );">Revision of Prior Period, Error Correction, Adjustment [Member] | Convertible Notes to Warrant [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember', window );">Revision of Prior Period, Error Correction, Adjustment [Member] | Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Shares for the convertible note proceeds received</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=amix_ConvertibleNotesToWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=amix_ConvertibleNotesToWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=amix_ReverseStockSplitAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=amix_ReverseStockSplitAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Convertible Notes Payable - 10Q (Details Textual)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">7 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 28, 2025</div></th>
<th class="th">
<div>Jan. 26, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($) </div>
<div>yr</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($) </div>
<div>yr</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($) </div>
<div>yr</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Sep. 09, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionByUniqueDescriptionAxis=amix_ConversionOfConvertibleNotesToCommonStockMember', window );">Conversion of Convertible Notes to Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt Conversion, Converted Instrument, Shares Issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=amix_BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember', window );">Bridge Financing Warrants in Connection with Convertible Notes [Member[</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and Rights Outstanding, Term (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0125<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=amix_BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember', window );">Bridge Financing Warrants in Connection with Convertible Notes [Member[ | Measurement Input, Price Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.0188<span></span>
</td>
<td class="nump">1.0188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.0188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=amix_BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember', window );">Bridge Financing Warrants in Connection with Convertible Notes [Member[ | Measurement Input, Expected Term [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input | yr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=amix_BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember', window );">Bridge Financing Warrants in Connection with Convertible Notes [Member[ | Measurement Input, Risk Free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.044<span></span>
</td>
<td class="nump">0.044<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.044<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=amix_BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember', window );">Bridge Financing Warrants in Connection with Convertible Notes [Member[ | Measurement Input, Discount Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.20<span></span>
</td>
<td class="nump">0.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=amix_BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember', window );">Bridge Financing Warrants in Connection with Convertible Notes [Member[ | Measurement Input, Discount for Lack of Marketability [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amix_TheNotesMember', window );">The Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_DebtInstrumentConvertibleMaximumBeneficialOwnershipPercentage', window );">Debt Instrument, Convertible, Maximum Beneficial Ownership, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.99%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest Expense, Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amix_TheNotesMember', window );">The Notes [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest Expense, Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amix_ConvertibleDebtWith499PercentBeneficialOwnershipLimitationMember', window );">Convertible Debt with 4.99% Beneficial Ownership Limitation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Debt Instrument, Interest Rate, Effective Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments', window );">Debt Instrument, Convertible, Number of Equity Instruments</a></td>
<td class="nump">33,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_DebtInstrumentConvertibleMaximumBeneficialOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of maximum beneficial ownership upon conversion of the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_DebtInstrumentConvertibleMaximumBeneficialOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity instruments that the holder of the debt instrument would receive if the debt was converted to equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-7<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionByUniqueDescriptionAxis=amix_ConversionOfConvertibleNotesToCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionByUniqueDescriptionAxis=amix_ConversionOfConvertibleNotesToCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=amix_BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=amix_BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amix_TheNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amix_TheNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amix_ConvertibleDebtWith499PercentBeneficialOwnershipLimitationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amix_ConvertibleDebtWith499PercentBeneficialOwnershipLimitationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Convertible Notes Payable - Schedule of Detachable Warrants - 10Q (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Balance, outstanding (in shares)</a></td>
<td class="nump">25,003<span></span>
</td>
<td class="nump">25,003<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_ClassOfWarrantOrRightOutstandingOutstandingWeightedAverageExercisePrice', window );">Outstanding, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 20<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_ClassOfWarrantOrRightGrantsInPeriod', window );">Granted, outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_ClassOfWarrantOrRightGrantsInPeriodWeightedAverageExercise', window );">Granted, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_ClassOfWarrantOrRightExercisesInPeriod', window );">Exercised, outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_ClassOfWarrantOrRightExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_ClassOfWarrantOrRightForfeituresInPeriod', window );">Forfeited/Cancelled, outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_ClassOfWarrantOrRightForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited/Cancelled, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_ClassOfWarrantOrRightExpirationsInPeriod', window );">Expired, outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_ClassOfWarrantOrRightExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Balance, outstanding (in shares)</a></td>
<td class="nump">25,003<span></span>
</td>
<td class="nump">25,003<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_ClassOfWarrantOrRightOutstandingOutstandingWeightedAverageExercisePrice', window );">Outstanding, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 20<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_ClassOfWarrantOrRightExercisableNumber', window );">Exercisable (in shares)</a></td>
<td class="nump">25,003<span></span>
</td>
<td class="nump">25,003<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice', window );">Exercisable, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 20<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_ClassOfWarrantOrRightExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested warrants outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_ClassOfWarrantOrRightExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which holders can acquire the shares on warrants outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_ClassOfWarrantOrRightExercisesInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_ClassOfWarrantOrRightExercisesInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_ClassOfWarrantOrRightExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which warrant holders acquired shares when converting their warrants into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_ClassOfWarrantOrRightExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_ClassOfWarrantOrRightExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_ClassOfWarrantOrRightExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_ClassOfWarrantOrRightExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which holders could have acquired the underlying shares with respect to the warrants that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_ClassOfWarrantOrRightExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_ClassOfWarrantOrRightForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants that were cancelled during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_ClassOfWarrantOrRightForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_ClassOfWarrantOrRightForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which holders could have acquired the underlying shares with respect to warrants that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_ClassOfWarrantOrRightForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_ClassOfWarrantOrRightGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of warrants granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_ClassOfWarrantOrRightGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_ClassOfWarrantOrRightGrantsInPeriodWeightedAverageExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which holders can acquire shares of common stock by exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_ClassOfWarrantOrRightGrantsInPeriodWeightedAverageExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_ClassOfWarrantOrRightOutstandingOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which holders can acquire the shares reserved for issuance under the warrant plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_ClassOfWarrantOrRightOutstandingOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Equity - 10Q (Details Textual)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 01, 2025 </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 25, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 22, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 10, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 01, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 15, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th"><div>Aug. 31, 2023</div></th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 28, 2025 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Oct. 24, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Nov. 29, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, Shares Authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, Shares Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">143,303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,882,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 103,000<span></span>
</td>
<td class="nump">$ 2,840,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of Stock Issuance Costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ (0)<span></span>
</td>
<td class="nump">$ 176,000<span></span>
</td>
<td class="nump">$ (0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of Warrant or Right, Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,003<span></span>
</td>
<td class="nump">25,003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=amix_SeriesAWarrantsMember', window );">Series A Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_NumberOfWarrantsPerPrefundedUnit', window );">Number of Warrants Per Pre-funded Unit (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_ClassOfWarrantsOrRightsMaximumBeneficialOwnership', window );">Class of Warrants or Rights, Maximum Beneficial Ownership</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and Rights Outstanding, Term (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_ClassOfWarrantOrRightFairValuePerShare', window );">Class of Warrant or Right, Fair Value Per Share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.3597<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of Warrant or Right, Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,533,096<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=amix_PrefundedWarrantsMember', window );">Pre-funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_NumberOfWarrantsPerPrefundedUnit', window );">Number of Warrants Per Pre-funded Unit (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_ClassOfWarrantsOrRightsMaximumBeneficialOwnership', window );">Class of Warrants or Rights, Maximum Beneficial Ownership</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_ClassOfWarrantOrRightFairValuePerShare', window );">Class of Warrant or Right, Fair Value Per Share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.329<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=amix_RepresentativesWarrantsMember', window );">Representative's Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_ClassOfWarrantOrRightLockupPeriod', window );">Class of Warrant or Right, Lock-up Period (Day)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">180 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_ClassOfWarrantOrRightFairValuePerShare', window );">Class of Warrant or Right, Fair Value Per Share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.2125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of Warrant or Right, Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91,985<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=amix_CommonWarrantsMember', window );">Common Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of Warrant or Right, Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,531<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=amix_RfInnovationsIncMember', window );">RF Innovations, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_CommonStockDiscountForLackOfMarketability', window );">Common Stock, Discount for Lack of Marketability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_MaximumPercentageOfSharesSoldInThirtyDays', window );">Maximum Percentage of Shares Sold in Thirty Days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=amix_UnderwritersMember', window );">Underwriters [Member] | Series A Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_EquityOfferingOptionMaximumWarrants', window );">Equity Offering, Option, Maximum Warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">206,422<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_ClassOfWarrantOrRightIssuedDuringPeriod', window );">Class of Warrant or Right, Issued During Period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">156,809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=amix_UnderwritersMember', window );">Underwriters [Member] | Representative's Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_ClassOfWarrantOrRightIssuedDuringPeriod', window );">Class of Warrant or Right, Issued During Period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91,985<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member] | RF Innovations, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-Based Payment Arrangement, Expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=amix_BlackscholesModelMember', window );">Black-Scholes Model [Member] | Series A Warrants and the Representative's Warrants [Member] | Measurement Input, Discount Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=amix_BlackscholesModelMember', window );">Black-Scholes Model [Member] | Series A Warrants and the Representative's Warrants [Member] | Measurement Input, Price Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.4415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">144.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=amix_The2023StockPlanMember', window );">The 2023 Stock Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares)</a></td>
<td class="nump">124,852<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=amix_ATMAgreementMember', window );">ATM Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_EquityOfferingMaximumOfferingAmount', window );">Equity Offering, Maximum Offering Amount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,304,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,746<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from Issuance or Sale of Equity | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,746<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=amix_UnderwrittenPublicOfferingMember', window );">Underwritten Public Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_NumberOfCommonUnitsIssued', window );">Number of Common Units Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">458,691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_NumberOfSharesPerCommonUnit', window );">Number of Shares Per Common Unit (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_NumberOfWarrantsPerCommonUnit', window );">Number of Warrants Per Common Unit (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_NumberOfPrefundedUnitsIssued', window );">Number of Pre-funded Units Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">917,596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_CommonUnitsIssuedPurchasePrice', window );">Common Units Issued, Purchase Price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_PrefundedUnitsIssuedPurchasePrice', window );">Pre-funded Units Issued, Purchase Price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.539<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from Issuance or Sale of Equity | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_CommissionPercentage', window );">Commission Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of Stock Issuance Costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=amix_UnderwrittenPublicOfferingMember', window );">Underwritten Public Offering [Member] | Non-cash Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option [Member] | Underwriters [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">156,809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_EquityOfferingOptionPeriod', window );">Equity Offering, Option Period (Day)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">45 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_EquityOfferingOptionMaximumShares', window );">Equity Offering, Option, Maximum Shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">206,422<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-Based Payment Arrangement, Expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,250<span></span>
</td>
<td class="nump">116,375<span></span>
</td>
<td class="nump">16,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member] | General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-Based Payment Arrangement, Expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,250<span></span>
</td>
<td class="nump">116,375<span></span>
</td>
<td class="nump">16,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member] | Marketing Consultant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock Issued During Period, Shares, Issued for Services (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Stock Issued During Period, Value, Issued for Services | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 133,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Month)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,300,000<span></span>
</td>
<td class="nump">3,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-Based Payment Arrangement, Expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member] | General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-Based Payment Arrangement, Expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member] | Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-Based Payment Arrangement, Expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member] | Black-Scholes Model [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantDateFairValue', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grant Date Fair Value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsDiscountRate', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Discount Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.06%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">139.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member] | The 2023 Stock Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Month)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">143,303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-Based Payment Arrangement, Expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_ClassOfWarrantOrRightFairValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit fair value price of warrants or rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_ClassOfWarrantOrRightFairValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_ClassOfWarrantOrRightIssuedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of warrants or rights issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_ClassOfWarrantOrRightIssuedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_ClassOfWarrantOrRightLockupPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of lock-up for warrants or rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_ClassOfWarrantOrRightLockupPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_ClassOfWarrantsOrRightsMaximumBeneficialOwnership">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of maximum beneficial ownership of warrants or rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_ClassOfWarrantsOrRightsMaximumBeneficialOwnership</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_CommissionPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Refers to the amount of commission percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_CommissionPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_CommonStockDiscountForLackOfMarketability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of discount for lack of marketability on common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_CommonStockDiscountForLackOfMarketability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_CommonUnitsIssuedPurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit price of common units issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_CommonUnitsIssuedPurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_EquityOfferingMaximumOfferingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum value of company's equity authorized for issuance under equity offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_EquityOfferingMaximumOfferingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_EquityOfferingOptionMaximumShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum shares to be issued in option under equity offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_EquityOfferingOptionMaximumShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_EquityOfferingOptionMaximumWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum warrants to be issued in option of equity offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_EquityOfferingOptionMaximumWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_EquityOfferingOptionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of the option in the equity offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_EquityOfferingOptionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_MaximumPercentageOfSharesSoldInThirtyDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum percentage of shares allowed to be sold within 30 days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_MaximumPercentageOfSharesSoldInThirtyDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_NumberOfCommonUnitsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of common units issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_NumberOfCommonUnitsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_NumberOfPrefundedUnitsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of pre-funded units issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_NumberOfPrefundedUnitsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_NumberOfSharesPerCommonUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares per common unit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_NumberOfSharesPerCommonUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_NumberOfWarrantsPerCommonUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of warrants per common unit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_NumberOfWarrantsPerCommonUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_NumberOfWarrantsPerPrefundedUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of warrants per pre-funded unit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_NumberOfWarrantsPerPrefundedUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_PrefundedUnitsIssuedPurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit price of pre-funded units issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_PrefundedUnitsIssuedPurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The grant-date fair value of options as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=amix_SeriesAWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=amix_SeriesAWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=amix_PrefundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=amix_PrefundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=amix_RepresentativesWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=amix_RepresentativesWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=amix_CommonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=amix_CommonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=amix_RfInnovationsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=amix_RfInnovationsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=amix_UnderwritersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=amix_UnderwritersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=amix_BlackscholesModelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=amix_BlackscholesModelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=amix_SeriesAWarrantsAndTheRepresentativesWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=amix_SeriesAWarrantsAndTheRepresentativesWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=amix_The2023StockPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=amix_The2023StockPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=amix_ATMAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=amix_ATMAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=amix_UnderwrittenPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=amix_UnderwrittenPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfExpenseAxis=amix_NoncashExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfExpenseAxis=amix_NoncashExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=amix_MarketingConsultantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=amix_MarketingConsultantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Equity - General and Administrative Expense - 10Q (Details) - Restricted Stock [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-Based Payment Arrangement, Expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 33,250<span></span>
</td>
<td class="nump">$ 116,375<span></span>
</td>
<td class="nump">$ 16,625<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-Based Payment Arrangement, Expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 33,250<span></span>
</td>
<td class="nump">$ 116,375<span></span>
</td>
<td class="nump">$ 16,625<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Equity - Schedule of Stock Option Activity - 10Q (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, options (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">243,483<span></span>
</td>
<td class="nump">100,180<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, options, weighted average exercise price (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 32.72<span></span>
</td>
<td class="nump">$ 46.59<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted, options (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">143,303<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted, options, weighted average exercise price (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1.85<span></span>
</td>
<td class="nump">$ 23.02<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised, options (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised, options, weighted average exercise price (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited/Cancelled, options (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited/Cancelled, options, weighted average exercise price (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expired, options (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired, options, weighted average exercise price (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, options (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">248,483<span></span>
</td>
<td class="nump">243,483<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, options, weighted average exercise price (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 32.1<span></span>
</td>
<td class="nump">$ 32.72<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable, options (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">69,916<span></span>
</td>
<td class="nump">37,923<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable, options, weighted average exercise price (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 37.24<span></span>
</td>
<td class="nump">$ 44.35<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Aggregate Intrinsic Value = Excess of market value over the exercise price of all in-the-money stock.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Equity - Schedule of Equity-Based Stock Warrants - 10Q (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2"><div>Jun. 30, 2025</div></th>
<th class="th" colspan="2"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Outstanding, warrants (in shares)</a></td>
<td class="nump">1,934,874<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">287,231<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, warrants, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 5.89<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 1.64<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Granted, warrants (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,542,677<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted, warrants, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 4.31<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Exercised, warrants (in shares)</a></td>
<td class="num">(222,132)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(892,432)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised, warrants, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 0.04<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures', window );">Forfeited/Cancelled, warrants (in shares)</a></td>
<td class="num">(130)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(2,602)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited/Cancelled, warrants, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations', window );">Expired, warrants (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired, warrants, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Outstanding, warrants (in shares)</a></td>
<td class="nump">1,712,612<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">1,934,874<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, warrants, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 6.6498<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">$ 5.89<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_SharebasedCompensationArrangementBySharebasedPaymentAwardNonoptionEquityInstrumentsExercisableNumberOutstandingNumber', window );">Exercisable, warrants (in shares)</a></td>
<td class="nump">1,712,612<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,842,889<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable, warrants, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 6.6498<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 5.67<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">197,098 exercised shares utilized the &#8220;cashless exercise&#8221; option and 695,334 exercised shares were paid in cash.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Amount includes 87,531 common warrants; 91,985 Representative's Warrants and 1,533,096 Series A Warrants.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price at which holders can acquire the shares on vested portions of warrants outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which warrant holders acquired shares when converting their warrants into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which holders could have acquired the underlying shares with respect to warrants of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which holders could have acquired the underlying shares with respect to warrants that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which holders can acquire shares of common stock by exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which holders can acquire the shares under the warrant plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_SharebasedCompensationArrangementBySharebasedPaymentAwardNonoptionEquityInstrumentsExercisableNumberOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which equity instruments other than options can be currently converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_SharebasedCompensationArrangementBySharebasedPaymentAwardNonoptionEquityInstrumentsExercisableNumberOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements for which rights to exercise lapsed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Commitments and Contingencies - 10Q (Details Textual)<br> Pure in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 01, 2024 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_StockRequiredToBeIssuedForStockSplitShares', window );">Stock Required to be Issued for Stock Split, Shares (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">271,846<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_EmploymentContractsMember', window );">Employment Contracts [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation', window );">Employee Benefits and Share-Based Compensation</a></td>
<td class="nump">$ 1.2<span></span>
</td>
<td class="nump">$ 1.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_EmploymentContractsMember', window );">Employment Contracts [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation', window );">Employee Benefits and Share-Based Compensation</a></td>
<td class="nump">$ 1.7<span></span>
</td>
<td class="nump">$ 1.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember', window );">Pending Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Loss Contingency, Pending Claims, Number</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_StockRequiredToBeIssuedForStockSplitShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares required to be issued for the stock split.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_StockRequiredToBeIssuedForStockSplitShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for employee benefit and equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeBenefitsAndShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyPendingClaimsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of pending claims pertaining to a loss contingency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyPendingClaimsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_EmploymentContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_EmploymentContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 5 - Related Party Transactions - 10Q (Details Textual) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th"><div>Jul. 07, 2023</div></th>
<th class="th"><div>Jan. 29, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.02<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=amix_TheWarrantMember', window );">The Warrant [Member] | Termination Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_ClassOfWarrantOrRightValueOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Value of Securities Called by Warrants or Rights</a></td>
<td class="nump">$ 8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)</a></td>
<td class="nump">$ 0.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and Rights Outstanding, Term (Year)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants and Rights Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=amix_TheWarrantMember', window );">The Warrant [Member] | Termination Agreement [Member] | Common Stock, 6 Months Lock-up Period [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_ClassOfWarrantOrRightLockupAgreementTermOfUnderlyingShares', window );">Class of Warrant or Right, Lock-up Agreement Term of Underlying Shares (Day)</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_ClassOfWarrantOrRightPercentageOfOutstandingStock', window );">Class of Warrant or Right, Percentage of Outstanding Stock</a></td>
<td class="nump">12.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=amix_TheWarrantMember', window );">The Warrant [Member] | Termination Agreement [Member] | Common Stock, 12 Months Lock-up Period [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_ClassOfWarrantOrRightLockupAgreementTermOfUnderlyingShares', window );">Class of Warrant or Right, Lock-up Agreement Term of Underlying Shares (Day)</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_ClassOfWarrantOrRightLockupAgreementTermOfUnderlyingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Pertains to the term of the lock-up agreement associated with the shares underlying the warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_ClassOfWarrantOrRightLockupAgreementTermOfUnderlyingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_ClassOfWarrantOrRightPercentageOfOutstandingStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the warrants as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_ClassOfWarrantOrRightPercentageOfOutstandingStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_ClassOfWarrantOrRightValueOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of securities into which the class of warrant or right may be converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_ClassOfWarrantOrRightValueOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=amix_TheWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=amix_TheWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=amix_TerminationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=amix_TerminationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnderlyingAssetClassAxis=amix_CommonStock6MonthsLockupPeriodMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnderlyingAssetClassAxis=amix_CommonStock6MonthsLockupPeriodMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnderlyingAssetClassAxis=amix_CommonStock12MonthsLockupPeriodMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnderlyingAssetClassAxis=amix_CommonStock12MonthsLockupPeriodMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Subsequent Events - 10Q (Details Textual) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 11, 2025</div></th>
<th class="th"><div>Aug. 05, 2025</div></th>
<th class="th"><div>Jul. 21, 2025</div></th>
<th class="th"><div>Jul. 31, 2025</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Jul. 01, 2025</div></th>
<th class="th"><div>Feb. 28, 2025</div></th>
<th class="th"><div>Nov. 25, 2024</div></th>
<th class="th"><div>Oct. 24, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Nov. 29, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_ClassOfWarrantOrRightExercisesInPeriod', window );">Class of Warrant or Right, Exercises in Period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">(0)<span></span>
</td>
<td class="nump">(0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of Warrant or Right, Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,003<span></span>
</td>
<td class="nump">25,003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">(0)<span></span>
</td>
<td class="nump">(0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period (in shares)</a></td>
<td class="nump">177,652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,331<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Board of Directors Chairman [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period (in shares)</a></td>
<td class="nump">8,773<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Executive Chair of the Board [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period (in shares)</a></td>
<td class="nump">65,542<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period (in shares)</a></td>
<td class="nump">3,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Chief Executive Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period (in shares)</a></td>
<td class="nump">45,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Chief Technology Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period (in shares)</a></td>
<td class="nump">8,773<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Chief Medical Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period (in shares)</a></td>
<td class="nump">13,159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Chief Financial Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period (in shares)</a></td>
<td class="nump">32,655<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=amix_ExistingWarrantsMember', window );">Existing Warrants [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,477,596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_ClassOfWarrantOrRightExchangesPercentageOfUnderlyingShares', window );">Class of Warrant or Right, Exchanges, Percentage of Underlying Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from Issuance of Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_PaymentsForWarrantIssuanceFees', window );">Payments for Warrant Issuance Fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=amix_ExistingWarrantsAt1723ExercisePriceMember', window );">Existing Warrants at 1.723 Exercise Price [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.723<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_ClassOfWarrantOrRightExercisesInPeriod', window );">Class of Warrant or Right, Exercises in Period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">855,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=amix_ExistingWarrantsAt1722ExercisePriceMember', window );">Existing Warrants at 1.722 Exercise Price [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">622,596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and Rights Outstanding, Term (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=amix_SeriesBWarrantsMember', window );">Series B Warrants [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,477,596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.723<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and Rights Outstanding, Term (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=amix_RepresentativesWarrantsMember', window );">Representative's Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of Warrant or Right, Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91,985<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=amix_RepresentativesWarrantsMember', window );">Representative's Warrants [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88,656<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.6707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and Rights Outstanding, Term (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=amix_SeriesAWarrantsMember', window );">Series A Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and Rights Outstanding, Term (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of Warrant or Right, Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,533,096<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=amix_SeriesAWarrantsMember', window );">Series A Warrants [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_ClassOfWarrantOrRightExercisesInPeriod', window );">Class of Warrant or Right, Exercises in Period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">268,072<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of Warrant or Right, Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">354,524<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">622,596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=amix_PreipoWarrantsMember', window );">Pre-IPO Warrants [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amix_ClassOfWarrantOrRightExercisesInPeriod', window );">Class of Warrant or Right, Exercises in Period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_ClassOfWarrantOrRightExchangesPercentageOfUnderlyingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percent of underlying shares related to the exchange of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_ClassOfWarrantOrRightExchangesPercentageOfUnderlyingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_ClassOfWarrantOrRightExercisesInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_ClassOfWarrantOrRightExercisesInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amix_PaymentsForWarrantIssuanceFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the payment of warrant issuance fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amix_PaymentsForWarrantIssuanceFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=amix_ExecutiveChairOfTheBoardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=amix_ExecutiveChairOfTheBoardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=amix_ChiefTechnologyOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=amix_ChiefTechnologyOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=amix_ChiefMedicalOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=amix_ChiefMedicalOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=amix_ExistingWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=amix_ExistingWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=amix_ExistingWarrantsAt1723ExercisePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=amix_ExistingWarrantsAt1723ExercisePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=amix_ExistingWarrantsAt1722ExercisePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=amix_ExistingWarrantsAt1722ExercisePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=amix_SeriesBWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=amix_SeriesBWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=amix_RepresentativesWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=amix_RepresentativesWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=amix_SeriesAWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=amix_SeriesAWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=amix_PreipoWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=amix_PreipoWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>288</ContextCount>
  <ElementCount>308</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>93</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="amix20251001c_424b3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://autonomix.com/20250630/role/statement-document-and-entity-information</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="amix20251001c_424b3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>001 - Statement - Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://autonomix.com/20250630/role/statement-balance-sheets</Role>
      <ShortName>Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="amix20251001c_424b3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>002 - Statement - Balance Sheets (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://autonomix.com/20250630/role/statement-balance-sheets-parentheticals</Role>
      <ShortName>Balance Sheets (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="amix20251001c_424b3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>003 - Statement - Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://autonomix.com/20250630/role/statement-statements-of-operations</Role>
      <ShortName>Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="amix20251001c_424b3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>004 - Statement - Statements of Changes in Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://autonomix.com/20250630/role/statement-statements-of-changes-in-stockholders-equity</Role>
      <ShortName>Statements of Changes in Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="amix20251001c_424b3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>005 - Statement - Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://autonomix.com/20250630/role/statement-statements-of-cash-flows</Role>
      <ShortName>Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="amix20251001c_424b3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>006 - Statement - Condensed Balance Sheets (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://autonomix.com/20250630/role/statement-condensed-balance-sheets-unaudited-</Role>
      <ShortName>Condensed Balance Sheets (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="amix20251001c_424b3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>007 - Statement - Condensed Balance Sheets (Unaudited) (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://autonomix.com/20250630/role/statement-condensed-balance-sheets-unaudited-parentheticals</Role>
      <ShortName>Condensed Balance Sheets (Unaudited) (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="amix20251001c_424b3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>008 - Statement - Condensed Statements of Operations (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://autonomix.com/20250630/role/statement-condensed-statements-of-operations-unaudited</Role>
      <ShortName>Condensed Statements of Operations (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="amix20251001c_424b3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>009 - Statement - Condensed Statements of Changes in Stockholders' Equity (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://autonomix.com/20250630/role/statement-condensed-statements-of-changes-in-stockholders-equity-unaudited</Role>
      <ShortName>Condensed Statements of Changes in Stockholders' Equity (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="amix20251001c_424b3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>010 - Statement - Condensed Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://autonomix.com/20250630/role/statement-condensed-statements-of-cash-flows-unaudited</Role>
      <ShortName>Condensed Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="amix20251001c_424b3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>011 - Disclosure - Note 1 - Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies</Role>
      <ShortName>Note 1 - Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="amix20251001c_424b3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>012 - Disclosure - Note 2 - Warrant Liability and Fair Value of Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments</Role>
      <ShortName>Note 2 - Warrant Liability and Fair Value of Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="amix20251001c_424b3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>013 - Disclosure - Note 3 - Convertible Notes Payable</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable</Role>
      <ShortName>Note 3 - Convertible Notes Payable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="amix20251001c_424b3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>014 - Disclosure - Note 4 - Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://autonomix.com/20250630/role/statement-note-4-equity</Role>
      <ShortName>Note 4 - Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="amix20251001c_424b3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>015 - Disclosure - Note 5 - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://autonomix.com/20250630/role/statement-note-5-commitments-and-contingencies</Role>
      <ShortName>Note 5 - Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="amix20251001c_424b3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>016 - Disclosure - Note 6 - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://autonomix.com/20250630/role/statement-note-6-related-party-transactions</Role>
      <ShortName>Note 6 - Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="amix20251001c_424b3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>017 - Disclosure - Note 7 - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://autonomix.com/20250630/role/statement-note-7-income-taxes</Role>
      <ShortName>Note 7 - Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="amix20251001c_424b3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>018 - Disclosure - Note 8 - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://autonomix.com/20250630/role/statement-note-8-subsequent-events</Role>
      <ShortName>Note 8 - Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="amix20251001c_424b3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>019 - Disclosure - Note 1 - Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies - 10-Q</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q</Role>
      <ShortName>Note 1 - Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies - 10-Q</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="amix20251001c_424b3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>020 - Disclosure - Note 2 - Convertible Notes Payable - 10Q</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://autonomix.com/20250630/role/statement-note-2-convertible-notes-payable-10q</Role>
      <ShortName>Note 2 - Convertible Notes Payable - 10Q</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="amix20251001c_424b3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>021 - Disclosure - Note 3 - Equity - 10Q</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://autonomix.com/20250630/role/statement-note-3-equity-10q</Role>
      <ShortName>Note 3 - Equity - 10Q</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="amix20251001c_424b3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>022 - Disclosure - Note 4 - Commitments and Contingencies - 10Q</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://autonomix.com/20250630/role/statement-note-4-commitments-and-contingencies-10q</Role>
      <ShortName>Note 4 - Commitments and Contingencies - 10Q</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="amix20251001c_424b3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>023 - Disclosure - Note 5 - Related Party Transactions - 10Q</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://autonomix.com/20250630/role/statement-note-5-related-party-transactions-10q</Role>
      <ShortName>Note 5 - Related Party Transactions - 10Q</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="amix20251001c_424b3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>024 - Disclosure - Note 6 - Subsequent Events - 10Q</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://autonomix.com/20250630/role/statement-note-6-subsequent-events-10q</Role>
      <ShortName>Note 6 - Subsequent Events - 10Q</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="amix20251001c_424b3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>025 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://autonomix.com/20250630/role/statement-significant-accounting-policies-policies</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="amix20251001c_424b3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>026 - Disclosure - Note 1 - Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-tables</Role>
      <ShortName>Note 1 - Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="amix20251001c_424b3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>027 - Disclosure - Note 2 - Warrant Liability and Fair Value of Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-tables</Role>
      <ShortName>Note 2 - Warrant Liability and Fair Value of Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="amix20251001c_424b3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>028 - Disclosure - Note 3 - Convertible Notes Payable (Tables)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable-tables</Role>
      <ShortName>Note 3 - Convertible Notes Payable (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="amix20251001c_424b3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>029 - Disclosure - Note 4 - Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://autonomix.com/20250630/role/statement-note-4-equity-tables</Role>
      <ShortName>Note 4 - Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://autonomix.com/20250630/role/statement-note-4-equity</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="amix20251001c_424b3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>030 - Disclosure - Note 7 - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://autonomix.com/20250630/role/statement-note-7-income-taxes-tables</Role>
      <ShortName>Note 7 - Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://autonomix.com/20250630/role/statement-note-7-income-taxes</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="amix20251001c_424b3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>031 - Disclosure - Note 1 - Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies - 10-Q (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q-tables</Role>
      <ShortName>Note 1 - Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies - 10-Q (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="amix20251001c_424b3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>032 - Disclosure - Note 2 - Convertible Notes Payable - 10Q (Tables)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://autonomix.com/20250630/role/statement-note-2-convertible-notes-payable-10q-tables</Role>
      <ShortName>Note 2 - Convertible Notes Payable - 10Q (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://autonomix.com/20250630/role/statement-note-2-convertible-notes-payable-10q</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="amix20251001c_424b3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>033 - Disclosure - Note 3 - Equity - 10Q (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://autonomix.com/20250630/role/statement-note-3-equity-10q-tables</Role>
      <ShortName>Note 3 - Equity - 10Q (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://autonomix.com/20250630/role/statement-note-3-equity-10q</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="amix20251001c_424b3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>034 - Disclosure - Note 1 - Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual</Role>
      <ShortName>Note 1 - Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-tables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="amix20251001c_424b3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>035 - Disclosure - Note 1 - Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies - Anti-dilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-antidilutive-securities-details</Role>
      <ShortName>Note 1 - Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies - Anti-dilutive Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q-tables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="amix20251001c_424b3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>036 - Disclosure - Note 1 - Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies - Prior Period Corrections (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-prior-period-corrections-details</Role>
      <ShortName>Note 1 - Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies - Prior Period Corrections (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q-tables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="amix20251001c_424b3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>037 - Disclosure - Note 2 - Warrant Liability and Fair Value of Financial Instruments (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-details-textual</Role>
      <ShortName>Note 2 - Warrant Liability and Fair Value of Financial Instruments (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-tables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="amix20251001c_424b3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>038 - Disclosure - Note 2 - Warrant Liability and Fair Value of Financial Instruments - Schedule of Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-schedule-of-fair-value-measurements-details</Role>
      <ShortName>Note 2 - Warrant Liability and Fair Value of Financial Instruments - Schedule of Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="amix20251001c_424b3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>039 - Disclosure - Note 2 - Warrant Liability and Fair Value of Financial Instruments - Fair Value Measurement Inputs and Valuation Techniques (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-fair-value-measurement-inputs-and-valuation-techniques-details</Role>
      <ShortName>Note 2 - Warrant Liability and Fair Value of Financial Instruments - Fair Value Measurement Inputs and Valuation Techniques (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="amix20251001c_424b3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>040 - Disclosure - Note 3 - Convertible Notes Payable (Details Textual)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable-details-textual</Role>
      <ShortName>Note 3 - Convertible Notes Payable (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable-tables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="amix20251001c_424b3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>041 - Disclosure - Note 3 - Convertible Notes Payable - Schedule of Convertible Notes Payable (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable-schedule-of-convertible-notes-payable-details</Role>
      <ShortName>Note 3 - Convertible Notes Payable - Schedule of Convertible Notes Payable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="amix20251001c_424b3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>042 - Disclosure - Note 3 - Convertible Notes Payable - Schedule of Detachable Warrants (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable-schedule-of-detachable-warrants-details</Role>
      <ShortName>Note 3 - Convertible Notes Payable - Schedule of Detachable Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="amix20251001c_424b3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>043 - Disclosure - Note 4 - Equity (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://autonomix.com/20250630/role/statement-note-4-equity-details-textual</Role>
      <ShortName>Note 4 - Equity (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://autonomix.com/20250630/role/statement-note-4-equity-tables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="amix20251001c_424b3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>044 - Disclosure - Note 4 - Equity - General and Administrative Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://autonomix.com/20250630/role/statement-note-4-equity-general-and-administrative-expense-details</Role>
      <ShortName>Note 4 - Equity - General and Administrative Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="amix20251001c_424b3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>045 - Disclosure - Note 4 - Equity - Restricted Stock Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://autonomix.com/20250630/role/statement-note-4-equity-restricted-stock-activity-details</Role>
      <ShortName>Note 4 - Equity - Restricted Stock Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="amix20251001c_424b3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>046 - Disclosure - Note 4 - Equity - Schedule of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://autonomix.com/20250630/role/statement-note-4-equity-schedule-of-stock-option-activity-details</Role>
      <ShortName>Note 4 - Equity - Schedule of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="amix20251001c_424b3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>047 - Disclosure - Note 4 - Equity - Schedule of Equity-Based Stock Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://autonomix.com/20250630/role/statement-note-4-equity-schedule-of-equitybased-stock-warrants-details</Role>
      <ShortName>Note 4 - Equity - Schedule of Equity-Based Stock Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="amix20251001c_424b3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>048 - Disclosure - Note 4 - Equity - Black-Scholes Option Pricing Model (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://autonomix.com/20250630/role/statement-note-4-equity-blackscholes-option-pricing-model-details</Role>
      <ShortName>Note 4 - Equity - Black-Scholes Option Pricing Model (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="amix20251001c_424b3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>049 - Disclosure - Note 5 - Commitments and Contingencies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://autonomix.com/20250630/role/statement-note-5-commitments-and-contingencies-details-textual</Role>
      <ShortName>Note 5 - Commitments and Contingencies (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://autonomix.com/20250630/role/statement-note-5-commitments-and-contingencies</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="amix20251001c_424b3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>050 - Disclosure - Note 6 - Related Party Transactions (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://autonomix.com/20250630/role/statement-note-6-related-party-transactions-details-textual</Role>
      <ShortName>Note 6 - Related Party Transactions (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://autonomix.com/20250630/role/statement-note-6-related-party-transactions</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="amix20251001c_424b3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>051 - Disclosure - Note 7 - Income Taxes (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://autonomix.com/20250630/role/statement-note-7-income-taxes-details-textual</Role>
      <ShortName>Note 7 - Income Taxes (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://autonomix.com/20250630/role/statement-note-7-income-taxes-tables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="amix20251001c_424b3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>052 - Disclosure - Note 7 - Income Taxes - Schedule of Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://autonomix.com/20250630/role/statement-note-7-income-taxes-schedule-of-reconciliation-details</Role>
      <ShortName>Note 7 - Income Taxes - Schedule of Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="amix20251001c_424b3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>053 - Disclosure - Note 7 - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://autonomix.com/20250630/role/statement-note-7-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details</Role>
      <ShortName>Note 7 - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="amix20251001c_424b3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>054 - Disclosure - Note 8 - Subsequent Events (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://autonomix.com/20250630/role/statement-note-8-subsequent-events-details-textual</Role>
      <ShortName>Note 8 - Subsequent Events (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://autonomix.com/20250630/role/statement-note-8-subsequent-events</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="amix20251001c_424b3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>055 - Disclosure - Note 1 - Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies - 10-Q (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q-details-textual</Role>
      <ShortName>Note 1 - Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies - 10-Q (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-tables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="amix20251001c_424b3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>056 - Disclosure - Note 1 - Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Anti-dilutive Securities - 10Q (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-10q-details</Role>
      <ShortName>Note 1 - Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Anti-dilutive Securities - 10Q (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="amix20251001c_424b3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>057 - Disclosure - Note 1 - Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Prior Period Corrections - 10Q (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-schedule-of-prior-period-corrections-10q-details</Role>
      <ShortName>Note 1 - Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Prior Period Corrections - 10Q (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="amix20251001c_424b3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>058 - Disclosure - Note 2 - Convertible Notes Payable - 10Q (Details Textual)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://autonomix.com/20250630/role/statement-note-2-convertible-notes-payable-10q-details-textual</Role>
      <ShortName>Note 2 - Convertible Notes Payable - 10Q (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://autonomix.com/20250630/role/statement-note-2-convertible-notes-payable-10q-tables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="amix20251001c_424b3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>059 - Disclosure - Note 2 - Convertible Notes Payable - Schedule of Detachable Warrants - 10Q (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://autonomix.com/20250630/role/statement-note-2-convertible-notes-payable-schedule-of-detachable-warrants-10q-details</Role>
      <ShortName>Note 2 - Convertible Notes Payable - Schedule of Detachable Warrants - 10Q (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="amix20251001c_424b3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>060 - Disclosure - Note 3 - Equity - 10Q (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://autonomix.com/20250630/role/statement-note-3-equity-10q-details-textual</Role>
      <ShortName>Note 3 - Equity - 10Q (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://autonomix.com/20250630/role/statement-note-3-equity-10q-tables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="amix20251001c_424b3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>061 - Disclosure - Note 3 - Equity - General and Administrative Expense - 10Q (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://autonomix.com/20250630/role/statement-note-3-equity-general-and-administrative-expense-10q-details</Role>
      <ShortName>Note 3 - Equity - General and Administrative Expense - 10Q (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="amix20251001c_424b3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>062 - Disclosure - Note 3 - Equity - Schedule of Stock Option Activity - 10Q (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://autonomix.com/20250630/role/statement-note-3-equity-schedule-of-stock-option-activity-10q-details</Role>
      <ShortName>Note 3 - Equity - Schedule of Stock Option Activity - 10Q (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="amix20251001c_424b3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>063 - Disclosure - Note 3 - Equity - Schedule of Equity-Based Stock Warrants - 10Q (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://autonomix.com/20250630/role/statement-note-3-equity-schedule-of-equitybased-stock-warrants-10q-details</Role>
      <ShortName>Note 3 - Equity - Schedule of Equity-Based Stock Warrants - 10Q (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="amix20251001c_424b3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>064 - Disclosure - Note 4 - Commitments and Contingencies - 10Q (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://autonomix.com/20250630/role/statement-note-4-commitments-and-contingencies-10q-details-textual</Role>
      <ShortName>Note 4 - Commitments and Contingencies - 10Q (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://autonomix.com/20250630/role/statement-note-4-commitments-and-contingencies-10q</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="amix20251001c_424b3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>065 - Disclosure - Note 5 - Related Party Transactions - 10Q (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://autonomix.com/20250630/role/statement-note-5-related-party-transactions-10q-details-textual</Role>
      <ShortName>Note 5 - Related Party Transactions - 10Q (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://autonomix.com/20250630/role/statement-note-5-related-party-transactions-10q</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="amix20251001c_424b3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>066 - Disclosure - Note 6 - Subsequent Events - 10Q (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://autonomix.com/20250630/role/statement-note-6-subsequent-events-10q-details-textual</Role>
      <ShortName>Note 6 - Subsequent Events - 10Q (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://autonomix.com/20250630/role/statement-note-6-subsequent-events-10q</ParentRole>
      <Position>67</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>amix-20250630.xsd</File>
    <File>amix-20250630_cal.xml</File>
    <File>amix-20250630_def.xml</File>
    <File>amix-20250630_lab.xml</File>
    <File>amix-20250630_pre.xml</File>
    <File doctype="424B3" isDefinitelyFs="true" isUsgaap="true" original="amix20251001c_424b3.htm">amix20251001c_424b3.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>a01.jpg</File>
    <File>a02.jpg</File>
    <File>a03.jpg</File>
    <File>a04.jpg</File>
    <File>a05.jpg</File>
    <File>a06.jpg</File>
    <File>a07.jpg</File>
    <File>amix20251001c_424b3img010.jpg</File>
    <File>logolrg.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="919">http://fasb.org/us-gaap/2025</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>90
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "amix20251001c_424b3.htm": {
   "nsprefix": "amix",
   "nsuri": "http://autonomix.com/20250630",
   "dts": {
    "schema": {
     "local": [
      "amix-20250630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/currency/2025/currency-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd",
      "https://xbrl.sec.gov/exch/2025/exch-2025.xsd",
      "https://xbrl.sec.gov/naics/2025/naics-2025.xsd",
      "https://xbrl.sec.gov/sic/2025/sic-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "amix-20250630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "amix-20250630_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "amix-20250630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "amix-20250630_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "amix20251001c_424b3.htm"
     ]
    }
   },
   "keyStandard": 221,
   "keyCustom": 87,
   "axisStandard": 31,
   "axisCustom": 0,
   "memberStandard": 36,
   "memberCustom": 52,
   "hidden": {
    "total": 124,
    "http://xbrl.sec.gov/dei/2025": 4,
    "http://fasb.org/us-gaap/2025": 95,
    "http://autonomix.com/20250630": 25
   },
   "contextCount": 288,
   "entityCount": 1,
   "segmentCount": 93,
   "elementCount": 518,
   "unitCount": 8,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2025": 919,
    "http://xbrl.sec.gov/dei/2025": 4
   },
   "report": {
    "R1": {
     "role": "http://autonomix.com/20250630/role/statement-document-and-entity-information",
     "longName": "000 - Document - Document And Entity Information",
     "shortName": "Document And Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": null,
     "uniqueAnchor": null
    },
    "R2": {
     "role": "http://autonomix.com/20250630/role/statement-balance-sheets",
     "longName": "001 - Statement - Balance Sheets",
     "shortName": "Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "i_2025-03-31",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "amix20251001c_424b3.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2025-03-31",
      "name": "us-gaap:LiabilitiesNoncurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "amix20251001c_424b3.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://autonomix.com/20250630/role/statement-balance-sheets-parentheticals",
     "longName": "002 - Statement - Balance Sheets (Parentheticals)",
     "shortName": "Balance Sheets (Parentheticals)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "i_2023-11-29",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "amix20251001c_424b3.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R4": {
     "role": "http://autonomix.com/20250630/role/statement-statements-of-operations",
     "longName": "003 - Statement - Statements of Operations",
     "shortName": "Statements of Operations",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "d_2025-04-01_2025-06-30",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "amix20251001c_424b3.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R5": {
     "role": "http://autonomix.com/20250630/role/statement-statements-of-changes-in-stockholders-equity",
     "longName": "004 - Statement - Statements of Changes in Stockholders' Equity",
     "shortName": "Statements of Changes in Stockholders' Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "i_2023-03-31_StatementEquityComponentsAxis-CommonStockMember",
      "name": "us-gaap:SharesOutstanding",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "b",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "amix20251001c_424b3.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-04-01_2024-03-31_StatementEquityComponentsAxis-CommonStockMember",
      "name": "amix:StockIssuedDuringPeriodSharesInitialPublicOffering",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "amix20251001c_424b3.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://autonomix.com/20250630/role/statement-statements-of-cash-flows",
     "longName": "005 - Statement - Statements of Cash Flows",
     "shortName": "Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "d_2024-04-01_2025-03-31",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-4",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "amix20251001c_424b3.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-04-01_2025-03-31",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "amix20251001c_424b3.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://autonomix.com/20250630/role/statement-condensed-balance-sheets-unaudited-",
     "longName": "006 - Statement - Condensed Balance Sheets (Unaudited)",
     "shortName": "Condensed Balance Sheets (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "i_2025-06-30",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "amix20251001c_424b3.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2025-06-30",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "amix20251001c_424b3.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://autonomix.com/20250630/role/statement-condensed-balance-sheets-unaudited-parentheticals",
     "longName": "007 - Statement - Condensed Balance Sheets (Unaudited) (Parentheticals)",
     "shortName": "Condensed Balance Sheets (Unaudited) (Parentheticals)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "8",
     "firstAnchor": {
      "contextRef": "i_2023-11-29",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "amix20251001c_424b3.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R9": {
     "role": "http://autonomix.com/20250630/role/statement-condensed-statements-of-operations-unaudited",
     "longName": "008 - Statement - Condensed Statements of Operations (Unaudited)",
     "shortName": "Condensed Statements of Operations (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "9",
     "firstAnchor": {
      "contextRef": "d_2025-04-01_2025-06-30",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "amix20251001c_424b3.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R10": {
     "role": "http://autonomix.com/20250630/role/statement-condensed-statements-of-changes-in-stockholders-equity-unaudited",
     "longName": "009 - Statement - Condensed Statements of Changes in Stockholders' Equity (Unaudited)",
     "shortName": "Condensed Statements of Changes in Stockholders' Equity (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "10",
     "firstAnchor": {
      "contextRef": "i_2023-03-31_StatementEquityComponentsAxis-CommonStockMember",
      "name": "us-gaap:SharesOutstanding",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "b",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "amix20251001c_424b3.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R11": {
     "role": "http://autonomix.com/20250630/role/statement-condensed-statements-of-cash-flows-unaudited",
     "longName": "010 - Statement - Condensed Statements of Cash Flows (Unaudited)",
     "shortName": "Condensed Statements of Cash Flows (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "11",
     "firstAnchor": {
      "contextRef": "d_2025-04-01_2025-06-30",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "amix20251001c_424b3.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-04-01_2025-06-30",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "amix20251001c_424b3.htm",
      "unique": true
     }
    },
    "R12": {
     "role": "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies",
     "longName": "011 - Disclosure - Note 1 - Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies",
     "shortName": "Note 1 - Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "d_2025-04-01_2025-06-30",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "amix20251001c_424b3.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R13": {
     "role": "http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments",
     "longName": "012 - Disclosure - Note 2 - Warrant Liability and Fair Value of Financial Instruments",
     "shortName": "Note 2 - Warrant Liability and Fair Value of Financial Instruments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "d_2024-04-01_2025-03-31",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "amix20251001c_424b3.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-04-01_2025-03-31",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "amix20251001c_424b3.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable",
     "longName": "013 - Disclosure - Note 3 - Convertible Notes Payable",
     "shortName": "Note 3 - Convertible Notes Payable",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "d_2025-04-01_2025-06-30",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "amix20251001c_424b3.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R15": {
     "role": "http://autonomix.com/20250630/role/statement-note-4-equity",
     "longName": "014 - Disclosure - Note 4 - Equity",
     "shortName": "Note 4 - Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "d_2025-04-01_2025-06-30",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "amix20251001c_424b3.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R16": {
     "role": "http://autonomix.com/20250630/role/statement-note-5-commitments-and-contingencies",
     "longName": "015 - Disclosure - Note 5 - Commitments and Contingencies",
     "shortName": "Note 5 - Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "d_2025-04-01_2025-06-30",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "amix20251001c_424b3.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R17": {
     "role": "http://autonomix.com/20250630/role/statement-note-6-related-party-transactions",
     "longName": "016 - Disclosure - Note 6 - Related Party Transactions",
     "shortName": "Note 6 - Related Party Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "d_2025-04-01_2025-06-30",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "amix20251001c_424b3.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R18": {
     "role": "http://autonomix.com/20250630/role/statement-note-7-income-taxes",
     "longName": "017 - Disclosure - Note 7 - Income Taxes",
     "shortName": "Note 7 - Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "d_2024-04-01_2025-03-31",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "amix20251001c_424b3.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-04-01_2025-03-31",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "amix20251001c_424b3.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://autonomix.com/20250630/role/statement-note-8-subsequent-events",
     "longName": "018 - Disclosure - Note 8 - Subsequent Events",
     "shortName": "Note 8 - Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "d_2025-04-01_2025-06-30",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "amix20251001c_424b3.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R20": {
     "role": "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q",
     "longName": "019 - Disclosure - Note 1 - Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies - 10-Q",
     "shortName": "Note 1 - Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies - 10-Q",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "d_2025-04-01_2025-06-30",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "amix20251001c_424b3.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R21": {
     "role": "http://autonomix.com/20250630/role/statement-note-2-convertible-notes-payable-10q",
     "longName": "020 - Disclosure - Note 2 - Convertible Notes Payable - 10Q",
     "shortName": "Note 2 - Convertible Notes Payable - 10Q",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "d_2025-04-01_2025-06-30",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "amix20251001c_424b3.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R22": {
     "role": "http://autonomix.com/20250630/role/statement-note-3-equity-10q",
     "longName": "021 - Disclosure - Note 3 - Equity - 10Q",
     "shortName": "Note 3 - Equity - 10Q",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "d_2025-04-01_2025-06-30",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "amix20251001c_424b3.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R23": {
     "role": "http://autonomix.com/20250630/role/statement-note-4-commitments-and-contingencies-10q",
     "longName": "022 - Disclosure - Note 4 - Commitments and Contingencies - 10Q",
     "shortName": "Note 4 - Commitments and Contingencies - 10Q",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "d_2025-04-01_2025-06-30",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "amix20251001c_424b3.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R24": {
     "role": "http://autonomix.com/20250630/role/statement-note-5-related-party-transactions-10q",
     "longName": "023 - Disclosure - Note 5 - Related Party Transactions - 10Q",
     "shortName": "Note 5 - Related Party Transactions - 10Q",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "d_2025-04-01_2025-06-30",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "amix20251001c_424b3.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R25": {
     "role": "http://autonomix.com/20250630/role/statement-note-6-subsequent-events-10q",
     "longName": "024 - Disclosure - Note 6 - Subsequent Events - 10Q",
     "shortName": "Note 6 - Subsequent Events - 10Q",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "d_2025-04-01_2025-06-30",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "amix20251001c_424b3.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R26": {
     "role": "http://autonomix.com/20250630/role/statement-significant-accounting-policies-policies",
     "longName": "025 - Disclosure - Significant Accounting Policies (Policies)",
     "shortName": "Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "26",
     "firstAnchor": {
      "contextRef": "d_2025-04-01_2025-06-30",
      "name": "amix:ReverseStockSplitPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "amix20251001c_424b3.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-04-01_2025-06-30",
      "name": "amix:ReverseStockSplitPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "amix20251001c_424b3.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-tables",
     "longName": "026 - Disclosure - Note 1 - Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies (Tables)",
     "shortName": "Note 1 - Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "d_2025-04-01_2025-06-30",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "amix20251001c_424b3.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R28": {
     "role": "http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-tables",
     "longName": "027 - Disclosure - Note 2 - Warrant Liability and Fair Value of Financial Instruments (Tables)",
     "shortName": "Note 2 - Warrant Liability and Fair Value of Financial Instruments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "d_2024-04-01_2025-03-31",
      "name": "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "amix20251001c_424b3.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-04-01_2025-03-31",
      "name": "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "amix20251001c_424b3.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable-tables",
     "longName": "028 - Disclosure - Note 3 - Convertible Notes Payable (Tables)",
     "shortName": "Note 3 - Convertible Notes Payable (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "d_2024-04-01_2025-03-31",
      "name": "us-gaap:ConvertibleDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "amix20251001c_424b3.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-04-01_2025-03-31",
      "name": "us-gaap:ConvertibleDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "amix20251001c_424b3.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://autonomix.com/20250630/role/statement-note-4-equity-tables",
     "longName": "029 - Disclosure - Note 4 - Equity (Tables)",
     "shortName": "Note 4 - Equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "d_2025-04-01_2025-06-30",
      "name": "amix:RestrictedStockExpensesGeneralAndAdministrativeTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "amix20251001c_424b3.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-04-01_2025-03-31",
      "name": "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "amix20251001c_424b3.htm",
      "unique": true
     }
    },
    "R31": {
     "role": "http://autonomix.com/20250630/role/statement-note-7-income-taxes-tables",
     "longName": "030 - Disclosure - Note 7 - Income Taxes (Tables)",
     "shortName": "Note 7 - Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "d_2024-04-01_2025-06-30",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "amix20251001c_424b3.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-04-01_2025-06-30",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "amix20251001c_424b3.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q-tables",
     "longName": "031 - Disclosure - Note 1 - Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies - 10-Q (Tables)",
     "shortName": "Note 1 - Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies - 10-Q (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "d_2025-04-01_2025-06-30",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "amix20251001c_424b3.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R33": {
     "role": "http://autonomix.com/20250630/role/statement-note-2-convertible-notes-payable-10q-tables",
     "longName": "032 - Disclosure - Note 2 - Convertible Notes Payable - 10Q (Tables)",
     "shortName": "Note 2 - Convertible Notes Payable - 10Q (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "d_2025-04-01_2025-06-30",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "amix20251001c_424b3.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R34": {
     "role": "http://autonomix.com/20250630/role/statement-note-3-equity-10q-tables",
     "longName": "033 - Disclosure - Note 3 - Equity - 10Q (Tables)",
     "shortName": "Note 3 - Equity - 10Q (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "d_2025-04-01_2025-06-30",
      "name": "amix:RestrictedStockExpensesGeneralAndAdministrativeTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "amix20251001c_424b3.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R35": {
     "role": "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual",
     "longName": "034 - Disclosure - Note 1 - Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies (Details Textual)",
     "shortName": "Note 1 - Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "i_2024-10-24",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "USDPerShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "amix:ReverseStockSplitPolicyTextBlock",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "amix20251001c_424b3.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-26_2024-01-26_SubsidiarySaleOfStockAxis-IPOMember",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "amix:SubstantialDoubtAboutGoingConcernPolicyPolicyTextBlock",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "amix20251001c_424b3.htm",
      "unique": true
     }
    },
    "R36": {
     "role": "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-antidilutive-securities-details",
     "longName": "035 - Disclosure - Note 1 - Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies - Anti-dilutive Securities (Details)",
     "shortName": "Note 1 - Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies - Anti-dilutive Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "d_2025-04-01_2025-06-30",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "amix20251001c_424b3.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R37": {
     "role": "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-prior-period-corrections-details",
     "longName": "036 - Disclosure - Note 1 - Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies - Prior Period Corrections (Details)",
     "shortName": "Note 1 - Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies - Prior Period Corrections (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "d_2025-04-01_2025-06-30",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "amix20251001c_424b3.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R38": {
     "role": "http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-details-textual",
     "longName": "037 - Disclosure - Note 2 - Warrant Liability and Fair Value of Financial Instruments (Details Textual)",
     "shortName": "Note 2 - Warrant Liability and Fair Value of Financial Instruments (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "d_2024-04-01_2025-03-31",
      "name": "us-gaap:GainLossOnDerivativeInstrumentsNetPretax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "amix20251001c_424b3.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2025-03-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "amix20251001c_424b3.htm",
      "unique": true
     }
    },
    "R39": {
     "role": "http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-schedule-of-fair-value-measurements-details",
     "longName": "038 - Disclosure - Note 2 - Warrant Liability and Fair Value of Financial Instruments - Schedule of Fair Value Measurements (Details)",
     "shortName": "Note 2 - Warrant Liability and Fair Value of Financial Instruments - Schedule of Fair Value Measurements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "i_2023-03-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByLiabilityClassAxis-WarrantMember",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "amix20251001c_424b3.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2023-03-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByLiabilityClassAxis-WarrantMember",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "amix20251001c_424b3.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-fair-value-measurement-inputs-and-valuation-techniques-details",
     "longName": "039 - Disclosure - Note 2 - Warrant Liability and Fair Value of Financial Instruments - Fair Value Measurement Inputs and Valuation Techniques (Details)",
     "shortName": "Note 2 - Warrant Liability and Fair Value of Financial Instruments - Fair Value Measurement Inputs and Valuation Techniques (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "i_2023-12-31_MeasurementInputTypeAxis-MeasurementInputProbabilityRateMember_StatementScenarioAxis-QualifiedOfferingOccurringOneMember_ValuationTechniqueAxis-ValuationProbabilityweightedExpectedReturnMethodPWERMMember",
      "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "1",
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "amix20251001c_424b3.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R41": {
     "role": "http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable-details-textual",
     "longName": "040 - Disclosure - Note 3 - Convertible Notes Payable (Details Textual)",
     "shortName": "Note 3 - Convertible Notes Payable (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "i_2023-12-31",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "unitRef": "USDPerShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "amix20251001c_424b3.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-09-09_2023-09-09_ClassOfWarrantOrRightAxis-BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember",
      "name": "amix:ClassOfWarrantOrRightLockupAgreementTermOfUnderlyingShares",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "amix20251001c_424b3.htm",
      "unique": true
     }
    },
    "R42": {
     "role": "http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable-schedule-of-convertible-notes-payable-details",
     "longName": "041 - Disclosure - Note 3 - Convertible Notes Payable - Schedule of Convertible Notes Payable (Details)",
     "shortName": "Note 3 - Convertible Notes Payable - Schedule of Convertible Notes Payable (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "i_2024-03-31",
      "name": "us-gaap:ConvertibleLongTermNotesPayable",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "amix20251001c_424b3.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-04-01_2025-03-31_DebtConversionByUniqueDescriptionAxis-IssuanceOfCommonStockForExtinguishmentOfConvertibleDebtMember",
      "name": "us-gaap:DebtConversionConvertedInstrumentAmount1",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ConvertibleDebtTableTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "amix20251001c_424b3.htm",
      "unique": true
     }
    },
    "R43": {
     "role": "http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable-schedule-of-detachable-warrants-details",
     "longName": "042 - Disclosure - Note 3 - Convertible Notes Payable - Schedule of Detachable Warrants (Details)",
     "shortName": "Note 3 - Convertible Notes Payable - Schedule of Detachable Warrants (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "i_2025-03-31",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "amix20251001c_424b3.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-04-01_2025-03-31",
      "name": "amix:ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "amix20251001c_424b3.htm",
      "unique": true
     }
    },
    "R44": {
     "role": "http://autonomix.com/20250630/role/statement-note-4-equity-details-textual",
     "longName": "043 - Disclosure - Note 4 - Equity (Details Textual)",
     "shortName": "Note 4 - Equity (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "i_2024-10-24",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-8",
      "ancestors": [
       "p",
       "amix:ReverseStockSplitPolicyTextBlock",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "amix20251001c_424b3.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2024-01-26_ClassOfWarrantOrRightAxis-EquitybasedWarrantsMember",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "amix20251001c_424b3.htm",
      "unique": true
     }
    },
    "R45": {
     "role": "http://autonomix.com/20250630/role/statement-note-4-equity-general-and-administrative-expense-details",
     "longName": "044 - Disclosure - Note 4 - Equity - General and Administrative Expense (Details)",
     "shortName": "Note 4 - Equity - General and Administrative Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "d_2025-04-01_2025-06-30_AwardTypeAxis-RestrictedStockMember",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "amix:RestrictedStockExpensesGeneralAndAdministrativeTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "amix20251001c_424b3.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R46": {
     "role": "http://autonomix.com/20250630/role/statement-note-4-equity-restricted-stock-activity-details",
     "longName": "045 - Disclosure - Note 4 - Equity - Restricted Stock Activity (Details)",
     "shortName": "Note 4 - Equity - Restricted Stock Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "i_2024-03-31_AwardTypeAxis-RestrictedStockMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "amix20251001c_424b3.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2024-03-31_AwardTypeAxis-RestrictedStockMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "amix20251001c_424b3.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://autonomix.com/20250630/role/statement-note-4-equity-schedule-of-stock-option-activity-details",
     "longName": "046 - Disclosure - Note 4 - Equity - Schedule of Stock Option Activity (Details)",
     "shortName": "Note 4 - Equity - Schedule of Stock Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "i_2025-03-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "amix20251001c_424b3.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-04-01_2025-03-31",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "amix20251001c_424b3.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://autonomix.com/20250630/role/statement-note-4-equity-schedule-of-equitybased-stock-warrants-details",
     "longName": "047 - Disclosure - Note 4 - Equity - Schedule of Equity-Based Stock Warrants (Details)",
     "shortName": "Note 4 - Equity - Schedule of Equity-Based Stock Warrants (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "i_2025-03-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "amix20251001c_424b3.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-04-01_2025-03-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "amix20251001c_424b3.htm",
      "unique": true
     }
    },
    "R49": {
     "role": "http://autonomix.com/20250630/role/statement-note-4-equity-blackscholes-option-pricing-model-details",
     "longName": "048 - Disclosure - Note 4 - Equity - Black-Scholes Option Pricing Model (Details)",
     "shortName": "Note 4 - Equity - Black-Scholes Option Pricing Model (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "i_2024-01-26",
      "name": "us-gaap:SharePrice",
      "unitRef": "USDPerShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "amix20251001c_424b3.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R50": {
     "role": "http://autonomix.com/20250630/role/statement-note-5-commitments-and-contingencies-details-textual",
     "longName": "049 - Disclosure - Note 5 - Commitments and Contingencies (Details Textual)",
     "shortName": "Note 5 - Commitments and Contingencies (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "d_2025-04-01_2025-06-30",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "amix20251001c_424b3.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-06-17_2024-06-17_TitleOfIndividualAxis-ChiefExecutiveOfficerMember_TypeOfArrangementAxis-EmploymentContractsMember",
      "name": "amix:AnnualBaseSalary",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "amix20251001c_424b3.htm",
      "unique": true
     }
    },
    "R51": {
     "role": "http://autonomix.com/20250630/role/statement-note-6-related-party-transactions-details-textual",
     "longName": "050 - Disclosure - Note 6 - Related Party Transactions (Details Textual)",
     "shortName": "Note 6 - Related Party Transactions (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "i_2023-12-31",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "unitRef": "USDPerShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "amix20251001c_424b3.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2024-01-29_ClassOfWarrantOrRightAxis-TheWarrantMember_RelatedPartyTransactionAxis-TerminationAgreementMember",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "amix20251001c_424b3.htm",
      "unique": true
     }
    },
    "R52": {
     "role": "http://autonomix.com/20250630/role/statement-note-7-income-taxes-details-textual",
     "longName": "051 - Disclosure - Note 7 - Income Taxes (Details Textual)",
     "shortName": "Note 7 - Income Taxes (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "i_2025-03-31",
      "name": "us-gaap:OperatingLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "amix20251001c_424b3.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2025-03-31",
      "name": "us-gaap:OperatingLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "amix20251001c_424b3.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://autonomix.com/20250630/role/statement-note-7-income-taxes-schedule-of-reconciliation-details",
     "longName": "052 - Disclosure - Note 7 - Income Taxes - Schedule of Reconciliation (Details)",
     "shortName": "Note 7 - Income Taxes - Schedule of Reconciliation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "d_2024-04-01_2025-03-31",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "amix20251001c_424b3.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-04-01_2025-03-31",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "amix20251001c_424b3.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://autonomix.com/20250630/role/statement-note-7-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details",
     "longName": "053 - Disclosure - Note 7 - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)",
     "shortName": "Note 7 - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "i_2025-03-31",
      "name": "amix:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "amix20251001c_424b3.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2025-03-31",
      "name": "amix:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "amix20251001c_424b3.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://autonomix.com/20250630/role/statement-note-8-subsequent-events-details-textual",
     "longName": "054 - Disclosure - Note 8 - Subsequent Events (Details Textual)",
     "shortName": "Note 8 - Subsequent Events (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "d_2025-04-01_2025-06-30",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "amix20251001c_424b3.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-04-17_2025-04-17_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_SubsequentEventTypeAxis-SubsequentEventMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "amix20251001c_424b3.htm",
      "unique": true
     }
    },
    "R56": {
     "role": "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q-details-textual",
     "longName": "055 - Disclosure - Note 1 - Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies - 10-Q (Details Textual)",
     "shortName": "Note 1 - Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies - 10-Q (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "i_2024-10-24",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "USDPerShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "amix:ReverseStockSplitPolicyTextBlock",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "amix20251001c_424b3.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2025-06-30",
      "name": "us-gaap:Cash",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "amix:SubstantialDoubtAboutGoingConcernPolicyPolicyTextBlock",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "amix20251001c_424b3.htm",
      "unique": true
     }
    },
    "R57": {
     "role": "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-10q-details",
     "longName": "056 - Disclosure - Note 1 - Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Anti-dilutive Securities - 10Q (Details)",
     "shortName": "Note 1 - Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Anti-dilutive Securities - 10Q (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "d_2025-04-01_2025-06-30",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "amix20251001c_424b3.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R58": {
     "role": "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-schedule-of-prior-period-corrections-10q-details",
     "longName": "057 - Disclosure - Note 1 - Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Prior Period Corrections - 10Q (Details)",
     "shortName": "Note 1 - Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Prior Period Corrections - 10Q (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "d_2025-04-01_2025-06-30",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "amix20251001c_424b3.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R59": {
     "role": "http://autonomix.com/20250630/role/statement-note-2-convertible-notes-payable-10q-details-textual",
     "longName": "058 - Disclosure - Note 2 - Convertible Notes Payable - 10Q (Details Textual)",
     "shortName": "Note 2 - Convertible Notes Payable - 10Q (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "i_2023-12-31",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "unitRef": "USDPerShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "amix20251001c_424b3.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R60": {
     "role": "http://autonomix.com/20250630/role/statement-note-2-convertible-notes-payable-schedule-of-detachable-warrants-10q-details",
     "longName": "059 - Disclosure - Note 2 - Convertible Notes Payable - Schedule of Detachable Warrants - 10Q (Details)",
     "shortName": "Note 2 - Convertible Notes Payable - Schedule of Detachable Warrants - 10Q (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "i_2025-03-31",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "amix20251001c_424b3.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R61": {
     "role": "http://autonomix.com/20250630/role/statement-note-3-equity-10q-details-textual",
     "longName": "060 - Disclosure - Note 3 - Equity - 10Q (Details Textual)",
     "shortName": "Note 3 - Equity - 10Q (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "i_2024-10-24",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-8",
      "ancestors": [
       "p",
       "amix:ReverseStockSplitPolicyTextBlock",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "amix20251001c_424b3.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2025-06-30_ClassOfWarrantOrRightAxis-CommonWarrantsMember",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "amix20251001c_424b3.htm",
      "unique": true
     }
    },
    "R62": {
     "role": "http://autonomix.com/20250630/role/statement-note-3-equity-general-and-administrative-expense-10q-details",
     "longName": "061 - Disclosure - Note 3 - Equity - General and Administrative Expense - 10Q (Details)",
     "shortName": "Note 3 - Equity - General and Administrative Expense - 10Q (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "d_2025-04-01_2025-06-30_AwardTypeAxis-RestrictedStockMember",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "amix:RestrictedStockExpensesGeneralAndAdministrativeTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "amix20251001c_424b3.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R63": {
     "role": "http://autonomix.com/20250630/role/statement-note-3-equity-schedule-of-stock-option-activity-10q-details",
     "longName": "062 - Disclosure - Note 3 - Equity - Schedule of Stock Option Activity - 10Q (Details)",
     "shortName": "Note 3 - Equity - Schedule of Stock Option Activity - 10Q (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "i_2025-03-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "amix20251001c_424b3.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R64": {
     "role": "http://autonomix.com/20250630/role/statement-note-3-equity-schedule-of-equitybased-stock-warrants-10q-details",
     "longName": "063 - Disclosure - Note 3 - Equity - Schedule of Equity-Based Stock Warrants - 10Q (Details)",
     "shortName": "Note 3 - Equity - Schedule of Equity-Based Stock Warrants - 10Q (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "i_2025-03-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "amix20251001c_424b3.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R65": {
     "role": "http://autonomix.com/20250630/role/statement-note-4-commitments-and-contingencies-10q-details-textual",
     "longName": "064 - Disclosure - Note 4 - Commitments and Contingencies - 10Q (Details Textual)",
     "shortName": "Note 4 - Commitments and Contingencies - 10Q (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "i_2024-11-01",
      "name": "amix:StockRequiredToBeIssuedForStockSplitShares",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "amix20251001c_424b3.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R66": {
     "role": "http://autonomix.com/20250630/role/statement-note-5-related-party-transactions-10q-details-textual",
     "longName": "065 - Disclosure - Note 5 - Related Party Transactions - 10Q (Details Textual)",
     "shortName": "Note 5 - Related Party Transactions - 10Q (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "i_2023-12-31",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "unitRef": "USDPerShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "amix20251001c_424b3.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R67": {
     "role": "http://autonomix.com/20250630/role/statement-note-6-subsequent-events-10q-details-textual",
     "longName": "066 - Disclosure - Note 6 - Subsequent Events - 10Q (Details Textual)",
     "shortName": "Note 6 - Subsequent Events - 10Q (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "i_2023-12-31",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "unitRef": "USDPerShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "amix20251001c_424b3.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2025-07-21_SubsequentEventTypeAxis-SubsequentEventMember",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "USDPerShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "amix20251001c_424b3.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "amix_ATMAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "ATMAgreementMember",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual",
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q",
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-4-equity",
      "http://autonomix.com/20250630/role/statement-note-4-equity-details-textual",
      "http://autonomix.com/20250630/role/statement-note-8-subsequent-events",
      "http://autonomix.com/20250630/role/statement-note-8-subsequent-events-details-textual",
      "http://autonomix.com/20250630/role/statement-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ATM Agreement [Member]",
        "documentation": "Represents the ATM Agreement."
       }
      }
     },
     "auth_ref": []
    },
    "amix_AccountingAndFinancialReportingServicesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "AccountingAndFinancialReportingServicesMember",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-6-related-party-transactions",
      "http://autonomix.com/20250630/role/statement-note-6-related-party-transactions-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting and Financial Reporting Services [Member]",
        "documentation": "Transaction between related party."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountingPoliciesAbstract",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://autonomix.com/20250630/role/statement-condensed-balance-sheets-unaudited-": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      },
      "http://autonomix.com/20250630/role/statement-balance-sheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://autonomix.com/20250630/role/statement-balance-sheets",
      "http://autonomix.com/20250630/role/statement-condensed-balance-sheets-unaudited-"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r660"
     ]
    },
    "us-gaap_AccountsPayableCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-6-related-party-transactions-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_AccountsPayableCurrentAndNoncurrent",
        "terseLabel": "Accounts Payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r822"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://autonomix.com/20250630/role/statement-balance-sheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      },
      "http://autonomix.com/20250630/role/statement-condensed-balance-sheets-unaudited-": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://autonomix.com/20250630/role/statement-balance-sheets",
      "http://autonomix.com/20250630/role/statement-condensed-balance-sheets-unaudited-"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued expenses",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://autonomix.com/20250630/role/statement-condensed-balance-sheets-unaudited-": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      },
      "http://autonomix.com/20250630/role/statement-balance-sheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://autonomix.com/20250630/role/statement-balance-sheets",
      "http://autonomix.com/20250630/role/statement-condensed-balance-sheets-unaudited-"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid-in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r660",
      "r827"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-condensed-statements-of-changes-in-stockholders-equity-unaudited",
      "http://autonomix.com/20250630/role/statement-statements-of-changes-in-stockholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r514",
      "r708",
      "r709",
      "r710",
      "r713",
      "r792",
      "r830"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-condensed-statements-of-changes-in-stockholders-equity-unaudited",
      "http://autonomix.com/20250630/role/statement-statements-of-changes-in-stockholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r289"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual",
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-4-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
        "terseLabel": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r64"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockSplit",
     "crdr": "debit",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit",
        "terseLabel": "Adjustments to Additional Paid in Capital, Stock Split",
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from a stock split in which per-share par value or stated value is not changed proportionately."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r64"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "crdr": "credit",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-statements-of-changes-in-stockholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants issued for debt issuance costs",
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r27",
      "r64"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-condensed-statements-of-cash-flows-unaudited",
      "http://autonomix.com/20250630/role/statement-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdvertisingCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdvertisingCostsPolicyTextBlock",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Advertising Cost [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for advertising cost."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "us-gaap_AdvertisingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdvertisingExpense",
     "crdr": "debit",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_AdvertisingExpense",
        "terseLabel": "Advertising Expense",
        "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line."
       }
      }
     },
     "auth_ref": [
      "r335",
      "r632"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-3-equity-general-and-administrative-expense-10q-details",
      "http://autonomix.com/20250630/role/statement-note-4-equity-details-textual",
      "http://autonomix.com/20250630/role/statement-note-4-equity-general-and-administrative-expense-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_AllocatedShareBasedCompensationExpense",
        "terseLabel": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r320",
      "r324",
      "r333"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AmortizationOfDebtDiscountPremium",
     "crdr": "debit",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable-schedule-of-convertible-notes-payable-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of debt discount",
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r51",
      "r241",
      "r806"
     ]
    },
    "amix_AnnualBaseSalary": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "AnnualBaseSalary",
     "crdr": "debit",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-5-commitments-and-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "amix_AnnualBaseSalary",
        "terseLabel": "Annual Base Salary",
        "documentation": "Represents the annual base salary."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-antidilutive-securities-details",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-prior-period-corrections-details",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-10q-details",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-schedule-of-prior-period-corrections-10q-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive securities (in shares)",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r157"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-antidilutive-securities-details",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-prior-period-corrections-details",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-10q-details",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-schedule-of-prior-period-corrections-10q-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r157"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-antidilutive-securities-details",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-prior-period-corrections-details",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-10q-details",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-schedule-of-prior-period-corrections-10q-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r157"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-4-commitments-and-contingencies-10q",
      "http://autonomix.com/20250630/role/statement-note-4-commitments-and-contingencies-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-5-commitments-and-contingencies",
      "http://autonomix.com/20250630/role/statement-note-5-commitments-and-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r377"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://autonomix.com/20250630/role/statement-balance-sheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://autonomix.com/20250630/role/statement-condensed-balance-sheets-unaudited-": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://autonomix.com/20250630/role/statement-balance-sheets",
      "http://autonomix.com/20250630/role/statement-condensed-balance-sheets-unaudited-"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_Assets",
        "totalLabel": "Total Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r87",
      "r107",
      "r122",
      "r124",
      "r125",
      "r160",
      "r166",
      "r181",
      "r182",
      "r188",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r378",
      "r380",
      "r425",
      "r467",
      "r468",
      "r473",
      "r541",
      "r609",
      "r610",
      "r621",
      "r660",
      "r662",
      "r663",
      "r674",
      "r743",
      "r744",
      "r812"
     ]
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://autonomix.com/20250630/role/statement-balance-sheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      },
      "http://autonomix.com/20250630/role/statement-condensed-balance-sheets-unaudited-": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://autonomix.com/20250630/role/statement-balance-sheets",
      "http://autonomix.com/20250630/role/statement-condensed-balance-sheets-unaudited-"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_AssetsCurrent",
        "totalLabel": "Total current assets",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r109",
      "r122",
      "r124",
      "r125",
      "r188",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r378",
      "r380",
      "r425",
      "r660",
      "r743",
      "r744",
      "r812"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-balance-sheets",
      "http://autonomix.com/20250630/role/statement-condensed-balance-sheets-unaudited-"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_AssetsFairValueDisclosure",
        "terseLabel": "Assets, Fair Value Disclosure",
        "documentation": "Fair value portion of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r403",
      "r404",
      "r643"
     ]
    },
    "us-gaap_AssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://autonomix.com/20250630/role/statement-balance-sheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 0.0
      },
      "http://autonomix.com/20250630/role/statement-condensed-balance-sheets-unaudited-": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://autonomix.com/20250630/role/statement-balance-sheets",
      "http://autonomix.com/20250630/role/statement-condensed-balance-sheets-unaudited-"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_AssetsNoncurrent",
        "totalLabel": "Total long-term assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r124",
      "r125",
      "r188",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r378",
      "r380",
      "r425",
      "r743",
      "r744",
      "r812"
     ]
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsNoncurrentAbstract",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-balance-sheets",
      "http://autonomix.com/20250630/role/statement-condensed-balance-sheets-unaudited-"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q",
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-3-equity-general-and-administrative-expense-10q-details",
      "http://autonomix.com/20250630/role/statement-note-4-equity",
      "http://autonomix.com/20250630/role/statement-note-4-equity-blackscholes-option-pricing-model-details",
      "http://autonomix.com/20250630/role/statement-note-4-equity-details-textual",
      "http://autonomix.com/20250630/role/statement-note-4-equity-general-and-administrative-expense-details",
      "http://autonomix.com/20250630/role/statement-note-4-equity-restricted-stock-activity-details",
      "http://autonomix.com/20250630/role/statement-note-5-commitments-and-contingencies",
      "http://autonomix.com/20250630/role/statement-note-5-commitments-and-contingencies-details-textual",
      "http://autonomix.com/20250630/role/statement-note-8-subsequent-events",
      "http://autonomix.com/20250630/role/statement-note-8-subsequent-events-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r291",
      "r292",
      "r293",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r700"
     ]
    },
    "amix_BlackscholesModelMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "BlackscholesModelMember",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q",
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-4-equity",
      "http://autonomix.com/20250630/role/statement-note-4-equity-blackscholes-option-pricing-model-details",
      "http://autonomix.com/20250630/role/statement-note-4-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Black-Scholes Model [Member]",
        "documentation": "Black-Scholes-Merton used to estimate fair value of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "srt_BoardOfDirectorsChairmanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "BoardOfDirectorsChairmanMember",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-6-subsequent-events-10q",
      "http://autonomix.com/20250630/role/statement-note-6-subsequent-events-10q-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Board of Directors Chairman [Member]"
       }
      }
     },
     "auth_ref": [
      "r722"
     ]
    },
    "amix_BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-2-convertible-notes-payable-10q",
      "http://autonomix.com/20250630/role/statement-note-2-convertible-notes-payable-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable",
      "http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Bridge Financing Warrants in Connection with Convertible Notes [Member[",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Cash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Cash",
     "crdr": "debit",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_Cash",
        "terseLabel": "Cash",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r476",
      "r516",
      "r536",
      "r660",
      "r662",
      "r663",
      "r674",
      "r682"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://autonomix.com/20250630/role/statement-balance-sheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 0.0
      },
      "http://autonomix.com/20250630/role/statement-condensed-balance-sheets-unaudited-": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://autonomix.com/20250630/role/statement-balance-sheets",
      "http://autonomix.com/20250630/role/statement-condensed-balance-sheets-unaudited-"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents",
        "documentation": "Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r106",
      "r593"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-condensed-statements-of-cash-flows-unaudited",
      "http://autonomix.com/20250630/role/statement-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
        "periodStartLabel": "Cash and cash equivalents, at beginning of period",
        "periodEndLabel": "Cash and cash equivalents, at end of period",
        "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r53",
      "r121"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://autonomix.com/20250630/role/statement-statements-of-cash-flows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://autonomix.com/20250630/role/statement-condensed-statements-of-cash-flows-unaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://autonomix.com/20250630/role/statement-condensed-statements-of-cash-flows-unaudited",
      "http://autonomix.com/20250630/role/statement-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
        "totalLabel": "Net change in cash and cash equivalents",
        "documentation": "Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r53"
     ]
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-condensed-statements-of-cash-flows-unaudited",
      "http://autonomix.com/20250630/role/statement-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-cash financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ChiefExecutiveOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ChiefExecutiveOfficerMember",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-5-commitments-and-contingencies",
      "http://autonomix.com/20250630/role/statement-note-5-commitments-and-contingencies-details-textual",
      "http://autonomix.com/20250630/role/statement-note-6-subsequent-events-10q",
      "http://autonomix.com/20250630/role/statement-note-6-subsequent-events-10q-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Executive Officer [Member]"
       }
      }
     },
     "auth_ref": [
      "r722"
     ]
    },
    "srt_ChiefFinancialOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ChiefFinancialOfficerMember",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-6-subsequent-events-10q",
      "http://autonomix.com/20250630/role/statement-note-6-subsequent-events-10q-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Financial Officer [Member]"
       }
      }
     },
     "auth_ref": [
      "r722"
     ]
    },
    "amix_ChiefMedicalOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "ChiefMedicalOfficerMember",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-6-subsequent-events-10q",
      "http://autonomix.com/20250630/role/statement-note-6-subsequent-events-10q-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Medical Officer [Member]",
        "documentation": "Related to Chief Medical Officer."
       }
      }
     },
     "auth_ref": []
    },
    "amix_ChiefTechnologyOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "ChiefTechnologyOfficerMember",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-6-subsequent-events-10q",
      "http://autonomix.com/20250630/role/statement-note-6-subsequent-events-10q-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Technology Officer [Member]",
        "documentation": "Related to Chief Technology Officer."
       }
      }
     },
     "auth_ref": []
    },
    "amix_ClassOfWarrantOrRightAggregateIntrinsicValueExercisable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "ClassOfWarrantOrRightAggregateIntrinsicValueExercisable",
     "crdr": "debit",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable-schedule-of-detachable-warrants-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercisable, intrinsic value",
        "documentation": "Intrinsic value of warrants currently exercisable."
       }
      }
     },
     "auth_ref": []
    },
    "amix_ClassOfWarrantOrRightAggregateIntrinsicValueOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "ClassOfWarrantOrRightAggregateIntrinsicValueOutstanding",
     "crdr": "debit",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable-schedule-of-detachable-warrants-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding, intrinsic value",
        "documentation": "Intrinsic value of outstanding warrants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual",
      "http://autonomix.com/20250630/role/statement-note-2-convertible-notes-payable-10q",
      "http://autonomix.com/20250630/role/statement-note-2-convertible-notes-payable-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments",
      "http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-details-textual",
      "http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable",
      "http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable-details-textual",
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q",
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-4-equity",
      "http://autonomix.com/20250630/role/statement-note-4-equity-details-textual",
      "http://autonomix.com/20250630/role/statement-note-5-related-party-transactions-10q",
      "http://autonomix.com/20250630/role/statement-note-5-related-party-transactions-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-6-related-party-transactions",
      "http://autonomix.com/20250630/role/statement-note-6-related-party-transactions-details-textual",
      "http://autonomix.com/20250630/role/statement-note-6-subsequent-events-10q",
      "http://autonomix.com/20250630/role/statement-note-6-subsequent-events-10q-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r747"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual",
      "http://autonomix.com/20250630/role/statement-note-2-convertible-notes-payable-10q",
      "http://autonomix.com/20250630/role/statement-note-2-convertible-notes-payable-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments",
      "http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-details-textual",
      "http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable",
      "http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable-details-textual",
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q",
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-4-equity",
      "http://autonomix.com/20250630/role/statement-note-4-equity-details-textual",
      "http://autonomix.com/20250630/role/statement-note-5-related-party-transactions-10q",
      "http://autonomix.com/20250630/role/statement-note-5-related-party-transactions-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-6-related-party-transactions",
      "http://autonomix.com/20250630/role/statement-note-6-related-party-transactions-details-textual",
      "http://autonomix.com/20250630/role/statement-note-6-subsequent-events-10q",
      "http://autonomix.com/20250630/role/statement-note-6-subsequent-events-10q-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "amix_ClassOfWarrantOrRightExchangesPercentageOfUnderlyingShares": {
     "xbrltype": "percentItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "ClassOfWarrantOrRightExchangesPercentageOfUnderlyingShares",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-6-subsequent-events-10q-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "amix_ClassOfWarrantOrRightExchangesPercentageOfUnderlyingShares",
        "terseLabel": "Class of Warrant or Right, Exchanges, Percentage of Underlying Shares",
        "documentation": "The percent of underlying shares related to the exchange of warrants."
       }
      }
     },
     "auth_ref": []
    },
    "amix_ClassOfWarrantOrRightExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "ClassOfWarrantOrRightExercisableNumber",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-2-convertible-notes-payable-schedule-of-detachable-warrants-10q-details",
      "http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable-schedule-of-detachable-warrants-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercisable (in shares)",
        "documentation": "The number of shares into which fully or partially vested warrants outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": []
    },
    "amix_ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-2-convertible-notes-payable-schedule-of-detachable-warrants-10q-details",
      "http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable-schedule-of-detachable-warrants-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercisable, weighted average exercise price (in dollars per share)",
        "documentation": "The weighted-average price as of the balance sheet date at which holders can acquire the shares on warrants outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": []
    },
    "amix_ClassOfWarrantOrRightExercisableWeightedAverageRemainingContractualTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "ClassOfWarrantOrRightExercisableWeightedAverageRemainingContractualTerm",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable-schedule-of-detachable-warrants-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercisable, remaining term (Year)",
        "documentation": "Weighted average remaining contractual term for vested portions of warrants currently exercisable or convertible."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual",
      "http://autonomix.com/20250630/role/statement-note-2-convertible-notes-payable-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-details-textual",
      "http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable-details-textual",
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-4-equity-details-textual",
      "http://autonomix.com/20250630/role/statement-note-5-related-party-transactions-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-6-related-party-transactions-details-textual",
      "http://autonomix.com/20250630/role/statement-note-6-subsequent-events-10q-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
        "terseLabel": "Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r127",
      "r272"
     ]
    },
    "amix_ClassOfWarrantOrRightExercisedInPeriodCash": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "ClassOfWarrantOrRightExercisedInPeriodCash",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-4-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "amix_ClassOfWarrantOrRightExercisedInPeriodCash",
        "terseLabel": "Class of Warrant Or Right Exercised In Period, Cash (in shares)",
        "documentation": "Number of warrants exercised during the current period."
       }
      }
     },
     "auth_ref": []
    },
    "amix_ClassOfWarrantOrRightExercisedInPeriodCashless": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "ClassOfWarrantOrRightExercisedInPeriodCashless",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-4-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "amix_ClassOfWarrantOrRightExercisedInPeriodCashless",
        "terseLabel": "Class of Warrant Or Right Exercised In Period, Cashless (in shares)",
        "documentation": "Number of warrants exercised during the current period."
       }
      }
     },
     "auth_ref": []
    },
    "amix_ClassOfWarrantOrRightExercisesInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "ClassOfWarrantOrRightExercisesInPeriod",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-2-convertible-notes-payable-schedule-of-detachable-warrants-10q-details",
      "http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable-schedule-of-detachable-warrants-details",
      "http://autonomix.com/20250630/role/statement-note-6-subsequent-events-10q-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "amix_ClassOfWarrantOrRightExercisesInPeriod",
        "terseLabel": "Class of Warrant or Right, Exercises in Period (in shares)",
        "negatedLabel": "Exercised, outstanding (in shares)",
        "documentation": "Number of warrants exercised during the current period."
       }
      }
     },
     "auth_ref": []
    },
    "amix_ClassOfWarrantOrRightExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "ClassOfWarrantOrRightExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-2-convertible-notes-payable-schedule-of-detachable-warrants-10q-details",
      "http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable-schedule-of-detachable-warrants-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercised, weighted average exercise price (in dollars per share)",
        "documentation": "Weighted average price at which warrant holders acquired shares when converting their warrants into shares."
       }
      }
     },
     "auth_ref": []
    },
    "amix_ClassOfWarrantOrRightExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "ClassOfWarrantOrRightExpirationsInPeriod",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-2-convertible-notes-payable-schedule-of-detachable-warrants-10q-details",
      "http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable-schedule-of-detachable-warrants-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "amix_ClassOfWarrantOrRightExpirationsInPeriod",
        "negatedLabel": "Expired, outstanding (in shares)",
        "documentation": "Number of warrants for which the right to exercise has lapsed under the terms of the plan agreements."
       }
      }
     },
     "auth_ref": []
    },
    "amix_ClassOfWarrantOrRightExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "ClassOfWarrantOrRightExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-2-convertible-notes-payable-schedule-of-detachable-warrants-10q-details",
      "http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable-schedule-of-detachable-warrants-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expired, weighted average exercise price (in dollars per share)",
        "documentation": "Weighted average price at which holders could have acquired the underlying shares with respect to the warrants that expired."
       }
      }
     },
     "auth_ref": []
    },
    "amix_ClassOfWarrantOrRightFairValueIssuedForIssuanceCostsFromIpo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "ClassOfWarrantOrRightFairValueIssuedForIssuanceCostsFromIpo",
     "crdr": "credit",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of warrants issued for issuance costs as part of IPO",
        "documentation": "Represents the fair value of the warrants or rights issued for issuance costs from an initial public offering."
       }
      }
     },
     "auth_ref": []
    },
    "amix_ClassOfWarrantOrRightFairValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "ClassOfWarrantOrRightFairValuePerShare",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-4-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "amix_ClassOfWarrantOrRightFairValuePerShare",
        "terseLabel": "Class of Warrant or Right, Fair Value Per Share (in dollars per share)",
        "documentation": "Per share or per unit fair value price of warrants or rights."
       }
      }
     },
     "auth_ref": []
    },
    "amix_ClassOfWarrantOrRightForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "ClassOfWarrantOrRightForfeituresInPeriod",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-2-convertible-notes-payable-schedule-of-detachable-warrants-10q-details",
      "http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable-schedule-of-detachable-warrants-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "amix_ClassOfWarrantOrRightForfeituresInPeriod",
        "negatedLabel": "Forfeited/Cancelled, outstanding (in shares)",
        "documentation": "Number of warrants that were cancelled during the period."
       }
      }
     },
     "auth_ref": []
    },
    "amix_ClassOfWarrantOrRightForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "ClassOfWarrantOrRightForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-2-convertible-notes-payable-schedule-of-detachable-warrants-10q-details",
      "http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable-schedule-of-detachable-warrants-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forfeited/Cancelled, weighted average exercise price (in dollars per share)",
        "documentation": "Weighted average price at which holders could have acquired the underlying shares with respect to warrants that were terminated."
       }
      }
     },
     "auth_ref": []
    },
    "amix_ClassOfWarrantOrRightGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "ClassOfWarrantOrRightGrantsInPeriod",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-2-convertible-notes-payable-schedule-of-detachable-warrants-10q-details",
      "http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable-schedule-of-detachable-warrants-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Granted, outstanding (in shares)",
        "documentation": "The number of warrants granted during the period."
       }
      }
     },
     "auth_ref": []
    },
    "amix_ClassOfWarrantOrRightGrantsInPeriodWeightedAverageExercise": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "ClassOfWarrantOrRightGrantsInPeriodWeightedAverageExercise",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-2-convertible-notes-payable-schedule-of-detachable-warrants-10q-details",
      "http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable-schedule-of-detachable-warrants-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Granted, weighted average exercise price (in dollars per share)",
        "documentation": "Weighted average per share amount at which holders can acquire shares of common stock by exercise of warrants."
       }
      }
     },
     "auth_ref": []
    },
    "amix_ClassOfWarrantOrRightIssuedDuringPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "ClassOfWarrantOrRightIssuedDuringPeriod",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual",
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-4-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "amix_ClassOfWarrantOrRightIssuedDuringPeriod",
        "terseLabel": "Class of Warrant or Right, Issued During Period (in shares)",
        "documentation": "The number of warrants or rights issued during the period."
       }
      }
     },
     "auth_ref": []
    },
    "amix_ClassOfWarrantOrRightLockupAgreementTermOfUnderlyingShares": {
     "xbrltype": "durationItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "ClassOfWarrantOrRightLockupAgreementTermOfUnderlyingShares",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable-details-textual",
      "http://autonomix.com/20250630/role/statement-note-5-related-party-transactions-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-6-related-party-transactions-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "amix_ClassOfWarrantOrRightLockupAgreementTermOfUnderlyingShares",
        "terseLabel": "Class of Warrant or Right, Lock-up Agreement Term of Underlying Shares (Day)",
        "documentation": "Pertains to the term of the lock-up agreement associated with the shares underlying the warrants."
       }
      }
     },
     "auth_ref": []
    },
    "amix_ClassOfWarrantOrRightLockupPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "ClassOfWarrantOrRightLockupPeriod",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-4-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "amix_ClassOfWarrantOrRightLockupPeriod",
        "terseLabel": "Class of Warrant or Right, Lock-up Period (Day)",
        "documentation": "Period of lock-up for warrants or rights."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual",
      "http://autonomix.com/20250630/role/statement-note-2-convertible-notes-payable-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable-details-textual",
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-4-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
        "terseLabel": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)",
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-details-textual",
      "http://autonomix.com/20250630/role/statement-note-4-equity-details-textual",
      "http://autonomix.com/20250630/role/statement-note-5-related-party-transactions-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-6-subsequent-events-10q-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
        "terseLabel": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r272"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-2-convertible-notes-payable-schedule-of-detachable-warrants-10q-details",
      "http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable-schedule-of-detachable-warrants-details",
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-6-subsequent-events-10q-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ClassOfWarrantOrRightOutstanding",
        "terseLabel": "Class of Warrant or Right, Outstanding (in shares)",
        "periodStartLabel": "Balance, outstanding (in shares)",
        "periodEndLabel": "Balance, outstanding (in shares)",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "amix_ClassOfWarrantOrRightOutstandingOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "ClassOfWarrantOrRightOutstandingOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-2-convertible-notes-payable-schedule-of-detachable-warrants-10q-details",
      "http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable-schedule-of-detachable-warrants-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "amix_ClassOfWarrantOrRightOutstandingOutstandingWeightedAverageExercisePrice",
        "periodStartLabel": "Outstanding, weighted average exercise price (in dollars per share)",
        "periodEndLabel": "Outstanding, weighted average exercise price (in dollars per share)",
        "documentation": "Weighted average price at which holders can acquire the shares reserved for issuance under the warrant plan."
       }
      }
     },
     "auth_ref": []
    },
    "amix_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable-schedule-of-detachable-warrants-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding, remaining term (Year)",
        "documentation": "Weighted average remaining contractual term for warrants outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "amix_ClassOfWarrantOrRightPercentageOfOutstandingStock": {
     "xbrltype": "percentItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "ClassOfWarrantOrRightPercentageOfOutstandingStock",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable-details-textual",
      "http://autonomix.com/20250630/role/statement-note-5-related-party-transactions-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-6-related-party-transactions-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "amix_ClassOfWarrantOrRightPercentageOfOutstandingStock",
        "terseLabel": "Class of Warrant or Right, Percentage of Outstanding Stock",
        "documentation": "Represents the warrants as a proportion of outstanding capital stock."
       }
      }
     },
     "auth_ref": []
    },
    "amix_ClassOfWarrantOrRightValueOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "ClassOfWarrantOrRightValueOfSecuritiesCalledByWarrantsOrRights",
     "crdr": "credit",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-details-textual",
      "http://autonomix.com/20250630/role/statement-note-5-related-party-transactions-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-6-related-party-transactions-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "amix_ClassOfWarrantOrRightValueOfSecuritiesCalledByWarrantsOrRights",
        "terseLabel": "Class of Warrant or Right, Value of Securities Called by Warrants or Rights",
        "documentation": "Value of securities into which the class of warrant or right may be converted."
       }
      }
     },
     "auth_ref": []
    },
    "amix_ClassOfWarrantsOrRightsMaximumBeneficialOwnership": {
     "xbrltype": "percentItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "ClassOfWarrantsOrRightsMaximumBeneficialOwnership",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual",
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-4-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "amix_ClassOfWarrantsOrRightsMaximumBeneficialOwnership",
        "terseLabel": "Class of Warrants or Rights, Maximum Beneficial Ownership",
        "documentation": "Percentage of maximum beneficial ownership of warrants or rights."
       }
      }
     },
     "auth_ref": []
    },
    "amix_CommissionPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "CommissionPercentage",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual",
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-4-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "amix_CommissionPercentage",
        "terseLabel": "Commission Percentage",
        "documentation": "Refers to the amount of commission percentage."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://autonomix.com/20250630/role/statement-condensed-balance-sheets-unaudited-": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      },
      "http://autonomix.com/20250630/role/statement-balance-sheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://autonomix.com/20250630/role/statement-balance-sheets",
      "http://autonomix.com/20250630/role/statement-condensed-balance-sheets-unaudited-"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and contingencies (Note 5)",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r80",
      "r475",
      "r527"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-4-commitments-and-contingencies-10q",
      "http://autonomix.com/20250630/role/statement-note-5-commitments-and-contingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r202",
      "r203",
      "r588",
      "r734",
      "r739"
     ]
    },
    "amix_CommonStock12MonthsLockupPeriodMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "CommonStock12MonthsLockupPeriodMember",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-5-related-party-transactions-10q",
      "http://autonomix.com/20250630/role/statement-note-5-related-party-transactions-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-6-related-party-transactions",
      "http://autonomix.com/20250630/role/statement-note-6-related-party-transactions-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, 12 Months Lock-up Period [Member]",
        "documentation": "Pertains to the shares underlying the warrants."
       }
      }
     },
     "auth_ref": []
    },
    "amix_CommonStock6MonthsLockupPeriodMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "CommonStock6MonthsLockupPeriodMember",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-5-related-party-transactions-10q",
      "http://autonomix.com/20250630/role/statement-note-5-related-party-transactions-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-6-related-party-transactions",
      "http://autonomix.com/20250630/role/statement-note-6-related-party-transactions-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, 6 Months Lock-up Period [Member]",
        "documentation": "Pertains to the shares underlying the warrants."
       }
      }
     },
     "auth_ref": []
    },
    "amix_CommonStockDiscountForLackOfMarketability": {
     "xbrltype": "percentItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "CommonStockDiscountForLackOfMarketability",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-4-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "amix_CommonStockDiscountForLackOfMarketability",
        "terseLabel": "Common Stock, Discount for Lack of Marketability",
        "documentation": "Percentage of discount for lack of marketability on common stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockMember",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-condensed-statements-of-changes-in-stockholders-equity-unaudited",
      "http://autonomix.com/20250630/role/statement-statements-of-changes-in-stockholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r664",
      "r665",
      "r666",
      "r668",
      "r669",
      "r670",
      "r671",
      "r708",
      "r709",
      "r713",
      "r792",
      "r825",
      "r830"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-balance-sheets-parentheticals",
      "http://autonomix.com/20250630/role/statement-condensed-balance-sheets-unaudited-parentheticals",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual",
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-4-equity-details-textual",
      "http://autonomix.com/20250630/role/statement-note-6-subsequent-events-10q-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, par value (in dollars per share)",
        "terseLabel": "Common Stock, Par or Stated Value Per Share (in dollars per share)",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-balance-sheets-parentheticals",
      "http://autonomix.com/20250630/role/statement-condensed-balance-sheets-unaudited-parentheticals",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual",
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-4-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, authorized (in shares)",
        "terseLabel": "Common Stock, Shares Authorized (in shares)",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r528"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-balance-sheets-parentheticals",
      "http://autonomix.com/20250630/role/statement-condensed-balance-sheets-unaudited-parentheticals",
      "http://autonomix.com/20250630/role/statement-note-6-related-party-transactions-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, issued (in shares)",
        "terseLabel": "Common Stock, Shares, Issued (in shares)",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-balance-sheets-parentheticals",
      "http://autonomix.com/20250630/role/statement-condensed-balance-sheets-unaudited-parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, outstanding (in shares)",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r41",
      "r528",
      "r547",
      "r830",
      "r831"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://autonomix.com/20250630/role/statement-balance-sheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      },
      "http://autonomix.com/20250630/role/statement-condensed-balance-sheets-unaudited-": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://autonomix.com/20250630/role/statement-balance-sheets",
      "http://autonomix.com/20250630/role/statement-condensed-balance-sheets-unaudited-"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, $0.001 par value, 500,000,000 shares authorized, 2,497,033 and 942,575 shares issued and outstanding as of March 31, 2025 and March 31, 2024, respectively.",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r250",
      "r256",
      "r478",
      "r660"
     ]
    },
    "amix_CommonUnitsIssuedPurchasePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "CommonUnitsIssuedPurchasePrice",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual",
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-4-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "amix_CommonUnitsIssuedPurchasePrice",
        "terseLabel": "Common Units Issued, Purchase Price (in dollars per share)",
        "documentation": "Per share or per unit price of common units issued."
       }
      }
     },
     "auth_ref": []
    },
    "amix_CommonWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "CommonWarrantsMember",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q",
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Warrants [Member]",
        "documentation": "Represents common warrants."
       }
      }
     },
     "auth_ref": []
    },
    "amix_ConsultingFirmOwnedByFormerCFOMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "ConsultingFirmOwnedByFormerCFOMember",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-6-related-party-transactions",
      "http://autonomix.com/20250630/role/statement-note-6-related-party-transactions-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consulting Firm Owned by Former CFO [MEmber]",
        "documentation": "Represents the consulting firm owned by the former CFO."
       }
      }
     },
     "auth_ref": []
    },
    "amix_ConversionOfConvertibleNotesToCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "ConversionOfConvertibleNotesToCommonStockMember",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-2-convertible-notes-payable-10q",
      "http://autonomix.com/20250630/role/statement-note-2-convertible-notes-payable-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable",
      "http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of Convertible Notes to Common Stock [Member]",
        "documentation": "The name of the original debt issue that has been converted in a noncash (or part noncash) transaction during the accounting period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertibleDebtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConvertibleDebtMember",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable-schedule-of-convertible-notes-payable-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Debt [Member]",
        "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r220",
      "r221",
      "r231",
      "r232",
      "r233",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620"
     ]
    },
    "us-gaap_ConvertibleDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConvertibleDebtSecuritiesMember",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-antidilutive-securities-details",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-prior-period-corrections-details",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-10q-details",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-schedule-of-prior-period-corrections-10q-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Debt Securities [Member]",
        "documentation": "Debt securities that can be exchanged for equity of the debt issuer at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r748",
      "r749"
     ]
    },
    "us-gaap_ConvertibleDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConvertibleDebtTableTextBlock",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Debt [Table Text Block]",
        "documentation": "Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount."
       }
      }
     },
     "auth_ref": []
    },
    "amix_ConvertibleDebtWith499PercentBeneficialOwnershipLimitationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "ConvertibleDebtWith499PercentBeneficialOwnershipLimitationMember",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-2-convertible-notes-payable-10q",
      "http://autonomix.com/20250630/role/statement-note-2-convertible-notes-payable-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable",
      "http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Debt with 4.99% Beneficial Ownership Limitation [Member]",
        "documentation": "Information pertaining to the convertible debt."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertibleLongTermNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConvertibleLongTermNotesPayable",
     "crdr": "credit",
     "calculation": {
      "http://autonomix.com/20250630/role/statement-balance-sheets": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://autonomix.com/20250630/role/statement-balance-sheets",
      "http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable-schedule-of-convertible-notes-payable-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ConvertibleLongTermNotesPayable",
        "terseLabel": "Long term debt - convertible notes, net of unamortized debt discount",
        "periodStartLabel": "Outstanding, net carrying amount",
        "periodEndLabel": "Outstanding, net carrying amount",
        "documentation": "Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_ConvertibleNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConvertibleNotesPayable",
     "crdr": "credit",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ConvertibleNotesPayable",
        "terseLabel": "Convertible Notes Payable",
        "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r79",
      "r823"
     ]
    },
    "amix_ConvertibleNotesToWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "ConvertibleNotesToWarrantsMember",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-antidilutive-securities-details",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-prior-period-corrections-details",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-10q-details",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-schedule-of-prior-period-corrections-10q-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Notes to Warrant [Member]",
        "documentation": "Represents convertible notes to warrants."
       }
      }
     },
     "auth_ref": []
    },
    "amix_CorrectionOfAnImmaterialErrorPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "CorrectionOfAnImmaterialErrorPolicyTextBlock",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Correction of an Immaterial Error [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for correction of an immaterial error."
       }
      }
     },
     "auth_ref": []
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual",
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q",
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-4-equity",
      "http://autonomix.com/20250630/role/statement-note-4-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r122",
      "r130",
      "r131",
      "r223",
      "r261",
      "r452",
      "r462",
      "r472",
      "r594",
      "r595",
      "r596",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r788",
      "r789",
      "r790",
      "r791"
     ]
    },
    "us-gaap_DebtConversionByUniqueDescriptionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtConversionByUniqueDescriptionAxis",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-2-convertible-notes-payable-10q",
      "http://autonomix.com/20250630/role/statement-note-2-convertible-notes-payable-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable",
      "http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable-details-textual",
      "http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable-schedule-of-convertible-notes-payable-details",
      "http://autonomix.com/20250630/role/statement-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Conversion Description [Axis]",
        "documentation": "Information by description of debt issuances converted in a noncash or part noncash transaction."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r19"
     ]
    },
    "us-gaap_DebtConversionConvertedInstrumentAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtConversionConvertedInstrumentAmount1",
     "crdr": "credit",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable-schedule-of-convertible-notes-payable-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DebtConversionConvertedInstrumentAmount1",
        "negatedTerseLabel": "Issuance of common stock for extinguishment of convertible debt",
        "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r19"
     ]
    },
    "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtConversionConvertedInstrumentSharesIssued1",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-2-convertible-notes-payable-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DebtConversionConvertedInstrumentSharesIssued1",
        "terseLabel": "Debt Conversion, Converted Instrument, Shares Issued (in shares)",
        "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r19"
     ]
    },
    "amix_DebtConversionDebtIssuanceCostsConvertedCommonShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "DebtConversionDebtIssuanceCostsConvertedCommonShares",
     "crdr": "credit",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable-schedule-of-convertible-notes-payable-details",
      "http://autonomix.com/20250630/role/statement-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Settlement/conversion to common shares for debt issuance costs",
        "negatedTerseLabel": "Issuance of common stock for extinguishment of convertible debt, amortized debt discuont",
        "documentation": "Represents the debt issuance costs that were converted into common shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtConversionNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtConversionNameDomain",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-2-convertible-notes-payable-10q",
      "http://autonomix.com/20250630/role/statement-note-2-convertible-notes-payable-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable",
      "http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable-details-textual",
      "http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable-schedule-of-convertible-notes-payable-details",
      "http://autonomix.com/20250630/role/statement-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Conversion, Name [Domain]",
        "documentation": "The name of the original debt issue that has been converted in a noncash (or part noncash) transaction during the accounting period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r19"
     ]
    },
    "us-gaap_DebtConversionOriginalDebtAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtConversionOriginalDebtAmount1",
     "crdr": "credit",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable-schedule-of-convertible-notes-payable-details",
      "http://autonomix.com/20250630/role/statement-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible notes converted into common stock",
        "negatedTerseLabel": "Issuance of common stock for extinguishment of convertible debt",
        "documentation": "The amount of the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r19"
     ]
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-2-convertible-notes-payable-10q",
      "http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Text Block]",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r122",
      "r123",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r208",
      "r209",
      "r219",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r235",
      "r242",
      "r243",
      "r244",
      "r386",
      "r436"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-2-convertible-notes-payable-10q",
      "http://autonomix.com/20250630/role/statement-note-2-convertible-notes-payable-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable",
      "http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable-details-textual",
      "http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable-schedule-of-convertible-notes-payable-details",
      "http://autonomix.com/20250630/role/statement-note-6-related-party-transactions",
      "http://autonomix.com/20250630/role/statement-note-6-related-party-transactions-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r31",
      "r32",
      "r77",
      "r79",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r226",
      "r231",
      "r232",
      "r233",
      "r234",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r651",
      "r701",
      "r702",
      "r703",
      "r707",
      "r735",
      "r736",
      "r737",
      "r805",
      "r807",
      "r821"
     ]
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-2-convertible-notes-payable-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DebtInstrumentConvertibleConversionPrice1",
        "terseLabel": "Debt Instrument, Convertible, Conversion Price (in dollars per share)",
        "documentation": "The price per share of the conversion feature embedded in the debt instrument."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r222"
     ]
    },
    "amix_DebtInstrumentConvertibleMaximumBeneficialOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "DebtInstrumentConvertibleMaximumBeneficialOwnershipPercentage",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-2-convertible-notes-payable-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "amix_DebtInstrumentConvertibleMaximumBeneficialOwnershipPercentage",
        "terseLabel": "Debt Instrument, Convertible, Maximum Beneficial Ownership, Percentage",
        "documentation": "Percentage of maximum beneficial ownership upon conversion of the debt instrument."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentConvertibleNumberOfEquityInstruments",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-2-convertible-notes-payable-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments",
        "terseLabel": "Debt Instrument, Convertible, Number of Equity Instruments",
        "documentation": "The number of equity instruments that the holder of the debt instrument would receive if the debt was converted to equity."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r35",
      "r62",
      "r63",
      "r222"
     ]
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-2-convertible-notes-payable-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable-details-textual",
      "http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable-schedule-of-convertible-notes-payable-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DebtInstrumentFaceAmount",
        "terseLabel": "Debt Instrument, Face Amount",
        "periodStartLabel": "Outstanding, principal amount",
        "periodEndLabel": "Outstanding, principal amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r220",
      "r436",
      "r437",
      "r617",
      "r618",
      "r651"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-2-convertible-notes-payable-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DebtInstrumentInterestRateEffectivePercentage",
        "terseLabel": "Debt Instrument, Interest Rate, Effective Percentage",
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r245",
      "r436",
      "r437",
      "r651"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-2-convertible-notes-payable-10q",
      "http://autonomix.com/20250630/role/statement-note-2-convertible-notes-payable-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable",
      "http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable-details-textual",
      "http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable-schedule-of-convertible-notes-payable-details",
      "http://autonomix.com/20250630/role/statement-note-6-related-party-transactions",
      "http://autonomix.com/20250630/role/statement-note-6-related-party-transactions-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r226",
      "r231",
      "r232",
      "r233",
      "r234",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r651",
      "r701",
      "r702",
      "r703",
      "r707",
      "r735",
      "r736",
      "r737",
      "r805",
      "r807",
      "r821"
     ]
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentUnamortizedDiscountPremiumNet",
     "crdr": "debit",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable-schedule-of-convertible-notes-payable-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedPeriodStartLabel": "Outstanding, amortized debt discount",
        "negatedPeriodEndLabel": "Outstanding, amortized debt discount",
        "label": "us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet",
        "documentation": "Amount, after accumulated amortization, of debt discount (premium)."
       }
      }
     },
     "auth_ref": [
      "r746",
      "r804",
      "r805",
      "r807"
     ]
    },
    "us-gaap_DebtPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtPolicyTextBlock",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_DeferredCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredCosts",
     "crdr": "debit",
     "calculation": {
      "http://autonomix.com/20250630/role/statement-balance-sheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 0.0
      },
      "http://autonomix.com/20250630/role/statement-condensed-balance-sheets-unaudited-": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://autonomix.com/20250630/role/statement-balance-sheets",
      "http://autonomix.com/20250630/role/statement-condensed-balance-sheets-unaudited-"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred offering costs",
        "documentation": "Amount of deferred cost, excluding capitalized cost related to contract with customer; classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r683"
     ]
    },
    "amix_DeferredFinancingCostsRelatedToTheIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "DeferredFinancingCostsRelatedToTheIssuanceOfCommonStock",
     "crdr": "credit",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-condensed-statements-of-cash-flows-unaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recognition of deferred financing costs associated with issuance of common stock",
        "documentation": "The amount of deferred financing costs related to the issuance of common stock."
       }
      }
     },
     "auth_ref": []
    },
    "amix_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts",
     "crdr": "debit",
     "calculation": {
      "http://autonomix.com/20250630/role/statement-note-7-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-7-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capitalized R&amp;D costs",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from research and development costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://autonomix.com/20250630/role/statement-note-7-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-7-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DeferredTaxAssetsGross",
        "totalLabel": "Total deferred tax assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r356"
     ]
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://autonomix.com/20250630/role/statement-note-7-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-7-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
        "totalLabel": "Net deferred tax",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r783"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://autonomix.com/20250630/role/statement-note-7-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-7-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DeferredTaxAssetsNet",
        "totalLabel": "Net deferred tax assets",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r783"
     ]
    },
    "us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsNetOfValuationAllowanceAbstract",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-7-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets related to:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://autonomix.com/20250630/role/statement-note-7-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-7-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net operating losses",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r784"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://autonomix.com/20250630/role/statement-note-7-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-7-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
        "terseLabel": "Stock-based compensation",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r784"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals",
     "crdr": "debit",
     "calculation": {
      "http://autonomix.com/20250630/role/statement-note-7-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-7-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accruals and reserves",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals."
       }
      }
     },
     "auth_ref": [
      "r784"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://autonomix.com/20250630/role/statement-note-7-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-7-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DeferredTaxAssetsValuationAllowance",
        "negatedLabel": "Valuation allowance for deferred tax assets",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r357"
     ]
    },
    "us-gaap_DeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://autonomix.com/20250630/role/statement-note-7-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-7-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DeferredTaxLiabilities",
        "negatedTotalLabel": "Net deferred tax liabilities",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r783"
     ]
    },
    "amix_DeferredTaxLiabilitiesChangeInAccountingMethod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "DeferredTaxLiabilitiesChangeInAccountingMethod",
     "crdr": "credit",
     "calculation": {
      "http://autonomix.com/20250630/role/statement-note-7-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details": {
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-7-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "amix_DeferredTaxLiabilitiesChangeInAccountingMethod",
        "negatedLabel": "Section 481A method change",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from Section 481A method change."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxLiabilitiesNetAbstract",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-7-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities related to:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://autonomix.com/20250630/role/statement-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://autonomix.com/20250630/role/statement-condensed-statements-of-cash-flows-unaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://autonomix.com/20250630/role/statement-condensed-statements-of-cash-flows-unaudited",
      "http://autonomix.com/20250630/role/statement-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation and amortization expense",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r119",
      "r160",
      "r171",
      "r182",
      "r597",
      "r609",
      "r610"
     ]
    },
    "srt_DirectorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "DirectorMember",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-6-subsequent-events-10q",
      "http://autonomix.com/20250630/role/statement-note-6-subsequent-events-10q-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]"
       }
      }
     },
     "auth_ref": [
      "r722",
      "r826"
     ]
    },
    "us-gaap_DisclosureTextBlockAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureTextBlockAbstract",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q",
      "http://autonomix.com/20250630/role/statement-note-2-convertible-notes-payable-10q",
      "http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments",
      "http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable",
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q",
      "http://autonomix.com/20250630/role/statement-note-4-commitments-and-contingencies-10q",
      "http://autonomix.com/20250630/role/statement-note-4-equity",
      "http://autonomix.com/20250630/role/statement-note-5-commitments-and-contingencies",
      "http://autonomix.com/20250630/role/statement-note-5-related-party-transactions-10q",
      "http://autonomix.com/20250630/role/statement-note-6-related-party-transactions",
      "http://autonomix.com/20250630/role/statement-note-6-subsequent-events-10q",
      "http://autonomix.com/20250630/role/statement-note-7-income-taxes",
      "http://autonomix.com/20250630/role/statement-note-8-subsequent-events"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DisclosureTextBlockAbstract",
        "terseLabel": "Notes to Financial Statements"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentInformationTable",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-condensed-statements-of-operations-unaudited",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-prior-period-corrections-details",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-schedule-of-prior-period-corrections-10q-details",
      "http://autonomix.com/20250630/role/statement-statements-of-operations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Loss per share - basic and diluted (in dollars per share)",
        "label": "Loss per share - basic and diluted (in dollars per share)",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r117",
      "r137",
      "r138",
      "r139",
      "r140",
      "r142",
      "r143",
      "r144",
      "r146",
      "r151",
      "r152",
      "r154",
      "r155",
      "r156",
      "r159",
      "r248",
      "r323",
      "r373",
      "r376",
      "r400",
      "r401",
      "r466",
      "r487",
      "r602"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r24",
      "r158"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://autonomix.com/20250630/role/statement-note-7-income-taxes-schedule-of-reconciliation-details": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-7-income-taxes-schedule-of-reconciliation-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
        "totalLabel": "Effective income tax rate",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r343",
      "r633"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://autonomix.com/20250630/role/statement-note-7-income-taxes-schedule-of-reconciliation-details": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-7-income-taxes-schedule-of-reconciliation-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax benefit at the U.S. federal statutory rate, percent",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r126",
      "r343",
      "r364",
      "r633"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://autonomix.com/20250630/role/statement-note-7-income-taxes-schedule-of-reconciliation-details": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-7-income-taxes-schedule-of-reconciliation-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation allowance, percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r347",
      "r633",
      "r701",
      "r706",
      "r780"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate",
     "calculation": {
      "http://autonomix.com/20250630/role/statement-note-7-income-taxes-schedule-of-reconciliation-details": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-7-income-taxes-schedule-of-reconciliation-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax rate change, percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates."
       }
      }
     },
     "auth_ref": [
      "r346",
      "r633",
      "r701",
      "r706",
      "r780"
     ]
    },
    "amix_EffectiveIncomeTaxRateReconciliationChangeInStateRateAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInStateRateAmount",
     "crdr": "debit",
     "calculation": {
      "http://autonomix.com/20250630/role/statement-note-7-income-taxes-schedule-of-reconciliation-details": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-7-income-taxes-schedule-of-reconciliation-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in state rate, amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to the change in stat rate."
       }
      }
     },
     "auth_ref": []
    },
    "amix_EffectiveIncomeTaxRateReconciliationChangeInStateRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInStateRatePercent",
     "calculation": {
      "http://autonomix.com/20250630/role/statement-note-7-income-taxes-schedule-of-reconciliation-details": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-7-income-taxes-schedule-of-reconciliation-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in state rate, percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to the change in state rate."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense",
     "calculation": {
      "http://autonomix.com/20250630/role/statement-note-7-income-taxes-schedule-of-reconciliation-details": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-7-income-taxes-schedule-of-reconciliation-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Permanent differences, percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r348",
      "r349",
      "r701",
      "r706",
      "r780"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes",
     "calculation": {
      "http://autonomix.com/20250630/role/statement-note-7-income-taxes-schedule-of-reconciliation-details": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-7-income-taxes-schedule-of-reconciliation-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Return to provision, percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense."
       }
      }
     },
     "auth_ref": [
      "r701",
      "r706",
      "r780",
      "r781"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://autonomix.com/20250630/role/statement-note-7-income-taxes-schedule-of-reconciliation-details": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-7-income-taxes-schedule-of-reconciliation-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State tax (net of federal benefit)",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r345",
      "r633",
      "r701",
      "r706",
      "r780"
     ]
    },
    "us-gaap_EmployeeBenefitsAndShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeBenefitsAndShareBasedCompensation",
     "crdr": "debit",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-4-commitments-and-contingencies-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-5-commitments-and-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_EmployeeBenefitsAndShareBasedCompensation",
        "terseLabel": "Employee Benefits and Share-Based Compensation",
        "documentation": "Amount of expense for employee benefit and equity-based compensation."
       }
      }
     },
     "auth_ref": [
      "r693"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-4-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
        "terseLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r321"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "crdr": "debit",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-4-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
        "terseLabel": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r777"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-4-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
        "terseLabel": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r777"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-antidilutive-securities-details",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-prior-period-corrections-details",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-10q-details",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-schedule-of-prior-period-corrections-10q-details",
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q",
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-4-equity",
      "http://autonomix.com/20250630/role/statement-note-4-equity-details-textual",
      "http://autonomix.com/20250630/role/statement-note-8-subsequent-events",
      "http://autonomix.com/20250630/role/statement-note-8-subsequent-events-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": [
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776"
     ]
    },
    "amix_EmploymentAgreementBonusAsAPercentageOfAnnualBaseCompensation": {
     "xbrltype": "percentItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "EmploymentAgreementBonusAsAPercentageOfAnnualBaseCompensation",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-5-commitments-and-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "amix_EmploymentAgreementBonusAsAPercentageOfAnnualBaseCompensation",
        "terseLabel": "Employment Agreement, Bonus as a Percentage of Annual Base Compensation",
        "documentation": "Commitment made to pay an annual bonus expressed as a percentage of the individual's base salary."
       }
      }
     },
     "auth_ref": []
    },
    "amix_EmploymentAgreementTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "EmploymentAgreementTermOfContract",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-5-commitments-and-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "amix_EmploymentAgreementTermOfContract",
        "terseLabel": "Employment Agreement, Term of Contract (Year)",
        "documentation": "Pertains to the terms of the employment agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmploymentContractsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmploymentContractsMember",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-4-commitments-and-contingencies-10q",
      "http://autonomix.com/20250630/role/statement-note-4-commitments-and-contingencies-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-5-commitments-and-contingencies",
      "http://autonomix.com/20250630/role/statement-note-5-commitments-and-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employment Contracts [Member]",
        "documentation": "Contracts securing the services of employees, which may define the period of employment and the nature of the business relationship, and which may include nondisclosure and noncompete restrictions."
       }
      }
     },
     "auth_ref": [
      "r638",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r675"
     ]
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityDomain",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-balance-sheets",
      "http://autonomix.com/20250630/role/statement-balance-sheets-parentheticals",
      "http://autonomix.com/20250630/role/statement-condensed-balance-sheets-unaudited-",
      "http://autonomix.com/20250630/role/statement-condensed-balance-sheets-unaudited-parentheticals",
      "http://autonomix.com/20250630/role/statement-condensed-statements-of-cash-flows-unaudited",
      "http://autonomix.com/20250630/role/statement-condensed-statements-of-operations-unaudited",
      "http://autonomix.com/20250630/role/statement-document-and-entity-information",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q-tables",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-antidilutive-securities-details",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-prior-period-corrections-details",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-10q-details",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-schedule-of-prior-period-corrections-10q-details",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-tables",
      "http://autonomix.com/20250630/role/statement-note-2-convertible-notes-payable-10q",
      "http://autonomix.com/20250630/role/statement-note-2-convertible-notes-payable-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-2-convertible-notes-payable-10q-tables",
      "http://autonomix.com/20250630/role/statement-note-2-convertible-notes-payable-schedule-of-detachable-warrants-10q-details",
      "http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments",
      "http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-details-textual",
      "http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-fair-value-measurement-inputs-and-valuation-techniques-details",
      "http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-schedule-of-fair-value-measurements-details",
      "http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-tables",
      "http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable",
      "http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable-details-textual",
      "http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable-schedule-of-convertible-notes-payable-details",
      "http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable-schedule-of-detachable-warrants-details",
      "http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable-tables",
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q",
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q-tables",
      "http://autonomix.com/20250630/role/statement-note-3-equity-general-and-administrative-expense-10q-details",
      "http://autonomix.com/20250630/role/statement-note-3-equity-schedule-of-equitybased-stock-warrants-10q-details",
      "http://autonomix.com/20250630/role/statement-note-3-equity-schedule-of-stock-option-activity-10q-details",
      "http://autonomix.com/20250630/role/statement-note-4-commitments-and-contingencies-10q",
      "http://autonomix.com/20250630/role/statement-note-4-commitments-and-contingencies-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-4-equity",
      "http://autonomix.com/20250630/role/statement-note-4-equity-blackscholes-option-pricing-model-details",
      "http://autonomix.com/20250630/role/statement-note-4-equity-details-textual",
      "http://autonomix.com/20250630/role/statement-note-4-equity-general-and-administrative-expense-details",
      "http://autonomix.com/20250630/role/statement-note-4-equity-restricted-stock-activity-details",
      "http://autonomix.com/20250630/role/statement-note-4-equity-schedule-of-equitybased-stock-warrants-details",
      "http://autonomix.com/20250630/role/statement-note-4-equity-schedule-of-stock-option-activity-details",
      "http://autonomix.com/20250630/role/statement-note-4-equity-tables",
      "http://autonomix.com/20250630/role/statement-note-5-commitments-and-contingencies",
      "http://autonomix.com/20250630/role/statement-note-5-commitments-and-contingencies-details-textual",
      "http://autonomix.com/20250630/role/statement-note-5-related-party-transactions-10q",
      "http://autonomix.com/20250630/role/statement-note-5-related-party-transactions-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-6-related-party-transactions",
      "http://autonomix.com/20250630/role/statement-note-6-related-party-transactions-details-textual",
      "http://autonomix.com/20250630/role/statement-note-6-subsequent-events-10q",
      "http://autonomix.com/20250630/role/statement-note-6-subsequent-events-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-7-income-taxes",
      "http://autonomix.com/20250630/role/statement-note-7-income-taxes-details-textual",
      "http://autonomix.com/20250630/role/statement-note-7-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details",
      "http://autonomix.com/20250630/role/statement-note-7-income-taxes-schedule-of-reconciliation-details",
      "http://autonomix.com/20250630/role/statement-note-7-income-taxes-tables",
      "http://autonomix.com/20250630/role/statement-note-8-subsequent-events",
      "http://autonomix.com/20250630/role/statement-note-8-subsequent-events-details-textual",
      "http://autonomix.com/20250630/role/statement-significant-accounting-policies-policies",
      "http://autonomix.com/20250630/role/statement-statements-of-cash-flows",
      "http://autonomix.com/20250630/role/statement-statements-of-operations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r675"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-condensed-statements-of-changes-in-stockholders-equity-unaudited",
      "http://autonomix.com/20250630/role/statement-statements-of-changes-in-stockholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r96",
      "r98",
      "r99",
      "r113",
      "r114",
      "r115",
      "r132",
      "r133",
      "r134",
      "r136",
      "r144",
      "r147",
      "r149",
      "r161",
      "r189",
      "r192",
      "r193",
      "r247",
      "r273",
      "r323",
      "r362",
      "r363",
      "r370",
      "r371",
      "r372",
      "r374",
      "r375",
      "r376",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r399",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r438",
      "r440",
      "r445",
      "r486",
      "r493",
      "r494",
      "r495",
      "r514",
      "r568"
     ]
    },
    "amix_EquityOfferingMaximumOfferingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "EquityOfferingMaximumOfferingAmount",
     "crdr": "credit",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual",
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-4-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "amix_EquityOfferingMaximumOfferingAmount",
        "terseLabel": "Equity Offering, Maximum Offering Amount",
        "documentation": "Maximum value of company's equity authorized for issuance under equity offering."
       }
      }
     },
     "auth_ref": []
    },
    "amix_EquityOfferingMaximumSharesToBeIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "EquityOfferingMaximumSharesToBeIssued",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-4-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "amix_EquityOfferingMaximumSharesToBeIssued",
        "terseLabel": "Equity Offering, Maximum Shares to be Issued (in shares)",
        "documentation": "The maximum number of shares to be issued in the equity offering."
       }
      }
     },
     "auth_ref": []
    },
    "amix_EquityOfferingOptionMaximumShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "EquityOfferingOptionMaximumShares",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual",
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-4-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "amix_EquityOfferingOptionMaximumShares",
        "terseLabel": "Equity Offering, Option, Maximum Shares (in shares)",
        "documentation": "The maximum shares to be issued in option under equity offering."
       }
      }
     },
     "auth_ref": []
    },
    "amix_EquityOfferingOptionMaximumWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "EquityOfferingOptionMaximumWarrants",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual",
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-4-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "amix_EquityOfferingOptionMaximumWarrants",
        "terseLabel": "Equity Offering, Option, Maximum Warrants (in shares)",
        "documentation": "The maximum warrants to be issued in option of equity offering."
       }
      }
     },
     "auth_ref": []
    },
    "amix_EquityOfferingOptionPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "EquityOfferingOptionPeriod",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual",
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-4-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "amix_EquityOfferingOptionPeriod",
        "terseLabel": "Equity Offering, Option Period (Day)",
        "documentation": "Period of the option in the equity offering."
       }
      }
     },
     "auth_ref": []
    },
    "amix_EquitybasedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "EquitybasedWarrantsMember",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual",
      "http://autonomix.com/20250630/role/statement-note-4-equity",
      "http://autonomix.com/20250630/role/statement-note-4-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity-based Warrants [Member]",
        "documentation": "Represents equity-based warrants."
       }
      }
     },
     "auth_ref": []
    },
    "amix_ExecutiveChairOfTheBoardMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "ExecutiveChairOfTheBoardMember",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-6-subsequent-events-10q",
      "http://autonomix.com/20250630/role/statement-note-6-subsequent-events-10q-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Chair of the Board [Member]",
        "documentation": "Related to the Executive Chair of the Board."
       }
      }
     },
     "auth_ref": []
    },
    "amix_ExecutiveViceChairAndStrategicAdvisorToTheChiefExecutiveOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "ExecutiveViceChairAndStrategicAdvisorToTheChiefExecutiveOfficerMember",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-5-commitments-and-contingencies",
      "http://autonomix.com/20250630/role/statement-note-5-commitments-and-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Vice Chair and Strategic Advisor to the Chief Executive Officer [Member]",
        "documentation": "Represents information pertaining to the executive vice chair and strategic advisor to the CEO."
       }
      }
     },
     "auth_ref": []
    },
    "amix_ExistingWarrantsAt1722ExercisePriceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "ExistingWarrantsAt1722ExercisePriceMember",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-6-subsequent-events-10q",
      "http://autonomix.com/20250630/role/statement-note-6-subsequent-events-10q-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Existing Warrants at 1.722 Exercise Price [Member]",
        "documentation": "Represents the existing warrants with an exercise price of $1.722."
       }
      }
     },
     "auth_ref": []
    },
    "amix_ExistingWarrantsAt1723ExercisePriceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "ExistingWarrantsAt1723ExercisePriceMember",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-6-subsequent-events-10q",
      "http://autonomix.com/20250630/role/statement-note-6-subsequent-events-10q-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Existing Warrants at 1.723 Exercise Price [Member]",
        "documentation": "Represents the existing warrants at an exercise price of $1.723."
       }
      }
     },
     "auth_ref": []
    },
    "amix_ExistingWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "ExistingWarrantsMember",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-6-subsequent-events-10q",
      "http://autonomix.com/20250630/role/statement-note-6-subsequent-events-10q-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Existing Warrants [Member]",
        "documentation": "Represents the existing warrants."
       }
      }
     },
     "auth_ref": []
    },
    "amix_ExpirationCommencingTaxYear20342037Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "ExpirationCommencingTaxYear20342037Member",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-7-income-taxes",
      "http://autonomix.com/20250630/role/statement-note-7-income-taxes-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expiration Commencing, Tax Year 2034-2037 [Member]",
        "documentation": "The identified tax year, period, for the expiration of the net operating loss carryforward."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAdjustmentOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://autonomix.com/20250630/role/statement-statements-of-operations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 0.0
      },
      "http://autonomix.com/20250630/role/statement-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-details-textual",
      "http://autonomix.com/20250630/role/statement-statements-of-cash-flows",
      "http://autonomix.com/20250630/role/statement-statements-of-operations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant liability - mark-to-market",
        "terseLabel": "Fair Value Adjustment of Warrants",
        "negatedLabel": "Warrant liability - mark-to-market",
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r405",
      "r406",
      "r646"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments",
      "http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-details-textual",
      "http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-schedule-of-fair-value-measurements-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r233",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r282",
      "r283",
      "r402",
      "r404",
      "r405",
      "r406",
      "r407",
      "r416",
      "r417",
      "r419",
      "r424",
      "r457",
      "r458",
      "r459",
      "r592",
      "r617",
      "r618",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r643",
      "r646",
      "r650"
     ]
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByLiabilityClassAxis",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-schedule-of-fair-value-measurements-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liability Class [Axis]",
        "documentation": "Information by class of liability."
       }
      }
     },
     "auth_ref": [
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r418"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-fair-value-measurement-inputs-and-valuation-techniques-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r403",
      "r404",
      "r405",
      "r407",
      "r643",
      "r797",
      "r801"
     ]
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r405",
      "r412",
      "r414",
      "r415",
      "r416",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r465",
      "r643",
      "r647"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments",
      "http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-details-textual",
      "http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-schedule-of-fair-value-measurements-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r233",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r282",
      "r283",
      "r404",
      "r405",
      "r406",
      "r407",
      "r417",
      "r424",
      "r459",
      "r592",
      "r617",
      "r618",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r643",
      "r646",
      "r650"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-schedule-of-fair-value-measurements-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value by Liability Class [Domain]",
        "documentation": "Represents classes of liabilities measured and disclosed at fair value."
       }
      }
     },
     "auth_ref": [
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r418"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-fair-value-measurement-inputs-and-valuation-techniques-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r403",
      "r404",
      "r405",
      "r407",
      "r643",
      "r797",
      "r801"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements",
     "crdr": "credit",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-schedule-of-fair-value-measurements-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements",
        "negatedLabel": "Settlement and reclassification to equity",
        "documentation": "Amount of settlement of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r411",
      "r418",
      "r644"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "crdr": "credit",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-schedule-of-fair-value-measurements-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in fair value measurements - warrants mark-to-market",
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r409",
      "r418"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements",
     "crdr": "credit",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-schedule-of-fair-value-measurements-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additions",
        "documentation": "Amount of purchases, (sales), issuances and (settlements) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r799",
      "r800"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "crdr": "credit",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-schedule-of-fair-value-measurements-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r408",
      "r418"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments",
      "http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-details-textual",
      "http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-schedule-of-fair-value-measurements-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r233",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r282",
      "r283",
      "r402",
      "r404",
      "r405",
      "r406",
      "r407",
      "r416",
      "r417",
      "r419",
      "r424",
      "r457",
      "r458",
      "r459",
      "r592",
      "r617",
      "r618",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r643",
      "r646",
      "r650"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-fair-value-measurement-inputs-and-valuation-techniques-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r643",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r801"
     ]
    },
    "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset) using recurring unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r408",
      "r413",
      "r418"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r802"
     ]
    },
    "us-gaap_GainLossOnDerivativeInstrumentsNetPretax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GainLossOnDerivativeInstrumentsNetPretax",
     "crdr": "credit",
     "calculation": {
      "http://autonomix.com/20250630/role/statement-statements-of-operations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": -1.0,
       "order": 1.0
      },
      "http://autonomix.com/20250630/role/statement-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-details-textual",
      "http://autonomix.com/20250630/role/statement-statements-of-cash-flows",
      "http://autonomix.com/20250630/role/statement-statements-of-operations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_GainLossOnDerivativeInstrumentsNetPretax",
        "terseLabel": "Gain (Loss) on Derivative Instruments, Net, Pretax",
        "negatedLabel": "Warrant expense - termination agreement",
        "documentation": "Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects."
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://autonomix.com/20250630/role/statement-condensed-statements-of-operations-unaudited": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      },
      "http://autonomix.com/20250630/role/statement-statements-of-operations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://autonomix.com/20250630/role/statement-condensed-statements-of-operations-unaudited",
      "http://autonomix.com/20250630/role/statement-statements-of-operations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and administrative",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r550"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q",
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-3-equity-general-and-administrative-expense-10q-details",
      "http://autonomix.com/20250630/role/statement-note-4-equity",
      "http://autonomix.com/20250630/role/statement-note-4-equity-details-textual",
      "http://autonomix.com/20250630/role/statement-note-4-equity-general-and-administrative-expense-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "us-gaap_GranteeStatusAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GranteeStatusAxis",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-8-subsequent-events",
      "http://autonomix.com/20250630/role/statement-note-8-subsequent-events-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grantee Status [Axis]",
        "documentation": "Information by status of recipient to whom award is granted."
       }
      }
     },
     "auth_ref": [
      "r288",
      "r290",
      "r291",
      "r292",
      "r293",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319"
     ]
    },
    "us-gaap_GranteeStatusDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GranteeStatusDomain",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-8-subsequent-events",
      "http://autonomix.com/20250630/role/statement-note-8-subsequent-events-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grantee Status [Domain]",
        "documentation": "Status of recipient to whom award is granted."
       }
      }
     },
     "auth_ref": [
      "r288",
      "r290",
      "r291",
      "r292",
      "r293",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319"
     ]
    },
    "us-gaap_IPOMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IPOMember",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "IPO [Member]",
        "documentation": "First sale of stock by a private company to the public."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://autonomix.com/20250630/role/statement-statements-of-operations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 0.0
      },
      "http://autonomix.com/20250630/role/statement-condensed-statements-of-operations-unaudited": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://autonomix.com/20250630/role/statement-condensed-statements-of-operations-unaudited",
      "http://autonomix.com/20250630/role/statement-statements-of-operations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
        "totalLabel": "Loss before income taxes",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r82",
      "r86",
      "r467",
      "r469",
      "r484",
      "r598",
      "r600",
      "r601",
      "r605",
      "r609",
      "r715",
      "r717",
      "r718",
      "r719",
      "r720"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q",
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-3-equity-general-and-administrative-expense-10q-details",
      "http://autonomix.com/20250630/role/statement-note-4-equity",
      "http://autonomix.com/20250630/role/statement-note-4-equity-details-textual",
      "http://autonomix.com/20250630/role/statement-note-4-equity-general-and-administrative-expense-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r194",
      "r200",
      "r201",
      "r382",
      "r383",
      "r384",
      "r385",
      "r409",
      "r413",
      "r418",
      "r426",
      "r427",
      "r428",
      "r490",
      "r492",
      "r553",
      "r591",
      "r592",
      "r634",
      "r635",
      "r641",
      "r642",
      "r645",
      "r650",
      "r785",
      "r786",
      "r824"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q",
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-3-equity-general-and-administrative-expense-10q-details",
      "http://autonomix.com/20250630/role/statement-note-4-equity",
      "http://autonomix.com/20250630/role/statement-note-4-equity-details-textual",
      "http://autonomix.com/20250630/role/statement-note-4-equity-general-and-administrative-expense-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r200",
      "r201",
      "r382",
      "r383",
      "r384",
      "r385",
      "r409",
      "r413",
      "r418",
      "r426",
      "r427",
      "r428",
      "r490",
      "r492",
      "r553",
      "r591",
      "r592",
      "r634",
      "r635",
      "r641",
      "r642",
      "r645",
      "r650",
      "r785",
      "r786",
      "r824"
     ]
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-7-income-taxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r126",
      "r338",
      "r343",
      "r350",
      "r351",
      "r352",
      "r353",
      "r359",
      "r365",
      "r367",
      "r368",
      "r369",
      "r471",
      "r504",
      "r510",
      "r633"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://autonomix.com/20250630/role/statement-condensed-statements-of-operations-unaudited": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 0.0
      },
      "http://autonomix.com/20250630/role/statement-statements-of-operations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      },
      "http://autonomix.com/20250630/role/statement-note-7-income-taxes-schedule-of-reconciliation-details": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://autonomix.com/20250630/role/statement-condensed-statements-of-operations-unaudited",
      "http://autonomix.com/20250630/role/statement-note-7-income-taxes-schedule-of-reconciliation-details",
      "http://autonomix.com/20250630/role/statement-statements-of-operations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income taxes",
        "totalLabel": "Effective income tax rate, Total, amount",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r95",
      "r122",
      "r148",
      "r149",
      "r160",
      "r172",
      "r182",
      "r342",
      "r343",
      "r366",
      "r488",
      "r598",
      "r600",
      "r601",
      "r633"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r340",
      "r341",
      "r353",
      "r354",
      "r358",
      "r361",
      "r507"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://autonomix.com/20250630/role/statement-note-7-income-taxes-schedule-of-reconciliation-details": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-7-income-taxes-schedule-of-reconciliation-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation allowance, amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r347",
      "r633",
      "r780"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationChangeInEnactedTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://autonomix.com/20250630/role/statement-note-7-income-taxes-schedule-of-reconciliation-details": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-7-income-taxes-schedule-of-reconciliation-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax rate change, amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates."
       }
      }
     },
     "auth_ref": [
      "r339",
      "r343",
      "r346",
      "r633"
     ]
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://autonomix.com/20250630/role/statement-note-7-income-taxes-schedule-of-reconciliation-details": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-7-income-taxes-schedule-of-reconciliation-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax benefit at the U.S. federal statutory rate, amount",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r343",
      "r633"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationNondeductibleExpense",
     "crdr": "debit",
     "calculation": {
      "http://autonomix.com/20250630/role/statement-note-7-income-taxes-schedule-of-reconciliation-details": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-7-income-taxes-schedule-of-reconciliation-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Permanent differences, amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r348",
      "r349",
      "r780"
     ]
    },
    "us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationPriorYearIncomeTaxes",
     "crdr": "debit",
     "calculation": {
      "http://autonomix.com/20250630/role/statement-note-7-income-taxes-schedule-of-reconciliation-details": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-7-income-taxes-schedule-of-reconciliation-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Return to provision, amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r780",
      "r781"
     ]
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "crdr": "debit",
     "calculation": {
      "http://autonomix.com/20250630/role/statement-note-7-income-taxes-schedule-of-reconciliation-details": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-7-income-taxes-schedule-of-reconciliation-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State tax (net of federal benefit), amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r345",
      "r633",
      "r780"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableTrade": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsPayableTrade",
     "crdr": "debit",
     "calculation": {
      "http://autonomix.com/20250630/role/statement-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      },
      "http://autonomix.com/20250630/role/statement-condensed-statements-of-cash-flows-unaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://autonomix.com/20250630/role/statement-condensed-statements-of-cash-flows-unaudited",
      "http://autonomix.com/20250630/role/statement-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_IncreaseDecreaseInAccountsPayableTrade",
        "terseLabel": "Accounts payable",
        "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://autonomix.com/20250630/role/statement-condensed-statements-of-cash-flows-unaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      },
      "http://autonomix.com/20250630/role/statement-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://autonomix.com/20250630/role/statement-condensed-statements-of-cash-flows-unaudited",
      "http://autonomix.com/20250630/role/statement-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_IncreaseDecreaseInAccruedLiabilities",
        "terseLabel": "Accrued expenses",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingAssetsAbstract",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-condensed-statements-of-cash-flows-unaudited",
      "http://autonomix.com/20250630/role/statement-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets - (increase)/decrease:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingLiabilitiesAbstract",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-condensed-statements-of-cash-flows-unaudited",
      "http://autonomix.com/20250630/role/statement-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating liabilities - increase:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOtherCurrentAssets",
     "crdr": "credit",
     "calculation": {
      "http://autonomix.com/20250630/role/statement-condensed-statements-of-cash-flows-unaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      },
      "http://autonomix.com/20250630/role/statement-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://autonomix.com/20250630/role/statement-condensed-statements-of-cash-flows-unaudited",
      "http://autonomix.com/20250630/role/statement-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_IncreaseDecreaseInOtherCurrentAssets",
        "negatedLabel": "Other current assets",
        "documentation": "Amount of increase (decrease) in current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r698"
     ]
    },
    "amix_InducementOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "InducementOptionsMember",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-5-commitments-and-contingencies",
      "http://autonomix.com/20250630/role/statement-note-5-commitments-and-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inducement Options [Member]",
        "documentation": "Represents information pertaining to inducement options."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestExpenseDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestExpenseDebt",
     "crdr": "debit",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-2-convertible-notes-payable-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_InterestExpenseDebt",
        "terseLabel": "Interest Expense, Debt",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r239",
      "r246",
      "r619",
      "r620",
      "r829"
     ]
    },
    "us-gaap_InterestExpenseNonoperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestExpenseNonoperating",
     "crdr": "debit",
     "calculation": {
      "http://autonomix.com/20250630/role/statement-condensed-statements-of-operations-unaudited": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 0.0
      },
      "http://autonomix.com/20250630/role/statement-statements-of-operations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://autonomix.com/20250630/role/statement-condensed-statements-of-operations-unaudited",
      "http://autonomix.com/20250630/role/statement-statements-of-operations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_InterestExpenseNonoperating",
        "negatedLabel": "Interest expense",
        "documentation": "Amount of interest expense classified as nonoperating."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r598",
      "r601",
      "r695"
     ]
    },
    "amix_InterestHeldInCompanyReceivingWarrants": {
     "xbrltype": "percentItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "InterestHeldInCompanyReceivingWarrants",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-6-related-party-transactions-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "amix_InterestHeldInCompanyReceivingWarrants",
        "terseLabel": "Interest Held in Company Receiving Warrants",
        "documentation": "The percentage of interest held in the company receiving warrants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterimPeriodCostsNotAllocableDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterimPeriodCostsNotAllocableDomain",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual",
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q",
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-4-equity",
      "http://autonomix.com/20250630/role/statement-note-4-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interim Period, Costs Not Allocable [Domain]",
        "documentation": "This element represents the type of costs and expenses incurred during an interim period that cannot be readily identified with the activities or benefits of other interim periods and are charged to the interim period in which incurred."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "calculation": {
      "http://autonomix.com/20250630/role/statement-condensed-statements-of-operations-unaudited": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      },
      "http://autonomix.com/20250630/role/statement-statements-of-operations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://autonomix.com/20250630/role/statement-condensed-statements-of-operations-unaudited",
      "http://autonomix.com/20250630/role/statement-statements-of-operations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest income",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r169",
      "r182",
      "r609",
      "r694"
     ]
    },
    "amix_IpoProceedsHoldbackProvision": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "IpoProceedsHoldbackProvision",
     "crdr": "credit",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Holdback of IPO proceeds",
        "documentation": "Represents the portion of proceeds from initial public offering that is under holdback."
       }
      }
     },
     "auth_ref": []
    },
    "amix_IssuanceOfCommonStockForExtinguishmentOfConvertibleDebtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "IssuanceOfCommonStockForExtinguishmentOfConvertibleDebtMember",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable-schedule-of-convertible-notes-payable-details",
      "http://autonomix.com/20250630/role/statement-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of Common Stock for Extinguishment of Convertible Debt [Member]",
        "documentation": "Represents the issuance of common stock for extinguishment of convertible debt."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims",
     "crdr": "debit",
     "calculation": {
      "http://autonomix.com/20250630/role/statement-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://autonomix.com/20250630/role/statement-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock, net of discount for lack of marketability",
        "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "amix_JumpstartOurBusinessStartupsJobsActAccountingElectionPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "JumpstartOurBusinessStartupsJobsActAccountingElectionPolicyPolicyTextBlock",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Jumpstart Our Business Startups (JOBS) Act Accounting Election Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy regarding the Jumpstart Our Business Startups Act (the \u201cJOBS Act\u201d)."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-balance-sheets",
      "http://autonomix.com/20250630/role/statement-balance-sheets-parentheticals",
      "http://autonomix.com/20250630/role/statement-condensed-balance-sheets-unaudited-",
      "http://autonomix.com/20250630/role/statement-condensed-balance-sheets-unaudited-parentheticals",
      "http://autonomix.com/20250630/role/statement-condensed-statements-of-cash-flows-unaudited",
      "http://autonomix.com/20250630/role/statement-condensed-statements-of-operations-unaudited",
      "http://autonomix.com/20250630/role/statement-document-and-entity-information",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q-tables",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-antidilutive-securities-details",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-prior-period-corrections-details",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-10q-details",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-schedule-of-prior-period-corrections-10q-details",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-tables",
      "http://autonomix.com/20250630/role/statement-note-2-convertible-notes-payable-10q",
      "http://autonomix.com/20250630/role/statement-note-2-convertible-notes-payable-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-2-convertible-notes-payable-10q-tables",
      "http://autonomix.com/20250630/role/statement-note-2-convertible-notes-payable-schedule-of-detachable-warrants-10q-details",
      "http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments",
      "http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-details-textual",
      "http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-fair-value-measurement-inputs-and-valuation-techniques-details",
      "http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-schedule-of-fair-value-measurements-details",
      "http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-tables",
      "http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable",
      "http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable-details-textual",
      "http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable-schedule-of-convertible-notes-payable-details",
      "http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable-schedule-of-detachable-warrants-details",
      "http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable-tables",
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q",
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q-tables",
      "http://autonomix.com/20250630/role/statement-note-3-equity-general-and-administrative-expense-10q-details",
      "http://autonomix.com/20250630/role/statement-note-3-equity-schedule-of-equitybased-stock-warrants-10q-details",
      "http://autonomix.com/20250630/role/statement-note-3-equity-schedule-of-stock-option-activity-10q-details",
      "http://autonomix.com/20250630/role/statement-note-4-commitments-and-contingencies-10q",
      "http://autonomix.com/20250630/role/statement-note-4-commitments-and-contingencies-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-4-equity",
      "http://autonomix.com/20250630/role/statement-note-4-equity-blackscholes-option-pricing-model-details",
      "http://autonomix.com/20250630/role/statement-note-4-equity-details-textual",
      "http://autonomix.com/20250630/role/statement-note-4-equity-general-and-administrative-expense-details",
      "http://autonomix.com/20250630/role/statement-note-4-equity-restricted-stock-activity-details",
      "http://autonomix.com/20250630/role/statement-note-4-equity-schedule-of-equitybased-stock-warrants-details",
      "http://autonomix.com/20250630/role/statement-note-4-equity-schedule-of-stock-option-activity-details",
      "http://autonomix.com/20250630/role/statement-note-4-equity-tables",
      "http://autonomix.com/20250630/role/statement-note-5-commitments-and-contingencies",
      "http://autonomix.com/20250630/role/statement-note-5-commitments-and-contingencies-details-textual",
      "http://autonomix.com/20250630/role/statement-note-5-related-party-transactions-10q",
      "http://autonomix.com/20250630/role/statement-note-5-related-party-transactions-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-6-related-party-transactions",
      "http://autonomix.com/20250630/role/statement-note-6-related-party-transactions-details-textual",
      "http://autonomix.com/20250630/role/statement-note-6-subsequent-events-10q",
      "http://autonomix.com/20250630/role/statement-note-6-subsequent-events-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-7-income-taxes",
      "http://autonomix.com/20250630/role/statement-note-7-income-taxes-details-textual",
      "http://autonomix.com/20250630/role/statement-note-7-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details",
      "http://autonomix.com/20250630/role/statement-note-7-income-taxes-schedule-of-reconciliation-details",
      "http://autonomix.com/20250630/role/statement-note-7-income-taxes-tables",
      "http://autonomix.com/20250630/role/statement-note-8-subsequent-events",
      "http://autonomix.com/20250630/role/statement-note-8-subsequent-events-details-textual",
      "http://autonomix.com/20250630/role/statement-significant-accounting-policies-policies",
      "http://autonomix.com/20250630/role/statement-statements-of-cash-flows",
      "http://autonomix.com/20250630/role/statement-statements-of-operations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://autonomix.com/20250630/role/statement-balance-sheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      },
      "http://autonomix.com/20250630/role/statement-condensed-balance-sheets-unaudited-": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://autonomix.com/20250630/role/statement-balance-sheets",
      "http://autonomix.com/20250630/role/statement-condensed-balance-sheets-unaudited-"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_Liabilities",
        "totalLabel": "Total Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r31",
      "r32",
      "r33",
      "r36",
      "r37",
      "r38",
      "r39",
      "r122",
      "r124",
      "r125",
      "r188",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r379",
      "r380",
      "r381",
      "r425",
      "r526",
      "r604",
      "r621",
      "r674",
      "r743",
      "r812",
      "r813"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://autonomix.com/20250630/role/statement-balance-sheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://autonomix.com/20250630/role/statement-condensed-balance-sheets-unaudited-": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://autonomix.com/20250630/role/statement-balance-sheets",
      "http://autonomix.com/20250630/role/statement-condensed-balance-sheets-unaudited-"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_LiabilitiesAndStockholdersEquity",
        "totalLabel": "Total Liabilities and Stockholders' Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r81",
      "r480",
      "r660",
      "r662",
      "r663",
      "r701",
      "r705",
      "r723",
      "r803"
     ]
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://autonomix.com/20250630/role/statement-condensed-balance-sheets-unaudited-": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 0.0
      },
      "http://autonomix.com/20250630/role/statement-balance-sheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://autonomix.com/20250630/role/statement-balance-sheets",
      "http://autonomix.com/20250630/role/statement-condensed-balance-sheets-unaudited-"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_LiabilitiesCurrent",
        "totalLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r105",
      "r122",
      "r124",
      "r125",
      "r188",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r379",
      "r380",
      "r381",
      "r425",
      "r660",
      "r743",
      "r812",
      "r813"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-balance-sheets",
      "http://autonomix.com/20250630/role/statement-condensed-balance-sheets-unaudited-"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://autonomix.com/20250630/role/statement-balance-sheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://autonomix.com/20250630/role/statement-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_LiabilitiesNoncurrent",
        "totalLabel": "Total long-term liabilities",
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r36",
      "r37",
      "r38",
      "r39",
      "r122",
      "r124",
      "r125",
      "r188",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r379",
      "r380",
      "r381",
      "r425",
      "r743",
      "r812",
      "r813"
     ]
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesNoncurrentAbstract",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilityForUncertainTaxPositionsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilityForUncertainTaxPositionsCurrent",
     "crdr": "credit",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_LiabilityForUncertainTaxPositionsCurrent",
        "terseLabel": "Liability for Uncertainty in Income Taxes, Current",
        "documentation": "Amount recognized for uncertainty in income taxes classified as current."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "us-gaap_LitigationStatusAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LitigationStatusAxis",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-4-commitments-and-contingencies-10q",
      "http://autonomix.com/20250630/role/statement-note-4-commitments-and-contingencies-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-5-commitments-and-contingencies",
      "http://autonomix.com/20250630/role/statement-note-5-commitments-and-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Status [Axis]",
        "documentation": "Information by status of pending, threatened, or settled litigation."
       }
      }
     },
     "auth_ref": [
      "r735",
      "r736",
      "r737",
      "r740"
     ]
    },
    "us-gaap_LitigationStatusDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LitigationStatusDomain",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-4-commitments-and-contingencies-10q",
      "http://autonomix.com/20250630/role/statement-note-4-commitments-and-contingencies-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-5-commitments-and-contingencies",
      "http://autonomix.com/20250630/role/statement-note-5-commitments-and-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Status [Domain]",
        "documentation": "Status of pending, threatened, or settled litigation."
       }
      }
     },
     "auth_ref": [
      "r735",
      "r736",
      "r737",
      "r740"
     ]
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable-schedule-of-convertible-notes-payable-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Type [Axis]",
        "documentation": "Information by type of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r735",
      "r736",
      "r737"
     ]
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongtermDebtTypeDomain",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable-schedule-of-convertible-notes-payable-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Type [Domain]",
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r26",
      "r735",
      "r736",
      "r737"
     ]
    },
    "us-gaap_LossContingencyPendingClaimsNumber": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LossContingencyPendingClaimsNumber",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-4-commitments-and-contingencies-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-5-commitments-and-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_LossContingencyPendingClaimsNumber",
        "terseLabel": "Loss Contingency, Pending Claims, Number",
        "documentation": "Number of pending claims pertaining to a loss contingency."
       }
      }
     },
     "auth_ref": [
      "r741",
      "r742"
     ]
    },
    "amix_ManagementBoardOfDirectorFamilyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "ManagementBoardOfDirectorFamilyMember",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-6-related-party-transactions",
      "http://autonomix.com/20250630/role/statement-note-6-related-party-transactions-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Management, Board of Director, and Family [Member]",
        "documentation": "Pertains to the related party."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ManagementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ManagementMember",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-6-related-party-transactions",
      "http://autonomix.com/20250630/role/statement-note-6-related-party-transactions-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Management [Member]"
       }
      }
     },
     "auth_ref": [
      "r722",
      "r810"
     ]
    },
    "amix_MarketingConsultantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "MarketingConsultantMember",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q",
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-4-equity",
      "http://autonomix.com/20250630/role/statement-note-4-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketing Consultant [Member]",
        "documentation": "Represents marketing consultant."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MaximumMember",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual",
      "http://autonomix.com/20250630/role/statement-note-2-convertible-notes-payable-10q",
      "http://autonomix.com/20250630/role/statement-note-2-convertible-notes-payable-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-fair-value-measurement-inputs-and-valuation-techniques-details",
      "http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable",
      "http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable-details-textual",
      "http://autonomix.com/20250630/role/statement-note-4-commitments-and-contingencies-10q",
      "http://autonomix.com/20250630/role/statement-note-4-commitments-and-contingencies-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-4-equity",
      "http://autonomix.com/20250630/role/statement-note-4-equity-blackscholes-option-pricing-model-details",
      "http://autonomix.com/20250630/role/statement-note-4-equity-details-textual",
      "http://autonomix.com/20250630/role/statement-note-5-commitments-and-contingencies",
      "http://autonomix.com/20250630/role/statement-note-5-commitments-and-contingencies-details-textual",
      "http://autonomix.com/20250630/role/statement-note-6-related-party-transactions",
      "http://autonomix.com/20250630/role/statement-note-6-related-party-transactions-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r165",
      "r204",
      "r205",
      "r206",
      "r207",
      "r285",
      "r316",
      "r317",
      "r318",
      "r334",
      "r407",
      "r463",
      "r489",
      "r491",
      "r503",
      "r518",
      "r519",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r584",
      "r585",
      "r586",
      "r587",
      "r589",
      "r590",
      "r613",
      "r622",
      "r628",
      "r634",
      "r636",
      "r637",
      "r646",
      "r647",
      "r648",
      "r649",
      "r661",
      "r745",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819"
     ]
    },
    "amix_MaximumPercentageOfSharesSoldInThirtyDays": {
     "xbrltype": "percentItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "MaximumPercentageOfSharesSoldInThirtyDays",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-4-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "amix_MaximumPercentageOfSharesSoldInThirtyDays",
        "terseLabel": "Maximum Percentage of Shares Sold in Thirty Days",
        "documentation": "The maximum percentage of shares allowed to be sold within 30 days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputDiscountForLackOfMarketabilityMember",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-2-convertible-notes-payable-10q",
      "http://autonomix.com/20250630/role/statement-note-2-convertible-notes-payable-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable",
      "http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Discount for Lack of Marketability [Member]",
        "documentation": "Measurement input using amount by which value of business ownership interest is reduced to reflect lack of ability to convert business interest into cash quickly."
       }
      }
     },
     "auth_ref": [
      "r646",
      "r796",
      "r797",
      "r798"
     ]
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputDiscountRateMember",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-2-convertible-notes-payable-10q",
      "http://autonomix.com/20250630/role/statement-note-2-convertible-notes-payable-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-fair-value-measurement-inputs-and-valuation-techniques-details",
      "http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable",
      "http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable-details-textual",
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q",
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-4-equity",
      "http://autonomix.com/20250630/role/statement-note-4-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Discount Rate [Member]",
        "documentation": "Measurement input using interest rate to determine present value of future cash flows."
       }
      }
     },
     "auth_ref": [
      "r634",
      "r636",
      "r637",
      "r796",
      "r797",
      "r798"
     ]
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputExpectedTermMember",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-2-convertible-notes-payable-10q",
      "http://autonomix.com/20250630/role/statement-note-2-convertible-notes-payable-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-fair-value-measurement-inputs-and-valuation-techniques-details",
      "http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable",
      "http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable-details-textual",
      "http://autonomix.com/20250630/role/statement-note-4-equity",
      "http://autonomix.com/20250630/role/statement-note-4-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Expected Term [Member]",
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date."
       }
      }
     },
     "auth_ref": [
      "r315",
      "r796",
      "r797",
      "r798"
     ]
    },
    "amix_MeasurementInputFixedPriceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "MeasurementInputFixedPriceMember",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-fair-value-measurement-inputs-and-valuation-techniques-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Fixed Price [Member]",
        "documentation": "Measurement input using fixed payment value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputPriceVolatilityMember",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-2-convertible-notes-payable-10q",
      "http://autonomix.com/20250630/role/statement-note-2-convertible-notes-payable-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable",
      "http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable-details-textual",
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q",
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-4-equity",
      "http://autonomix.com/20250630/role/statement-note-4-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Price Volatility [Member]",
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns."
       }
      }
     },
     "auth_ref": [
      "r316",
      "r646",
      "r796",
      "r797",
      "r798"
     ]
    },
    "amix_MeasurementInputProbabilityRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "MeasurementInputProbabilityRateMember",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments",
      "http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-details-textual",
      "http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-fair-value-measurement-inputs-and-valuation-techniques-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Probability Rate [Member]",
        "documentation": "Measurement input using probability."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-2-convertible-notes-payable-10q",
      "http://autonomix.com/20250630/role/statement-note-2-convertible-notes-payable-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable",
      "http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss."
       }
      }
     },
     "auth_ref": [
      "r318",
      "r796",
      "r797",
      "r798"
     ]
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-2-convertible-notes-payable-10q",
      "http://autonomix.com/20250630/role/statement-note-2-convertible-notes-payable-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments",
      "http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-details-textual",
      "http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-fair-value-measurement-inputs-and-valuation-techniques-details",
      "http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable",
      "http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable-details-textual",
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q",
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-4-equity",
      "http://autonomix.com/20250630/role/statement-note-4-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r405",
      "r406",
      "r407",
      "r634",
      "r636",
      "r637",
      "r646"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-2-convertible-notes-payable-10q",
      "http://autonomix.com/20250630/role/statement-note-2-convertible-notes-payable-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments",
      "http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-details-textual",
      "http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-fair-value-measurement-inputs-and-valuation-techniques-details",
      "http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable",
      "http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable-details-textual",
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q",
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-4-equity",
      "http://autonomix.com/20250630/role/statement-note-4-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Domain]",
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r405",
      "r406",
      "r407",
      "r634",
      "r636",
      "r637",
      "r646"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MinimumMember",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual",
      "http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-fair-value-measurement-inputs-and-valuation-techniques-details",
      "http://autonomix.com/20250630/role/statement-note-4-commitments-and-contingencies-10q",
      "http://autonomix.com/20250630/role/statement-note-4-commitments-and-contingencies-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-4-equity",
      "http://autonomix.com/20250630/role/statement-note-4-equity-blackscholes-option-pricing-model-details",
      "http://autonomix.com/20250630/role/statement-note-4-equity-details-textual",
      "http://autonomix.com/20250630/role/statement-note-5-commitments-and-contingencies",
      "http://autonomix.com/20250630/role/statement-note-5-commitments-and-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r165",
      "r204",
      "r205",
      "r206",
      "r207",
      "r285",
      "r316",
      "r317",
      "r318",
      "r334",
      "r407",
      "r463",
      "r489",
      "r491",
      "r503",
      "r518",
      "r519",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r584",
      "r585",
      "r586",
      "r587",
      "r589",
      "r590",
      "r613",
      "r622",
      "r628",
      "r634",
      "r636",
      "r637",
      "r646",
      "r647",
      "r648",
      "r661",
      "r745",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819"
     ]
    },
    "us-gaap_NatureOfExpenseAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NatureOfExpenseAxis",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual",
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q",
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-4-equity",
      "http://autonomix.com/20250630/role/statement-note-4-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature of Expense [Axis]",
        "documentation": "Information by type of cost or expense."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://autonomix.com/20250630/role/statement-statements-of-cash-flows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      },
      "http://autonomix.com/20250630/role/statement-condensed-statements-of-cash-flows-unaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://autonomix.com/20250630/role/statement-condensed-statements-of-cash-flows-unaudited",
      "http://autonomix.com/20250630/role/statement-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
        "totalLabel": "Net cash provided by financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r120"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-condensed-statements-of-cash-flows-unaudited",
      "http://autonomix.com/20250630/role/statement-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flows from Financing Activities (increase/decrease):"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://autonomix.com/20250630/role/statement-condensed-statements-of-cash-flows-unaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 0.0
      },
      "http://autonomix.com/20250630/role/statement-statements-of-cash-flows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://autonomix.com/20250630/role/statement-condensed-statements-of-cash-flows-unaudited",
      "http://autonomix.com/20250630/role/statement-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
        "totalLabel": "Net cash used in investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r120"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-condensed-statements-of-cash-flows-unaudited",
      "http://autonomix.com/20250630/role/statement-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flows from Investing Activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://autonomix.com/20250630/role/statement-statements-of-cash-flows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 0.0
      },
      "http://autonomix.com/20250630/role/statement-condensed-statements-of-cash-flows-unaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://autonomix.com/20250630/role/statement-condensed-statements-of-cash-flows-unaudited",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual",
      "http://autonomix.com/20250630/role/statement-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
        "terseLabel": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation",
        "totalLabel": "Net cash used in operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r54",
      "r55"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-condensed-statements-of-cash-flows-unaudited",
      "http://autonomix.com/20250630/role/statement-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flows from Operating Activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://autonomix.com/20250630/role/statement-condensed-statements-of-cash-flows-unaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 0.0
      },
      "http://autonomix.com/20250630/role/statement-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      },
      "http://autonomix.com/20250630/role/statement-statements-of-operations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://autonomix.com/20250630/role/statement-condensed-statements-of-operations-unaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://autonomix.com/20250630/role/statement-condensed-statements-of-cash-flows-unaudited",
      "http://autonomix.com/20250630/role/statement-condensed-statements-of-changes-in-stockholders-equity-unaudited",
      "http://autonomix.com/20250630/role/statement-condensed-statements-of-operations-unaudited",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-prior-period-corrections-details",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-schedule-of-prior-period-corrections-10q-details",
      "http://autonomix.com/20250630/role/statement-statements-of-cash-flows",
      "http://autonomix.com/20250630/role/statement-statements-of-changes-in-stockholders-equity",
      "http://autonomix.com/20250630/role/statement-statements-of-operations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net Loss (in thousands)",
        "label": "Net loss",
        "terseLabel": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r55",
      "r83",
      "r99",
      "r103",
      "r110",
      "r111",
      "r115",
      "r122",
      "r124",
      "r125",
      "r129",
      "r135",
      "r139",
      "r140",
      "r142",
      "r143",
      "r144",
      "r148",
      "r149",
      "r153",
      "r188",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r248",
      "r251",
      "r253",
      "r257",
      "r323",
      "r373",
      "r376",
      "r401",
      "r425",
      "r485",
      "r548",
      "r566",
      "r567",
      "r598",
      "r600",
      "r601",
      "r672",
      "r743"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "amix_NoQualifiedOfferingOccurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "NoQualifiedOfferingOccurringMember",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments",
      "http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-details-textual",
      "http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-fair-value-measurement-inputs-and-valuation-techniques-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Qualified Offering Occurring [Member]",
        "documentation": "Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts."
       }
      }
     },
     "auth_ref": []
    },
    "amix_NolGeneratedDuring20172024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "NolGeneratedDuring20172024Member",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-7-income-taxes",
      "http://autonomix.com/20250630/role/statement-note-7-income-taxes-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NOL Generated During 2017-2024 [Member]",
        "documentation": "The NOL generated from 2017 through 2024."
       }
      }
     },
     "auth_ref": []
    },
    "amix_NoncashExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "NoncashExpensesMember",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual",
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q",
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-4-equity",
      "http://autonomix.com/20250630/role/statement-note-4-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-cash Expenses [Member]",
        "documentation": "Represents non-cash expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonmonetaryTransactionTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonmonetaryTransactionTypeAxis",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonmonetary Transaction Type [Axis]",
        "documentation": "Information by nature of the nonmonetary transaction or group of similar transactions, such as a barter or exchange."
       }
      }
     },
     "auth_ref": [
      "r442",
      "r443",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659"
     ]
    },
    "us-gaap_NonmonetaryTransactionTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonmonetaryTransactionTypeDomain",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonmonetary Transaction Type [Domain]",
        "documentation": "Identifies the nature of the nonmonetary transaction or group of similar transactions, such as a barter or exchange."
       }
      }
     },
     "auth_ref": [
      "r442",
      "r443",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659"
     ]
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://autonomix.com/20250630/role/statement-condensed-statements-of-operations-unaudited": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 0.0
      },
      "http://autonomix.com/20250630/role/statement-statements-of-operations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://autonomix.com/20250630/role/statement-condensed-statements-of-operations-unaudited",
      "http://autonomix.com/20250630/role/statement-statements-of-operations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_NonoperatingIncomeExpense",
        "totalLabel": "Total other income (expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-condensed-statements-of-operations-unaudited",
      "http://autonomix.com/20250630/role/statement-statements-of-operations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other income (expense):"
       }
      }
     },
     "auth_ref": []
    },
    "amix_NoteToFinancialStatementDetailsTextual": {
     "xbrltype": "stringItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "NoteToFinancialStatementDetailsTextual",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note To Financial Statement Details Textual"
       }
      }
     },
     "auth_ref": []
    },
    "amix_NotesToFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "NotesToFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes To Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "amix_NumberOfCommonUnitsIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "NumberOfCommonUnitsIssued",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual",
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-4-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "amix_NumberOfCommonUnitsIssued",
        "terseLabel": "Number of Common Units Issued (in shares)",
        "documentation": "The number of common units issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_NumberOfOperatingSegments",
        "terseLabel": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r610",
      "r716"
     ]
    },
    "amix_NumberOfPrefundedUnitsIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "NumberOfPrefundedUnitsIssued",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual",
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-4-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "amix_NumberOfPrefundedUnitsIssued",
        "terseLabel": "Number of Pre-funded Units Issued (in shares)",
        "documentation": "The number of pre-funded units issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_NumberOfReportableSegments",
        "terseLabel": "Number of Reportable Segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r606",
      "r612",
      "r716"
     ]
    },
    "amix_NumberOfSharesPerCommonUnit": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "NumberOfSharesPerCommonUnit",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual",
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-4-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "amix_NumberOfSharesPerCommonUnit",
        "terseLabel": "Number of Shares Per Common Unit (in shares)",
        "documentation": "The number of shares per common unit."
       }
      }
     },
     "auth_ref": []
    },
    "amix_NumberOfWarrantsPerCommonUnit": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "NumberOfWarrantsPerCommonUnit",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual",
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-4-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "amix_NumberOfWarrantsPerCommonUnit",
        "terseLabel": "Number of Warrants Per Common Unit (in shares)",
        "documentation": "The number of warrants per common unit."
       }
      }
     },
     "auth_ref": []
    },
    "amix_NumberOfWarrantsPerPrefundedUnit": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "NumberOfWarrantsPerPrefundedUnit",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual",
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-4-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "amix_NumberOfWarrantsPerPrefundedUnit",
        "terseLabel": "Number of Warrants Per Pre-funded Unit (in shares)",
        "documentation": "The number of warrants per pre-funded unit."
       }
      }
     },
     "auth_ref": []
    },
    "amix_OfferingCostsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "OfferingCostsPolicyPolicyTextBlock",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Costs, Policy [Policy Text Block]",
        "documentation": "In reference to offering costs in the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingCostsAndExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingCostsAndExpensesAbstract",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-condensed-statements-of-operations-unaudited",
      "http://autonomix.com/20250630/role/statement-statements-of-operations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://autonomix.com/20250630/role/statement-statements-of-operations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 0.0
      },
      "http://autonomix.com/20250630/role/statement-condensed-statements-of-operations-unaudited": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://autonomix.com/20250630/role/statement-condensed-statements-of-operations-unaudited",
      "http://autonomix.com/20250630/role/statement-statements-of-operations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_OperatingExpenses",
        "totalLabel": "Total operating expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r601"
     ]
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://autonomix.com/20250630/role/statement-statements-of-operations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 0.0
      },
      "http://autonomix.com/20250630/role/statement-condensed-statements-of-operations-unaudited": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://autonomix.com/20250630/role/statement-condensed-statements-of-operations-unaudited",
      "http://autonomix.com/20250630/role/statement-statements-of-operations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_OperatingIncomeLoss",
        "totalLabel": "Loss from operations",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r598",
      "r601",
      "r605",
      "r715",
      "r717",
      "r718",
      "r719",
      "r720"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-7-income-taxes-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_OperatingLossCarryforwards",
        "terseLabel": "Operating Loss Carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r360"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r681",
      "r699"
     ]
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://autonomix.com/20250630/role/statement-condensed-balance-sheets-unaudited-": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 0.0
      },
      "http://autonomix.com/20250630/role/statement-balance-sheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://autonomix.com/20250630/role/statement-balance-sheets",
      "http://autonomix.com/20250630/role/statement-condensed-balance-sheets-unaudited-"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other current assets",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r660"
     ]
    },
    "us-gaap_OverAllotmentOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OverAllotmentOptionMember",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual",
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q",
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-4-equity",
      "http://autonomix.com/20250630/role/statement-note-4-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Over-Allotment Option [Member]",
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment."
       }
      }
     },
     "auth_ref": []
    },
    "amix_PaymentsForInitialPublicOfferingIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "PaymentsForInitialPublicOfferingIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://autonomix.com/20250630/role/statement-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual",
      "http://autonomix.com/20250630/role/statement-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "amix_PaymentsForInitialPublicOfferingIssuanceCosts",
        "terseLabel": "Payments for Initial Public Offering Issuance Costs",
        "negatedLabel": "Payment of issuance costs for IPO",
        "documentation": "Represents the payments for the issuance costs from an initial public offering."
       }
      }
     },
     "auth_ref": []
    },
    "amix_PaymentsForWarrantIssuanceFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "PaymentsForWarrantIssuanceFees",
     "crdr": "credit",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-6-subsequent-events-10q-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "amix_PaymentsForWarrantIssuanceFees",
        "terseLabel": "Payments for Warrant Issuance Fees",
        "documentation": "The cash outflow for the payment of warrant issuance fees."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsOfFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsOfFinancingCosts",
     "crdr": "credit",
     "calculation": {
      "http://autonomix.com/20250630/role/statement-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual",
      "http://autonomix.com/20250630/role/statement-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_PaymentsOfFinancingCosts",
        "terseLabel": "Payments of Financing Costs",
        "negatedLabel": "Payment of issuance costs for financing",
        "documentation": "The cash outflow for loan and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://autonomix.com/20250630/role/statement-condensed-statements-of-cash-flows-unaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 1.0
      },
      "http://autonomix.com/20250630/role/statement-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://autonomix.com/20250630/role/statement-condensed-statements-of-cash-flows-unaudited",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual",
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-4-equity-details-textual",
      "http://autonomix.com/20250630/role/statement-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_PaymentsOfStockIssuanceCosts",
        "terseLabel": "Payments of Stock Issuance Costs",
        "negatedLabel": "Payment of issuance costs for registration statement",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://autonomix.com/20250630/role/statement-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 0.0
      },
      "http://autonomix.com/20250630/role/statement-condensed-statements-of-cash-flows-unaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://autonomix.com/20250630/role/statement-condensed-statements-of-cash-flows-unaudited",
      "http://autonomix.com/20250630/role/statement-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment",
        "negatedLabel": "Purchase of property and equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_PendingLitigationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PendingLitigationMember",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-4-commitments-and-contingencies-10q",
      "http://autonomix.com/20250630/role/statement-note-4-commitments-and-contingencies-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-5-commitments-and-contingencies",
      "http://autonomix.com/20250630/role/statement-note-5-commitments-and-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pending Litigation [Member]",
        "documentation": "Risk of loss associated with the outcome of pending litigation against the entity, for example, but not limited to, litigation in arbitration or within the trial process."
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "us-gaap_PercentageOfFIFOInventory": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PercentageOfFIFOInventory",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-fair-value-measurement-inputs-and-valuation-techniques-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discount rate at issuance (1)",
        "documentation": "The percentage of FIFO (first in first out) inventory to total inventory as of the balance sheet date if other than 100 percent."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q",
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-4-equity",
      "http://autonomix.com/20250630/role/statement-note-4-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q",
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-4-equity",
      "http://autonomix.com/20250630/role/statement-note-4-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776"
     ]
    },
    "us-gaap_PolicyTextBlockAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PolicyTextBlockAbstract",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_PolicyTextBlockAbstract",
        "terseLabel": "Accounting Policies"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-balance-sheets-parentheticals",
      "http://autonomix.com/20250630/role/statement-condensed-balance-sheets-unaudited-parentheticals",
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-4-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, par value (in dollars per share)",
        "terseLabel": "Preferred Stock, Par or Stated Value Per Share (in dollars per share)",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r259"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-balance-sheets-parentheticals",
      "http://autonomix.com/20250630/role/statement-condensed-balance-sheets-unaudited-parentheticals",
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-4-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, authorized (in shares)",
        "terseLabel": "Preferred Stock, Shares Authorized (in shares)",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r528"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-balance-sheets-parentheticals",
      "http://autonomix.com/20250630/role/statement-condensed-balance-sheets-unaudited-parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, issued (in shares)",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r259"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-balance-sheets-parentheticals",
      "http://autonomix.com/20250630/role/statement-condensed-balance-sheets-unaudited-parentheticals",
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-4-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, outstanding (in shares)",
        "terseLabel": "Preferred Stock, Shares Outstanding (in shares)",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r528",
      "r547",
      "r830",
      "r831"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://autonomix.com/20250630/role/statement-balance-sheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      },
      "http://autonomix.com/20250630/role/statement-condensed-balance-sheets-unaudited-": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://autonomix.com/20250630/role/statement-balance-sheets",
      "http://autonomix.com/20250630/role/statement-condensed-balance-sheets-unaudited-"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, $0.001 par value, 10,000,000 shares authorized, no shares issued and outstanding as of March 31, 2025 and March 31, 2024, respectively.",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r250",
      "r255",
      "r477",
      "r660"
     ]
    },
    "amix_PrefundedAndSeriesAWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "PrefundedAndSeriesAWarrantsMember",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-funded and Series A Warrants [Member]",
        "documentation": "Represents pre-funded and Series A warrants."
       }
      }
     },
     "auth_ref": []
    },
    "amix_PrefundedUnitsIssuedPurchasePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "PrefundedUnitsIssuedPurchasePrice",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual",
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-4-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "amix_PrefundedUnitsIssuedPurchasePrice",
        "terseLabel": "Pre-funded Units Issued, Purchase Price (in dollars per share)",
        "documentation": "Per share or per unit price of pre-funded units issued."
       }
      }
     },
     "auth_ref": []
    },
    "amix_PrefundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "PrefundedWarrantsMember",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual",
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q",
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-4-equity",
      "http://autonomix.com/20250630/role/statement-note-4-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-funded Warrants [Member]",
        "documentation": "Represents the pre-funded warrants."
       }
      }
     },
     "auth_ref": []
    },
    "amix_PreipoWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "PreipoWarrantsMember",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-6-subsequent-events-10q",
      "http://autonomix.com/20250630/role/statement-note-6-subsequent-events-10q-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-IPO Warrants [Member]",
        "documentation": "Pre-IPO warrants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-condensed-statements-of-cash-flows-unaudited",
      "http://autonomix.com/20250630/role/statement-note-4-equity",
      "http://autonomix.com/20250630/role/statement-note-4-equity-details-textual",
      "http://autonomix.com/20250630/role/statement-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement [Member]",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromConvertibleDebt",
     "crdr": "debit",
     "calculation": {
      "http://autonomix.com/20250630/role/statement-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-2-convertible-notes-payable-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable-details-textual",
      "http://autonomix.com/20250630/role/statement-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of convertible debt",
        "terseLabel": "Proceeds from Convertible Debt",
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "crdr": "debit",
     "calculation": {
      "http://autonomix.com/20250630/role/statement-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://autonomix.com/20250630/role/statement-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock from IPO",
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://autonomix.com/20250630/role/statement-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 0.0
      },
      "http://autonomix.com/20250630/role/statement-condensed-statements-of-cash-flows-unaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://autonomix.com/20250630/role/statement-condensed-statements-of-cash-flows-unaudited",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual",
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-4-equity-details-textual",
      "http://autonomix.com/20250630/role/statement-note-8-subsequent-events-details-textual",
      "http://autonomix.com/20250630/role/statement-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Proceeds from issuance of common stock",
        "label": "Proceeds from issuance of common stock",
        "terseLabel": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "amix_ProceedsFromIssuanceOfCommonStockAndWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "ProceedsFromIssuanceOfCommonStockAndWarrants",
     "crdr": "debit",
     "calculation": {
      "http://autonomix.com/20250630/role/statement-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://autonomix.com/20250630/role/statement-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock, pre-funded and common warrants",
        "documentation": "The cash inflow from the additional capital contribution to the entity and issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfDebt",
     "crdr": "debit",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-6-related-party-transactions-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ProceedsFromIssuanceOfDebt",
        "terseLabel": "Proceeds from Issuance of Debt",
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt."
       }
      }
     },
     "auth_ref": [
      "r697"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfWarrants",
     "crdr": "debit",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-6-subsequent-events-10q-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ProceedsFromIssuanceOfWarrants",
        "terseLabel": "Proceeds from Issuance of Warrants",
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "crdr": "debit",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual",
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-4-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ProceedsFromIssuanceOrSaleOfEquity",
        "terseLabel": "Proceeds from Issuance or Sale of Equity",
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r508"
     ]
    },
    "amix_ProceedsFromIssuanceOrSaleOfEquityNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "ProceedsFromIssuanceOrSaleOfEquityNet",
     "crdr": "debit",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "amix_ProceedsFromIssuanceOrSaleOfEquityNet",
        "terseLabel": "Proceeds from Issuance or Sale of Equity, Net",
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "calculation": {
      "http://autonomix.com/20250630/role/statement-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://autonomix.com/20250630/role/statement-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from exercise of warrants",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r696"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://autonomix.com/20250630/role/statement-condensed-balance-sheets-unaudited-": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 0.0
      },
      "http://autonomix.com/20250630/role/statement-balance-sheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://autonomix.com/20250630/role/statement-balance-sheets",
      "http://autonomix.com/20250630/role/statement-condensed-balance-sheets-unaudited-"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fixed assets, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r441",
      "r470",
      "r483",
      "r660"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r93",
      "r94",
      "r482"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_PropertyPlantAndEquipmentUsefulLife",
        "terseLabel": "Property, Plant and Equipment, Useful Life (Year)",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "amix_QualifiedOfferingOccurringOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "QualifiedOfferingOccurringOneMember",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments",
      "http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-details-textual",
      "http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-fair-value-measurement-inputs-and-valuation-techniques-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Qualified Offering Occurring, One [Member]",
        "documentation": "Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts."
       }
      }
     },
     "auth_ref": []
    },
    "amix_QualifiedOfferingOccurringTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "QualifiedOfferingOccurringTwoMember",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments",
      "http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-details-textual",
      "http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-fair-value-measurement-inputs-and-valuation-techniques-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Qualified Offering Occurring, Two [Member]",
        "documentation": "Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts."
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeAxis",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual",
      "http://autonomix.com/20250630/role/statement-note-2-convertible-notes-payable-10q",
      "http://autonomix.com/20250630/role/statement-note-2-convertible-notes-payable-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-fair-value-measurement-inputs-and-valuation-techniques-details",
      "http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable",
      "http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable-details-textual",
      "http://autonomix.com/20250630/role/statement-note-4-commitments-and-contingencies-10q",
      "http://autonomix.com/20250630/role/statement-note-4-commitments-and-contingencies-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-4-equity",
      "http://autonomix.com/20250630/role/statement-note-4-equity-blackscholes-option-pricing-model-details",
      "http://autonomix.com/20250630/role/statement-note-4-equity-details-textual",
      "http://autonomix.com/20250630/role/statement-note-5-commitments-and-contingencies",
      "http://autonomix.com/20250630/role/statement-note-5-commitments-and-contingencies-details-textual",
      "http://autonomix.com/20250630/role/statement-note-6-related-party-transactions",
      "http://autonomix.com/20250630/role/statement-note-6-related-party-transactions-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r165",
      "r204",
      "r205",
      "r206",
      "r207",
      "r274",
      "r285",
      "r316",
      "r317",
      "r318",
      "r322",
      "r334",
      "r407",
      "r460",
      "r461",
      "r463",
      "r489",
      "r491",
      "r503",
      "r518",
      "r519",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r584",
      "r585",
      "r586",
      "r587",
      "r589",
      "r590",
      "r613",
      "r622",
      "r628",
      "r634",
      "r636",
      "r637",
      "r646",
      "r647",
      "r648",
      "r649",
      "r661",
      "r666",
      "r738",
      "r745",
      "r797",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeMember",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual",
      "http://autonomix.com/20250630/role/statement-note-2-convertible-notes-payable-10q",
      "http://autonomix.com/20250630/role/statement-note-2-convertible-notes-payable-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-fair-value-measurement-inputs-and-valuation-techniques-details",
      "http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable",
      "http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable-details-textual",
      "http://autonomix.com/20250630/role/statement-note-4-commitments-and-contingencies-10q",
      "http://autonomix.com/20250630/role/statement-note-4-commitments-and-contingencies-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-4-equity",
      "http://autonomix.com/20250630/role/statement-note-4-equity-blackscholes-option-pricing-model-details",
      "http://autonomix.com/20250630/role/statement-note-4-equity-details-textual",
      "http://autonomix.com/20250630/role/statement-note-5-commitments-and-contingencies",
      "http://autonomix.com/20250630/role/statement-note-5-commitments-and-contingencies-details-textual",
      "http://autonomix.com/20250630/role/statement-note-6-related-party-transactions",
      "http://autonomix.com/20250630/role/statement-note-6-related-party-transactions-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r165",
      "r204",
      "r205",
      "r206",
      "r207",
      "r274",
      "r285",
      "r316",
      "r317",
      "r318",
      "r322",
      "r334",
      "r407",
      "r460",
      "r461",
      "r463",
      "r489",
      "r491",
      "r503",
      "r518",
      "r519",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r584",
      "r585",
      "r586",
      "r587",
      "r589",
      "r590",
      "r613",
      "r622",
      "r628",
      "r634",
      "r636",
      "r637",
      "r646",
      "r647",
      "r648",
      "r649",
      "r661",
      "r666",
      "r738",
      "r745",
      "r797",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-6-related-party-transactions",
      "http://autonomix.com/20250630/role/statement-note-6-related-party-transactions-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Domain]",
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r128",
      "r129",
      "r187",
      "r281",
      "r284",
      "r449",
      "r450",
      "r474",
      "r481",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r546",
      "r576",
      "r828"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-6-related-party-transactions",
      "http://autonomix.com/20250630/role/statement-note-6-related-party-transactions-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party [Member]",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r128",
      "r129",
      "r449",
      "r450",
      "r451",
      "r452",
      "r474",
      "r481",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r546",
      "r576"
     ]
    },
    "us-gaap_RelatedPartyTransactionAmountsOfTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionAmountsOfTransaction",
     "crdr": "debit",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-6-related-party-transactions-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_RelatedPartyTransactionAmountsOfTransaction",
        "terseLabel": "Related Party Transaction, Amounts of Transaction",
        "documentation": "Amount of transactions with related party during the financial reporting period."
       }
      }
     },
     "auth_ref": [
      "r449"
     ]
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionAxis",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments",
      "http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-details-textual",
      "http://autonomix.com/20250630/role/statement-note-5-related-party-transactions-10q",
      "http://autonomix.com/20250630/role/statement-note-5-related-party-transactions-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-6-related-party-transactions",
      "http://autonomix.com/20250630/role/statement-note-6-related-party-transactions-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Axis]",
        "documentation": "Information by type of related party transaction."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r128",
      "r129",
      "r449",
      "r450",
      "r811"
     ]
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionDomain",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments",
      "http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-details-textual",
      "http://autonomix.com/20250630/role/statement-note-5-related-party-transactions-10q",
      "http://autonomix.com/20250630/role/statement-note-5-related-party-transactions-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-6-related-party-transactions",
      "http://autonomix.com/20250630/role/statement-note-6-related-party-transactions-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Domain]",
        "documentation": "Transaction between related party."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r128",
      "r129",
      "r811"
     ]
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-6-related-party-transactions",
      "http://autonomix.com/20250630/role/statement-note-6-related-party-transactions-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r128",
      "r129",
      "r187",
      "r281",
      "r284",
      "r449",
      "r450",
      "r474",
      "r481",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r546",
      "r576",
      "r811",
      "r828"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-5-related-party-transactions-10q",
      "http://autonomix.com/20250630/role/statement-note-6-related-party-transactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions Disclosure [Text Block]",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r446",
      "r447",
      "r448",
      "r450",
      "r453",
      "r511",
      "r512",
      "r513",
      "r551",
      "r552",
      "r553",
      "r573",
      "r575"
     ]
    },
    "amix_RelatedPartyTransactionsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "RelatedPartyTransactionsPolicyPolicyTextBlock",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for related party transactions."
       }
      }
     },
     "auth_ref": []
    },
    "amix_RepresentativesWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "RepresentativesWarrantsMember",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-antidilutive-securities-details",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-10q-details",
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q",
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-4-equity",
      "http://autonomix.com/20250630/role/statement-note-4-equity-details-textual",
      "http://autonomix.com/20250630/role/statement-note-6-subsequent-events-10q",
      "http://autonomix.com/20250630/role/statement-note-6-subsequent-events-10q-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Representative's Warrants [Member]",
        "documentation": "Represents Representative's Warrants."
       }
      }
     },
     "auth_ref": []
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual",
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q",
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-4-equity",
      "http://autonomix.com/20250630/role/statement-note-4-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r122",
      "r130",
      "r131",
      "r223",
      "r261",
      "r452",
      "r462",
      "r472",
      "r594",
      "r595",
      "r596",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r788",
      "r789",
      "r790",
      "r791"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://autonomix.com/20250630/role/statement-statements-of-operations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 0.0
      },
      "http://autonomix.com/20250630/role/statement-condensed-statements-of-operations-unaudited": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://autonomix.com/20250630/role/statement-condensed-statements-of-operations-unaudited",
      "http://autonomix.com/20250630/role/statement-statements-of-operations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r337",
      "r591",
      "r598",
      "r599",
      "r609",
      "r820"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q",
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-4-equity",
      "http://autonomix.com/20250630/role/statement-note-4-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r336"
     ]
    },
    "amix_ReserveForUncertainTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "ReserveForUncertainTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-7-income-taxes-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "amix_ReserveForUncertainTaxPositions",
        "terseLabel": "Reserve for Uncertain Tax Positions",
        "documentation": "The amount of money reserved for uncertain tax positions."
       }
      }
     },
     "auth_ref": []
    },
    "srt_RestatementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RestatementAxis",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-prior-period-corrections-details",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-schedule-of-prior-period-corrections-10q-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Axis]"
       }
      }
     },
     "auth_ref": [
      "r97",
      "r98",
      "r99",
      "r100",
      "r118",
      "r132",
      "r133",
      "r134",
      "r135",
      "r136",
      "r139",
      "r140",
      "r141",
      "r142",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r159",
      "r190",
      "r191",
      "r247",
      "r248",
      "r323",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r398",
      "r399",
      "r400",
      "r401",
      "r439",
      "r444",
      "r445",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r505",
      "r721"
     ]
    },
    "srt_RestatementDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RestatementDomain",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-prior-period-corrections-details",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-schedule-of-prior-period-corrections-10q-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Domain]"
       }
      }
     },
     "auth_ref": [
      "r97",
      "r98",
      "r99",
      "r100",
      "r118",
      "r132",
      "r133",
      "r134",
      "r135",
      "r136",
      "r139",
      "r140",
      "r141",
      "r142",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r159",
      "r190",
      "r191",
      "r247",
      "r248",
      "r323",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r398",
      "r399",
      "r400",
      "r401",
      "r439",
      "r444",
      "r445",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r505",
      "r721"
     ]
    },
    "amix_RestrictedStockExpensesGeneralAndAdministrativeTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "RestrictedStockExpensesGeneralAndAdministrativeTableTextBlock",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q-tables",
      "http://autonomix.com/20250630/role/statement-note-4-equity-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Expenses, General and Administrative [Table Text Block]",
        "documentation": "Tabular disclosure of the general and administrative costs for restricted stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedStockMember",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q",
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-3-equity-general-and-administrative-expense-10q-details",
      "http://autonomix.com/20250630/role/statement-note-4-equity",
      "http://autonomix.com/20250630/role/statement-note-4-equity-details-textual",
      "http://autonomix.com/20250630/role/statement-note-4-equity-general-and-administrative-expense-details",
      "http://autonomix.com/20250630/role/statement-note-4-equity-restricted-stock-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock [Member]",
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r714",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://autonomix.com/20250630/role/statement-balance-sheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      },
      "http://autonomix.com/20250630/role/statement-condensed-balance-sheets-unaudited-": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://autonomix.com/20250630/role/statement-balance-sheets",
      "http://autonomix.com/20250630/role/statement-condensed-balance-sheets-unaudited-",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated deficit",
        "terseLabel": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r64",
      "r479",
      "r497",
      "r502",
      "r509",
      "r529",
      "r660"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-condensed-statements-of-changes-in-stockholders-equity-unaudited",
      "http://autonomix.com/20250630/role/statement-statements-of-changes-in-stockholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r98",
      "r99",
      "r132",
      "r133",
      "r134",
      "r136",
      "r144",
      "r147",
      "r149",
      "r189",
      "r192",
      "r193",
      "r247",
      "r323",
      "r362",
      "r363",
      "r370",
      "r371",
      "r372",
      "r374",
      "r375",
      "r376",
      "r387",
      "r389",
      "r390",
      "r392",
      "r399",
      "r438",
      "r440",
      "r493",
      "r495",
      "r514",
      "r830"
     ]
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Revenues",
     "crdr": "credit",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_Revenues",
        "terseLabel": "Revenues",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r85",
      "r116",
      "r122",
      "r124",
      "r125",
      "r160",
      "r167",
      "r168",
      "r180",
      "r182",
      "r184",
      "r185",
      "r186",
      "r188",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r425",
      "r467",
      "r469",
      "r609",
      "r639",
      "r662",
      "r663",
      "r743"
     ]
    },
    "amix_ReverseStockSplitAdjustmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "ReverseStockSplitAdjustmentMember",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-prior-period-corrections-details",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-schedule-of-prior-period-corrections-10q-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reverse Stock Split Adjustment [Member]",
        "documentation": "Represents the reverse stock split adjustment."
       }
      }
     },
     "auth_ref": []
    },
    "amix_ReverseStockSplitMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "ReverseStockSplitMember",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reverse Stock Split [Member]",
        "documentation": "Represents reverse stock split."
       }
      }
     },
     "auth_ref": []
    },
    "amix_ReverseStockSplitPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "ReverseStockSplitPolicyTextBlock",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reverse Stock Split [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for reverse stock split."
       }
      }
     },
     "auth_ref": []
    },
    "srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RevisionOfPriorPeriodErrorCorrectionAdjustmentMember",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-prior-period-corrections-details",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-schedule-of-prior-period-corrections-10q-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period, Error Correction, Adjustment [Member]"
       }
      }
     },
     "auth_ref": [
      "r139",
      "r140",
      "r141",
      "r146",
      "r147",
      "r148",
      "r149"
     ]
    },
    "amix_RfInnovationsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "RfInnovationsIncMember",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q",
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-4-equity",
      "http://autonomix.com/20250630/role/statement-note-4-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "RF Innovations, Inc. [Member]",
        "documentation": "Represents information pertaining to RF Innovations, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-condensed-statements-of-cash-flows-unaudited",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual",
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q",
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-4-equity",
      "http://autonomix.com/20250630/role/statement-note-4-equity-details-textual",
      "http://autonomix.com/20250630/role/statement-note-8-subsequent-events",
      "http://autonomix.com/20250630/role/statement-note-8-subsequent-events-details-textual",
      "http://autonomix.com/20250630/role/statement-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "amix_ScenarioContractTerminationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "ScenarioContractTerminationMember",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-5-commitments-and-contingencies",
      "http://autonomix.com/20250630/role/statement-note-5-commitments-and-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario, Contract Termination [Member]",
        "documentation": "Information pertaining to the termination of the employment contract."
       }
      }
     },
     "auth_ref": []
    },
    "amix_ScenarioContractTerminationWithoutCauseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "ScenarioContractTerminationWithoutCauseMember",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-5-commitments-and-contingencies",
      "http://autonomix.com/20250630/role/statement-note-5-commitments-and-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario, Contract Termination, Without Cause [Member]",
        "documentation": "Information pertaining to contract termination."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScenarioPreviouslyReportedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ScenarioPreviouslyReportedMember",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-prior-period-corrections-details",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-schedule-of-prior-period-corrections-10q-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Previously Reported [Member]"
       }
      }
     },
     "auth_ref": [
      "r97",
      "r98",
      "r99",
      "r132",
      "r134",
      "r135",
      "r136",
      "r139",
      "r140",
      "r149",
      "r159",
      "r247",
      "r248",
      "r323",
      "r371",
      "r373",
      "r374",
      "r375",
      "r376",
      "r398",
      "r399",
      "r400",
      "r439",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r505",
      "r678",
      "r679",
      "r680",
      "r711",
      "r712",
      "r721",
      "r724",
      "r725",
      "r793",
      "r808",
      "r809"
     ]
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments",
      "http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-details-textual",
      "http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-fair-value-measurement-inputs-and-valuation-techniques-details",
      "http://autonomix.com/20250630/role/statement-note-5-commitments-and-contingencies",
      "http://autonomix.com/20250630/role/statement-note-5-commitments-and-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]"
       }
      }
     },
     "auth_ref": [
      "r101",
      "r102",
      "r150",
      "r286",
      "r676"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q-tables",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-7-income-taxes-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r783"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-7-income-taxes-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r344",
      "r633",
      "r780"
     ]
    },
    "us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q-tables",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Error Corrections and Prior Period Adjustments [Table Text Block]",
        "documentation": "Tabular disclosure of prior period adjustments to previously issued financial statements including (1) the effect of the correction on each financial statement line item and any per-share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustments (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r21",
      "r22"
     ]
    },
    "us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfOtherShareBasedCompensationActivityTableTextBlock",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q-tables",
      "http://autonomix.com/20250630/role/statement-note-4-equity-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Outstanding Award, Activity, Excluding Option [Table Text Block]",
        "documentation": "Tabular disclosure of activity for outstanding award under share-based payment arrangement excluding share and unit options and nonvested award."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q-tables",
      "http://autonomix.com/20250630/role/statement-note-4-equity-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r11",
      "r66"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-4-equity-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-4-equity-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]",
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": [
      "r761"
     ]
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-2-convertible-notes-payable-10q-tables",
      "http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r747"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r183",
      "r185",
      "r607",
      "r608",
      "r611"
     ]
    },
    "amix_SellingAgentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "SellingAgentMember",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling Agent [Member]",
        "documentation": "Refers to the selling agent."
       }
      }
     },
     "auth_ref": []
    },
    "amix_SeriesAWarrantsAndTheRepresentativesWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "SeriesAWarrantsAndTheRepresentativesWarrantsMember",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q",
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-4-equity",
      "http://autonomix.com/20250630/role/statement-note-4-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A Warrants and the Representative's Warrants [Member]",
        "documentation": "Represents the Series A Warrants and the Representative's Warrants."
       }
      }
     },
     "auth_ref": []
    },
    "amix_SeriesAWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "SeriesAWarrantsMember",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-antidilutive-securities-details",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-10q-details",
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q",
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-4-equity",
      "http://autonomix.com/20250630/role/statement-note-4-equity-details-textual",
      "http://autonomix.com/20250630/role/statement-note-6-subsequent-events-10q",
      "http://autonomix.com/20250630/role/statement-note-6-subsequent-events-10q-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A Warrants [Member]",
        "documentation": "Represents Series A Warrants."
       }
      }
     },
     "auth_ref": []
    },
    "amix_SeriesBWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "SeriesBWarrantsMember",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-6-subsequent-events-10q",
      "http://autonomix.com/20250630/role/statement-note-6-subsequent-events-10q-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series B Warrants [Member]",
        "documentation": "Represents the series B warrants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://autonomix.com/20250630/role/statement-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 0.0
      },
      "http://autonomix.com/20250630/role/statement-condensed-statements-of-cash-flows-unaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://autonomix.com/20250630/role/statement-condensed-statements-of-cash-flows-unaudited",
      "http://autonomix.com/20250630/role/statement-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensation",
        "terseLabel": "Stock-based compensation",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-4-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Month)",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r629"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-4-equity-restricted-stock-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Granted, unvested restricted stock units, shares (in shares)",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r306"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-4-equity-restricted-stock-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Granted, unvested restricted stock units, weighted average grant date fair value (in dollars per share)",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r306"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-4-equity-restricted-stock-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
        "periodStartLabel": "Balance, unvested restricted stock units, shares (in shares)",
        "periodEndLabel": "Balance, unvested restricted stock units, shares (in shares)",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r303",
      "r304"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-4-equity-restricted-stock-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
        "periodStartLabel": "Balance, unvested restricted stock units, weighted average grant date fair value (in dollars per share)",
        "periodEndLabel": "Balance, unvested restricted stock units, weighted average grant date fair value (in dollars per share)",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r303",
      "r304"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-4-equity-schedule-of-equitybased-stock-warrants-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding, warrants, weighted average remaining contractual term (Year)",
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-4-equity-restricted-stock-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
        "negatedLabel": "Vested restricted stock units, shares (in shares)",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r307"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-4-equity-restricted-stock-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vested restricted stock units, weighted average grant date fair value (in dollars per share)",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r307"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-4-equity-blackscholes-option-pricing-model-details",
      "http://autonomix.com/20250630/role/statement-note-4-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r316"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-3-equity-schedule-of-equitybased-stock-warrants-10q-details",
      "http://autonomix.com/20250630/role/statement-note-4-equity-schedule-of-equitybased-stock-warrants-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
        "negatedLabel": "Exercised, warrants (in shares)",
        "documentation": "Number of non-option equity instruments exercised by participants."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-3-equity-schedule-of-equitybased-stock-warrants-10q-details",
      "http://autonomix.com/20250630/role/statement-note-4-equity-schedule-of-equitybased-stock-warrants-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations",
        "negatedLabel": "Expired, warrants (in shares)",
        "documentation": "Number of shares under non-option equity instrument agreements for which rights to exercise lapsed."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-3-equity-schedule-of-equitybased-stock-warrants-10q-details",
      "http://autonomix.com/20250630/role/statement-note-4-equity-schedule-of-equitybased-stock-warrants-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures",
        "negatedLabel": "Forfeited/Cancelled, warrants (in shares)",
        "documentation": "Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-3-equity-schedule-of-equitybased-stock-warrants-10q-details",
      "http://autonomix.com/20250630/role/statement-note-4-equity-schedule-of-equitybased-stock-warrants-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Granted, warrants (in shares)",
        "documentation": "Net number of non-option equity instruments granted to participants."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-3-equity-schedule-of-equitybased-stock-warrants-10q-details",
      "http://autonomix.com/20250630/role/statement-note-4-equity-schedule-of-equitybased-stock-warrants-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
        "periodStartLabel": "Outstanding, warrants (in shares)",
        "periodEndLabel": "Outstanding, warrants (in shares)",
        "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r68"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-4-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares)",
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r779"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-4-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r631"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-4-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-3-equity-schedule-of-stock-option-activity-10q-details",
      "http://autonomix.com/20250630/role/statement-note-4-equity-schedule-of-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercisable, options (in shares)",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r297"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-3-equity-schedule-of-stock-option-activity-10q-details",
      "http://autonomix.com/20250630/role/statement-note-4-equity-schedule-of-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercisable, options, weighted average exercise price (in dollars per share)",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r297"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-3-equity-schedule-of-stock-option-activity-10q-details",
      "http://autonomix.com/20250630/role/statement-note-4-equity-schedule-of-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
        "negatedLabel": "Expired, options (in shares)",
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements."
       }
      }
     },
     "auth_ref": [
      "r302"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-3-equity-schedule-of-stock-option-activity-10q-details",
      "http://autonomix.com/20250630/role/statement-note-4-equity-schedule-of-stock-option-activity-details",
      "http://autonomix.com/20250630/role/statement-note-6-subsequent-events-10q-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period (in shares)",
        "negatedLabel": "Forfeited/Cancelled, options (in shares)",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r301"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-3-equity-schedule-of-stock-option-activity-10q-details",
      "http://autonomix.com/20250630/role/statement-note-4-equity-details-textual",
      "http://autonomix.com/20250630/role/statement-note-4-equity-schedule-of-stock-option-activity-details",
      "http://autonomix.com/20250630/role/statement-note-5-commitments-and-contingencies-details-textual",
      "http://autonomix.com/20250630/role/statement-note-8-subsequent-events-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Granted, options (in shares)",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r299"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-4-equity-schedule-of-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding, aggregate intrinsic value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-3-equity-schedule-of-stock-option-activity-10q-details",
      "http://autonomix.com/20250630/role/statement-note-4-equity-schedule-of-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
        "periodStartLabel": "Outstanding, options (in shares)",
        "periodEndLabel": "Outstanding, options (in shares)",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r295",
      "r296"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-3-equity-schedule-of-stock-option-activity-10q-details",
      "http://autonomix.com/20250630/role/statement-note-4-equity-schedule-of-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
        "periodStartLabel": "Outstanding, options, weighted average exercise price (in dollars per share)",
        "periodEndLabel": "Outstanding, options, weighted average exercise price (in dollars per share)",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r295",
      "r296"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-4-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum",
        "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock."
       }
      }
     },
     "auth_ref": [
      "r779"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q",
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-3-equity-general-and-administrative-expense-10q-details",
      "http://autonomix.com/20250630/role/statement-note-4-equity",
      "http://autonomix.com/20250630/role/statement-note-4-equity-blackscholes-option-pricing-model-details",
      "http://autonomix.com/20250630/role/statement-note-4-equity-details-textual",
      "http://autonomix.com/20250630/role/statement-note-4-equity-general-and-administrative-expense-details",
      "http://autonomix.com/20250630/role/statement-note-4-equity-restricted-stock-activity-details",
      "http://autonomix.com/20250630/role/statement-note-5-commitments-and-contingencies",
      "http://autonomix.com/20250630/role/statement-note-5-commitments-and-contingencies-details-textual",
      "http://autonomix.com/20250630/role/statement-note-8-subsequent-events",
      "http://autonomix.com/20250630/role/statement-note-8-subsequent-events-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r291",
      "r292",
      "r293",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-3-equity-schedule-of-stock-option-activity-10q-details",
      "http://autonomix.com/20250630/role/statement-note-4-equity-schedule-of-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercised, options, weighted average exercise price (in dollars per share)",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r300"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-3-equity-schedule-of-stock-option-activity-10q-details",
      "http://autonomix.com/20250630/role/statement-note-4-equity-schedule-of-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expired, options, weighted average exercise price (in dollars per share)",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired."
       }
      }
     },
     "auth_ref": [
      "r302"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-3-equity-schedule-of-stock-option-activity-10q-details",
      "http://autonomix.com/20250630/role/statement-note-4-equity-schedule-of-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forfeited/Cancelled, options, weighted average exercise price (in dollars per share)",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r301"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-3-equity-schedule-of-stock-option-activity-10q-details",
      "http://autonomix.com/20250630/role/statement-note-4-equity-schedule-of-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Granted, options, weighted average exercise price (in dollars per share)",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r299"
     ]
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-5-commitments-and-contingencies",
      "http://autonomix.com/20250630/role/statement-note-5-commitments-and-contingencies-details-textual",
      "http://autonomix.com/20250630/role/statement-note-8-subsequent-events",
      "http://autonomix.com/20250630/role/statement-note-8-subsequent-events-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Tranche One [Member]",
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": [
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r287",
      "r294",
      "r313",
      "r314",
      "r315",
      "r316",
      "r319",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332"
     ]
    },
    "us-gaap_ShareBasedPaymentArrangementEmployeeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedPaymentArrangementEmployeeMember",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-8-subsequent-events",
      "http://autonomix.com/20250630/role/statement-note-8-subsequent-events-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Employee [Member]",
        "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor exercises or has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Includes, but is not limited to, nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires."
       }
      }
     },
     "auth_ref": [
      "r290",
      "r291",
      "r292",
      "r293",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319"
     ]
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharePrice",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-4-equity-blackscholes-option-pricing-model-details",
      "http://autonomix.com/20250630/role/statement-note-4-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_SharePrice",
        "terseLabel": "Share Price (in dollars per share)",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding",
     "crdr": "debit",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-4-equity-schedule-of-equitybased-stock-warrants-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding, warrants, aggregate intrinsic value",
        "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r778"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested",
     "crdr": "debit",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-4-equity-schedule-of-equitybased-stock-warrants-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercisable, warrants, aggregate intrinsic value",
        "documentation": "Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r778"
     ]
    },
    "amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-3-equity-schedule-of-equitybased-stock-warrants-10q-details",
      "http://autonomix.com/20250630/role/statement-note-4-equity-schedule-of-equitybased-stock-warrants-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercisable, warrants, weighted average exercise price (in dollars per share)",
        "documentation": "The weighted-average price at which holders can acquire the shares on vested portions of warrants outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": []
    },
    "amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerm",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-4-equity-schedule-of-equitybased-stock-warrants-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercisable, warrants, weighted average remaining contractual term ( (Year)",
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, currently exercisable, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-3-equity-schedule-of-equitybased-stock-warrants-10q-details",
      "http://autonomix.com/20250630/role/statement-note-4-equity-schedule-of-equitybased-stock-warrants-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercised, warrants, weighted average exercise price (in dollars per share)",
        "documentation": "Weighted average price at which warrant holders acquired shares when converting their warrants into shares."
       }
      }
     },
     "auth_ref": []
    },
    "amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-3-equity-schedule-of-equitybased-stock-warrants-10q-details",
      "http://autonomix.com/20250630/role/statement-note-4-equity-schedule-of-equitybased-stock-warrants-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expired, warrants, weighted average exercise price (in dollars per share)",
        "documentation": "Weighted average price at which holders could have acquired the underlying shares with respect to warrants of the plan that expired."
       }
      }
     },
     "auth_ref": []
    },
    "amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-3-equity-schedule-of-equitybased-stock-warrants-10q-details",
      "http://autonomix.com/20250630/role/statement-note-4-equity-schedule-of-equitybased-stock-warrants-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forfeited/Cancelled, warrants, weighted average exercise price (in dollars per share)",
        "documentation": "Weighted average price at which holders could have acquired the underlying shares with respect to warrants that were terminated."
       }
      }
     },
     "auth_ref": []
    },
    "amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-3-equity-schedule-of-equitybased-stock-warrants-10q-details",
      "http://autonomix.com/20250630/role/statement-note-4-equity-schedule-of-equitybased-stock-warrants-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Granted, warrants, weighted average exercise price (in dollars per share)",
        "documentation": "Weighted average per share amount at which holders can acquire shares of common stock by exercise of warrants."
       }
      }
     },
     "auth_ref": []
    },
    "amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-3-equity-schedule-of-equitybased-stock-warrants-10q-details",
      "http://autonomix.com/20250630/role/statement-note-4-equity-schedule-of-equitybased-stock-warrants-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "amix_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice",
        "periodStartLabel": "Outstanding, warrants, weighted average exercise price (in dollars per share)",
        "periodEndLabel": "Outstanding, warrants, weighted average exercise price (in dollars per share)",
        "documentation": "Weighted average price at which holders can acquire the shares under the warrant plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-4-equity-details-textual",
      "http://autonomix.com/20250630/role/statement-note-5-commitments-and-contingencies-details-textual",
      "http://autonomix.com/20250630/role/statement-note-8-subsequent-events-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r630"
     ]
    },
    "amix_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsDiscountRate",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-4-equity-blackscholes-option-pricing-model-details",
      "http://autonomix.com/20250630/role/statement-note-4-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "amix_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsDiscountRate",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Discount Rate",
        "documentation": "The interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-4-equity-blackscholes-option-pricing-model-details",
      "http://autonomix.com/20250630/role/statement-note-4-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term (Year)",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r315"
     ]
    },
    "amix_SharebasedCompensationArrangementBySharebasedPaymentAwardNonoptionEquityInstrumentsExercisableNumberOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNonoptionEquityInstrumentsExercisableNumberOutstandingNumber",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-3-equity-schedule-of-equitybased-stock-warrants-10q-details",
      "http://autonomix.com/20250630/role/statement-note-4-equity-schedule-of-equitybased-stock-warrants-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercisable, warrants (in shares)",
        "documentation": "The number of shares into which equity instruments other than options can be currently converted."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-4-equity-schedule-of-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercisable, aggregate intrinsic value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-4-equity-schedule-of-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercisable, options, Weighted average remaining contractual term (Year)",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "amix_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantDateFairValue",
     "crdr": "debit",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-4-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "amix_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantDateFairValue",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grant Date Fair Value",
        "documentation": "The grant-date fair value of options as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-4-equity-schedule-of-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding, options, Weighted average remaining contractual term (Year)",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "crdr": "credit",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-5-commitments-and-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value",
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock."
       }
      }
     },
     "auth_ref": [
      "r310"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-8-subsequent-events-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares (in shares)",
        "documentation": "Number of options vested."
       }
      }
     },
     "auth_ref": [
      "r779"
     ]
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual",
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-4-equity-details-textual",
      "http://autonomix.com/20250630/role/statement-note-6-related-party-transactions-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_SharesIssuedPricePerShare",
        "terseLabel": "Shares Issued, Price Per Share (in dollars per share)",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-condensed-statements-of-changes-in-stockholders-equity-unaudited",
      "http://autonomix.com/20250630/role/statement-statements-of-changes-in-stockholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_SharesOutstanding",
        "periodStartLabel": "Balance (in shares)",
        "periodEndLabel": "Balance (in shares)",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-condensed-statements-of-changes-in-stockholders-equity-unaudited",
      "http://autonomix.com/20250630/role/statement-statements-of-changes-in-stockholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r41",
      "r44",
      "r45",
      "r96",
      "r98",
      "r99",
      "r113",
      "r114",
      "r115",
      "r132",
      "r133",
      "r134",
      "r136",
      "r144",
      "r147",
      "r149",
      "r161",
      "r189",
      "r192",
      "r193",
      "r247",
      "r273",
      "r323",
      "r362",
      "r363",
      "r370",
      "r371",
      "r372",
      "r374",
      "r375",
      "r376",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r399",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r438",
      "r440",
      "r445",
      "r486",
      "r493",
      "r494",
      "r495",
      "r514",
      "r568"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementLineItems",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-balance-sheets",
      "http://autonomix.com/20250630/role/statement-balance-sheets-parentheticals",
      "http://autonomix.com/20250630/role/statement-condensed-balance-sheets-unaudited-",
      "http://autonomix.com/20250630/role/statement-condensed-balance-sheets-unaudited-parentheticals",
      "http://autonomix.com/20250630/role/statement-condensed-statements-of-cash-flows-unaudited",
      "http://autonomix.com/20250630/role/statement-condensed-statements-of-changes-in-stockholders-equity-unaudited",
      "http://autonomix.com/20250630/role/statement-condensed-statements-of-operations-unaudited",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q-tables",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-antidilutive-securities-details",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-prior-period-corrections-details",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-10q-details",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-schedule-of-prior-period-corrections-10q-details",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-tables",
      "http://autonomix.com/20250630/role/statement-note-2-convertible-notes-payable-10q",
      "http://autonomix.com/20250630/role/statement-note-2-convertible-notes-payable-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-2-convertible-notes-payable-10q-tables",
      "http://autonomix.com/20250630/role/statement-note-2-convertible-notes-payable-schedule-of-detachable-warrants-10q-details",
      "http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments",
      "http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-details-textual",
      "http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-fair-value-measurement-inputs-and-valuation-techniques-details",
      "http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-schedule-of-fair-value-measurements-details",
      "http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-tables",
      "http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable",
      "http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable-details-textual",
      "http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable-schedule-of-convertible-notes-payable-details",
      "http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable-schedule-of-detachable-warrants-details",
      "http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable-tables",
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q",
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q-tables",
      "http://autonomix.com/20250630/role/statement-note-3-equity-general-and-administrative-expense-10q-details",
      "http://autonomix.com/20250630/role/statement-note-3-equity-schedule-of-equitybased-stock-warrants-10q-details",
      "http://autonomix.com/20250630/role/statement-note-3-equity-schedule-of-stock-option-activity-10q-details",
      "http://autonomix.com/20250630/role/statement-note-4-commitments-and-contingencies-10q",
      "http://autonomix.com/20250630/role/statement-note-4-commitments-and-contingencies-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-4-equity",
      "http://autonomix.com/20250630/role/statement-note-4-equity-blackscholes-option-pricing-model-details",
      "http://autonomix.com/20250630/role/statement-note-4-equity-details-textual",
      "http://autonomix.com/20250630/role/statement-note-4-equity-general-and-administrative-expense-details",
      "http://autonomix.com/20250630/role/statement-note-4-equity-restricted-stock-activity-details",
      "http://autonomix.com/20250630/role/statement-note-4-equity-schedule-of-equitybased-stock-warrants-details",
      "http://autonomix.com/20250630/role/statement-note-4-equity-schedule-of-stock-option-activity-details",
      "http://autonomix.com/20250630/role/statement-note-4-equity-tables",
      "http://autonomix.com/20250630/role/statement-note-5-commitments-and-contingencies",
      "http://autonomix.com/20250630/role/statement-note-5-commitments-and-contingencies-details-textual",
      "http://autonomix.com/20250630/role/statement-note-5-related-party-transactions-10q",
      "http://autonomix.com/20250630/role/statement-note-5-related-party-transactions-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-6-related-party-transactions",
      "http://autonomix.com/20250630/role/statement-note-6-related-party-transactions-details-textual",
      "http://autonomix.com/20250630/role/statement-note-6-subsequent-events-10q",
      "http://autonomix.com/20250630/role/statement-note-6-subsequent-events-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-7-income-taxes",
      "http://autonomix.com/20250630/role/statement-note-7-income-taxes-details-textual",
      "http://autonomix.com/20250630/role/statement-note-7-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details",
      "http://autonomix.com/20250630/role/statement-note-7-income-taxes-schedule-of-reconciliation-details",
      "http://autonomix.com/20250630/role/statement-note-7-income-taxes-tables",
      "http://autonomix.com/20250630/role/statement-note-8-subsequent-events",
      "http://autonomix.com/20250630/role/statement-note-8-subsequent-events-details-textual",
      "http://autonomix.com/20250630/role/statement-significant-accounting-policies-policies",
      "http://autonomix.com/20250630/role/statement-statements-of-cash-flows",
      "http://autonomix.com/20250630/role/statement-statements-of-changes-in-stockholders-equity",
      "http://autonomix.com/20250630/role/statement-statements-of-operations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r133",
      "r134",
      "r161",
      "r249",
      "r250",
      "r252",
      "r254",
      "r440",
      "r464",
      "r506",
      "r515",
      "r517",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r528",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r537",
      "r538",
      "r539",
      "r540",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r549",
      "r550",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r568",
      "r600",
      "r601",
      "r667",
      "r828"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments",
      "http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-details-textual",
      "http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-fair-value-measurement-inputs-and-valuation-techniques-details",
      "http://autonomix.com/20250630/role/statement-note-5-commitments-and-contingencies",
      "http://autonomix.com/20250630/role/statement-note-5-commitments-and-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "auth_ref": [
      "r101",
      "r102",
      "r150",
      "r286",
      "r676",
      "r677"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementTable",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-balance-sheets",
      "http://autonomix.com/20250630/role/statement-balance-sheets-parentheticals",
      "http://autonomix.com/20250630/role/statement-condensed-balance-sheets-unaudited-",
      "http://autonomix.com/20250630/role/statement-condensed-balance-sheets-unaudited-parentheticals",
      "http://autonomix.com/20250630/role/statement-condensed-statements-of-cash-flows-unaudited",
      "http://autonomix.com/20250630/role/statement-condensed-statements-of-changes-in-stockholders-equity-unaudited",
      "http://autonomix.com/20250630/role/statement-condensed-statements-of-operations-unaudited",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q-tables",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-antidilutive-securities-details",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-prior-period-corrections-details",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-10q-details",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-schedule-of-prior-period-corrections-10q-details",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-tables",
      "http://autonomix.com/20250630/role/statement-note-2-convertible-notes-payable-10q",
      "http://autonomix.com/20250630/role/statement-note-2-convertible-notes-payable-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-2-convertible-notes-payable-10q-tables",
      "http://autonomix.com/20250630/role/statement-note-2-convertible-notes-payable-schedule-of-detachable-warrants-10q-details",
      "http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments",
      "http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-details-textual",
      "http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-fair-value-measurement-inputs-and-valuation-techniques-details",
      "http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-schedule-of-fair-value-measurements-details",
      "http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-tables",
      "http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable",
      "http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable-details-textual",
      "http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable-schedule-of-convertible-notes-payable-details",
      "http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable-schedule-of-detachable-warrants-details",
      "http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable-tables",
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q",
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q-tables",
      "http://autonomix.com/20250630/role/statement-note-3-equity-general-and-administrative-expense-10q-details",
      "http://autonomix.com/20250630/role/statement-note-3-equity-schedule-of-equitybased-stock-warrants-10q-details",
      "http://autonomix.com/20250630/role/statement-note-3-equity-schedule-of-stock-option-activity-10q-details",
      "http://autonomix.com/20250630/role/statement-note-4-commitments-and-contingencies-10q",
      "http://autonomix.com/20250630/role/statement-note-4-commitments-and-contingencies-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-4-equity",
      "http://autonomix.com/20250630/role/statement-note-4-equity-blackscholes-option-pricing-model-details",
      "http://autonomix.com/20250630/role/statement-note-4-equity-details-textual",
      "http://autonomix.com/20250630/role/statement-note-4-equity-general-and-administrative-expense-details",
      "http://autonomix.com/20250630/role/statement-note-4-equity-restricted-stock-activity-details",
      "http://autonomix.com/20250630/role/statement-note-4-equity-schedule-of-equitybased-stock-warrants-details",
      "http://autonomix.com/20250630/role/statement-note-4-equity-schedule-of-stock-option-activity-details",
      "http://autonomix.com/20250630/role/statement-note-4-equity-tables",
      "http://autonomix.com/20250630/role/statement-note-5-commitments-and-contingencies",
      "http://autonomix.com/20250630/role/statement-note-5-commitments-and-contingencies-details-textual",
      "http://autonomix.com/20250630/role/statement-note-5-related-party-transactions-10q",
      "http://autonomix.com/20250630/role/statement-note-5-related-party-transactions-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-6-related-party-transactions",
      "http://autonomix.com/20250630/role/statement-note-6-related-party-transactions-details-textual",
      "http://autonomix.com/20250630/role/statement-note-6-subsequent-events-10q",
      "http://autonomix.com/20250630/role/statement-note-6-subsequent-events-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-7-income-taxes",
      "http://autonomix.com/20250630/role/statement-note-7-income-taxes-details-textual",
      "http://autonomix.com/20250630/role/statement-note-7-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details",
      "http://autonomix.com/20250630/role/statement-note-7-income-taxes-schedule-of-reconciliation-details",
      "http://autonomix.com/20250630/role/statement-note-7-income-taxes-tables",
      "http://autonomix.com/20250630/role/statement-note-8-subsequent-events",
      "http://autonomix.com/20250630/role/statement-note-8-subsequent-events-details-textual",
      "http://autonomix.com/20250630/role/statement-significant-accounting-policies-policies",
      "http://autonomix.com/20250630/role/statement-statements-of-cash-flows",
      "http://autonomix.com/20250630/role/statement-statements-of-changes-in-stockholders-equity",
      "http://autonomix.com/20250630/role/statement-statements-of-operations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Presentation of information about comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r133",
      "r134",
      "r161",
      "r187",
      "r249",
      "r250",
      "r252",
      "r254",
      "r440",
      "r464",
      "r506",
      "r515",
      "r517",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r528",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r537",
      "r538",
      "r539",
      "r540",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r549",
      "r550",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r568",
      "r600",
      "r601",
      "r667",
      "r828"
     ]
    },
    "amix_StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-statements-of-changes-in-stockholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common shares and equity classified warrants, net of offering costs (in shares)",
        "documentation": "Number of shares of common stock and warrants for common stock issued."
       }
      }
     },
     "auth_ref": []
    },
    "amix_StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants",
     "crdr": "credit",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-statements-of-changes-in-stockholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common shares and equity classified warrants, net of offering costs",
        "documentation": "Value of common stock and warrants for common stock issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssued1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssued1",
     "crdr": "credit",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-condensed-statements-of-cash-flows-unaudited",
      "http://autonomix.com/20250630/role/statement-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from cashless exercise of warrants",
        "documentation": "The fair value of stock issued in noncash financing activities."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r18",
      "r19"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-statements-of-changes-in-stockholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock for extinguishment of convertible debt (in shares)",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r28",
      "r41",
      "r44",
      "r64",
      "r236"
     ]
    },
    "amix_StockIssuedDuringPeriodSharesInitialPublicOffering": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "StockIssuedDuringPeriodSharesInitialPublicOffering",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-statements-of-changes-in-stockholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock from IPO, net of costs (in shares)",
        "documentation": "Represents the stock issued during the period from initial public offerings in shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-4-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices",
        "terseLabel": "Stock Issued During Period, Shares, Issued for Services (in shares)",
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-condensed-statements-of-changes-in-stockholders-equity-unaudited",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual",
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-4-equity-details-textual",
      "http://autonomix.com/20250630/role/statement-note-8-subsequent-events-details-textual",
      "http://autonomix.com/20250630/role/statement-statements-of-changes-in-stockholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock (in shares)",
        "terseLabel": "Stock Issued During Period, Shares, New Issues (in shares)",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r40",
      "r41",
      "r64",
      "r508",
      "r568",
      "r582"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-statements-of-changes-in-stockholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of restricted common stock (in shares)",
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r40",
      "r41",
      "r64"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-3-equity-schedule-of-stock-option-activity-10q-details",
      "http://autonomix.com/20250630/role/statement-note-4-equity-schedule-of-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercised, options (in shares)",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r40",
      "r41",
      "r64",
      "r300"
     ]
    },
    "amix_StockIssuedDuringPeriodSharesWarrantsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "StockIssuedDuringPeriodSharesWarrantsExercised",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-condensed-statements-of-changes-in-stockholders-equity-unaudited",
      "http://autonomix.com/20250630/role/statement-statements-of-changes-in-stockholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock - warrants exercised (in shares)",
        "documentation": "Number of warrants exercised during the current period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "crdr": "credit",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-statements-of-changes-in-stockholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock for extinguishment of convertible debt",
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r41",
      "r44",
      "r45",
      "r64"
     ]
    },
    "amix_StockIssuedDuringPeriodValueInitialPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "StockIssuedDuringPeriodValueInitialPublicOffering",
     "crdr": "credit",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-statements-of-changes-in-stockholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock from IPO, net of costs",
        "documentation": "Represents the value of the stock issued during the period from the initial public offering."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "crdr": "credit",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-4-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_StockIssuedDuringPeriodValueIssuedForServices",
        "terseLabel": "Stock Issued During Period, Value, Issued for Services",
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-condensed-statements-of-changes-in-stockholders-equity-unaudited",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual",
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-4-equity-details-textual",
      "http://autonomix.com/20250630/role/statement-statements-of-changes-in-stockholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock",
        "terseLabel": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r40",
      "r41",
      "r64",
      "r514",
      "r568",
      "r582",
      "r673"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures",
     "crdr": "credit",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-statements-of-changes-in-stockholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of restricted common stock",
        "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r64"
     ]
    },
    "amix_StockIssuedDuringPeriodValueWarrantsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "StockIssuedDuringPeriodValueWarrantsExercised",
     "crdr": "credit",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-condensed-statements-of-changes-in-stockholders-equity-unaudited",
      "http://autonomix.com/20250630/role/statement-statements-of-changes-in-stockholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock - warrants exercised",
        "documentation": "Value of stock issued as a result of the exercise of warrants."
       }
      }
     },
     "auth_ref": []
    },
    "amix_StockRequiredToBeIssuedForStockSplitShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "StockRequiredToBeIssuedForStockSplitShares",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-4-commitments-and-contingencies-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-5-commitments-and-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "amix_StockRequiredToBeIssuedForStockSplitShares",
        "terseLabel": "Stock Required to be Issued for Stock Split, Shares (in shares)",
        "documentation": "The number of shares required to be issued for the stock split."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://autonomix.com/20250630/role/statement-balance-sheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      },
      "http://autonomix.com/20250630/role/statement-condensed-balance-sheets-unaudited-": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://autonomix.com/20250630/role/statement-balance-sheets",
      "http://autonomix.com/20250630/role/statement-condensed-balance-sheets-unaudited-",
      "http://autonomix.com/20250630/role/statement-condensed-statements-of-changes-in-stockholders-equity-unaudited",
      "http://autonomix.com/20250630/role/statement-statements-of-changes-in-stockholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_StockholdersEquity",
        "totalLabel": "Total Stockholders' Equity",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r44",
      "r45",
      "r56",
      "r530",
      "r547",
      "r569",
      "r570",
      "r660",
      "r674",
      "r701",
      "r704",
      "r705",
      "r723",
      "r803",
      "r830"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-balance-sheets",
      "http://autonomix.com/20250630/role/statement-condensed-balance-sheets-unaudited-"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' equity:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q",
      "http://autonomix.com/20250630/role/statement-note-4-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r258",
      "r260",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r273",
      "r386",
      "r397",
      "r571",
      "r574",
      "r583"
     ]
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "xbrltype": "pureItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1",
        "terseLabel": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "us-gaap_StockholdersEquityPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityPolicyTextBlock",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r572"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-6-subsequent-events-10q",
      "http://autonomix.com/20250630/role/statement-note-6-subsequent-events-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-8-subsequent-events",
      "http://autonomix.com/20250630/role/statement-note-8-subsequent-events-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r435",
      "r455"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-6-subsequent-events-10q",
      "http://autonomix.com/20250630/role/statement-note-6-subsequent-events-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-8-subsequent-events",
      "http://autonomix.com/20250630/role/statement-note-8-subsequent-events-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r435",
      "r455"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-6-subsequent-events-10q",
      "http://autonomix.com/20250630/role/statement-note-6-subsequent-events-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-8-subsequent-events",
      "http://autonomix.com/20250630/role/statement-note-8-subsequent-events-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r435",
      "r455"
     ]
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-6-subsequent-events-10q",
      "http://autonomix.com/20250630/role/statement-note-8-subsequent-events"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r454",
      "r456"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-condensed-statements-of-cash-flows-unaudited",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual",
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q",
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-4-equity",
      "http://autonomix.com/20250630/role/statement-note-4-equity-details-textual",
      "http://autonomix.com/20250630/role/statement-note-8-subsequent-events",
      "http://autonomix.com/20250630/role/statement-note-8-subsequent-events-details-textual",
      "http://autonomix.com/20250630/role/statement-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "amix_SubstantialDoubtAboutGoingConcernPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "SubstantialDoubtAboutGoingConcernPolicyPolicyTextBlock",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Substantial Doubt About Going Concern Policy [Policy Text Block]",
        "documentation": "Disclosure of the accounting policy for substantial doubt about the ability to continue as a going concern."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TableTextBlock": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TableTextBlock",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q-tables",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-tables",
      "http://autonomix.com/20250630/role/statement-note-2-convertible-notes-payable-10q-tables",
      "http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-tables",
      "http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable-tables",
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q-tables",
      "http://autonomix.com/20250630/role/statement-note-4-equity-tables",
      "http://autonomix.com/20250630/role/statement-note-7-income-taxes-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_TableTextBlock",
        "terseLabel": "Notes Tables"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TaxPeriodAxis",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-7-income-taxes",
      "http://autonomix.com/20250630/role/statement-note-7-income-taxes-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Period [Axis]",
        "documentation": "Information by period subject to enacted tax law."
       }
      }
     },
     "auth_ref": [
      "r782"
     ]
    },
    "us-gaap_TaxPeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TaxPeriodDomain",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-7-income-taxes",
      "http://autonomix.com/20250630/role/statement-note-7-income-taxes-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Period [Domain]",
        "documentation": "Identified tax period."
       }
      }
     },
     "auth_ref": [
      "r782"
     ]
    },
    "amix_TerminationAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "TerminationAgreementMember",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments",
      "http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-details-textual",
      "http://autonomix.com/20250630/role/statement-note-5-related-party-transactions-10q",
      "http://autonomix.com/20250630/role/statement-note-5-related-party-transactions-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-6-related-party-transactions",
      "http://autonomix.com/20250630/role/statement-note-6-related-party-transactions-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Termination Agreement [Member]",
        "documentation": "Information by type of related party transaction."
       }
      }
     },
     "auth_ref": []
    },
    "amix_The2023StockPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "The2023StockPlanMember",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q",
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-4-equity",
      "http://autonomix.com/20250630/role/statement-note-4-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "The 2023 Stock Plan [Member]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "amix_TheBridgeOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "TheBridgeOfferingMember",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-6-related-party-transactions",
      "http://autonomix.com/20250630/role/statement-note-6-related-party-transactions-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "The Bridge Offering [Member]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": []
    },
    "amix_TheNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "TheNotesMember",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-2-convertible-notes-payable-10q",
      "http://autonomix.com/20250630/role/statement-note-2-convertible-notes-payable-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable",
      "http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable-details-textual",
      "http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable-schedule-of-convertible-notes-payable-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "The Notes [Member]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": []
    },
    "amix_TheWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "TheWarrantMember",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments",
      "http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-details-textual",
      "http://autonomix.com/20250630/role/statement-note-5-related-party-transactions-10q",
      "http://autonomix.com/20250630/role/statement-note-5-related-party-transactions-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-6-related-party-transactions",
      "http://autonomix.com/20250630/role/statement-note-6-related-party-transactions-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "The Warrant [Member]",
        "documentation": "Information pertaining to warrants."
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q",
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-4-equity",
      "http://autonomix.com/20250630/role/statement-note-4-equity-details-textual",
      "http://autonomix.com/20250630/role/statement-note-5-commitments-and-contingencies",
      "http://autonomix.com/20250630/role/statement-note-5-commitments-and-contingencies-details-textual",
      "http://autonomix.com/20250630/role/statement-note-6-subsequent-events-10q",
      "http://autonomix.com/20250630/role/statement-note-6-subsequent-events-10q-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Axis]"
       }
      }
     },
     "auth_ref": [
      "r722",
      "r810"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q",
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-4-equity",
      "http://autonomix.com/20250630/role/statement-note-4-equity-details-textual",
      "http://autonomix.com/20250630/role/statement-note-5-commitments-and-contingencies",
      "http://autonomix.com/20250630/role/statement-note-5-commitments-and-contingencies-details-textual",
      "http://autonomix.com/20250630/role/statement-note-6-subsequent-events-10q",
      "http://autonomix.com/20250630/role/statement-note-6-subsequent-events-10q-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-4-commitments-and-contingencies-10q",
      "http://autonomix.com/20250630/role/statement-note-4-commitments-and-contingencies-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-5-commitments-and-contingencies",
      "http://autonomix.com/20250630/role/statement-note-5-commitments-and-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r377"
     ]
    },
    "us-gaap_UnderlyingAssetClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnderlyingAssetClassAxis",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-5-related-party-transactions-10q",
      "http://autonomix.com/20250630/role/statement-note-5-related-party-transactions-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-6-related-party-transactions",
      "http://autonomix.com/20250630/role/statement-note-6-related-party-transactions-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Asset Class [Axis]",
        "documentation": "Information by underlying asset class."
       }
      }
     },
     "auth_ref": [
      "r640"
     ]
    },
    "us-gaap_UnderlyingAssetClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnderlyingAssetClassDomain",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-5-related-party-transactions-10q",
      "http://autonomix.com/20250630/role/statement-note-5-related-party-transactions-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-6-related-party-transactions",
      "http://autonomix.com/20250630/role/statement-note-6-related-party-transactions-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Asset Class [Domain]",
        "documentation": "Major types of referenced/underlying asset classes (for example, corporate debt, sovereign debt, and structured finance)."
       }
      }
     },
     "auth_ref": [
      "r640"
     ]
    },
    "amix_UnderwritersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "UnderwritersMember",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual",
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q",
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-4-equity",
      "http://autonomix.com/20250630/role/statement-note-4-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underwriters [Member]",
        "documentation": "Represents the Underwriters."
       }
      }
     },
     "auth_ref": []
    },
    "amix_UnderwrittenPublicOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "UnderwrittenPublicOfferingMember",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual",
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q",
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-4-equity",
      "http://autonomix.com/20250630/role/statement-note-4-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underwritten Public Offering [Member]",
        "documentation": "Represents the underwritten public offering."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r92",
      "r162",
      "r163",
      "r164",
      "r165",
      "r467",
      "r469",
      "r603"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-7-income-taxes-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount",
        "terseLabel": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r355"
     ]
    },
    "amix_ValuationProbabilityweightedExpectedReturnMethodPWERMMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "ValuationProbabilityweightedExpectedReturnMethodPWERMMember",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments",
      "http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-details-textual",
      "http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-fair-value-measurement-inputs-and-valuation-techniques-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation, Probability-weighted Expected Return Method (PWERM) [Member]",
        "documentation": "Information by valuation approach and technique."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ValuationTechniqueAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ValuationTechniqueAxis",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments",
      "http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-details-textual",
      "http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-fair-value-measurement-inputs-and-valuation-techniques-details",
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q",
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-4-equity",
      "http://autonomix.com/20250630/role/statement-note-4-equity-blackscholes-option-pricing-model-details",
      "http://autonomix.com/20250630/role/statement-note-4-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Approach and Technique [Axis]",
        "documentation": "Information by valuation approach and technique."
       }
      }
     },
     "auth_ref": [
      "r405",
      "r406",
      "r634",
      "r637",
      "r646",
      "r798"
     ]
    },
    "us-gaap_ValuationTechniqueDiscountedCashFlowMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ValuationTechniqueDiscountedCashFlowMember",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-4-equity",
      "http://autonomix.com/20250630/role/statement-note-4-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Technique, Discounted Cash Flow [Member]",
        "documentation": "Valuation technique calculating present value of future cash flows."
       }
      }
     },
     "auth_ref": [
      "r614",
      "r615",
      "r646",
      "r796",
      "r797",
      "r798"
     ]
    },
    "us-gaap_ValuationTechniqueDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ValuationTechniqueDomain",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments",
      "http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-details-textual",
      "http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-fair-value-measurement-inputs-and-valuation-techniques-details",
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q",
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-4-equity",
      "http://autonomix.com/20250630/role/statement-note-4-equity-blackscholes-option-pricing-model-details",
      "http://autonomix.com/20250630/role/statement-note-4-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Approach and Technique [Domain]",
        "documentation": "Valuation approach and technique."
       }
      }
     },
     "auth_ref": [
      "r405",
      "r406",
      "r634",
      "r637",
      "r646",
      "r798"
     ]
    },
    "us-gaap_VestingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "VestingAxis",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-5-commitments-and-contingencies",
      "http://autonomix.com/20250630/role/statement-note-5-commitments-and-contingencies-details-textual",
      "http://autonomix.com/20250630/role/statement-note-8-subsequent-events",
      "http://autonomix.com/20250630/role/statement-note-8-subsequent-events-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Axis]",
        "documentation": "Information by vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776"
     ]
    },
    "us-gaap_VestingDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "VestingDomain",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-5-commitments-and-contingencies",
      "http://autonomix.com/20250630/role/statement-note-5-commitments-and-contingencies-details-textual",
      "http://autonomix.com/20250630/role/statement-note-8-subsequent-events",
      "http://autonomix.com/20250630/role/statement-note-8-subsequent-events-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Domain]",
        "documentation": "Vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776"
     ]
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantMember",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-antidilutive-securities-details",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-prior-period-corrections-details",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-10q-details",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-schedule-of-prior-period-corrections-10q-details",
      "http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-schedule-of-fair-value-measurements-details",
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q",
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-4-equity",
      "http://autonomix.com/20250630/role/statement-note-4-equity-blackscholes-option-pricing-model-details",
      "http://autonomix.com/20250630/role/statement-note-4-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r664",
      "r665",
      "r668",
      "r669",
      "r670",
      "r671"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantsAndRightsOutstanding",
     "crdr": "credit",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-details-textual",
      "http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable-details-textual",
      "http://autonomix.com/20250630/role/statement-note-5-related-party-transactions-10q-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_WarrantsAndRightsOutstanding",
        "terseLabel": "Warrants and Rights Outstanding",
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price."
       }
      }
     },
     "auth_ref": [
      "r796",
      "r797",
      "r798"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-2-convertible-notes-payable-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-details-textual",
      "http://autonomix.com/20250630/role/statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-fair-value-measurement-inputs-and-valuation-techniques-details",
      "http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable-details-textual",
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-4-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant measurement input",
        "terseLabel": "Warrants and Rights Outstanding, Measurement Input",
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur."
       }
      }
     },
     "auth_ref": [
      "r796",
      "r797",
      "r798"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantsAndRightsOutstandingTerm",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual",
      "http://autonomix.com/20250630/role/statement-note-2-convertible-notes-payable-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-3-convertible-notes-payable-details-textual",
      "http://autonomix.com/20250630/role/statement-note-3-equity-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-4-equity-details-textual",
      "http://autonomix.com/20250630/role/statement-note-5-related-party-transactions-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-6-related-party-transactions-details-textual",
      "http://autonomix.com/20250630/role/statement-note-6-subsequent-events-10q-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_WarrantsAndRightsOutstandingTerm",
        "terseLabel": "Warrants and Rights Outstanding, Term (Year)",
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r796",
      "r797",
      "r798"
     ]
    },
    "amix_WarrantsIssuedFairValueIssuedForTerminationAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "WarrantsIssuedFairValueIssuedForTerminationAgreement",
     "crdr": "credit",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-statements-of-changes-in-stockholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of warrants issued - termination agreement",
        "documentation": "Represents the fair value of the warrants issued for termination agreements."
       }
      }
     },
     "auth_ref": []
    },
    "amix_WarrantsIssuedForDebtIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "WarrantsIssuedForDebtIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "amix_WarrantsIssuedForDebtIssuanceCosts",
        "terseLabel": "Warrants issued for debt issuance costs",
        "documentation": "Amount of warrants issued for debt issuance costs in noncash or part noncash transaction."
       }
      }
     },
     "auth_ref": []
    },
    "amix_WarrantsIssuedForEquityCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "WarrantsIssuedForEquityCosts",
     "crdr": "credit",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants issued for equity issuance costs",
        "documentation": "Amount of warrants issued for equity costs in noncash or part noncash transaction."
       }
      }
     },
     "auth_ref": []
    },
    "amix_WarrantsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "WarrantsPolicyPolicyTextBlock",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants, Policy [Policy Text Block]",
        "documentation": "Disclosure of Warrant related activity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-condensed-statements-of-operations-unaudited",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-prior-period-corrections-details",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-schedule-of-prior-period-corrections-10q-details",
      "http://autonomix.com/20250630/role/statement-statements-of-operations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted average shares outstanding - basic and diluted (in shares)",
        "label": "Weighted average shares outstanding - basic and diluted (in shares)",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r156"
     ]
    },
    "amix_WorkingCapitalDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "WorkingCapitalDeficit",
     "crdr": "debit",
     "presentation": [
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q-details-textual",
      "http://autonomix.com/20250630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "amix_WorkingCapitalDeficit",
        "terseLabel": "Working Capital (Deficit)",
        "documentation": "Information pertaining to capital available to meet current, short-term obligations."
       }
      }
     },
     "auth_ref": []
    },
    "amix_statement-statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q-tables": {
     "xbrltype": "stringItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "statement-statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-10q-tables",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 1 - Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies - 10-Q"
       }
      }
     },
     "auth_ref": []
    },
    "amix_statement-statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-antidilutive-securities-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "statement-statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-antidilutive-securities-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 1 - Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies - Anti-dilutive Securities (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "amix_statement-statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-prior-period-corrections-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "statement-statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-prior-period-corrections-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 1 - Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies - Prior Period Corrections (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "amix_statement-statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-10q-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "statement-statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-10q-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 1 - Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Anti-dilutive Securities - 10Q (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "amix_statement-statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-schedule-of-prior-period-corrections-10q-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "statement-statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-schedule-of-prior-period-corrections-10q-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 1 - Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Prior Period Corrections - 10Q (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "amix_statement-statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-tables": {
     "xbrltype": "stringItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "statement-statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-tables",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 1 - Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies"
       }
      }
     },
     "auth_ref": []
    },
    "amix_statement-statement-note-2-convertible-notes-payable-10q-tables": {
     "xbrltype": "stringItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "statement-statement-note-2-convertible-notes-payable-10q-tables",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 2 - Convertible Notes Payable - 10Q"
       }
      }
     },
     "auth_ref": []
    },
    "amix_statement-statement-note-2-convertible-notes-payable-schedule-of-detachable-warrants-10q-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "statement-statement-note-2-convertible-notes-payable-schedule-of-detachable-warrants-10q-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 2 - Convertible Notes Payable - Schedule of Detachable Warrants - 10Q (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "amix_statement-statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-fair-value-measurement-inputs-and-valuation-techniques-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "statement-statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-fair-value-measurement-inputs-and-valuation-techniques-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 2 - Warrant Liability and Fair Value of Financial Instruments - Fair Value Measurement Inputs and Valuation Techniques (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "amix_statement-statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-schedule-of-fair-value-measurements-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "statement-statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-schedule-of-fair-value-measurements-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 2 - Warrant Liability and Fair Value of Financial Instruments - Schedule of Fair Value Measurements (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "amix_statement-statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-tables": {
     "xbrltype": "stringItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "statement-statement-note-2-warrant-liability-and-fair-value-of-financial-instruments-tables",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 2 - Warrant Liability and Fair Value of Financial Instruments"
       }
      }
     },
     "auth_ref": []
    },
    "amix_statement-statement-note-3-convertible-notes-payable-schedule-of-convertible-notes-payable-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "statement-statement-note-3-convertible-notes-payable-schedule-of-convertible-notes-payable-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 3 - Convertible Notes Payable - Schedule of Convertible Notes Payable (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "amix_statement-statement-note-3-convertible-notes-payable-schedule-of-detachable-warrants-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "statement-statement-note-3-convertible-notes-payable-schedule-of-detachable-warrants-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 3 - Convertible Notes Payable - Schedule of Detachable Warrants (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "amix_statement-statement-note-3-convertible-notes-payable-tables": {
     "xbrltype": "stringItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "statement-statement-note-3-convertible-notes-payable-tables",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 3 - Convertible Notes Payable"
       }
      }
     },
     "auth_ref": []
    },
    "amix_statement-statement-note-3-equity-10q-tables": {
     "xbrltype": "stringItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "statement-statement-note-3-equity-10q-tables",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 3 - Equity - 10Q"
       }
      }
     },
     "auth_ref": []
    },
    "amix_statement-statement-note-3-equity-general-and-administrative-expense-10q-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "statement-statement-note-3-equity-general-and-administrative-expense-10q-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 3 - Equity - General and Administrative Expense - 10Q (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "amix_statement-statement-note-3-equity-schedule-of-equitybased-stock-warrants-10q-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "statement-statement-note-3-equity-schedule-of-equitybased-stock-warrants-10q-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 3 - Equity - Schedule of Equity-Based Stock Warrants - 10Q (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "amix_statement-statement-note-3-equity-schedule-of-stock-option-activity-10q-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "statement-statement-note-3-equity-schedule-of-stock-option-activity-10q-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 3 - Equity - Schedule of Stock Option Activity - 10Q (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "amix_statement-statement-note-4-equity-blackscholes-option-pricing-model-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "statement-statement-note-4-equity-blackscholes-option-pricing-model-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 4 - Equity - Black-Scholes Option Pricing Model (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "amix_statement-statement-note-4-equity-general-and-administrative-expense-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "statement-statement-note-4-equity-general-and-administrative-expense-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 4 - Equity - General and Administrative Expense (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "amix_statement-statement-note-4-equity-restricted-stock-activity-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "statement-statement-note-4-equity-restricted-stock-activity-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 4 - Equity - Restricted Stock Activity (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "amix_statement-statement-note-4-equity-schedule-of-equitybased-stock-warrants-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "statement-statement-note-4-equity-schedule-of-equitybased-stock-warrants-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 4 - Equity - Schedule of Equity-Based Stock Warrants (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "amix_statement-statement-note-4-equity-schedule-of-stock-option-activity-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "statement-statement-note-4-equity-schedule-of-stock-option-activity-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 4 - Equity - Schedule of Stock Option Activity (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "amix_statement-statement-note-4-equity-tables": {
     "xbrltype": "stringItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "statement-statement-note-4-equity-tables",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 4 - Equity"
       }
      }
     },
     "auth_ref": []
    },
    "amix_statement-statement-note-7-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "statement-statement-note-7-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 7 - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "amix_statement-statement-note-7-income-taxes-schedule-of-reconciliation-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "statement-statement-note-7-income-taxes-schedule-of-reconciliation-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 7 - Income Taxes - Schedule of Reconciliation (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "amix_statement-statement-note-7-income-taxes-tables": {
     "xbrltype": "stringItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "statement-statement-note-7-income-taxes-tables",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 7 - Income Taxes"
       }
      }
     },
     "auth_ref": []
    },
    "amix_statement-statement-significant-accounting-policies-policies": {
     "xbrltype": "stringItemType",
     "nsuri": "http://autonomix.com/20250630",
     "localname": "statement-statement-significant-accounting-policies-policies",
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-1"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "270",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-8"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "25",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-2"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-10"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-5"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB Topic 4.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "210",
   "Topic": "946",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-20"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "35",
   "Topic": "720",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483406/720-35-50-1"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483504/205-10-50-1"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481003/205-10-S50-2"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SAB Topic 1.B.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480922/205-10-S99-7"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-23"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-12"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-6"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-1"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-3"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-3"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Subparagraph": "(24)(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479983/718-10-S45-1"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-2"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-3"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-4"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-5"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "35",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483406/720-35-50-1"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-15"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8A"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-30"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-32"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482804/825-20-50-1"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "845",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482864/845-10-50-1"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "845",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482864/845-10-50-3"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478671/942-235-S50-1"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477617/942-740-50-1"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478822/944-740-50-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-3"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-6"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-21"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478322/948-310-S50-2"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-10"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-12"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-14"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-18"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-21"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-4"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-6"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "64",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-64"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "720",
   "SubTopic": "35",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483385/720-35-55-1"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-8"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-41"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "43",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-43"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-47"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4L",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4L"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "182",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-182"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "184",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-184"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-12"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "845",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482819/845-10-05-4"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "845",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482819/845-10-05-4"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "845",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482819/845-10-05-4"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "845",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482819/845-10-05-4"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "845",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482819/845-10-05-5"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "845",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482819/845-10-05-6"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "845",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482819/845-10-05-6"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "845",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482819/845-10-05-6"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-11"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-14"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3"
  },
  "r678": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r679": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r680": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r681": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r682": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r684": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r685": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r686": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r687": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r688": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r689": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r690": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r691": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10"
  },
  "r692": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-12"
  },
  "r693": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r694": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r695": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r696": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r697": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r698": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r699": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r701": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r702": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r703": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r704": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r705": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r706": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r707": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r708": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r709": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r710": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r711": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-12"
  },
  "r712": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r713": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r714": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r715": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r716": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r717": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r718": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r719": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r720": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r721": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r722": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r723": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r724": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r725": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r726": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r727": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r728": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r729": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r730": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r731": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r732": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r733": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r734": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r735": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r736": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r737": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r738": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r739": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r740": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r741": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r742": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r743": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r744": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r745": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r746": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r747": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r748": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r749": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r750": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r751": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r752": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r753": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r754": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r755": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r756": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r757": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r758": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r759": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r760": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r761": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r762": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r763": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r764": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r765": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r766": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r767": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r768": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r769": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r770": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r771": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r772": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r773": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r774": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r775": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r776": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r777": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r778": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r779": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-4"
  },
  "r780": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r781": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r782": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r783": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r784": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r785": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r786": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r787": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r788": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7A"
  },
  "r789": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r790": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r791": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r792": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r793": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r794": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r795": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r796": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r797": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r798": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r799": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r800": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r801": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r802": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1"
  },
  "r803": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r804": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A"
  },
  "r805": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r806": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3"
  },
  "r807": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r808": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r809": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r810": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r811": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r812": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r813": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r814": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r815": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r816": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r817": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r818": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r819": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r820": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r821": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r822": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r823": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r824": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r825": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r826": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r827": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r828": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r829": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r830": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r831": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>91
<FILENAME>0001437749-25-030544-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001437749-25-030544-xbrl.zip
M4$L#!!0    ( "B(1EM(V_8QW80  -.*   '    83 Q+FIP9YR[!U03W]<N
M/$B3&NDB)2I-142E8R"B/T%$0$1!:5&1+B B$" D"M*;@(*"$E00E=X[H4=$
M1*D2D)!$14H@H831M!O_;[GW6]]][WKO/<G.G#4Y<V;VG+V?_>PY9[A?N?/
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M](N^CLD+&O&>_LC>F2M6G3;(R^8^ .3)PN&0P<J/JJIZSC[8U/YS>_YY2\:
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M;5YGV=-Y28$C78]D64%;P OWFAJP$YZ_?%)_JM9WE?0@AVBXEJO@-9LY,D3
MG=F^L./+&5G X?]"+M@)RAJ= ]Z^>__%;^JB%:=F7SCBC; <:$,;XH@*DJF0
MWLZ==,VGS+/(-C>06(6RR>O=5N6?V-&9Q( '(^>D^W=8OMTIKCYKA\1'L6=P
M]ROKF4GCI.+DAS)+EMKKT',\0_#AC'IHLM,;(-.]#F $#6?U>4M7RAUAU*<8
M9A$2XQF@L4UH_W5=K",H9/WM+(!W 9AB%".6W(XU$A>@ON,".]JU:7D#T%TP
M=Y_K7A4>;HNUZH:&\HXUSOG6ZHOU"Z+'71LNT>$L.<0ET(>>V=OJG&DN!O9V
MHX7I$4E3/02?Y."UBJ<E;>$S,F8OCSW>E]4L&5/F.8]9R2*O)?"8S(7,)%58
MKHTS+:%AWDRMU^7RQJ=1#^L07]&V<XFE<,-HIG.?$P_@UP@*"#HO]!?TF2O0
M5NO(]A(LV\3^*%Q?*E'6)C2RTF_H]LVS@517;?GW[R\6AS:E '_,(> !GP3,
M38PP9W0.-J% ]DG300G3A52.<P&[CN=!L&2M=<JEL8>0+;CQODB8<QGG Y;F
MJ LBL/5A"[T0>90>/:)G3<;-C[\O2L!EK'_OE#ZUV^7R^N#ZMRMI [/D3@PX
MR&,G7\$*BGT\KCXH[S7AU\L-LGV_V8G^5E&S.;[J6-_S;9_,G7I47G7$2%5Q
MACBZXUQ@_@V''WRK' XA24"Z\O+E5@8<&)D-@\=KWW@LG80Q+PB/[ZL]Z+>#
M%&+S=U;D7\+W_5*H7(JF=^"[=S90BXNJC[LYHYPCP8+H3X6FD_+V=8T%17.S
MAY]_R57H9M%/0H>Q+#DHXTT+NP4S7X0^-/6]U8FVEGC$Z\M=<TR$8#&DT1*@
MYYJ,*$_ITK9/UXZOEM(-*E+=$(CC.H^:2L4"17[OB@>N/XD]N:E8M9O6'X]/
M#XL^$>;)2/<'@T:&FM^O?(SI5O?NP%(:RSL!6G\AMO3]:YOG/8:?/B.")G/X
MB\1Z,K[=">@?&&SM_*3K%(7\YY5JY'.G=/K<4$^.OWRK3M9DBA2#:OG30J5]
M'7,WZ'L\8[.RC6$$)H=AZ&L]3<<#S,\BI AZ?9II9;'?Y=S$*2JUH0@3T-XR
MMM>BP4CF3, 1RF&'8DW&NN/X(_O65VR*1S(3YGZ&"TBHS;NF7IY02V]H,PB]
M,TEC]9SW&8(:H6>G<E*Z'2]$N$.L(&F!E8Y+(Z#VIX[C:(*M<E1:KE@ J;TY
MZ5W[](CPWC@NP*<^]1&M D[%D' 0:]];U#!?;W%E@W%;O=(P[>[O(>#49P3-
MF1DPA)M!.#;4BVGT1875Q3SSWS5S7LBT]KVQRGHBK>IQPU4N4(NJH@8:!ASG
M._4G_='%KM!O0?N^8]HM\"[D#S3ZW4_EEZ-5_@E=A.]NUV)HU0<Z6[02#Z;=
MRT]X.+@=6]@5AC?9T;YV%LR)89J@7&B)F3 =G8G,)'/5)1&]NAM&^6;=G>[-
MWY2*]GY7OJS+#SY&0>C[ S0V*E:"-02%GT _8$A#XD&0SW_B7+ -T#CJ9AM;
MR[%N)Z/UD8Y_C=ZJ[Q/Q)S,SS56A8K:?RXN(_37?R3HNSZEOV>?0(SB%<@Z<
MI4#+2Z__AKU.MRR0?/G$I#M,X%Y,@1JMDMRIP07B8F#!7$"DB27=1&J+?%%@
MK6 :+JPA$&JH0!/J_ K)09Q"4M[P",E?4O)[F2-:/X.9S\<HXU9LQS&;-LZG
M>4[#,F''=T*XP%=L"1=8/!S&8V;=SO:L !M*'CNY-9.3[/^+EQHBUF]P 6$N
ML&(_R@4V\TVG..ZH+H8F"3+:7L# L5^\XG$1,7_S8^TT3#(JL'1QO5B!$)3H
M?61UN(VV'HD82#E^=G-WE:O:_K)494N%$V>5[K1#7=Y#WD.G$^UHS@,84'LA
M%KT/_0'-3V^ZQU)@/T43Y8ZLZB??#12["%$\^H_.S:Z +,T[[XL@D^WV9)6\
M)#04TZW;J32CF4?6@?2+,4_[&Q$NA;=&-D]1W[=D3=HH.4%Q"VO\ Z.157,E
M8Q/ P,3,R(?FP2T#$K:1R)+A CW$1LYCDK6!F6>?APS=ZEZ#7CDRH,]%8F1Z
MK3[ZI6C=B[UOQ25W2PT#*&&F(7+(@JZ0 O?3H+^NH^M=9+\VWX^"M>[O[2M4
MY/2Z/C]$()S),#.7FU47[<M=,-%\"2[2ZEP*.!+=H,K+:?"T<^ -7G9\9_A5
M_PVB?Z-7N_C*%[Z'SF_-0G(009R/<-KY&(5Y*[P)YQ"R=(!S'*RAZ]1O%+LL
M=VHT.P4:#F=X[-Y_4HH?VAZIV?DXX_VA^-^W2_?*D>Q5! &40C$2X9+*$:NJ
M6!:VFH#7NL[/&I:]B7F2ZOW$OAG_\RZ1BC!FP< 0LB\/[F;LT_<HS^V>2F@*
M*U_.%'JJD\I^?3GPK.GC)/&'5GLS7N*N2^,'$7E!I('P+55._9'"-]&H;Y;&
M+$$ ?0E<QAMAJZU8LF(D([RN"M*HWR6S-U,:!:VAQ0_4O/:SC]&-7Z-<>HC7
M]Q4K"LEZ#'6I8X;P3.E4>P3=<FH>E[2)Y.B@E$ )BDV'!<JJRJ]358=LB<11
M)L3]%:FD1VFK [<#M@Q=!1\;<@'(*XDNCE#"V&,.0S$Z5J]M#'X.8)T!^>9'
M=BT1JW$L6=6_Y.SQ&RMR\BC%$MN?"V$W5>$9MSO]W%MBIBG0DA@^YEV4V405
MYCKT:^.(+6WU;4A(,1+7DQDA(*\^5#KPL)*!'$?=4]W]+#J?;2IOC%K5R;8?
M'NRF;C)*# ]%W"X-&5&;D>7[W4LC4J31@UB:6U6:O/GQSRPW'8[A5=_;H+-C
M_6AQZ]BJQX$/9[//QTE1U2'8(B'<6<=<1RJQXA]"E/RWK#:300"[L?GV6\A&
MZ/J?B")A!P>QHH]MX:16Y:VWOL#_;V[]?R-:.\I>OWQ]Q@IQQ%+@G;S PT-7
M;Q)VJJ4Y4^I-@Q-A?%Q 4(1^)H_J]1;E2*M*9YVF6(31B'A#PC,&1Z&]>O;U
M9+>XU8<4BP^MY\QO;<GR,<48'YMVGEW&;A )3_++ _>_\)T8'##*.+N<Z>;<
M"]^-F7^!4];%^0>G$,7-95!JM+648M#6T^?M-_\_E=6!GJT9OBAB71'!OG#F
MK$J+4,N:)&?67(;]IE,?_8$HI<-2>#?C[Z'_&681':C^I_@AS\G@!L\D&*F1
M>T_7!L\=O/#QN+#Y.-\?!<9'+B!V\QG?Y\_;&LX_3T\!DJ]Q!F@Y3+<W6AN9
MV(43[SR(K)K_]+2(9S#WR3O;=37^!*BBRP)A>1!QYQM[FWUMM$*Q)1'8)EZR
M7T;.6[$G=T2[87O@XL5@-"GRNJY?-#D>(1/@5/FK*B3P5A$EB'P*?E@HY@W_
MJA!=)VD27H>>#F 7?U$\4_4,1GT5R]1[WK+FJ&;9^_$RWQ741R1EBK6!@/SJ
MW-]$#V8IJ/6:-K2>;?S3U(UI/)E];%;:IKKWD*31-8KQVA5B8T5G"],'TVT'
M4V*:N"&Q"-I(K[MNCPQRK/^8[Y2M7P39<*/O*$%_:$/=WXZ2)FT\$@4P?YK(
MIB]=?CPRIZ)4JD;;'(8 J<<-B<>2OO/'<9!5J:Q 3Y(]N-]J98J,W87T8X52
MM,VBG>K&VO5(,5:7HH=;'RU\R-BID:>C'(0_;#W/OU6*,N*QRWC6)3"&:6E%
MPU$PO3@(&-"GJDF;6$M&:6.*EFPCO9"!CJA)QR"^W,L>$8"%R@%^JB"A:D-H
M!,@VIC3ZOT3&]ALTW^4"C00NX-ON[=5P7/#YJT]B#Y;K5<&J3YD IMNG\^ 2
MIM9L"@^102F-WL4*@\DOOJ!D2F:65;U+>6$K(+<IZ>Q1@0O2(CK/[D'D(%U5
M*B@7>A-+ =I=PT+0G![/#T?;@UZH:X%*EP*^P2^EK\HN/-R9#6^U4)UG%$'&
MSOTO*Q.D6APWJS)P\RW8^DOP.BQ+!H//DSCRS;%_5U7B)@V><O63I'!M0E6-
M2K6I-TX%,[\"3;IH35J+\Y!H>LH:8I];=O =O]U]R;(BC:%.?GW1VCW#M$UM
M?8/A0WM@>-RV;%BQ\.:#F:]E=R]!M=^;=<.<S>BO^G"T;-8_[6>\H]W-SA2;
M(QPRFC<-%O,*[;O7@+GAD-1(G7+"R2(N\*;1/G<?9S/[&5LX*H(:P]Q/1'\D
MUDUUZ<H2748"WJ#.?=::,)#/2?NFWR**KME%S#Q'IU6':9\K;KT59=!!0)46
M@(=G$<C(U]ES)U)M]!KR;;"U?O1HO<SGLW]N:X_"O<QLF*Z,1R#&4[*$=,(I
MI\^I)NG%V/?G27,0Z8>WHWU@857[: EO5<HSLEV_?OB<3A]&V5C<.M&<^>KH
MDMZB!Y6Y&UP//,UH!OW5QK>&"C2F;JC>C$*%,]1*U1F(Q2L_Q7(E+Q(&GL#3
MU0BX^?K*PUP@,""^X&+U&"5P__ZR-XL8__J<-WW'V2M_%E)^&W8-FY7CIINB
M N<^7TW(0WX9RJ R(HUOJMA!["8832SY63=?:$/ATYA@K>1 IS5+-_N2GKRC
M.2VU%3+LV84WGP)(57+(5J)3@F7VTHB'U#.1A3KYJ,=QC&Z/KG6KJ/7UR\-V
MOU;P@Y;V3\AA8@GMXS>;#UW/^G[\P#\S#8E-M$(V%Q!E;)2XLFZ COJU<JY#
M!5=*OF6V12A=HXP9=[_&=)MR 2\&NQYW2T*A*U1_6/5%*1'QJ7>-7_F\HYGQ
M+, *4)KO&)^3G&H_33*[9M#F9Y0SXV:)_WG_])-B^.43MM%?EX(.&:BUPF;%
M6UY3=#(G[4&#',I*5%47-@DJIFMH]0YYVB70<N?0G<_VVTFJ]Z<J[4().&>1
MF126),_E=BU%$$7@\Q4UOZ:D8PKA"L@;2R(9QU1(#Q+2<\:S-J*=UV['K&48
M+L1"7%9[+S$>C;<^:R -.0W=B#KPLE7\5,J!(D@A9KX,MYZNFX%@:"[!_VC\
MV[,9S& J"\H%:N V7&#4=_DY;U\E%_B@WVF"^5KPA@O\RJU,Y8AL<0%-71J&
MT\?6Y0+6KRIP/Z8^0FYJ[:AF^=$5K,%@DLUP1)\"H]4\\S7^Y[<Y][/22B%=
M@YXS6A6!+;\A6U79/$[01#A/F&))8R@/CLW81NREL;*?D"]^E%.QV27\,C9@
MEWGJ%$<?1/0P\I7_9'043_>2DRD-7^9<'U\>+\EY=#:3KB=^3;*E\C092NV@
M99+4OFFEF*LC]2RR!T"_O&-S_EEXC8[!@?U>6OM:5HVK/D%FM!A98"C]=!><
M9M\!Z>4<I<VU5%A3="&(,SX^X3FF?;D?,E9D66VN0$+W2)"V#\.%G<F19V'8
M#9C@S%W(J1X7W92P5+.0S>;B\1M7LT?Y;WP\]>JF]@+V*.KKVDEH"4<#7"#!
MA4",_41#L)1O:WA.V;F'7SUF/? J'<OOC2S5'CZO:(G\%) QQNLO;L_4@_8S
M9#%X,D>X]0M,[5C39+#GQ,NCBY].F(R$=@W<":!O.'W1YP*I&-HI+C"MU</1
M?-K@KKI![LA(H V%/-6H=QUZ("7\*3R>SWXON3.53EP1HWGH@KIYO;P =WH>
M*CD#1G#D*@;>&B8+G#JA5)8:^>#VD$'S;PTO@?EJ+5BV+_]F$R^Y'U@395T&
M,<%DG"0RSG*RW2A4S"[_>0G9.J#&\DJ>L.\,4?U&2V8\HA'7@\TPBNK /4#O
M0UKUZ?F*KKTIR2U13O=/$HG<^>F\I_ 1<P_3*8I1?X?I&DEX19")1,))F]F^
M'(7/G*.NTT.ETVTQ!=9CWKYSBX#'11F6Q4F^".?/" !S8YFHR.&EQ'7;Z14H
M+^81T-62-EQ&Z+T^?]2S@YZ19]#,!4X]%M'6]\SM%5\='/$'F H,7@(26\_2
M93?# L@CDK_V/$\O;"!]"U^PKJO+_V-4X)JP"T*@CL?\FL%Z/ \@HJ+IJ;UP
ML>NU.7VMC$P2N'4P3;[JC7M)J]V\]$EOXT]" 1NEG)V1\R/QA5!P@?D/H;<8
MU+*D-V;2K1R;1F]-[KXQOG*X\;6T+-RT-S:DWC/''<I2&"%-)7*.\L(2,;[=
M,5B%D5B%NEQ?U][D!ZL)44Q//M4K[(<WWBJ"-'+$.>-8",9WZ 0S$P#QO9U'
M,\\5O&\W=5]R4_)92!"]<]S2I+P#P9@$'8M85Q*[(HB[VJ$^%!/L!W=5=R>-
M5LFH?8I=H>S14"I"XC2MX"0['S/?MIT/[_DF9D>K8JG#!5=75S>IA_8%2[#'
M96XU/NQKODBYWZ9HMDS.G+9B!$]P@8!,4,LYI;X-*\L9SI>O>8?,X"QXT'53
MSF>!>(OQ45IUKI^U>.51@6BDVHY[\%!S0_2X.3^[X*Z-NQ5^[@B-"SP(#$8,
M-07:T:_[S9C)H>G;>W=IWQDC$Q.VUA*SP-<C;J-!,-V00$;]!*4C<P5MI_<S
MLH6@,+M-QNWC'/BE>F "/E^][2)9\XZE2A=DI-)PUJF]=UBV5C$G+B<_U)D8
M*#PN59+U&[4N7PWWQ4YS@0OLQYCYS*B1A(9,*!+1CX5LK:491ICOM1>8'=3,
M(5%5R227I2YSF\.B1.2.'7$GH;=8O&P[-G\&S&1\9C^'Z=(R!PHA=)\X]-Z
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MH0'! 0+@HTOEX$S0JZ[%$#=<5LM"8RAB?)L\^VR4<W"2#-TW!<_5!Y!X[9$
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MX=J0]EH;HT.J<"_:Y'D/5[4S]L^7JOTEJ,D9Q_K*8]YGY5X_M:RE%I?H^N/
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MHS4QK5+<Y&EV0F#.I61N711Y,D#0#V;L_.C">G%$]]V'SA^WS\M'982OM14
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M!"%-C!1JD"D,AI'+<8 -E;UGX-UJ:$P+CV$L?GWS^Z$&"=UYFBXF&RN+FCP
MQ'!W;:.A=5G/\#U[65TJCD1?9FR>"/[WEQ%GNNYOE[>9-]H<U8]:>;#KBNZ9
M4OUI3RE9O:FB"'E7JF#V=.Q;R@'@P)P>*K%,"$]??GMQ\KC.5UO.IE8/FACH
M1O)U)KE/E!(GM<Z K1S'YA1C-\T]?\O%:%O\.@!XV-\>C])08"?E1\NH[Q=@
MCWKCCOAMRH%UP10\4[3D;;EE!;A1*;#Y!F-V;"']2P=A%:ZG]#5)T.?54!UL
MFGT>S1#.(!(VSI8AO:B.*74A:IKA8=VAAM2"T7S+$,//\603#>WR\@QF.Z86
MRRK![>HH"8;0:-V:M#:YI[DX*[[6$JFCJ3\8[Z=&JA]=F)_I^J3.6_ ( @_=
M&8#2/"BQD73M;DJVM+1CFU>A--O3*7'<GNQ)4PFW[X^N0-X70 9PTSY,7AC5
MP)ZRVZ/V/!]B:!/&BD+C!K(-'S$U2O*[[L^;_)%.!X!] R%&H\E-TN\$^\3G
MP9@1U(0D[!E*!_1OIR)-F-\R.BAS""X',/4TAE8KV1C>H$TRT[U__\>7FT"%
MR7>EU2T!ENZ:3$'0F688-Z^"BR;#^$F.GCLK\FX:EC\E.#K@+:<A416"%PY]
M,A0] #B:P8!Y0ER>"F60%M<E8#_:<Z.>%MP@F?I\TT_M1.RQ6?&8_@='2X%7
M]+8 D^,ZC*/GR=*8%,.S9%M![SQEL+@,W.W 7[4@V0HP+B3#Z@SU'LN%G)3F
MG%(I]OV6Q"/ELW0 3'?27H#=U#7:"M@W#^?\P7 :?<@46@E*)/;#.7I]G@=*
MD#14OK]=.J?&?HY7Y)%(]7>S\'&Z*JJ+R;7_8CVPGA*#+0[\@$@/S+\Y$6B]
M.Z:E8ID6U".7?<6JX&O,.D]5,"W^ (CR0*KOEQC+'P =/A7.8,8%JGMW]@J^
M.2NN[G7MY^0KXZAU'9E;,O?*#(6_B+!18!MA]##44/ZGDDK*A'18MZ1K',D_
M=4ZX;KCNS9D_F<[H6,GTKQ_[JMC%#7S?.,L_;LOP@X@2YE #3J/H=E^DM*]\
M]Z ,"S!">>^-J_J=;$X-JCSNJ)C*-A\MTB7VD/_7.9\U5I6/<D="Q_ ]G=<I
MWZ8[$=N=$TR1<>>K+>DDB]$3]M7M4GJGSUWYU;;PD6.G!"QD\J12<-VN<B"\
M\K8S(D$Z>'[CPTTP^'KM>$G"^HRJ.L<F9(O\Y_HK9$HMVY]=2ARM:+_T /!*
M)HBV0/RIIM>HP@BFC2K!M%X[NMUN>6B6VSW*I.O2IS\AX4MO.N<^#R:'#O9L
M)<&.'  ^K?YFX"+)GW,9Q[YYJI7R/;7DPK'. .E_&Y\VWFM"\*D.O/EE>Q?N
M#$>WGV$*-733,>(K]4Q%RG[/VP]G,"'%GGO[W9EI80C!RX/>R1_30W1[0@:"
M/6BR8!"D^XSDY4CF^5<R2OY&+PDQJ7U2%I1[ABGZ&29026?&0["8'L8<AO$A
M!=RH,'O0XJY\AP$L/O153_QSZ8F:LA]I4N&;QH/0.46#M%S'=^AV0&7SW?[S
MP&7_NOBZ?K EI&IF=C5M8^:]5</IR_."&K/,5ZMP4=S\RP. BZGAY<I>/U9K
MX_3=/W8/,:)I/:!S/?,[34DHDF8IS4T0ZE7T&44_@$R=;X=5$SJAH"D3ZEEZ
M@?*G)><J7?'RR,.\![.RG&YYMIIL?Y(II]!'F=TW< V.W0.RO2@5ZIEBRE)7
MP\?VXE5'OM/)BYWM0BFK@>RP9D(/+,9GI,6 !$\X *JWNE.G KK$#@"I%C.J
M_2AY?-4+=698RU1X*JNQCF[27,U]_N@_5V:;3F",?-:Z6?'A@U1)I452@[M2
MUZU+)EK0=_;0SY7_%MDIIZ_Z#[W.U'^?>%DJ50ZA!; Z6S.D][-0<EZLD9B+
M*7?QSCZNYO].M;S<.MR?N)R_9>%Q_%E\Y$I>X^9A(%S%>RH->V/U@OPD^??:
MM4MZHM(?+I7^E#+7E=@W+MP;2QW)F.3^N8"7O<,#S@8> '=8'AR.;5XQWG@2
M!/WE[(=;%\G?.S=:6G%K\!K9XLX;&)O-9UBC$=?=?*?0 \#*O?>'M'I:^]:%
M(237 7#X><,( TZ_S.QS%:5^ZF3QS,';U 5,A2DB:&K.I=-OP./X K7VBP;;
M?)I+*4-4GO0F:]V.KH'(Z$4+[OAS+\./:LE74V;K/RH3;VFN^>2\BK]]2>1^
MKXSE58+JQ6VX"6KD *CABD3[#,8XNO* SPMF$(D7QN1N7;[F?K\A4X/7AB])
MTZ^40^.%A=8""U^AY],)AYD2B&L]3DJ>^KTL:!M8*B!["WW4QU&_:/>8S^Y=
MQ[0:R??M+HUZP,\(0T$59Q)Z'4;W!'6(^_@>_Z/(ZY2M;MO#:T[)"Z&$5Z=_
MQJ'=O4^+U6]&/(R]^.@(HV#G3 MZ'M:-2<%!C'F9 ^CC=8/)J%-47WS7H-@,
M(O@F96.\Q;)$.S_ L#I2,E"XP"0XX+O/)F9JD,GC3\FB>8S]3K:],!I8>>W&
M^$Y&@79AE?>HM]B-T,>'4?WL7RQ3#$.?/-+3:L%1;#$Q]?G<+7SS#D.;D%BF
ME/>P3[9H6;._QMRJO(?%X V@FHSU9)\G3'42"?%8+H;7?@OC<3'#FAHSL!2M
MIB8?^]62[!.6$UWZ^EVV0_O)=S#%R![ Z$,O0UDMF< &F\\C""!OA5/+;^*Q
M)U##S=BX0N/6][U'JBG7'6]YR=4G*4C1&)]SRH_C9V1._2=4SU)AO81C#/,<
MZ_&[5+%4S=@10U.!5L:+FZM#+2B[D#M<7AD/S#=;',W(L,EH8D,7?,IO=/Y[
M*_%+("QN0OO%K>F;@[(A$VN"_%?2^37ZI "'L06W;0#T)Y\I)K,B/HODWY,:
M&8KOV@@C-40S+E#@-Z@N+=EDBS.E1'K9A>=I17;?[#E_L+.E3%7!28ZIS%-(
MA?U\M ?ZZ*K3;E>J '-0W[;S,]=$8/ZA/_[HMZOY)\7$J/6W*KXAD07S^!]P
M;MA\)H&;R8>P[G'R3<FJ\,;#C]1N%Z[M86L^V(1_@-\2.;L@%7<Z\UPKT+9R
M"RV,FT]GS<],Q17F\9IQE18'F0QBJPRAL[_8:2VCVZULLC-55:HL<D:!J\I"
MMX 3W6["*JQ&IC1?EJ]\?7#"AL)ETZO9I3275)IY=8"X9\T3MQ2#WHOJ$7(_
M+"H1%G&!T 1HM<Y&($6^LSFNIS*,]#V1VG]Y[!Y><_9^MUQ]UM6I\"+O8V;
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MY1(A&B9XDNK<7@HFWFRA-L2EQM3E;#@ZYS%7=Z_("?&$\$R+L8NO*PWGT#1
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M"GK^#8$;=8K9IT)1I7=HOZ<,.1<I%3OK)74Y1&\YTF?ZD=W/^_0J"4+,G@,
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M<<:G?(XLHZ2I@IA"*6?I&R%N:C(2'QV<.0Z9]/56AJ5V8*8'.V'B,,_4>)A
MK1:N<0(KH?)A3<?XBO*$\S/5%UR;JXUR@=)4N#9S$EH3[95/,>,+AW;M2OK'
M("TIF(X@R<4W,Y_B-5L=;9+=D\H%]9Y.];K\\-!B,;IV$:RDCQ-LW<&-RM<C
MI(0T 4<13#VJU.&>!TV]F=%3LM=[[V8#GZE;3#X>RM*\15>J, )-%^LU5FX
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M2^)C-FY8+_L*7G[A+#P2 @!A#YJ3?9B\'O.0*=>O4&Z;4L9U:CM%)L/W,5G
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M &8DOX[L<U0K.333VF5'A0^/N$)0?[?JW^BPS;3.Q_<AXA&=&*)A"7@>B'Q
M8G9WM)%@JGR$H0D"<3^XU9M\LX+%5YN2^/4@+J'9$)^QP .(_)]?5S;2,&.[
MBI[YE?4R:UWQ9H4Y?5"+')9)*_AO2MGDC^B#;+\?,E;-UEHQHRFJ B,;%HRR
MSW).1S']?Q&%__,H]O\3E/];R_6(UWD"DG$JR _/=G/)5]POXIQ8U?@JP>J
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MOZ,CMON+G_E=P(W&8Q!^^N[:P04OF*S9)\V&A,>J\=O;4&@KT$&\&&Z:<^L
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MKV?E>]2AS/ZE_^6IX6G%*6?FHXN!M;:=3S.^GOQXR0ORX73-\0%Q&KER-A2
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MEDM^Q"LEMDT.Q%2Y75G7^N:49O.E.W% 15S>3^GB5S'!_%JT8YV=IJ6?-G!
MOT@B@CO  JI"Q*9**..ZC?(O(B;FQNA^II06AELAX?_JZSVCFGK"K]$H*J)
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M.@5K XL3],5"\F?QY %(=ZML:OL85E=_R5]<R+S":+,@17,36%+9<8O!G(M
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M@7ZQK0)57VFQ*5<N)'US@.>.G?7S%(D[DE@D^^A';\ ,[O9<]-N(:=5Z? O
MKJA>QG_%_$OD^;<7?150#!25>)N!G>-Q[$!($>9&:W(>3ZPIH=W%WL+'SUP'
M$4M6'FH8OK"[L,:<$-^SK$2I&XMHFSU(209%H[!"JWUH1'<K.+5=E#+M##?W
M[ <+T'CP%^U.!-G]W-?O>7G>OJK!.-QV<7!-@"0W'&XOT3UV _WJLZL?<04Z
MBEL[P@3#;>EI#*]2N&W7Y,/6POQEJV]]XCF/7=](:BY7Z)U=@4:CJ/=G&;+%
M*1#7-,6]J6EX!ZD?29M'X\4,9G(_I4F,@]I;./;5QAH"N%N%<3/##&8PY#-<
MKU/>KD*^CX:9J4V'0 )1KT,;9Y7RBKJQECT<P$MN::D0RC]B:[C46.U&+.)$
M"@WMWCKR1WCTRI/Y_ . #U)IIK8##B%S@P4:",?>GD@A?7U["_F"W4D<:I2L
MB^D;M+,Q%8OF4I#JN1<14:]!H:@$%-XA..0JCQ6:7GVQL3Y[4]JQM8H&B;79
ML AJ&EH74E6>"9/^&T9SMB+K76Z&5(2HJO;*BGUY!\KPG^*<FFE2%O',2FTS
M"ZQ%\V2L&#?HU-=:-5[D3$];ZM;>J4">&RQF',K5FN=H#VG.,)OYU?&=*?:@
MP[\?AB;:J,#^0K/;S/0Y1-X!X+06_4)UC%CT1W6&J%3'AN&%3Z4&#!=.BC.L
M<*6<[*.PEM#'/82=P*QM:N&UYS(DKOGF8P5*#U-+,NUV,W4COOFJ?YV1_8?V
M%(21#:@+-4C%B.PWUDZ[TDT8?3"*CZ! 4U5+^JKN=%3Q>N!YU&%T?_O."ZP-
MD-??DP0__!!ARR?OYUI+!(,4![;,O(>[9S='-)>YRGSF<JXIR*T_214&:5RG
MSM(_4(6ZI@45!I0[!8/,.\[9+?.>SYU@ELH=B30X.1#TAI%N7H?=XBW-^_<$
M6<'T=@G;J109^O67;3QCU5]J+I24%DORX]&*53J48RK.WS6#4-Y_-13-);3N
M-K:.^IXCF%7?E-E-#R]+,&"F$SAR87T(><0$DK=5Q%BU[E#"<6D6"X$>CR""
M7*/:D(V<&)V*U D4_3;COU)>^;2!PI1$V"'2^K4_U)Q3G"GJ;9\^(_[F]0&@
M,O.3RQ/>"(79WOK@L\Z$K)KPP=R?]2B>Z*BF7\(@;C /G,(^+<VTFF!P?K<<
M*(9K&;EH2%B]RXZ0)T+4KAX <BO5:@*7_:'#LZOQ3$6&!5V/(?29!:':9//F
MY/W57#GWFB.P\X/8_)O=8/UTI]E51>8)!B>;ZP! =1AL:^48R:_&6LJT-@>"
MO'X5=XO:9Y>"HSYS"JS1AT/\=F]4:K>QW^_64,S?R\;D?YOM9X>2N3=#HH/&
M.ON%4=X"S[Q&+<,9_UGD2KX'99ANDPN^%+\W^/YJ0="3^GDS!$"YT*JT_PTY
M]_XT&1./I-:WGEC!DY2[F5)VL_9* UJ='<U"0\I]%UE'FI/;6\>E-9SI@FEB
MOAQID;=_*I2?3BB-#1^=Q62M,E_^"Z-@DD2A+/Y!TDPATX#E3V5!N)">LSP'
M@((E2Z<WZON^)%VS1UHFY].E5#V"#10VR^E%5 2:RCGG&TO=@&)]()T8<F+Y
M@/>8WWN29W=G+_U^4NE?HZO08:$U-/,8 TB?9R ED\EK.J31FJU%+]'YQ)#0
MHGB5/R;'.KBO$GV?P38MV*<2F5?"#:F0UWDC""W'/K+RZK,TN =Y/=/7=-:Q
M\E;0Y.@IKG/RJ3N?72@8C;\593'^P$>QWFI_LUE\6ZL1%J=HZM\F,PXQ)%?0
M82$PS SRQ;'$72XI8Z'U%4.-1"HWE$E,;NB.4%A "7GQP<7(W&F_3?T"?90F
M'C6]Q!I+@?<Y#^G-^<,U_N@8?G/!-]K"-P?6WN6FL?F7*3_DCS7^E^WJ_X &
M'ZRXSC*N9!F,2?,$%$R[!IP[FSU2 G\=5]!8ZS;YB 1$6S,*"[5B-1P?/OZ-
MS:@X?;Q4WZ.LJW3)9J] XL[+B^#WI,?+AOB;R\_#Q=<+^3)IAF7_*:JI>J<O
M_'O$CRQ^FBE#JVOSK];LLGO 5]!=8KZ3-W2"J/(;V2<2J[& $U._+OBYL?;E
MU!49[<E#=FRUC,@TSWYPWWVV&WD\,<YC\_NTY!-S<.VB@]L&O?O=UQYHO_5E
MJ4%_PC];#-RV<YAE3N6V=85-.Q:_EW?-S8'UL%Q=9H3&^FGSKNGZKBWN#[+\
MA_;TZ,=IA$.Z1M.*%9QX$N-ZHJ N3OM35%75^)F3.MI+4$?$.%BDVH^');V)
M'/&M.01+1_[H3>$K91. /5[#<#?FV?Y&6WR\ACOW<++VQ6'6W=O?]V$;H$FQ
MMDPA%)<ZC_>-8KLA7_2.YWZ=2B]R5H9MO3!<K%S1Q)+KH\B'Z98J%>?"_.M2
M25.Q&1:JE+7G<42]# W.]3W_KA!^(I";6&W$M/7RN )>\6"I0D1W_!*Q5775
MX77+KG5IKX?EBC8^4(AZN#N;H',:@^,.8L+Y6?;"G,!=6[DDMC:E?B TK6_9
M]6+IO91]BU-UCVYR<#U *UDWS,_6:'7YP![\JH$"&)*"J&[$A9/65#O/NM5G
M(SV<TX/"@TXT:!'DR %@[AWX$DVHW0+HM)PKG4NT$TS#0R;/'^L%D+)Q!M<J
M< R98-:YM'"1,C,:!/^FEEY;<=LC1J^DKKD7O+#.=CC,4JR5[46S&L>@\[8B
M'%3ZGNW*1R6/N![J<H:@C\DZ4HL69/&*<L4"B[^_/ZINLG[8HZ0R4P'1M0=:
M;2LTDU$U*X$)]8,)85)].OH  W[D'0K.:Y8AU\L>A9YAA91X.PQ]'6%9D835
M)<"WKS-MDDNF?FYV1/ %R7<^ TJ=G6G]TN@G+Z57A6<0^Y#".!\('_P^?688
M?,ZST>-U34WKH>8SW(A;_U/+_LW;Y3S3B>DER!TK_:\B'$)-#"ID/8:1NZPV
M^6/32=(VQLZ)F_]"HW3G(.LLI4LP5"@RI;2,88S/RLTFW6;)D>&!J!I'^^5+
MV(L!_F<2.?WE9"U$VO!'F_SB451S:)SH8K?8DCKD'-P<3_K90,Y1Z"+6836?
M:Q9RUUG*0-WB8W_,OXGB1CSZ1ZST/,RH5H/1HAN=Z/OM7QD)4*Q7/'SE.7W5
M!Y/\=KTYA4M7K_W(#&?>BKWD?[?XT"P16O!+E@G94R/Y7I\9]==KW4_=6V89
M8Z9]]JB^!+AUY);5[\B3Y 8+NRV,V*'>U6D]CV>J,(+;P/RTV%@?=T(MVOP
MX%CW=F*NFG;,UN>\X4?*_L+?YN\!+,-K&K.(;LC7(C13%=[7$8K>C5-?NV,
M_%['YL_0/N^VY9X2]*Z?ZV^!N ]=((_LQ[@$C&'QE1N7PXA6?V> B>T>G9F/
MZ2/6O\[?5TDVB>/VT8OD*)7UO^<%H=Y7CFZ<[3#=.-?FCP&N3M]3%*AI4&^0
M'OW3E '1O#3V.QG_(L3%/^GH<Q5/CK\%.<]PFL^U=]1E?S_G+H^14%58F(W#
M42T?"B ?&9A2D*]>/'3LG'2ZNB!F[_,'FW95.\%$]JZO'47O8YP$/T7CYU\H
MMJCT,TN'6ARG;ZCU<F=P#2UF/?:=6O@;^Z/BII=PFN%'A=V&(QTNKW@ $4^K
MR_EBEMKR^^]#%1AA[%-=U+&5.624OE?E3;(RT(2BP#E*-*VO4@QYY/V:2TG6
M$FSWX(W6[F#H-B866F?["J'(^N^<(2F[:<V7:8I-(-/I([^RND?O),IXCVS_
M[KD9Z@JY ]BASNWN%I;DD?9O.W&D_%+\'YL:55 C^!7J[O]\"ADZJOW[<M,A
MNJX0_GX^<>Q"\J>P^X<//D_W[D4_W2FVNL:M<  8^WR1!YP >)02^2D4>-WB
M2Z2HZ_?NR\="]%.[488 =7Q** HM9H[L))1\/G%R$]+],>#(BW\!31#H5I>9
M(<!M"2Q</5RK4)[HJ.!HCXD+BW^<[!H6L^I4TG=&N^\<S/+_=M"9>/"-]A\9
M5ZAMD%O?LM_;C5G;&5 U-9VR\T.['Y=-<./^%C6JHG,L[''=?_>@4*&Z;1.O
M':,64I)8M8<1&G<8=+7@8_OY7=VU5+QE.FDV3JNV=_)64\W2@HY>';)/U6(7
MO@+-W<.MYM.FZ'*CN"J$'%R3YC/7ZPC+>N$3\BA$F/W/:4WF">O["\R2IF=_
M*79^Y:<1O,RA.!8="-.L:\#&+(]=L_[RGB./<U2<;3TA[J,EZ73K 4YMJMW#
MVFO /'2<_51PT7QTU1UEW/AJK_UN_-JMO"P.UDW)]Y39,\T@K4A]0UEZ:HN/
M,M@]$5*(-$2)0N;2(4?9NA8:W:5S$A>[]YZN-Q*.?$L'U]\%CK0&T; LL0 J
M%FJ;:DKS2Z[YX)@F]E"Q/6]'+!J^H^HDZQ70[H1=1R1&4E8O%.0Y**IM$MA<
M>%I@N!9M NVN>!1&4ORMQ?KZ-!6UC:= ;R+;+%M%!LB82+9\ DS?:>H+M)-!
MJGNC6DP\T9I,0,X14T]Y29ZO_:6(4("WSNQU7[]RKK#9_IZNO_-$*;)-X"E;
MVNN'&V4C@:U/,\PR_*/1J&[C_P.TZ^CYHZ*4.B-Z;H'^@Y7B9"OH(J=U[S)J
M4.BEN@'P :&JQ-B+NU?K"CKZ<7$E$N0,:V7X,(_#5^C%HU\(;'$&!$J[\K;G
M6/!90YF@-/&7#?-/I:Q0#NRHUI/(MK,0#^#+$S-F6J36[(A WZFN[B]KP>=]
M&_ZE0.[LQ7;DGB*$2S^2R$TMFEC*2-L?]W&U.VO\U?)XJ#I56Y>79FY!U?\-
M%3>\F<XC!E[\X[%Z&.<GL'];3X^BFPUI'398XD;4%?RUD;:406G.IR,1B_AG
MVN#:O8DY8(R#7 >09](S%S2R^L)'LOV\0$OANPO"CZV&CHLC#,Q\KUQ!S^:&
M/>C)-O.Y?_9R6/FM<",U%4P<2L-()?_R^NBV.*&D8A43$/?_*;A<V53U7W1/
M.WZL7\R=VU30Z\P5K*:9I_H7+=MH[L7DP OEZG*ORMPKE1!QE%I<<E0G+MT7
M+@%[>K;_6$<XLJ=Q5%]<+.+\ <!KY7 <Z^CPRTBX RR5=U9I39[VCQE;(9/;
MD5J(<&?$TD-H@ZLFM L&(#Q;[!=+6?1'K:][4LN[UA65WC2\B('"WHL<+0QC
M$R*_&!Y Q5QG%)*FDN4ZL\ HM%?PG7NFL/$,LA;G/BF-83NL))-[,2O_(X)F
M[,Z6W3H J(D^SY'_-,1,;5M2_$Q+[:#_RZ\WD>Y5?Z)I7()1HZY_J<L4"E4<
MGA;_=,L$,XI*/829:ZG'85JVHL7MJ#/+*)Y D_BT"I*K?V'_;ZJKZWL)7=M.
M9 TGZYP'/9'Q\/D6-N9I^$,_[^#]IAN9DBXB?]H[Q9FI*\Z^:C'4#QO((_8!
MR"LU+(LA;63R)=)^OY//0FINH)A[C$*Y3G"(][."0_ _4@%55Y2M6)YM^H?P
M);>H=>GR-I'^V8#.PET[LWC^N+HFHL'6(GMK= R$UE406F"J?K>(9#1V3$ &
MH;')2.$=\.J;6WA(*=W3X-7LA=W_5I:^NJV#B69?.4PI2:Q,O^W3(]>W12XT
M^B74G5F.&Q MYSHRD4#6P)V>\=9TS'\Y:??3$H-^,2-!Q<?K/\HS]&TTH_1_
MEE(0><JV[N,5[,_&2C,K D8IW&4)OM:VLP&CD#G4+FU94F/37;K?L618[==7
M(&AQ!&>E'T *IF6VP^*D9WRS9J.GMHY+&"EL$>CR^PD(I>L4S)J/5IMN=Z&?
M6NSM_A/3P=PNF>$ <&[MGNF<W[@<^0#0+7P^%N]\J99J'A4I9CJ$@!5#UYOQ
M>3I_HIPS^%[+"CN*R(J%+"-@G>(1L8%^KYI19B*;L2EHVV[GBW7#-=KK&@^M
MOMSFL_AV4Z:WXY5P"M^GY_Y[Q''0UT76N>EPV0@/<FJ<#7W+.PVD.V5JD772
MPE79<EV'OM#Z83_G ."ZP<$>R(),-*M]<9PTD]K?^8-J;FPTF/BC_]8L-+FE
M-'[*S^+N-L9;M8/T:/5K^0("&0_O[RVN[>Z;7IL=3>BXRY1Y9*-A^5F)G_:2
MP%%G<-PI_K9?$V,TTL7*::_%_J_199DTGFWG%X[/@ ;_<Z&7./MU,1X'0PI[
M!67%)JDG0F+IP399+PG(JO<[IGIQXCJ:V,\QB8A?QU*N]6Q +537^7,=]BRM
M:,7MLPQ9#Y8\ZAR\;)+@,*2LKU-QLUQ"<V'E-A#M]7;Y5+NEW/2K?/]%0%T(
M>O\FF^M7@%^^8R6J<DDHTP8!P%)EGJV(WINVMQ"_MZYF>D9:+]:0<UY_1V#'
MXUU-R(U(\&7"(=U\2Y0FH7-C2U@W1C5,RY' '*[*=<7F]GCZGZ8C'%?_G5'.
M* MX&35N>[BYCY_=?]EL3PY9^-6L.;G0<#C+ EY[E959C[NQ>_J:=>Z H7-]
MN!" RO(12.I?Y7>712'K0YS]L]68=DR"+>AK73)I)2Y<BXKO'O//#KOT^9MC
MGYZCVYM5^T=RODO2D&; I[<AE8<1QSH7 XK.K N-7DS(@*W$:Y3GV)P6.U[W
M3=7[:HB;SV/.,]U1<IXK64P1Q2H%-9?J0*D7I<>N67*V8Z%4$Y[0 X Q578L
MCZ+,RXCJ1/ ,/:$F@C%?Q!(E3(U5-Y)EXK0[>U0Y7N@LM-S\?@#XZEY.2IWB
ML&"\;94FO&B1,R9 JA^/J/OHK7H\2.T[61K45M=;1?DC\\1#XGB$QOPI:[.B
MR NUT7F6.$U^%P_< :"LZ/]*H?_[W.?_P1?H_Z\5]3Y[9W6M\.OP4,2E%4/^
M29OZNO'+PG-6AAYNL%<^O?W\B[4RS4E6AD9[:HXR2D'D5/*7!'3!6[6F8-G[
M:68\6U:&]W_#'HU:&5K^O_\D_4_3V+,RE/O*4X2[<ZE8WM__%\>(EHB:JU^^
M?T)\:H:CQ*4O>>7EK5%,\>D[NI6IQ8P$1>QD1 [9P\N>9*]V (C@<*HL92JQ
M=,8DLBC?6_FR^YE=VSWQD)1+7[#)WFFF&6:AF@&^V>X1V-40*N;.&W4(D*64
M9&'E@B(]/)%,A;7-\"'5S*B544\. ,$O-/U+V<ZC5@ZF?/;E.I"6=%%+OP>M
ME")L7<JEA [Q9R7B\DE'_CW^]$9 ?BJV"-#%;RN>J;:;7&*O=Z&=BHN^8KQ;
MG-J=(.\=5BE_'AA2]\/S2\+XT/_)/^!@XG\!4$L#!!0    ( "B(1EMC=6$-
MSW4   !Z   '    83 S+FIP9[RY=U134= O&D1$NJ#T$A65#HH@TA(5 4$1
M 2G2(B+207J D*A(;P(""D)41$!*I(82B-0(B'0B'0)(AX02 BG<^-W[OOO6
M>]\?][[UUMW)Y)R5LW/.S.R9WV]FY^C/T2S@E+&!D0& A84%\)CY AS- 9[K
M0]V? 0 F)@!Y  !P$G""Y0K@&/.,DRE6K"P -N:1A2F/65G_X_A/ &:G_OOY
MOP\S?L#Q__X];YN9P/\\_S?/T-_%Q2? S3>0^5WT1P"@(N5H J '.,;"\N_]
M/P8K&^N_<>+X<58V]A/L[/_D) <7Q\F3G"?9V3EY.#FYN)F#G8.7CX>;]]_Y
MOYO\^_F_7S'?W"?93W+_;X^C'P#^DX#]8QRL+.<!Q_A96/E9CMH!0*:F;"S_
M,0#_8[ <8SW.=H*I$B<7<T+-*:;ZK*S'F,JR'6<:RQ+!O XXSL\F<.[*S1.G
MS9S8S_N=47V9^NFD]*V*%D'S >*%JT_\7W%P"@F+B(I=O"0C*R>OIGY-X[JF
MEMYM?0/#.T;&%@\MK:QM'MDZ/W5YYNKF[A$0&!0< @T-BWP=%1T3&Q>?EOXV
M(S/KW?OLS_E?"KX6%A5_JZRJKJE%U]4WM+:U=W3B?G9U#PX-CXSB_XR-SQ'F
M%Q;_+BVOK)*V=W;WR/N4@\-_=K$ 6%G^K_%?VL7/M.L8<PV.L_^SB^58R+\)
M_,?9SETY(7#3C-W)[_1YU9<GS]Q*_531PB%]U9PH^,1_@%/H@MK<1=(_T_[#
MLO\UPU[]?[+L/PW[GW:- [B9(7J,GY4?  ;0:9_C90'_9\3K_?:$R._K?<:
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M]N>/ !3%D+BO>,:Y-2 G@V-U1H A1CO7G-?6X7C)Q)%+*,_MA$_4:[X=DT7
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M)ZLYZOY$&= +L*[>(>1@2AE1F&Q*1'3XQI)!0,I(V:K84@+,)+RT>GQD6&B
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MKR*:&@YGM0\9/6\8+68E6"6[)QQ+!@]WLAP@BP'XH06:3,(OYXWB<EM/0OJ
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M@;%P#O>Z1(D(:'3_4=L4UU(R&G)Y.<OO". -U>@0NZ=,N-;X7N@NU.AZE\*
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MU'G+[,-Q[9*@[I]Q<W^<#[#1S6W)F#N_ @Z?M^*-+T=WJ?R:N?[;T_E\T?"
M,FZAC!XU5NLKCWM +=RTTZ!8[[(? 4X02_L1S!J-%\W?Q8WTQ!P\9;.C!X3A
M7_10H32=5TH5%!_BP8<7V6KLA];3D._L[8U\"<BJX/3RE=IT=[+UZ>XXWPM<
M',<U'#YCE8)4E"U:%NWR)V4_QW-RRGY^\5]*="C<@E;<3K*'=/;%'X)_8%\?
M'@$2:L8R)65N5F4>+J3W1-E'22T5SM^.6'J2+RS3#84P:P$&Y]7/C!8D9[[;
M7(H-"14K.-^_F_CB]Y3.BNYYO5<1+U%M,[$S9W3T24C<>$P"QKW4A, GX,'M
M&%Y_<-L<;O/1],!%C)=]_T4QUFUFW-"!7@+7\(2<TC%22W-<N]?EY(/;#S-)
M2Z\4.0),L\JLV>MV%K1N_-;&*SLED!72,I?PCY^G?KI/-TFIJ<Y?!*M8].KI
M-#:MYN;VY<G3GB\J_/6TK/J;B:I?,7M;4&_@VW0/N:EDERGE4=.N RQX_KO2
MU=[=OC!@!BWI"7K.LEBUECV8)\%V.&+WXC@RZ<D:R"X?VH*[;>&BHG95<<A0
MO3$FVN;I]F+M8W]1\0IV9!F\ =$BAIA%A0 %4=78UPA!=;;TC@01$U:'#P>N
MCOKSW6]WA3DO7Z'=PDHO/4"(E?#TCF1LE$V53=9JC%XMZR@8-A2PZSZI<)Y^
M$I@1]AX4. =V>30E05EGT[FM=!$5<(A)RJ@'MD>$#6=L VD"5\DKD D$V;VJ
M>>1I/%@,ZI)U#_]D)E-5MM6>S_VAZQK$]M-/FN?Z1<\2C_<'O\\G%C\,7.S/
MBY?]V"Y7&=%V_^/NQY-=/U!)B-FJ9H&$3FQ55LS&L[3KM]:(5T)//V=U[Q(D
M/X-#?C=#F1 811-+F0]I[07>S3%G]-BH7U_D6=S<N3)!*I=HF>#ME3T"G*)E
M$ONB7/IUG EIE4H]>J&"E7?RW=Q:GS(R L@/,$> **.O-+LAVL^IP"83UUHS
MVC6\9QUB?F1 (SK'D(1*\'J4^5=<R=_&ZD;P$I/&%A&GE'UHYTBKX^+!+FA2
M9BSQ7BG(0K?6%CC8;.!WWR\'5,)Z4<O\Z^_&V;[761V(&H?>Y(_>HPH]IU5%
M#;M5M:G6@R'(RL[L!IVT@VS['!8OQ4<6\0?@V<W<;X^4$T 5@<HUWH8F>:.>
M[_!LD6G\AD/QA_C9S(*(.=3+;-[T;UMV:^+!M1E?-!5YC1'&NW[O4,Y2'EY$
M=Z>#PAYG',U[+D'E^(12*\[-::?=IYA]2G0!CZ9I$VNP+W:M:FI<TS3C?UN+
M<-4]PZ3/6SBWH$UPF_B0-<?<N11!P] Y;V4#N..H.NW;]J2E;>7^6*Y+]ZZ6
MP@$ZOF5X$T0J=%Q+K9UU /EH65GEERITU-CJ6-<%Y!P!JOZ6T3-(0S>?;2BW
M' &.V5N/9SL6YCH**=3#!MYH[T!88#JC^/N43Q]_#<)*PCBDB:CR14I"1.&:
M^;>5BB[N  7%1'I _ Y)^&^#W*UEFBB]@!;QE:9"+V-<=V=<(BKM)TOU=>#1
M0FL2[\98+Y]#:/6/(O[MUQ\*MRD=FX4I5"3K&E\)$?RR#2/.SB[@LYF8[.CE
M4X;PV4H<_>I9!GX08>23=S<$GB+P77!')0ZF%R'3!F%O*X;<(W9(U 7R/O5%
M-D60^:Z72%SP2FU;?QK.AVLZL6]#>0TS>Z8&/FFW.JBTF%17?P1("1+Y2?.S
MGR[YLF9;6R94409-:-L1_S+!E;/'';S;$>J:#'-KEAWR7B?$6-59/0 -7-:V
MEHSRR\[-Z*C!9&[K^9U?4-.?W]IP=/!(+=I2+RR&6%MXF-L!;]+LZDCLR<TB
M*Q4>8GM)^W\NR/E*9!T!SJO4N-*$OL>T(45TM 4Q"3+C9S,UZ*L-OE=26U R
M,1:I-#Y/;DI<1@JO)KF\C>P_DJ:2!!=*[1S>Z:XPJ_L^]IL];+%$WCSJ<W*\
M?Q78MEEHO.LKC&5PMT<SXQEZZ,O.!:O)LSP<)G^VDL9P,.L($JI5A:K-^(WE
M;F;M0!FA5IK9AZP8FWL67<(A&K=[OJ,BZE$Q-*;GV;B)*J\Q%\NASH:#092]
MDC467Z^+TEUIS^1OSOSQP0EN6>4I4N)(R XT\%3S!8J&&7$XJ\&E(#KI='O7
MTV9S6<7"1JTC@!:Q0B3JE@0U]^WSWS6.MP.T?F=YNA.VUM$Q79YOK][ U4EZ
M:G0,32V+J>/3&Z;I3L]>%Y)>\"J4C>Z*HX0<W2M7^213_CQ-NT-#8>8Z+[L?
MYI8GN?L@QP/T0M&+R1J2IDZ/<*#D\QGY)K5A?C\]^XLF\Z)-HS%!023KEC#'
MVN\_MSV$W)[JGDP5=],\C*>+TS,0'KH*[6+P3P2^,Q[G]DQCFB5BC+<QZ[W/
M[?[ZOS@"B#]6@C^FV5 &RBA<;57V;H<1;P443JY[_WT@S<HL+S%VH01D'&G5
MVBJX=MPG,[/*WIZKK"(A146'!9\WLM[?0E@TS"M5?,]?:)S@[[-.%P=6EZ$Z
M@+'!S>I(D[JJ$26SLO5/JFPVYR7?A>75#$'!\][D]R$7R.2!LKUAPPL20L=W
M46\8['8F!*" 27GL5JFWF4Z=TCO&*FPOU7.9CU>/S/-, ?'NI= 1X-UN+[3F
M<O6<\L.42ZK^(:X8:,B\%Y[D71]2\S[L+^P)9JL36"651=+#)1&DY\ML>R>V
M6M2^S3-8&;W/.ES)Q9P+/)-/R<4876*, 2DJD:M$&7U5H7;./6BQ^/[\=AFH
MQ,0C]>&JK%=OKBGY,07A[GK> SNFE4YBY(W'O&VCS];@/!!53'!63Q$_Z;TW
MFMDIRVF<:2'_PJ]UT\<D4.H<19>X1C7@=YZC[EF)/[V;L]V;.K-E"1&& MN:
MI8@+J2MP\:KO.R=/KEUMM$,_F;&PC"GNTOY9U*5I3P+SP-NQ8[52BL3D!++W
M$ZK1J+#%]Q$5GTS53(MR_8K[5+L/(SD(B@P^_OQH""9;7.\LRTBAP[>($I#O
M24\Q9/O,F4GW\:0.#/&F5R+K'(?T![$UQ%.^A##3%)AKT%QXF7E/AYP6I@$6
MC_(-^MK+WJ->_8,X^32Z?+WO<I2<S.2WZJ&,L:I9OC&^#D=>(CY6<5-'/'\M
MRZN@NF0L2(00W?7]N03O\_M@3JHT@T.;F- !/GX$<#;ANTGZ,!H C=>>*$F(
MKL[J?0GK,N),6J]#98$NPG^AI:Y3D!_7PGP3U9/8C:I\=^D")Y0\BU[VR53,
M"Y)#UJ52L3^X1,\#Z\/7HF^(9 #N=%^A>R:P)5NNAA<J&?O(H,WT!=?>1_V7
M6UUF-TYM'O!!6K&*1X#9>95Q90>55O@IBD5A[P5O D<RNN3 MRJB&JSHUE;W
M;(/1"_^J@2A @)F-E0TP-@WVD+F("= Q3)\6ONV[W?)H9,C4>.,7NHFE9M%0
MKF'_7F4V:+!B&Y]M[?'-)^F[(&(I5Q7J$,H0FT@PGJ[;([R_EK*85SK&X)\9
M;U:NO6+\M7P);\@E6_[,Y<]DJ(/6:$?-M+-@0"N0.P@5URP;:43\^QY47#3%
M3ZTS[/XPOX28DRJL"7\62>4\ K1>](%TCK=%?&9!KD_P[]PV?88PGF\WJMN1
M-A:(GR2&EC^4LI8Z6'FXB#'?J$DQO5^SVXM\J2,SQ[(XMER[L:+4M2.^9EFC
MO<8E?BW5:W<DCM>FE,.1QZL[0R4NKTE,P*_1L/?2SH8$(B3/(X&Q:]##& G?
M1!<M'[[:S+D[-'YMWO_KJ,>BNB\3$_ ?GU4(N*>[?M#HAM=DZ'3GW@DO-&[I
MR\K&I=ZQUYB_'P7KO) T15IS8(^#L8?/323VBAN=0(3(!ZKG+'H!-::9;<'Y
MO56IKL)OH%RF>R\S!O' JI2-@4^/?JY)O22QG(@I^L3@Z)KR.0+L#PC2CSW:
MD']Y?P/;L;8&Z6'+*]&(JDD"6]5Z5RWO$R&W([A]RB!#N!:$D$HR2!CJ^XC:
M9C-4AKKZ@=8G<@E[OXOD.''BR[YA"\E*T*+H&ZYX;$!?<#G@ZD)K-+5ZL.W,
M3&8NE:W#QW .HHMHT<,$A<^J1&EY,Y 7S'XU9*.VV-GC#WERO&%8)N0_&&9#
MMN3RQ&_NJ#\\B(#;+G1>7+=_%.CB/DDY;8D6!BF1V+9+N,JL_,(U]L6\ E):
M,>GD],RM-A(EH-U.S ["[7D%TB4B<: X;9?R,WM_PEMK[2%VPM?%OW7Q:NS<
MU <K%69>(SL@PCK"I>ZUV9)#AD6/[CF[^BIN65Z UVS7R.ZH!.5M6L>:E97M
M7?<]-:T?3A:?$ ]&1YHV95ZW[/0OB$0QM+,1&QQ40TIK#\&P+>EJ"SGX,#.!
M<#<ZQGYG]@API\;FQ\6WARSI%&M3*@B.FU:E#!#Q;=/G:X:K?VXJJT4EK//(
M;;>3@$IQ1P!/P7Y$6S/C'!1,4*JMB2@K2I;LXGDU??M[0^J./^V%9V6RI8ZE
M"H5[->-.?X?Q0'TZZ:;06IO&6C5\6^D'V@PGB"4&V%$1K4V":%>A#JTP=<-Y
M+*=*S-E,W0#S_L Z,XY$4/YI'Z^0%A02=I=JA9M-G'!#ISD8<E56![^I'FB-
MB"?UAHL:W$ST'^3[6QIJ6=QMZKSJ65)$ALW_/;3D^F/N E2$'EIWX8\ Z%&4
M&N=HI0?/!5<^[DQ=PT+U6[X36_:#S5=7LI%D$SQ-&LW_;F'(YQ)G6F\*MA&M
M6[(\WT9!UKCL7#[,U5MM4L^Z1U+.E<G$-F*2L.=Y(N+\OI66#UX;0 L$=0):
M4+B9X_ _C.LD7$<.I$+OR?=5C<_7O7T^='&?_<Y:>%UJY/!\@VLGCWFW8#T)
M_7H76G##2EM2XE=W@:%Y9V7[4V/E[6(@9CG_=<,(4A0^,T.\3P\GOZ!_QSB0
MI%L;9J(R<?:O3C+ZE/!;-IW8RQ,SUU>FFRU&C@ NB'BKL'/>?+<&@VQ&G\5/
M/#=]BYJ>P![B5X(+J*HF!--8H=JPK>2@\ +,59ST(UN<1ZFA3"&SM&2E.!$M
M]$=4E,$UY>I3!G:2\"73]#YL.IMELSVA.NF>I*Q_=^'<$> XLMB<X;RSU(%E
M 5TPA ]Z2DG8V:TAIG*WQ'!]$L?++S)$H5VE/CIT2=L[]K'M9IM=&[@P^@/2
MUH\C #N33U%1ZTZ#CU/N8C#)FM*9!NG^;Z^#K^RIC]G11+^3G#V$KI'&5H+#
M(O;'QC[&+&F'/2:KJ^WH%(?&C+CAG$F$GEF9=NS)1WU%$)CNB/C=NH.DD;W4
M4W2K6H9H=RKM=K_Y_,V!_(;DA?,XGL8XT7BBPNY.Q_A6K"\FI QZS=MV=>=F
M5="5">,V"=ZO=1%Z<X)O0SS]>!.<+Q!]$)H/74XN@:/X8B]?@6^ <0P6J:UM
M9,Z,(,;TTR1T\XYKS;;OQ^$'P/.367J8YZ:^9? 6QAA(C92)IEZCR0TY#^M(
M^[KRO [)''AT4]O^MDX!+AM"24$+;O?%P=AFJ1-RRIN[%N0HA6;HJX7+/MBH
M,)F8O3M!&W)ITU3'IN215S+D#\V^;^N6(RE6WT0[A?E!$!=@'<0V<.]K:9\T
M)<-[7OS.2+EZAV><L'Q%1R+GSL2RCXWM9$]$D?U4B5/;-6&B^A;DC+H"HEI5
M3KSLA17-LWM/24N;NE'273QM$(8/]/SFL_LYZV?V>[*\QZ!K!%6+ID-$=:B(
MG-31=PX*^#K^*.'%;>J+M_X:R?.ZAF$])'+./(?ZQ#O8U8\3E'3#YA'>##7;
ML++&6]*+%V#;5X>2:Z;@G>/!.4$$[R>C;@M4A4=E[7C=9%Q7"JE3 ?*C$AKY
M<)CF_75%Z_4U!O_PWHJZG-E9B_._ %<V<M#W,WHL=-K1ZQ[J/>,MAH):"3.Z
M,BU(D5TP-]339&#O;C1QM+Y@(I;+L8,::Y.L2B=ZCL"!T%=*=J;5V3.V S5Q
M+E8G/+5?@[\&V!N^HID%S?<!Q]T8ZD1&AB F,T?ETWO6+,XKDK]<FS>CTSL1
M%7PM37<?6*=YHKC5VNOJ:^J@PB"LC"G*X^!P>%(^P,A]LCMP(2]F0.Q^CA]/
MJ;D1=Q.(>&^S#,+M,;B2/.V2U%92\GA=6I $CL0^%8=PT/3MZ,+D4KRBU_%?
MJ6Y'  _/*,B]K#)D'++B*9@[$%J.<:8^A-VS\751X6FJZ59< +NP(E60W?41
MU7:+^B.%]_G_6V_O'=3D$\;[Q@8J DHO0E044 247A,5 0$1$0&E1:4(1$"D
M0TA4I$B+@'0%D2XETCN1#B*$'@@U";TFU!<2PLWOS-R9,W?NF3MSS\SY8_]\
MWWUW]RF?[SN[^\Q#BAKP">W$G,#*?5<$WAC=6T(WI08T-PKU>QE:MJ9=Z=MN
M$)^:4)S >>;H=*@<"R /-+(.,?CHG.AVI5JK1DV@@,Q^CQ)7N4S--(-DK2]9
MYX9"Q.B0/NF;"&DB-&3+$/ZVA6;T9*A88Z?1WO529/J&I\14N*KKE7<+>36V
M$W@V2X[A0?E&/H0Q+!I;[OV]L (?5JS!6@RS$G]_8%V./C')<^.SJO&8WTE\
MGP4D4;%J[26EHY5/37/G>W2\O5*<GS?!O8H_5O^T(&-7Z9!LK;S:12U[7 8D
M%L%39#_((FZ[9T^()[OEV#P/\]QO- YRZT &U_VWC](^'0T5T1#..D2W,2[4
M#QZ!B.+4MIU_N4]+N;2SE\:596,G2UM -'QBBO$3#"Z0K<A8WX:X8O;D1.!9
M8F3 Z*W==D,O*.6^$<^D;]WNS5C2\H'+W9=4&PQ[_< 1"'?!D_8T4"J,RA_6
M%ER<GZ]J&BMLD%K?7G?<)0IMU(P&E##61Z!/&,896^*:B?=&%1#Q+-VG>*5#
MX2V=ZUWLHFTX86%ZR%@[T+CY?SZ]^3\W\VJ7O&E]AML1R)6MLO&P$GG30,*$
M9/ >>ESJX%[M$<@8]VB'OHEJ>EC/#V4*'S=H^*T)W;DNK_RHN^!A>ZLCD'['
M!9]/W\Q-%JO?Z2O";I-'N'^ULGW_I?:-#([RQ_])']-] E06_%J.$V%M_CW;
M)1559NU?R#8M%DD;J5IMHLF@FO5RM$A8OOM]BX9;3KNQYQIHLNJC/G<"_,U+
M$?I C9.+%P_2RD/RD];92YLCUXPCI1$77_V8R K4?G/_5X&)#),'C3,0[)2&
M]E"BIKC(=1XI!>PFP>-P-VYG?*H^LQW&MU&<&3OI8+KUV<%]+^G 3#?2:[A6
M-W"/RP5Z6;:9N\_\6"'PH4HC?-K1_I3^@C"\J<.A>.*W9F25M(EY\@:L%+LZ
M3,(15EH)P3E! =GC!*>;08^K:^+D.M+O;WR /5Y)__VZA3G*EE(@M0V_6SN?
MS>7*+Y0: 3_]0) D2VJ7V@IHPI;O11V!'# "LA&($X462P=#MQ3+]BDAX<1G
MMGMYO@XBGS%7 #(UD\2YIDGR'H&(^=8]HYYJCGURYO7ML69.1[(-]"SPS]O2
MG%_&%0F+[\E.)-M<Z:+EEC#ZH0(:EZDGR!SY?C/[8G EB=Y-D[\5I_Q7H6VK
M4A]$K]TVJA'X+?%C&8Y3X G5-I)&>1<UAP^ZP/_"=N(7C5MJ'\]&0$J#3YU^
M7I>&?DF6]P#'BXM'5=LA?_@4<O(L]H_KX\U<:*%S<;2<FE07YWM-]?_(*5B.
M<HD5"=8B-T&]B]6%:OX_0PHU>HX3RX)F:W@/KZ*:U#"Y0]A7T!"NR5M.J2TC
MP8T?;X<S7+TH.-M*7G-XXOD;,=\27D"+D >(<X<Q#$E+!!>E-UZBW5KW_F"1
M9\2SEY6#GKZO?$%WO/>CNE;0S5A;HO-M1N]"'%25?-;8^)/=#N2/3(:OVTB9
M%XS+B7#_)KXV..J7Y-7]P9^V6XHS;K1CX_!SV/$C$!=$$FX9<E6KL*'PG?\W
M'5:8K870:SIW*%'GF]8$@"0_BWGT,"4G0W-0^7![@J&XK5'N0D6R-M%4?-0Y
MN9 C4 Z$2/4R1(/24!,YD^E\NXSSATEL8+#[02B=)Y2HX:''GE/G4V@E2R\;
M]%R)*&H9=]ZR3@S!VF%#&.<6C"C0$&D<9O3"^ Y+71&XN=8UE$LZ+=T6+D1F
M8Z]M9YV]KJ/BN)K*>B.0DP4VOCEM%8EJUJ1,DY -"V\C%1RJ(M,F.G58&U4P
MZH<_&R%T;>I&D (S()P,KBCTR3.AH<Q#1+W3PE47"(W]A-N#X&R$$9/+VT;&
MM0Z_:T@KN,C) R$\DX)+\:Z&X&?9_,B[@T4"O;L:6 /@.]6RU>G&F!.*C7[E
M2]?<&N>UV9A#[Z'813"/[,-W-HCG V]Z-U)$).Z;D:M9M&#2@'";STBBB;7E
MLGDEGEWXC)7>YD(E_#<02-->MKF4,J+B);FAT=!9=HLS^8[*DT <;]=AD8SK
M,Q/TA#]&1-(@62P+<*.Q _O;F/..TY1*#5-B4L;P?.V@K,*@\.<U\?WTVYA)
MEYW%-('#]W016^)X@!N_L^@-ZE0VV[J+[N.A>2-YS?J*-QY+,%FZ*%,B#3DE
MIHQ$9 #8IH/&9 S,QF8)_UI+RYTCW>,-,+JHVBW#P5H4F#R#B7P,E-T/?5("
M#RFO.?9QHOU5/#)O4JHV+3 L5U1;'1'3;2E?I/RO[7^<E Y%"G\ZC/C3*&IJ
M]%5C9-H1U5I3H);;A#[MS.=PE<)(S*%GN99]?B6QR%=5 >4G+-8:MK7GSU\K
MAU>OJCH(+(CN+##$@0:/7U8=A^A==0.'AU=C.:>.0 ?+C37A>1N].,BSE%AY
M1=Q84)-:X:#N84+B@(S\)HO[#@8"?*;Q ISF%9;6%B*BCFN6".^]LSP=2W_?
M07+J7+2>#BLJ'($,AG*2JDS8WI#*YGZ'#(5:OL!-XGK7=A1,=C&D. ?D@#4N
M=>,(] IS%G#K6/GEZ*^3[\:2T@Q_75HC>^:%QYYE7B<3H_,&&V4K<D,+I^Q,
M'5\^YLT<NWS)IY#-,E#K6<VM44)L*_E$A<O2$0BD*.TU7"%5&8RJ5L,,U*P8
M9S$41 =+>B;I!C# H'!'I_*-Q8.!)'S!!OEX/8Y)OV>\I QASU+$TZA>[ [6
MAJ^B5,-N+TX-;V>C_QQ*&'U23MAZ@)790Y9O"/@6-#,M5$-8O(CD M>F)(2Z
MGI%WYF=SM?H0]V$O?5%5L<.$57N]V*@\W>/O#G1,']\A*C;@%>6]\IC?3$Y7
MLUXIZ)J^Y^2:'K0YG0<P>8K/JJBJ&)'VLNQWA\]^CQ(8_PB>BB/"Z#SD&6A[
MH/^"(64Z"C+I=3'-X$$EEW1=M8JPG89H('S*2N<EY\7P\2]Z%S_3'\"A>0.+
M46(6#P!N$N8]PIVX$9%(F.GS2K"^=RO8Q45C#A2 CZ&_ )9(F)#*W6X_HJ:_
M8X54C,-]?\^Z+ZKM\V*_>^$[3]23?1CK.AT5JJUXX2J_=Y(B5^]8_%0-5# ?
MN8J4]CT"D76RLYY;CULY<6O-*NF\]$($4 EUX""H\"Q5L>B@S656,>G./UVK
M@_##BT !2>I"H973B+],7-'T'[G^BJPW3\$;%STQT4@($-%2*]NJSE;DH?]<
M_)5M0HM.A:5*C%[3N2-0Z^C:5%7+BTQ]Q&S71!M HT#P1-2'(J\NA+9;/FRE
MR:ZJ8K-D_OHR]"PE7U9\<%XOV8S/])JI>@J-N]5BHT66<-R%M:7,\!=39UN2
M6AZ-:MTYW?ZPX,]!"C"]B\'7"U/J2"+M$43L^0EG[CN1,J\VJ[1=)YN0\PV.
M))ER55--HU(DN"-S,4V$TIB>-4H@3/BF&CZOT$SW"P/[XED4A%'L0&K'OQ*E
MB-S1>O[K>7YUK<$AIS>Q17Z]R32M)8C2$(-7E^GZAQQPSZI2IWE$^6+UUAGP
M!&[)DO\(5&%!%SK,I=]ERO;/0GS9.=\#[/Q92BZJEQ\:I'_E6^347.GY:'J#
MX#!@*-665@$-XTC.>38.A$MEA[0?<[?/'Y-WK63O*PO8(<"[44Y8@H3EH$X<
MO,"93UG-NF-]#?.*15702,!K?6IGG8NN"5$, %\8F[9H_QM#Z/PLZ3L7>5X_
M*13S$,]DGZ;7V]4(50J>R"C*VE?J%B_>W;LG6?-.AT53=<-ZH.#4^E-S76NU
M ?V!Z_1;PX6>&^<MEV7/#1(LXK_4MLU?OQ3=.&RT^P>H8@K.J)0R6;I8PLJO
M#K; .&MXS>4$KD\O7#1<3IX%<+M(8(X$9?&=%X:[O-H4<"U>/Q8\'0KRW%[(
MY=W96U6DQC$=J9(U$DKDI>I\8"\<X(-5M/L(^FK:,LIU5$QE["_\S;+RLX"X
M4SG#F<M/$O8[1\C)^RWSAPJ9A65@?AV!9E(8G'&M,!&%NH@(S7<D]6="NR;N
M ;4C/0>2YX] OFD[&_Y[?S:"L)Q%*3B/TF:C=5+$RPEUTXVQA:=]YJ2_@$]+
M92)?5=4%:7KT#"H/UWTP_(IJDL]A^E.5+&-])?!RIF_[PGVJ0@^;WR:KT@A5
MWFT"U-6QAVPH:*3BUCB+QA#\5"V]O4+/((D$%*+?1;53I+-#?Y._IGK@<L(2
MUL]G=TSL^6E:^JT%2G%*CY<4L!!.FK.+=H3)81YR[QE5^*I\TU3635YWTC$T
MB!>U)$,C+7KCF:EQCYH;H;CR&5I^M<_K3-%K1WHRY._?;IY83B0(\_8(%&2A
M<P0"Q-Q:-KM#X(=WTM^Y"BSL8+ZB9C!IZDR&EF6<&:2>M1Y'3KJPAYB\'T\%
MCS06_?>4I0_] H:(K]@!CD!=(<4/P\^8I&XIM!H8@'^6&VL'Y$K^WU<!_#_:
ML7-8!</Q(%@BBF)V!!K;N#N ?9-^AGX'_\,C<T7(]ODO\NVNO#\^]R_Z"XRB
M 7;D3Y6)!F_:@?DG5-,=E(,*4X6AQQ:>];TDU/:4"$6C)?9D?I[,.P)] .F2
MM=7_<D4L^PNZBHWA\;:;/B18>W+%ROPFQ%#1Y'1,<6>?K/#3 'S\,O*:9:5E
MQ'S,Y53O/T96QF3LA>YL04]:Q/.;,M+613)%L[21+9U1W_'%NQTCU=U%'KU1
MZ)>'C&E].D8M7M_+6AQ9D_#"J?IZQZOV,DQ716F'*](HVZ.VL:[F-K9(WGC$
M0/GO\&</GWG]<??J=_"YN=<UV[=S!5:5GPQ1P0!>^5>M57?='N+B<)3)$]K]
MN4.(16MM.M?M@MQ_;J)/#11(\H0?"5LIV>Y^>XWQZ4KY<]_<>[QTI)/_5B07
MB>?/54[;W'BF> _K]<'USW;Q*T.C!87IM;9(!YWQ:+WMXEH!/;/TLH]R^3;+
MAYS9V)DT*(LKU&ECW("X\8F$[BUE#!MJ/6;KLQBG,W,C^BPC25HZYJ3SKPNO
M'O^"CBU*;1Z!&.SMAR$R$&&$XA#DMF\LKFM$X]7/:6U=L&)E6NYG2*DH\B/V
M21QH!S/R]IEY:,L]M&D-T,'C '[6]MSE_/%O=SLLO'B';><[V]15;,J7):M>
M]$6:MZ(HUMW5EPX3$9"RMP/POD^XAVMOS"?8![":J!G24C9ZUY3B$P>-J6L[
M/]>@TYZ7+US$4@556J"*YA?@.!*Y*N+1HG;=_2M]$"Z$8! Q-$QHT# Y8Q!Q
MI\N+Y9$W[$0R*_TT2FUKX]1WF1'<&G]BR/I#6V[#3[ ?&]:Z8?4NMF08Q\32
M[67S$<JD[ESYR/.H#)'3YU1-%K7]JOT]'JU./5I(1_9/GWF#/,; =Q>OE"P3
MH)^0UW5DUKQ$-"M1KX#8"3N6EWO: ^S):]_P8^#31R G5+ 2C+V0;O!CZ: ]
MFZ/(&3):I<SIV<^S;P-.!(8_L!(J(6S?P1U0MC4%0_WFP:<5)>'J\#I-/>WF
MV*"Y=Y;?.VC#L]@+J)DT:0J:;)9!!<]@HJ4USJ;,WNDA&MX;+BX/;@1WE!6J
MDF.:BG*UDB>3MW1K/'8M*=!/"'5J0"NA([11;=HWHADI.22ZN]!\,!0I(\UV
M+C!- FGZ..U4X&DLAX+FR^_EUO[W6^SO_W@8%G@,TR$;;!$:IC -2.+;7#A)
M.NFY2PRQ8861FEO/Y/7LSRV5?WX!;JE^$8_YB74X O$#6ZTVEX<+UU#ETLCV
M_L $2R<$MD*00_G6MLABO,57!A?9\ &-P-3UL,_2!*U3[:D%.BQW0LA_W7=L
MF.*W,]& RA<3$YBUK+1$EYW;#T,FD1J]* MK[B1#MM8J@F95A(9ZL;.0R;XY
MGY'GQV>X3*'MM1.[>R/E)ES.4^!JPELA2S]$)W4B;\-"5VX."-L5?3T(*^LI
MM,C]Z(HQDYRMCEW,Q$Y\ :E=L)Y->?,@2?P^>Q/O#(KU" 27@H:K)8YM\S94
M)WEH&+F5W-F(6[/YD.=+?I9J%@LNC0^9YQMUK_O[5@7Z'39B:B*HG5E:TW^"
MY=EX]P2'L.#X!F#^#UO.2>>.)N]^3LZD:N^B29W#H^,B.E!@F_4'S-T&^YKV
M< DI@*]7)[JXXA^C;? 9<5V;F7(Z\S+/$M<ZG%?7Z"[9TV2XE>[X0@1O@ZI,
MUC)BCI+*.!-'G ZVD&Y,=PEDKZB=2UWU?L#[8)7=GP[CK%@3"GCF>?A*M<CT
M_AN9'T]TU,R=->"9HT>@PJ'+P0'[WVRI:U;*K;AQ,+&J18FFV%OC]LLY]&MI
M27>-9JESIH-0XE74>:<S"S:CH]-:;![7,OT>_? 9GUZR>4G=V\WJTQ#..@*]
M)CC_)DQ/:245GW6-%E_//?Q%AMQ #ME< 3IR]6QM7RLE9DV42/%BN?]""9 =
MHBWQ(4.8:E^P,F4]W(!/*B$\\+D9$")GY+" *5*U$/X=-9K.CG6FL;.1>Z)3
M<Y<3\8]7Y.I6E.7;*B>?!@X(_^X)@+:Y14R?<:!X)DY)#=5+_7+ZJW_S3N:$
M^NZ9:(^E#1M.*C=QKM#";6P[$')Z=',\I!]()QWX8.+H1C-K!D:'50AN8H#@
MS75B[.1Z<<:#1\-?WDT<2L5FOY9HB-H7[&,,IE?)=10NBYX#7F?EAI9_9CTP
MRST"R9K?K05U_. E)J3Q5XQXTH)3J/%VPMURZ]ZNA?_@K&TIK5.7@(@"V,-F
MU76969BT[E]>F(L7Y&:9"S=Q*OM==GQQ#/?U<3'>X4>RB4G=7[>A'W/8T+Q.
MKQ_$W?[[1+GZ"X/:_Z 9\T.\(8#LLZ:>31< NIGLSG[5%]LD-!\;MJM^L@CN
MP78JYL>>"'P>-[;5AB.NF1MN%A'6#<SOE>C498VG,X4"HP];YA8%N44_61]G
M-.@F-E2O65A98._U3J,BI=W^< :L96(,]S357,?]A-H9?60(U/3+UAM1<MO+
M '0SXY)MOJ&M]#1!MORY\(;$5S]3V)(% W+XM0(WKM6> FU)YW>6^@GPD>BP
MG&RXRQ&(6UA0S(J\.(KIYAQ--1NF*U.]BC64R5*XD,:; VZ?E!B7)VP&7O14
MN+RN8DCW_-GI0?8S>E#EE?D8^A-*92C)$-*C876B$>.3TS%O@:O0X\@$+![)
M:2X_0> =8@=M-P<[IDN+,R@19"L(F&KRL!8<[)6Z?]-U;:VR*_"-[[D.VNBA
MLQ%PC3,$HP >K]))KHJX+GI8&-%%:T>S"F(R(8ITQ6&(K(TO5G_0M:+K"I4_
MS*$1WG/W"!28Y8+P<X0&"^-_%T+'IG>]!E$.,(*L =7#>==GU]GN 2AUX<5*
M^4?-\0:7OY&'&3MNG^EL1&GSUG#\@%MRQ.3D]<3+IH^,P'>M.IHVPALY !^:
MN7(81E%2VO/PT?1JNN,7N9^GB.\"./WG&)>1 RCV^LNH? T\S+&Q7F+MMU]6
MQ M4*-IBT\5D-YK"&7%S0[1#M[HZU"CR\M/@:6^RA0Z_1;)^O=C0H>@0W?@'
M$-*VPZYL.3A?MO79X(/,]LEH=F?@!DMMWX[4H2C>N+'LZP?- :W:X[HVS/X
M[ RZ-=5%?L8[?1:PH1E4C&AH[PH+6X:-&9).[]51.Q^KD2L"[U)PNV54SF"D
M0'$B4=63)B7RBI7;Z:%2T0^3T%>6\9T]?@)_OQ(\C1OY?J;.ZW9B*6_-HXY
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M9/!R9)"F/Q.\ZZ=DXAZ']':9K6A7/1ZAU'DZZ3YIJ91JW98^\90*;8_R\WJ
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MAH?:S83B26N.?PS>+?Q:(.T1?+HL)V_DRLBXU<!ZD6[\ EA\7I7S'B=54K-
MM=D$2<WF*T30\ND0M/F0JVS%)7!O3):DL//=54._]$CHS ^+T-4(JM #B$C1
M!SSQ3N(>_V^6SU^.0"";_:44/'6^R(NF[>OJ\@IO637H92WS$/?C9K.*V]<C
M$!?*+]1]JKX %NL685&FYSXS[C4D_?1Y(=42K.+-8F3EQ=NODQ(=)3+TMK1
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M+#^&43/Y1R"!1"-&#]J(TON^BB,/SV?V,NWD11?86[4GN7I5U?OH\HHJM.G
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M""N';WP>N) +R^Y(W5NU#>O\\^Y'9]9YM7#0-OHCM K=@B5P/A\JHJOG.4?
M;5W==/)1N5U.N;#Q@C=R31H1)7VW+L4L62?4T>X#$BU(L4%/2PR/TYE"N)*)
MLY!]K)68E?.M^]G?,Q\CW]A66>P;IY-S:F@7P2$]%'6]P1VWLTLC:I;=?GF6
MDTX']6_CGUN,R!2V\;_[?*L.K<H[!RN;7N6GLA)S(QB"0*X-X)R25:MY! HK
MXC$(Y$E,$ZFL/SG65::.J% ]Q1\_F0*B[<V@U]B(6 (W,2V5A.:<U+X6G<V9
M/F<HR651_,S!%->U]TC>F@O8TK(6INE5%"G3%).":Y6-]^6J[AWKE=-4PR_P
M8NG<W"3=CY S8TN0,P,N='F2M.4?'PNWL-S*84O7;-1NOUKKOX#R@';J2O@4
M8,MDD_DAA*$+A3%N1@G]_(KR#ZG(F*3R!6.<C=DLC462[R><SE AV(-*TW(%
M?W#6('2IV)9&7B"5F'YF"B8'3Y/3RQJ\HCU1EB75,*IL5*LMV^H6G28,P&8P
MW/#$@T_FQH!^VT:%5,!ULX \6^T)C_.JF N'&+HP69-[-P%0)N-8 :&M=@M8
M4)QQ64-9:6TX 6Z7IA@EP+K\0]9Y/_'Y(1JIAC $]DAK_EM_O$4O,H;Z$'=S
M>A.42SI>(ZO>HDO$(&M;>M]"'8C",0/?FSL/+P)PJI0N@"$:0BWZ-E[4EPQ=
MBB9ZZXMD<F2\?\MA^MM?:.G6"4],&). DZ!EG)$0=KKAL%>1UI\""K8%2XE8
M2N$A<"W?VW:V^'IBKZKIZUH3J^MZ$;XBL$'?_ 7/J_]353G_1EQ]6)@1_^'D
MA6_,J'36>(EOL9)ZF#9T\VJY\Q6!R /,GM% T3Z/\1U0*$O:G3:>QR?NZW,.
M?#._1.O7!LEW_M *TN8Y=NU_<?C\_ZN!C\;^+U!+ P04    "  HB$9;+R"4
MR9B&  #BBP  !P   &$P-"YJ<&?$NW=44]^W+QI40*FB-$5 !4%%0'HG*M)$
M0'HG*DH+17H+B8KT$@4!!2$B(%(C)=1 I$9 0&JD"(1()Y)00B"%R_=WSCWG
MGC?.'^^]>\>X*WMFK[&S]LZ:<WWFG)^YLW/XZW ></J>@;$!@(6%!?#PZ 4X
MQ .>Z8=[N0, IJ: ZP  X"2 C44!<.RHQW$DML=9 *Q'>Y8C>7C\^+_V_PC
MXO2_]?]YL^ #G/BWXSR=%F?^L__/.,/ IT_]@CS]@X^.Q7T$ *KAA], /< Q
M%I9_MG]OQUF/_]/83IPXSLK.QL[^CYP\Q7GJY$F.D^SL'-P<')Q<1XW]% \O
M-Q?//_U_+O+/Z?^<=;1QG60_R?7_N1U^ _"=9%$_%GB<Y3+@&!_+<3Z6PRZ
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MP.K#L'-GE!*>D.QBW-87?=6V/N[Y/9_8)6!]/[\CI&F%WYZZG AI'.-Y9\$
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M_8"+[RN_$-X>O!]B5VE6'_K*7&T-Z Z#U91TQ5//T:P@&N1@W^HZQF/)#X>
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M19RW>S*],.Y/6\7!(.Z/%I2R8#YZP>8MK:/H.+_=S%8;&)$&<HH]*I0N_B]
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MJ&1DKG Q00QVG4X_@@L<<K&6:GH(.+E3NS;5@XDH=2)8M+1E7^EXDW%^QSD
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MOU?WW-X'3<^A@B(/ =W1\B:>/S29V?Z7SPRK/(?=B.8E1\LDJ4=@@TJFK;[
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M9\^Y(Y8^RUW%&8PMSPGMFH_2N1$O>G]6EKN]MGEL49)TMPGWFV+KW#$@#P;
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M//0QU?V8C>P&M_3MNW(J[=/>D)=4Y\<F3B4@ES8#>/21AJM^J4N*FS[]&[M
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M'N8BC=?U@S4U-O?XRXWM!U")QO1_7'<_V$E5(#H\_(!<,VW(+F 4]BKHABV
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MR++=X(EH(KH;RP7+0'-O/VN@O(;=ICUP#@#_EH8LQI(2R)&F\_BS9!+](HF
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MBU;(2?]<<[$MSK7_7*M$/6?..^5E&<Q?A<YWKY^Y;2-SUCQS_L0;77L,X_N
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MJ$5PIU/!&8#^/#E795MIP8-0@6>UT_AP!D O)0R$G5H?])\!Z#X3Q+] 0\\
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M7/:U^-LWMZO(%_5BR;'N,?;6X[#,(V7B X+ZPNZV,Q&PULR.;\IX4R4#8L.
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M),DHV-^WD-#?(03[NM!-_-%>$NRY?\G)M\^<S]9("M2J:W>PN8M <6CS$A]
MI#KA7# 9(VQXG"[K[,9XIFX<$]@KK&I$Z?.NGV+<Y1;;Z^R/&46LUX!O*L$Q
MS7(X4KU!80'![,'02LZVDIV#/LO;QF]+?QXE^NE,%Q;,> '9D-8F^U32=V$&
M[IQG6!":<AOC;" @S6?XYUM ]&\T+ZJ2@@7;46<]0_"GQA@Z0L<B)@HH\/2
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M&HU?&=E@'$C&(U!^WX4W\W%0HP4-OMYO]3'SE(4M<::!AJ^W'V'?+0GA@-%
M$3?\^"MM&FP.$\&SK9FFL69$V_)+;P3V\_B4^W:[4&@*\GFAR+XPATZ4VSF?
M@P9+,,VF$Z\OPRFF3=WN4DJQ7,'?%)TR_;5F6^%G.HJF@U]Q[+'%SXF.NI@V
M*[53XW(;0[\4@VKG&.%N .M'$1%7R1)W862Y<?O0#LP:8G@T3JB:]Y]LFP>_
MUI;!2Q$?;S9SHD;=\$[( '_O8>\'NNW#.U<^\)P#-6[ (6T (;(M@09)B.H
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MU&Q'$KI]5AT-9B>IXMD-ADH;(4\734*?^LW/!O@J&ZB=2[[)A;SWTM3#YPR
M,Z>N!-0DJ_59&S[A%@&.!?-"S@#M]2JPJVFFALDF6E<3I@PY VI8#.5A1SX'
M7)@V$*N<-J]"S-<A$A 8>^7RMZ&.QG-]M^\;*;IZ:1[RMI-NDS]2V$EW\>"H
M8%,3,]SF-(1_F]9T&/#:JZ64WU50O',XD47D680T\<[Q&ZI=!,#G,^&BVN9$
M UCG' _>,U&[3K5H5_=*8S+M.>\ ?66TZ(#>\9T?7\N&LV5F2JU[&'7?1^81
MNMLRU3[SEE0=9?CZ^S4[!!A*H$6\-6@>/0.@O3,7%Z[$&W;_]-K.5ER-7SGR
M[5O+_! /13P4GG_DPY=5\C.1?3LAA\Q4CO)!(OA0%0I;FXL*H@ZDMK:P1S6*
M!D5-^9^2?G4R%OVQ-*S+)_'B5]*\\KWG/+Z[E%PIU#H#()T"]9]GG@'>-,HL
M)#!4C,JK1-P>NBWXI?9YJMK%):YO',\,#,+CQ[ZY?7^1^*PV'M:KE9-PRA@/
MM<1I'=D2=G&['5/ 9&WU8+Q,JSGT5CF<>\4QL_ SJ)*/M83R\[KKXY>(^F<
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M="^-DXR^>'.#":\B++ DVWP?3GOM&E,X,WXY].<CQGFV#POU*#;8*%R@F,)
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M!7LJZEL07$P]ZIQ:7Q1X>(T!O6JW''13H-AO#'TG]UN)9#8X)HP!M,1>< ;
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MG5"4%;]9U:R/.B)7G0(&8FQR<Y8YS'ME[O>IO%@-='9Z@0H_/G,*2+6)H)"
M.#!9RH@]Z^B=\^8IX#4/62I[_/JXE*9_1@R[@?<M'ES)6P9^W:Q3 (*'?$,
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M":1H,@]MW!!P_E"\>;L^=+U]9T.!5R055!1+#Z*8QJ;[F%@)4YC^6##P$&V
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M>)(E1PX:R*4..0N9VJ5' #,0CM09_L^LQ!B=RK[-'>4K08,8;]0C\W5(O*9
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M&RW'0OTD4"':"E'U(GP,*J< #>@^CPXG.+_MU^V*=-V%KX L2_(@D0UU_A2
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M!I5#MW\>*)2LZ^BN4>?4HMLO[7 ?%Z%>R";N'KRBC7*2)?G)<!%<2B)">M]
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MM93?+S:[L\V:;O;^ 8 ^!NE\I8F3%5D'AV1=>PR#-M>:3461&VZ/$%ESB^P
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M.GLF4CE,?*I-AYLX],JD/EXLV$+ -$ _K%KQ)!KIBJ:1$Z:K.N8O)-&)F)Y
M+,&>@M*J-6T](SF_B32'7&YMVI.9DP2W.HWVHYNN1&L?G90@?<TN4(<=)(EC
M"8?>6H%](E=)R+=_+1(*9D^JS9OB;PBLS[Y4UF<S5=-*X-G/JZ#A(Z06H">[
M(.R)ZWT6I L=G#\*QG<5:TH\3%2.>"JGU#(B9O699?=4?;)6+6D.C5[K)(L"
M(YMNM'!K,Q''XG;JO;G?_H1GPYQ@<I;$K%E1EE+QU*@C^><M"L^6<,T1IR!
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M%I)H(5W6<7,6L#2<I,B(;5#/0_FW0OE4=K*+#/VY>??IYQ9<:D7.X**UZYH
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MW3])]]=! <FE3NRB\9VVFNDVM9)ECU/0Q<-.@<K_E*'M+!&7DIA):?_%O?Y
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ML^U?^+]7:?__8MP'X_\!4$L#!!0    ( "B(1EO;#Y U8WP   Y_   '
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MX&%DT-)  (4:A=,)DT*$ *\J2MEBC [Z+E!Y.^8H"URPB3'%[@TF'7;342<
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M 02.[H>ND;WQ%SO1$X$[4MK/EGHK@U;XN+*2N_]TWCP#7!>_1;5IWUO<P%4
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M]J*V8TDOSRN'*HU6WSYCG@=KK4T/<.35WC8X;Z,^(8)_/:+W"]E5=L4BG>V
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M)"-VB\CIT#0K$T9^@>G'/D[6LB5?U$>$81SHGUA+0X?M2N+C8ZAAIG(S*,F
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M[PTT=)O;'XUD]-M5=%B*,<&7KC0]P'^$/F]E^8HF-(9GPVT\9TY?$T 6/+]
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M@>X5U74W.C.YAR9"O*P"M3D5_C:"HHF'"MGMS_VLEYMH8O,]@9"RA'9?:ZE
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MT?A:6E@U\EW_J"+(=<PIL (-;BPG-F,9J-=\Y>'DRJ(\DU'JN-S0AHIL'NS
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M HJJ$,CS))5^G>\6TKD1DSV2=[O]=I[,?]\?]+\"<C+V_P!02P,$%     @
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M!F?8)SR@7=^1RJ%5S+N5."[9+CB("49?)?ZU<VP+[M1GU"J#L,I5$]HI?4A
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M4(M3^K<2-&4.A:(M2>GLU;2:(]+8$5[#;^:AB/UYY@_P1_9' /U#5=$XP_M
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M%@$C;"8Y]2ZVGI#Y>>90\QDCQOD6,)',2WMFW0?!&,^Y.FK<._P6JRX3>"Q
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MBST+;>6?H8!R@XIG>^L3]PB>NG%Q04PI\T[&AS9LZ/THY1/7$V[(\#"639A
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MTU[>:%0ZUSWT^KGX\'D&DG+\-_UXH6>WDOW/F;JZUYYMH68(+*+!294MJ"S
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M7_P 81O.CH/AQO(3EXGBV  'CDIR+M;\Y.=26E%Y<#3FB)AMR[7;F_[Y]TB
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M'8<PJT&9T8$<<^3L)LS>ZR"L:B=WLVF#H$BJ/'^^'EAR GJQ;;&&0M@MUN/
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MY.%>_XK+R7J.Y/YY#A&G3/!9L1'"I(<C&)T"35,H<Z$##IG)FVH!LG.ZIID
M"4'G:+!2:0K)L41^-41MO0V->1MWS;V-&QYG]KX#)=A'K48#:J0YIB("R +/
M#Z/DIQ#@ZPLTMCFZGP90CK(@^W[I1"C+7E#)X0N@2/^M:DN.V5FDI-G![!LH
M.@+8#AW;ZY'-LFV FJ0N2@F_>X' T?N;($:"P:^%PSN YSN%,([=NF&HYRM#
M\R$_C[@#2#P^"8&&F$K<OT9%-+/W=C>@/? :WY#L8OS!/%=/O-%Z\8?VBKW
M.\X5P@\4W9&XNI*X?M,@.5FP=9X7<->0W189)(3]G/Q 6+A]CC 21R@/FX4$
M?Y2% ;6.$056F<M!*NC'9IW0F!:Y($V0QFO^!:D,O8A.(8$7307[<=<KH@.X
MY7'A&. _XX4T9NMP^7/,ZFZ<)9&GM$006+U;%PVA/#1^G>S(HG0"JZ0#N7JD
MY+J5IGT_^UCL77L'B)03"$F\9J,!P1/+K';M7]]C.E"<HZSW9^0\J89.@1N'
MUNFF(MGF.OW-AT3#0,OR3V;'(#O:*<B1.&1Y)&](CJ-3#EY+00IA^VS6TJ6J
M0)&^OW2?A,:/#,[UI/X<++25;\A$\K2,4%'(W>O7=MK2+U!)M_^C)56PE<G#
MZ@]#BK-X0_@YF0&EY>UCD%*4D!BHE;YVKT]#_O9KA\;.(Y^QCGI+Y2,J_U&C
MA(;B>4-3$R(]1=\Z/ZSG5+::*! B?@/8P+QH8]YC8N?KFS']\E/V,TQ]PH!]
MD\*"K%)\L\):N4"IEX<=I[%>_X<<RM-]5X)(H(0[=[(G__;G:G9VA/:A/[OH
MQW1&3=7N1OD^)W0:L\JR%78%Q"8/N%^^M:] '9+XDI1 W!JE(Q#K9KU;)$!3
M4F S01:T? #U/UOFV:!D<)<.UP0(YTD*Z&9[V-GU-#BA5H_LJ:);U?VVE.=?
M.L%S+RZ*=!W&J$<<87\[[!#0_.;FDPLCA9T?^TSS#SEZG#WZ9]O^]T5&&Z/V
MO_W_]0\N[/T_4$L#!!0    ( "B(1EL!+0FP]!@  +15 0 1    86UI>"TR
M,#(U,#8S,"YX<V3M75MSVSB6?M^J^0\<O6QOU3*6Y5PZJ:2GY%N/I^+88RO=
MLT]3$ E)6%.D I"^[*_? _ BD@))4(0M*.9#*C)Y )P/YP-P<'#AY[\]+CWK
M'E-& O_+X/#-<&!AWPE<XL^_#+[?VN/;DXN+@<5"Y+O("WS\9> '@[_]]I?_
M^/Q7V_X=^YBB$+O6],F:+"+?Q?0T6&+K7\<W7RW;&AY]&KZ_OK2^3TZLT7#T
MSCX<VL.WMOW;YT?F?F+. B^1!1KX[!,\^#)8A.'JT\'!P\/#FX>C-P&='XR&
MP\.#?UU^O16R@T08+<EC)HVB,/ #>/+&"98'O)CA^Z-A*NH$D1_2ITSZ<4J]
M-PP[;^;!_4'R4B3*$D240A54I4C>%I*XF,BEX451,*1V^+3"K !5).%@X?4!
M?\W30$4=VJ/#-"5V7'D1\*)0!/:CY:@H&M?C:'B 'T/L,S+UL,W%N.G [,P>
MO<FJ"S\ZBXJ"X$VA)(_X=W(<8+2C _YZBAA.Q7U$'";/6KPJY,V((Q>%%T5!
M&F:",\2FHGQX6!8J57M>-'Y53!"N:$7Y\*8@&C%[CM!J,^?D15FX0H_T34&<
ME^R&,F,.WQW$+_.BI,8:Q.=-V,FL\;AAO:3!'7[\^/% O!U8* PIF48A/@_H
M\A3/4.2!-I'_(T(>F1'L0F?AX27VPX) [G6(Z!R'W] 2LQ5R<%.;A6[%LD3?
M0):K@(:6OY%28N2X'_D:.(+.L21+ZVM#_@![(1-VYW^]@<(&!PKE5C2ZVK++
MXOQ'NU+K#"DK6IJ$_V6GZ6S^R#X<V4>'VV%?]VE*V%-Q_J-+C:]['[4J3^7%
MKPX%YQJ\4L&9O/BU1<$;#5S1SFD";N ML98&-R6\A3397QTJ/#\8*&FP3A#_
M[%!VT1]0PY]+DO[1H8U+78 J19I2BK_9-O1K<A:4-&K*1EFQBC%5K=_/IXG[
M_N1)ETXA\T+4^H1$G/]H5VJ5?] !NLAF2RW*WM*V(^\6.I2[NX\'-/#P@8_G
M?/ZAUDMZE!92\:[R(Q\+#]^7]4"^'X0B*_$L?;I:$7\6)(_@(?>3/J6>[@V>
M6<)S^H2HP\NI]Z\.5C1881H2J,Z<LRPR6% \^S+@TQP[=8[^[:'I&W#>4I&-
M HJ#OL )2;#W=:U>FI;7_Y<!@\KV<(+ZQ>$XR&L+!Y(XD2>L8B@H%\_:@H(D
MQ"<&8UI1W!83)&$P*]C*4CR#"0A8!&:\X+.&8H)ANX$3B1_(=V$D"4GX9/.V
M2)>BE('%TWV_N6B88L3ZJ6>;*9>JMS97/)-2F0'_-AP.+=LZ3<K*_QS[KG4F
MBK4NUL5^/BB5M:%&Q+![Y?\F?I>:19(XD:A+6*2>>KJR>>4IDZ>I/=7,/$6>
MF*6P!<8AV]:JI5QT&?$0+'>;%@*_C^-BK%M13&^TN+KM%8(Y0+C (0&0FFQ8
MSE2724>U)K5^N2X4^U^OU\;9+V8',YL/(+$COZUY*_/39=FCDF6SW\P*9M95
M5F!OTM@$S@+Y<_#*B0\O N=N$7@NILS&/R(8G?28N:$,7:9_6VOZDU@)B_CP
M8JW$?UIG0HN>#XFM$%O8,R]XT-3$<_GILO.[>CM#@=8Y+_#UFM0)?!?[D%%Y
M.(U\%+F$SX&WM:Y*UKH,_;YDZ).T[(WQ^GM:^"L>JA4LH\=%:U^0+D)\V((0
MO3,G,5R5&[8V87=R*)2ABQ>_5O*BROWKNXPZ8]4[;,]'$N5R=1'GHR)Q&IS'
MGDVU5LU<P&=DCJP,32PY'*JR)',]>T)P8_E!B.U#V\7,H63%"^"F@I'8GD:,
M^)@Q\" 8$0;,JR&BLBQ:+A%]XN\8F?MD!J,W#]@Z8K65^'-[%7C$(7AK/^:E
MU--%0QZ'/"7,\0(640Q_? , EGBZAL!Y"!"LXP3"?X-K!!CXX^L<!@LP6+<Q
M!O[N=HW!&F<8K.L$PROG\,A^0)1R^WH$38G'!R-.@ADBU+Y'7H0Y#T!W\$$)
MBG?=4!'I[T;.+N7J8MU(RCK^],]8-^MKJIL@U3GH9OW!=>.\.D]ULR[6NKUR
M-AWQ4>R>+\7Q[1'\$8]S/R'XJQ-;ZO+5Q88C*1N.XD$Q+5L\9-9U7/8KM_;;
MCJ'48B:Z[/A6:D?^]+6'0T5]OX.FM%R2,/8O>9<+38N/B-CO['$TY:W+Q.^D
M)GXGFFI6ONBR3_+EOW++O[<I]E 2PX+A-H0ACB&GTZ)7<\:Z;/Y>:G/^]"8N
M'#IE*-R:Y I_Y0;_ %X3& _;(7KLV+)+6>DRZ@>I4?G3"U&<->'%O7(S_@HS
MLBF#49(_P?>=76]9?KH,^JO4H"*(F95IG=WWKO(+S,[MP^$/PP,(0D5=W/NX
MNR "E'$XM/_YRBD]JIZE=>9B4]Z:2#0:5L8$*F>!POBOW?9'Z4I&5T,7,M)E
M57E\\2B;$_8F%#/QVME;9\NJY*_+X/+0WMNF&6+/ S&+KY[.=29!8^:Z&" /
MY[VKG2_VYA>S^8WI06>K5^6IR]CRF-][V;3CM=NXR2/ONO2HG+\NVV\$ YM\
M]5_27_WZ];//[T+N()N^C)UJJ8N1\E#ERTQ$?YD(+*^=VAV6EW5P5D/QNL@H
M#[%V6N3N2=:X*JV#1 K9ZR*)/&Q;N_;=DZ"X?JW#XN6\=)E7'AE=+XGWMI2M
M<NFPJ#Q'378]D@<KR\MGO75?<CEC3US>G*:ZV+C#39S)^DO/=*7%$CT>KE(1
MNKA5O56S85FFI\3FLHH>YW0S/UW&KMZ)F5^MZ2W[8H.%BT-$/'!?\&,8(<_T
ML:VLKBY>RJ/,+Q37.8U!69,85,_Z9Z<1/"<N\:*0W&.;82>B),S1R_16T*2^
MKE8AWXS[4F[?&)[8*4SK-H.9-9B^H3P[TU:4!-1>8?B/K^E3BI/UW#UI*8WZ
MZVHJNUP8L"$UP+2N!4QPFS.8?5/1$+77Z2+IU$,7=9]E&:'W:;39G=\6ZT9>
M++&67V+$[57@QLZXV49'7;R5KVQTXZUMW29(A,PZQ64.2=^K:F",G"4@LHJ2
M+83\93SHA]A9^.1'I,E#WZ':NK@O7_;IRGTYWT&(@Q/Y_)&"@XX]!=<W!X55
M79U.1)MR-!'NK7P]JF$9N7<"E.V6'T ;K?ML[&FGA2YN56_AKUL!R _4S1SL
MN:=F=6Y;9R$>)X.DGC%71_FZ^"9?<6K#M]-,RW2\[4?!C9TN.H>\RDQU<4*^
M,)7?1],/9G*+S,5W%3WA^R)W"<J"2XE$:!H_KOB-8UHZD&W*TT6.IGM'X$?\
M=4E/.,GC@E;66:Q5WT&4+0GEA)0XH;@7+W#N;'Y6YS[7RO40IKD873R1KY<4
M>'*3*1/?R6B-$V5Z>I3MEG<+8L,%\4K!\]!$O3A==)&O&13HDG<Z8KY<Q2L)
M/6U4[!@_XO6=MGVM3NVV9>HBD#QR7TF@^*%]S%5+V-1[KU4FG7K(N0.[@BQ+
M>X(5]-Q\>7$9N-C3RR#UXG211QX^+Y#GF"MEW\9:I3W/=:R5=<FUZGFC=C^:
MULE0V[)T,48>=&Z\FZV?.K6X5$TK45H5I(DE[^21XOK;W'J*U!\NT4F*AJQU
MT4 >U-T\P-(;OLXZ><>28NCF'>*1>'51A_O1OC1=])#'8#?H471@;PHZ];Y'
MLQ5!94PI# #PRD:,X<1A2!>^=6UZU:2"+G;)H[D-[#I-%.4OK;%05#@S7]>*
M]I2KOFA2ZR"EDK\NLLBCN]*++?OA:C?'&??LE(I,95ULW>V>_/@H9M\(7II1
M^0&UZO1'CG6F-Y"V<'0UGMWNTL\[&Y6'6Y(#D+V?L0LN5AX7V=.VI81'5^.2
MKT;LHG%5'H?I&U>;@_YZ#[ZT*TL7*:L/"33>+M![.<H6;-K!IZO[U*6#+G95
M;\/OLI.P[Z4JKZ/0NXV^)F--#'E?O6^^>.%%W]G(;:.PVT]7Y[)MF;JHHG"3
MO<(NP[[SD-JT>7>7=AJU*U(7BZHWM[?85-:3J-&B-=N\GI5)BN7JHI/"A4VJ
M6\QZ4K7\9(;F$Q3MR]-%HNK]\PJ?[.A]HY;?V="\UZQE8;HX4_TAT*:/?/2$
M4?M$A^:M9FIEZ*)']3=#*SX+\JI8\?G@D;F?T&I%_%D@GB5/?# 6RK!^YL^P
M%Y_R1U,^EW#"+X.01G@@B(3 ]O\>3R['<XJ%U"5>3C$=6#Y:XB\#Z1OB>3R<
MD6;#:1&2,.*%_DZ#:/5EP*U*/A&@S\ *0>DO S>D-O_%/KG!$A'_ MYQ. ,K
MEHTCV)-8-J("P>"@#88L9CSVW>SZ@QN\"BA_>(OI/7$P*\%KF6B7R-=(?1_(
MS1VP6^0A^I2!V7R^C;[QDV7@0V.B3V5MIY"U[W!5\92$VJQWG-L<+[:=%^U4
M_=I(+AY3XLYQPB=_GOK'%SXX/WZ\4O$G"1>Y"*((()8P=\S$R)HY61 \N\0N
M@<[V:C:#QD6+J.L$S$4DKDH)O&#^5 VJ6L:(7N7$0XQ=S1*:7=$;,E^$XSET
M_G-P R[\D!*?$4?<'7/VB*E#&%<Z@[AU\EWT4?R^'U!36X5<12'/T(5VNDV%
M%)/O586</3H+!-,Y=@TVY<[,'%_-OOLNIMX3'T$7B/++JFOJ1#6';JUD%6=>
MUTPZU$'&YV]1H=VK2F]O<B:JY[EA_8GY ^R.8:@!^R1O,#\H5M\#J.?1V;R"
M*,_3#5:CN,&\\P6:\K &'Q_  YM@NMRR4FJRVYXB*>YGK1OL7OCQ=HP3Q!8J
M\#=2/&<CT(P/W-"F3JTZE=DX6:JQ$KZ\])[@ZMJ7*>=D=H^V(G%:57O+Y$VU
M^(:N'6S>-B^3K<YO?Q0.YP5C$7;/ \I_<-?P)& A.Z?!\F(5U%:(<A;/Z,4Z
M%.:'K6,/BE5SG5A K19RTL]O^*T].;#2#(,N5+%WE\N;V=HENF[=VMOG97)K
M_SV)%RD8?$/43%L7U:PP30N@U3F8;->XYSV-*,P3%&PK%3?3OE\#YRY:90L.
M?.;3,IB@FH.ILZE8?P6KE@1-Q9.+;.5^;MU!;Y6=P0-S-8BM @M;96<J=?+A
MP!PPL>6HMA8:$CY[''%[R'$P>+8^*W:"/ ^[QT_IXD\B5]\'MLEE7[ST3.=+
M]$B6T?(8^WA&^&+MU8./*5N0E;Q.U!*:$5OF.Z48@S+7#,Y R=_M4N_J%3'0
M-?!%<SL<74)_LV#YT:JT-*8H;.;:WUKY]RV ULF:L1:XUI7OP.%;)&!J]!4Y
M=U>S2T3OH.''7YZ0@&M,8$Q;"_SO/H')@/"/KR/J+%#9!VF2VNTTH8&7:0\H
MX^'&.T/;E\\BC^_$.2?@R$.'#:,8$&N)Z<GY51F7DJRI.,%-X[W[U:R\GV,2
MY!K7!N26R0Q&+U0_Q=.0;VIY^_%C,LY)QNNO9$GB+6ZRZNB4C^GUDYBVJF4W
MRADRNJ3'M:]F8_]BN40A9(&\,TH#*LY[/_$-G,=>WM%OEZ8;SC#-J3-4SL-U
M*^5_%:+EB<6PF[350GQCR[3F>O0"0O8UJAQ;JUWS34>X:R9&>!_I/639YCYA
MT637^R28+'!J:MZQ9]WXN@ZV36XR.6),$_087\QV@E;0.WOD_[![@QE&X'B-
M??<4WV,O6,6V9R$K5TG[Y*;NMLHAREU/=R*V2EWXZXW+ESA<K&.%K5/MA!';
MS"I/ T<T>;#B&4 (GR[\&7AW,;-2]/4R'8+>?+?>O/-P<#:;\4'L'L=W%(*1
M;J#)%N^\3&UURT]?\-?C);=9"K%;%J;M!^]6,TG'WJEJUGF8$1<\6ZZ\X$F0
M.%W$. [\B(W9.!_77._UAPZ>'PLOM(.NF1A;%?%Z3AK#KH&[(6A E#L^.7L%
M+.6=2>*OI'^66KF2J&E]=SW2V$.=!,?)UI%:K!+A7>^1+>H9GZ<O:"L')!<T
M&$PZ:52 DQ,U$5!Q&;568G?=0Z7#<[:^!D ^WZ\3,#*0<?:('7$;(HS"A%[-
M8*)R'"!:"I0W2IF-[0_BQ)J#$WK+KV[!<^*,W7O" BKF9N(P4"8N/2^D*S-#
M:XJP,'>@;1P>?AB-"HOVY=I03[ _B(_:(JY(L!>(Z^&9CB7= LQC*5@$7&!N
M\3\8T='PZ"W\^U"&IY[ 2,07OALY0B8>)4OFJWYM1'CYP@\Q_R#DW['G\L.R
MRQ7RGV 6B,E]CG-K,(K21@0.+U;!-0T<C%WV]\!SI\BY@[]A.,A-_AIDC L!
M5M-0%L0\#^C9(^\\(L(6@H.STKI/B:P=,S&"TO^(EBL@!PVO(II>JWO+_XY6
M[!_!E(V=<!W:._/BA9)X5:1B/45KCCM>;:DDT"7RT3R)?H #>34[)7P1*:#G
M\-I[*A)%5=C('CO>8Q%O[^.KX*A\CT>=@!$43V:4^?!4/%F^#7C'/%D0&CZ=
MHB>V1J2>P,AM4I<8\8MMN-"%OXK"<_*(78DSJ"!G)B=+>L,@-$UV ?' :SW(
M*F$CD7X+_ADAC\P(=K/P@N-$5,2S"C"5) W%Z,57DX;I68+1$"8EP]';,L)&
M.4/Q^0YBB^2.558&)7]I*)(03X+L,J/;]!:OY'*L27H56 I-47I7BV>U.)E,
M=9;'5BFQ1WC&29)F7#G)G2]VQI=;I'YW;A-E!J-&8.?GDU+EKBF>1;Z+W1H
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M;H"?#]3R@5HG7Q01<)2BND<7K/S@=A*J:Y? 2/GM!,V-/XS,HGN3RBB"S]5
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MCE174\/(L=5N2V$64XQ\+%> QDM8[8-(+3CZN65L,1. Q&D.7>!>K\I!8TP
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M@\V5W1C(4$F:6P2U6>A@6-(._0#;^SY ;*U]+,!KFRM*K0C<R29 M;Q7-+4
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MXW_<U!@79^4Q>H"%K#R2=*H'&LT7-CA9\LK!"+/T=']:7Y1DM2[!3" /Z8M
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M044RQU7-!\<N%3[J#F/%/ZCDA)8G/6"C5]74YU_R^9<4Z6@D!WNJ>Y#&R,]
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M!%$I/YH9)Z$<L>@^6OF)H>2P:#LFN:NA'%'I.=K)KZ$LL:@\TDU3+XT)U'B
M11\R"Q> LL2B%=FH*P#EC$H%,BH! 66*11LR#2N&\L2B$FE;B)0)[J C@$QG
MTLXY#>6)16_:WJB),WE *6'1EAJ4C/*K0/EBT9SD,>E0-M@T)-V\ - [!BSJ
M$#0'.)07%@5HJ^$>Y:V$,L&BUC0V>[V4&U"BV+0:LP1A4+;X=!MYZE<H+RP:
MRW;; R8>VO%S4"CQPR2L;L*+F.&I_I1/5L$K1V>APJ'AT^MQZ+LT82=PG6H*
MGF5Q]$RNXI3IK6R6;XZC3'.G:4HJ_]L_XV)QOH/'G1<D=3VL/% GI8&P=M[&
MJX)?B>V_[)$VKNW%5 P?80U\];8+\E3P ?OTVV_L=!SR\J?'MH'/\3*N*U:J
MV'1_I@5Z_/W7:<YD8.T8NP4FMGZL<0;/K:62K#S0 K''A6IYM+<P3N'A2[G8
M0(6WE O.,BF^( G:@B0:J7Q\\GZ?O-\G[_?)^^V,!E?!=@KSV>N7-/ZK9)KF
MMN*Z1+)H]1V0U5JQY!;BC:Y97ZO75QNB*6WVD %Y"BLY09N/$?N@$G3_ *-8
M*NT-!\3;.'#M1K:2U;(EH=4?![N-%*XO]G9-8%]+YT$#\KT*0K+OZ2YE==Q\
M0.Q5-!_)B_N@()?S.;<WO1"A[:#3,P9D"9)QLN9CQ#ZH?-[,B?4M ,<H@"]I
MZ13Q#0GR,B/UA%Z5Q46<AWR17M'L<Q!^G<UO@NPK*=:W.=(\_UT>A8(S7\E&
M#(\[#LJ'SZF0:8[<!4Z+C[CCH'RJ+?X/F@2%_B24]AV4U7V<?[W*"&GN(UK4
MU \8E-]APD,%F_8\E@-BE^X^Z@YCQ3_H_MGTDCNXB!(0 ?3PA1I.H%"#S-7[
M<#(+6)@\ @U'GS1_^%S.IYXT'V \HKJ'1ZS\X'9DJFO/Q$CY[10'4.J55%^+
M<\O38NXQE1G8\0=4^R4JA0H%.,A (_FL3TM9GK%N0A5#!E*? =Y.SO$3R@"/
M+WWZ6TC';-%W%M64M:VL8!":-O<\NZZYT* $=$O<P T$W7)7GB2H#>=RE*O;
M^NFKTS+'D\U;SS".;D8#SE(2DH!K&I23V<YI<R0;5;=/K+I<=*MR]DX7>COG
M=AONG;;J2MRM6'9&%^[C !P /'GL?:IL[<WUR:?*[C4N&>99B&Y#,2$']GE%
MMX\,F,(+6WZ 8?*:8LLFX"Y1'9:,2+:#CH'TL65/ OOH /EARY;4P2\<R!A;
M1J4NH4I0G0-+=B7EO@P,TH#RQJ9LF;M-01ECT\"4OOD[8@[RW7R<D&IB64AN
M WF4FTPV<"2=TM:(*PPWDVVHZA!WRO5QE@3AUSQ<L$'(;VA$$DE.''E3&PEC
MVE2PJR#.6BON[*6%T>K9%U1Q$E@E5E7^6/M@/]/P:[G2A-G6R3I C33"8L#:
MN8@[ICI:+N,\K[.P2U+\R-I9@K&^<).;_D38M#I; ZQ*U'^,$I;:WP*T]K*"
MQX!DY0<[P= HY=1$I5T!RB)(2<9^,41EFO^^ !ZFVP=";,_2;QVD6#Y#2T!T
M@E2O>YZXE:9YF3"]6J*H*!M; 52-_DYZ;NHI/="$'? >%W%6O%X$KZV?4[NS
M!<#2PK--<( *M=V J"IK[8&!E>&R DA62J@-D[KTD!58DC)=;:B45;VL@))6
MUVJ#!2C'91M8:\$D!39)D:5.\,"U@)KX- L(V0&H5C0432V N2<K-H>Y:.1&
MP5P-"=3!!K#Y=9K2E\I9,+].0PDB:4L+4 YJP4_3Z'%!M ?._"GV*8!1V@?"
M9695O9O))K[M!;7M+>/^W]S<<?:Z:W(7O%:A"=^"+-J>[*=L<2XKU2=ONG:T
MDNG[94,.2*W^Y;_S[W3!,&TQ6QT)Y5OL))]E?_Q8UUQ. DDJ8'E+"U"^,&&;
M?<OB@F2212)N91-"0=*[\BF)P^V13@U(T0='@EQ<:'RZWJSXUSF7;"1;!>PT
MQ/V8!3ER9<WZ3TY+5FN-;&L;/\33^L&-^IX&&_NI,Q2L'N."UX^Z3J/X)8[*
M(!%,)&D[]RAYX,H]26H5<A&O'JE$@'1XPNDQ&S0YBXT*;@>I*^P5A7,U!DGU
M(A)5^MO9H8IW4/WED*U69[>\N/:IR-C4VL8I2I^*W*<B]ZG(?2KR'D>CX=RD
M0[:EFULNNZOENR";996C4R3SZC#H.12CVO(_+8L%S>)_']U=:/1PRN!RN4KH
M*R$/)'MA0J!]T[_E?H0Y&_%J=V5:$--XFK]S5>>6%O]%BGL2TN=4PK_W]YW&
MZ.V>5'>:%0N2/2Z"=&U\<SVZ4#PG,OI\>0XUTBWO'F94=T"D&5^5[9VB_YVD
M) N2:1I-HV6<QGF15?<HZW.+E(E67Z>LZE+5.\=@_M:#) 1'J;N5/3 PD.KE
MH#[C9C%\(OAX6;L+5>8*)HSJ\S^/?)&3@G<])4Z#?J]33PE_FBG4%08KGV(<
M)_Y!5_IM4#!4L_E:\Y!,'TE+IXAG+R3CLK*RDP.T1F5[I^C7[@WY;+XUY*MN
M!2!=W')(@E1P3RMK,@A&Z9IL;X0=Y\ E"<B<9-GZ]*AI7-/K/" OH(D-UFEP
M'FHC+K"78R:[,/F-S-LXB%<PA5R _89GDST$_+J[CJS0H=/:T2F?>Y*3( L7
MTS2Z("\DH2N^1T%L'QH]73,JF&I?K!>!BH.XK5/4]42H4/ =8C9_S((T#T*E
ML0#>\53X#+IOMIMMCWU@SPY]8*O_]P>;;]M 7='%:Q^O&,<8M7E,;_(K[D[J
M+8[: [QY'".ZN:W>.2$!52(';QS7"+H:MW&/5M/3/[]>QY7^GM%<6"^LOS>-
M8\2:0:4-5;W61^JX4]M#I_%*7&.82W>^R@Z:1J"3>)^O\F,&?]7PNIRMR*YF
M'FBI9M?K"]V/WR;.E=^F*,Q&RO9NT?N2ECWAW#JV-],2-3_^%<W67C#B,3=Y
M"!Z>M^1;]9,1OZ/.&'A5XJ?CYY,_ PU+PX_7WM<MJ_(ICZ,XR%X;9A3)]8ZR
MO5/T? "K'?&1A(NJ?(H$NKSQP+BE>I2J^1BQ#ZK'K7W6I9;>UC9#H/2EGO5X
M^5+/3DL]2X.S::<X:$Q4-S,/XO1*E<W'PK8]U)&Z-(M@'):W4T5:YOMUF"E:
MRU<7(]GQE\R&\51HPE17\\3(L=4/C1[_/A8^ZH-74RIK7O%C(JS.TT$M),-P
MR]AB54Q)\@''7Q%09:!/Y: Q)@"G'%2UV0;5KC#4V+2P'H#I?-"LB2X2:U-!
M"9CV&-5<[TN<=YK&E@JM6!3K0+LJFNELH&EL9K&JR@BJZ=N3^M5I]N*K1"\.
M^D W8<7:!#C5)\H)JG?>P: $(%(@@?D%@.-CJ>JFQ?4)N?I"MU*5MH?-F@65
MBT*Y:+L;8CHM9#RUM76LZSAG*\S0WZ!JD D$Y1RV>2$RDFU)^UMK1SX!*5NJ
M[VOI.*Y.TXQFU9I=2FXV'$CI!U1KU?H][4@6JL'I5"^G/9"QI4+4%C=:8$98
M- M6YS)U\RD!1450K5+;M\LC6:0ZGQ14F<BM$="Z&-KT J8O0?,]N^VIJN(F
MZ#ZJSK35J+?DU@;8K\35+C8%)/]W=-LI+,,6NMT4X,0B(:E*\89R<[7CXS.2
MK;7;]P7DNP,R_@W=@E7F-$.W5K5<[#8"&5#J%>4JM>AVV&FI6C+E6]YFU87
MT6E+KFYR)%$;T(F.Q^=+69H-U=K5C&KHM"Z%WVC]1\H$P_?B,JG&E1U-R#/_
M#VW&09(HOMGGHPA?JORR.'4%&"5P;0E\$@C$3R>Q'[JCFO8GA"5B1+=7FG]*
M86I#($=+-Z;6.':)>G=[QV2/,BPGA%O+?-\?%!('[]9X8O=[]I*\SNWAU-J
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MMFM(0 ;6R6VD16N&B49>J+/779.UO:$J';*NWWY%LSF)BS(3&O4<O,G'TIQ
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MV+["_GM&<^'%1G]O&M6(-=+;[>?6Z&G<E.\;Z^CUNK<*WS/6T1I@;^TQ[_N
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M=Y>Y3R#G\O'Z16(R DH^F&TO"K?I?INM7D:E5]8(K(%X9UTL"(-=E4-/7IS
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M@4$."7$#BX@%^T&P"%2K$@J4 'I0A$.4 ')$A%N4 ')(!#:40!2@"C<H >2
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M\<I'8[=C[R>%G-%G'XS=?MYQW :?)G@;T1F]18L)[D5P+X)[H<S#&"_MD2'
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MHQ^8>%B]$WOULGHQ0'LDEN@Q\K9J' A'HNMZ67&Y+!%HP^WZ7-.YY3]W?+"
MOM>XGASZ7PJ\-%3XHC8J)YU_)?=9LDY6'/))M%JQ'3_,9?<G6\8WN806S3_Z
M[(&-^3#FP@2N:VMRT^)!E@T>Y*H"[U\8K2P2L\YY2WO7C3!@RCO7R'"3?:MG
M6J^[5@]\M$FW0HO1CB4Q<+)?62'.QFXE"9G17C6F&8<[U207'>Q3&?>/3]Z<
MQ+18Y<E61!G9^H0?+D_N=D62T:(XN8N*I(#?5F=/&8N,LOBDV&TV4?X,?YNR
M5F5TEZKO=F&PLK5G^L7>RZGP#3GA1\"&'E U"$"<5O0LR"D0!+^^ZA!$.$'D
M1A(D+-!+V,0#R=Z8*Q!2H%1M#JQ%4><SK*/B3JS&KCBYCZ+MMV",OJ5I6=2_
M$>9)F*;J%_]QD7&+36^CIVL*RY:DB:"A^?7YTY9F!3VE&5TGY;)\1V.:RQ/]
MCNOK<_L]9]N!H7$*0]-L.,'%M1'@8,B=Q(1$I=#]3]_<?$/6$BE(M)%8$<BK
M69!H \+E5:'=KC'SLG"N-OCO3JIC_ E']HYC7#X+V[".DOSD,4IW%,S#NHZ2
MB3RA7#ACJ)W;'CBK6[(Y6E[VVN_X7EL%+<C[&E&QE;[CB)*? 5'83=LP[46+
MZ(SV4(M2,+DYVEY:0T6\*=GJMV46U[$G>?'W=@=7&S(;2JRB]/,/!_>IFI4)
M,<ID!-BUN@ RD,[8N1ZN#H"@+?1O.U"<51H5!?=Z:-S$,A<DHR5\5%^6\:^+
M*=T)SQS< ;FQ%S6'  _!H":TNV;Y_E^#7:_;D7-F?WU<[<S?GW"6/-*\3+@1
M$K\J3K;1,Y@DS,ZK/IW5G74:K)>=\WN^<YZUB!#X94&N)"(SVADU5FERY]-E
MO:$@[ZO2.Y:_I7=E;8?/P(KVR:OZ5QBQG)[=2]1X&@WM#<8%98@8<G/7*?<%
ML5_$'!/QL]B <?NG"_)PF^12G%?W[CO':25)1C*N_U'Q0/B(;927S<\EGZ"(
M5H! @"U40]<8<AT,;<BY<,S@I4BSV0XGJTT.QEB,P4E=&PH)^$1 ;E,(T'EI
M%NDP3DBC7=)J+0H@_],"P_2XY\KU^^&D8AG"SQOXUJI3=P##BP?W _?@Y++,
MR%T;8O:D;S;*05=B]>>31 08.= GW,7;Z Q61:P7DA=!^S,7-!F();< >T;B
M-L[^2:%3X*GSZ):\R;89WE*9T4U\:PSR"PMP&>5Z^.84SB'Y>)@*\L4$OI0T
M0#WRI;Y8AM;BBO\1'BK$G2<P5WSU'KC?=94GJ\.[6KV/,#H_.;F7<,$D%MH:
MZH N1+" 8W$BT=A[BK8@-2I$X")L4<S2-,IEOI;05WVSY(!HG.6YJFD0\0#^
M V2>D:V@E1NA;<N6P$_8U'6+X7C\@M/4WKS^VTQ3U8XQ>VGI:BT%7T[*&H?Q
MYO7)_YG1Z2&,*,XA>VU(OKQEL-7)&AR9CWSY=GD.#_GOBC*/5H?I\UK?(#/,
M1N=VK8/O&5\;[CYL2-JB\9<@&6%J/&8HQAGN=4>/PR<]8[4O,'O#^,Q>?.)Q
M%+1]0]L4(;SAGJ(,KCQAV]0Z<8/G4<5!48D8@K/&!B$K=BEL;.^2?'/Y.:/Q
MZ?,[EF]H?O;N<OB:3.<[G'&8GM^UB6AQ(( $$5A "3^)!^&(D%\_G..NTMP0
M:*7,PZJE>PUTLYIN^..ZH3V('FE('4-SVEU:]'#N#/(DJ#>EY?1F%=#>4I@'
M$['$F6E.1R;--5-(1M9?""LI%77UE$MQROH0/26;W48&>H=3*Q0^PJ=8C$SN
MQ:&<Q *9<F&5+H1;*;%H*ALMB$1D02I4ZL>^)A<^#BC%/_'=5'15MSHE(W>T
M3M'B-#(9XQ$%D>I[L8"5D-0UB^&8;>,&]QKXE$.1TU/:9'Z)O]QL^>%WV&[H
M?XV^F56"XL62J*.#NUEU1"G"M@B@I,:G4K6+-AM2_EU@M;!A9UR2;[&F0+[/
MD$YZ*+CA\OJX %Q#W1[K:20SY+Z[!Q%5SA32 1_YWO*3AR,XWMXX5+O_W/SH
M,=8KO&.8X*<##UEF0JBZQONC;?G$<M9@SK $;\4WQ%)BS_TE$@7RZFWT;,??
MQ=*$CIT"^M5-9>73\IT5?IJG4WN@$V/>;!\K_1>7>)L4JY05NYQ"Z<=3#NBW
M _W7^<2T]$//U,Y3"IND5])")[\"?"(0F B=NJ[:,,;MOB(,DRQ\P=DH_/=)
MG*2[,GFD)P5=[7)Q)\D!B^*E<TM1443WI>6M3)#U126S+/EO3FIBR4U#+-]2
M);43V^J7ENJB*M)SR'_1DE-+=2+[,@/[S)+*>)-*D7WS>BT5V8< NIRB'6J,
MBD4.9/%:J19IASP;H9WY).4J*<AAP<AI1KY@YV?+CPOYR5:>&E8LSZEX43U;
M[T<5WY?F_DS1]47Y/U= ;!U&.&N)_4?U?Y2%>@X.D)ZDFEZA<3"T6$X7,!@=
MB+H8ZYO0>?UU 90L+10ML(2_<6K5$4DA+FY&A8.I<VR.E2.AOVR\2^6(=OR&
M1A"ND6,PF[EGG&93@U(#]_D7JN3?WE3TB#'M%Q\Z],QRW_4M?TZK7Z*%RGZ7
MI+WCS%@48>H;2[V2]N8.U2YI#PD;#84,J;+7-.D@Q&"[<9(AG=9[)QW$&N;1
M/ZE??49:*(UPU=MEGDA'.86R36=L [6VQ1HM <=[8;%.G]LA5]$S_&K)UR*&
M34;L,<N"'RO$2:2 :MVKDL8_LY1/ Z9SI'Z\1\C(JT4/&+JVA!Y)T;$SL^8P
M)LT/D#P16)(N):1#"CPRZ8ZKR"&"GD77:>O0M" U5:0EBTRSV]'-LD^=90'%
M9(XGP'Z'D@_9[LI"S )_E,&>DJX>LN1O.^3]=G@T9W-.-"/G11P=^X^+?!"0
M*.;YN2:1W#8D?G&G24N"Z_2 :5,:0U1A[QZ0AT=A3)9UJ-YJNFMA%[[T^T&L
M:7C<'.V#?2DQJBEOL/0A"K&<R>(= ^>YX8'F)5>J"7V=EHXA8PXW-O O61FE
M>F>16_B$5(56N@5C0M>+.92*_B(QO:PR+00!53V;T,ME?IW</Y3'91S[-AS-
M3U'E(-1 ^"D:HX:+?D4(5S1BRL@ +IT(*A17$?@LZL0LB5+S L(@ENJ,;JLA
M5<Z '!!K&C7$D@&0%B)3 $+4P]#4/&;"\M#.,.SQJP?QZWI5G+K!"O""., C
M>,W.]7W;X-K>Q;QDIU=%)JRYN\H+;:MB\C*+E=.,E#\RJI@\-+EK0>_<%8J<
M/GO92 Y(,\Y,V@Y0&["KBKIX'14-5F.L\RXK]S2#-KPBXA3%FR1+H)ZC>"Q!
M9<=>U.YE,+^;;BWJ>'CNZ,+_\9/$34CU<@\W4G5-GN5N9++&ZDUBL MGFH@C
MNY95_!_9848'HE)N^B9T+Y39B>C25H/%;QV6\#?>+K*:I$I,0NP/X\+!U#GF
M+4C8<9FAW=TM^'53;\*5OD&&#D?G]E!:LSD_ '3RJX!/0C\+5V,X0W'1N<?!
M^5WF"=S;GXCR0"?0$_(1_F+D:"A/Z\:_F 3OWZVX;E"JBE,M*Y3F[4VH+Z2Z
M$Z&Y.L8G5;:B-"[><;+K7E67^4V4TLNU7)V/M#>35^M#W(E5 8"G/C\*F"".
MK4[H0_7[D9@0D'W2=BS+"6 #02>)SX+,B$Y\*%HX6DFV3MEG23$$G)O>P ?=
MQA9PE%_3',K&5;\H<Y$$\5S_+ O'L3IU#DY&C$^9$\!&A/RE9@<Y\^LH*<.O
MF-_,X;OII+P[G:2\6YIOWHPE##L%:)(G[ 0QK^G!3BA 9P7/A)\S308&:LBK
MO](H]^N->=3%P_Q?#P+A_!33O0&1+J7<K"R=9K2G=W.J44;#_^FF>W\GCS=5
MM<.7<<K17V#UTPYRU0QUYA-4&?^<)V!GA\.EPZ,P$GP\FVM![$+$QTAMX&VE
MB4H7D0"^](@T,$56>;7T\E=B<ZHTRRC'PQ"&>YL_C4M8PR]_67E><A>8=0*'
MZ8+C]@#=5737=66LV[W&9Y8[K_CJ6Z^*A\V>)'C:7/1?:97330<6/+7F/5B:
M',R!+BQ-S&INU:J'E$RA"4L_OYUOR7=IM/J-6S@&Y? KWQ9Z*4+=JPV+:6JV
M&VM/[V8C5D;#_QY\"JB=W$C<FC+S$C?R 7";]_:KO\+J.R]RV:P^C"BJ9.FB
MTM-3FM%U H\0H;%@7CPDVS[50$]B_EA" 5B 9Q,*6!D^)'!"MX6G%$7SEJ)H
MM^\6.3)K^M%])E;PT;TX6M3;^EU+,ZLQZG]R$?QEA8["]K^QT%Z-^5>WD7M6
MYYW\)=PCWCY$F=RVBLM=R4UY%G/[_ L%XFF\?*0Y%X-KNHF2C/_^C&6BR?DN
M2B'6?.A6S!I'WQ5S7-#BVO)W4%HTBLW_5:%'(HD?R6L$H?EPC2$IYW"#,Y>E
M&KSTF0N"?HXJ?SY)1"N6DS)ZHOOE!',*:YJDB2SN@#FIH&>W>E#1QL++.>7/
M_'C2=O.AAQ4UK_<PF^4I!;^ZDX<4PR6S]8)+X]V6@]=:P=YH67R6%?PQEGA0
MW)(VAS=8JB^O0KRW&E&\N$J%@S^=<&><5O5_.O4>;&\2")"^=@X-U.:PG;RM
M\QBA<]Q2H"N2%3ME,%[:'H,1#I.-![WBWLZ>X@HZ?>;.I%AA<61^R\"_'#@(
M3G^ /)4-3^PE[T% EF).9,#H5PD]S#,8!38S?=Z]X.9 7;4:ZGL&C81GVBL(
MB?Y+:QVD2>87U4FHNW<.=E44';QGN6W.3SK4M^#YX1XJE%QA>;GNCSJ)/*(J
MP-342^VD'2N]B74#!!O,M8J,\Z9*W<S>X<SZ;M(O-U!M9=L.XG-YL.M(&IB?
M)?Y"/*+!1F@OQ"72P?\E^T0J='ZQ3M%@J\7?G2*,&LS-*]*7[?F_ IV\I5O>
MW^?TGK/](BOS)"N2E7C)U;F\&[M0#XR2[Y>D%E /=%T>U8B1I,:,B KW+^M=
MHTW9L?'RT;I N&N)@B\8B77!+,.TW*S$"F[>.H^85$N=KW=B6T(4NH(X6/8O
MUPOXF18E/2S8/A-L7LK>+[%V;2C.GVB^2@J0V-^W_2&)";GC]XF!NW+HZO4Y
ML9N[(0S+9<]1N'@K=:Y33':^F[7IBBL4-;>PC(8Z=4T?X7V&B,C>;-.D7,;_
MN2M*0'(X(4[Y(XS43T[N6HPK!*J8OD"!M#C@\^4<$&8E<RZOZ)5ES@I!;]2@
M%B")3EV\&(ZUQCK31N >:3&=0*KT 4Y71B9VKR==X'\H+*246J;'6#T&20RB
M%2I"Q/0YZ=PKFRX!9.R4H4"X\<FT4/'ODDV7JGH!'AENN=4=,H,U]*I-(\54
MK*J4'ASW>J6&3UCE&BL'],)43'/Y<7J&65/O[4J?W['\$V=MSI');J.G*U8D
M(@JBUL14]7/#UJ938'PW/)W"QZ0-JGU:$04+VO[H:Y:3!AW^<Y+MO=A8$"62
M'7=-51;#GEZJ>OP.FD?9C71V4\YJ3P>=.XF;V&*^I!X"SG,D^_(BV\AR6WFK
M<3%GG F)7-N)[$>3!3-N'E72XI:]2[(H@^(9-_5>W.L73H_&M9$:FM6'CU:0
M6T8:V*0%'J('TR1[F2;/@KX\6SXE0P5(IH9;?'4&TX9Z<P:PY_/B;(_!$^_-
MCKGFS-(L[PI1]T+/XAQ^9=?RU+,'M4!<?BHT_,J0+N>GC5(_.ZT6DJOJ0375
M]Z]H+G;8/JG2^]*\9-P0A !UXH90L=-EW@*%%BK"-07A]II:<)3D(QU1TC5F
M:1KE!;2:E^5=]:N[NN( NB:<) 2H!ZIV65*2-= O<EP(5':D,ZT'-ZF"_47@
MU'C^!51^^TDLV$4F7UL<%) 2?WS+36W#A[$<M3GA-[N*;YITN+;? B*-%UR7
M'T7&%&G; U8W\J#E?07@[H4AC"'9K6,#,);OQ=6"PPJCESIP1A+FPF%ZSZ5H
MMY7H*/M*?1]9<Y.ZDX?SD+I8V'$-S.BRZQ<!+B>[;?U\[]7;Z-F2 V1&)=KW
M 2HXI6E%%T3:Y^OG]*K/J(LSS-4OP+N1V<#S]6Z0^,W.N]&DP[7M_?EWE\:U
M!'IQ:8S$RM"EN>$P:;&L<R>667S[0+53,/&S8)P>?6C.[^@$1F39YJ! 3CZD
M_SI(X_1!OI749P17 C@8!K+++*U(J'O\HQ=+U\U6(JY1.2$'O_D$6XO)#;\3
MD';N_JVB%CPKH$6U2H\#W3OZ)5 P^\P!-S(SG%/@4!"^@,/&1U;%TN9WSM!'
M;79'#'42O+:9#TPKNB']BULC62_HIHSR4B]6=1KQ'U<T;*C[RUN)\RQ^@>OP
MXL[G",OMY6B.%; O:9__N.LY]@>#/]\=6^+Y!6W+DJ"96GPLMSULL++;,;;Q
M\8OAH<.M49>#+W>_.S!N?C>UOO4/$(L2^ V0BPLUH6<TCB1I0PX>*.H4#ZSK
M;=>8+LCYTRK=B3]5[YAG%R'"+W5O ,AP_;X OV\_P29P)MQLO;Y]-.>3Q_;%
M[YP#\A$@]^R+T_S]>^C 62*SU?Q]-%_^<6^?GGF=5-"\_E'R.A.E$S6/*1-I
M-5^\A1W0PP"I,':3=]EFP[+I7):Q<:@4W9[Y7%L-"=-"KHD=Y(VS25:2GH"M
M9T>E@BES:_Y>0J6(G0K !Z'OZB_T"IY#V782<-!]^PAZ6'HMULSJ)EE'MTNT
MPJEZQ_8E7"LAI<7&3F8B O.O\#Y)W36%;JI)=G_&,O$P>1>EMS3?O!DS"&$P
M\5W9'8]Q&$/QRZ&AR&O\^+;;($A*CB%Y]5<:Y0&-1" )LE'IW998O$3CL5^[
MWH.-&  8WA0<(.95X[^0[@WJJ^U&;4>7\,5HY_Y!N\EB<:6;4^ ":>806EZC
M>@[P1T?Q9L%+Q$O=[BUG%_WN52>Y>QYK,MRV%Y;Q/WX^DJ1TBZ"\2%,YJ7P6
M#:6:%+S$,(B;-+@I..%#&W[2VOK.)B\WQCZYJFY"$&'S>0PM1R</1?%D])TC
M9\4 DT!^# )CKYUC_]&"#2829'$S-A:+%[-/=RC=/Y\YVJ\GX07:MP?Q\JKN
M,XPT.%UKB[NYX@*^F%W]YTZB<?6\=JBDL4M00>,+^RB]K-C"/N[AX@JF/)Q%
M3&%!)!FB.]2,THA<*9WUN,*8%+Q$7R5 :H4F]/!^3,C4"L_D>$V^=,UI]$.[
M_I.CBWR6%\E1[6=W_O@Y?P?>=WX02A;FLY,5$^2]8_F:)N6.2]] ^3HK6YHC
M-%SM;9;1=;W)5>C0^-LS>)Z;IN"H?I%VPI4<Z1@,I\+Q<BS'^=,VR<5'02T'
M$HU0ED,37?>7=AR=?UAK@94=F];"2"#F8RV&J/S(JH=!QP^'6L?*S<4\ K3O
ML[(&BK,_*&O0XO5,YY3'=H[(]:NH8 5G//#([-"KSZ&YG60QULC&,1:]M//9
M6Z:VT-&&,EZ<4'T,0OF?ZIAZJXCQ#^EZ(B3&IM>)%8.78Q1J(@(?3A%(A#N:
M:B#K*9OT']8^X"3'[L$4+0Z&=1[XS*L=M%PX>XB2_')]^T!/&4=LN.*#VA>8
MV@_C,WO0 @F="/"0=0#--P0&^)(0MFG"%H=(H;(+*9F@:8S4 -4B%"6*(5CJ
M;0]=KE;YCL;OD^@N29,RH<79+L_Y0@UL=Y/CD3O3X+RNU:<"S/<),(!3R4^.
MMH)IKC)M5ID6TGE(Z/H#C9-5E%ZNU]Q^YR/5=*8&HTKJ#$WJO*X. "859%*!
M-JBN8X\.8RO:2UJ(0CN3 L/TN&=#VF_IZB%C*;M_5A/XB?%HF1^8UX_8M\ M
M2;XU:BP)_S&!H>1_2GZ8-AOG<_36#S4VISE_=SQ'(.=SM].@]H+O=!H:9G)/
M@>&I28G)3GSB2[Z;.-8BMW<2 \OXDFU?)QW(G_7K 3H?^]=![@5;P X5,[&!
M.+Z:6,'>Q,,OV1[VZ95;BSBXJ"_9)G:2GGQZA$= YV,3.\B]8)O8H6(F-A''
M5S//L$JI_)+M8)\NN?8,!Q;29SB=[3@F'%\HU3(92Q\9C ^D]TSJ(8HNH)*M
M!!LJBC[&3Z;'I/GOG<>OCYQ6KYI-1NP0/K/?%(<0#_Q^,6QBJW89L)GSP\K+
MS9?K#TP:"S?O+N>=G:KORE29C_Y./@< YW/JJ1#SEFKZ);ODAXOLUAWO7;GY
M*^7PHRM'CM4(I&"%08\P>BG.50_J(=P),PY:B2U\*:[$F'I8K; ZL6+SMUP<
MZQ4D2-Q#B]O6-[J!QG8?HJ=DL]O8-F$:('W;,@749F_4%&CP:MV<\#1,U;:6
M%,@C[O;'%M00)?;.S63JJ*,-VZDM#]Z,Z!5+D]5ST\![>5>("K@#]F]B--)T
M#<SJR^H,@,<8#&N4('2]"M:"9@HTDD!)VE,RPC39Y4T5WK.B@ K0G(,T6SU?
M4:&C9VF4;(K1B+'ZAT@%F0;@2U>F,<&HC0OZ$!H$:) .'K#YR:U.HE)7+ VB
M5AI"QO"<G;_SOE_U=/D8)2G<3;UCN8BC6(\$JH'S'@<<1VOV#OL$_GXS'FSS
M,HRC?E1-N:&$K%E.!"TO-\BAJH=60K4Z N'/8L)AX:(H=C0>;$S7,P1KF3I3
MN;8F5SE;41H7!&2%K*+B(:5\)VZ>I'.1KF\;P@AM'UN9"J_\'>.D^!:W;+GZ
MVR[)*>?IEN;E\Q7G=+G,8KAUV&Z&DVST)\ >]I0!>3O_*6.$.A*ZH-<D\'W%
M?_\02;7:5KB0*(L)52/3U;%17P"9.9=?CK^[C.,$/HG2:EO:E0\L3_[NX/);
M&6(HKW<8LQ?C^ Z3$,3WM<G1T.YO2TOC"3?4O'P'6$$K;?K JH(Q_QY,[<7E
M=):"S?E]=ULZQ&/V+98.$?;:5\F<6V',78MWU9CY17:('-09&\V2QI?VY7A^
MOOR]N7EY+]:WFX5']_+]N"_0>?/BLLW)4</0(?X'6MPEV;VTW(/Q3@<@?%N[
M'E1F;^AZ</9JXZSP+(QY$_\A%>Z-Z_:!9>7#"[-I8SIDPYQ-+K(W2R83].E-
M&96[XBV#9N$#!FED)-*N],SHYXD')1(F^55"G2AKYD@ZQQC*-+@41E:63\E0
M48;!<3;D!.;S+24 <P8RLL?*(0DYYH^_)+.C<J03*9?3'V"3R@8G=EY!48(C
M:8O!7\+D5$WSENDSS)LL59OCB)7I&8&4ELY,KL6C=HX"FI0^OC$%9OA>^E%G
MI'>,V?+[<4 : 0CI>?1S[U@(@GH; \XU>,ZW?,-;/=#+C/:6YS68P>X)N0^2
M:P'K/9^U)Y(%J1 B'"/%LKY^3V>CRS-]^)KFN;]*0$5!RZ'M:_^/V$H_8A)?
M,14)#1,-P>)9LC)*]>(8M_ )44'550FB_85EXUSPET7'N?0QVM 1CZIO"#83
MKC.5\Q1+_A,!8"&]JE[>,16&>)> 4<>J?Y"A%/AQK3IR$-*Y&N!@CRP$=:_.
M-]N4/5-Z0_/'9$7[=]./+'ODKB"5 <M"V-;NW\]847YDY5]I>4U7[#Z#*QF1
M,5P]J!\0,J^PD;+K!4=?.[<78C".P4RY;'A_TNMW-U34UR42NP4!]/E?2_),
M2])2L"#+#3QZ#6+$_&HH"RH0GDTN2 ,\6X3@6C%Z?IT<;V3:>N9UWJ>N 4P:
MR&'/H-,L/I+-2;Y] 5MX,Y/\Z+)\H/GM0Y2%VM85\9G=5C^!]\O?_B<(G)=+
M8'TUO+@)YT^K="=>ZO]C.@RJNN_%B= 2H9>_$?@V]',UY"_>4,_*$,_4T/Y#
MF56O9M-JG\YEENVB%/"ZB=(H?SZP4:-C,/TX#^=R;0MZ@6KWW33'&E.F2P E
M )4$PQO;(W3+_PK/K$4_\4A2 N]N2"$0"= A=%"*F1*S#/7L>GV19>RQ+H>Z
M&NZ$.SX2HW/],[K6O.MWI -VP7]8?8/O?&N+!F-Y3K(URS<RF1OJ!D1)!J>)
MDI$^@OV+^83X, U^&HK\^1-=[<KDD?[,M[^SARC)EUE\4^912>^3U3)^3 J6
MW[+;!RKZ\3;#)WM%6YT8HU!6$' >'JRA$L"2"#1%]8X&45)A"L(+9EJV<VZ_
M,VY7'8A/#G4<V$0;!H%?1U8-8XN&L=$!8\\O U@"NVK"W*VIH9VYR.+=2AQ#
MJKC!L.68&(JQ!0-3NM;N%FP5R%(-_;LDP:'B)2V]51G^ !HU)3Y,AZ'^4C]7
M#S3>I5P#S_.<Y6<LS^E*H,4U]RI/6"X?32WC_]P5I2R.5!?:'<H%M3 E-CG4
M +3S;-$*-WB3++ C'?3$%B$0K!_S=5 DO]Z*^HN *A&X!LHBM;&PS,5JA<Z4
M;H-=Q>@[Q%N.)]"FDA[F$I2KU\D(E)SWRA0O90%TV%PUI\NI\U#6>(V\*=M'
M6O+#)]M0*#\]H"6]8Y#BO3>7OEP^TOR.Z<;Q.$PB"H9#48KR@>T*OA/@>C(:
MHJ^G5H!WRN$$0!01+05L)4CR"H!^399EF2=WNU)LK-R%O(IR9&5.4VKT\^[5
M>._(CO4K'%/BA[_G((TI&T[![QV#?1S2G<OGCA8N"[^??4R))][DX)H67,U7
M9963.)H".#H6*1>]<SJ/K3= J]Y*0=/^QMG*M'CE36[.X.8U+Q.^.;RE=^4-
M7>UR\6)[5((4OT+*TL3LSE_;M^ )P"<M F$%3)7K#,E*_ZE%;?JT0L[RR'C3
MU)[#>8._IY7(S"&->8SK?6D>XZST)F*_R/X'HV+5.P8I2GMSN1:?"EA8\>CG
M'E-B28"@[S(KDSA)Q25,:P9E'BR-WW'2((JPDT'[R_5YE$/,O;BBN5!6]5"P
M;4#& 6);"/D,&W=Q[NZ_-=:R\TD';Q%KKC"'P+(L*3>_>+)UZ>B-,KM9<G^'
M6C/T3Y_[)Q@[(KN'B#UPN\/,^?%]0(E#GN4]K#,+L'B!57/RBD?U,ZM*XO'J
MI5_2%S.H'*#,^4FQ#7Y+\IZC<2]49;):Y-A0=/F_XRE=RU4+<P9E(T=YRG08
M%4QB1FW4^&!+4N/''O7(34@;-,'9$=D):F^JYK\M3J/1A(G1V&HW_;,Z+WM3
M]7'N"%+08,,4<YDFQSS&US>;1&;T++.X[2S-]].W2;%*6;&;#B[@)D%'WW6
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M('D8X"1398__'+C3YR9YYRR-BF(D:5+I&]/<LKZY78M0 Y$(D"%3*=5XW)?
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M&+;\'.7Q1UI>KM^Q?$V3<G?<B,_ZO"Z.]RKP?5XKYPT^^S?,LS[^:RVB:C1
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M5<I?OV/Y#<T?DQ6J\.G@' ZJG![!\G8MK8.41;6U1;5E[15H+>H_@D>M1GN
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M& ',FL"#M(C,R[*-K\2(<5-@K\?@*/>!:5&?G$!O!L.@@R/1 <^C&7T=7GI
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M.*"B0\.0VG0XG?L'R=TBF?_M]3>O7[\AVZA*AEJ0/[Y^O7@M_[]ZHT"B7?G
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M+?;\:27:'%]S53E?K^EHRRG_2(0X(VDC^R).2=I4>??U/? =6>M: B8B*7#
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ME=-DRZ8-Y]@XC-WLF\]]]Q)Z<G%U:<%JVL$>9S1K*@(:R5%A8,H\,KU*X;H
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M%KEP,C>V&I0-')P7CNH@28JVJ'7HNM5V%Y Y715#AZ_7I>0;S?D31&!W2?$
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M3RL/8O%C[N_H6*RN]<WIR9T5D9_F/G'0:].]>71*J)[]<$2A*U4;E2^FQ<O
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M;'?_0 "K "JD+%8,Q=,0AWCQR.>!I=Q=+60O9O73_/2WYL?Z81A>S_==-/Y
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M*$0H3(T* 5S /:VP(0TZ9'9D&O<JJU+<DYKVAXIV<2-<T9\W] =L5*:I;,R
M\2[:,;Z+DAR>85)Y9("$QV[83-BX+>NS,A:FL]:040VL:WL$6(BG@7O-\^IS
M*'B6!Q'9J"#;*"^K:)F=YH.N6&'E8+[>XQ#\IN$2^-V _QB_YI=F;$,)1OL4
M8I;336!.8F$8EYN>Q&)8;AC8S*)RMB)Q-@FVHN][JJX2E1-O"V:CW7@AGHC&
MJ2Z4H2;7;D1E.XY,R2W-^;E?5F"XSZFX<NY39I-Y,/J,@1=V<S\A98L3B6JD
MM!7;#^6N]_+.#M[+EA!^NI$,,VO+8[HWTY0/NE_>\XF''P0-CT+MKD>SN4^
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MVKZ&$./\,DY2Y<[;"D3V<KW,+C8;#C1/HO0\SUFND.J-^1Z7U*H.Q[E -;B
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M2V"AANM=9/7R!2KQ0H+9F'S! W(YJ09?N!Z6"5\S$.N!+RM&?&7K]:7[DBG
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M0HD0X'SQ!0M^ 2Y I*_K0(#.#YFT0E_J<0!2O&'V>M=7B-(U#'&D>[-2(,"
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M8LN5#B*CGP=]D:+Y#4K2.,IF\WD:HX+CC18-UN$II^^H*S7C##\^PV@2C-=
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M=[VY9%_W,((';?B"FHWR)\Y6@('Z7D^P_ DT4/ $JY\H!\&>8/4361_N"19
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M#<9+^D16"%GY,3O-$3;8,MW[ AS;,W ;)%P#S&1!,&^P[]!!5_$YHN[-)A=
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M\&WB;)2%L*D('(.1GQ4 ][$@*Q,,A?1J&&UO>HFZV.;NE-&B(U?HRYR8-EJ
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M6I %>(&>4(97E)%S7+YHS*'C41IR%EH4?-RC=EYG(5_GT[BV7M>[AUI$!#P
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M.H1,VW&:.T\P!W<4FE%(TS5AGSJ-;-V1QD,8R.'U.,M,Q:ER&GF_XPT=#-G
MYETTIY$8/.;PP9 N;,&I>R*9PV..2P[YQ/:<<:>68CP2J\MI9AZ/)2+T1%*3
MQYC(=B(9RR//:PMYS/8=_Y:3G-]MO<6/*"<K(YN0XW 2)4NR. @WY*5/:()^
M4##0Y,WK;XI)SCW?8BO)60N99GK']B0-E$>@A?V01S"2/()I5K\()=WZPF7S
M(1DA-+#)DV'Z&]1G[CUY8P?ZW#%6J?RSV433/)D>;*$-=C>($V\I-=<J5]<Y
M.471_CZE;Z67)/M+ &:,@8/.PT5JCE4N[HCH0,1FND-I.!=W-7''CBN$F5F
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MW9M=V:R\'&.5RJU?:3;?G7%=S@?1\*$N\#T]]>7+<^] I@S-QCV>QM_6*8W
MPF0Y5\\TM:$B(@6UQJWH$ %3X@<,QF*M3")"3\P.2H -MDSWWGMYY"5F$B^<
M,1@'V]7>Z4,&\ .:/SAW!]YE":XZY_G!S608,V&;KHU:M&LR"&"%-<5N?G24
M;94[:D*>S>\)3241*T2EK>$31U"W@<5#Y^"062]'+]F*&R>22+B%3 G5 3KI
MW AS*&%6FN@88I?&]4.9)FE4/+>.!HXC3CC>GRQ[J?4?,N?]SYS?>PMEG-&8
M-='W_'#Q48'5!1-O0!)GA,%.7->S0J56#2A3P/5\4:5]!#%3>+-4A'M'(6S(
M%W"D+RG=R0G>;+]0UWS,:<L#(?&2SQ8:?=U!OJ#5 X=#-%D>*5\.:V"E?..Y
M%%Y5%S *ES"YV5ZM LME>RRA*A^2ZXO 80OA'E%B!@2;#PW4>=TX._'SI% .
M9/:E_HTMH"5"X'TY-6 BA&+HL@&Y8,C]+H\"'T)Q\+!WFJ#J*A-&CWLE@BH"
MP842DA[B56$L0R *<E$,EL#"592Y!J%Z+*\OLDLOTP\XMMNSF[8''&VGAGHH
MJ<&3T/XVUH.F>J(%&,Q?/=[*X,0;SZVX$!RV;B7U>DL&]N\(ST,@EM(I#P:$
M&)_0 V1;^**X:8(.' CMB]2G'S= 9+^Y>_8)%0_8M@)G"</C? (PBK^=VA+D
MI@"!8?O]U&"3R#0"@_C'"5R\&JJ%@O'\X*X:)[DRU2L@P&5J>1NKJV@.6XT.
M_D6DS12KFC:B\1;5R7V7GC4OX5]%V@;<?)7+W*ES?)!O\JOB-QFY4 <S0>FM
M\^B+04H;*EO9!%["VI<H+IT0BG,9#?K2[+LCS:\^87UW7XQ2VJ'4UI##%_.5
M=H3A73=\<1:9."HE"^CZ(O1H7XW]6];LH37=)HH(MPG*";[,7DN3=1X1T9C0
MNZ51W#I*Y:D6VDFID]6KQ=3%9NT?NL7N4$9-9O?X?H$@%6QT/"IT/-D1%#J>
MA(XG+O3B"!U/0L>3T/%$!]*AXXE\#ML1OZ/M2!&:'4#Y"LT.0K.#T.P@M $(
M;0!"&X!^G([QBX8V 'TX'?J+.M4&(-315TQ^"G7T3ZJR>:@*'JJ"AZK@H2JX
M!AI#5?!0%1R.2:@*#MH#H=QU*'<=BCOW7BGZRNZZ4M(KE-T-97=#V=VAEE4H
MNSO*&H^A[&XHNVO_, @%--50" 4T-:VR4$ S%- <!XBA@&8HH!D*:#I1\C$4
MT-2)9BB@Z7H!S5 &K=<&'N&!.(H:D"Y(,LX4GY)6Y)P%TY':4]+B92@]9;[T
ME+2@$"I/A<I3H?+4> I8:*@RX(N/8ZBB5*8K?^3X_V_ORIH;QXWP+V*RL\G6
M[CQJ/-XM5VU9+L]44GE*T21DL4*16AX>Z]\'('70$HF+N-DOR8X%@MT?<32Z
MOVXT*/H4I9>[ETDIC&:+HI>VQI.PKJ.7N,ZZ AE#(:*X2*.ZW>WBZD!^J[/7
M(MMD"3ZR1W'OQ,2(1/LRSQ)B:>WQREY%_0(?)27^RDF_DJ6HB;/\/,_9545<
MD]A Q1(W59Y5#650YOD1:U=_+T^EQD89^D+/B-!1)\1[1J1N#^IFZ+=]GC67
M&.>T?-P/*1#P,CC<'29#;'R0%^KBZ*^+4U?-@.2-_W61#/_CO\1 /@Z/$<DH
M+4Q*-OH9J6T,2->7N5MOGLA@[P_>]U555G?G\<Y8PN9VHUW';PDJ8BS04X6E
M+-LZ/SRC?4E*J$WJP_N(V7I/>%JE6=Z2&W:_H:2M.I/Q_IV< +&UW=V!L-NW
M_5JWWMS'58&7,^),Z6A%?16^*V6U].T3*E\.XQU0$D,,O-$!! F%GYI@Q_N8
MV4H]'V\!N<A%S=_D?,JH)C?#!ELTR83\HVTM)6S>X_-,>4"]-;ONK#,J]LSV
M;J>1VTJ+]349T_%$QN/!D#IB1]N8E1*1&M H7>%5*WY%CRV19+WI:\&NVP9;
MDP5Q"M/6#*$^^$:Y7_Y/?XZ7D'$9?L8E[8A:<IT2?4? I'E=RIJQH8 \G8;'
M])7X'IGAF&EBQW_? >%/S31V\@T%4L-K&<4R]3VCB3%K9>(HOJ??<)D,<_VR
MOH\;2S-1R*/D^T TC+%$3#>4=!/#HYC3-Q?*&F&B/(?C4]CE\AQ6$ARXLT*F
M7<+ZC%F'$>$*2>A;.!Q&9I;C-;AUA@J5AJBT88;DKU'6K0M1$[^C.JJ3+4K;
M'!'W<'4L>-'7I9#D,TKW;XI].%/ 65S!/C<$CYU^;?X>OY.,D></K[WK,DD>
MBFY DI]':1*JNE- X).2 L^(!"G4ZJH_G;Q$Z0'$Q2*<.3R!\^?(77CCH_BN
MSX#!>P+SOC#^#BP5].>9IZOF=X1W_S@G$Q6OT=7A0V,AU:5Z=@Z1T\IURDG!
MC?IB/.3RY%ZS/"]_D&24&>A(O,59I.Z+F.29S1\R] Z=T_^1W.Z:MDGG4KI_
M)\77YFA/Z\XYW3OG\']07)W;3%Y\,K<[YW3O;)I5D?Z)1<K5Z,_JTO0M6_W[
MCX/P"RK0)J-<&S;6VM*>=\%8\:*NKF.7\.!:NJ7Z<$'+B:$I9_-H>8<+* EL
M8Q(]N*"AP&8ET8,+&@IN29*] %_9/%_9+[*8+M<)\%G#Y[.:C*DZ3@)S.:;J
M8M1'HVT6W)"B JG<L1<<T4-F'/*<E)85IE7E#0R%I35K>+&/7_KJJ+D(DQIG
MZ[(*G4F?>[EA^C4$F-3XLKDQ^\UGS-0R(+@Q^[Q,S$;Y%?S&:\C' #ZW%C]6
MB['T50.W!!M?.!#$#]_B+'^-6 J?!RR4U18<C_3X*S\TPF< 9Z&19V@9YOP:
M*!TQ=+9/EI'X]--?[E9)E=4@H*JI\R" *JI7\BVEBJKLL'&EJNJ\80^,:ZBR
M"E56H<JJJ_5$H<HJ5%D50!"JK$*55:BR.B8Q5%EUAK4(55:ARJJW55:ECYO
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MREK$GA<%SN.Z7F^.R_.Z>LY>M\VQ=@AY_V,[&0L6>E)!O)/UPG\C\@>4KC#
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MC*$""0ZS88$$AY']&A(<(,%A-E20X& XP>'X"_D?<J,/_LO_ 5!+ P04
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MGY']\-O1N><"R,+J/0SPR##%7[\=A8"]=Z3-WIU^?"='^K'O65,C"*<.,-@
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M^"BST.VL0L-M__=6Y$\Y\\%G66<[(6O5SP8>O GWP^F- R.#@:&=,,'0]/<
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M+?'RI IK8.T/L$IUFF&;P)I)R$ZN:JB]7[(V6JII\.T?^ Y1\F&7AN#>VXW
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M0OPE5*S75J'BYD_&@3G7T:1[B37<V93^;1<STDR54!0UK5[OAOLFW/&)NWP
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M#P$J5H*-TD&,%![ "9 :9!@7=9K%QS#84 P>GS@O*14_DPQ#JQQQ*$?<AR4
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M <8Y%VB1BR(. 8R$^Z3J$LL\T,R@XK1,K)Z%]Z*35)01BHDCLDK\P!>)P9B
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MAP'Z=S!VL>(P51B,A6N#KR6O>^(%Q%,Q'$BGQVXE#;4X9ND2FE6\1ZW)C*;
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M?ELV81V5=&+1KS>E2UB*-=%N[Z97H_TXS7Z,P7N!YT#R<U<=A)B:AJ6\#G:
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MXNKY[U?A6 _O*J9$?9\-;Y-[;*) W(6;;>NP7GD)K<OA%I=\.X9EGM.WOOD
M#[6<74&_B&E[W7<Y"NE_K(!\&FA'3S86(^#50TA/@:+JNU&$8>68F^Y0\P$B
MS#O1D\+FPG/@F-R4Y! O63\Q2U0M=8D$TR1_MBS4#TX.S>5YM<?VM*:$<)_N
MN9.Y=M9E"\WC$/'W A#Y:CVR0\"C7'7^\]CAN7.W"X<A<I6$GU0BUFD'FR/8
M, A?A%BB$#I2]Z\X=K2SM)W"#=&"P\N?=H)\0$IILL26<2F+8_<X#^*%O?]M
MN7&KVLRPK]O;HKTU(XH^"YVFL@U3$5DW9V71D6N4H.0X'%@H$QDAO71'<ZK
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MQR8,(7X?@L]A9_)5KD$/[LHV^"?-WW+X-XA!/NB!B#='09-.>HHUPO!?[<&
MOYE96A)3Q(RYJ" 2L!@"J9E96<I]UAHO<&6IPDTG.FW;T7CAMQ,5"CKI-V--
M6@3D+2P\FK:#$+8=N4[N#@]#0;JO?V2-(54"X4[961BL7)O3.>X%,L_B,$BV
M2H,M=W61UW -J4GQY\/Q#H\OR0G*6N5;LL&<I(G7%A(V]5/)E<S'(=DDDZJ)
ME[/=%WQ*8J.@8Q) ;"2C"FB&F%B&YA1&N(/A34IVBK'YUG5"4YZ"ITR+RS.4
M3FT'S27*O'[:HHR>FCX*'1@4ZAYSBG$2B":,L-B0WN7=&GO U9OOT8[G&"]B
MN))O/DRPPD)()")-^39\"[W=6O^ETU:ZS0SC_.3.B2^1J&*?DKT73HQH!X3Q
ME*:5(&@?CHV4@MPH1[HG&#9UJHG<,G6QY]A7',\["PP/BL1W7>K4DLX>-Y(0
MRFH:_GC%T0/53[;;E@*%?)#.=^Z0Z\HK$8DB$5K=O+BIW]4O$4BB( <HHKAO
MZHUVC3<@\@D]?3!@ -RIAB&*G?0LD!P>O.#0A$) R3!!7ZTA8>Z5'$7S&Z%"
M!<?0]AGR#V':<-C+ZZZ\MD)O,<*?_MQX%!Q]A5[O\TGNV08[OL*SU;>[$#/Z
M80FCKJ@?:C$$J0-UP^S*I;=QX=%<?IO>PY@:*">AE0#J$MZ"P%;3#GVPV+QJ
MA!B8@P]_\SM&E5*'%IC)B-)E#ET9D]\#=4USF\["931UH6&;>O&&$XFS/9V_
MDW:23:IST>A]LEFK7N$<EF8ZD79<DVJ"K)WS6J;G:;"-8!BWH(=UC8SW,=0?
MO O8VE0*#+*P6<;KTKOQ\'HWGG]R:=ZX-&]<FC=.NDY?)4>FR%W388:T;HFV
MP;KJ=TH[N$B:>>\C1-RHFXHDU/.^;20PT>,V!12%LZ32$&L&#G'^BR:P.U!0
MF&NQZ)[12WTOCWL8.VA&*88LK.W(O)]JM49&$(;IE,FY<0B^YZ8*X4\XF]QX
M(OBGTY<[)$_[9J?'Z\3!#PW-LNM42AD_;KM\1-K?KLG)D0SNS)[DC4G\"0&@
M<#4)RQK'GV!L"S&:S4[;D."M3E$F7D3?UB-.[XF#Y)P5N:^I:+4$O"/!(DTI
M[LOAV>H/)<>55H"!^]4,"?H*TU+7DROW]$I1/]60LCBX_2OHTTX?=E_USB!4
M[ ZC22DFC*.B! ;)3:A3YI^&>MPU$=H3PQU#CW"!*+3JDC9:^J&+D\]#Y"0\
MIR&V?RK1VK?LEUH$2]D3$$4*=XFPQ?SJDU^I=4Q"YQ>;@9Q 75<LXC'A68OE
M&,AZ1&H[7"_JA!?MAJ@[(BV"BDXX_\^>='WT3^>%>U$?DTR4K0C5OG39]"'7
MB$3)U'Y@K*87 C" )#>&S*QS(6MO0G0)JR.]F@$)TG#7@M<]/CM%P50+5)1_
M9UP<\:2:\0*ST"H*W6LB]^PIX(.0>=**@STBDPA[=*2@!,2TI4K:Y@/#81A;
MR2?<A_(L>M/(%,9N"I!ZS/*TEMZB2!LO_Y+WL\CW1EL^?ZH_'8N?M_S4(C.D
MA2&%S+0@2=+#, %GLQZ49"X *2LDL1*F3QR7)9,YY63P=\>&K5%B?6/JJD)H
M2N1GM#>L2])?KD"M"E [WYI<%,K4/;G\W)M_^W]_\^M/?_O[S]/4U4_O< :'
M"(:R)2NI(/P;[O/\L_SJ^:\_VG[LY"W?17Z:+[^74L.+#=6/GO_^LU]QWGY?
MDD+F1_B"8 G\AR-'V/T=/$H.RGX<_;(U@QGCX_7C >!2H6?+Q-TEKS.54J75
MH[]WV&M"0'3,&.H0BD1*U :7FZ69P*1"Z%/?'V&P)P,H9/^8'_]/\^'OZ[5K
M-1LI5&1[< Z=$ "@K>;2QWWI@?HIN@'5@6S%<:&ZI%)G R2 PH]@RORZ*Z %
M4)L#)G6&;5YU%,1M:XX^2T^G:1 $@O;Z*NY=3=X7,WD($CLG-EX./I)IIE +
MME.2(GJ,?9B,*H3;]]IU_X']5;G\J&UU4U8'Y:ZFJ*T::&.54$^<2GIL]J,(
MV4#YB(5'"/.Q:[OJ;['U)SVZJ%%0S[7)/:BP=#'S?T4SC_Z%),<$K"(!)J=4
MQ)I#I"I&0O890OE>HMF1503<)CBQD*@%SZ09KA%C6K.*M:H)UY>MH$MSZ=UY
MH$C\PZ[A9$'+Z%KQDA$VVQ^65)VDCKAAP)40K:'18+S*BAR?Q R#T;]I;X%#
M3)'O3FG+Z$>&1X[9R\SR30PAYDHQ[F?#4BF&9I(G8Q_!Q@;I)\I]^6\[PWL"
M!O4U)PH >)\ DW.7,'-BM&48S?98"EVQ(!/*&)1JZY+B<U)28@ W# 6K K9A
MO6^W!'YJKEE*M!V''AL903YJ=*50E1_ZP>A:A\UQVVZP-&IDX Y5ADO8$SY;
M?1%)7H%L[BV;)19DU,F",- >UJ*,XKR6*'1T5?H^LG<:6L':'SC#&?=C28!,
MEY:\%=<J) L^DZ\^@W;;Y=T>98A[I 5Q6;[II'',<C"9193*4WLR <BY>LT3
M N6GZ6)KR2JZ]I 2GC[.-:4YODEQ!CR>%7'&%BME%)\B/FFH4Q*'E$"3]BQ\
MYT-YC&:=)<M"F-VJOA71'S6G43B:8R<$8)QF2^FC1#"*5[1QRD.9HC4)]%%7
M#<%9^R%\B9]("0BJOTV_RD:\MHQ4\%2C0VW]_$\NP2='.4@9R/V"7^\.['V)
M'=>.ZIBO&LI\GR6]DK>4?;%6:@*Z3DD)N+BRJ\H;ZWNA9+R5&A4/IDA PI,H
MW3S;WEXJJF)^-)F3UF/EX3&CU<<6+F->'?O8Y2U);7>#G&4B"!T$M\.?29)!
MQ)4YLR;YPU5ED@=4DK*JASL+WKL1HQ6JXX6/IOR*O@<\GG=[ZM()XUD6Y:GQ
MC!CF.+ 7B-/#@S@]OT"<+A"G"\3I+#^M"@1JO^J":*HQ?:3R;^%#=4$H;FX3
MD1Y0<H2/:.&Y05?J7$HM'XBTQHFUNIO&ML^,(<^X8R9QAC6(VJ,M*KGQ*8N6
MQY,WS_3.=.$V;.$(;^24[C]4-?ILW;'R.@TUS0LJ4Q_(>V&9AQWX4#Z$T4I8
MX[J5TL8@'G &BY/#V)>D8421=]2*8KFWF9\FA?C,)QUYM VQS*TH/*QP[_4C
MQ,! JHG$I*%!M#8#NTY/07 S81,]K60*\, D:&?VHQ&'?W+TGZ6IA?!DX0[K
M8Z3*<$&\F_%OB6*H-*L[;<&QP5R\Y!#@EAV4! Z(J<)%QH'M:UVUZ:_HF<-O
M$]B]=)%DVC#$DG$Y]:BY<J#-EN?A-W#V)+A<6 W"N^0>_@X6K%?2_0? 1@C7
M6].SY!0<5F,.884G0WF!3>&EI7WH8'C=;*),%HWV'XYH;<_8FW55;(PB82 T
ML-\2MTJ8Y2:FD> )<NE8TV&:2A>,DR3+9ME[8AY#:8%9?6+]ER%X^=&U\"'V
M_DZ8VT2 B%I01NF?5XXWBQ\H;-^U-4E/K256U?<N'?)+<C9<9RA9&Y=*WB0@
M-$Q?+RD6/+D8[L>W)IZ\N44A5ENT*MH](C*24@$"[\GTM$ X[S+U[[Y\F<UN
MLFVCR5'^#@)(8:=E0(62PSE-(KP483&$QD,ZZ@@$<,1[!A."4&D48'* D1>R
MKU4]-Q&AYS(+]Q(R#FQFCW@?>DLT5F^E[2?8P1^CZM-;ZW&D ?I:9&U?'& E
M8<=_M,O+6O^Y:0S#D@+*O08Z,Q1*/VC;0=A'LK78OZ3]UNGYL'=DY*<RF+H@
MG.B6_2D%?,;.TX3FR+MX3V[S>TUHM$/;,Q0MHMJ5/:_8AVT' D\T;BI3P8Y/
M(H:EC8+D0PNB8V%N?9H2-TKE,]T:^E+J%F$?^N@77[SYXY>_^-CX ,--\OZ#
M<.4H\ZB[?XDSN''6Q9R<FW%(:^]"7S-T8>[A89EUVL,2 PFEYR)@4K)QL^[C
ME!+PS"@2BK/J-R-MK-1@G]?^^1D\EDM$T%(I#GDK,?578!O!7[[HQNO5B^3B
M*;93>O:K(95UBH6TB5L<-9,)2Q&FAB: D.0;AN'):),28#T01T&MZJ(B[2H\
MK09\PQ&RZ2JFLRC",Z<^MGL_%"$LX!G@W0H0+7U,%VEDU)PPF2$@XX1G\",B
MR4!@-#9T;'T\U^72WDUY>YI+42,4$JG.'\\R=0J\^$578A60%/DO%K<SWP^L
M.J_$T@2_$6T9RE-D?\7OQT:.]=Y]S((M_>273=F%Z.5MO*V_YL+8B/6B*28.
M0H@KDG+5;!B[>,ZE*=)33)GM.-1M^^$1.P#AF'OO>J?!3Q N4+I-]-47+SB.
M9J*O7S__Y*,/'W,[4_C&3=@GZS+O5*$P)PX0KL;9"2:L7[1R/O*(\T]58OSK
MKUXDOW\NO__8F@8X?9)4<K8QI!12HEC-L8?B(%1]%EHV2]>[/2U4[C(S:!&8
MAJA/ZZA]0[K!>:$CAP)S417$TNR3+; :9QBHT<XMQ]M%VTE@&;_OG:-\%4R$
M2R?XDR8I^".LC8F[25["IM4%,K8/&<%*M!9ZIKYB"O,ML8$::9M/I>5,:_HZ
M#$DI/&7Z-$)2QL7MOXX4\6ZYIB[+(5DG"ZM$4U)6Y\1/E$!"C#8*OP#3BMF[
MM#$39>Z?S[6(//-DD>HM=35,E@&C+IH3K?PI;PYXA^BB+F7XN!,X2PXH82V4
M-$8V(]\ D9RHMAEQ9E0W*B:M3;JS^$J9#*_J'WM_-8825M?.TL5W8@/D!'FV
MN!FV9A&KLMGA(M*D-9M^71HU$3H$KV--/9N6LIVN1V%C(F+<)V,=;Y(59CV
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M]YA:QR9TZ*6TS("DI7E-9]//7)(:6Y@VCQ&#%ZCMZ#Z4_#9BXOE Q[_T)OP
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MY 3@C)1R"A$:!%=KKK0,+O"W.<C1GPVK?K,+6W4MS$I"Y\@IN;!889<4ID_
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M'DQJMX@O*=.N!4S9=B6"(?IIYJ^(.=CH0IOC?>][:U)V7P;OT)HF< CEAZH
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MV&*Z>,S=(NVPJPZQ592&H\=P:'^K9[0HOZ?FEAO86S@9RDZC%VB):2)*VRE
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MW '"22:'C"'.YVG;O?.#A%]0J94<;5=*G:W=XI4P(^J;:J,08\$=";TG<SX
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MG/VXNL9H9J\ZU/$ QVQ(.)G*IZ)L&0>LUH7C1=1]FH*Z]<)SH?K8TIH+U,H
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M;4@^2%BHL@BFW4/>!V\:(!90:%N5V:BD9%2O;"B/U2EP 8F99"K=E-E55/(
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MJ]=RVNLUCJ9M+=K[4"9#[89HG*$-R/$ZC!1=W&J.WGZ3!>%X#CN'AUUO+Z2
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M6J-*'";J+#W1^P71OD\G7@$X)4JWSC/T8'%; 3BCX97DPAU&@"DE'QK,GZ9
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M-"8-"L;IA@MNX. J&UPP?KRE\FVBH5]<W_ _+<MRNX/I"ODC;J3TV_SN_DW
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MM9$OZL4\CEU_GA-)_'@;_KU<S[]<5Y^0WU5@R+"XGW317"=OU=(".]-Z31#
M6:HKPP&&C3%@18:_B<R\$>5+VK7/AE1NK%MKVIH@M-C1=9)\;^.C<'U%_QOS
M&MEHSX$3'2^CJR;Y]8)U+(^W]9"-%^ 3AL@>)?VY(%=6UX R6K35EP<-=E5.
M#Z_*Z?FNRFE7Y;2K<EIE=+0G1'91<*.*5N]/>RC<6!6QCB<>D>>@EHC@'YE
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MG> UP@CF<>4,\5$&G/37UE-;P,.]3=UB).J"AA7^(]&C6Z?@-T>9,=I9*#!
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M<NSMVM]L+AXRKAA=F)$%DU^GIA\);H\@4G--FB)2&^P6&$N?C93D\2/J-GI
M7W707P%;DL,TY\,5(_@2AGJ9E[:_QN6G46HT (Z7X+4N#IX0(I#*01.BWB)(
MHS?<5)N4FLP-31-=8B<Z\G'Z47DKP[4K??TX1VD"4< @&T%O'P3BIF%HQ5#"
M=9:X6 &KR1/,I:;2X%2QGL98J%V ]^$%>(]W =Y=@'<K>RG:)DH_%+G_1\,4
M203)+"?+?9(G&B/@N2M1JKJA_/%)*D5QM#UPNM^S:5S1&^+A-CG:C=8/[7/H
MWW!,]KV,=TO*A<8/=5)*=5$.+IPM\"%B>/\LDJB6"=>J%K>-'SJDJ,=XBMW0
M//C_F?V_G*8N.;*?,JCM591J<4_KH,#23(\VK])'G1_^14-J9=R<[R--G!@K
M(,-_DLP6-B4%D@8I_3"("F-Z>D^'4:-O.+%OL$-X:J^X2LK$X0'3=A1C#CR0
M>2Q!!@//$Y@Y/'!<,.[(O,RK;*\*VM&A6LB**9 )V*$MH)-:ZN6# F5V)'P.
M3 3 I%LN [UR72C#F UQ<89T#I$!$[))E6H^S7E*BX_N:,+^XK!AW+ =#L4M
M "@_8#JCUZ)#I8CS*T64K,'!S(!^2A[.4%[/]2X)CY% ,5XSE\2^A'X$AI5\
MMNV^]3=*31]_>%QLC9D/)K9-$](C%"L.+?&G/\<\Z@_S*<^OXUW7PKA%4O)K
M>\:)0L4&R!@ANS6U;.^/:R"C[4 &4NF%DK6TM5@#\LOIW?D,Z4 0XKO+B[>O
M2D:]TL)%GHZ 2I01@]?X_KUI=,-\L'@4ZLS3@U0C8#SI01)Z6E):ZG0LC*JA
M;1WD>I479W.0NGHIXGA)2UMXGL;J8DH9$]A;QTGH)"T.0HIC7[H*+F^X(CGM
M;+JI"Y[%(Y(96T6A4]>MAI@_1G9SJYL@+LOT6.-\LL$B$,DW3):"7@Y@\WD9
ML/T,%/<]E=#O7G[X267IOE?.%2'&,YAK!5.P!Q27C#1_:ILM)4E#TF0_B-$^
MDZ/TZM\Z_-RAB=,ACCD@:HB9#K8@JVG.R&[!RT\8:IG)W,FJPG@9*?4J3.C#
M/'S/"R!K_;T9 *]@<7EFT-_W;3H6-?X&1,6QJHAGB7"(6EE 6.D$'WEF2LKX
M]JI/S!!@#Y2J8E09+BFP^"TV3V5%QB#BFL$TCH96V[E@'/?>Z6<B>95PT2Z*
MS:2RL-[+@&V;)F,SP=;K=8A$UYO(\SR[CC@+[G/8UO"- C*CO2L$^HYOQ,FT
MH[K!]LZQS$MAF0_",C^!9?B,V'"##U<PL9-!C-K20<7NW4)4>K&55ZOO+LC,
M@4$0_%<^+S)!I_YY83IP[_#P+ S^F:>=[F$OV.L1=\XZQT>'!\='S\/@ M,+
MZ*W'P-LF,1 =V!H_-D)L?2\)7Q#A__(05XOKKK-OR_EX')=&[)KR$B-BY4D0
M$%+SD:4WZCNJ>JND]A6EFZP$S/Q5$^RUDMM]NR/Z(BD_Z[@F7[S5M &C5B51
M49"]&4KQ(Z^0NX@D=\MSBX@>9MK'F@'U42J5K^B['7)<"@Y#/Z\$3(N(9R^A
M7:(QTM$:IZ96/@%()_.U0:=*,@Y#0S+RS BCL<.@3PJ2Z_E'>:$K F9,Y$3!
M!#@PQ82L@)!,?J+$5.>'R=4E6;M0XPRBA//4415L=^BOC'R1OLLTF?:YL$8*
M;$R3P#2OZ'>F!"JT=HS;3PL\-8RFO)SKB&>@ZV?/S<X- 4&S-7+CK6@1TE%5
MP_3VDRQNKJGI(),Z<Y33<$<E)F05.KB@$-M+:HEM48%T=;>F9NI.@^F6]PQV
MSWG@'C5(I^5>C6F(039SF.MT!<[$5+8142!K@YP#&RG:EJ\23*_>EF/_E(N]
MSF:KIH)H;XK86=8 N/C_V7L3Y[:1)&_T7T%X9W?L"$CB?;1[.D*6Y1[-M&V-
MY9[>][WXX@4(%$6T08"-0S+GKW]Y5:% 4K+LMFF*K(V=&5G"4<C*RO.7F=C,
M3A^;&LL'9K[2(H.%&;:'I:M+J_43]GW,X4FQ*0==0;U0A:DVZ:1C''ADR&!W
M^I%-,Z(ACCRN/ .YH<UQ%.:-=]KM_3Z5,,1&#4A)J\ZTAM2(#N':'IKM:Q"(
M;'S%J49HFLY7;".9RDF9M6J*:F^4;L% (LGTE^+)*4P6\=?IR!&V#H<(J6N<
MZLLD! ,QI-I^&77'-E^L7[N90H?"].0^\O=;#50%DB$Z?4T(UCQA# 7<=9(H
M).NRR0VJ1M;MFT3FIGZ4OM354H63U4<,_8#$5$H(J]W)80QZT<-<J6DDEIZL
M,C/>(V8?PBQ(R<$/VF*+JGJV%%6G!$5MX6#)%F5>T8_0PIQFB/QN 3Y%=N@J
MCRJMJQ#5QT564-4EXV!D2 ;W<(BD[2T+;,&(-D).6H^;130MIH+[R?',PW!_
M\2#Q3R^(^P@C>*8'4[TGP?QRF<*+P^+DG%/@P KOZJSW)4-^#RF&_1+.2US6
M^&(=T:\HHH]^O=UOP[2;-O.^Q%VXS?(D(H3%QJ%L= +K -<GC!)&0QFX&N8M
M#0J"JHUO&6AN6@SH]+;I+%L/4$\Q;4[Q<_CP(VZROP:QJ,=^KBA<;'G 7Q\7
MIEL42D5P\4T6G<(7M4$E<53N2 !"KY28'R+OT2E"G$68([H5;Z9>LDC#_3R.
MF[(F;!H4V$Z;.SE,%#?DE^VUT1,+(%VLQS[EVIK5B0R:FX[1:WM<G=74*V!?
M3E(<MK:RH"Y!!695SO@9O!K#2*+R4%IB_D+<*7O.W:S*N>0!6W,CY$Y,>@;C
MY8WQNQ37F:ED ;(?? +,1<C?25=EW*\*JWWER#1Z7_(T[<**L')6)I*!A;SJ
M>A2T^@B>*$'_M&5#C;XV?Z] ,A4C_KWK"E$_I9+S9IC3?(@&7/+$714=>Q=W
M/_S;$%-@YK=DY)'C3STU")ZY_F@2)0UA19.T?+O&73(;]JA@9,S"C.[B2!&'
MAB(94$BA4*P7Y;O3.I!AM4_0[KB%N^&!B=R&6F'Y,!BA9DCU#VR^VP,L/@T5
M.AC)<86X_RF+4SK-'-[D(&E0"V&"UBG209@C2&T EL"J9.J:-1)-Y@PT2GBP
M4@<!N0K!AN:<8(O=]6WB471<#"W&+"D&]GU2$R"V6$'?6C^,%H,H0:[_-G.]
M<?:FEGK5@J/9=,IU5P;T@.KP@6F]R&.PCZJ%3J?JK[5;:/"H;CVAC>#',L,[
MC2R#%U]D&!:# 1@M700I8YL9]3"'9\PHJ'#']YH'&++?!'%"M \2\H_A/,+2
MP@\)>6"U29 K;;Q3T_6-"+Q9ME"$F=:H3!VS,(=6A^LYH\[R0"\%U#T:W^*J
MXX> ^J" &04RERJ@&7@$_) J-\)?%JR6UDPB/*P,.+?X3Z^$PG)2WVYN)3!W
M;8.)+X,-O3XHW8Y,$L_,'=1OVD'X=A#"UW<0/@?A.T@(WUU.^6MNYX/R^<Q
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M[-32^OC2I^>7STSJJZ@=.XK:-!*'&R>7QB8=*&^0'(#_13--;_ 3J4;0-&I
M_UGFF&81M[PU:^347'TB37&Q)#4E/6E/L^5HTPU/C]?9G3JS8E7DQ!:^E"/5
MZ\0CJ*,XN]8RK!@VCHE S!6UE\.<I*DEO-MR7C'DJ8 ,(VJKR9XZ+1!H&ME.
M>*-$A[)0I%YD^@CLK-2.%X8.YY<'$_NRW"\C]BV);\\976\S1QLAHTHJ8A,I
M'4,B_F78-\R]ZL?Q+A':+8RMBM?7H(9@#S!K#C=>4U!V)<6J!0(XT_"!<,C?
M<5^<1A)Z3L^)K<=0$CJ6>XY8^"#D /R<>ETZ)7UL.>>(!9T&85T&$W"%I;^B
M':5\#EEHW>J0_,^=I (QI4G5&')HT:F.[V,6/H,-@8,IM+@C$\\7\3,:R7A#
M!YWC/V&A=62__ @3OS5%J&++,O?J+&9MCIR]O7SI>W$.4HL^E&N2"S%X6!02
M9I(M%3'>)(Y'<B*ZK_)5>G-NKA$4ZZV9:V[9<GI--,1J?U-GDY_.UAHY7B;!
M_@Y'I B;76S%.9%#"J69C@8"\;8*)W0;5E,3U-3O<.-+Y;W);C(.!%!NJV0
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MC9SUYX2?$WZ/5/A125R_U6NWQ__>%WYQ)7&/BWY.##Y.,?BCFRFYZS,EV[(
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M9.EU@!0%V1=589GES3PP4/AU\$&'_'ZE:%\Y4]Y5,%^UN_=3X(U/VJ.6/W8
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MOO5-SC2)I^JHP.(0\,E0,LDO%B*J4*FCXP2K)C5HUI#EJR_&*$D3P8)\"R8
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M., *Q[0H[,-!',]3[K&<I(+/DWFSTDGQD/9.)7$0>C@/HRID Q'*]R'%"$W
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M!$E[N$<4<K*T+:#,&MQ8H/"G? P9W=IJP*)#WWY_<^'PD6?G;TU:G:L_*<S
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M>.*?8C2HI[#[ 1:=VY/ZDMC4ML)Z)/,BR3G93FN%+CXC7C<'C14DN*CMP0]
M76^35/FE=E!K4 <I^O&!-;Y[JMH8-2NC]R; %S9(!X67=U134'0:>C^Y62D(
MK6XB'1F,%\1_8N,5NE9L:2!+UQL'1UH4RJ'0B$D>79"C,RVI(!RY?<<C1V5N
MN0/KKUS7K2@$2@?#"YZ&?2+WWHO!9*&[)9]<K)MV\;VZ(V?FS6*'W1W&P0NM
M=\9 %TYT';@EO-+,I;.)1Z)UUJB]T7Q%8;&B%VZF4%A_:YH7E+=TD@Y[Q%>
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M2[[S&!-(<=3LL!P:&"+5[T(>X$XG0L=T5^4$%.((0_7^$E9E"0BXWWX;6N?
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M=7/-X#+%_P @A3JN;SV2SM)R&<$QS13GHK8I@#+I<!*B,!146+--N_YR6#O
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M3R&KP+T/$RK1T-/'6FK2>$:5\)(]HF;0*@=8$.S2$'']XTZVNI-@%F$24PV
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M3W>:D7_Y\K'* 5C!'(##*@>@R@'8RAP H:(BDX>K\SJ_[6"[/1!Z.^H>X3L
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MOM':2CBS(<E5)##$Z*<^OG(>Z^HOK:AC>MY/E0']2YWK(FA13IW30]<04/T
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MB64?5-&\3N''_(1$8(=J)J>\KE38"X;FS@/:G^>SD05_185OO9@OQ\7BW!Q
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MA 7FG\N)>N9CG)/BGZ\?^C2"/;G(Y]RQ'143?0W.N=E[/%=9N)/\(:PB%(/
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M.+LGG>*\V#O@ GC,A*0Z?AI?F@FP080MT ;8=/C>#> HV!,*OG<'298C_F=
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M5+;BJ\%MH7'X9P;AQX9_EQ1^/ZV-J2;-_EABO/U9P?8G@?J98?;WSDK$U<U
M__@8^X3;UO_[ZD'U&0/JKQY+S\KI<J'TL?'.:<V%7N2L^7SQ)70XRK(QGES+
M+(0("AXAK*9 *0W&4)HSB &AU%\%_C(W"RSBKME9!?#U)X*6,\C>)Y%QS#]<
M!U]&'[20.6=)ZMS<YQBAZ@]&FMZB%E4P/*E-R.Q[U@9Y[B8XE.,'.^AHWB7C
M*DQCL"+0,J-^Y.AZP"Z/*8_9I9[)V$?9V6,WM,KY>P' Y K6<7U .T#7X+>=
MX^F2>!%P&U5$\D7R5!_/E?+1?6NW9EOX_WNO>HME ,C?[#DZ"5[THBQA*B9<
M"K='N: ;2+PC.+KQ-+!:R*TS$%Z1$U6XO&A<;E3\?':4UR;[$MEYA1RKBQR'
MRT:.BC]6ZU?K;_KZFLI?B:1+')3(AQNU0]MJ-$_AOXZ.]EZ*\)=CE9?Q>W(R
MG<>QZ5Q:7X2"=U%;X+ODMWE)<3]EZ[7;IKJH%]AF55C<T1%QMTUD<3L?/DKK
M:H=XVJ]KSM"J]:OU*PUK7=B/_L\9LR(LR-"5:9A7^>#X'*XM84HJ]/5FD<*N
M'+]>8*LRQ^XOX_9MO,GKHI2(\;)G>>_]_#4(@\\1#R&F '"[WCP\.FX>'1_M
M4/XHG.@[!H*]_T.?V'ZMN=^L[UAIX/''?]Y^VK$"IP\ODL;[]XXS^!5O^#SH
MX/]<9M=[GGQTH@@KE_X; UT[%LY*@E\U=RSNZ@];_$Q^#=+^?B=,]CMNV^MC
M-S'Y(_YM9[^Y\^',KC>/W[_-GWM$87FEJWPU/*I0=C:4/2Y!V<-EH^RI?5P[
M74647171M[F:=T'T75,Z>#NGBV^BU)O5IS_Y1*_.7&8^]T0>=#*OV"3L8*>3
MF&MS,IS#D^92V$U9T&)KQ.96X_SIO')W83A_<KH^.+\J<G=S34YJ')1@ =RF
MR]J58RA3.,79O-)Q$4SB##3QLU74Q"ML7 HVGM3FE5N+P<;F67T5L7%5Y-/F
MVH6P[Y<0M ;L-5/%9*KUJ_57D@%MKH)<<$Q]]GYRHS 7^Q8$;E)IRDO73>KS
M:LHW$?8X2X8W6.A\'G30H3W !@+?W'E5E<9*ZBD59BX',QOS:LTO@)GUE0P&
MKHH VUP-NB# /JEFL&$7_N#VBO%&.GRVVM%\TIQ7*"H$^8AH,2^O.5D.LZGB
M*MN*[H?S2MJ9T+V+6O_^?]PH+&(Z-0!JO%L;;%\5>;NY!J..J/@%OU4E8C>,
MY\R=]L<^\6]AT'Z66[Q^=K(V?*?"^$W ^+FS!A>%\>NC5JZ*H'T5PW:37.K5
M^M7Z54AFQ37L]RU1LJ>4'J^YLC%5C#=!C.-T%1P74)#C+2Q&&*U071D-9.+1
M)VHA<^<-,[+,G81R6BM3/\:#^"55D.8VZ=P5&921P=RIQ,\D@\-:F=FYNF2P
M*@*YTL2K]:OU*TU\DS3QL2V!OG@\U$\-J+HUAJ_^W;JDL:M5PZ 7VWKMMJDN
MZ@6V614&N+G)->^RAD%^QO&J#/5J_6K]U>)!FZN$%1+\9/HI#FD<XMB,K?"+
MKD_GE9/YZSKE8F_X7I]74G>\I R]K759K@^&GLY?Z[E(##T\:ZPBAJZ*/-M<
MG7I4GD4I3AW].7"#V*W2Z#8LJ>AT[O(MP0S#U?0\CE.W:\WEE&]5&77;BOQS
M5X@M&OD;IT=K@_JK(H,WUZ9\5VP+9'BW-E  KQQSF<(UYB[N6J"L/"E- UBZ
M?EZAY')0<NX"K(6AY,G)2B+DJ@BKS348WYD]@JHP3+5^M?[*<J'-59D+;BOD
M2!9QI([;2JQ]E(X$=,ST#,($]PK<Q J[(!V=?@C?_,?M\,,=+R9'Z@9JVMMM
M[<\_*")#'D2L.\"K;XA#XFG?_+KU"O\W ?_GGSHQ'_Y/=_C6EA-D6F>OUT8;
M$L76#9OM]]IN;C1W'9GALIA>TE[)X KK5PGKYRX;>Q+65Y)W78WG3?)Z5.M7
MZV^"UVRC56[=R^&+J6MO9D.'F27XI)JA-5! )I>NG\Z= VV@R((#U\NI7Z_4
M[JU#_K.YTZL7@OPG96.=5A?Y5T4"5ZIWM7ZU?J5Z;Y;J_3'L][T$YTIPEP:4
M2\"AW:"-?1MV,<1B'>U5:32SK!\/G$ MOA^[[7WOYW[/ZW3<X%<6_4>-QDEV
M&GQ\C?LI;,CZLUS:Z5(N;57X7Z7X5.M7ZU>*SV8I/OEV5"ZUHZK2A:OUJ_57
MBPEM0;IP_72@^NAY 2B>\/@^IQ#?1&I66XSLRK9^F4%?K3>; *99GCO<^5 [
MJ-7J6JVE_[$&3F0].'[JVM9,RQS-N-WQSH=ZS:[5Z#^%/>.>$P&0G33IA1'F
M0<^X]\F,>Y_-^-SI;,\=UG8^!&'^'<K?R(MC[%V MG68)G$"?^#(/2?&O.^O
M3M3N6<TZ8'>M<40/Y3X"W(<U!FX[\1Y<?WBP@0&QE<NQF9P\<_:,4;-"RZ1Y
M_#?2UWHEC&U)D&K=$/(9$V8W&R%718/97#-J!@T&_<MA\"3UY; ^HPQN+$1]
M.9Q16SH$;>FHMF#]Y7!&W>D0])R&?7AV8M>:S<+6J#7,M,;QC'N!#G1VV+"/
M3HXJE68;),C<O228N*>+CVF-9U91>E3(N!QDG+N+Q(*0<3GMO]9$E=E<9PSL
M>][I>'CAC@\JA-<!3<9J.P,O<?Q*1BV=+<P_:5??Z@U<ZE7PD:]T3NYP=&H?
M5GUS*\3,$'/^@;@+1<S#8QO.LHJ(N2JR:W/-\'?4(C?MI[Z34 .1KM?VJM8A
MJ\-"9C[W[D16,W>U\G<W<;S [5PZ40"6>FQ@RR=&EOFXCA4#_. O=(S8S=*\
M\B6PG](L\YT/>Q4M;! MS%W#_/*T /;1V?%:T,*JB.;--2OS'G*CTO%)T_"V
MA%-M>-77W"6/)JXPILQI))S:M;/U*OZJ:&"3:."X-G?EX\)HX,0^;IRN%0VL
MBI2NIE=7ZU?K5RFX&Z2>C^D]\O1YU6NNG4P5^$T0^)TPQ<[%HQ+_EY76528>
M?:*R,G>JIX%*YT%G8:K+F7U:*W/Q+T=U:6Z3^EX12!F!S)UZ^F($<KA"G7UF
M(1 6\6^35M@9XK^PE?$'Z[\L$# =[X'_*I6+?R^<\>_OLO/0<7*R3T2?2+[\
M,083=BEL,LL>!BJW7<"-*+_KK>M:3KL=]@=.,,2L06J$;R6AE?1<J^L%3M#V
M0!K'B9.XU)9@\@D7#@< N]7VG1A0ZN;WBW_N%#&F5GM31E/R"1$O?;1#RQ76
M^WSW72]HTKQ RC(VD=_G%NAU]Z/P47U3_*KM^KYU\_NW/[].W*-<2YJ!  !6
MO*]U6I<#:"3-_6W^V=/:Z\WY[Y?[%]\OS_^Y?_[Y[O+[KY;C/SK#6/$C5- "
M-P>#=U;/98 VD)9$)_U;C?ZO3%V5KW;>E@'_CT_EP,=;7 3H[ZX_?O&"'WJ/
MCA</? =@Z@6^%[C[+1_87)[7T]8:K.\=JQ<AQ_P;,,2='+8_"AP\8*H>*K%\
MB_A$\4.M[^8_GN6"2T3L'7(DS.O]B(R>R-'Y,./M3^-AU@CQSBC,A.:*D"RC
M93HK?SS#B1;/[U"$.B0UPT&\H^X7/@<PGJ=)&(1][Z?UU>V@86=;5T'[0!L9
MKWO,6\UQ\;JO!V[DH/B,IQ_G)7BPX!()1&$0O^V@]Q H302M_G<\<-KZWTR3
M($CN9"P GU=T'N 3OC.( 9_47P6&,S=W+*)NKABB1E&W]R+FP:+/COF'Z^#+
M[+R6D;\9?CNX/2Q)^&WG>+JL>Z$<I]=S6)2]6=Z)\3F,2'_Z7]>)8NL2L*[S
MBJT,M)^JPNHUQ^J9XSRKA/RZO.A%47Y,)L4VT(&2D"<@()?HJ/4^['H!L+DP
MC9V@ ZNY/]ON(.&J-'+9@LXB_^HXB;/W_JU7[JU]>0)N5 0\.P&C6W79M%LA
MQ^HBQ^&RD6-3&?MFA4NK]:OUJW#[BH?;Q:\4W(/V-G"#N)K17:U?K;]J+&AS
M:^5F:%GSNQL C_+)HG0Z?2_PX@1YUH.[%:D_.YBNL"*I"A-K;X_KA02=CN0?
MP/_79\[5D=L^#SKGN;N^9/$T9R;"L7UZW%R-$J!MR<A9([QME.!M,\/;F5)H
M7@9OC^S&X8J4KJVF9-Q<Y7P&R?C=C5URMJ-H[+@/KA\.,&*\@7)QY>IFI["4
MY@)$H;I>X"F?LLM]'D,YM$_0N;MZ#*5"U.4@ZN$"9-]+(&K#;JPFHJZ*Y-MJ
MF_ O)XK@Y\II9>W#4Q&H790B93GWD>MNJ"!<8)^)I4>V2ACA%&YUM @+T_&"
M+V$<7P>?X'T>2$N_"D!?3RG;[IN;W$1NXOQ\<O/EK.7$,KLP5V7=&]R$92)Q
M'"_"C'TF<<S:E.70/CI:3GNT=2[YKD:_5>M7ZU<!H U2]K&FA>J]PY%(=*6]
M;YB"<K( [5TG+(A[(9ZWKWC=/CHM:SRSFAI(10";0 "G"]#0%T( AT  #;O6
MK*T- :R*)*Y4\&K]:OU*!=\L%1Q=/E8W"OM*#:="XXU3OU=.K9C<5OFX?K9(
MC?DJ:(=]%Z_ZN=Z[)2K/)2#<L$[BZX:DC=HBM=KG(>FAB:3+4W#'(^FJ2+-*
MC:W6K]:OU-C-4F.ODYX;61Z)$&M7_,A[5453M7ZU_FJQH:W.VU;9:[ZTW1Q:
M^[C"C_TDW,?_=3<Q<6W)&6E/335K+**8Z;/C133\]KSSKS1.,(7FNBNW/]:^
M6?'\LBT)5*V=%;Z((J:Y\'5*H+5I'QX>K@JFKI@5OKG*^ Q2\ K;R[BQ3N+>
M4IFW4DQD$65+ZEXE/OTM#'1JS[RY&JLSXKGR-2\701=1KK1X!%V54:LK)^"V
MVLS3 HX=4ALHW[8ZFZNQB&*DJ^#!946; U\*9^95MH^6HVI7*8W;2@2+*#I:
M,!'4&V5#9U:3"%9%4%?#)*OUJ_6K0,P&:>A995%I5+A2QS=,$UE$=9'I"V!=
MY'E=3.HG58E1104+IH+)'K)%U!@MF RRP&73;IZMB"]W3)_Y%7.@57IYM7ZU
M?J67;Y9>3N5&+1<DB*OT\L3YN9$5_RNG9DS3'Q91<I05<7R.PCZ.*O6"%&1M
M-L7R@BZ?G[O#J[_\F40.*$!>X$3#J\3MQZ"$X$&BT/=)#9G?)WB8+UTZK*]:
M54B%[,M!]N8B2I=6#-ES=7I']F%C1?3M2K6NUJ_6W^;U5X7P-UJUOMIL=7JK
MV]\V%U&3H-40<>E=N(';]<:J&F.K$:HFMQ4)+($$%E'FL+4DL"H2N%*]J_6K
M]2O5>[-4[V]N8OEAO)%J]U0!WP0!WPG3EN\6U9#5&0,W^YDG>PT7424%R++
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M7JL J.:)6BE\*4\4)@GN.6(_6& Y/#A:FTOK8BX]6DO\LF)[$C:F"W';*S/
M.E*5?8+1.O' M404KP"CVAZJU<%UL+X0@"O,NQ(U[]LZ[ZL6/_ROVW@4.K9C
M!D^W<)&RV>L/)VR?W7TYDVTVO[#IB 75B5"ADV;5(D5U)$3[!-5UXI;50HKK
M -6:OVK5<KWQ.7O*5.M$?JK%WY20GQOJ$<MN7-/2)&CO.6N=Y,5J03IU >TE
M5:A[K9.!KD.M%=@J#-:C.QBY#&!HM*]^RSHQV;4$\2B$Y3R]XD]PPYI;[BB,
MUHE;KB62Y_DP6L;VCI#M=3J:[6F]\GEZI2A9=W.M>=_6>=]:0G8*A.HK>-\Q
MW9MXY#K6]7@,._#N-2?<48BM$2<\7DL,STLA=GE*TLE1;8+.ZL@8]UH?+(]O
M;29C7&,=MU?DG]46^6PV>_R2P"">D2:B#B_]H)!0-2$,4;<MVM<RA\<O"4I:
M'WXLS:SJG=:$J>M*A]ME\N^RE0YGHEJ8,7I*\S-UM<.M5CLLI3>O6.PPR9)[
M6:6X(38M.BFTKFVMS&$3&6_M..H22?(5:QRN"7('6)VS->AJP_"V]=\FU:C3
MX^OQ7S)^71"_T3(Q"<03T[MG6/>;1&.JZX4?L&W' _ 2G:E6!S'B)86]I!B!
M,@3^>Y'>[#<61H%C1<S&!V>>G?U">?,&-N+;\[V&+3=&Q?;B!X>C;V;$+D"'
MMU;M33#L%?5)W+H<HN%^.W#_DM)@.P7WQZWC0;^.D%\71JPE<#V^'E]+X,V2
MP,\7R=PMPXR,$8-7/;1-8U,]XD0-E,4;[TLKE7!RT<S.9L2:1(#YY(0S/S3=
MWP'Q9O +^!N7XW@QLT4C=-];U0-WTCKJ;$><U[[I?<6GDP)\ZC<%GXZV4S=[
M%6RJB_B@]08]OAY?ZPW-TAMD=Z*%J@.#!XK2T,AXEN4B1!]$"-N/,7DS+T.,
M/ORM5D$PSUIZJ01T6B !O;Z#8#,2T&FKVR^*Z=M,C$U>#NKODU:AD:T V4XZ
M>ZB^UQ?9ZB)[:*5#CZ_'UTI'PY2.<&9Z<F;BU\ O?,YC?C.P+V#@.AY[9QQ\
MN(UG,Y?*_)@N5U#&KO]HV,">7#^, Q;^]OY7'&[7^Z3J\?7X32-BS4WVQ9A'
MWVMS@E20^/.;ID9Z?#U^K:A1<T6J"J4'9-=2*CS ;-3>R=0;/>5*$>R%>?<
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MA;AA/XBR'X[G^0^PJ@<&S-V:>"#5W3O"5 >X%%)I$,"D*& F(0S(6"0\AD8
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M;&9#I4'[V4'AH &:SV0,'_+PA!=5&F]0O,C,XM3CNI4SRL9/\LS>T1[>.,L
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M[F9Z!8D<Y11UL/ ^AB7WD=# [(U43(8K&O9"K)LH:/(P%$_#E5/UB]/CU$Q
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M\X$E31/"5;J(9:FFE&R- 3.4=>P)Q0T@QX\#JC%"YN\QVH=%V5<T0],O1!X
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MCU$[*8I1JUI+F2> F$]D1KCT@RMN6<EFD*PGEVF^<K2::2/3F/FE<>B1]A]
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M#E4> S=S9K[" T_:@4L@G#-:FM*P*VH-P0H2[" /)NG_%+:4E,C#691HG]3
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M!CWY5XLO*.W)[')-'WMP4"&?XG!Q(9<U37U?"@;]U;A21L[ NU2S!\6O%6&
MNS\ID3+SILR&X\Y@;LEK8)7A5 50$"2%OTSV)UICN87*22RKZ,T&6 X8B*<\
M!T*(FR!(H2&2RVAH4<'K2TJ#EM^)(J =&O\[<=RL87L^HS(/#<(DBY7Y@!2
ML)NUV"FES9(,#"&E\IQ%O/<4KB@))\@FT:J>F-SJ>?(C]W 3?5$&E2;AG$1J
MJJFX9#8G 9VG"<,/@J?Y%%ZNHR@'B75.TK3>='1^&%P!\4=2E^",331A)'MC
MLDAN-N+FXCC"FEI<+6@:[*O*A^V4!DHFSA+1$^EI@4PK(-?.^LN>'27-XS"7
M] JB$%^^*M%H!=B8^X3EMY<6"_3C()KPWRI% K,AYV,'8P]7"SU. DD#1LT6
MS511!I#"N2J2?PX5"W.N6PD[5H!6Y'$+4F69,N5-F$K%1E/6*O*P?$L$WW/*
M)N#Q.9EW=$I+?Y<[*A$1?XD4)JTEIV1YMV!O<C7.!W2:5Q">VK+/B?$Y,1]0
M/D@U ]#A?_]T-.P=GS8MI/Y.=94\R&,()T!VVR2!98H#I&Y,3&=LI0%/HK1@
MBY>E I!)JAKP1/F<6RGCHW-][Y[/Q7VE2OU8E638<5++D2S^A-M\I3(I@FH]
M4)KHDT2#D&U#9-0V?FWCK^^T+\O\^\;=;3=8KOQ.*;%>(0FPV]N>H5\LV\!U
M.XV/LA*&6^/L]KS4BC;LM!2I(G=,3\:GU&2,!];*"A_<GID(%, WI"MVQ@\Y
M5]$P_T;&8H_I@ Q5_T 8#$(KYH7VA;. @N-0U?$?N4KEA**TKJ;JNSA!8\GK
MKE%UZ;F]\E"SO3-_E-/P_O9H.%^A 4ML/ &/0Q8J7D_52INTE<D6?24/$S^@
M" \H;<F"A))^T4ICJ."5A47-J.&@L.7862.6M(E81(JYBS5KH$U--C(?&Z=*
MJM2F%= 63"Z"^!*[@1+YYYD\+!/&"Y)*7J[Y*.T_HCH\5E#A9A\J)Y]?MBE2
MIBT1,X3%W(.095VOTS@DJQ%W<(?\*ESG3^8Z$U]V]$GS-GA@Y_S1RB4%C =L
M8O7YU#2';3$?*8R*(C3]!P<U(EJT0T;!*?9^I%G1+FZ6MDU*##*TM!#!@"["
MIY@IT07;+%@E7V2UO@OJ1O ZGZG:IV:<Y]H$YO-P%0@UN<.@Z&#1U"*,V739
M_G@<BM+YA:B AAEAJ"1@E;7O1(@H?.*5<)IL^4N4>J0HL2>;[. QR>2IL*C$
MM#"H/C@AO0'GMT3Z/,:VX1BW4.:)YZ\ 5CC6A,*8*8*3WQ,9K;DQ:P)/)MBY
MAZ(ME,@.D!#A!]AT [=34)TQ)Z!FMQF9?S*OA1BDDHP12Q[P9 0B22R* R]+
M1M)D!V&"@P,+R5JZZ%PSU%:$6^?;8& ;L7!U^N#S4H8ASBY+-+$? %B>P!Y8
M*M(T,L H5L3DD@EA8F H0>(RE%__.PZ<T':L!$CXO6&Y*L*@57HTK9%H3,S2
MUDZ#SH)F@\MSUA.CXJ4??)=W2[*4N-ESWJ5E0?XZ)C-B#OLC @CS,NGK?1X"
MF\]>7P!!6AG:Q0D:JY7LJC)$G=4^(C%&VL&\D&CC-?D;SSP;-!%&H?.8M5X<
MU#K8GIY$93/:G)6HRV^@SG0QG;G^$V.\79W8LZ7LF?BDXH1$=G!/?B";W. 9
MAJMF>XGT\$<SL$4(3";K $7%I/-@FN)$PB:08N2<P0/&SXH*SOQHR*F%0XKR
MEB8^)C[ BZ]X,GTCLX4D>2FS@J5S&LY8*!+<S^VR5&\IG#;15W#>$(,:#@UE
MQ2 Y8,-N)HX\7!A#4+QXD7D%:(;"C,<H*\3)9B@A@Z9(8BJ7*0V-]SY&,&"H
M$-]?+DXV+>T\?X>^+"0M*AA$3VK(1I*!1Q"1:)L84RQ^AX%3^-74MYE[:%P4
MWH1(2Q75"K@.:V/(+R\:\R"#:D)&\@FOD) V:<OXRF#/8R8;B8E"9"G(1;+^
M=5+H2[/['9R@L7QWU]@]>;1$8$ E#]86VV3)93:0BR\T/R0$&FB?""7E5+RM
M4'$UXK2="<A+$Q\3-F]*DY[,_E7":)(\]5 4II3=))&@SV8 %SR&4NB^G+3?
MQPXW@F#GCK/;C\NL'H,3X7-#[QJ:E(!W3Y#%?%;,H)3&ROO1)LVXEH\K6G6)
M!M^XZF7^O^Y0KB6I;,"W^P>S[W%1%2>'@3*3<P:M''1:\5N6:5#.G7.Z<0 R
M1023DS6[*.(WTXRX\C%3LTR10.QX2?$?-3]II7'QF HW0Q,*BVLBGZG=,G*"
MB/"?\HZKE6\LC<59>**(9#_2S-A\-0;_D7*GX*2#)]GN><&F#+2ML4 VLICY
M&('/ [9EK+  %"S10,);:CF2_>PI]--R BN>XCUC^G <(53D0NV2!8KNJMG.
MJ8FT6G*6"'Y.J,!?2QBBD@XQ2H1KIBJNC')N49D*F"JVHE1QD-G0\E22/&C>
M4X32H4V8!D/:>2\0&4T(!R6$<H;2'YK6'I,XWLREX9D(+-#Y/XOQX$3G_^C\
MGV;D_Z"*+6H44!ZLG5-.N?T_QU0LP / !7,Q$6S-TQ;5%392*A.)\@S3&6 #
MEXJ4R%O4Q]M8FT;T-%]0&8*;"I;NP_8K>2F2[:Y_KY%(TY!=KE2#@7 7BX2$
MM.@%F0^0LA>61F<!,\<8B&2<IQ6@L@5OYBU+N<5F#$MD9R$NFBEZX2MQV$IW
ML6P)&Y*\2J9SPDRY1;)W&!]=H&OM6PO8/,L9/<A];'Q!I#/.S<#U,8,,2R(V
M,/GG3A5">+RWA.@4BGT4%ZV)&3(I-,$1 _* C *+!.)JO''>+BKF]#%P[/NT
M:'T+WH67S9 "XBCT&@@YW<D]%YM52V:I@T_)?H Q%Z_@ JE;B)K+9\<B8]8=
M.=+Y'&?W((63Q/X&7Q9"7>$;LC$PQXXWSD-F'_AKN4MYEH?&1]7:FFA.'N4H
M4DT>$-0RT2<\LJ-:H:SB?:2%WPI*TKB97  NK$\!Y4BLSLV:Z!'5Y/E#)=&@
MR.1(551Y0SD>AI+U6B\B-RTA-Y88,W%DPGTB=E@'2%0N\S 9YBR4P97\))?F
M3[1D7 E3CBN9+!5U70I,>LX):=OE#D[06"/BKMDNI:ORP@R07H4W+""O9;D!
M<XN];C^C# .K1!:+S))6VT!K)C YN$F2V&9DL."BP81,,MP[%B,7&F&6Y8-#
M-APTF] O1CP%GJM9S&Z;#R#9@<3@Q=,13TI4QPM5<X':098;&Z390Z1;A?)'
M)-C*W'V@YU04;8E@SKF M.,)DY5L[\9^L,!RN#U%AJ7,&VHETS@T/CDN'<'"
M0U)$@#0"=%V'(LNR) Y&&Y>#(I$(',T+=&I/0,PFY0.%/%93],;C8CR/;FVM
MOERA?(8+%]!2:YN2&D/R' I"B:#C14Y;[NG0^%U64<\X;%,SH#)[1H9 )20I
MG$3!CTI1/=496:FH*JP)P,R67F3AYR0H#/"<> XYX@/SN+=7_J'N7KW.!T;V
M<UXI N4WRD6N ,3^R'7NDRS8<>S9#0WK_,-_Q.CFS+W_$J:W;$O)/"F,*03"
MI:%V/25M2(K.%<7T5/=!V%D"8(GA610>X^(EPDL&7  IJ)C",P!2  &'2!4&
M5 0'5,5O93G-"K E0O =:FWJ6TIE2M07D^WEKT38HO%+X,ND"3P)W.>Q^P>\
M^+0P75,4!0]4%A5_BRA8FG6;J89I6*9KB:8&*7$5JIXS;HL?DLJ#4Q]* [Y,
M*(#MS;_5REQ>P'B!AL3^DKXN[$<C!H#K*?46$NJ<:&(RM#Y++?,U?KEKQ_-)
M]_.3O'U;L!BY62IN*N@]K] A+?(C1IW698ED;75?;'4_U59W;75OCM5]2560
MZ)&Y#P45+9X1O"XW^*SJ)0DQ5RAJVH"S"G/+TT>%"":-I8ME;T6X?%H@4::C
M4[P=I1H#!=U8E<B$;KXPQ->:,#MVV?7X#'8G-W>;'/D%!TC[,O"GYZ2S\1C@
M<5[ASJO:_4[WZ'0X%_\KULU%7DX)_^>@<V @$9FAO\6[3_X.9Z:5_,W)SACS
M">"G"6'@0R!!=,U9""@K/[TS^,FU TXTAC\G).\4/Z_,)%H&?8V</G#&@IH)
MK#(Z0+A!S8]&OOT$_PF4=?_!3-Q=LG(22P D)24<^5'D3U=?QSS9>A_916#X
MLD$E"$;V1L:'Z\0.5I0J4L#*,BQ_#?-+H$&VA+<927;=YM<#K\U^&*'O.K81
MW(_>=%H&_O,6:5XQTK]H-5E>)BA"H<PCR(0A;G[T(:' [W\="=O2*]V9(?!6
M/:+<1?X:!1_^2Z-##<<'2)%3()ADIWE-3%LR]<Y-LXAN];9$MVI'D% <>75:
MI,E.,Z%Y5[DP"MYU8, :1NH+(V^H/,.#$S+[;1U@15--/;X>O^GC)UB^(90N
M,%\C6>YU!BVCUS^!_QL.W[X.XDN[S]')SQNE_EE*+Q*9> Y682!EQL-3R 6D
M=?WG=9+:8JC;PE3]G#^'+'>OJR,MKH/2/STZ/JAB4?W7"PVG'Y^*!SC[X81M
MD>[X!5OY!DKQ%?IEWI;[PH6<4:&=I#9+)U.;!>NRM&T_:HN:+&IQEJNOE]B+
MIC7L=^<JM&P K(KNM38PW6CTD1+B[Y=__[]!^]/55Z#LTW9@W[>C"27RV?Z4
MM2W7 =&W#33-!TK'PO9Y&'X3?[0GT=1M,YXBUY[ BET>+K0$-4\*4+.?HN9
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M6^X_@LT=+-[2XJBM$('^&&UJ/0(UI=2"_QY(UP!V?C.3-V5&2'>AFH]7$O_
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M!QG4/<F5D?93O,-XQ^272:Q$]NLBFZ\X!J4*8,B6SI!U@)3Z]-X8+TIJ[[-
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MES_@YD'5MQZJ83]""\'R!KQJ.C:L<=7G@1?Y)@^J9T%P(_^H]L.!4^4.G6F
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M(?8$3+KJ<X?2>=._$ 5C'G&Y43)P'Q@],=A#=@D2TK)L_$/D"V>F:7E#',L
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M^0S<&VT-RF?!&[YPL.AMX&@C=N='02ARUQS@S;@M9YX_]$2:"GM[\.7N[.R
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M1E ;IYZ7*P'+")LM@'DM[W?()U N>;^+,GX%/5;6S*!>TF!B<\>#RPNJ3?'
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M&#?H%<)YRK[Z7T!J8-FF%(P6M?#UHD#*^?3EX) 4=)\_H/0E?>#)#OLP*C<
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M22>L]%1312U]1G37L'#KW L>HATM[,T/1;G?+E_!LX 1@S(Q4$FL_KJ'YE/
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M"E9+QTC;65VW'LM(GQ$/#@J)"$7AJN750M$7/K3].Q@[;16+(C&)K#J"22A
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ML #<1.FI$\G\Z!?UA]8BU)HR9@*4[ .]DFM"@1Y0"8W<H4/A4GH^Q,-H?CN
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M> :Q4KA$"H<O)JR48A(J\I%'B/]9 3N;.]#\M#'S.,GC,W^:FP/=K?$5SN6
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MMTA$\Z8Z2HCCQ0AU>:'I33*229MK>KKFAPP2J<AK)KVS#<1"P^@D40\2K)K
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M]C"KV5$N!CR*WZ;Q8 &?+0MZ%(6S;EW=+0YG52!5\=;=\]:L-DN;X*WJCI_
M7I.RQ(4D)!7$EH_/9C4,VAR?G<.)=53:BM]6FNPC^>UY$ Z$"W#V[A3KXF")
MP8KS[ISS9A7/V@3GE;<=AQ7OK6#V!?'>K,XWF^.]&5A1<=]*V]V*MCMVPU)R
MW,WT+=T^D=M(@^+#K$IZF]&< 5XH*^\%\^^JG6]YT6)W(D)60Y]-JN=SB%<*
M$>$E-]3=NM:^[>2)A8%@M73Z_RL0'];L?+9[0KE>J\_#!7%DJ_0D*V$<V:ON
MP_D$$"M.$%KQ.P(>+@A6>XK4\!J"U=;O!+A["6(+EH=RY0-4XU?CER&?Y)6I
M#F=FSDBE.I1:=3C**M[\U% =6]?@K[2'EX4,E?:P%>WAZ'FC< TTK+2'Q7W$
MLYI?;ZFBWO;[;F>7W5O2B?NX6:Q.W.W%G;AY3Z^W[?;WX%[V!%G8=EL7D93-
MM['N]WCL@42-I)%ZV>C&D]@B]YXK? (8^?PTU@#%TNR9G0]1-A_ 6%RZW?7[
M03@.V E"+\,WH:#V$U0R-.G\+9OH+&E#-)NXH*J+-^NMDZ4VSJ1]&/?]ZNK9
MU^XBT&B A$+_KMP6B"KNYFTQJZ/ BEN\"L5 A*%P-KK+YDJ;'*NY>9\UV7V%
M^O\"R3;:LN16T9T-F5VP_;P.O<D]7]GA97B#T.K\ V=/7EF[^7$CHV;N3#]>
MK)N+2, RCFZ*-G- ^(;G85<WH[=,;\K]7A URU N5X>N',^0LQ,9S_A)@ZQ%
M-V:]Z Y0AH#[[S@"2CA=_2RZW&)GU?+=&0V?AO82RI+5FF%%!U$695GN'\*F
M[8A4#]B76OBS];;]X!$$Q0J2Z<J &@L:I5W+[HH*(5XT/CQ)ECD7O3#&PMG-
MSL)NJ5PV6RX_#_2S@D%!5F[5FQWS8_<!"*_N'I+<A=%T]%^W[@0K6%\ )-Z[
M3FQ[W&F$&HD ;)YB U</ '6R6I-2&II;D'+E?XX4,5N3G@?AC0CO05E;NW=A
M,[M':9A VP)Q119W3_I0CM1&N54M[=22O<Y41U/N=K:4U1]FT*/MW$2.^& >
M/"G(3Q4:C@ZS%.7\!I\L2,SWA8N$NB<W6G*X6;%-6X?XC/X%"^"=Y+/-@7N[
MG2FOTKDFAW@/VP70IP8:V(CV'@0Y>ZF:O:U3S(#+SZ@Z(<@(/R*EJHL6GSLR
M/'V>)H]<V5-J+H'+HO_[!RQ)GW5S+PTJQ_-,VXE#.A4XRM:LF:).OZ#4"V.!
M  LDGOK-RE[ 1).9)#L@>>^D:]%Z5A*RI<U<GFRS$7T5O@CASGRGZX"L[L)#
M-C;'H,X!V6:35M6GH*KJN$Z1T\.JR.FCBIS>8B\D:A0[C*PS:H.D=*6J[&D9
M$:2J OPX!&&O_>XQH8*10L/(01%@I"CA/J^X?.RUZ =W/KEE7-^Z8\F7/44I
MV5=U@BMC0-#Z>)T; K'S]64$82R)4EBMHL]**O"%WP]&@APRJ)[^$?19B<4W
M%BE84@%;Q;30]3P<43C9NK(<:8T\*_)OMCX4(MKA564^/A,6%C(-,A\+LRH)
M9307??%8N,RRUV[76AF6[*)B8E&DF2T$+Y<KZKP:OQJ_#%D+.U%C=J>ZW*++
M[%7J(VO&9.]^@8_72%:K=+:*+%3I$U5F0WDS&_*Q:$%(S!H:1:4/O.P\A&T%
M?*T=XA@*Z\%>%O"2DXO_=" ^&XV]8"J$#$S)!N7O@<\1)31=1+*(^?MI$$V^
M!Y/_$Y/$PIJ,Q"]=XG9OA[9_.:;*06O@!8969@<<Q7Z8F'8IT*C>HV#\OK%*
M9=6U0N$AVF((V&Q48HD#,#E\O S1R)N)OFP=+PPX)E<2.0DP0<2WNK??K.Y=
M*,BLM&]=Q6$48W2@C"'$*'<=#:^?JYEA<(3F8XR&GTC(BX3G68,P&%D3. $:
M"O^;1"O.I: 8870UF7\ E )PVT4GQAW,>X?I*1%@591$*L9C'#N7PBS*DFW5
M6\?_NHE[D>NX<&(W-H9Y$?P0M8%3T9O-(S44?<0)3)>#@<#0N&_V3W<4C]2?
MW1&H=Q--$0Y7IPB=O4^M_8S,!0 M#S[L6T^//H\"+S_\?,5TQW5/\O'!M8!,
M]-,3@FK;H%ZW#A?GQ8QG4""%(3B7Y8L) &'0%\*A*Z"<*[AU %%ON@0>5_3,
M/!TTDRP 7N@YX",>'5;_OAP8"3?/ 9LEI;_ :IC'7'DVY\;QGY+OEYCS7.1S
M'B(TV;F+ENT$8V ,-3JOK 3$S/Q%9C'=>!+X 1!9ZYMPT!17LR[\_G[>6G 5
MM ;+N*HW.!A.V&I\P"_H8_/#6X[9ID=<F'NQ?#7&1R9#FQ#_WG7@=)$2.&[4
M#P4^@6SWCGHH(460V2\,%C6514C"(AT#?X%HJ[X%8O.G /8L959X"1"KKOZ$
MB4 *G 1AQ,>8A/'CZ''OW_ C#H&YG+:+K%,%+,.B@:CAZ5J>"RR::UN:^V8N
M"X1+[LRAG3%OS25E6:E);4F_<.CO0(>(9,%<^!.G]\$/*_*!=8.GN8 %T,P-
MY5*VEB12PCGU9 BUD[H-V\&,,EP7W'J4G*_+0==X%/O<Z3UBV()/\'X8"BQA
M@*F%HF_'$<DZ UV[O(;"OBQ26K,X#5'^ ??6Y^X.,GL7QK/O;=>CZ&6\UE#4
M7<D$=A+D+7[VO=@1*JP:H%1%6%Y]_?[CV]ZL[D^QT N#P=:)C_Z@8KKSB$BS
M>< TA)>IL_GA\U"[!ZZZ7\_JGZ_/NG^O=\]OSZ[?6[;W8$\C9>Q!>[<_&]<]
MI+(.[ZT6&AZDT?^7!OV3Y0^0/^V]RSRQW[]<9T;,H24C-6^R9^/]X: >!@_Z
MI]1OMY>G?[C^GQ8\@^"4?2] _8 N3O'@/-<7]1Z&TZ>OBU:23&%]M"V@1X#R
MOP QV$N!W8,\&4F0U!7C$[-?:H="^NM5;C_#E$D!^JR6 &P!LGY\9R>'8MQ]
M&A"2ST094I!M@KK"@KEG"L&YN_$=T*A9WDV< ?4Z*B$@JPEX7O! 1 1E'V#,
M0$#=OJX.H)3$A-Y(\HAO*)H#RAU:AGI3E7B2AX/1A'$0!J:\](&+]-N:"CNL
MI5-8<C<(ZJ)G<>?T ]XAM5?G3NOP\AM9XP!N!KYYN^I@[38/YOIT'J3F6>(_
MQ'*#O$$&[KW@C8'2C.3,>I/+9H\S- 9@L\=28Z"/[>8C.2[H^9MCN%>\#_L.
M% LCP9@-=:P.:]Y;;ZW,?%M[GSIS3/?7MPK0.-/.)V9/,I=I7DC,048*\@I
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M.1[07CP4"2]\8WV&.WX*0L]ZYT41.HMG:FK>/S'!G',9 @*?<3H+0<F?.DL
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M)'F7?WL51,&84_\"4$L! A0#%     @ *(A&6TC;]C'=A   TXH   <
M         ( !     &$P,2YJ<&=02P$"% ,4    "  HB$9;X+8\,DFL  ![
MKP  !P              @ $"A0  83 R+FIP9U!+ 0(4 Q0    ( "B(1EMC
M=6$-SW4   !Z   '              "  7 Q 0!A,#,N:G!G4$L! A0#%
M  @ *(A&6R\@E,F8A@  XHL   <              ( !9*<! &$P-"YJ<&=0
M2P$"% ,4    "  HB$9;]=44PAK8  !9VP  !P              @ $A+@(
M83 U+FIP9U!+ 0(4 Q0    ( "B(1EO;#Y U8WP   Y_   '
M  "  6 & P!A,#8N:G!G4$L! A0#%     @ *(A&6_XPH$A_;@  \',   <
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M+3(P,C4P-C,P7VQA8BYX;6Q02P$"% ,4    "  HB$9;\FKVTNN1   A6@T
M%0              @ $P(04 86UI>"TR,#(U,#8S,%]P<F4N>&UL4$L! A0#
M%     @ *(A&6V[%VH*'L , *N$F !<              ( !3K,% &%M:7@R
M,#(U,3 P,6-?-#(T8C,N:'1M4$L! A0#%     @ *(A&6_NU*.D>#   <PT
M !T              ( !"F0) &%M:7@R,#(U,3 P,6-?-#(T8C-I;6<P,3 N
M:G!G4$L! A0#%     @ *(A&6UM0<=AI%0  @Q8   L              ( !
E8W ) &QO9V]L<F<N:G!G4$L%!@     /  \ AP,  /6%"0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>amix20251001c_424b3_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:amix="http://autonomix.com/20250630"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2025"
  xmlns:thunderdome="http://www.RDGFilings.com"
  xmlns:us-gaap="http://fasb.org/us-gaap/2025"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="amix-20250630.xsd" xlink:type="simple"/>
    <context id="d_2025-04-01_2025-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="i_2025-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="i_2024-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="d_2024-04-01_2025-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="d_2023-04-01_2024-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="i_2023-03-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i_2023-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i_2023-03-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i_2023-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="d_2023-04-01_2024-03-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="d_2023-04-01_2024-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="d_2023-04-01_2024-03-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="i_2024-03-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="i_2024-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="i_2024-03-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="d_2024-04-01_2025-03-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="d_2024-04-01_2025-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="d_2024-04-01_2025-03-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="i_2025-03-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="i_2025-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="i_2025-03-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="d_2024-04-01_2025-03-31_SubsidiarySaleOfStockAxis-ATMAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">amix:ATMAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="d_2023-04-01_2024-03-31_SubsidiarySaleOfStockAxis-ATMAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">amix:ATMAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="d_2024-04-01_2025-03-31_SubsidiarySaleOfStockAxis-PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="d_2023-04-01_2024-03-31_SubsidiarySaleOfStockAxis-PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="d_2024-04-01_2025-03-31_DebtConversionByUniqueDescriptionAxis-IssuanceOfCommonStockForExtinguishmentOfConvertibleDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">amix:IssuanceOfCommonStockForExtinguishmentOfConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="d_2023-04-01_2024-03-31_DebtConversionByUniqueDescriptionAxis-IssuanceOfCommonStockForExtinguishmentOfConvertibleDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">amix:IssuanceOfCommonStockForExtinguishmentOfConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="d_2024-10-17_2024-10-17_NonmonetaryTransactionTypeAxis-ReverseStockSplitMember_RangeAxis-MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:NonmonetaryTransactionTypeAxis">amix:ReverseStockSplitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-17</startDate>
            <endDate>2024-10-17</endDate>
        </period>
    </context>
    <context id="d_2024-10-17_2024-10-17_NonmonetaryTransactionTypeAxis-ReverseStockSplitMember_RangeAxis-MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:NonmonetaryTransactionTypeAxis">amix:ReverseStockSplitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-17</startDate>
            <endDate>2024-10-17</endDate>
        </period>
    </context>
    <context id="d_2024-10-24_2024-10-24_NonmonetaryTransactionTypeAxis-ReverseStockSplitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:NonmonetaryTransactionTypeAxis">amix:ReverseStockSplitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-24</startDate>
            <endDate>2024-10-24</endDate>
        </period>
    </context>
    <context id="i_2024-10-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
        </entity>
        <period>
            <instant>2024-10-24</instant>
        </period>
    </context>
    <context id="d_2024-10-24_2024-10-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
        </entity>
        <period>
            <startDate>2024-10-24</startDate>
            <endDate>2024-10-24</endDate>
        </period>
    </context>
    <context id="d_2024-01-26_2024-01-26_SubsidiarySaleOfStockAxis-IPOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-26</startDate>
            <endDate>2024-01-26</endDate>
        </period>
    </context>
    <context id="i_2024-01-26_SubsidiarySaleOfStockAxis-IPOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-26</instant>
        </period>
    </context>
    <context id="d_2024-11-22_2024-11-25_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">amix:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-22</startDate>
            <endDate>2024-11-25</endDate>
        </period>
    </context>
    <context id="i_2024-11-25_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">amix:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-25</instant>
        </period>
    </context>
    <context id="i_2024-11-25_ClassOfWarrantOrRightAxis-SeriesAWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amix:SeriesAWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-25</instant>
        </period>
    </context>
    <context id="i_2024-11-25_ClassOfWarrantOrRightAxis-PrefundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amix:PrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-25</instant>
        </period>
    </context>
    <context id="d_2024-11-22_2024-11-22_CounterpartyNameAxis-UnderwritersMember_SubsidiarySaleOfStockAxis-OverAllotmentOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">amix:UnderwritersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-22</startDate>
            <endDate>2024-11-22</endDate>
        </period>
    </context>
    <context id="i_2024-11-22_CounterpartyNameAxis-UnderwritersMember_SubsidiarySaleOfStockAxis-OverAllotmentOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">amix:UnderwritersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-22</instant>
        </period>
    </context>
    <context id="i_2024-11-22_ClassOfWarrantOrRightAxis-SeriesAWarrantsMember_CounterpartyNameAxis-UnderwritersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">amix:UnderwritersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amix:SeriesAWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-22</instant>
        </period>
    </context>
    <context id="i_2024-11-25_ClassOfWarrantOrRightAxis-PrefundedAndSeriesAWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amix:PrefundedAndSeriesAWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-25</instant>
        </period>
    </context>
    <context id="d_2024-11-22_2024-11-22_ClassOfWarrantOrRightAxis-SeriesAWarrantsMember_CounterpartyNameAxis-UnderwritersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">amix:UnderwritersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amix:SeriesAWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-22</startDate>
            <endDate>2024-11-22</endDate>
        </period>
    </context>
    <context id="d_2024-11-22_2024-11-25_NatureOfExpenseAxis-NoncashExpensesMember_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">amix:NoncashExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">amix:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-22</startDate>
            <endDate>2024-11-25</endDate>
        </period>
    </context>
    <context id="i_2025-02-28_SubsidiarySaleOfStockAxis-ATMAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">amix:ATMAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-28</instant>
        </period>
    </context>
    <context id="i_2025-02-28_CounterpartyNameAxis-SellingAgentMember_SubsidiarySaleOfStockAxis-ATMAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">amix:SellingAgentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">amix:ATMAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-28</instant>
        </period>
    </context>
    <context id="d_2025-03-01_2025-03-31_SubsidiarySaleOfStockAxis-ATMAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">amix:ATMAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="d_2024-04-01_2025-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="d_2023-04-01_2024-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="d_2024-04-01_2025-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-ConvertibleDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="d_2023-04-01_2024-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-ConvertibleDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="d_2024-04-01_2025-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-ConvertibleNotesToWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">amix:ConvertibleNotesToWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="d_2023-04-01_2024-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-ConvertibleNotesToWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">amix:ConvertibleNotesToWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="d_2024-04-01_2025-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="d_2023-04-01_2024-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="d_2024-04-01_2025-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-SeriesAWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">amix:SeriesAWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="d_2023-04-01_2024-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-SeriesAWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">amix:SeriesAWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="d_2024-04-01_2025-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-RepresentativesWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">amix:RepresentativesWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="d_2023-04-01_2024-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-RepresentativesWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">amix:RepresentativesWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="i_2024-12-31_ClassOfWarrantOrRightAxis-EquitybasedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amix:EquitybasedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="d_2023-04-01_2024-03-31_RestatementAxis-ScenarioPreviouslyReportedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="d_2023-04-01_2024-03-31_RestatementAxis-ReverseStockSplitAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">amix:ReverseStockSplitAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="d_2023-04-01_2024-03-31_RestatementAxis-RevisionOfPriorPeriodErrorCorrectionAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="d_2023-04-01_2024-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember_RestatementAxis-ScenarioPreviouslyReportedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="d_2023-04-01_2024-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember_RestatementAxis-ReverseStockSplitAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">amix:ReverseStockSplitAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="d_2023-04-01_2024-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember_RestatementAxis-RevisionOfPriorPeriodErrorCorrectionAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="d_2023-04-01_2024-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-ConvertibleDebtSecuritiesMember_RestatementAxis-ScenarioPreviouslyReportedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="d_2023-04-01_2024-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-ConvertibleDebtSecuritiesMember_RestatementAxis-ReverseStockSplitAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">amix:ReverseStockSplitAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="d_2023-04-01_2024-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-ConvertibleDebtSecuritiesMember_RestatementAxis-RevisionOfPriorPeriodErrorCorrectionAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="d_2023-04-01_2024-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-ConvertibleNotesToWarrantsMember_RestatementAxis-ScenarioPreviouslyReportedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">amix:ConvertibleNotesToWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="d_2023-04-01_2024-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-ConvertibleNotesToWarrantsMember_RestatementAxis-ReverseStockSplitAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">amix:ReverseStockSplitAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">amix:ConvertibleNotesToWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="d_2023-04-01_2024-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-ConvertibleNotesToWarrantsMember_RestatementAxis-RevisionOfPriorPeriodErrorCorrectionAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">amix:ConvertibleNotesToWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="d_2023-04-01_2024-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember_RestatementAxis-ScenarioPreviouslyReportedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="d_2023-04-01_2024-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember_RestatementAxis-ReverseStockSplitAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">amix:ReverseStockSplitAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="d_2023-04-01_2024-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember_RestatementAxis-RevisionOfPriorPeriodErrorCorrectionAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="i_2025-03-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="i_2023-03-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByLiabilityClassAxis-WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="d_2023-04-01_2024-03-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByLiabilityClassAxis-WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="i_2024-03-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByLiabilityClassAxis-WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="i_2023-07-07_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_MeasurementInputTypeAxis-MeasurementInputDiscountRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-07</instant>
        </period>
    </context>
    <context id="i_2023-07-07_MeasurementInputTypeAxis-MeasurementInputProbabilityRateMember_StatementScenarioAxis-QualifiedOfferingOccurringOneMember_ValuationTechniqueAxis-ValuationProbabilityweightedExpectedReturnMethodPWERMMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">amix:QualifiedOfferingOccurringOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">amix:MeasurementInputProbabilityRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">amix:ValuationProbabilityweightedExpectedReturnMethodPWERMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-07</instant>
        </period>
    </context>
    <context id="i_2023-07-07_MeasurementInputTypeAxis-MeasurementInputProbabilityRateMember_StatementScenarioAxis-QualifiedOfferingOccurringTwoMember_ValuationTechniqueAxis-ValuationProbabilityweightedExpectedReturnMethodPWERMMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">amix:QualifiedOfferingOccurringTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">amix:MeasurementInputProbabilityRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">amix:ValuationProbabilityweightedExpectedReturnMethodPWERMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-07</instant>
        </period>
    </context>
    <context id="i_2023-07-07_MeasurementInputTypeAxis-MeasurementInputProbabilityRateMember_StatementScenarioAxis-NoQualifiedOfferingOccurringMember_ValuationTechniqueAxis-ValuationProbabilityweightedExpectedReturnMethodPWERMMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">amix:NoQualifiedOfferingOccurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">amix:MeasurementInputProbabilityRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">amix:ValuationProbabilityweightedExpectedReturnMethodPWERMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-07</instant>
        </period>
    </context>
    <context id="i_2023-07-07_MeasurementInputTypeAxis-MeasurementInputFixedPriceMember_RangeAxis-MinimumMember_ValuationTechniqueAxis-ValuationProbabilityweightedExpectedReturnMethodPWERMMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">amix:MeasurementInputFixedPriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">amix:ValuationProbabilityweightedExpectedReturnMethodPWERMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-07</instant>
        </period>
    </context>
    <context id="i_2023-07-07_MeasurementInputTypeAxis-MeasurementInputFixedPriceMember_RangeAxis-MaximumMember_ValuationTechniqueAxis-ValuationProbabilityweightedExpectedReturnMethodPWERMMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">amix:MeasurementInputFixedPriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">amix:ValuationProbabilityweightedExpectedReturnMethodPWERMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-07</instant>
        </period>
    </context>
    <context id="i_2023-07-07_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember_RangeAxis-MinimumMember_ValuationTechniqueAxis-ValuationProbabilityweightedExpectedReturnMethodPWERMMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">amix:ValuationProbabilityweightedExpectedReturnMethodPWERMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-07</instant>
        </period>
    </context>
    <context id="i_2023-07-07_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember_RangeAxis-MaximumMember_ValuationTechniqueAxis-ValuationProbabilityweightedExpectedReturnMethodPWERMMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">amix:ValuationProbabilityweightedExpectedReturnMethodPWERMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-07</instant>
        </period>
    </context>
    <context id="i_2023-12-31_MeasurementInputTypeAxis-MeasurementInputProbabilityRateMember_StatementScenarioAxis-QualifiedOfferingOccurringOneMember_ValuationTechniqueAxis-ValuationProbabilityweightedExpectedReturnMethodPWERMMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">amix:QualifiedOfferingOccurringOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">amix:MeasurementInputProbabilityRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">amix:ValuationProbabilityweightedExpectedReturnMethodPWERMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="i_2023-12-31_MeasurementInputTypeAxis-MeasurementInputProbabilityRateMember_StatementScenarioAxis-QualifiedOfferingOccurringTwoMember_ValuationTechniqueAxis-ValuationProbabilityweightedExpectedReturnMethodPWERMMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">amix:QualifiedOfferingOccurringTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">amix:MeasurementInputProbabilityRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">amix:ValuationProbabilityweightedExpectedReturnMethodPWERMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="i_2023-12-31_MeasurementInputTypeAxis-MeasurementInputProbabilityRateMember_StatementScenarioAxis-NoQualifiedOfferingOccurringMember_ValuationTechniqueAxis-ValuationProbabilityweightedExpectedReturnMethodPWERMMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">amix:NoQualifiedOfferingOccurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">amix:MeasurementInputProbabilityRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">amix:ValuationProbabilityweightedExpectedReturnMethodPWERMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="i_2023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="d_2023-07-07_2023-07-07_ClassOfWarrantOrRightAxis-TheWarrantMember_RelatedPartyTransactionAxis-TerminationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amix:TheWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">amix:TerminationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-07</startDate>
            <endDate>2023-07-07</endDate>
        </period>
    </context>
    <context id="i_2024-01-29_ClassOfWarrantOrRightAxis-TheWarrantMember_RelatedPartyTransactionAxis-TerminationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amix:TheWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">amix:TerminationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-29</instant>
        </period>
    </context>
    <context id="i_2023-09-09_DebtInstrumentAxis-TheNotesMember_RangeAxis-MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amix:TheNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-09</instant>
        </period>
    </context>
    <context id="i_2023-09-09_DebtInstrumentAxis-TheNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amix:TheNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-09</instant>
        </period>
    </context>
    <context id="i_2023-09-09_ClassOfWarrantOrRightAxis-BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amix:BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-09</instant>
        </period>
    </context>
    <context id="d_2023-09-09_2023-09-09_ClassOfWarrantOrRightAxis-BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amix:BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-09</startDate>
            <endDate>2023-09-09</endDate>
        </period>
    </context>
    <context id="d_2023-09-10_2024-03-31_DebtInstrumentAxis-TheNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amix:TheNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-10</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="i_2024-01-26_DebtInstrumentAxis-TheNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amix:TheNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-26</instant>
        </period>
    </context>
    <context id="i_2025-03-31_DebtInstrumentAxis-ConvertibleDebtWith499PercentBeneficialOwnershipLimitationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amix:ConvertibleDebtWith499PercentBeneficialOwnershipLimitationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="d_2024-04-01_2025-03-31_DebtInstrumentAxis-ConvertibleDebtWith499PercentBeneficialOwnershipLimitationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amix:ConvertibleDebtWith499PercentBeneficialOwnershipLimitationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="d_2024-04-01_2025-03-31_DebtConversionByUniqueDescriptionAxis-ConversionOfConvertibleNotesToCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">amix:ConversionOfConvertibleNotesToCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="i_2024-03-31_DebtInstrumentAxis-TheNotesMember_LongtermDebtTypeAxis-ConvertibleDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amix:TheNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="d_2024-04-01_2025-03-31_DebtInstrumentAxis-TheNotesMember_LongtermDebtTypeAxis-ConvertibleDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amix:TheNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="i_2025-03-31_DebtInstrumentAxis-TheNotesMember_LongtermDebtTypeAxis-ConvertibleDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amix:TheNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="i_2024-03-31_ClassOfWarrantOrRightAxis-BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amix:BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="i_2024-03-31_ClassOfWarrantOrRightAxis-BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amix:BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="i_2024-03-31_ClassOfWarrantOrRightAxis-BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amix:BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="i_2024-03-31_ClassOfWarrantOrRightAxis-BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amix:BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="i_2024-03-31_ClassOfWarrantOrRightAxis-BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember_MeasurementInputTypeAxis-MeasurementInputDiscountRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amix:BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="i_2023-12-31_ClassOfWarrantOrRightAxis-BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember_MeasurementInputTypeAxis-MeasurementInputDiscountForLackOfMarketabilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amix:BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountForLackOfMarketabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="d_2024-04-01_2025-03-31_DebtInstrumentAxis-TheNotesMember_RangeAxis-MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amix:TheNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="i_2023-11-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
        </entity>
        <period>
            <instant>2023-11-29</instant>
        </period>
    </context>
    <context id="d_2024-02-15_2024-02-15_AwardTypeAxis-RestrictedStockMember_TitleOfIndividualAxis-MarketingConsultantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">amix:MarketingConsultantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-15</startDate>
            <endDate>2024-02-15</endDate>
        </period>
    </context>
    <context id="i_2024-02-15_AwardTypeAxis-RestrictedStockMember_TitleOfIndividualAxis-MarketingConsultantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">amix:MarketingConsultantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-15</instant>
        </period>
    </context>
    <context id="d_2024-04-01_2025-03-31_AwardTypeAxis-RestrictedStockMember_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="d_2023-04-01_2024-03-31_AwardTypeAxis-RestrictedStockMember_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="d_2024-04-01_2025-03-31_AwardTypeAxis-RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="d_2023-04-01_2024-03-31_AwardTypeAxis-RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="i_2025-03-31_AwardTypeAxis-RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="i_2024-03-31_AwardTypeAxis-RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="i_2023-04-06_SubsidiarySaleOfStockAxis-PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-06</instant>
        </period>
    </context>
    <context id="i_2025-02-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
        </entity>
        <period>
            <instant>2025-02-28</instant>
        </period>
    </context>
    <context id="i_2023-06-30_PlanNameAxis-The2023StockPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">amix:The2023StockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="i_2025-03-31_PlanNameAxis-The2023StockPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">amix:The2023StockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="d_2023-08-01_2023-08-31_PlanNameAxis-The2023StockPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">amix:The2023StockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-01</startDate>
            <endDate>2023-08-31</endDate>
        </period>
    </context>
    <context id="d_2024-04-01_2024-04-01_PlanNameAxis-The2023StockPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">amix:The2023StockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-04-01</endDate>
        </period>
    </context>
    <context id="d_2025-04-01_2025-04-01_PlanNameAxis-The2023StockPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">amix:The2023StockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-04-01</endDate>
        </period>
    </context>
    <context id="i_2024-04-01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
        </entity>
        <period>
            <instant>2024-04-01</instant>
        </period>
    </context>
    <context id="d_2024-04-01_2025-03-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2023StockPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">amix:The2023StockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="i_2025-03-31_AwardTypeAxis-EmployeeStockOptionMember_ValuationTechniqueAxis-BlackscholesModelMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">amix:BlackscholesModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="i_2025-03-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MinimumMember_ValuationTechniqueAxis-BlackscholesModelMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">amix:BlackscholesModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="i_2025-03-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MaximumMember_ValuationTechniqueAxis-BlackscholesModelMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">amix:BlackscholesModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="d_2024-04-01_2025-03-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MinimumMember_ValuationTechniqueAxis-BlackscholesModelMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">amix:BlackscholesModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="d_2024-04-01_2025-03-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MaximumMember_ValuationTechniqueAxis-BlackscholesModelMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">amix:BlackscholesModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="d_2024-04-01_2025-03-31_AwardTypeAxis-EmployeeStockOptionMember_ValuationTechniqueAxis-BlackscholesModelMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">amix:BlackscholesModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="i_2025-03-31_AwardTypeAxis-EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="d_2024-04-01_2025-03-31_AwardTypeAxis-EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="d_2024-04-01_2025-03-31_AwardTypeAxis-EmployeeStockOptionMember_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="d_2024-04-01_2025-03-31_AwardTypeAxis-EmployeeStockOptionMember_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="i_2024-03-31_AwardTypeAxis-EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="d_2023-04-01_2024-03-31_AwardTypeAxis-EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="d_2023-04-01_2024-03-31_AwardTypeAxis-EmployeeStockOptionMember_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="d_2023-04-01_2024-03-31_AwardTypeAxis-EmployeeStockOptionMember_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="d_2024-07-10_2024-07-10_CounterpartyNameAxis-RfInnovationsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">amix:RfInnovationsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-10</startDate>
            <endDate>2024-07-10</endDate>
        </period>
    </context>
    <context id="i_2024-07-10_CounterpartyNameAxis-RfInnovationsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">amix:RfInnovationsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-10</instant>
        </period>
    </context>
    <context id="d_2024-10-01_2024-12-31_CounterpartyNameAxis-RfInnovationsIncMember_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">amix:RfInnovationsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-11-22_2024-11-25_ClassOfWarrantOrRightAxis-RepresentativesWarrantsMember_CounterpartyNameAxis-UnderwritersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">amix:UnderwritersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amix:RepresentativesWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-22</startDate>
            <endDate>2024-11-25</endDate>
        </period>
    </context>
    <context id="d_2024-11-22_2024-11-25_ClassOfWarrantOrRightAxis-RepresentativesWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amix:RepresentativesWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-22</startDate>
            <endDate>2024-11-25</endDate>
        </period>
    </context>
    <context id="i_2024-11-25_ClassOfWarrantOrRightAxis-RepresentativesWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amix:RepresentativesWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-25</instant>
        </period>
    </context>
    <context id="i_2024-11-25_ClassOfWarrantOrRightAxis-SeriesAWarrantsAndTheRepresentativesWarrantsMember_MeasurementInputTypeAxis-ValuationTechniqueDiscountedCashFlowMember_ValuationTechniqueAxis-BlackscholesModelMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amix:SeriesAWarrantsAndTheRepresentativesWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">amix:BlackscholesModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-25</instant>
        </period>
    </context>
    <context id="i_2024-11-25_ClassOfWarrantOrRightAxis-SeriesAWarrantsAndTheRepresentativesWarrantsMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember_ValuationTechniqueAxis-BlackscholesModelMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amix:SeriesAWarrantsAndTheRepresentativesWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">amix:BlackscholesModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-25</instant>
        </period>
    </context>
    <context id="i_2024-01-26_ClassOfWarrantOrRightAxis-EquitybasedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amix:EquitybasedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-26</instant>
        </period>
    </context>
    <context id="i_2024-01-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
        </entity>
        <period>
            <instant>2024-01-26</instant>
        </period>
    </context>
    <context id="i_2024-01-26_ClassOfWarrantOrRightAxis-EquitybasedWarrantsMember_MeasurementInputTypeAxis-MeasurementInputDiscountRateMember_ValuationTechniqueAxis-BlackscholesModelMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amix:EquitybasedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">amix:BlackscholesModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-26</instant>
        </period>
    </context>
    <context id="i_2024-01-26_ClassOfWarrantOrRightAxis-EquitybasedWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember_ValuationTechniqueAxis-BlackscholesModelMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amix:EquitybasedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">amix:BlackscholesModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-26</instant>
        </period>
    </context>
    <context id="i_2024-01-26_ClassOfWarrantOrRightAxis-EquitybasedWarrantsMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember_ValuationTechniqueAxis-BlackscholesModelMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amix:EquitybasedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">amix:BlackscholesModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-26</instant>
        </period>
    </context>
    <context id="d_2024-04-01_2025-03-31_ClassOfWarrantOrRightAxis-EquitybasedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amix:EquitybasedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="i_2025-03-31_AwardTypeAxis-WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="d_2024-04-01_2025-03-31_AwardTypeAxis-WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="i_2024-03-31_AwardTypeAxis-WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="d_2023-04-01_2024-03-31_AwardTypeAxis-WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="i_2024-03-31_AwardTypeAxis-WarrantMember_RangeAxis-MinimumMember_ValuationTechniqueAxis-BlackscholesModelMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">amix:BlackscholesModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="i_2024-03-31_AwardTypeAxis-WarrantMember_RangeAxis-MaximumMember_ValuationTechniqueAxis-BlackscholesModelMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">amix:BlackscholesModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="d_2023-04-01_2024-03-31_AwardTypeAxis-WarrantMember_RangeAxis-MinimumMember_ValuationTechniqueAxis-BlackscholesModelMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">amix:BlackscholesModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="d_2023-04-01_2024-03-31_AwardTypeAxis-WarrantMember_RangeAxis-MaximumMember_ValuationTechniqueAxis-BlackscholesModelMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">amix:BlackscholesModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="i_2025-03-31_LitigationStatusAxis-PendingLitigationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="d_2024-04-01_2025-03-31_RangeAxis-MinimumMember_TypeOfArrangementAxis-EmploymentContractsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:EmploymentContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="d_2024-04-01_2025-03-31_RangeAxis-MaximumMember_TypeOfArrangementAxis-EmploymentContractsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:EmploymentContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="d_2024-06-17_2024-06-17_TitleOfIndividualAxis-ChiefExecutiveOfficerMember_TypeOfArrangementAxis-EmploymentContractsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:EmploymentContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-17</startDate>
            <endDate>2024-06-17</endDate>
        </period>
    </context>
    <context id="d_2024-06-17_2024-06-17_AwardTypeAxis-InducementOptionsMember_TitleOfIndividualAxis-ChiefExecutiveOfficerMember_TypeOfArrangementAxis-EmploymentContractsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amix:InducementOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:EmploymentContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-17</startDate>
            <endDate>2024-06-17</endDate>
        </period>
    </context>
    <context id="d_2024-06-17_2024-06-17_AwardTypeAxis-InducementOptionsMember_TitleOfIndividualAxis-ChiefExecutiveOfficerMember_TypeOfArrangementAxis-EmploymentContractsMember_VestingAxis-ShareBasedCompensationAwardTrancheOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amix:InducementOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:EmploymentContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-17</startDate>
            <endDate>2024-06-17</endDate>
        </period>
    </context>
    <context id="d_2024-06-17_2024-06-17_StatementScenarioAxis-ScenarioContractTerminationMember_TitleOfIndividualAxis-ChiefExecutiveOfficerMember_TypeOfArrangementAxis-EmploymentContractsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">amix:ScenarioContractTerminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:EmploymentContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-17</startDate>
            <endDate>2024-06-17</endDate>
        </period>
    </context>
    <context id="d_2024-06-17_2024-06-17_StatementScenarioAxis-ScenarioContractTerminationWithoutCauseMember_TitleOfIndividualAxis-ChiefExecutiveOfficerMember_TypeOfArrangementAxis-EmploymentContractsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">amix:ScenarioContractTerminationWithoutCauseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:EmploymentContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-17</startDate>
            <endDate>2024-06-17</endDate>
        </period>
    </context>
    <context id="d_2024-06-17_2024-06-17_TitleOfIndividualAxis-ExecutiveViceChairAndStrategicAdvisorToTheChiefExecutiveOfficerMember_TypeOfArrangementAxis-EmploymentContractsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">amix:ExecutiveViceChairAndStrategicAdvisorToTheChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:EmploymentContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-17</startDate>
            <endDate>2024-06-17</endDate>
        </period>
    </context>
    <context id="i_2024-11-01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
        </entity>
        <period>
            <instant>2024-11-01</instant>
        </period>
    </context>
    <context id="d_2024-04-01_2025-03-31_RangeAxis-MaximumMember_RelatedPartyTransactionAxis-AccountingAndFinancialReportingServicesMember_RelatedPartyTransactionsByRelatedPartyAxis-ConsultingFirmOwnedByFormerCFOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">amix:AccountingAndFinancialReportingServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">amix:ConsultingFirmOwnedByFormerCFOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="i_2025-03-31_RelatedPartyTransactionAxis-AccountingAndFinancialReportingServicesMember_RelatedPartyTransactionsByRelatedPartyAxis-ConsultingFirmOwnedByFormerCFOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">amix:AccountingAndFinancialReportingServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">amix:ConsultingFirmOwnedByFormerCFOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="i_2024-03-31_RelatedPartyTransactionAxis-AccountingAndFinancialReportingServicesMember_RelatedPartyTransactionsByRelatedPartyAxis-ConsultingFirmOwnedByFormerCFOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">amix:AccountingAndFinancialReportingServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">amix:ConsultingFirmOwnedByFormerCFOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="d_2024-04-01_2025-03-31_DebtInstrumentAxis-TheBridgeOfferingMember_RelatedPartyTransactionsByRelatedPartyAxis-ManagementBoardOfDirectorFamilyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amix:TheBridgeOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">amix:ManagementBoardOfDirectorFamilyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="d_2024-04-01_2025-03-31_DebtInstrumentAxis-TheBridgeOfferingMember_RelatedPartyTransactionsByRelatedPartyAxis-ManagementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amix:TheBridgeOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="d_2024-04-01_2025-03-31_DebtInstrumentAxis-TheBridgeOfferingMember_RelatedPartyTransactionsByRelatedPartyAxis-RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amix:TheBridgeOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="i_2023-07-07_ClassOfWarrantOrRightAxis-TheWarrantMember_RelatedPartyTransactionAxis-TerminationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amix:TheWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">amix:TerminationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-07</instant>
        </period>
    </context>
    <context id="d_2023-07-07_2023-07-07_ClassOfWarrantOrRightAxis-TheWarrantMember_RelatedPartyTransactionAxis-TerminationAgreementMember_UnderlyingAssetClassAxis-CommonStock6MonthsLockupPeriodMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amix:TheWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">amix:TerminationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:UnderlyingAssetClassAxis">amix:CommonStock6MonthsLockupPeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-07</startDate>
            <endDate>2023-07-07</endDate>
        </period>
    </context>
    <context id="d_2023-07-07_2023-07-07_ClassOfWarrantOrRightAxis-TheWarrantMember_RelatedPartyTransactionAxis-TerminationAgreementMember_UnderlyingAssetClassAxis-CommonStock12MonthsLockupPeriodMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amix:TheWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">amix:TerminationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:UnderlyingAssetClassAxis">amix:CommonStock12MonthsLockupPeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-07</startDate>
            <endDate>2023-07-07</endDate>
        </period>
    </context>
    <context id="i_2025-03-31_TaxPeriodAxis-ExpirationCommencingTaxYear20342037Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">amix:ExpirationCommencingTaxYear20342037Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="i_2025-03-31_TaxPeriodAxis-NolGeneratedDuring20172024Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">amix:NolGeneratedDuring20172024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="d_2025-04-01_2025-05-28_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-ATMAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">amix:ATMAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-05-28</endDate>
        </period>
    </context>
    <context id="d_2025-04-17_2025-04-17_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_SubsequentEventTypeAxis-SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-17</startDate>
            <endDate>2025-04-17</endDate>
        </period>
    </context>
    <context id="d_2025-04-17_2025-04-17_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_SubsequentEventTypeAxis-SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-17</startDate>
            <endDate>2025-04-17</endDate>
        </period>
    </context>
    <context id="d_2025-04-17_2025-04-17_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_SubsequentEventTypeAxis-SubsequentEventMember_VestingAxis-ShareBasedCompensationAwardTrancheOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-17</startDate>
            <endDate>2025-04-17</endDate>
        </period>
    </context>
    <context id="i_2025-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="d_2024-04-01_2024-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="i_2024-06-30_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="i_2024-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="i_2024-06-30_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="i_2024-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="i_2025-06-30_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="i_2025-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="i_2025-06-30_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="d_2025-04-01_2025-06-30_SubsidiarySaleOfStockAxis-PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="d_2024-04-01_2024-06-30_SubsidiarySaleOfStockAxis-PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2025-04-01_2025-06-30_SubsidiarySaleOfStockAxis-ATMAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">amix:ATMAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="d_2025-04-01_2025-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="d_2024-04-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2025-04-01_2025-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-ConvertibleDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="d_2024-04-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-ConvertibleDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2025-04-01_2025-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-ConvertibleNotesToWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">amix:ConvertibleNotesToWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="d_2024-04-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-ConvertibleNotesToWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">amix:ConvertibleNotesToWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2025-04-01_2025-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="d_2024-04-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2025-04-01_2025-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-SeriesAWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">amix:SeriesAWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="d_2024-04-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-SeriesAWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">amix:SeriesAWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2025-04-01_2025-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-RepresentativesWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">amix:RepresentativesWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="d_2024-04-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-RepresentativesWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">amix:RepresentativesWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2024-04-01_2024-06-30_RestatementAxis-ScenarioPreviouslyReportedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2024-04-01_2024-06-30_RestatementAxis-ReverseStockSplitAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">amix:ReverseStockSplitAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2024-04-01_2024-06-30_RestatementAxis-RevisionOfPriorPeriodErrorCorrectionAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2024-04-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember_RestatementAxis-ScenarioPreviouslyReportedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2024-04-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember_RestatementAxis-ReverseStockSplitAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">amix:ReverseStockSplitAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2024-04-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember_RestatementAxis-RevisionOfPriorPeriodErrorCorrectionAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2024-04-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-ConvertibleDebtSecuritiesMember_RestatementAxis-ScenarioPreviouslyReportedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2024-04-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-ConvertibleDebtSecuritiesMember_RestatementAxis-ReverseStockSplitAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">amix:ReverseStockSplitAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2024-04-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-ConvertibleDebtSecuritiesMember_RestatementAxis-RevisionOfPriorPeriodErrorCorrectionAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2024-04-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-ConvertibleNotesToWarrantsMember_RestatementAxis-ScenarioPreviouslyReportedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">amix:ConvertibleNotesToWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2024-04-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-ConvertibleNotesToWarrantsMember_RestatementAxis-ReverseStockSplitAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">amix:ReverseStockSplitAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">amix:ConvertibleNotesToWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2024-04-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-ConvertibleNotesToWarrantsMember_RestatementAxis-RevisionOfPriorPeriodErrorCorrectionAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">amix:ConvertibleNotesToWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2024-04-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember_RestatementAxis-ScenarioPreviouslyReportedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2024-04-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember_RestatementAxis-ReverseStockSplitAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">amix:ReverseStockSplitAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2024-04-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember_RestatementAxis-RevisionOfPriorPeriodErrorCorrectionAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2023-09-09_2024-03-31_DebtInstrumentAxis-TheNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amix:TheNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-09</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="i_2025-06-30_DebtInstrumentAxis-ConvertibleDebtWith499PercentBeneficialOwnershipLimitationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amix:ConvertibleDebtWith499PercentBeneficialOwnershipLimitationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="d_2024-01-26_2024-01-26_DebtConversionByUniqueDescriptionAxis-ConversionOfConvertibleNotesToCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">amix:ConversionOfConvertibleNotesToCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-26</startDate>
            <endDate>2024-01-26</endDate>
        </period>
    </context>
    <context id="d_2025-03-28_2025-03-28_DebtInstrumentAxis-ConvertibleDebtWith499PercentBeneficialOwnershipLimitationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amix:ConvertibleDebtWith499PercentBeneficialOwnershipLimitationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-28</startDate>
            <endDate>2025-03-28</endDate>
        </period>
    </context>
    <context id="d_2025-04-01_2025-06-30_DebtInstrumentAxis-TheNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amix:TheNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="d_2024-04-01_2024-06-30_DebtInstrumentAxis-TheNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amix:TheNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2025-04-01_2025-06-30_AwardTypeAxis-RestrictedStockMember_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="d_2024-04-01_2024-06-30_AwardTypeAxis-RestrictedStockMember_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2025-04-01_2025-06-30_AwardTypeAxis-RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="d_2024-04-01_2024-06-30_AwardTypeAxis-RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="i_2025-06-30_AwardTypeAxis-RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="d_2025-04-01_2025-06-30_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2023StockPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">amix:The2023StockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="i_2025-06-30_AwardTypeAxis-EmployeeStockOptionMember_ValuationTechniqueAxis-BlackscholesModelMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">amix:BlackscholesModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="d_2025-04-01_2025-06-30_AwardTypeAxis-EmployeeStockOptionMember_ValuationTechniqueAxis-BlackscholesModelMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">amix:BlackscholesModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="i_2025-06-30_AwardTypeAxis-EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="d_2025-04-01_2025-06-30_AwardTypeAxis-EmployeeStockOptionMember_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="d_2025-04-01_2025-06-30_AwardTypeAxis-EmployeeStockOptionMember_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="d_2024-04-01_2024-06-30_AwardTypeAxis-EmployeeStockOptionMember_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="d_2024-04-01_2024-06-30_AwardTypeAxis-EmployeeStockOptionMember_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="i_2025-06-30_ClassOfWarrantOrRightAxis-SeriesAWarrantsAndTheRepresentativesWarrantsMember_MeasurementInputTypeAxis-MeasurementInputDiscountRateMember_ValuationTechniqueAxis-BlackscholesModelMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amix:SeriesAWarrantsAndTheRepresentativesWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">amix:BlackscholesModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="i_2025-06-30_ClassOfWarrantOrRightAxis-SeriesAWarrantsAndTheRepresentativesWarrantsMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember_ValuationTechniqueAxis-BlackscholesModelMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amix:SeriesAWarrantsAndTheRepresentativesWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">amix:BlackscholesModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="i_2025-06-30_ClassOfWarrantOrRightAxis-CommonWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amix:CommonWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="i_2025-06-30_ClassOfWarrantOrRightAxis-RepresentativesWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amix:RepresentativesWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="i_2025-06-30_ClassOfWarrantOrRightAxis-SeriesAWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amix:SeriesAWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="i_2025-06-30_AwardTypeAxis-WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="d_2025-04-01_2025-06-30_AwardTypeAxis-WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="d_2024-04-01_2024-06-30_AwardTypeAxis-WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="i_2025-06-30_LitigationStatusAxis-PendingLitigationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="d_2025-04-01_2025-06-30_RangeAxis-MinimumMember_TypeOfArrangementAxis-EmploymentContractsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:EmploymentContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="d_2025-04-01_2025-06-30_RangeAxis-MaximumMember_TypeOfArrangementAxis-EmploymentContractsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:EmploymentContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="i_2025-07-21_ClassOfWarrantOrRightAxis-ExistingWarrantsMember_SubsequentEventTypeAxis-SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amix:ExistingWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-21</instant>
        </period>
    </context>
    <context id="i_2025-07-21_ClassOfWarrantOrRightAxis-ExistingWarrantsAt1723ExercisePriceMember_SubsequentEventTypeAxis-SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amix:ExistingWarrantsAt1723ExercisePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-21</instant>
        </period>
    </context>
    <context id="d_2025-07-21_2025-07-21_ClassOfWarrantOrRightAxis-ExistingWarrantsAt1723ExercisePriceMember_SubsequentEventTypeAxis-SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amix:ExistingWarrantsAt1723ExercisePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-21</startDate>
            <endDate>2025-07-21</endDate>
        </period>
    </context>
    <context id="i_2025-07-21_ClassOfWarrantOrRightAxis-ExistingWarrantsAt1722ExercisePriceMember_SubsequentEventTypeAxis-SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amix:ExistingWarrantsAt1722ExercisePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-21</instant>
        </period>
    </context>
    <context id="i_2025-07-21_SubsequentEventTypeAxis-SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-21</instant>
        </period>
    </context>
    <context id="i_2025-07-21_ClassOfWarrantOrRightAxis-SeriesBWarrantsMember_SubsequentEventTypeAxis-SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amix:SeriesBWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-21</instant>
        </period>
    </context>
    <context id="i_2025-07-21_ClassOfWarrantOrRightAxis-RepresentativesWarrantsMember_SubsequentEventTypeAxis-SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amix:RepresentativesWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-21</instant>
        </period>
    </context>
    <context id="d_2025-07-21_2025-07-21_ClassOfWarrantOrRightAxis-ExistingWarrantsMember_SubsequentEventTypeAxis-SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amix:ExistingWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-21</startDate>
            <endDate>2025-07-21</endDate>
        </period>
    </context>
    <context id="i_2025-07-01_ClassOfWarrantOrRightAxis-SeriesAWarrantsMember_SubsequentEventTypeAxis-SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amix:SeriesAWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-01</instant>
        </period>
    </context>
    <context id="d_2025-07-01_2025-07-31_ClassOfWarrantOrRightAxis-SeriesAWarrantsMember_SubsequentEventTypeAxis-SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amix:SeriesAWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-07-31</endDate>
        </period>
    </context>
    <context id="i_2025-07-31_ClassOfWarrantOrRightAxis-SeriesAWarrantsMember_SubsequentEventTypeAxis-SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amix:SeriesAWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-31</instant>
        </period>
    </context>
    <context id="d_2025-08-05_2025-08-05_ClassOfWarrantOrRightAxis-PreipoWarrantsMember_SubsequentEventTypeAxis-SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amix:PreipoWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-08-05</startDate>
            <endDate>2025-08-05</endDate>
        </period>
    </context>
    <context id="d_2025-07-01_2025-07-31_SubsequentEventTypeAxis-SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-07-31</endDate>
        </period>
    </context>
    <context id="d_2025-08-11_2025-08-11_SubsequentEventTypeAxis-SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-08-11</startDate>
            <endDate>2025-08-11</endDate>
        </period>
    </context>
    <context id="d_2025-08-11_2025-08-11_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-08-11</startDate>
            <endDate>2025-08-11</endDate>
        </period>
    </context>
    <context id="d_2025-08-11_2025-08-11_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-ExecutiveChairOfTheBoardMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">amix:ExecutiveChairOfTheBoardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-08-11</startDate>
            <endDate>2025-08-11</endDate>
        </period>
    </context>
    <context id="d_2025-08-11_2025-08-11_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-08-11</startDate>
            <endDate>2025-08-11</endDate>
        </period>
    </context>
    <context id="d_2025-08-11_2025-08-11_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-ChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-08-11</startDate>
            <endDate>2025-08-11</endDate>
        </period>
    </context>
    <context id="d_2025-08-11_2025-08-11_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-ChiefTechnologyOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">amix:ChiefTechnologyOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-08-11</startDate>
            <endDate>2025-08-11</endDate>
        </period>
    </context>
    <context id="d_2025-08-11_2025-08-11_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-ChiefMedicalOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">amix:ChiefMedicalOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-08-11</startDate>
            <endDate>2025-08-11</endDate>
        </period>
    </context>
    <context id="d_2025-08-11_2025-08-11_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-ChiefFinancialOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-08-11</startDate>
            <endDate>2025-08-11</endDate>
        </period>
    </context>
    <context id="d_2024-04-01_2025-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001617867</identifier>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <unit id="NonApplicable">
        <measure>thunderdome:item</measure>
    </unit>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="USDPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Share">
        <measure>shares</measure>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="Day">
        <measure>utr:D</measure>
    </unit>
    <unit id="Year">
        <measure>utr:Y</measure>
    </unit>
    <unit id="Month">
        <measure>utr:M</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="d_2025-04-01_2025-06-30"
      id="thunderdome-EntityCentralIndexKey">0001617867</dei:EntityCentralIndexKey>
    <dei:EntityRegistrantName
      contextRef="d_2025-04-01_2025-06-30"
      id="thunderdome-EntityRegistrantName">Autonomix Medical, Inc.</dei:EntityRegistrantName>
    <dei:AmendmentFlag contextRef="d_2025-04-01_2025-06-30" id="ixv-16476">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="d_2025-04-01_2025-06-30"
      id="val1759590397299768">424B3</dei:DocumentType>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i_2025-03-31"
      id="c134565227"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i_2024-03-31"
      id="c134565228"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i_2025-03-31"
      decimals="INF"
      id="c134565133"
      unitRef="USDPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i_2024-03-31"
      decimals="INF"
      id="c134565134"
      unitRef="USDPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i_2025-03-31"
      decimals="INF"
      id="c134565135"
      unitRef="Share">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i_2024-03-31"
      decimals="INF"
      id="c134565136"
      unitRef="Share">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i_2025-03-31"
      decimals="-3"
      id="c134565137"
      unitRef="Share">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i_2025-03-31"
      decimals="-3"
      id="c134565139"
      unitRef="Share">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i_2024-03-31"
      decimals="-3"
      id="c134565138"
      unitRef="Share">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i_2024-03-31"
      decimals="-3"
      id="c134565140"
      unitRef="Share">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i_2025-03-31"
      decimals="INF"
      id="c134565141"
      unitRef="USDPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i_2024-03-31"
      decimals="INF"
      id="c134565142"
      unitRef="USDPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i_2025-03-31"
      decimals="INF"
      id="c134565143"
      unitRef="Share">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i_2024-03-31"
      decimals="INF"
      id="c134565144"
      unitRef="Share">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i_2025-03-31"
      decimals="INF"
      id="c134565145"
      unitRef="Share">2497033</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i_2025-03-31"
      decimals="INF"
      id="c134565147"
      unitRef="Share">2497033</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i_2024-03-31"
      decimals="INF"
      id="c134565146"
      unitRef="Share">942575</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i_2024-03-31"
      decimals="INF"
      id="c134565148"
      unitRef="Share">942575</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="d_2024-10-24_2024-10-24_NonmonetaryTransactionTypeAxis-ReverseStockSplitMember"
      decimals="INF"
      id="c134564311"
      unitRef="Pure">20</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="d_2024-10-24_2024-10-24_NonmonetaryTransactionTypeAxis-ReverseStockSplitMember"
      decimals="INF"
      id="c134564315"
      unitRef="Pure">20</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:Revenues
      contextRef="d_2023-04-01_2024-03-31"
      decimals="-3"
      id="c134565165"
      unitRef="USD">0</us-gaap:Revenues>
    <amix:NumberOfSharesPerCommonUnit
      contextRef="i_2024-11-25_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember"
      decimals="INF"
      id="c134564342"
      unitRef="Share">1</amix:NumberOfSharesPerCommonUnit>
    <amix:NumberOfWarrantsPerCommonUnit
      contextRef="i_2024-11-25_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember"
      decimals="INF"
      id="c134564343"
      unitRef="Share">1</amix:NumberOfWarrantsPerCommonUnit>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="i_2024-11-25_ClassOfWarrantOrRightAxis-SeriesAWarrantsMember"
      decimals="INF"
      id="c134564344"
      unitRef="Share">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <amix:NumberOfWarrantsPerPrefundedUnit
      contextRef="i_2024-11-25_ClassOfWarrantOrRightAxis-PrefundedWarrantsMember"
      decimals="INF"
      id="c134564346"
      unitRef="Share">1</amix:NumberOfWarrantsPerPrefundedUnit>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="i_2024-11-25_ClassOfWarrantOrRightAxis-PrefundedWarrantsMember"
      decimals="INF"
      id="c134564347"
      unitRef="Share">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <amix:NumberOfWarrantsPerPrefundedUnit
      contextRef="i_2024-11-25_ClassOfWarrantOrRightAxis-SeriesAWarrantsMember"
      decimals="INF"
      id="c134564348"
      unitRef="Share">1</amix:NumberOfWarrantsPerPrefundedUnit>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i_2024-11-25_ClassOfWarrantOrRightAxis-SeriesAWarrantsMember"
      id="c134564356">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="i_2025-03-31" id="c134564384">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:LiabilityForUncertainTaxPositionsCurrent
      contextRef="i_2024-03-31"
      decimals="-3"
      id="c134565166"
      unitRef="USD">0</us-gaap:LiabilityForUncertainTaxPositionsCurrent>
    <us-gaap:NumberOfReportableSegments
      contextRef="d_2024-04-01_2025-03-31"
      decimals="INF"
      id="c134564434"
      unitRef="Pure">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:NumberOfOperatingSegments
      contextRef="d_2024-04-01_2025-03-31"
      decimals="INF"
      id="c134564463"
      unitRef="Pure">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:PercentageOfFIFOInventory
      contextRef="i_2023-07-07_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_MeasurementInputTypeAxis-MeasurementInputDiscountRateMember"
      decimals="1"
      id="c134565294"
      unitRef="Pure">0.20</us-gaap:PercentageOfFIFOInventory>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2023-07-07_MeasurementInputTypeAxis-MeasurementInputProbabilityRateMember_StatementScenarioAxis-QualifiedOfferingOccurringOneMember_ValuationTechniqueAxis-ValuationProbabilityweightedExpectedReturnMethodPWERMMember"
      decimals="1"
      id="c134565295"
      unitRef="Pure">0.70</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2023-07-07_MeasurementInputTypeAxis-MeasurementInputProbabilityRateMember_StatementScenarioAxis-QualifiedOfferingOccurringTwoMember_ValuationTechniqueAxis-ValuationProbabilityweightedExpectedReturnMethodPWERMMember"
      decimals="1"
      id="c134565296"
      unitRef="Pure">0.10</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2023-07-07_MeasurementInputTypeAxis-MeasurementInputProbabilityRateMember_StatementScenarioAxis-NoQualifiedOfferingOccurringMember_ValuationTechniqueAxis-ValuationProbabilityweightedExpectedReturnMethodPWERMMember"
      decimals="1"
      id="c134565297"
      unitRef="Pure">0.20</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2023-07-07_MeasurementInputTypeAxis-MeasurementInputFixedPriceMember_RangeAxis-MinimumMember_ValuationTechniqueAxis-ValuationProbabilityweightedExpectedReturnMethodPWERMMember"
      decimals="-3"
      id="c134565299"
      unitRef="Pure">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2023-07-07_MeasurementInputTypeAxis-MeasurementInputFixedPriceMember_RangeAxis-MaximumMember_ValuationTechniqueAxis-ValuationProbabilityweightedExpectedReturnMethodPWERMMember"
      decimals="INF"
      id="c134565300"
      unitRef="Pure">8000000</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2023-07-07_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember_RangeAxis-MinimumMember_ValuationTechniqueAxis-ValuationProbabilityweightedExpectedReturnMethodPWERMMember"
      decimals="INF"
      id="c134565302"
      unitRef="Pure">0.48</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2023-07-07_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember_RangeAxis-MaximumMember_ValuationTechniqueAxis-ValuationProbabilityweightedExpectedReturnMethodPWERMMember"
      decimals="INF"
      id="c134565303"
      unitRef="Pure">0.98</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2023-12-31_MeasurementInputTypeAxis-MeasurementInputProbabilityRateMember_StatementScenarioAxis-QualifiedOfferingOccurringTwoMember_ValuationTechniqueAxis-ValuationProbabilityweightedExpectedReturnMethodPWERMMember"
      decimals="1"
      id="c134564500"
      unitRef="Pure">0.10</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2023-12-31_MeasurementInputTypeAxis-MeasurementInputProbabilityRateMember_StatementScenarioAxis-NoQualifiedOfferingOccurringMember_ValuationTechniqueAxis-ValuationProbabilityweightedExpectedReturnMethodPWERMMember"
      decimals="1"
      id="c134564502"
      unitRef="Pure">0.20</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i_2023-09-09_ClassOfWarrantOrRightAxis-BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember"
      id="c134564513">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i_2023-11-29"
      decimals="INF"
      id="c134564542"
      unitRef="USDPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i_2023-11-29"
      decimals="INF"
      id="c134564544"
      unitRef="USDPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="d_2023-04-01_2024-03-31_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="-3"
      id="c134564555"
      unitRef="USD">0</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="d_2024-04-01_2025-03-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2023StockPlanMember"
      id="c134564574">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="d_2024-04-01_2025-03-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2023StockPlanMember"
      id="c134564575">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <amix:NumberOfSharesPerCommonUnit
      contextRef="i_2024-11-25_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember"
      decimals="INF"
      id="c134564614"
      unitRef="Share">1</amix:NumberOfSharesPerCommonUnit>
    <amix:NumberOfWarrantsPerCommonUnit
      contextRef="i_2024-11-25_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember"
      decimals="INF"
      id="c134564616"
      unitRef="Share">1</amix:NumberOfWarrantsPerCommonUnit>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="i_2024-11-25_ClassOfWarrantOrRightAxis-SeriesAWarrantsMember"
      decimals="INF"
      id="c134564617"
      unitRef="Share">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <amix:NumberOfWarrantsPerPrefundedUnit
      contextRef="i_2024-11-25_ClassOfWarrantOrRightAxis-PrefundedWarrantsMember"
      decimals="INF"
      id="c134564619"
      unitRef="Share">1</amix:NumberOfWarrantsPerPrefundedUnit>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="i_2024-11-25_ClassOfWarrantOrRightAxis-PrefundedWarrantsMember"
      decimals="INF"
      id="c134564620"
      unitRef="Share">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <amix:NumberOfWarrantsPerPrefundedUnit
      contextRef="i_2024-11-25_ClassOfWarrantOrRightAxis-SeriesAWarrantsMember"
      decimals="INF"
      id="c134564621"
      unitRef="Share">1</amix:NumberOfWarrantsPerPrefundedUnit>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i_2024-11-25_ClassOfWarrantOrRightAxis-SeriesAWarrantsMember"
      id="c134564635">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i_2024-01-26_ClassOfWarrantOrRightAxis-EquitybasedWarrantsMember"
      id="c134564655">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <amix:ClassOfWarrantOrRightExercisedInPeriodCashless
      contextRef="d_2024-04-01_2025-03-31_ClassOfWarrantOrRightAxis-EquitybasedWarrantsMember"
      decimals="INF"
      id="c134564667"
      unitRef="Share">197098</amix:ClassOfWarrantOrRightExercisedInPeriodCashless>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i_2024-03-31_AwardTypeAxis-WarrantMember"
      decimals="-5"
      id="c134564671"
      unitRef="USD">100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i_2025-03-31_LitigationStatusAxis-PendingLitigationMember"
      decimals="-3"
      id="c134564674"
      unitRef="Pure">0</us-gaap:LossContingencyPendingClaimsNumber>
    <amix:EmploymentAgreementTermOfContract
      contextRef="d_2024-06-17_2024-06-17_TitleOfIndividualAxis-ChiefExecutiveOfficerMember_TypeOfArrangementAxis-EmploymentContractsMember"
      id="c134564678">P3Y</amix:EmploymentAgreementTermOfContract>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="d_2024-06-17_2024-06-17_AwardTypeAxis-InducementOptionsMember_TitleOfIndividualAxis-ChiefExecutiveOfficerMember_TypeOfArrangementAxis-EmploymentContractsMember"
      id="c134564681">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <amix:EmploymentAgreementTermOfContract
      contextRef="d_2024-06-17_2024-06-17_TitleOfIndividualAxis-ExecutiveViceChairAndStrategicAdvisorToTheChiefExecutiveOfficerMember_TypeOfArrangementAxis-EmploymentContractsMember"
      id="c134564696">P2Y</amix:EmploymentAgreementTermOfContract>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i_2023-07-07_ClassOfWarrantOrRightAxis-TheWarrantMember_RelatedPartyTransactionAxis-TerminationAgreementMember"
      id="c134564722">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <amix:ClassOfWarrantOrRightLockupAgreementTermOfUnderlyingShares
      contextRef="d_2023-07-07_2023-07-07_ClassOfWarrantOrRightAxis-TheWarrantMember_RelatedPartyTransactionAxis-TerminationAgreementMember_UnderlyingAssetClassAxis-CommonStock6MonthsLockupPeriodMember"
      id="c134564724">P6M</amix:ClassOfWarrantOrRightLockupAgreementTermOfUnderlyingShares>
    <amix:ClassOfWarrantOrRightLockupAgreementTermOfUnderlyingShares
      contextRef="d_2023-07-07_2023-07-07_ClassOfWarrantOrRightAxis-TheWarrantMember_RelatedPartyTransactionAxis-TerminationAgreementMember_UnderlyingAssetClassAxis-CommonStock12MonthsLockupPeriodMember"
      id="c134564726">P12M</amix:ClassOfWarrantOrRightLockupAgreementTermOfUnderlyingShares>
    <amix:ReserveForUncertainTaxPositions
      contextRef="i_2025-03-31"
      decimals="-3"
      id="c134564749"
      unitRef="USD">0</amix:ReserveForUncertainTaxPositions>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="d_2025-04-17_2025-04-17_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_SubsequentEventTypeAxis-SubsequentEventMember"
      id="c134564760">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i_2025-06-30"
      id="c134565269"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i_2025-03-31"
      id="c134565270"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i_2025-06-30"
      decimals="INF"
      id="c134565149"
      unitRef="USDPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i_2025-03-31"
      decimals="INF"
      id="c134565150"
      unitRef="USDPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i_2025-06-30"
      decimals="INF"
      id="c134565151"
      unitRef="Share">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i_2025-03-31"
      decimals="INF"
      id="c134565152"
      unitRef="Share">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i_2025-06-30"
      decimals="-3"
      id="c134565153"
      unitRef="Share">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i_2025-06-30"
      decimals="-3"
      id="c134565155"
      unitRef="Share">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i_2025-03-31"
      decimals="-3"
      id="c134565154"
      unitRef="Share">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i_2025-03-31"
      decimals="-3"
      id="c134565156"
      unitRef="Share">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i_2025-06-30"
      decimals="INF"
      id="c134565157"
      unitRef="USDPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i_2025-03-31"
      decimals="INF"
      id="c134565158"
      unitRef="USDPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i_2025-06-30"
      decimals="INF"
      id="c134565159"
      unitRef="Share">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i_2025-03-31"
      decimals="INF"
      id="c134565160"
      unitRef="Share">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i_2025-06-30"
      decimals="INF"
      id="c134565161"
      unitRef="Share">4022625</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i_2025-06-30"
      decimals="INF"
      id="c134565163"
      unitRef="Share">4022625</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i_2025-03-31"
      decimals="INF"
      id="c134565162"
      unitRef="Share">2497033</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i_2025-03-31"
      decimals="INF"
      id="c134565164"
      unitRef="Share">2497033</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="d_2024-10-24_2024-10-24_NonmonetaryTransactionTypeAxis-ReverseStockSplitMember"
      decimals="INF"
      id="c134564773"
      unitRef="Pure">20</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="d_2024-10-24_2024-10-24_NonmonetaryTransactionTypeAxis-ReverseStockSplitMember"
      decimals="INF"
      id="c134564777"
      unitRef="Pure">20</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <amix:NumberOfSharesPerCommonUnit
      contextRef="i_2024-11-25_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember"
      decimals="INF"
      id="c134564791"
      unitRef="Share">1</amix:NumberOfSharesPerCommonUnit>
    <amix:NumberOfWarrantsPerCommonUnit
      contextRef="i_2024-11-25_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember"
      decimals="INF"
      id="c134564792"
      unitRef="Share">1</amix:NumberOfWarrantsPerCommonUnit>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="i_2024-11-25_ClassOfWarrantOrRightAxis-SeriesAWarrantsMember"
      decimals="INF"
      id="c134564793"
      unitRef="Share">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <amix:NumberOfWarrantsPerPrefundedUnit
      contextRef="i_2024-11-25_ClassOfWarrantOrRightAxis-PrefundedWarrantsMember"
      decimals="INF"
      id="c134564795"
      unitRef="Share">1</amix:NumberOfWarrantsPerPrefundedUnit>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="i_2024-11-25_ClassOfWarrantOrRightAxis-PrefundedWarrantsMember"
      decimals="INF"
      id="c134564796"
      unitRef="Share">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <amix:NumberOfWarrantsPerPrefundedUnit
      contextRef="i_2024-11-25_ClassOfWarrantOrRightAxis-SeriesAWarrantsMember"
      decimals="INF"
      id="c134564797"
      unitRef="Share">1</amix:NumberOfWarrantsPerPrefundedUnit>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i_2024-11-25_ClassOfWarrantOrRightAxis-SeriesAWarrantsMember"
      id="c134564805">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:Revenues
      contextRef="d_2024-04-01_2024-06-30"
      decimals="-3"
      id="c134565170"
      unitRef="USD">0</us-gaap:Revenues>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="i_2025-06-30" id="c134564843">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:LiabilityForUncertainTaxPositionsCurrent
      contextRef="i_2025-03-31"
      decimals="-3"
      id="c134565171"
      unitRef="USD">0</us-gaap:LiabilityForUncertainTaxPositionsCurrent>
    <us-gaap:NumberOfReportableSegments
      contextRef="d_2025-04-01_2025-06-30"
      decimals="INF"
      id="c134564899"
      unitRef="Pure">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i_2023-09-09_ClassOfWarrantOrRightAxis-BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember"
      id="c134564938">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="d_2025-04-01_2025-06-30_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2023StockPlanMember"
      id="c134564987">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <amix:NumberOfSharesPerCommonUnit
      contextRef="i_2024-11-25_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember"
      decimals="INF"
      id="c134565018"
      unitRef="Share">1</amix:NumberOfSharesPerCommonUnit>
    <amix:NumberOfWarrantsPerCommonUnit
      contextRef="i_2024-11-25_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember"
      decimals="INF"
      id="c134565019"
      unitRef="Share">1</amix:NumberOfWarrantsPerCommonUnit>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="i_2024-11-25_ClassOfWarrantOrRightAxis-SeriesAWarrantsMember"
      decimals="INF"
      id="c134565020"
      unitRef="Share">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <amix:NumberOfWarrantsPerPrefundedUnit
      contextRef="i_2024-11-25_ClassOfWarrantOrRightAxis-PrefundedWarrantsMember"
      decimals="INF"
      id="c134565022"
      unitRef="Share">1</amix:NumberOfWarrantsPerPrefundedUnit>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="i_2024-11-25_ClassOfWarrantOrRightAxis-PrefundedWarrantsMember"
      decimals="INF"
      id="c134565023"
      unitRef="Share">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <amix:NumberOfWarrantsPerPrefundedUnit
      contextRef="i_2024-11-25_ClassOfWarrantOrRightAxis-SeriesAWarrantsMember"
      decimals="INF"
      id="c134565024"
      unitRef="Share">1</amix:NumberOfWarrantsPerPrefundedUnit>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i_2024-11-25_ClassOfWarrantOrRightAxis-SeriesAWarrantsMember"
      id="c134565038">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <amix:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i_2025-03-31"
      decimals="INF"
      id="c134564291"
      unitRef="USDPerShare">5.89</amix:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i_2025-06-30_LitigationStatusAxis-PendingLitigationMember"
      decimals="-3"
      id="c134565070"
      unitRef="Pure">0</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i_2023-07-07_ClassOfWarrantOrRightAxis-TheWarrantMember_RelatedPartyTransactionAxis-TerminationAgreementMember"
      id="c134565085">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <amix:ClassOfWarrantOrRightLockupAgreementTermOfUnderlyingShares
      contextRef="d_2023-07-07_2023-07-07_ClassOfWarrantOrRightAxis-TheWarrantMember_RelatedPartyTransactionAxis-TerminationAgreementMember_UnderlyingAssetClassAxis-CommonStock6MonthsLockupPeriodMember"
      id="c134565087">P6M</amix:ClassOfWarrantOrRightLockupAgreementTermOfUnderlyingShares>
    <amix:ClassOfWarrantOrRightLockupAgreementTermOfUnderlyingShares
      contextRef="d_2023-07-07_2023-07-07_ClassOfWarrantOrRightAxis-TheWarrantMember_RelatedPartyTransactionAxis-TerminationAgreementMember_UnderlyingAssetClassAxis-CommonStock12MonthsLockupPeriodMember"
      id="c134565089">P12M</amix:ClassOfWarrantOrRightLockupAgreementTermOfUnderlyingShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="d_2025-08-11_2025-08-11_SubsequentEventTypeAxis-SubsequentEventMember"
      decimals="INF"
      id="c134565119"
      unitRef="Share">177652</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="d_2025-08-11_2025-08-11_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-BoardOfDirectorsChairmanMember"
      decimals="INF"
      id="c134565120"
      unitRef="Share">8773</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="d_2025-08-11_2025-08-11_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-ExecutiveChairOfTheBoardMember"
      decimals="INF"
      id="c134565121"
      unitRef="Share">65542</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="d_2025-08-11_2025-08-11_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-DirectorMember"
      decimals="INF"
      id="c134565122"
      unitRef="Share">3750</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="d_2025-08-11_2025-08-11_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-ChiefExecutiveOfficerMember"
      decimals="INF"
      id="c134565123"
      unitRef="Share">45000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="d_2025-08-11_2025-08-11_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-ChiefTechnologyOfficerMember"
      decimals="INF"
      id="c134565124"
      unitRef="Share">8773</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="d_2025-08-11_2025-08-11_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-ChiefMedicalOfficerMember"
      decimals="INF"
      id="c134565125"
      unitRef="Share">13159</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="d_2025-08-11_2025-08-11_SubsequentEventTypeAxis-SubsequentEventMember_TitleOfIndividualAxis-ChiefFinancialOfficerMember"
      decimals="INF"
      id="c134565126"
      unitRef="Share">32655</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i_2025-03-31"
      decimals="-3"
      id="c134563565"
      unitRef="USD">9136000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i_2024-03-31"
      decimals="-3"
      id="c134563566"
      unitRef="USD">8608000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:OtherAssetsCurrent
      contextRef="i_2025-03-31"
      decimals="-3"
      id="c134563567"
      unitRef="USD">473000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i_2024-03-31"
      decimals="-3"
      id="c134563568"
      unitRef="USD">783000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i_2025-03-31"
      decimals="-3"
      id="c134563569"
      unitRef="USD">9609000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i_2024-03-31"
      decimals="-3"
      id="c134563570"
      unitRef="USD">9391000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i_2025-03-31"
      decimals="-3"
      id="c134563571"
      unitRef="USD">21000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i_2024-03-31"
      decimals="-3"
      id="c134563572"
      unitRef="USD">16000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DeferredCosts
      contextRef="i_2025-03-31"
      decimals="-3"
      id="c134563573"
      unitRef="USD">176000</us-gaap:DeferredCosts>
    <us-gaap:DeferredCosts
      contextRef="i_2024-03-31"
      decimals="-3"
      id="c134563574"
      unitRef="USD">0</us-gaap:DeferredCosts>
    <us-gaap:AssetsNoncurrent
      contextRef="i_2025-03-31"
      decimals="-3"
      id="c134563575"
      unitRef="USD">197000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="i_2024-03-31"
      decimals="-3"
      id="c134563576"
      unitRef="USD">16000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i_2025-03-31"
      decimals="-3"
      id="c134563577"
      unitRef="USD">9806000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i_2024-03-31"
      decimals="-3"
      id="c134563578"
      unitRef="USD">9407000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i_2025-03-31"
      decimals="-3"
      id="c134563579"
      unitRef="USD">676000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i_2024-03-31"
      decimals="-3"
      id="c134563580"
      unitRef="USD">492000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i_2025-03-31"
      decimals="-3"
      id="c134563581"
      unitRef="USD">1031000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i_2024-03-31"
      decimals="-3"
      id="c134563582"
      unitRef="USD">285000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i_2025-03-31"
      decimals="-3"
      id="c134563583"
      unitRef="USD">1707000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i_2024-03-31"
      decimals="-3"
      id="c134563584"
      unitRef="USD">777000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ConvertibleLongTermNotesPayable
      contextRef="i_2025-03-31"
      decimals="-3"
      id="c134563585"
      unitRef="USD">0</us-gaap:ConvertibleLongTermNotesPayable>
    <us-gaap:ConvertibleLongTermNotesPayable
      contextRef="i_2024-03-31"
      decimals="-3"
      id="c134563586"
      unitRef="USD">1002000</us-gaap:ConvertibleLongTermNotesPayable>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="i_2025-03-31"
      decimals="-3"
      id="c134563587"
      unitRef="USD">0</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="i_2024-03-31"
      decimals="-3"
      id="c134563588"
      unitRef="USD">1002000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i_2025-03-31"
      decimals="-3"
      id="c134563589"
      unitRef="USD">1707000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i_2024-03-31"
      decimals="-3"
      id="c134563590"
      unitRef="USD">1779000</us-gaap:Liabilities>
    <us-gaap:PreferredStockValue
      contextRef="i_2025-03-31"
      decimals="-3"
      id="c134563591"
      unitRef="USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i_2024-03-31"
      decimals="-3"
      id="c134563592"
      unitRef="USD">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockValue
      contextRef="i_2025-03-31"
      decimals="-3"
      id="c134563593"
      unitRef="USD">2000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i_2024-03-31"
      decimals="-3"
      id="c134563594"
      unitRef="USD">1000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i_2025-03-31"
      decimals="-3"
      id="c134563595"
      unitRef="USD">58476000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i_2024-03-31"
      decimals="-3"
      id="c134563596"
      unitRef="USD">46596000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i_2025-03-31"
      decimals="-3"
      id="c134563597"
      unitRef="USD">-50379000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i_2024-03-31"
      decimals="-3"
      id="c134563598"
      unitRef="USD">-38969000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i_2025-03-31"
      decimals="-3"
      id="c134563599"
      unitRef="USD">8099000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2024-03-31"
      decimals="-3"
      id="c134563600"
      unitRef="USD">7628000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i_2025-03-31"
      decimals="-3"
      id="c134563601"
      unitRef="USD">9806000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i_2024-03-31"
      decimals="-3"
      id="c134563602"
      unitRef="USD">9407000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="d_2024-04-01_2025-03-31"
      decimals="-3"
      id="c134563611"
      unitRef="USD">6863000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="d_2023-04-01_2024-03-31"
      decimals="-3"
      id="c134563612"
      unitRef="USD">5249000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2024-04-01_2025-03-31"
      decimals="-3"
      id="c134563613"
      unitRef="USD">4725000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2023-04-01_2024-03-31"
      decimals="-3"
      id="c134563614"
      unitRef="USD">2225000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="d_2024-04-01_2025-03-31"
      decimals="-3"
      id="c134563615"
      unitRef="USD">-0</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="d_2023-04-01_2024-03-31"
      decimals="-3"
      id="c134563616"
      unitRef="USD">-4556000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:OperatingExpenses
      contextRef="d_2024-04-01_2025-03-31"
      decimals="-3"
      id="c134563617"
      unitRef="USD">11588000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="d_2023-04-01_2024-03-31"
      decimals="-4"
      id="c134563618"
      unitRef="USD">12030000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2024-04-01_2025-03-31"
      decimals="-3"
      id="c134563619"
      unitRef="USD">-11588000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2023-04-01_2024-03-31"
      decimals="-4"
      id="c134563620"
      unitRef="USD">-12030000</us-gaap:OperatingIncomeLoss>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="d_2024-04-01_2025-03-31"
      decimals="-3"
      id="c134563621"
      unitRef="USD">-0</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="d_2023-04-01_2024-03-31"
      decimals="-3"
      id="c134563622"
      unitRef="USD">3444000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:InterestExpenseNonoperating
      contextRef="d_2024-04-01_2025-03-31"
      decimals="-3"
      id="c134563623"
      unitRef="USD">176000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating
      contextRef="d_2023-04-01_2024-03-31"
      decimals="-3"
      id="c134563624"
      unitRef="USD">79000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InvestmentIncomeInterest
      contextRef="d_2024-04-01_2025-03-31"
      decimals="-3"
      id="c134563625"
      unitRef="USD">354000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="d_2023-04-01_2024-03-31"
      decimals="-3"
      id="c134563626"
      unitRef="USD">127000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="d_2024-04-01_2025-03-31"
      decimals="-3"
      id="c134563627"
      unitRef="USD">178000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="d_2023-04-01_2024-03-31"
      decimals="-3"
      id="c134563628"
      unitRef="USD">-3396000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="d_2024-04-01_2025-03-31"
      decimals="-4"
      id="c134563629"
      unitRef="USD">-11410000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="d_2023-04-01_2024-03-31"
      decimals="-3"
      id="c134563630"
      unitRef="USD">-15426000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="d_2024-04-01_2025-03-31"
      decimals="-3"
      id="c134563631"
      unitRef="USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="d_2023-04-01_2024-03-31"
      decimals="-3"
      id="c134563632"
      unitRef="USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-04-01_2025-03-31"
      decimals="-4"
      id="c134563633"
      unitRef="USD">-11410000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2023-04-01_2024-03-31"
      decimals="-3"
      id="c134563634"
      unitRef="USD">-15426000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="d_2024-04-01_2025-03-31"
      decimals="INF"
      id="c134563635"
      unitRef="USDPerShare">-6.46</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="d_2023-04-01_2024-03-31"
      decimals="INF"
      id="c134563636"
      unitRef="USDPerShare">-14.82</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="d_2024-04-01_2025-03-31"
      decimals="INF"
      id="c134563637"
      unitRef="Share">1766425</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="d_2023-04-01_2024-03-31"
      decimals="INF"
      id="c134563638"
      unitRef="Share">1040720</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:SharesOutstanding
      contextRef="i_2023-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c134563641"
      unitRef="Share">617000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2023-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c134563642"
      unitRef="USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2023-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c134563643"
      unitRef="USD">24186000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2023-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c134563644"
      unitRef="USD">-23543000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2023-03-31"
      decimals="-3"
      id="c134563645"
      unitRef="USD">644000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="d_2023-04-01_2024-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c134563647"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2023-04-01_2024-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c134563648"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2023-04-01_2024-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c134563649"
      unitRef="USD">-15426000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2023-04-01_2024-03-31"
      decimals="-3"
      id="c134563650"
      unitRef="USD">-15426000</us-gaap:NetIncomeLoss>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2023-04-01_2024-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c134563652"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2023-04-01_2024-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c134563653"
      unitRef="USD">618000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2023-04-01_2024-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c134563654"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2023-04-01_2024-03-31"
      decimals="-3"
      id="c134563655"
      unitRef="USD">618000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2023-04-01_2024-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c134563656"
      unitRef="Share">105000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2023-04-01_2024-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c134563657"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2023-04-01_2024-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-4"
      id="c134563658"
      unitRef="USD">2840000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2023-04-01_2024-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c134563659"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2023-04-01_2024-03-31"
      decimals="-4"
      id="c134563660"
      unitRef="USD">2840000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <amix:StockIssuedDuringPeriodSharesInitialPublicOffering
      contextRef="d_2023-04-01_2024-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c134563661"
      unitRef="Share">111000</amix:StockIssuedDuringPeriodSharesInitialPublicOffering>
    <amix:StockIssuedDuringPeriodValueInitialPublicOffering
      contextRef="d_2023-04-01_2024-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c134563662"
      unitRef="USD">0</amix:StockIssuedDuringPeriodValueInitialPublicOffering>
    <amix:StockIssuedDuringPeriodValueInitialPublicOffering
      contextRef="d_2023-04-01_2024-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c134563663"
      unitRef="USD">9875000</amix:StockIssuedDuringPeriodValueInitialPublicOffering>
    <amix:StockIssuedDuringPeriodValueInitialPublicOffering
      contextRef="d_2023-04-01_2024-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c134563664"
      unitRef="USD">0</amix:StockIssuedDuringPeriodValueInitialPublicOffering>
    <amix:StockIssuedDuringPeriodValueInitialPublicOffering
      contextRef="d_2023-04-01_2024-03-31"
      decimals="-3"
      id="c134563665"
      unitRef="USD">9875000</amix:StockIssuedDuringPeriodValueInitialPublicOffering>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="d_2023-04-01_2024-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c134563666"
      unitRef="Share">17000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="d_2023-04-01_2024-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c134563667"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="d_2023-04-01_2024-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-5"
      id="c134563668"
      unitRef="USD">500000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="d_2023-04-01_2024-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c134563669"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="d_2023-04-01_2024-03-31"
      decimals="-5"
      id="c134563670"
      unitRef="USD">500000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <amix:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="d_2023-04-01_2024-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c134563671"
      unitRef="Share">91000</amix:StockIssuedDuringPeriodSharesWarrantsExercised>
    <amix:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="d_2023-04-01_2024-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c134563672"
      unitRef="USD">0</amix:StockIssuedDuringPeriodValueWarrantsExercised>
    <amix:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="d_2023-04-01_2024-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c134563673"
      unitRef="USD">0</amix:StockIssuedDuringPeriodValueWarrantsExercised>
    <amix:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="d_2023-04-01_2024-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c134563674"
      unitRef="USD">0</amix:StockIssuedDuringPeriodValueWarrantsExercised>
    <amix:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="d_2023-04-01_2024-03-31"
      decimals="-3"
      id="c134563675"
      unitRef="USD">0</amix:StockIssuedDuringPeriodValueWarrantsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="d_2023-04-01_2024-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c134563676"
      unitRef="Share">2000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="d_2023-04-01_2024-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c134563677"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="d_2023-04-01_2024-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c134563678"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="d_2023-04-01_2024-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c134563679"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="d_2023-04-01_2024-03-31"
      decimals="-3"
      id="c134563680"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="d_2023-04-01_2024-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c134563682"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="d_2023-04-01_2024-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c134563683"
      unitRef="USD">577000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="d_2023-04-01_2024-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c134563684"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="d_2023-04-01_2024-03-31"
      decimals="-3"
      id="c134563685"
      unitRef="USD">577000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <amix:WarrantsIssuedFairValueIssuedForTerminationAgreement
      contextRef="d_2023-04-01_2024-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c134563687"
      unitRef="USD">0</amix:WarrantsIssuedFairValueIssuedForTerminationAgreement>
    <amix:WarrantsIssuedFairValueIssuedForTerminationAgreement
      contextRef="d_2023-04-01_2024-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-6"
      id="c134563688"
      unitRef="USD">8000000</amix:WarrantsIssuedFairValueIssuedForTerminationAgreement>
    <amix:WarrantsIssuedFairValueIssuedForTerminationAgreement
      contextRef="d_2023-04-01_2024-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c134563689"
      unitRef="USD">0</amix:WarrantsIssuedFairValueIssuedForTerminationAgreement>
    <amix:WarrantsIssuedFairValueIssuedForTerminationAgreement
      contextRef="d_2023-04-01_2024-03-31"
      decimals="-6"
      id="c134563690"
      unitRef="USD">8000000</amix:WarrantsIssuedFairValueIssuedForTerminationAgreement>
    <us-gaap:SharesOutstanding
      contextRef="i_2024-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c134563691"
      unitRef="Share">943000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2024-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c134563692"
      unitRef="USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2024-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c134563693"
      unitRef="USD">46596000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2024-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c134563694"
      unitRef="USD">-38969000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2024-03-31"
      decimals="-3"
      id="c134563695"
      unitRef="USD">7628000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-04-01_2025-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c134563697"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-04-01_2025-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c134563698"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-04-01_2025-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-4"
      id="c134563699"
      unitRef="USD">-11410000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-04-01_2025-03-31"
      decimals="-4"
      id="c134563700"
      unitRef="USD">-11410000</us-gaap:NetIncomeLoss>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2024-04-01_2025-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c134563702"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2024-04-01_2025-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c134563703"
      unitRef="USD">1628000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2024-04-01_2025-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c134563704"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2024-04-01_2025-03-31"
      decimals="-3"
      id="c134563705"
      unitRef="USD">1628000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2024-04-01_2025-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c134563706"
      unitRef="Share">13000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2024-04-01_2025-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c134563707"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2024-04-01_2025-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c134563708"
      unitRef="USD">103000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2024-04-01_2025-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c134563709"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2024-04-01_2025-03-31"
      decimals="-3"
      id="c134563710"
      unitRef="USD">103000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <amix:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="d_2024-04-01_2025-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c134563711"
      unitRef="Share">892000</amix:StockIssuedDuringPeriodSharesWarrantsExercised>
    <amix:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="d_2024-04-01_2025-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c134563712"
      unitRef="USD">1000</amix:StockIssuedDuringPeriodValueWarrantsExercised>
    <amix:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="d_2024-04-01_2025-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c134563713"
      unitRef="USD">0</amix:StockIssuedDuringPeriodValueWarrantsExercised>
    <amix:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="d_2024-04-01_2025-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c134563714"
      unitRef="USD">0</amix:StockIssuedDuringPeriodValueWarrantsExercised>
    <amix:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="d_2024-04-01_2025-03-31"
      decimals="-3"
      id="c134563715"
      unitRef="USD">1000</amix:StockIssuedDuringPeriodValueWarrantsExercised>
    <amix:StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants
      contextRef="d_2024-04-01_2025-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c134563716"
      unitRef="Share">616000</amix:StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants>
    <amix:StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants
      contextRef="d_2024-04-01_2025-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c134563717"
      unitRef="USD">0</amix:StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants>
    <amix:StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants
      contextRef="d_2024-04-01_2025-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c134563718"
      unitRef="USD">8972000</amix:StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants>
    <amix:StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants
      contextRef="d_2024-04-01_2025-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c134563719"
      unitRef="USD">0</amix:StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants>
    <amix:StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants
      contextRef="d_2024-04-01_2025-03-31"
      decimals="-3"
      id="c134563720"
      unitRef="USD">8972000</amix:StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="d_2024-04-01_2025-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c134563721"
      unitRef="Share">33000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="d_2024-04-01_2025-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c134563722"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="d_2024-04-01_2025-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c134563723"
      unitRef="USD">1177000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="d_2024-04-01_2025-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c134563724"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="d_2024-04-01_2025-03-31"
      decimals="-3"
      id="c134563725"
      unitRef="USD">1177000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:SharesOutstanding
      contextRef="i_2025-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c134563726"
      unitRef="Share">2497000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2025-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c134563727"
      unitRef="USD">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2025-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c134563728"
      unitRef="USD">58476000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2025-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c134563729"
      unitRef="USD">-50379000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2025-03-31"
      decimals="-3"
      id="c134563730"
      unitRef="USD">8099000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-04-01_2025-03-31"
      decimals="-4"
      id="c134563731"
      unitRef="USD">-11410000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2023-04-01_2024-03-31"
      decimals="-3"
      id="c134563732"
      unitRef="USD">-15426000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="d_2024-04-01_2025-03-31"
      decimals="-3"
      id="c134563733"
      unitRef="USD">1628000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="d_2023-04-01_2024-03-31"
      decimals="-3"
      id="c134563734"
      unitRef="USD">618000</us-gaap:ShareBasedCompensation>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="d_2024-04-01_2025-03-31"
      decimals="-3"
      id="c134563735"
      unitRef="USD">183000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="d_2023-04-01_2024-03-31"
      decimals="-3"
      id="c134563736"
      unitRef="USD">81000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="d_2024-04-01_2025-03-31"
      decimals="-3"
      id="c134563737"
      unitRef="USD">101000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="d_2023-04-01_2024-03-31"
      decimals="-3"
      id="c134563738"
      unitRef="USD">0</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="d_2024-04-01_2025-03-31"
      decimals="-3"
      id="c134563739"
      unitRef="USD">-0</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="d_2023-04-01_2024-03-31"
      decimals="-3"
      id="c134563740"
      unitRef="USD">-4556000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="d_2024-04-01_2025-03-31"
      decimals="-3"
      id="c134563741"
      unitRef="USD">0</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="d_2023-04-01_2024-03-31"
      decimals="-3"
      id="c134563742"
      unitRef="USD">3444000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets
      contextRef="d_2024-04-01_2025-03-31"
      decimals="-4"
      id="c134563743"
      unitRef="USD">-310000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets
      contextRef="d_2023-04-01_2024-03-31"
      decimals="-3"
      id="c134563744"
      unitRef="USD">478000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="d_2024-04-01_2025-03-31"
      decimals="-3"
      id="c134563745"
      unitRef="USD">184000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="d_2023-04-01_2024-03-31"
      decimals="-4"
      id="c134563746"
      unitRef="USD">320000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="d_2024-04-01_2025-03-31"
      decimals="-3"
      id="c134563747"
      unitRef="USD">746000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="d_2023-04-01_2024-03-31"
      decimals="-3"
      id="c134563748"
      unitRef="USD">237000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="d_2024-04-01_2025-03-31"
      decimals="-3"
      id="c134563749"
      unitRef="USD">-8258000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="d_2023-04-01_2024-03-31"
      decimals="-3"
      id="c134563750"
      unitRef="USD">-6648000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="d_2024-04-01_2025-03-31"
      decimals="-3"
      id="c134563751"
      unitRef="USD">14000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="d_2023-04-01_2024-03-31"
      decimals="-3"
      id="c134563752"
      unitRef="USD">19000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="d_2024-04-01_2025-03-31"
      decimals="-3"
      id="c134563753"
      unitRef="USD">-14000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="d_2023-04-01_2024-03-31"
      decimals="-3"
      id="c134563754"
      unitRef="USD">-19000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <amix:ProceedsFromIssuanceOfCommonStockAndWarrants
      contextRef="d_2024-04-01_2025-03-31"
      decimals="-3"
      id="c134563755"
      unitRef="USD">10025000</amix:ProceedsFromIssuanceOfCommonStockAndWarrants>
    <amix:ProceedsFromIssuanceOfCommonStockAndWarrants
      contextRef="d_2023-04-01_2024-03-31"
      decimals="-3"
      id="c134563756"
      unitRef="USD">0</amix:ProceedsFromIssuanceOfCommonStockAndWarrants>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="d_2024-04-01_2025-03-31"
      decimals="-3"
      id="c134563757"
      unitRef="USD">1052000</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="d_2023-04-01_2024-03-31"
      decimals="-3"
      id="c134563758"
      unitRef="USD">-0</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="d_2024-04-01_2025-03-31"
      decimals="-3"
      id="c134563759"
      unitRef="USD">176000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="d_2023-04-01_2024-03-31"
      decimals="-3"
      id="c134563760"
      unitRef="USD">-0</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="d_2024-04-01_2025-03-31"
      decimals="-3"
      id="c134563761"
      unitRef="USD">1000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="d_2023-04-01_2024-03-31"
      decimals="-3"
      id="c134563762"
      unitRef="USD">0</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="d_2024-04-01_2025-03-31_SubsidiarySaleOfStockAxis-ATMAgreementMember"
      decimals="-3"
      id="c134563763"
      unitRef="USD">2000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="d_2023-04-01_2024-03-31_SubsidiarySaleOfStockAxis-ATMAgreementMember"
      decimals="-3"
      id="c134563764"
      unitRef="USD">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="d_2024-04-01_2025-03-31_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="-3"
      id="c134563765"
      unitRef="USD">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="d_2023-04-01_2024-03-31_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="-4"
      id="c134563766"
      unitRef="USD">2840000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="d_2024-04-01_2025-03-31"
      decimals="-3"
      id="c134563767"
      unitRef="USD">0</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="d_2023-04-01_2024-03-31"
      decimals="-6"
      id="c134563768"
      unitRef="USD">2000000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="d_2024-04-01_2025-03-31"
      decimals="-3"
      id="c134563769"
      unitRef="USD">0</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="d_2023-04-01_2024-03-31"
      decimals="-3"
      id="c134563770"
      unitRef="USD">10866000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <amix:PaymentsForInitialPublicOfferingIssuanceCosts
      contextRef="d_2024-04-01_2025-03-31"
      decimals="-3"
      id="c134563771"
      unitRef="USD">-0</amix:PaymentsForInitialPublicOfferingIssuanceCosts>
    <amix:PaymentsForInitialPublicOfferingIssuanceCosts
      contextRef="d_2023-04-01_2024-03-31"
      decimals="-3"
      id="c134563772"
      unitRef="USD">1296000</amix:PaymentsForInitialPublicOfferingIssuanceCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="d_2024-04-01_2025-03-31"
      decimals="-5"
      id="c134563773"
      unitRef="USD">8800000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="d_2023-04-01_2024-03-31"
      decimals="-4"
      id="c134563774"
      unitRef="USD">14410000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="d_2024-04-01_2025-03-31"
      decimals="-3"
      id="c134563775"
      unitRef="USD">528000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="d_2023-04-01_2024-03-31"
      decimals="-3"
      id="c134563776"
      unitRef="USD">7743000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2024-03-31"
      decimals="-3"
      id="c134563777"
      unitRef="USD">8608000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2023-03-31"
      decimals="-3"
      id="c134563778"
      unitRef="USD">865000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2025-03-31"
      decimals="-3"
      id="c134563779"
      unitRef="USD">9136000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2024-03-31"
      decimals="-3"
      id="c134563780"
      unitRef="USD">8608000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <amix:WarrantsIssuedForEquityCosts
      contextRef="d_2024-04-01_2025-03-31"
      decimals="-3"
      id="c134563781"
      unitRef="USD">479000</amix:WarrantsIssuedForEquityCosts>
    <amix:WarrantsIssuedForEquityCosts
      contextRef="d_2023-04-01_2024-03-31"
      decimals="-3"
      id="c134563782"
      unitRef="USD">0</amix:WarrantsIssuedForEquityCosts>
    <us-gaap:StockIssued1
      contextRef="d_2024-04-01_2025-03-31"
      decimals="-3"
      id="c134563783"
      unitRef="USD">39000</us-gaap:StockIssued1>
    <us-gaap:StockIssued1
      contextRef="d_2023-04-01_2024-03-31"
      decimals="-3"
      id="c134563784"
      unitRef="USD">2000</us-gaap:StockIssued1>
    <amix:WarrantsIssuedForDebtIssuanceCosts
      contextRef="d_2024-04-01_2025-03-31"
      decimals="-3"
      id="c134563785"
      unitRef="USD">0</amix:WarrantsIssuedForDebtIssuanceCosts>
    <amix:WarrantsIssuedForDebtIssuanceCosts
      contextRef="d_2023-04-01_2024-03-31"
      decimals="-3"
      id="c134563786"
      unitRef="USD">577000</amix:WarrantsIssuedForDebtIssuanceCosts>
    <amix:ClassOfWarrantOrRightFairValueIssuedForIssuanceCostsFromIpo
      contextRef="d_2024-04-01_2025-03-31"
      decimals="-3"
      id="c134563787"
      unitRef="USD">0</amix:ClassOfWarrantOrRightFairValueIssuedForIssuanceCostsFromIpo>
    <amix:ClassOfWarrantOrRightFairValueIssuedForIssuanceCostsFromIpo
      contextRef="d_2023-04-01_2024-03-31"
      decimals="-3"
      id="c134563788"
      unitRef="USD">225000</amix:ClassOfWarrantOrRightFairValueIssuedForIssuanceCostsFromIpo>
    <amix:IpoProceedsHoldbackProvision
      contextRef="d_2024-04-01_2025-03-31"
      decimals="-3"
      id="c134563789"
      unitRef="USD">0</amix:IpoProceedsHoldbackProvision>
    <amix:IpoProceedsHoldbackProvision
      contextRef="d_2023-04-01_2024-03-31"
      decimals="-3"
      id="c134563790"
      unitRef="USD">305000</amix:IpoProceedsHoldbackProvision>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="d_2024-04-01_2025-03-31_DebtConversionByUniqueDescriptionAxis-IssuanceOfCommonStockForExtinguishmentOfConvertibleDebtMember"
      decimals="-4"
      id="c134563791"
      unitRef="USD">1330000</us-gaap:DebtConversionOriginalDebtAmount1>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="d_2023-04-01_2024-03-31_DebtConversionByUniqueDescriptionAxis-IssuanceOfCommonStockForExtinguishmentOfConvertibleDebtMember"
      decimals="-4"
      id="c134563792"
      unitRef="USD">670000</us-gaap:DebtConversionOriginalDebtAmount1>
    <amix:DebtConversionDebtIssuanceCostsConvertedCommonShares
      contextRef="d_2024-04-01_2025-03-31_DebtConversionByUniqueDescriptionAxis-IssuanceOfCommonStockForExtinguishmentOfConvertibleDebtMember"
      decimals="-3"
      id="c134563793"
      unitRef="USD">-153000</amix:DebtConversionDebtIssuanceCostsConvertedCommonShares>
    <amix:DebtConversionDebtIssuanceCostsConvertedCommonShares
      contextRef="d_2023-04-01_2024-03-31_DebtConversionByUniqueDescriptionAxis-IssuanceOfCommonStockForExtinguishmentOfConvertibleDebtMember"
      decimals="-4"
      id="c134563794"
      unitRef="USD">-170000</amix:DebtConversionDebtIssuanceCostsConvertedCommonShares>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock contextRef="d_2024-04-01_2025-03-31" id="c3016953">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;1&lt;/em&gt; &lt;/b&gt;&#x2013;&lt;b&gt; Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies &lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;Description of the Business&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;Autonomix Medical, Inc (&#x201c;we,&#x201d; &#x201c;our,&#x201d; the &#x201c;Company&#x201d;) is a medical device company organized as a Delaware corporation on &lt;em style="font: inherit;"&gt; June 10, 2014. &lt;/em&gt;The Company is a pre-revenue, clinical stage life sciences company focused on advancing innovative technologies for sensing and treating disorders relating to the peripheral nervous system.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;Reverse Stock Split&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;The Company&#160;held its annual meeting of stockholders (the "Annual Meeting") on&#160;&lt;em style="font: inherit;"&gt; October 17, 2024&lt;/em&gt;&lt;i&gt;.&lt;/i&gt;&#160;In that Annual Meeting, stockholders of the Company approved an amendment to the Company&#x2019;s amended and restated certificate of incorporation (the "Amendment&#x201d;) to effect the reverse stock split at a ratio in the range of&#160;&lt;em style="font: inherit;"&gt;1&lt;/em&gt;-for-2&#160;to&#160;&lt;em style="font: inherit;"&gt;1&lt;/em&gt;-for-50, with such ratio to be determined in the discretion of the Company&#x2019;s board of directors and with such reverse stock split to be effected at such time and date, if at all, as determined by the Company&#x2019;s board of directors in its sole discretion prior to the&#160;&lt;em style="font: inherit;"&gt;one&lt;/em&gt;-year anniversary of the Annual Meeting.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;Pursuant to such authority granted by the Company&#x2019;s stockholders, the Company&#x2019;s board of directors approved a&#160;&lt;em style="font: inherit;"&gt;one&lt;/em&gt;-for-&#160;&lt;span style="-sec-ix-hidden:c134564311"&gt;twenty&lt;/span&gt;&#160;(&lt;em style="font: inherit;"&gt;1:20&lt;/em&gt;) reverse stock split (the "Reverse Stock Split&#x201d;) of the Company&#x2019;s common stock and the filing of the Amendment to effectuate the Reverse Stock Split. The Amendment was filed with the Secretary of State of the State of Delaware and the Reverse Stock Split became effective in accordance with the terms of the Amendment at&#160;&lt;em style="font: inherit;"&gt;11:59&lt;/em&gt;&#160;p.m. Eastern Time on&#160;&lt;em style="font: inherit;"&gt; October 24, 2024 (&lt;/em&gt;the "Effective Time&#x201d;), and the Company&#x2019;s common stock opened&#160;for trading on The Nasdaq Capital Market on&#160;&lt;em style="font: inherit;"&gt; October 25, 2024&#160;&lt;/em&gt;on a post-split basis, under the existing ticker symbol "AMIX&#x201d; but with a new CUSIP number&#160;&lt;em style="font: inherit;"&gt;05330T205.&lt;/em&gt;&#160;The Amendment provided that, at the Effective Time, every&#160;&lt;span style="-sec-ix-hidden:c134564315"&gt;twenty&lt;/span&gt;&#160;shares of the Company&#x2019;s issued and outstanding common stock automatically combined into&#160;&lt;em style="font: inherit;"&gt;one&lt;/em&gt;&#160;issued and outstanding share of common stock, without any change in par value per share, which remained $0.001.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;The number of authorized shares of common stock remained&#160;at&#160;500&#160;million shares. As a result of the Reverse Stock Split, proportionate adjustments were made to the per share exercise price and/or the number of shares issuable upon the exercise or vesting of all outstanding stock options, restricted stock unit awards, warrants and convertible notes, which resulted in a proportional decrease in the number of shares of the Company&#x2019;s common stock reserved for issuance upon exercise or vesting of such stock options, restricted stock unit awards, warrants and convertible notes and, in the case of stock options and warrants, a proportional increase in the exercise price of all such stock options and warrants.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;The Company&#x2019;s stock option awards did &lt;em style="font: inherit;"&gt;not&lt;/em&gt; automatically adjust for the Reverse Stock Split.&#160;However, the Company chose to exercise its rights under the agreements to adjust the exercise price and number of shares exercisable or issuable upon vesting proportionately for the Reverse Stock Split.&#160;Based on the analysis performed, the Company does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; need to recognize any additional compensation expense as a result of the modification.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;In addition, the number of shares reserved for issuance under the Company&#x2019;s equity compensation plan immediately prior to the Effective Time was reduced proportionately.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;em style="font: inherit;"&gt;No&lt;/em&gt;&#160;fractional shares were issued as a result of the Reverse Stock Split. Any stockholder who would have been entitled to receive a fractional share as a result of the process was entitled to the rounding up of the fractional share to the nearest whole number. See "&#160;Fractional Shares" in Note&#160;&lt;em style="font: inherit;"&gt;5&lt;/em&gt;&#160;for further disclosure regarding fractional shares.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;The Reverse Stock Split has been retroactively adjusted throughout these interim financial statements and footnotes for all periods presented, including exercise prices and share data. As a result of the Reverse Stock Split, the Company reclassified approximately $18&#160;thousand between common stock par value and additional paid-in capital.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;Liquidity and Going Concern&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;The Company's&#xfeff; financial statements are prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The Company is an early-stage company that is subject to all the risks associated with early-stage and emerging growth companies and has incurred losses since inception.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;For the years ended &lt;em style="font: inherit;"&gt; March 31, 2025 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2024,&lt;/em&gt; the Company has net losses of approximately $11.4 million and $15.4 million, respectively and had net cash flows used in operating activities of $8.3&#160;million&#160;and $6.6 million, respectively. The Company had no revenues for the years ended &lt;em style="font: inherit;"&gt; March 31, 2025 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2024,&lt;/em&gt; respectively. The Company had an accumulated deficit of $50.4 million and working capital of approximately $7.9 million as of &lt;em style="font: inherit;"&gt; March 31, 2025. &lt;/em&gt;The Company does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; expect to generate positive cash flows from operating activities in the near future. These conditions, and the Company's ability to comply with such conditions, raise substantial doubt about the Company's ability to continue as a going concern within &lt;em style="font: inherit;"&gt;one&lt;/em&gt; year after the date that the financial statements are issued. The accompanying financial statements have been prepared on a going concern basis and do &lt;em style="font: inherit;"&gt;not&lt;/em&gt; include any adjustments that might be necessary if the Company is unable to continue as a going concern.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;On &lt;em style="font: inherit;"&gt; January 26, 2024, &lt;/em&gt;the Company completed its IPO, pursuant to which it sold a total of 111,962&#160;shares of common stock at a purchase price of $100.00 per share for gross proceeds of $11.2 million and net proceeds of $9.8 million.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;On &lt;em style="font: inherit;"&gt; November 22, 2024, &lt;/em&gt;the Company completed a firm commitment underwritten public offering (the &#x201c;Offering&#x201d;) of: (i) 458,691 common units (the &#x201c;Common Units&#x201d;), each Common Unit consisting of &lt;span style="-sec-ix-hidden:c134564342"&gt;one&lt;/span&gt; share of Company common stock and &lt;span style="-sec-ix-hidden:c134564343"&gt;one&lt;/span&gt; series A warrant to purchase &lt;span style="-sec-ix-hidden:c134564344"&gt;one&lt;/span&gt; share of common stock (the &#x201c;Series A Warrants&#x201d;); and (ii) 917,596 pre-funded units (the &#x201c;Pre-Funded Units&#x201d;) and together with the Common Units, the "Units", each Pre-Funded Unit consisting of &lt;span style="-sec-ix-hidden:c134564346"&gt;one&lt;/span&gt; pre-funded warrant to purchase &lt;span style="-sec-ix-hidden:c134564347"&gt;one&lt;/span&gt; share of common stock (the &#x201c;Pre-Funded Warrant&#x201d;) and &lt;span style="-sec-ix-hidden:c134564348"&gt;one&lt;/span&gt; Series A Warrant. The purchase price of each Common Unit was $6.540, and the purchase price of each Pre-Funded Unit was $6.539.&#160;In addition, the Company granted the underwriters in the Offering a 45-day option to purchase an additional 206,422 shares of common stock, and/or an additional 206,422 Series A Warrants, solely to cover over-allotments, if any. The Pre-Funded Warrants have an exercise price of $0.001 per share, are immediately exercisable and &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be exercised at any time until all of the Pre-Funded Warrants are exercised in full. The Series A Warrants have an exercise price of $6.540 per share, are immediately exercisable and &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be exercised at any time until the &lt;span style="-sec-ix-hidden:c134564356"&gt;five&lt;/span&gt;-year anniversary of the date of issuance. Both the Pre-Funded Warrants and the Series A Warrants are subject to a beneficial ownership limitation of 4.99%. The Offering closed on &lt;em style="font: inherit;"&gt; November 25, 2024. &lt;/em&gt;On &lt;em style="font: inherit;"&gt; November 22, 2024, &lt;/em&gt;the underwriters partially exercised their over-allotment option with respect to 156,809 shares of common stock and 156,809 Series A Warrants. The aggregate gross proceeds to the Company, including the partial exercise of the over-allotment option, were approximately $10.0 million, before deducting underwriting discounts and other expenses by the Company of $1.5 million, including $0.5 million of non-cash expenses. The net cash proceeds to the Company were approximately $9.0 million.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;On &lt;em style="font: inherit;"&gt; February 28, 2025, &lt;/em&gt;the Company entered into an At Market Issuances Sales Agreement (the &#x201c;ATM Agreement&#x201d;) with Ladenburg Thalmann &amp;amp; Co. Inc. (the &#x201c;Agent&#x201d;). Pursuant to the terms of the ATM Agreement, the Company &lt;em style="font: inherit;"&gt; may &lt;/em&gt;sell from time to time through the Agent, as sales agent or principal, shares of the Company&#x2019;s common stock with an initial aggregate sales price of up to $2.1 million (the &#x201c;Shares&#x201d;). Any sale of Shares pursuant to the Agreement will be made under the Company&#x2019;s &#x201c;shelf&#x201d; registration statement (the &#x201c;Registration Statement&#x201d;) on Form S-&lt;em style="font: inherit;"&gt;3&lt;/em&gt; filed on &lt;em style="font: inherit;"&gt; February 28, 2025 &lt;/em&gt;with the Securities and Exchange Commission (the &#x201c;SEC&#x201d;). Under the ATM Agreement, the Company &lt;em style="font: inherit;"&gt; may &lt;/em&gt;sell Shares through the Agent by any method that is deemed an &#x201c;at the market offering&#x201d; (as defined in Rule &lt;em style="font: inherit;"&gt;415&lt;/em&gt;(a)(&lt;em style="font: inherit;"&gt;4&lt;/em&gt;) under the Securities Act of &lt;em style="font: inherit;"&gt;1933,&lt;/em&gt; as amended). Under the ATM Agreement, the Agent will also be able to sell shares of Common Stock by any other method permitted by law, including in negotiated transactions with the Company&#x2019;s prior written consent. The Company will pay a commission to the Agent of 3.0% of the gross proceeds of the sale of the Shares sold under the ATM Agreement and reimburse the Agent for certain expenses. As of &lt;em style="font: inherit;"&gt; March 31, 2025, &lt;/em&gt;the Company sold 800 shares pursuant to the ATM Agreement for net proceeds of approximately $1,746.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;The Company estimates its current cash resources are sufficient to fund its operations into but &lt;em style="font: inherit;"&gt;not&lt;/em&gt; beyond the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; calendar quarter of &lt;em style="font: inherit;"&gt;2026.&lt;/em&gt; The Company recognizes it will need to raise additional capital to continue to execute its business plan, including obtaining regulatory clearance for its products currently under development and commercializing and generating revenues from products under development. There is &lt;em style="font: inherit;"&gt;no&lt;/em&gt; assurance that additional financing will be available when needed or that management will be able to obtain financing on terms acceptable to the Company. A failure to raise sufficient capital, generate sufficient product revenues, control expenditures and regulatory matters, among other factors, will adversely impact the Company&#x2019;s ability to meet its financial obligations as they become due and payable and to achieve its intended business objectives. If the Company is unable to raise sufficient additional funds, it will have to scale back its operations.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;Basis of Presentation&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;The annual financial statements and disclosures have been prepared using the accrual basis of accounting in accordance with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;).&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;


   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;Use of Estimates in Financial Statement Presentation&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;The preparation of these financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The Company's significant estimates and assumptions include the valuation of equity related instruments, and initial and recurring fair value measurements for the warrant liability. Although the Company believes that its estimates and assumptions are reasonable, they are based upon information available at the time the estimates and assumptions were made. Some of these judgments can be subjective and complex, and, consequently, actual results could differ from those estimates.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;Cash and Cash Equivalents&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;The Company considers all highly liquid accounts with original maturities of &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months or less at the date of acquisition to be cash equivalents.&#160;Periodically, the Company &lt;em style="font: inherit;"&gt; may &lt;/em&gt;carry cash balances at financial institutions in excess of the federally insured limit of &lt;em style="font: inherit;"&gt;$250,000.&lt;/em&gt; The Company has &lt;em style="font: inherit;"&gt;not&lt;/em&gt; experienced losses on these accounts and management believes, based upon the quality of the financial institutions, that the credit risk with regard to these deposits is &lt;em style="font: inherit;"&gt;not&lt;/em&gt; significant.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;Offering and Financing Costs&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;Offering costs consist of professional costs incurred through the balance sheet date that were direct and incremental to the Company&#x2019;s equity financing activities. Specifically, offering costs were incurred on the Company's IPO, the Offering and the Registration Statement. The costs for the Registration Statement are recorded in deferred offering costs on the balance sheet as of &lt;em style="font: inherit;"&gt; March 31, 2025. &lt;/em&gt;Costs associated with salaries and other period costs were expensed as incurred.&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;During the year ended &lt;em style="font: inherit;"&gt; March 31, 2024, &lt;/em&gt;the Company paid $1.3 million of issuance&#160;costs related to its IPO.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;During the year ended &lt;em style="font: inherit;"&gt; March 31, 2025, &lt;/em&gt;the Company paid $1.1 million of issuance costs related to its Offering and $0.2 million of offering costs related to its Registration Statement.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;Property and Equipment&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;Property and equipment are stated at historical cost and depreciated on a straight-line basis over their estimated useful lives, generally&#160;&lt;span style="-sec-ix-hidden:c134564384"&gt;three&lt;/span&gt; years. Upon disposition of the assets, the costs and related accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the results of operations.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;Convertible Notes&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;The Company evaluates embedded redemption, conversion and other features within its debt to determine whether any embedded features should be bifurcated from the host instrument and accounted for as a derivative at fair value, with changes in fair value recorded in the statement of operations.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;The Company&#x2019;s debt is carried on the balance sheet on a historical cost basis net of unamortized discounts and premiums because the Company has &lt;em style="font: inherit;"&gt;not&lt;/em&gt; elected the fair value option of accounting. Costs associated with acquiring debt, including detachable warrants issued in connection with the financing, are capitalized as a debt discount. The debt discount is presented in the balance sheet as a direct deduction from the carrying amount of the debt liability. The costs are amortized over the estimated contractual life of the related debt instrument using the effective interest method and are included in interest expense in the statement of operations.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;If the Company incurs costs associated with its convertible notes, in advance of the receipt of proceeds, the Company will record a deferred asset. Upon receipt of proceeds the Company will reclassify the deferred asset as a direct deduction from the carrying amount, as described above.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;In addition, since the instruments included a substantive conversion feature at the time of issuance, the issuance of equity securities were accounted for as a contractual conversion with &lt;em style="font: inherit;"&gt;no&lt;/em&gt; gain or loss recognized related to the equity securities issued to settle the instrument. &#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;Fair Value of Financial Instruments&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs. The Company utilizes a &lt;em style="font: inherit;"&gt;three&lt;/em&gt;-level valuation hierarchy for disclosures of fair value measurements, defined as follows:&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;Level &lt;em style="font: inherit;"&gt;1&lt;/em&gt; &#x2013; inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;Level &lt;em style="font: inherit;"&gt;2&lt;/em&gt; &#x2013; inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the assets or liability, either directly or indirectly, for substantially the full term of the financial instruments.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;Level &lt;em style="font: inherit;"&gt;3&lt;/em&gt; &#x2013; inputs to the valuation methodology are unobservable and significant to the fair value and require significant judgment and estimation.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;Financial assets and financial liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. While the Company believes that its valuation methods are appropriate, the Company recognizes that the use of different methodologies or assumptions to determine the fair value could result in a different estimate of fair value at the reporting date. The primary assumptions that would significantly affect the fair values are the probability weighting of the different settlement outcomes used.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;The Company did &lt;em style="font: inherit;"&gt;not&lt;/em&gt; have any assets or liabilities measured at fair value as of &lt;em style="font: inherit;"&gt; March 31, 2025 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2024,&lt;/em&gt; respectively. In the &lt;em style="font: inherit;"&gt;fourth&lt;/em&gt; quarter of the Company's fiscal year ended &lt;em style="font: inherit;"&gt; March 31, 2024 &lt;/em&gt;there was a transfer out of Level &lt;em style="font: inherit;"&gt;3&lt;/em&gt;&#160;for the warrant liability, for the settlement and reclassification to equity of the instrument, that occurred in the&#160;&lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended&#160;&lt;em style="font: inherit;"&gt; March 31, 2024. &lt;/em&gt;For additional information, see&#160;&lt;i&gt;Note &lt;em style="font: inherit;"&gt;2&lt;/em&gt; - Warrant Liability and Fair Value of Financial Instruments&lt;/i&gt;.&#xfeff;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;The carrying value of short-term instruments, including cash, accounts payable, accrued expenses and convertible notes included in long-term debt, approximate fair value due to the relatively short period to maturity for these instruments.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;Related Parties&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;The Company follows ASC &lt;em style="font: inherit;"&gt;850,&lt;/em&gt;&#160;&lt;i&gt;Related Party Disclosures&lt;/i&gt;,&#160;for the identification of related parties and disclosure of related party transactions. See further discussion in the Notes below on this matter.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting and the tax basis of reported assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company must then assess the likelihood that the resulting deferred tax assets will be realized. A valuation allowance is provided when it is more likely than &lt;em style="font: inherit;"&gt;not&lt;/em&gt; that some portion or all of a deferred tax asset will &lt;em style="font: inherit;"&gt;not&lt;/em&gt; be realized. As of&#160;&lt;em style="font: inherit;"&gt; March 31, 2025 &lt;/em&gt;and&#160;&lt;em style="font: inherit;"&gt; March 31, 2024 &lt;/em&gt;the Company determined a full valuation allowance was required to offset its deferred tax assets as a result of recurring operating losses.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;The Company accounts for uncertain tax positions in accordance with the provisions of ASC &lt;em style="font: inherit;"&gt;740&lt;/em&gt;-&lt;em style="font: inherit;"&gt;10&lt;/em&gt; which prescribes a recognition threshold and measurement attribute for financial statement disclosure of tax positions taken, or expected to be taken, on its tax return. The Company evaluates and records any uncertain tax positions based on the amount that management deems is more likely than &lt;em style="font: inherit;"&gt;not&lt;/em&gt; to be sustained upon examination and ultimate settlement with the tax authorities in the tax jurisdictions in which it operates. As of &lt;em style="font: inherit;"&gt; March 31, 2025 &lt;/em&gt;and&#160;&lt;em style="font: inherit;"&gt; March 31, 2024 &lt;/em&gt;the Company had no uncertain tax positions.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;Stock-based Compensation&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;Employee share-based compensation is measured at the grant date, based on the fair value of the award, and is recognized as an expense over the requisite service period.&#160;For awards with a performance condition, compensation expense is recognized over the requisite service period if it is probable that the performance condition will be satisfied. For awards to non-employees, the Company recognizes compensation expense in the same manner as if the Company had paid cash for the goods or services. The Company estimates the fair value of options and equity classified warrants granted using an options pricing model. Expense is recognized within general and administrative and research and development expenses and forfeitures are recognized as they are incurred.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;Warrants&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#x2019;s specific terms and applicable authoritative guidance in FASB ASC &lt;em style="font: inherit;"&gt;480,&lt;/em&gt; Distinguishing Liabilities from Equity (&#x201c;ASC &lt;em style="font: inherit;"&gt;480&#x201d;&lt;/em&gt;) and ASC &lt;em style="font: inherit;"&gt;815,&lt;/em&gt; Derivatives and Hedging (&#x201c;ASC &lt;em style="font: inherit;"&gt;815&#x201d;&lt;/em&gt;). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC &lt;em style="font: inherit;"&gt;480,&lt;/em&gt; meet the definition of a liability pursuant to ASC &lt;em style="font: inherit;"&gt;480,&lt;/em&gt; and whether the warrants meet all of the requirements for equity classification under ASC &lt;em style="font: inherit;"&gt;815,&lt;/em&gt; including whether the warrants are indexed to the Company&#x2019;s own ordinary shares and whether the warrant holders could potentially require &#x201c;net cash settlement&#x201d; in a circumstance outside of the Company&#x2019;s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do &lt;em style="font: inherit;"&gt;not&lt;/em&gt; meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss on the&#160;statements of operations. The fair value of the warrants is estimated using a Black-Scholes pricing model or a Monte Carlo simulation.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;The Company&#xfeff; issued warrants to purchase shares of common stock (i) in connection with the Bridge Offering, (ii) as part of selling agent compensation in &lt;em style="font: inherit;"&gt;2024,&lt;/em&gt; (iii) in connection with the Exclusive License Termination Agreement (the &#x201c;Termination Agreement&#x201d;), and (iv) as part of the Offering&#xfeff;. Based on the guidance noted above, we determined that warrants issued in connection with the Termination Agreement should be accounted for as a liability and the remaining warrants issued meet the requirements for equity classification. Liability classified warrants are subject to remeasurement at each balance sheet date, while equity classified warrants are valued at inception only. As discussed in Note &lt;em style="font: inherit;"&gt;2,&lt;/em&gt; the liability warrants subsequently met the requirements for equity classification.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;Loss Per Common Share&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;Basic loss per common share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period, which includes shares issuable for little to &lt;em style="font: inherit;"&gt;no&lt;/em&gt; consideration upon the exercise of certain equity-classified warrants. Diluted loss per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. In periods when losses are reported, the weighted-average number of common shares outstanding excludes common stock equivalents, because their inclusion would be anti-dilutive. Generally, the Company&#x2019;s outstanding warrants are non-participating securities as they are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; entitled to non-forfeitable rights to dividends or dividend equivalents during the vesting term and have &lt;em style="font: inherit;"&gt;no&lt;/em&gt; obligation to fund losses.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;However, the Company's warrants d&#xfeff;escribed in Note&#160;&lt;em style="font: inherit;"&gt;2&lt;/em&gt;&#160;and the warrants issued in connection with the Offering, are participating securities as the holders receive the right to dividends, but they are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; obligated to fund losses. In periods of loss, since &lt;em style="font: inherit;"&gt;no&lt;/em&gt; income is allocated to these securities, the Company's use of the "treasury stock method" derives the same result. The dilutive effect of convertible securities is calculated using the &#x201c;if-converted method.&#x201d; Under the if-converted method, securities are assumed to be converted at the beginning of the period, and the resulting common shares are included in the denominator of the diluted calculation for the entire period being presented.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;For the &lt;em style="font: inherit;"&gt;twelve&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; March 31, 2025&#160;&lt;/em&gt;and &lt;em style="font: inherit;"&gt;2024,&lt;/em&gt; dilutive securities that were &lt;em style="font: inherit;"&gt;not&lt;/em&gt; included in the calculations of the loss per common share because they would be anti-dilutive included the following:&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 5%; width: 95%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;March 31,&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;(as revised)&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 68%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Equity based warrants to purchase common shares&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;87,531&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4,334&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Convertible Notes - common shares (1)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;33,250&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Convertible Notes - equity-based warrants to purchase common shares&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;25,003&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;25,003&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Stock options granted under Company's incentive plan&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;243,483&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;100,180&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Series A Warrants&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,533,096&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Representative Warrants&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;91,985&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total potentially dilutive securities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,981,098&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;162,767&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
    &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 108pt;"&gt;(&lt;em style="font: inherit;"&gt;1&lt;/em&gt;) Shares for the convertible note proceeds received&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;Research and Development Costs&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;Research and development costs are expensed as incurred.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;Advertising&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;It is our policy to expense advertising costs as incurred. Advertising&#160;expenses are included within general and administrative expenses within the statement of operations. For the years ended &lt;em style="font: inherit;"&gt; March 31, 2025 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2024,&lt;/em&gt; the Company recorded less than $0.1&#160;million and $1.8&#160;million, respectively.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;Fair Value of Common Stock&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;Prior to establishing a public market for the Company&#x2019;s common stock, the estimated fair value of the Company&#x2019;s common stock was determined by the Company&#x2019;s Board of Directors (the "Board") as of the date of each option grant, with input from management, considering the Company&#x2019;s most recently available &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party valuations of common stock, recent sales of common stock to &lt;em style="font: inherit;"&gt;third&lt;/em&gt; parties, and the Company&#x2019;s board of directors&#x2019; assessment of additional objective and subjective factors that it believed were relevant and which &lt;em style="font: inherit;"&gt; may &lt;/em&gt;have changed from the date of the most recent valuation through the date of the grant.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;JOBS Act Accounting Election&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;The Company qualifies as an emerging growth company ("EGC"), as defined in the Jumpstart Our Business Startups Act of &lt;em style="font: inherit;"&gt;2012&lt;/em&gt; (the &#x201c;JOBS Act&#x201d;). The JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected &lt;em style="font: inherit;"&gt;not&lt;/em&gt; to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This &lt;em style="font: inherit;"&gt; may &lt;/em&gt;make comparison of the Company&#x2019;s financial statements with another public company which is neither an early-stage company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;Segments&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker ("CODM"), or decision-making group, in deciding how to allocate resources in assessing performance. Management has determined that the Company operates in&#160;&lt;span style="-sec-ix-hidden:c134564434"&gt;one&lt;/span&gt;&#160;reportable segment, which is advancing the development of innovative technologies for sensing and treating disorders relating to the nervous system. The Company is initially focused on developing the technology for patients with pancreatic cancer, however, the Company believes the technology constitutes a platform with the potential to address several indications, including chronic pain management, hypertension, cardiovascular disease and a wide range of other nerve-related disorders. The Company's CODM is its Chief Executive Officer.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;The accounting policies of the segment are the same as those described in the summary of significant accounting policies. The CODM assesses performance based on net loss, which is reported on the Statements of Operations. The measure of segment assets is reported on the balance sheet as total assets.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;To date, the Company has &lt;em style="font: inherit;"&gt;not&lt;/em&gt; generated any product revenue. The Company expects to continue to incur significant expenses and operating losses for the foreseeable future as it advances its' technology through all stages of development and clinical trials and, ultimately, seek regulatory approval.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;As such, the CODM primarily evaluates performance of the Company using various financial metrics, including the combined net income (loss) from operations, also shown on the Statements of Operations, forecasted cash expenditures and existing and forecasted cash balances. These financial metrics are used by the CODM to make key operating decisions, such as the assessment of segment performance and allocation of resources. The significant expense categories within net loss from operations that the CODM regularly reviews are expenses related to research and development, general and administrative, and depreciation and amortization. The significant expense categories and subcategories are reported on the Statements of Operations.&#160;Other expenses included in the Company&#x2019;s net loss include change in fair value of warrant liabilities, other income (expense), interest income, net, and any additional non-operating expenses that are reported on the Statements of Operations.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;Recent Accounting Pronouncements&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;In&#160;&lt;em style="font: inherit;"&gt; November 2024 &lt;/em&gt;and &lt;em style="font: inherit;"&gt; January 2025,&#160;&lt;/em&gt;FASB issued ASU&#160;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;-&lt;em style="font: inherit;"&gt;03&lt;/em&gt; and ASU &lt;em style="font: inherit;"&gt;2025&lt;/em&gt;-&lt;em style="font: inherit;"&gt;01,&lt;/em&gt;&#160;Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic&#160;&lt;em style="font: inherit;"&gt;220&lt;/em&gt;-&lt;em style="font: inherit;"&gt;40&lt;/em&gt;): Disaggregation of Income Statement Expenses, which requires disclosure in the notes to the financial statements of specified information about certain costs and expenses. The amendments to the standards are effective for fiscal years beginning after&#160;&lt;em style="font: inherit;"&gt; December 15, 2026,&#160;&lt;/em&gt;and for interim periods within fiscal years beginning after&#160;&lt;em style="font: inherit;"&gt; December 15, 2027.&#160;&lt;/em&gt;Early adoption is permitted. The amendments should be applied either prospectively to financial statements issued for reporting periods after the effective date of this ASU or retrospectively to any or all prior periods presented in the financial statements. The Company is currently evaluating the new guidance to determine the impact it&#160;&lt;em style="font: inherit;"&gt; may&#160;&lt;/em&gt;have on its financial statements and related disclosures.&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;In &lt;em style="font: inherit;"&gt; December 2023, &lt;/em&gt;the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update, or ASU &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;-&lt;em style="font: inherit;"&gt;09,&lt;/em&gt; Income Taxes (Topic &lt;em style="font: inherit;"&gt;740&lt;/em&gt;): Improvements to Income Tax Disclosures. ASU &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;-&lt;em style="font: inherit;"&gt;09&lt;/em&gt;&#160;improves the transparency of income tax disclosures by requiring consistent categories and greater disaggregation of information in the effective tax rate reconciliation and income taxes paid disaggregated by jurisdiction. It also includes certain other amendments to improve the effectiveness of income tax disclosures. This guidance will be effective for the annual periods beginning after the year ended &lt;em style="font: inherit;"&gt; December 31, 2024. &lt;/em&gt;The Company is currently assessing the impact of ASU &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;-&lt;em style="font: inherit;"&gt;09&lt;/em&gt; on its disclosures.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;In &lt;em style="font: inherit;"&gt; November 2023, &lt;/em&gt;the FASB issued ASU &lt;em style="font: inherit;"&gt;No.&lt;/em&gt; &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;-&lt;em style="font: inherit;"&gt;07,&lt;/em&gt; Improvements to Reportable Segment Disclosures (ASU &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;-&lt;em style="font: inherit;"&gt;07&lt;/em&gt;) which is intended to improve reportable segment disclosures primarily through enhanced disclosure of reportable segment expenses and requires that a public entity that has a single reportable segment provide all the disclosures required by ASU &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;-&lt;em style="font: inherit;"&gt;07&lt;/em&gt; and all existing segment disclosures in Topic &lt;em style="font: inherit;"&gt;280.&lt;/em&gt; The new guidance is required to be applied retrospectively to all prior periods presented in the financial statements and is effective for the Company for fiscal periods beginning after &lt;em style="font: inherit;"&gt; December 15, 2023 &lt;/em&gt;and interim periods within fiscal years beginning after &lt;em style="font: inherit;"&gt; December 15, 2024. &lt;/em&gt;The Company adopted ASU &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;-&lt;em style="font: inherit;"&gt;07&lt;/em&gt; during the year ended &lt;em style="font: inherit;"&gt; March 31, 2025. &lt;/em&gt;There was &lt;em style="font: inherit;"&gt;no&lt;/em&gt; impact upon adoption of ASU &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;-&lt;em style="font: inherit;"&gt;07.&lt;/em&gt;&#160;The Company views its operations and manages its business in&#160;&lt;span style="-sec-ix-hidden:c134564463"&gt;one&lt;/span&gt;&#160;operating segment.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;There are &lt;em style="font: inherit;"&gt;no&lt;/em&gt; other effective pronouncements, or pronouncements issued but &lt;em style="font: inherit;"&gt;not&lt;/em&gt; yet effective, if adopted, that would have a material effect on the accompanying financial statements.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;Correction of an Immaterial Error in the Prior Period Financial Statements&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;D&#xfeff;uring the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; December 31, 2024, &lt;/em&gt;the Company determined that previously filed quarterly and annual financial statements had an immaterial earnings per share error resulting from the exclusion of certain unexercised equity based warrants to purchase common shares that had an exercise price of approximately $0.01 or less from the basic earnings per share calculations in accordance with &lt;i&gt;ASC &lt;em style="font: inherit;"&gt;260&lt;/em&gt;-&lt;em style="font: inherit;"&gt;10&lt;/em&gt;-&lt;em style="font: inherit;"&gt;45&lt;/em&gt;-&lt;em style="font: inherit;"&gt;13&lt;/em&gt;&lt;/i&gt;. As a&#160;result, the prior year earnings per share calculations have been revised for consistency with the current year presentation. The Company assessed the materiality of this change in presentation on prior period financial statements in accordance with &lt;i&gt;SEC Staff Accounting Bulletin &lt;em style="font: inherit;"&gt;No.&lt;/em&gt; &lt;em style="font: inherit;"&gt;99&lt;/em&gt;&lt;/i&gt;, &#x201c;&lt;i&gt;Materiality&lt;/i&gt;,&#x201d; (&lt;i&gt;ASC Topic &lt;em style="font: inherit;"&gt;250,&lt;/em&gt; Accounting Changes and Error Corrections&lt;/i&gt;). Based on this assessment, the Company concluded that this error correction in its&#160;&lt;i&gt;Statements of Operations&lt;/i&gt;&#160;and &lt;i&gt;Note &lt;em style="font: inherit;"&gt;1&lt;/em&gt; &lt;/i&gt;&#x2013;&lt;i&gt; Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies (Loss Per Common Share)&lt;/i&gt; is &lt;em style="font: inherit;"&gt;not&lt;/em&gt; material to any previously presented financial statements based upon overall considerations of both quantitative and qualitative factors. The corrections had &lt;em style="font: inherit;"&gt;no&lt;/em&gt; impact in the comparative period Balance Sheet,&#160;Statements of Cash Flows, or Statement of Changes in Stockholders&#x2019;&#160;Equity. Further, the immaterial correction did &lt;em style="font: inherit;"&gt;not&lt;/em&gt; result in a change in operating losses or net loss in the Statement of Operations and the effects of including unexercised warrants in the earnings per share calculation have an antidilutive effect reducing the net loss per share amount. Accordingly, the Company corrected the previously reported earnings per share calculation for the &lt;em style="font: inherit;"&gt;twelve&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; March 31, 2024 &lt;/em&gt;in this Annual Report on Form &lt;em style="font: inherit;"&gt;10&lt;/em&gt;-K.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;A summary of the impact of the Company&#x2019;s Reverse Stock Split and immaterial corrections reflecting the prior period impact to the Company&#x2019;s Statement of Operations and earnings per share are shown below:&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="14" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Twelve Months Ended March 31, 2024&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Originally&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Filed&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Adjusted &lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;for 1-for-20 &lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Reverse &lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Stock Split&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Correction&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;As Revised&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 52%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Net Loss (in thousands)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(15,426&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(15,426&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Loss per share - basic and diluted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(1.05&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(21.09&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;6.27&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(14.82&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Weighted average shares outstanding - basic and diluted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;14,626,282&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;731,372&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;309,348&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,040,720&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
    &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;A summary of the impact of the Company&#x2019;s Reverse Stock Split and immaterial corrections reflecting the prior period impact to the disclosure of dilutive securities that were &lt;em style="font: inherit;"&gt;not&lt;/em&gt; included in the calculations of the loss per common share because they would be anti-dilutive are shown below:&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

     &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="14" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Twelve Months Ended March 31, 2024&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Originally &lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Filed&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Adjusted f&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;or 1-for-20 &lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Reverse &lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Stock Split&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Correction&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;As Revised&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 52%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Equity based warrants to purchase common shares&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;5,744,569&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;287,231&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(282,897&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4,334&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Convertible Notes - common shares&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;665,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;33,250&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;33,250&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Convertible Notes - equity-based warrants to purchase common shares&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;500,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;25,003&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;25,003&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Stock options granted under Company's incentive plan&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2,003,600&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;100,180&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;100,180&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Total potentially dilutive securities&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;b&gt;8,913,169&lt;/b&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;b&gt;445,664&lt;/b&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;b&gt;(282,897&lt;/b&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;b&gt;162,767&lt;/b&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
     &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;


  </us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <amix:ReverseStockSplitPolicyTextBlock contextRef="d_2024-04-01_2025-03-31" id="c134565403">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;Reverse Stock Split&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;The Company&#160;held its annual meeting of stockholders (the "Annual Meeting") on&#160;&lt;em style="font: inherit;"&gt; October 17, 2024&lt;/em&gt;&lt;i&gt;.&lt;/i&gt;&#160;In that Annual Meeting, stockholders of the Company approved an amendment to the Company&#x2019;s amended and restated certificate of incorporation (the "Amendment&#x201d;) to effect the reverse stock split at a ratio in the range of&#160;&lt;em style="font: inherit;"&gt;1&lt;/em&gt;-for-2&#160;to&#160;&lt;em style="font: inherit;"&gt;1&lt;/em&gt;-for-50, with such ratio to be determined in the discretion of the Company&#x2019;s board of directors and with such reverse stock split to be effected at such time and date, if at all, as determined by the Company&#x2019;s board of directors in its sole discretion prior to the&#160;&lt;em style="font: inherit;"&gt;one&lt;/em&gt;-year anniversary of the Annual Meeting.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;Pursuant to such authority granted by the Company&#x2019;s stockholders, the Company&#x2019;s board of directors approved a&#160;&lt;em style="font: inherit;"&gt;one&lt;/em&gt;-for-&#160;&lt;span style="-sec-ix-hidden:c134564311"&gt;twenty&lt;/span&gt;&#160;(&lt;em style="font: inherit;"&gt;1:20&lt;/em&gt;) reverse stock split (the "Reverse Stock Split&#x201d;) of the Company&#x2019;s common stock and the filing of the Amendment to effectuate the Reverse Stock Split. The Amendment was filed with the Secretary of State of the State of Delaware and the Reverse Stock Split became effective in accordance with the terms of the Amendment at&#160;&lt;em style="font: inherit;"&gt;11:59&lt;/em&gt;&#160;p.m. Eastern Time on&#160;&lt;em style="font: inherit;"&gt; October 24, 2024 (&lt;/em&gt;the "Effective Time&#x201d;), and the Company&#x2019;s common stock opened&#160;for trading on The Nasdaq Capital Market on&#160;&lt;em style="font: inherit;"&gt; October 25, 2024&#160;&lt;/em&gt;on a post-split basis, under the existing ticker symbol "AMIX&#x201d; but with a new CUSIP number&#160;&lt;em style="font: inherit;"&gt;05330T205.&lt;/em&gt;&#160;The Amendment provided that, at the Effective Time, every&#160;&lt;span style="-sec-ix-hidden:c134564315"&gt;twenty&lt;/span&gt;&#160;shares of the Company&#x2019;s issued and outstanding common stock automatically combined into&#160;&lt;em style="font: inherit;"&gt;one&lt;/em&gt;&#160;issued and outstanding share of common stock, without any change in par value per share, which remained $0.001.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;The number of authorized shares of common stock remained&#160;at&#160;500&#160;million shares. As a result of the Reverse Stock Split, proportionate adjustments were made to the per share exercise price and/or the number of shares issuable upon the exercise or vesting of all outstanding stock options, restricted stock unit awards, warrants and convertible notes, which resulted in a proportional decrease in the number of shares of the Company&#x2019;s common stock reserved for issuance upon exercise or vesting of such stock options, restricted stock unit awards, warrants and convertible notes and, in the case of stock options and warrants, a proportional increase in the exercise price of all such stock options and warrants.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;The Company&#x2019;s stock option awards did &lt;em style="font: inherit;"&gt;not&lt;/em&gt; automatically adjust for the Reverse Stock Split.&#160;However, the Company chose to exercise its rights under the agreements to adjust the exercise price and number of shares exercisable or issuable upon vesting proportionately for the Reverse Stock Split.&#160;Based on the analysis performed, the Company does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; need to recognize any additional compensation expense as a result of the modification.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;In addition, the number of shares reserved for issuance under the Company&#x2019;s equity compensation plan immediately prior to the Effective Time was reduced proportionately.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;em style="font: inherit;"&gt;No&lt;/em&gt;&#160;fractional shares were issued as a result of the Reverse Stock Split. Any stockholder who would have been entitled to receive a fractional share as a result of the process was entitled to the rounding up of the fractional share to the nearest whole number. See "&#160;Fractional Shares" in Note&#160;&lt;em style="font: inherit;"&gt;5&lt;/em&gt;&#160;for further disclosure regarding fractional shares.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;The Reverse Stock Split has been retroactively adjusted throughout these interim financial statements and footnotes for all periods presented, including exercise prices and share data. As a result of the Reverse Stock Split, the Company reclassified approximately $18&#160;thousand between common stock par value and additional paid-in capital.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</amix:ReverseStockSplitPolicyTextBlock>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="d_2024-10-17_2024-10-17_NonmonetaryTransactionTypeAxis-ReverseStockSplitMember_RangeAxis-MinimumMember"
      decimals="INF"
      id="c134564306"
      unitRef="Pure">2</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="d_2024-10-17_2024-10-17_NonmonetaryTransactionTypeAxis-ReverseStockSplitMember_RangeAxis-MaximumMember"
      decimals="INF"
      id="c134564308"
      unitRef="Pure">50</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i_2024-10-24"
      decimals="INF"
      id="c134564317"
      unitRef="USDPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i_2024-10-24"
      decimals="-8"
      id="c134564318"
      unitRef="Share">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit
      contextRef="d_2024-10-24_2024-10-24"
      decimals="-3"
      id="c134564323"
      unitRef="USD">18000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit>
    <amix:SubstantialDoubtAboutGoingConcernPolicyPolicyTextBlock contextRef="d_2024-04-01_2025-03-31" id="c134565404">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;Liquidity and Going Concern&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;The Company's&#xfeff; financial statements are prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The Company is an early-stage company that is subject to all the risks associated with early-stage and emerging growth companies and has incurred losses since inception.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;For the years ended &lt;em style="font: inherit;"&gt; March 31, 2025 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2024,&lt;/em&gt; the Company has net losses of approximately $11.4 million and $15.4 million, respectively and had net cash flows used in operating activities of $8.3&#160;million&#160;and $6.6 million, respectively. The Company had no revenues for the years ended &lt;em style="font: inherit;"&gt; March 31, 2025 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2024,&lt;/em&gt; respectively. The Company had an accumulated deficit of $50.4 million and working capital of approximately $7.9 million as of &lt;em style="font: inherit;"&gt; March 31, 2025. &lt;/em&gt;The Company does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; expect to generate positive cash flows from operating activities in the near future. These conditions, and the Company's ability to comply with such conditions, raise substantial doubt about the Company's ability to continue as a going concern within &lt;em style="font: inherit;"&gt;one&lt;/em&gt; year after the date that the financial statements are issued. The accompanying financial statements have been prepared on a going concern basis and do &lt;em style="font: inherit;"&gt;not&lt;/em&gt; include any adjustments that might be necessary if the Company is unable to continue as a going concern.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;On &lt;em style="font: inherit;"&gt; January 26, 2024, &lt;/em&gt;the Company completed its IPO, pursuant to which it sold a total of 111,962&#160;shares of common stock at a purchase price of $100.00 per share for gross proceeds of $11.2 million and net proceeds of $9.8 million.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;On &lt;em style="font: inherit;"&gt; November 22, 2024, &lt;/em&gt;the Company completed a firm commitment underwritten public offering (the &#x201c;Offering&#x201d;) of: (i) 458,691 common units (the &#x201c;Common Units&#x201d;), each Common Unit consisting of &lt;span style="-sec-ix-hidden:c134564342"&gt;one&lt;/span&gt; share of Company common stock and &lt;span style="-sec-ix-hidden:c134564343"&gt;one&lt;/span&gt; series A warrant to purchase &lt;span style="-sec-ix-hidden:c134564344"&gt;one&lt;/span&gt; share of common stock (the &#x201c;Series A Warrants&#x201d;); and (ii) 917,596 pre-funded units (the &#x201c;Pre-Funded Units&#x201d;) and together with the Common Units, the "Units", each Pre-Funded Unit consisting of &lt;span style="-sec-ix-hidden:c134564346"&gt;one&lt;/span&gt; pre-funded warrant to purchase &lt;span style="-sec-ix-hidden:c134564347"&gt;one&lt;/span&gt; share of common stock (the &#x201c;Pre-Funded Warrant&#x201d;) and &lt;span style="-sec-ix-hidden:c134564348"&gt;one&lt;/span&gt; Series A Warrant. The purchase price of each Common Unit was $6.540, and the purchase price of each Pre-Funded Unit was $6.539.&#160;In addition, the Company granted the underwriters in the Offering a 45-day option to purchase an additional 206,422 shares of common stock, and/or an additional 206,422 Series A Warrants, solely to cover over-allotments, if any. The Pre-Funded Warrants have an exercise price of $0.001 per share, are immediately exercisable and &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be exercised at any time until all of the Pre-Funded Warrants are exercised in full. The Series A Warrants have an exercise price of $6.540 per share, are immediately exercisable and &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be exercised at any time until the &lt;span style="-sec-ix-hidden:c134564356"&gt;five&lt;/span&gt;-year anniversary of the date of issuance. Both the Pre-Funded Warrants and the Series A Warrants are subject to a beneficial ownership limitation of 4.99%. The Offering closed on &lt;em style="font: inherit;"&gt; November 25, 2024. &lt;/em&gt;On &lt;em style="font: inherit;"&gt; November 22, 2024, &lt;/em&gt;the underwriters partially exercised their over-allotment option with respect to 156,809 shares of common stock and 156,809 Series A Warrants. The aggregate gross proceeds to the Company, including the partial exercise of the over-allotment option, were approximately $10.0 million, before deducting underwriting discounts and other expenses by the Company of $1.5 million, including $0.5 million of non-cash expenses. The net cash proceeds to the Company were approximately $9.0 million.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;On &lt;em style="font: inherit;"&gt; February 28, 2025, &lt;/em&gt;the Company entered into an At Market Issuances Sales Agreement (the &#x201c;ATM Agreement&#x201d;) with Ladenburg Thalmann &amp;amp; Co. Inc. (the &#x201c;Agent&#x201d;). Pursuant to the terms of the ATM Agreement, the Company &lt;em style="font: inherit;"&gt; may &lt;/em&gt;sell from time to time through the Agent, as sales agent or principal, shares of the Company&#x2019;s common stock with an initial aggregate sales price of up to $2.1 million (the &#x201c;Shares&#x201d;). Any sale of Shares pursuant to the Agreement will be made under the Company&#x2019;s &#x201c;shelf&#x201d; registration statement (the &#x201c;Registration Statement&#x201d;) on Form S-&lt;em style="font: inherit;"&gt;3&lt;/em&gt; filed on &lt;em style="font: inherit;"&gt; February 28, 2025 &lt;/em&gt;with the Securities and Exchange Commission (the &#x201c;SEC&#x201d;). Under the ATM Agreement, the Company &lt;em style="font: inherit;"&gt; may &lt;/em&gt;sell Shares through the Agent by any method that is deemed an &#x201c;at the market offering&#x201d; (as defined in Rule &lt;em style="font: inherit;"&gt;415&lt;/em&gt;(a)(&lt;em style="font: inherit;"&gt;4&lt;/em&gt;) under the Securities Act of &lt;em style="font: inherit;"&gt;1933,&lt;/em&gt; as amended). Under the ATM Agreement, the Agent will also be able to sell shares of Common Stock by any other method permitted by law, including in negotiated transactions with the Company&#x2019;s prior written consent. The Company will pay a commission to the Agent of 3.0% of the gross proceeds of the sale of the Shares sold under the ATM Agreement and reimburse the Agent for certain expenses. As of &lt;em style="font: inherit;"&gt; March 31, 2025, &lt;/em&gt;the Company sold 800 shares pursuant to the ATM Agreement for net proceeds of approximately $1,746.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;The Company estimates its current cash resources are sufficient to fund its operations into but &lt;em style="font: inherit;"&gt;not&lt;/em&gt; beyond the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; calendar quarter of &lt;em style="font: inherit;"&gt;2026.&lt;/em&gt; The Company recognizes it will need to raise additional capital to continue to execute its business plan, including obtaining regulatory clearance for its products currently under development and commercializing and generating revenues from products under development. There is &lt;em style="font: inherit;"&gt;no&lt;/em&gt; assurance that additional financing will be available when needed or that management will be able to obtain financing on terms acceptable to the Company. A failure to raise sufficient capital, generate sufficient product revenues, control expenditures and regulatory matters, among other factors, will adversely impact the Company&#x2019;s ability to meet its financial obligations as they become due and payable and to achieve its intended business objectives. If the Company is unable to raise sufficient additional funds, it will have to scale back its operations.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</amix:SubstantialDoubtAboutGoingConcernPolicyPolicyTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-04-01_2025-03-31"
      decimals="-5"
      id="c134564326"
      unitRef="USD">-11400000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2023-04-01_2024-03-31"
      decimals="-5"
      id="c134564327"
      unitRef="USD">-15400000</us-gaap:NetIncomeLoss>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="d_2024-04-01_2025-03-31"
      decimals="-5"
      id="c134564328"
      unitRef="USD">-8300000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="d_2023-04-01_2024-03-31"
      decimals="-5"
      id="c134564329"
      unitRef="USD">-6600000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:Revenues
      contextRef="d_2024-04-01_2025-03-31"
      decimals="-3"
      id="c134564330"
      unitRef="USD">0</us-gaap:Revenues>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i_2025-03-31"
      decimals="-5"
      id="c134564332"
      unitRef="USD">-50400000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <amix:WorkingCapitalDeficit
      contextRef="i_2025-03-31"
      decimals="-5"
      id="c134564333"
      unitRef="USD">7900000</amix:WorkingCapitalDeficit>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2024-01-26_2024-01-26_SubsidiarySaleOfStockAxis-IPOMember"
      decimals="INF"
      id="c134564337"
      unitRef="Share">111962</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="i_2024-01-26_SubsidiarySaleOfStockAxis-IPOMember"
      decimals="INF"
      id="c134564338"
      unitRef="USDPerShare">100</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2024-01-26_2024-01-26_SubsidiarySaleOfStockAxis-IPOMember"
      decimals="-5"
      id="c134564339"
      unitRef="USD">11200000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="d_2024-01-26_2024-01-26_SubsidiarySaleOfStockAxis-IPOMember"
      decimals="-5"
      id="c134564340"
      unitRef="USD">9800000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <amix:NumberOfCommonUnitsIssued
      contextRef="d_2024-11-22_2024-11-25_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember"
      decimals="INF"
      id="c134564341"
      unitRef="Share">458691</amix:NumberOfCommonUnitsIssued>
    <amix:NumberOfPrefundedUnitsIssued
      contextRef="d_2024-11-22_2024-11-25_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember"
      decimals="INF"
      id="c134564345"
      unitRef="Share">917596</amix:NumberOfPrefundedUnitsIssued>
    <amix:CommonUnitsIssuedPurchasePrice
      contextRef="d_2024-11-22_2024-11-25_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember"
      decimals="INF"
      id="c134564349"
      unitRef="USDPerShare">6.54</amix:CommonUnitsIssuedPurchasePrice>
    <amix:PrefundedUnitsIssuedPurchasePrice
      contextRef="d_2024-11-22_2024-11-25_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember"
      decimals="INF"
      id="c134564350"
      unitRef="USDPerShare">6.539</amix:PrefundedUnitsIssuedPurchasePrice>
    <amix:EquityOfferingOptionPeriod
      contextRef="d_2024-11-22_2024-11-22_CounterpartyNameAxis-UnderwritersMember_SubsidiarySaleOfStockAxis-OverAllotmentOptionMember"
      id="c134564351">P45D</amix:EquityOfferingOptionPeriod>
    <amix:EquityOfferingOptionMaximumShares
      contextRef="i_2024-11-22_CounterpartyNameAxis-UnderwritersMember_SubsidiarySaleOfStockAxis-OverAllotmentOptionMember"
      decimals="INF"
      id="c134564352"
      unitRef="Share">206422</amix:EquityOfferingOptionMaximumShares>
    <amix:EquityOfferingOptionMaximumWarrants
      contextRef="i_2024-11-22_ClassOfWarrantOrRightAxis-SeriesAWarrantsMember_CounterpartyNameAxis-UnderwritersMember"
      decimals="INF"
      id="c134564353"
      unitRef="Share">206422</amix:EquityOfferingOptionMaximumWarrants>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2024-11-25_ClassOfWarrantOrRightAxis-PrefundedWarrantsMember"
      decimals="INF"
      id="c134564354"
      unitRef="USDPerShare">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2024-11-25_ClassOfWarrantOrRightAxis-SeriesAWarrantsMember"
      decimals="INF"
      id="c134564355"
      unitRef="USDPerShare">6.54</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <amix:ClassOfWarrantsOrRightsMaximumBeneficialOwnership
      contextRef="i_2024-11-25_ClassOfWarrantOrRightAxis-PrefundedAndSeriesAWarrantsMember"
      decimals="4"
      id="c134564357"
      unitRef="Pure">0.0499</amix:ClassOfWarrantsOrRightsMaximumBeneficialOwnership>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2024-11-22_2024-11-22_CounterpartyNameAxis-UnderwritersMember_SubsidiarySaleOfStockAxis-OverAllotmentOptionMember"
      decimals="INF"
      id="c134564358"
      unitRef="Share">156809</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <amix:ClassOfWarrantOrRightIssuedDuringPeriod
      contextRef="d_2024-11-22_2024-11-22_ClassOfWarrantOrRightAxis-SeriesAWarrantsMember_CounterpartyNameAxis-UnderwritersMember"
      decimals="INF"
      id="c134564359"
      unitRef="Share">156809</amix:ClassOfWarrantOrRightIssuedDuringPeriod>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="d_2024-11-22_2024-11-25_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember"
      decimals="-7"
      id="c134564360"
      unitRef="USD">10000000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="d_2024-11-22_2024-11-25_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember"
      decimals="-5"
      id="c134564361"
      unitRef="USD">1500000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="d_2024-11-22_2024-11-25_NatureOfExpenseAxis-NoncashExpensesMember_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember"
      decimals="-5"
      id="c134564362"
      unitRef="USD">500000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <amix:ProceedsFromIssuanceOrSaleOfEquityNet
      contextRef="d_2024-11-22_2024-11-25_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember"
      decimals="-6"
      id="c134564363"
      unitRef="USD">9000000</amix:ProceedsFromIssuanceOrSaleOfEquityNet>
    <amix:EquityOfferingMaximumOfferingAmount
      contextRef="i_2025-02-28_SubsidiarySaleOfStockAxis-ATMAgreementMember"
      decimals="-5"
      id="c134564364"
      unitRef="USD">2100000</amix:EquityOfferingMaximumOfferingAmount>
    <amix:CommissionPercentage
      contextRef="i_2025-02-28_CounterpartyNameAxis-SellingAgentMember_SubsidiarySaleOfStockAxis-ATMAgreementMember"
      decimals="2"
      id="c134564369"
      unitRef="Pure">0.03</amix:CommissionPercentage>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2025-03-01_2025-03-31_SubsidiarySaleOfStockAxis-ATMAgreementMember"
      decimals="INF"
      id="c134564370"
      unitRef="Share">800</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="d_2025-03-01_2025-03-31_SubsidiarySaleOfStockAxis-ATMAgreementMember"
      decimals="INF"
      id="c134564371"
      unitRef="USD">1746</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="d_2024-04-01_2025-03-31" id="c134565405">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;Basis of Presentation&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;The annual financial statements and disclosures have been prepared using the accrual basis of accounting in accordance with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;).&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="d_2024-04-01_2025-03-31" id="c134565406">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;Use of Estimates in Financial Statement Presentation&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;The preparation of these financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The Company's significant estimates and assumptions include the valuation of equity related instruments, and initial and recurring fair value measurements for the warrant liability. Although the Company believes that its estimates and assumptions are reasonable, they are based upon information available at the time the estimates and assumptions were made. Some of these judgments can be subjective and complex, and, consequently, actual results could differ from those estimates.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="d_2024-04-01_2025-03-31" id="c134565407">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;Cash and Cash Equivalents&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;The Company considers all highly liquid accounts with original maturities of &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months or less at the date of acquisition to be cash equivalents.&#160;Periodically, the Company &lt;em style="font: inherit;"&gt; may &lt;/em&gt;carry cash balances at financial institutions in excess of the federally insured limit of &lt;em style="font: inherit;"&gt;$250,000.&lt;/em&gt; The Company has &lt;em style="font: inherit;"&gt;not&lt;/em&gt; experienced losses on these accounts and management believes, based upon the quality of the financial institutions, that the credit risk with regard to these deposits is &lt;em style="font: inherit;"&gt;not&lt;/em&gt; significant.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <amix:OfferingCostsPolicyPolicyTextBlock contextRef="d_2024-04-01_2025-03-31" id="c134565408">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;Offering and Financing Costs&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;Offering costs consist of professional costs incurred through the balance sheet date that were direct and incremental to the Company&#x2019;s equity financing activities. Specifically, offering costs were incurred on the Company's IPO, the Offering and the Registration Statement. The costs for the Registration Statement are recorded in deferred offering costs on the balance sheet as of &lt;em style="font: inherit;"&gt; March 31, 2025. &lt;/em&gt;Costs associated with salaries and other period costs were expensed as incurred.&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;During the year ended &lt;em style="font: inherit;"&gt; March 31, 2024, &lt;/em&gt;the Company paid $1.3 million of issuance&#160;costs related to its IPO.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;During the year ended &lt;em style="font: inherit;"&gt; March 31, 2025, &lt;/em&gt;the Company paid $1.1 million of issuance costs related to its Offering and $0.2 million of offering costs related to its Registration Statement.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</amix:OfferingCostsPolicyPolicyTextBlock>
    <amix:PaymentsForInitialPublicOfferingIssuanceCosts
      contextRef="d_2023-04-01_2024-03-31"
      decimals="-5"
      id="c134564381"
      unitRef="USD">1300000</amix:PaymentsForInitialPublicOfferingIssuanceCosts>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="d_2024-04-01_2025-03-31"
      decimals="-5"
      id="c134564382"
      unitRef="USD">1100000</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="d_2024-04-01_2025-03-31"
      decimals="-5"
      id="c134564383"
      unitRef="USD">200000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="d_2024-04-01_2025-03-31" id="c134565409">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;Property and Equipment&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;Property and equipment are stated at historical cost and depreciated on a straight-line basis over their estimated useful lives, generally&#160;&lt;span style="-sec-ix-hidden:c134564384"&gt;three&lt;/span&gt; years. Upon disposition of the assets, the costs and related accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the results of operations.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:DebtPolicyTextBlock contextRef="d_2024-04-01_2025-03-31" id="c134565410">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;Convertible Notes&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;The Company evaluates embedded redemption, conversion and other features within its debt to determine whether any embedded features should be bifurcated from the host instrument and accounted for as a derivative at fair value, with changes in fair value recorded in the statement of operations.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;The Company&#x2019;s debt is carried on the balance sheet on a historical cost basis net of unamortized discounts and premiums because the Company has &lt;em style="font: inherit;"&gt;not&lt;/em&gt; elected the fair value option of accounting. Costs associated with acquiring debt, including detachable warrants issued in connection with the financing, are capitalized as a debt discount. The debt discount is presented in the balance sheet as a direct deduction from the carrying amount of the debt liability. The costs are amortized over the estimated contractual life of the related debt instrument using the effective interest method and are included in interest expense in the statement of operations.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;If the Company incurs costs associated with its convertible notes, in advance of the receipt of proceeds, the Company will record a deferred asset. Upon receipt of proceeds the Company will reclassify the deferred asset as a direct deduction from the carrying amount, as described above.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;In addition, since the instruments included a substantive conversion feature at the time of issuance, the issuance of equity securities were accounted for as a contractual conversion with &lt;em style="font: inherit;"&gt;no&lt;/em&gt; gain or loss recognized related to the equity securities issued to settle the instrument. &#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:DebtPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="d_2024-04-01_2025-03-31" id="c134565411">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;Fair Value of Financial Instruments&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs. The Company utilizes a &lt;em style="font: inherit;"&gt;three&lt;/em&gt;-level valuation hierarchy for disclosures of fair value measurements, defined as follows:&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;Level &lt;em style="font: inherit;"&gt;1&lt;/em&gt; &#x2013; inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;Level &lt;em style="font: inherit;"&gt;2&lt;/em&gt; &#x2013; inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the assets or liability, either directly or indirectly, for substantially the full term of the financial instruments.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;Level &lt;em style="font: inherit;"&gt;3&lt;/em&gt; &#x2013; inputs to the valuation methodology are unobservable and significant to the fair value and require significant judgment and estimation.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;Financial assets and financial liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. While the Company believes that its valuation methods are appropriate, the Company recognizes that the use of different methodologies or assumptions to determine the fair value could result in a different estimate of fair value at the reporting date. The primary assumptions that would significantly affect the fair values are the probability weighting of the different settlement outcomes used.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;The Company did &lt;em style="font: inherit;"&gt;not&lt;/em&gt; have any assets or liabilities measured at fair value as of &lt;em style="font: inherit;"&gt; March 31, 2025 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2024,&lt;/em&gt; respectively. In the &lt;em style="font: inherit;"&gt;fourth&lt;/em&gt; quarter of the Company's fiscal year ended &lt;em style="font: inherit;"&gt; March 31, 2024 &lt;/em&gt;there was a transfer out of Level &lt;em style="font: inherit;"&gt;3&lt;/em&gt;&#160;for the warrant liability, for the settlement and reclassification to equity of the instrument, that occurred in the&#160;&lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended&#160;&lt;em style="font: inherit;"&gt; March 31, 2024. &lt;/em&gt;For additional information, see&#160;&lt;i&gt;Note &lt;em style="font: inherit;"&gt;2&lt;/em&gt; - Warrant Liability and Fair Value of Financial Instruments&lt;/i&gt;.&#xfeff;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;The carrying value of short-term instruments, including cash, accounts payable, accrued expenses and convertible notes included in long-term debt, approximate fair value due to the relatively short period to maturity for these instruments.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <amix:RelatedPartyTransactionsPolicyPolicyTextBlock contextRef="d_2024-04-01_2025-03-31" id="c134565412">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;Related Parties&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;The Company follows ASC &lt;em style="font: inherit;"&gt;850,&lt;/em&gt;&#160;&lt;i&gt;Related Party Disclosures&lt;/i&gt;,&#160;for the identification of related parties and disclosure of related party transactions. See further discussion in the Notes below on this matter.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</amix:RelatedPartyTransactionsPolicyPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="d_2024-04-01_2025-03-31" id="c134565413">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting and the tax basis of reported assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company must then assess the likelihood that the resulting deferred tax assets will be realized. A valuation allowance is provided when it is more likely than &lt;em style="font: inherit;"&gt;not&lt;/em&gt; that some portion or all of a deferred tax asset will &lt;em style="font: inherit;"&gt;not&lt;/em&gt; be realized. As of&#160;&lt;em style="font: inherit;"&gt; March 31, 2025 &lt;/em&gt;and&#160;&lt;em style="font: inherit;"&gt; March 31, 2024 &lt;/em&gt;the Company determined a full valuation allowance was required to offset its deferred tax assets as a result of recurring operating losses.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;The Company accounts for uncertain tax positions in accordance with the provisions of ASC &lt;em style="font: inherit;"&gt;740&lt;/em&gt;-&lt;em style="font: inherit;"&gt;10&lt;/em&gt; which prescribes a recognition threshold and measurement attribute for financial statement disclosure of tax positions taken, or expected to be taken, on its tax return. The Company evaluates and records any uncertain tax positions based on the amount that management deems is more likely than &lt;em style="font: inherit;"&gt;not&lt;/em&gt; to be sustained upon examination and ultimate settlement with the tax authorities in the tax jurisdictions in which it operates. As of &lt;em style="font: inherit;"&gt; March 31, 2025 &lt;/em&gt;and&#160;&lt;em style="font: inherit;"&gt; March 31, 2024 &lt;/em&gt;the Company had no uncertain tax positions.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:LiabilityForUncertainTaxPositionsCurrent
      contextRef="i_2025-03-31"
      decimals="-3"
      id="c134564404"
      unitRef="USD">0</us-gaap:LiabilityForUncertainTaxPositionsCurrent>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="d_2024-04-01_2025-03-31" id="c134565414">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;Stock-based Compensation&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;Employee share-based compensation is measured at the grant date, based on the fair value of the award, and is recognized as an expense over the requisite service period.&#160;For awards with a performance condition, compensation expense is recognized over the requisite service period if it is probable that the performance condition will be satisfied. For awards to non-employees, the Company recognizes compensation expense in the same manner as if the Company had paid cash for the goods or services. The Company estimates the fair value of options and equity classified warrants granted using an options pricing model. Expense is recognized within general and administrative and research and development expenses and forfeitures are recognized as they are incurred.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <amix:WarrantsPolicyPolicyTextBlock contextRef="d_2024-04-01_2025-03-31" id="c134565415">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;Warrants&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#x2019;s specific terms and applicable authoritative guidance in FASB ASC &lt;em style="font: inherit;"&gt;480,&lt;/em&gt; Distinguishing Liabilities from Equity (&#x201c;ASC &lt;em style="font: inherit;"&gt;480&#x201d;&lt;/em&gt;) and ASC &lt;em style="font: inherit;"&gt;815,&lt;/em&gt; Derivatives and Hedging (&#x201c;ASC &lt;em style="font: inherit;"&gt;815&#x201d;&lt;/em&gt;). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC &lt;em style="font: inherit;"&gt;480,&lt;/em&gt; meet the definition of a liability pursuant to ASC &lt;em style="font: inherit;"&gt;480,&lt;/em&gt; and whether the warrants meet all of the requirements for equity classification under ASC &lt;em style="font: inherit;"&gt;815,&lt;/em&gt; including whether the warrants are indexed to the Company&#x2019;s own ordinary shares and whether the warrant holders could potentially require &#x201c;net cash settlement&#x201d; in a circumstance outside of the Company&#x2019;s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do &lt;em style="font: inherit;"&gt;not&lt;/em&gt; meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss on the&#160;statements of operations. The fair value of the warrants is estimated using a Black-Scholes pricing model or a Monte Carlo simulation.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;The Company&#xfeff; issued warrants to purchase shares of common stock (i) in connection with the Bridge Offering, (ii) as part of selling agent compensation in &lt;em style="font: inherit;"&gt;2024,&lt;/em&gt; (iii) in connection with the Exclusive License Termination Agreement (the &#x201c;Termination Agreement&#x201d;), and (iv) as part of the Offering&#xfeff;. Based on the guidance noted above, we determined that warrants issued in connection with the Termination Agreement should be accounted for as a liability and the remaining warrants issued meet the requirements for equity classification. Liability classified warrants are subject to remeasurement at each balance sheet date, while equity classified warrants are valued at inception only. As discussed in Note &lt;em style="font: inherit;"&gt;2,&lt;/em&gt; the liability warrants subsequently met the requirements for equity classification.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</amix:WarrantsPolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="d_2024-04-01_2025-03-31" id="c134565416">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;Loss Per Common Share&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;Basic loss per common share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period, which includes shares issuable for little to &lt;em style="font: inherit;"&gt;no&lt;/em&gt; consideration upon the exercise of certain equity-classified warrants. Diluted loss per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. In periods when losses are reported, the weighted-average number of common shares outstanding excludes common stock equivalents, because their inclusion would be anti-dilutive. Generally, the Company&#x2019;s outstanding warrants are non-participating securities as they are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; entitled to non-forfeitable rights to dividends or dividend equivalents during the vesting term and have &lt;em style="font: inherit;"&gt;no&lt;/em&gt; obligation to fund losses.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;However, the Company's warrants d&#xfeff;escribed in Note&#160;&lt;em style="font: inherit;"&gt;2&lt;/em&gt;&#160;and the warrants issued in connection with the Offering, are participating securities as the holders receive the right to dividends, but they are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; obligated to fund losses. In periods of loss, since &lt;em style="font: inherit;"&gt;no&lt;/em&gt; income is allocated to these securities, the Company's use of the "treasury stock method" derives the same result. The dilutive effect of convertible securities is calculated using the &#x201c;if-converted method.&#x201d; Under the if-converted method, securities are assumed to be converted at the beginning of the period, and the resulting common shares are included in the denominator of the diluted calculation for the entire period being presented.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;For the &lt;em style="font: inherit;"&gt;twelve&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; March 31, 2025&#160;&lt;/em&gt;and &lt;em style="font: inherit;"&gt;2024,&lt;/em&gt; dilutive securities that were &lt;em style="font: inherit;"&gt;not&lt;/em&gt; included in the calculations of the loss per common share because they would be anti-dilutive included the following:&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 5%; width: 95%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;March 31,&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;(as revised)&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 68%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Equity based warrants to purchase common shares&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;87,531&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4,334&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Convertible Notes - common shares (1)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;33,250&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Convertible Notes - equity-based warrants to purchase common shares&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;25,003&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;25,003&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Stock options granted under Company's incentive plan&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;243,483&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;100,180&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Series A Warrants&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,533,096&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Representative Warrants&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;91,985&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total potentially dilutive securities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,981,098&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;162,767&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
    &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 108pt;"&gt;(&lt;em style="font: inherit;"&gt;1&lt;/em&gt;) Shares for the convertible note proceeds received&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="d_2024-04-01_2025-03-31" id="c3016954">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 5%; width: 95%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;March 31,&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;(as revised)&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 68%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Equity based warrants to purchase common shares&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;87,531&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4,334&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Convertible Notes - common shares (1)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;33,250&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Convertible Notes - equity-based warrants to purchase common shares&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;25,003&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;25,003&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Stock options granted under Company's incentive plan&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;243,483&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;100,180&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Series A Warrants&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,533,096&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Representative Warrants&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;91,985&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total potentially dilutive securities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,981,098&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;162,767&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2024-04-01_2025-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember"
      decimals="INF"
      id="c134563967"
      unitRef="Share">87531</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2023-04-01_2024-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember"
      decimals="INF"
      id="c134563968"
      unitRef="Share">4334</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2024-04-01_2025-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-ConvertibleDebtSecuritiesMember"
      decimals="INF"
      id="c134563969"
      unitRef="Share">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2023-04-01_2024-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-ConvertibleDebtSecuritiesMember"
      decimals="INF"
      id="c134563970"
      unitRef="Share">33250</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2024-04-01_2025-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-ConvertibleNotesToWarrantsMember"
      decimals="INF"
      id="c134563971"
      unitRef="Share">25003</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2023-04-01_2024-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-ConvertibleNotesToWarrantsMember"
      decimals="INF"
      id="c134563972"
      unitRef="Share">25003</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2024-04-01_2025-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember"
      decimals="INF"
      id="c134563973"
      unitRef="Share">243483</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2023-04-01_2024-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember"
      decimals="INF"
      id="c134563974"
      unitRef="Share">100180</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2024-04-01_2025-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-SeriesAWarrantsMember"
      decimals="INF"
      id="c134563975"
      unitRef="Share">1533096</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2023-04-01_2024-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-SeriesAWarrantsMember"
      decimals="INF"
      id="c134563976"
      unitRef="Share">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2024-04-01_2025-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-RepresentativesWarrantsMember"
      decimals="INF"
      id="c134563977"
      unitRef="Share">91985</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2023-04-01_2024-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-RepresentativesWarrantsMember"
      decimals="INF"
      id="c134563978"
      unitRef="Share">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2024-04-01_2025-03-31"
      decimals="INF"
      id="c134563979"
      unitRef="Share">1981098</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2023-04-01_2024-03-31"
      decimals="INF"
      id="c134563980"
      unitRef="Share">162767</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="d_2024-04-01_2025-03-31" id="c134565417">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;Research and Development Costs&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;Research and development costs are expensed as incurred.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:AdvertisingCostsPolicyTextBlock contextRef="d_2024-04-01_2025-03-31" id="c134565418">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;Advertising&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;It is our policy to expense advertising costs as incurred. Advertising&#160;expenses are included within general and administrative expenses within the statement of operations. For the years ended &lt;em style="font: inherit;"&gt; March 31, 2025 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2024,&lt;/em&gt; the Company recorded less than $0.1&#160;million and $1.8&#160;million, respectively.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:AdvertisingCostsPolicyTextBlock>
    <us-gaap:AdvertisingExpense
      contextRef="d_2024-04-01_2025-03-31"
      decimals="-5"
      id="c134564428"
      unitRef="USD">100000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="d_2023-04-01_2024-03-31"
      decimals="-5"
      id="c134564429"
      unitRef="USD">1800000</us-gaap:AdvertisingExpense>
    <us-gaap:StockholdersEquityPolicyTextBlock contextRef="d_2024-04-01_2025-03-31" id="c134565419">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;Fair Value of Common Stock&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;Prior to establishing a public market for the Company&#x2019;s common stock, the estimated fair value of the Company&#x2019;s common stock was determined by the Company&#x2019;s Board of Directors (the "Board") as of the date of each option grant, with input from management, considering the Company&#x2019;s most recently available &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party valuations of common stock, recent sales of common stock to &lt;em style="font: inherit;"&gt;third&lt;/em&gt; parties, and the Company&#x2019;s board of directors&#x2019; assessment of additional objective and subjective factors that it believed were relevant and which &lt;em style="font: inherit;"&gt; may &lt;/em&gt;have changed from the date of the most recent valuation through the date of the grant.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:StockholdersEquityPolicyTextBlock>
    <amix:JumpstartOurBusinessStartupsJobsActAccountingElectionPolicyPolicyTextBlock contextRef="d_2024-04-01_2025-03-31" id="c134565420">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;JOBS Act Accounting Election&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;The Company qualifies as an emerging growth company ("EGC"), as defined in the Jumpstart Our Business Startups Act of &lt;em style="font: inherit;"&gt;2012&lt;/em&gt; (the &#x201c;JOBS Act&#x201d;). The JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected &lt;em style="font: inherit;"&gt;not&lt;/em&gt; to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This &lt;em style="font: inherit;"&gt; may &lt;/em&gt;make comparison of the Company&#x2019;s financial statements with another public company which is neither an early-stage company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</amix:JumpstartOurBusinessStartupsJobsActAccountingElectionPolicyPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="d_2024-04-01_2025-03-31" id="c134565421">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;Segments&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker ("CODM"), or decision-making group, in deciding how to allocate resources in assessing performance. Management has determined that the Company operates in&#160;&lt;span style="-sec-ix-hidden:c134564434"&gt;one&lt;/span&gt;&#160;reportable segment, which is advancing the development of innovative technologies for sensing and treating disorders relating to the nervous system. The Company is initially focused on developing the technology for patients with pancreatic cancer, however, the Company believes the technology constitutes a platform with the potential to address several indications, including chronic pain management, hypertension, cardiovascular disease and a wide range of other nerve-related disorders. The Company's CODM is its Chief Executive Officer.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;The accounting policies of the segment are the same as those described in the summary of significant accounting policies. The CODM assesses performance based on net loss, which is reported on the Statements of Operations. The measure of segment assets is reported on the balance sheet as total assets.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;To date, the Company has &lt;em style="font: inherit;"&gt;not&lt;/em&gt; generated any product revenue. The Company expects to continue to incur significant expenses and operating losses for the foreseeable future as it advances its' technology through all stages of development and clinical trials and, ultimately, seek regulatory approval.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;As such, the CODM primarily evaluates performance of the Company using various financial metrics, including the combined net income (loss) from operations, also shown on the Statements of Operations, forecasted cash expenditures and existing and forecasted cash balances. These financial metrics are used by the CODM to make key operating decisions, such as the assessment of segment performance and allocation of resources. The significant expense categories within net loss from operations that the CODM regularly reviews are expenses related to research and development, general and administrative, and depreciation and amortization. The significant expense categories and subcategories are reported on the Statements of Operations.&#160;Other expenses included in the Company&#x2019;s net loss include change in fair value of warrant liabilities, other income (expense), interest income, net, and any additional non-operating expenses that are reported on the Statements of Operations.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="d_2024-04-01_2025-03-31" id="c134565422">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;Recent Accounting Pronouncements&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;In&#160;&lt;em style="font: inherit;"&gt; November 2024 &lt;/em&gt;and &lt;em style="font: inherit;"&gt; January 2025,&#160;&lt;/em&gt;FASB issued ASU&#160;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;-&lt;em style="font: inherit;"&gt;03&lt;/em&gt; and ASU &lt;em style="font: inherit;"&gt;2025&lt;/em&gt;-&lt;em style="font: inherit;"&gt;01,&lt;/em&gt;&#160;Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic&#160;&lt;em style="font: inherit;"&gt;220&lt;/em&gt;-&lt;em style="font: inherit;"&gt;40&lt;/em&gt;): Disaggregation of Income Statement Expenses, which requires disclosure in the notes to the financial statements of specified information about certain costs and expenses. The amendments to the standards are effective for fiscal years beginning after&#160;&lt;em style="font: inherit;"&gt; December 15, 2026,&#160;&lt;/em&gt;and for interim periods within fiscal years beginning after&#160;&lt;em style="font: inherit;"&gt; December 15, 2027.&#160;&lt;/em&gt;Early adoption is permitted. The amendments should be applied either prospectively to financial statements issued for reporting periods after the effective date of this ASU or retrospectively to any or all prior periods presented in the financial statements. The Company is currently evaluating the new guidance to determine the impact it&#160;&lt;em style="font: inherit;"&gt; may&#160;&lt;/em&gt;have on its financial statements and related disclosures.&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;In &lt;em style="font: inherit;"&gt; December 2023, &lt;/em&gt;the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update, or ASU &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;-&lt;em style="font: inherit;"&gt;09,&lt;/em&gt; Income Taxes (Topic &lt;em style="font: inherit;"&gt;740&lt;/em&gt;): Improvements to Income Tax Disclosures. ASU &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;-&lt;em style="font: inherit;"&gt;09&lt;/em&gt;&#160;improves the transparency of income tax disclosures by requiring consistent categories and greater disaggregation of information in the effective tax rate reconciliation and income taxes paid disaggregated by jurisdiction. It also includes certain other amendments to improve the effectiveness of income tax disclosures. This guidance will be effective for the annual periods beginning after the year ended &lt;em style="font: inherit;"&gt; December 31, 2024. &lt;/em&gt;The Company is currently assessing the impact of ASU &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;-&lt;em style="font: inherit;"&gt;09&lt;/em&gt; on its disclosures.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;In &lt;em style="font: inherit;"&gt; November 2023, &lt;/em&gt;the FASB issued ASU &lt;em style="font: inherit;"&gt;No.&lt;/em&gt; &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;-&lt;em style="font: inherit;"&gt;07,&lt;/em&gt; Improvements to Reportable Segment Disclosures (ASU &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;-&lt;em style="font: inherit;"&gt;07&lt;/em&gt;) which is intended to improve reportable segment disclosures primarily through enhanced disclosure of reportable segment expenses and requires that a public entity that has a single reportable segment provide all the disclosures required by ASU &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;-&lt;em style="font: inherit;"&gt;07&lt;/em&gt; and all existing segment disclosures in Topic &lt;em style="font: inherit;"&gt;280.&lt;/em&gt; The new guidance is required to be applied retrospectively to all prior periods presented in the financial statements and is effective for the Company for fiscal periods beginning after &lt;em style="font: inherit;"&gt; December 15, 2023 &lt;/em&gt;and interim periods within fiscal years beginning after &lt;em style="font: inherit;"&gt; December 15, 2024. &lt;/em&gt;The Company adopted ASU &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;-&lt;em style="font: inherit;"&gt;07&lt;/em&gt; during the year ended &lt;em style="font: inherit;"&gt; March 31, 2025. &lt;/em&gt;There was &lt;em style="font: inherit;"&gt;no&lt;/em&gt; impact upon adoption of ASU &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;-&lt;em style="font: inherit;"&gt;07.&lt;/em&gt;&#160;The Company views its operations and manages its business in&#160;&lt;span style="-sec-ix-hidden:c134564463"&gt;one&lt;/span&gt;&#160;operating segment.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;There are &lt;em style="font: inherit;"&gt;no&lt;/em&gt; other effective pronouncements, or pronouncements issued but &lt;em style="font: inherit;"&gt;not&lt;/em&gt; yet effective, if adopted, that would have a material effect on the accompanying financial statements.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <amix:CorrectionOfAnImmaterialErrorPolicyTextBlock contextRef="d_2024-04-01_2025-03-31" id="c134565423">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;Correction of an Immaterial Error in the Prior Period Financial Statements&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;D&#xfeff;uring the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; December 31, 2024, &lt;/em&gt;the Company determined that previously filed quarterly and annual financial statements had an immaterial earnings per share error resulting from the exclusion of certain unexercised equity based warrants to purchase common shares that had an exercise price of approximately $0.01 or less from the basic earnings per share calculations in accordance with &lt;i&gt;ASC &lt;em style="font: inherit;"&gt;260&lt;/em&gt;-&lt;em style="font: inherit;"&gt;10&lt;/em&gt;-&lt;em style="font: inherit;"&gt;45&lt;/em&gt;-&lt;em style="font: inherit;"&gt;13&lt;/em&gt;&lt;/i&gt;. As a&#160;result, the prior year earnings per share calculations have been revised for consistency with the current year presentation. The Company assessed the materiality of this change in presentation on prior period financial statements in accordance with &lt;i&gt;SEC Staff Accounting Bulletin &lt;em style="font: inherit;"&gt;No.&lt;/em&gt; &lt;em style="font: inherit;"&gt;99&lt;/em&gt;&lt;/i&gt;, &#x201c;&lt;i&gt;Materiality&lt;/i&gt;,&#x201d; (&lt;i&gt;ASC Topic &lt;em style="font: inherit;"&gt;250,&lt;/em&gt; Accounting Changes and Error Corrections&lt;/i&gt;). Based on this assessment, the Company concluded that this error correction in its&#160;&lt;i&gt;Statements of Operations&lt;/i&gt;&#160;and &lt;i&gt;Note &lt;em style="font: inherit;"&gt;1&lt;/em&gt; &lt;/i&gt;&#x2013;&lt;i&gt; Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies (Loss Per Common Share)&lt;/i&gt; is &lt;em style="font: inherit;"&gt;not&lt;/em&gt; material to any previously presented financial statements based upon overall considerations of both quantitative and qualitative factors. The corrections had &lt;em style="font: inherit;"&gt;no&lt;/em&gt; impact in the comparative period Balance Sheet,&#160;Statements of Cash Flows, or Statement of Changes in Stockholders&#x2019;&#160;Equity. Further, the immaterial correction did &lt;em style="font: inherit;"&gt;not&lt;/em&gt; result in a change in operating losses or net loss in the Statement of Operations and the effects of including unexercised warrants in the earnings per share calculation have an antidilutive effect reducing the net loss per share amount. Accordingly, the Company corrected the previously reported earnings per share calculation for the &lt;em style="font: inherit;"&gt;twelve&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; March 31, 2024 &lt;/em&gt;in this Annual Report on Form &lt;em style="font: inherit;"&gt;10&lt;/em&gt;-K.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;A summary of the impact of the Company&#x2019;s Reverse Stock Split and immaterial corrections reflecting the prior period impact to the Company&#x2019;s Statement of Operations and earnings per share are shown below:&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="14" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Twelve Months Ended March 31, 2024&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Originally&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Filed&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Adjusted &lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;for 1-for-20 &lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Reverse &lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Stock Split&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Correction&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;As Revised&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 52%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Net Loss (in thousands)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(15,426&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(15,426&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Loss per share - basic and diluted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(1.05&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(21.09&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;6.27&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(14.82&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Weighted average shares outstanding - basic and diluted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;14,626,282&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;731,372&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;309,348&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,040,720&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
    &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;A summary of the impact of the Company&#x2019;s Reverse Stock Split and immaterial corrections reflecting the prior period impact to the disclosure of dilutive securities that were &lt;em style="font: inherit;"&gt;not&lt;/em&gt; included in the calculations of the loss per common share because they would be anti-dilutive are shown below:&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

     &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="14" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Twelve Months Ended March 31, 2024&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Originally &lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Filed&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Adjusted f&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;or 1-for-20 &lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Reverse &lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Stock Split&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Correction&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;As Revised&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 52%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Equity based warrants to purchase common shares&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;5,744,569&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;287,231&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(282,897&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4,334&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Convertible Notes - common shares&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;665,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;33,250&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;33,250&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Convertible Notes - equity-based warrants to purchase common shares&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;500,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;25,003&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;25,003&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Stock options granted under Company's incentive plan&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2,003,600&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;100,180&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;100,180&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Total potentially dilutive securities&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;b&gt;8,913,169&lt;/b&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;b&gt;445,664&lt;/b&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;b&gt;(282,897&lt;/b&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;b&gt;162,767&lt;/b&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
     &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</amix:CorrectionOfAnImmaterialErrorPolicyTextBlock>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2024-12-31_ClassOfWarrantOrRightAxis-EquitybasedWarrantsMember"
      decimals="INF"
      id="c134564467"
      unitRef="USDPerShare">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock
      contextRef="d_2024-04-01_2025-03-31"
      id="c463F7915-270B-4FCB-A5DA-407E83B25EB3">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="14" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Twelve Months Ended March 31, 2024&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Originally&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Filed&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Adjusted &lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;for 1-for-20 &lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Reverse &lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Stock Split&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Correction&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;As Revised&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 52%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Net Loss (in thousands)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(15,426&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(15,426&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Loss per share - basic and diluted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(1.05&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(21.09&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;6.27&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(14.82&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Weighted average shares outstanding - basic and diluted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;14,626,282&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;731,372&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;309,348&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,040,720&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

     &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="14" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Twelve Months Ended March 31, 2024&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Originally &lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Filed&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Adjusted f&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;or 1-for-20 &lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Reverse &lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Stock Split&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Correction&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;As Revised&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 52%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Equity based warrants to purchase common shares&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;5,744,569&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;287,231&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(282,897&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4,334&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Convertible Notes - common shares&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;665,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;33,250&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;33,250&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Convertible Notes - equity-based warrants to purchase common shares&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;500,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;25,003&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;25,003&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Stock options granted under Company's incentive plan&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2,003,600&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;100,180&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;100,180&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Total potentially dilutive securities&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;b&gt;8,913,169&lt;/b&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;b&gt;445,664&lt;/b&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;b&gt;(282,897&lt;/b&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;b&gt;162,767&lt;/b&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
    </us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="d_2023-04-01_2024-03-31_RestatementAxis-ScenarioPreviouslyReportedMember"
      decimals="-3"
      id="c134563981"
      unitRef="USD">-15426000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2023-04-01_2024-03-31_RestatementAxis-ReverseStockSplitAdjustmentMember"
      decimals="-3"
      id="c134563982"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2023-04-01_2024-03-31_RestatementAxis-RevisionOfPriorPeriodErrorCorrectionAdjustmentMember"
      decimals="-3"
      id="c134563983"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2023-04-01_2024-03-31"
      decimals="-3"
      id="c134563984"
      unitRef="USD">-15426000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="d_2023-04-01_2024-03-31_RestatementAxis-ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="c134563985"
      unitRef="USDPerShare">-1.05</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="d_2023-04-01_2024-03-31_RestatementAxis-ReverseStockSplitAdjustmentMember"
      decimals="INF"
      id="c134563986"
      unitRef="USDPerShare">-21.09</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="d_2023-04-01_2024-03-31_RestatementAxis-RevisionOfPriorPeriodErrorCorrectionAdjustmentMember"
      decimals="INF"
      id="c134563987"
      unitRef="USDPerShare">6.27</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="d_2023-04-01_2024-03-31"
      decimals="INF"
      id="c134563988"
      unitRef="USDPerShare">-14.82</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="d_2023-04-01_2024-03-31_RestatementAxis-ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="c134563989"
      unitRef="Share">14626282</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="d_2023-04-01_2024-03-31_RestatementAxis-ReverseStockSplitAdjustmentMember"
      decimals="INF"
      id="c134563990"
      unitRef="Share">731372</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="d_2023-04-01_2024-03-31_RestatementAxis-RevisionOfPriorPeriodErrorCorrectionAdjustmentMember"
      decimals="INF"
      id="c134563991"
      unitRef="Share">309348</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="d_2023-04-01_2024-03-31"
      decimals="INF"
      id="c134563992"
      unitRef="Share">1040720</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2023-04-01_2024-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember_RestatementAxis-ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="c134563993"
      unitRef="Share">5744569</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2023-04-01_2024-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember_RestatementAxis-ReverseStockSplitAdjustmentMember"
      decimals="INF"
      id="c134563994"
      unitRef="Share">287231</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2023-04-01_2024-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember_RestatementAxis-RevisionOfPriorPeriodErrorCorrectionAdjustmentMember"
      decimals="INF"
      id="c134563995"
      unitRef="Share">-282897</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2023-04-01_2024-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember"
      decimals="INF"
      id="c134563996"
      unitRef="Share">4334</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2023-04-01_2024-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-ConvertibleDebtSecuritiesMember_RestatementAxis-ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="c134563997"
      unitRef="Share">665000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2023-04-01_2024-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-ConvertibleDebtSecuritiesMember_RestatementAxis-ReverseStockSplitAdjustmentMember"
      decimals="INF"
      id="c134563998"
      unitRef="Share">33250</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2023-04-01_2024-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-ConvertibleDebtSecuritiesMember_RestatementAxis-RevisionOfPriorPeriodErrorCorrectionAdjustmentMember"
      decimals="INF"
      id="c134563999"
      unitRef="Share">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2023-04-01_2024-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-ConvertibleDebtSecuritiesMember"
      decimals="INF"
      id="c134564000"
      unitRef="Share">33250</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2023-04-01_2024-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-ConvertibleNotesToWarrantsMember_RestatementAxis-ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="c134564001"
      unitRef="Share">500000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2023-04-01_2024-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-ConvertibleNotesToWarrantsMember_RestatementAxis-ReverseStockSplitAdjustmentMember"
      decimals="INF"
      id="c134564002"
      unitRef="Share">25003</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2023-04-01_2024-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-ConvertibleNotesToWarrantsMember_RestatementAxis-RevisionOfPriorPeriodErrorCorrectionAdjustmentMember"
      decimals="INF"
      id="c134564003"
      unitRef="Share">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2023-04-01_2024-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-ConvertibleNotesToWarrantsMember"
      decimals="INF"
      id="c134564004"
      unitRef="Share">25003</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2023-04-01_2024-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember_RestatementAxis-ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="c134564005"
      unitRef="Share">2003600</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2023-04-01_2024-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember_RestatementAxis-ReverseStockSplitAdjustmentMember"
      decimals="INF"
      id="c134564006"
      unitRef="Share">100180</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2023-04-01_2024-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember_RestatementAxis-RevisionOfPriorPeriodErrorCorrectionAdjustmentMember"
      decimals="INF"
      id="c134564007"
      unitRef="Share">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2023-04-01_2024-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember"
      decimals="INF"
      id="c134564008"
      unitRef="Share">100180</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2023-04-01_2024-03-31_RestatementAxis-ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="c134564009"
      unitRef="Share">8913169</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2023-04-01_2024-03-31_RestatementAxis-ReverseStockSplitAdjustmentMember"
      decimals="INF"
      id="c134564010"
      unitRef="Share">445664</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2023-04-01_2024-03-31_RestatementAxis-RevisionOfPriorPeriodErrorCorrectionAdjustmentMember"
      decimals="INF"
      id="c134564011"
      unitRef="Share">-282897</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2023-04-01_2024-03-31"
      decimals="INF"
      id="c134564012"
      unitRef="Share">162767</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="d_2024-04-01_2025-03-31" id="c3016957">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;2&lt;/em&gt; &lt;/b&gt;&#x2013;&lt;b&gt; Warrant Liability and Fair Value of Financial Instruments&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;Financial assets and financial liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. While the Company believes that its valuation methods are appropriate, the Company recognizes that the use of different methodologies or assumptions to determine the fair value could result in a different estimate of fair value at the reporting date. The primary assumptions that would significantly affect the fair values are the probability weighting of the different settlement outcomes used.&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;There were no outstanding instruments classified as Level &lt;em style="font: inherit;"&gt;3&lt;/em&gt; measurements as of &lt;em style="font: inherit;"&gt; March 31, 2025 &lt;/em&gt;or &#160;&lt;em style="font: inherit;"&gt; March 31, 2024.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;There were &lt;em style="font: inherit;"&gt;not&lt;/em&gt; any transfers into or out of Level &lt;em style="font: inherit;"&gt;3&lt;/em&gt; as of &lt;em style="font: inherit;"&gt; March 31, 2025 &lt;/em&gt;and &lt;em style="font: inherit;"&gt; March 31, 2024.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;The following table summarizes the activity of the Level &lt;em style="font: inherit;"&gt;3&lt;/em&gt; fair value measurements during the &lt;em style="font: inherit;"&gt;twelve&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; March 31, 2024&#160;(&lt;/em&gt;in thousands):&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 5%; width: 95%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;Warrant&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;Liabilities&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 84%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Balance as of March 31, 2023&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Additions&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4,556&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Change in fair value measurements - warrants mark-to-market&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3,444&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Settlement and reclassification to equity&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(8,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Balance as of March 31, 2024&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;The Company recognized the initial warrant expense as a component of operating expenses on the statement of operations under &lt;i&gt;warrant expense &lt;/i&gt;&#x2013;&lt;i&gt; termination agreement&lt;/i&gt; for $4.6 million and the changes in the fair value under &lt;i&gt;warrant liability &lt;/i&gt;&#x2013;&lt;i&gt; mark-to-market &lt;/i&gt;for $3.4&#160;million. There were &lt;em style="font: inherit;"&gt;no&lt;/em&gt; changes to the valuation approaches or techniques used for Level &lt;em style="font: inherit;"&gt;3&lt;/em&gt; measurements.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;Warrant Liabilities&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;As more fully detailed in &lt;i&gt;Note &lt;em style="font: inherit;"&gt;6&lt;/em&gt; &lt;/i&gt;&#x2013;&lt;i&gt; Related Party Transactions&lt;/i&gt;, on &lt;em style="font: inherit;"&gt; July 7, 2023, &lt;/em&gt;the Company entered into an Exclusive License Termination Agreement (the &#x201c;Termination Agreement&#x201d;) with a licensee in exchange for the issuance, upon the closing of the Company&#x2019;s IPO within &lt;em style="font: inherit;"&gt;one&lt;/em&gt; year of the agreement&#x2019;s execution, of a warrant (the "Warrant") to purchase shares of the Company for a variable number of shares.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;The fair value of the warrant liability has been estimated using a discounted cash flow model under various scenarios and used the probability-weighted expected return method (&#x201c;PWERM&#x201d;) comparing the probabilities of different outcomes. The outcomes considered included (i) the closing of a qualified financing as part of the Company&#x2019;s IPO at various points in time and (ii) the possibility of default whereby the licensee receives nothing. Key assumptions for the model were as follows for the initial measurement:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 83%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Discount rate at issuance (1)&lt;/p&gt; &lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 3%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 3%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 3%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 4%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="-sec-ix-hidden:c134565294"&gt;20.00&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 83%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Probability (2)&lt;/p&gt; &lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 3%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="-sec-ix-hidden:c134565295"&gt;&#160;70%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 3%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: center;"&gt;-&lt;/td&gt;&lt;td style="width: 3%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: center;"&gt;&lt;span style="-sec-ix-hidden:c134565296"&gt;10%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 3%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: center;"&gt;-&lt;/td&gt;&lt;td style="width: 4%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="-sec-ix-hidden:c134565297"&gt;20&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 83%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Payment (3)&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 3%;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 3%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 3%; text-align: center;"&gt;&lt;span style="-sec-ix-hidden:c134565299"&gt;$0&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 3%; text-align: center;"&gt;-&lt;/td&gt;&lt;td colspan="1" style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 4%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"&gt;&lt;span style="-sec-ix-hidden:c134565300"&gt;&#160;$8,000,000&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 83%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Expected term (in years)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 3%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 3%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: center;"&gt;&lt;span style="-sec-ix-hidden:c134565302"&gt;0.48&lt;/span&gt;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 3%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: center;"&gt;-&lt;/td&gt;&lt;td style="width: 4%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="-sec-ix-hidden:c134565303"&gt;0.98&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 18pt;"&gt; &lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;(&lt;em style="font: inherit;"&gt;1&lt;/em&gt;)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: auto;"&gt; &lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;The initial discount rate was chosen based on private equity rates of return as described in the AICPA Practice Aid on Valuation of Privately-Held-Company Equity securities issued as compensation. For the recurring fair value measurement, the Company updated the discount rate based upon yield curves estimated to be similar in credit quality to the Company;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 18pt;"&gt; &lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;(&lt;em style="font: inherit;"&gt;2&lt;/em&gt;)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: auto;"&gt; &lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;Scenario probability as of issuance was based on timing expectations of management that a qualified offering occurring as of &lt;em style="font: inherit;"&gt; December 31, 2023 &lt;/em&gt;was estimated at 70%, respectively; a qualified offering occurring as of &lt;em style="font: inherit;"&gt; June 30, 2024 &lt;/em&gt;was estimated at &lt;span style="-sec-ix-hidden:c134564500"&gt;10%;&lt;/span&gt; and &lt;em style="font: inherit;"&gt;no&lt;/em&gt; qualified offering occurring was estimated at &lt;span style="-sec-ix-hidden:c134564502"&gt;20%;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 18pt;"&gt; &lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;(&lt;em style="font: inherit;"&gt;3&lt;/em&gt;)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: auto;"&gt; &lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;The warrant has a $0.02&#160;strike price, however, the strike price is low relative to the stock price, making the warrant value close to the value of a stock unit. The agreement has a fixed payment value of $8.0 million, see Note &lt;em style="font: inherit;"&gt;6&lt;/em&gt; &#x2013;&#160;Related Party Transactions.&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;On &lt;em style="font: inherit;"&gt; January 29, 2024, &lt;/em&gt;the Company issued 80,000 warrant shares pursuant to the Termination Agreement.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;The completion of the Company&#x2019;s IPO fixed the number of warrant shares issuable and the Company re-classified the Warrant to additional-paid in capital as it met the requirements for equity classification. Upon reclassification, the Company valued the warrant at $8.0 million, which represented the fair value of the shares issued on that date.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&#160;&lt;/p&gt;


  </us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i_2025-03-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member"
      decimals="-3"
      id="c134564485"
      unitRef="USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock contextRef="d_2024-04-01_2025-03-31" id="c3016958">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 5%; width: 95%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;Warrant&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;Liabilities&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 84%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Balance as of March 31, 2023&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Additions&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4,556&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Change in fair value measurements - warrants mark-to-market&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3,444&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Settlement and reclassification to equity&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(8,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Balance as of March 31, 2024&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i_2023-03-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByLiabilityClassAxis-WarrantMember"
      decimals="-3"
      id="c134564013"
      unitRef="USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements
      contextRef="d_2023-04-01_2024-03-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByLiabilityClassAxis-WarrantMember"
      decimals="-3"
      id="c134564014"
      unitRef="USD">4556000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="d_2023-04-01_2024-03-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByLiabilityClassAxis-WarrantMember"
      decimals="-3"
      id="c134564015"
      unitRef="USD">3444000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements
      contextRef="d_2023-04-01_2024-03-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByLiabilityClassAxis-WarrantMember"
      decimals="-6"
      id="c134564016"
      unitRef="USD">8000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i_2024-03-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByLiabilityClassAxis-WarrantMember"
      decimals="-3"
      id="c134564017"
      unitRef="USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="d_2023-04-01_2024-03-31"
      decimals="-5"
      id="c134564491"
      unitRef="USD">-4600000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="d_2023-04-01_2024-03-31"
      decimals="-5"
      id="c134564492"
      unitRef="USD">3400000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="d_2024-04-01_2025-03-31" id="c3016959">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 83%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Discount rate at issuance (1)&lt;/p&gt; &lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 3%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 3%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 3%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 4%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="-sec-ix-hidden:c134565294"&gt;20.00&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 83%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Probability (2)&lt;/p&gt; &lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 3%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="-sec-ix-hidden:c134565295"&gt;&#160;70%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 3%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: center;"&gt;-&lt;/td&gt;&lt;td style="width: 3%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: center;"&gt;&lt;span style="-sec-ix-hidden:c134565296"&gt;10%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 3%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: center;"&gt;-&lt;/td&gt;&lt;td style="width: 4%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="-sec-ix-hidden:c134565297"&gt;20&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 83%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Payment (3)&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 3%;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 3%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 3%; text-align: center;"&gt;&lt;span style="-sec-ix-hidden:c134565299"&gt;$0&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 3%; text-align: center;"&gt;-&lt;/td&gt;&lt;td colspan="1" style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 4%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"&gt;&lt;span style="-sec-ix-hidden:c134565300"&gt;&#160;$8,000,000&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 83%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Expected term (in years)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 3%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 3%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: center;"&gt;&lt;span style="-sec-ix-hidden:c134565302"&gt;0.48&lt;/span&gt;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 3%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: center;"&gt;-&lt;/td&gt;&lt;td style="width: 4%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="-sec-ix-hidden:c134565303"&gt;0.98&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2023-12-31_MeasurementInputTypeAxis-MeasurementInputProbabilityRateMember_StatementScenarioAxis-QualifiedOfferingOccurringOneMember_ValuationTechniqueAxis-ValuationProbabilityweightedExpectedReturnMethodPWERMMember"
      decimals="1"
      id="c134564499"
      unitRef="Pure">0.70</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c134564504"
      unitRef="USDPerShare">0.02</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <amix:ClassOfWarrantOrRightValueOfSecuritiesCalledByWarrantsOrRights
      contextRef="d_2023-07-07_2023-07-07_ClassOfWarrantOrRightAxis-TheWarrantMember_RelatedPartyTransactionAxis-TerminationAgreementMember"
      decimals="-6"
      id="c134564505"
      unitRef="USD">8000000</amix:ClassOfWarrantOrRightValueOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2024-01-29_ClassOfWarrantOrRightAxis-TheWarrantMember_RelatedPartyTransactionAxis-TerminationAgreementMember"
      decimals="INF"
      id="c134564507"
      unitRef="Share">80000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="i_2024-01-29_ClassOfWarrantOrRightAxis-TheWarrantMember_RelatedPartyTransactionAxis-TerminationAgreementMember"
      decimals="-6"
      id="c134564508"
      unitRef="USD">8000000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:DebtDisclosureTextBlock contextRef="d_2024-04-01_2025-03-31" id="c3016960">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;3&lt;/em&gt; &lt;/b&gt;&#x2013;&lt;b&gt; Convertible Notes Payable&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;On &lt;em style="font: inherit;"&gt; September 9, 2023, &lt;/em&gt;the Company's Board authorized an offering up to $2.0 million in unsecured, non-interest bearing convertible promissory notes (the &#x201c;Notes&#x201d;) and accompanying warrants (the &#x201c;Bridge Financing Warrants&#x201d;) (collectively, the &#x201c;Bridge Offering&#x201d;) that will mature on &lt;em style="font: inherit;"&gt; December 31, 2025. &lt;/em&gt;The Notes provided that, on the closing date of the IPO, the outstanding principal would be&#160;automatically converted into common stock at the conversion price of $40.00. Each dollar in principal amount of Notes purchased were&#160;accompanied by a &lt;span style="-sec-ix-hidden:c134564513"&gt;five&lt;/span&gt;-year Bridge Financing Warrant to purchase 0.0125 shares of Common stock with an exercise price of $20.00 per share. The Company records the Bridge Financing Warrants as a discount to the Notes.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;The Bridge Financing Warrants can be exercised from the date of Notes issuance through the &lt;em style="font: inherit;"&gt;five&lt;/em&gt;-year anniversary of the issuance of the Notes. The shares issuable pursuant to the Notes and Bridge Financing Warrants had a 180-day lock-up after the Company&#x2019;s IPO. Thereafter, the foregoing lock-up agreement ceased to apply to 25% of the purchased shares each month for a period of &lt;em style="font: inherit;"&gt;four&lt;/em&gt; months. The Note holders were &lt;em style="font: inherit;"&gt;not&lt;/em&gt; permitted to convert their Notes when the holders or any of their affiliates would beneficially own in excess of 4.99% of the Company&#x2019;s common stock after such conversion.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;As of &lt;em style="font: inherit;"&gt; March 31, 2024, &lt;/em&gt;the Company received proceeds of $2.0 million of Notes executed from the Bridge Offering.&#160;Upon the closing of the IPO, certain notes were to be automatically converted according to their terms into the Company&#x2019;s common stock to the extent and provided that certain holders of these notes are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; permitted to convert such notes to the extent that the holders or any of its affiliates would beneficially own in excess of 4.99% of the Company&#x2019;s common stock after such conversion. Due to this 4.99% limitation, principal representing $1.3 million, or 33,250 shares, of these notes remained outstanding.&#160;As discussed in Note &lt;em style="font: inherit;"&gt;1,&lt;/em&gt; the remaining notes converted into common stock in accordance with their original terms on the IPO. During the year ended &lt;em style="font: inherit;"&gt; March 31, 2025, &lt;/em&gt;the remaining Notes were converted into 33,250 shares.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;The Company&#x2019;s effective interest rate for the Notes was 15.3% due to the amortization of the discount stemming from the issuance of the Bridge Financing Warrants.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;The following table presents a summary of activity for the Company&#x2019;s &lt;em style="font: inherit;"&gt;zero&lt;/em&gt;-coupon convertible notes payable (in thousands):&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 5%; width: 95%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;Principal Amount&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;Amortized Debt&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;Discount&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;Net Carrying&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;Amount&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 52%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Outstanding, March 31, 2024&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,330&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(328&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,002&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Amortization of debt discount&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;175&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;175&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Issuance of common stock for extinguishment of convertible debt&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(1,330&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;153&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(1,177&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Outstanding, March 31, 2025&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;Warrants&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;The Company issued the Notes with detachable warrants for the purchase of shares of the Company&#x2019;s common stock. The Company utilized a Monte Carlo simulation model to determine the fair value of each Bridge Offering Warrant. During the year ended &lt;em style="font: inherit;"&gt; March 31, 2024, &lt;/em&gt;the Company issued warrants valued at $0.6 million. The key inputs to the Monte Carlo simulation used to determine the fair value of each warrant include, the Company&#x2019;s stock price fair value which was determined through a back solve calculation such that the stock price results in the average total value of the Notes and the Bridge Offering Warrants being equal to the cash proceeds received, volatility based on a selection of publicly held peer companies of 101.88%, expected term of 5 years, risk free rate of 4.40%, discount rate of 20.00% and a discount for lack of marketability of 15.77%.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;During the year ended &lt;em style="font: inherit;"&gt; March 31, 2025, &lt;/em&gt;the Company recorded less than $0.2 million in interest expense related to the amortization of the debt discount.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;The following table presents a summary of activity for the warrants issued in connection with the Company&#x2019;s Notes:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Warrants&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Weighted-&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Average &lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Exercise &lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Price Per &lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Share&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Remaining &lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Life (In &lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Years)&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Aggregate &lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Intrinsic &lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Value*&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 48%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Outstanding and exercisable, March 31, 2024&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;25,003&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;20.00&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4.48&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,010,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Granted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Exercised&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Forfeited/Cancelled&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Expired&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Outstanding, March 31, 2025&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;25,003&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;20.00&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;3.48&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Exercisable, March 31, 2025&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;25,003&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;20.00&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;3.48&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;*Aggregate Intrinsic Value = Excess of market value over the exercise price of all in-the-money warrants.&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


  </us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i_2023-09-09_DebtInstrumentAxis-TheNotesMember_RangeAxis-MaximumMember"
      decimals="-6"
      id="c134564511"
      unitRef="USD">2000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="i_2023-09-09_DebtInstrumentAxis-TheNotesMember"
      decimals="INF"
      id="c134564512"
      unitRef="USDPerShare">40</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="i_2023-09-09_ClassOfWarrantOrRightAxis-BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember"
      decimals="INF"
      id="c134564514"
      unitRef="Share">0.0125</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2023-09-09_ClassOfWarrantOrRightAxis-BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember"
      decimals="INF"
      id="c134564515"
      unitRef="USDPerShare">20</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <amix:ClassOfWarrantOrRightLockupAgreementTermOfUnderlyingShares
      contextRef="d_2023-09-09_2023-09-09_ClassOfWarrantOrRightAxis-BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember"
      id="c134564517">P180D</amix:ClassOfWarrantOrRightLockupAgreementTermOfUnderlyingShares>
    <amix:ClassOfWarrantOrRightPercentageOfOutstandingStock
      contextRef="d_2023-09-09_2023-09-09_ClassOfWarrantOrRightAxis-BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember"
      decimals="2"
      id="c134564518"
      unitRef="Pure">0.25</amix:ClassOfWarrantOrRightPercentageOfOutstandingStock>
    <amix:DebtInstrumentConvertibleMaximumBeneficialOwnershipPercentage
      contextRef="i_2023-09-09_DebtInstrumentAxis-TheNotesMember"
      decimals="4"
      id="c134564521"
      unitRef="Pure">0.0499</amix:DebtInstrumentConvertibleMaximumBeneficialOwnershipPercentage>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="d_2023-09-10_2024-03-31_DebtInstrumentAxis-TheNotesMember"
      decimals="-6"
      id="c134564522"
      unitRef="USD">2000000</us-gaap:ProceedsFromConvertibleDebt>
    <amix:DebtInstrumentConvertibleMaximumBeneficialOwnershipPercentage
      contextRef="i_2024-01-26_DebtInstrumentAxis-TheNotesMember"
      decimals="4"
      id="c134564524"
      unitRef="Pure">0.0499</amix:DebtInstrumentConvertibleMaximumBeneficialOwnershipPercentage>
    <amix:DebtInstrumentConvertibleMaximumBeneficialOwnershipPercentage
      contextRef="i_2024-01-26_DebtInstrumentAxis-TheNotesMember"
      decimals="4"
      id="c134564525"
      unitRef="Pure">0.0499</amix:DebtInstrumentConvertibleMaximumBeneficialOwnershipPercentage>
    <us-gaap:ConvertibleNotesPayable
      contextRef="i_2025-03-31_DebtInstrumentAxis-ConvertibleDebtWith499PercentBeneficialOwnershipLimitationMember"
      decimals="-5"
      id="c134564526"
      unitRef="USD">1300000</us-gaap:ConvertibleNotesPayable>
    <us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments
      contextRef="d_2024-04-01_2025-03-31_DebtInstrumentAxis-ConvertibleDebtWith499PercentBeneficialOwnershipLimitationMember"
      decimals="INF"
      id="c134564527"
      unitRef="Pure">33250</us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="d_2024-04-01_2025-03-31_DebtConversionByUniqueDescriptionAxis-ConversionOfConvertibleNotesToCommonStockMember"
      decimals="INF"
      id="c134564529"
      unitRef="Share">33250</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i_2025-03-31_DebtInstrumentAxis-ConvertibleDebtWith499PercentBeneficialOwnershipLimitationMember"
      decimals="3"
      id="c134564530"
      unitRef="Pure">0.153</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:ConvertibleDebtTableTextBlock contextRef="d_2024-04-01_2025-03-31" id="c3016961">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 5%; width: 95%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;Principal Amount&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;Amortized Debt&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;Discount&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;Net Carrying&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;Amount&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 52%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Outstanding, March 31, 2024&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,330&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(328&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,002&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Amortization of debt discount&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;175&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;175&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Issuance of common stock for extinguishment of convertible debt&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(1,330&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;153&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(1,177&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Outstanding, March 31, 2025&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ConvertibleDebtTableTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i_2024-03-31_DebtInstrumentAxis-TheNotesMember_LongtermDebtTypeAxis-ConvertibleDebtMember"
      decimals="-4"
      id="c134564038"
      unitRef="USD">1330000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet
      contextRef="i_2024-03-31_DebtInstrumentAxis-TheNotesMember_LongtermDebtTypeAxis-ConvertibleDebtMember"
      decimals="-3"
      id="c134564039"
      unitRef="USD">328000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet>
    <us-gaap:ConvertibleLongTermNotesPayable
      contextRef="i_2024-03-31_DebtInstrumentAxis-TheNotesMember_LongtermDebtTypeAxis-ConvertibleDebtMember"
      decimals="-3"
      id="c134564040"
      unitRef="USD">1002000</us-gaap:ConvertibleLongTermNotesPayable>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="d_2024-04-01_2025-03-31_DebtInstrumentAxis-TheNotesMember_LongtermDebtTypeAxis-ConvertibleDebtMember"
      decimals="-3"
      id="c134564042"
      unitRef="USD">175000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="d_2024-04-01_2025-03-31_DebtInstrumentAxis-TheNotesMember_LongtermDebtTypeAxis-ConvertibleDebtMember"
      decimals="-3"
      id="c134564043"
      unitRef="USD">175000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="d_2024-04-01_2025-03-31_DebtConversionByUniqueDescriptionAxis-IssuanceOfCommonStockForExtinguishmentOfConvertibleDebtMember"
      decimals="-4"
      id="c134564044"
      unitRef="USD">1330000</us-gaap:DebtConversionOriginalDebtAmount1>
    <amix:DebtConversionDebtIssuanceCostsConvertedCommonShares
      contextRef="d_2024-04-01_2025-03-31_DebtConversionByUniqueDescriptionAxis-IssuanceOfCommonStockForExtinguishmentOfConvertibleDebtMember"
      decimals="-3"
      id="c134564045"
      unitRef="USD">-153000</amix:DebtConversionDebtIssuanceCostsConvertedCommonShares>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="d_2024-04-01_2025-03-31_DebtConversionByUniqueDescriptionAxis-IssuanceOfCommonStockForExtinguishmentOfConvertibleDebtMember"
      decimals="-3"
      id="c134564046"
      unitRef="USD">1177000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i_2025-03-31_DebtInstrumentAxis-TheNotesMember_LongtermDebtTypeAxis-ConvertibleDebtMember"
      decimals="-3"
      id="c134564047"
      unitRef="USD">0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet
      contextRef="i_2025-03-31_DebtInstrumentAxis-TheNotesMember_LongtermDebtTypeAxis-ConvertibleDebtMember"
      decimals="-3"
      id="c134564048"
      unitRef="USD">-0</us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet>
    <us-gaap:ConvertibleLongTermNotesPayable
      contextRef="i_2025-03-31_DebtInstrumentAxis-TheNotesMember_LongtermDebtTypeAxis-ConvertibleDebtMember"
      decimals="-3"
      id="c134564049"
      unitRef="USD">0</us-gaap:ConvertibleLongTermNotesPayable>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="i_2024-03-31_ClassOfWarrantOrRightAxis-BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember"
      decimals="-5"
      id="c134564532"
      unitRef="USD">600000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2024-03-31_ClassOfWarrantOrRightAxis-BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember"
      decimals="4"
      id="c134564533"
      unitRef="Pure">1.0188</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2024-03-31_ClassOfWarrantOrRightAxis-BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember"
      decimals="INF"
      id="c134564534"
      unitRef="Year">5</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2024-03-31_ClassOfWarrantOrRightAxis-BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember"
      decimals="3"
      id="c134564535"
      unitRef="Pure">0.044</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2024-03-31_ClassOfWarrantOrRightAxis-BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember_MeasurementInputTypeAxis-MeasurementInputDiscountRateMember"
      decimals="1"
      id="c134564536"
      unitRef="Pure">0.20</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2023-12-31_ClassOfWarrantOrRightAxis-BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember_MeasurementInputTypeAxis-MeasurementInputDiscountForLackOfMarketabilityMember"
      decimals="4"
      id="c134564537"
      unitRef="Pure">0.1577</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:InterestExpenseDebt
      contextRef="d_2024-04-01_2025-03-31_DebtInstrumentAxis-TheNotesMember_RangeAxis-MaximumMember"
      decimals="-5"
      id="c134564538"
      unitRef="USD">200000</us-gaap:InterestExpenseDebt>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="d_2024-04-01_2025-03-31" id="c3016962">
    &lt;table cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Warrants&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Weighted-&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Average &lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Exercise &lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Price Per &lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Share&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Remaining &lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Life (In &lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Years)&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Aggregate &lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Intrinsic &lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Value*&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 48%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Outstanding and exercisable, March 31, 2024&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;25,003&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;20.00&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4.48&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,010,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Granted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Exercised&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Forfeited/Cancelled&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Expired&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Outstanding, March 31, 2025&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;25,003&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;20.00&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;3.48&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Exercisable, March 31, 2025&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;25,003&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;20.00&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;3.48&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i_2024-03-31"
      decimals="INF"
      id="c134564050"
      unitRef="Share">25003</us-gaap:ClassOfWarrantOrRightOutstanding>
    <amix:ClassOfWarrantOrRightOutstandingOutstandingWeightedAverageExercisePrice
      contextRef="i_2024-03-31"
      decimals="INF"
      id="c134564051"
      unitRef="USDPerShare">20</amix:ClassOfWarrantOrRightOutstandingOutstandingWeightedAverageExercisePrice>
    <amix:ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm contextRef="d_2023-04-01_2024-03-31" id="c134564052">P4Y5M23D</amix:ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm>
    <amix:ClassOfWarrantOrRightAggregateIntrinsicValueOutstanding
      contextRef="i_2024-03-31"
      decimals="INF"
      id="c134564053"
      unitRef="USD">1010000</amix:ClassOfWarrantOrRightAggregateIntrinsicValueOutstanding>
    <amix:ClassOfWarrantOrRightGrantsInPeriod
      contextRef="d_2024-04-01_2025-03-31"
      decimals="INF"
      id="c134564054"
      unitRef="Share">0</amix:ClassOfWarrantOrRightGrantsInPeriod>
    <amix:ClassOfWarrantOrRightGrantsInPeriodWeightedAverageExercise
      contextRef="d_2024-04-01_2025-03-31"
      decimals="INF"
      id="c134564055"
      unitRef="USDPerShare">0</amix:ClassOfWarrantOrRightGrantsInPeriodWeightedAverageExercise>
    <amix:ClassOfWarrantOrRightExercisesInPeriod
      contextRef="d_2024-04-01_2025-03-31"
      decimals="INF"
      id="c134564058"
      unitRef="Share">-0</amix:ClassOfWarrantOrRightExercisesInPeriod>
    <amix:ClassOfWarrantOrRightExercisesInPeriodWeightedAverageExercisePrice
      contextRef="d_2024-04-01_2025-03-31"
      decimals="INF"
      id="c134564059"
      unitRef="USDPerShare">0</amix:ClassOfWarrantOrRightExercisesInPeriodWeightedAverageExercisePrice>
    <amix:ClassOfWarrantOrRightForfeituresInPeriod
      contextRef="d_2024-04-01_2025-03-31"
      decimals="INF"
      id="c134564062"
      unitRef="Share">-0</amix:ClassOfWarrantOrRightForfeituresInPeriod>
    <amix:ClassOfWarrantOrRightForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="d_2024-04-01_2025-03-31"
      decimals="INF"
      id="c134564063"
      unitRef="USDPerShare">0</amix:ClassOfWarrantOrRightForfeituresInPeriodWeightedAverageExercisePrice>
    <amix:ClassOfWarrantOrRightExpirationsInPeriod
      contextRef="d_2024-04-01_2025-03-31"
      decimals="INF"
      id="c134564066"
      unitRef="Share">-0</amix:ClassOfWarrantOrRightExpirationsInPeriod>
    <amix:ClassOfWarrantOrRightExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="d_2024-04-01_2025-03-31"
      decimals="INF"
      id="c134564067"
      unitRef="USDPerShare">0</amix:ClassOfWarrantOrRightExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i_2025-03-31"
      decimals="INF"
      id="c134564070"
      unitRef="Share">25003</us-gaap:ClassOfWarrantOrRightOutstanding>
    <amix:ClassOfWarrantOrRightOutstandingOutstandingWeightedAverageExercisePrice
      contextRef="i_2025-03-31"
      decimals="INF"
      id="c134564071"
      unitRef="USDPerShare">20</amix:ClassOfWarrantOrRightOutstandingOutstandingWeightedAverageExercisePrice>
    <amix:ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm contextRef="d_2024-04-01_2025-03-31" id="c134564072">P3Y5M23D</amix:ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm>
    <amix:ClassOfWarrantOrRightAggregateIntrinsicValueOutstanding
      contextRef="i_2025-03-31"
      decimals="INF"
      id="c134564073"
      unitRef="USD">0</amix:ClassOfWarrantOrRightAggregateIntrinsicValueOutstanding>
    <amix:ClassOfWarrantOrRightExercisableNumber
      contextRef="i_2025-03-31"
      decimals="INF"
      id="c134564074"
      unitRef="Share">25003</amix:ClassOfWarrantOrRightExercisableNumber>
    <amix:ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice
      contextRef="d_2024-04-01_2025-03-31"
      decimals="INF"
      id="c134564075"
      unitRef="USDPerShare">20</amix:ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice>
    <amix:ClassOfWarrantOrRightExercisableWeightedAverageRemainingContractualTerm contextRef="d_2024-04-01_2025-03-31" id="c134564076">P3Y5M23D</amix:ClassOfWarrantOrRightExercisableWeightedAverageRemainingContractualTerm>
    <amix:ClassOfWarrantOrRightAggregateIntrinsicValueExercisable
      contextRef="i_2025-03-31"
      decimals="INF"
      id="c134564077"
      unitRef="USD">0</amix:ClassOfWarrantOrRightAggregateIntrinsicValueExercisable>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="d_2024-04-01_2025-03-31" id="c3016963">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;4&lt;/em&gt; &lt;/b&gt;&#x2013;&lt;b&gt; Equity&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;On &lt;em style="font: inherit;"&gt; November 29, 2023, &lt;/em&gt;the Company&#x2019;s Board of Directors and applicable shareholders approved to amend and restate the Company&#x2019;s certificate of incorporation and increased the authorized shares to 500,000,000 shares of common stock, with a par value of &lt;span style="-sec-ix-hidden:c134564542"&gt;$.001&lt;/span&gt; per share, and 10,000,000 shares of preferred stock, with a par value of &lt;span style="-sec-ix-hidden:c134564544"&gt;$.001&lt;/span&gt; per share. The specific rights of the preferred stock shall be determined by the Board of Directors.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;Preferred Stock &lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;As of &lt;em style="font: inherit;"&gt; March 31, 2025, &lt;/em&gt;the Company had no shares of preferred stock outstanding.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;Restricted Stock&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;On &lt;em style="font: inherit;"&gt; February 15, 2024, &lt;/em&gt;the Company issued&#160;1,750 restricted shares of common stock to the Company's marketing consultant at the closing price of $76.00 of the Company's common stock. The total value of these shares is $133,000. These shares vest monthly over a 12-month period beginning on the issue&#160;date.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Year ended March 31,&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 70%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Recognized in general and administrative expense&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;116,375&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;16,625&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;116,375&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;16,625&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;For the year ended &lt;em style="font: inherit;"&gt; March 31, 2025, &lt;/em&gt;there was no unrecognized stock-based compensation expense related to unvested Restricted Stock.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;A summary of activity regarding Restricted Stock issued is as follows:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Grant Date&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Number of &lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Fair Value Per &lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Share&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 70%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Outstanding, March 31, 2024&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,604&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;76.00&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Granted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Vested&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(1,604&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;76.00&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Outstanding, March 31, 2025&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;Common Stock &lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;On &lt;em style="font: inherit;"&gt; April 6, 2023, &lt;/em&gt;the Board of Directors approved a private placement offering of up to 100,000 common shares at a price of $40.00 per share. During the year ended &lt;em style="font: inherit;"&gt; March 31, 2024, &lt;/em&gt;the Company sold 71,000 shares for cash proceeds of $2,840,000. The Company did &lt;span style="-sec-ix-hidden:c134564555"&gt;not&lt;/span&gt; incur any costs that were direct and incremental to the private placement.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;On &lt;em style="font: inherit;"&gt; September 9, 2023, &lt;/em&gt;the Board approved a Bridge Offering. See Note &lt;em style="font: inherit;"&gt;3&lt;/em&gt; &lt;i&gt;Convertible Notes Payable&lt;/i&gt; for additional detail as these notes are convertible into common stock.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;On &lt;em style="font: inherit;"&gt; February 28, 2025, &lt;/em&gt;the Company entered into an ATM Agreement. Pursuant to the terms of the Agreement, the Company &lt;em style="font: inherit;"&gt; may &lt;/em&gt;sell from time to time, the Company&#x2019;s Common Stock, par value $0.001 per share, with an initial aggregate sales price of up to $2.1 million. As of &lt;em style="font: inherit;"&gt; March 31, 2025, &lt;/em&gt;the Company sold 800 shares pursuant to the ATM Agreement for net proceeds of approximately $1,746.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;Stock Plan and Stock Options&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;In &lt;em style="font: inherit;"&gt; June 2023, &lt;/em&gt;the Company adopted, and the Company&#x2019;s shareholders approved, the Autonomix Medical, Inc. &lt;em style="font: inherit;"&gt;2023&lt;/em&gt; Stock Plan (the &#x201c;Plan&#x201d;). The Plan is a stock-based compensation plan that provides for discretionary grants of stock options, stock awards and stock unit awards to key employees, non-employee directors, and consultants, subject to certain individual threshold limitations. The Plan provides for up to 200,000 shares to be issued. Shares that are surrendered because of forfeiture, expiration, termination, or cancellation are available for re-issuance. As of &lt;em style="font: inherit;"&gt; March 31, 2025, &lt;/em&gt;there were 75,633 shares remaining available in the Plan.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;In &lt;em style="font: inherit;"&gt; August 2023, &lt;/em&gt;the Plan was amended to allow for an automatic increase of the available shares for issuance, whereby on the &lt;em style="font: inherit;"&gt;1st&lt;/em&gt; of each fiscal year, beginning on &lt;em style="font: inherit;"&gt; April 1, 2024 &lt;/em&gt;and ending on (and including) &lt;em style="font: inherit;"&gt; April 1, 2033 &lt;/em&gt;in an amount equal to &lt;em style="font: inherit;"&gt;five&lt;/em&gt; percent (5%) of the total number of shares of Common Stock outstanding on the &lt;em style="font: inherit;"&gt; March &lt;/em&gt;&lt;em style="font: inherit;"&gt;31st&lt;/em&gt; immediately preceding the applicable date. However, the Board &lt;em style="font: inherit;"&gt; may &lt;/em&gt;act prior to the automatic increase of a given year to provide that there will be &lt;em style="font: inherit;"&gt;no&lt;/em&gt; increase for such year, or that the increase for such year will be a lesser number of shares of Common Stock. On &lt;em style="font: inherit;"&gt; April 1, 2024, &lt;/em&gt;the Plan was increased by 47,116 shares and on &lt;em style="font: inherit;"&gt; April 1, 2025, &lt;/em&gt;the Plan was increased by 124,852 shares.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;The following table summarizes the stock option activity for the year ended &lt;em style="font: inherit;"&gt; March 31, 2025.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Weighted-&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Average &lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Exercise &lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Price &lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Per Share&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Weighted-&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Average &lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Remaining&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Life &lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;(In Years)&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Aggregate &lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Intrinsic &lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Value*&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 52%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Outstanding, March 31, 2024&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;100,180&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;46.59&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;9.35&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,680,672&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Granted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;143,303&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;23.02&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Exercised&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Forfeited/Cancelled&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Expired&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Outstanding, March 31, 2025&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;243,483&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;32.72&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;8.92&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Exercisable, March 31, 2025*&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;37,923&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;44.35&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;8.20&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;*Aggregate Intrinsic Value = Excess of market value over the exercise price of all in-the-money stock.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;During the year ended &lt;em style="font: inherit;"&gt; March 31, 2025, &lt;/em&gt;the Company granted certain&#160;individuals options to purchase 143,303 shares of common stock with contractual terms&#160;of &lt;span style="-sec-ix-hidden:c134564574"&gt;ten&lt;/span&gt; years, and vesting periods of annually over &lt;span style="-sec-ix-hidden:c134564575"&gt;four&lt;/span&gt; years. The options had an aggregate grant date fair value of $2.6&#160;million that was calculated using the Black-Scholes option pricing model. Variables used in the Black-Scholes option pricing model included the following: (&lt;em style="font: inherit;"&gt;1&lt;/em&gt;) fair value of common stock on the measurement date ranging from $1.99 and $56.20 per share; (&lt;em style="font: inherit;"&gt;2&lt;/em&gt;) discount rate ranging from 4.17% to 4.39% based on the daily yield curve rates for U.S. Treasury obligations, (&lt;em style="font: inherit;"&gt;3&lt;/em&gt;) expected life of 6.25 years based on the simplified method (vesting plus contractual term divided by &lt;em style="font: inherit;"&gt;two&lt;/em&gt;), and (&lt;em style="font: inherit;"&gt;4&lt;/em&gt;) expected volatility ranging from 110% to 138% based on the historical volatility of comparable companies' stock.&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;All options issued and outstanding are being amortized over their respective vesting periods. The unrecognized compensation expense at &lt;em style="font: inherit;"&gt; March 31, 2025 &lt;/em&gt;was $4.3 million. During the year ended &lt;em style="font: inherit;"&gt; March 31, 2025, &lt;/em&gt;the Company recorded stock-based compensation - option expense of $1.5 million, of which $1.3 million was recorded&#160;in general and administrative expenses and $0.2 million was recorded in research and development expenses in the statements of operations. The unrecognized compensation expense at &lt;em style="font: inherit;"&gt; March 31, 2024 &lt;/em&gt;was $3.1 million. During the year ended &lt;em style="font: inherit;"&gt; March 31, 2024, &lt;/em&gt;the Company recorded stock-based compensation - option expense of $0.6 million, of which $0.5 million was recorded&#160;in general and administrative expenses and $0.1 million was recorded in research and development expenses in the statements of operations.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;License Agreement&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;On &lt;em style="font: inherit;"&gt; July 10, 2024, &lt;/em&gt;we entered into a license agreement (the &#x201c;Agreement&#x201d;) with RF Innovations, Inc. (&#x201c;RFI&#x201d;), a privately held medical technology company, to license products utilizing RFI&#x2019;s intellectual property related to its Apex &lt;em style="font: inherit;"&gt;6&lt;/em&gt; Radiofrequency Generator (the &#x201c;Licensed Products&#x201d;). The Apex &lt;em style="font: inherit;"&gt;6&lt;/em&gt; Generator is a United States Food and Drug Administration (&#x201c;FDA&#x201d;) cleared ablation technology designed to lesion neural tissue for pain management in the peripheral nervous system. Pursuant to the Agreement, RFI granted us a perpetual non-exclusive worldwide royalty free fully paid license related to the Licensed Products, provided that the license did &lt;em style="font: inherit;"&gt;not&lt;/em&gt; include the right to sell certain products to customers for the treatment of spine pain. In connection with the Agreement, we issued RFI 12,500 unregistered shares of our common stock as consideration for the license. The Company determined that the fair value of the shares granted was $0.1 million, which represented its stock price on the date of the Agreement less a 25.6% discount for lack of marketability (&#x201c;DLOM&#x201d;).&#160; The Company concluded a discount for lack of marketability was appropriate as the shares are subject to an initial lock-up period of &lt;em style="font: inherit;"&gt;six&lt;/em&gt;-months until they are eligible for registration pursuant to SEC Rule &lt;em style="font: inherit;"&gt;144&lt;/em&gt; followed by restrictions that allow for a maximum of 10% of total shares to be sold within a &lt;em style="font: inherit;"&gt;30&lt;/em&gt;-day period.&#160;The DLOM effectively reflects the value of an average strike put option relative to our stock price and was calculated based on the Finnerty average put model.&#160;The Company concluded that the licensed technology qualified as a research and development expense pursuant to ASC Topic &lt;em style="font: inherit;"&gt;730,&lt;/em&gt; Research and Development, as the Company does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; have an alternative future use for the technology and the Company does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; have a plan to otherwise monetize the Licensed Products.&#160;The Company recognized $0.1 million in Research and Development expense in its condensed statement of income for the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; and &lt;em style="font: inherit;"&gt;nine&lt;/em&gt;-months ended &lt;em style="font: inherit;"&gt; December 31, 2024.&#160;&lt;/em&gt;The Agreement provides RFI the right to terminate the license if we breach any representation, warranty or covenant contained in the Agreement, subject to any relevant cure periods, or if we are subject to a bankruptcy or insolvency event.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;Offering Agreement &lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;On &lt;em style="font: inherit;"&gt; November 22, 2024, &lt;/em&gt;the Company entered into the Offering, which consisted of: (i) 458,691 Common Units, each Common Unit consisting of &lt;span style="-sec-ix-hidden:c134564614"&gt;one&lt;/span&gt; share of common stock, par value $0.001 per share, and &lt;span style="-sec-ix-hidden:c134564616"&gt;one&lt;/span&gt; Series A Warrant to purchase &lt;span style="-sec-ix-hidden:c134564617"&gt;one&lt;/span&gt; share of common stock; and (ii) 917,596 Pre-Funded Units, each Pre-Funded Unit consisting of &lt;span style="-sec-ix-hidden:c134564619"&gt;one&lt;/span&gt; Pre-Funded Warrant to purchase &lt;span style="-sec-ix-hidden:c134564620"&gt;one&lt;/span&gt; share of common stock and &lt;span style="-sec-ix-hidden:c134564621"&gt;one&lt;/span&gt; Series A Warrant. The purchase price of each Common Unit was $6.540, and the purchase price of each Pre-Funded Unit was $6.539.&#160;In addition, the Company granted the Underwriters a 45-day option to purchase additional 206,422 shares of common stock, and/or additional 206,422 Series A Warrants, solely to cover over-allotments, if any. The Offering closed on &lt;em style="font: inherit;"&gt; November 25, 2024. &lt;/em&gt;On &lt;em style="font: inherit;"&gt; November 22, 2024, &lt;/em&gt;the Underwriters partially exercised their over-allotment option with respect to 156,809 shares of Common Stock and 156,809 Series A Warrants. The Company received gross proceeds of $10.0&#160;million, before deducting the placement agent's fees and other offering expenses payable by the Company.&#160;Under the terms of the Underwriting Agreement, the Underwriters received an underwriting discount of 8.0% to the public offering price for the Units.&#160; The Company also issued to the Representative&#x2019;s Warrants to purchase up to 91,985 shares of Common Stock.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;The Pre-Funded Warrants have an exercise price of $0.001 per share, are immediately exercisable and &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be exercised at any time until all of the Pre-Funded Warrants are exercised in full, subject to a beneficial ownership limitation of 4.99%. The Series A Warrants have an exercise price of $6.540 per share and &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be exercised at any time until the &lt;span style="-sec-ix-hidden:c134564635"&gt;five&lt;/span&gt;-year anniversary of the date of issuance, subject to a beneficial ownership limitation of 4.99%. The Pre-Funded Warrants and Series A Warrants were issued pursuant a Warrant Agency Agreement between the Company and Equity Stock Transfer, LLC.&#160;The Series A Warrants and the Representative&#x2019;s Warrants, largely have the same terms and conditions, except the Representative&#x2019;s Warrants were &lt;em style="font: inherit;"&gt;not&lt;/em&gt; exercisable until &lt;em style="font: inherit;"&gt; May 21, 2025 &lt;/em&gt;and were subject to a 180-day lock-up prior to being transferable.&#160;The Series A Warrants and Representative&#x2019;s Warrants &lt;em style="font: inherit;"&gt; may, &lt;/em&gt;at the option of the holder be settled upon a change of control at the Black-Scholes value, as defined in the agreement.&#160;Upon a change of control the holder &lt;em style="font: inherit;"&gt; may &lt;/em&gt;receive cash, other assets or shares of the successor entity, depending on the specific nature of the change of control transaction and the settlement options afforded to the holders of Common Stock.&#160;The Company analyzed the Pre-Funded Warrants, the Series A Warrants, and the Representative&#x2019;s Warrants (collectively the &#x201c;Offering Warrants&#x201d;) in accordance with ASC Topic &lt;em style="font: inherit;"&gt;480,&lt;/em&gt; Distinguishing Liabilities from Equity and ASC Topic &lt;em style="font: inherit;"&gt;815,&lt;/em&gt; Derivatives and Hedging.&#160;Management concluded that the Offering Warrants meet all the requirements for equity classification.&#160;Since the Offering Warrants meet the requirements for equity classification and the Offering represents an arms-length cash transaction, the Common Units and Pre-Funded Units were recorded in equity based on the proceeds received, net of issuance costs.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;At issuance the Pre-Funded Warrants had a fair value of $6.3290 per share, which represented the common stock issuance price less the $0.001 exercise price.&#160;At issuance, the Series A Warrants and the Representative&#x2019;s Warrants had&#160;a fair value of $5.3597 and $5.2125&#160;per share, respectively, which was determined using a Black-Scholes option pricing model.&#160;Variables used in the Black-Scholes option pricing model included the following: (&lt;em style="font: inherit;"&gt;1&lt;/em&gt;) fair value of common stock on the measurement date; (&lt;em style="font: inherit;"&gt;2&lt;/em&gt;) discount rate of 4.17% based on the daily yield curve rates for U.S. Treasury obligations, (&lt;em style="font: inherit;"&gt;3&lt;/em&gt;) the contractual term of the warrants and (&lt;em style="font: inherit;"&gt;4&lt;/em&gt;) expected volatility of 144.15% based on the historical volatility of comparable companies' stock. Due to the relative volume of Series A Warrants and Representative&#x2019;s Warrants issued compared with the Company&#x2019;s outstanding shares, the Company's stock price was adjusted for the effects of dilution.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;In connection with the Offering, the Company incurred total offering costs of $1.5 million.&#160;This was comprised of $1.0 million in cash offering costs and $0.5 million&#160;for the fair value of the Representative&#x2019;s Warrant issued.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Equity-Based Stock Warrants&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;On &lt;em style="font: inherit;"&gt; January 26, 2024, &lt;/em&gt;the Company issued &lt;span style="-sec-ix-hidden:c134564655"&gt;five&lt;/span&gt;-year warrants to the selling agent in the Company's IPO to purchase 2,988 shares of common stock at an exercise price of $125.00. Under the fair value method, the fair value of these warrants was estimated on the grant date using the Black-Scholes option pricing model. Variables used in the Black-Scholes warrant pricing model included the following: (&lt;em style="font: inherit;"&gt;1&lt;/em&gt;) fair value of common stock on the measurement date of $100.00 split-adjusted per share; (&lt;em style="font: inherit;"&gt;2&lt;/em&gt;) discount rate of 4.04% based on the daily yield curve rates for U.S. Treasury obligations; (&lt;em style="font: inherit;"&gt;3&lt;/em&gt;) expected life of 5 years and (&lt;em style="font: inherit;"&gt;4&lt;/em&gt;) expected volatility of 104% based on the historical volatility of comparable companies' stock. The costs associated with these shares were reclassified to additional paid-in capital upon completion of the Company&#x2019;s IPO on &lt;em style="font: inherit;"&gt; January 26, 2024.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;The Company will periodically grant warrants to investors in connection with equity financing or to &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party service providers in exchange for services rendered. The following table summarizes the stock warrant activity for the year ended &lt;em style="font: inherit;"&gt; March 31, 2025:&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Warrants&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Weighted-&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Average &lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Exercise &lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Price Per &lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Share&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Weighted-&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Average &lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Remaining &lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Life (In &lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Years)&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Aggregate &lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Intrinsic &lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Value*&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 52%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Outstanding and exercisable, March 31, 2024&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;287,231&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1.64&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4.80&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;17,072,147&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Granted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,542,677&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4.31&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Exercised**&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(892,432&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;0.04&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Forfeited/Cancelled&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(2,602&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;0.20&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Expired&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Outstanding, March 31, 2025&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,934,874&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;5.89&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;4.09&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;532,060&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Exercisable, March 31, 2025&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,842,889&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;5.67&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;4.06&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;532,060&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;*Aggregate Intrinsic Value = Excess of market value over the exercise price of all in-the-money stock.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;span style="-sec-ix-hidden:c134564667"&gt;**197,098&lt;/span&gt;&#160;exercised shares utilized the &#x201c;cashless exercise&#x201d; option and 695,334 exercised shares were paid in cash.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;The unrecognized compensation expense at &lt;em style="font: inherit;"&gt; March 31, 2025 &lt;/em&gt;was $0. During the year ended &lt;em style="font: inherit;"&gt; March 31, 2025, &lt;/em&gt;the Company recorded stock-based compensation - warrant expense of less than $0.1 million. The unrecognized compensation expense at &lt;em style="font: inherit;"&gt; March 31, 2024 &lt;/em&gt;was less than &lt;span style="-sec-ix-hidden:c134564671"&gt;$0.1&lt;/span&gt; million.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;During the year ended &lt;em style="font: inherit;"&gt; March 31, 2024, &lt;/em&gt;the Company recorded stock-based compensation - warrant expense of less than $0.1 million.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;Under the fair value method, the fair value of each warrant was estimated on the grant date using the Black-Scholes option pricing model. Variables used in the Black-Scholes warrant pricing model included the following:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 71%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="7" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 23%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;Range&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 71%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;2025&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="3" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 8%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;2024&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 71%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Fair value of common stock on the measurement date (per share)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2013;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 4%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;$2.00&lt;/td&gt;&lt;td style="width: 4%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;em style="font: inherit;"&gt;to&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 4%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;5.00&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 71%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Discount rate based on the daily yield curve rates for U.S. Treasury obligations&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2013;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 4%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right;"&gt;4.04%&lt;/td&gt;&lt;td style="width: 4%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: center;"&gt;&lt;em style="font: inherit;"&gt;to&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 4%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4.54%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 71%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Expected life (in years)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2013;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 4%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right;"&gt;3&lt;/td&gt;&lt;td style="width: 4%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: center;"&gt;&lt;em style="font: inherit;"&gt;to&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 4%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;5&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 71%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Expected volatility based on the historical volatility of comparable companies' stock&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2013;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 4%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right;"&gt;104%&lt;/td&gt;&lt;td style="width: 4%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: center;"&gt;&lt;em style="font: inherit;"&gt;to&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 4%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;119%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
  </us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i_2023-11-29"
      decimals="INF"
      id="c134564541"
      unitRef="Share">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i_2023-11-29"
      decimals="INF"
      id="c134564543"
      unitRef="Share">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i_2025-03-31"
      decimals="-3"
      id="c134564545"
      unitRef="Share">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="d_2024-02-15_2024-02-15_AwardTypeAxis-RestrictedStockMember_TitleOfIndividualAxis-MarketingConsultantMember"
      decimals="INF"
      id="c134564546"
      unitRef="Share">1750</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="i_2024-02-15_AwardTypeAxis-RestrictedStockMember_TitleOfIndividualAxis-MarketingConsultantMember"
      decimals="INF"
      id="c134564547"
      unitRef="USDPerShare">76</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2024-02-15_2024-02-15_AwardTypeAxis-RestrictedStockMember_TitleOfIndividualAxis-MarketingConsultantMember"
      decimals="INF"
      id="c134564548"
      unitRef="USD">133000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="d_2024-02-15_2024-02-15_AwardTypeAxis-RestrictedStockMember_TitleOfIndividualAxis-MarketingConsultantMember"
      id="c134564549">P12M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <amix:RestrictedStockExpensesGeneralAndAdministrativeTableTextBlock contextRef="d_2024-04-01_2025-03-31" id="c3016964">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Year ended March 31,&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 70%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Recognized in general and administrative expense&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;116,375&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;16,625&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;116,375&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;16,625&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </amix:RestrictedStockExpensesGeneralAndAdministrativeTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2024-04-01_2025-03-31_AwardTypeAxis-RestrictedStockMember_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"
      decimals="INF"
      id="c134564078"
      unitRef="USD">116375</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2023-04-01_2024-03-31_AwardTypeAxis-RestrictedStockMember_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"
      decimals="INF"
      id="c134564079"
      unitRef="USD">16625</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2024-04-01_2025-03-31_AwardTypeAxis-RestrictedStockMember"
      decimals="INF"
      id="c134564080"
      unitRef="USD">116375</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2023-04-01_2024-03-31_AwardTypeAxis-RestrictedStockMember"
      decimals="INF"
      id="c134564081"
      unitRef="USD">16625</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="i_2025-03-31_AwardTypeAxis-RestrictedStockMember"
      decimals="-3"
      id="c134564550"
      unitRef="USD">0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock contextRef="d_2024-04-01_2025-03-31" id="c3016965">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Grant Date&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Number of &lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Fair Value Per &lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Share&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 70%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Outstanding, March 31, 2024&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,604&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;76.00&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Granted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Vested&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(1,604&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;76.00&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Outstanding, March 31, 2025&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i_2024-03-31_AwardTypeAxis-RestrictedStockMember"
      decimals="INF"
      id="c134564082"
      unitRef="Share">1604</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i_2024-03-31_AwardTypeAxis-RestrictedStockMember"
      decimals="INF"
      id="c134564083"
      unitRef="USDPerShare">76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="d_2024-04-01_2025-03-31_AwardTypeAxis-RestrictedStockMember"
      decimals="INF"
      id="c134564084"
      unitRef="Share">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="d_2024-04-01_2025-03-31_AwardTypeAxis-RestrictedStockMember"
      decimals="INF"
      id="c134564085"
      unitRef="USDPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="d_2024-04-01_2025-03-31_AwardTypeAxis-RestrictedStockMember"
      decimals="INF"
      id="c134564086"
      unitRef="Share">1604</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="d_2024-04-01_2025-03-31_AwardTypeAxis-RestrictedStockMember"
      decimals="INF"
      id="c134564087"
      unitRef="USDPerShare">76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i_2025-03-31_AwardTypeAxis-RestrictedStockMember"
      decimals="INF"
      id="c134564088"
      unitRef="Share">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i_2025-03-31_AwardTypeAxis-RestrictedStockMember"
      decimals="INF"
      id="c134564089"
      unitRef="USDPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <amix:EquityOfferingMaximumSharesToBeIssued
      contextRef="i_2023-04-06_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="INF"
      id="c134564551"
      unitRef="Share">100000</amix:EquityOfferingMaximumSharesToBeIssued>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="i_2023-04-06_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="INF"
      id="c134564552"
      unitRef="USDPerShare">40</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2023-04-01_2024-03-31_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="INF"
      id="c134564553"
      unitRef="Share">71000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2023-04-01_2024-03-31_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="INF"
      id="c134564554"
      unitRef="USD">2840000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i_2025-02-28"
      decimals="INF"
      id="c134564557"
      unitRef="USDPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <amix:EquityOfferingMaximumOfferingAmount
      contextRef="i_2025-02-28_SubsidiarySaleOfStockAxis-ATMAgreementMember"
      decimals="-5"
      id="c134564558"
      unitRef="USD">2100000</amix:EquityOfferingMaximumOfferingAmount>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2025-03-01_2025-03-31_SubsidiarySaleOfStockAxis-ATMAgreementMember"
      decimals="INF"
      id="c134564559"
      unitRef="Share">800</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="d_2025-03-01_2025-03-31_SubsidiarySaleOfStockAxis-ATMAgreementMember"
      decimals="INF"
      id="c134564560"
      unitRef="USD">1746</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i_2023-06-30_PlanNameAxis-The2023StockPlanMember"
      decimals="INF"
      id="c134564562"
      unitRef="Share">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i_2025-03-31_PlanNameAxis-The2023StockPlanMember"
      decimals="INF"
      id="c134564563"
      unitRef="Share">75633</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="d_2023-08-01_2023-08-31_PlanNameAxis-The2023StockPlanMember"
      decimals="2"
      id="c134564567"
      unitRef="Pure">0.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="d_2024-04-01_2024-04-01_PlanNameAxis-The2023StockPlanMember"
      decimals="INF"
      id="c134564570"
      unitRef="Share">47116</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="d_2025-04-01_2025-04-01_PlanNameAxis-The2023StockPlanMember"
      decimals="INF"
      id="c134564571"
      unitRef="Share">124852</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="d_2024-04-01_2025-03-31" id="c3016966">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Weighted-&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Average &lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Exercise &lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Price &lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Per Share&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Weighted-&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Average &lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Remaining&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Life &lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;(In Years)&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Aggregate &lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Intrinsic &lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Value*&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 52%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Outstanding, March 31, 2024&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;100,180&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;46.59&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;9.35&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,680,672&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Granted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;143,303&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;23.02&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Exercised&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Forfeited/Cancelled&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Expired&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Outstanding, March 31, 2025&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;243,483&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;32.72&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;8.92&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Exercisable, March 31, 2025*&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;37,923&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;44.35&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;8.20&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2024-03-31"
      decimals="INF"
      id="c134564090"
      unitRef="Share">100180</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i_2024-03-31"
      decimals="INF"
      id="c134564091"
      unitRef="USDPerShare">46.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="d_2023-04-01_2024-03-31" id="c134564092">P9Y4M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i_2024-04-01"
      decimals="INF"
      id="c134564093"
      unitRef="USD">1680672</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="d_2024-04-01_2025-03-31"
      decimals="INF"
      id="c134564094"
      unitRef="Share">143303</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="d_2024-04-01_2025-03-31"
      decimals="INF"
      id="c134564095"
      unitRef="USDPerShare">23.02</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="d_2024-04-01_2025-03-31"
      decimals="INF"
      id="c134564098"
      unitRef="Share">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="d_2024-04-01_2025-03-31"
      decimals="INF"
      id="c134564099"
      unitRef="USDPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="d_2024-04-01_2025-03-31"
      decimals="INF"
      id="c134564102"
      unitRef="Share">-0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="d_2024-04-01_2025-03-31"
      decimals="INF"
      id="c134564103"
      unitRef="USDPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="d_2024-04-01_2025-03-31"
      decimals="INF"
      id="c134564106"
      unitRef="Share">-0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="d_2024-04-01_2025-03-31"
      decimals="INF"
      id="c134564107"
      unitRef="USDPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2025-03-31"
      decimals="INF"
      id="c134564110"
      unitRef="Share">243483</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i_2025-03-31"
      decimals="INF"
      id="c134564111"
      unitRef="USDPerShare">32.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="d_2024-04-01_2025-03-31" id="c134564112">P8Y11M1D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i_2025-03-31"
      decimals="INF"
      id="c134564113"
      unitRef="USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i_2025-03-31"
      decimals="INF"
      id="c134564114"
      unitRef="Share">37923</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i_2025-03-31"
      decimals="INF"
      id="c134564115"
      unitRef="USDPerShare">44.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="d_2024-04-01_2025-03-31" id="c134564116">P8Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i_2025-03-31"
      decimals="INF"
      id="c134564117"
      unitRef="USD">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="d_2024-04-01_2025-03-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2023StockPlanMember"
      decimals="INF"
      id="c134564573"
      unitRef="Share">143303</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <amix:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantDateFairValue
      contextRef="i_2025-03-31_AwardTypeAxis-EmployeeStockOptionMember_ValuationTechniqueAxis-BlackscholesModelMember"
      decimals="-5"
      id="c134564576"
      unitRef="USD">2600000</amix:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantDateFairValue>
    <us-gaap:SharePrice
      contextRef="i_2025-03-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MinimumMember_ValuationTechniqueAxis-BlackscholesModelMember"
      decimals="INF"
      id="c134564578"
      unitRef="USDPerShare">1.99</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="i_2025-03-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MaximumMember_ValuationTechniqueAxis-BlackscholesModelMember"
      decimals="INF"
      id="c134564579"
      unitRef="USDPerShare">56.2</us-gaap:SharePrice>
    <amix:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsDiscountRate
      contextRef="d_2024-04-01_2025-03-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MinimumMember_ValuationTechniqueAxis-BlackscholesModelMember"
      decimals="4"
      id="c134564581"
      unitRef="Pure">0.0417</amix:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsDiscountRate>
    <amix:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsDiscountRate
      contextRef="d_2024-04-01_2025-03-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MaximumMember_ValuationTechniqueAxis-BlackscholesModelMember"
      decimals="4"
      id="c134564582"
      unitRef="Pure">0.0439</amix:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsDiscountRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="d_2024-04-01_2025-03-31_AwardTypeAxis-EmployeeStockOptionMember_ValuationTechniqueAxis-BlackscholesModelMember"
      id="c134564584">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="d_2024-04-01_2025-03-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MinimumMember_ValuationTechniqueAxis-BlackscholesModelMember"
      decimals="1"
      id="c134564587"
      unitRef="Pure">1.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="d_2024-04-01_2025-03-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MaximumMember_ValuationTechniqueAxis-BlackscholesModelMember"
      decimals="2"
      id="c134564588"
      unitRef="Pure">1.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i_2025-03-31_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="-5"
      id="c134564589"
      unitRef="USD">4300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2024-04-01_2025-03-31_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="-5"
      id="c134564590"
      unitRef="USD">1500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2024-04-01_2025-03-31_AwardTypeAxis-EmployeeStockOptionMember_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"
      decimals="-5"
      id="c134564591"
      unitRef="USD">1300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2024-04-01_2025-03-31_AwardTypeAxis-EmployeeStockOptionMember_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"
      decimals="-5"
      id="c134564592"
      unitRef="USD">200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i_2024-03-31_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="-5"
      id="c134564593"
      unitRef="USD">3100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2023-04-01_2024-03-31_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="-5"
      id="c134564594"
      unitRef="USD">600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2023-04-01_2024-03-31_AwardTypeAxis-EmployeeStockOptionMember_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"
      decimals="-5"
      id="c134564595"
      unitRef="USD">500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2023-04-01_2024-03-31_AwardTypeAxis-EmployeeStockOptionMember_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"
      decimals="-5"
      id="c134564596"
      unitRef="USD">100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2024-07-10_2024-07-10_CounterpartyNameAxis-RfInnovationsIncMember"
      decimals="INF"
      id="c134564600"
      unitRef="Share">12500</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2024-07-10_2024-07-10_CounterpartyNameAxis-RfInnovationsIncMember"
      decimals="-5"
      id="c134564601"
      unitRef="USD">100000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <amix:CommonStockDiscountForLackOfMarketability
      contextRef="i_2024-07-10_CounterpartyNameAxis-RfInnovationsIncMember"
      decimals="3"
      id="c134564602"
      unitRef="Pure">0.256</amix:CommonStockDiscountForLackOfMarketability>
    <amix:MaximumPercentageOfSharesSoldInThirtyDays
      contextRef="i_2024-07-10_CounterpartyNameAxis-RfInnovationsIncMember"
      decimals="1"
      id="c134564605"
      unitRef="Pure">0.10</amix:MaximumPercentageOfSharesSoldInThirtyDays>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2024-10-01_2024-12-31_CounterpartyNameAxis-RfInnovationsIncMember_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"
      decimals="-5"
      id="c134564610"
      unitRef="USD">100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <amix:NumberOfCommonUnitsIssued
      contextRef="d_2024-11-22_2024-11-25_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember"
      decimals="INF"
      id="c134564613"
      unitRef="Share">458691</amix:NumberOfCommonUnitsIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i_2024-11-25_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember"
      decimals="INF"
      id="c134564615"
      unitRef="USDPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <amix:NumberOfPrefundedUnitsIssued
      contextRef="d_2024-11-22_2024-11-25_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember"
      decimals="INF"
      id="c134564618"
      unitRef="Share">917596</amix:NumberOfPrefundedUnitsIssued>
    <amix:CommonUnitsIssuedPurchasePrice
      contextRef="d_2024-11-22_2024-11-25_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember"
      decimals="INF"
      id="c134564622"
      unitRef="USDPerShare">6.54</amix:CommonUnitsIssuedPurchasePrice>
    <amix:PrefundedUnitsIssuedPurchasePrice
      contextRef="d_2024-11-22_2024-11-25_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember"
      decimals="INF"
      id="c134564623"
      unitRef="USDPerShare">6.539</amix:PrefundedUnitsIssuedPurchasePrice>
    <amix:EquityOfferingOptionPeriod
      contextRef="d_2024-11-22_2024-11-22_CounterpartyNameAxis-UnderwritersMember_SubsidiarySaleOfStockAxis-OverAllotmentOptionMember"
      id="c134564624">P45D</amix:EquityOfferingOptionPeriod>
    <amix:EquityOfferingOptionMaximumShares
      contextRef="i_2024-11-22_CounterpartyNameAxis-UnderwritersMember_SubsidiarySaleOfStockAxis-OverAllotmentOptionMember"
      decimals="INF"
      id="c134564625"
      unitRef="Share">206422</amix:EquityOfferingOptionMaximumShares>
    <amix:EquityOfferingOptionMaximumWarrants
      contextRef="i_2024-11-22_ClassOfWarrantOrRightAxis-SeriesAWarrantsMember_CounterpartyNameAxis-UnderwritersMember"
      decimals="INF"
      id="c134564626"
      unitRef="Share">206422</amix:EquityOfferingOptionMaximumWarrants>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2024-11-22_2024-11-22_CounterpartyNameAxis-UnderwritersMember_SubsidiarySaleOfStockAxis-OverAllotmentOptionMember"
      decimals="INF"
      id="c134564627"
      unitRef="Share">156809</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <amix:ClassOfWarrantOrRightIssuedDuringPeriod
      contextRef="d_2024-11-22_2024-11-22_ClassOfWarrantOrRightAxis-SeriesAWarrantsMember_CounterpartyNameAxis-UnderwritersMember"
      decimals="INF"
      id="c134564628"
      unitRef="Share">156809</amix:ClassOfWarrantOrRightIssuedDuringPeriod>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="d_2024-11-22_2024-11-25_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember"
      decimals="-7"
      id="c134564629"
      unitRef="USD">10000000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <amix:CommissionPercentage
      contextRef="i_2024-11-25_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember"
      decimals="2"
      id="c134564630"
      unitRef="Pure">0.08</amix:CommissionPercentage>
    <amix:ClassOfWarrantOrRightIssuedDuringPeriod
      contextRef="d_2024-11-22_2024-11-25_ClassOfWarrantOrRightAxis-RepresentativesWarrantsMember_CounterpartyNameAxis-UnderwritersMember"
      decimals="INF"
      id="c134564631"
      unitRef="Share">91985</amix:ClassOfWarrantOrRightIssuedDuringPeriod>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2024-11-25_ClassOfWarrantOrRightAxis-PrefundedWarrantsMember"
      decimals="INF"
      id="c134564632"
      unitRef="USDPerShare">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <amix:ClassOfWarrantsOrRightsMaximumBeneficialOwnership
      contextRef="i_2024-11-25_ClassOfWarrantOrRightAxis-PrefundedWarrantsMember"
      decimals="4"
      id="c134564633"
      unitRef="Pure">0.0499</amix:ClassOfWarrantsOrRightsMaximumBeneficialOwnership>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2024-11-25_ClassOfWarrantOrRightAxis-SeriesAWarrantsMember"
      decimals="INF"
      id="c134564634"
      unitRef="USDPerShare">6.54</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <amix:ClassOfWarrantsOrRightsMaximumBeneficialOwnership
      contextRef="i_2024-11-25_ClassOfWarrantOrRightAxis-SeriesAWarrantsMember"
      decimals="4"
      id="c134564636"
      unitRef="Pure">0.0499</amix:ClassOfWarrantsOrRightsMaximumBeneficialOwnership>
    <amix:ClassOfWarrantOrRightLockupPeriod
      contextRef="d_2024-11-22_2024-11-25_ClassOfWarrantOrRightAxis-RepresentativesWarrantsMember"
      id="c134564638">P180D</amix:ClassOfWarrantOrRightLockupPeriod>
    <amix:ClassOfWarrantOrRightFairValuePerShare
      contextRef="i_2024-11-25_ClassOfWarrantOrRightAxis-PrefundedWarrantsMember"
      decimals="INF"
      id="c134564642"
      unitRef="USDPerShare">6.329</amix:ClassOfWarrantOrRightFairValuePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2024-11-25_ClassOfWarrantOrRightAxis-PrefundedWarrantsMember"
      decimals="INF"
      id="c134564643"
      unitRef="USDPerShare">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <amix:ClassOfWarrantOrRightFairValuePerShare
      contextRef="i_2024-11-25_ClassOfWarrantOrRightAxis-SeriesAWarrantsMember"
      decimals="INF"
      id="c134564644"
      unitRef="USDPerShare">5.3597</amix:ClassOfWarrantOrRightFairValuePerShare>
    <amix:ClassOfWarrantOrRightFairValuePerShare
      contextRef="i_2024-11-25_ClassOfWarrantOrRightAxis-RepresentativesWarrantsMember"
      decimals="INF"
      id="c134564645"
      unitRef="USDPerShare">5.2125</amix:ClassOfWarrantOrRightFairValuePerShare>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2024-11-25_ClassOfWarrantOrRightAxis-SeriesAWarrantsAndTheRepresentativesWarrantsMember_MeasurementInputTypeAxis-ValuationTechniqueDiscountedCashFlowMember_ValuationTechniqueAxis-BlackscholesModelMember"
      decimals="4"
      id="c134564648"
      unitRef="Pure">0.0417</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2024-11-25_ClassOfWarrantOrRightAxis-SeriesAWarrantsAndTheRepresentativesWarrantsMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember_ValuationTechniqueAxis-BlackscholesModelMember"
      decimals="4"
      id="c134564651"
      unitRef="Pure">1.4415</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="d_2024-11-22_2024-11-25_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember"
      decimals="-5"
      id="c134564652"
      unitRef="USD">1500000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="d_2024-11-22_2024-11-25_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember"
      decimals="-6"
      id="c134564653"
      unitRef="USD">1000000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="d_2024-11-22_2024-11-25_NatureOfExpenseAxis-NoncashExpensesMember_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember"
      decimals="-5"
      id="c134564654"
      unitRef="USD">500000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2024-01-26_ClassOfWarrantOrRightAxis-EquitybasedWarrantsMember"
      decimals="INF"
      id="c134564656"
      unitRef="Share">2988</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2024-01-26_ClassOfWarrantOrRightAxis-EquitybasedWarrantsMember"
      decimals="INF"
      id="c134564657"
      unitRef="USDPerShare">125</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SharePrice
      contextRef="i_2024-01-26"
      decimals="INF"
      id="c134564659"
      unitRef="USDPerShare">100</us-gaap:SharePrice>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2024-01-26_ClassOfWarrantOrRightAxis-EquitybasedWarrantsMember_MeasurementInputTypeAxis-MeasurementInputDiscountRateMember_ValuationTechniqueAxis-BlackscholesModelMember"
      decimals="4"
      id="c134564661"
      unitRef="Pure">0.0404</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2024-01-26_ClassOfWarrantOrRightAxis-EquitybasedWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember_ValuationTechniqueAxis-BlackscholesModelMember"
      decimals="INF"
      id="c134564663"
      unitRef="Pure">5</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2024-01-26_ClassOfWarrantOrRightAxis-EquitybasedWarrantsMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember_ValuationTechniqueAxis-BlackscholesModelMember"
      decimals="2"
      id="c134564665"
      unitRef="Pure">1.04</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock contextRef="d_2024-04-01_2025-03-31" id="c3016967">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Warrants&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Weighted-&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Average &lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Exercise &lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Price Per &lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Share&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Weighted-&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Average &lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Remaining &lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Life (In &lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Years)&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Aggregate &lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Intrinsic &lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Value*&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 52%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Outstanding and exercisable, March 31, 2024&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;287,231&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1.64&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4.80&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;17,072,147&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Granted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,542,677&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4.31&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Exercised**&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(892,432&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;0.04&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Forfeited/Cancelled&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(2,602&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;0.20&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Expired&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Outstanding, March 31, 2025&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,934,874&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;5.89&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;4.09&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;532,060&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Exercisable, March 31, 2025&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,842,889&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;5.67&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;4.06&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;532,060&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="i_2024-03-31"
      decimals="INF"
      id="c134564118"
      unitRef="Share">287231</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <amix:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i_2024-03-31"
      decimals="INF"
      id="c134564119"
      unitRef="USDPerShare">1.64</amix:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="d_2023-04-01_2024-03-31" id="c134564120">P4Y9M18D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="i_2024-04-01"
      decimals="INF"
      id="c134564121"
      unitRef="USD">17072147</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="d_2024-04-01_2025-03-31"
      decimals="INF"
      id="c134564122"
      unitRef="Share">2542677</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <amix:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="d_2024-04-01_2025-03-31"
      decimals="INF"
      id="c134564123"
      unitRef="USDPerShare">4.31</amix:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="d_2024-04-01_2025-03-31"
      decimals="INF"
      id="c134564126"
      unitRef="Share">892432</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <amix:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="d_2024-04-01_2025-03-31"
      decimals="INF"
      id="c134564127"
      unitRef="USDPerShare">0.04</amix:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures
      contextRef="d_2024-04-01_2025-03-31"
      decimals="INF"
      id="c134564130"
      unitRef="Share">2602</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures>
    <amix:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="d_2024-04-01_2025-03-31"
      decimals="INF"
      id="c134564131"
      unitRef="USDPerShare">0.2</amix:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations
      contextRef="d_2024-04-01_2025-03-31"
      decimals="INF"
      id="c134564134"
      unitRef="Share">-0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations>
    <amix:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="d_2024-04-01_2025-03-31"
      decimals="INF"
      id="c134564135"
      unitRef="USDPerShare">0</amix:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="i_2025-03-31"
      decimals="INF"
      id="c134564138"
      unitRef="Share">1934874</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <amix:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i_2025-03-31"
      decimals="INF"
      id="c134564139"
      unitRef="USDPerShare">5.89</amix:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="d_2024-04-01_2025-03-31" id="c134564140">P4Y1M2D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="i_2025-03-31"
      decimals="INF"
      id="c134564141"
      unitRef="USD">532060</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <amix:SharebasedCompensationArrangementBySharebasedPaymentAwardNonoptionEquityInstrumentsExercisableNumberOutstandingNumber
      contextRef="i_2025-03-31"
      decimals="INF"
      id="c134564142"
      unitRef="Share">1842889</amix:SharebasedCompensationArrangementBySharebasedPaymentAwardNonoptionEquityInstrumentsExercisableNumberOutstandingNumber>
    <amix:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice
      contextRef="i_2025-03-31"
      decimals="INF"
      id="c134564143"
      unitRef="USDPerShare">5.67</amix:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice>
    <amix:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerm contextRef="d_2024-04-01_2025-03-31" id="c134564144">P4Y21D</amix:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerm>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
      contextRef="d_2024-04-01_2025-03-31"
      decimals="INF"
      id="c134564145"
      unitRef="USD">532060</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
    <amix:ClassOfWarrantOrRightExercisedInPeriodCash
      contextRef="d_2024-04-01_2025-03-31_ClassOfWarrantOrRightAxis-EquitybasedWarrantsMember"
      decimals="INF"
      id="c134564668"
      unitRef="Share">695334</amix:ClassOfWarrantOrRightExercisedInPeriodCash>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i_2025-03-31_AwardTypeAxis-WarrantMember"
      decimals="-3"
      id="c134564669"
      unitRef="USD">0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2024-04-01_2025-03-31_AwardTypeAxis-WarrantMember"
      decimals="-5"
      id="c134564670"
      unitRef="USD">100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2023-04-01_2024-03-31_AwardTypeAxis-WarrantMember"
      decimals="-5"
      id="c134564672"
      unitRef="USD">100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="d_2024-04-01_2025-03-31" id="c3016968">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 71%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="7" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 23%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;Range&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 71%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;2025&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="3" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 8%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;2024&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 71%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Fair value of common stock on the measurement date (per share)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2013;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 4%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;$2.00&lt;/td&gt;&lt;td style="width: 4%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;em style="font: inherit;"&gt;to&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 4%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;5.00&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 71%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Discount rate based on the daily yield curve rates for U.S. Treasury obligations&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2013;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 4%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right;"&gt;4.04%&lt;/td&gt;&lt;td style="width: 4%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: center;"&gt;&lt;em style="font: inherit;"&gt;to&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 4%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4.54%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 71%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Expected life (in years)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2013;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 4%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right;"&gt;3&lt;/td&gt;&lt;td style="width: 4%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: center;"&gt;&lt;em style="font: inherit;"&gt;to&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 4%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;5&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 71%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Expected volatility based on the historical volatility of comparable companies' stock&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2013;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 4%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right;"&gt;104%&lt;/td&gt;&lt;td style="width: 4%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: center;"&gt;&lt;em style="font: inherit;"&gt;to&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 4%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;119%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharePrice
      contextRef="i_2024-03-31_AwardTypeAxis-WarrantMember_RangeAxis-MinimumMember_ValuationTechniqueAxis-BlackscholesModelMember"
      decimals="INF"
      id="c134564146"
      unitRef="USDPerShare">2</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="i_2024-03-31_AwardTypeAxis-WarrantMember_RangeAxis-MaximumMember_ValuationTechniqueAxis-BlackscholesModelMember"
      decimals="INF"
      id="c134564148"
      unitRef="USDPerShare">5</us-gaap:SharePrice>
    <amix:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsDiscountRate
      contextRef="d_2023-04-01_2024-03-31_AwardTypeAxis-WarrantMember_RangeAxis-MinimumMember_ValuationTechniqueAxis-BlackscholesModelMember"
      decimals="4"
      id="c134564149"
      unitRef="Pure">0.0404</amix:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsDiscountRate>
    <amix:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsDiscountRate
      contextRef="d_2023-04-01_2024-03-31_AwardTypeAxis-WarrantMember_RangeAxis-MaximumMember_ValuationTechniqueAxis-BlackscholesModelMember"
      decimals="4"
      id="c134564151"
      unitRef="Pure">0.0454</amix:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsDiscountRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="d_2023-04-01_2024-03-31_AwardTypeAxis-WarrantMember_RangeAxis-MinimumMember_ValuationTechniqueAxis-BlackscholesModelMember"
      id="c134564152">P3Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="d_2023-04-01_2024-03-31_AwardTypeAxis-WarrantMember_RangeAxis-MaximumMember_ValuationTechniqueAxis-BlackscholesModelMember"
      id="c134564154">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="d_2023-04-01_2024-03-31_AwardTypeAxis-WarrantMember_RangeAxis-MinimumMember_ValuationTechniqueAxis-BlackscholesModelMember"
      decimals="2"
      id="c134564155"
      unitRef="Pure">1.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="d_2023-04-01_2024-03-31_AwardTypeAxis-WarrantMember_RangeAxis-MaximumMember_ValuationTechniqueAxis-BlackscholesModelMember"
      decimals="2"
      id="c134564157"
      unitRef="Pure">1.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="d_2024-04-01_2025-03-31" id="c3016969">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;5&lt;/em&gt; &lt;/b&gt;&#x2013;&lt;b&gt; Commitments and Contingencies&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Legal Proceedings&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;From time to time, we &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be involved in claims that arise during the ordinary course of business. Although the results of litigation and claims cannot be predicted with certainty, we do &lt;span style="-sec-ix-hidden:c134564674"&gt;not&lt;/span&gt; currently have any pending litigation to which we are a party or to which our property is subject that we believe to be material. Regardless of the outcome, litigation can be costly and time consuming, and it can divert management&#x2019;s attention from important business matters and initiatives, negatively impacting our overall operations.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Employment Agreements&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;The Company has agreements with key employees to provide certain benefits, including salary and other wage-related benefits, in the event of termination. In addition, the Company has adopted a severance policy for certain key members of executive management to provide certain benefits, including salary and other wage-related benefits, in the event of termination without cause. In total, these benefits would amount to a range of $1.1 million to $1.6 million&#160;using the rate of compensation in effect at &lt;em style="font: inherit;"&gt; March 31, 2025.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;Brad Hauser - Chief Executive Officer&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;On &lt;em style="font: inherit;"&gt; June 17, 2024, &lt;/em&gt;we entered into an employment agreement with Brad Hauser pursuant to which Mr. Hauser agreed to serve as our chief executive officer and president for an initial &lt;span style="-sec-ix-hidden:c134564678"&gt;three&lt;/span&gt;-year period, which &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be extended on a year-to-year basis. Mr. Hauser&#x2019;s agreement provides for an initial annual base salary of $450,000 (subject to an annual review and increase at the discretion of our Compensation Committee) and a target annual bonus of 60% of his base salary. Pursuant to the agreement, Mr. Hauser was granted a &lt;span style="-sec-ix-hidden:c134564681"&gt;ten&lt;/span&gt;-year option (the &#x201c;Inducement Options&#x201d;) to purchase 45,000 shares of common stock at an exercise price equal to the closing price of our common stock on the date of the employment agreement. The option vests in &lt;em style="font: inherit;"&gt;four&lt;/em&gt; equal annual installments (or 11,250 shares each installment) on each of the succeeding &lt;em style="font: inherit;"&gt;four&lt;/em&gt; anniversary dates of the execution of the employment agreement, provided Mr. Hauser is employed by us on each vesting date. In the event of a &#x201c;change of control&#x201d; or the termination of the agreement by us without &#x201c;cause&#x201d; or by Mr. Hauser for &#x201c;good reason,&#x201d; all of the unvested options shall immediately vest. The Inducement Options were granted outside of our &lt;em style="font: inherit;"&gt;2023&lt;/em&gt; Stock Plan as an inducement material to Mr. Hauser&#x2019;s entering into employment with us in accordance with Nasdaq Stock Market Listing Rule &lt;em style="font: inherit;"&gt;5635&lt;/em&gt;(c)(&lt;em style="font: inherit;"&gt;4&lt;/em&gt;). Commencing with the year ending &lt;em style="font: inherit;"&gt; March 31, 2025, &lt;/em&gt;Mr. Hauser will be eligible to receive annual option grants as determined by the Compensation Committee of the Board of Directors, based on criteria established by the Compensation Committee. The number of shares underlying the target annual option grant will be equal to $1,000,000 divided by the Black-Scholes value per share of our common stock on the date of grant.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;If Mr. Hauser&#x2019;s employment is terminated at our election without &#x201c;cause,&#x201d; or by Mr. Hauser for &#x201c;good reason,&#x201d; Mr. Hauser shall be entitled to receive severance payments equal to &lt;em style="font: inherit;"&gt;twelve&lt;/em&gt; months of Mr. Hauser&#x2019;s base salary and 100% of the target bonus for the year in which such termination occurs; provided that such amounts shall be increased by 50% if Mr. Hauser&#x2019;s agreement is terminated without &#x201c;cause&#x201d; or by Mr. Hauser for &#x201c;good reason&#x201d; within &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months prior to or &lt;em style="font: inherit;"&gt;twelve&lt;/em&gt; months after a &#x201c;change of control.&#x201d; In the event that any payments or benefits provided to Mr. Hauser would trigger the excise tax under Section &lt;em style="font: inherit;"&gt;4999&lt;/em&gt; of the Internal Revenue Code or any similar provision, the Company agreed to provide Mr. Hauser with a gross-up payment to ensure that, after payment of all taxes (including the excise tax, federal, state, and local income taxes, and employment taxes) imposed on the gross-up payment, Mr. Hauser receives a net amount equal to the payments or benefits Mr. Hauser would have received if the excise tax didn't apply.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;Lori Bisson&lt;/i&gt;&#160;-&#160;Executive &lt;i&gt;Vice Chairman (former Chief Executive Officer)&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;On &lt;em style="font: inherit;"&gt; June 17, 2024, &lt;/em&gt;we entered into an employment agreement with Lori Bisson pursuant to which Ms. Bisson agreed to serve as our Executive Vice Chairman and Strategic Adviser to the Chief Executive Officer for a &lt;span style="-sec-ix-hidden:c134564696"&gt;two&lt;/span&gt;-year period. Ms. Bisson&#x2019;s agreement provides for an initial annual base salary of $150,000 (subject to an annual review and increase at the discretion of our Compensation Committee) and a target annual bonus of 50% of her base salary. Pursuant to the agreement, Ms. Bisson continued to vest in the option grants issued to Ms. Bisson in her role as chief executive officer and president in accordance with the vesting schedule set out in her initial employment agreement. In the event of a &#x201c;change of control&#x201d; or the termination of the agreement by us without &#x201c;cause&#x201d; or by Ms. Bisson for &#x201c;good reason,&#x201d; all of the unvested options shall immediately vest. Ms. Bisson is entitled to receive any compensation, including incentive compensation, for the fiscal year ended &lt;em style="font: inherit;"&gt; March 31, 2024 &lt;/em&gt;that has &lt;em style="font: inherit;"&gt;not&lt;/em&gt; been paid as of the date of the agreement. Commencing with the year ending &lt;em style="font: inherit;"&gt; March 31, 2025, &lt;/em&gt;Ms. Bisson will be eligible to receive annual option grants as determined by the Compensation Committee of the Board of Directors, based on criteria established by the Compensation Committee. Ms. Bisson agreed to waive any severance payments due to her in connection with the termination of the prior employment agreement that we entered into with her on &lt;em style="font: inherit;"&gt; June 30, 2023.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Fractional Shares&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;See &lt;i&gt;Note &lt;em style="font: inherit;"&gt;1&lt;/em&gt; - Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies&lt;/i&gt; - "&lt;i&gt;Reverse Stock Split&lt;/i&gt;" for additional information.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;On &lt;em style="font: inherit;"&gt; November 1, 2024, &lt;/em&gt;the Company received notice from the Depository Trust and Clearing Corporation ("DTCC") on behalf of the brokerage firms that hold the shares of Company common stock held in &#x201c;street name&#x201d; that in connection with the rounding of fractional shares in connection with the Reverse Stock Split, the Company would need to issue 271,846 shares of common stock (the &#x201c;Shares&#x201d;) for the rounding of shares. The Company does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; believe the number of Shares being requested is correct based on the historical number of shareholders of its common stock and is aware of similar anomalies in recent months for other companies completing a Reverse Stock Split. As such, the Company has begun an inquiry into the calculations set forth in the request. During the pendency of this inquiry, the Company does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; intend to issue any shares in connection with the fractional shares being requested and has concluded that an obligation should &lt;em style="font: inherit;"&gt;not&lt;/em&gt; be recorded in its financial statements. The Company is &lt;em style="font: inherit;"&gt;not&lt;/em&gt; currently subject to any pending litigation as a result of the fractional roundup shares.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


  </us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="d_2024-04-01_2025-03-31_RangeAxis-MinimumMember_TypeOfArrangementAxis-EmploymentContractsMember"
      decimals="-5"
      id="c134564676"
      unitRef="USD">1100000</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="d_2024-04-01_2025-03-31_RangeAxis-MaximumMember_TypeOfArrangementAxis-EmploymentContractsMember"
      decimals="-5"
      id="c134564677"
      unitRef="USD">1600000</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <amix:AnnualBaseSalary
      contextRef="d_2024-06-17_2024-06-17_TitleOfIndividualAxis-ChiefExecutiveOfficerMember_TypeOfArrangementAxis-EmploymentContractsMember"
      decimals="INF"
      id="c134564679"
      unitRef="USD">450000</amix:AnnualBaseSalary>
    <amix:EmploymentAgreementBonusAsAPercentageOfAnnualBaseCompensation
      contextRef="d_2024-06-17_2024-06-17_TitleOfIndividualAxis-ChiefExecutiveOfficerMember_TypeOfArrangementAxis-EmploymentContractsMember"
      decimals="1"
      id="c134564680"
      unitRef="Pure">0.60</amix:EmploymentAgreementBonusAsAPercentageOfAnnualBaseCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="d_2024-06-17_2024-06-17_AwardTypeAxis-InducementOptionsMember_TitleOfIndividualAxis-ChiefExecutiveOfficerMember_TypeOfArrangementAxis-EmploymentContractsMember"
      decimals="INF"
      id="c134564682"
      unitRef="Share">45000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="d_2024-06-17_2024-06-17_AwardTypeAxis-InducementOptionsMember_TitleOfIndividualAxis-ChiefExecutiveOfficerMember_TypeOfArrangementAxis-EmploymentContractsMember_VestingAxis-ShareBasedCompensationAwardTrancheOneMember"
      decimals="INF"
      id="c134564684"
      unitRef="Share">11250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="d_2024-06-17_2024-06-17_TitleOfIndividualAxis-ChiefExecutiveOfficerMember_TypeOfArrangementAxis-EmploymentContractsMember"
      decimals="INF"
      id="c134564689"
      unitRef="USD">1000000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <amix:EmploymentAgreementBonusAsAPercentageOfAnnualBaseCompensation
      contextRef="d_2024-06-17_2024-06-17_StatementScenarioAxis-ScenarioContractTerminationMember_TitleOfIndividualAxis-ChiefExecutiveOfficerMember_TypeOfArrangementAxis-EmploymentContractsMember"
      decimals="0"
      id="c134564691"
      unitRef="Pure">1</amix:EmploymentAgreementBonusAsAPercentageOfAnnualBaseCompensation>
    <amix:EmploymentAgreementBonusAsAPercentageOfAnnualBaseCompensation
      contextRef="d_2024-06-17_2024-06-17_StatementScenarioAxis-ScenarioContractTerminationWithoutCauseMember_TitleOfIndividualAxis-ChiefExecutiveOfficerMember_TypeOfArrangementAxis-EmploymentContractsMember"
      decimals="1"
      id="c134564692"
      unitRef="Pure">0.50</amix:EmploymentAgreementBonusAsAPercentageOfAnnualBaseCompensation>
    <amix:AnnualBaseSalary
      contextRef="d_2024-06-17_2024-06-17_TitleOfIndividualAxis-ExecutiveViceChairAndStrategicAdvisorToTheChiefExecutiveOfficerMember_TypeOfArrangementAxis-EmploymentContractsMember"
      decimals="INF"
      id="c134564697"
      unitRef="USD">150000</amix:AnnualBaseSalary>
    <amix:EmploymentAgreementBonusAsAPercentageOfAnnualBaseCompensation
      contextRef="d_2024-06-17_2024-06-17_TitleOfIndividualAxis-ExecutiveViceChairAndStrategicAdvisorToTheChiefExecutiveOfficerMember_TypeOfArrangementAxis-EmploymentContractsMember"
      decimals="1"
      id="c134564698"
      unitRef="Pure">0.50</amix:EmploymentAgreementBonusAsAPercentageOfAnnualBaseCompensation>
    <amix:StockRequiredToBeIssuedForStockSplitShares
      contextRef="i_2024-11-01"
      decimals="INF"
      id="c134564701"
      unitRef="Share">271846</amix:StockRequiredToBeIssuedForStockSplitShares>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="d_2024-04-01_2025-03-31" id="c3016970">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;6&lt;/em&gt; &lt;/b&gt;&#x2013;&lt;b&gt; Related Party Transactions&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;The Company utilizes a consulting firm that is owned by the Company&#x2019;s former Chief Financial Officer to provide accounting and financial reporting services and pays certain expenses on behalf of the Company. During the year ended &lt;em style="font: inherit;"&gt; March 31, 2025 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2024,&lt;/em&gt; the Company incurred fees of less than $0.1 million, respectively, for these services, excluding officer compensation. As of &lt;em style="font: inherit;"&gt; March 31, 2025 &lt;/em&gt;and &lt;em style="font: inherit;"&gt; March 31, 2024, &lt;/em&gt;the Company owed the consulting firm $0 and less than $0.1 million, respectively, for services and expenses.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;As of &lt;em style="font: inherit;"&gt; March 31, 2025, &lt;/em&gt;members of the Company&#x2019;s management/Board and an immediate family member of the Company&#x2019;s management (related party), collectively purchased $0.5 million ($0.4 million and $0.1 million, respectively) of the Bridge Offering.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;On &lt;em style="font: inherit;"&gt; December 21, 2021, &lt;/em&gt;the Company entered into a perpetual, worldwide, exclusive license agreement (the &#x201c;License&#x201d; or &#x201c;License Agreement&#x201d;) with a company controlled by a significant stockholder of the Company (the &#x201c;Licensee&#x201d;). The License allows the Licensee to use certain intellectual property and technology related to the diagnosis and treatment of cardiovascular conditions held by the Company. Upon &lt;em style="font: inherit;"&gt;90&lt;/em&gt; days following the completion of an IPO or special purpose acquisition company transaction, the Licensee &lt;em style="font: inherit;"&gt; may &lt;/em&gt;enter into sublicenses of the licensed intellectual property and technology.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;On &lt;em style="font: inherit;"&gt; July 7, 2023, &lt;/em&gt;the Company and the Licensee entered into an Exclusive License Termination Agreement (the &#x201c;Termination Agreement&#x201d;) in exchange for the issuance, upon the closing of the Company&#x2019;s IPO within &lt;em style="font: inherit;"&gt;one&lt;/em&gt; year of the agreement&#x2019;s execution, of a warrant to purchase shares of the Company for a variable number of shares. Upon the Company's closing of its IPO on &lt;em style="font: inherit;"&gt; January 29, 2024, &lt;/em&gt;80,000&#160;warrant shares were issued at $100.00 per share for a fixed value of $8.0 million. The warrants are&#160;exercisable at a price of $0.02 per share and &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be exercised any time after the issuance date, subject to a beneficial ownership limitation, and expire &lt;span style="-sec-ix-hidden:c134564722"&gt;five&lt;/span&gt; years from the original issuance. The warrants contain dividend rights commensurate with the holders of common stock. The warrants do &lt;em style="font: inherit;"&gt;not&lt;/em&gt; include any other stockholder rights or privileges prior to exercise.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;The shares underlying the warrant will be subject to a lockup agreement for a period of &lt;span style="-sec-ix-hidden:c134564724"&gt;six&lt;/span&gt; months after the closing of the IPO with respect to 12.5% of the shares issued and &lt;span style="-sec-ix-hidden:c134564726"&gt;twelve&lt;/span&gt; months after the closing of the IPO for the remainder of the shares. In connection with the Termination Agreement, the Company agreed to register the resale of the shares of common stock. One of the Company&#x2019;s directors holds a 20% interest in the company receiving the warrant.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
  </us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="d_2024-04-01_2025-03-31_RangeAxis-MaximumMember_RelatedPartyTransactionAxis-AccountingAndFinancialReportingServicesMember_RelatedPartyTransactionsByRelatedPartyAxis-ConsultingFirmOwnedByFormerCFOMember"
      decimals="-5"
      id="c134564709"
      unitRef="USD">100000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:AccountsPayableCurrentAndNoncurrent
      contextRef="i_2025-03-31_RelatedPartyTransactionAxis-AccountingAndFinancialReportingServicesMember_RelatedPartyTransactionsByRelatedPartyAxis-ConsultingFirmOwnedByFormerCFOMember"
      decimals="-3"
      id="c134564710"
      unitRef="USD">0</us-gaap:AccountsPayableCurrentAndNoncurrent>
    <us-gaap:AccountsPayableCurrentAndNoncurrent
      contextRef="i_2024-03-31_RelatedPartyTransactionAxis-AccountingAndFinancialReportingServicesMember_RelatedPartyTransactionsByRelatedPartyAxis-ConsultingFirmOwnedByFormerCFOMember"
      decimals="-5"
      id="c134564711"
      unitRef="USD">100000</us-gaap:AccountsPayableCurrentAndNoncurrent>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="d_2024-04-01_2025-03-31_DebtInstrumentAxis-TheBridgeOfferingMember_RelatedPartyTransactionsByRelatedPartyAxis-ManagementBoardOfDirectorFamilyMember"
      decimals="-5"
      id="c134564712"
      unitRef="USD">500000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="d_2024-04-01_2025-03-31_DebtInstrumentAxis-TheBridgeOfferingMember_RelatedPartyTransactionsByRelatedPartyAxis-ManagementMember"
      decimals="-5"
      id="c134564713"
      unitRef="USD">400000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="d_2024-04-01_2025-03-31_DebtInstrumentAxis-TheBridgeOfferingMember_RelatedPartyTransactionsByRelatedPartyAxis-RelatedPartyMember"
      decimals="-5"
      id="c134564714"
      unitRef="USD">100000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:CommonStockSharesIssued
      contextRef="i_2024-01-29_ClassOfWarrantOrRightAxis-TheWarrantMember_RelatedPartyTransactionAxis-TerminationAgreementMember"
      decimals="INF"
      id="c134564718"
      unitRef="Share">80000</us-gaap:CommonStockSharesIssued>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="i_2024-01-29_ClassOfWarrantOrRightAxis-TheWarrantMember_RelatedPartyTransactionAxis-TerminationAgreementMember"
      decimals="INF"
      id="c134564719"
      unitRef="USDPerShare">100</us-gaap:SharesIssuedPricePerShare>
    <amix:ClassOfWarrantOrRightValueOfSecuritiesCalledByWarrantsOrRights
      contextRef="d_2023-07-07_2023-07-07_ClassOfWarrantOrRightAxis-TheWarrantMember_RelatedPartyTransactionAxis-TerminationAgreementMember"
      decimals="-6"
      id="c134564720"
      unitRef="USD">8000000</amix:ClassOfWarrantOrRightValueOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2023-07-07_ClassOfWarrantOrRightAxis-TheWarrantMember_RelatedPartyTransactionAxis-TerminationAgreementMember"
      decimals="INF"
      id="c134564721"
      unitRef="USDPerShare">0.02</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <amix:ClassOfWarrantOrRightPercentageOfOutstandingStock
      contextRef="d_2023-07-07_2023-07-07_ClassOfWarrantOrRightAxis-TheWarrantMember_RelatedPartyTransactionAxis-TerminationAgreementMember_UnderlyingAssetClassAxis-CommonStock6MonthsLockupPeriodMember"
      decimals="3"
      id="c134564725"
      unitRef="Pure">0.125</amix:ClassOfWarrantOrRightPercentageOfOutstandingStock>
    <amix:InterestHeldInCompanyReceivingWarrants
      contextRef="i_2023-07-07_ClassOfWarrantOrRightAxis-TheWarrantMember_RelatedPartyTransactionAxis-TerminationAgreementMember"
      decimals="1"
      id="c134564727"
      unitRef="Pure">0.20</amix:InterestHeldInCompanyReceivingWarrants>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="d_2024-04-01_2025-03-31" id="c3016971">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;7&lt;/em&gt; &lt;/b&gt;&#x2013;&lt;b&gt; Income Taxes&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;The Company files U.S. federal and various U.S. state income tax returns. Due to the Company&#x2019;s losses, there was &lt;em style="font: inherit;"&gt;no&lt;/em&gt; income tax expense for the years ended &lt;em style="font: inherit;"&gt; March 31, 2025 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2024&lt;/em&gt; (in thousands):&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;March 31,&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;March 31,&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Amount&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;%&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Amount&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;%&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 52%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Tax benefit at the U.S. federal statutory rate&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(2,396&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;21.00&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(3,239&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;21.00&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Tax rate change&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Permanent differences&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;5&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(0.05&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,697&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(11.01&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Return to provision&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(44&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;0.39&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(69&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;0.45&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Change in state rate&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;234&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(2.05&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(190&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1.23&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;State tax (net of federal benefit)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(63&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;0.55&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(192&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1.24&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Valuation allowance&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2,264&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(19.84&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,993&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(12.91&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Effective income tax rate&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;The effective income tax rate varied from the statutory rate in &lt;em style="font: inherit;"&gt;2025&lt;/em&gt; primarily due to permanent differences and the increase in the valuation allowance.&#160;The effective income tax rate varied from the statutory rate in &lt;em style="font: inherit;"&gt;2024&lt;/em&gt; primarily as a result of the increase&#160;in the valuation allowance.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;Deferred tax assets and liabilities consist of the following (in thousands):&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;March 31,&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;March 31,&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 70%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Assets related to:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Capitalized R&amp;amp;D costs&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,380&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;602&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Net operating losses&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;761&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,643&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Accruals and reserves&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3,438&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;72&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Stock-based compensation&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;450&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;142&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total deferred tax assets&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;6,029&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3,459&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Valuation allowance for deferred tax assets&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(5,723&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(3,459&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Net deferred tax assets&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;306&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Liabilities related to:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Section 481A method change&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(306&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Net deferred tax liabilities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(306&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Net deferred tax&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;At &lt;em style="font: inherit;"&gt; March 31, 2025, &lt;/em&gt;the Company had U.S. federal net operating loss ("NOL") carry forwards of $3.6 million. Approximately $0.9 million of the U.S. federal NOLs will start expiring in &lt;em style="font: inherit;"&gt;2037.&lt;/em&gt; Additionally, the Company generated a U.S. federal NOL carry-forward of approximately $2.7 million post-&lt;em style="font: inherit;"&gt;2017&lt;/em&gt; to &lt;em style="font: inherit;"&gt;2024.&lt;/em&gt; Under the new Tax Act, post-&lt;em style="font: inherit;"&gt;2017&lt;/em&gt; federal NOL carry forwards do &lt;em style="font: inherit;"&gt;not&lt;/em&gt; expire, but can only offset &lt;em style="font: inherit;"&gt;80%&lt;/em&gt; of taxable income in the year the loss carry forward is used.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;Sections &lt;em style="font: inherit;"&gt;382&lt;/em&gt; and &lt;em style="font: inherit;"&gt;383&lt;/em&gt; of the Internal Revenue Code limit the annual use of NOL &#160;carry-forwards and tax credit carry forwards, respectively, following an ownership change. NOL carry-forwards &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be subject to annual limitations under Internal Revenue Code Section &lt;em style="font: inherit;"&gt;382&lt;/em&gt; (Section &lt;em style="font: inherit;"&gt;382&lt;/em&gt;) (or comparable provisions of state law) if certain changes in ownership were to occur.&#160;Determination of ownership change, or limitation hasn&#x2019;t been calculated; however, the Company will perform the NOL limitation analysis under Section&#160;&lt;em style="font: inherit;"&gt;382&lt;/em&gt;&#160;before any NOLs are expected to be utilized.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;The Company has recorded a full valuation allowance against its net total deferred tax assets as of &lt;em style="font: inherit;"&gt; March 31, 2025 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2024&lt;/em&gt; because management determined that it is &lt;span style="-sec-ix-hidden:c134564749"&gt;not&lt;/span&gt; more-likely-than &lt;em style="font: inherit;"&gt;not&lt;/em&gt; that those assets will be realized. In assessing the realization of deferred tax assets, management considers whether it is more likely than &lt;em style="font: inherit;"&gt;not&lt;/em&gt; that some portion or all of deferred assets will &lt;em style="font: inherit;"&gt;not&lt;/em&gt; be realized. The ultimate realization of the deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. During the year ended &lt;em style="font: inherit;"&gt; March 31, 2025, &lt;/em&gt;the valuation allowance increased by $2.3 million mainly due to additional capitalized R&amp;amp;D and Start-up Costs.&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;The Company is subject to income taxes in the U.S. federal jurisdiction and various state jurisdictions. Tax regulations within each jurisdiction are subject to the interpretation of the related tax laws and regulations and require significant judgment to apply. As of &lt;em style="font: inherit;"&gt; March 31, 2025, &lt;/em&gt;all of the tax years remained open to examination by the federal and state taxing authorities, for &lt;em style="font: inherit;"&gt;three&lt;/em&gt; or &lt;em style="font: inherit;"&gt;four&lt;/em&gt; years from the tax year in which net operating losses or tax credits are utilized completely.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;As of &lt;em style="font: inherit;"&gt; March 31, 2025, &lt;/em&gt;the Company has &lt;em style="font: inherit;"&gt;no&lt;/em&gt; uncertain tax positions.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
  </us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="d_2024-04-01_2025-06-30" id="c3016972">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;March 31,&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;March 31,&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Amount&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;%&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Amount&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;%&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 52%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Tax benefit at the U.S. federal statutory rate&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(2,396&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;21.00&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(3,239&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;21.00&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Tax rate change&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Permanent differences&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;5&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(0.05&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,697&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(11.01&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Return to provision&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(44&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;0.39&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(69&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;0.45&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Change in state rate&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;234&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(2.05&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(190&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1.23&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;State tax (net of federal benefit)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(63&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;0.55&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(192&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1.24&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Valuation allowance&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2,264&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(19.84&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,993&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(12.91&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Effective income tax rate&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="d_2024-04-01_2025-03-31"
      decimals="-3"
      id="c134564158"
      unitRef="USD">-2396000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="d_2024-04-01_2025-03-31"
      decimals="2"
      id="c134564159"
      unitRef="Pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="d_2023-04-01_2024-03-31"
      decimals="-3"
      id="c134564160"
      unitRef="USD">-3239000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="d_2023-04-01_2024-03-31"
      decimals="2"
      id="c134564161"
      unitRef="Pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate
      contextRef="d_2024-04-01_2025-03-31"
      decimals="-3"
      id="c134564162"
      unitRef="USD">0</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="d_2024-04-01_2025-03-31"
      decimals="0"
      id="c134564163"
      unitRef="Pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate
      contextRef="d_2023-04-01_2024-03-31"
      decimals="-3"
      id="c134564164"
      unitRef="USD">0</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="d_2023-04-01_2024-03-31"
      decimals="0"
      id="c134564165"
      unitRef="Pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense
      contextRef="d_2024-04-01_2025-03-31"
      decimals="-3"
      id="c134564166"
      unitRef="USD">5000</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="d_2024-04-01_2025-03-31"
      decimals="4"
      id="c134564167"
      unitRef="Pure">-0.0005</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense
      contextRef="d_2023-04-01_2024-03-31"
      decimals="-3"
      id="c134564168"
      unitRef="USD">1697000</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="d_2023-04-01_2024-03-31"
      decimals="4"
      id="c134564169"
      unitRef="Pure">-0.1101</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes
      contextRef="d_2024-04-01_2025-03-31"
      decimals="-3"
      id="c134564170"
      unitRef="USD">-44000</us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes
      contextRef="d_2024-04-01_2025-03-31"
      decimals="4"
      id="c134564171"
      unitRef="Pure">0.0039</us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes
      contextRef="d_2023-04-01_2024-03-31"
      decimals="-3"
      id="c134564172"
      unitRef="USD">-69000</us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes
      contextRef="d_2023-04-01_2024-03-31"
      decimals="4"
      id="c134564173"
      unitRef="Pure">0.0045</us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes>
    <amix:EffectiveIncomeTaxRateReconciliationChangeInStateRateAmount
      contextRef="d_2024-04-01_2025-03-31"
      decimals="-3"
      id="c134564174"
      unitRef="USD">234000</amix:EffectiveIncomeTaxRateReconciliationChangeInStateRateAmount>
    <amix:EffectiveIncomeTaxRateReconciliationChangeInStateRatePercent
      contextRef="d_2024-04-01_2025-03-31"
      decimals="4"
      id="c134564175"
      unitRef="Pure">-0.0205</amix:EffectiveIncomeTaxRateReconciliationChangeInStateRatePercent>
    <amix:EffectiveIncomeTaxRateReconciliationChangeInStateRateAmount
      contextRef="d_2023-04-01_2024-03-31"
      decimals="-4"
      id="c134564176"
      unitRef="USD">-190000</amix:EffectiveIncomeTaxRateReconciliationChangeInStateRateAmount>
    <amix:EffectiveIncomeTaxRateReconciliationChangeInStateRatePercent
      contextRef="d_2023-04-01_2024-03-31"
      decimals="4"
      id="c134564177"
      unitRef="Pure">0.0123</amix:EffectiveIncomeTaxRateReconciliationChangeInStateRatePercent>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="d_2024-04-01_2025-03-31"
      decimals="-3"
      id="c134564178"
      unitRef="USD">-63000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="d_2024-04-01_2025-03-31"
      decimals="4"
      id="c134564179"
      unitRef="Pure">0.0055</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="d_2023-04-01_2024-03-31"
      decimals="-3"
      id="c134564180"
      unitRef="USD">-192000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="d_2023-04-01_2024-03-31"
      decimals="4"
      id="c134564181"
      unitRef="Pure">0.0124</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="d_2024-04-01_2025-03-31"
      decimals="-3"
      id="c134564182"
      unitRef="USD">2264000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="d_2024-04-01_2025-03-31"
      decimals="4"
      id="c134564183"
      unitRef="Pure">-0.1984</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="d_2023-04-01_2024-03-31"
      decimals="-3"
      id="c134564184"
      unitRef="USD">1993000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="d_2023-04-01_2024-03-31"
      decimals="4"
      id="c134564185"
      unitRef="Pure">-0.1291</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="d_2024-04-01_2025-03-31"
      decimals="-3"
      id="c134564186"
      unitRef="USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="d_2024-04-01_2025-03-31"
      decimals="0"
      id="c134564187"
      unitRef="Pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="d_2023-04-01_2024-03-31"
      decimals="-3"
      id="c134564188"
      unitRef="USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="d_2023-04-01_2024-03-31"
      decimals="0"
      id="c134564189"
      unitRef="Pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="d_2024-04-01_2025-03-31" id="c3016973">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;March 31,&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;March 31,&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 70%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Assets related to:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Capitalized R&amp;amp;D costs&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,380&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;602&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Net operating losses&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;761&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,643&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Accruals and reserves&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3,438&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;72&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Stock-based compensation&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;450&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;142&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total deferred tax assets&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;6,029&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3,459&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Valuation allowance for deferred tax assets&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(5,723&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(3,459&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Net deferred tax assets&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;306&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Liabilities related to:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Section 481A method change&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(306&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Net deferred tax liabilities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(306&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Net deferred tax&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <amix:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts
      contextRef="i_2025-03-31"
      decimals="INF"
      id="c134564190"
      unitRef="USD">1380</amix:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts>
    <amix:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts
      contextRef="i_2024-03-31"
      decimals="INF"
      id="c134564191"
      unitRef="USD">602</amix:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i_2025-03-31"
      decimals="INF"
      id="c134564192"
      unitRef="USD">761</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i_2024-03-31"
      decimals="INF"
      id="c134564193"
      unitRef="USD">2643</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="i_2025-03-31"
      decimals="INF"
      id="c134564194"
      unitRef="USD">3438</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="i_2024-03-31"
      decimals="INF"
      id="c134564195"
      unitRef="USD">72</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i_2025-03-31"
      decimals="INF"
      id="c134564196"
      unitRef="USD">450</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i_2024-03-31"
      decimals="INF"
      id="c134564197"
      unitRef="USD">142</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i_2025-03-31"
      decimals="INF"
      id="c134564198"
      unitRef="USD">6029</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i_2024-03-31"
      decimals="INF"
      id="c134564199"
      unitRef="USD">3459</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i_2025-03-31"
      decimals="INF"
      id="c134564200"
      unitRef="USD">5723</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i_2024-03-31"
      decimals="INF"
      id="c134564201"
      unitRef="USD">3459</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i_2025-03-31"
      decimals="INF"
      id="c134564202"
      unitRef="USD">306</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i_2024-03-31"
      decimals="INF"
      id="c134564203"
      unitRef="USD">0</us-gaap:DeferredTaxAssetsNet>
    <amix:DeferredTaxLiabilitiesChangeInAccountingMethod
      contextRef="i_2025-03-31"
      decimals="INF"
      id="c134564204"
      unitRef="USD">306</amix:DeferredTaxLiabilitiesChangeInAccountingMethod>
    <amix:DeferredTaxLiabilitiesChangeInAccountingMethod
      contextRef="i_2024-03-31"
      decimals="INF"
      id="c134564205"
      unitRef="USD">-0</amix:DeferredTaxLiabilitiesChangeInAccountingMethod>
    <us-gaap:DeferredTaxLiabilities
      contextRef="i_2025-03-31"
      decimals="INF"
      id="c134564206"
      unitRef="USD">306</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="i_2024-03-31"
      decimals="INF"
      id="c134564207"
      unitRef="USD">-0</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i_2025-03-31"
      decimals="INF"
      id="c134564208"
      unitRef="USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i_2024-03-31"
      decimals="INF"
      id="c134564209"
      unitRef="USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i_2025-03-31"
      decimals="-5"
      id="c134564734"
      unitRef="USD">3600000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i_2025-03-31_TaxPeriodAxis-ExpirationCommencingTaxYear20342037Member"
      decimals="-5"
      id="c134564735"
      unitRef="USD">900000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i_2025-03-31_TaxPeriodAxis-NolGeneratedDuring20172024Member"
      decimals="-5"
      id="c134564737"
      unitRef="USD">2700000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="d_2024-04-01_2025-03-31"
      decimals="-5"
      id="c134564753"
      unitRef="USD">2300000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:SubsequentEventsTextBlock contextRef="d_2024-04-01_2025-03-31" id="c3016974">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;8&lt;/em&gt; &lt;/b&gt;&#x2013;&lt;b&gt; Subsequent Events&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;As of &lt;em style="font: inherit;"&gt; May 28, 2025, &lt;/em&gt;the Company has sold 289,144 shares pursuant to the ATM Agreement for net proceeds of approximately $0.6 million.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;On &lt;em style="font: inherit;"&gt; April 17, 2025, &lt;/em&gt;we granted a new employee a &lt;span style="-sec-ix-hidden:c134564760"&gt;ten&lt;/span&gt;-year option (the &#x201c;Inducement Options&#x201d;) to purchase 5,000 shares of common stock at an exercise price equal to the closing price of our common stock on the date of the employment. The option vests in &lt;em style="font: inherit;"&gt;four&lt;/em&gt; equal annual installments (or 1,250 shares each installment) on each of the succeeding &lt;em style="font: inherit;"&gt;four&lt;/em&gt; anniversary dates of the execution of the date of employment, provided the employee is employed by us on each vesting date.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


  </us-gaap:SubsequentEventsTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2025-04-01_2025-05-28_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-ATMAgreementMember"
      decimals="INF"
      id="c134564758"
      unitRef="Share">289144</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="d_2025-04-01_2025-05-28_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-ATMAgreementMember"
      decimals="-5"
      id="c134564759"
      unitRef="USD">600000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="d_2025-04-17_2025-04-17_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_SubsequentEventTypeAxis-SubsequentEventMember"
      decimals="INF"
      id="c134564761"
      unitRef="Share">5000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="d_2025-04-17_2025-04-17_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_SubsequentEventTypeAxis-SubsequentEventMember_VestingAxis-ShareBasedCompensationAwardTrancheOneMember"
      decimals="INF"
      id="c134564763"
      unitRef="Share">1250</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i_2025-06-30"
      decimals="-3"
      id="c134563803"
      unitRef="USD">8589000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i_2025-03-31"
      decimals="-3"
      id="c134563804"
      unitRef="USD">9136000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:OtherAssetsCurrent
      contextRef="i_2025-06-30"
      decimals="-3"
      id="c134563805"
      unitRef="USD">389000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i_2025-03-31"
      decimals="-3"
      id="c134563806"
      unitRef="USD">473000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i_2025-06-30"
      decimals="-3"
      id="c134563807"
      unitRef="USD">8978000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i_2025-03-31"
      decimals="-3"
      id="c134563808"
      unitRef="USD">9609000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i_2025-06-30"
      decimals="-3"
      id="c134563809"
      unitRef="USD">19000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i_2025-03-31"
      decimals="-3"
      id="c134563810"
      unitRef="USD">21000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DeferredCosts
      contextRef="i_2025-06-30"
      decimals="-3"
      id="c134563811"
      unitRef="USD">0</us-gaap:DeferredCosts>
    <us-gaap:DeferredCosts
      contextRef="i_2025-03-31"
      decimals="-3"
      id="c134563812"
      unitRef="USD">176000</us-gaap:DeferredCosts>
    <us-gaap:AssetsNoncurrent
      contextRef="i_2025-06-30"
      decimals="-3"
      id="c134563813"
      unitRef="USD">19000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="i_2025-03-31"
      decimals="-3"
      id="c134563814"
      unitRef="USD">197000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i_2025-06-30"
      decimals="-3"
      id="c134563815"
      unitRef="USD">8997000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i_2025-03-31"
      decimals="-3"
      id="c134563816"
      unitRef="USD">9806000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i_2025-06-30"
      decimals="-3"
      id="c134563817"
      unitRef="USD">815000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i_2025-03-31"
      decimals="-3"
      id="c134563818"
      unitRef="USD">676000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i_2025-06-30"
      decimals="-4"
      id="c134563819"
      unitRef="USD">1150000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i_2025-03-31"
      decimals="-3"
      id="c134563820"
      unitRef="USD">1031000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i_2025-06-30"
      decimals="-3"
      id="c134563821"
      unitRef="USD">1965000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i_2025-03-31"
      decimals="-3"
      id="c134563822"
      unitRef="USD">1707000</us-gaap:LiabilitiesCurrent>
    <us-gaap:Liabilities
      contextRef="i_2025-06-30"
      decimals="-3"
      id="c134563823"
      unitRef="USD">1965000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i_2025-03-31"
      decimals="-3"
      id="c134563824"
      unitRef="USD">1707000</us-gaap:Liabilities>
    <us-gaap:PreferredStockValue
      contextRef="i_2025-06-30"
      decimals="-3"
      id="c134563825"
      unitRef="USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i_2025-03-31"
      decimals="-3"
      id="c134563826"
      unitRef="USD">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockValue
      contextRef="i_2025-06-30"
      decimals="-3"
      id="c134563827"
      unitRef="USD">4000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i_2025-03-31"
      decimals="-3"
      id="c134563828"
      unitRef="USD">2000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i_2025-06-30"
      decimals="-3"
      id="c134563829"
      unitRef="USD">60744000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i_2025-03-31"
      decimals="-3"
      id="c134563830"
      unitRef="USD">58476000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i_2025-06-30"
      decimals="-3"
      id="c134563831"
      unitRef="USD">-53716000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i_2025-03-31"
      decimals="-3"
      id="c134563832"
      unitRef="USD">-50379000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i_2025-06-30"
      decimals="-3"
      id="c134563833"
      unitRef="USD">7032000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2025-03-31"
      decimals="-3"
      id="c134563834"
      unitRef="USD">8099000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i_2025-06-30"
      decimals="-3"
      id="c134563835"
      unitRef="USD">8997000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i_2025-03-31"
      decimals="-3"
      id="c134563836"
      unitRef="USD">9806000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2025-04-01_2025-06-30"
      decimals="-3"
      id="c134563844"
      unitRef="USD">1593000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2024-04-01_2024-06-30"
      decimals="-3"
      id="c134563845"
      unitRef="USD">954000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="d_2025-04-01_2025-06-30"
      decimals="-3"
      id="c134563846"
      unitRef="USD">1828000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="d_2024-04-01_2024-06-30"
      decimals="-3"
      id="c134563847"
      unitRef="USD">1799000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="d_2025-04-01_2025-06-30"
      decimals="-3"
      id="c134563848"
      unitRef="USD">3421000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="d_2024-04-01_2024-06-30"
      decimals="-3"
      id="c134563849"
      unitRef="USD">2753000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2025-04-01_2025-06-30"
      decimals="-3"
      id="c134563850"
      unitRef="USD">-3421000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2024-04-01_2024-06-30"
      decimals="-3"
      id="c134563851"
      unitRef="USD">-2753000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpenseNonoperating
      contextRef="d_2025-04-01_2025-06-30"
      decimals="-3"
      id="c134563852"
      unitRef="USD">-0</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating
      contextRef="d_2024-04-01_2024-06-30"
      decimals="-3"
      id="c134563853"
      unitRef="USD">41000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InvestmentIncomeInterest
      contextRef="d_2025-04-01_2025-06-30"
      decimals="-3"
      id="c134563854"
      unitRef="USD">84000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="d_2024-04-01_2024-06-30"
      decimals="-3"
      id="c134563855"
      unitRef="USD">95000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="d_2025-04-01_2025-06-30"
      decimals="-3"
      id="c134563856"
      unitRef="USD">84000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="d_2024-04-01_2024-06-30"
      decimals="-3"
      id="c134563857"
      unitRef="USD">54000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="d_2025-04-01_2025-06-30"
      decimals="-3"
      id="c134563858"
      unitRef="USD">-3337000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="d_2024-04-01_2024-06-30"
      decimals="-3"
      id="c134563859"
      unitRef="USD">-2699000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="d_2025-04-01_2025-06-30"
      decimals="-3"
      id="c134563860"
      unitRef="USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="d_2024-04-01_2024-06-30"
      decimals="-3"
      id="c134563861"
      unitRef="USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="d_2025-04-01_2025-06-30"
      decimals="-3"
      id="c134563862"
      unitRef="USD">-3337000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-04-01_2024-06-30"
      decimals="-3"
      id="c134563863"
      unitRef="USD">-2699000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="d_2025-04-01_2025-06-30"
      decimals="INF"
      id="c134563864"
      unitRef="USDPerShare">-1.07</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="d_2024-04-01_2024-06-30"
      decimals="INF"
      id="c134563865"
      unitRef="USDPerShare">-2.2</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="d_2025-04-01_2025-06-30"
      decimals="INF"
      id="c134563866"
      unitRef="Share">3105156</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="d_2024-04-01_2024-06-30"
      decimals="INF"
      id="c134563867"
      unitRef="Share">1225423</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:SharesOutstanding
      contextRef="i_2024-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c134563870"
      unitRef="Share">943000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2024-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c134563871"
      unitRef="USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2024-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c134563872"
      unitRef="USD">46596000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2024-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c134563873"
      unitRef="USD">-38969000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2024-03-31"
      decimals="-3"
      id="c134563874"
      unitRef="USD">7628000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c134563876"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c134563877"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c134563878"
      unitRef="USD">-2699000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-04-01_2024-06-30"
      decimals="-3"
      id="c134563879"
      unitRef="USD">-2699000</us-gaap:NetIncomeLoss>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c134563881"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-4"
      id="c134563882"
      unitRef="USD">360000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c134563883"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2024-04-01_2024-06-30"
      decimals="-4"
      id="c134563884"
      unitRef="USD">360000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <amix:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-4"
      id="c134563885"
      unitRef="Share">20000</amix:StockIssuedDuringPeriodSharesWarrantsExercised>
    <amix:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c134563886"
      unitRef="USD">0</amix:StockIssuedDuringPeriodValueWarrantsExercised>
    <amix:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c134563887"
      unitRef="USD">0</amix:StockIssuedDuringPeriodValueWarrantsExercised>
    <amix:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="d_2024-04-01_2024-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c134563888"
      unitRef="USD">0</amix:StockIssuedDuringPeriodValueWarrantsExercised>
    <amix:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="d_2024-04-01_2024-06-30"
      decimals="-3"
      id="c134563889"
      unitRef="USD">0</amix:StockIssuedDuringPeriodValueWarrantsExercised>
    <us-gaap:SharesOutstanding
      contextRef="i_2024-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c134563890"
      unitRef="Share">963000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2024-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c134563891"
      unitRef="USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2024-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c134563892"
      unitRef="USD">46956000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2024-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c134563893"
      unitRef="USD">-41668000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c134563894"
      unitRef="USD">5289000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i_2025-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c134563895"
      unitRef="Share">2497000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2025-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c134563896"
      unitRef="USD">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2025-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c134563897"
      unitRef="USD">58476000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2025-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c134563898"
      unitRef="USD">-50379000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2025-03-31"
      decimals="-3"
      id="c134563899"
      unitRef="USD">8099000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c134563901"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c134563902"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c134563903"
      unitRef="USD">-3337000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2025-04-01_2025-06-30"
      decimals="-3"
      id="c134563904"
      unitRef="USD">-3337000</us-gaap:NetIncomeLoss>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c134563906"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c134563907"
      unitRef="USD">388000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c134563908"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2025-04-01_2025-06-30"
      decimals="-3"
      id="c134563909"
      unitRef="USD">388000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c134563910"
      unitRef="Share">1304000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c134563911"
      unitRef="USD">2000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-4"
      id="c134563912"
      unitRef="USD">1880000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c134563913"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2025-04-01_2025-06-30"
      decimals="-3"
      id="c134563914"
      unitRef="USD">1882000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <amix:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c134563915"
      unitRef="Share">222000</amix:StockIssuedDuringPeriodSharesWarrantsExercised>
    <amix:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c134563916"
      unitRef="USD">0</amix:StockIssuedDuringPeriodValueWarrantsExercised>
    <amix:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c134563917"
      unitRef="USD">0</amix:StockIssuedDuringPeriodValueWarrantsExercised>
    <amix:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="d_2025-04-01_2025-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c134563918"
      unitRef="USD">0</amix:StockIssuedDuringPeriodValueWarrantsExercised>
    <amix:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="d_2025-04-01_2025-06-30"
      decimals="-3"
      id="c134563919"
      unitRef="USD">0</amix:StockIssuedDuringPeriodValueWarrantsExercised>
    <us-gaap:SharesOutstanding
      contextRef="i_2025-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c134563920"
      unitRef="Share">4023000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2025-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c134563921"
      unitRef="USD">4000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2025-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c134563922"
      unitRef="USD">60744000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2025-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c134563923"
      unitRef="USD">-53716000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2025-06-30"
      decimals="-3"
      id="c134563924"
      unitRef="USD">7032000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="d_2025-04-01_2025-06-30"
      decimals="-3"
      id="c134563925"
      unitRef="USD">-3337000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-04-01_2024-06-30"
      decimals="-3"
      id="c134563926"
      unitRef="USD">-2699000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="d_2025-04-01_2025-06-30"
      decimals="-3"
      id="c134563927"
      unitRef="USD">388000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="d_2024-04-01_2024-06-30"
      decimals="-4"
      id="c134563928"
      unitRef="USD">360000</us-gaap:ShareBasedCompensation>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="d_2025-04-01_2025-06-30"
      decimals="-3"
      id="c134563929"
      unitRef="USD">3000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="d_2024-04-01_2024-06-30"
      decimals="-3"
      id="c134563930"
      unitRef="USD">43000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets
      contextRef="d_2025-04-01_2025-06-30"
      decimals="-3"
      id="c134563931"
      unitRef="USD">-84000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets
      contextRef="d_2024-04-01_2024-06-30"
      decimals="-3"
      id="c134563932"
      unitRef="USD">-458000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="d_2025-04-01_2025-06-30"
      decimals="-4"
      id="c134563933"
      unitRef="USD">140000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="d_2024-04-01_2024-06-30"
      decimals="-3"
      id="c134563934"
      unitRef="USD">-205000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="d_2025-04-01_2025-06-30"
      decimals="-3"
      id="c134563935"
      unitRef="USD">118000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="d_2024-04-01_2024-06-30"
      decimals="-3"
      id="c134563936"
      unitRef="USD">191000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="d_2025-04-01_2025-06-30"
      decimals="-3"
      id="c134563937"
      unitRef="USD">-2604000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="d_2024-04-01_2024-06-30"
      decimals="-3"
      id="c134563938"
      unitRef="USD">-1852000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="d_2025-04-01_2025-06-30"
      decimals="-3"
      id="c134563939"
      unitRef="USD">-0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="d_2024-04-01_2024-06-30"
      decimals="-3"
      id="c134563940"
      unitRef="USD">5000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="d_2025-04-01_2025-06-30"
      decimals="-3"
      id="c134563941"
      unitRef="USD">0</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="d_2024-04-01_2024-06-30"
      decimals="-3"
      id="c134563942"
      unitRef="USD">-5000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="d_2025-04-01_2025-06-30_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="-3"
      id="c134563943"
      unitRef="USD">2121000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="d_2024-04-01_2024-06-30_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="-3"
      id="c134563944"
      unitRef="USD">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="d_2025-04-01_2025-06-30"
      decimals="-3"
      id="c134563945"
      unitRef="USD">64000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="d_2024-04-01_2024-06-30"
      decimals="-3"
      id="c134563946"
      unitRef="USD">-0</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="d_2025-04-01_2025-06-30"
      decimals="-3"
      id="c134563947"
      unitRef="USD">2057000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="d_2024-04-01_2024-06-30"
      decimals="-3"
      id="c134563948"
      unitRef="USD">0</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="d_2025-04-01_2025-06-30"
      decimals="-3"
      id="c134563949"
      unitRef="USD">-547000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="d_2024-04-01_2024-06-30"
      decimals="-3"
      id="c134563950"
      unitRef="USD">-1857000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2025-03-31"
      decimals="-3"
      id="c134563951"
      unitRef="USD">9136000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2024-03-31"
      decimals="-3"
      id="c134563952"
      unitRef="USD">8608000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2025-06-30"
      decimals="-3"
      id="c134563953"
      unitRef="USD">8589000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2024-06-30"
      decimals="-3"
      id="c134563954"
      unitRef="USD">6751000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <amix:DeferredFinancingCostsRelatedToTheIssuanceOfCommonStock
      contextRef="d_2025-04-01_2025-06-30"
      decimals="-3"
      id="c134563955"
      unitRef="USD">-176000</amix:DeferredFinancingCostsRelatedToTheIssuanceOfCommonStock>
    <amix:DeferredFinancingCostsRelatedToTheIssuanceOfCommonStock
      contextRef="d_2024-04-01_2024-06-30"
      decimals="-3"
      id="c134563956"
      unitRef="USD">0</amix:DeferredFinancingCostsRelatedToTheIssuanceOfCommonStock>
    <us-gaap:StockIssued1
      contextRef="d_2025-04-01_2025-06-30"
      decimals="-3"
      id="c134563957"
      unitRef="USD">0</us-gaap:StockIssued1>
    <us-gaap:StockIssued1
      contextRef="d_2024-04-01_2024-06-30"
      decimals="-3"
      id="c134563958"
      unitRef="USD">4000</us-gaap:StockIssued1>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock contextRef="d_2025-04-01_2025-06-30" id="c3016975">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;1&lt;/em&gt; &lt;/b&gt;&#x2013;&lt;b&gt; Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies &lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;Description of the Business&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;Autonomix Medical, Inc. (&#x201c;we,&#x201d; &#x201c;our,&#x201d; the &#x201c;Company&#x201d;) is a medical device company organized as a Delaware corporation on &lt;em style="font: inherit;"&gt; June 10, 2014. &lt;/em&gt;The Company is a pre-revenue, clinical stage life sciences company focused on advancing innovative technologies for sensing and treating disorders relating to the peripheral nervous system.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;Reverse Stock Split&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;The Company&#160;held its annual meeting of stockholders (the "Annual Meeting") on &lt;em style="font: inherit;"&gt; October 17, 2024. &lt;/em&gt;In that Annual Meeting, stockholders of the Company approved an amendment to the Company&#x2019;s amended and restated certificate of incorporation (the "Amendment&#x201d;) to effect the reverse stock split at a ratio in the range of &lt;em style="font: inherit;"&gt;1&lt;/em&gt;-for-2 to &lt;em style="font: inherit;"&gt;1&lt;/em&gt;-for-50, with such ratio to be determined in the discretion of the Company&#x2019;s Board of Directors (the "Board") and with such reverse stock split to be effected at such time and date, if at all, as determined by the Company&#x2019;s Board in its sole discretion prior to the &lt;em style="font: inherit;"&gt;one&lt;/em&gt;-year anniversary of the Annual Meeting.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;Pursuant to such authority granted by the Company&#x2019;s stockholders, the Company&#x2019;s Board approved a &lt;em style="font: inherit;"&gt;one&lt;/em&gt;-for-&lt;span style="-sec-ix-hidden:c134564773"&gt;twenty&lt;/span&gt; (&lt;em style="font: inherit;"&gt;1:20&lt;/em&gt;) reverse stock split (the "Reverse Stock Split&#x201d;) of the Company&#x2019;s common stock and the filing of the Amendment to effectuate the Reverse Stock Split. The Amendment was filed with the Secretary of State of the State of Delaware and the Reverse Stock Split became effective in accordance with the terms of the Amendment at &lt;em style="font: inherit;"&gt;11:59&lt;/em&gt; p.m. Eastern Time on &lt;em style="font: inherit;"&gt; October 24, 2024 (&lt;/em&gt;the "Effective Time&#x201d;), and the Company&#x2019;s common stock opened&#160;for trading on The Nasdaq Capital Market on &lt;em style="font: inherit;"&gt; October 25, 2024 &lt;/em&gt;on a post-split basis, under the existing ticker symbol "AMIX&#x201d; but with a new CUSIP number &lt;em style="font: inherit;"&gt;05330T205.&lt;/em&gt; The Amendment provides that, at the Effective Time, every &lt;span style="-sec-ix-hidden:c134564777"&gt;twenty&lt;/span&gt; shares of the Company&#x2019;s issued and outstanding common stock was automatically combined into &lt;em style="font: inherit;"&gt;one&lt;/em&gt; issued and outstanding share of common stock, without any change in par value per share, which will remain $0.001.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;The number of authorized shares of common stock remained&#160;at 500 million shares. As a result of the Reverse Stock Split, proportionate adjustments were made to the per share exercise price and/or the number of shares issuable upon the exercise or vesting of all outstanding stock options, restricted stock unit awards, warrants and convertible notes, which resulted in a proportional decrease in the number of shares of the Company&#x2019;s common stock reserved for issuance upon exercise or vesting of such stock options, restricted stock unit awards, warrants and convertible notes and, in the case of stock options and warrants, a proportional increase in the exercise price of all such stock options and warrants.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;The Company&#x2019;s stock option awards did &lt;em style="font: inherit;"&gt;not&lt;/em&gt; automatically adjust for the Reverse Stock Split.&#160;However, the Company chose to exercise its rights under the agreements to adjust the exercise price and number of shares exercisable or issuable upon vesting proportionately for the Reverse Stock Split.&#160;Based on the analysis performed, the Company does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; need to recognize any additional compensation expense as a result of the modification.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;In addition, the number of shares reserved for issuance under the Company&#x2019;s equity compensation plan immediately prior to the Effective Time was reduced proportionately.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;em style="font: inherit;"&gt;No&lt;/em&gt; fractional shares were issued as a result of the Reverse Stock Split. Any stockholder who would have been entitled to receive a fractional share as a result of the process was entitled to the rounding up of the fractional share to the nearest whole number. See "&lt;i&gt;Fractional Shares&lt;/i&gt;" in Note &lt;em style="font: inherit;"&gt;4&lt;/em&gt; for further disclosure regarding fractional shares.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;The Reverse Stock Split has been retroactively adjusted throughout these interim financial statements and footnotes for all periods presented, including exercise prices and share data. As a result of the Reverse Stock Split, the Company reclassified approximately $18 thousand between common stock par value and additional paid-in capital.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;Liquidity and Going Concern&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;The Company's financial statements are prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The Company is an early-stage company that is subject to all the risks associated with early-stage and emerging growth companies and has incurred losses since inception.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;O&#xfeff;n &lt;em style="font: inherit;"&gt; February 28, 2025,&#160;&lt;/em&gt;the Company entered into an At Market Issuances Sales Agreement (the &#x201c;ATM Agreement&#x201d;) with Ladenburg Thalmann &amp;amp; Co. Inc. (the &#x201c;Agent&#x201d;). Pursuant to the terms of the ATM Agreement, The Company &lt;em style="font: inherit;"&gt; may &lt;/em&gt;sell from time to time through the Agent, as sales agent or principal, shares of its common stock with an initial aggregate sales price of up to $2.1 million (the &#x201c;Shares&#x201d;). As of &lt;em style="font: inherit;"&gt; June 30, 2025, &lt;/em&gt;the Company sold 1,304,260 Shares pursuant to the ATM Agreement for net proceeds of approximately $2.1 million.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;On &lt;em style="font: inherit;"&gt; November 22, 2024, &lt;/em&gt;the Company entered into&#160;an Underwriting Agreement (the &#x201c;Underwriting Agreement&#x201d;) with Ladenburg Thalmann &amp;amp; Co. Inc., as representative of the several underwriters, if any, named on Schedule I of the Underwriting Agreement (the &#x201c;Underwriters&#x201d;), in connection with a firm commitment underwritten public offering (the &#x201c;Offering&#x201d;) of: (i) 458,691 common units (the &#x201c;Common Units&#x201d;), each Common Unit consisting of &lt;span style="-sec-ix-hidden:c134564791"&gt;one&lt;/span&gt; share of Company common stock and &lt;span style="-sec-ix-hidden:c134564792"&gt;one&lt;/span&gt; series A warrant to purchase &lt;span style="-sec-ix-hidden:c134564793"&gt;one&lt;/span&gt; share of common stock (the &#x201c;Series A Warrants&#x201d;); and (ii) 917,596 pre-funded units (the &#x201c;Pre-Funded Units&#x201d;) and together with the Common Units, the "Units", each Pre-Funded Unit consisting of &lt;span style="-sec-ix-hidden:c134564795"&gt;one&lt;/span&gt; pre-funded warrant to purchase &lt;span style="-sec-ix-hidden:c134564796"&gt;one&lt;/span&gt; share of common stock (the &#x201c;Pre-Funded Warrant&#x201d;) and &lt;span style="-sec-ix-hidden:c134564797"&gt;one&lt;/span&gt; Series A Warrant. The purchase price of each Common Unit was $6.540, and the purchase price of each Pre-Funded Unit was $6.539.&#160;In addition, the Company granted the Underwriters a 45-day option to purchase an additional 206,422 shares of common stock, and/or an additional 206,422 Series A Warrants, solely to cover over-allotments, if any. The Pre-Funded Warrants have an exercise price of $0.001 per share, are immediately exercisable and &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be exercised at any time until all of the Pre-Funded Warrants are exercised in full. The Series A Warrants have an exercise price of $6.540 per share, are immediately exercisable and &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be exercised at any time until the &lt;span style="-sec-ix-hidden:c134564805"&gt;five&lt;/span&gt;-year anniversary of the date of issuance. Both the Pre-Funded Warrants and the Series A Warrants are subject to a beneficial ownership limitation of 4.99%. The Pre-Funded Warrants and Series A Warrants were issued pursuant to a warrant agency agreement between the Company and Equity Stock Transfer, LLC (the &#x201c;Warrant Agency Agreement&#x201d;). The Offering closed on &lt;em style="font: inherit;"&gt; November 25, 2024. &lt;/em&gt;On &lt;em style="font: inherit;"&gt; November 22, 2024, &lt;/em&gt;the Underwriters partially exercised their over-allotment option with respect to 156,809 shares of common stock and 156,809 Series A Warrants. The aggregate gross proceeds to the Company, including the partial exercise of the over-allotment option, were approximately $10.0 million, before deducting underwriting discounts and other expenses by the Company of $1.5 million, including $0.5 million of non-cash expenses. The net cash proceeds to the Company were approximately $9.0 million. See Note &lt;em style="font: inherit;"&gt;6&lt;/em&gt; - Subsequent Events for additional information regarding events occurring after &lt;em style="font: inherit;"&gt; June 30, 2025.&lt;/em&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;For the&#160;&lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2025 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2024,&lt;/em&gt; the Company incurred net losses of $3.3 million and $2.7 million, respectively, and had net cash flows used in operating activities of $2.6 million and $1.9&#160;million, respectively. The Company had no revenues for the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2025 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2024,&lt;/em&gt; respectively, and an accumulated deficit of $53.7&#160;million, working capital of $7.0 million and cash of $8.6 million as of &lt;em style="font: inherit;"&gt; June 30, 2025. &lt;/em&gt;The Company does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; expect to&#160;generate&#160;positive cash flows from operating activities in the near future.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;The Company estimates its current cash resources&#160;are sufficient to fund its operations into but &lt;em style="font: inherit;"&gt;not&lt;/em&gt; beyond the &lt;em style="font: inherit;"&gt;second&lt;/em&gt; calendar quarter of &lt;em style="font: inherit;"&gt;2026.&lt;/em&gt; The Company recognizes it will need to raise additional capital to continue to execute its business plan, including obtaining regulatory clearance for its products currently under development and commercializing and generating revenues from products under development. There is &lt;em style="font: inherit;"&gt;no&lt;/em&gt; assurance that additional financing will be available when needed or that management will be able to obtain financing on terms acceptable to the Company. A failure to raise sufficient capital, generate sufficient product revenues, control expenditures and regulatory matters, among other factors, will adversely impact the Company&#x2019;s ability to meet its financial obligations as they become due and payable and to achieve its intended business objectives. If the Company is unable to raise sufficient additional funds, it will have to scale back its operations.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;These factors raise substantial doubt about the Company's ability to continue as a going concern within &lt;em style="font: inherit;"&gt;one&lt;/em&gt; year after the date the financial statements are issued. The accompanying condensed financial statements have been prepared on a going concern basis and do &lt;em style="font: inherit;"&gt;not&lt;/em&gt; include any adjustments that might be necessary if the Company is unable to continue as a going concern.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;Basis of Presentation&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;The accompanying condensed interim financial statements are unaudited. These unaudited condensed interim financial statements have been prepared in accordance with the rules and regulations of the U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;) for interim financial information. Accordingly, they do &lt;em style="font: inherit;"&gt;not&lt;/em&gt; include all the information and notes required by generally accepted accounting principles in the United States of America (&#x201c;GAAP&#x201d;) for complete financial statements. The Company&#x2019;s fiscal year end is &lt;em style="font: inherit;"&gt; March 31&lt;/em&gt;&lt;sup style="vertical-align:top;line-height:120%;"&gt;st&lt;/sup&gt;. These unaudited condensed interim financial statements should be read in conjunction with the audited financial statements and accompanying notes for the year ended &lt;em style="font: inherit;"&gt; March 31, 2025 &lt;/em&gt;as found in the Annual Report in the Company's Form &lt;em style="font: inherit;"&gt;10&lt;/em&gt;-K filed with the SEC on &lt;em style="font: inherit;"&gt; May 29, 2025. &lt;/em&gt;In the opinion of management, the unaudited condensed interim financial statements reflect all the adjustments (consisting of normal recurring adjustments) necessary to state fairly the Company&#x2019;s financial position, results of operations and cash flows for the quarterly and year-to-date periods, as applicable. The interim results of operations are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; necessarily indicative of the results that &lt;em style="font: inherit;"&gt; may &lt;/em&gt;occur for the full fiscal year. The &lt;em style="font: inherit;"&gt; March 31, 2025 &lt;/em&gt;audited condensed balance sheet included herein was derived from the audited financial statements, but does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; include all disclosures, including notes, required by GAAP for complete financial statements.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;Use of Estimates in Financial Statement Presentation&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;The preparation of these unaudited condensed interim financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The Company's significant estimates and assumptions include work performed but &lt;em style="font: inherit;"&gt;not&lt;/em&gt; yet billed by contract manufacturers, engineers and research organizations and the valuation of equity related instruments. Although the Company believes that its estimates and assumptions are reasonable, they are based upon information available at the time the estimates and assumptions were made. Some of these judgments can be subjective and complex, and, consequently, actual results could differ from those estimates.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;


   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;Cash and Cash Equivalents&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;The Company considers all highly liquid accounts with original maturities of &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months or less at the date of acquisition to be cash equivalents.&#160;Periodically, the Company &lt;em style="font: inherit;"&gt; may &lt;/em&gt;carry cash balances at financial institutions in excess of the federally insured limit of &lt;em style="font: inherit;"&gt;$250&lt;/em&gt; thousand. The Company has &lt;em style="font: inherit;"&gt;not&lt;/em&gt; experienced losses on these accounts and management believes, based upon the quality of the financial institutions, that the credit risk with regard to these deposits is &lt;em style="font: inherit;"&gt;not&lt;/em&gt; significant.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;Offering and Financing Costs&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;Offering costs consist of professional costs incurred through the balance sheet date that are direct and incremental related to the Company&#x2019;s equity financing activities. Specifically, offering costs were incurred during the Company&#x2019;s initial public offering ("IPO"), Offering from &lt;em style="font: inherit;"&gt; November 2024 &lt;/em&gt;and ATM Agreement. The Company includes offering costs in additional paid-in capital, to the extent there is sufficient cash proceeds, upon completion of the sale of equity. Costs associated with salaries and other period costs are expensed as incurred.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;text-indent:9pt;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;text-indent:9pt;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;text-indent:9pt;"&gt;&lt;i&gt;Property and Equipment&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;Property and equipment (comprised of computer and IT equipment) are stated at historical cost and depreciated on a straight-line basis over their estimated useful lives, generally&#160;&lt;span style="-sec-ix-hidden:c134564843"&gt;three&lt;/span&gt; years. Upon disposition of the assets, the costs and related accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the results of operations.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;Convertible Notes&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;For the period ended &lt;em style="font: inherit;"&gt; March 31, 2025, &lt;/em&gt;the Company evaluated embedded redemption, conversion and other features within its debt to determine whether any embedded features should be bifurcated from the host instrument and accounted for as a derivative at fair value, with changes in fair value recorded in the condensed statements of operations. The Company&#x2019;s debt was carried on the condensed balance sheets on a historical cost basis, net of unamortized discounts and premiums, because the Company did &lt;em style="font: inherit;"&gt;not&lt;/em&gt; elect the fair value option of accounting. Costs associated with acquiring debt, including detachable warrants issued in connection with the financing, were&#160;capitalized as a debt discount. The debt discount was&#160;presented in the condensed balance sheets, in prior year periods, as a direct deduction from the carrying amount of the debt liability. The costs were&#160;amortized over the estimated contractual life of the related debt instrument using the effective interest method and were&#160;included in interest expense in the condensed statements of operations.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;In addition, since the instruments included a substantive conversion feature as of time of issuance, the issuance of equity securities to settle the outstanding notes with the conversion were accounted for as a contractual conversion with &lt;em style="font: inherit;"&gt;no&lt;/em&gt; gain or loss recognized related to the equity securities issued to settle the instrument. See &lt;i&gt;Note &lt;em style="font: inherit;"&gt;2&lt;/em&gt; - Convertible Notes Payable&lt;/i&gt; for additional information.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;Fair Value of Financial Instruments&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs. The Company utilizes a &lt;em style="font: inherit;"&gt;three&lt;/em&gt;-level valuation hierarchy for disclosures of fair value measurements, defined as follows:&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;Level &lt;em style="font: inherit;"&gt;1&lt;/em&gt; &#x2013; inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;Level &lt;em style="font: inherit;"&gt;2&lt;/em&gt; &#x2013; inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the assets or liability, either directly or indirectly, for substantially the full term of the financial instrument&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;"&gt;Level &lt;em style="font: inherit;"&gt;3&lt;/em&gt; &#x2013; inputs to the valuation methodology are unobservable and significant to the fair value and require significant judgment and estimation&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;Financial assets and financial liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. While the Company believes that its valuation methods are appropriate, the Company recognizes that the use of different methodologies or assumptions to determine the fair value could result in a different estimate of fair value at the reporting date. The primary assumptions that would significantly affect the fair values are the probability weighting of the different settlement outcomes used.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;The Company did &lt;em style="font: inherit;"&gt;not&lt;/em&gt; have any assets or liabilities measured at fair value as of &lt;em style="font: inherit;"&gt; June 30, 2025 &lt;/em&gt;and &lt;em style="font: inherit;"&gt; March 31, 2025.&lt;/em&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;"&gt;The carrying value of short-term instruments, including cash, accounts payable and accrued expenses, approximate fair value due to the relatively short period to maturity for these instruments.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;"&gt;&lt;i&gt;Related Parties&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company follows Accounting Standards Codification ("ASC") &lt;em style="font: inherit;"&gt;850,&lt;/em&gt; &lt;i&gt;Related Party Disclosures&lt;/i&gt;, for the identification of related parties and disclosure of related party transactions. See further discussion in Note &lt;em style="font: inherit;"&gt;5&lt;/em&gt; below on this matter.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting and the tax basis of reported assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company must then assess the likelihood that the resulting deferred tax assets will be realized. A valuation allowance is provided when it is more likely than &lt;em style="font: inherit;"&gt;not&lt;/em&gt; that some portion or all of a deferred tax asset will &lt;em style="font: inherit;"&gt;not&lt;/em&gt; be realized. As of &lt;em style="font: inherit;"&gt; June 30, 2025 &lt;/em&gt;and &lt;em style="font: inherit;"&gt; March 31, 2025 &lt;/em&gt;the Company determined a full valuation allowance was required to offset its deferred tax assets as a result of recurring operating losses.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;The Company accounts for uncertain tax positions in accordance with the provisions of ASC &lt;em style="font: inherit;"&gt;740&lt;/em&gt;-&lt;em style="font: inherit;"&gt;10&lt;/em&gt; which prescribes a recognition threshold and measurement attribute for financial statement disclosure of tax positions taken, or expected to be taken, on its tax return. The Company evaluates and records any uncertain tax positions based on the amount that management deems is more likely than &lt;em style="font: inherit;"&gt;not&lt;/em&gt; to be sustained upon examination and ultimate settlement with the tax authorities in the tax jurisdictions in which it operates. As of &lt;em style="font: inherit;"&gt; June 30, 2025 &lt;/em&gt;and &lt;em style="font: inherit;"&gt; March 31, 2025 &lt;/em&gt;the Company had no uncertain tax positions.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;The Company does&#160;&lt;em style="font: inherit;"&gt;not&lt;/em&gt;&#160;expect to pay any significant federal, state, or foreign income taxes in&#160;its fiscal year &lt;em style="font: inherit;"&gt;2026&lt;/em&gt; (ending &lt;em style="font: inherit;"&gt; March 31, 2026) &lt;/em&gt;as a result of the losses recorded during the&#160;&lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2025&#160;&lt;/em&gt;and the additional losses expected for the remainder of&#160;its fiscal year &lt;em style="font: inherit;"&gt;2026&lt;/em&gt;&#160;and cumulative net operating loss carryforwards. Accounting standards require the consideration of a valuation allowance for deferred tax assets if it is &#x201c;more likely than&#160;&lt;em style="font: inherit;"&gt;not&#x201d;&lt;/em&gt;&#160;that some component or all of the benefits of deferred tax assets will &lt;em style="font: inherit;"&gt;not&lt;/em&gt; be realized.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;The Company recorded&#160;&lt;em style="font: inherit;"&gt;no&lt;/em&gt;&#160;income tax provision for the&#160;&lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2025 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2024,&lt;/em&gt; respectively. The effective tax rate for the&#160;&lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2025 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&#160;is zero.&#160;The Company estimates its annual effective tax rate at the end of each quarterly period. Jurisdictions with a projected loss for the year where&#160;&lt;em style="font: inherit;"&gt;no&lt;/em&gt;&#160;tax benefit can be recognized due to the valuation allowance could result in a higher or lower effective tax rate during a particular quarter depending on the mix and timing of actual earnings versus annual projections.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;Stock-based Compensation&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;Employee and non-employee share-based compensation is measured at the grant date, based on the fair value of the award, and is recognized as an expense over the requisite service period. For awards with a performance condition, compensation expense is recognized over the requisite service period if it is probable that the performance condition will be satisfied. For awards to non-employees, the Company recognizes compensation expense in the same manner as if the Company had paid cash for the goods or services. The Company estimates the fair value of options and equity classified warrants granted using an options pricing model. Expense is recognized within general and administrative and research and development expenses and forfeitures are recognized as they are incurred.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;Warrants&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#x2019;s specific terms and applicable authoritative guidance in FASB ASC &lt;em style="font: inherit;"&gt;480,&lt;/em&gt; Distinguishing Liabilities from Equity (&#x201c;ASC &lt;em style="font: inherit;"&gt;480&#x201d;&lt;/em&gt;) and ASC &lt;em style="font: inherit;"&gt;815,&lt;/em&gt; Derivatives and Hedging (&#x201c;ASC &lt;em style="font: inherit;"&gt;815&#x201d;&lt;/em&gt;). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC &lt;em style="font: inherit;"&gt;480,&lt;/em&gt; meet the definition of a liability pursuant to ASC &lt;em style="font: inherit;"&gt;480,&lt;/em&gt; and whether the warrants meet all of the requirements for equity classification under ASC &lt;em style="font: inherit;"&gt;815,&lt;/em&gt; including whether the warrants are indexed to the Company&#x2019;s own ordinary shares and whether the warrant holders could potentially require &#x201c;net cash settlement&#x201d; in a circumstance outside of the Company&#x2019;s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do &lt;em style="font: inherit;"&gt;not&lt;/em&gt; meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss on the&#160;statements of operations. The fair value of the warrants is estimated using a Black-Scholes pricing model or a Monte Carlo simulation.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;


   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;Loss Per Common Share&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;Basic loss per common share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period, which includes shares issuable for little to &lt;em style="font: inherit;"&gt;no&lt;/em&gt; consideration upon the exercise of certain equity-classified warrants. Diluted loss per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. In periods when losses are reported, the weighted-average number of common shares outstanding excludes common stock equivalents, because their inclusion would be anti-dilutive. Generally, the Company&#x2019;s outstanding warrants are non-participating securities as they are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; entitled to non-forfeitable rights to dividends or dividend equivalents during the vesting term and have &lt;em style="font: inherit;"&gt;no&lt;/em&gt; obligation to fund losses.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;However, the Company's warrants described in Note&#160;&lt;em style="font: inherit;"&gt;2&lt;/em&gt;&#160;and the warrants issued in connection with the Offering, are participating securities as the holders receive the right to dividends, but they are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; obligated to fund losses. In periods of loss, since &lt;em style="font: inherit;"&gt;no&lt;/em&gt; income is allocated to these securities, the Company's use of the "treasury stock method" derives the same result. The dilutive effect of convertible securities is calculated using the &#x201c;if-converted method.&#x201d; Under the if-converted method, securities are assumed to be converted at the beginning of the period, and the resulting common shares are included in the denominator of the diluted calculation for the entire period being presented.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;For the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2025 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2024,&lt;/em&gt; dilutive securities that were &lt;em style="font: inherit;"&gt;not&lt;/em&gt; included in the calculations of the loss per common share because they would be anti-dilutive included the following:&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 5%; margin-left: 54pt; width: 95%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;June 30,&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;(as revised)&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 68%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Equity based warrants to purchase common shares&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;87,531&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4,334&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Convertible Notes - common shares (1)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;33,250&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Convertible Notes - equity-based warrants to purchase common shares&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;25,003&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;25,003&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Stock options granted under Company's incentive plan&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;248,483&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;216,483&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Series A Warrants&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,533,096&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Representative Warrants&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;91,985&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Total potentially dilutive securities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,986,098&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;279,070&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
    &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 54pt;"&gt;(&lt;em style="font: inherit;"&gt;1&lt;/em&gt;) Shares for the convertible note proceeds received&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;Research and Development Costs&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;Research and development costs are expensed as incurred.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;Advertising&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;It is the Company's policy to expense advertising costs as incurred. Advertising&#160;expenses are included within general and administrative expenses within the statement of operations. For the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2025 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2024,&lt;/em&gt; the Company recorded $0 and less than $0.1&#160;million, respectively, of advertising expenses.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;JOBS Act Accounting Election&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;The Company qualifies as an emerging growth company (&#x201c;EGC&#x201d;), as defined in the Jumpstart Our Business Startups Act of &lt;em style="font: inherit;"&gt;2012&lt;/em&gt; (the &#x201c;JOBS Act&#x201d;). The JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected &lt;em style="font: inherit;"&gt;not&lt;/em&gt; to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This &lt;em style="font: inherit;"&gt; may &lt;/em&gt;make comparison of the Company&#x2019;s financial statements with another public company which is neither an early-stage company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;


   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;Segments&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker ("CODM"), or decision-making group, in deciding how to allocate resources in assessing performance. Management has determined that the Company operates in&#160;&lt;span style="-sec-ix-hidden:c134564899"&gt;one&lt;/span&gt;&#160;reportable segment, which is advancing the development of innovative technologies for sensing and treating disorders relating to the nervous system. The Company is initially focused on developing the technology for patients with pancreatic cancer, however, the Company believes the technology constitutes a platform with the potential to address several indications, including chronic pain management, hypertension, cardiovascular disease and a wide range of other nerve-related disorders. The Company's CODM is its Chief Executive Officer.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;The accounting policies of the segment are the same as those described in the summary of significant accounting policies. The CODM assesses performance based on net loss, which is reported on the Statements of Operations. The measure of segment assets is reported on the balance sheet as total assets.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;To date, the Company has &lt;em style="font: inherit;"&gt;not&lt;/em&gt; generated any product revenue. The Company expects to continue to incur significant expenses and operating losses for the foreseeable future as it advances its' technology through all stages of development and clinical trials and, ultimately, seek regulatory approval.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;As such, the CODM primarily evaluates performance of the Company using various financial metrics, including the combined net income (loss) from operations, also shown on the Statements of Operations, forecasted cash expenditures and existing and forecasted cash balances. These financial metrics are used by the CODM to make key operating decisions, such as the assessment of segment performance and allocation of resources. All of the Company's assets are located in the United States. The significant expense categories within net loss from operations that the CODM regularly reviews are expenses related to research and development, general and administrative, and depreciation and amortization. The significant expense categories and subcategories are reported on the Statements of Operations.&#160;Other expenses included in the Company&#x2019;s net loss include other income (expense), interest income, net, and any additional non-operating expenses that are reported on the Statements of Operations.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;Recent Accounting Pronouncements&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;In&#160;&lt;em style="font: inherit;"&gt; November 2024 &lt;/em&gt;and &lt;em style="font: inherit;"&gt; January 2025,&#160;&lt;/em&gt;FASB issued ASU&#160;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;-&lt;em style="font: inherit;"&gt;03&lt;/em&gt; and ASU &lt;em style="font: inherit;"&gt;2025&lt;/em&gt;-&lt;em style="font: inherit;"&gt;01,&lt;/em&gt;&#160;Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic&#160;&lt;em style="font: inherit;"&gt;220&lt;/em&gt;-&lt;em style="font: inherit;"&gt;40&lt;/em&gt;): Disaggregation of Income Statement Expenses, which requires disclosure in the notes to the financial statements of specified information about certain costs and expenses. The amendments to the standards are effective for fiscal years beginning after&#160;&lt;em style="font: inherit;"&gt; December 15, 2026,&#160;&lt;/em&gt;and for interim periods within fiscal years beginning after&#160;&lt;em style="font: inherit;"&gt; December 15, 2027.&#160;&lt;/em&gt;Early adoption is permitted. The amendments should be applied either prospectively to financial statements issued for reporting periods after the effective date of this ASU or retrospectively to any or all prior periods presented in the financial statements. The Company is currently evaluating the new guidance to determine the impact it&#160;&lt;em style="font: inherit;"&gt; may&#160;&lt;/em&gt;have on its financial statements and related disclosures.&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;In &lt;em style="font: inherit;"&gt; December 2023, &lt;/em&gt;the FASB issued &lt;i&gt;ASU &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;-&lt;em style="font: inherit;"&gt;09,&lt;/em&gt; &lt;/i&gt;&#x201c;&lt;i&gt;Income Taxes (Topic &lt;em style="font: inherit;"&gt;740&lt;/em&gt;): Improvements to Income Tax Disclosures,&lt;/i&gt;&#x201d; which requires disaggregated information about a reporting entity&#x2019;s effective tax rate reconciliation as well as information on income taxes paid. The guidance is effective for the Company&#x2019;s fiscal years beginning after &lt;em style="font: inherit;"&gt; December 15, 2024. &lt;/em&gt;The Company is currently evaluating the new guidance to determine the impact it&#160;&lt;em style="font: inherit;"&gt; may&#160;&lt;/em&gt;have on its financial statements and related disclosures.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;In &lt;em style="font: inherit;"&gt; November 2023, &lt;/em&gt;the FASB issued &lt;i&gt;ASU &lt;em style="font: inherit;"&gt;No.&lt;/em&gt; &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;-&lt;em style="font: inherit;"&gt;07,&lt;/em&gt; Segment Reporting (Topic &lt;em style="font: inherit;"&gt;280&lt;/em&gt;): Improvements to Reportable Segment Disclosures.&lt;/i&gt; The ASU updates reportable segment disclosure requirements, primarily through requiring enhanced disclosures about significant segment expenses and information used to assess segment performance and allocate resources. The guidance is effective for fiscal years beginning after &lt;em style="font: inherit;"&gt; December 15, 2023 &lt;/em&gt;and interim periods for fiscal years beginning after &lt;em style="font: inherit;"&gt; December 15, 2024, &lt;/em&gt;on a retrospective basis. There was &lt;em style="font: inherit;"&gt;no&lt;/em&gt; material impact upon the adoption of &lt;i&gt;ASU &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;-&lt;em style="font: inherit;"&gt;07&lt;/em&gt;&lt;/i&gt; on the Company's interim disclosures.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;There are &lt;em style="font: inherit;"&gt;no&lt;/em&gt; other effective pronouncements, or pronouncements issued but &lt;em style="font: inherit;"&gt;not&lt;/em&gt; yet effective, if adopted, that would have a material effect on the accompanying financial statements.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;text-indent:9pt;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;text-indent:9pt;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;text-indent:9pt;"&gt;&lt;i&gt;Correction of an Immaterial Error in the Prior Period Financial Statements&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;D&#xfeff;uring the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; December 31, 2024, &lt;/em&gt;the Company determined that previously filed quarterly and annual financial statements had an immaterial earnings per share error resulting from the exclusion of certain unexercised equity based warrants to purchase common shares that had an exercise price of approximately $0.01 or less from the basic earnings per share calculations in accordance with &lt;i&gt;ASC &lt;em style="font: inherit;"&gt;260&lt;/em&gt;-&lt;em style="font: inherit;"&gt;10&lt;/em&gt;-&lt;em style="font: inherit;"&gt;45&lt;/em&gt;-&lt;em style="font: inherit;"&gt;13&lt;/em&gt;&lt;/i&gt;. As a&#160;result, the prior year earnings per share calculations have been revised for consistency with the current year presentation. The Company assessed the materiality of this change in presentation on prior period financial statements in accordance with &lt;i&gt;SEC Staff Accounting Bulletin &lt;em style="font: inherit;"&gt;No.&lt;/em&gt; &lt;em style="font: inherit;"&gt;99&lt;/em&gt;&lt;/i&gt;, &#x201c;&lt;i&gt;Materiality&lt;/i&gt;,&#x201d; (&lt;i&gt;ASC Topic &lt;em style="font: inherit;"&gt;250,&lt;/em&gt; Accounting Changes and Error Corrections&lt;/i&gt;). Based on this assessment, the Company concluded that this error correction in its&#160;&lt;i&gt;Statements of Operations&lt;/i&gt;&#160;and &lt;i&gt;Note &lt;em style="font: inherit;"&gt;1&lt;/em&gt; &lt;/i&gt;&#x2013;&lt;i&gt; Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies (Loss Per Common Share)&lt;/i&gt; is &lt;em style="font: inherit;"&gt;not&lt;/em&gt; material to any previously presented financial statements based upon overall considerations of both quantitative and qualitative factors. The corrections had &lt;em style="font: inherit;"&gt;no&lt;/em&gt; impact in the comparative period Balance Sheet,&#160;Statements of Cash Flows, or Statement of Changes in Stockholders&#x2019;&#160;Equity. Further, the immaterial correction did &lt;em style="font: inherit;"&gt;not&lt;/em&gt; result in a change in operating losses or net loss in the Statement of Operations and the effects of including unexercised warrants in the earnings per share calculation have an antidilutive effect reducing the net loss per share amount. Accordingly, the Company corrected the previously reported earnings per share calculation for the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2024 &lt;/em&gt;in this Quarterly Report on Form &lt;em style="font: inherit;"&gt;10&lt;/em&gt;-Q.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;A summary of the impact of the Company&#x2019;s Reverse Stock Split and immaterial corrections reflecting the prior period impact to the Company&#x2019;s Statement of Operations and earnings per share are shown below:&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

     &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="14" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Three Months Ended June 30, 2024&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Originally &lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Filed&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Adjusted &lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;for 1-for-20 &lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Reverse &lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Stock Split&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Correction&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;As Revised&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 52%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Net Loss (in thousands)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(2,699&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(2,699&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Loss per share - basic and diluted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(0.14&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(2.85&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;0.65&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(2.20&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Weighted average shares outstanding - basic and diluted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;18,902,248&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;945,382&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;280,041&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,225,423&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
     &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;A summary of the impact of the Company&#x2019;s Reverse Stock Split and immaterial corrections reflecting the prior period impact are shown below:&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

     &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="14" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Three Months Ended June 30, 2024&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Originally &lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Filed&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Adjusted &lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;for 1-for-20 &lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Reverse &lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Stock Split&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Correction&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;As Revised&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 52%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Equity based warrants to purchase common shares&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;5,344,569&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;267,231&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(262,897&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4,334&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Convertible Notes - common shares&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;665,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;33,250&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;33,250&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Convertible Notes - equity-based warrants to purchase common shares&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;500,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;25,003&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;25,003&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Stock options granted under Company's incentive plan&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;4,329,579&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;216,483&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;216,483&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total potentially dilutive securities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;10,839,148&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;541,967&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(262,897&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;279,070&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
     &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;
  </us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <amix:ReverseStockSplitPolicyTextBlock contextRef="d_2025-04-01_2025-06-30" id="c134565383">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;Reverse Stock Split&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;The Company&#160;held its annual meeting of stockholders (the "Annual Meeting") on &lt;em style="font: inherit;"&gt; October 17, 2024. &lt;/em&gt;In that Annual Meeting, stockholders of the Company approved an amendment to the Company&#x2019;s amended and restated certificate of incorporation (the "Amendment&#x201d;) to effect the reverse stock split at a ratio in the range of &lt;em style="font: inherit;"&gt;1&lt;/em&gt;-for-2 to &lt;em style="font: inherit;"&gt;1&lt;/em&gt;-for-50, with such ratio to be determined in the discretion of the Company&#x2019;s Board of Directors (the "Board") and with such reverse stock split to be effected at such time and date, if at all, as determined by the Company&#x2019;s Board in its sole discretion prior to the &lt;em style="font: inherit;"&gt;one&lt;/em&gt;-year anniversary of the Annual Meeting.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;Pursuant to such authority granted by the Company&#x2019;s stockholders, the Company&#x2019;s Board approved a &lt;em style="font: inherit;"&gt;one&lt;/em&gt;-for-&lt;span style="-sec-ix-hidden:c134564773"&gt;twenty&lt;/span&gt; (&lt;em style="font: inherit;"&gt;1:20&lt;/em&gt;) reverse stock split (the "Reverse Stock Split&#x201d;) of the Company&#x2019;s common stock and the filing of the Amendment to effectuate the Reverse Stock Split. The Amendment was filed with the Secretary of State of the State of Delaware and the Reverse Stock Split became effective in accordance with the terms of the Amendment at &lt;em style="font: inherit;"&gt;11:59&lt;/em&gt; p.m. Eastern Time on &lt;em style="font: inherit;"&gt; October 24, 2024 (&lt;/em&gt;the "Effective Time&#x201d;), and the Company&#x2019;s common stock opened&#160;for trading on The Nasdaq Capital Market on &lt;em style="font: inherit;"&gt; October 25, 2024 &lt;/em&gt;on a post-split basis, under the existing ticker symbol "AMIX&#x201d; but with a new CUSIP number &lt;em style="font: inherit;"&gt;05330T205.&lt;/em&gt; The Amendment provides that, at the Effective Time, every &lt;span style="-sec-ix-hidden:c134564777"&gt;twenty&lt;/span&gt; shares of the Company&#x2019;s issued and outstanding common stock was automatically combined into &lt;em style="font: inherit;"&gt;one&lt;/em&gt; issued and outstanding share of common stock, without any change in par value per share, which will remain $0.001.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;The number of authorized shares of common stock remained&#160;at 500 million shares. As a result of the Reverse Stock Split, proportionate adjustments were made to the per share exercise price and/or the number of shares issuable upon the exercise or vesting of all outstanding stock options, restricted stock unit awards, warrants and convertible notes, which resulted in a proportional decrease in the number of shares of the Company&#x2019;s common stock reserved for issuance upon exercise or vesting of such stock options, restricted stock unit awards, warrants and convertible notes and, in the case of stock options and warrants, a proportional increase in the exercise price of all such stock options and warrants.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;The Company&#x2019;s stock option awards did &lt;em style="font: inherit;"&gt;not&lt;/em&gt; automatically adjust for the Reverse Stock Split.&#160;However, the Company chose to exercise its rights under the agreements to adjust the exercise price and number of shares exercisable or issuable upon vesting proportionately for the Reverse Stock Split.&#160;Based on the analysis performed, the Company does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; need to recognize any additional compensation expense as a result of the modification.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;In addition, the number of shares reserved for issuance under the Company&#x2019;s equity compensation plan immediately prior to the Effective Time was reduced proportionately.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;em style="font: inherit;"&gt;No&lt;/em&gt; fractional shares were issued as a result of the Reverse Stock Split. Any stockholder who would have been entitled to receive a fractional share as a result of the process was entitled to the rounding up of the fractional share to the nearest whole number. See "&lt;i&gt;Fractional Shares&lt;/i&gt;" in Note &lt;em style="font: inherit;"&gt;4&lt;/em&gt; for further disclosure regarding fractional shares.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;The Reverse Stock Split has been retroactively adjusted throughout these interim financial statements and footnotes for all periods presented, including exercise prices and share data. As a result of the Reverse Stock Split, the Company reclassified approximately $18 thousand between common stock par value and additional paid-in capital.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</amix:ReverseStockSplitPolicyTextBlock>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="d_2024-10-17_2024-10-17_NonmonetaryTransactionTypeAxis-ReverseStockSplitMember_RangeAxis-MinimumMember"
      decimals="INF"
      id="c134564768"
      unitRef="Pure">2</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="d_2024-10-17_2024-10-17_NonmonetaryTransactionTypeAxis-ReverseStockSplitMember_RangeAxis-MaximumMember"
      decimals="INF"
      id="c134564770"
      unitRef="Pure">50</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i_2024-10-24"
      decimals="INF"
      id="c134564779"
      unitRef="USDPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i_2024-10-24"
      decimals="-8"
      id="c134564780"
      unitRef="Share">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit
      contextRef="d_2024-10-24_2024-10-24"
      decimals="-3"
      id="c134564785"
      unitRef="USD">18000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit>
    <amix:SubstantialDoubtAboutGoingConcernPolicyPolicyTextBlock contextRef="d_2025-04-01_2025-06-30" id="c134565384">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;Liquidity and Going Concern&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;The Company's financial statements are prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The Company is an early-stage company that is subject to all the risks associated with early-stage and emerging growth companies and has incurred losses since inception.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;O&#xfeff;n &lt;em style="font: inherit;"&gt; February 28, 2025,&#160;&lt;/em&gt;the Company entered into an At Market Issuances Sales Agreement (the &#x201c;ATM Agreement&#x201d;) with Ladenburg Thalmann &amp;amp; Co. Inc. (the &#x201c;Agent&#x201d;). Pursuant to the terms of the ATM Agreement, The Company &lt;em style="font: inherit;"&gt; may &lt;/em&gt;sell from time to time through the Agent, as sales agent or principal, shares of its common stock with an initial aggregate sales price of up to $2.1 million (the &#x201c;Shares&#x201d;). As of &lt;em style="font: inherit;"&gt; June 30, 2025, &lt;/em&gt;the Company sold 1,304,260 Shares pursuant to the ATM Agreement for net proceeds of approximately $2.1 million.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;On &lt;em style="font: inherit;"&gt; November 22, 2024, &lt;/em&gt;the Company entered into&#160;an Underwriting Agreement (the &#x201c;Underwriting Agreement&#x201d;) with Ladenburg Thalmann &amp;amp; Co. Inc., as representative of the several underwriters, if any, named on Schedule I of the Underwriting Agreement (the &#x201c;Underwriters&#x201d;), in connection with a firm commitment underwritten public offering (the &#x201c;Offering&#x201d;) of: (i) 458,691 common units (the &#x201c;Common Units&#x201d;), each Common Unit consisting of &lt;span style="-sec-ix-hidden:c134564791"&gt;one&lt;/span&gt; share of Company common stock and &lt;span style="-sec-ix-hidden:c134564792"&gt;one&lt;/span&gt; series A warrant to purchase &lt;span style="-sec-ix-hidden:c134564793"&gt;one&lt;/span&gt; share of common stock (the &#x201c;Series A Warrants&#x201d;); and (ii) 917,596 pre-funded units (the &#x201c;Pre-Funded Units&#x201d;) and together with the Common Units, the "Units", each Pre-Funded Unit consisting of &lt;span style="-sec-ix-hidden:c134564795"&gt;one&lt;/span&gt; pre-funded warrant to purchase &lt;span style="-sec-ix-hidden:c134564796"&gt;one&lt;/span&gt; share of common stock (the &#x201c;Pre-Funded Warrant&#x201d;) and &lt;span style="-sec-ix-hidden:c134564797"&gt;one&lt;/span&gt; Series A Warrant. The purchase price of each Common Unit was $6.540, and the purchase price of each Pre-Funded Unit was $6.539.&#160;In addition, the Company granted the Underwriters a 45-day option to purchase an additional 206,422 shares of common stock, and/or an additional 206,422 Series A Warrants, solely to cover over-allotments, if any. The Pre-Funded Warrants have an exercise price of $0.001 per share, are immediately exercisable and &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be exercised at any time until all of the Pre-Funded Warrants are exercised in full. The Series A Warrants have an exercise price of $6.540 per share, are immediately exercisable and &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be exercised at any time until the &lt;span style="-sec-ix-hidden:c134564805"&gt;five&lt;/span&gt;-year anniversary of the date of issuance. Both the Pre-Funded Warrants and the Series A Warrants are subject to a beneficial ownership limitation of 4.99%. The Pre-Funded Warrants and Series A Warrants were issued pursuant to a warrant agency agreement between the Company and Equity Stock Transfer, LLC (the &#x201c;Warrant Agency Agreement&#x201d;). The Offering closed on &lt;em style="font: inherit;"&gt; November 25, 2024. &lt;/em&gt;On &lt;em style="font: inherit;"&gt; November 22, 2024, &lt;/em&gt;the Underwriters partially exercised their over-allotment option with respect to 156,809 shares of common stock and 156,809 Series A Warrants. The aggregate gross proceeds to the Company, including the partial exercise of the over-allotment option, were approximately $10.0 million, before deducting underwriting discounts and other expenses by the Company of $1.5 million, including $0.5 million of non-cash expenses. The net cash proceeds to the Company were approximately $9.0 million. See Note &lt;em style="font: inherit;"&gt;6&lt;/em&gt; - Subsequent Events for additional information regarding events occurring after &lt;em style="font: inherit;"&gt; June 30, 2025.&lt;/em&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;For the&#160;&lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2025 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2024,&lt;/em&gt; the Company incurred net losses of $3.3 million and $2.7 million, respectively, and had net cash flows used in operating activities of $2.6 million and $1.9&#160;million, respectively. The Company had no revenues for the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2025 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2024,&lt;/em&gt; respectively, and an accumulated deficit of $53.7&#160;million, working capital of $7.0 million and cash of $8.6 million as of &lt;em style="font: inherit;"&gt; June 30, 2025. &lt;/em&gt;The Company does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; expect to&#160;generate&#160;positive cash flows from operating activities in the near future.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;The Company estimates its current cash resources&#160;are sufficient to fund its operations into but &lt;em style="font: inherit;"&gt;not&lt;/em&gt; beyond the &lt;em style="font: inherit;"&gt;second&lt;/em&gt; calendar quarter of &lt;em style="font: inherit;"&gt;2026.&lt;/em&gt; The Company recognizes it will need to raise additional capital to continue to execute its business plan, including obtaining regulatory clearance for its products currently under development and commercializing and generating revenues from products under development. There is &lt;em style="font: inherit;"&gt;no&lt;/em&gt; assurance that additional financing will be available when needed or that management will be able to obtain financing on terms acceptable to the Company. A failure to raise sufficient capital, generate sufficient product revenues, control expenditures and regulatory matters, among other factors, will adversely impact the Company&#x2019;s ability to meet its financial obligations as they become due and payable and to achieve its intended business objectives. If the Company is unable to raise sufficient additional funds, it will have to scale back its operations.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;These factors raise substantial doubt about the Company's ability to continue as a going concern within &lt;em style="font: inherit;"&gt;one&lt;/em&gt; year after the date the financial statements are issued. The accompanying condensed financial statements have been prepared on a going concern basis and do &lt;em style="font: inherit;"&gt;not&lt;/em&gt; include any adjustments that might be necessary if the Company is unable to continue as a going concern.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</amix:SubstantialDoubtAboutGoingConcernPolicyPolicyTextBlock>
    <amix:EquityOfferingMaximumOfferingAmount
      contextRef="i_2025-02-28_SubsidiarySaleOfStockAxis-ATMAgreementMember"
      decimals="-5"
      id="c134564786"
      unitRef="USD">2100000</amix:EquityOfferingMaximumOfferingAmount>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2025-04-01_2025-06-30_SubsidiarySaleOfStockAxis-ATMAgreementMember"
      decimals="INF"
      id="c134564787"
      unitRef="Share">1304260</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2025-04-01_2025-06-30_SubsidiarySaleOfStockAxis-ATMAgreementMember"
      decimals="-5"
      id="c134564788"
      unitRef="USD">2100000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <amix:NumberOfCommonUnitsIssued
      contextRef="d_2024-11-22_2024-11-25_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember"
      decimals="INF"
      id="c134564790"
      unitRef="Share">458691</amix:NumberOfCommonUnitsIssued>
    <amix:NumberOfPrefundedUnitsIssued
      contextRef="d_2024-11-22_2024-11-25_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember"
      decimals="INF"
      id="c134564794"
      unitRef="Share">917596</amix:NumberOfPrefundedUnitsIssued>
    <amix:CommonUnitsIssuedPurchasePrice
      contextRef="d_2024-11-22_2024-11-25_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember"
      decimals="INF"
      id="c134564798"
      unitRef="USDPerShare">6.54</amix:CommonUnitsIssuedPurchasePrice>
    <amix:PrefundedUnitsIssuedPurchasePrice
      contextRef="d_2024-11-22_2024-11-25_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember"
      decimals="INF"
      id="c134564799"
      unitRef="USDPerShare">6.539</amix:PrefundedUnitsIssuedPurchasePrice>
    <amix:EquityOfferingOptionPeriod
      contextRef="d_2024-11-22_2024-11-22_CounterpartyNameAxis-UnderwritersMember_SubsidiarySaleOfStockAxis-OverAllotmentOptionMember"
      id="c134564800">P45D</amix:EquityOfferingOptionPeriod>
    <amix:EquityOfferingOptionMaximumShares
      contextRef="i_2024-11-22_CounterpartyNameAxis-UnderwritersMember_SubsidiarySaleOfStockAxis-OverAllotmentOptionMember"
      decimals="INF"
      id="c134564801"
      unitRef="Share">206422</amix:EquityOfferingOptionMaximumShares>
    <amix:EquityOfferingOptionMaximumWarrants
      contextRef="i_2024-11-22_ClassOfWarrantOrRightAxis-SeriesAWarrantsMember_CounterpartyNameAxis-UnderwritersMember"
      decimals="INF"
      id="c134564802"
      unitRef="Share">206422</amix:EquityOfferingOptionMaximumWarrants>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2024-11-25_ClassOfWarrantOrRightAxis-PrefundedWarrantsMember"
      decimals="INF"
      id="c134564803"
      unitRef="USDPerShare">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2024-11-25_ClassOfWarrantOrRightAxis-SeriesAWarrantsMember"
      decimals="INF"
      id="c134564804"
      unitRef="USDPerShare">6.54</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <amix:ClassOfWarrantsOrRightsMaximumBeneficialOwnership
      contextRef="i_2024-11-25_ClassOfWarrantOrRightAxis-PrefundedAndSeriesAWarrantsMember"
      decimals="4"
      id="c134564806"
      unitRef="Pure">0.0499</amix:ClassOfWarrantsOrRightsMaximumBeneficialOwnership>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2024-11-22_2024-11-22_CounterpartyNameAxis-UnderwritersMember_SubsidiarySaleOfStockAxis-OverAllotmentOptionMember"
      decimals="INF"
      id="c134564807"
      unitRef="Share">156809</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <amix:ClassOfWarrantOrRightIssuedDuringPeriod
      contextRef="d_2024-11-22_2024-11-22_ClassOfWarrantOrRightAxis-SeriesAWarrantsMember_CounterpartyNameAxis-UnderwritersMember"
      decimals="INF"
      id="c134564808"
      unitRef="Share">156809</amix:ClassOfWarrantOrRightIssuedDuringPeriod>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="d_2024-11-22_2024-11-25_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember"
      decimals="-7"
      id="c134564809"
      unitRef="USD">10000000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="d_2024-11-22_2024-11-25_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember"
      decimals="-5"
      id="c134564810"
      unitRef="USD">1500000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="d_2024-11-22_2024-11-25_NatureOfExpenseAxis-NoncashExpensesMember_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember"
      decimals="-5"
      id="c134564811"
      unitRef="USD">500000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <amix:ProceedsFromIssuanceOrSaleOfEquityNet
      contextRef="d_2024-11-22_2024-11-25_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember"
      decimals="-6"
      id="c134564812"
      unitRef="USD">9000000</amix:ProceedsFromIssuanceOrSaleOfEquityNet>
    <us-gaap:NetIncomeLoss
      contextRef="d_2025-04-01_2025-06-30"
      decimals="-5"
      id="c134564816"
      unitRef="USD">-3300000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-04-01_2024-06-30"
      decimals="-5"
      id="c134564817"
      unitRef="USD">-2700000</us-gaap:NetIncomeLoss>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="d_2025-04-01_2025-06-30"
      decimals="-5"
      id="c134564818"
      unitRef="USD">-2600000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="d_2024-04-01_2024-06-30"
      decimals="-5"
      id="c134564819"
      unitRef="USD">-1900000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:Revenues
      contextRef="d_2025-04-01_2025-06-30"
      decimals="-3"
      id="c134564820"
      unitRef="USD">0</us-gaap:Revenues>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i_2025-06-30"
      decimals="-5"
      id="c134564823"
      unitRef="USD">-53700000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <amix:WorkingCapitalDeficit
      contextRef="i_2025-06-30"
      decimals="-6"
      id="c134564824"
      unitRef="USD">7000000</amix:WorkingCapitalDeficit>
    <us-gaap:Cash
      contextRef="i_2025-06-30"
      decimals="-5"
      id="c134564825"
      unitRef="USD">8600000</us-gaap:Cash>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="d_2025-04-01_2025-06-30" id="c134565385">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;Basis of Presentation&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;The accompanying condensed interim financial statements are unaudited. These unaudited condensed interim financial statements have been prepared in accordance with the rules and regulations of the U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;) for interim financial information. Accordingly, they do &lt;em style="font: inherit;"&gt;not&lt;/em&gt; include all the information and notes required by generally accepted accounting principles in the United States of America (&#x201c;GAAP&#x201d;) for complete financial statements. The Company&#x2019;s fiscal year end is &lt;em style="font: inherit;"&gt; March 31&lt;/em&gt;&lt;sup style="vertical-align:top;line-height:120%;"&gt;st&lt;/sup&gt;. These unaudited condensed interim financial statements should be read in conjunction with the audited financial statements and accompanying notes for the year ended &lt;em style="font: inherit;"&gt; March 31, 2025 &lt;/em&gt;as found in the Annual Report in the Company's Form &lt;em style="font: inherit;"&gt;10&lt;/em&gt;-K filed with the SEC on &lt;em style="font: inherit;"&gt; May 29, 2025. &lt;/em&gt;In the opinion of management, the unaudited condensed interim financial statements reflect all the adjustments (consisting of normal recurring adjustments) necessary to state fairly the Company&#x2019;s financial position, results of operations and cash flows for the quarterly and year-to-date periods, as applicable. The interim results of operations are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; necessarily indicative of the results that &lt;em style="font: inherit;"&gt; may &lt;/em&gt;occur for the full fiscal year. The &lt;em style="font: inherit;"&gt; March 31, 2025 &lt;/em&gt;audited condensed balance sheet included herein was derived from the audited financial statements, but does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; include all disclosures, including notes, required by GAAP for complete financial statements.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="d_2025-04-01_2025-06-30" id="c134565386">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;Use of Estimates in Financial Statement Presentation&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;The preparation of these unaudited condensed interim financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The Company's significant estimates and assumptions include work performed but &lt;em style="font: inherit;"&gt;not&lt;/em&gt; yet billed by contract manufacturers, engineers and research organizations and the valuation of equity related instruments. Although the Company believes that its estimates and assumptions are reasonable, they are based upon information available at the time the estimates and assumptions were made. Some of these judgments can be subjective and complex, and, consequently, actual results could differ from those estimates.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="d_2025-04-01_2025-06-30" id="c134565387">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;Cash and Cash Equivalents&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;The Company considers all highly liquid accounts with original maturities of &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months or less at the date of acquisition to be cash equivalents.&#160;Periodically, the Company &lt;em style="font: inherit;"&gt; may &lt;/em&gt;carry cash balances at financial institutions in excess of the federally insured limit of &lt;em style="font: inherit;"&gt;$250&lt;/em&gt; thousand. The Company has &lt;em style="font: inherit;"&gt;not&lt;/em&gt; experienced losses on these accounts and management believes, based upon the quality of the financial institutions, that the credit risk with regard to these deposits is &lt;em style="font: inherit;"&gt;not&lt;/em&gt; significant.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <amix:OfferingCostsPolicyPolicyTextBlock contextRef="d_2025-04-01_2025-06-30" id="c134565388">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;Offering and Financing Costs&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;Offering costs consist of professional costs incurred through the balance sheet date that are direct and incremental related to the Company&#x2019;s equity financing activities. Specifically, offering costs were incurred during the Company&#x2019;s initial public offering ("IPO"), Offering from &lt;em style="font: inherit;"&gt; November 2024 &lt;/em&gt;and ATM Agreement. The Company includes offering costs in additional paid-in capital, to the extent there is sufficient cash proceeds, upon completion of the sale of equity. Costs associated with salaries and other period costs are expensed as incurred.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</amix:OfferingCostsPolicyPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="d_2025-04-01_2025-06-30" id="c134565389">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;text-indent:9pt;"&gt;&lt;i&gt;Property and Equipment&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;Property and equipment (comprised of computer and IT equipment) are stated at historical cost and depreciated on a straight-line basis over their estimated useful lives, generally&#160;&lt;span style="-sec-ix-hidden:c134564843"&gt;three&lt;/span&gt; years. Upon disposition of the assets, the costs and related accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the results of operations.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:DebtPolicyTextBlock contextRef="d_2025-04-01_2025-06-30" id="c134565390">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;Convertible Notes&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;For the period ended &lt;em style="font: inherit;"&gt; March 31, 2025, &lt;/em&gt;the Company evaluated embedded redemption, conversion and other features within its debt to determine whether any embedded features should be bifurcated from the host instrument and accounted for as a derivative at fair value, with changes in fair value recorded in the condensed statements of operations. The Company&#x2019;s debt was carried on the condensed balance sheets on a historical cost basis, net of unamortized discounts and premiums, because the Company did &lt;em style="font: inherit;"&gt;not&lt;/em&gt; elect the fair value option of accounting. Costs associated with acquiring debt, including detachable warrants issued in connection with the financing, were&#160;capitalized as a debt discount. The debt discount was&#160;presented in the condensed balance sheets, in prior year periods, as a direct deduction from the carrying amount of the debt liability. The costs were&#160;amortized over the estimated contractual life of the related debt instrument using the effective interest method and were&#160;included in interest expense in the condensed statements of operations.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;In addition, since the instruments included a substantive conversion feature as of time of issuance, the issuance of equity securities to settle the outstanding notes with the conversion were accounted for as a contractual conversion with &lt;em style="font: inherit;"&gt;no&lt;/em&gt; gain or loss recognized related to the equity securities issued to settle the instrument. See &lt;i&gt;Note &lt;em style="font: inherit;"&gt;2&lt;/em&gt; - Convertible Notes Payable&lt;/i&gt; for additional information.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:DebtPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="d_2025-04-01_2025-06-30" id="c134565391">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;Fair Value of Financial Instruments&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs. The Company utilizes a &lt;em style="font: inherit;"&gt;three&lt;/em&gt;-level valuation hierarchy for disclosures of fair value measurements, defined as follows:&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;Level &lt;em style="font: inherit;"&gt;1&lt;/em&gt; &#x2013; inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;Level &lt;em style="font: inherit;"&gt;2&lt;/em&gt; &#x2013; inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the assets or liability, either directly or indirectly, for substantially the full term of the financial instrument&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;"&gt;Level &lt;em style="font: inherit;"&gt;3&lt;/em&gt; &#x2013; inputs to the valuation methodology are unobservable and significant to the fair value and require significant judgment and estimation&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;Financial assets and financial liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. While the Company believes that its valuation methods are appropriate, the Company recognizes that the use of different methodologies or assumptions to determine the fair value could result in a different estimate of fair value at the reporting date. The primary assumptions that would significantly affect the fair values are the probability weighting of the different settlement outcomes used.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;The Company did &lt;em style="font: inherit;"&gt;not&lt;/em&gt; have any assets or liabilities measured at fair value as of &lt;em style="font: inherit;"&gt; June 30, 2025 &lt;/em&gt;and &lt;em style="font: inherit;"&gt; March 31, 2025.&lt;/em&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;"&gt;The carrying value of short-term instruments, including cash, accounts payable and accrued expenses, approximate fair value due to the relatively short period to maturity for these instruments.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <amix:RelatedPartyTransactionsPolicyPolicyTextBlock contextRef="d_2025-04-01_2025-06-30" id="c134565392">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;"&gt;&lt;i&gt;Related Parties&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company follows Accounting Standards Codification ("ASC") &lt;em style="font: inherit;"&gt;850,&lt;/em&gt; &lt;i&gt;Related Party Disclosures&lt;/i&gt;, for the identification of related parties and disclosure of related party transactions. See further discussion in Note &lt;em style="font: inherit;"&gt;5&lt;/em&gt; below on this matter.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</amix:RelatedPartyTransactionsPolicyPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="d_2025-04-01_2025-06-30" id="c134565393">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting and the tax basis of reported assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company must then assess the likelihood that the resulting deferred tax assets will be realized. A valuation allowance is provided when it is more likely than &lt;em style="font: inherit;"&gt;not&lt;/em&gt; that some portion or all of a deferred tax asset will &lt;em style="font: inherit;"&gt;not&lt;/em&gt; be realized. As of &lt;em style="font: inherit;"&gt; June 30, 2025 &lt;/em&gt;and &lt;em style="font: inherit;"&gt; March 31, 2025 &lt;/em&gt;the Company determined a full valuation allowance was required to offset its deferred tax assets as a result of recurring operating losses.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;The Company accounts for uncertain tax positions in accordance with the provisions of ASC &lt;em style="font: inherit;"&gt;740&lt;/em&gt;-&lt;em style="font: inherit;"&gt;10&lt;/em&gt; which prescribes a recognition threshold and measurement attribute for financial statement disclosure of tax positions taken, or expected to be taken, on its tax return. The Company evaluates and records any uncertain tax positions based on the amount that management deems is more likely than &lt;em style="font: inherit;"&gt;not&lt;/em&gt; to be sustained upon examination and ultimate settlement with the tax authorities in the tax jurisdictions in which it operates. As of &lt;em style="font: inherit;"&gt; June 30, 2025 &lt;/em&gt;and &lt;em style="font: inherit;"&gt; March 31, 2025 &lt;/em&gt;the Company had no uncertain tax positions.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;The Company does&#160;&lt;em style="font: inherit;"&gt;not&lt;/em&gt;&#160;expect to pay any significant federal, state, or foreign income taxes in&#160;its fiscal year &lt;em style="font: inherit;"&gt;2026&lt;/em&gt; (ending &lt;em style="font: inherit;"&gt; March 31, 2026) &lt;/em&gt;as a result of the losses recorded during the&#160;&lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2025&#160;&lt;/em&gt;and the additional losses expected for the remainder of&#160;its fiscal year &lt;em style="font: inherit;"&gt;2026&lt;/em&gt;&#160;and cumulative net operating loss carryforwards. Accounting standards require the consideration of a valuation allowance for deferred tax assets if it is &#x201c;more likely than&#160;&lt;em style="font: inherit;"&gt;not&#x201d;&lt;/em&gt;&#160;that some component or all of the benefits of deferred tax assets will &lt;em style="font: inherit;"&gt;not&lt;/em&gt; be realized.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;The Company recorded&#160;&lt;em style="font: inherit;"&gt;no&lt;/em&gt;&#160;income tax provision for the&#160;&lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2025 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2024,&lt;/em&gt; respectively. The effective tax rate for the&#160;&lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2025 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2024&lt;/em&gt;&#160;is zero.&#160;The Company estimates its annual effective tax rate at the end of each quarterly period. Jurisdictions with a projected loss for the year where&#160;&lt;em style="font: inherit;"&gt;no&lt;/em&gt;&#160;tax benefit can be recognized due to the valuation allowance could result in a higher or lower effective tax rate during a particular quarter depending on the mix and timing of actual earnings versus annual projections.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:LiabilityForUncertainTaxPositionsCurrent
      contextRef="i_2025-06-30"
      decimals="-3"
      id="c134564860"
      unitRef="USD">0</us-gaap:LiabilityForUncertainTaxPositionsCurrent>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="d_2025-04-01_2025-06-30" id="c134565394">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;Stock-based Compensation&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;Employee and non-employee share-based compensation is measured at the grant date, based on the fair value of the award, and is recognized as an expense over the requisite service period. For awards with a performance condition, compensation expense is recognized over the requisite service period if it is probable that the performance condition will be satisfied. For awards to non-employees, the Company recognizes compensation expense in the same manner as if the Company had paid cash for the goods or services. The Company estimates the fair value of options and equity classified warrants granted using an options pricing model. Expense is recognized within general and administrative and research and development expenses and forfeitures are recognized as they are incurred.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <amix:WarrantsPolicyPolicyTextBlock contextRef="d_2025-04-01_2025-06-30" id="c134565395">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;Warrants&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#x2019;s specific terms and applicable authoritative guidance in FASB ASC &lt;em style="font: inherit;"&gt;480,&lt;/em&gt; Distinguishing Liabilities from Equity (&#x201c;ASC &lt;em style="font: inherit;"&gt;480&#x201d;&lt;/em&gt;) and ASC &lt;em style="font: inherit;"&gt;815,&lt;/em&gt; Derivatives and Hedging (&#x201c;ASC &lt;em style="font: inherit;"&gt;815&#x201d;&lt;/em&gt;). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC &lt;em style="font: inherit;"&gt;480,&lt;/em&gt; meet the definition of a liability pursuant to ASC &lt;em style="font: inherit;"&gt;480,&lt;/em&gt; and whether the warrants meet all of the requirements for equity classification under ASC &lt;em style="font: inherit;"&gt;815,&lt;/em&gt; including whether the warrants are indexed to the Company&#x2019;s own ordinary shares and whether the warrant holders could potentially require &#x201c;net cash settlement&#x201d; in a circumstance outside of the Company&#x2019;s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do &lt;em style="font: inherit;"&gt;not&lt;/em&gt; meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss on the&#160;statements of operations. The fair value of the warrants is estimated using a Black-Scholes pricing model or a Monte Carlo simulation.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</amix:WarrantsPolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="d_2025-04-01_2025-06-30" id="c134565396">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;Loss Per Common Share&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;Basic loss per common share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period, which includes shares issuable for little to &lt;em style="font: inherit;"&gt;no&lt;/em&gt; consideration upon the exercise of certain equity-classified warrants. Diluted loss per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. In periods when losses are reported, the weighted-average number of common shares outstanding excludes common stock equivalents, because their inclusion would be anti-dilutive. Generally, the Company&#x2019;s outstanding warrants are non-participating securities as they are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; entitled to non-forfeitable rights to dividends or dividend equivalents during the vesting term and have &lt;em style="font: inherit;"&gt;no&lt;/em&gt; obligation to fund losses.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;However, the Company's warrants described in Note&#160;&lt;em style="font: inherit;"&gt;2&lt;/em&gt;&#160;and the warrants issued in connection with the Offering, are participating securities as the holders receive the right to dividends, but they are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; obligated to fund losses. In periods of loss, since &lt;em style="font: inherit;"&gt;no&lt;/em&gt; income is allocated to these securities, the Company's use of the "treasury stock method" derives the same result. The dilutive effect of convertible securities is calculated using the &#x201c;if-converted method.&#x201d; Under the if-converted method, securities are assumed to be converted at the beginning of the period, and the resulting common shares are included in the denominator of the diluted calculation for the entire period being presented.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;For the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2025 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2024,&lt;/em&gt; dilutive securities that were &lt;em style="font: inherit;"&gt;not&lt;/em&gt; included in the calculations of the loss per common share because they would be anti-dilutive included the following:&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 5%; margin-left: 54pt; width: 95%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;June 30,&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;(as revised)&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 68%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Equity based warrants to purchase common shares&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;87,531&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4,334&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Convertible Notes - common shares (1)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;33,250&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Convertible Notes - equity-based warrants to purchase common shares&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;25,003&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;25,003&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Stock options granted under Company's incentive plan&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;248,483&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;216,483&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Series A Warrants&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,533,096&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Representative Warrants&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;91,985&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Total potentially dilutive securities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,986,098&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;279,070&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
    &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 54pt;"&gt;(&lt;em style="font: inherit;"&gt;1&lt;/em&gt;) Shares for the convertible note proceeds received&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="d_2025-04-01_2025-06-30" id="c3016976">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 5%; margin-left: 54pt; width: 95%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;June 30,&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;(as revised)&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 68%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Equity based warrants to purchase common shares&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;87,531&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4,334&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Convertible Notes - common shares (1)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;33,250&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Convertible Notes - equity-based warrants to purchase common shares&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;25,003&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;25,003&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Stock options granted under Company's incentive plan&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;248,483&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;216,483&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Series A Warrants&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,533,096&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Representative Warrants&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;91,985&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Total potentially dilutive securities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,986,098&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;279,070&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2025-04-01_2025-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember"
      decimals="INF"
      id="c134564212"
      unitRef="Share">87531</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2024-04-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember"
      decimals="INF"
      id="c134564213"
      unitRef="Share">4334</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2025-04-01_2025-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-ConvertibleDebtSecuritiesMember"
      decimals="INF"
      id="c134564214"
      unitRef="Share">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2024-04-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-ConvertibleDebtSecuritiesMember"
      decimals="INF"
      id="c134564215"
      unitRef="Share">33250</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2025-04-01_2025-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-ConvertibleNotesToWarrantsMember"
      decimals="INF"
      id="c134564216"
      unitRef="Share">25003</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2024-04-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-ConvertibleNotesToWarrantsMember"
      decimals="INF"
      id="c134564217"
      unitRef="Share">25003</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2025-04-01_2025-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember"
      decimals="INF"
      id="c134564218"
      unitRef="Share">248483</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2024-04-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember"
      decimals="INF"
      id="c134564219"
      unitRef="Share">216483</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2025-04-01_2025-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-SeriesAWarrantsMember"
      decimals="INF"
      id="c134564220"
      unitRef="Share">1533096</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2024-04-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-SeriesAWarrantsMember"
      decimals="INF"
      id="c134564221"
      unitRef="Share">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2025-04-01_2025-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-RepresentativesWarrantsMember"
      decimals="INF"
      id="c134564222"
      unitRef="Share">91985</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2024-04-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-RepresentativesWarrantsMember"
      decimals="INF"
      id="c134564223"
      unitRef="Share">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2025-04-01_2025-06-30"
      decimals="INF"
      id="c134564224"
      unitRef="Share">1986098</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2024-04-01_2024-06-30"
      decimals="INF"
      id="c134564225"
      unitRef="Share">279070</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="d_2025-04-01_2025-06-30" id="c134565397">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;Research and Development Costs&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;Research and development costs are expensed as incurred.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:AdvertisingCostsPolicyTextBlock contextRef="d_2025-04-01_2025-06-30" id="c134565398">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;Advertising&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;It is the Company's policy to expense advertising costs as incurred. Advertising&#160;expenses are included within general and administrative expenses within the statement of operations. For the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2025 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2024,&lt;/em&gt; the Company recorded $0 and less than $0.1&#160;million, respectively, of advertising expenses.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:AdvertisingCostsPolicyTextBlock>
    <us-gaap:AdvertisingExpense
      contextRef="d_2025-04-01_2025-06-30"
      decimals="-3"
      id="c134564894"
      unitRef="USD">0</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="d_2024-04-01_2024-06-30"
      decimals="-5"
      id="c134564895"
      unitRef="USD">100000</us-gaap:AdvertisingExpense>
    <amix:JumpstartOurBusinessStartupsJobsActAccountingElectionPolicyPolicyTextBlock contextRef="d_2025-04-01_2025-06-30" id="c134565399">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;JOBS Act Accounting Election&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;The Company qualifies as an emerging growth company (&#x201c;EGC&#x201d;), as defined in the Jumpstart Our Business Startups Act of &lt;em style="font: inherit;"&gt;2012&lt;/em&gt; (the &#x201c;JOBS Act&#x201d;). The JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected &lt;em style="font: inherit;"&gt;not&lt;/em&gt; to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This &lt;em style="font: inherit;"&gt; may &lt;/em&gt;make comparison of the Company&#x2019;s financial statements with another public company which is neither an early-stage company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</amix:JumpstartOurBusinessStartupsJobsActAccountingElectionPolicyPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="d_2025-04-01_2025-06-30" id="c134565400">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;Segments&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker ("CODM"), or decision-making group, in deciding how to allocate resources in assessing performance. Management has determined that the Company operates in&#160;&lt;span style="-sec-ix-hidden:c134564899"&gt;one&lt;/span&gt;&#160;reportable segment, which is advancing the development of innovative technologies for sensing and treating disorders relating to the nervous system. The Company is initially focused on developing the technology for patients with pancreatic cancer, however, the Company believes the technology constitutes a platform with the potential to address several indications, including chronic pain management, hypertension, cardiovascular disease and a wide range of other nerve-related disorders. The Company's CODM is its Chief Executive Officer.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;The accounting policies of the segment are the same as those described in the summary of significant accounting policies. The CODM assesses performance based on net loss, which is reported on the Statements of Operations. The measure of segment assets is reported on the balance sheet as total assets.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;To date, the Company has &lt;em style="font: inherit;"&gt;not&lt;/em&gt; generated any product revenue. The Company expects to continue to incur significant expenses and operating losses for the foreseeable future as it advances its' technology through all stages of development and clinical trials and, ultimately, seek regulatory approval.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;As such, the CODM primarily evaluates performance of the Company using various financial metrics, including the combined net income (loss) from operations, also shown on the Statements of Operations, forecasted cash expenditures and existing and forecasted cash balances. These financial metrics are used by the CODM to make key operating decisions, such as the assessment of segment performance and allocation of resources. All of the Company's assets are located in the United States. The significant expense categories within net loss from operations that the CODM regularly reviews are expenses related to research and development, general and administrative, and depreciation and amortization. The significant expense categories and subcategories are reported on the Statements of Operations.&#160;Other expenses included in the Company&#x2019;s net loss include other income (expense), interest income, net, and any additional non-operating expenses that are reported on the Statements of Operations.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="d_2025-04-01_2025-06-30" id="c134565401">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;Recent Accounting Pronouncements&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;In&#160;&lt;em style="font: inherit;"&gt; November 2024 &lt;/em&gt;and &lt;em style="font: inherit;"&gt; January 2025,&#160;&lt;/em&gt;FASB issued ASU&#160;&lt;em style="font: inherit;"&gt;2024&lt;/em&gt;-&lt;em style="font: inherit;"&gt;03&lt;/em&gt; and ASU &lt;em style="font: inherit;"&gt;2025&lt;/em&gt;-&lt;em style="font: inherit;"&gt;01,&lt;/em&gt;&#160;Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic&#160;&lt;em style="font: inherit;"&gt;220&lt;/em&gt;-&lt;em style="font: inherit;"&gt;40&lt;/em&gt;): Disaggregation of Income Statement Expenses, which requires disclosure in the notes to the financial statements of specified information about certain costs and expenses. The amendments to the standards are effective for fiscal years beginning after&#160;&lt;em style="font: inherit;"&gt; December 15, 2026,&#160;&lt;/em&gt;and for interim periods within fiscal years beginning after&#160;&lt;em style="font: inherit;"&gt; December 15, 2027.&#160;&lt;/em&gt;Early adoption is permitted. The amendments should be applied either prospectively to financial statements issued for reporting periods after the effective date of this ASU or retrospectively to any or all prior periods presented in the financial statements. The Company is currently evaluating the new guidance to determine the impact it&#160;&lt;em style="font: inherit;"&gt; may&#160;&lt;/em&gt;have on its financial statements and related disclosures.&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;In &lt;em style="font: inherit;"&gt; December 2023, &lt;/em&gt;the FASB issued &lt;i&gt;ASU &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;-&lt;em style="font: inherit;"&gt;09,&lt;/em&gt; &lt;/i&gt;&#x201c;&lt;i&gt;Income Taxes (Topic &lt;em style="font: inherit;"&gt;740&lt;/em&gt;): Improvements to Income Tax Disclosures,&lt;/i&gt;&#x201d; which requires disaggregated information about a reporting entity&#x2019;s effective tax rate reconciliation as well as information on income taxes paid. The guidance is effective for the Company&#x2019;s fiscal years beginning after &lt;em style="font: inherit;"&gt; December 15, 2024. &lt;/em&gt;The Company is currently evaluating the new guidance to determine the impact it&#160;&lt;em style="font: inherit;"&gt; may&#160;&lt;/em&gt;have on its financial statements and related disclosures.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;In &lt;em style="font: inherit;"&gt; November 2023, &lt;/em&gt;the FASB issued &lt;i&gt;ASU &lt;em style="font: inherit;"&gt;No.&lt;/em&gt; &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;-&lt;em style="font: inherit;"&gt;07,&lt;/em&gt; Segment Reporting (Topic &lt;em style="font: inherit;"&gt;280&lt;/em&gt;): Improvements to Reportable Segment Disclosures.&lt;/i&gt; The ASU updates reportable segment disclosure requirements, primarily through requiring enhanced disclosures about significant segment expenses and information used to assess segment performance and allocate resources. The guidance is effective for fiscal years beginning after &lt;em style="font: inherit;"&gt; December 15, 2023 &lt;/em&gt;and interim periods for fiscal years beginning after &lt;em style="font: inherit;"&gt; December 15, 2024, &lt;/em&gt;on a retrospective basis. There was &lt;em style="font: inherit;"&gt;no&lt;/em&gt; material impact upon the adoption of &lt;i&gt;ASU &lt;em style="font: inherit;"&gt;2023&lt;/em&gt;-&lt;em style="font: inherit;"&gt;07&lt;/em&gt;&lt;/i&gt; on the Company's interim disclosures.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;There are &lt;em style="font: inherit;"&gt;no&lt;/em&gt; other effective pronouncements, or pronouncements issued but &lt;em style="font: inherit;"&gt;not&lt;/em&gt; yet effective, if adopted, that would have a material effect on the accompanying financial statements.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <amix:CorrectionOfAnImmaterialErrorPolicyTextBlock contextRef="d_2025-04-01_2025-06-30" id="c134565402">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;text-indent:9pt;"&gt;&lt;i&gt;Correction of an Immaterial Error in the Prior Period Financial Statements&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;D&#xfeff;uring the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; December 31, 2024, &lt;/em&gt;the Company determined that previously filed quarterly and annual financial statements had an immaterial earnings per share error resulting from the exclusion of certain unexercised equity based warrants to purchase common shares that had an exercise price of approximately $0.01 or less from the basic earnings per share calculations in accordance with &lt;i&gt;ASC &lt;em style="font: inherit;"&gt;260&lt;/em&gt;-&lt;em style="font: inherit;"&gt;10&lt;/em&gt;-&lt;em style="font: inherit;"&gt;45&lt;/em&gt;-&lt;em style="font: inherit;"&gt;13&lt;/em&gt;&lt;/i&gt;. As a&#160;result, the prior year earnings per share calculations have been revised for consistency with the current year presentation. The Company assessed the materiality of this change in presentation on prior period financial statements in accordance with &lt;i&gt;SEC Staff Accounting Bulletin &lt;em style="font: inherit;"&gt;No.&lt;/em&gt; &lt;em style="font: inherit;"&gt;99&lt;/em&gt;&lt;/i&gt;, &#x201c;&lt;i&gt;Materiality&lt;/i&gt;,&#x201d; (&lt;i&gt;ASC Topic &lt;em style="font: inherit;"&gt;250,&lt;/em&gt; Accounting Changes and Error Corrections&lt;/i&gt;). Based on this assessment, the Company concluded that this error correction in its&#160;&lt;i&gt;Statements of Operations&lt;/i&gt;&#160;and &lt;i&gt;Note &lt;em style="font: inherit;"&gt;1&lt;/em&gt; &lt;/i&gt;&#x2013;&lt;i&gt; Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies (Loss Per Common Share)&lt;/i&gt; is &lt;em style="font: inherit;"&gt;not&lt;/em&gt; material to any previously presented financial statements based upon overall considerations of both quantitative and qualitative factors. The corrections had &lt;em style="font: inherit;"&gt;no&lt;/em&gt; impact in the comparative period Balance Sheet,&#160;Statements of Cash Flows, or Statement of Changes in Stockholders&#x2019;&#160;Equity. Further, the immaterial correction did &lt;em style="font: inherit;"&gt;not&lt;/em&gt; result in a change in operating losses or net loss in the Statement of Operations and the effects of including unexercised warrants in the earnings per share calculation have an antidilutive effect reducing the net loss per share amount. Accordingly, the Company corrected the previously reported earnings per share calculation for the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2024 &lt;/em&gt;in this Quarterly Report on Form &lt;em style="font: inherit;"&gt;10&lt;/em&gt;-Q.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;A summary of the impact of the Company&#x2019;s Reverse Stock Split and immaterial corrections reflecting the prior period impact to the Company&#x2019;s Statement of Operations and earnings per share are shown below:&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

     &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="14" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Three Months Ended June 30, 2024&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Originally &lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Filed&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Adjusted &lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;for 1-for-20 &lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Reverse &lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Stock Split&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Correction&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;As Revised&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 52%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Net Loss (in thousands)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(2,699&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(2,699&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Loss per share - basic and diluted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(0.14&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(2.85&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;0.65&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(2.20&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Weighted average shares outstanding - basic and diluted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;18,902,248&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;945,382&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;280,041&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,225,423&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
     &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;A summary of the impact of the Company&#x2019;s Reverse Stock Split and immaterial corrections reflecting the prior period impact are shown below:&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

     &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="14" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Three Months Ended June 30, 2024&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Originally &lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Filed&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Adjusted &lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;for 1-for-20 &lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Reverse &lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Stock Split&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Correction&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;As Revised&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 52%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Equity based warrants to purchase common shares&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;5,344,569&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;267,231&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(262,897&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4,334&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Convertible Notes - common shares&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;665,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;33,250&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;33,250&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Convertible Notes - equity-based warrants to purchase common shares&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;500,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;25,003&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;25,003&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Stock options granted under Company's incentive plan&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;4,329,579&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;216,483&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;216,483&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total potentially dilutive securities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;10,839,148&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;541,967&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(262,897&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;279,070&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
     &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</amix:CorrectionOfAnImmaterialErrorPolicyTextBlock>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2024-12-31_ClassOfWarrantOrRightAxis-EquitybasedWarrantsMember"
      decimals="INF"
      id="c134564920"
      unitRef="USDPerShare">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock
      contextRef="d_2025-04-01_2025-06-30"
      id="EDBFCD1B-5AC0-4A4A-9FF1-7B073398C2A1">
     &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="14" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Three Months Ended June 30, 2024&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Originally &lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Filed&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Adjusted &lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;for 1-for-20 &lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Reverse &lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Stock Split&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Correction&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;As Revised&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 52%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Net Loss (in thousands)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(2,699&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(2,699&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Loss per share - basic and diluted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(0.14&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(2.85&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;0.65&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(2.20&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Weighted average shares outstanding - basic and diluted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;18,902,248&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;945,382&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;280,041&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,225,423&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

     &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="14" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Three Months Ended June 30, 2024&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Originally &lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Filed&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Adjusted &lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;for 1-for-20 &lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Reverse &lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Stock Split&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Correction&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;As Revised&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 52%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Equity based warrants to purchase common shares&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;5,344,569&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;267,231&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(262,897&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4,334&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Convertible Notes - common shares&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;665,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;33,250&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;33,250&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Convertible Notes - equity-based warrants to purchase common shares&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;500,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;25,003&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;25,003&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Stock options granted under Company's incentive plan&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;4,329,579&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;216,483&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;216,483&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total potentially dilutive securities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;10,839,148&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;541,967&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(262,897&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;279,070&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
    </us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-04-01_2024-06-30_RestatementAxis-ScenarioPreviouslyReportedMember"
      decimals="-3"
      id="c134564226"
      unitRef="USD">-2699000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-04-01_2024-06-30_RestatementAxis-ReverseStockSplitAdjustmentMember"
      decimals="-3"
      id="c134564227"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-04-01_2024-06-30_RestatementAxis-RevisionOfPriorPeriodErrorCorrectionAdjustmentMember"
      decimals="-3"
      id="c134564228"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-04-01_2024-06-30"
      decimals="-3"
      id="c134564229"
      unitRef="USD">-2699000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="d_2024-04-01_2024-06-30_RestatementAxis-ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="c134564230"
      unitRef="USDPerShare">-0.14</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="d_2024-04-01_2024-06-30_RestatementAxis-ReverseStockSplitAdjustmentMember"
      decimals="INF"
      id="c134564231"
      unitRef="USDPerShare">-2.85</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="d_2024-04-01_2024-06-30_RestatementAxis-RevisionOfPriorPeriodErrorCorrectionAdjustmentMember"
      decimals="INF"
      id="c134564232"
      unitRef="USDPerShare">0.65</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="d_2024-04-01_2024-06-30"
      decimals="INF"
      id="c134564233"
      unitRef="USDPerShare">-2.2</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="d_2024-04-01_2024-06-30_RestatementAxis-ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="c134564234"
      unitRef="Share">18902248</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="d_2024-04-01_2024-06-30_RestatementAxis-ReverseStockSplitAdjustmentMember"
      decimals="INF"
      id="c134564235"
      unitRef="Share">945382</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="d_2024-04-01_2024-06-30_RestatementAxis-RevisionOfPriorPeriodErrorCorrectionAdjustmentMember"
      decimals="INF"
      id="c134564236"
      unitRef="Share">280041</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="d_2024-04-01_2024-06-30"
      decimals="INF"
      id="c134564237"
      unitRef="Share">1225423</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2024-04-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember_RestatementAxis-ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="c134564238"
      unitRef="Share">5344569</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2024-04-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember_RestatementAxis-ReverseStockSplitAdjustmentMember"
      decimals="INF"
      id="c134564239"
      unitRef="Share">267231</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2024-04-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember_RestatementAxis-RevisionOfPriorPeriodErrorCorrectionAdjustmentMember"
      decimals="INF"
      id="c134564240"
      unitRef="Share">-262897</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2024-04-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember"
      decimals="INF"
      id="c134564241"
      unitRef="Share">4334</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2024-04-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-ConvertibleDebtSecuritiesMember_RestatementAxis-ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="c134564242"
      unitRef="Share">665000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2024-04-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-ConvertibleDebtSecuritiesMember_RestatementAxis-ReverseStockSplitAdjustmentMember"
      decimals="INF"
      id="c134564243"
      unitRef="Share">33250</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2024-04-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-ConvertibleDebtSecuritiesMember_RestatementAxis-RevisionOfPriorPeriodErrorCorrectionAdjustmentMember"
      decimals="INF"
      id="c134564244"
      unitRef="Share">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2024-04-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-ConvertibleDebtSecuritiesMember"
      decimals="INF"
      id="c134564245"
      unitRef="Share">33250</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2024-04-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-ConvertibleNotesToWarrantsMember_RestatementAxis-ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="c134564246"
      unitRef="Share">500000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2024-04-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-ConvertibleNotesToWarrantsMember_RestatementAxis-ReverseStockSplitAdjustmentMember"
      decimals="INF"
      id="c134564247"
      unitRef="Share">25003</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2024-04-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-ConvertibleNotesToWarrantsMember_RestatementAxis-RevisionOfPriorPeriodErrorCorrectionAdjustmentMember"
      decimals="INF"
      id="c134564248"
      unitRef="Share">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2024-04-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-ConvertibleNotesToWarrantsMember"
      decimals="INF"
      id="c134564249"
      unitRef="Share">25003</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2024-04-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember_RestatementAxis-ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="c134564250"
      unitRef="Share">4329579</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2024-04-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember_RestatementAxis-ReverseStockSplitAdjustmentMember"
      decimals="INF"
      id="c134564251"
      unitRef="Share">216483</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2024-04-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember_RestatementAxis-RevisionOfPriorPeriodErrorCorrectionAdjustmentMember"
      decimals="INF"
      id="c134564252"
      unitRef="Share">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2024-04-01_2024-06-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember"
      decimals="INF"
      id="c134564253"
      unitRef="Share">216483</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2024-04-01_2024-06-30_RestatementAxis-ScenarioPreviouslyReportedMember"
      decimals="INF"
      id="c134564254"
      unitRef="Share">10839148</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2024-04-01_2024-06-30_RestatementAxis-ReverseStockSplitAdjustmentMember"
      decimals="INF"
      id="c134564255"
      unitRef="Share">541967</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2024-04-01_2024-06-30_RestatementAxis-RevisionOfPriorPeriodErrorCorrectionAdjustmentMember"
      decimals="INF"
      id="c134564256"
      unitRef="Share">-262897</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2024-04-01_2024-06-30"
      decimals="INF"
      id="c134564257"
      unitRef="Share">279070</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:DebtDisclosureTextBlock contextRef="d_2025-04-01_2025-06-30" id="c3016979">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;2&lt;/em&gt;&lt;/b&gt;&#160;&#x2013;&lt;b&gt; Convertible Notes Payable&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;On &lt;em style="font: inherit;"&gt; September 9, 2023, &lt;/em&gt;the Company's Board authorized an offering of up to $2.0 million in unsecured, non-interest bearing convertible promissory notes (the &#x201c;Notes&#x201d;) and accompanying warrants (the &#x201c;Bridge Financing Warrants&#x201d;) (collectively, the &#x201c;Bridge Offering&#x201d;) that mature on &lt;em style="font: inherit;"&gt; December 31, 2025. &lt;/em&gt;The Notes provided that, on the closing date of the IPO, the outstanding principal would be automatically converted into common stock at the conversion price of $40.00. Each dollar in principal amount of Notes purchased were accompanied by a &lt;span style="-sec-ix-hidden:c134564938"&gt;five&lt;/span&gt;-year Bridge Financing Warrant to purchase approximately 0.0125 shares of Common stock with an exercise price of $20.00 per share. The Company records the Bridge Financing Warrants as a discount to the Notes.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;The Bridge Financing Warrants can be exercised from the date of Notes issuance through the &lt;em style="font: inherit;"&gt;five&lt;/em&gt;-year anniversary of the issuance of the Notes. The Note holders are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; permitted to convert their Notes when the holders or any of their affiliates would beneficially own in excess of 4.99% of the Company&#x2019;s common stock after such conversion.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;The Company received proceeds of $2.0 million of Notes from the Bridge Offering. The Company&#x2019;s effective interest rate for the Notes was 15.3% due to the amortization of the discount stemming from the issuance of the Bridge Financing Warrants. On &lt;em style="font: inherit;"&gt; January 26, 2024, &lt;/em&gt;the Company consummated its initial public offering (&#x201c;IPO&#x201d;). In connection with the closing of the IPO, a portion of the Notes were converted into 16,750 shares of common stock. Upon the closing of the IPO, certain Notes that were to be automatically converted according to their terms into &#xfeff;common stock were &lt;em style="font: inherit;"&gt;not&lt;/em&gt; converted due to restrictions on the holders of the Notes or any of their affiliates beneficially owning in excess of 4.99% of the Company's common stock after such conversion. The remaining portion of the N&#xfeff;otes was converted into 33,250 shares of common stock on &lt;em style="font: inherit;"&gt; March 28, 2025.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;Warrants - Convertible Promissory Notes&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;During &lt;em style="font: inherit;"&gt; September &lt;/em&gt;to &lt;em style="font: inherit;"&gt; December 2023, &lt;/em&gt;the Company issued the Notes with the detachable Bridge Financing Warrants. The Company utilized a Monte Carlo simulation model to determine the fair value of each Bridge Offering Warrant. The key inputs to the Monte Carlo simulation used to determine the fair value of each warrant include, the Company&#x2019;s stock price fair value which was determined through a back solve calculation such that the stock price results in the average total value of the Notes and the Bridge Offering Warrants being equal to the cash proceeds received, volatility based on a selection of publicly held peer companies of 101.88%, expected term of 5 years, risk free rate of 4.40%, discount rate of 20.00% and a discount for lack of marketability of 15.77%.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;During the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2025 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2024,&lt;/em&gt; the Company recorded $0 and less than $0.1 million, respectively, in interest expense related to the amortization of the debt discount.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;The following table presents a summary of activity for the warrants issued in connection with the Company&#x2019;s Notes:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Weighted-&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Warrants&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Per Share&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 70%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Outstanding and exercisable, March 31, 2025&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;25,003&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;20.00&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Granted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Exercised&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Forfeited/Cancelled&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Expired&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Outstanding, June 30, 2025&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;25,003&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;20.00&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Exercisable, June 30, 2025&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;25,003&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;20.00&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
  </us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i_2023-09-09_DebtInstrumentAxis-TheNotesMember_RangeAxis-MaximumMember"
      decimals="-6"
      id="c134564936"
      unitRef="USD">2000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="i_2023-09-09_DebtInstrumentAxis-TheNotesMember"
      decimals="INF"
      id="c134564937"
      unitRef="USDPerShare">40</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="i_2023-09-09_ClassOfWarrantOrRightAxis-BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember"
      decimals="INF"
      id="c134564939"
      unitRef="Share">0.0125</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2023-09-09_ClassOfWarrantOrRightAxis-BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember"
      decimals="INF"
      id="c134564940"
      unitRef="USDPerShare">20</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <amix:DebtInstrumentConvertibleMaximumBeneficialOwnershipPercentage
      contextRef="i_2023-09-09_DebtInstrumentAxis-TheNotesMember"
      decimals="4"
      id="c134564943"
      unitRef="Pure">0.0499</amix:DebtInstrumentConvertibleMaximumBeneficialOwnershipPercentage>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="d_2023-09-09_2024-03-31_DebtInstrumentAxis-TheNotesMember"
      decimals="-6"
      id="c134564944"
      unitRef="USD">2000000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i_2025-06-30_DebtInstrumentAxis-ConvertibleDebtWith499PercentBeneficialOwnershipLimitationMember"
      decimals="3"
      id="c134564945"
      unitRef="Pure">0.153</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="d_2024-01-26_2024-01-26_DebtConversionByUniqueDescriptionAxis-ConversionOfConvertibleNotesToCommonStockMember"
      decimals="INF"
      id="c134564946"
      unitRef="Share">16750</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <amix:DebtInstrumentConvertibleMaximumBeneficialOwnershipPercentage
      contextRef="i_2024-01-26_DebtInstrumentAxis-TheNotesMember"
      decimals="4"
      id="c134564948"
      unitRef="Pure">0.0499</amix:DebtInstrumentConvertibleMaximumBeneficialOwnershipPercentage>
    <us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments
      contextRef="d_2025-03-28_2025-03-28_DebtInstrumentAxis-ConvertibleDebtWith499PercentBeneficialOwnershipLimitationMember"
      decimals="INF"
      id="c134564949"
      unitRef="Pure">33250</us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2024-03-31_ClassOfWarrantOrRightAxis-BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember"
      decimals="4"
      id="c134564950"
      unitRef="Pure">1.0188</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2024-03-31_ClassOfWarrantOrRightAxis-BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember"
      decimals="INF"
      id="c134564951"
      unitRef="Year">5</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2024-03-31_ClassOfWarrantOrRightAxis-BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember"
      decimals="3"
      id="c134564952"
      unitRef="Pure">0.044</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2024-03-31_ClassOfWarrantOrRightAxis-BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember_MeasurementInputTypeAxis-MeasurementInputDiscountRateMember"
      decimals="1"
      id="c134564953"
      unitRef="Pure">0.20</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2023-12-31_ClassOfWarrantOrRightAxis-BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember_MeasurementInputTypeAxis-MeasurementInputDiscountForLackOfMarketabilityMember"
      decimals="4"
      id="c134564954"
      unitRef="Pure">0.1577</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:InterestExpenseDebt
      contextRef="d_2025-04-01_2025-06-30_DebtInstrumentAxis-TheNotesMember"
      decimals="-3"
      id="c134564958"
      unitRef="USD">0</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="d_2024-04-01_2024-06-30_DebtInstrumentAxis-TheNotesMember"
      decimals="-5"
      id="c134564959"
      unitRef="USD">100000</us-gaap:InterestExpenseDebt>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="d_2025-04-01_2025-06-30" id="c3016980">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Weighted-&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Warrants&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Per Share&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 70%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Outstanding and exercisable, March 31, 2025&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;25,003&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;20.00&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Granted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Exercised&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Forfeited/Cancelled&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Expired&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Outstanding, June 30, 2025&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;25,003&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;20.00&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Exercisable, June 30, 2025&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;25,003&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;20.00&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i_2025-03-31"
      decimals="INF"
      id="c134564258"
      unitRef="Share">25003</us-gaap:ClassOfWarrantOrRightOutstanding>
    <amix:ClassOfWarrantOrRightOutstandingOutstandingWeightedAverageExercisePrice
      contextRef="i_2025-03-31"
      decimals="INF"
      id="c134564259"
      unitRef="USDPerShare">20</amix:ClassOfWarrantOrRightOutstandingOutstandingWeightedAverageExercisePrice>
    <amix:ClassOfWarrantOrRightGrantsInPeriod
      contextRef="d_2025-04-01_2025-06-30"
      decimals="INF"
      id="c134564260"
      unitRef="Share">0</amix:ClassOfWarrantOrRightGrantsInPeriod>
    <amix:ClassOfWarrantOrRightGrantsInPeriodWeightedAverageExercise
      contextRef="d_2025-04-01_2025-06-30"
      decimals="INF"
      id="c134564261"
      unitRef="USDPerShare">0</amix:ClassOfWarrantOrRightGrantsInPeriodWeightedAverageExercise>
    <amix:ClassOfWarrantOrRightExercisesInPeriod
      contextRef="d_2025-04-01_2025-06-30"
      decimals="INF"
      id="c134564262"
      unitRef="Share">-0</amix:ClassOfWarrantOrRightExercisesInPeriod>
    <amix:ClassOfWarrantOrRightExercisesInPeriodWeightedAverageExercisePrice
      contextRef="d_2025-04-01_2025-06-30"
      decimals="INF"
      id="c134564263"
      unitRef="USDPerShare">0</amix:ClassOfWarrantOrRightExercisesInPeriodWeightedAverageExercisePrice>
    <amix:ClassOfWarrantOrRightForfeituresInPeriod
      contextRef="d_2025-04-01_2025-06-30"
      decimals="INF"
      id="c134564264"
      unitRef="Share">-0</amix:ClassOfWarrantOrRightForfeituresInPeriod>
    <amix:ClassOfWarrantOrRightForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="d_2025-04-01_2025-06-30"
      decimals="INF"
      id="c134564265"
      unitRef="USDPerShare">0</amix:ClassOfWarrantOrRightForfeituresInPeriodWeightedAverageExercisePrice>
    <amix:ClassOfWarrantOrRightExpirationsInPeriod
      contextRef="d_2025-04-01_2025-06-30"
      decimals="INF"
      id="c134564266"
      unitRef="Share">-0</amix:ClassOfWarrantOrRightExpirationsInPeriod>
    <amix:ClassOfWarrantOrRightExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="d_2025-04-01_2025-06-30"
      decimals="INF"
      id="c134564267"
      unitRef="USDPerShare">0</amix:ClassOfWarrantOrRightExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i_2025-06-30"
      decimals="INF"
      id="c134564268"
      unitRef="Share">25003</us-gaap:ClassOfWarrantOrRightOutstanding>
    <amix:ClassOfWarrantOrRightOutstandingOutstandingWeightedAverageExercisePrice
      contextRef="i_2025-06-30"
      decimals="INF"
      id="c134564269"
      unitRef="USDPerShare">20</amix:ClassOfWarrantOrRightOutstandingOutstandingWeightedAverageExercisePrice>
    <amix:ClassOfWarrantOrRightExercisableNumber
      contextRef="i_2025-06-30"
      decimals="INF"
      id="c134564270"
      unitRef="Share">25003</amix:ClassOfWarrantOrRightExercisableNumber>
    <amix:ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice
      contextRef="d_2025-04-01_2025-06-30"
      decimals="INF"
      id="c134564271"
      unitRef="USDPerShare">20</amix:ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="d_2025-04-01_2025-06-30" id="c3016981">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;3&lt;/em&gt;&lt;/b&gt;&#160;&#x2013;&lt;b&gt; Equity&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;On &lt;em style="font: inherit;"&gt; November 29, 2023, &lt;/em&gt;the Company&#x2019;s Board and applicable shareholders approved to amend and restate the Company&#x2019;s certificate of incorporation and increased the authorized shares to 500,000,000 shares of common stock and 10,000,000 shares of preferred stock, each with a par value of $0.001 per share. The specific rights of the preferred stock shall be determined by the Board.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;text-indent:9pt;"&gt;&lt;i&gt;Preferred Stock &lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;text-indent:9pt;"&gt;As of &lt;em style="font: inherit;"&gt; June 30, 2025, &lt;/em&gt;the Company had no shares of preferred stock outstanding.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;Restricted Stock&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;On &lt;em style="font: inherit;"&gt; February 15, 2024, &lt;/em&gt;the Company issued&#160;1,750 restricted shares of common stock to the Company's marketing consultant at the closing price of $76.00 of the Company's common stock. The total value of these shares is $133,000. These shares vested monthly over a 12-month period beginning on the issue&#160;date.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Three Months Ended June 30,&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 70%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Recognized in general and administrative expense&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;33,250&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;33,250&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;As of &lt;em style="font: inherit;"&gt; June 30, 2025, &lt;/em&gt;there was $0 of unrecognized stock-based compensation expense related to Restricted Stock.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;Common Stock &lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;On &lt;em style="font: inherit;"&gt; February 28, 2025, &lt;/em&gt;the Company entered into an ATM Agreement. Pursuant to the terms of the Agreement, the Company was permitted to sell from time to time shares of Company&#x2019;s common stock, with an initial aggregate sales price of up to $2.1 million. As of &lt;em style="font: inherit;"&gt; June 30, 2025, &lt;/em&gt;the Company sold 1,304,260 shares pursuant to the ATM Agreement for net proceeds of approximately $2.1 million.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;Stock Plan and Stock Options&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;In &lt;em style="font: inherit;"&gt; June 2023, &lt;/em&gt;the Company adopted, and the Company&#x2019;s shareholders approved, the Autonomix Medical, Inc. &lt;em style="font: inherit;"&gt;2023&lt;/em&gt; Stock Plan (the &#x201c;Plan&#x201d;). The Plan is a stock-based compensation plan that provides for discretionary grants of stock options, stock awards and stock unit awards to key employees, non-employee directors, and consultants, subject to certain individual threshold limitations. The Plan initially provided for up to 200,000 shares to be issued, subject to adjustments as provided in the Plan. Shares that are surrendered because of forfeiture, expiration, termination, or cancellation are available for re-issuance.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;In &lt;em style="font: inherit;"&gt; August 2023, &lt;/em&gt;the Plan was amended to allow for an automatic increase of the available shares for issuance, whereby on the &lt;em style="font: inherit;"&gt;1st&lt;/em&gt; of each fiscal year, beginning on &lt;em style="font: inherit;"&gt; April 1, 2024 &lt;/em&gt;and ending on (and including) &lt;em style="font: inherit;"&gt; April 1, 2033 &lt;/em&gt;in an amount equal to &lt;em style="font: inherit;"&gt;five&lt;/em&gt; percent (5%) of the total number of shares of Common Stock outstanding on the &lt;em style="font: inherit;"&gt; March &lt;/em&gt;&lt;em style="font: inherit;"&gt;31st&lt;/em&gt; immediately preceding the applicable date. However, the Board &lt;em style="font: inherit;"&gt; may &lt;/em&gt;act prior to the automatic increase of a given year to provide that there will be &lt;em style="font: inherit;"&gt;no&lt;/em&gt; increase for such year, or that the increase for such year will be a lesser number of shares of Common Stock. On &lt;em style="font: inherit;"&gt; April 1, 2025, &lt;/em&gt;the Plan was increased by 124,852 shares.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;The following table summarizes the stock option activity for the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2025:&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Weighted-&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Per Share&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 70%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Outstanding, March 31, 2025&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;243,483&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;32.72&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Granted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;5,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1.85&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Exercised&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Forfeited/Cancelled&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Expired&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Outstanding, June 30, 2025&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;248,483&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;32.10&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Exercisable, June 30, 2025&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;69,916&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;37.24&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;The Company&#x2019;s stock option awards did &lt;em style="font: inherit;"&gt;not&lt;/em&gt; automatically adjust for the Reverse Stock Split.&#160;However, the Company chose to exercise its rights under the Plan to adjust the exercise price and number of shares exercisable or issuable upon vesting proportionately for the Reverse Stock Split.&#160;Based on the analysis performed, the Company does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; need to recognize any additional compensation expense as a result of the modification.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;During the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2025, &lt;/em&gt;the Company granted&#160;options to purchase 5,000 shares of common stock with a contractual term that vests&#xfeff; annually over &lt;span style="-sec-ix-hidden:c134564987"&gt;four&lt;/span&gt; years on the anniversary date. The options had an aggregate grant date fair value of $9 thousand that was calculated using the Black-Scholes option pricing model. Variables used in the Black-Scholes option pricing model included the following: (&lt;em style="font: inherit;"&gt;1&lt;/em&gt;) fair value of common stock on the measurement date; (&lt;em style="font: inherit;"&gt;2&lt;/em&gt;) discount rate ranging of 4.06% based on the daily yield curve rates for U.S. Treasury obligations, (&lt;em style="font: inherit;"&gt;3&lt;/em&gt;) expected life of 6.25 years based on the simplified method (vesting plus contractual term divided by &lt;em style="font: inherit;"&gt;two&lt;/em&gt;) and (&lt;em style="font: inherit;"&gt;4&lt;/em&gt;) expected volatility of 139%&#160;based on the historical volatility of comparable companies' stock.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;All options issued and outstanding are being amortized over their respective vesting periods. The unrecognized compensation expense at &lt;em style="font: inherit;"&gt; June 30, 2025 &lt;/em&gt;was $3.9 million. During the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2025, &lt;/em&gt;the Company recorded stock-based compensation - option expense of $0.3 million in general and administrative expense and less than $0.1 million in research and development expense. During the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2024,&#160;&lt;/em&gt;the Company recorded stock-based compensation - option expense of $0.3 million in general and administrative expense and less than $0.1 million in research and development expense
    &lt;span style="text-decoration: line-through; "&gt;
      .
    &lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;text-indent:9pt;"&gt;&lt;i&gt;License Agreement&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;On &lt;em style="font: inherit;"&gt; July 10, 2024, &lt;/em&gt;the Company entered into a license agreement (the &#x201c;Agreement&#x201d;) with RF Innovations, Inc. (&#x201c;RFI&#x201d;), a privately held medical technology company, to license products utilizing RFI&#x2019;s intellectual property related to its Apex &lt;em style="font: inherit;"&gt;6&lt;/em&gt; Radiofrequency Generator (the &#x201c;Licensed Products&#x201d;). The Apex &lt;em style="font: inherit;"&gt;6&lt;/em&gt; Generator is a United States Food and Drug Administration (&#x201c;FDA&#x201d;) cleared ablation technology designed to lesion neural tissue for pain management in the peripheral nervous system. Pursuant to the Agreement, RFI granted us a perpetual non-exclusive worldwide royalty free fully paid license related to the Licensed Products, provided that the license did &lt;em style="font: inherit;"&gt;not&lt;/em&gt; include the right to sell certain products to customers for the treatment of spine pain. In connection with the Agreement, the Company issued RFI 12,500 unregistered shares of its common stock as consideration for the license. The Company determined that the fair value of the shares granted was $0.1 million, which represented its stock price on the date of the Agreement less a 25.6% discount for lack of marketability (&#x201c;DLOM&#x201d;). The Company concluded a DLOM was appropriate as the shares were subject to an initial lock-up period of &lt;em style="font: inherit;"&gt;six&lt;/em&gt; months followed by restrictions that allow for a maximum of 10% of total shares to be sold within a &lt;em style="font: inherit;"&gt;30&lt;/em&gt;-day period.&#160;The DLOM effectively reflects the value of an average strike put option relative to the Company's stock price and was calculated based on the Finnerty average put model.&#160;The Company concluded that the licensed technology qualified as a research and development expense pursuant to ASC Topic &lt;em style="font: inherit;"&gt;730,&lt;/em&gt; &lt;i&gt;Research and Development&lt;/i&gt;, as the Company does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; have an alternative future use for the technology and the Company does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; have a plan to otherwise monetize the Licensed Products.&#160;The Agreement provides RFI the right to terminate the license if we breach any representation, warranty or covenant contained in the Agreement, subject to any relevant cure periods, or if we are subject to a bankruptcy or insolvency event.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;&lt;i&gt;Offering Agreement &lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;On &lt;em style="font: inherit;"&gt; November 22, 2024, &lt;/em&gt;the Company entered into the Offering, which consisted of: (i) 458,691 Common Units, each Common Unit consisting of &lt;span style="-sec-ix-hidden:c134565018"&gt;one&lt;/span&gt; share of common stock and &lt;span style="-sec-ix-hidden:c134565019"&gt;one&lt;/span&gt; Series A Warrant to purchase &lt;span style="-sec-ix-hidden:c134565020"&gt;one&lt;/span&gt; share of common stock; and (ii) 917,596 Pre-Funded Units, each Pre-Funded Unit consisting of &lt;span style="-sec-ix-hidden:c134565022"&gt;one&lt;/span&gt; Pre-Funded Warrant to purchase &lt;span style="-sec-ix-hidden:c134565023"&gt;one&lt;/span&gt; share of common stock and &lt;span style="-sec-ix-hidden:c134565024"&gt;one&lt;/span&gt; Series A Warrant. The purchase price of each Common Unit was $6.540, and the purchase price of each Pre-Funded Unit was $6.539.&#160;In addition, the Company granted the Underwriters a 45-day option to purchase additional 206,422 shares of common stock, and/or additional 206,422 Series A Warrants, solely to cover over-allotments, if any. The Offering closed on &lt;em style="font: inherit;"&gt; November 25, 2024. &lt;/em&gt;On &lt;em style="font: inherit;"&gt; November 22, 2024, &lt;/em&gt;the Underwriters partially exercised their over-allotment option with respect to 156,809 shares of Common Stock and 156,809 Series A Warrants. The Company received gross proceeds of $10.0&#160;million, before deducting the Underwriter's fees and other offering expenses payable by the Company.&#160;Under the terms of the Underwriting Agreement, the Underwriters received an underwriting discount of 8.0% to the public offering price for the Units. The Company also issued to the representative of the Underwriters (the "Representative") Representative's Warrants to purchase up to 91,985 shares of common stock.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;The Pre-Funded Warrants have an exercise price of $0.001 per share, are immediately exercisable and &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be exercised at any time until all of the Pre-Funded Warrants are exercised in full, subject to a beneficial ownership limitation of 4.99%. The Series A Warrants have an exercise price of $6.540 per share and &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be exercised at any time until the &lt;span style="-sec-ix-hidden:c134565038"&gt;five&lt;/span&gt;-year anniversary of the date of issuance, subject to a beneficial ownership limitation of 4.99%. The Pre-Funded Warrants and Series A Warrants were issued pursuant a Warrant Agency Agreement between the Company and Equity Stock Transfer, LLC.&#160;The Series A Warrants and the Representative&#x2019;s Warrants, largely have the same terms and conditions, except the Representative&#x2019;s Warrants were &lt;em style="font: inherit;"&gt;not&lt;/em&gt; exercisable until &lt;em style="font: inherit;"&gt; May 21, 2025 &lt;/em&gt;and are subject to a 180-day lock-up prior to being transferable.&#160;The Series A Warrants and Representative&#x2019;s Warrants &lt;em style="font: inherit;"&gt; may, &lt;/em&gt;at the option of the holder be settled upon a change of control at the Black-Scholes value, as defined in the agreement.&#160;Upon a change of control the holder &lt;em style="font: inherit;"&gt; may &lt;/em&gt;receive cash, other assets or shares of the successor entity, depending on the specific nature of the change of control transaction and the settlement options afforded to the holders of common stock.&#160;The Company analyzed the Pre-Funded Warrants, the Series A Warrants, and the Representative&#x2019;s Warrants (collectively the &#x201c;Offering Warrants&#x201d;) in accordance with ASC Topic &lt;em style="font: inherit;"&gt;480,&lt;/em&gt; Distinguishing Liabilities from Equity and ASC Topic &lt;em style="font: inherit;"&gt;815,&lt;/em&gt; Derivatives and Hedging.&#160;Management concluded that the Offering Warrants meet all the requirements for equity classification.&#160;Since the Offering Warrants meet the requirements for equity classification and the Offering represents an arms-length cash transaction, the Common Units and Pre-Funded Units will be recorded in equity based on the proceeds received, net of issuance costs.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;At issuance the Pre-Funded Warrants had a fair value of $6.3290 per share, which represented the common stock issuance price less the $0.001 exercise price.&#160;At issuance, the Series A Warrants and the Representative&#x2019;s Warrants had&#160;a fair value of $5.3597 and $5.2125&#160;per share, respectively, which was determined using a Black-Scholes option pricing model.&#160;Variables used in the Black-Scholes option pricing model included the following: (&lt;em style="font: inherit;"&gt;1&lt;/em&gt;) fair value of common stock on the measurement date; (&lt;em style="font: inherit;"&gt;2&lt;/em&gt;) discount rate of 4.17% based on the daily yield curve rates for U.S. Treasury obligations, (&lt;em style="font: inherit;"&gt;3&lt;/em&gt;) the contractual term of the warrants and (&lt;em style="font: inherit;"&gt;4&lt;/em&gt;) expected volatility of 144.15% based on the historical volatility of comparable companies' stock. Due to the relative volume of Series A Warrants and Representative&#x2019;s Warrants issued compared with the Company&#x2019;s outstanding shares, the Company's stock price was adjusted for the effects of dilution.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;In connection with the Offering, the Company incurred total offering costs of $1.5 million.&#160;This was comprised of $1.0 million in cash offering costs and $0.5 million&#160;for the fair value of the Representative&#x2019;s Warrant issued.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Equity-Based Stock Warrants&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;The Company will periodically grant warrants to investors in connection with equity financing or to &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party service providers in exchange for services rendered. The following table summarizes the stock warrant activity for the&#160;&lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2025:&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Weighted-&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Warrants&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Per Share&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 70%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Outstanding, March 31, 2025&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,934,874&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="-sec-ix-hidden:c134564291"&gt;5.8860&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Granted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Exercised&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(222,132&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;0.0010&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Forfeited/Cancelled&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(130&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;0.0010&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Expired&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Outstanding, June 30, 2025*&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,712,612&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;6.6498&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Exercisable, June 30, 2025&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,712,612&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;6.6498&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 18pt;"&gt; &lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;*&lt;/p&gt; &lt;/td&gt;&lt;td style="width: auto;"&gt; &lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;Amount includes 87,531 common warrants; 91,985 Representative's Warrants and 1,533,096 Series A Warrants.&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;The unrecognized compensation expense at &lt;em style="font: inherit;"&gt; June 30, 2025 &lt;/em&gt;for warrants issued to &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party service providers was $0. During the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2025 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2024,&lt;/em&gt; the Company recorded stock-based compensation - warrant expense of $0 and less than $0.1 million, respectively.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
  </us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i_2023-11-29"
      decimals="INF"
      id="c134564961"
      unitRef="Share">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i_2023-11-29"
      decimals="INF"
      id="c134564962"
      unitRef="Share">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i_2023-11-29"
      decimals="INF"
      id="c134564963"
      unitRef="USDPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i_2025-06-30"
      decimals="-3"
      id="c134564964"
      unitRef="Share">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="d_2024-02-15_2024-02-15_AwardTypeAxis-RestrictedStockMember_TitleOfIndividualAxis-MarketingConsultantMember"
      decimals="INF"
      id="c134564965"
      unitRef="Share">1750</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="i_2024-02-15_AwardTypeAxis-RestrictedStockMember_TitleOfIndividualAxis-MarketingConsultantMember"
      decimals="INF"
      id="c134564966"
      unitRef="USDPerShare">76</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2024-02-15_2024-02-15_AwardTypeAxis-RestrictedStockMember_TitleOfIndividualAxis-MarketingConsultantMember"
      decimals="INF"
      id="c134564967"
      unitRef="USD">133000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="d_2024-02-15_2024-02-15_AwardTypeAxis-RestrictedStockMember_TitleOfIndividualAxis-MarketingConsultantMember"
      id="c134564968">P12M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <amix:RestrictedStockExpensesGeneralAndAdministrativeTableTextBlock contextRef="d_2025-04-01_2025-06-30" id="c3016982">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Three Months Ended June 30,&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 70%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Recognized in general and administrative expense&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;33,250&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;33,250&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </amix:RestrictedStockExpensesGeneralAndAdministrativeTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2025-04-01_2025-06-30_AwardTypeAxis-RestrictedStockMember_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"
      decimals="INF"
      id="c134564272"
      unitRef="USD">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2024-04-01_2024-06-30_AwardTypeAxis-RestrictedStockMember_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"
      decimals="INF"
      id="c134564273"
      unitRef="USD">33250</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2025-04-01_2025-06-30_AwardTypeAxis-RestrictedStockMember"
      decimals="INF"
      id="c134564274"
      unitRef="USD">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2024-04-01_2024-06-30_AwardTypeAxis-RestrictedStockMember"
      decimals="INF"
      id="c134564275"
      unitRef="USD">33250</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="i_2025-06-30_AwardTypeAxis-RestrictedStockMember"
      decimals="-3"
      id="c134564969"
      unitRef="USD">0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <amix:EquityOfferingMaximumOfferingAmount
      contextRef="i_2025-02-28_SubsidiarySaleOfStockAxis-ATMAgreementMember"
      decimals="-5"
      id="c134564970"
      unitRef="USD">2100000</amix:EquityOfferingMaximumOfferingAmount>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2025-04-01_2025-06-30_SubsidiarySaleOfStockAxis-ATMAgreementMember"
      decimals="INF"
      id="c134564971"
      unitRef="Share">1304260</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="d_2025-04-01_2025-06-30_SubsidiarySaleOfStockAxis-ATMAgreementMember"
      decimals="-5"
      id="c134564972"
      unitRef="USD">2100000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i_2023-06-30_PlanNameAxis-The2023StockPlanMember"
      decimals="INF"
      id="c134564974"
      unitRef="Share">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="d_2023-08-01_2023-08-31_PlanNameAxis-The2023StockPlanMember"
      decimals="2"
      id="c134564978"
      unitRef="Pure">0.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="d_2025-04-01_2025-04-01_PlanNameAxis-The2023StockPlanMember"
      decimals="INF"
      id="c134564981"
      unitRef="Share">124852</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="d_2025-04-01_2025-06-30" id="c3016983">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Weighted-&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Per Share&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 70%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Outstanding, March 31, 2025&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;243,483&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;32.72&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Granted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;5,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1.85&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Exercised&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Forfeited/Cancelled&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Expired&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Outstanding, June 30, 2025&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;248,483&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;32.10&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Exercisable, June 30, 2025&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;69,916&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;37.24&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2025-03-31"
      decimals="INF"
      id="c134564276"
      unitRef="Share">243483</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i_2025-03-31"
      decimals="INF"
      id="c134564277"
      unitRef="USDPerShare">32.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="d_2025-04-01_2025-06-30"
      decimals="INF"
      id="c134564278"
      unitRef="Share">5000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="d_2025-04-01_2025-06-30"
      decimals="INF"
      id="c134564279"
      unitRef="USDPerShare">1.85</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="d_2025-04-01_2025-06-30"
      decimals="INF"
      id="c134564280"
      unitRef="Share">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="d_2025-04-01_2025-06-30"
      decimals="INF"
      id="c134564281"
      unitRef="USDPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="d_2025-04-01_2025-06-30"
      decimals="INF"
      id="c134564282"
      unitRef="Share">-0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="d_2025-04-01_2025-06-30"
      decimals="INF"
      id="c134564283"
      unitRef="USDPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="d_2025-04-01_2025-06-30"
      decimals="INF"
      id="c134564284"
      unitRef="Share">-0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="d_2025-04-01_2025-06-30"
      decimals="INF"
      id="c134564285"
      unitRef="USDPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2025-06-30"
      decimals="INF"
      id="c134564286"
      unitRef="Share">248483</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i_2025-06-30"
      decimals="INF"
      id="c134564287"
      unitRef="USDPerShare">32.1</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i_2025-06-30"
      decimals="INF"
      id="c134564288"
      unitRef="Share">69916</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i_2025-06-30"
      decimals="INF"
      id="c134564289"
      unitRef="USDPerShare">37.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="d_2025-04-01_2025-06-30_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2023StockPlanMember"
      decimals="INF"
      id="c134564986"
      unitRef="Share">5000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <amix:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantDateFairValue
      contextRef="i_2025-06-30_AwardTypeAxis-EmployeeStockOptionMember_ValuationTechniqueAxis-BlackscholesModelMember"
      decimals="INF"
      id="c134564988"
      unitRef="USD">9</amix:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantDateFairValue>
    <amix:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsDiscountRate
      contextRef="d_2025-04-01_2025-06-30_AwardTypeAxis-EmployeeStockOptionMember_ValuationTechniqueAxis-BlackscholesModelMember"
      decimals="4"
      id="c134564991"
      unitRef="Pure">0.0406</amix:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsDiscountRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="d_2025-04-01_2025-06-30_AwardTypeAxis-EmployeeStockOptionMember_ValuationTechniqueAxis-BlackscholesModelMember"
      id="c134564993">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="d_2025-04-01_2025-06-30_AwardTypeAxis-EmployeeStockOptionMember_ValuationTechniqueAxis-BlackscholesModelMember"
      decimals="2"
      id="c134564996"
      unitRef="Pure">1.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i_2025-06-30_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="-5"
      id="c134564997"
      unitRef="USD">3900000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2025-04-01_2025-06-30_AwardTypeAxis-EmployeeStockOptionMember_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"
      decimals="-5"
      id="c134564999"
      unitRef="USD">300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2025-04-01_2025-06-30_AwardTypeAxis-EmployeeStockOptionMember_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"
      decimals="-5"
      id="c134565000"
      unitRef="USD">100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2024-04-01_2024-06-30_AwardTypeAxis-EmployeeStockOptionMember_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"
      decimals="-5"
      id="c134565002"
      unitRef="USD">300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2024-04-01_2024-06-30_AwardTypeAxis-EmployeeStockOptionMember_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"
      decimals="-5"
      id="c134565003"
      unitRef="USD">100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2024-07-10_2024-07-10_CounterpartyNameAxis-RfInnovationsIncMember"
      decimals="INF"
      id="c134565007"
      unitRef="Share">12500</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2024-07-10_2024-07-10_CounterpartyNameAxis-RfInnovationsIncMember"
      decimals="-5"
      id="c134565008"
      unitRef="USD">100000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <amix:CommonStockDiscountForLackOfMarketability
      contextRef="i_2024-07-10_CounterpartyNameAxis-RfInnovationsIncMember"
      decimals="3"
      id="c134565009"
      unitRef="Pure">0.256</amix:CommonStockDiscountForLackOfMarketability>
    <amix:MaximumPercentageOfSharesSoldInThirtyDays
      contextRef="i_2024-07-10_CounterpartyNameAxis-RfInnovationsIncMember"
      decimals="1"
      id="c134565011"
      unitRef="Pure">0.10</amix:MaximumPercentageOfSharesSoldInThirtyDays>
    <amix:NumberOfCommonUnitsIssued
      contextRef="d_2024-11-22_2024-11-25_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember"
      decimals="INF"
      id="c134565017"
      unitRef="Share">458691</amix:NumberOfCommonUnitsIssued>
    <amix:NumberOfPrefundedUnitsIssued
      contextRef="d_2024-11-22_2024-11-25_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember"
      decimals="INF"
      id="c134565021"
      unitRef="Share">917596</amix:NumberOfPrefundedUnitsIssued>
    <amix:CommonUnitsIssuedPurchasePrice
      contextRef="d_2024-11-22_2024-11-25_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember"
      decimals="INF"
      id="c134565025"
      unitRef="USDPerShare">6.54</amix:CommonUnitsIssuedPurchasePrice>
    <amix:PrefundedUnitsIssuedPurchasePrice
      contextRef="d_2024-11-22_2024-11-25_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember"
      decimals="INF"
      id="c134565026"
      unitRef="USDPerShare">6.539</amix:PrefundedUnitsIssuedPurchasePrice>
    <amix:EquityOfferingOptionPeriod
      contextRef="d_2024-11-22_2024-11-22_CounterpartyNameAxis-UnderwritersMember_SubsidiarySaleOfStockAxis-OverAllotmentOptionMember"
      id="c134565027">P45D</amix:EquityOfferingOptionPeriod>
    <amix:EquityOfferingOptionMaximumShares
      contextRef="i_2024-11-22_CounterpartyNameAxis-UnderwritersMember_SubsidiarySaleOfStockAxis-OverAllotmentOptionMember"
      decimals="INF"
      id="c134565028"
      unitRef="Share">206422</amix:EquityOfferingOptionMaximumShares>
    <amix:EquityOfferingOptionMaximumWarrants
      contextRef="i_2024-11-22_ClassOfWarrantOrRightAxis-SeriesAWarrantsMember_CounterpartyNameAxis-UnderwritersMember"
      decimals="INF"
      id="c134565029"
      unitRef="Share">206422</amix:EquityOfferingOptionMaximumWarrants>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2024-11-22_2024-11-22_CounterpartyNameAxis-UnderwritersMember_SubsidiarySaleOfStockAxis-OverAllotmentOptionMember"
      decimals="INF"
      id="c134565030"
      unitRef="Share">156809</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <amix:ClassOfWarrantOrRightIssuedDuringPeriod
      contextRef="d_2024-11-22_2024-11-22_ClassOfWarrantOrRightAxis-SeriesAWarrantsMember_CounterpartyNameAxis-UnderwritersMember"
      decimals="INF"
      id="c134565031"
      unitRef="Share">156809</amix:ClassOfWarrantOrRightIssuedDuringPeriod>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="d_2024-11-22_2024-11-25_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember"
      decimals="-7"
      id="c134565032"
      unitRef="USD">10000000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <amix:CommissionPercentage
      contextRef="i_2024-11-25_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember"
      decimals="2"
      id="c134565033"
      unitRef="Pure">0.08</amix:CommissionPercentage>
    <amix:ClassOfWarrantOrRightIssuedDuringPeriod
      contextRef="d_2024-11-22_2024-11-25_ClassOfWarrantOrRightAxis-RepresentativesWarrantsMember_CounterpartyNameAxis-UnderwritersMember"
      decimals="INF"
      id="c134565034"
      unitRef="Share">91985</amix:ClassOfWarrantOrRightIssuedDuringPeriod>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2024-11-25_ClassOfWarrantOrRightAxis-PrefundedWarrantsMember"
      decimals="INF"
      id="c134565035"
      unitRef="USDPerShare">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <amix:ClassOfWarrantsOrRightsMaximumBeneficialOwnership
      contextRef="i_2024-11-25_ClassOfWarrantOrRightAxis-PrefundedWarrantsMember"
      decimals="4"
      id="c134565036"
      unitRef="Pure">0.0499</amix:ClassOfWarrantsOrRightsMaximumBeneficialOwnership>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2024-11-25_ClassOfWarrantOrRightAxis-SeriesAWarrantsMember"
      decimals="INF"
      id="c134565037"
      unitRef="USDPerShare">6.54</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <amix:ClassOfWarrantsOrRightsMaximumBeneficialOwnership
      contextRef="i_2024-11-25_ClassOfWarrantOrRightAxis-SeriesAWarrantsMember"
      decimals="4"
      id="c134565039"
      unitRef="Pure">0.0499</amix:ClassOfWarrantsOrRightsMaximumBeneficialOwnership>
    <amix:ClassOfWarrantOrRightLockupPeriod
      contextRef="d_2024-11-22_2024-11-25_ClassOfWarrantOrRightAxis-RepresentativesWarrantsMember"
      id="c134565041">P180D</amix:ClassOfWarrantOrRightLockupPeriod>
    <amix:ClassOfWarrantOrRightFairValuePerShare
      contextRef="i_2024-11-25_ClassOfWarrantOrRightAxis-PrefundedWarrantsMember"
      decimals="INF"
      id="c134565044"
      unitRef="USDPerShare">6.329</amix:ClassOfWarrantOrRightFairValuePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2024-11-25_ClassOfWarrantOrRightAxis-PrefundedWarrantsMember"
      decimals="INF"
      id="c134565045"
      unitRef="USDPerShare">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <amix:ClassOfWarrantOrRightFairValuePerShare
      contextRef="i_2024-11-25_ClassOfWarrantOrRightAxis-SeriesAWarrantsMember"
      decimals="INF"
      id="c134565046"
      unitRef="USDPerShare">5.3597</amix:ClassOfWarrantOrRightFairValuePerShare>
    <amix:ClassOfWarrantOrRightFairValuePerShare
      contextRef="i_2024-11-25_ClassOfWarrantOrRightAxis-RepresentativesWarrantsMember"
      decimals="INF"
      id="c134565047"
      unitRef="USDPerShare">5.2125</amix:ClassOfWarrantOrRightFairValuePerShare>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2025-06-30_ClassOfWarrantOrRightAxis-SeriesAWarrantsAndTheRepresentativesWarrantsMember_MeasurementInputTypeAxis-MeasurementInputDiscountRateMember_ValuationTechniqueAxis-BlackscholesModelMember"
      decimals="INF"
      id="c134565050"
      unitRef="Pure">4.17</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2025-06-30_ClassOfWarrantOrRightAxis-SeriesAWarrantsAndTheRepresentativesWarrantsMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember_ValuationTechniqueAxis-BlackscholesModelMember"
      decimals="INF"
      id="c134565053"
      unitRef="Pure">144.15</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="d_2024-11-22_2024-11-25_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember"
      decimals="-5"
      id="c134565054"
      unitRef="USD">1500000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="d_2024-11-22_2024-11-25_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember"
      decimals="-6"
      id="c134565055"
      unitRef="USD">1000000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="d_2024-11-22_2024-11-25_NatureOfExpenseAxis-NoncashExpensesMember_SubsidiarySaleOfStockAxis-UnderwrittenPublicOfferingMember"
      decimals="-5"
      id="c134565056"
      unitRef="USD">500000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock contextRef="d_2025-04-01_2025-06-30" id="c3016984">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Weighted-&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Warrants&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Per Share&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 70%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Outstanding, March 31, 2025&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,934,874&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="-sec-ix-hidden:c134564291"&gt;5.8860&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Granted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Exercised&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(222,132&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;0.0010&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Forfeited/Cancelled&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(130&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;0.0010&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Expired&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Outstanding, June 30, 2025*&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,712,612&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;6.6498&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Exercisable, June 30, 2025&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,712,612&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;6.6498&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="i_2025-03-31"
      decimals="INF"
      id="c134564290"
      unitRef="Share">1934874</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="d_2025-04-01_2025-06-30"
      decimals="INF"
      id="c134564292"
      unitRef="Share">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <amix:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="d_2025-04-01_2025-06-30"
      decimals="INF"
      id="c134564293"
      unitRef="USDPerShare">0</amix:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="d_2025-04-01_2025-06-30"
      decimals="INF"
      id="c134564294"
      unitRef="Share">222132</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <amix:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="d_2025-04-01_2025-06-30"
      decimals="INF"
      id="c134564295"
      unitRef="USDPerShare">0.001</amix:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures
      contextRef="d_2025-04-01_2025-06-30"
      decimals="INF"
      id="c134564296"
      unitRef="Share">130</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures>
    <amix:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="d_2025-04-01_2025-06-30"
      decimals="INF"
      id="c134564297"
      unitRef="USDPerShare">0.001</amix:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations
      contextRef="d_2025-04-01_2025-06-30"
      decimals="INF"
      id="c134564298"
      unitRef="Share">-0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations>
    <amix:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="d_2025-04-01_2025-06-30"
      decimals="INF"
      id="c134564299"
      unitRef="USDPerShare">0</amix:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="i_2025-06-30"
      decimals="INF"
      id="c134564300"
      unitRef="Share">1712612</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <amix:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i_2025-06-30"
      decimals="INF"
      id="c134564301"
      unitRef="USDPerShare">6.6498</amix:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice>
    <amix:SharebasedCompensationArrangementBySharebasedPaymentAwardNonoptionEquityInstrumentsExercisableNumberOutstandingNumber
      contextRef="i_2025-06-30"
      decimals="INF"
      id="c134564302"
      unitRef="Share">1712612</amix:SharebasedCompensationArrangementBySharebasedPaymentAwardNonoptionEquityInstrumentsExercisableNumberOutstandingNumber>
    <amix:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice
      contextRef="i_2025-06-30"
      decimals="INF"
      id="c134564303"
      unitRef="USDPerShare">6.6498</amix:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i_2025-06-30_ClassOfWarrantOrRightAxis-CommonWarrantsMember"
      decimals="INF"
      id="c134565059"
      unitRef="Share">87531</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i_2025-06-30_ClassOfWarrantOrRightAxis-RepresentativesWarrantsMember"
      decimals="INF"
      id="c134565060"
      unitRef="Share">91985</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i_2025-06-30_ClassOfWarrantOrRightAxis-SeriesAWarrantsMember"
      decimals="INF"
      id="c134565061"
      unitRef="Share">1533096</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i_2025-06-30_AwardTypeAxis-WarrantMember"
      decimals="-3"
      id="c134565064"
      unitRef="USD">0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2025-04-01_2025-06-30_AwardTypeAxis-WarrantMember"
      decimals="-3"
      id="c134565067"
      unitRef="USD">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2024-04-01_2024-06-30_AwardTypeAxis-WarrantMember"
      decimals="-5"
      id="c134565068"
      unitRef="USD">100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="d_2025-04-01_2025-06-30" id="c3016985">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;4&lt;/em&gt;&lt;/b&gt;&#160;&#x2013;&lt;b&gt; Commitments and Contingencies&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Legal Proceedings&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;From time to time, the Company &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be involved in claims that arise during the ordinary course of business. Although the results of litigation and claims cannot be predicted with certainty, the Company does &lt;span style="-sec-ix-hidden:c134565070"&gt;not&lt;/span&gt; currently have any pending litigation to which it is a party or to which its property is subject that we believe to be material. There are &lt;em style="font: inherit;"&gt;no&lt;/em&gt; legal matters for which a reasonably estimated range of losses can be determined. Regardless of the outcome, litigation can be costly and time consuming, and it can divert management&#x2019;s attention from important business matters and initiatives, negatively impacting our overall operations.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Employment Agreements&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;The Company has agreements with key employees to provide certain benefits, including salary and other wage-related benefits, in the event of termination. In addition, the Company has adopted a severance policy for certain key members of executive management to provide certain benefits, including salary and other wage-related benefits, in the event of termination. In total, these benefits would amount to a range of $1.2&#160;million to $1.7 million using the rate of compensation in effect at &lt;em style="font: inherit;"&gt; June 30, 2025. &lt;/em&gt;See Note &lt;em style="font: inherit;"&gt;6&lt;/em&gt; - Subsequent Events for additional information regarding events occurring after &lt;em style="font: inherit;"&gt; June 30, 2025.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Fractional Shares&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;See &lt;i&gt;Note &lt;em style="font: inherit;"&gt;1&lt;/em&gt; - Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies&lt;/i&gt; - "&lt;i&gt;Reverse Stock Split&lt;/i&gt;" for additional information.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;On &lt;em style="font: inherit;"&gt; November 1, 2024, &lt;/em&gt;the Company received notice from the Depository Trust and Clearing Corporation ("DTCC") on behalf of the brokerage firms that hold the shares of Company common stock held in &#x201c;street name&#x201d; that in connection with the rounding of fractional shares in connection with the Reverse Stock Split, the Company would need to issue 271,846 shares of common stock (the &#x201c;Shares&#x201d;) for the rounding of shares. The Company does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; believe the number of Shares being requested is correct based on the historical number of shareholders of its common stock and is aware of similar anomalies in recent months for other companies completing a Reverse Stock Split. As such, the Company has begun an inquiry into the calculations set forth in the request. During the pendency of this inquiry, the Company does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; intend to issue any shares in connection with the fractional shares being requested and has concluded that an obligation should &lt;em style="font: inherit;"&gt;not&lt;/em&gt; be recorded in its financial statements. The Company is &lt;em style="font: inherit;"&gt;not&lt;/em&gt; currently subject to any pending litigation as a result of the fractional roundup shares.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
  </us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="d_2025-04-01_2025-06-30_RangeAxis-MinimumMember_TypeOfArrangementAxis-EmploymentContractsMember"
      decimals="-5"
      id="c134565072"
      unitRef="USD">1200000</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="d_2025-04-01_2025-06-30_RangeAxis-MaximumMember_TypeOfArrangementAxis-EmploymentContractsMember"
      decimals="-5"
      id="c134565073"
      unitRef="USD">1700000</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <amix:StockRequiredToBeIssuedForStockSplitShares
      contextRef="i_2024-11-01"
      decimals="INF"
      id="c134565076"
      unitRef="Share">271846</amix:StockRequiredToBeIssuedForStockSplitShares>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="d_2025-04-01_2025-06-30" id="c3016986">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;5&lt;/em&gt;&lt;/b&gt;&#160;&#x2013;&lt;b&gt; Related Party Transactions&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;On &lt;em style="font: inherit;"&gt; December 21, 2021, &lt;/em&gt;the Company entered into a license agreement with a company controlled by a significant stockholder of the Company (&#x201c;Licensee&#x201d;). On &lt;em style="font: inherit;"&gt; July 7, 2023, &lt;/em&gt;the Company and the Licensee entered into an Exclusive License Termination Agreement (the &#x201c;Termination Agreement&#x201d;) in exchange for the issuance, upon the closing of the Company&#x2019;s initial public offering within &lt;em style="font: inherit;"&gt;one&lt;/em&gt; year of the agreement&#x2019;s execution, of a warrant to purchase shares of the Company for a variable number of shares. The variable number of shares issued was based upon a fixed value of $8.0 million divided by the price per share in the offering. The warrants were exercisable at a price of $0.02 per share and &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be exercised any time after the issuance date, subject to a beneficial ownership limitation, and expired &lt;span style="-sec-ix-hidden:c134565085"&gt;five&lt;/span&gt; years from the original issuance. The warrants did &lt;em style="font: inherit;"&gt;not&lt;/em&gt; provide voting rights, dividend rights, and other rights of a shareholder prior to exercise. The shares underlying the warrant were subject to a lockup agreement for a period of &lt;span style="-sec-ix-hidden:c134565087"&gt;six&lt;/span&gt; months after the closing of the offering with respect to 12.5% of the shares issued and &lt;span style="-sec-ix-hidden:c134565089"&gt;twelve&lt;/span&gt; months after the closing of the offering for the remainder of the shares. The Company agreed to register the resale of the shares of common stock underlying the warrant upon a notice of &lt;em style="font: inherit;"&gt;20&lt;/em&gt; business days by the Warrant holder.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;On &lt;em style="font: inherit;"&gt; January 29, 2024, &lt;/em&gt;pursuant to the Termination Agreement, the Company issued a warrant to purchase 80,000 shares (the &#x201c;Warrant&#x201d;) pursuant to the Termination Agreement to the Licensee&lt;i&gt;.&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"&gt;The completion of the Company&#x2019;s IPO fixed the number of warrant shares issuable and the Company re-classified the Warrant to additional-paid in capital as it met the requirements for equity classification. Upon reclassification, the Company valued the warrant at $8.0&#160;million, which represented the fair value of the shares issued on that date.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


  </us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <amix:ClassOfWarrantOrRightValueOfSecuritiesCalledByWarrantsOrRights
      contextRef="d_2023-07-07_2023-07-07_ClassOfWarrantOrRightAxis-TheWarrantMember_RelatedPartyTransactionAxis-TerminationAgreementMember"
      decimals="-6"
      id="c134565083"
      unitRef="USD">8000000</amix:ClassOfWarrantOrRightValueOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2023-07-07_ClassOfWarrantOrRightAxis-TheWarrantMember_RelatedPartyTransactionAxis-TerminationAgreementMember"
      decimals="INF"
      id="c134565084"
      unitRef="USDPerShare">0.02</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <amix:ClassOfWarrantOrRightPercentageOfOutstandingStock
      contextRef="d_2023-07-07_2023-07-07_ClassOfWarrantOrRightAxis-TheWarrantMember_RelatedPartyTransactionAxis-TerminationAgreementMember_UnderlyingAssetClassAxis-CommonStock6MonthsLockupPeriodMember"
      decimals="3"
      id="c134565088"
      unitRef="Pure">0.125</amix:ClassOfWarrantOrRightPercentageOfOutstandingStock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2024-01-29_ClassOfWarrantOrRightAxis-TheWarrantMember_RelatedPartyTransactionAxis-TerminationAgreementMember"
      decimals="INF"
      id="c134565091"
      unitRef="Share">80000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="i_2024-01-29_ClassOfWarrantOrRightAxis-TheWarrantMember_RelatedPartyTransactionAxis-TerminationAgreementMember"
      decimals="-6"
      id="c134565092"
      unitRef="USD">8000000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:SubsequentEventsTextBlock contextRef="d_2025-04-01_2025-06-30" id="c3016987">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;6&lt;/em&gt;&lt;/b&gt;&#160;&#x2013;&lt;b&gt; Subsequent Events&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;On &lt;em style="font: inherit;"&gt; July 21, 2025, &lt;/em&gt;the Company entered into a warrant exercise inducement offer letter (the "Inducement Letter") with the holders ("Holders") of certain existing warrants issued in the Offering from &lt;em style="font: inherit;"&gt; November 2024 &lt;/em&gt;to purchase up to 1,477,596 shares of the Company's common stock (the "Existing Warrants"). Pursuant to the Inducement Letter, the Company agreed to reduce the exercise price of the Existing Warrants to $1.723 per share, and the Holders agreed: (i) to exercise Existing Warrants to purchase 855,000 shares of Company common stock; and (ii) to prepay $1.722 per share of the reduced exercise price for Existing Warrants to purchase 622,596 shares of Company common stock in consideration of the Company further reducing the exercise price of such Existing Warrants to purchase 622,596 shares of Company common stock to $0.001 per share with an exercise term of 5.5 years. In consideration of the foregoing, the Company agreed to issue the Holders new warrants to purchase up to a number of shares of Company common stock equal to 100% of the number of shares of Company common stock underlying the Existing Warrants, comprised of new Series B warrants to purchase up to 1,477,596 shares of Company common stock (the &#x201c;Inducement Warrants&#x201d; and the shares of Company common stock underlying the Inducement Warrants, the &#x201c;Inducement Warrant Shares&#x201d;) at $1.723 per share with an exercise term of 5.5 years from the initial exercise date. In addition, the Company issued 88,656 Representative's Warrants at $2.6707 per share with an exercise term of 5&#160;years. The Company received total gross proceeds of approximately $2.6 million, less expenses paid to the Placement Agent of approximately $0.3 million.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;In &lt;em style="font: inherit;"&gt; July 2025, &lt;/em&gt;of the 622,596 Amended Series A Warrants above, 268,072 were exercised, leaving 354,524 of the Amended Series A Warrants at the time of this filing.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;On &lt;em style="font: inherit;"&gt; August 5, 2025, &lt;/em&gt;54,400 of pre-IPO warrants were exercised on a cashless basis.&#xfeff;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;In &lt;em style="font: inherit;"&gt; July 2025, &lt;/em&gt;the Company entered into stock option cancellation agreements with certain employees to cancel an aggregate of 57,331 stock options. Employees that elected to cancel their stock options were granted severance agreements for three, &lt;em style="font: inherit;"&gt;six&lt;/em&gt; or &lt;em style="font: inherit;"&gt;nine&lt;/em&gt; months of their base salary (under certain conditions). On &lt;em style="font: inherit;"&gt; August 11, 2025, &lt;/em&gt;the Company entered into stock option cancellation agreements with Board members and certain officers of the Company to cancel an aggregate of &lt;span style="-sec-ix-hidden:c134565119"&gt;177,652&lt;/span&gt; stock options. The Company's Board members included Mr. Walter Klemp, Chairman of the Board; Ms. Lori Bisson, Executive Vice Chairman of the Board; and Mr. Chris Capelli, Director, respectively, and included amounts of &lt;span style="-sec-ix-hidden:c134565120"&gt;8,773;&lt;/span&gt; &lt;span style="-sec-ix-hidden:c134565121"&gt;65,542;&lt;/span&gt; and &lt;span style="-sec-ix-hidden:c134565122"&gt;3,750,&lt;/span&gt; respectively. The Company's officers included Mr. Brad Hauser, Chief Executive Officer and President; Mr. Landy Toth, Chief Technology Officer; Mr. Robert Schwartz, Chief Medical Officer; and Mr. Trent Smith, Chief Financial Officer, respectively, and included amounts of &lt;span style="-sec-ix-hidden:c134565123"&gt;45,000;&lt;/span&gt; &lt;span style="-sec-ix-hidden:c134565124"&gt;8,773;&lt;/span&gt; &lt;span style="-sec-ix-hidden:c134565125"&gt;13,159;&lt;/span&gt; and &lt;span style="-sec-ix-hidden:c134565126"&gt;32,655,&lt;/span&gt; respectively. Mr. Hauser was granted &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months of his base salary, in addition to the &lt;em style="font: inherit;"&gt;twelve&lt;/em&gt; months of his base salary per his &lt;em style="font: inherit;"&gt; July 17, 2024 &lt;/em&gt;employment agreement. Mr. Toth and Mr. Schwartz were granted severance agreements that amounted to &lt;em style="font: inherit;"&gt;nine&lt;/em&gt; months of their base salary. Mr. Smith was granted &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months of his base salary, in addition to the &lt;em style="font: inherit;"&gt;nine&lt;/em&gt; months of his base salary per his &lt;em style="font: inherit;"&gt; July 24, 2023 &lt;/em&gt;employment agreement.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&#160;&lt;/p&gt;
  </us-gaap:SubsequentEventsTextBlock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2025-07-21_ClassOfWarrantOrRightAxis-ExistingWarrantsMember_SubsequentEventTypeAxis-SubsequentEventMember"
      decimals="INF"
      id="c134565095"
      unitRef="Share">1477596</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2025-07-21_ClassOfWarrantOrRightAxis-ExistingWarrantsAt1723ExercisePriceMember_SubsequentEventTypeAxis-SubsequentEventMember"
      decimals="INF"
      id="c134565096"
      unitRef="USDPerShare">1.723</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <amix:ClassOfWarrantOrRightExercisesInPeriod
      contextRef="d_2025-07-21_2025-07-21_ClassOfWarrantOrRightAxis-ExistingWarrantsAt1723ExercisePriceMember_SubsequentEventTypeAxis-SubsequentEventMember"
      decimals="INF"
      id="c134565097"
      unitRef="Share">855000</amix:ClassOfWarrantOrRightExercisesInPeriod>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2025-07-21_ClassOfWarrantOrRightAxis-ExistingWarrantsAt1722ExercisePriceMember_SubsequentEventTypeAxis-SubsequentEventMember"
      decimals="INF"
      id="c134565098"
      unitRef="USDPerShare">1.722</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2025-07-21_ClassOfWarrantOrRightAxis-ExistingWarrantsAt1722ExercisePriceMember_SubsequentEventTypeAxis-SubsequentEventMember"
      decimals="INF"
      id="c134565099"
      unitRef="Share">622596</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2025-07-21_ClassOfWarrantOrRightAxis-ExistingWarrantsAt1722ExercisePriceMember_SubsequentEventTypeAxis-SubsequentEventMember"
      decimals="INF"
      id="c134565100"
      unitRef="Share">622596</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i_2025-07-21_SubsequentEventTypeAxis-SubsequentEventMember"
      decimals="INF"
      id="c134565101"
      unitRef="USDPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i_2025-07-21_ClassOfWarrantOrRightAxis-ExistingWarrantsAt1722ExercisePriceMember_SubsequentEventTypeAxis-SubsequentEventMember"
      id="c134565102">P5Y6M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <amix:ClassOfWarrantOrRightExchangesPercentageOfUnderlyingShares
      contextRef="i_2025-07-21_ClassOfWarrantOrRightAxis-ExistingWarrantsMember_SubsequentEventTypeAxis-SubsequentEventMember"
      decimals="0"
      id="c134565103"
      unitRef="Pure">1</amix:ClassOfWarrantOrRightExchangesPercentageOfUnderlyingShares>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2025-07-21_ClassOfWarrantOrRightAxis-SeriesBWarrantsMember_SubsequentEventTypeAxis-SubsequentEventMember"
      decimals="INF"
      id="c134565104"
      unitRef="Share">1477596</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2025-07-21_ClassOfWarrantOrRightAxis-SeriesBWarrantsMember_SubsequentEventTypeAxis-SubsequentEventMember"
      decimals="INF"
      id="c134565105"
      unitRef="USDPerShare">1.723</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i_2025-07-21_ClassOfWarrantOrRightAxis-SeriesBWarrantsMember_SubsequentEventTypeAxis-SubsequentEventMember"
      id="c134565106">P5Y6M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2025-07-21_ClassOfWarrantOrRightAxis-RepresentativesWarrantsMember_SubsequentEventTypeAxis-SubsequentEventMember"
      decimals="INF"
      id="c134565107"
      unitRef="Share">88656</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2025-07-21_ClassOfWarrantOrRightAxis-RepresentativesWarrantsMember_SubsequentEventTypeAxis-SubsequentEventMember"
      decimals="INF"
      id="c134565108"
      unitRef="USDPerShare">2.6707</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i_2025-07-21_ClassOfWarrantOrRightAxis-RepresentativesWarrantsMember_SubsequentEventTypeAxis-SubsequentEventMember"
      id="c134565109">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="d_2025-07-21_2025-07-21_ClassOfWarrantOrRightAxis-ExistingWarrantsMember_SubsequentEventTypeAxis-SubsequentEventMember"
      decimals="-5"
      id="c134565110"
      unitRef="USD">2600000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <amix:PaymentsForWarrantIssuanceFees
      contextRef="d_2025-07-21_2025-07-21_ClassOfWarrantOrRightAxis-ExistingWarrantsMember_SubsequentEventTypeAxis-SubsequentEventMember"
      decimals="-5"
      id="c134565111"
      unitRef="USD">300000</amix:PaymentsForWarrantIssuanceFees>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i_2025-07-01_ClassOfWarrantOrRightAxis-SeriesAWarrantsMember_SubsequentEventTypeAxis-SubsequentEventMember"
      decimals="INF"
      id="c134565112"
      unitRef="Share">622596</us-gaap:ClassOfWarrantOrRightOutstanding>
    <amix:ClassOfWarrantOrRightExercisesInPeriod
      contextRef="d_2025-07-01_2025-07-31_ClassOfWarrantOrRightAxis-SeriesAWarrantsMember_SubsequentEventTypeAxis-SubsequentEventMember"
      decimals="INF"
      id="c134565113"
      unitRef="Share">268072</amix:ClassOfWarrantOrRightExercisesInPeriod>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i_2025-07-31_ClassOfWarrantOrRightAxis-SeriesAWarrantsMember_SubsequentEventTypeAxis-SubsequentEventMember"
      decimals="INF"
      id="c134565114"
      unitRef="Share">354524</us-gaap:ClassOfWarrantOrRightOutstanding>
    <amix:ClassOfWarrantOrRightExercisesInPeriod
      contextRef="d_2025-08-05_2025-08-05_ClassOfWarrantOrRightAxis-PreipoWarrantsMember_SubsequentEventTypeAxis-SubsequentEventMember"
      decimals="INF"
      id="c134565115"
      unitRef="Share">54400</amix:ClassOfWarrantOrRightExercisesInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="d_2025-07-01_2025-07-31_SubsequentEventTypeAxis-SubsequentEventMember"
      decimals="INF"
      id="c134565116"
      unitRef="Share">57331</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#c134564300"
          xlink:label="c134564300"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#c134564301"
          xlink:label="c134564301"
          xlink:type="locator"/>
        <link:footnote id="f2101127c-6f04-408f-a0d3-ad12ee1ffc63" xlink:label="f2101127c-6f04-408f-a0d3-ad12ee1ffc63" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-us">Amount includes 87,531 common warrants; 91,985 Representative's Warrants and 1,533,096 Series A Warrants.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c134564300"
          xlink:to="f2101127c-6f04-408f-a0d3-ad12ee1ffc63"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c134564301"
          xlink:to="f2101127c-6f04-408f-a0d3-ad12ee1ffc63"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#c134564126"
          xlink:label="c134564126"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#c134564127"
          xlink:label="c134564127"
          xlink:type="locator"/>
        <link:footnote id="fd967692e-d595-4e25-9ffc-c4169328cef1" xlink:label="fd967692e-d595-4e25-9ffc-c4169328cef1" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-us">197,098 exercised shares utilized the &#x201c;cashless exercise&#x201d; option and 695,334 exercised shares were paid in cash.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c134564126"
          xlink:to="fd967692e-d595-4e25-9ffc-c4169328cef1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c134564127"
          xlink:to="fd967692e-d595-4e25-9ffc-c4169328cef1"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#c134563969"
          xlink:label="c134563969"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#c134563970"
          xlink:label="c134563970"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#c134564214"
          xlink:label="c134564214"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#c134564215"
          xlink:label="c134564215"
          xlink:type="locator"/>
        <link:footnote id="f51af5ba4-7538-4bb9-928c-0265d9c40dbd" xlink:label="f51af5ba4-7538-4bb9-928c-0265d9c40dbd" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-us">Shares for the convertible note proceeds received

</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c134563969"
          xlink:to="f51af5ba4-7538-4bb9-928c-0265d9c40dbd"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c134563970"
          xlink:to="f51af5ba4-7538-4bb9-928c-0265d9c40dbd"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c134564214"
          xlink:to="f51af5ba4-7538-4bb9-928c-0265d9c40dbd"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c134564215"
          xlink:to="f51af5ba4-7538-4bb9-928c-0265d9c40dbd"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#c134565294"
          xlink:label="c134565294"
          xlink:type="locator"/>
        <link:footnote id="fa49c6ab1-4932-47d6-9f7c-6d5dd8f7d72e" xlink:label="fa49c6ab1-4932-47d6-9f7c-6d5dd8f7d72e" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-us">The initial discount rate was chosen based on private equity rates of return as described in the AICPA Practice Aid on Valuation of Privately-Held-Company Equity securities issued as compensation. For the recurring fair value measurement, the Company updated the discount rate based upon yield curves estimated to be similar in credit quality to the Company;</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c134565294"
          xlink:to="fa49c6ab1-4932-47d6-9f7c-6d5dd8f7d72e"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#c134564114"
          xlink:label="c134564114"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#c134564141"
          xlink:label="c134564141"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#c134564115"
          xlink:label="c134564115"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#c134564145"
          xlink:label="c134564145"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#c134564121"
          xlink:label="c134564121"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#c134564289"
          xlink:label="c134564289"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#c134564288"
          xlink:label="c134564288"
          xlink:type="locator"/>
        <link:footnote id="f0ea65d84-d12a-4647-986e-2fe346aff60b" xlink:label="f0ea65d84-d12a-4647-986e-2fe346aff60b" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-us">Aggregate Intrinsic Value = Excess of market value over the exercise price of all in-the-money stock.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c134564114"
          xlink:to="f0ea65d84-d12a-4647-986e-2fe346aff60b"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c134564141"
          xlink:to="f0ea65d84-d12a-4647-986e-2fe346aff60b"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c134564115"
          xlink:to="f0ea65d84-d12a-4647-986e-2fe346aff60b"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c134564145"
          xlink:to="f0ea65d84-d12a-4647-986e-2fe346aff60b"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c134564121"
          xlink:to="f0ea65d84-d12a-4647-986e-2fe346aff60b"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c134564289"
          xlink:to="f0ea65d84-d12a-4647-986e-2fe346aff60b"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c134564288"
          xlink:to="f0ea65d84-d12a-4647-986e-2fe346aff60b"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#c134564077"
          xlink:label="c134564077"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#c134564073"
          xlink:label="c134564073"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#c134564053"
          xlink:label="c134564053"
          xlink:type="locator"/>
        <link:footnote id="f72ee9f5c-8d9f-48fc-99e0-bf910aeb8f9b" xlink:label="f72ee9f5c-8d9f-48fc-99e0-bf910aeb8f9b" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-us">Aggregate Intrinsic Value = Excess of market value over the exercise price of all in-the-money warrants. No outstanding or exercisable warrants were in-the-money as of March 31, 2024.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c134564077"
          xlink:to="f72ee9f5c-8d9f-48fc-99e0-bf910aeb8f9b"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c134564073"
          xlink:to="f72ee9f5c-8d9f-48fc-99e0-bf910aeb8f9b"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c134564053"
          xlink:to="f72ee9f5c-8d9f-48fc-99e0-bf910aeb8f9b"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#c134565295"
          xlink:label="c134565295"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#c134565296"
          xlink:label="c134565296"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#c134565297"
          xlink:label="c134565297"
          xlink:type="locator"/>
        <link:footnote id="fc7d7f5f5-efe3-420b-8ea0-4b5582e112b7" xlink:label="fc7d7f5f5-efe3-420b-8ea0-4b5582e112b7" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-us">Scenario probability as of issuance was based on timing expectations of management that a qualified offering occurring as of December 31, 2023 was estimated at 70%, respectively; a qualified offering occurring as of June 30, 2024 was estimated at 10%; and no qualified offering occurring was estimated at 20%;</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c134565295"
          xlink:to="fc7d7f5f5-efe3-420b-8ea0-4b5582e112b7"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c134565296"
          xlink:to="fc7d7f5f5-efe3-420b-8ea0-4b5582e112b7"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c134565297"
          xlink:to="fc7d7f5f5-efe3-420b-8ea0-4b5582e112b7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#c134565300"
          xlink:label="c134565300"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#c134565299"
          xlink:label="c134565299"
          xlink:type="locator"/>
        <link:footnote id="f6d625244-82fa-42e1-9733-da3f33829574" xlink:label="f6d625244-82fa-42e1-9733-da3f33829574" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-us">The warrant has a $0.02 strike price, however, the strike price is low relative to the stock price, making the warrant value close to the value of a stock unit. The agreement has a fixed payment value of $8.0 million, see Note 6 &#x2013; Related Party Transactions.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c134565300"
          xlink:to="f6d625244-82fa-42e1-9733-da3f33829574"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c134565299"
          xlink:to="f6d625244-82fa-42e1-9733-da3f33829574"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
